PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Shimizu, T; Hirai, S; Yokoyama, E; Ichimura, K; Noda, M				Shimizu, Takeshi; Hirai, Shinichiro; Yokoyama, Eiji; Ichimura, Kimitoshi; Noda, Masatoshi			An evolutionary analysis of nitric oxide reductase gene norV in enterohemorrhagic Escherichia coli O157	INFECTION GENETICS AND EVOLUTION			English	Article						EHEC O157; norV; Evolution; Cade; Cluster; Nitric oxide	THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRULENCE; CLADES; INFECTIONS; EMERGENCE; OUTBREAKS; INSERTION; PROFILES; STRAINS; TOXINS	A novel virulence gene, norV, that encodes nitric oxide (NO) reductase, was examined to investigate the emergence of enterohemorrhagic Escherichia coli (EHEC) O157 subgroup C clusters 2 and 3 from subgroup C cluster 1. Deletion of norV occurred at a point between cluster 1 and cluster 2 just after or at the same time that an stx2 bacteriophage, which retains Shiga toxin 2 gene, was inserted into wrbA, which encodes a novel multimeric flavodoxin-like protein, in EHEC O157. Sensitivity of NO to anaerobic growth was correlated with the deletion of norV in all EHEC O157 individuals tested. The C467A mutation of fimH, which encodes minor component of type 1 fimbriae, occurred within cluster 1, not as a transition from cluster 1 to cluster 2, indicating that there is a cluster 1 minority branch that leads to cluster 2. These data refine the evolutionary history of an emerging EHEC O157. (C) 2015 Elsevier B.V. All rights reserved.	[Shimizu, Takeshi; Ichimura, Kimitoshi; Noda, Masatoshi] Chiba Univ, Grad Sch Med, Dept Mol Infectiol, Chiba 2608670, Japan; [Hirai, Shinichiro; Yokoyama, Eiji] Chiba Prefectural Inst Publ Hlth, Div Bacteriol, Chiba 2608715, Japan	Shimizu, T (reprint author), Chiba Univ, Grad Sch Med, Dept Mol Infectiol, 1-8-1 Inohana, Chiba 2608670, Japan.	tshimizu@faculty.chiba-u.jp			Japan Society for the Promotion of Science (JSPS) [26670208]	We are grateful to Kanako Hirano for her technical assistance. We thank Casey Moran for critical reading of the manuscript. This research was supported by Grants-in-Aid for Scientific Research (26670208) from Japan Society for the Promotion of Science (JSPS).	GRIFFIN PM, 1988, ANN INTERN MED, V109, P705; Shimizu T, 2012, MOL MICROBIOL, V85, P492, DOI 10.1111/j.1365-2958.2012.08122.x; Kulasekara BR, 2009, INFECT IMMUN, V77, P3713, DOI 10.1128/IAI.00198-09; CALDERWOOD SB, 1987, J BACTERIOL, V169, P4759; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Rangel JM, 2005, EMERG INFECT DIS, V11, P603; Brown PK, 2001, MOL MICROBIOL, V41, P349, DOI 10.1046/j.1365-2958.2001.02529.x; Grandori R, 1998, J BIOL CHEM, V273, P20960, DOI 10.1074/jbc.273.33.20960; Yang Z, 2004, APPL ENVIRON MICROB, V70, P6846, DOI 10.1128/AEM.70.11.6846-6854.2004; Shaikh N, 2003, J BACTERIOL, V185, P3596, DOI 10.1128/JB.185.12.3596-3605.2003; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Kyle JL, 2012, J BACTERIOL, V194, P1885, DOI 10.1128/JB.00120-12; Leopold SR, 2009, P NATL ACAD SCI USA, V106, P8713, DOI 10.1073/pnas.0812949106; Hirai S, 2013, INFECT GENET EVOL, V18, P94, DOI 10.1016/j.meegid.2013.05.006; OSTROFF SM, 1989, J INFECT DIS, V160, P994; Eklund M, 2002, J CLIN MICROBIOL, V40, P4585, DOI 10.1128/JCM.40.12.4585-4593.2002; Manning SD, 2008, P NATL ACAD SCI USA, V105, P4868, DOI 10.1073/pnas.0710834105; Shimizu T, 2009, INFECT IMMUN, V77, P2813, DOI 10.1128/IAI.00060-09; Hirai S, 2014, J APPL MICROBIOL, V117, P1191, DOI 10.1111/jam.12604; HOFMANN SL, 1993, AM J MED SCI, V306, P398, DOI 10.1097/00000441-199312000-00009; Keusch GT, 1997, SEMIN HEMATOL, V34, P106; KLEANTHOUS H, 1990, ARCH DIS CHILD, V65, P722; Lansbury LE, 1997, J INFECTION, V34, P189, DOI 10.1016/S0163-4453(97)94059-7; Shaikh N, 2007, FEMS MICROBIOL LETT, V273, P58, DOI 10.1111/j.1574-6968.2007.00781.x; WHITTAM TS, 1988, INFECT IMMUN, V56, P2467; Yokoyama E, 2012, INFECT GENET EVOL, V12, P1724, DOI 10.1016/j.meegid.2012.07.003	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-1348	1567-7257		INFECT GENET EVOL	Infect. Genet. Evol.	JUL	2015	33						176	181		10.1016/j.meegid.2015.04.027		6	Infectious Diseases	Infectious Diseases	CM1JX	WOS:000357438300024		
J	Suzuki, T; Matsuzaki, R; Todoroki, A; Mizutani, Y				Suzuki, Takuya; Matsuzaki, Ryosuke; Todoroki, Akira; Mizutani, Yoshihiro			Prediction of the macroscopic fracture toughness of a composite/adhesive interface with periodic surface microstructures	INTERNATIONAL JOURNAL OF ADHESION AND ADHESIVES			English	Article						Interface; Composites; Surface modification; Fracture mechanics; Nanoimprint lithography	ADHESIVE JOINTS; MODE; DELAMINATION; COMPOSITES; TOPOGRAPHY; STRENGTH; GROWTH	We developed a formula for predicting the macroscopic fracture toughness of a composite/adhesive interface with periodic surface microstructures. The formula is an expression of the total energy consumption along the interface averaged by the macroscopic crack length. The formula takes the effect of the crack kinking energy into consideration to compensate for the difference between the otherwise predicted consumed energy and that determined by finite element (FE) analysis. The predictions of the developed formula indicate that the macroscopic fracture toughness increases with increasing aspect ratio and decreases with decreasing height of the microstructures, which is in agreement with the findings of our previous studies on crack growth analysis using a cohesive zone model. The validity of the formula was investigated using microstructures of various shapes and sizes, and good agreement was observed between its predictions and the results of FE analyses. (C) 2015 Elsevier Ltd. All rights reserved.	[Suzuki, Takuya] IHI Corp, Struct Strength Dept, Res Lab, Isogo Ku, Yokohama, Kanagawa 2358501, Japan; [Matsuzaki, Ryosuke] Tokyo Univ Sci, Dept Mech Engn, Noda, Chiba 2788510, Japan; [Todoroki, Akira; Mizutani, Yoshihiro] Tokyo Inst Technol, Dept Mech Sci & Engn, Meguro Ku, Tokyo 1528552, Japan	Matsuzaki, R (reprint author), Tokyo Univ Sci, Dept Mech Engn, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	rmatsuza@rs.tus.ac.jp					Adams R. D., 2005, ADHESIVE BONDING SCI; FABER KT, 1983, ACTA METALL MATER, V31, P565, DOI 10.1016/0001-6160(83)90046-9; Harris AF, 1999, INT J ADHES ADHES, V19, P445, DOI 10.1016/S0143-7496(98)00061-X; Marat-Mendes RM, 2010, COMPOS STRUCT, V92, P2292, DOI 10.1016/j.compstruct.2009.07.017; Shahid M, 2002, INT J ADHES ADHES, V22, P235, DOI 10.1016/S0143-7496(01)00059-8; Alfano G, 2001, INT J NUMER METH ENG, V50, P1701, DOI 10.1002/nme.93; CHOU SY, 1995, APPL PHYS LETT, V67, P3114, DOI 10.1063/1.114851; CRITCHLOW GW, 1995, INT J ADHES ADHES, V15, P173, DOI 10.1016/0143-7496(95)91628-J; Volinsky AA, 2002, ACTA MATER, V50, P441, DOI 10.1016/S1359-6454(01)00354-8; Xie D, 2006, ENG FRACT MECH, V73, P1783, DOI 10.1016/j.engfracmech.2006.03.006; Kim WS, 2010, INT J ADHES ADHES, V30, P408, DOI 10.1016/j.ijadhadh.2010.05.004; CHEN D, 1998, T JPN SOC MECH ENG A, V64, P2574; Hikosaka Y, 2013, EXPRESS POLYM LETT, V7, P293, DOI 10.3144/expresspolymlett.2013.26; Matsuzaki Ryosuke, 2010, Journal of Solid Mechanics and Materials Engineering, V4, DOI 10.1299/jmmp.4.963; Miyairi H, 2006, BASIS APPL STRUCT AD; Niu Michael CY, 1999, AIRFRAME STRUCTURAL; Riccio A, 2014, AEROSP SCI TECHNOL, V39, P307, DOI 10.1016/j.ast.2014.10.003; Rider AN, 2001, J ADHESION, V75, P203, DOI 10.1080/00218460108029601; Schliekelmann RJ, 1969, GELIJMDE METALEN CON; Suzuki T, 2013, INT J ADHES ADHES, V42, P36, DOI 10.1016/j.ijadhadh.2013.01.008; Yukimoto Y, 2015, COMPOS PART A-APPL S, V69, P139, DOI 10.1016/j.compositesa.2014.11.014; Yukimoto Y, 2014, INT J ADHES ADHES, V50, P191, DOI 10.1016/j.ijadhadh.2014.01.034; Yuuki R, 1993, MECH INTERFACE; Zavattieri PD, 2007, INT J FRACTURE, V145, P167, DOI 10.1007/s10704-007-9109-y	24	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0143-7496	1879-0127		INT J ADHES ADHES	Int. J. Adhes. Adhes.	JUL	2015	60						16	22		10.1016/j.ijadhadh.2015.03.003		7	Engineering, Chemical; Materials Science, Multidisciplinary	Engineering; Materials Science	CM0ET	WOS:000357351900003		
J	Karyu, N; Shitajima, K; Fujii, S; Nakamura, Y; Urahama, Y				Karyu, Nozomi; Shitajima, Kohei; Fujii, Syuji; Nakamura, Yoshinobu; Urahama, Yoshiaki			Contact time dependence of tack for crosslinked polyacrylic pressure-sensitive adhesives with two different molecular structures	INTERNATIONAL JOURNAL OF ADHESION AND ADHESIVES			English	Article						Pressure-sensitive; Tack; Interfaces; Wettability	SOFT ADHESIVES; TEMPERATURE; PERFORMANCE; POLYMERS; GROWTH; BLENDS	The influence of molecular structure of pressure-sensitive adhesive on the wetting to adherend surface was investigated. For this purpose, crosslinked poly(n-butyl acrylate-acrylic acid) (A) and poly(2-ethylhexyl acrylate-acrylic acid) random copolymer (B) with an acrylic acid content of 5 wt% and various crosslinking degrees were used. Tack was measured by a probe tack test with a debonding rate of 10 mm/s and various contact times ranging from 3 to 30,000 s. The probe was made of stainless steel (SS). The tack increased with contact time and the degree of tack rising was B > A. The tack was A > B below the contact time of about 100 s, whereas it was B > A above 100 s. The order of molecular mobility was B > A from pulse nuclear magnetic resonance analysis, so the wettability to adherend surface became B > A. This is the reason why tack was B > A above 100 s. The interfacial tension at a water/toluene interface was decreased more effectively by A than B. This result indicates that the acrylic acid unit in A forms the interaction with the high energy surface such as SS in short contact time. The 2-ethylhexyl group is bulker than the n-butyl group. The bulky group promotes steric hindrance for the interaction of the acrylic acid unit. This seems to be the reason why tack was A > B below 100 s. (C) 2015 Elsevier Ltd. All rights reserved.	[Karyu, Nozomi; Shitajima, Kohei; Fujii, Syuji; Nakamura, Yoshinobu] Osaka Inst Technol, Dept Appl Chem, Asahi Ku, Osaka 5358585, Japan; [Urahama, Yoshiaki] Univ Hyogo, Grad Sch Engn, Himeji, Hyogo 6712201, Japan	Nakamura, Y (reprint author), Osaka Inst Technol, Dept Appl Chem, Asahi Ku, 5-16-1 Ohmiya, Osaka 5358585, Japan.	nakamura@chem.oit.ac.jp			Fujikura Foundation	The authors are grateful to the Fujikura Foundation for financial support. The authors are also thank to Fujikura Kasei Co., Ltd. (Tokyo, Japan) and Toagosei Co., Ltd. (Tokyo, Japan) for the polyacrylic polymer preparations and to Mitsubishi Gas Chemical Company, Inc., (Tokyo, Japan) for the kind donation of the crosslinking agent.	Creton C, 2001, LANGMUIR, V17, P4948, DOI 10.1021/la010117g; Tobing SD, 2001, J APPL POLYM SCI, V79, P2230, DOI 10.1002/1097-4628(20010321)79:12<2230::AID-APP1030>3.0.CO;2-2; [Anonymous], 2009, ASTMD297901; TOYAMA M, 1970, J APPL POLYM SCI, V14, P2039, DOI 10.1002/app.1970.070140812; Nakamura Y, 2013, J ADHES SCI TECHNOL, V27, P1951, DOI 10.1080/01694243.2013.766564; Nakamura Y, 2013, POLYM POLYM COMPOS, V21, P367; Chiche A, 2005, EUR PHYS J E, V17, P389, DOI 10.1140/epje/i2004-10148-3; Brown KR, 2002, EUR PHYS J E, V9, P35, DOI [10.1140/epje/i2002-10050-0, 10.1141/epje/i2002-10050-0]; Peykova Y, 2010, INT J ADHES ADHES, V30, P245, DOI 10.1016/j.ijadhadh.2010.02.005; ZOSEL A, 1991, J ADHESION, V34, P201, DOI 10.1080/00218469108026514; O'Connor AE, 2004, INT J ADHES ADHES, V24, P335, DOI 10.1016/j.ijadhadh.2003.11.005; Creton C, 2009, MACROMOLECULES, V42, P7605, DOI 10.1021/ma900821k; Belhaneche-Bensemra N, 2003, MACROMOL SYMP, V202, P151, DOI 10.1002/masy.200351214; Benedek I., 2005, PRESSURE SENSITIVE A, V2nd; Brandrup J., 1989, POLYM HDB; Deplace F, 2009, ACS APPL MATER INTER, V1, P2021, DOI 10.1021/am9003792; Diethert A, 2010, ACS APPL MATER INTER, V2, P2060, DOI 10.1021/am100322j; Hammond Jr FH, 1965, USP, Patent No. 3214971; HEDDLESON SS, 1994, CEREAL CHEM, V71, P564; Kim DJ, 2006, J ADHES SCI TECHNOL, V20, P1367, DOI 10.1163/156856106778456618; Lakrout H, 1999, J ADHESION, V69, P307, DOI 10.1080/00218469908017233; Lau C, 2001, J POLYM SCI POL PHYS, V39, P2390, DOI 10.1002/polb.1210; Tanaka M, 2009, J PHYS SOC JPN, V78; Toyama M, 1970, J SOC ADHESION JAPAN, V6, P356; TSE MF, 1989, J ADHES SCI TECHNOL, V3, P551; Urahama Y, 2010, J ADHES SOC JPN, V46, P53, DOI 10.11618/adhesion.46.53; YANG HWH, 1995, J APPL POLYM SCI, V55, P645, DOI 10.1002/app.1995.070550413; Yarnamura K, 2013, J APPL POLYM SCI, V129, P1008; Zosel A., 1992, ADV PRESSURE SENSITI, V1, P92	29	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0143-7496	1879-0127		INT J ADHES ADHES	Int. J. Adhes. Adhes.	JUL	2015	60						75	82		10.1016/j.ijadhadh.2015.04.001		8	Engineering, Chemical; Materials Science, Multidisciplinary	Engineering; Materials Science	CM0ET	WOS:000357351900010		
J	Zhang, Y; Noda, NA; Wu, PZ; Duan, ML				Zhang, Yu; Noda, Nao-Aki; Wu, Peizhen; Duan, Menglan			A mesh-independent technique to evaluate stress singularities in adhesive joints (vol 57, pg 105, 2015)	INTERNATIONAL JOURNAL OF ADHESION AND ADHESIVES			English	Correction									[Zhang, Yu; Wu, Peizhen; Duan, Menglan] China Univ Petr, Offshore Oil Gas Res Ctr, Beijing 102249, Peoples R China; [Noda, Nao-Aki] Kyushu Inst Technol, Dept Mech Engn, Kitakyushu, Fukuoka 8048550, Japan	Zhang, Y (reprint author), China Univ Petr, Offshore Oil Gas Res Ctr, 18 Fuxue Rd, Beijing 102249, Peoples R China.	zyzhangyu1225@yahoo.com					Zhang Y, 2015, INT J ADHES ADHES, V57, P105, DOI 10.1016/j.ijadhadh.2014.12.003	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0143-7496	1879-0127		INT J ADHES ADHES	Int. J. Adhes. Adhes.	JUL	2015	60						130	130		10.1016/j.ijadhadh.2015.05.004		1	Engineering, Chemical; Materials Science, Multidisciplinary	Engineering; Materials Science	CM0ET	WOS:000357351900018		
J	Chumrum, P; Koga, N; Premanond, V				Chumrum, Pakorn; Koga, Nobuhiro; Premanond, Varunee			Experimental investigation of energy and punch wear in piercing of advanced high-strength steel sheet	INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY			English	Article						Advanced high-strength steels [AHSS]; Energy; Piercing; Wear; Tool clearance; Punch force	SPRINGBACK; SIMULATION; BLANKING; EDGE; WARM	The short service life of tools used to pierce advanced high-strength steel sheet (AHSS) is one of the primary concerns of the automotive industry. A high tool wear rate is expected due to high strength of the sheet to be pierced. This work investigated the effects of tool clearances on the quality of pierced holes, the piercing force, the piercing energy, and tool wear in piercing operations of AHSS and carbon steel sheet. The piercing energy was observed to be the major factor affecting tool wear. The energy was high when using a small tool clearance on AHSS. The tool with large clearance piercing AHSS exhibited a similar degree of wear as that piercing the low carbon sheet. A double shear zone on the cutting edge of AHSS was responsible for the high piercing energy, especially the energy required to push the slug through the die hole and that required for the return stroke, and the high wear rate of the piercing tool with small clearance.	[Chumrum, Pakorn; Premanond, Varunee] King Mongkuts Univ Technol Thonburi, Dept Tool & Mat Engn, Bangkok, Thailand; [Koga, Nobuhiro] Nippon Inst Technol, Dept Mech Engn, Saitama, Japan	Premanond, V (reprint author), King Mongkuts Univ Technol Thonburi, Dept Tool & Mat Engn, Bangkok, Thailand.	varunee.pre@kmutt.ac.th			Royal Golden Jubilee Ph.D. Programme [PHD/0078/2552]; Thailand Research Fund	The authors would like to acknowledge the financial support received from the Royal Golden Jubilee Ph.D. Programme (Grant No. PHD/0078/2552), The Thailand Research Fund. We would also like to acknowledge the Thai Summit Co., Ltd, Thailand, for providing materials and A. Matsumoto, T. Kaneda, T. Tsuchiya for providing help with experiments.	Sresomroeng B, 2011, SURF COAT TECH, V205, P4198, DOI 10.1016/j.surfcoat.2011.03.010; Komori K, 2013, INT J MECH SCI, V68, P150, DOI 10.1016/j.ijmecsci.2013.01.009; Chen P, 2007, J MATER PROCESS TECH, V190, P189, DOI 10.1016/j.jmatprotec.2007.02.046; Soares JA, 2013, INT J ADV MANUF TECH, V65, P451, DOI 10.1007/s00170-012-4184-2; Achouri M, 2014, INT J ADV MANUF TECH, V71, P1019, DOI 10.1007/s00170-013-5522-8; Ozturk F, 2009, J IRON STEEL RES INT, V16, P41, DOI 10.1016/S1006-706X(10)60025-8; Rafsanjani A, 2009, INT J ADV MANUF TECH, V45, P459, DOI 10.1007/s00170-009-1988-9; Mori K, 2010, J MATER PROCESS TECH, V210, P653, DOI 10.1016/j.jmatprotec.2009.11.014; Mori K, 2013, INT J MACH TOOL MANU, V65, P41, DOI 10.1016/j.ijmachtools.2012.09.005; Cora ON, 2009, INT J MACH TOOL MANU, V49, P897, DOI 10.1016/j.ijmachtools.2009.07.003; Shivpuri R, 2011, CIRP ANN-MANUF TECHN, V60, P307, DOI 10.1016/j.cirp.2011.03.139; ARCHARD JF, 1953, J APPL PHYS, V24, P981, DOI 10.1063/1.1721448; Mucha J, 2010, INT J ADV MANUF TECH, V50, P495, DOI 10.1007/s00170-010-2554-1; Kleiner M, 2003, CIRP ANN-MANUF TECHN, V52, P521, DOI 10.1016/S0007-8506(07)60202-9; Koga N, 2002, PRESS WORKING BLANKI; Lee SW, 1998, J MATER PROCESS TECH, V80-1, P60, DOI 10.1016/S0924-0136(98)00177-0; LIU HW, 2014, IEEE T APPL SUPERCON, V24, DOI DOI 10.1007/S00170-014-6479-Y; Mackensen A, 2010, CIRP ANN-MANUF TECHN, V59, P283, DOI 10.1016/j.cirp.2010.03.110; Mori K, 2008, CIRP ANN-MANUF TECHN, V57, P321, DOI 10.1016/j.cirp.2008.0:3.125	19	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-3768	1433-3015		INT J ADV MANUF TECH	Int. J. Adv. Manuf. Technol.	JUL	2015	79	5-8					1035	1042		10.1007/s00170-015-6902-z		8	Automation & Control Systems; Engineering, Manufacturing	Automation & Control Systems; Engineering	CL9FX	WOS:000357283000028		
J	Ma, WZ; Zhang, B; Nakajima, A; Mawatari, T				Ma, Wenzhuo; Zhang, Bo; Nakajima, Akira; Mawatari, Toshifumi			Electrolytic in-process dressing grinding of ceramic balls	INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY			English	Article						Ceramic ball; Electrolytic in-process dressing; Superfine diamond grinding wheel; Metal bond	DIAMOND WHEELS	The electrolytic in-process dressing grinding of ceramic balls was investigated on a magnetic fluid support grinding machine by using fine diamond grinding wheels SD16000 of both bronze bond and cast iron bond under different dressing currents in two different electrolytes. The experimental results showed that the grinding efficiency increased with the dressing current. However, the ground surface was roughened when the current increased to over 160 mA in the study. The bronze-bonded grinding wheel showed a higher dressing effectiveness than the cast iron-bonded grinding wheel in both tap water and the CG-7 solution. As an electrolyte, tap water was more effective than CG-7 solution in terms of the grinding efficiency improvement.	[Ma, Wenzhuo; Zhang, Bo; Nakajima, Akira; Mawatari, Toshifumi] Saga Univ, Grad Sch Sci & Engn, Dept Mech Engn, Saga 8408502, Japan	Zhang, B (reprint author), Saga Univ, Grad Sch Sci & Engn, Dept Mech Engn, 1 Honjo Machi, Saga 8408502, Japan.	zhang@me.saga-u.ac.jp					Beverskog B, 1996, CORROS SCI, V38, P2121, DOI 10.1016/S0010-938X(96)00067-4; Kim JD, 1996, INT J ADV MANUF TECH, V12, P246, DOI 10.1007/BF01239611; Kumar AS, 2002, J ELECTRON MATER, V31, P1039, DOI 10.1007/s11664-002-0040-8; Lim HS, 2002, INT J MACH TOOL MANU, V42, P935, DOI 10.1016/S0890-6955(02)00023-8; Ohmori H, 1996, J MATER PROCESS TECH, V57, P272, DOI 10.1016/0924-0136(95)02079-9; OHMORI H, 1997, CIRP ANN-MANUF TECHN, V46, P261, DOI 10.1016/S0007-8506(07)60821-X; Ohmori H, 1990, CIRP ANN-MANUF TECHN, V39, P329, DOI 10.1016/S0007-8506(07)61065-8; Pavel R, 2004, J MATER PROCESS TECH, V149, P591, DOI 10.1016/j.jmatprotec.2004.02.026; Pourbaix M, 1963, ATLAS EQUIFIBRES ELE, P380; Rahman M, 2003, SADHANA-ACAD P ENG S, V28, P957, DOI 10.1007/BF02703325; Suzuki K., 1987, ANN CIRP, V36, P115; Tonshoff HK, 2000, PRECIS ENG, V24, P58, DOI 10.1016/S0141-6359(99)00028-8; Umehara N, 1988, J JSME C, V54, P1599; Westkamper E., 1995, CIRP ANN-MANUF TECHN, V44, P317, DOI 10.1016/S0007-8506(07)62333-6; Zhang B, 2003, PRECIS ENG, V27, P1, DOI 10.1016/S0141-6359(02)00152-6; Zhang B, 1998, JSME INT J C-MECH SY, V41, P499	16	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-3768	1433-3015		INT J ADV MANUF TECH	Int. J. Adv. Manuf. Technol.	JUL	2015	79	5-8					1153	1160		10.1007/s00170-015-6918-4		8	Automation & Control Systems; Engineering, Manufacturing	Automation & Control Systems; Engineering	CL9FX	WOS:000357283000039		
J	Wu, L; Suzuki, S				Wu, Lang; Suzuki, Sadami			Cell formation design with improved similarity coefficient method and decomposed mathematical model	INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY			English	Article						Cellular manufacturing system; Cell formation; Similarity coefficient method; Decomposed mathematical model	MANUFACTURING SYSTEMS; GROUP-TECHNOLOGY; GENETIC ALGORITHM; OPERATION SEQUENCES; PART FAMILIES; DEMAND; ENVIRONMENT; COSTS	This research develops a new methodology for a cell formation problem in the cellular manufacturing system. The methodology includes two phases. In the first phase, an improved similarity coefficient method, which considers the operation sequence and the number of repeated operations firstly in related researches, is proposed to identify part families. A new decomposed mathematical model is presented in the second phase, which considers some crucial operational aspects such as alternative routing, machine capacity, part demand, operation time, and lot splitting, to assign machines into part families for minimum machine cost, operation cost, and inter-cell movement cost. The model puts emphasis on the effect of trade-off between machine duplication and material inter-cell movement on performance of the cell formation to optimize machine utilization and workload balance. This paper also provides a concrete production schedule with optimum system utilization for cell formation. Test problems and sensitivity analyses are carried out to reveal the effectiveness and feasibility of the proposed methodology.	[Wu, Lang; Suzuki, Sadami] Tokyo Inst Technol, Dept Ind Engn & Management, Meguro Ku, Tokyo 152, Japan	Wu, L (reprint author), Tokyo Inst Technol, Dept Ind Engn & Management, Meguro Ku, 2-12-1 O Okayama, Tokyo 152, Japan.	wu.1.ad@m.titech.ac.jp; suzuki.s.ag@m.titech.ac.jp					Ah kioon Steve, 2009, European Journal of Operational Research, V192, DOI 10.1016/j.ejor.2007.09.023; Anderberg MR, 1973, CLUSTER ANAL APPL, P84; WAGHODEKAR PH, 1984, INT J PROD RES, V22, P937, DOI 10.1080/00207548408942513; Defersha FM, 2008, EUR J OPER RES, V187, P46, DOI 10.1016/j.ejor.2007.02.040; KAMRANI AK, 1993, COMPUT IND ENG, V25, P487, DOI 10.1016/0360-8352(93)90326-S; Yin Y, 2006, INT J PROD ECON, V101, P329, DOI 10.1016/j.ijpe.2005.01.014; Won YY, 2001, INT J PROD RES, V39, P2755, DOI 10.1080/00207540010005060; Papaioannou G, 2010, EUR J OPER RES, V206, P509, DOI 10.1016/j.ejor.2009.10.020; Jeon G, 2006, COMPUT OPER RES, V33, P263, DOI 10.1016/j.cor.2005.03.033; Chen MY, 1998, ANN OPER RES, V77, P109, DOI 10.1023/A:1018917109580; Selim HM, 1998, COMPUT IND ENG, V34, P3, DOI 10.1016/S0360-8352(97)00147-2; Safaei N, 2008, EUR J OPER RES, V185, P563, DOI 10.1016/j.ejor.2006.12.058; KUSIAK A, 1992, INT J PROD RES, V30, P2633, DOI 10.1080/00207549208948181; Szwarc D, 1997, INT J ADV MANUF TECH, V13, P134, DOI 10.1007/BF01225760; Bajestani MA, 2009, COMPUT OPER RES, V36, P777, DOI 10.1016/j.cor.2007.10.026; BALLAKUR A, 1987, INT J PROD RES, V25, P639, DOI 10.1080/00207548708919868; BARONIURBANI C, 1976, SYST ZOOL, V25, P251, DOI 10.2307/2412493; Chen HW, 2013, INT J ADV MANUF TECH, V66, P417, DOI 10.1007/s00170-012-4336-4; Dalfard VM, 2013, APPL MATH MODEL, V37, P1884, DOI 10.1016/j.apm.2012.04.034; Diaby M, 2006, J OPER RES SOC, V57, P1100, DOI 10.1057/palgrave.jors.2602072; Foulds LR, 2006, COMPUT OPER RES, V33, P1010, DOI 10.1016/j.cor.2004.09.001; Green TJ, 1984, J OPERATIONS MANAGEM, V4, P85, DOI 10.1016/0272-6963(84)90025-1; GUNASINGH KR, 1989, COMPUT IND ENG, V16, P469, DOI 10.1016/0360-8352(89)90164-2; GUPTA T, 1993, INT J PROD RES, V31, P1259, DOI 10.1080/00207549308956790; GUPTA T, 1990, INT J PROD RES, V28, P1247, DOI 10.1080/00207549008942791; Hachicha W, 2008, INT J ADV MANUF TECH, V36, P1157, DOI 10.1007/s00170-007-0928-9; HOLLEY JW, 1964, EDUC PSYCHOL MEAS, V24, P749, DOI 10.1177/001316446402400402; Islam KMS, 2000, INT J PROD RES, V38, P699, DOI 10.1080/002075400189374; Kao YC, 2013, INT J ADV MANUF TECH, V65, P1247, DOI 10.1007/s00170-012-4254-5; Krishnan KK, 2012, INT J ADV MANUF TECH, V59, P737, DOI 10.1007/s00170-011-3523-z; Mansouri SA, 2003, PROD PLAN CONTROL, V14, P437, DOI 10.1080/09537280310001597334; McAuley J., 1972, PRODUCTION ENG, V51, P53; OFFODILE OF, 1991, J MANUF SYST, V10, P442, DOI 10.1016/0278-6125(91)90002-J; OFFODILE OF, 1994, J MANUF SYST, V13, P196; Romesburg HC, 1984, CLUSTER ANAL RES; Sarker BR, 1998, PROD PLAN CONTROL, V9, P771, DOI 10.1080/095372898233542; Tavakkoli-Moghaddam R, 2008, INT J ENG T A, V21, P159; VAKHARIA AJ, 1990, IIE TRANS, V22, P84, DOI 10.1080/07408179008964161; Wicks EM, 1999, IIE TRANS, V31, P11, DOI 10.1023/A:1007516532572; Wilhelm WE, 1998, ANN OPER RES, V77, P97, DOI 10.1023/A:1018985630053; Witte JD, 1980, INT J PROD RES, V18, P503; Yasuda K, 2005, INT J PROD RES, V43, P829, DOI 10.1080/00207540412331311859; Yin Yong, 2002, Industrial Engineeering & Management Systems An International Journal, V1, P19	43	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-3768	1433-3015		INT J ADV MANUF TECH	Int. J. Adv. Manuf. Technol.	JUL	2015	79	5-8					1335	1352		10.1007/s00170-015-6931-7		18	Automation & Control Systems; Engineering, Manufacturing	Automation & Control Systems; Engineering	CL9FX	WOS:000357283000054		
J	Takahashi, Y				Takahashi, Yoshiro			ORPHANED DAUGHTERS: ON THE SO-CALLED PROPERTY RIGHTS OF DAUGHTERS IN THE SOUTHERN SONG PERIOD	INTERNATIONAL JOURNAL OF ASIAN STUDIES			English	Article						Chinese law; Chinese legal history; Chinese inheritance law; gender studies; women's property rights		A longstanding and contentious issue in Chinese legal history is whether women had the legal right to inherit and own property. During the Southern Song in particular, certain historical and legal sources have been interpreted by scholars in such a way as to propose that they did, at least to a limited extent, as reflected, for example, in the "daughter's half-share law" (nuzi fenfa), which stipulated that a daughter would receive half a son's portion upon the death of both parents. The current study, through an examination of documentary sources on the inheritance rights of daughters, clarifies the historical circumstances surrounding the phenomenon, and concludes that no fundamental legal right to inherit and own property such as that enjoyed by men was intended. Rather, laws specifying the inheritance rights of women were the result of legislative measures for the protection of orphaned daughters, out of a concern to ensure that they would not be deprived of property that they would have received (for example, as dowry) had their parents not died. The Song's uniqueness lay not in the elevation of women's property rights, but rather in the implementation of explicit policies for the social good. That similar laws were not continued in the Ming and Qing did not in itself mean that the principle of protecting orphaned daughters had been abandoned, but rather that this principle would be applied through the discretionary powers of magistrates, as records of actual legal judgments demonstrate.	Hokkaido Univ, Sapporo, Hokkaido 060, Japan	Takahashi, Y (reprint author), Hokkaido Univ, Sapporo, Hokkaido 060, Japan.			Fraleigh, Matthew/0000-0001-5760-5340			[Anonymous], 1195, QINGYUANG; [Anonymous], HOUCIUN; [Anonymous], 1987, QINGMING; Bernhardt Kathryn, 1999, WOMEN; Bernhardt Kathryn, 1997, CHOGUKU, V12, P233; BERNHARDT K, 1995, MOD CHINA, V21, P269, DOI 10.1177/009770049502100302; Chugoku noson kanko chosa kankokai, 1952, CHUGOKU, V1; Fang Jianxin, 1986, LIASH; Haruhito Sadate, 1999, KYOTO, V29, P32; Kazuyasu Shimasue, 1993, SODAI; Keiko Komatsu, 1991, HIROSHIMA, V13; Koji Hosono, 1967, TYOY, V50, P3; Li Weiguo, 1987, SONG; Li Yuan, 1988, SONGSHI, V2; Masaaki Osawa, 1998, REIKISHI, V717, P14; Mie Nagata, 1991, HOKUDAI, V31, P1; Noboru Niida, 1942, SHINA; Noboru Niida, 1962, DOREI; Noboru Niida, 1933, TORIE; Reiko Shinno, 1990, CHUGOKU, V2, P2; Setsuko Yanagida, 1995, SO GEN SHAKI; Setsuko Yanagida, 1990, HOSEI SHIGAKU, V42, P1; Setsuko Yanagida, 1995, SO GEN SHAKAI; Setsuko Yanagida, 1996, HOSEISHI, V46, P273; Setsuko Yanagida, 1992, HOSEISHI KENKYU, V42, P300; Shigeru Kato, 1952, SHINA, V2; Shin'ichi Itabashi, 1993, CHUGOKU; Shuzo Shiga, 1967, CHUGOKU; Shuzo Shiga, 1953, KOKKA, p[5/6, 9/10, 11/12, 7/8]; Shuzo Shiga, 1950, CHUGOKU; Tian'an Wei, 1988, ZHONGGUO; Yasushi Kawamura, 1991, HOSEISHI, V41, P325; Yoshiro Takahashi, 1995, TOHOKU, V6; Yoshiro Takahashi, 2002, SODAI, P249	34	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1479-5914	1479-5922		INT J ASIAN STUD	Int. J. Asian Stud.	JUL	2015	12	2					131	165		10.1017/S1479591415000145		35	Asian Studies	Asian Studies	CM3VL	WOS:000357613000001		
J	Nawa, K				Nawa, Katsuo			Maoists at the Hearth: Everyday Life in Nepal's Civil War	INTERNATIONAL JOURNAL OF ASIAN STUDIES			English	Book Review									[Nawa, Katsuo] Univ Tokyo, Tokyo 1138654, Japan	Nawa, K (reprint author), Univ Tokyo, Tokyo 1138654, Japan.	nawa@ioc.u-tokyo.ac.jp					Pettigrew J, 2013, ETHNOGR POLIT VIOLEN, P1	1	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1479-5914	1479-5922		INT J ASIAN STUD	Int. J. Asian Stud.	JUL	2015	12	2					239	241		10.1017/S1479591415000042		3	Asian Studies	Asian Studies	CM3VL	WOS:000357613000005		
J	Zhong, YJ				Zhong, Yijiang			The "Greatest Problem": Religion and State Formation in Meiji Japan	INTERNATIONAL JOURNAL OF ASIAN STUDIES			English	Book Review									[Zhong, Yijiang] Univ Tokyo, Tokyo 1138654, Japan	Zhong, YJ (reprint author), Univ Tokyo, Tokyo 1138654, Japan.	yijiangzhong@ioc.u-tokyo.ac.jp					MAXEY TE, 2014, GREATEST PROBLEM REL	1	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1479-5914	1479-5922		INT J ASIAN STUD	Int. J. Asian Stud.	JUL	2015	12	2					247	249		10.1017/S1479591415000091		4	Asian Studies	Asian Studies	CM3VL	WOS:000357613000009		
J	Takano, S				Takano, Sayaka			Creole Identity in Postcolonial Indonesia	INTERNATIONAL JOURNAL OF ASIAN STUDIES			English	Book Review									[Takano, Sayaka] Japan Soc Promot Sci, Tokyo, Japan	Takano, S (reprint author), Japan Soc Promot Sci, Tokyo, Japan.	utkn-syk@mail.ecc.u-tokyo.ac.jp					KNORR J, 2014, CREOLE IDENTITY POST	1	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1479-5914	1479-5922		INT J ASIAN STUD	Int. J. Asian Stud.	JUL	2015	12	2					254	255		10.1017/S1479591415000078		2	Asian Studies	Asian Studies	CM3VL	WOS:000357613000012		
J	Cock, A				Cock, Andrew			Archiving the Unspeakable: Silence, Memory, and the Photographic Record in Cambodia	INTERNATIONAL JOURNAL OF ASIAN STUDIES			English	Book Review									[Cock, Andrew] Res Inst Humanity & Nat, Kyoto, Japan	Cock, A (reprint author), Res Inst Humanity & Nat, Kyoto, Japan.	arcock@gmail.com					CASWELL M, 2014, ARCH UNSPEAKABLE SIL	1	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1479-5914	1479-5922		INT J ASIAN STUD	Int. J. Asian Stud.	JUL	2015	12	2					258	262		10.1017/S1479591415000029		6	Asian Studies	Asian Studies	CM3VL	WOS:000357613000014		
J	Kimura, T				Kimura, Takuma			A Review of Political Skill: Current Research Trend and Directions for Future Research	INTERNATIONAL JOURNAL OF MANAGEMENT REVIEWS			English	Review							JOB-PERFORMANCE RELATIONSHIP; CAREER SUCCESS; ORGANIZATIONAL POLITICS; IMPRESSION MANAGEMENT; CONSTRUCTIVE REPLICATION; DECISION-MAKING; SELF-REGULATION; PROACTIVE PERSONALITY; WORKPLACE OSTRACISM; MODERATING ROLE	This paper reviews theoretical and empirical research on the use of political skill in organizations and proposes some agendas for future research. Although political skill is a relatively new construct in organizational politics research, a large number of theoretical and empirical studies have been conducted. Five major themes were identified in previous research. These are: (a) definition and measurement of political skill; (b) political skill and stress management; (c) political skill and career success; (d) political skill and individual performance; and (e) political skill and leadership effectiveness. This review critically examines previous empirical studies in light of this theoretical background and points out that, although previous empirical studies support the theoretically assumed effects of political skills, they fail to confirm how and why these skills bring about these effects. Based on this examination, the author suggests the examination of mediators and dimensional differences derived from theory that can lead to more effective exploration of the impact of political skill. In addition, several issues for future research are proposed, which may provide useful insights for both literature and practice.	Hosei Univ, Chiyoda Ku, Tokyo 1028160, Japan	Kimura, T (reprint author), Hosei Univ, Chiyoda Ku, 2-17-1 Fujimi, Tokyo 1028160, Japan.	ktakuma@hosei.ac.jp					Allison GT, 1971, ESSENCE DECISION; Andrews MC, 2009, J APPL PSYCHOL, V94, P1427, DOI 10.1037/a0017154; Andrews MC, 2001, J ORGAN BEHAV, V22, P347, DOI 10.1002/job.92; Ewen C, 2013, LEADERSHIP QUART, V24, P516, DOI 10.1016/j.leaqua.2013.03.006; DeRue DS, 2011, PERS PSYCHOL, V64, P7, DOI 10.1111/j.1744-6570.2010.01201.x; Treadway DC, 2005, J ORGAN BEHAV, V26, P229, DOI 10.1002/job.310; Blickle G, 2010, J VOCAT BEHAV, V76, P326, DOI 10.1016/j.jvb.2009.10.005; FERRIS GR, 1991, J MANAGE, V17, P447, DOI 10.1177/014920639101700208; Lind EA, 2002, RES ORGAN BEHAV, V24, P181, DOI 10.1016/S0191-3085(02)24006-X; Harvey P, 2007, J OCCUP HEALTH PSYCH, V12, P105, DOI 10.1037/1076-8998.12.2.105; Hogan R, 1998, HUM PERFORM, V11, P129, DOI 10.1207/s15327043hup1102&3_2; Fang RL, 2011, J MANAGE, V37, P127, DOI 10.1177/0149206310384630; Wolff HG, 2009, J APPL PSYCHOL, V94, P196, DOI 10.1037/a0013350; Douglas C, 2004, LEADERSHIP QUART, V15, P537, DOI 10.1016/j.leaqua.2004.05.006; Jawahar IM, 2008, HUM PERFORM, V21, P138, DOI 10.1080/08959280801917685; Vigoda-Gadot E, 2010, PUBLIC ADMIN REV, V70, P72; Fugate M, 2004, J VOCAT BEHAV, V65, P14, DOI 10.1016/j.jvb.2003.10.005; Harris KJ, 2010, J SOC PSYCHOL, V150, P608, DOI 10.1080/00224540903365489; Treadway DC, 2013, J MANAGE PSYCHOL, V28, P273, DOI 10.1108/02683941311321169; Zhao HD, 2013, INT J HOSP MANAG, V33, P219, DOI 10.1016/j.ijhm.2012.08.006; Ferris GR, 2008, J MANAGE PSYCHOL, V23, P744, DOI 10.1108/02683940810896321; Hochwarter WA, 2007, ORGAN BEHAV HUM DEC, V102, P226, DOI 10.1016/j.obhdp.2006.09.003; Ferris GR, 2009, J MANAGE PSYCHOL, V24, P584, DOI 10.1108/02683940910989002; Scott BA, 2012, ACAD MANAGE J, V55, P905, DOI 10.5465/amj.2010.1050; Gangestad SW, 2000, PSYCHOL BULL, V126, P530, DOI 10.1037//0033-2909.126.4.530; Inkson K, 2004, J VOCAT BEHAV, V65, P96, DOI 10.1016/S0001-8791(03)00053-8; Zellars KL, 2008, J ORGAN BEHAV, V29, P549, DOI 10.1002/job.484; House RJ, 1997, J MANAGE, V23, P409, DOI 10.1177/014920639702300306; Meurs JA, 2010, J VOCAT BEHAV, V76, P520, DOI 10.1016/j.jvb.2010.01.005; Perrewe PL, 2004, ACAD MANAGE J, V47, P141; Kacmar KM, 2013, J BUS ETHICS, V115, P33, DOI 10.1007/s10551-012-1373-8; Laird MD, 2012, CAREER DEV INT, V17, P557, DOI 10.1108/13620431211280132; Blickle G, 2012, APPL PSYCHOL-INT REV, V61, P295, DOI 10.1111/j.1464-0597.2011.00469.x; Hobfoll SE, 2002, REV GEN PSYCHOL, V6, P307, DOI 10.1037//1089-2680.6.4.307; GANDZ J, 1980, ACAD MANAGE J, V23, P237, DOI 10.2307/255429; PFEFFER J, 1974, ADMIN SCI QUART, V19, P135, DOI 10.2307/2393885; Ferris GR, 2000, ORGAN DYN, V28, P25, DOI 10.1016/S0090-2616(00)00007-3; Ferris GR, 2005, J MANAGE, V31, P126, DOI 10.1177/0149206304271386; Rosen CC, 2013, HUM PERFORM, V26, P44, DOI 10.1080/08959285.2012.736901; Harvey M, 2004, INT J HUM RESOUR MAN, V15, P1173, DOI 10.1080/0958519042000238392; Ferris GR, 2007, J MANAGE, V33, P290, DOI 10.1177/0149206307300813; Ammeter AP, 2002, LEADERSHIP QUART, V13, P751, DOI 10.1016/S1048-9843(02)00157-1; Kolodinsky RW, 2007, HUM RELAT, V60, P1747, DOI 10.1177/0018726707084913; BANDURA A, 1982, J PERS SOC PSYCHOL, V43, P5, DOI 10.1037/0022-3514.43.1.5; Perrewe PL, 2005, J OCCUP HEALTH PSYCH, V10, P239, DOI 10.1037/1076-8998.10.3.239; Liu YM, 2007, J VOCAT BEHAV, V71, P146, DOI 10.1016/j.jvb.2007.04.003; Treadway DC, 2007, J APPL PSYCHOL, V92, P848, DOI 10.1037/0021-9010.92.3.848; Blickle G, 2009, J VOCAT BEHAV, V74, P94, DOI 10.1016/j.jvb.2008.10.008; Murphy KR, 2005, HUM PERFORM, V18, P343, DOI 10.1207/s15327043hup1804_2; Blickle G, 2008, J VOCAT BEHAV, V72, P377, DOI 10.1016/j.jvb.2007.11.008; Ahearn KK, 2004, J MANAGE, V30, P309, DOI 10.1016/j.jm.2003.01.004; Blickle G, 2011, INT J SELECT ASSESS, V19, P98, DOI 10.1111/j.1468-2389.2010.00537.x; DAVISBLAKE A, 1989, ACAD MANAGE REV, V14, P385, DOI 10.5465/AMR.1989.4279071; Turnley WH, 2001, J APPL PSYCHOL, V86, P351, DOI 10.1037/0021-9010.86.2.351; Davis WD, 2004, LEADERSHIP QUART, V15, P439, DOI 10.1016/j.leaqua.2004.05.002; Ferris GR, 2002, RES PERS H, V21, P65; Huang L, 2013, J APPL PSYCHOL, V98, P1005, DOI 10.1037/a0034125; Blass FR, 2007, HUM RESOURCE MANAGE, V46, P5, DOI 10.1002/hrm.20142; Seibert SE, 2001, ACAD MANAGE J, V44, P219, DOI 10.2307/3069452; Semadar A, 2006, J ORGAN BEHAV, V27, P443, DOI 10.1002/job.385; Schmitt N, 2004, HUM PERFORM, V17, P347, DOI 10.1207/s15327043hup1703_5; JUDGE TA, 1994, J MANAGE, V20, P43, DOI 10.1177/014920639402000103; Tocher N, 2012, ENTREP REGION DEV, V24, P283, DOI 10.1080/08985626.2010.535856; Hogan R, 2013, IND ORGAN PSYCHOL-US, V6, P3, DOI 10.1111/iops.12001; Blickle G, 2011, APPL PSYCHOL-INT REV, V60, P449, DOI 10.1111/j.1464-0597.2011.00443.x; Brouer RL, 2009, LEADERSHIP QUART, V20, P61, DOI 10.1016/j.leaqua.2009.01.015; Vohs KD, 2005, J PERS SOC PSYCHOL, V88, P632, DOI 10.1037/0022-3514.88.4.632; Ng TWH, 2005, PERS PSYCHOL, V58, P367, DOI 10.1111/j.1744-6570.2005.00515.x; Meyer RD, 2010, J MANAGE, V36, P121, DOI 10.1177/0149206309349309; Wu LZ, 2012, J MANAGE STUD, V49, P178, DOI 10.1111/j.1467-6486.2011.01017.x; Wayne SJ, 1997, PERS PSYCHOL, V50, P979, DOI 10.1111/j.1744-6570.1997.tb01491.x; Shi JQ, 2011, J BUS PSYCHOL, V26, P359, DOI 10.1007/s10869-010-9195-0; Moeller M, 2011, INT J HUM RESOUR MAN, V22, P2593, DOI 10.1080/09585192.2011.588035; CHAO GT, 1994, J APPL PSYCHOL, V79, P730, DOI 10.1037//0021-9010.79.5.730; Davey KM, 2008, GENDER WORK ORGAN, V15, P650, DOI 10.1111/j.1468-0432.2008.00420.x; Goulding A, 2012, AUST LIBR J, V61, P105; Whitaker BG, 2013, HUM PERFORM, V26, P353, DOI 10.1080/08959285.2013.836198; Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373; BANDURA A, 1991, ORGAN BEHAV HUM DEC, V50, P248, DOI 10.1016/0749-5978(91)90022-L; Treadway DC, 2004, LEADERSHIP QUART, V15, P493, DOI 10.1016/j.leaqua.2004.05.004; Muraven M, 1999, J SOC PSYCHOL, V139, P446; HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Blickle G, 2011, J APPL SOC PSYCHOL, V41, P3026, DOI 10.1111/j.1559-1816.2011.00862.x; Seibert SE, 1999, J APPL PSYCHOL, V84, P416, DOI 10.1037//0021-9010.84.3.416; JUDGE TA, 1995, PERS PSYCHOL, V48, P485, DOI 10.1111/j.1744-6570.1995.tb01767.x; Johns G, 2006, ACAD MANAGE REV, V31, P386; Ashton MC, 2005, J PERS, V73, P1321, DOI 10.1111/j.1467-6494.2005.00351.x; Bing MN, 2011, J VOCAT BEHAV, V79, P563, DOI 10.1016/j.jvb.2011.02.006; Blau P. M., 1964, EXCHANGE POWER SOCIA; Blickle G, 2013, GROUP ORGAN MANAGE, V38, P601, DOI 10.1177/1059601113503183; Blickle G, 2011, J APPL SOC PSYCHOL, V41, P488, DOI 10.1111/j.1559-1816.2010.00723.x; Blickle G, 2009, CAREER DEV INT, V14, P333, DOI 10.1108/13620430910979835; Blickle G, 2012, EUR J WORK ORGAN PSY, V21, P899, DOI 10.1080/1359432X.2011.603900; Blickle G, 2013, J ORGAN BEHAV, V34, P1145, DOI 10.1002/job.1843; Blickle G, 2010, INT J SELECT ASSESS, V18, P155; Breland J, 2007, J LEADERSHIP ORG STU, V13, P1, DOI DOI 10.1177/10717919070130030101; Brouer RL, 2013, J LEADERSH ORG STUD, V20, P185, DOI 10.1177/1548051812460099; Brouer RL, 2011, J ORGAN BEHAV, V32, P869, DOI 10.1002/job.718; Burt RS, 1997, ADMIN SCI QUART, V42, P339, DOI 10.2307/2393923; Butcher D, 2006, ELGAR ORIG REF, P286; CARSTENSEN LL, 1995, CURR DIR PSYCHOL SCI, V4, P151, DOI 10.1111/1467-8721.ep11512261; Chaudhry N. I., 2012, INT J BUSINESS MANAG, V7, P120; Chen YY, 2008, J BUS ETHICS, V79, P263, DOI 10.1007/s10551-007-9379-3; Chopin S. M., 2012, J LEADERSHIP STUDIES, V6, P17; Dhiman M. C., 2012, Anatolia, V23, P359, DOI 10.1080/13032917.2012.711249; Doldor E, 2013, BRIT J MANAGE, V24, P414, DOI 10.1111/j.1467-8551.2012.00812.x; EISENHARDT KM, 1992, STRATEGIC MANAGE J, V13, P17, DOI 10.1002/smj.4250130904; Ferris G. R., 1999, 59 ANN M AC MAN CHIC; Ferris G. R., 2005, POLITICAL SKILL WORK; Ferris G. R., 1989, IMPRESSION MANAGEMEN, P143; Ferris G. R., 2012, POLITICS ORG THEORY, P487; Ferris G. R., 2002, J LEADERSHIP ORG STU, V9, P49, DOI [10.1177/107179190200900104, DOI 10.1177/107179190200900104]; Ferris GR, 2002, RES MAN EDU, P3; GABRENYA WK, 1980, PERS SOC PSYCHOL B, V6, P13, DOI 10.1177/014616728061002; Gallagher VC, 2008, J APPL SOC PSYCHOL, V38, P2336, DOI 10.1111/j.1559-1816.2008.00394.x; Gentry WA, 2012, J ORGAN BEHAV, V33, P89, DOI 10.1002/job.740; Gunn J, 2006, ELGAR ORIG REF, P209; Harris K. J., 2009, J SOC PSYCHOL, V149, P179, DOI [10.3200/SOCP.149.3.279-304, DOI 10.3200/SOCP.149.3.279-304]; Harris KJ, 2009, J APPL SOC PSYCHOL, V39, P2373; Harris KJ, 2007, J APPL PSYCHOL, V92, P278, DOI 10.1037/0021-9010.92.1.278; Hochwarter W., 2012, POLITICS ORG THEORY, P27; Hochwarter W. A., 2010, J APPL PSYCHOL, V92, P567; Holland J. L., 1973, MAKING VOCATIONAL CH; Hope O., 2010, J CHANGE MANAGEMENT, V10, P195; Jawahar I. M., 2007, INT J STRESS MANAGE, V14, P142, DOI DOI 10.1037/1072-5245.14.2.142; Kapoutsis I, 2011, J VOCAT BEHAV, V78, P123, DOI 10.1016/j.jvb.2010.09.009; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; Kimura T, 2013, J BUS ETHICS, V116, P587, DOI 10.1007/s10551-012-1497-x; Kurchner-Hawkins R, 2006, ELGAR ORIG REF, P328; LAZARUS RS, 1991, AM PSYCHOL, V46, P819, DOI 10.1037//0003-066X.46.8.819; Liu YM, 2010, J MANAGE, V36, P1432, DOI 10.1177/0149206309359810; Lvina E., 2012, INT J CROSS CULTURAL, V12, P171; Madison L., 1980, HUM RELAT, V33, P79; Mainiero L. A, 1994, ORGAN DYN, V22, P4; March James, 1986, AMBIGUITY COMMAND OR, P11; MARCH JG, 1962, J POLIT, V24, P662; Meurs JA, 2011, HUM PERFORM, V24, P119, DOI 10.1080/08959285.2011.554469; Mintzberg H., 1983, POWER ORG; Mischel W., 1968, PERSONALITY ASSESSME; Momm T, 2010, PERS INDIV DIFFER, V49, P396, DOI 10.1016/j.paid.2010.04.006; Momm T, 2013, J APPL SOC PSYCHOL, V43, P2307, DOI 10.1111/jasp.12180; Moss JA, 2010, J BEHAV APPL MANAGEM, V11, P155; Munyon TP, 2015, PERS PSYCHOL, V68, P143, DOI 10.1111/peps.12066; Peled A, 2000, LEADERSHIP ORG DEV J, V21, P20, DOI 10.1108/01437730010310703; Perrewe PL, 2000, ACAD MANAGE EXEC, V14, P115; Pfeffer J, 1981, POWER ORG; Pfeffer J, 2010, HARVARD BUS REV, V88, P84; Phipps S. T. A., 2012, ACAD ENTREPRENEURSHI, V18, P77; Prieto L. C., 2010, ACAD ENTREPRENEURSHI, V16, P107; Randel AE, 2011, J SOC PSYCHOL, V151, P395; Salovey Peter, 1990, IMAGINATION COGNITIO, V9, P185, DOI DOI 10.2190/DUGG-P24E-52WK-6CDG; Shaughnessy BA, 2011, J MANAGE PSYCHOL, V26, P584, DOI 10.1108/02683941111164490; Shi JQ, 2012, PSYCHOL REP, V110, P233, DOI 10.2466/03.08.17.PR0.110.1.233-246; Shi JQ, 2013, J APPL PSYCHOL, V98, P374, DOI 10.1037/a0031129; Smith AD, 2009, J OPER MANAG, V27, P428, DOI 10.1016/j.jom.2009.01.003; SNYDER M, 1974, J PERS SOC PSYCHOL, V30, P526, DOI 10.1037/h0037039; Spence A. M., 1974, MARKET SIGNALING INF; Sunindijo R., 2012, CIV ENG DIMEN, V14, P182; Treadway DC, 2010, SOC NETWORKS, V32, P138, DOI 10.1016/j.socnet.2009.09.004; Treadway DC, 2013, J MANAGE, V39, P1529, DOI 10.1177/0149206311410887; Vroom V.H, 1964, WORK MOTIVATION; Wei LQ, 2012, J MANAGE STUD, V49, P381, DOI 10.1111/j.1467-6486.2010.00987.x; Wei LQ, 2010, J MANAGE STUD, V47, P437, DOI 10.1111/j.1467-6486.2009.00871.x; Westbrook Thomas S., 2013, Journal of Leadership Studies, V7, DOI 10.1002/jls.21275; Whitman MV, 2013, HEALTH CARE MANAGE R, V38, P248, DOI 10.1097/HMR.0b013e3182678fe7; Zettler I, 2015, APPL PSYCHOL-INT REV, V64, P541, DOI 10.1111/apps.12018; Zinko R, 2013, J APPL SOC PSYCHOL, V43, P1750, DOI 10.1111/jasp.12114	167	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1460-8545	1468-2370		INT J MANAG REV	Int. J. Manag. Rev.	JUL	2015	17	3					312	332		10.1111/ijmr.12041		21	Business; Management	Business & Economics	CM6WS	WOS:000357832700002		
J	Nagai, M; Miura, N; Shiratori, M				Nagai, M.; Miura, N.; Shiratori, M.			Stress intensity factor solution for a surface crack with high aspect ratio subjected to an arbitrary stress distribution using the influence function method	INTERNATIONAL JOURNAL OF PRESSURE VESSELS AND PIPING			English	Article						Stress intensity factor; Influence function method; High aspect ratio; Stress corrosion cracking; Crack growth analysis		In nuclear power plants, a number of cracks attributed to stress corrosion cracking (SCC) have been detected in welds made with nickel alloy weld metals. One of characteristics of these cracks is that the crack depth is greater than one half of the crack length. When a crack is detected in a component of a nuclear power plant during an in-service inspection, a flaw evaluation is conducted according to the requirement of fitness-for-service codes such as the JSME Rules on Fitness-for-Service for Nuclear Power Plants and the ASME Boiler and Pressure Vessel Code. Here, the stress intensity factor plays an important role for predicting crack growth behavior due to fatigue and/or SCC. Although several solutions of the stress intensity factor are already given in the codes, no solutions are available for the cracks having an aspect ratio greater than unity. Surface cracks with an aspect ratio greater than unity are characterized as semicircular. To evaluate these cracks in a rational manner, we developed a database of influence coefficients by means of the influence function method in conjunction with the finite element method. By using these influence coefficients, a solution for the stress intensity factor was developed for a semi-elliptical surface crack with high-aspect-ratio up to 8.0 subjected to a fifth-order-polynomial stress distribution. (C) 2015 Elsevier Ltd. All rights reserved.	[Nagai, M.; Miura, N.] Cent Res Inst Elect Power Ind, Mat Sci Res Lab, Yokosuka, Kanagawa 2400196, Japan; [Shiratori, M.] Yokohama Natl Univ, Ctr Risk Management & Safety Sci, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan	Nagai, M (reprint author), Cent Res Inst Elect Power Ind, Mat Sci Res Lab, 2-6-1 Nagasaka, Yokosuka, Kanagawa 2400196, Japan.	nagai@criepi.denken.or.jp					BENTHEM JP, 1977, INT J SOLIDS STRUCT, V13, P479, DOI 10.1016/0020-7683(77)90042-7; Aoki T., 2006, MAINTENOLOGY, V5, P46; Barsoum SR, 1976, INT J NUMERICAL METH, V10, P25; Irwin GR, 1962, T ASME E, V29, P651; Iwamatsu F, 2013, PVP201397465, P1; [李永全 Li Yongquan], 2012, [海洋湖沼通报, Transactions of Oceanology and Limnology], P1; Malekian C, 2009, PVP200977917, P1; Nakamura T, 2009, P 13 INT C MIN SYST, P1; Raju I. S., 1984, 85793 NASA, P85793; Scott P, 2010, DEV PRO LOCA PROBABI, P46; Shah R. C., 1971, Engineering Fracture Mechanics, V3, DOI 10.1016/0013-7944(71)90052-X; Shiratori M., 1986, Bulletin of the Faculty of Engineering, Yokohama National University, V35; Shiratori M, 2011, P IEEE INF TECHN MUL, P1; The Japan Society of Mechanical Engineers, 2012, SNA12012 JSME	14	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0308-0161	1879-3541		INT J PRES VES PIP	Int. J. Pressure Vessels Pip.	JUL	2015	131						2	9		10.1016/j.ijpvp.2015.04.003		8	Engineering, Multidisciplinary; Engineering, Mechanical	Engineering	CL8OW	WOS:000357235000002		
J	Ogawa, T; Itatani, M; Narazaki, C; Saito, T				Ogawa, Takuya; Itatani, Masao; Narazaki, Chihiro; Saito, Toshiyuki			Fracture behavior evaluations for ferritic steel piping with circumferential double flaws on the inner surface	INTERNATIONAL JOURNAL OF PRESSURE VESSELS AND PIPING			English	Article						Fracture assessment; Ferritic steel piping; Multiple flaws; Plastic collapse; Elastic-plastic fracture		Methods for assessing the structural integrity of nuclear components having some flaws are provided in the Rules on Fitness-for-Service for Nuclear Power Plants of the JSME code (JSME FFS code). Although the JSME FFS code provides such methods for piping with a single flaw, it does not describe any method for fracture assessment of piping with multiple flaws including flaw coalescence criteria. Some investigations on the fracture behavior of mainly austenitic stainless steel piping with multiple flaws, whose fracture mode is plastic collapse, have recently been reported and fracture assessment methods have been proposed. In the present study, fracture tests and analyses of carbon steel piping with a single and two circumferential flaw(s) on the inner surface were conducted to investigate a method for fracture assessment of ferritic steel piping with multiple flaws. It was found that fracture assessment based on the twice elastic slope method and the plastic collapse mechanism gave inadequate results for a large single flaw. Including this case, two kinds of elastic plastic fracture assessment method, one using the Z-factor in the JSME FFS code and the other by ductile instability analysis, gave conservative estimates of fracture strength even when the structural factor SF was not considered (i.e. SF = 1). (C) 2015 Elsevier Ltd. All rights reserved.	[Ogawa, Takuya; Itatani, Masao; Narazaki, Chihiro; Saito, Toshiyuki] Toshiba Corp Power Syst Co, Power & Ind Syst Res & Dev Ctr, Isogo Ku, Yokohama, Kanagawa 2358523, Japan	Ogawa, T (reprint author), Toshiba Corp Power Syst Co, Power & Ind Syst Res & Dev Ctr, Isogo Ku, 8 Shinsugita Cho, Yokohama, Kanagawa 2358523, Japan.	takuya4.ogawa@toshiba.co.jp					Asada S., 2011, T JAPAN SOC MECH E A, V77, P1135; ASTM International, 2006, E1820006 ASTM; Hamanaka T, 2011, P ASME 2011 PRESS VE; Hasegawa K, 2010, P ASME 2010 PRESS VE; Hasegawa K, 2007, P ASME 2007 PRESS VE; Hasegawa K, 2009, P ASME 2009 PRESS VE; Hasegawa K, 2004, PVP20042712, V480; Hasegawa K, 2011, P ASME 2001 PRESS VE; Itatani M, 2009, P ASME 2009 PRESS VE; Iwamatsu F, 2011, P ASME PRESS VESS PI; Li Y., 2009, T JSME A, V75, P56; Machida H, 2008, P 2008 ASME PRESS VE; Machida H, 2011, P ASME 2011 PRESS VE; Miyazaki K, 2009, P ASME 2009 PRESS VE; Miyazaki K, 2011, P ASME 2011 PRESS VE; Narazaki C, 2010, P ASME 2010 PRESS VE; Tamako H, 2007, T JSME A, V73, P544; The Japan Society of Mechanical Engineers, 2012, SNA12012 JSME; Zahoor A, 1989, DUCTILE FRACT HDB, V1	19	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0308-0161	1879-3541		INT J PRES VES PIP	Int. J. Pressure Vessels Pip.	JUL	2015	131						15	21		10.1016/j.ijpvp.2015.04.005		7	Engineering, Multidisciplinary; Engineering, Mechanical	Engineering	CL8OW	WOS:000357235000004		
J	Kamaya, M				Kamaya, Masayuki			Elastic-plastic failure assessment of cold worked stainless steel pipes	INTERNATIONAL JOURNAL OF PRESSURE VESSELS AND PIPING			English	Article						Cold working; Stainless steel; Two-parameter method; J-integral; Fracture toughness; Stress-strain curve	SEMIELLIPTIC SURFACE CRACKS; STRESS-STRAIN CURVES; FRACTURE-TOUGHNESS; IRRADIATION; PRESTRAIN	The change in fracture strength due to cold working was investigated for cracked stainless steel pipes. The cold working was introduced into Type 316 stainless steel plates. Then, material properties were identified in order to make elastic plastic fracture assessments for a pipe with a circumferential crack under bending load. The two-parameter method was employed for deriving fracture strength considering the change in the flow stress (yield and ultimate strengths), fracture toughness and stress strain curve caused by the cold working. It was found that the fracture strength was not reduced even if 40% cold working was introduced, while the failure mode was altered from the plastic collapse mode to the elastic plastic failure mode. Although cold working decreased the fracture toughness, the change in the stress strain curve reduced the driving force for fracture (J-integral) and increased the fracture strength. It was shown that the failure assessment curve of cold worked material can be derived using the yield and ultimate strengths of the material that is free of cold working. (C) 2015 Elsevier Ltd. All rights reserved.	Inst Nucl Safety Syst Inc, Mihama, Fukui 9191205, Japan	Kamaya, M (reprint author), Inst Nucl Safety Syst Inc, 64 Sata, Mihama, Fukui 9191205, Japan.	kamaya@inss.co.jp					[Anonymous], 2010, ASME BOIL PRESS VESS; [Anonymous], 2012, COD NUCL POW GEN FAC; Byun TS, 2004, ACTA MATER, V52, P1597, DOI 10.1016/j.actamat.2003.12.023; Jitsukawa S, 1996, J NUCL MATER, V233, P152, DOI 10.1016/S0022-3115(96)00204-8; Kamaya M, 2011, MECH MATER, V43, P243, DOI 10.1016/j.mechmat.2011.02.007; Lei Y, 2004, INT J PRES VES PIP, V81, P43, DOI 10.1016/j.ijpvp.2003.12.002; Kamaya M, 2014, ENG FRACT MECH, V127, P194, DOI 10.1016/j.engfracmech.2014.06.008; JITSUKAWA S, 1992, J NUCL MATER, V191, P790, DOI 10.1016/0022-3115(92)90580-E; Kim YJ, 2004, ENG FRACT MECH, V71, P925, DOI 10.1016/S0013-7944(03)00159-0; HISHINUMA A, 1989, J NUCL MATER, V169, P241, DOI 10.1016/0022-3115(89)90540-0; CHIPPERFIELD CG, 1976, INT J FRACTURE, V12, P873; Kamaya M, 2014, ENG FRACT MECH, V127, P31, DOI 10.1016/j.engfracmech.2014.05.005; [Anonymous], 2008, E182008 ASTM; Kamaya M, 2014, J NUCL MATER, V451, P264, DOI 10.1016/j.jnucmat.2014.04.006; Asada S., 2011, T JAPAN SOC MECH E A, V77, P1135; Banks-Sills L, 1997, ENG FRACT MECH, V57, P67, DOI 10.1016/S0013-7944(96)00134-8; Bar-on I, 1989, ASTM STP, V995, P244; British Energy Generation Ltd, 2007, R6 REV 4 ASS INT STR; Clayton J. Q., 1976, Metal Science, V10; Electric Power Research Institute, 1989, NP6301 EPRI; Kamaya M, 2010, T JPN SOC MECH ENG A, V76, P205; Kamaya Masayuki, 2012, Journal of Solid Mechanics and Materials Engineering, V6, DOI 10.1299/jmmp.6.871; Kamaya M, 2009, J SOLID MECH MAT ENG, V3, P1115; Kamaya Masayuki, 2008, Journal of Pressure Vessel Technology, V130, DOI 10.1115/1.2826424; Kamaya M, 2010, INT J PRES VES PIP, V87, P66, DOI 10.1016/j.ijpvp.2009.11.002; Kamaya M, J NUCL MAT UNPUB; Kim YJ, 2002, INT J FRACTURE, V116, P347, DOI 10.1023/A:1020779611803; LIAW PK, 1986, METALL TRANS A, V17, P473, DOI 10.1007/BF02643954; Miyata T, 1997, AM SOC TEST MATER, V1321, P167, DOI 10.1520/STP12307S; Rao AS, 2014, NUCL ENG DES, V269, P78, DOI 10.1016/j.nucengdes.2013.08.010; Sivaprasad S, 2000, MAT SCI ENG A-STRUCT, V284, P195, DOI 10.1016/S0921-5093(00)00739-5; YAGAWA G, 1993, INT J PRES VES PIP, V53, P457, DOI 10.1016/0308-0161(93)90073-3	32	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0308-0161	1879-3541		INT J PRES VES PIP	Int. J. Pressure Vessels Pip.	JUL	2015	131						45	51		10.1016/j.ijpvp.2015.04.008		7	Engineering, Multidisciplinary; Engineering, Mechanical	Engineering	CL8OW	WOS:000357235000007		
J	Udagawa, M; Katsuyama, J; Onizawa, K; Li, YS				Udagawa, Makoto; Katsuyama, Jinya; Onizawa, Kunio; Li, Yinsheng			Failure probability analyses for PWSCC in Ni-based alloy welds	INTERNATIONAL JOURNAL OF PRESSURE VESSELS AND PIPING			English	Article						Probabilistic fracture mechanics; Primary water stress corrosion cracking; PASCAL-NP; Dissimilar metal welds; Failure probability	STRESS INTENSITY FACTORS; SURFACE CRACKS	A number of cracks due to primary water stress corrosion cracking (PWSCC) in pressurized water reactors and Ni-based alloy stress corrosion cracking (NiSCC) in boiling water reactors have been detected around Ni-based alloy welds. The causes of crack initiation and growth due to stress corrosion cracking include weld residual stress, operating stress, the materials, and the environment. We have developed the analysis code PASCAL-NP for calculating the failure probability and assessment of the structural integrity of cracked components on the basis of probabilistic fracture mechanics (PFM) considering PWSCC and NiSCC. This PFM analysis code has functions for calculating the incubation time of PWSCC and NiSCC crack initiation, evaluation of crack growth behavior considering certain crack location and orientation patterns, and evaluation of failure behavior near Ni-based alloy welds due to PWSCC and NiSCC in a probabilistic manner. Herein, actual plants affected by PWSCC have been analyzed using PASCAL-NP. Failure probabilities calculated by PASCAL-NP are in reasonable agreement with the detection data. Furthermore, useful knowledge related to leakage due to PWSCC was obtained through parametric studies using this code. (C) 2015 Elsevier Ltd. All rights reserved.	[Udagawa, Makoto; Katsuyama, Jinya; Onizawa, Kunio; Li, Yinsheng] Japan Atom Energy Agcy, Tokai, Ibaraki 3191195, Japan	Udagawa, M (reprint author), Japan Atom Energy Agcy, Tokai, Ibaraki 3191195, Japan.	udagawa.makoto@jaea.go.jp					Agency for Natural Resources and Energy, 1999, CRACKS FOUND PER INS; American Petroleum Institute, 2007, 5791 API; Amzallag C, 2000, P 2000 ASME PRESS VE, P163; Bamford WH, 2002, P 10 INT C ENV DEGR; BERGMAN M, 1995, FATIGUE FRACT ENG M, V18, P1155, DOI 10.1111/j.1460-2695.1995.tb00845.x; Chapuliot S., 2000, CEAR5900; Cipolla R, 2004, P 2004 ASME PRESS VE; Couvant T, 2011, 15TH INTERNATIONAL CONFERENCE ON ENVIRONMENTAL DEGRADATION OF MATERIALS IN NUCLEAR POWER SYSTEMS-WATER REACTORS, P1141; FETT T, 1990, ENG FRACT MECH, V36, P647, DOI 10.1016/0013-7944(90)90120-6; Fukumura T, 2008, INSS J, V15, P113; Fyfitch S, 2002, P 10 INT C ENV DEGR; Hiser Jr AL, 2005, P C VESS PEN INSP CR, P253; International Atomic Energy Agency, 2011, IAEA NUCL EN SER, P25; Japanese Industrial Standards, 2008, G4903 JIS; Nuclear and Industrial Safety Agency, 2001, WAT LEAK PEN PORT CO; Nuclear and Industrial Safety Agency, 2004, REP KANS EL POW CO L; Nuclear and Industrial Safety Agency, 2008, FLAWS FOUND WELD POR; Ogawa K, 2008, P M M2008 MAT MECH C; Rempe J, 1993, NUREGCR5642; Rudland D, 2005, P C VESS PEN INSP CR, P161; Sanders J., 1983, ASME, V50, P221; Shiratori M., 1990, ANAL STRESS INTENSIT, P900; The Japan Society of Mechanical Engineers, 2012, SNA12012 JSME; Thomas S, 2004, P 12 INT C NUCL ENG; Totuka N, 2010, INSS J, V17, P344; Udagawa M, 2013, USERS MANUALS PROBAB; United States Nuclear Regulatory Commission, 2002, DAV BESS REACT VESS; United States Nuclear Regulatory Commission, 2001, NRC B; White G, 2005, P C VESS PEN INSP CR, P27; White G. A., 2005, P 12 INT C ENV DEGR, P511; White GA, 2003, P 11 INT C ENV DEGR, P166; Xu H., 2005, P 12 INT C ENV DEGR, P833; Zang W., 1997, SINTAPSAQ02	33	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0308-0161	1879-3541		INT J PRES VES PIP	Int. J. Pressure Vessels Pip.	JUL	2015	131						85	95		10.1016/j.ijpvp.2015.04.013		11	Engineering, Multidisciplinary; Engineering, Mechanical	Engineering	CL8OW	WOS:000357235000012		
J	Daiko, H; Fujita, T				Daiko, Hiroyuki; Fujita, Takeo			Laparoscopic assisted versus open gastric pull-up following thoracoscopic esophagectomy: A cohort study	INTERNATIONAL JOURNAL OF SURGERY			English	Article						Thoracoscopic surgery; Laparoscopic surgery; Esophageal cancer	MINIMALLY INVASIVE ESOPHAGECTOMY; IVOR-LEWIS ESOPHAGECTOMY; LYMPH-NODE DISSECTION; PERIOPERATIVE OUTCOMES; PRONE POSITION; CANCER; SURGERY; EXPERIENCE; CARCINOMA; ESOPHAGUS	Background: Thoracolaparoscopic esophagectomy (TLE) is a type of minimally invasive esophagectomy (MIE) for esophageal cancer which consists of thoracoscopic resection and laparoscopic reconstruction. The aim of the present study was to evaluate the technical and oncological feasibility of alimentary tract reconstruction with laparoscopically assisted gastric pull-up (LAG) following thoracoscopic esophagectomy in the prone position (TSEP) in comparison with reconstruction with open laparotomy gastric pull-up (OLG) following TSEP, to establish TLE with extended lymph node dissection as a standard operation for esophageal cancer. Methods: Sixty-four patients with esophageal cancer underwent TSEP with 3-field lymphadenectomy from 2008 through 2010: for reconstruction after TSEP, 31 patients underwent LAG, and 33 patients underwent OLG. We retrospectively evaluated the technical and oncological feasibility of TLE with 3-field lymphadenectomy and compared surgical outcomes after reconstruction with OLG and that with LAG. Results: TLE with 3-field lymphadenectomy was successfully completed in 30 of 31 (97%) patients, and no surgery-related postoperative deaths occurred. No significant difference was found between LAG and OLG in the mean number of dissected abdominal lymph nodes, amount of blood loss, incidence of postoperative complications, mean postoperative hospital stay, restoration rate of respiratory function, or rate of complete resection or locoregional control, but the mean duration of abdominal procedures was significantly longer with LAG than with OLG. Conclusion: This study demonstrates that the quality and safety of surgery and the oncological effectiveness of LAG for esophageal cancer. TLE consisting of LAG following TSEP with extended lymph-node dissection is a feasible surgical technique for thoracic esophageal carcinoma. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Limited.	[Daiko, Hiroyuki; Fujita, Takeo] Natl Canc Ctr Hosp East, Dept Surg, Kashiwa, Chiba 2778577, Japan	Daiko, H (reprint author), Natl Canc Ctr Hosp East, Dept Surg, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hdaikou@east.ncc.go.jp					Noshiro H, 2010, SURG ENDOSC, V24, P2965, DOI 10.1007/s00464-010-1072-4; Stage JG, 1997, BRIT J SURG, V84, P391, DOI 10.1002/bjs.1800840339; Mariette C, 2007, LANCET ONCOL, V8, P545, DOI 10.1016/S1470-2045(07)70172-9; Parameswaran R, 2009, WORLD J SURG, V33, P1868, DOI 10.1007/s00268-009-0116-1; Kinjo Y, 2012, SURG ENDOSC, V26, P381, DOI 10.1007/s00464-011-1883-y; Luketich JD, 2003, ANN SURG, V238, P486, DOI 10.1097/01.sla.0000089858.40725.68; Palanivelu C, 2006, J AM COLL SURGEONS, V203, P7, DOI 10.1016/j.jamcollsurg.2006.03.016; Sihag S, 2012, EUR J CARDIO-THORAC, V42, P430, DOI 10.1093/ejcts/ezs031; Tsujimoto H, 2012, SURGERY, V151, P667, DOI 10.1016/j.surg.2011.12.006; AKIYAMA H, 1994, ANN SURG, V220, P364, DOI 10.1097/00000658-199409000-00012; Smithers BM, 2007, ANN SURG, V245, P232, DOI 10.1097/01.sla.0000225093.58071.c6; Daiko H, 2012, SURG ENDOSC, V26, P673, DOI 10.1007/s00464-011-1934-4; Pham TH, 2010, AM J SURG, V199, P594, DOI 10.1016/j.amjsurg.2010.01.005; Orringer MB, 1999, ANN SURG, V230, P392, DOI 10.1097/00000658-199909000-00012; Zingg U, 2009, ANN THORAC SURG, V87, P911, DOI 10.1016/j.athoracsur.2008.11.060; Choileain NN, 2006, ARCH SURG-CHICAGO, V141, P1132; Cuschieri A, 1994, Endosc Surg Allied Technol, V2, P21; Fabian T, 2008, DIS ESOPHAGUS, V21, P220, DOI 10.1111/j.1442-2050.2007.00783.x; Kitano S, 2002, SURGERY, V131, pS306, DOI 10.1067/msy.2002.120115; Law S, 1997, SURGERY, V122, P8, DOI 10.1016/S0039-6060(97)90257-9; MCMAHON AJ, 1993, BRIT J SURG, V80, P1252, DOI 10.1002/bjs.1800801010; Nguyen NT, 2003, J AM COLL SURGEONS, V197, P902, DOI 10.1016/j.jamcollsurg.2003.07.005; Rindani R, 1999, AUST NZ J SURG, V69, P187, DOI 10.1046/j.1440-1622.1999.01520.x; Shiraishi T, 2006, ANN THORAC SURG, V81, P1083, DOI 10.1016/j.athoracsur.2005.08.057; Taguchi S, 2003, SURG ENDOSC, V17, P1445, DOI 10.1007/s00464-002-9232-9; Urschel JD, 1998, J INVEST SURG, V11, P245, DOI 10.3109/08941939809032198	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1743-9191	1743-9159		INT J SURG	Int. J. Surg.	JUL	2015	19						61	66		10.1016/j.ijsu.2015.04.040		6	Surgery	Surgery	CM0SV	WOS:000357389700013		
J	Takai, Y; Yamamoto-Mitani, N; Abe, Y; Suzuki, M				Takai, Yukari; Yamamoto-Mitani, Noriko; Abe, Yoshiki; Suzuki, Mizue			Literature review of pain management for people with chronic pain	JAPAN JOURNAL OF NURSING SCIENCE			English	Review						chronic pain; pain management; review; self-efficacy; self-management	RANDOMIZED CONTROLLED-TRIAL; LOW-BACK-PAIN; LONG-TERM-CARE; SELF-MANAGEMENT; OLDER-ADULTS; NURSING-HOMES; UNITED-STATES; PROGRAM; PREVALENCE; COMMUNITY	AimMultimodal approaches toward relieving pain, patients' participation, and improving self-efficacy are important for chronic pain management. The aims of this review were to identify possible options of nursing strategies for pain management in individuals with chronic pain and to determine the effectiveness of these strategies for pain relief/pain-related problems; therefore, nurses and researchers could consider and/or adopt multimodal chronic pain management strategies. MethodsA Systematic Integrated Literature Review was conducted. Published work related to pain management in individuals with chronic pain was identified by searching databases and reviewed. ResultsAmong the studies reviewed, we identified 35 studies that focused on pain management strategies. In 10 studies, interventions such as integrated and multidisciplinary pain management programs were associated with significant decreases in pain intensity. However, they reported that the long-term effectiveness of pain relief was not satisfactory. Individuals with chronic pain reported that strategies including pharmacotherapy, physical activity, social support from friends and family, acupuncture, heating, rest, diets, or life-style changes helped them to effectively manage their pain. ConclusionWe identified possible options of pain management strategies and explored effectiveness of chronic pain interventions. The long-term effects of pain relief interventions and social support for individuals with chronic pain require further investigation.	[Takai, Yukari; Yamamoto-Mitani, Noriko] Univ Tokyo, Grad Sch Med, Div Hlth Sci & Nursing, Dept Adult Nursing Palliat Care Nursing, Tokyo 1130033, Japan; [Abe, Yoshiki] Univ Tsukuba, Sch Nursing, Tsukuba, Ibaraki, Japan; [Suzuki, Mizue] Hamamatsu Univ Sch Med, Fac Nursing, Hamamatsu, Shizuoka 4313192, Japan	Takai, Y (reprint author), Univ Tokyo, Grad Sch Med, Div Hlth Sci & Nursing, Dept Adult Nursing Palliat Care Nursing,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	takaiyukari-tky@umin.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in Japan	This research was funded by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	AGS Panel on Persistent Pain in Older Persons, 2002, J AM GERIATRICS SOC, V50, P205; Achterberg WP, 2010, PAIN, V148, P70, DOI 10.1016/j.pain.2009.10.008; Johannes CB, 2010, J PAIN, V11, P1230, DOI [10.1016/j.jpain.2010.07.002, 10.1016/j.jpain.2010.08.002]; Takai Y, 2010, PAIN MANAG NURS, V11, P209, DOI 10.1016/j.pmn.2010.08.006; Courtenay M, 2008, J CLIN NURS, V17, P2001, DOI 10.1111/j.1365-2702.2008.02361.x; Haller G, 2011, PAIN MED, V12, P138, DOI 10.1111/j.1526-4637.2010.01020.x; Barrett ME, 2013, JAMA DERMATOL, V149, P300, DOI 10.1001/jamadermatol.2013.1560; Price CJ, 2007, ALTERN THER HEALTH M, V13, P32; Gillespie SM, 2007, J AM MED DIR ASSOC, V8, P307, DOI 10.1016/j.jamda.2007.04.006; West C, 2012, J CLIN NURS, V21, P1284, DOI 10.1111/j.1365-2702.2011.04005.x; Reid MC, 2008, PAIN MED, V9, P409, DOI 10.1111/j.1526-4637.2008.00428.x; Gudmannsdottir GD, 2009, SCAND J CARING SCI, V23, P317, DOI 10.1111/j.1471-6712.2008.00625.x; Wu SFV, 2011, J ADV NURS, V67, P1491, DOI 10.1111/j.1365-2648.2010.05603.x; Richardson C, 2006, J CLIN NURS, V15, P1196, DOI 10.1111/j.1365-2702.2006.01456.x; Castro-Sanchez AM, 2012, J PHYSIOTHER, V58, P89, DOI 10.1016/S1836-9553(12)70088-7; Yip YB, 2007, J ADV NURS, V59, P20, DOI 10.1111/j.1365-2648.2007.04292.x; McGillion MH, 2008, J PAIN SYMPTOM MANAG, V36, P126, DOI 10.1016/j.jpainsymman.2007.09.015; Finnerup NB, 2010, PAIN, V150, P573, DOI 10.1016/j.pain.2010.06.019; Austrian JS, 2005, J AM GERIATR SOC, V53, P856, DOI 10.1111/j.1532-5415.2005.53268.x; Sorensen J, 2008, EUR J PAIN, V12, P164, DOI 10.1016/j.ejpain.2007.04.004; Bourbonnais FF, 2012, NEPHROL NURS J, V39, P13; Burnham Robert, 2010, Can J Rural Med, V15, P7; Chen YL, 2010, PAIN MANAG NURS, V11, P159, DOI 10.1016/j.pmn.2009.05.005; Chiou AF, 2009, J CLIN NURS, V18, P2206, DOI 10.1111/j.1365-2702.2008.02759.x; Chung JWY, 2007, PAIN MED, V8, P235, DOI 10.1111/j.1526-4637.2006.00205.x; Crowe M, 2010, J ADV NURS, V66, P1478, DOI 10.1111/j.1365-2648.2010.05316.x; Davis GC, 2008, PAIN MANAG NURS, V9, P171, DOI 10.1016/j.pmn.2008.02.007; Dewar A, 2006, AUST J ADV NURS, V24, P33; Dysvik E, 2005, INT J NURS STUD, V42, P297, DOI 10.1016/j.ijnurstu.2004.06.009; Dysvik E, 2012, J ADV NURS, V68, P1061, DOI 10.1111/j.1365-2648.2011.05810.x; Elliott J, 2007, PAIN MANAG NURS, V8, P35, DOI 10.1016/j.pmn.2006.12.005; Goeppinger J, 2007, ARTHRIT RHEUM-ARTHR, V57, P1081, DOI 10.1002/art.22896; Hager KK, 2007, J GERONTOL NURS, V33, P14; Husebo BS, 2011, INT J GERIATR PSYCH, V26, P1012, DOI 10.1002/gps.2649; Im EO, 2012, J NURS EDUC, V51, P632, DOI 10.3928/01484834-20120914-02; Kawi J, 2014, PAIN MANAG NURS, V15, P258, DOI 10.1016/j.pmn.2012.09.003; Kristjansdottir B., 2011, BMC MUSCULOSKEL DIS, V12, P51; Kristjansdottir OB, 2013, J MED INTERNET RES, V15, P41, DOI 10.2196/jmir.2249; Larsen D., 2007, PAIN MANAGEMENT NURS; Lewandowski Wendy, 2007, Issues Ment Health Nurs, V28, P1019, DOI 10.1080/01612840701522200; Meghani SH, 2009, PUBLIC HEALTH NURS, V26, P307, DOI 10.1111/j.1525-1446.2009.00785.x; Menzies V, 2008, FAM COMMUNITY HEALTH, V31, P204, DOI 10.1097/01.FCH.0000324477.48083.08; Nakamura M, 2014, J ORTHOP SCI, V19, P339, DOI 10.1007/s00776-013-0525-8; Nes AAG, 2013, PATIENT EDUC COUNS, V93, P451, DOI 10.1016/j.pec.2013.01.022; Nunez DE, 2009, WORLDV EVID-BASED NU, V6, P130, DOI 10.1111/j.1741-6787.2009.00157.x; Oliver Susan, 2004, Nurs Stand, V18, P43; Oliver S., 2004, NURSING STANDARD, V18, P56; Oliver S., 2004, NURSING STANDARD, V18, P54; Onieva-Zafra María Dolores, 2013, Pain Manag Nurs, V14, pe39, DOI 10.1016/j.pmn.2010.09.004; Planton J, 2010, J GERONTOL NURS, V36, P49, DOI 10.3928/00989134-20100202-02; Du SZ, 2011, PATIENT EDUC COUNS, V85, pE299, DOI 10.1016/j.pec.2011.02.021; Ryan S, 2012, Musculoskeletal Care, V10, P196, DOI 10.1002/msc.1018; Sauro KM, 2008, CAN J NEUROL SCI, V35, P46; Shin SY, 2010, PAIN MANAG NURS, V11, P234, DOI 10.1016/j.pmn.2009.06.001; Smalbrugge Martin, 2007, BMC Geriatr, V7, P3, DOI 10.1186/1471-2318-7-3; Stinson J, 2013, CLIN J PAIN, V29, P600, DOI 10.1097/AJP.0b013e31826dce65; Traska TK, 2012, J CLIN NURS, V21, P626, DOI 10.1111/j.1365-2702.2010.03501.x; Tsai YF, 2010, J PAIN SYMPTOM MANAG, V40, P575, DOI 10.1016/j.jpainsymman.2010.02.013; Tsai YF, 2008, J CLIN NURS, V17, P2596, DOI 10.1111/j.1365-2702.2008.02306.x; Tse Mimi MY, 2013, PAIN MANAG NURS, V14, P10; West C, 2011, COLLEGIAN, V18, P3, DOI 10.1016/j.colegn.2010.08.004	61	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7932	1742-7924		JPN J NURS SCI	Jpn. J. Nurs. Sci.	JUL	2015	12	3					167	183		10.1111/jjns.12065		17	Nursing	Nursing	CL9YE	WOS:000357334200001		
J	Kamei, T; Kajii, F; Yamamoto, Y; Irie, Y; Kozakai, R; Sugimoto, T; Chigira, A; Niino, N				Kamei, Tomoko; Kajii, Fumiko; Yamamoto, Yuko; Irie, Yukako; Kozakai, Rumi; Sugimoto, Tomoko; Chigira, Ayako; Niino, Naoakira			Effectiveness of a home hazard modification program for reducing falls in urban community-dwelling older adults: A randomized controlled trial	JAPAN JOURNAL OF NURSING SCIENCE			English	Article						accidental falls; aged; home hazards; program evaluation; randomized controlled trial	MULTIFACTORIAL INTERVENTION; PREVENTION; PEOPLE; CIRCUMSTANCES; CONSEQUENCES	AimTo evaluate the potential improvement of fall prevention awareness and home modification behaviors and to decrease indoor falls by applying a home hazard modification program (HHMP) in community-dwelling older adults followed up to 1 year in this randomized controlled trial. MethodsThe present authors randomly assigned 130 older adults living in the Tokyo metropolitan region to either the HHMP intervention group (n=67) or the control group (n=63). Both groups received four, 2h fall prevention multifactorial programs including education regarding fall risk factors, food and nutrition, foot self-care, and exercise sessions. However, only the HHMP group received education and practice regarding home safety by using a model mock-up of a typical Japanese home. ResultsThe mean age of the HHMP group was 75.7 years and the control group 75.8. The HHMP group showed a 10.9% reduction in overall falls, and falls indoors showed an 11.7% reduction at 52 weeks. Those aged 75 years and over showed a significant reduction in both overall falls and indoor falls at 12 weeks. Fall prevention awareness and home modifications were significantly improved in the HHMP group. ConclusionHHMP has the potential to improve fall prevention awareness and home modification behaviors, and specifically decreased overall and indoor falls in 12 weeks in those aged 75 years and older in community-dwelling older adults.	[Kamei, Tomoko; Kajii, Fumiko; Yamamoto, Yuko; Chigira, Ayako] St Lukes Int Univ, Coll Nursing, Tokyo 1040044, Japan; [Niino, Naoakira] JF Oberlin Univ, Grad Sch, Fac Gerontol, Tokyo, Japan; [Irie, Yukako] Takasaki Univ Commerce, Jr Coll, Gunma, Japan; [Kozakai, Rumi] Hokusho Univ, Sch Lifelong Sport, Ebetsu, Hokkaido, Japan; [Sugimoto, Tomoko] Chiba Prefectural Univ Hlth Sci, Sch Nursing, Fac Hlth Care Sci, Chiba, Japan	Kamei, T (reprint author), St Lukes Int Univ, Gerontol Nursing, Chuo Ku, 10-1 Akashi Cho, Tokyo 1040044, Japan.	kamei@slcn.ac.jp			St. Luke's collaborative fund; TERUMO collaborative fund, Japan	The authors acknowledge the participants and program volunteers of the fall prevention classes at St. Luke's International University. The present authors would also like to thank Waka Itoi, RN, PHN, PhD, Lecturer of Teikyo University of Science School of Nursing; Takuya Kanamori, RN, MSN, Junior Assistant Professor of St. Luke's International University, College of Nursing; Reiko Watanabe, RN, MSN, Former Graduate School of Nursing, St. Luke's International University; and Hiroyuki Sugimori, MD, PhD, Professor of Daito University who contributed to the data collection. They would also like to give great thanks to Former Professor Sarah E. Porter, RN, MPH, PhD, at St. Luke's International University. This study was funded by the St. Luke's and TERUMO collaborative fund (2008-2011), Japan.	Kamel HK, 2001, J AM GERIATR SOC, V49, P179, DOI 10.1046/j.1532-5415.2001.49040.x; Berg WP, 1997, AGE AGEING, V26, P261, DOI 10.1093/ageing/26.4.261; LORD SR, 1994, J AM GERIATR SOC, V42, P1110; Day L, 2002, BRIT MED J, V325, P128, DOI 10.1136/bmj.325.7356.128; Rubenstein LZ, 2002, CLIN GERIATR MED, V18, P141, DOI 10.1016/S0749-0690(02)00002-2; Jensen J, 2002, ANN INTERN MED, V136, P733; Nikolaus T, 2003, J AM GERIATR SOC, V51, P300, DOI 10.1046/j.1532-5415.2003.51102.x; Costello E, 2008, J REHABIL RES DEV, V45, P1135, DOI 10.1682/JRRD.2007.10.0169; Gillespie LD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007146.pub3; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; Centers for Disease Control and Prevention, 2005, CHECK SAF HOM FALL P; Centers for Disease Control and Prevention, 2011, HOM RECR SAF; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397; Gibson MJ, 1990, IMPROVING HLTH OLDER; Grobbee D. E., 2011, CLIN EPIDEMIOLOGY PR; Japan Industrial Society of Bed Manufactures, 2013, DIFF RAT BEDS JAP; Kamei T., 2009, B ST LUKES COLL NURS, V35, P52; Kamei T., 2010, J JAPAN ACAD GERONTO, V14, P42; Leclerc BS, 2010, REV EPIDEMIOL SANTE, V58, P3, DOI 10.1016/j.respe.2009.10.008; Mahoney JE, 2007, J AM GERIATR SOC, V55, P489, DOI 10.1111/j.1532-5415.2007.01144.x; Ministry of Health Labor and Welfare, 2009, POL REP 2009; Newton R. A., 2006, ANN LONG TERM CARE C, V14, P28; Niino N, 2000, J Epidemiol, V10, pS90; NORTHRIDGE ME, 1995, AM J PUBLIC HEALTH, V85, P509, DOI 10.2105/AJPH.85.4.509; Pynoos J, 2010, CLIN GERIATR MED, V26, P633, DOI 10.1016/j.cger.2010.07.001; Schepens SL, 2011, AM J OCCUP THER, V65, P702, DOI 10.5014/ajot.2011.001180; Steinberg M, 2000, J EPIDEMIOL COMMUN H, V54, P227, DOI 10.1136/jech.54.3.227; Turner S., 2011, COCHRANE DB SYST REV, V11, P1; Yasumura S., 2009, JMAJ - Japan Medical Association Journal, V52, P231; YASUMURA S, 1994, AGE AGEING, V23, P323, DOI 10.1093/ageing/23.4.323	32	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7932	1742-7924		JPN J NURS SCI	Jpn. J. Nurs. Sci.	JUL	2015	12	3					184	197		10.1111/jjns.12059		14	Nursing	Nursing	CL9YE	WOS:000357334200002		
J	Oyama, Y; Fukahori, H; Miyashita, M; Narama, M; Kono, A; Atogami, F; Kashiwagi, M; Okaya, K; Takamizawa, E; Yoshizawa, T				Oyama, Yumiko; Fukahori, Hiroki; Miyashita, Mitsunori; Narama, Miho; Kono, Ayumi; Atogami, Fumi; Kashiwagi, Masayo; Okaya, Keiko; Takamizawa, Emiko; Yoshizawa, Toyoko			Cross-sectional online survey of research productivity in young Japanese nursing faculty	JAPAN JOURNAL OF NURSING SCIENCE			English	Article						nursing scholars; publication; research productivity; young researcher	PUBLICATION; SCHOLARSHIP; STRATEGIES; BARRIERS	AimTo investigate the factors affecting the research productivity of young nursing faculty in Japan. MethodsAn online survey targeting young nursing scholars (aged 39years) who were members of the Japan Academy of Nursing Science was conducted from October to November 2012. Of 1634 potential respondents, 648 completed the survey (39.7%), and 400 full-time faculty of a baccalaureate degree program were selected for the analysis. The numbers of English-language and Japanese publications in the past 3years were regressed onto personal characteristics, such as academic degree and type of university. ResultsThe mean numbers of publications in English and Japanese in the past 3years were 0.41 and 1.63, respectively. Holding a doctoral degree was significantly related to a higher number of publications in English and Japanese (e=5.78 and e=1.89, respectively). Working at a national university (e=2.15), having a research assistant (e=2.05), and the ability to read research articles in English (e=2.27) were significantly related to more English-language publications. Having the confidence to conduct quantitative research (e=1.67) was related to a larger number of Japanese publications. The lack of mentoring (e=0.97) and university workload (e=0.96) were associated with a lesser number of Japanese publications. ConclusionThe research productivity of young nursing faculty appeared to be quite low. Strategies to enhance research productivity in young nursing faculty, such as encouraging the achievement of a doctoral degree or enrichment of research resources, should be undertaken.	[Oyama, Yumiko; Fukahori, Hiroki] Tokyo Med & Dent Univ, Grad Sch Healthcare Sci, Dept Syst Management Nursing, Tokyo 1138510, Japan; [Okaya, Keiko] Tokyo Med Univ, Sch Med, Fac Med, Tokyo 1608402, Japan; [Miyashita, Mitsunori] Tohoku Univ, Grad Sch Med, Div Palliat Nursing, Hlth Sci, Sendai, Miyagi 980, Japan; [Atogami, Fumi; Yoshizawa, Toyoko] Tohoku Univ, Grad Sch Med, Womens Hlth Nursing, Sendai, Miyagi 980, Japan; [Narama, Miho] Nagoya Univ, Grad Sch Med, Dept Nursing, Nagoya, Aichi 4648601, Japan; [Kono, Ayumi] Osaka City Univ, Sch Nursing, Osaka 558, Japan; [Takamizawa, Emiko] Osaka Prefecture Univ, Sch Nursing, Osaka, Japan; [Kashiwagi, Masayo] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan	Fukahori, H (reprint author), Tokyo Med & Dent Univ, Grad Sch Healthcare Sci, Dept Syst Management Nursing, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	hfukahori.kanr@tmd.ac.jp					Altman DG, 1991, PRACTICAL STAT MED R; Anderson CA, 2002, NURS OUTLOOK, V50, P43, DOI 10.1067/mno.2002.123582; Chang CWD, 2013, JAMA OTOLARYNGOL, V139, P1285, DOI 10.1001/jamaoto.2013.5303; Keen A, 2007, NURS EDUC TODAY, V27, P382, DOI 10.1016/j.nedt.2006.05.019; Nagata S, 2012, NURS EDUC TODAY, V32, P361, DOI 10.1016/j.nedt.2011.05.019; Turale S, 2009, NURS HEALTH SCI, V11, P166, DOI 10.1111/j.1442-2018.2009.00447.x; Berlin LE, 2002, NURS OUTLOOK, V50, P50, DOI 10.1067/mno.2002.124270; Schreuder JAH, 2010, INT J NURS STUD, V47, P569, DOI 10.1016/j.ijnurstu.2009.10.002; Arimoto Azusa, 2012, Nurse Educ Today, V32, pe1, DOI 10.1016/j.nedt.2011.06.007; BARHYTE DY, 1993, NURS RES, V42, P179; Byrne MW, 2002, J NURS SCHOLARSHIP, V34, P391, DOI 10.1111/j.1547-5069.2002.00391.x; Doi Y., 2012, J SCH NURSING OSAKA, V18, P33; Jacelon CS, 2003, J PROF NURS, V19, P335, DOI 10.1016/S8755-7223(03)00131-5; Japan Academy of Nursing Science, 2013, REP SURV RES IMPL ST; Japan Association of Nursing Programs in Universities, 2013, LIST BACC PROGR NURS; Kataoka M., 2009, J NURSING INVESTIGAT, V7, P23; Kim S., 2003, J TOKYO ACAD HLTH SC, V5, P208; LIAHOAGBERG B, 1985, NURS RES, V34, P155; Maas ML, 2009, J NURS SCHOLARSHIP, V41, P411, DOI 10.1111/j.1547-5069.2009.01309.x; Ministry of Education Culture Sports Science and Technology, 2009, BAS DAT NURS; Ministry of Education of the People's Republic of China, 2001, SOS TERV JULK, P4; Phillips T. P., 1973, DISSERTATION ABSTR A, V34, p1377A; Roberts K, 1997, Aust J Adv Nurs, V14, P5; Roberts Kay Kathryn L, 2004, Contemp Nurse, V17, P282; Sanderson BK, 2012, NURS EDUC, V37, P206, DOI 10.1097/NNE.0b013e318262eae9; Stokes M.E., 2000, CATEGORICAL DATA ANA; Taylor Julie, 2005, Nurse Educ Pract, V5, P91, DOI 10.1016/j.nepr.2004.03.007; Turale S, 2010, J CLIN NURS, V19, P2601, DOI 10.1111/j.1365-2702.2009.03100.x; UCLA: Statistical Consulting Group, 2013, POISS REGR	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7932	1742-7924		JPN J NURS SCI	Jpn. J. Nurs. Sci.	JUL	2015	12	3					198	207		10.1111/jjns.12060		10	Nursing	Nursing	CL9YE	WOS:000357334200003		
J	Asazawa, K; Mori, A				Asazawa, Kyoko; Mori, Akiko			Development of a partnership causal model for couples undergoing fertility treatment	JAPAN JOURNAL OF NURSING SCIENCE			English	Article						couples; fertility; partnership; structural equation modeling	QUALITY-OF-LIFE; INFERTILE COUPLES; PSYCHOSOCIAL CHARACTERISTICS; WOMEN; MEN; FERTIQOL; STRESS	AimThe goals of this study were to develop a partnership causal model and verify the model's fitness for couples undergoing fertility treatment. MethodsA purposive sample of 1004 consenting participants (502 couples) undergoing fertility treatment was selected from five fertility clinics across Japan. A mailed self-administered questionnaire was used to collect data. The partnership causal model was examined with structural equation modeling. ResultsA total of 565 questionnaires were returned (56.3%) and the number of valid responses was 466 (46.4%). The factor medical professionals' support (nurses and physicians) influenced the couples' partnership (=0.16) and had a direct effect on the men's quality of life (QOL) and an indirect effect on the women's QOL (=0.20). Couples' partnership had a significant impact on couples' QOL (=0.20) and on satisfaction in their relationship with their partner (=0.48). The multi-population path analysis revealed that married couples influenced each other's perceptions of their partnership (men, =0.84; women, =0.88). Additionally, the spouse's partnership influenced both individual's QOL (men, =0.77; women, =0.77) and the satisfaction with the relationship (men, =0.46; women, =0.59). The participants' distress significantly and negatively affected the participants' QOL. ConclusionThe results revealed that for a couple undergoing fertility treatments, a strong partnership maintains their QOL, and this could decrease the couples' distress (particularly in women). Partnership was also related to the variability of medical professionals' support.	[Asazawa, Kyoko] Tokyo Healthcare Univ, Tokyo 1528558, Japan; [Mori, Akiko] St Lukes Int Univ, Tokyo, Japan	Asazawa, K (reprint author), Tokyo Healthcare Univ, Meguro Ku, 2-5-1 Higashigaoka, Tokyo 1528558, Japan.	k-asazawa@thcu.ac.jp			Policy-Based Medical Service Foundation	The present authors are grateful to the couples who participated in this research, as well as to the facility staff who allowed the authors to conduct the data collection and assisted them. Part of this study was presented at the 16th East Asian Forum of Nursing Scholars. The Policy-Based Medical Service Foundation provided a grant for this study; Professor Haruo Yanai of St Luke's College of Nursing, Tokyo, provided technical support in the statistical analysis, and Dr Sarah E. Porter of St Luke's College of Nursing, Tokyo, provided educational advice.	Akizuki Y., 2009, J JAPAN ACAD MIDWIFE, V23, P271; Chachamovich JR, 2010, J PSYCHOSOM OBST GYN, V31, P101, DOI 10.3109/0167482X.2010.481337; Matsubayashi H, 2004, GEN HOSP PSYCHIAT, V26, P398, DOI 10.1016/j.genhosppsych.2004.05.002; Peterson BD, 2011, FERTIL STERIL, V95, P1759, DOI 10.1016/j.fertnstert.2011.01.125; Lau JTF, 2008, J SEX MARITAL THER, V34, P248, DOI 10.1080/00926230701866117; Wischmann T, 2001, HUM REPROD, V16, P1753, DOI 10.1093/humrep/16.8.1753; Olivius C, 2004, FERTIL STERIL, V81, P258, DOI 10.1016/j.fertnster.2003.06.029; Drosdzol A, 2009, J SEX MED, V6, P3335, DOI 10.1111/j.1743-6109.2009.01355.x; Kelley K, 2003, INT J QUAL HEALTH C, V15, P261, DOI 10.1093/intqhc/mzg031; Aarts JWM, 2011, HUM REPROD, V26, P1112, DOI 10.1093/humrep/der051; Boivin J, 2011, HUM REPROD, V26, P2084, DOI 10.1093/humrep/der171; Boivin J, 2005, FERTIL STERIL, V83, P1745, DOI 10.1016/j.fertnstert.2004.12.039; Schanz S, 2011, FERTIL STERIL, V96, P416, DOI 10.1016/j.fertnstert.2011.05.064; BERG BJ, 1991, J BEHAV MED, V14, P11, DOI 10.1007/BF00844765; Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046; Schmidt Lone, 2005, Patient Educ Couns, V59, P244, DOI 10.1016/j.pec.2005.07.015; Asazawa K., 2013, J JAPAN ACAD NURSING, V33, P14; Asazawa K., 2012, J JAPANESE SOC FERTI, V9, P5; Asazawa K., 2013, J ST LUKES SOC NURSI, V17, P1; Japan Society of Obstetrics & Gynecology, 2012, 2011 ETH COMM REP HE; Kitamura K., 2001, JAPANESE J FERTILITY, V46, P19; Ministry of Health Labor and Welfare, 2003, SURV ASS REPR TECHN; Ministry of Health Labor and Welfare, 2007, SUPP COUPL SUFF INF; Niino Y., 2008, JAPANESE J MATERNAL, V49, P138; Nishiwaki M., 2000, B YAMANASHI MED U, V17, P48; Nozawa M., 2011, J JAPANESE SOC FERTI, V8, P13; OECD, 2012, MEAN AG MOTH 1 CHILD; Oshio A., 2011, PSYCHOL RES DATA ANA, P154; Ozaki K., 2003, COVARIANCE STRUCTURE, P239; Schmidt L, 2005, Patient Educ Couns, V59, P252, DOI 10.1016/j.pec.2005.05.013; Shirai C., 2004, SOCIOLOGY INFERTILIT; Shirai C., 2007, JAPANESE J HLTH MED, V18, P25; Wischmann T, 2009, HUM REPROD, V24, P378, DOI 10.1093/humrep/den401	33	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7932	1742-7924		JPN J NURS SCI	Jpn. J. Nurs. Sci.	JUL	2015	12	3					208	221		10.1111/jjns.12061		14	Nursing	Nursing	CL9YE	WOS:000357334200004		
J	Oga-Baldwin, WLQ; Nakata, Y				Oga-Baldwin, William Ludwell Quint; Nakata, Yoshiyuki			Structure also supports autonomy: Measuring and defining autonomy-supportive teaching in Japanese elementary foreign language classes	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						self-determination theory; autonomy-support; engagement; situated culture; education	SELF-DETERMINATION THEORY; INTRINSIC MOTIVATION; STUDENTS; PERSPECTIVE; ENGAGEMENT; BELIEFS; CHOICE	Recent discussions of autonomy have included the perspective that, as a basic human need across cultural environments, it includes not only choice but also personal endorsement of action. The present study focused on the cultural experience of autonomy-support in Japanese elementary school foreign language classes. Three studies were conducted to investigate how students understand autonomy-supportive teaching. In Study 1, exploratory focus groups defined cultural perspectives on autonomy-support and structure. Exploratory and confirmatory factor analysis indicated that clarity, pacing, and teachers' positive affect correspond to students' perception of supportive teaching. Study 2 investigated teacher support in relation to in-class engagement using longitudinal structural equation modeling. The results indicated a strong relationship between perceptions of support and classroom behavioral engagement, with stable effects over time. Study 3 longitudinally investigated teacher support in relation to students' perceptions of personal autonomy, relatedness, and competence need satisfaction. Findings show a strong positive relationship between teacher support and need satisfaction with high test-retest reliability. Discussion focuses on how autonomy need satisfaction is experienced in different cultures with differing social norms.	[Oga-Baldwin, William Ludwell Quint] Fukuoka Univ Educ, Akama Bunkyo Machi, Munakata 8114192, Japan; [Nakata, Yoshiyuki] Hyogo Univ Teachers Educ, Kato, Hyogo, Japan	Oga-Baldwin, WLQ (reprint author), Fukuoka Univ Educ, Dept English Language Educ, Akama Bunkyo Machi, Munakata 8114192, Japan.	qogab1@fukuoka-edu.ac.jp			JSPS [24720260]	This research was supported by JSPS grant-in-aid for young scientists (B) 24720260 (KAKENHI).	MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; Skinner E, 2008, J EDUC PSYCHOL, V100, P765, DOI 10.1037/a0012840; Littlewood W, 1999, APPL LINGUIST, V20, P71, DOI 10.1093/applin/20.1.71; Yamauchi H, 1998, PSYCHOL REP, V82, P803, DOI 10.2466/PR0.82.3.803-816; Furtak EM, 2012, J EXP EDUC, V80, P284, DOI 10.1080/00220973.2011.573019; Wang Q, 2007, CHILD DEV, V78, P1592, DOI 10.1111/j.1467-8624.2007.01085.x; Spinath B, 2008, CHILD DEV, V79, P1555, DOI 10.1111/j.1467-8624.2008.01205.x; Sierens E, 2009, BRIT J EDUC PSYCHOL, V79, P57, DOI 10.1348/000709908X304398; Jang H, 2010, J EDUC PSYCHOL, V102, P588, DOI 10.1037/a0019682; Chen BW, 2013, J CROSS CULT PSYCHOL, V44, P1184, DOI 10.1177/0022022113480038; Jang H, 2009, J EDUC PSYCHOL, V101, P644, DOI 10.1037/a0014241; Reeve J, 2012, HANDBOOK OF RESEARCH ON STUDENT ENGAGEMENT, P149, DOI 10.1007/978-1-4614-2018-7_7; Black AE, 2000, SCI EDUC, V84, P740, DOI 10.1002/1098-237X(200011)84:6<740::AID-SCE4>3.0.CO;2-3; Vansteenkiste M, 2006, EDUC PSYCHOL, V41, P19, DOI 10.1207/s15326985ep4101_4; Iyengar SS, 1999, J PERS SOC PSYCHOL, V76, P349, DOI 10.1037/0022-3514.76.3.349; Bandura A., 1997, SELF EFFICACY EXERCI; Carifio J., 2007, J SOCIAL SCI, V3, P106, DOI DOI 10.3844/JSSP.2007.106.116; Cave P, 2007, JPN ANTHROPOL WORKSH, P1; Chen C. C., 2010, OXFORD HDB CHINESE P, P599; Doi T., 1994, ANATOMY DEPENDENCE; Hardre P. L., 2006, ASIA PACIFIC J ED, V26, P198; Hau K. T., 2010, OXFORD HDB CHINESE P, P187; Hofstede Geert H., 1984, CULTURES CONSEQUENCE; Hwang KK, 2012, INT CULT PSYCHOL, P1, DOI 10.1007/978-1-4614-1439-1; Katz I, 2007, EDUC PSYCHOL REV, V19, P429, DOI 10.1007/s10648-006-9027-y; Kawakami R., 1999, GAKKOU HOUKAI; Kline R. B., 2011, PRINCIPLES PRACTICE; Lee W, 2012, EDUC PSYCHOL-UK, V32, P727, DOI 10.1080/01443410.2012.732385; Lewis Catherine C., 1995, ED HEARTS MINDS REFL; Muthen L. K., 2012, MPLUS VERSION 7; Nakata Y., 2009, MAPPING TERRAIN LEAR, P190; REEVE J, 1994, EDUC PSYCHOL MEAS, V54, P506, DOI 10.1177/0013164494054002025; ROTH G, 2006, MOTIV EMOTION, V30, P361, DOI 10.1007/s11031-006-9052-7; Ryan R. M., 2002, HDB SELF DETERMINATI, P3; Sorrentino R. M., 2000, UNCERTAIN MIND INDIV; StataCorp, 2011, STAT STAT SOFTW REL; Szeto ACH, 2011, MOTIV EMOTION, V35, P338, DOI 10.1007/s11031-011-9211-3; Tabachnick B. G., 2007, USING MULTIVARIATE S	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					167	179		10.1111/jpr.12077		13	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000001		
J	Ishikawa, S				Ishikawa, Shin-ichi			A cognitive-behavioral model of anxiety disorders in children and adolescents	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						anxiety disorders; cognitive-behavioral model; children; adolescents	JAPANESE CHILDREN; CONTENT-SPECIFICITY; AUTOMATIC THOUGHTS; CHILDHOOD ANXIETY; DIATHESIS-STRESS; SYMPTOMS; DEPRESSION; ERRORS; YOUTH; ASSOCIATIONS	This study investigated a cognitive-behavioral model of anxiety disorders in Japanese children and adolescents. Participants comprised 532 children from elementary schools and 751 adolescents from junior high schools as a community group, and 41 children and adolescents who fulfilled the criteria for childhood anxiety disorders as a clinical group. All participants completed three questionnaires about anxiety symptoms, self-statements, and cognitive errors. While the clinical group showed more anxiety symptoms, negative self-statements, and cognitive errors than the community group, there was no significant difference in positive self-statements. Multigroup structural equation modeling found the presence of cognitive links for the community and clinical groups. Specifically, cognitive errors generated negative self-statements, exacerbating a higher-order factor (childhood anxiety) affecting six anxiety symptoms corresponding to the diagnostic criteria of psychological disorders. Mediated relationships were supported in only the community sample. Clinical implications for prevention and treatment of anxiety disorders in children and adolescents are discussed.	[Ishikawa, Shin-ichi] Doshisha Univ, Tatara Miyakodani, Kyotanabe 6100394, Japan	Ishikawa, S (reprint author), Doshisha Univ, Fac Psychol, Tatara Miyakodani, Kyotanabe 6100394, Japan.	ishinn@mail.doshisha.ac.jp					Abela JRZ, 2003, J EARLY ADOLESCENCE, V23, P384, DOI 10.1177/0272431603258345; Abela JRZ, 2002, BRIT J CLIN PSYCHOL, V41, P111, DOI 10.1348/014466502163912; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Schniering CA, 2002, BEHAV RES THER, V40, P1091, DOI 10.1016/S0005-7967(02)00022-0; Treadwell KRH, 1996, J CONSULT CLIN PSYCH, V64, P941, DOI 10.1037/0022-006X.64.5.941; Ollendick TH, 2009, J CONSULT CLIN PSYCH, V77, P504, DOI 10.1037/a0015158; Reynolds S, 2008, BEHAV COGN PSYCHOTH, V36, P463, DOI 10.1017/S1352465808004463; Spence SH, 1998, BEHAV RES THER, V36, P545, DOI 10.1016/S0005-7967(98)00034-5; Hodson KJ, 2008, BEHAV COGN PSYCHOTH, V36, P449, DOI 10.1017/S1352465808004487; Ishikawa S, 2009, J ANXIETY DISORD, V23, P104, DOI 10.1016/j.janxdis.2008.04.003; Alfano CA, 2002, CLIN PSYCHOL REV, V22, P1209, DOI 10.1016/S0272-7358(02)00205-2; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Costello EJ, 2005, CHILD ADOL PSYCH CL, V14, P631, DOI 10.1016/j.chc.2005.06.003; Neil AL, 2009, CLIN PSYCHOL REV, V29, P208, DOI 10.1016/j.cpr.2009.01.002; LEITENBERG H, 1986, J CONSULT CLIN PSYCH, V54, P528, DOI 10.1037//0022-006X.54.4.528; Tofighi D, 2011, BEHAV RES METHODS, V43, P692, DOI 10.3758/s13428-011-0076-x; Kendall PC, 2007, J CONSULT CLIN PSYCH, V75, P380, DOI 10.1037/0022-006X.75.3.380; Weems CF, 2005, CLIN CHILD FAM PSYCH, V8, P107, DOI 10.1007/s10567-005-4751-2; Barrett P. M., 2004, FRIENDS LIFE PROGRAM, V4th; Beck A. T., 1985, ANXIETY DISORDERS PH; Browne MW, 1993, SAGE FOCUS EDITIONS, V154, P136, DOI DOI 10.1080/10705511.2012.687671; CASTANEDA A, 1956, CHILD DEV, V27, P317; Clark D., 1995, SOCIAL PHOBIA DIAGNO, P69; Essau C. A., 2013, TREATMENT CHILDHOOD; Ishikawa S., 2012, DOSHISHA CLIN PSYCHO, V2, P93; Ishikawa S., 2005, JAPANESE J BEHAV THE, V31, P159; Ishikawa S, 2014, CHILD PSYCHIAT HUM D, V45, P306, DOI 10.1007/s10578-013-0401-y; Ishikawa S, 2012, BEHAV COGN PSYCHOTH, V40, P271, DOI 10.1017/S1352465811000713; Ishikawa S, 2012, INT J COGN THER, V5, P38; Ishikawa S., 2003, JAPANESE J BEHAV THE, V29, P145; Ishikawa S., 2005, JAPANESE J BEHAV THE, V31, P45; Ishikawa S, 2007, CHILD ADOLESCENT MEN, V12, P164, DOI DOI 10.1111/J.1475-3588.2006.00433.X; Ishikawa S., 2001, WASEDA J CLIN PSYCHO, V1, P75; Kano H., 2003, GURAFIKAL TAHENRYO K; Kazdin AE, 2003, RES DESIGN CLIN PSYC; Kazdin AE, 2002, CHILD ADOLESCENT MEN, V7, P53, DOI 10.1111/1475-3588.00011; KENDALL PC, 1992, BEHAV THER, V23, P1, DOI 10.1016/S0005-7894(05)80304-1; Kendall PC, 2006, COPING CAT WORKBOOK; Prins P., 2001, ANXIETY DISORDERS CH, P23; Rapee RM, 2000, TREATING ANXIOUS CHI; Salkovskis P. M., 1999, BEHAV RES THER, V37, P529; Schniering CA, 2004, J ABNORM PSYCHOL, V113, P464, DOI 10.1037/0021-843x.113.3.464; Silverman W. K., 1996, MANUAL ANXIETY DISOR; Toyoda H., 2007, KYOBUNSAN KOZO BUNSE; Vasey M. W., 2001, DEV PSYCHOPATHOL, P253; Watts SE, 2006, J ABNORM CHILD PSYCH, V34, P841, DOI 10.1007/s10802-006-9066-3; Weems CF, 2007, BEHAV MODIF, V31, P174, DOI 10.1177/0145445506297016	47	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					180	193		10.1111/jpr.12078		14	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000002		
J	Muto, H				Muto, Hiroyuki			The effects of linearity on sentence comprehension in oral and silent reading	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						linearity; sentence comprehension; oral and silent reading; reading span test; digit span test	WORKING-MEMORY CAPACITY; SPAN TEST; WORD	This study examined the effects of linearity of language (e.g., de Saussure, 1916/1972) on performance on a sentence comprehension task, manipulating (a) presentation method (simultaneous, phrase, or flow) and (b) reading method (oral or silent reading). The study also examined the predictive powers of the digit span test (DST) and the reading span test (RST) for task performance. Fifty-four undergraduate and graduate students participated in the experiment. The results showed that the DST score predicted performance on both garden-path (GP) and non-garden-path (NGP) sentences, whereas the RST score did so only for GP sentences. This suggests that the sentence comprehension task requires not only comprehension but also temporarily storing verbal information, and that the RST score reflects the degree of tolerance for deviation from linearity. The results also revealed that silent reading has an advantage over oral reading in simultaneous presentation and vice versa in flow presentation, whereas the difference between reading methods disappeared in phrase presentation. This suggests that oral and silent reading require different strategies to facilitate sentence comprehension.	[Muto, Hiroyuki] Osaka Univ, Suita, Osaka 5650871, Japan	Muto, H (reprint author), Osaka Univ, Grad Sch Human Sci, Suita, Osaka 5650871, Japan.	h_muto@hus.osaka-u.ac.jp					McCallum RS, 2004, PSYCHOL SCHOOLS, V41, P241, DOI 10.1002/pits.10152; Friedman NP, 2005, BEHAV RES METHODS, V37, P581, DOI 10.3758/BF03192728; RUBIN GS, 1992, VISION RES, V32, P895, DOI 10.1016/0042-6989(92)90032-E; Osaka M, 2002, MEM COGNITION, V30, P562, DOI 10.3758/BF03194957; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; COLTHEART V, 1990, Q J EXP PSYCHOL-A, V42, P375; desSaussure F., 1972, IPPAN GENGOGAKU KOGI; Endo K., 2012, JAPANESE J PSYCHOL, V82, P554; Kirk R., 1982, EXPT DESIGN PROCEDUR; Kita S., 2000, COGNITIVE STUDIES, V7, P9; Kosaka K, 2000, JPN J EDUC PSYCHOL, V48, P343; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Mori T., 1980, JAPANESE J ED PSYCHO, V28, P57; Morishita M., 2007, JAPANESE J PSYCHOL, V77, P495; Osaka M., 2002, NO NO MEMO CHO WAKIN; OSAKA M, 1994, JPN J PSYCHOL, V65, P339; Oyama Y., 2011, COGNITIVE STUDIES, V18, P559; SALASOO A, 1986, READ RES QUART, V21, P59, DOI 10.2307/747960; Shimizu Y., 1985, B KYOTO U ED, V66, P33; Takahashi M., 2013, COGNITIVE STUDIES, V20, P470; Takahashi M, 2007, JPN J EDUC PSYCHOL, V55, P538; Takahashi M., 2011, COGNITIVE STUDIES, V18, P595; YAMADA J, 1990, J GEN PSYCHOL, V117, P311; YOKOYAMA S, 1989, JPN J PSYCHOL, V60, P61	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					194	205		10.1111/jpr.12079		12	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000003		
J	Kawashima, T				Kawashima, Takayuki			Change deafness for simultaneous voices	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						change deafness; auditory organization; multiple voices	COMPLEX AUDITORY SCENES; CHANGE-BLINDNESS; ATTENTION; SPEECH; REPRESENTATIONS; PERCEPTION	Apparent changes in auditory scenes are often unnoticed. This change deafness phenomenon was examined in auditory scenes that comprise human voices. In two experiments, listeners were required to detect changes between two auditory scenes comprising two, three, and four talkers who voiced four-syllable words. One of the voices in the first scene was randomly selected and was replaced with a new word in change trials. The rationale was that higher stimulus familiarity conferred by human voices compared to other everyday sounds, together with encoding and memory advantages for verbal stimuli and the modular processing of speech in auditory processing, should positively influence the change detection efficiency, and the change deafness phenomenon should not be observed when listeners are explicitly required to detect the obvious changes. Contrary to the prediction, change deafness was significantly observed in three- and four-talker conditions. This indicates that change deafness occurs in listeners even for highly familiar stimuli. This suggests the limited ability for perceptual organization of auditory scenes comprising even a relatively small number of voices (three or four).	[Kawashima, Takayuki] Teikyo Heisei Univ, Tokyo 1708445, Japan	Kawashima, T (reprint author), Teikyo Heisei Univ, Fac Hlth & Med Sci, Toshima Ku, Tokyo 1708445, Japan.	takayuki.kawashima@thu.ac.jp			JSPS KAKENHI [19730456]	This research was supported in part by JSPS KAKENHI (19730456).	PHILLIPS WA, 1974, PERCEPT PSYCHOPHYS, V16, P283, DOI 10.3758/BF03203943; Vitevitch MS, 2003, J EXP PSYCHOL HUMAN, V29, P333, DOI 10.1037/0096-1523.29.2.333; Simons DJ, 1997, TRENDS COGN SCI, V1, P261, DOI 10.1016/S1364-6613(97)01080-2; Rensink RA, 1997, PSYCHOL SCI, V8, P368, DOI 10.1111/j.1467-9280.1997.tb00427.x; Backer KC, 2012, J EXP PSYCHOL HUMAN, V38, P1554, DOI 10.1037/a0027858; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; Rensink RA, 2000, VIS COGN, V7, P345, DOI 10.1080/135062800394847; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Constantino FC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046167; Davies TN, 2002, PERCEPTION, V31, P1123, DOI 10.1068/p3391; desCheveigne A., 2003, YIN VERSION 28 CODE; Eramudugolla R, 2005, CURR BIOL, V15, P1108, DOI 10.1016/j.cub.2005.05.051; Gregg MK, 2008, J EXP PSYCHOL HUMAN, V34, P974, DOI 10.1037/0096-1523.34.4.974; Gregg MK, 2009, ATTEN PERCEPT PSYCHO, V71, P607, DOI 10.3758/APP.71.3.607; Kashino M., 1996, J ACOUST SOC AM, V99, P2597; Kondo T, 1999, LEXICAL PROPERTIES J; LIBERMAN AM, 1982, AM PSYCHOL, V37, P148, DOI 10.1037//0003-066X.37.2.148; Macmillan NA, 1991, DETECTION THEORY USE; McAnally KI, 2010, J EXP PSYCHOL HUMAN, V36, P994, DOI 10.1037/a0016895; Nagaoka University of Technology, 2002, HRTF DAT HEAD REL TR; Neuhoff JG, 2014, PERCEPTION, V43, P219, DOI 10.1068/p7665; Pavani F, 2008, PERCEPT PSYCHOPHYS, V70, P619, DOI 10.3758/PP.70.4.619; RAND TC, 1974, J ACOUST SOC AM, V55, P678, DOI 10.1121/1.1914584; Tohoku University, 2001, DAT HRTFS HEAD REL T; Tohoku University-Matsushita Communication Industrial, 1992, IS WORD DAT; Vitevitch MS, 2011, Q J EXP PSYCHOL, V64, P1484, DOI 10.1080/17470218.2011.578749	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					206	217		10.1111/jpr.12088		12	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000004		
J	Adachi, M				Adachi, Masaki			Study of a cognitive effects model in Dohsa-hou for the elderly	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						dohsa-hou for the elderly; body sway; cognitive task performance; information-processing capacity; attentional bias	POSTURAL CONTROL; EFFECT SIZE; STATISTICS; DESIGNS	This study investigates the primary factors responsible for cognitive performance improvements as a result of dohsa-hou (Japanese body-oriented psychotherapy) for the elderly. The study divided participants into two homogeneous groups: an experimental group that attempted to improve upright balance by performing dohsa-hou, and a control group to establish the drop-off period for the effect of performing the given activities. The task processing time of Stroop Test and body sway and the situational anxiety during task processing of Stroop Tests were measured before and after the dohsa-hou and drop-off period. The results confirm that only the experimental group improved in body sway, had a shorter Stroop Color Test processing time and lower situational anxiety. From this study, it has been identified that: (a) information-processing capacities spared for posture control are affected by distribution of processing resources towards solving other cognitive tasks; and (b) the effect of the release of attention from threat-related information due to a decrease in attentional bias, which accompanied the decrease in situational anxiety, are primary factors in improving cognitive task performance.	[Adachi, Masaki] Hirosaki Univ, Hirosaki, Aomori 0368562, Japan	Adachi, M (reprint author), Hirosaki Univ, Grad Sch Med, Res Ctr Child Mental Dev, Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	ko-jo-cho-ko-jo-cho@hotmail.co.jp					Adachi M., 2011, JAPANESE J GERONTOLO, V33, P3; Adachi M., 2013, J JAPANESE CLIN PSYC, V31, P245; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; Marsh AP, 2000, GAIT POSTURE, V12, P105, DOI 10.1016/S0966-6362(00)00074-6; GEURTS ACH, 1991, ARCH PHYS MED REHAB, V72, P1059; Olejnik S, 2003, PSYCHOL METHODS, V8, P434, DOI 10.1037/1082-989X.8.4.434; MATHEWS A, 1994, ANNU REV PSYCHOL, V45, P25, DOI 10.1146/annurev.psych.45.1.25; Beck A. T., 1988, ANXIETY RES, V1, P23, DOI DOI 10.1080/10615808808248218; Berg K., 1992, CAN J PUBLIC HLTH, V83, P7; Clark D. M., 1988, PANIC PSYCHOL PERSPE, P71; Foa F. B., 1986, COGNITIVE THERAPY RE, V10, P477; Fujiwara Y., 2007, JAPANESE J BEHAV THE, V33, P145; Harizuka S., 1992, J REHABILITATION PSY, V20, P15; Koga S., 2001, J REHABILITATION PSY, V29, P45; Miyazato S., 2010, J REHABILITATION PSY, V37, P1; Mizuguchi K., 1991, NIHONBAN STAI SHIYOU; Nakajima K., 2012, ELDERLY DOHSA HOU; Nakajima K., 1989, DOHSA THERAPY DEPRES; Nakajima K., 2001, DOHSA HOU DEMENTIA E; Naruse G., 2000, DOHSA THERAPY, P18; Ohno H., 2005, AUTONOMIC NERVOUS SY, V42, P135; Ohno T., 2002, J HLTH SCI HIROSHIMA, V2, P78; Saito T., 2002, J REHABILITATION PSY, V30, P85; Takeda S., 2005, J JAPANESE CLIN PSYC, V23, P305; Williams J. M. G., 1997, COGNITIVE PSYCHOL EM; Yule W., 1991, CLIN CHILD PSYCHOL S, P349	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					218	230		10.1111/jpr.12081		13	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000005		
J	Liu, T; Saito, H; Oi, M				Liu, Tao; Saito, Hirofumi; Oi, Misato			Online monitoring of the social presence effects in a two-person-like driving video game using near-infrared spectroscopy	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						presence of others; near-infrared spectroscopy (NIRS); online monitoring; prefrontal cortex (PFC); task proficiency	PREFRONTAL CORTEX; BRAIN; FACILITATION; CHILDREN; NETWORK; SYSTEM	We examined how a friend's presence affects a performer's prefrontal activation in daily-life activities using two wireless portable near-infrared spectroscopy (NIRS) devices. Participants played a driving video game either solely in the single group or with a friend in the paired group. The two groups (single and paired) were subdivided according to their game proficiency (low and high). The NIRS data demonstrated a significant interaction of group by proficiency. Low-proficiency players in the paired group showed lower activation than those in the single group, but high-proficiency players did not. In the paired group, high-proficiency players showed higher activation than low-proficiency players, but not in the single group. These results suggest that NIRS detects social presence effects in everyday situations: decreasing prefrontal activation in low-proficiency performers due to tension reduction and increasing prefrontal activation in high-proficiency performers due to increased arousal.	[Liu, Tao] Sun Yat Sen Univ, Guangzhou 510275, Guangdong, Peoples R China; [Saito, Hirofumi; Oi, Misato] Nagoya Univ, Nagoya, Aichi 4648601, Japan	Saito, H (reprint author), Nagoya Univ, Grad Sch Informat Sci, Dept Cognit Informat, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	saito@is.nagoya-u.ac.jp					Allport F., 1924, SOCIAL PSYCHOL; Allport G. W., 1954, HDB SOCIAL PSYCHOL, P3; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; ZAJONC RB, 1965, SCIENCE, V149, P269, DOI 10.1126/science.149.3681.269; Hoshi Y, 2001, J APPL PHYSIOL, V90, P1657; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Aiello JR, 2001, GROUP DYN-THEOR RES, V5, P163, DOI 10.1037//1089-2699.5.3.163; Matsuda G, 2006, NEUROIMAGE, V29, P706, DOI 10.1016/j.neuroimage.2005.08.019; BOND CF, 1983, PSYCHOL BULL, V94, P265, DOI 10.1037/0033-2909.94.2.265; HOSHI Y, 1993, J APPL PHYSIOL, V75, P1842; Koechlin E, 2007, TRENDS COGN SCI, V11, P229, DOI 10.1016/j.tics.2007.04.005; Albert D, 2013, CURR DIR PSYCHOL SCI, V22, P114, DOI 10.1177/0963721412471347; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Karremans JC, 2011, INT J PSYCHOPHYSIOL, V81, P44, DOI 10.1016/j.ijpsycho.2011.04.003; Liu T, 2012, NEUROREPORT, V23, P835, DOI 10.1097/WNR.0b013e328357bb3b; Uziel L, 2007, J RES PERS, V41, P579, DOI 10.1016/j.jrp.2006.06.008; GEEN RG, 1991, ANNU REV PSYCHOL, V42, P377, DOI 10.1146/annurev.ps.42.020191.002113; Spreng RN, 2009, J COGNITIVE NEUROSCI, V21, P489, DOI 10.1162/jocn.2008.21029; Baron RS, 1986, ADV EXPT SOCIAL PSYC, V19, P1, DOI [10.1016/S0065-2601(08)60211-7, DOI 10.1016/50065-2601]; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chein J, 2011, DEVELOPMENTAL SCI, V14, pF1, DOI 10.1111/j.1467-7687.2010.01035.x; Fitts P. M., 1973, HUMAN PERFORMANCE; Folkman S., 1984, STRESS APPRAISAL COP; GRAYDON J, 1995, PERS INDIV DIFFER, V19, P265, DOI 10.1016/0191-8869(95)00052-8; Guerin B., 1993, SOCIAL FACILITATION; Hoffman S. G., 2005, EMOTION, V5, P464; Ito H, 2011, PSYCHOPHYSIOLOGY, V48, P1562, DOI 10.1111/j.1469-8986.2011.01220.x; Jääskeläinen Iiro P, 2008, Open Neuroimag J, V2, P14, DOI 10.2174/1874440000802010014; Japan Society for Occupational Heath, 2002, SUBJECTIVE SYMPTOM T; Liu T, 2012, NEUROSCI LETT, V506, P220, DOI 10.1016/j.neulet.2011.11.009; Piper SK, 2014, NEUROIMAGE, V85, P64, DOI 10.1016/j.neuroimage.2013.06.062; Pontari BA, 2009, PERS SOC PSYCHOL B, V35, P283, DOI 10.1177/0146167208328063; Scholkmann F, 2014, NEUROIMAGE, V85, P6, DOI 10.1016/j.neuroimage.2013.05.004; Tsujimoto S, 2013, CHILD PSYCHIAT HUM D, V44, P678, DOI 10.1007/s10578-013-0361-2; Wan XH, 2011, SCIENCE, V331, P341, DOI 10.1126/science.1194732; Zajonc RB, 1980, PSYCHOL GROUP INFLUE, P35	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					242	253		10.1111/jpr.12080		12	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000007		
J	Kawamoto, T				Kawamoto, Tetsuya			The translation and validation of the Mini-K scale in Japanese	JAPANESE PSYCHOLOGICAL RESEARCH			English	Article						Mini-K scale in Japanese; life history theory; test reliability; test validity; psychometrics	LIFE-HISTORY STRATEGY; GENERAL FACTOR; REPRODUCTIVE STRATEGY; PERSONALITY; SOCIOSEXUALITY; EXPECTANCY; ATTACHMENT; HYPOTHESIS; COVITALITY; ILLNESS	The purpose of this study was to validate the 20-item Mini-K scale, which is the short form of the Arizona Life History Battery, as translated into Japanese. Two samples of Japanese adults (N=2000; 50.0% men; Mage=40.9 for the first survey; N=400; 50.0% men; Mage=42.2 for the second survey) completed a web-based questionnaire, including the Japanese translation of the Mini-K. The results showed that the psychometric properties of the Japanese Mini-K scale were comparable to those of the original English version. The scale had good reliability based on Cronbach's and McDonald's . Convergent validity was demonstrated by the correlation between the Mini-K scores and life history indicators. In addition, the Mini-K score was related to both personality and psychosomatic health. The translated scale provides a valid and reliable instrument in Japanese that measures human life-history strategy.	[Kawamoto, Tetsuya] Univ Tokyo, Tokyo 1130033, Japan	Kawamoto, T (reprint author), Univ Tokyo, Grad Sch Educ, Bunkyo Ku, Tokyo 1130033, Japan.	tk5049@p.u-tokyo.ac.jp			JSPS KAKENHI [26-12061]	This research was supported by JSPS KAKENHI Grant Number 26-12061.	Anderson KG, 2010, HUM NATURE-INT BIOS, V21, P103, DOI 10.1007/s12110-010-9087-z; Laran J, 2013, PSYCHOL SCI, V24, P167, DOI 10.1177/0956797612450033; Figueredo AJ, 2005, PERS INDIV DIFFER, V39, P1349, DOI 10.1016/j.paid.2005.06.009; van der Linden D, 2010, J RES PERS, V44, P315, DOI 10.1016/j.jrp.2010.03.003; Brumbach BH, 2009, HUM NATURE-INT BIOS, V20, P25, DOI 10.1007/s12110-009-9059-3; Penke L, 2008, J PERS SOC PSYCHOL, V95, P1113, DOI 10.1037/0022-3514.95.5.1113; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Brim OG, 2004, MAC FDN MEN, P1; Figueredo AJ, 2006, DEV REV, V26, P243, DOI 10.1016/j.dr.2006.02.002; Belsky J, 2010, PSYCHOL SCI, V21, P1195, DOI 10.1177/0956797610379867; Just C, 2011, PERS INDIV DIFFER, V50, P765, DOI 10.1016/j.paid.2011.01.008; RUSHTON JP, 1985, PERS INDIV DIFFER, V6, P441, DOI 10.1016/0191-8869(85)90137-0; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; Rothbart MK, 2000, J PERS SOC PSYCHOL, V78, P122, DOI 10.1037//0022-3514.78.1.122; Furukawa TA, 2008, INT J METH PSYCH RES, V17, P152, DOI 10.1002/mpr.257; Figueredo AJ, 2004, SOC BIOL, V51, P121; Ten Berge JMF, 2004, PSYCHOMETRIKA, V69, P613; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Ashton MC, 2009, J PERS ASSESS, V91, P340, DOI 10.1080/00223890902935878; Kuzawa CW, 2010, P NATL ACAD SCI USA, V107, P16800, DOI 10.1073/pnas.1006008107; Waynforth D, 2012, P ROY SOC B-BIOL SCI, V279, P2998, DOI 10.1098/rspb.2012.0220; Rushton JP, 2008, J RES PERS, V42, P1173, DOI 10.1016/j.jrp.2008.03.002; Schmitt DP, 2004, J CROSS CULT PSYCHOL, V35, P367, DOI 10.1177/0022022104266105; Wakabayashi A, 2014, JPN PSYCHOL RES, V56, P211, DOI 10.1111/jpr.12045; BAILEY JM, 1994, J PERS SOC PSYCHOL, V66, P1081, DOI 10.1037/0022-3514.66.6.1081; Brennan K. A., 1998, ATTACHMENT THEORY CL, P46; Brim O. G., 2000, NATL SURVEY MIDLIFE, DOI DOI 10.3886/ICPSR02760.V8>(10; Bulled NL, 2010, HUM NATURE-INT BIOS, V21, P269, DOI 10.1007/s12110-010-9092-2; Dunkel C.S., 2013, J SOC EVOL CULTUR PS, V7, P12; Figueredo A. J, 2005, HDB EVOLUTIONARY PSY, P851; Figueredo A. J., 2014, EVOLUTIONARY BEHAV S, V8, P148, DOI DOI 10.1037/H0099837; Figueredo A. J, 2007, ARIZOA LIFE HI UNPUB; Figueredo AJ, 2007, HUM NATURE-INT BIOS, V18, P47, DOI 10.1007/BF02820846; Figueredo AJ, 2009, TWIN RES HUM GENET, V12, P555, DOI 10.1375/twin.12.6.555; Figueredo AJ, 2013, PERS INDIV DIFFER, V55, P251, DOI 10.1016/j.paid.2012.04.033; Hackman J, 2013, EVOL HUM BEHAV, V34, P118, DOI 10.1016/j.evolhumbehav.2012.11.002; Jackson JJ, 2007, EVOL HUM BEHAV, V28, P382, DOI 10.1016/j.evolhumbehav.2007.04.005; Kanzaki M., 2012, J JAPAN ACAD NURSING, V32, P50; Kirkpatrick L. A., 1998, ATTACHMENT THEORY CL, P353; Lee EO, 2002, INT J NURS STUD, V39, P705, DOI 10.1016/S0020-7489(02)00009-3; Listl S, 2014, AM J PUBLIC HEALTH, V104, pE55, DOI 10.2105/AJPH.2014.301918; Liu JH, 2011, EVOL HUM BEHAV, V32, P433, DOI 10.1016/j.evolhumbehav.2010.10.007; McArthur R. H., 1967, THEORY ISLAND BIOGEO; Moroi K, 1996, JAPANESE J FAMILY PS, V10, P15; Nakamine S., 2014, P 55 C JAP SOC SOC P, P134; Nakao T., 2004, KYUSHU U PSYCHOL RES, V5, P19; NORTON R, 1983, J MARRIAGE FAM, V45, P141, DOI 10.2307/351302; Sotomayor-Peterson M, 2013, J CROSS CULT PSYCHOL, V44, P620, DOI 10.1177/0022022112455456; Tal I. R., 2006, MEDIO AMBIENTE COMPO, V7, P7; Veselka L, 2009, TWIN RES HUM GENET, V12, P420, DOI 10.1375/twin.12.5.420; Wilson E.O., 1975, SOCIOBIOLOGY NEW SYN; Yamagata S., 2005, JAPANESE J PERSONALI, V14, P30, DOI DOI 10.2132/PERS0NALITY.14.30	52	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-5368	1468-5884		JPN PSYCHOL RES	Jpn. Psychol. Res.	JUL	2015	57	3					254	267		10.1111/jpr.12083		14	Psychology, Multidisciplinary	Psychology	CM1HX	WOS:000357433000008		
J	Miyazaki, K; Tomiyama, T; Yamada, K; Tamaoki, M				Miyazaki, Katsumi; Tomiyama, Takeshi; Yamada, Katsumasa; Tamaoki, Masanori			18S ANALYSIS OF THE TAXONOMIC POSITION OF AN ENDOPARASITIC PYCNOGONID, NYMPHONELLA TAPETIS (ARTHROPODA: PYCNOGONIDA: ASCORHYNCHIDAE)	JOURNAL OF CRUSTACEAN BIOLOGY			English	Article						endoparasitism; molecular phylogeny; sea spider; taxonomy	SEA SPIDERS; PHYLOGENY	We obtained the nucleotide sequence of 18S rDNA of Nymphonella tapetis, a pycnogonid endoparasitic on some bivalves, together with that of other species belonging to Ascorhynchidae Hoek, 1881. The phylogenetic tree based on these sequences as well as those of selected species from a database strongly supports the monophyly of Ascorhynchidae and the inclusion of Nymphonella in the family. Nymphonella seems to be an aberrant form in the Ascorhynchidae, but multi-gene analysis with more species is required for the exact determination of the taxonomic position of the genus.	[Miyazaki, Katsumi] Kyoto Univ, Field Sci Educ & Res Ctr, Seto Marine Biol Lab, Wakayama 6492211, Japan; [Tomiyama, Takeshi] Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan; [Yamada, Katsumasa] Fisheries Res Agcy, Seikai Natl Fisheries Res Inst, Nagasaki 8512213, Japan; [Tamaoki, Masanori] Natl Inst Environm Studies, Ctr Environm Biol & Ecosyst Studies, Tsukuba, Ibaraki 3058506, Japan	Miyazaki, K (reprint author), Kyoto Univ, Field Sci Educ & Res Ctr, Seto Marine Biol Lab, Wakayama 6492211, Japan.	miyazaki.katsumi.7e@kyoto-u.ac.jp			JSPS KAKENHI [26292105]	The authors would like to thank Dr. Masato Kiyomoto and Dr. Mamiko Hirose, Tateyama Marine Laboratory, Marine and Coastal Research Center, Ochanomizu University for their kind assistance in providing some materials. This study was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (B), No. 26292105. This paper is dedicated to the memory of the late Dr. Roger N. Bamber, a great inquirer of the various aspects in pycnogonid biology.	TAMURA K, 1993, MOL BIOL EVOL, V10, P512; Bamber RN, 2007, ZOOTAXA, P295; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; ARNAUD F, 1987, ADV MAR BIOL, V24, P1; Arabi J, 2010, CR BIOL, V333, P438, DOI 10.1016/j.crvi.2010.01.018; Arabi J., 2003, MOL PHYLOGENET EVOL, V28, P588; Arabi J., 2007, CLADISTICS, V23, P255; Arango CP, 2002, ORG DIVERS EVOL, V2, P107, DOI 10.1078/1439-6092-00035; Bamber R. N., 2015, PYCNOBASE WORLD PYCN; Bell T., 1853, LAST ARCTIC VOYAGES, V2, P408; Child CA, 1979, SMITHSON CONTR ZOOL, V293, P1, DOI 10.5479/si.00810282.293; Chow S, 2012, NIPPON SUISAN GAKK, V78, P895, DOI 10.2331/suisan.78.895; FRY WG, 1978, ZOOL J LINN SOC-LOND, V63, P35, DOI 10.1111/j.1096-3642.1978.tb02089.x; Gordon I., 1932, Discovery Reports, VVol. 6, P1; Guille A., 1968, VIE MILIEU, V18, P345; HEDGPETH JOEL W., 1949, PROC U S NATION MUS, V98, P233; Helfer H., 1935, HG BRONNS KLASSEN OR, V5; Hilton W. A., 1916, Journal of Entomology and Zoology Claremont, V8; Hoek P. P. C., 1881, ARCH ZOOLOGIE EXPT G, V9, P445; Ives J. E., 1891, P ACAD NAT SCI PHILA, V210-221, P12; Johnston G., 1837, MAGAZINE ZOOLOGY BOT, V1; King P.E., 1973, PYCNOGONIDS; Loman J. C. C., 1912, B I OCEANOGRAPHIQUE, V238; Losina-Losinslcy L. K., 1929, ZOOLOGISCHE JB SYSTE, V575, P537; Miyazaki K., 2011, P ARTHROPODAN EMBRYO, V46, P35; Miyazaki Katsumi, 2010, Taxa, V28, P45; Muller HG, 1993, WORLD CATALOGUE BIBL; Munilla T., 1988, Monografias de Zoologia Marina, V3, P177; Nakamura K., 1983, SMITHSONIAN CONTRIBU, V386, P1, DOI DOI 10.5479/SI.00810282.386; Nakamura K, 2007, MAR BIOL, V153, P213, DOI 10.1007/s00227-007-0803-0; Nei M., 2000, MOL EVOLUTION PHYLOG; Ohshima H., 1938, Annotationes Zoologicae Japonenses, V17, P229; OHSHIMA HIROSHI, 1927, ANNOT ZOOL JAPONENSES, V11, P257; Ohshima H., 1937, COMPT REND 12 C INT, P1616; OHSHIMA HIROSHI, 1933, ANNOT ZOOL JAPONENSES, V14, P53; Ortmann A. E., 1890, ZOOLOGISCHE JB SYSTE, V5, P157; SAITOU N, 1987, MOL BIOL EVOL, V4, P406; Schimkewitsch W., 1913, ANNUAIRE MUSEE ZOOLO, V18, P240; Slater H. H., 1879, ANN MAGAZINE NATURAL, V5, P281; Stock J. H., 1959, Transactions of the Royal Society of South Africa, V35, P549; Stock J. H., 1957, Mitteilungen der Hamburgischen Zoologischen Museum, V55, P81; Stock Jan H., 1994, Beaufortia, V44, P17	43	0	0	CRUSTACEAN SOC	SAN ANTONIO	840 EAST MULBERRY, SAN ANTONIO, TX 78212 USA	0278-0372	1937-240X		J CRUSTACEAN BIOL	J. Crustac. Biol.	JUL	2015	35	4					491	494		10.1163/1937240X-00002348		4	Marine & Freshwater Biology	Marine & Freshwater Biology	CM0ED	WOS:000357350300004		
J	Nemoto, M; Sasaki, T				Nemoto, Masami; Sasaki, Takashi			High-throughput screening of small interfering ribonucleic acid identifies important modulators in islet dysfunction and apoptosis	JOURNAL OF DIABETES INVESTIGATION			English	Editorial Material									[Nemoto, Masami] Jikei Univ, Dept Internal Med, Katsushika Med Ctr, Tokyo, Japan; [Sasaki, Takashi] Jikei Univ, Sch Med, Inst Clin Med & Res, Chiba, Japan	Sasaki, T (reprint author), Jikei Univ, Sch Med, Inst Clin Med & Res, Chiba, Japan.	takashi_sasaki@jikei.ac.jp					Beck A, 2013, DIABETOLOGIA, V56, P1317, DOI 10.1007/s00125-013-2889-x; Kato K, 2014, MOL CELL, V53, P617, DOI 10.1016/j.molcel.2014.01.030; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Stephan Jean Philippe, 2014, V544, P129, DOI 10.1016/B978-0-12-417158-9.00006-6; Perwitasari Olivia, 2013, Pharmaceuticals (Basel), V6, P124, DOI 10.3390/ph6020124	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					390	392		10.1111/jdi.12283		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500004		
J	Yagihashi, S; Mizukami, H; Inaba, W				Yagihashi, Soroku; Mizukami, Hiroki; Inaba, Wataru			Quo vadis: Where have the -cells gone?	JOURNAL OF DIABETES INVESTIGATION			English	Editorial Material							DIABETIC-PATIENTS; PANCREATIC ALPHA; DNA-DAMAGE; MASS; JAPANESE; HUMANS; ISLET; STRESS		[Yagihashi, Soroku; Mizukami, Hiroki; Inaba, Wataru] Hirosaki Univ, Dept Pathol & Mol Med, Grad Sch Med, Hirosaki, Aomori, Japan	Yagihashi, S (reprint author), Hirosaki Univ, Dept Pathol & Mol Med, Grad Sch Med, Hirosaki, Aomori, Japan.	yagihasi@cc.hirosaki-u.ac.jp					Unger RH, 2010, P NATL ACAD SCI USA, V107, P16009, DOI 10.1073/pnas.1006639107; Mizukami H, 2014, DIABETES CARE, V37, P1966, DOI 10.2337/dc13-2018; Mezza T, 2014, DIABETES, V63, P994, DOI 10.2337/db13-1013; Saisho Y, 2013, DIABETES CARE, V36, P111, DOI 10.2337/dc12-0421; Rorsman P, 2014, DIABETOLOGIA, V57, P1749, DOI 10.1007/s00125-014-3279-8; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Henquin JC, 2011, DIABETOLOGIA, V54, P1720, DOI 10.1007/s00125-011-2118-4; Mizukami H, 2014, J DIABETES INVEST, V5, P38, DOI 10.1111/jdi.12118; Yoneda S, 2013, J Clin Endocrinol Metab, V98, P2053, DOI 10.1210/jc.2012-3832	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					393	395		10.1111/jdi.12287		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500005		
J	Yamada, C; Kondo, M; Kishimoto, N; Shibata, T; Nagai, Y; Imanishi, T; Oroguchi, T; Ishii, N; Nishizaki, Y				Yamada, Chizumi; Kondo, Masumi; Kishimoto, Noriaki; Shibata, Takeo; Nagai, Yoko; Imanishi, Tadashi; Oroguchi, Takashige; Ishii, Naoaki; Nishizaki, Yasuhiro			Association between insulin resistance and plasma amino acid profile in non-diabetic Japanese subjects	JOURNAL OF DIABETES INVESTIGATION			English	Article						Amino acids; Homeostasis model assessment of insulin resistance; Insulin resistance	HOMEOSTASIS MODEL ASSESSMENT; TYPE-2 DIABETES-MELLITUS; BRANCHED-CHAIN; DEHYDROGENASE KINASE; YOUNG-ADULTS; CATABOLISM; OBESITY; EXPRESSION; HUMANS; MEN	Aims/IntroductionElevation of the branched-chain amino acids (BCAAs), valine, leucine and isoleucine; and the aromatic amino acids, tyrosine and phenylalanine, has been observed in obesity-related insulin resistance. However, there have been few studies on Asians, who are generally less obese and less insulin-resistant than Caucasian or African-Americans. In the present study, we investigated the relationship between homeostasis model assessment of insulin resistance (HOMA-IR) and plasma amino acid concentration in non-diabetic Japanese participants. Materials and MethodsA total of 94 healthy men and women were enrolled, and plasma amino acid concentration was measured by liquid chromatography/mass spectrometry after overnight fasting. The associations between HOMA-IR and 20 amino acid concentrations, and anthropometric and clinical parameters of lifestyle-related diseases were evaluated. ResultsThe mean age and body mass index were 40.19.6years and 22.7 +/- 3.9, respectively. Significantly positive correlations were observed between HOMA-IR and valine, isoleucine, leucine, tyrosine, phenylalanine and total BCAA concentration. Compared with the HOMA-IR1.6 group, the HOMA-IR>1.6 group showed significantly exacerbated anthropometric and clinical parameters, and significantly elevated levels of valine, isoleucine, leucine, tyrosine, phenylalanine and BCAA. ConclusionsThe present study shows that the insulin resistance-related change in amino acid profile is also observed in non-diabetic Japanese subjects. These amino acids include BCAAs (valine, isoleucine and leucine) and aromatic amino acids (tyrosine and phenylalanine), in agreement with previous studies carried out using different ethnic groups with different degrees of obesity and insulin resistance.	[Yamada, Chizumi; Kondo, Masumi; Kishimoto, Noriaki; Nishizaki, Yasuhiro] Tokai Univ, Tokyo Hosp, Tokyo 151, Japan; [Shibata, Takeo; Nagai, Yoko; Imanishi, Tadashi; Ishii, Naoaki] Tokai Univ, Sch Med, Div Basic Med Sci & Mol Med, Dept Mol Life Sci, Tokyo 151, Japan; [Oroguchi, Takashige; Ishii, Naoaki; Nishizaki, Yasuhiro] Tokai Univ, Grad Sch Med, Life Care Ctr, Tokyo 151, Japan	Nishizaki, Y (reprint author), Tokai Univ, Tokyo Hosp, Tokyo 151, Japan.	dr-yasu@jcom.home.ne.jp					Lackey DE, 2013, AM J PHYSIOL-ENDOC M, V304, pE1175, DOI 10.1152/ajpendo.00630.2012; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Krebs M, 2002, DIABETES, V51, P599, DOI 10.2337/diabetes.51.3.599; Wurtz P, 2012, DIABETES, V61, P1372, DOI 10.2337/db11-1355; Rhee EP, 2011, J CLIN INVEST, V121, P1402, DOI 10.1172/JCI44442; Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Cheng SS, 2012, CIRCULATION, V125, P2222, DOI 10.1161/CIRCULATIONAHA.111.067827; Bain JR, 2009, DIABETES, V58, P2429, DOI 10.2337/db09-0580; Tai ES, 2010, DIABETOLOGIA, V53, P757, DOI 10.1007/s00125-009-1637-8; Wurtz P, 2013, DIABETES CARE, V36, P648, DOI 10.2337/dc12-0895; Doisaki M, 2010, BIOCHEM BIOPH RES CO, V393, P303, DOI 10.1016/j.bbrc.2010.02.004; Huffman KM, 2009, DIABETES CARE, V32, P1678, DOI 10.2337/dc08-2075; McCormack SE, 2013, PEDIATR OBES, V8, P52, DOI 10.1111/j.2047-6310.2012.00087.x; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Shah SH, 2012, DIABETOLOGIA, V55, P321, DOI 10.1007/s00125-011-2356-5; Costeas PA, 1996, BIOCHEM J, V318, P85; Emoto M, 1999, DIABETES CARE, V22, P818, DOI 10.2337/diacare.22.5.818; FELIG P, 1969, NEW ENGL J MED, V281, P811, DOI 10.1056/NEJM196910092811503; Japan Diabetes Society, 2014, TREATM GUID DIAB 201, P11; Kuzuya T, 2008, BIOCHEM BIOPH RES CO, V373, P94, DOI 10.1016/j.bbrc.2008.05.167; Lu Jingyi, 2013, Front Med, V7, P53, DOI 10.1007/s11684-013-0255-5; She PX, 2007, AM J PHYSIOL-ENDOC M, V293, pE1552, DOI 10.1152/ajpendo.00134.2007; Shimomura Y, 2006, J NUTR, V136, p250S; Shimomura Y, 2001, CURR OPIN CLIN NUTR, V4, P419, DOI 10.1097/00075197-200109000-00013; Tremblay F, 2005, DIABETES, V54, P2674, DOI 10.2337/diabetes.54.9.2674; Wurtz P, 2012, DIABETES CARE, V35, P1749, DOI 10.2337/dc11-1838; Yamada C, 2011, J DIABETES INVEST, V2, P373, DOI 10.1111/j.2040-1124.2011.00113.x	29	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					408	415		10.1111/jdi.12323		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500007		
J	Oya, J; Nakagami, T; Kurita, M; Yamamoto, Y; Hasegawa, Y; Tanaka, Y; Endo, Y; Uchigata, Y				Oya, Junko; Nakagami, Tomoko; Kurita, Moritoshi; Yamamoto, Yayoi; Hasegawa, Yukiko; Tanaka, Yuki; Endo, Yasuhiro; Uchigata, Yasuko			Association of birthweight with diabetes and insulin sensitivity or secretion in the Japanese general population	JOURNAL OF DIABETES INVESTIGATION			English	Article						Birthweight; Diabetes; Homeostasis model assessment	HOMEOSTASIS MODEL ASSESSMENT; BODY-MASS INDEX; GLUCOSE-TOLERANCE; THRIFTY PHENOTYPE; RISK-FACTORS; FETAL; RESISTANCE; MELLITUS; GROWTH; MEN	Aims/IntroductionLow birthweight (birthweight <2,500g) has been considered to be a risk factor for diabetes in data from Western countries, and its percentage is increasing in Japan. The aim of the present study was to assess the association between birth weight and diabetes, as well as both insulin resistance and secretion. Materials and MethodsThe participants were 847 adults who underwent health check-ups. The participants were divided by birthweight into four groups (low birthweight and tertiles1-3 above it). We assessed the effect of birthweight on diabetes using a logistic regression model. Multivariable liner regression analyses were carried out to examine whether birthweight is independently associated with homeostasis model assessment of insulin resistance and -cell function. ResultsThe prevalence of diabetes tended to increase with decreasing birthweight. The adjusted odds ratio for diabetes with low birthweight was 3.52 (1.04-11.96) as compared with the reference category, tertile2. Univariable linear regression analyses showed that homeostasis model assessment of insulin resistance was negatively associated with birthweight, and this association remained after adjusting for age, sex, current body mass index and family history of diabetes. There was no significant association between homeostasis model assessment of -cell function and birthweight. ConclusionsLow birthweight was inversely associated with diabetes and insulin resistance in the Japanese general population. Longitudinal data analyses are required to examine the causal relationship between bodyweight and diabetes or insulin resistance in adulthood.	[Oya, Junko; Nakagami, Tomoko; Kurita, Moritoshi; Yamamoto, Yayoi; Hasegawa, Yukiko; Tanaka, Yuki; Uchigata, Yasuko] Tokyo Womens Med Univ, Ctr Diabet, Saitama, Japan; [Endo, Yasuhiro] Saitama Ken Saiseikai Kurihashi Hosp, Dept Hlth & Community Med, Saitama, Japan	Oya, J (reprint author), Tokyo Womens Med Univ, Ctr Diabet, Saitama, Japan.	johya@dmc.twmu.ac.jp					Anazawa S, 2003, DIABETES CARE, V26, P2210, DOI 10.2337/diacare.26.7.2210; Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.3.CO;2-F; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Singhal A, 2002, AM J CLIN NUTR, V75, P993; Takimoto H, 2005, J OBSTET GYNAECOL RE, V31, P314, DOI 10.1111/j.1447-0756.2005.00294.x; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; Jensen CB, 2002, DIABETES, V51, P1271, DOI 10.2337/diabetes.51.4.1271; Harder T, 2007, AM J EPIDEMIOL, V165, P849, DOI 10.1093/aje/kwk071; Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57; Jaquet D, 2000, J CLIN ENDOCR METAB, V85, P1401, DOI 10.1210/jc.85.4.1401; Curhan GC, 1996, CIRCULATION, V94, P3246; Eriksson JG, 2003, DIABETOLOGIA, V46, P190, DOI 10.1007/s00125-002-1012-5; Rich-Edwards JW, 1999, ANN INTERN MED, V130, P278; WANG J, 1994, AM J CLIN NUTR, V60, P23; Lithell HO, 1996, BRIT MED J, V312, P406; Forsen T, 2000, ANN INTERN MED, V133, P176; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Johansson S, 2008, EPIDEMIOLOGY, V19, P659, DOI 10.1097/EDE.0b013e31818131b9; Children Equal Employment, 2011, YEAR 2010 REP CHILDR; Choi CS, 2000, DIABETES RES CLIN PR, V49, P53, DOI 10.1016/S0168-8227(00)00131-5; Clark PM, 1998, EUR J PEDIATR, V157, pS7; Clausen JO, 1997, AM J EPIDEMIOL, V146, P23; Dyck RF, 2001, CAN J PUBLIC HEALTH, V92, P340; Flanagan DE, 2000, AM J PHYSIOL-ENDOC M, V278, pE700; Godfrey K. M., 2000, AM J CLIN NUTR, V71, P1344; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BRIT MED J, V303, P1019; Jaquet D, 2000, Pediatr Diabetes, V1, P181, DOI 10.1046/j.1399543X.2000.010402.x; MCCANCE DR, 1994, BRIT MED J, V308, P942; Mi J, 2000, ANN INTERN MED, V132, P253; Ohmi H, 2001, INT J EPIDEMIOL, V30, P1269, DOI 10.1093/ije/30.6.1269; Schultz NS, 2014, DIABETES, V63, P111, DOI 10.2337/db13-0621; Tsukamoto H, 2007, EUR J OBSTET GYN R B, V133, P53, DOI 10.1016/j.ejogrb.2006.07.031; World Health Organization, 2006, DEF DIAGN DIAB MELL	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					430	435		10.1111/jdi.12325		6	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500009		
J	Ogawa, S; Nako, K; Okamura, M; Sakamoto, T; Ito, S				Ogawa, Susumu; Nako, Kazuhiro; Okamura, Masashi; Sakamoto, Takuya; Ito, Sadayoshi			Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy	JOURNAL OF DIABETES INVESTIGATION			English	Article						Intensive insulin therapy; Liraglutide; Postprandial blood glucose fluctuations	GLYCEMIC CONTROL; BETA-CELLS; LIRAGLUTIDE; PEPTIDE-1; SECRETION; HYPOGLYCEMIA; HUMANS; MEALS	Aims/IntroductionThe nature of the action of concomitant liraglutide to stabilize postprandial blood glucose level (PBG) in patients on intensive insulin therapy with unstable PBG remains unclear. The aim was to identify the nature of liraglutide's actions to stabilize PBGs. Materials and MethodsThe study participants consisted of 20 diabetes patients showing unstable PBGs after dinner despite undergoing intensive insulin therapy. The dose of bolus insulin was reduced by three units for each meal, and 0.9mg/day of liraglutide was added and used in combination. We evaluated the participants' data after the first evaluation (immediately before using liraglutide in combination) and the second evaluation (16weeks after starting concomitant therapy). PBGs after dinner were measured every day for a period of 28days immediately before carrying out both evaluations. The mean value of the 28 sets of blood glucose data and their standard deviation (SD) values were established as PBGs after dinner, as well as the SD for each participant. The changes in the mean values of the 20 participants, as well as their SD between before and after concomitant therapy, were evaluated. ResultsThe mean value of PBGs (12.01.0 to 10.1 +/- 0.9mmol/L) and SD values (5.1 +/- 0.7-3.5 +/- 0.8) after dinner both declined. A multiple regression analysis showed that the combined use of liraglutide was a significant independent variable of the SD values of PBGs after dinner. ConclusionThe treatment of reducing the dose of insulin and using liraglutide in combination not only suppresses PBGs, but also stabilizes their blood glucose fluctuations.	[Ogawa, Susumu; Nako, Kazuhiro; Okamura, Masashi; Sakamoto, Takuya; Ito, Sadayoshi] Tohoku Univ Hosp, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi, Japan; [Ogawa, Susumu] Tohoku Univ, Sect Clin Med, Div Res Student Support, Inst Excellence Higher Educ, Sendai, Miyagi 980, Japan	Ogawa, S (reprint author), Tohoku Univ Hosp, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi, Japan.	ogawa-s@hosp.tohoku.ac.jp					Hare KJ, 2010, DIABETES, V59, P1765, DOI 10.2337/db09-1414; Lane W, 2011, DIABETES TECHNOL THE, V13, P592, DOI 10.1089/dia.2010.0221; Imeryuz N, 1997, AM J PHYSIOL-GASTR L, V273, pG920; Lee YS, 2014, METABOLISM, V63, P9, DOI 10.1016/j.metabol.2013.09.010; Kristensen PL, 2012, DIABETES RES CLIN PR, V96, P17, DOI 10.1016/j.diabres.2011.10.046; Sarkar G, 2014, DIABETES CARE, V37, P666, DOI 10.2337/dc13-1473; Cryer PE, 2014, DIABETES, V63, P2188, DOI 10.2337/db14-0059; Kielgast U, 2011, DIABETES CARE, V34, P1463, DOI 10.2337/dc11-0096; Varanasi A, 2011, EUR J ENDOCRINOL, V165, P77, DOI 10.1530/EJE-11-0330; Naslund E, 1999, AM J PHYSIOL-REG I, V277, pR910; Behme M., 2003, BMC ENDOCR DISORD, V3, P3, DOI 10.1186/1472-6823-3-3; DesMarinis YZ, 2010, CELL METAB, V11, P543; Gannon MC, 1998, DIABETES CARE, V21, P1619, DOI 10.2337/diacare.21.10.1619; Gotoh K, 2013, J NEUROENDOCRINOL, V25, P302, DOI 10.1111/jne.12003; Hagemann D, 2007, REGUL PEPTIDES, V143, P64, DOI 10.1016/j.regpep.2007.03.002; KAWAI K, 1987, ENDOCRINOL JAPON, V34, P745; Lane W, 2014, DIABETES OBES METAB, V16, P827, DOI 10.1111/dom.12286; Li CJ, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-142; Ogawa S, 2013, J DIABETES MELLITUS, V3, P244; Schwasinger-Schmidt T, 2013, PHARMACOL RES, V76, P58, DOI 10.1016/j.phrs.2013.07.005; vansBloemendaal L, 2014, J ENDOCRINOL, V221, pT1; Wettergren A, 1998, AM J PHYSIOL-GASTR L, V275, pG984	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					436	442		10.1111/jdi.12314		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500010		
J	Seino, Y; Inagaki, N; Haneda, M; Kaku, K; Sasaki, T; Fukatsu, A; Ubukata, M; Sakai, S; Samukawa, Y				Seino, Yutaka; Inagaki, Nobuya; Haneda, Masakazu; Kaku, Kohei; Sasaki, Takashi; Fukatsu, Atsushi; Ubukata, Michito; Sakai, Soichi; Samukawa, Yoshishige			Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus	JOURNAL OF DIABETES INVESTIGATION			English	Article						Add-on therapy; Luseogliflozin; Oral antidiabetic drug	DOUBLE-BLIND; METFORMIN; GLUCOSE; PLACEBO; TRIAL; MONOTHERAPY; KIDNEY	IntroductionTwo studies were carried out to investigate the efficacy and safety of luseogliflozin added to existing oral antidiabetic drugs (OADs) in Japanese type 2 diabetic patients inadequately controlled with OAD monotherapy. Materials and MethodsIn the trial involving add-on to sulfonylureas (study 03-1), patients were randomly assigned to receive luseogliflozin 2.5mg or a placebo for a 24-week double-blind period, followed by a 28-week open-label period. In the open-label trial involving add-on to other OADs; that is, biguanides, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, glinides and -glucosidase inhibitors (study 03-2), patients received luseogliflozin for 52weeks. ResultsIn study 03-1, luseogliflozin significantly decreased glycated hemoglobin at the end of the 24-week double-blind period compared with the placebo (-0.88%, P<0.001), and glycated hemoglobin reduction from baseline at week52 was -0.63%. In study 03-2, luseogliflozin added to other OADs significantly decreased glycated hemoglobin from baseline at week52 (-0.52 to -0.68%, P<0.001 for all OADs). Bodyweight reduction was observed in all add-on therapies, even with agents associated with weight gain, such as sulfonylureas and thiazolidinediones. Most adverse events were mild in severity. When added to a sulfonylurea, incidences of hypoglycemia during the double-blind period were 8.7% and 4.2% for luseogliflozin and placebo, respectively, but no major hypoglycemic episodes occurred. The frequency and incidences of adverse events of special interest for sodium glucose cotransporter2 inhibitors and adverse events associated with combined OADs were acceptable. ConclusionsAdd-on therapies of luseogliflozin to existing OADs improved glycemic control, reduced bodyweight and were well tolerated in Japanese type2 diabetic patients. These trials were registered with the Japan Pharmaceutical Information Center (add on to sulfonylurea: JapicCTI-111507; add on to other OADs: JapicCTI-111508).	[Seino, Yutaka] Kansai Elect Power Hosp, Osaka, Japan; [Inagaki, Nobuya] Kyoto Univ, Grad Sch Med, Kyoto, Japan; [Haneda, Masakazu] Asahikawa Med Univ, Asahikawa, Hokkaido, Japan; [Kaku, Kohei] Kawasaki Med Univ, Dept Internal Med, Okayama, Japan; [Sasaki, Takashi] Jikei Univ, Div Diabet & Endocrinol, Grad Sch Med Res, Tokyo, Japan; [Ubukata, Michito; Sakai, Soichi; Samukawa, Yoshishige] Taisho Pharmaceut Co Ltd, Tokyo, Japan; [Fukatsu, Atsushi] Yachiyo Hosp, Aichi, Japan	Sakai, S (reprint author), Taisho Pharmaceut Co Ltd, Tokyo, Japan.	so-sakai@so.taisho.co.jp					Phung OJ, 2010, JAMA-J AM MED ASSOC, V303, P1410, DOI 10.1001/jama.2010.405; Endo Y, 2011, CELL METAB, V13, P550, DOI 10.1016/j.cmet.2011.02.015; Seino Y, 2014, CURR MED RES OPIN, V30, P1245, DOI 10.1185/03007995.2014.912983; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; DeFronzo RA, 2012, DIABETES OBES METAB, V14, P5, DOI 10.1111/j.1463-1326.2011.01511.x; Kodama K, 2013, DIABETES CARE, V36, P1789, DOI 10.2337/dc12-1235; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; [Anonymous], 1994, ICH HARM TRIP GUID E; [Anonymous], 2010, GUID CLIN EV OR HYP; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; Bailey CJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-43; Harada N, 2012, J DIABETES INVEST, V3, P352, DOI 10.1111/j.2040-1124.2012.00227.x; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI [10.2337/dc12-0413, 10.2337/dc12-041.3]; Kimura Tomomi, 2012, Pharmaceutics, V4, P479, DOI 10.3390/pharmaceutics4030479; Lavalle-Gonzalez FJ, 2013, DIABETOLOGIA, V56, P2582, DOI 10.1007/s00125-013-3039-1; Ridderstrale M, 2013, CARDIOVASC DIABETOL; Seino Y, 2013, INT DIAB FED 2013 WO	17	2	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					443	453		10.1111/jdi.12316		11	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500011		
J	Iwase, H; Tanaka, M; Kobayashi, Y; Wada, S; Kuwahata, M; Kido, Y; Hamaguchi, M; Asano, M; Yamazaki, M; Hasegawa, G; Nakamura, N; Fukui, M				Iwase, Hiroya; Tanaka, Muhei; Kobayashi, Yukiko; Wada, Sayori; Kuwahata, Masashi; Kido, Yasuhiro; Hamaguchi, Masahide; Asano, Mai; Yamazaki, Masahiro; Hasegawa, Goji; Nakamura, Naoto; Fukui, Michiaki			Lower vegetable protein intake and higher dietary acid load associated with lower carbohydrate intake are risk factors for metabolic syndrome in patients with type2 diabetes: Post-hoc analysis of a cross-sectional study	JOURNAL OF DIABETES INVESTIGATION			English	Article						Low-carbohydrate diet; Metabolic syndrome; Type2 diabetes mellitus	IMPAIRED GLUCOSE-TOLERANCE; EXCRETION; DISEASE; HUMANS; HYPERTENSION; COHORT; WOMEN; CALCIUM; OBESITY; ENERGY	Aims/IntroductionA low-carbohydrate diet based on animal sources is associated with higher all-cause mortality, whereas a vegetable-based low-carbohydrate diet is associated with lower cardiovascular disease mortality. It has been suggested that acid/base imbalance might play an important role in some cardiometabolic abnormalities. The aims of the present study were to evaluate whether carbohydrate intake is associated with quality of dietary protein and acid load, and whether these are related to metabolic syndrome in patients with type2 diabetes. Materials and MethodsThe present cross-sectional study involved 149 patients with type2 diabetes. Dietary intake was assessed using a validated self-administered diet history questionnaire. Dietary acid load was assessed by potential renal acid load and net endogenous acid production. ResultsMean daily total energy intake, carbohydrate intake, animal protein intake and vegetable protein intake were 1821.5kcal, 248.8g, 36.1g and 31.1g, respectively. Carbohydrate energy/total energy was negatively correlated with animal protein energy/total energy, potential renal acid load or net endogenous acid production score, and was positively correlated with vegetable protein energy/total energy. Logistic regression analyses showed that the subgroup of patients with a lower vegetable protein energy/total energy or higher potential renal acid load or net endogenous acid production score was significantly associated with the prevalence of metabolic syndrome. ConclusionsThe present study showed that carbohydrate intake was associated with the quality of dietary protein and dietary acid load. Furthermore, decreased vegetable protein intake and increased dietary acid load were associated with the prevalence of metabolic syndrome.	[Iwase, Hiroya; Tanaka, Muhei; Hamaguchi, Masahide; Asano, Mai; Yamazaki, Masahiro; Nakamura, Naoto; Fukui, Michiaki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kyoto, Japan; [Kobayashi, Yukiko; Wada, Sayori; Kuwahata, Masashi; Kido, Yasuhiro] Kyoto Prefectural Univ, Grad Sch Life & Environm Sci, Kyoto 606, Japan; [Hasegawa, Goji] Japanese Red Cross Kyoto Daini Hosp, Div Metab Nephrol & Rheumatol, Kyoto, Japan	Fukui, M (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kyoto, Japan.	sayarinapm@hotmail.com					American Diabetes Association, 2012, DIABETES CARE S1, V35, pS11, DOI DOI 10.2337/DC12-S011; Maurer M, 2003, AM J PHYSIOL-RENAL, V284, pF32, DOI 10.1152/ajprenal.00212.2002; Remer T, 2003, AM J CLIN NUTR, V77, P1255; Hamaguchi M, 2005, ANN INTERN MED, V143, P722; Souto G, 2011, METAB SYNDR RELAT D, V9, P247, DOI 10.1089/met.2010.0108; Adeva MM, 2011, CLIN NUTR, V30, P416, DOI 10.1016/j.clnu.2011.03.008; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261; DEFRONZO RA, 1979, AM J PHYSIOL, V236, pE328; Hession M, 2009, OBES REV, V10, P36, DOI 10.1111/j.1467-789X.2008.00518.x; Fung TT, 2010, ANN INTERN MED, V153, P289, DOI 10.7326/0003-4819-153-5-201009070-00003; FESKENS EJM, 1995, DIABETES CARE, V18, P1104, DOI 10.2337/diacare.18.8.1104; Engberink MF, 2012, AM J CLIN NUTR, V95, P1438, DOI 10.3945/ajcn.111.022343; Franz MJ, 2008, J AM DIET ASSOC, V108, pS52, DOI 10.1016/j.jada.2008.01.021; Wang YF, 2008, J HUM HYPERTENS, V22, P745, DOI 10.1038/jhh.2008.64; Sone H, 2009, J ATHEROSCLER THROMB, V16, P380; NATH KA, 1985, J CLIN INVEST, V76, P667, DOI 10.1172/JCI112020; SHARMA AM, 1990, HYPERTENSION, V16, P407; Cappuccio FP, 2000, J NEPHROL, V13, P169; Franz MJ, 2010, J AM DIET ASSOC, V110, P1852, DOI 10.1016/j.jada.2010.09.014; Hermsdorff HHM, 2011, EUR J NUTR, V50, P61, DOI 10.1007/s00394-010-0115-x; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Maalouf NM, 2007, CLIN J AM SOC NEPHRO, V2, P883, DOI 10.2215/CJN.00670207; Gogebakan O, 2011, CIRCULATION, V124, P2829, DOI 10.1161/CIRCULATIONAHA.111.033274; Fagherazzi G, 2014, DIABETOLOGIA, V57, P313, DOI 10.1007/s00125-013-3100-0; Floegel A, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3801; Lagiou P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4026; Livingstone MBE, 2003, J NUTR, V133, p895S; MARSHALL JA, 1994, DIABETES CARE, V17, P50, DOI 10.2337/diacare.17.1.50; Murakami K, 2008, EUR J CLIN NUTR, V62, P111, DOI 10.1038/sj.ejcn.1602683; Noto H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055030; Remer T, 1998, J CLIN ENDOCR METAB, V83, P2132, DOI 10.1210/jc.83.6.2132; Sasaki S, 1998, J Epidemiol, V8, P203; SHARMA AM, 1993, HYPERTENSION, V22, P884; Sicuro A, 1998, AM J PHYSIOL-RENAL, V274, pF650; Smogorzewski Miroslaw J, 2009, J Nephrol, V22 Suppl 14, P108; Steering Committee of the Western Pacific Region of the World Health Organization the International Association for the Study of Obesity the International Obesity Task Force, 2000, AS PAC PERSP RED OB; Taylor EN, 2006, AM J KIDNEY DIS, V47, P780, DOI 10.1053/j.ajkd.2006.01.024; vansNielen M, 2014, DIABETES CARE, V37, P1854	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					465	472		10.1111/jdi.12326		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500014		
J	Makino, H; Miyamoto, Y; Kikuchi-Taura, A; Soma, T; Taguchi, A; Kishimoto, I				Makino, Hisashi; Miyamoto, Yoshihiro; Kikuchi-Taura, Akie; Soma, Toshihiro; Taguchi, Akihiko; Kishimoto, Ichiro			Decreased levels of circulating CD34(+) cells are associated with coronary heart disease in Japanese patients with type 2 diabetes	JOURNAL OF DIABETES INVESTIGATION			English	Article						Circulating progenitor cell; Coronary heart disease; Endothelial function	ENDOTHELIAL PROGENITOR CELLS; CD34-POSITIVE CELLS; INTRACTABLE ANGINA; COMPLICATIONS; THERAPY; NUMBER; RISK	Aims/IntroductionCirculating progenitor cells, including CD34 positive (CD34(+)) cells, play a key role in neovascularisation and the maintenance of vascular endothelial function. Several lines of evidence show an association between decreased levels of circulating CD34(+) cells and cardiovascular disease. However, the contribution of circulating CD34(+) cells to the occurrence of cardiovascular events in diabetic patients remains unclear. Materials and MethodsIn the present study with a median follow up of 4.6years, we analyzed the level of circulating CD34(+) cells in 192 patients with type2 diabetes. The outcome variables were coronary heart disease (CHD) events (cardiovascular death, unstable angina, myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting) and cerebrovascular disease events (cerebral infarction, cerebral hemorrhage or transient ischemic attack). ResultsDecreased levels of circulating CD34(+) cells were associated with a significantly higher incidence of CHD based on Kaplan-Meier analysis (P=0.0052). After adjusting for age, sex, dyslipidemia, hypertension, glycated hemoglobin, history of cardiovascular disease, body mass index, and statin and renin angiotensin system inhibitors use, decreased levels of CD34(+) cells were significantly associated with the incidence of CHD events (hazard ratio of low tertile 2.61, 95% confidence interval 1.22-5.96; P=0.013, reference; high tertile). ConclusionsDecreased levels of circulating CD34(+) cells might predict CHD events in patients with diabetes, and this could be useful for identifying patients with diabetes at high risk of cardiovascular events.	[Makino, Hisashi; Kishimoto, Ichiro] Natl Cerebral & Cardiovasc Ctr, Div Endocrinol & Metab, Suita, Osaka, Japan; [Miyamoto, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Div Prevent Cardiol, Suita, Osaka, Japan; [Kikuchi-Taura, Akie] Natl Hosp Org Osaka Minami Med Ctr, Dept Clin Lab, Osaka, Japan; [Soma, Toshihiro] Hyogo Coll Med, Dept Hematol, Nishinomiya, Hyogo, Japan; [Taguchi, Akihiko] Inst Biomed Res & Innovat, Dept Regenerat Med Res, Kobe, Hyogo, Japan	Makino, H (reprint author), Natl Cerebral & Cardiovasc Ctr, Div Endocrinol & Metab, Suita, Osaka, Japan.	makinoh@hsp.ncvc.go.jp					Yoshihara T, 2008, J CEREBR BLOOD F MET, V28, P1086, DOI 10.1038/jcbfm.2008.1; Sone H, 2011, J CLIN ENDOCR METAB, V96, P3448, DOI 10.1210/jc.2011-0622; Fadini GP, 2005, J AM COLL CARDIOL, V45, P1449, DOI 10.1016/j.jacc.2004.11.067; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Taguchi A, 2004, CIRCULATION, V109, P2972, DOI 10.1161/01.CIR.0000133311.25587.DE; Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340; Fadini GP, 2010, DIABETES CARE, V33, P1097, DOI 10.2337/dc09-1999; Losordo DW, 2007, CIRCULATION, V115, P3165, DOI 10.1161/CIRCULATIONAHA.106.687376; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Bielak Lawrence F, 2009, Clin Med Cardiol, V3, P53; Fadini GP, 2009, ATHEROSCLEROSIS, V207, P213, DOI 10.1016/j.atherosclerosis.2009.03.040; Kashiwagi A, 2012, DIABETOL INT, V3, P8, DOI DOI 10.1007/S13340-012-0069-8; Kikuchi-Taura A, 2006, TEX HEART I J, V33, P427; Okada S, 2008, DIABETES CARE, V31, P157, DOI 10.2337/dc07-1125; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Taguchi A, 2011, PSYCHOGERIATRICS, V11, P113, DOI 10.1111/j.1479-8301.2010.00343.x; Wang SH, 2010, CARDIOLOGY, V117, P140, DOI 10.1159/000320217	18	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					473	478		10.1111/jdi.12310		6	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500015		
J	Kamei, S; Kaneto, H; Irie, S; Kinoshita, T; Tanabe, A; Hirukawa, H; Tatsumi, F; Shimoda, M; Kohara, K; Mune, T; Kaku, K				Kamei, Shinji; Kaneto, Hideaki; Irie, Shintaro; Kinoshita, Tomoe; Tanabe, Akihito; Hirukawa, Hidenori; Tatsumi, Fuminori; Shimoda, Masashi; Kohara, Kenji; Mune, Tomoatsu; Kaku, Kohei			Pseudoaldosteronism induced by Yokukansan in an elderly Japanese type 2 diabetic patient with Alzheimer's disease	JOURNAL OF DIABETES INVESTIGATION			English	Letter							METAANALYSIS; DEMENTIA		[Kamei, Shinji; Kaneto, Hideaki; Irie, Shintaro; Kinoshita, Tomoe; Tanabe, Akihito; Hirukawa, Hidenori; Tatsumi, Fuminori; Shimoda, Masashi; Kohara, Kenji; Mune, Tomoatsu; Kaku, Kohei] Kawasaki Med Univ, Div Diabet Metab & Endocrinol, Kurashiki, Okayama, Japan	Kamei, S (reprint author), Kawasaki Med Univ, Div Diabet Metab & Endocrinol, Kurashiki, Okayama, Japan.	s.kamei@med.kawasaki-m.ac.jp					Matsuda Y, 2013, HUM PSYCHOPHARM CLIN, V28, P80, DOI 10.1002/hup.2286; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Maher AR, 2011, JAMA-J AM MED ASSOC, V306, P1359, DOI 10.1001/jama.2011.1360; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Nishiyama Naoki, 2011, Nihon Ronen Igakkai Zasshi, V48, P553	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	JUL	2015	6	4					487	488		10.1111/jdi.12297		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CM2MU	WOS:000357515500017		
J	Eddy, C; Sase, E				Eddy, Christopher; Sase, Eriko			Implications of the Fukushima Nuclear Disaster: Man-Made Hazards, Vulnerability Factors, and Risk to Environmental Health	JOURNAL OF ENVIRONMENTAL HEALTH			English	Article								The objective of this article was to examine the environmental health implications of the 2011 Fukushima nuclear disaster from an all-hazards perspective. The authors performed a literature review that included Japanese and international nuclear guidance and policy, scientific papers, and reports on the Chernobyl and Three Mile Island disasters while also considering all-hazards preparedness rubrics in the U.S. The examination of the literature resulted in the following: a) the authors' "All-Hazards Planning Reference Model" that distinguishes three planning categories Disaster Trigger Event, Man-Made Hazards, and Vulnerability Factors; b) the generalization of their model to other countries; and c) advocacy for environmental health end fate to be considered in planning phases to minimize risk to environmental health. This article discusses inconsistencies in disaster planning and nomenclature existing in the studied materials and international guidance and proposes new opportunity for developing predisaster risk assessment, risk communication, and prevention capacity building.	[Eddy, Christopher] Grand Canyon Univ, Coll Sci Engn & Technol, Phoenix, AZ 85017 USA; [Sase, Eriko] Univ Tokyo, Grad Sch Med, Tokyo 1138654, Japan	Eddy, C (reprint author), Grand Canyon Univ, Coll Sci Engn & Technol, 3300 West Camelback Rd, Phoenix, AZ 85017 USA.	chris.eddy@my.gcu.edu					Alavarez R., 2011, SPENT NUCL FUEL POOL; American Nuclear Society, 2012, FUK DAI ICH ANS COMM; American Standards and Testing Material International, 2004, E2413 ASTM INT; [Anonymous], 2014, REUTERS         1222; Taebi B, 2008, SCI ENG ETHICS, V14, P177, DOI 10.1007/s11948-007-9049-y; [Anonymous], 2014, BBC NEWS; Stohl A, 2012, ATMOS CHEM PHYS, V12, P2313, DOI 10.5194/acp-12-2313-2012; Bisesi M., 2013, J ENV HLTH, V76, P72; Bokman L., 2003, NATURAL HAZARDS OBSE, V27, P10; Bolz F., 2005, COUNTERTERRORISM HDB, P58; Cruz M., 2004, STATE ART NATECH RIS; House of Commons Energy and Climate Change Committee, 2013, BUILD NEW NUCL CHALL; International Atomic Energy Agency, 2010, JOINT RAD EM MAN PLA; International Atomic Energy Agency, 2011, FUK NUCL ACC UPD LOG; Japan Atomic Energy Commission, 2009, WHIT PAP NUCL EN 200; Maurice J, 2013, LANCET, V381, P1611; Mousseau T.A., 2013, J HLTH POLLUTION, V3, P2; National Academies, 2012, DIS RES NAT IMPL; National Council on Radiation Protection and Measurements, 2010, RESP RAD NUCL TERR I, P144; National Diet of Japan, 2012, OFF REP FUK NUCL ACC; Occupational Safety and Health Administration, 2005, OSHA BEST PRACT HOSP; Organization for Economic Coordination and Development Nuclear Agency, 2011, BAS DES INF BOIL WAT; Perrow C., 2013, B ATOM SCI, V69, P66; Physicians for Social Responsibility, 2011, LESS LEARN FUK CHERN; Reconstruction Agency of Japan, 2014, NUMB EV; Rosenbaum W, 2014, ENV POLITICS POLICY, P157; Royal Society of Chemistry, 2013, ENV RISK ASS; Sase E., 2014, STUDY RIGHT HLTH POS; Sutton K. G., 2011, CASASTROPHE JAPAN EA, P77; Tokyo Electric Power Company, 2014, FUK DAI ICH NUCL POW; Tokyo Electric Power Company, 2014, DET AN RES PORT FUK; U. S. Nuclear Regulatory Commission, 2014, LIST POW REACT UN; U. S. Nuclear Regulatory Commission, 2011, REC ENH REACT SAF 21; United Nations, 2005, REV YOK STRAT PLAN A; U.S. Nuclear Regulatory Commission, 2014, LESS LEARN FUK NUCL; U.S. Nuclear Regulatory Commission, 2014, FACT SHEET PROB RISK; WHO, 2012, PREL DOS EST NUCL AC; World Health Organization, 2014, AL RESP CAP BUILD IN; World Health Organization, 2005, INT HLTH REG; World Health Organization, 2007, RISK RED EM PREP WHO; Yasui S, 2013, J OCCUP ENVIRON HYG, V10, pD119, DOI 10.1080/15459624.2013.818239	41	1	1	NATL ENVIRON HEALTH ASSOC	DENVER	720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA	0022-0892			J ENVIRON HEALTH	J. Environ. Health	JUL-AUG	2015	78	1					26	32				7	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	CM3BO	WOS:000357556900005		
J	Tsuchiya, M; Toyofuku, T; Uematsu, K; Bruchert, V; Collen, J; Yamamoto, H; Kitazato, H				Tsuchiya, Masashi; Toyofuku, Takashi; Uematsu, Katsuyuki; Bruchert, Volker; Collen, John; Yamamoto, Hiroyuki; Kitazato, Hiroshi			Cytologic and Genetic Characteristics of Endobiotic Bacteria and Kleptoplasts of Virgulinella fragilis (Foraminifera)	JOURNAL OF EUKARYOTIC MICROBIOLOGY			English	Article						Molecular phylogeny; multiple endosymbiosis; transmission electron microscopy	16S RIBOSOMAL-RNA; BENTHIC FORAMINIFERA; HYDROGEN-SULFIDE; OXYGEN CONCENTRATIONS; MOLECULAR PHYLOGENY; CHLOROPLASTS; SYMBIOSIS; PLASTIDS; ANOXIA; CLASSIFICATION	The benthic foraminifer Virgulinella fragilis Grindell and Collen 1976 has multiple putative symbioses with both bacterial and kleptoplast endobionts, possibly aiding its survival in environments from dysoxia (5-45mol-O-2/L) to microxia (0-5mol-O-2/L) and in the dark. To clarify the origin and function of V. fragilis endobionts, we used genetic analyses and transmission electron microscope observations. Virgulinella fragilis retained -proteobacteria concentrated at its cell periphery just beneath the cell membranes. Unlike another foraminifer Stainforthia spp., which retains many bacterial species, V. fragilis has a less variable bacterial community. This suggests that V. fragilis maintains a specific intracellular bacterial flora. Unlike the endobiotic bacteria, V. fragilis klepto-plasts originated from various diatom species and are found in the interior cytoplasm. We found evidence of both retention and digestion of kleptoplasts, and of fragmentation of the kleptoplastid outer membrane that likely facilitates transport of kleptoplastid products to the host. Accumulations of mitochondria were observed encircling endobiotic bacteria. It is likely that the bacteria use host organic material for carbon oxidation. The mitochondria may use oxygen available around the -proteobacteria and synthesize adenosine triphosphate, perhaps for sulfide oxidation.	[Tsuchiya, Masashi; Toyofuku, Takashi; Yamamoto, Hiroyuki; Kitazato, Hiroshi] Japan Agcy Marine Earth Sci & Technol, Yokosuka, Kanagawa 2370061, Japan; [Uematsu, Katsuyuki] Marine Works Japan Ltd, Yokosuka, Kanagawa 2370036, Japan; [Bruchert, Volker] Stockholm Univ, Dept Geol & Geochem, S-10691 Stockholm, Sweden; [Collen, John] Victoria Univ Wellington, Sch Geog Environm & Earth Sci, Wellington, New Zealand	Tsuchiya, M (reprint author), Japan Agcy Marine Earth Sci & Technol, Dept Marine Biodivers Res, 2-15 Natsushima Cho, Yokosuka, Kanagawa 2370061, Japan.	tsuchiyam@jamstec.go.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [24340131, 21244079]	We are grateful to Dr. Kay-Christian Emeis, Institut fuer Biogeochemie und Meereschemie, Universitaet Hamburg, for providing the opportunity to embark on FS Meteor to collect Virgulinella specimens off the coast of Namibia. We are grateful to the crew of the research vessel (R/V) Raukawa Challenger at the Island Bay Marine Laboratory, Victoria University of Wellington; the crews of FS Meteor (M76-2) and R/V Tansei-maru (KT04-04) for their help in collecting sediment samples; Dr. J. Gardner of Victoria University of Wellington for valuable comments on the environmental data in Wellington Harbor; Dr. T. Maruyama of the Japan Agency for Marine-Earth Science and Technology (JAMSTEC), for helpful comments on our study; Drs K. Oguri, S. Sakai, and H. Nomaki of JAMSTEC and Dr. S. Kawagata of Yokohama National University, for their cooperation in environmental observations and sampling at Namako-ike, Sagami Bay and Wellington Harbor; Mr. S. Higashi, Planning Division of the Kamikoshiki Village Office, for arranging the sampling; Mr. M. Kawato, JAMSTEC, for technical assistance in molecular work; Dr. K. Takishita for technical advice on using primers for plastids; and Dr. S. Arakawa for technical advice in T-RFLP analysis. We are very grateful to Prof. Roberto Docampo, editor in chief of the Journal of Eukaryotic Microbiology, and anonymous reviewers for their valuable comments on this manuscript. This Research was supported by Grants-in-Aid for Scientific Research (no. 24340131 to M. Tsuchiya and no. 21244079 to H. Kitazato) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Altenbach A. V., 2004, WORKSH LIV BENTH FOR; Altenbach A. V., 2002, FOR 2002 INT S FOR, P20; Schweizer M, 2005, MAR MICROPALEONTOL, V57, P51, DOI 10.1016/j.marmicro.2005.07.001; Park MG, 2006, AQUAT MICROB ECOL, V45, P101, DOI 10.3354/ame045101; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; FELBECK H, 1981, NATURE, V293, P291, DOI 10.1038/293291a0; LOPEZ E, 1979, MAR BIOL, V53, P201, DOI 10.1007/BF00952427; Ruehland C, 2008, ENVIRON MICROBIOL, V10, P3404, DOI 10.1111/j.1462-2920.2008.01728.x; Bernhard JM, 1999, EARTH-SCI REV, V46, P149, DOI 10.1016/S0012-8252(99)00017-3; Holzmann M, 1996, J FORAMIN RES, V26, P264; WEISBURG WG, 1991, J BACTERIOL, V173, P697; Grzymski J, 2002, LIMNOL OCEANOGR, V47, P1569; Licari L, 2005, MAR MICROPALEONTOL, V55, P205, DOI 10.1016/j.marmicro.2005.03.001; Pawlowski J, 2000, MICROPALEONTOLOGY, V46, P1; ALVE E, 1995, MAR ECOL PROG SER, V116, P137, DOI 10.3354/meps116137; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; FENCHEL T, 1977, J PROTOZOOL, V24, P154, DOI 10.1111/j.1550-7408.1977.tb05294.x; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454; Bernhard JM, 2001, DEEP-SEA RES PT I, V48, P2233, DOI 10.1016/S0967-0637(01)00017-6; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Amann J, 2010, J MOL MICROB BIOTECH, V18, P74, DOI 10.1159/000277655; Bernhard JM, 2003, SCIENCE, V299, P861, DOI 10.1126/science.1077314; Dubilier N, 2001, NATURE, V411, P298, DOI 10.1038/35077067; Bernhard JM, 2000, NATURE, V403, P77, DOI 10.1038/47476; Koike K, 2005, PROTIST, V156, P225, DOI 10.1016/j.protis.2005.04.002; Bernhard JM, 2008, J EUKARYOT MICROBIOL, V55, P135, DOI 10.1111/j.1550-7408.2008.00318.x; Bruchert V, 2006, NATO SCI S SS IV EAR, V64, P161; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Blazejak A, 2005, APPL ENVIRON MICROB, V71, P1553, DOI 10.1128/AEM.71.3.1553-1561.2005; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; Pillet L, 2011, PROTIST, V162, P394, DOI 10.1016/j.protis.2010.10.001; FENCHEL T, 1992, ARCH MICROBIOL, V158, P394; Green BJ, 2000, PLANT PHYSIOL, V124, P331, DOI 10.1104/pp.124.1.331; REVETS SA, 1991, J FORAMIN RES, V21, P293; WAUGH GR, 1986, MAR BIOL, V92, P483, DOI 10.1007/BF00392508; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; MOODLEY L, 1992, BIOL BULL, V183, P94, DOI 10.2307/1542410; RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3; Bernhard JM, 2010, ENVIRON MICROBIOL, V12, P2107, DOI 10.1111/j.1462-2920.2009.02073.x; Stoimenova M, 2007, PLANTA, V226, P465, DOI 10.1007/s00425-007-0496-0; Rumpho ME, 2000, PLANT PHYSIOL, V123, P29, DOI 10.1104/pp.123.1.29; Maeda T, 2010, BIOL BULL-US, V219, P17; Liu WT, 1997, APPL ENVIRON MICROB, V63, P4516; ARNOLD ZACH M., 1964, UNIV CALIF PUBLICATIONS ZOOL, V72, P1; Bedoshvili Y. D., 2009, CELL TISSUE BIOL, V3, P297, DOI DOI 10.1134/S1990519X09030122; Bernhard JM, 1996, MAR MICROPALEONTOL, V28, P5, DOI 10.1016/0377-8398(95)00036-4; Bernhard J. M., 2002, FOR 2002 INT S FORM, P24; BERNHARD JM, 1993, MAR MICROPALEONTOL, V20, P203, DOI 10.1016/0377-8398(93)90033-T; Bernhard JM, 2006, J GEOPHYS RES-BIOGEO, V111, DOI [10.1029/2005JG000158, 10.1029/2005GJ000158]; Bernhard Joan M., 1996, Revue de Paleobiologie, V15, P261; Cardich J, 2012, ANOXIA EVIDENCE EUKA, V21, P323; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/ijs.0.02058-0; CEDHAGEN T, 1991, OPHELIA, V33, P17; GRINDELL D S, 1976, Revista Espanola de Micropaleontologia, V8, P273; Correia MJ, 2002, SYMBIOSIS, V32, P15; Dodge J.D., 1973, FINE STRUCTURE ALGAL; Esteban G. F., 2008, ENVIRON MICROBIOL, DOI [10.1111/j.1462-2920.2008.01797, DOI 10.1111/J.1462-2920.2008.01797]; Fenchel T, 1995, OXFORD SERIES ECOLOG; GIBBS SP, 1979, J CELL SCI, V35, P253; Hayat MA, 2000, PRINCIPLES TECHNIQUE; Horiguchi Takeo, 1992, Japanese Journal of Phycology, V40, P353; Isaksen MF, 1996, ARCH MICROBIOL, V166, P160, DOI 10.1007/s002030050371; Johannesson K. J., 1955, NZ J SCI TECHNOL B, V37, P224; Johannesson K. J., 1955, NZ J SCI TECHNOL B, V37, P445; KAWAGUTI S, 1965, Biological Journal of Okayama University, V11, P57; Lane D. J., 1991, NUCL ACID TECHNIQUES, V4, P115, DOI DOI 10.1002/JOBM.3620310616; LARSEN J, 1988, PHYCOLOGIA, V27, P366, DOI 10.2216/i0031-8884-27-3-366.1; Lee J.J., 1991, P157; LesCalvez J., 1938, ARCH ZOOL EXP GEN, V80, P163; Mann David G., 1996, P249; Margulis L., 1970, ORIGIN EUKARYOTIC CE; MCENERY ME, 1976, J PROTOZOOL, V23, P94; McFadden GI, 2001, J PHYCOL, V37, P951, DOI 10.1046/j.1529-8817.2001.01126.x; NYHOLM K-G, 1975, ZOON (Uppsala), V3, P141; Pawlowski Jan, 1995, Grzybowski Foundation Special Publication, V3, P233; Rambaut A, 1996, SE AL VER2 0A11 SEQU; Risgaard-Petersen N, 2006, NATURE, V443, P93, DOI 10.1038/nature05070; ROUND F. E., 1990, DIATOMS BIOL MORPHOL; Sagan L, 1967, J Theor Biol, V14, P255; Takishita Kiyotaka, 1999, Phycological Research, V47, P207, DOI 10.1111/j.1440-1835.1999.tb00300.x; Takishita Kiyotaka, 2000, Phycological Research, V48, P85, DOI 10.1046/j.1440-1835.2000.00189.x; Takishita Kiyotaka, 1999, Phycological Research, V47, P257, DOI 10.1111/j.1440-1835.1999.tb00306.x; TRENCH RK, 1973, PROC R SOC SER B-BIO, V184, P51, DOI 10.1098/rspb.1973.0030; Tsuchiya M., 2006, FOR 2006 INT S FOR N; Tsuchiya M, 2009, MAR MICROPALEONTOL, V70, P8, DOI 10.1016/j.marmicro.2008.10.001; Vande W. J. G., 1999, J BIOL CHEM, V274, P13250, DOI 10.1074/jbc.274.19.13250	86	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5234	1550-7408		J EUKARYOT MICROBIOL	J. Eukaryot. Microbiol.	JUL-AUG	2015	62	4					454	469		10.1111/jeu.12200		16	Microbiology	Microbiology	CL9WO	WOS:000357329400003		
J	Fukuda, Y; Akematsu, T; Attiq, R; Tada, C; Nakai, Y; Pearlman, RE				Fukuda, Yasuhiro; Akematsu, Takahiko; Attiq, Rizwan; Tada, Chika; Nakai, Yutaka; Pearlman, Ronald E.			Role of the Cytosolic Heat Shock Protein 70 Ssa5 in the Ciliate Protozoan Tetrahymena thermophila	JOURNAL OF EUKARYOTIC MICROBIOLOGY			English	Article						Fertilization; macronuclear development; programmed nuclear death; pronuclear fusion	PROGRAMMED NUCLEAR DEATH; ENDOPLASMIC-RETICULUM; ARABIDOPSIS-THALIANA; CELLULAR FUNCTIONS; GENOMIC EXCLUSION; DNA ELIMINATION; BINDING-PROTEIN; GENE-EXPRESSION; QUALITY-CONTROL; HUMAN HSP70	Heat shock protein 70 (Hsp70) is a member of a family of conserved chaperone proteins whose function is well investigated in many model organisms. Here we focus on an Hsp70 called Ssa5 in the ciliate protozoan Tetrahymena thermophila, and reveal that its translation is heat inducible as for general Hsps. Moreover, the protein is abundantly expressed in the cytoplasm during sexual reproduction (conjugation) as well as in response to heat-stress. Knocking out of SSA5 (SSA5) does not affect the survival of the cell under heat-stress, likely due to other Hsp70 paralogs compensating for the defect. During conjugation, SSA5 leads to a fertilization defect in which the two pronuclei are in close proximity but never fuse. The unfertilized pronuclei differentiate, resulting in a heterokaryon with developed haploid germline and somatic nuclei. In addition, degeneration of the parental somatic nucleus is not affected. These results suggest a specific involvement of Ssa5 in pronuclear fusion and fertilization.	[Fukuda, Yasuhiro; Tada, Chika; Nakai, Yutaka] Tohoku Univ, Grad Sch Agr Sci, Div Biol Resource Sci, Dept Biodivers Sci, Osaki City, Miyagi, Japan; [Akematsu, Takahiko; Attiq, Rizwan; Pearlman, Ronald E.] York Univ, Dept Biol, Toronto, ON M3J 2R7, Canada	Fukuda, Y (reprint author), Tohoku Univ, Grad Sch Agr Sci, Div Biol Resource Sci, Dept Biodivers Sci, 232-3 Yomogida Naruko Onsen, Osaki City, Miyagi, Japan.	yasufuku@bios.tohoku.ac.jp			Japan Society for the Promotion of Science; Natural Sciences and Engineering Research Council of Canada; Natural Sciences and Engineering Research Council of Canada [539509]; Canadian Institutes for Health Research [MOP13347]	This study was supported by the Institutional Program for Young Researcher Overseas Visits through the Japan Society for the Promotion of Science to Y.F., a Banting Postdoctoral Fellowship through the Natural Sciences and Engineering Research Council of Canada to T.A., and grants from the Natural Sciences and Engineering Research Council of Canada (539509) and the Canadian Institutes for Health Research (MOP13347) to R.E.P.	Akematsu T, 2010, AUTOPHAGY, V6, P901, DOI 10.4161/auto.6.7.13287; Akematsu T, 2014, AUTOPHAGY, V10, P209, DOI 10.4161/auto.26929; Akematsu T, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-13; Akematsu T., 2012, JPN J PROTOZOOL, V45, P2; ALLEN SL, 1967, GENETICS, V55, P797; ALLEN SL, 1967, SCIENCE, V155, P575, DOI 10.1126/science.155.3762.575; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Kashino Y, 2001, ELECTROPHORESIS, V22, P1004, DOI 10.1002/1522-2683()22:6<1004::AID-ELPS1004>3.0.CO;2-Y; Mochizuki K, 2004, GENE DEV, V18, P2068, DOI 10.1101/gad.1219904; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Jacobs ME, 2006, EUKARYOT CELL, V5, P1990, DOI 10.1128/EC.00195-06; Mochizuki K, 2008, GENE, V425, P79, DOI 10.1016/j.gene.2008.08.007; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039; CassidyHanley D, 1997, GENETICS, V146, P135; Noh SJ, 2003, GENE, V311, P81, DOI 10.1016/S0378-1119(03)00559-6; Noto T, 2010, CELL, V140, P692, DOI 10.1016/j.cell.2010.02.010; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Cole ES, 2015, EUKARYOT CELL, V14, P116, DOI 10.1128/EC.00164-14; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Stricher F, 2013, AUTOPHAGY, V9, P1937, DOI 10.4161/auto.26448; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; Mayer MP, 1998, BIOL CHEM, V379, P261; Sarkar NK, 2013, CELL STRESS CHAPERON, V18, P427, DOI 10.1007/s12192-012-0395-6; Smith DGS, 2007, J MOL BIOL, V374, P837, DOI 10.1016/j.jmb.2007.09.051; Adl SM, 2012, J EUKARYOT MICROBIOL, V59, P429, DOI 10.1111/j.1550-7408.2012.00644.x; Brodsky JL, 2011, CURR OPIN CELL BIOL, V23, P464, DOI 10.1016/j.ceb.2011.05.004; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Liu ML, 2012, EUKARYOT CELL, V11, P494, DOI 10.1128/EC.05296-11; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BLOCH MA, 1995, J CELL SCI, V108, P3541; Carbonell-Bejerano P, 2010, PLANT PHYSIOL, V154, P163, DOI 10.1104/pp.110.160044; Cassidy-Hanley Donna M, 2012, Methods Cell Biol, V109, P237, DOI 10.1016/B978-0-12-385967-9.00008-6; Chalker DL, 2012, METHOD CELL BIOL, V109, P327, DOI 10.1016/B978-0-12-385967-9.00011-6; Cole E, 2012, METHOD CELL BIOL, V109, P177, DOI 10.1016/B978-0-12-385967-9.00007-4; Cole ES, 2006, MOL B INT U, P39; Coyne RS, 1999, MOL CELL, V4, P865, DOI 10.1016/S1097-2765(00)80396-2; Crozier R.H., 1975, Animal Cytogenetics, V3, P1; Eisen JA, 2006, PLOS BIOL, V4, P1620, DOI 10.1371/journal.pbio.0040286; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; HALLBERG RL, 1985, MOL CELL BIOL, V5, P2061; HAMILTON EP, 1988, GENETICS, V118, P627; Howard-Till RA, 2006, MOL CELL BIOL, V26, P8731, DOI 10.1128/MCB.01430-06; KACZANOWSKI A, 1991, EXP CELL RES, V195, P330, DOI 10.1016/0014-4827(91)90381-4; KANEY AR, 1985, EXP CELL RES, V157, P315, DOI 10.1016/0014-4827(85)90116-8; Kataoka K, 2010, J MICROBIOL METH, V82, P342, DOI 10.1016/j.mimet.2010.07.009; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; Li Z, 2004, CURR PROTOC IMMUNOL, DOI [10.1002/0471142735.ima01ts58, DOI 10.1002/0471142735.IMA01TS58]; Lin IT, 2012, MOL BIOL CELL, V23, P2213, DOI 10.1091/mbc.E11-11-0952; LIU RY, 1994, J CELL SCI, V107, P2209; Lu Q, 2006, EUR J OBSTET GYN R B, V126, P72, DOI 10.1016/j.ejogrb.2005.10.038; Maruyama D, 2010, P NATL ACAD SCI USA, V107, P1684, DOI 10.1073/pnas.0905795107; Melloy P, 2009, MOL BIOL CELL, V20, P3773, DOI 10.1091/mbc.E09-02-0163; Miao W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004429; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Mochizuki K., 2011, DEV GROWTH DIFFER, V54, P108; Nakagawa T, 2008, CELL STRUCT FUNCT, V33, P151, DOI 10.1247/csf.08011; Ng DTW, 1996, J CELL BIOL, V132, P499, DOI 10.1083/jcb.132.4.499; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; Orias E, 2011, RES MICROBIOL, V162, P578, DOI 10.1016/j.resmic.2011.05.001; ORIAS JD, 1983, SCIENCE, V222, P181, DOI 10.1126/science.6623070; Osada E, 2014, BIOL CELL, V106, P97, DOI 10.1111/boc.201300037; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4152, DOI 10.1073/pnas.82.12.4152; Silflow CD, 2011, GENETICS, V189, P1249, DOI 10.1534/genetics.111.133587; WENT DF, 1982, BIOL REV, V57, P319, DOI 10.1111/j.1469-185X.1982.tb00371.x; Xiong J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030630; Xu J., 2012, INT J ANTENN PROPAG, V2012, P1; Yaguchi T, 2007, ANN NY ACAD SCI, V1100, P306, DOI 10.1196/annals.1395.032; Yamano Shuji, 2000, Journal of Medical Investigation, V47, P1; Yao MC, 2007, J CELL SCI, V120, P1978, DOI 10.1242/jcs.006502; Yu T, 2012, PROTIST, V163, P284, DOI 10.1016/j.protis.2011.07.003	80	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5234	1550-7408		J EUKARYOT MICROBIOL	J. Eukaryot. Microbiol.	JUL-AUG	2015	62	4					481	493		10.1111/jeu.12203		13	Microbiology	Microbiology	CL9WO	WOS:000357329400005		
J	Yubuki, N; Panek, T; Yabuki, A; Cepicka, I; Takishita, K; Inagaki, Y; Leander, BS				Yubuki, Naoji; Panek, Tomas; Yabuki, Akinori; Cepicka, Ivan; Takishita, Kiyotaka; Inagaki, Yuji; Leander, Brian S.			Morphological Identities of Two Different Marine Stramenopile Environmental Sequence Clades: Bicosoeca kenaiensis (Hilliard, 1971) and Cantina marsupialis (Larsen and Patterson, 1990) gen. nov., comb. nov.	JOURNAL OF EUKARYOTIC MICROBIOLOGY			English	Article						Bicosoecid; biodiversity; culture-independent molecular methods; environmental DNA sequence surveys; MAST; molecular phylogeny; protist; ultrastructure	MICROBIAL EUKARYOTES; FLAGELLATES PROTISTA; ELECTRON-MICROSCOPY; EXCAVATA DISCOBA; DIVERSITY; AUSTRALIA; SEDIMENTS; EVOLUTION; SEA; SYSTEMATICS	Although environmental DNA surveys improve our understanding of biodiversity, interpretation of unidentified lineages is limited by the absence of associated morphological traits and living cultures. Unidentified lineages of marine stramenopiles are called MAST clades. Twenty-five MAST clades have been recognized: MAST-1 through MAST-25; seven of these have been subsequently discarded because the sequences representing those clades were found to either (1) be chimeric or (2) affiliate within previously described taxonomic groups. Eighteen MAST clades remain without a cellular identity. Moreover, the discarded MAST-13 has been used in different studies to refer to two different environmental sequence clades. After establishing four cultures representing two different species of heterotrophic stramenopiles and then characterizing their morphology and molecular phylogenetic positions, we determined that the two different species represented the two different MAST-13 clades: (1) a lorica-bearing Bicosoeca kenaiensis and (2) a microaerophilic flagellate previously named Cafeteria marsupialis. Both species were previously described with only light microscopy; no cultures, ultrastructural data or DNA sequences were available from these species prior to this study. The molecular phylogenetic position of three different C. marsupialis isolates was not closely related to the type species of Cafeteria; therefore, we established a new genus for these isolates, Cantina gen. nov.	[Yubuki, Naoji; Leander, Brian S.] Univ British Columbia, Dept Bot, Beaty Biodivers Res Ctr & Museum, Vancouver, BC V6T 1Z4, Canada; [Yubuki, Naoji; Leander, Brian S.] Univ British Columbia, Dept Zool, Beaty Biodivers Res Ctr & Museum, Vancouver, BC V6T 1Z4, Canada; [Panek, Tomas; Cepicka, Ivan] Charles Univ Prague, Fac Sci, Dept Zool, CR-12844 Prague, Czech Republic; [Yabuki, Akinori; Takishita, Kiyotaka] Japan Agcy Marine Earth Sci & Technol JAMSTEC, Yokosuka, Kanagawa 2370061, Japan; [Inagaki, Yuji] Univ Tsukuba, Ctr Computat Sci, Tsukuba, Ibaraki 3058577, Japan; [Inagaki, Yuji] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058577, Japan	Yubuki, N (reprint author), Univ British Columbia, Dept Bot, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	yubuki@mail.ubc.ca	Yubuki, Naoji/E-4913-2012		Tula Foundation's Center for Microbial Diversity and Evolution at the University of British Columbia; Canadian Institute for Advanced Research; Czech Science Foundation [14-14105S]; Japanese Society for the Promotion of Science (JSPS) for Young Scientists [236484]; JSPS [23117006]	This study was supported by the Tula Foundation's Center for Microbial Diversity and Evolution at the University of British Columbia. BSL was also supported by the Canadian Institute for Advanced Research, Program in Integrated Microbial Biodiversity. IC and TP were supported by the Czech Science Foundation (project 14-14105S). AY was supported by Research Fellowship from the Japanese Society for the Promotion of Science (JSPS) for Young Scientists (no. 236484). YI is supported by a grant from the JSPS (no. 23117006). We thank the captain and crew of the R/V Mirai (JAMSTEC) and the chief scientist of the research cruise MR11-02, Dr. Makio Honda (JAMSTEC) who helped with sampling during the cruise, as well as Professor Alastair G. B. Simpson (Dalhousie University) for sampling assistance to collect Cantina marsupialis (NY0206) and Dr. Frantisek Stahlavsky (Charles University in Prague) for providing the sample to IC and TP.	Al-Quassab S., 2002, ACTA PROTOZOOL, V41, P1; Kolisko M, 2010, ENVIRON MICROBIOL, V12, P2700, DOI 10.1111/j.1462-2920.2010.02239.x; Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109; Yabuki A, 2010, PROTIST, V161, P523, DOI 10.1016/j.protis.2010.03.001; Richards TA, 2005, CURR OPIN MICROBIOL, V8, P240, DOI 10.1016/j.mib.2005.04.010; Panek T, 2014, INT J SYST EVOL MICR, V64, P2280, DOI 10.1099/ijs.0.063487-0; Heger TJ, 2014, J EUKARYOT MICROBIOL, V61, P214, DOI 10.1111/jeu.12095; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Hampl V, 2009, P NATL ACAD SCI USA, V106, P3859, DOI 10.1073/pnas.0807880106; Orsi W, 2011, ISME J, V5, P1357, DOI 10.1038/ismej.2011.7; Wylezich C, 2011, ENVIRON MICROBIOL, V13, P2939, DOI 10.1111/j.1462-2920.2011.02569.x; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Panek T, 2012, PROTIST, V163, P807, DOI 10.1016/j.protis.2011.11.002; Takishita K, 2007, PROTIST, V158, P51, DOI 10.1016/j.protis.2006.07.003; Massana R, 2004, APPL ENVIRON MICROB, V70, P3528, DOI 10.1128/AEM.70.6.3528-3534.2004; Cavalier-Smith T, 2013, EUR J PROTISTOL, V49, P328, DOI 10.1016/j.ejop.2012.09.002; Lee WJ, 1998, PROTIST, V149, P229; Kim E, 2011, P NATL ACAD SCI USA, V108, P1496, DOI 10.1073/pnas.1013337108; Kolodziej K, 2007, APPL ENVIRON MICROB, V73, P2718, DOI 10.1128/AEM.02158-06; Gomez F, 2011, ENVIRON MICROBIOL, V13, P193, DOI 10.1111/j.1462-2920.2010.02320.x; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Stechmann A, 2008, CURR BIOL, V18, P580, DOI 10.1016/j.cub.2008.03.037; Massana R, 2006, ENVIRON MICROBIOL, V8, P1515, DOI 10.1111/j.1462-2920.2006.01042.x; Arndt H, 2000, SYST ASSOC SPEC VOL, V59, P240; Andersen RA, 2004, AM J BOT, V91, P1508, DOI 10.3732/ajb.91.10.1508; Stoeck T, 2007, MICROB ECOL, V53, P328, DOI 10.1007/s00248-006-9166-1; Lin YC, 2012, APPL ENVIRON MICROB, V78, P3387, DOI 10.1128/AEM.06952-11; Aydin EE, 2012, ACTA PROTOZOOL, V51, P119, DOI 10.4467/16890027AP.12.010.0514; BELCHER J H, 1975, Archiv fuer Protistenkunde, V117, P78; Boenigk J, 2002, ANTON LEEUW INT J G, V81, P465, DOI 10.1023/A:1020509305868; Edgcomb Virginia P., 2013, Life-Basel, V3, P346, DOI 10.3390/life3020346; Ekebom J, 1996, ARCH PROTISTENKD, V146, P251; HAMAR J, 1979, Tiscia (Szeged), V14, P147; Hampl V, 2005, MOL BIOL EVOL, V22, P2508, DOI 10.1093/molbev/msi245; HILLIARD D K, 1971, Archiv fuer Protistenkunde, V113, P98; Karpov Serguei A., 2001, Protistology, V2, P34; Kim E, 2010, PROTIST, V161, P177, DOI 10.1016/j.protis.2009.09.003; LARSEN J, 1990, J NAT HIST, V24, P801, DOI 10.1080/00222939000770571; Lee Won Je, 2006, Ocean Science Journal, V41, P75; Lee WJ, 2003, OPHELIA, V57, P63; Lee WJ, 2000, J NAT HIST, V34, P483, DOI 10.1080/002229300299435; Lee Won Je, 2002, Korean Journal of Biological Sciences, V6, P125; Lee Won Je, 2007, Algae, V22, P23; Maddison W. P., 2011, MESQUITE MODULAR SYS; Massana R, 2014, ISME J, V8, P854, DOI 10.1038/ismej.2013.204; MIGNOT J P, 1974, Protistologica, V10, P543; MOESTRUP O, 1976, PROTISTOLOGICA, V12, P101; Park JS, 2006, EXTREMOPHILES, V10, P493, DOI 10.1007/s00792-006-0001-x; Park JS, 2010, ENVIRON MICROBIOL, V12, P1173, DOI 10.1111/j.1462-2920.2010.02158.x; Patterson D. J., 1989, SYSTEMATICS ASS, V38, P357; Picken LER, 1941, PHILOS T ROY SOC B, V230, P451, DOI 10.1098/rstb.1941.0002; PREISIG HR, 1991, SYST ASSOC SPEC VOL, V45, P361; Rodriguez-Martinez R, 2012, MOL BIOL EVOL, V29, P1393, DOI 10.1093/molbev/msr303; Ronquist F, 2011, MRBAYES VER IN PRESS; Takishita K, 2012, PROTIST, V163, P344, DOI 10.1016/j.protis.2011.12.007; Takishita K, 2010, J EUKARYOT MICROBIOL, V57, P76, DOI 10.1111/j.1550-7408.2009.00457.x; Tarbe AL, 2011, AQUAT MICROB ECOL, V62, P177, DOI 10.3354/ame01465; Tong SM, 1997, OPHELIA, V47, P71; Tong SM, 1998, EUR J PROTISTOL, V34, P162; VORS N, 1993, J EUKARYOT MICROBIOL, V40, P272, DOI 10.1111/j.1550-7408.1993.tb04917.x; Yubuki N, 2013, EUR J PROTISTOL, V49, P32, DOI 10.1016/j.ejop.2012.07.001; Yubuki N, 2010, PROTIST, V161, P264, DOI 10.1016/j.protis.2009.10.004; Zubkov MV, 2001, EUR J PROTISTOL, V37, P155, DOI 10.1078/0932-4739-00815; Zuendorf A, 2006, FEMS MICROBIOL ECOL, V58, P476, DOI 10.1111/j.1574-6941.2006.00171.x	64	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5234	1550-7408		J EUKARYOT MICROBIOL	J. Eukaryot. Microbiol.	JUL-AUG	2015	62	4					532	542		10.1111/jeu.12207		11	Microbiology	Microbiology	CL9WO	WOS:000357329400009		
J	Wada, H; Shiozawa, M; Katayama, K; Okamoto, N; Miyagi, Y; Rino, Y; Masuda, M; Akaike, M				Wada, Hiroo; Shiozawa, Manabu; Katayama, Kayoko; Okamoto, Naoyuki; Miyagi, Yohei; Rino, Yasushi; Masuda, Munetaka; Akaike, Makoto			Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer	JOURNAL OF GASTROENTEROLOGY			English	Review						Anti-human podoplanin antibody; Lymphatic vessel invasion; Budding; Lymph node metastasis; Colorectal cancer	MONOCLONAL-ANTIBODY D2-40; INVASIVE-CARCINOMA; RISK-FACTORS; RECTUM; COLON; MANAGEMENT; POLYPS	In this study we examined whether histopathological findings, specifically lymphatic vessel invasion identified by an anti-human podoplanin antibody, and several other factors are associated with lymph node metastasis in T1 colorectal cancer. We searched PubMed and Cochrane Library, and also handsearched relevant journals, for reports written in English and published between 1998 and 2012, utilizing combination headings, such as 'colorectal cancer,' 'lymph node metastasis,' and 'risk factors.' For the report to be included in our study, the following criteria had to be met: (1) data on the frequency of lymph node metastasis in T1 colorectal cancer in relation to histopathological factors were reported; (2) patients had undergone bowel resection and had histologically diagnosed T1 colorectal cancer; (3) lymphatic vessel invasion was identified by immunohistochemistry with an anti-human podoplanin antibody rather than by hematoxylin and eosin staining; (4) univariate and multivariate analyses were conducted. Studies investigating molecular markers were excluded. The independent predictive factors were confirmed in at least one study included in the meta-analysis in the present systematic review. Microsoft Excel 2013 for Windows was used for the statistical analysis. Initially, 369 publications were identified in the database searches and handsearches, of which five ultimately met all of the inclusion criteria and selected for this systematic review. The meta-analysis revealed that only two factors were significantly associated with T1 colorectal cancer lymph node metastasis: (1) lymphatic vessel invasion identified by an anti-human podoplanin antibody [Mantel-Haenszel odds ratio (OR) 5.19; (95 % confidence interval (CI) 3.31-8.15; P = 0.01]; (2) tumor budding (OR 7.45; 95 % CI 4.27-13.02; P = 0.0077). Our meta-analysis revealed that lymphatic vessel invasion identified by an anti-human podoplanin antibody and tumor budding were significantly associated with T1 colorectal cancer lymph node metastasis.	[Wada, Hiroo; Shiozawa, Manabu; Akaike, Makoto] Kanagawa Canc Ctr Hosp, Gastrointestinal Surg, Asahi Ku, Yokohama, Kanagawa 2418515, Japan; [Katayama, Kayoko; Okamoto, Naoyuki] Kanagawa Canc Ctr, Canc Prevent & Canc Control Div, Asahi Ku, Yokohama, Kanagawa 2410815, Japan; [Miyagi, Yohei] Kanagawa Canc Ctr, Res Inst, Mol Pathol & Genet Div, Asahi Ku, Yokohama, Kanagawa 2410815, Japan; [Rino, Yasushi; Masuda, Munetaka] Yokohama City Univ, Dept Surg, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Wada, H (reprint author), Kanagawa Canc Ctr Hosp, Gastrointestinal Surg, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2418515, Japan.	hiroo.wada@nifty.ne.jp					Kaneko I, 2007, DIS COLON RECTUM, V50, P13, DOI 10.1007/s10350-006-0745-5; Suzuki A, 2009, AM J SURG PATHOL, V33, P1601, DOI 10.1097/PAS.0b013e3181ae29d6; Mou S, 2013, SURG ENDOSC, V27, P2692, DOI 10.1007/s00464-013-2835-5; Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4; Nascimbeni R, 2002, DIS COLON RECTUM, V45, P200, DOI 10.1007/s10350-004-6147-7; Beaton C, 2013, COLORECTAL DIS, V15, P788, DOI 10.1111/codi.12129; Kahn HJ, 2002, LAB INVEST, V82, P1255, DOI 10.1097/01.LAB.0000028824.03032.AB; Son HJ, 2008, HEPATO-GASTROENTEROL, V55, P1293; Kawaura K, 2007, PATHOBIOLOGY, V74, P328, DOI 10.1159/000110026; Sakuragi M, 2003, DIS COLON RECTUM, V46, P1626, DOI 10.1097/01.DCR.0000100821.53077.DD; HACKELSBERGER A, 1995, ENDOSCOPY, V27, P153, DOI 10.1055/s-2007-1005654; TANAKA S, 1995, J GASTROENTEROL, V30, P710, DOI 10.1007/BF02349636; MULLER S, 1989, GUT, V30, P1385, DOI 10.1136/gut.30.10.1385; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Okabe S, 2004, J GASTROINTEST SURG, V8, P1032, DOI 10.1016/j.gassur.2004.09.038; Yamamoto S, 2004, HEPATO-GASTROENTEROL, V51, P998; VOLK EE, 1995, GASTROENTEROLOGY, V109, P1801, DOI 10.1016/0016-5085(95)90746-7; Ishii M, 2009, INT J COLORECTAL DIS, V24, P1069, DOI 10.1007/s00384-009-0699-x; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; Wada H, 2013, INT J CLIN ONCOL, V18, P1025, DOI 10.1007/s10147-012-0490-9; Walgenbach-Bruenagel G, 2006, EUR SURG RES, V38, P438, DOI 10.1159/000095086	21	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					727	734		10.1007/s00535-015-1057-0		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400003		
J	Oshima, T; Fukui, H; Watari, J; Miwa, H				Oshima, Tadayuki; Fukui, Hirokazu; Watari, Jiro; Miwa, Hiroto			Childhood abuse history is associated with the development of dyspepsia: a population-based survey in Japan	JOURNAL OF GASTROENTEROLOGY			English	Article						Dyspepsia; Sexual child abuse; Consultation; Prevalence; Epidemiology	FUNCTIONAL GASTROINTESTINAL DISORDERS; GASTROESOPHAGEAL-REFLUX DISEASE; NEONATAL MATERNAL SEPARATION; IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; PHYSICAL ABUSE; PSYCHOSOCIAL FACTORS; SYMPTOMS; SMOKING; EPIDEMIOLOGY	Functional dyspepsia (FD) is a heterogeneous disorder, and it is not clear whether childhood abuse influences the severity of dyspeptic symptoms and the type of dyspepsia. Accordingly, we administered a questionnaire survey to evaluate the association of abuse history in the development of dyspepsia. Study subjects were selected from among a panel of volunteers, to make equal distribution of age, sex, and residential area. A Web-based questionnaire was administered to uninvestigated dyspepsia subjects who had obtained a consultation at a medical institute, dyspepsia subjects who had not, and healthy control subjects. Dyspepsia was categorized into epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) using the Rome III adult FGID questionnaire. Physical, sexual, and psychological abuse history and severity of dyspeptic symptoms were assessed by a questionnaire. Each type of abuse was significantly prevalent in uninvestigated dyspepsia subjects. Childhood abuse history was significantly prevalent in dyspepsia. However, these abuse histories were not associated with consultation behavior. Childhood abuse was more prevalent in subjects with dyspepsia and in females. Severity of dyspeptic symptoms was significantly greater in dyspepsia subjects with a history of abuse. Childhood abuse was more prevalent in dyspepsia subjects with the overlap of EPS and PDS and in those who also had irritable bowel syndrome (IBS). Childhood abuse history was associated with the development of dyspepsia especially in the overlapping diagnoses of EPS and PDS, and overlapping with IBS but not with consultation behavior. Abuse history should be assessed in the care of patients with dyspepsia.	[Oshima, Tadayuki; Fukui, Hirokazu; Watari, Jiro; Miwa, Hiroto] Hyogo Coll Med, Div Gastroenterol, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan	Oshima, T (reprint author), Hyogo Coll Med, Div Gastroenterol, Dept Internal Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	t-oshima@hyo-med.ac.jp			Zeria pharmaceutical Co Ltd. (Tokyo, Japan)	This study was funded by Zeria pharmaceutical Co Ltd. (Tokyo, Japan).	Coutinho SV, 2002, AM J PHYSIOL-GASTR L, V282, pG307; Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008; Brook RA, 2010, CLIN GASTROENTEROL H, V8, P498, DOI 10.1016/j.cgh.2010.03.003; Van Oudenhove L, 2010, GASTROENTEROLOGY, V139, P36, DOI 10.1053/j.gastro.2010.04.015; Koloski NA, 2001, AM J GASTROENTEROL, V96, P1340, DOI 10.1016/S0002-9270(01)02352-8; Gareau MG, 2007, AM J PHYSIOL-GASTR L, V293, pG198, DOI 10.1152/ajpgi.00392.2006; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828; Leserman J, 1995, BEHAV MED, V21, P141; Delvaux M, 1997, EUR J GASTROEN HEPAT, V9, P345; Locke GR, 2004, AM J GASTROENTEROL, V99, P350, DOI 10.1111/j.1572-0241.2004.04043.x; Castillo EJ, 2004, CLIN GASTROENTEROL H, V2, P985, DOI 10.1053/S1542-3565(04)00454-9; Geeraerts B, 2009, NEUROGASTROENT MOTIL, V21, P33, DOI 10.1111/j.1365-2982.2008.01178.x; Ford AC, 2007, AM J GASTROENTEROL, V102, P957, DOI 10.1111/j.1572-0241.2007.01080.x; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; El-Serag HB, 2004, ALIMENT PHARM THERAP, V19, P643, DOI 10.1111/j.1365-2036.2004.01897.x; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; TALLEY NJ, 1994, GASTROENTEROLOGY, V107, P1040; Fujiwara Y, 2011, INTERNAL MED, V50, P2443, DOI 10.2169/internalmedicine.50.6012; Biggs AM, 2004, GUT, V53, P180, DOI 10.1136/gut.2003.020974; Carey RN, 2013, J CLIN EPIDEMIOL, V66, P1417, DOI 10.1016/j.jclinepi.2013.03.007; DROSSMAN DA, 1995, ANN INTERN MED, V123, P782; El-Serag HB, 2003, ALIMENT PHARM THERAP, V18, P387, DOI 10.1046/j.0269-2813.2003.01706.x; Fukudo S, 2008, JAPANESE TRANSLATION, P570; Handa Masanori, 2008, Biopsychosoc Med, V2, P8, DOI 10.1186/1751-0759-2-8; Hongo M, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2011.06632.x; Hungin APS, 2009, ALIMENT PHARM THER, V30, P331, DOI 10.1111/j.1365-2036.2009.04047.x; JOHNSEN R, 1991, BRIT MED J, V302, P749; Koepsell TD, 1996, AM J EPIDEMIOL, V144, P704; Matsuzaki J, 2012, NEUROGASTROENT MOTIL, V24, DOI 10.1111/j.1365-2982.2011.01859.x; Miwa H, 2012, J GASTROEN HEPATOL, V27, P626, DOI 10.1111/j.1440-1746.2011.07037.x; Miwa H, 2012, J GASTROENTEROL, V47, P862, DOI 10.1007/s00535-012-0625-9; Shaib Y, 2004, AM J GASTROENTEROL, V99, P2210, DOI 10.1111/j.1572-0241.2004.40052.x; TALLEY NJ, 1994, AM J GASTROENTEROL, V89, P524; TALLEY NJ, 1988, DIGEST DIS SCI, V33, P641, DOI 10.1007/BF01540424; Tsuboi S, 2013, ASIA PAC J PUBLIC HL; Van Oudenhove L, 2011, PSYCHOSOM MED, V73, P648, DOI 10.1097/PSY.0b013e31822f32bf	36	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					744	750		10.1007/s00535-014-1014-3		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400005		
J	Ishimoto, T; Izumi, D; Watanabe, M; Yoshida, N; Hidaka, K; Miyake, K; Sugihara, H; Sawayama, H; Imamura, Y; Iwatsuki, M; Iwagami, S; Baba, Y; Horlad, H; Komohara, Y; Takeya, M; Baba, H				Ishimoto, Takatsugu; Izumi, Daisuke; Watanabe, Masayuki; Yoshida, Naoya; Hidaka, Kosei; Miyake, Keisuke; Sugihara, Hidetaka; Sawayama, Hiroshi; Imamura, Yu; Iwatsuki, Masaaki; Iwagami, Shiro; Baba, Yoshifumi; Horlad, Hasita; Komohara, Yoshihiro; Takeya, Motohiro; Baba, Hideo			Chronic inflammation with Helicobacter pylori infection is implicated in CD44 overexpression through miR-328 suppression in the gastric mucosa	JOURNAL OF GASTROENTEROLOGY			English	Article						Helicobacter pylori; Metaplasia; Gastric cancer; CD44; microRNA	POLYPEPTIDE-EXPRESSING METAPLASIA; CANCER-CELLS; HEPATOCELLULAR-CARCINOMA; PROSTAGLANDIN E-2; ALPHA; MICE; WNT; ADENOCARCINOMA; IDENTIFICATION; TUMORIGENESIS	Infection with Helicobacter pylori is the main risk factor for development of gastric cancer. CD44 overexpression, especially that of variant 9 (CD44v9), has also been implicated in the local inflammatory response and metaplasia-carcinoma sequence in human stomach. We recently identified miR-328 as one of the microRNAs targeting CD44 in gastric cancer. The aim of the current study was to determine the relationship between miR-328 and CD44v9 expression in H. pylori-infected gastric mucosa during the development of preneoplastic lesions. Immunohistochemical staining of myeloperoxidase and CD44v9 was performed using paraffin-embedded tissue sections obtained from 54 patients who underwent gastric resection without preoperative treatment. The levels of miR-328 expression in the gastric mucosa were measured in the same patients using quantitative reverse transcription polymerase chain reaction. Both infiltration of myeloperoxidase-positive inflammatory cells and expression of proinflammatory cytokines closely correlated with H. pylori infection in the cancer-afflicted gastric mucosa. High CD44v9 expression levels, identified in the gastric mucosa in 61 % of samples (33/54), correlated significantly with H. pylori infection in the gastric mucosa. Notably, high CD44v9 expression was significantly associated with low miR-328 expression, whereas low CD44v9 expression was significantly associated with high miR-328 expression. We showed that miR-328 downregulation and de novo expression of CD44v9 occurred in H. pylori-infected gastric mucosa adjacent to gastric cancer compared with gastric mucosa not infected with H. pylori adjacent to gastric cancer. CD44v9-overexpressing cells are known to acquire reactive oxygen species resistance; thus, these cells may avoid cell death caused by various stress inducers, which may be linked to the origin of gastric cancer development.	[Ishimoto, Takatsugu; Izumi, Daisuke; Watanabe, Masayuki; Yoshida, Naoya; Hidaka, Kosei; Miyake, Keisuke; Sugihara, Hidetaka; Sawayama, Hiroshi; Imamura, Yu; Iwatsuki, Masaaki; Iwagami, Shiro; Baba, Yoshifumi; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto 8608556, Japan; [Horlad, Hasita; Komohara, Yoshihiro; Takeya, Motohiro] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto 8608556, Japan	Baba, H (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hdobaba@kumamoto-u.ac.jp			Okukubo Memorial Fund for Medical Research at Kumamoto University School of Medicine; Japan Society for the Promotion of Science [24591912]	This work was supported in part by the Okukubo Memorial Fund for Medical Research at Kumamoto University School of Medicine, the Medical Research Encouragement Prize of the Japan Medical Association, and the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (24591912) (given to T.I.).	Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Schmidt PH, 1999, LAB INVEST, V79, P639; Nozaki K, 2008, GASTROENTEROLOGY, V134, P511, DOI 10.1053/j.gastro.2007.11.058; Halldorsdottir AM, 2003, DIGEST DIS SCI, V48, P431, DOI 10.1023/A:1022564027468; Gee K, 2002, J IMMUNOL, V169, P5660; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Ishimoto T, 2014, CARCINOGENESIS, V35, P1003, DOI 10.1093/carcin/bgt402; Yamaguchi H, 2002, DIGEST DIS SCI, V47, P573, DOI 10.1023/A:1017920220149; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Nomura S, 2004, GASTROENTEROLOGY, V127, P582, DOI 10.1053/j.gastro.2004.05.029; Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Muthukumaran N, 2006, MOL CANCER RES, V4, P511, DOI 10.1158/1541-7786.MCR-05-0232; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Ishimoto T, 2010, CANCER SCI, V101, P673, DOI 10.1111/j.1349-7006.2009.01430.x; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Khurana SS, 2013, J BIOL CHEM, V288, P16085, DOI 10.1074/jbc.M112.445551; Utsunomiya T, 2014, HEPATOL RES, V44, P631, DOI 10.1111/hepr.12164; Cheng WW, 2012, FEBS J, V279, P2047, DOI 10.1111/j.1742-4658.2012.08589.x; Dhingra S, 2011, INT J CLIN EXP PATHO, V4, P733; Fan XJ, 1996, GUT, V38, P507, DOI 10.1136/gut.38.4.507; Higashikawa K, 1996, INT J CANCER, V66, P11, DOI 10.1002/(SICI)1097-0215(19960328)66:1<11::AID-IJC3>3.0.CO;2-1; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Nishizawa T, 2013, INT J MOL SCI, V14, P9487, DOI 10.3390/ijms14059487; Tovuu LO, 2013, INT J CLIN ONCOL, V18, P651, DOI 10.1007/s10147-012-0432-6; Wada T, 2013, CANCER SCI, V104, P1323, DOI 10.1111/cas.12236	30	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					751	757		10.1007/s00535-014-1019-y		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400006		
J	Aoki, T; Kokudo, N; Komoto, I; Takaori, K; Kimura, W; Sano, K; Takamoto, T; Hashimoto, T; Okusaka, T; Morizane, C; Ito, T; Imamura, M				Aoki, Taku; Kokudo, Norihiro; Komoto, Izumi; Takaori, Kyoichi; Kimura, Wataru; Sano, Keiji; Takamoto, Takeshi; Hashimoto, Takuya; Okusaka, Takuji; Morizane, Chigusa; Ito, Tetsuhide; Imamura, Masayuki			Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan	JOURNAL OF GASTROENTEROLOGY			English	Article						Neuroendocrine tumors; Streptozocin; Multi-center survey; Tumor response; Progression-free survival rate	ISLET-CELL CARCINOMA; DOXORUBICIN; FLUOROURACIL; EPIDEMIOLOGY	Neuroendocrine tumors (NETs) are believed to be relatively rare and to follow a generally indolent course. However, liver metastases are common in NET patients and the outcome of NET liver metastasis is poor. In Western countries, streptozocin (STZ) has been established as a first-line anticancer drug for unresectable NET; however, STZ cannot be used in daily practice in Japan. The aim of the present study was to determine the status of STZ usage in Japan and to evaluate the effectiveness and safety of STZ chemotherapy in Japanese NET patients. A retrospective multi-center survey was conducted. Five institutions with experience performing STZ chemotherapy participated in the study. The patient demographics, tumor characteristics, context of STZ chemotherapy, and patient outcome were collected and assessed. Fifty-four patients were enrolled. The main recipients of STZ chemotherapy were middle-aged patients with pancreatic NET and unresectable liver metastases. The predominant regimen was the weekly/bi-weekly intravenous administration of STZ combined with other oral anticancer agents. STZ monotherapy was used in one-fourth of the patients. The median progression-free and overall survival periods were 11.8 and 38.7 months, respectively, and sustained stable disease was obtained in some selected patients. The adverse events profile was mild and tolerable. Our survey showed the clinical benefit and safety of STZ therapy for Japanese patients with unresectable NET. Therefore, we recommend that STZ, which is the only cytotoxic agent available against NET, should be used in daily practice in Japan.	[Aoki, Taku; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Hepatobiliarypancreat Surg Div, Dept Surg,Bunkyo Ku, Tokyo 1138655, Japan; [Aoki, Taku; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Artificial Organ & Transplantat Div, Dept Surg,Bunkyo Ku, Tokyo 1138655, Japan; [Komoto, Izumi; Imamura, Masayuki] Kansai Elect Power Co Hosp, Dept Surg, Osaka, Japan; [Takaori, Kyoichi] Kyoto Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg & Transplantat, Kyoto, Japan; [Kimura, Wataru] Yamagata Univ, Fac Med, Dept Gastroenterol Breast Thyroid & Gen Surg, Yamagata 990, Japan; [Sano, Keiji] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan; [Takamoto, Takeshi; Hashimoto, Takuya] Japanese Red Cross Med Ctr, Div Hepatobiliarypancreat Surg, Tokyo, Japan; [Okusaka, Takuji; Morizane, Chigusa] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan; [Ito, Tetsuhide] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan	Aoki, T (reprint author), Univ Tokyo, Grad Sch Med, Hepatobiliarypancreat Surg Div, Dept Surg,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	aoki-2su@h.u-tokyo.ac.jp					Hauso O, 2008, CANCER, V113, P2655, DOI 10.1002/cncr.23883; Frilling A, 2014, LANCET ONCOL, V15, pE8, DOI 10.1016/S1470-2045(13)70362-0; MOERTEL CG, 1980, NEW ENGL J MED, V303, P1189, DOI 10.1056/NEJM198011203032101; Ito T, 2010, J GASTROENTEROL, V45, P234, DOI 10.1007/s00535-009-0194-8; Cheng PNM, 1999, CANCER, V86, P944, DOI 10.1002/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Kouvaraki MA, 2004, J CLIN ONCOL, V22, P4762, DOI 10.1200/JCO.2004.04.024; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; ERIKSSON B, 1990, CANCER, V65, P1883, DOI 10.1002/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3; Ito T, 2014, J GASTROENTEROL, P6; Kaplan E, 1958, J AM STAT ASSOC, V53, P257; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOERTEL CG, 1992, NEW ENGL J MED, V326, P519, DOI 10.1056/NEJM199202203260804; Rivera E, 1998, AM J CLIN ONCOL-CANC, V21, P36, DOI 10.1097/00000421-199802000-00008; VONSCHRENCK T, 1988, GASTROENTEROLOGY, V94, P1326	17	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					769	775		10.1007/s00535-014-1006-3		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400008		
J	Abe, M; Miyake, T; Kuno, A; Imai, Y; Sawai, Y; Hino, K; Hara, Y; Hige, S; Sakamoto, M; Yamada, G; Kage, M; Korenaga, M; Hiasa, Y; Mizokami, M; Narimatsu, H				Abe, Masanori; Miyake, Teruki; Kuno, Atsushi; Imai, Yasuharu; Sawai, Yoshiyuki; Hino, Keisuke; Hara, Yuichi; Hige, Shuhei; Sakamoto, Michiie; Yamada, Gotaro; Kage, Masayoshi; Korenaga, Masaaki; Hiasa, Yoichi; Mizokami, Masashi; Narimatsu, Hisashi			Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease	JOURNAL OF GASTROENTEROLOGY			English	Article						Mac-2 binding protein; Glycoprotein; Non-alcoholic fatty liver disease; Fibrosis marker; Cirrhosis	CHRONIC HEPATITIS-C; INTEROBSERVER VARIATION; NATURAL-HISTORY; SCORING SYSTEM; STEATOHEPATITIS; BIOPSY; SERUM; VALIDATION; CIRRHOSIS; MARKER	Accurately evaluating liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is important for identifying those who may develop complications. The aims of this study were (1) to measure serum Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP) using the glycan sugar chain-based immunoassay and (2) to compare the results with clinical assessments of fibrosis. Serum WFA(+)-M2BP values were retrospectively evaluated in 289 patients with NAFLD who had undergone liver biopsy. Histological findings were evaluated by three blinded, experienced liver-specific pathologists. For stages 0 (n = 35), 1 (n = 113), 2 (n = 49), 3 (n = 41), and 4 (n = 51) of liver fibrosis, the serum WFA(+)-M2BP cutoff indexes were 0.57, 0.70, 1.02, 1.57, and 2.96, respectively. Multivariate regression analysis showed that serum WFA(+)-M2BP values were associated with the stage of fibrosis (a parts per thousand yenstage 2). The areas under the receiver operating characteristic curve (AUROC), sensitivity, and specificity of serum WFA(+)-M2BP were 0.876, 85.9, and 74.6 %, respectively, for severe fibrosis (a parts per thousand yenstage 3) and were 0.879, 74.6, and 87.0 %, respectively, for cirrhosis. When compared with six non-invasive conventional markers, serum WFA(+)-M2BP had the greatest AUROC for diagnosing severe fibrosis and cirrhosis. Serum WFA(+)-M2BP values are useful for assessing the stage of liver fibrosis in patients with NAFLD.	[Abe, Masanori; Miyake, Teruki; Hiasa, Yoichi] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon, Ehime 7910295, Japan; [Abe, Masanori; Miyake, Teruki; Kuno, Atsushi; Imai, Yasuharu; Sawai, Yoshiyuki; Hino, Keisuke; Hara, Yuichi; Hige, Shuhei; Sakamoto, Michiie; Korenaga, Masaaki; Mizokami, Masashi; Narimatsu, Hisashi] Hepatitis Glycobiomarker Study Grp, Tokyo, Japan; [Kuno, Atsushi; Narimatsu, Hisashi] Natl Inst Adv Ind Sci & Technol, Res Ctr Med Glycosci, Tsukuba, Ibaraki, Japan; [Imai, Yasuharu; Sawai, Yoshiyuki] Ikeda Municipal Hosp, Dept Gastroenterol, Ikeda, Osaka, Japan; [Hino, Keisuke; Hara, Yuichi] Kawasaki Med Univ, Dept Hepatol & Pancreatol, Kurashiki, Okayama, Japan; [Hige, Shuhei] Sapporo Kosei Gen Hosp, Dept Hepatol, Sapporo, Hokkaido, Japan; [Sakamoto, Michiie] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan; [Yamada, Gotaro] Kawasaki Med Univ, Dept Gen Internal Med 2, Kurashiki, Okayama, Japan; [Kage, Masayoshi] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka, Japan; [Korenaga, Masaaki; Mizokami, Masashi] Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Ichikawa, Chiba, Japan	Abe, M (reprint author), Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon, Ehime 7910295, Japan.	masaben@m.ehime-u.ac.jp			Ministry of Health, Labour, and Welfare of Japan	This study was supported by a Grant-in-Aid from the Ministry of Health, Labour, and Welfare of Japan. This research was performed by the Hepatitis Glyco-biomarker Study Group.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014; Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669; Wong VWS, 2010, HEPATOLOGY, V51, P454, DOI 10.1002/hep.23312; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496; Suzuki A, 2005, LIVER INT, V25, P779, DOI 10.1111/j.1478-3231.2005.01064.x; Sumida Y, 2014, WORLD J GASTROENTERO, V20, P475, DOI 10.3748/wjg.v20.i2.475; Bhala N, 2011, HEPATOLOGY, V54, P1208, DOI 10.1002/hep.24491; Ito K, 2012, HEPATOLOGY, V56, P1448, DOI 10.1002/hep.25815; Yoneda M, 2010, RADIOLOGY, V256, P640, DOI 10.1148/radiol.10091662; Guha IN, 2008, HEPATOLOGY, V47, P455, DOI 10.1002/hep.21984; Younossi ZM, 1998, MODERN PATHOL, V11, P560; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Harrison SA, 2008, GUT, V57, P1441, DOI 10.1136/gut.2007.146019; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Artini M, 1996, J HEPATOL, V25, P212, DOI 10.1016/S0168-8278(96)80076-6; Gawrieh S, 2011, ANN DIAGN PATHOL, V15, P19, DOI 10.1016/j.anndiagpath.2010.08.001; Kamada Y, 2013, PROTEOM CLIN APPL, V7, P648, DOI 10.1002/prca.201200137; Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084; Wong VWS, 2008, AM J GASTROENTEROL, V103, P1682, DOI 10.1111/j.1572-0241.2008.01933.x; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Yasui K, 2011, CLIN GASTROENTEROL H, V9, P428, DOI 10.1016/j.cgh.2011.01.023; Inohara H, 1996, CANCER RES, V56, P4530; Ochi H, 2012, HEPATOLOGY, V56, P1271, DOI 10.1002/hep.25756; Cheung KJ, 2009, J VIRAL HEPATITIS, V16, P418, DOI 10.1111/j.1365-2893.2009.01083.x; Kuno A, 2013, PROTEOM CLIN APPL, V7, P642, DOI 10.1002/prca.201300010; Brunt EM, 2010, NAT REV GASTRO HEPAT, V7, P195, DOI 10.1038/nrgastro.2010.21; Hui JM, 2003, HEPATOLOGY, V38, P420, DOI 10.1053/jhep.2003.50320; Bhala N, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2474; Fukusato T, 2005, HEPATOL RES, V33, P122, DOI 10.1016/j.hepres.2005.09.018; IACOBELLI S, 1986, CANCER RES, V46, P3005; Kuno A, 2013, SCI REP-UK, V3, DOI 10.1038/srep01065; Laurin J, 2002, CAN J GASTROENTEROL, V16, P722; Miyaoka H, 2008, DIGEST ENDOSC, V20, P22, DOI 10.1111/j.1443-1661.2007.00771.x; Sumida Y, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-2; Toshima T, 2014, J GASTROENTEROL; Yamasaki K, 2014, HEPATOLOGY, V60, P1563, DOI 10.1002/hep.27305; Yoneda M, 2007, J GASTROENTEROL, V42, P375, DOI 10.1007/s00535-007-2014-3	41	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					776	784		10.1007/s00535-014-1007-2		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400009		
J	Yamada, R; Hiramatsu, N; Oze, T; Morishita, N; Harada, N; Yakushijin, T; Iio, S; Doi, Y; Yamada, A; Kaneko, A; Hagiwara, H; Mita, E; Oshita, M; Itoh, T; Fukui, H; Hijioka, T; Katayama, K; Tamura, S; Yoshihara, H; Imai, Y; Kato, M; Miyagi, T; Yoshida, Y; Tatsumi, T; Kasahara, A; Hamasaki, T; Hayashi, N; Takehara, T				Yamada, Ryoko; Hiramatsu, Naoki; Oze, Tsugiko; Morishita, Naoki; Harada, Naoki; Yakushijin, Takayuki; Iio, Sadaharu; Doi, Yoshinori; Yamada, Akira; Kaneko, Akira; Hagiwara, Hideki; Mita, Eiji; Oshita, Masahide; Itoh, Toshifumi; Fukui, Hiroyuki; Hijioka, Taizo; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Imai, Yasuharu; Kato, Michio; Miyagi, Takuya; Yoshida, Yuichi; Tatsumi, Tomohide; Kasahara, Akinori; Hamasaki, Toshimitsu; Hayashi, Norio; Takehara, Tetsuo		Osaka Liver Forum	Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection	JOURNAL OF GASTROENTEROLOGY			English	Article						Hepatitis B virus; Entecavir; Risk factors for hepatocellular carcinoma incidence; Alpha-fetoprotein	NATURAL-HISTORY; INTERFERON THERAPY; LAMIVUDINE TREATMENT; EPIDEMIOLOGY; PROGRESSION; CIRRHOSIS; DISEASE; MARKER; RISK; DNA	Entecavir (ETV) is one of the first-line nucleoside analogs for treating patients with chronic hepatitis B virus (HBV) infection. However, the hepatocellular carcinoma (HCC) risk for ETV-treated patients remains unclear. A total of 496 Japanese patients with chronic HBV infection undergoing ETV treatment were enrolled in this study. The baseline characteristics were as follows: age 52.6 +/- A 12.0 years, males 58 %, positive for hepatitis B e antigen 45 %, cirrhosis 19 %, and median HBV DNA level 6.9 log copies (LC) per milliliter. The mean treatment duration was 49.9 +/- A 17.5 months. The proportions of HBV DNA negativity (below 2.6 LC/mL) were 68 % at 24 weeks and 86 % at 1 year, and the rates of alanine aminotransferase (ALT) level normalization were 62 and 72 %, respectively. The mean serum alpha-fetoprotein (AFP) levels decreased significantly at 24 weeks after ETV treatment initiation (from 29.0 +/- A 137.1 to 5.7 +/- A 27.9 ng/mL, p < 0.001). The cumulative incidence of HCC at 3, 5, and 7 years was 6.0, 9.6, and 17.2 %, respectively, among all enrolled patients. In a multivariate analysis, advanced age [55 years or older, hazard ratio (HR) 2.84; p = 0.018], cirrhosis (HR 5.59, p < 0.001), and a higher AFP level (10 ng/mL or greater) at 24 weeks (HR 2.38, p = 0.034) were independent risk factors for HCC incidence. HCC incidence was not affected by HBV DNA negativity or by ALT level normalization at 24 weeks. The AFP level at 24 weeks after ETV treatment initiation can be the on-treatment predictive factor for HCC incidence among patients with chronic HBV infection.	[Yamada, Ryoko; Hiramatsu, Naoki; Oze, Tsugiko; Morishita, Naoki; Harada, Naoki; Yakushijin, Takayuki; Miyagi, Takuya; Yoshida, Yuichi; Tatsumi, Tomohide; Takehara, Tetsuo] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Suita, Osaka 5650871, Japan; [Iio, Sadaharu] Higashiosaka City Cent Hosp, Higashiosaka, Osaka, Japan; [Doi, Yoshinori] Otemae Hosp, Osaka, Osaka, Japan; [Yamada, Akira] Sumitomo Hosp, Osaka, Osaka, Japan; [Kaneko, Akira] NTT West Osaka Hosp, Osaka, Osaka, Japan; [Hagiwara, Hideki; Hayashi, Norio] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan; [Mita, Eiji] Osaka Natl Hosp, Natl Hosp Org, Osaka, Osaka, Japan; [Oshita, Masahide] Osaka Police Hosp, Osaka, Osaka, Japan; [Itoh, Toshifumi] Osaka Hosp, Japan Community Hlth Care Org, Osaka, Osaka, Japan; [Fukui, Hiroyuki] Yao Municipal Hosp, Yao, Osaka, Japan; [Hijioka, Taizo] Osaka Minami Med Ctr, Natl Hosp Org, Kawachi Nagano, Osaka, Japan; [Katayama, Kazuhiro] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Osaka, Japan; [Tamura, Shinji] Minoh City Hosp, Mino, Osaka, Japan; [Yoshihara, Harumasa] Osaka Rosai Hosp, Sakai, Osaka, Japan; [Imai, Yasuharu] Ikeda Municipal Hosp, Ikeda, Osaka, Japan; [Kato, Michio] Minami Wakayama Med Ctr, Natl Hosp Org, Wakayama, Japan; [Kasahara, Akinori] Osaka Univ Hosp, Dept Gen Med, Suita, Osaka, Japan; [Hamasaki, Toshimitsu] Osaka Univ, Dept Biomed Stat, Grad Sch Med, Suita, Osaka 5650871, Japan	Hiramatsu, N (reprint author), Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	hiramatsu@gh.med.osaka-u.ac.jp	Hamasaki, Toshimitsu/N-3851-2015	Hamasaki, Toshimitsu/0000-0002-4928-1160	Ministry of Health Labour and Welfare of Japan; Ministry of Education, Science, and Culture of Japan	The authors thank Atsuo Inoue (Osaka General Medical Center), Masami Inada (Toyonaka Municipal Hospital), Ikuo Suzuki (Saiseikai Senri Hospital), Akira Takeda (Ashiya Municipal Hospital), Hiroyuki Ogawa (Nishinomiya Municipal Central Hospital), Mitsunari Yamamoto (Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan), and Yukiko Saji (Itami City Hospital) for their support. This work was supported by a Grant-in-Aid for Research on Hepatitis from the Ministry of Health Labour and Welfare of Japan, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan.	Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Matsumoto A, 2005, HEPATOL RES, V32, P173, DOI 10.1016/j.hepres.2005.02.006; Ono A, 2012, J HEPATOL, V57, P508, DOI 10.1016/j.jhep.2012.04.037; Wong GLH, 2014, HEPATOLOGY, V59, P986, DOI 10.1002/hep.26739; Asahina Y, 2013, HEPATOLOGY, V58, P1253, DOI 10.1002/hep.26442; Lai CL, 2006, NEW ENGL J MED, V354, P1011, DOI 10.1056/NEJMoa051287; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Fattovich G, 2008, J HEPATOL, V48, P335, DOI 10.1016/j.jhep.2007.11.011; DIBISCEGLIE AM, 1989, CANCER, V64, P2117, DOI 10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7; Yim HJ, 2006, HEPATOLOGY, V43, pS173, DOI 10.1002/hep.20956; Hosaka T, 2013, HEPATOLOGY, V58, P98, DOI 10.1002/hep.26180; McMahon BJ, 2009, HEPATOLOGY, V49, pS45, DOI 10.1002/hep.22898; Kurokawa M, 2012, J GASTROENTEROL, V47, P577, DOI 10.1007/s00535-011-0522-7; Lin SM, 2007, J HEPATOL, V46, P45, DOI 10.1016/j.jhep.2006.08.021; Wong GLH, 2013, HEPATOLOGY, V58, P1537, DOI 10.1002/hep.26301; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; Hoofnagle JH, 2007, HEPATOLOGY, V45, P1056, DOI 10.1002/hep.21627; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; Tenney DJ, 2009, HEPATOLOGY, V49, P1503, DOI 10.1002/hep.22841; Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Di Marco V, 2004, HEPATOLOGY, V40, P883, DOI 10.1002/hep.20381; Yamamoto M, 2011, CLIN EXP IMMUNOL, V165, P211, DOI 10.1111/j.1365-2249.2011.04421.x; Oze T, 2014, CLIN GASTROENTEROL H, V12, P1186, DOI 10.1016/j.cgh.2013.11.033; Kobashi H, 2011, HEPATOL RES, V41, P405, DOI 10.1111/j.1872-034X.2011.00785.x; Rokuhara A, 2003, J VIRAL HEPATITIS, V10, P324, DOI 10.1046/j.1365-2893.2003.00437.x; Sherman M, 2010, ONCOLOGY-BASEL, V78, P7, DOI 10.1159/000315223; Tseng KC, 2014, ANTIVIR THER, V19, P755, DOI 10.3851/IMP2754	28	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					785	794		10.1007/s00535-014-1010-7		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400010		
J	Tada, T; Kumada, T; Toyoda, H; Kiriyama, S; Tanikawa, M; Hisanaga, Y; Kanamori, A; Kitabtake, S; Ito, T				Tada, Toshifumi; Kumada, Takashi; Toyoda, Hidenori; Kiriyama, Seiki; Tanikawa, Makoto; Hisanaga, Yasuhiro; Kanamori, Akira; Kitabtake, Shusuke; Ito, Takanori			Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy	JOURNAL OF GASTROENTEROLOGY			English	Article						Hepatitis B; Nucleos(t)ide analogue; Hepatocellular carcinoma; Survival; Mortality	HEPATOCELLULAR-CARCINOMA; PROPENSITY SCORE; VIRUS INFECTION; LIVER FIBROSIS; EPIDEMIOLOGY; RISK; DNA	Long-term nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) patients has been reported to reduce the risk of hepatocellular carcinoma (HCC) development. However, survival rates and causes of death in CHB patients either treated or not treated with NA therapy are unclear. Therefore, we investigated the prognosis of CHB in both of these groups. A total of 919 CHB patients who were treated (n = 189) or not treated (n = 730) with NA therapy were enrolled; of these, 135 were selected from each group by propensity score matching. Survival, mortality from both HCC and non-liver related diseases, and causes of death were analyzed. In all patients (n = 919), cumulative survival and mortality from both HCC and non-liver related diseases did not differ significantly according to NA therapy status. Of 66 patients who died during the follow-up period, 59.1 % died due to liver-related diseases (including HCC); of the remainder, 48.1 % died of non-liver related malignancies. In patients selected by propensity score matching (n = 270), cumulative survival and mortality from HCC were significantly improved in those who received NA therapy compared with those who did not (p = 0.015 and 0.018, respectively). Cox proportional hazards models indicated that NA therapy was independently associated with survival of CHB patients (hazard ratio, 0.286; 95 % confidence interval, 0.122-0.668; p = 0.004). Approximately 40 % of CHB patients died of non-liver-related diseases. Additionally, in patients who required anti-viral therapy for CHB, NA therapy improved survival and mortality from HCC.	[Tada, Toshifumi; Kumada, Takashi; Toyoda, Hidenori; Kiriyama, Seiki; Tanikawa, Makoto; Hisanaga, Yasuhiro; Kanamori, Akira; Kitabtake, Shusuke; Ito, Takanori] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Gifu 5038502, Japan	Tada, T (reprint author), Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, 4-86 Minaminokawa, Ogaki, Gifu 5038502, Japan.	tadat0627@gmail.com					Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Shen L, 2006, WORLD J GASTROENTERO, V12, P1292; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Liaw YF, 2012, HEPATOL INT, V6, P531, DOI 10.1007/s12072-012-9365-4; Hosaka T, 2013, HEPATOLOGY, V58, P98, DOI 10.1002/hep.26180; HANLEY JA, 1982, RADIOLOGY, V143, P29; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Kao JH, 2000, J HEPATOL, V33, P998, DOI 10.1016/S0168-8278(00)80135-X; Liu CJ, 2004, J MED VIROL, V74, P237, DOI 10.1002/jmv.20176; Kumada T, 2013, J HEPATOL, V58, P427, DOI 10.1016/j.jhep.2012.10.025; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Yuen MF, 2005, GUT, V54, P1610, DOI 10.1136/gut.2005.065136; Iacobellis A, 2005, ALIMENT PHARM THERAP, V22, P769, DOI 10.1111/j.1365-2036.2005.02633.x; Szmuness W, 1978, Prog Med Virol, V24, P40; BEASLEY RP, 1981, LANCET, V2, P1129; Kiyosawa K, 2004, GASTROENTEROLOGY, V127, pS17, DOI 10.1053/j.gastro.2004.09.012; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Liaw YF, 2009, LIVER INT, V29, P100, DOI 10.1111/j.1478-3231.2008.01941.x; Caturelli E, 2003, RADIOLOGY, V226, P691, DOI 10.1148/radiol.2263011737; Chen G, 2005, INT J EPIDEMIOL, V34, P132, DOI 10.1093/ije/dyh339; European Association for the Study of the Liver, 2012, J HEPATOL, V57, P167, DOI DOI 10.1016/J.JHEP.2012.02.010]; Hosmer DW, 2000, APPL LOGISTIC REGRES; Kato H, 2001, J VIROL METHODS, V98, P153, DOI 10.1016/S0166-0934(01)00374-3; Kimura T, 2003, J CLIN MICROBIOL, V41, P1901, DOI 10.1128/JCM.41.5.1901-1906.2003; Kumada T, 2010, J MED VIROL, V82, P539, DOI 10.1002/jmv.21686; Lai CL, 2004, J GASTROEN HEPATOL, V19, pS5, DOI 10.1111/j.1440-1746.2003.03391.x; Leung Nancy, 2005, Med J Malaysia, V60 Suppl B, P22; RUSTGI VK, 1987, GASTROENTEROL CLIN N, V16, P545; Takeda A, 2007, J VIRAL HEPATITIS, V14, P75, DOI 10.1111/j.1365-2893.2006.00808.x; The Japan Society of Hepatology, 2010, HEPATOLOGY RES SS1, V40, P6; Wong DKH, 2007, J CLIN MICROBIOL, V45, P3942, DOI 10.1128/JCM.00366-07; World Health Organization, 1992, ICD 10 CLASS MENT BE	35	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					795	804		10.1007/s00535-014-1011-6		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400011		
J	Kawa, S; Okazaki, K; Notohara, K; Watanabe, M; Shimosegawa, T				Kawa, Shigeyuki; Okazaki, Kazuichi; Notohara, Kenji; Watanabe, Mamoru; Shimosegawa, Tooru			Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis	JOURNAL OF GASTROENTEROLOGY			English	Article						Autoimmune pancreatitis (AIP); Lymphoplasmacytic sclerosing pancreatitis (LPSP); Idiopathic duct-centric chronic pancreatitis (IDCP); Granulocytic epithelial lesion (GEL); Inflammatory bowel disease (IBD); Ulcerative colitis (UC); Crohn's disease	LYMPHOPLASMACYTIC SCLEROSING PANCREATITIS; GRANULOCYTIC EPITHELIAL LESIONS; CONSENSUS DIAGNOSTIC-CRITERIA; INTERNATIONAL CONSENSUS; ULCERATIVE-COLITIS; FEATURES; SUBTYPES; MULTICENTER; PROPOSAL	Two types of autoimmune pancreatitis (AIP) have been reported, lymphoplasmacytic sclerosing pancreatitis and idiopathic duct-centric chronic pancreatitis (IDCP), which are now recognized as type 1 and type 2 AIP, respectively. Since the clinical features of type 2 AIP have not been fully elucidated and this condition is frequently accompanied by inflammatory bowel disease (IBD), we performed a nationwide survey of patients with AIP complicated with IBD to precisely characterize this disease entity. We collected 138 cases of pancreatitis with complicating IBD from affiliated institutes specializing in AIP or IBD, and comparative study between the IDCP groups and type 1 AIP was performed. Histological examination revealed 15 AIP cases to be IDCP of institutional diagnosis, among which 11 cases were upgraded to IDCP of central diagnosis by an expert pathologist. The IDCP group exhibited younger onset age, no gender bias, frequent abdominal pain, and normal IgG4 value, similar to those of type 2 AIP reported previously. We also witnessed a lower prevalence of jaundice in type 2 AIP than in type 1 AIP that corresponded to imaging findings of less frequent pancreatic head swelling and scarce bile duct stenosis. A characteristic feature of type 2 AIP compared with type 1 AIP is a low frequency of obstructive jaundice that is related to rare lower bile duct stricture due to lower prevalence of pancreatic head swelling. Contrary to type 1 AIP, lower bile duct stricture in this condition has no apparent relation to sclerosing cholangitis.	[Kawa, Shigeyuki] Shinshu Univ, Ctr Hlth Safety & Environm Management, Matsumoto, Nagano 3908621, Japan; [Okazaki, Kazuichi] Kansai Med Univ, Dept Gastroenterol & Hepatol, Osaka, Japan; [Notohara, Kenji] Kurashiki Cent Hosp, Dept Anat Pathol, Kurashiki, Okayama, Japan; [Watanabe, Mamoru] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan; [Shimosegawa, Tooru] Tokyo Med & Dent Univ, Grad Sch, Dept Gastroenterol & Hepatol, Tokyo, Japan	Kawa, S (reprint author), Shinshu Univ, Ctr Hlth Safety & Environm Management, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	skawapc@shinshu-u.ac.jp			Ministry of Health, Labor, and Welfare of Japan	This work was supported partially by the Research Program of Intractable Disease provided by the Ministry of Health, Labor, and Welfare of Japan. We thank Trevor Ralph for his English editorial assistance.	Zamboni G, 2004, VIRCHOWS ARCH, V445, P552, DOI 10.1007/s00428-004-1140-z; KAWAGUCHI K, 1991, HUM PATHOL, V22, P387, DOI 10.1016/0046-8177(91)90087-6; Maire F, 2011, AM J GASTROENTEROL, V106, P151, DOI 10.1038/ajg.2010.314; Sugumar A, 2009, AM J GASTROENTEROL, V104, P2308, DOI 10.1038/ajg.2009.336; Kamisawa T, 2011, PANCREAS, V40, P809, DOI 10.1097/MPA.0b013e3182258a15; Kanno A, 2012, GASTROINTEST ENDOSC, V76, P594, DOI 10.1016/j.gie.2012.05.014; Song TJ, 2012, J GASTROEN HEPATOL, V27, P700, DOI 10.1111/j.1440-1746.2011.06934.x; Hart PA, 2013, GUT, V62, P1771, DOI 10.1136/gutjnl-2012-303617; Notohara K, 2003, AM J SURG PATHOL, V27, P1119, DOI 10.1097/00000478-200308000-00009; Sah RP, 2010, GASTROENTEROLOGY, V139, P140, DOI 10.1053/j.gastro.2010.03.054; Park SH, 2013, J CLIN GASTROENTEROL, V47, P520, DOI 10.1097/MCG.0b013e31827fd4a2; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Naitoh I, 2009, J GASTROENTEROL, V44, P1147, DOI 10.1007/s00535-009-0108-9; Hamano H, 2002, LANCET, V359, P1403, DOI 10.1016/S0140-6736(02)08359-9; Chari ST, 2010, PANCREATOLOGY, V10, P664, DOI 10.1159/000318809; Shimosegawa T, 2011, PANCREAS, V40, P352, DOI 10.1097/MPA.0b013e3182142fd2; Hirano K, 2010, GASTROINTEST ENDOSC, V71, P85, DOI 10.1016/j.gie.2009.08.008; Ikeura T, 2012, INTERNAL MED, V51, P733, DOI 10.2169/internalmedicine.51.6859; Ishikawa T, 2012, WORLD J GASTROENTERO, V18, P3883, DOI 10.3748/wjg.v18.i29.3883; Kawa S, 2013, AUTOIMMUNE DIS, P935; Kloppel G, 2010, J GASTROENTEROL, V45, P787, DOI 10.1007/s00535-010-0265-x; Kusuda T, 2010, INTERNAL MED, V49, P2569, DOI 10.2169/internalmedicine.49.4165; Nve E, 2006, HPB (Oxford), V8, P153, DOI 10.1080/13651820600686998; Oishi Y, 2004, J GASTROENTEROL, V39, P26, DOI 10.1007/s00535-003-1241-5; Okano A, 2001, INTERNAL MED, V40, P1205, DOI 10.2169/internalmedicine.40.1205; Pitchumoni CS, 2010, J CLIN GASTROENTEROL, V44, P246, DOI 10.1097/MCG.0b013e3181cadbe1; Sah RP, 2010, GASTROENTEROLOGY, V139, pe112; Okazaki K, 2012, PANCREAS, V41, P1341; Toda N, 2005, INFLAMM BOWEL DIS, V11, P903, DOI 10.1097/01.MIB.0000183419.17563.17; Toki F, 1992, ENDOSCOPY, V24, P640; Ueki T, PANCREAS IN PRESS; YOSHIDA K, 1995, DIGEST DIS SCI, V40, P1561, DOI 10.1007/BF02285209	32	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					805	815		10.1007/s00535-014-1012-5		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400012		
J	Motoo, Y				Motoo, Yoshiharu			Description of Kampo medicines in the clinical practice guidelines for irritable bowel syndrome	JOURNAL OF GASTROENTEROLOGY			English	Letter									Kanazawa Med Univ, Dept Med Oncol, Kanazawa, Ishikawa, Japan	Motoo, Y (reprint author), Kanazawa Med Univ, Dept Med Oncol, Kanazawa, Ishikawa, Japan.	motoo@kanazawa-med.ac.jp					Fukudo S, 2015, J GASTROENTEROL, V50, P11, DOI 10.1007/s00535-014-1017-0; Ishii F, 1993, PROG MED, V13, P2893; Sasaki D, 1998, JPN J CLIN EXP MED, V75, P1136; Sugano K, 2014, JAPANESE SOC GASTROE	4	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					816	816		10.1007/s00535-015-1075-y		1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400013		
J	Fukudo, S; Kaneko, H; Akiho, H; Inamori, M; Endo, Y; Okumura, T; Kanazawa, M; Kamiya, T; Sato, K; Chiba, T; Furuta, K; Yamato, S; Arakawa, T; Fujiyama, Y; Azuma, T; Fujimoto, K; Mine, T; Miura, S; Kinoshita, Y; Watanabe, M; Sugano, K; Shimosegawa, T				Fukudo, Shin; Kaneko, Hiroshi; Akiho, Hirotada; Inamori, Masahiko; Endo, Yuka; Okumura, Toshikatsu; Kanazawa, Motoyori; Kamiya, Takeshi; Sato, Ken; Chiba, Toshimi; Furuta, Kenji; Yamato, Shigeru; Arakawa, Tetsuo; Fujiyama, Yoshihide; Azuma, Takeshi; Fujimoto, Kazuma; Mine, Tetsuya; Miura, Soichiro; Kinoshita, Yoshikazu; Watanabe, Mamoru; Sugano, Kentaro; Shimosegawa, Tooru			Evaluation of Kampo medicine in the clinical practice guideline for irritable bowel syndrome	JOURNAL OF GASTROENTEROLOGY			English	Letter									[Fukudo, Shin; Kaneko, Hiroshi; Akiho, Hirotada; Inamori, Masahiko; Endo, Yuka; Okumura, Toshikatsu; Kanazawa, Motoyori; Kamiya, Takeshi; Sato, Ken; Chiba, Toshimi; Furuta, Kenji; Yamato, Shigeru; Arakawa, Tetsuo; Fujiyama, Yoshihide; Azuma, Takeshi; Fujimoto, Kazuma; Mine, Tetsuya; Miura, Soichiro; Kinoshita, Yoshikazu; Watanabe, Mamoru; Sugano, Kentaro; Shimosegawa, Tooru] Japanese Soc Gastroenterol, Chuou, Tokyo 1040061, Japan; [Fukudo, Shin] Tohoku Univ, Dept Behav Med, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan	Fukudo, S (reprint author), Japanese Soc Gastroenterol, K-18 Bldg 8F,8-9-13 Ginza, Chuou, Tokyo 1040061, Japan.	sfukudo@med.tohoku.ac.jp					Qaseem A, 2010, ANN INTERN MED, V153, P194, DOI 10.7326/0003-4819-153-3-201008030-00010; Fukudo S, 2015, J GASTROENTEROL, V50, P11, DOI 10.1007/s00535-014-1017-0; Ishii F, 1993, PROG MED, V13, P2893; Kux L, 2012, FED REGISTER, V77, P32124; Motoo Y, J GASTROENT IN PRESS; Sasaki D, 1998, RINSHO TO KENKYU, V75, P1136	6	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	JUL	2015	50	7					817	818		10.1007/s00535-015-1074-z		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM4RC	WOS:000357671400014		
J	Ohta, A; Imai, N; Terashima, S; Tachibana, Y				Ohta, Atsuyuki; Imai, Noboru; Terashima, Shigeru; Tachibana, Yoshiko			The spatial distribution of multiple elements in the Kanto region of Japan: Transport of chalcophile elements from land to sea	JOURNAL OF GEOCHEMICAL EXPLORATION			English	Article						Geochemical mapping; Particle transfer; Chalcophile element; Factor analysis; Analysis of variance (ANOVA); Multiple comparison	WALAWE GANGA BASIN; STREAM SEDIMENTS; STATISTICAL-ANALYSIS; MARINE ENVIRONMENTS; COMPOSITIONAL DATA; GEOCHEMICAL DATA; COASTAL SEA; SRI-LANKA; CONTAMINATION; TERRESTRIAL	The transport of particles in the Kanto region of Japan is discussed, using comprehensive geochemical maps of 53 elements in terrestrial and marine areas, generated by the Geological Survey of Japan (AIST). This study investigates the transport processes of elements (Cu, Zn, Mo, As, Cd, Sn, Sb, Hg, Pb, and Bi), the concentrations of which are highly increased as a result of mining and anthropogenic activities. The Kanto region was selected as a study area, because it includes large-scale economic mines, as well as the metropolis of Japan with its associated densely populated and industrial areas. Although metalliferous deposits typically enhance the concentrations of chalcophile elements, and Mo and Sn, marine sediments located adjacent the mining areas show no significant enrichment in these elements. Other elements show that their concentrations are mainly controlled by lithology, and display discontinuous spatial distribution patterns across the land and sea. The coastal sea adjacent to the mining area faces the open sea on the Pacific side. It is, therefore, assumed that sediments supplied from the land would be dispersed by wave and coastal sea currents in the coastal sea environment. In contrast, chalcophile elements, P, Mo, and Sn are highly abundant in both the stream sediments of metropolitan areas and the coastal sea sediments of the adjoining inner Tokyo Bay. The contaminated sediments in the bay appear not to extend into the outer sea. In Tokyo Bay, sea water flows along the bottom from the outer sea towards the inner bay, while surface water in the bay flows out steadily. Accordingly, the spatial distribution patterns of contaminated sediments supplied from the nearby urban areas are controlled by water circulation in the bay. (C) 2014 Elsevier B.V. All rights reserved.	[Ohta, Atsuyuki; Imai, Noboru; Terashima, Shigeru; Tachibana, Yoshiko] Geol Survey Japan, Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058567, Japan	Ohta, A (reprint author), Geol Survey Japan, Natl Inst Adv Ind Sci & Technol, Cent 7,1-1-1 Higashi, Tsukuba, Ibaraki 3058567, Japan.	a.ohta@aist.go.jp	Ohta, Atsuyuki/B-9808-2009	Ohta, Atsuyuki/0000-0002-0770-3273			Aitchison J, 1986, STAT ANAL COMPOSITIO; Andersson M., 2014, GEOCHEMICAL ATLAS SW; Li XD, 2001, MAR POLLUT BULL, V42, P215, DOI 10.1016/S0025-326X(00)00145-4; Reimann C, 2012, SCI TOTAL ENVIRON, V426, P196, DOI 10.1016/j.scitotenv.2012.02.032; Leoni L, 1996, MAR ENVIRON RES, V41, P73, DOI 10.1016/0141-1136(94)00153-7; Fang TH, 2009, MAR ENVIRON RES, V68, P178, DOI 10.1016/j.marenvres.2009.06.005; Johnson CC, 2008, ENVIRON GEOCHEM HLTH, V30, P511, DOI 10.1007/s10653-008-9189-2; IMAI N, 1995, GEOSTANDARD NEWSLETT, V19, P135, DOI 10.1111/j.1751-908X.1995.tb00158.x; Aoyama M, 2012, GEOCHEM J, V46, P321; Filzmoser P, 2009, SCI TOTAL ENVIRON, V407, P6100, DOI 10.1016/j.scitotenv.2009.08.008; Reimann C, 2002, APPL GEOCHEM, V17, P185, DOI 10.1016/S0883-2927(01)00066-X; Xie XJ, 1997, J GEOCHEM EXPLOR, V60, P99; Thornton I, 2008, ENVIRON GEOCHEM HLTH, V30, P565, DOI 10.1007/s10653-008-9182-9; IMAI N, 1990, ANAL SCI, V6, P389, DOI 10.2116/analsci.6.389; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709; Li XD, 2004, ENVIRON POLLUT, V129, P113, DOI 10.1016/j.envpol.2003.09.030; WATSON DF, 1985, GEO-PROCESSING, V2, P315; Reimann C, 2005, GEOCHEM-EXPLOR ENV A, V5, P359, DOI 10.1144/1467-7873/03-051; Egozcue JJ, 2011, COMPOSITIONAL DATA ANALYSIS: THEORY AND APPLICATIONS, P12; Cicchella D, 2008, GEOCHEM-EXPLOR ENV A, V8, P19, DOI 10.1144/1467-7873/07-147; Bolviken B., 1986, GEOCHEMICAL ATLAS NO; BUCKLEY DE, 1992, CAN J EARTH SCI, V29, P2617, DOI 10.1139/e92-208; Caritat P., 2011, NATL GEOCHEMICAL SUR; Caritat P. de, 2011, GEOSCIENCE AUSTR REC, V20, P557; Chandrajith R, 2000, APPL GEOCHEM, V15, P1369, DOI 10.1016/S0883-2927(99)00121-3; Chandrajith R, 2001, APPL GEOCHEM, V16, P339, DOI 10.1016/S0883-2927(00)00038-X; Darnley A. G., 1995, GLOBAL GEOCHEMICAL D, V19, P122; DeVos W., 2006, GEOCHEMICAL ATLAS 2; Fauth H., 1985, GEOCHEMISCHER ATLAS; Filzmoser P., 2014, GEOLOGISCHES JB B, P67; Filzmoser P, 2010, SCI TOTAL ENVIRON, V408, P4230, DOI 10.1016/j.scitotenv.2010.05.011; Gustavsson N., 2001, US GEOL SURV PROF PA, V1648, P1; Hawkes H.E., 1962, GEOCHEMISTRY MINERAL; Hawkes H.E., 1957, US GEOL SURV B F, V100-F, P225; Higashi H., 2008, P HYDRAUL ENG, V52, P1405; Howarth R.J., 1983, APPL ENV GEOCHEMISTR, P41; Imai N., 2011, ADV TOPICS MASS TRAN, P373; Imai N., 2010, GEOLOGICAL SURVEY JA; Imai N., 2004, GEOCHEMICAL MAP JAPA, V1st; Jarva J., 2008, ENVIRON GEOCHEM HLTH, V30, P613; Johnson C.C., 2011, MAPPING CHEM ENV URB; Koljonen T., 1992, GEOCHEMICAL ATLAS 2; Kubo J., 1989, NATURAL CONDITION SO, P1; Lahermo P., 1996, GEOCHEMICAL ATLAS 3; Lahermo P., 1990, GEOCHEMICAL ATLAS 1; Levinson A.A., 1974, INTRO EXPLORATION GE, P1980; Levinson AA, 1980, INTRO EXPLORATION GE; Mogi A., 1970, KAIYO KAGAKU, V2, P23; Ohta A, 2005, APPL GEOCHEM, V20, P1017, DOI 10.1016/j.apgeochem.2004.12.005; Ohta A, 2010, APPL GEOCHEM, V25, P357, DOI 10.1016/j.apgeochem.2009.12.003; Ohta A, 2007, APPL GEOCHEM, V22, P2872, DOI 10.1016/j.apgeochem.2007.08.001; Ohta A, 2004, APPL GEOCHEM, V19, P1453, DOI 10.1016/j.apgeochem.2004.01.026; Ohta A, 2011, GEOCHEM-EXPLOR ENV A, V11, P211, DOI 10.1144/1467-7873/10-042; Omori M., 1986, REGIONAL GEOLOGY J 3; Reimann C., 2014, GEOLOGISCHES JB B; Reimann C., 2003, AGR SOILS NO EUROPE; Reimann C., 2014, GEOLOGISCHES JB B; Rose A. W., 1979, GEOCHEMISTRY MINERAL; Salminen R, 2005, GEOCHEMICAL ATLAS 1; Shacklette H. T., 1984, ELEMENT CONCENTRATIO; Smith D. B., 2013, US GEOLOGICAL SURVEY, V801, P19; Smith D.B., 2014, 20141082 US GEOL SUR; Weaver T.A., 1983, GEOCHEMICAL ATLAS AL; Webb J. S., 1978, WOLFSON GEOCHEMICAL; Whalley C, 1999, MAR POLLUT BULL, V38, P394, DOI 10.1016/S0025-326X(98)00158-1; Zheng C., 1994, ATLAS SOIL ENV BACKG	66	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0375-6742	1879-1689		J GEOCHEM EXPLOR	J. Geochem. Explor.	JUL	2015	154				SI		156	170		10.1016/j.gexplo.2014.11.016		15	Geochemistry & Geophysics	Geochemistry & Geophysics	CM2ZE	WOS:000357550100012		
J	Shimazaki, Y; Yajima, T; Yamauchi, O				Shimazaki, Yuichi; Yajima, Tatsuo; Yamauchi, Osamu			Properties of the indole ring in metal complexes. A comparison with the phenol ring	JOURNAL OF INORGANIC BIOCHEMISTRY			English	Article						Tryptophan; Tyrosine; Metal complexes; sigma- and pi-bondings; Radical formation	ACCELERATED ELECTRON FLOW; MIXED-LIGAND COMPLEXES; PRION PROTEIN INSIGHTS; CATION-PI INTERACTION; CHAIN AROMATIC RING; H BOND ARYLATION; GALACTOSE-OXIDASE; AMINO-ACIDS; SIDE-CHAIN; PALLADIUM(II) COMPLEXES	Tryptophan (Trp), an essential amino acid, has an indole ring with a high electron density and is frequently seen at the proximal position of the metal site in metalloproteins. For example, the indole ring of Trp has been reported to interact weakly with Cu(I) in a Cu chaperone CusF. Another aromatic amino acid, tyrosine (Tyr), has a phenol ring, which is an important metal binding site in various metalloproteins. Although the structures of the aromatic rings are different, they both have a weakly acidic moiety and perform some similar roles in biological systems, such as radical formation and electron transfer. In this review, we focus on these and other properties of the indole and phenol rings in metal-containing systems. (C) 2015 Elsevier Inc. All rights reserved.	[Shimazaki, Yuichi] Ibaraki Univ, Coll Sci, Mito, Ibaraki 3108512, Japan; [Yajima, Tatsuo; Yamauchi, Osamu] Kansai Univ, Fac Chem Mat & Bioengn, Suita, Osaka 5648680, Japan; [Yamauchi, Osamu] Nagoya Univ, Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Shimazaki, Y (reprint author), Ibaraki Univ, Coll Sci, Mito, Ibaraki 3108512, Japan.	yshima@mx.ibaraki.ac.jp; oyamauchi36bioin@wonder.ocn.ne.jp	Shimazaki, Yuichi/O-1560-2015	Shimazaki, Yuichi/0000-0003-0695-8001	Ministry of Education, Culture, Sports, Science, and Technology of Japan [22550055, 25410060]; Cooperative Research in Joint Studies Programs at Institute for Molecular Science by the Cooperative Research Program of "Network Joint Research Center for Materials and Devices" (Institute for Materials Chemistry and Engineering, Kyushu University)	We would like to thank Prof. Dr. Takamitsu Kohzuma of the Institute of Applied Beam Science, Ibaraki University, and Prof. Dr. Akira Odani of the School of Pharmaceutical Sciences, Kanazawa University, for their valuable comments and suggestions on this manuscript. This work was supported in part by Grants-in-Aid for Scientific Research (Nos. 22550055 and 25410060 to Y. S.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Cooperative Research in Joint Studies Programs at Institute for Molecular Science by the Cooperative Research Program of "Network Joint Research Center for Materials and Devices" (Institute for Materials Chemistry and Engineering, Kyushu University).	Shih C, 2008, SCIENCE, V320, P1760, DOI 10.1126/science.1158241; Nocek JM, 1996, CHEM REV, V96, P2459, DOI 10.1021/cr9500444; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; SOLAR S, 1991, J PHYS CHEM-US, V95, P3639, DOI 10.1021/j100162a038; Takematsu K, 2013, J AM CHEM SOC, V135, P15515, DOI 10.1021/ja406830d; TRIPATHI GNR, 1984, J CHEM PHYS, V81, P113, DOI 10.1063/1.447373; Asami K, 2014, DALTON T, V43, P2283, DOI 10.1039/c3dt52338a; Chaudhuri P, 2001, PROG INORG CHEM, V50, P151; Whittaker JW, 2003, CHEM REV, V103, P2347, DOI 10.1021/cr020425z; Storr T, 2008, J AM CHEM SOC, V130, P15448, DOI 10.1021/ja804339m; Feng L, 2011, J AM CHEM SOC, V133, P5976, DOI 10.1021/ja1112996; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Zhou FM, 2012, COORDIN CHEM REV, V256, P2285, DOI 10.1016/j.ccr.2012.04.035; Lyons CT, 2013, COORDIN CHEM REV, V257, P528, DOI 10.1016/j.ccr.2012.06.003; Lane BS, 2004, ORG LETT, V6, P2897, DOI 10.1021/ol0490072; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; Xue Y, 2008, NAT CHEM BIOL, V4, P107, DOI 10.1038/nchembio.2007.57; Tabbi G, 2013, J INORG BIOCHEM, V128, P137, DOI 10.1016/j.jinorgbio.2013.07.035; Shimazaki Y, 2009, INORG CHEM, V48, P8383, DOI 10.1021/ic901003q; Shimazaki Y, 2007, J AM CHEM SOC, V129, P2559, DOI 10.1021/ja067022r; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Kochem A, 2012, CHEM-EUR J, V18, P1068, DOI 10.1002/chem.201102882; Jazdzewski BA, 2000, COORDIN CHEM REV, V200, P633, DOI 10.1016/S0010-8545(00)00342-8; Mahadevi AS, 2013, CHEM REV, V113, P2100, DOI 10.1021/cr300222d; Gaggelli E, 2006, CHEM REV, V106, P1995, DOI 10.1021/cr040410w; DEFELIPPIS MR, 1991, J PHYS CHEM-US, V95, P3416, DOI 10.1021/j100161a081; RYABOV AD, 1990, CHEM REV, V90, P403, DOI 10.1021/cr00100a004; Alves FRD, 2009, MINI-REV MED CHEM, V9, P782; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Jensen LMR, 2010, SCIENCE, V327, P1392, DOI 10.1126/science.1182492; Arena G, 2012, COORDIN CHEM REV, V256, P2202, DOI 10.1016/j.ccr.2012.03.038; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Sugimori T, 1997, INORG CHEM, V36, P576, DOI 10.1021/ic9608556; THOMPSON JS, 1983, J AM CHEM SOC, V105, P3522, DOI 10.1021/ja00349a026; NAUMANN CF, 1974, J AM CHEM SOC, V96, P2750, DOI 10.1021/ja00816a016; Asami K, 2012, INORG CHEM, V51, P12450, DOI 10.1021/ic3018503; Shimazaki Y, 2011, DALTON T, V40, P2469, DOI 10.1039/c0dt01574a; SIGEL H, 1975, ANGEW CHEM INT EDIT, V14, P394, DOI 10.1002/anie.197503941; Wang X, 2007, J ORG CHEM, V72, P1476, DOI 10.1021/jo061979v; AOKI K, 1987, J CHEM SOC DALTON, P2017, DOI 10.1039/dt9870002017; Dieterich F., 1998, METAL CATALYZED CROS; dos Santos NV, 2012, J INORG BIOCHEM, V114, P1, DOI 10.1016/j.jinorgbio.2012.04.008; Dougherty DA, 2013, ACCOUNTS CHEM RES, V46, P885, DOI 10.1021/ar300265y; Fihri A, 2011, DALTON T, V40, P3116, DOI 10.1039/c0dt01637c; FISCHER BE, 1980, J AM CHEM SOC, V102, P2998, DOI 10.1021/ja00529a021; Hureau C, 2008, J BIOL INORG CHEM, V13, P1055, DOI 10.1007/s00775-008-0389-0; HURSTHOUSE MB, 1975, J CHEM SOC DALTON, P2569, DOI 10.1039/dt9750002569; Isied S.S., 1991, MET IONS BIOL SYST, V27, P1; Iwatsuki S, 2011, INORG CHIM ACTA, V377, P111, DOI 10.1016/j.ica.2011.07.045; Iwatsuki S, 2014, PURE APPL CHEM, V86, P151, DOI 10.1515/pac-2014-5020; Kozlowski H, 2010, DALTON T, V39, P6371, DOI 10.1039/c001267j; Laurie S.H., 1987, COMPREHENSIVE COORDI, V2, P739; LIANG GG, 1989, Z NATURFORSCH B, V44, P1555; Martin R.B., 1979, MET IONS BIOL SYST, V9, P1; MASUDA H, 1987, J ORGANOMET CHEM, V322, P121, DOI 10.1016/0022-328X(87)85031-3; Millhauser GL, 2004, ACCOUNTS CHEM RES, V37, P79, DOI 10.1021/ar0301678; Milovic NM, 2001, MET IONS BIOL SYST, V38, P145; Miura R., 2005, BIOCHEMISTRY-US, V44, P8712; Motoyama T, 2004, J AM CHEM SOC, V126, P7378, DOI 10.1021/ja031587v; ODANI A, 1984, INORG CHIM A-BIOINOR, V93, P13, DOI 10.1016/S0020-1693(00)85951-4; PARSHALL GW, 1970, ACCOUNTS CHEM RES, V3, P139, DOI 10.1021/ar50028a004; PETTIT LD, 1982, J CHEM SOC DALTON, P485, DOI 10.1039/dt9820000485; POULOS TL, 1994, MET IONS BIOL SYST, V30, P25; Pratt RC, 2003, J AM CHEM SOC, V125, P8716, DOI 10.1021/ja035837j; Pratt RC, 2005, INORG CHEM, V44, P2367, DOI 10.1021/ic048695i; Pushie MJ, 2009, J TOXICOL ENV HEAL A, V72, P1040, DOI 10.1080/15287390903084389; ROBSON R, 1982, INORG CHIM A-ARTICLE, V57, P71, DOI 10.1016/S0020-1693(00)86952-2; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; Shimazaki Y., 2014, CHEM METAL PHENOLATE, P593; Shimazaki Y, 2009, COORDIN CHEM REV, V253, P479, DOI 10.1016/j.ccr.2008.04.012; Shimazaki Y, 2007, INORG CHEM, V46, P6083, DOI 10.1021/ic700596g; Shimazaki Y., 2013, ELECTROCHEMISTRY, P51; Shimazaki Y, 2011, INDIAN J CHEM A, V50, P383; Shimazaki Y, 2009, INORG CHIM ACTA, V362, P887, DOI 10.1016/j.ica.2008.01.046; Shimazaki Y, 2001, ANGEW CHEM INT EDIT, V40, P3859, DOI 10.1002/1521-3773(20011015)40:20<3859::AID-ANIE3859>3.0.CO;2-K; Shimazaki Y, 2014, PURE APPL CHEM, V86, P163, DOI 10.1515/pac-2014-5022; Shimazaki Y, 2005, INORG CHEM, V44, P6044, DOI 10.1021/ic0504801; Shimazaki Y, 1999, ANGEW CHEM INT EDIT, V38, P2401; Shimazaki Y., 2013, ADV MAT PHYS CHEM, V3, P60; Shimazaki Y, 2009, DALTON T, P7854, DOI 10.1039/b905871k; TAKANI M, 1995, INORG CHIM ACTA, V235, P367, DOI 10.1016/0020-1693(95)90078-K; Tanooka S, 2013, INORG CHIM ACTA, V407, P41, DOI 10.1016/j.ica.2013.07.032; VANDERHE.D, 1972, ACTA CRYSTALL B-STRU, VB 28, P2307, DOI 10.1107/S0567740872006016; Thomas F, 2007, EUR J INORG CHEM, P2379, DOI 10.1002/ejic.200601091; THOMPSON JS, 1984, INORG CHEM, V23, P2813, DOI 10.1021/ic00186a020; TSANGARI.JM, 1970, J AM CHEM SOC, V92, P4255, DOI 10.1021/ja00717a020; WHITTAKER JW, 1994, MET IONS BIOL SYST, V30, P315; Wright C, 2001, J INORG BIOCHEM, V85, P237, DOI 10.1016/S0162-0134(01)00214-8; YAGIL G, 1967, J PHYS CHEM-US, V71, P1034, DOI 10.1021/j100863a040; Yajima T, 2002, INORG CHIM ACTA, V337, P193, DOI 10.1016/S0020-1693(02)01034-4; YAMAUCHI O, 1990, INORG CHEM, V29, P1856, DOI 10.1021/ic00335a019; YAMAUCHI O, 1985, INORG CHIM A-ART LET, V100, P165, DOI 10.1016/S0020-1693(00)88304-8; YAMAUCHI O, 1985, J AM CHEM SOC, V107, P5938, DOI 10.1021/ja00307a019; Yamauchi O, 2001, B CHEM SOC JPN, V74, P1525, DOI 10.1246/bcsj.74.1525; Yamauchi O, 2002, J CHEM SOC DALTON, P3411, DOI 10.1039/b202385g	95	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0162-0134	1873-3344		J INORG BIOCHEM	J. Inorg. Biochem.	JUL	2015	148				SI		105	115		10.1016/j.jinorgbio.2015.03.001		11	Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear	Biochemistry & Molecular Biology; Chemistry	CM5BP	WOS:000357702100014		
J	Wang, YJ; Zhao, LX				Wang, Yongjin; Zhao, Laixun			Saving good jobs from global competition by rewarding quality and efforts	JOURNAL OF INTERNATIONAL ECONOMICS			English	Article						Trade liberalization; Inequality; Efficiency wages; Unemployment	EFFICIENCY-WAGE THEORY; NHS INTERNAL MARKET; TRADE LIBERALIZATION; FIRM HETEROGENEITY; UNEMPLOYMENT; LABOR; PRODUCTIVITY; SUPERVISION; INDUSTRIES; INEQUALITY	This paper links firms' endogenous quality choices to worker effort and efficiency wages. In the model, firms differ in their ability to monitor workers who have an incentive to shirk. As high quality output requires high worker effort, it is firms with better monitoring ability that upgrade their quality. Indeed, these firms upgrade their quality to such a degree that they also end up paying higher wages to induce even more worker effort. Trade liberalization can induce greater or smaller wage inequality but always enlarges the welfare inequality as higher wages go hand in hand with even greater effort. (C) 2015 Elsevier B.V. All rights reserved.	[Wang, Yongjin] Nankai Univ, Sch Econ, Tianjin 300071, Peoples R China; [Zhao, Laixun] Kobe Univ, Res Inst Econ & Business, Kobe, Hyogo 6578501, Japan	Wang, YJ (reprint author), Nankai Univ, Sch Econ, Tianjin 300071, Peoples R China.	yjw@nankai.edu.cn; Zhao@rieb.kobe-u.ac.jp					AKERLOF GA, 1984, AM ECON REV, V74, P79; Propper C, 2004, J PUBLIC ECON, V88, P1247, DOI 10.1016/S0047-2727(02)00216-5; Bernard AB, 2003, AM ECON REV, V93, P1268, DOI 10.1257/000282803769206296; Bernard AB, 2007, J ECON PERSPECT, V21, P105, DOI 10.1257/jep.21.3.105; Crozet M, 2012, REV ECON STUD, V79, P609, DOI 10.1093/restud/rdr030; Propper C, 2008, ECON J, V118, P138; Melitz MJ, 2003, ECONOMETRICA, V71, P1695, DOI 10.1111/1468-0262.00467; Atkeson A, 2010, J POLIT ECON, V118, P433; Baldwin R, 2011, AM ECON J-MICROECON, V3, P60, DOI 10.1257/mic.3.2.60; Egger H, 2009, INT ECON REV, V50, P187; Helpman E, 2010, REV ECON STUD, V77, P1100, DOI 10.1111/j.1467-937X.2009.00600.x; Yeaple SR, 2005, J INT ECON, V65, P1, DOI 10.1016/j.jinteco.2004.01.001; Kugler M, 2012, REV ECON STUD, V79, P307, DOI 10.1093/restud/rdr021; Bernard AB, 2006, J INT ECON, V68, P219, DOI 10.1016/j.jinteco.2005.06.002; Helpman E, 2010, ECONOMETRICA, V78, P1239, DOI 10.3982/ECTA8640; SHAPIRO C, 1984, AM ECON REV, V74, P433; Felbermayr G, 2011, J ECON THEORY, V146, P39, DOI 10.1016/j.jet.2010.07.004; Davis DR, 2011, J INT ECON, V84, P26, DOI 10.1016/j.jinteco.2011.03.005; Faleye O, 2011, J FINANC ECON, V101, P160, DOI 10.1016/j.jfineco.2011.02.010; Bustos P, 2011, AM ECON REV, V101, P304, DOI 10.1257/aer.101.1.304; Mukamel DB, 2001, HEALTH SERV RES, V36, P1019; Bayard K, 1999, AM ECON REV, V89, P99, DOI 10.1257/aer.89.2.99; Blanchflower DG, 1996, Q J ECON, V111, P227, DOI 10.2307/2946663; Bloom N., 2012, 17850 NBER; Bloom N., 2012, HARVARD BUSINESS REV; Burstein A., 2013, ECONOMETRIC SOC, V2; Costantini J., 2009, DYNAMICS; Davis D. R., 2011, REV ECON STUD, V79, P1; Dinopoulos E., 2014, WORKING PAPER; Ghironi F, 2005, Q J ECON, V120, P865, DOI 10.1093/qje/120.3.865; Gibson J, 2009, REV ECON STAT, V91, P213, DOI 10.1162/rest.91.1.213; Grabowski David C, 2004, Int J Health Care Finance Econ, V4, P5, DOI 10.1023/B:IHFE.0000019258.29496.03; Groshen E.L., 1990, IND LABOR RELAT REV, V43, p135S; Grossman G. M, 2007, ORG FIRMS GLOBAL EC, V875, P273; Helpman E., 2012, W170011; Helpman E., 2011, W1662; Hu G., 2014, REV INT ECON, V22, P488; KRUEGER AB, 1991, Q J ECON, V106, P75, DOI 10.2307/2937907; Leamer EE, 1999, J POLIT ECON, V107, P1127, DOI 10.1086/250092; Learner E. E., 2000, EFFORT; Maddox T. M., 2013, JAMA INTERN MED, pE1; Martins Pedro S., 2008, WORKING PAPERS, V14; Matano A., 2014, WORKING PAPER; Mehta SR, 1998, RAND J ECON, V29, P137, DOI 10.2307/2555819; NEAL D, 1993, REV ECON STAT, V75, P409, DOI 10.2307/2109454; REBITZER JB, 1995, J ECON BEHAV ORGAN, V28, P107, DOI 10.1016/0167-2681(95)00023-0; Verhoogen EA, 2008, Q J ECON, V123, P489, DOI 10.1162/qjec.2008.123.2.489	47	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-1996	1873-0353		J INT ECON	J. Int. Econ.	JUL	2015	96	2					426	434		10.1016/j.jinteco.2015.03.005		9	Economics	Business & Economics	CM2YD	WOS:000357547400013		
J	Hirota, H; Kawano, T; Shinpo, M; Kazutaka, N; Honda, N; Kiyokura, T; Manabe, T				Hirota, Hidenobu; Kawano, Tomohiro; Shinpo, Makoto; Kazutaka, Noto; Honda, Nazuki; Kiyokura, Takanori; Manabe, Tetsuya			Fiber Identification Below an Optical Splitter With a Test Light Injection Tool	JOURNAL OF LIGHTWAVE TECHNOLOGY			English	Article						Access maintenance equipment; optical fiber communication; optical fiber network	FACILITIES	We propose a novel test light injection tool for fiber identification below an optical splitter in a passive optical network. This tool makes it easy to input a test light into a bent fiber with a lateral light injection technique. We designed a high precision alignment technique to improve the test light injection efficiency and confirmed that the proposed tool can be used for fiber identification below an optical splitter.	[Hirota, Hidenobu; Kawano, Tomohiro; Shinpo, Makoto; Kazutaka, Noto; Honda, Nazuki; Kiyokura, Takanori; Manabe, Tetsuya] NTT Corp, Access Network Serv Syst Lab, Tsukuba, Ibaraki 3050805, Japan	Hirota, H (reprint author), NTT Corp, Access Network Serv Syst Lab, Tsukuba, Ibaraki 3050805, Japan.	hirota.hidenobu@lab.ntt.co.jp; kawano.tomohiro@lab.ntt.co.jp; shinpo.makoto@lab.ntt.co.jp; noto.kazutaka@lab.ntt.co.jp; honda.nazuki@lab.ntt.co.jp; kiyokura.takanori@lab.ntt.co.jp; manabe.tetsuya@lab.ntt.co.jp					MARCUSE D, 1977, AT&T TECH J, V56, P703; Aozasa S, 2012, IEICE T COMMUN, VE95B, P876, DOI 10.1587/transcom.E95.B.876; Arakawa K., 1989, Proceedings of 38th International Wire and Cable Symposium; Enomoto Y., 2006, J LIGHTWAVE TECHNOL, V29, P1818; Izumita H., 2003, P OFS 16, P258; Natsume A., 2007, P IWCS, P359; Sankawa I, 2006, J LIGHTWAVE TECHNOL, V24, P3625, DOI 10.1109/JLT.2006.881481; SHIMIZU M, 1992, J LIGHTWAVE TECHNOL, V10, P686, DOI 10.1109/50.136105; Shinpo M., 2013, OFT201254 IEICE, P9; Yamagata T, 2009, IDE-JETRO SER, P1, DOI 10.1109/TEST.2009.5355768	10	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0733-8724	1558-2213		J LIGHTWAVE TECHNOL	J. Lightwave Technol.	JUL 1	2015	33	13					2751	2757		10.1109/JLT.2015.2411746		7	Engineering, Electrical & Electronic; Optics; Telecommunications	Engineering; Optics; Telecommunications	CM3RZ	WOS:000357602700006		
J	Albuquerque, AAC; Drummond, MV; Puttnam, BJ; Wada, N; Nogueira, RN				Albuquerque, Andre A. C.; Drummond, Miguel V.; Puttnam, Benjamin J.; Wada, Naoya; Nogueira, Rogerio N.			Investigation of PPLN-Based PSAs for High-Gain Optical Amplification	JOURNAL OF LIGHTWAVE TECHNOLOGY			English	Article						Nonlinear optics; periodically poled lithium niobate; phase-sensitive amplifiers	PHASE-SENSITIVE AMPLIFICATION; WAVE-GUIDE; NOISE; AMPLIFIERS	In this paper, different configurations of phasesensitive amplifiers (PSAs) built with periodically poled lithium niobate (PPLN) devices are theoretically and numerically investigated, focusing on their application for amplification in optical communications systems. Single-and dual-pump configurations of one-, two-, and four-mode PSAs are discussed. For each configuration, analytical expressions for the maximum and minimum gain of the amplifiers are provided, showing the influence of the power of the pump and signal waves, as well as the length and efficiency of the PPLN waveguide. The analytical expressions are numerically validated by solving the coupled differential equations describing the nonlinear interactions in the PPLN. The obtained results show that the gain of all PSA configurations exponentially increases with the power of the pump waves, and the length and efficiency of the PPLN device, whereas it is almost independent of the power of the signal wave. In addition, it is shown in this paper that PSA configurations where an intermediate interaction is necessary to generate waves at the second-harmonic band have a gain penalty of 6 dB. It is also shown that no significant difference in terms of gain bandwidth is observed for the single-and dual-pump configurations of two-mode PSAs with an intermediate interaction. Finally, it is shown that a four-mode PSA can only be implemented under very strict conditions, with no gain advantage over two-mode PSAs.	[Albuquerque, Andre A. C.; Drummond, Miguel V.; Nogueira, Rogerio N.] Inst Telecomunicacoes, Dept Polo Aveiro, P-3810193 Aveiro, Portugal; [Puttnam, Benjamin J.; Wada, Naoya] Natl Inst Informat & Commun Technol, Koganei, Tokyo 1848795, Japan	Albuquerque, AAC (reprint author), Inst Telecomunicacoes, Dept Polo Aveiro, Campus Univ Santiago, P-3810193 Aveiro, Portugal.	andrealbuquerque@av.it.pt; mvd@av.it.pt; ben@nict.go.jp; wada@nict.go.jp; rnogueira@av.it.pt			Fundacao para a Ciencia e Tecnologia [SFRH/BD/78425/2011]	The work of A. Albuquerque was supported by Fundacao para a Ciencia e Tecnologia under the Ph.D. Grant SFRH/BD/78425/2011.	Agrawal G. P., 2006, NONLINEAR FIBER OPTI; Albuquerque A, 2013, OPT EXPRESS, V21, P22063, DOI 10.1364/OE.21.022063; Albuquerque AAC, 2011, J LIGHTWAVE TECHNOL, V29, P3764, DOI 10.1109/JLT.2011.2174333; Andrekson P., 2012, OPT FIB COMM C LOS A; CAVES CM, 1982, PHYS REV D, V26, P1817, DOI 10.1103/PhysRevD.26.1817; Lundstrom C, 2012, OPT EXPRESS, V20, P21400, DOI 10.1364/OE.20.021400; Lee KJ, 2009, OPT EXPRESS, V17, P20393, DOI 10.1364/OE.17.020393; Radic S, 2008, LASER PHOTONICS REV, V2, P498, DOI 10.1002/lpor.200810049; Langrock C, 2006, J LIGHTWAVE TECHNOL, V24, P2579, DOI 10.1109/JLT.2006.874605; Tong Z, 2011, NAT PHOTONICS, V5, P430, DOI [10.1038/nphoton.2011.79, 10.1038/NPHOTON.2011.79]; Kakande J, 2011, NAT PHOTONICS, V5, P748, DOI 10.1038/nphoton.2011.254; Puttnam BJ, 2011, OPT EXPRESS, V19, P131; ARMSTRONG JA, 1962, PHYS REV, V127, P1918, DOI 10.1103/PhysRev.127.1918; Asobe M, 2012, OPT EXPRESS, V20, P13164, DOI 10.1364/OE.20.013164; Ellis A. D., 2013, OPT FIB COMM C AN CA; Kakande J., 2010, PHARMACOLOGYONLINE, V1, P1; Kakande J., 2011, OPT FIB COMM C LOS A; Lundstrom C., 2013, OPT FIB COMM C AN CA; Olsson S., 2014, EUR C OPT COMM CANN; Ros F. D., 2014, OPT EXP, V22, P7926; Slavik R, 2010, NAT PHOTONICS, V4, P690, DOI 10.1038/NPHOTON.2010.203; Suhara T., 2003, WAVEGUIDE NONLINEAR; Tang R., 2005, OPT EXP, V13, P281; Umeki Takeshi, 2011, Opt Express, V19, P6326, DOI 10.1364/OE.19.006326	24	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0733-8724	1558-2213		J LIGHTWAVE TECHNOL	J. Lightwave Technol.	JUL 1	2015	33	13					2802	2810		10.1109/JLT.2015.2413932		9	Engineering, Electrical & Electronic; Optics; Telecommunications	Engineering; Optics; Telecommunications	CM3RZ	WOS:000357602700013		
J	Bong, LJ; Neoh, KB; Jaal, Z; Lee, CY				Bong, Lee-Jin; Neoh, Kok-Boon; Jaal, Zairi; Lee, Chow-Yang			Paederus Outbreaks in Human Settings: A Review of Current Knowledge	JOURNAL OF MEDICAL ENTOMOLOGY			English	Review						dermatitis linearis; urban expansion; life history; population dynamics; habitat disturbance	FUSCIPES COLEOPTERA STAPHYLINIDAE; FLIGHT ACTIVITY; ROVE BEETLE; ENVIRONMENTAL-FACTORS; SOUTHERN NIGERIA; DIET QUALITY; DERMATITIS; REPRODUCTION; PREDATION; EPIDEMIC	Although rove beetles (Paederus spp.) play a beneficial role as biological control agents to manage crop pests in agro-ecosystems, their high prevalence in human settings has elevated them to pest status in urban areas. Rove beetles neither bite nor sting, but accidental crushing on human skin causes them to release the toxin paederin, which causes dermatitis linearis. This review integrates currently available knowledge about the issues pertaining to Paederus infestation. For instance, the results of life history studies conducted under different food and temperature regimes are summarized, as they indicate how large a population can be in a habitat to cause massive and widespread infestation and illustrate the physiological traits required to maintain the population at the maximum level even under adverse conditions. In contrast to what is generally reported, we speculate that climatic factors do not necessarily result in Paederus dispersal in temperate regions; instead, habitat disturbance and site unsuitability may be the main factors that lead to massive dispersal to human settings. Factors such as whether dispersers are adaptable to xeric conditions in human settings, the probability that dispersed Paederus mate with the opposite sex, and whether dispersers have adequate nutrient intake to reproduce are considered to evaluate their potential to reproduce in human settings. Finally, the effectiveness of current commercial insecticides, challenges faced in managing infestations, and sustainable management practices are discussed to provide information for long-term control programs.	[Bong, Lee-Jin; Neoh, Kok-Boon] Kyoto Univ, Res Inst Sustainable Humanosphere, Lab Innovat Humanohabitabil, Uji, Kyoto 6110011, Japan; [Bong, Lee-Jin; Jaal, Zairi; Lee, Chow-Yang] Univ Sains Malaysia, Sch Biol Sci, Vector Control Res Unit, George Town 11800, Malaysia	Bong, LJ (reprint author), Kyoto Univ, Res Inst Sustainable Humanosphere, Lab Innovat Humanohabitabil, Uji, Kyoto 6110011, Japan.	bongleejin@yahoo.com	Neoh, Kok-Boon/A-4070-2011	Neoh, Kok-Boon/0000-0002-8462-6662			ABROL DP, 1991, ACTA OECOL, V12, P819; Al-Dhalimi MA, 2008, SAUDI MED J, V29, P1490; Ali A., 2013, MED SCI, V2, P764; Alva-Davalos Victor, 2002, Rev Soc Bras Med Trop, V35, P23, DOI 10.1590/S0037-86822002000100005; ANDERSEN A, 1992, Norwegian Journal of Agricultural Sciences, V6, P265; Joern A, 1997, OECOLOGIA, V112, P201, DOI 10.1007/s004420050301; Edde PA, 2006, ENVIRON ENTOMOL, V35, P616; Cressey BD, 2013, WILD ENVIRON MED, V24, P124, DOI 10.1016/j.wem.2012.11.005; Denno RF, 2003, ECOLOGY, V84, P2522, DOI 10.1890/02-0370; FRANK JH, 1987, J MED ENTOMOL, V24, P155; TAYLOR LR, 1963, J ANIM ECOL, V32, P99, DOI 10.2307/2520; Grebennikov VV, 2009, EUR J ENTOMOL, V106, P275; Gnanaraj P, 2007, J AM ACAD DERMATOL, V57, P297, DOI 10.1016/j.jaad.2006.10.982; Symondson WOC, 2002, ANNU REV ENTOMOL, V47, P561, DOI 10.1146/annurev.ento.47.091201.145240; Thorbek P, 2004, J APPL ECOL, V41, P526, DOI 10.1111/j.0021-8901.2004.00913.x; ARMSTRON.RK, 1968, J MED ENTOMOL, V5, P362; ARMSTRON.RK, 1969, AM J TROP MED HYG, V18, P147; Assaf M, 2010, J EUR ACAD DERMATOL, V24, P1197, DOI 10.1111/j.1468-3083.2010.03621.x; Awad SS, 2013, CUTIS, V91, P300; Baba K, 1943, GUNIDAN ZASSHI, V360, P601; Baccaredda A., 1935, G ITAL DERMATOL SIFI, V6, P1423; Balina P. L., 1936, REV ARGENT DERMATOL, V20, P171; Banney A. L., 2000, AUST J DERMATOL, V41, P162; Bequaert J., 1921, J N Y ENTOMOL SOC, V29, P183; Bong LJ, 2013, J ECON ENTOMOL, V106, P2530, DOI 10.1603/EC13198; Bong LJ, 2013, ENVIRON ENTOMOL, V42, P1013, DOI 10.1603/EN13054; Bong LJ, 2014, J MED ENTOMOL, V51, P752, DOI 10.1603/ME13145; Bong LJ, 2013, J MED ENTOMOL, V50, P1003, DOI 10.1603/ME13058; Bong LJ, 2012, J MED ENTOMOL, V49, P451, DOI 10.1603/ME11163; Castelli A., 1934, B SOC MED CHIR PA, V1, P77; Castelli A., 1935, ANN OTTAMOL CLIN OCU, V63, P204; Chatzimanolis S, 2004, COLEOPTS BULL, V58, P569, DOI 10.1649/689.1; Claborn D M, 1999, Mil Med, V164, P209; Coondoo Arijit, 2013, Indian J Dermatol, V58, P410, DOI 10.4103/0019-5154.117357; Corbet P. S., 1999, DRAGONFLIES BEHAV EC; COUPPIE P, 1992, ANN DERMATOL VENER, V119, P191; Croft A, 1996, J ROY SOC MED, V89, P552; Davidson S. A., 2009, US ARMY MED DEP  JUL, P6; de Leon D., 1952, COLEOPT B, V6, P15; Deneys J. B., 1963, S AFR MED J, V21, P1284; DENNIS P, 1990, ANN APPL BIOL, V117, P267, DOI 10.1111/j.1744-7348.1990.tb04212.x; Diogenes Maria Jose, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P59; Drouet G, 2013, PRESSE MED, V42, P355, DOI 10.1016/j.lpm.2012.04.012; Dursteler BB, 2004, MIL MED, V169, P57; Earle K. V., 1945, J TROP MED HYG, V52, P183; Ekburanawat W., 2011, PUBLIC HLTH J BURAPH, V6, P139; Elliott NC, 2000, BIOL CONTROL, V17, P218, DOI 10.1006/bcon.1999.0797; Focarile A., 1964, Memorie della Societa Entomologica Italiana Genoa, V43, P80; FOX R, 1993, TROP DOCT, V23, P17; GACK C, 1994, ZOOMORPHOLOGY, V114, P227, DOI 10.1007/BF00416861; GELMETTI C, 1993, EUR J PEDIATR, V152, P6, DOI 10.1007/BF02072506; GEORGE AO, 1990, INT J DERMATOL, V29, P500, DOI 10.1111/j.1365-4362.1990.tb04844.x; GEORGE AO, 1989, CONTACT DERMATITIS, V20, P314, DOI 10.1111/j.1600-0536.1989.tb03161.x; Heo CC, 2013, SE ASIAN J TROP MED, V44, P197; Huang CZ, 2009, INT J DERMATOL, V48, P128, DOI 10.1111/j.1365-4632.2009.03876.x; Hugh-Jones M., 1998, PROMED DIGEST, V98, P27; ISAAC P. V., 1934, INDIAN JOUR AGRIC SCI, V4, P200; Isard S. A., 1999, AEROBIOLOGIA, V15, P95, DOI 10.1023/A:1007555015505; Iserson KV, 2012, WILD ENVIRON MED, V23, P251, DOI 10.1016/j.wem.2012.03.005; Jin H. C., 1990, Chinese Journal of Parasitic Disease Control, V3, P58; Johnson C.G., 1969, MIGRATION DISPERSAL; Joyce B., 1952, MED J AUSTRALIA, V1, P553; Kamal Bey M., 1951, Bulletin de la Societe Fouad ler d'Entomologie, V35, P221; Kamaladasa SD, 1997, INT J DERMATOL, V36, P34, DOI 10.1046/j.1365-4362.1997.00009.x; Kaspari M, 2001, ECOL ENTOMOL, V26, P245, DOI 10.1046/j.1365-2311.2001.00320.x; KASPARI M, 1993, OECOLOGIA, V96, P500, DOI 10.1007/BF00320507; KERDELVE.F, 1966, ARCH DERMATOL, V94, P175, DOI 10.1001/archderm.94.2.175; Kim J. O., 1995, KOREAN J DERMATOL, V33, P821; Kim S, 2007, ANN DERMATOL, V19, P88; KIM Y P, 1989, Korean Journal of Dermatology, V27, P402; Kurosa K., 1958, MED ENTOMOL ZOOL, V9, P245; Kurosa K., 1977, P123; Langlet X, 1998, CAN ENTOMOL, V130, P257; Li S. R., 1990, CHIN J PREV MED, V24, P149; Ma Y. X., 2009, J PATHOG BIOL, V4; Mammino Jere J, 2011, J Clin Aesthet Dermatol, V4, P44; Matsumura M, 2004, ECOLOGY, V85, P2601, DOI 10.1890/03-0629; Mayntz D, 2001, OECOLOGIA, V127, P207, DOI 10.1007/s004420000591; McCrae A. W. R., 1963, BIOCHEM J, V89, P79; McKEOWN K C, 1951, Med J Aust, V2, P772; Mendez E., 1982, B I SIEROTER MILAN, V31, P195; MHALU FS, 1981, ANN TROP MED PARASIT, V75, P231; Mokhtar N, 1993, Med J Malaysia, V48, P403; Morsy Tosson A., 1996, Journal of the Egyptian Society of Parasitology, V26, P337; Naya DE, 2007, J INSECT PHYSIOL, V53, P132, DOI 10.1016/j.jinsphys.2006.11.004; Neoh KB, 2009, ENVIRON ENTOMOL, V38, P1697, DOI 10.1603/022.038.0623; NICHOLLS DSH, 1990, J AM ACAD DERMATOL, V22, P815, DOI 10.1016/0190-9622(90)70114-W; Nikbakhtzadeh MR, 2008, J VENOM ANIM TOXINS, V14, P597, DOI 10.1590/S1678-91992008000400004; Nishihara H., 1939, KYUSU IGAKU SENMON G, V4, P294; Okiwelu SN, 1996, ANN TROP MED PARASIT, V90, P345; Padhi T, 2007, INDIAN J DERMATOL VE, V73, P333; Panta Y. R., 2013, J UNIVERSAL COLL MED, V1, P48; Papasarathorn T., 1961, J MED ASS THAI, V44, P60; PENCHENIER L, 1994, B SOC PATHOL EXOT, V87, P45; PENG RK, 1992, INT J BIOMETEOROL, V36, P69, DOI 10.1007/BF01208916; PICKEL D. B., 1940, Revue d'Entomologie, V11, P775; Polak M, 1998, P ROY SOC B-BIOL SCI, V265, P2197; Poole TRG, 1998, EYE, V12, P883; Pujatti D., 1947, MEM SOC ENTOMOL ITAL, V26; Qadir Syed Nurul Rasool, 2006, Dermatol Online J, V12, P9; Rahmah E, 2008, Malays J Pathol, V30, P53; Rivas L. G., 2001, DERM VENEZ, V39, P93; Roberts J. I., 1942, E AFR MED J, V19, P242; Roukhsi R., 2013, AM J LIFE SCI, V1, P171; Sakharov N., 1915, ENTOMOLOGIE STANTSII, V1914, P1; Scott H., 1950, ENTOMOL MON MAG, V86, P217; Sendur N, 1999, DERMATOLOGY, V199, P353, DOI 10.1159/000018290; Service M. W., 1963, ENTOMOLOGISTS MONTHL, V99, P7; Soeda I., 1950, JPN J SANIT ZOOL, V1, P55; Somerset E J, 1961, Br J Ophthalmol, V45, P395, DOI 10.1136/bjo.45.6.395; Szent-Ivany J. J. H., 1966, T PAPUA NEW GUINEA S, V7, P3; Todd RE, 1996, MED J AUSTRALIA, V164, P238; Toppo Neelam Anupama, 2013, Indian Dermatol Online J, V4, P153, DOI 10.4103/2229-5178.110643; Turan E, 2014, CUTAN OCUL TOXICOL, V33, P228, DOI 10.3109/15569527.2013.834499; Uslular C, 2002, CUTIS, V69, P277; Schayk I. M. C. J. van, 2005, Climate change and Africa, P240, DOI 10.1017/CBO9780511535864.032; Vasudevan B., 2010, Medical Journal Armed Forces India, V66, P121; Vegas F. K., 1996, ARCH DERMATOL, V94, P175; Veraldi S, 2013, EUR J DERMATOL, V23, P387, DOI 10.1684/ejd.2013.2028; Rajesh Verma, 2006, Medical Journal Armed Forces India, V62, P42; Vorderman A. G., 1901, GENEESK TIJDSCHR NED, V41, P282; WANG Y C, 1969, Chinese Journal of Microbiology, V2, P131; Willers Joachim, 2003, Cimbebasia, V19, P25; Williams A N, 1993, J R Army Med Corps, V139, P17; WILLIAMS CB, 1961, PHILOS T ROY SOC B, V244, P331, DOI 10.1098/rstb.1961.0011; WINDER L, 1990, ECOL ENTOMOL, V15, P105, DOI 10.1111/j.1365-2311.1990.tb00789.x; Yamamoto M., 1942, HIFUKA KIYO, V40, P351; Yao ChaoQun, 1990, Chinese Journal of Parasitic Disease Control, V3, P155; Zargari O, 2003, INT J DERMATOL, V42, P608, DOI 10.1046/j.1365-4362.2003.01771.x	129	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-2585	1938-2928		J MED ENTOMOL	J. Med. Entomol.	JUL	2015	52	4					517	526		10.1093/jme/tjv041		10	Entomology; Veterinary Sciences	Entomology; Veterinary Sciences	CM4XD	WOS:000357688400001		
J	Mogi, M; Armbruster, P; Tuno, N; Campos, R; Eritja, R				Mogi, Motoyoshi; Armbruster, Peter; Tuno, Nobuko; Campos, Raul; Eritja, Roger			Simple Indices Provide Insight to Climate Attributes Delineating the Geographic Range of Aedes albopictus (Diptera: Culicidae) Prior to Worldwide Invasion	JOURNAL OF MEDICAL ENTOMOLOGY			English	Article						Culicidae; Aedes albopictus; Distribution; Temperature; Precipitation	SUMMER MONSOON; SURVIVAL-TIME; NORTH-AMERICA; ASIAN MONSOON; MOSQUITOS; DESICCATION; DENGUE; EGGS; CLASSIFICATION; TEMPERATURE	Aedes albopictus (Skuse) has expanded its distribution worldwide during the past decades. Despite attempts to explain and predict its geographic occurrence, analyses of the distribution of Ae. albopictus in the context of broad climatic regions (biomes) has not been performed. We analyzed climate conditions at its distribution sites in the range before the worldwide invasions (from the easternmost Hawaii through westernmost Madagascar) by using thermal and aridity-humidity indices descriptive of major biomes. A significant advantage of this approach is that it uses simple indices clearly related to the population dynamics of Ae. albopictus. Although Ae. albopictus has been regarded as a forest species preferring humid climate, in areas with significant human habitation, the distribution sites extended from the perhumid, rain forest zone to the semiarid, steppe zone. This pattern was common from the tropics through the temperate zone. Across the distribution range, there was no seasonal discordance between temperature and precipitation; at sites where winter prevents Ae. albopictus reproduction (monthly means < 10 degrees C), precipitation was concentrated in warm months (> 10 degrees C) under the Asian summer monsoon. Absence of the species in northern and eastern coastal Australia and eastern coastal Africa was not attributable solely to climate conditions. However, Asia west of the summer monsoon range was climatically unsuitable because of low precipitation throughout the year or in warm months favorable to reproduction (concentration of precipitation in winter). We hypothesized that Ae. albopictus originated in continental Asia under the monsoon climate with distinct dry seasons and hot, wet summer, enabling rapid population growth.	[Mogi, Motoyoshi] Saga Univ, Dept Pathol & Biodefense, Div Parasitol, Fac Med, Saga 8498501, Japan; [Armbruster, Peter] Georgetown Univ, Dept Biol, Washington, DC 20057 USA; [Tuno, Nobuko] Kanazawa Univ, Grad Sch Nat Sci & Technol, Ecol Lab, Kanazawa, Ishikawa 9201192, Japan; [Campos, Raul] Univ Nacl La Plata, CONICET, CCT La Plata, Inst Limnol Dr Raul A Ringuelet, RA-1900 La Plata, Buenos Aires, Argentina; [Eritja, Roger] Consell Comarcal Baix Llobregat, Sant Feliu De Llobregat 08980, Spain	Mogi, M (reprint author), Saga Univ, Dept Pathol & Biodefense, Div Parasitol, Fac Med, Nabeshima 5-1-1, Saga 8498501, Japan.	motomogi@festa.ocn.ne.jp					Clift PD, 2008, NAT GEOSCI, V1, P875, DOI 10.1038/ngeo351; Blasco F, 1996, J VEG SCI, V7, P623, DOI 10.2307/3236374; Peel MC, 2007, HYDROL EARTH SYST SC, V11, P1633; Louys J, 2010, J BIOGEOGR, V37, P1432, DOI 10.1111/j.1365-2699.2010.02297.x; Delatte H, 2008, VECTOR-BORNE ZOONOT, V8, P25, DOI 10.1089/vbz.2007.0649; Medley KA, 2010, GLOBAL ECOL BIOGEOGR, V19, P122, DOI 10.1111/j.1466-8238.2009.00497.x; Wang YJ, 2008, NATURE, V451, P1090, DOI 10.1038/nature06692; Mogi M, 1996, J MED ENTOMOL, V33, P53; Juliano SA, 2005, ECOL LETT, V8, P558, DOI 10.1111/j.1461-0248.2005.00755.x; Angel Bennet, 2008, Journal of Vector Borne Diseases, V45, P56; Delatte H, 2009, J MED ENTOMOL, V46, P33, DOI 10.1603/033.046.0105; Benedict MQ, 2007, VECTOR-BORNE ZOONOT, V7, P76, DOI 10.1089/vbz.2006.0562; HANSON SM, 1995, J MED ENTOMOL, V32, P599; Fischer D, 2011, GLOBAL PLANET CHANGE, V78, P54, DOI 10.1016/j.gloplacha.2011.05.008; SOTA T, 1992, OECOLOGIA, V90, P353, DOI 10.1007/BF00317691; Gathorne-Hardy FJ, 2002, BIOL J LINN SOC, V75, P453, DOI 10.1046/j.1095-8312.2002.00031.x; HAWLEY WA, 1987, SCIENCE, V236, P1114, DOI 10.1126/science.3576225; Pearson RG, 2003, GLOBAL ECOL BIOGEOGR, V12, P361, DOI 10.1046/j.1466-822X.2003.00042.x; Mogi M, 2012, J MED ENTOMOL, V49, P1233, DOI 10.1603/ME12104; Wang B, 2002, J CLIMATE, V15, P386, DOI 10.1175/1520-0442(2002)015<0386:RSOTAP>2.0.CO;2; Thornthwaite CW, 1931, GEOGR REV, V21, P633, DOI 10.2307/209372; Kottek M, 2006, METEOROL Z, V15, P259, DOI 10.1127/0941-2948/2006/0130; Juliano SA, 2002, OECOLOGIA, V130, P458, DOI 10.1007/s004420100811; Paupy C, 2010, VECTOR-BORNE ZOONOT, V10, P259, DOI 10.1089/vbz.2009.0005; Becker N, 2013, PARASITOL RES, V112, P1787, DOI 10.1007/s00436-012-3230-1; Farjana T, 2012, MED VET ENTOMOL, V26, P210, DOI 10.1111/j.1365-2915.2011.00971.x; Arguez A., 2012, NOAAS 1981 2010 CLIM; Begon M., 1986, ECOLOGY; Bhat H. R., 1975, INTIAN J MED RES, V63, P1584; Bird MI, 2004, QUATERN INT, V118, P145, DOI 10.1016/S1040-6182(03)00135-6; COLLESS D H, 1957, Ann Trop Med Parasitol, V51, P102; Dieng H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011790; ECDC, 2009, DEV AED ALB RISK MAP; Eshita Y., 1979, Japanese Journal of Sanitary Zoology, V30, P181; FONTENILLE D, 1989, J AM MOSQUITO CONTR, V5, P219; Gupta AK, 2006, CURR SCI INDIA, V90, P1082; Haddad N, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-300; Hawley W.A., 1988, Journal of the American Mosquito Control Association, V4, P1; Hela I., 1953, GEOPHYSICA, V4, P41; Hope G, 2004, QUATERN INT, V118, P103, DOI 10.1016/S1040-6182(03)00133-2; Huang Y.-M., 1979, Contributions of the American Entomological Institute, V15, P1; Joshi V, 2006, J MED ENTOMOL, V43, P330, DOI 10.1603/0022-2585(2006)043[0330:IOSSAT]2.0.CO;2; KALRA NL, 1976, J COMMUNICABLE DIS, V8, P261; Kira T., 1976, HDB OF ECOLOGY, V2; Kira T, 1991, ECOL RES, V6, P186; MacDONALD W. W., 1957, STUD INST MED RES MALAYA, V28, P1; MATTINGLY P. F., 1953, BULL BRIT MUS [NAT HIST] ENT, V3, P1; Miyagi I., 1980, Japanese Journal of Sanitary Zoology, V31, P81; Mogi M, 2014, J MED ENTOMOL, V51, P572, DOI 10.1603/ME13178; Mukhtar M, 2011, DENGUE B, V35, P99; (NAO) National Astronomical Observatory, 1994, CHRON SCI TABL 1995; Nicholson J, 2014, J MED ENTOMOL, V51, P948, DOI 10.1603/ME14079; Porretta D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044515; Reuben R., 1971, WHOWBC71290; Russell Richard C, 2005, Commun Dis Intell Q Rep, V29, P296; Sharma R.S., 1979, Journal of Communicable Diseases, V10, P248; SOTA T, 1992, ENTOMOL EXP APPL, V63, P155; Suleman Mohammad, 1993, Pakistan Journal of Zoology, V25, P321; SUTHERST RW, 1993, CIBA F SYMP, V175, P124; Thornthwaite CW, 1933, GEOGR REV, V23, P433, DOI 10.2307/209629; Verma K.V.S., 1992, Journal of Communicable Diseases, V23, P263; (WHO) World Health Organization, 1989, WHOVBC89967; Winchester JC, 2013, J AM MOSQUITO CONTR, V29, P154, DOI 10.2987/12-6292R.1	63	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-2585	1938-2928		J MED ENTOMOL	J. Med. Entomol.	JUL	2015	52	4					647	657		10.1093/jme/tjv038		11	Entomology; Veterinary Sciences	Entomology; Veterinary Sciences	CM4XD	WOS:000357688400015		
J	Numata, K				Numata, Kazushi			Advances in ultrasound systems for hepatic lesions in Japan	JOURNAL OF MEDICAL ULTRASONICS			English	Editorial Material							CONTRAST-ENHANCED SONOGRAPHY; HEPATOCELLULAR-CARCINOMA; ABLATION; PHASE; AGENT		Yokohama City Univ, Gastroenterol Ctr, Med Ctr, Yokohama, Kanagawa, Japan	Numata, K (reprint author), Yokohama City Univ, Gastroenterol Ctr, Med Ctr, Yokohama, Kanagawa, Japan.	kz-numa@urahp.yokohama-cu.ac.jp					Luo W, 2009, EUR J RADIOL, V72, P425, DOI 10.1016/j.ejrad.2008.09.003; Albrecht T, 2001, AM J ROENTGENOL, V176, P1191; Numata K, 2008, J ULTRAS MED, V27, P395; Kunishi Y, 2012, AM J ROENTGENOL, V198, P106, DOI 10.2214/AJR.10.6039; Korenaga K, 2009, J GASTROENTEROL, V44, P733, DOI 10.1007/s00535-009-0053-7; Vlaisavljevich E, 2013, ULTRASOUND MED BIOL, V39, P1398, DOI 10.1016/j.ultrasmedbio.2013.02.005; Blomley MJK, 2001, RADIOLOGY, V220, P661, DOI 10.1148/radiol.2203992044; Fukuda H, 2011, EUR J RADIOL, V80, pE571, DOI 10.1016/j.ejrad.2011.09.001; Koizumi N, 2013, J ROBOT MECHATRONICS, V25, P1088; Luo W, 2009, AM J ROENTGENOL, V192, P165, DOI 10.2214/AJR.08.1107; Numata K, 2014, EUR J RADIOL, V83, P95, DOI 10.1016/j.ejrad.2013.09.025	11	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					297	301		10.1007/s10396-015-0630-8		5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700001		
J	Matsuki, H; Shibano, J; Kobayashi, M; Nakatsuchi, Y; Moriizumi, T; Kato, H				Matsuki, Hiroyuki; Shibano, Junichi; Kobayashi, Michiaki; Nakatsuchi, Yukio; Moriizumi, Tetsuji; Kato, Hiroyuki			Elastic modulus of the femoral trochanteric region measured by scanning acoustic microscopy in elderly women	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Scanning acoustic microscopy; Elastic modulus; Bone tissue; Trochanter	CORTICAL BONE TISSUE; TRABECULAR BONE; MECHANICAL-PROPERTIES; FORMALIN FIXATION; PROXIMAL FEMUR; HIP-FRACTURES; NANOINDENTATION; POROSITY; COMPRESSION; MORTALITY	We have devised a method that can obtain continuous detailed distributions of the elastic modulus along the measurement line in a non-decalcified specimen of human bone tissue. The aim of this study was to determine whether local variations exist in the distribution of mechanical properties within the trochanteric region of the femur of elderly females using a newly developed form of scanning acoustic microscopy (SAM) technology. Human proximal femurs were harvested from seven female cadavers aged between 67 and 88 years at death. Using data collected with SAM, the elastic modulus of cortical and trabecular bone tissue of the lateral and medial trochanter was calculated and statistically analyzed. The longitudinal and transverse elastic moduli in cortical bone tissue of the lateral trochanter were found to be significantly lower than those of the medial trochanter in all specimens from individuals over age 70 (p < 0.05). Compared to that of the distal region, the longitudinal and transverse elastic moduli of trabecular bone tissue of the proximal region of the lateral trochanter were significantly lower in all specimens from individuals over age 80 (p < 0.05). Our new method allows obtaining detailed distributions of the elastic modulus of bone tissue.	[Matsuki, Hiroyuki; Kato, Hiroyuki] Shinshu Univ, Dept Orthopaed Surg, Sch Med, Matsumoto, Nagano 3908621, Japan; [Shibano, Junichi; Kobayashi, Michiaki] Kitami Inst Technol, Dept Mech Engn, Kitami, Hokkaido 0908507, Japan; [Nakatsuchi, Yukio] Marunouchi Hosp, Dept Orthopaed Surg, Matsumoto, Nagano 3908601, Japan; [Moriizumi, Tetsuji] Shinshu Univ, Dept Anat, Sch Med, Matsumoto, Nagano 3908621, Japan	Matsuki, H (reprint author), Shinshu Univ, Dept Orthopaed Surg, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	matsuki_h@marunouchi.or.jp					Giversen IM, 2007, OSTEOPOROSIS INT, V18, P721, DOI 10.1007/s00198-006-0300-1; Hou FJ, 1998, J BIOMECH, V31, P1009, DOI 10.1016/S0021-9290(98)00110-9; JENSEN JS, 1980, ACTA ORTHOP SCAND, V51, P803, DOI 10.3109/17453678008990877; Zysset PK, 1999, J BIOMECH, V32, P1005, DOI 10.1016/S0021-9290(99)00111-6; Van Rietbergen B, 1998, J ORTHOPAED RES, V16, P23, DOI 10.1002/jor.1100160105; Schultz E, 1999, RADIOLOGY, V211, P237; Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532-5415.2003.51110.x; Bell KL, 1999, BONE, V24, P57, DOI 10.1016/S8756-3282(98)00143-4; Turner CH, 1999, J BIOMECH, V32, P437, DOI 10.1016/S0021-9290(98)00177-8; Van Rietbergen B, 2003, J BONE MINER RES, V18, P1781, DOI 10.1359/jbmr.2003.18.10.1781; Nazarian A, 2009, J BIOMECH, V42, P82, DOI 10.1016/j.jbiomech.2008.09.037; Rudman KE, 2006, BIOMED ENG ONLINE, V5, DOI 10.1186/1475-925X-5-12; CURREY JD, 1995, BIOMATERIALS, V16, P1267, DOI 10.1016/0142-9612(95)98135-2; Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756-3282(01)00697-4; Akhter MP, 2007, BONE, V41, P111, DOI 10.1016/j.bone.2007.03.019; Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142-9612(97)00073-2; Fan ZF, 2003, J BIOMED MATER RES A, V67A, P208, DOI 10.1002/jbm.a.10027; Duda GN, 1997, J BIOMECH, V30, P933, DOI 10.1016/S0021-9290(97)00057-2; Raum K, 2006, PHYS MED BIOL, V51, P747, DOI 10.1088/0031-9155/51/3/018; Bayraktar HH, 2004, J BIOMECH, V37, P27, DOI 10.1016/S0021-9290(03)00257-4; LEMONS RA, 1975, SCIENCE, V188, P905; Malo MKH, 2013, BONE, V53, P451, DOI 10.1016/j.bone.2013.01.015; Niebur GL, 2000, J BIOMECH, V33, P1575, DOI 10.1016/S0021-9290(00)00149-4; Ohman C, 2008, CLIN BIOMECH, V23, P1294, DOI 10.1016/j.clinbiomech.2008.07.007; Burkhart KJ, 2010, BIOMED TECH, V55, P361, DOI 10.1515/BMT.2010.043; Fung YC, 1965, FDN SOLID MECH, P178; Granke M, 2011, BONE, V49, P1020, DOI 10.1016/j.bone.2011.08.002; Hagino H, 2009, OSTEOPOROSIS INT, V20, P543, DOI 10.1007/s00198-008-0685-0; Ishikawa I, 1999, IEEE T ULTRASON FERR, V46, P41, DOI 10.1109/58.741422; Jacobs CR, 1999, J BIOMECH, V32, P1159, DOI 10.1016/S0021-9290(99)00115-3; Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756-3282(95)00381-9; Keaveny TM, 1997, J ORTHOPAED RES, V15, P101, DOI 10.1002/jor.1100150115; Kobayashi M, 2006, T JPN SOC MECH ENG, V72, P1072; Kobayashi M., 2000, Japan Patent Application, Patent No. [2000-028592, 2000028592]; Ladd AJC, 1998, J ORTHOP RES, V16, P622, DOI 10.1002/jor.1100160516; Modder UI, 2010, J BONE MINER RES, V25, P415, DOI 10.1359/jbmr.090721; Nakatsuchi Y, 2001, NIHON RINSHOU BIOMEC, V22, P269; Nakatsuchi Y, 1999, NIHON RINSHOU BIOMEC, V20, P213; PARMON W, 1979, ELECTRON LETT, V15, P684, DOI 10.1049/el:19790486; Popperl G, 1999, CALCIFIED TISSUE INT, V65, P192; Raum K, 2008, IEEE T ULTRASON FERR, V55, P1417, DOI 10.1109/TUFFC.2008.817; Shibano J, 2006, CHOUONPA TECHNO, V18, P108	42	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					303	313		10.1007/s10396-014-0608-y		11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700002		
J	Mano, I; Horii, K; Hagino, H; Miki, T; Matsukawa, M; Otani, T				Mano, Isao; Horii, Kaoru; Hagino, Hiroshi; Miki, Takami; Matsukawa, Mami; Otani, Takahiko			Estimation of in vivo cortical bone thickness using ultrasonic waves	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Distal radius; Cortical bone thickness; Fast and slow waves; pQCT	BOVINE CANCELLOUS BONE; TRABECULAR BONE; SLOW WAVES; PROPAGATION; MICROSTRUCTURE; ANISOTROPY; FEMUR; VITRO; MASS	To verify the measurement of cortical bone thickness at the distal radius in vivo using an ultrasonic method. The method for estimating cortical bone thickness was derived from experiments with in vitro bovine specimens. Propagation time of echo waves and propagation time of slow waves were used for the estimation. The outside diameter of cortical bone and the cortical bone thickness at the distal 5.5 % site of radius were measured with the new ultrasonic bone measurement system, and the results were compared with X-ray pQCT clinical measurements. There was a high positive correlation (r: 0.76) between the cortical bone thickness measured by the new ultrasonic system and the X-ray pQCT results. We will be able to measure not only cancellous bone density but also cortical bone thickness in vivo using ultrasonic waves (without X-ray) safely and repeatedly.	[Mano, Isao] Doshisha Univ, Off Res Initiat & Dev, Kyoto 6100321, Japan; [Horii, Kaoru] Oyo Elect Co Ltd, Joyo, Kyoto 6100101, Japan; [Hagino, Hiroshi] Tottori Univ, Fac Med, Yonago, Tottori 6830826, Japan; [Miki, Takami] Izumiotsu Municipal Hosp, Izumiotsu, Osaka 5950027, Japan; [Matsukawa, Mami; Otani, Takahiko] Doshisha Univ, Fac Sci & Engn, Kyoto 6100321, Japan	Mano, I (reprint author), Doshisha Univ, Off Res Initiat & Dev, Kyoto 6100321, Japan.	imano@mail.doshisha.ac.jp			Regional Innovation Strategy Support Program of the Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science	Part of this work was supported by the Regional Innovation Strategy Support Program of the Ministry of Education, Culture, Sports, Science and Technology, Japan, and a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science.	GOSS SA, 1978, J ACOUST SOC AM, V64, P423, DOI 10.1121/1.382016; Petit MA, 2010, J BONE MINER RES, V25, P285, DOI 10.1359/jbmr.090725; Hosokawa A, 1998, J ACOUST SOC AM, V103, P2718, DOI 10.1121/1.422790; Hosokawa A, 1997, JPN J APPL PHYS 1, V36, P3233, DOI 10.1143/JJAP.36.3233; Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81; Hosokawa A, 1997, J ACOUST SOC AM, V101, P558, DOI 10.1121/1.418118; Genant HK, 2010, BONE, V47, P131, DOI 10.1016/j.bone.2010.04.594; Breban S, 2010, BONE, V46, P1620, DOI 10.1016/j.bone.2010.03.005; Farr JN, 2013, J CLIN ENDOCR METAB, V98, pE249, DOI 10.1210/jc.2012-3406; Grondin J, 2012, ULTRASONICS, V52, P467, DOI 10.1016/j.ultras.2011.11.008; Mano Horii K, 2013, JPN J APPL PHYS, V52; Mano I, 2007, JPN J APPL PHYS 1, V46, P4858, DOI 10.1143/JJAP.46.4858; Mano I, 2006, JPN J APPL PHYS 1, V45, P4700, DOI 10.1143/JJAP.45.4700; Mano I, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.07KF07; Mizuno K, 2008, IEEE T ULTRASON FERR, V55, P1480, DOI 10.1109/TUFFC.2008.823; Mizuno K, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.07HF19; Mizuno K, 2010, J ACOUST SOC AM, V128, P3181, DOI 10.1121/1.3493444; Otani T, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.07GK05; Sai H, 2010, OSTEOPOROSIS INT, V21, P1781, DOI 10.1007/s00198-010-1217-2; Yamamoto T, 2009, OSTEOPOROSIS INT, V20, P1215, DOI 10.1007/s00198-008-0774-0; Yamashita K, 2012, IEEE T ULTRASON FERR, V59, P1160, DOI [http://dx.doi.org/10.1109/TUFFC.2012.2306, 10.1109/TUFFC.2012.2306]	21	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					315	322		10.1007/s10396-015-0617-5		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700003		
J	Takahashi, H; Hasegawa, H; Kanai, H				Takahashi, Hiroki; Hasegawa, Hideyuki; Kanai, Hiroshi			Temporal averaging of two-dimensional correlation functions for velocity vector imaging of cardiac blood flow	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Cardiac blood flow; Blood velocity vector; Speckle tracking; High-frame-rate acquisition	ECHOCARDIOGRAPHY; VELOCIMETRY; QUANTIFICATION; ULTRASOUND; PATTERNS; SIGNALS; PLANE; TIME	Ultrasonic imaging of blood flow in the cardiac lumen is a very useful tool to evaluate the pumping function of the human heart. The speckle tracking technique makes it possible to estimate the blood velocity vector. However, a stable estimation of the velocity vector of blood flow is difficult because signal-to-noise ratios of echoes from tiny blood particles are low. In this study, the speckle tracking technique with averaging of multiple two-dimensional correlation functions was employed for stable estimation of the blood velocity vector. Multiple two-dimensional correlation functions can be averaged during a very short period by using the echo data acquired by high-frame-rate echocardiography with diverging beam transmission. A steady flow experiment using blood-mimicking fluid (mean fluid velocity 0.2 m/s, flow angle 56A degrees from the transducer surface) was implemented to investigate the effect of the averaging of two-dimensional correlation functions at a frame rate of 6024 Hz. First, to examine the averaging duration required for stable estimation of the flow velocity vector, the accuracies of vector estimates were evaluated at different durations for averaging of two-dimensional correlation functions in the steady flow measurement. It was found that the proposed averaging process with an averaging duration of over 8 frames could reduce the directional error in vector estimation to almost half that of the conventional speckle tracking technique. In subsequent experiments, the averaging duration was set at 12 frames corresponding to 2 ms. Measurements of steady flow at higher velocities were further implemented. The steady flow measurements with higher flow velocities of 0.4 and 0.6 m/s were simulated by changing the frame interval of the echo data at a flow velocity of 0.2 m/s. Although the averaging duration was a mere 2 ms, directional errors at mean flow velocities of 0.2, 0.4, and 0.6 m/s were reduced significantly. In an in vivo experiment of the healthy human heart, to produce a fine B-mode image, the diverging wave transmissions with different steered angles for compounding were interleaved in the transmission sequence. From the in vivo experimental result, the blood velocity vector of the left ventricular cavity showed the flow getting into/out of the cavity in ejection and early diastolic phases. Furthermore, estimated flow directions revealed rotating flow in the cavity in mid-diastole. Our proposed method has the feasibility to visualize the vortex flow by velocity vector mapping without a contrast agent.	[Takahashi, Hiroki; Hasegawa, Hideyuki; Kanai, Hiroshi] Tohoku Univ, Grad Sch Biomed Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Hasegawa, Hideyuki; Kanai, Hiroshi] Tohoku Univ, Grad Sch Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan	Takahashi, H (reprint author), Tohoku Univ, Grad Sch Biomed Engn, Aoba Ku, 6-6-05 Aramaki Aza Aoba, Sendai, Miyagi 9808579, Japan.	h.takahashi@ecei.tohoku.ac.jp			JSPS Research Fellowship [25-5479]; International Advanced Research and Education Organization of Tohoku University	This work has been supported by the JSPS Research Fellowship (25-5479) and the International Advanced Research and Education Organization of Tohoku University.	Ekroll IK, 2013, IEEE T ULTRASON FERR, V60, P727, DOI 10.1109/TUFFC.2013.2621; Ohtsuki S, 2006, J VISUAL-JAPAN, V9, P69; Kripfgans OD, 2006, ULTRASOUND MED BIOL, V32, P1037, DOI 10.1016/j.ultrasmedbio.2006.04.007; Lovstakken L, 2006, IEEE T ULTRASON FERR, V53, P289, DOI 10.1109/TUFFC.2006.1593367; Hasegawa H, 2008, IEEE T ULTRASON FERR, V55, P2626, DOI 10.1109/TUFFC.2008.978; Garcia D, 2010, IEEE T MED IMAGING, V29, P1701, DOI 10.1109/TMI.2010.2049656; Bercoff J, 2011, IEEE T ULTRASON FERR, V58, P134, DOI 10.1109/TUFFC.2011.1780; Bohs LN, 2000, ULTRASONICS, V38, P369, DOI 10.1016/S0041-624X(99)00182-1; Hasegawa H, 2011, J MED ULTRASON, V38, P129, DOI 10.1007/s10396-011-0304-0; Faludi R, 2010, J THORAC CARDIOV SUR, V139, P1501, DOI 10.1016/j.jtcvs.2009.07.060; Hong GR, 2008, JACC-CARDIOVASC IMAG, V1, P705, DOI 10.1016/j.jcmg.2008.06.008; Capineri L, 2002, ULTRASOUND MED BIOL, V28, P237, DOI 10.1016/S0301-5629(01)00513-0; CESPEDES I, 1995, ULTRASONIC IMAGING, V17, P142, DOI 10.1006/uimg.1995.1007; de Korte CL, 2014, J MED ULTRASON, V41, P279, DOI 10.1007/s10396-013-0513-9; Ebbers T, 2011, CURR CARDIOVASC IMAG, V4, P127, DOI 10.1007/s12410-011-9065-9; Hasegawa H, 2010, P IEEE ULTR S, P1319; Hasegawa H, 2012, IEEE T ULTRASON FERR, V59, P2569, DOI 10.1109/TUFFC.2012.2490; Hasegawa H, 2013, J MED ULTRASON, V40, P91, DOI 10.1007/s10396-012-0400-9; Itatani K, 2013, JPN J APPL PHYS, V52; Kruizinga P, 2014, ULTRASOUND MED BIOL, V40, P2392, DOI 10.1016/j.ultrasmedbio.2014.03.009; Prinz C, 2012, CARDIOVASC ULTRASOUN, V10, DOI 10.1186/1476-7120-10-24; Takahashi H, 2014, JPN J APPL PHYS, V53; Takahashi H, 2013, IEEE INT ULTRA SYM, P2030, DOI 10.1109/ULTSYM.2013.0518	23	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					323	330		10.1007/s10396-015-0620-x		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700004		
J	Imai, Y; Taira, J; Okada, M; Ando, M; Sano, T; Miyata, Y; Sugimoto, K; Nakamura, I; Moriyasu, F				Imai, Yasuharu; Taira, Jun-ichi; Okada, Mayumi; Ando, Mayumi; Sano, Takatomo; Miyata, Yuhki; Sugimoto, Katsutoshi; Nakamura, Ikuo; Moriyasu, Fuminori			The close linkage between the elasticity modulus measured by real-time mapping shear wave elastography and the presence of hepatocellular carcinoma in patients with a sustained virological response to interferon for chronic hepatitis C	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Hepatitis C virus infection; Hepatocellular carcinoma; Shear wave elastography; Sustained virological response	SIMPLE NONINVASIVE INDEX; TRANSIENT ELASTOGRAPHY; SIGNIFICANT FIBROSIS; RISK-ASSESSMENT; LIVER FIBROSIS; THERAPY; CIRRHOSIS; PREDICTOR; ACCURACY	Some patients develop hepatocellular carcinoma (HCC) after sustained virological response (SVR) to interferon therapy for chronic hepatitis C (CH-C). The aim of this study was to examine the linkage between liver elasticity and the presence/absence of HCC in patients after SVR. We enrolled 42 patients who underwent real-time mapping shear wave elastography (SWE) after SVR to interferon therapy for CH-C. Of the 42 patients, six had HCC and 36 did not. We retrospectively compared the elasticity modulus and other clinical parameters between patients with and without HCC. Elasticity modulus measured by SWE, age, and serum albumin was significantly different between patients with and without HCC. Age, Fibrosis-4 index, serum gamma-globulin, total protein, and albumin levels were significantly correlated with the elasticity modulus. Areas under receiver operating characteristic curves of elasticity modulus, gamma-globulin, and age for the presence of HCC were 0.963, 0.888, and 0.778, respectively. In patients with an elasticity modulus a parts per thousand yen6.5 kPa, both sensitivity and specificity for the presence of HCC were 83.3 %. The study demonstrated the close linkage between the elasticity modulus measured by SWE and the presence of HCC in patients after SVR.	[Imai, Yasuharu; Taira, Jun-ichi; Okada, Mayumi; Ando, Mayumi; Sano, Takatomo; Miyata, Yuhki; Sugimoto, Katsutoshi; Nakamura, Ikuo; Moriyasu, Fuminori] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, Tokyo 1600023, Japan	Imai, Y (reprint author), Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	imaiyhosp@yahoo.co.jp					Hirakawa M, 2008, INTERNAL MED, V47, P1637, DOI 10.2169/internalmedicine.47.1087; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bavu E, 2011, ULTRASOUND MED BIOL, V37, P1361, DOI 10.1016/j.ultrasmedbio.2011.05.016; Ferraioli G, 2012, HEPATOLOGY, V56, P2125, DOI 10.1002/hep.25936; D'Ambrosio R, 2013, J HEPATOL, V59, P251, DOI 10.1016/j.jhep.2013.03.013; Yoshida H, 2002, GASTROENTEROLOGY, V123, P483, DOI 10.1053/gast.2002.34785; Wang JH, 2010, J GASTROEN HEPATOL, V25, P964, DOI 10.1111/j.1440-1746.2009.06194.x; Tokita H, 2005, J GASTROEN HEPATOL, V20, P752, DOI 10.1111/j.1400-1746.2005.03800.x; Masuzaki R, 2012, WORLD J GASTROENTERO, V18, P1385, DOI 10.3748/wjg.v18.i12.1385; Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529; Muller M, 2009, ULTRASOUND MED BIOL, V35, P219, DOI 10.1016/j.ultrasmedbio.2008.08.018; Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178; McHutchison JG, 2010, NEW ENGL J MED, V362, P1292, DOI 10.1056/NEJMoa0908014; Kobayashi S, 2007, LIVER INT, V27, P186, DOI 10.1111/j.1478-3231.2006.01406.x; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Foucher J, 2006, GUT, V55, P403, DOI 10.1136/gut.2005.069153; Wang HM, 2013, LIVER INT, V33, P756, DOI 10.1111/liv.12118; Masuzaki R, 2009, HEPATOLOGY, V49, P1954, DOI 10.1002/hep.22870; Ikeda K, 1999, HEPATOLOGY, V29, P1124, DOI 10.1002/hep.510290439; Akima T, 2011, HEPATOL RES, V41, P965, DOI 10.1111/j.1872-034X.2011.00846.x; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Yoshida H, 1999, ANN INTERN MED, V131, P174; Calvaruso V, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.7176; Hayashi N, 2014, J GASTROENTEROL, V49, P138, DOI 10.1007/s00535-013-0875-1; Kaserer K, 1998, HISTOPATHOLOGY, V32, P454; Martinez SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047715; Martinez SM, 2011, HEPATOLOGY, V53, P325, DOI 10.1002/hep.24013	28	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					341	347		10.1007/s10396-014-0604-2		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700006		
J	Kasai, Y; Moriyasu, F; Saito, K; Hara, T; Kobayashi, Y; Nakamura, I; Sugimoto, K				Kasai, Yoshitaka; Moriyasu, Fuminori; Saito, Kazuhiro; Hara, Takeshi; Kobayashi, Yoshiyuki; Nakamura, Ikuo; Sugimoto, Katsutoshi			Value of shear wave elastography for predicting hepatocellular carcinoma and esophagogastric varices in patients with chronic liver disease	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Shear wave elastography; Hepatocellular carcinoma; Esophagogastric varices; Ultrasound; Chronic liver disease	CHRONIC HEPATITIS-C; TRANSIENT ELASTOGRAPHY; PORTAL-HYPERTENSION; CIRRHOSIS; FIBROSIS; STIFFNESS; COMPLICATIONS; BIOPSY	To assess the value of shear wave elastography (SWE) for predicting the presence of hepatocellular carcinoma (HCC) and esophagogastric varices (EGV) in patients with chronic liver disease. Liver tissue stiffness, as well as various other parameters potentially associated with HCC and portal hypertension, was measured by SWE in 273 patients with chronic liver disease. Among these patients, HCC was present in 89 and absent in 184, and EGV were present in 16 and absent in 257. The diagnostic performance of liver tissue stiffness and other clinical parameters in predicting the presence of HCC and EGV was evaluated using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUROC). With regard to HCC, liver tissue stiffness was significantly higher in patients with HCC (18.65 +/- A 10.78 kPa) than in those without HCC (10.64 +/- A 8.04 kPa; P < 0.0001). Significant differences in patient age (P < 0.0001), albumin (P < 0.0001), platelet count (P < 0.0001), AFP (P < 0.0001), and DCP (P < 0.0001) were also observed between patients with and without HCC. Liver tissue stiffness showed the largest AUROC (0.791). With regard to EGV, liver tissue stiffness was significantly higher in patients with EGV (22.65 +/- A 10.19 kPa) than in those without EGV (12.67 +/- A 9.45 kPa; P < 0.0001). Significant differences in albumin (P < 0.0001) and platelet count (P < 0.0001) were also observed between patients with and without EGV. Liver tissue stiffness measured by SWE is an independent factor for predicting the presence of HCC and EGV in patients with chronic liver disease.	[Kasai, Yoshitaka; Moriyasu, Fuminori; Kobayashi, Yoshiyuki; Nakamura, Ikuo; Sugimoto, Katsutoshi] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, Tokyo 1600023, Japan; [Saito, Kazuhiro] Tokyo Med Univ, Dept Radiol, Tokyo 1600023, Japan; [Hara, Takeshi] Gifu Univ, Grad Sch Med, Dept Intelligent Image Informat, Gifu, Japan	Sugimoto, K (reprint author), Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	ykas731@msn.com; Moriyasu@tokyo-med.ac.jp; saito-k@tokyo-med.ac.jp; takeshi.hara@mac.com; ykobaya@tokyo-med.ac.jp; ikuonaka@tokyo-med.ac.jp; sugimoto@tokyo-med.ac.jp					Ferraioli G, 2012, HEPATOLOGY, V56, P2125, DOI 10.1002/hep.25936; Sagir A, 2008, HEPATOLOGY, V47, P592, DOI 10.1002/hep.22056; Colli A, 2010, RADIOLOGY, V257, P872, DOI 10.1148/radiol.10100013; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; Colecchia A, 2012, GASTROENTEROLOGY, V143, P646, DOI 10.1053/j.gastro.2012.05.035; Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018; [Anonymous], 2010, HEPATOL RES, V40, P2; Muller M, 2009, ULTRASOUND MED BIOL, V35, P219, DOI 10.1016/j.ultrasmedbio.2008.08.018; Tajiri T, 2010, DIGEST ENDOSC, V22, P1, DOI 10.1111/j.1443-1661.2009.00929.x; Millonig G, 2008, HEPATOLOGY, V48, P1718, DOI 10.1002/hep.22577; Foucher J, 2006, GUT, V55, P403, DOI 10.1136/gut.2005.069153; Masuzaki R, 2009, HEPATOLOGY, V49, P1954, DOI 10.1002/hep.22870; Kiyosawa K, 2004, GASTROENTEROLOGY, V127, pS17, DOI 10.1053/j.gastro.2004.09.012; Benvegnu L, 2004, GUT, V53, P744, DOI 10.1136/gut.2003.020263; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022; Baik SK, 2006, RADIOLOGY, V240, P574, DOI 10.1148/radiol.2402051142; Honjo M, 2014, J ULTRAS MED, V33, P61, DOI 10.7863/ultra.33.1.61	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					349	355		10.1007/s10396-014-0603-3		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700007		
J	Fukuda, K; Seki, Y; Ichihi, M; Okada, T; Hirata, A; Kogita, S; Sawai, Y; Igura, T; Tsugawa, M; Imai, Y				Fukuda, Kazuto; Seki, Yasushi; Ichihi, Masahiro; Okada, Takuya; Hirata, Ayumu; Kogita, Sachiyo; Sawai, Yoshiyuki; Igura, Takumi; Tsugawa, Mamiko; Imai, Yasuharu			Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients	JOURNAL OF MEDICAL ULTRASONICS			English	Article						NAFLD; NASH; Visceral fat; Diabetes mellitus; Ultrasonography	VISCERAL FAT; METABOLIC SYNDROME; HEPATOCELLULAR-CARCINOMA; CLINICAL-USEFULNESS; INSULIN-RESISTANCE; NATURAL-HISTORY; ABDOMINAL FAT; STEATOHEPATITIS; FIBROSIS; RISK	Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been regarded as the hepatic manifestation of metabolic syndrome. Abdominal wall fat index (AFI), defined as the ratio of preperitoneal and subcutaneous fat thickness in the abdomen estimated by ultrasonography (US), has been shown to be useful in screening for disorders related to metabolic syndrome. We investigated the relation between AFI and NAFLD/NASH in diabetic patients. The degree of fat accumulation in the liver and the thickness of preperitoneal and subcutaneous fat were determined by US in 340 diabetic patients. An NAFLD fibrosis score (NAFLD-FS) was used to assess the advancement of hepatic fibrosis in NAFLD patients. Of all 340 subjects, 209 (61 %) were diagnosed with NAFLD by US. AFI of NAFLD subjects was significantly higher than that of non-NAFLD subjects. Of the 209 subjects with NAFLD, 31 (15 %) were shown to have advanced NASH fibrosis according to NAFLD-FS. Multivariate analysis identified AFI as a significant predictor of advanced fibrosis. AFI easily obtained by US was significantly related to the presence of NAFLD and/or advanced hepatic fibrosis in diabetic patients.	[Fukuda, Kazuto; Kogita, Sachiyo; Sawai, Yoshiyuki; Igura, Takumi; Imai, Yasuharu] Ikeda Municipal Hosp, Dept Gastroenterol, Ikeda, Osaka 5638510, Japan; [Seki, Yasushi; Ichihi, Masahiro] Ikeda Municipal Hosp, Dept Ultrasonog, Ikeda, Osaka 5638510, Japan; [Okada, Takuya; Hirata, Ayumu; Tsugawa, Mamiko] Ikeda Municipal Hosp, Dept Endocrinol & Metab, Ikeda, Osaka 5638510, Japan	Fukuda, K (reprint author), Ikeda Municipal Hosp, Dept Gastroenterol, 3-1-18 Jonan, Ikeda, Osaka 5638510, Japan.	fukuda-imhp@umin.ac.jp					Amato MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091969; Musso G, 2008, DIABETES CARE, V31, P562, DOI 10.2337/dc07-1526; White DL, 2012, CLIN GASTROENTEROL H, V10, P1342, DOI 10.1016/j.cgh.2012.10.001; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Okamoto Y, 2006, CLIN SCI, V110, P267, DOI 10.1042/CS20050182; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496; Tolman KG, 2007, DIABETES CARE, V30, P734, DOI 10.2337/dc06-1539; Hamaguchi M, 2005, ANN INTERN MED, V143, P722; Cusi K, 2012, GASTROENTEROLOGY, V142, P711, DOI 10.1053/j.gastro.2012.02.003; van der Poorten D, 2008, HEPATOLOGY, V48, P449, DOI 10.1002/hep.22350; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Sogabe M, 2012, J GASTROENTEROL, V47, P293, DOI 10.1007/s00535-011-0489-4; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Yoshizumi T, 1999, RADIOLOGY, V211, P283; Tayama K, 1999, DIABETES RES CLIN PR, V43, P49, DOI 10.1016/S0168-8227(98)00118-1; Angulo P, 2013, GASTROENTEROLOGY, V145, P782, DOI 10.1053/j.gastro.2013.06.057; Positano V, 2004, J MAGN RESON IMAGING, V20, P684, DOI 10.1002/jmri.20167; Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167; Caldwell S, 2010, DIGEST DIS, V28, P162, DOI 10.1159/000282081; Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354; Yasui K, 2011, CLIN GASTROENTEROL H, V9, P428, DOI 10.1016/j.cgh.2011.01.023; Petta S, 2012, ALIMENT PHARM THER, V35, P238, DOI 10.1111/j.1365-2036.2011.04929.x; Nagaya T, 2010, J HEPATOL, V53, P724, DOI 10.1016/j.jhep.2010.04.033; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; van der Poorten D, 2013, HEPATOLOGY, V57, P2180, DOI 10.1002/hep.26072; Vettor R, 2005, ALIMENT PHARM THERAP, V22, P3, DOI 10.1111/j.1365-2036.2005.02587.x; Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038; Hirooka M, 2005, INTERNAL MED, V44, P794, DOI 10.2169/internalmedicine.44.794; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Hotta N, 2010, J DIABETES INVEST, V1, P6, DOI 10.1111/j.2040-1124.2010.00007.x; Kawamoto R, 2007, J MED ULTRASON, V34, P93, DOI 10.1007/s10396-007-0137-z; Kawamoto R, 2005, J ATHEROSCLER THROMB, V12, P85; Kawasaki S, 2008, J CLIN ULTRASOUND, V36, P129, DOI 10.1002/jcu.20426; Marco R, 1999, DIABETES CARE, V22, P756; Miyaaki H, 2008, LIVER INT, V28, P519, DOI 10.1111/j.1478-3231.2007.01614.x; Monaco L, 2014, AM J MED SCI, V347, P8, DOI 10.1097/MAJ.0b013e318288f795; Nakahara T, 2014, J GASTROENTEROL, V49, P1477, DOI 10.1007/s00535-013-0911-1; Nakanishi S, 2007, J MED ULTRASON, V34, P151, DOI 10.1007/s10396-007-0149-8; Okanoue T, 2011, J GASTROEN HEPATOL, V26, P153, DOI 10.1111/j.1440-1746.2010.06547.x; Ribeiro FF, 2001, HYPERTENSION, V38, P713; Soyama A, 2005, ENDOCR J, V52, P229, DOI 10.1507/endocrj.52.229; SUZUKI R, 1993, AM J MED, V95, P309, DOI 10.1016/0002-9343(93)90284-V	44	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					357	363		10.1007/s10396-015-0615-7		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700008		
J	Konno, S; Takada, E; Ejiri, N; Kawamata, M; Takase, N; Nakazato, Y; Suzuki, K; Takekawa, H				Konno, Sachiyo; Takada, Etsuo; Ejiri, Natsuki; Kawamata, Misaki; Takase, Naotoshi; Nakazato, Yoshimasa; Suzuki, Keisuke; Takekawa, Hidehiro			Stereoscopic images of breast tumors using 3D real-time tissue elastography	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Breast ultrasonography; 3D imaging; Elastography; 3D elastography	ULTRASOUND; DIAGNOSIS; LESIONS	This study aimed at evaluating the usefulness of 3D real-time tissue elastography (RTE) images for diagnosing breast tumors. A total of 166 breast tumor patients who underwent conventional ultrasound and 2D and 3D RTE examinations were retrospectively analyzed. The 3D RTE images were divided into three types according to the occupancy of blue contrast images. Elastic scores (ES) were obtained by 2D RTE examination. The diagnostic accuracy of 3D and 2D RTE images in differentiating malignant from benign breast tumors was evaluated. Of all cases, 89.4 % of the malignant cases were Type 3 and 86.6 % of the benign cases were Type 1 or 2 according to 3D RTE images. 3D RTE Type 3 and ES a parts per thousand yen 4 on 2D RTE examination diagnosed malignant tumors with an accuracy of 87.4 and 88.6 %, respectively. In addition, among 34 patients with an ES of 3, the presence of 3D RTE Type 3 diagnosed malignant tumors with an accuracy of 82.4 %. In this study, the utility of 3D RTE images was comparable to that of ES on 2D RTE examination in differentiating malignant from benign breast tumors. In addition, utilizing 3D RTE images in cases with an ES of 3 on 2D RTE may increase the diagnostic accuracy for breast tumors.	[Konno, Sachiyo; Takada, Etsuo; Ejiri, Natsuki; Kawamata, Misaki; Takase, Naotoshi; Takekawa, Hidehiro] Dokkyo Med Univ Hosp, Ctr Med Ultrason, Mibu, Tochigi 3210293, Japan; [Nakazato, Yoshimasa] Dokkyo Med Univ, Dept Pathol, Mibu, Tochigi 3210293, Japan; [Suzuki, Keisuke; Takekawa, Hidehiro] Dokkyo Med Univ, Dept Neurol, Mibu, Tochigi 3210293, Japan	Konno, S (reprint author), Dokkyo Med Univ Hosp, Ctr Med Ultrason, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	sakonno@dokkyomed.ac.jp					Ikeda K, 2012, BREAST CANCER-TOKYO, V19, P71, DOI 10.1007/s12282-011-0274-5; Itoh A, 2006, RADIOLOGY, V239, P341, DOI 10.1148/radiol.2391041676; Itoh A, 2006, MEDIX, V45, P10; Mori M, 2012, BREAST CANCER-TOKYO, V19, P60, DOI 10.1007/s12282-011-0268-3; Shiina T, 1996, P IEEE ULTR S, P1331; Shiina T, 2002, J MED ULTRASON, V29, P119, DOI 10.1007/BF02481234; The Japan Society of Ultrasonics in Medicine, 2005, J MED ULTRASON, V32, P127; Tohno E, 2008, BREAST CANCER-TOKYO, V15, P200, DOI 10.1007/s12282-008-0052-1; Ueno E, 2007, RSNA 2007; Wojcinski S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-159	10	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					365	371		10.1007/s10396-015-0618-4		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700009		
J	Mabuchi, S; Sasano, T; Kuroda, H; Takahashi, R; Nakagawa, S; Kimura, T				Mabuchi, Seiji; Sasano, Tomoyuki; Kuroda, Hiromasa; Takahashi, Ryoko; Nakagawa, Satoshi; Kimura, Tadashi			Real-time tissue sonoelastography for early response monitoring in cervical cancer patients treated with definitive chemoradiotherapy: preliminary results	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Sonoelastography; Cervical cancer; Radiotherapy; Response monitoring	CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; UTERINE CERVIX; BREAST-LESIONS; ONCOLOGY-GROUP; ELASTOGRAPHY; CARCINOMA; CHEMOTHERAPY; BRACHYTHERAPY; HYSTERECTOMY	To investigate the utility of real-time sonoelastography (RTE) for predicting treatment response during the course of definitive radiotherapy in patients with cervical cancer. Cervical cancer patients were prospectively evaluated with RTE by a single operator during the course of definitive radiotherapy to analyze the associations between the change in their tumor's strain ratio (SR) and the treatment response. The SR of the cervical tumors was significantly higher than that of the normal cervical tissue (mean 3.8 vs 1.2; median 3.4 vs 1.1, p < 0.01). Treating the cervical tumors with definitive radiotherapy significantly reduced their SR to the same level as the normal cervix among patients who achieved a complete response to definitive radiotherapy. In contrast, among patients who developed residual disease after radiotherapy, the SR of the tumor did not decrease significantly after definitive radiotherapy. Moreover, the reduction in the tumor SR detected by RTE preceded the reduction in tumor volume as assessed by transvaginal ultrasonography. RTE is a rapid and effective method for predicting treatment response during the course of definitive radiotherapy, potentially facilitating early and personalized treatment adaptation in patients with cervical cancer.	[Mabuchi, Seiji; Sasano, Tomoyuki; Kuroda, Hiromasa; Takahashi, Ryoko; Nakagawa, Satoshi; Kimura, Tadashi] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan	Mabuchi, S (reprint author), Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	smabuchi@gyne.med.osaka-u.ac.jp					Eifel PJ, 2004, J CLIN ONCOL, V22, P872, DOI 10.1200/JCO.2004.07.197; Thomas A, 2006, ULTRASOUND OBST GYN, V28, P356, DOI 10.1002/uog.3813; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Garra BS, 1997, RADIOLOGY, V202, P79; Leath CA, 2013, GYNECOL ONCOL, V129, P251, DOI 10.1016/j.ygyno.2012.12.035; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; Mabuchi S, 2010, GYNECOL OBSTET INVES, V69, P224, DOI 10.1159/000273207; Konig K, 2005, J UROLOGY, V174, P115, DOI 10.1097/01.ju.0000162043.72294.4a; ULDBJERG N, 1983, AM J OBSTET GYNECOL, V147, P662; Keys HM, 2003, GYNECOL ONCOL, V89, P343, DOI 10.1016/S0090-8258(03)00173-2; Park JJ, 2014, MAGN RESON IMAGING, V32, P993, DOI 10.1016/j.mri.2014.05.009; Ajiki W, 2004, JPN J CLIN ONCOL, V34, P352; Thomas A, 2006, ULTRASOUND OBST GYN, V28, P335, DOI 10.1002/uog.2823; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Hayashi M, 2012, ANN SURG ONCOL, V19, P3042, DOI 10.1245/s10434-012-2343-1; Kinkel K, 1997, RADIOLOGY, V204, P55; Classe JM, 2006, GYNECOL ONCOL, V102, P523, DOI 10.1016/j.ygyno.2006.01.022; Itoh A, 2006, RADIOLOGY, V239, P341, DOI 10.1148/radiol.2391041676; Thomas A, 2007, ACAD RADIOL, V14, P193, DOI 10.1016/j.acra.2006.11.010; Oxlund BS, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-82; ROTMAN M, 1979, INT J RADIAT ONCOL, V5, P327; Schwarz JK, 2009, J NUCL MED, V50, p64S, DOI 10.2967/jnumed.108.057257; Varghese T, 2004, ULTRASONIC IMAGING, V26, P18	25	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					379	385		10.1007/s10396-015-0616-6		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700011		
J	Nagamoto, H; Yamamoto, N; Kurokawa, D; Takahashi, H; Muraki, T; Tanaka, M; Koike, Y; Sano, H; Itoi, E				Nagamoto, Hideaki; Yamamoto, Nobuyuki; Kurokawa, Daisuke; Takahashi, Hiroyuki; Muraki, Takayuki; Tanaka, Minoru; Koike, Yoichi; Sano, Hirotaka; Itoi, Eiji			Evaluation of the thickness of the medial ulnar collateral ligament in junior high and high school baseball players	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Ultrasonography; Elbow; Medial ulnar collateral ligament; Youth baseball players; Valgus stress; Asymptomatic	ELBOW INJURIES; RISK-FACTORS; PITCHERS; SONOGRAPHY; SHOULDER; VALGUS	Thickening of the medial ulnar collateral ligament in the throwing arm of adult baseball players is a well-known phenomenon. However, onset of the thickening is unclear among young baseball players. The purpose of this study was to evaluate the thickness of the medial ulnar collateral ligament in junior high and high school baseball players. Seventy-one uninjured and asymptomatic junior high and high school baseball players were included in the study. Participants underwent physical examination after completing a questionnaire, followed by ultrasonographic evaluation. The thickness of the medial ulnar collateral ligament was measured bilaterally. The thickness of the throwing and non-throwing sides in high school and junior high school baseball players, and within each group, was compared and statistically analyzed. The medial ulnar collateral ligament in the throwing arm of high school baseball players was thicker than that in the non-throwing arm (5.5 vs. 4.4 mm), although no significant difference was seen in junior high school baseball players. High school baseball players showed a significantly thicker medial ulnar collateral ligament in the throwing arm than junior high school baseball players. Thickening of the medial ulnar collateral ligament in the throwing arm of asymptomatic and uninjured baseball players may begin by the time the players reach high school.	[Nagamoto, Hideaki; Yamamoto, Nobuyuki; Itoi, Eiji] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Kurokawa, Daisuke] Sendai Med Ctr, Dept Orthopaed Surg, Sendai, Miyagi, Japan; [Takahashi, Hiroyuki] Kesennuma City Hosp, Dept Orthopaed Surg, Kesennuma, Miyagi, Japan; [Muraki, Takayuki] Tohoku Univ, Sch Med, Dept Phys Med & Rehabil, Sendai, Miyagi 9808574, Japan; [Tanaka, Minoru] Tohoku Rosai Hosp, Dept Orthopaed Surg, Sendai, Miyagi, Japan; [Koike, Yoichi] Japan Red Cross Sendai Hosp, Dept Orthopaed Surg, Sendai, Miyagi, Japan; [Sano, Hirotaka] Sendai City Hosp, Dept Orthopaed Surg, Sendai, Miyagi, Japan	Itoi, E (reprint author), Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	itoi-eiji@med.tohoku.ac.jp					Fleisig GS, 1999, J BIOMECH, V32, P1371, DOI 10.1016/S0021-9290(99)00127-X; FLEISIG GS, 1995, AM J SPORT MED, V23, P233, DOI 10.1177/036354659502300218; Nazarian LN, 2003, RADIOLOGY, V227, P149, DOI 10.1148/radiol.2271020288; Hyman J, 2001, CLIN SPORT MED, V20, P25, DOI 10.1016/S0278-5919(05)70245-3; Harada M, 2006, AM J ROENTGENOL, V187, P1436, DOI 10.2214/AJR.05.1086; Sasaki J, 2002, J BONE JOINT SURG AM, V84A, P525; Popovic N, 2001, INT J SPORTS MED, V22, P60, DOI 10.1055/s-2001-11333; Kooima CL, 2004, AM J SPORT MED, V32, P1602, DOI 10.1177/0363546503262646; Lyman S, 2001, MED SCI SPORT EXER, V33, P1803, DOI 10.1097/00005768-200111000-00002; Miller TT, 2004, SKELETAL RADIOL, V33, P386, DOI 10.1007/s00256-004-0788-4; Olsen SJ, 2006, AM J SPORT MED, V34, P905, DOI 10.1177/0363546505284188; Harada M, 2010, J SHOULDER ELB SURG, V19, P502, DOI 10.1016/j.jse.2009.10.022; Azar FM, 2000, AM J SPORT MED, V28, P16; Hurd WJ, 2011, AM J SPORT MED, V39, P722, DOI 10.1177/0363546510390185; Ward SI, 2003, AM J ROENTGENOL, V180, P389; Werner SL, 2002, J SHOULDER ELB SURG, V11, P151, DOI 10.1067/mse.2002.121481; JOBE FW, 1986, J BONE JOINT SURG AM, V68A, P1158; MORREY BF, 1983, AM J SPORT MED, V11, P315, DOI 10.1177/036354658301100506	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					395	400		10.1007/s10396-014-0605-1		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700013		
J	Tsugu, T; Iwanaga, S; Murata, M; Fukuda, K				Tsugu, Toshimitsu; Iwanaga, Shiro; Murata, Mitsushige; Fukuda, Keiichi			Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Carcinoid heart disease; Echocardiography; Bioprosthetic valve replacement; Cartinoid tumor		Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 % of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.	[Tsugu, Toshimitsu; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan; [Tsugu, Toshimitsu] Hino Municipal Hosp, Dept Cardiol, Tokyo 1910062, Japan; [Iwanaga, Shiro] Saitama Int Med Ctr, Dept Cardiol, Saitama, Japan; [Murata, Mitsushige] Keio Univ, Sch Med, Dept Lab Med, Tokyo, Japan	Tsugu, T (reprint author), Hino Municipal Hosp, Dept Cardiol, 4-3-1 Tamadaira, Tokyo 1910062, Japan.	tsugu917@gmail.com					Chaowalit N, 2004, AM J CARDIOL, V93, P1314, DOI 10.1016/j.amjcard.2004.01.075; Zuetenhorst JM, 2003, CANCER, V97, P1609, DOI 10.1002/cncr.11226; Bernheim AM, 2007, PROG CARDIOVASC DIS, V49, P439, DOI 10.1016/j.pcad.2006.12.002; Brunaud L, 2001, EUR J OBSTET GYN R B, V98, P124, DOI 10.1016/S0301-2115(00)00563-7; Castillo JG, 2009, ANN THORAC SURG, V87, P321, DOI 10.1016/j.athoracsur.2008.04.061; Franko DM, 2000, ECHOCARDIOGR-J CARD, V17, P571, DOI 10.1046/j.1540-8175.2000.00571.x; Nallet O, 2003, ARCH MAL COEUR VAISS, V96, P144; OEI SG, 1989, EUR J OBSTET GYN R B, V31, P185, DOI 10.1016/0028-2243(89)90180-9; WILKOWSKE MA, 1994, CANCER, V73, P1889, DOI 10.1002/1097-0142(19940401)73:7<1889::AID-CNCR2820730719>3.0.CO;2-3	9	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					401	403		10.1007/s10396-015-0621-9		3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700014		
J	Fujii, M; Watanabe, K; Kataoka, M; Nose, S; Shiode, J				Fujii, Masakuni; Watanabe, Kazuhiko; Kataoka, Masafumi; Nose, Soichiro; Shiode, Junji			A case of a pancreatic tumor that was diagnosed as metastasis from lung cancer by endoscopic ultrasound-guided fine needle aspiration	JOURNAL OF MEDICAL ULTRASONICS			English	Article						EUS-FNA; Metastatic pancreatic tumor; Lung cancer; Duodenal papilla cancer	FNA	Metastatic tumors are rare in the pancreas, and some cases are difficult to distinguish from pancreatic cancer. However, distinguishing between them is very important to formulate a treatment plan. A case of a rare disease, called overlap cancer, involving metastatic tumors to the pancreas and right kidney from lung cancer, and duodenal papilla cancer, is described. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is useful for diagnosing metastatic pancreatic tumors, particularly in patients with multiple cancers.	[Fujii, Masakuni; Watanabe, Kazuhiko; Shiode, Junji] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama 7008511, Japan; [Kataoka, Masafumi] Okayama Saiseikai Gen Hosp, Dept Surg, Okayama 7008511, Japan; [Nose, Soichiro] Okayama Saiseikai Gen Hosp, Anat Pathol, Okayama 7008511, Japan	Fujii, M (reprint author), Okayama Saiseikai Gen Hosp, Dept Internal Med, 1-17-18 Ifuku Cho, Okayama 7008511, Japan.	sktng334@yahoo.co.jp					Adsay NV, 2004, VIRCHOWS ARCH, V444, P527, DOI 10.1007/s00428-004-0987-3; Hewitt MJ, 2012, GASTROINTEST ENDOSC, V75, P319, DOI 10.1016/j.gie.2011.08.049; Reddy S, 2009, LANCET ONCOL, V10, P287, DOI 10.1016/S1470-2045(09)70065-8; DeWitt J, 2005, GASTROINTEST ENDOSC, V61, P689, DOI 10.1016/S0016-5107(05)00287-7; Thompson LDR, 2000, CANCER, V89, P1076, DOI 10.1002/1097-0142(20000901)89:5<1076::AID-CNCR17>3.0.CO;2-M; Katsourakis A, 2012, CASE REP MED, V2012; Lasithiotakis Konstantinos, 2010, JOP, V11, P593	7	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					405	408		10.1007/s10396-015-0614-8		4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700015		
J	Yamada, K; Toda, K; Ebina, A; Motoi, N; Sugitani, I				Yamada, Keiko; Toda, Kazuhisa; Ebina, Aya; Motoi, Noriko; Sugitani, Iwao			Ultrasonographic and non-enhanced CT features of acute transient thyroid swelling following fine-needle aspiration biopsy: report of four cases	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Acute transient thyroid swelling; Fine-needle aspiration cytology; Thyroid nodule; Ultrasound; CT	SOCIETY	We report four cases of acute transient thyroid swelling following fine-needle aspiration biopsy, a rare complication of still unknown origin. The ultrasonographic pattern was fairly similar to that in previous reports: swelling of the thyroid with a patchy and heterogeneous appearance and diffusely scattered hypoechoic "cracks" that showed no blood flow signals with color Doppler ultrasound. There were also some features that differed from those in previous reports. Though thyroid swelling is typically diffuse and bilateral, it was unilateral or asymmetrical in some of our cases. While thyroid swelling is said to resolve spontaneously within 1-20 h, abnormal ultrasonographic findings persisted for more than 48 h in one case. Unlike previous reports, we have experienced cases with ultrasonographic findings of concomitant minor subcapsular hematomas. In one case, CT demonstrated not only thyroid swelling but also abnormal attenuation in perithyroid tissue extending to the retro-hypopharyngeal space and to the paraesophageal mediastinum. Although vasodilatation and diffuse vascular leakage are speculated to be the underlying mechanisms, our ultrasonograms at the time of the complication failed to demonstrate enlarged intrathyroidal vessels or hypervascularity with color Doppler ultrasound. More awareness and a description of the cases may help to clarify the pathogenesis of this self-limited complication.	[Yamada, Keiko] Canc Inst Hosp, Dept Ultrasound, Koto Ku, Tokyo 1358550, Japan; [Toda, Kazuhisa; Ebina, Aya] Canc Inst Hosp, Dept Head & Neck Surg, Koto Ku, Tokyo 1358550, Japan; [Motoi, Noriko] Japanese Fdn Canc Res, Dept Pathol, Koto Ku, Tokyo 1358550, Japan; [Sugitani, Iwao] Nippon Med Sch, Dept Endocrine Surg, Bunkyo Ku, Tokyo 1138603, Japan	Yamada, K (reprint author), Canc Inst Hosp, Dept Ultrasound, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	kyamada@jfcr.or.jp					Takami H, 2011, WORLD J SURG, V35, P111, DOI 10.1007/s00268-010-0832-6; Polyzos SA, 2009, CLIN ENDOCRINOL, V71, P157, DOI 10.1111/j.1365-2265.2009.03522.x; Frates MC, 2005, RADIOLOGY, V237, P794, DOI 10.1148/radiol.2373050220; Bouwman RA, 2009, CRIT CARE, V13, DOI 10.1186/cc8032; HAAS SN, 1982, NEW ENGL J MED, V307, P1349; Nakagawa Y, 2011, INT J CASE REP IMAGE, V2, P28; Nakatake Nobuhiro, 2012, Clin Endocrinol (Oxf), V77, P152, DOI 10.1111/j.1365-2265.2011.04294.x; Norrenberg S, 2011, CLIN ENDOCRINOL, V75, P568, DOI 10.1111/j.1365-2265.2011.04064.x; Polyzos SA, 2012, HORM-INT J ENDOCRINO, V11, P147; Takami H, 2013, TREATMENT THYOID TUM, P59; Van den Bruel A, 2008, THYROID, V18, P81, DOI 10.1089/thy.2007.0118; VELKENIERS B, 1988, J ENDOCRINOL INVEST, V11, P225; Ziambaras K, 2013, HORM-INT J ENDOCRINO, V12, P315	13	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					417	425		10.1007/s10396-014-0600-6		9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700018		
J	Tanaka, Y; Uchida, A; Umemoto, T; Morishima, I; Kikuchi, K; Tohno, E; Ueno, E				Tanaka, Yuko; Uchida, Atsushi; Umemoto, Takeshi; Morishima, Isamu; Kikuchi, Kazunori; Tohno, Eriko; Ueno, Ei			Spontaneous regression of breast angiosarcoma after conservative treatment with radiotherapy: a case report and review of the literature	JOURNAL OF MEDICAL ULTRASONICS			English	Review						Angiosarcoma; Breast cancer; Radiation-induced malignancy; Tumor regression	SARCOMA; RISK	Angiosarcoma of the breast is a rare disease, and approximately 1 % of all affected patients are treated with breast-conserving therapy (BCT) and radiotherapy (RT) for primary breast cancer. The prognosis for this tumor is quite dismal, with high rates of recurrence and poor overall survival. This report presents the case of a 73-year-old female who underwent BCT followed by RT for left breast carcinoma 18 years previously. The patient visited the hospital with a complaint of a new mass in the left breast. The lesion initially decreased in size; however, it subsequently began to rapidly enlarge. A core needle biopsy of the mass was performed under ultrasonography, with a diagnosis of a spindle cell sarcoma, most conceivably an angiosarcoma, originating from the left breast, suspected to be induced by RT. The tumor was resected with the surrounding skin, and immunohistochemically diagnosed as angiosarcoma of the left breast, without evidence of breast cancer in any lesion, suggesting that RT induced the tumor formation. We herein report this rare case and the ultrasound imaging findings.	[Tanaka, Yuko; Umemoto, Takeshi; Morishima, Isamu; Ueno, Ei] Tsukuba Med Ctr Hosp, Dept Senol, Tsukuba, Ibaraki 3058558, Japan; [Tanaka, Yuko] Kobe Univ, Dept Breast Surg, Kobe, Hyogo 6500017, Japan; [Uchida, Atsushi; Kikuchi, Kazunori] Tsukuba Med Ctr Hosp, Dept Pathol, Tsukuba, Ibaraki 3058558, Japan; [Tohno, Eriko] Total Hlth Evaluat Ctr Tsukuba, Tsukuba, Ibaraki 3058558, Japan	Tanaka, Y (reprint author), Kobe Univ, Dept Breast Surg, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	ytnk@med.kobe-u.ac.jp					Aljarrah A, 2014, ECANCERMEDICALSCIENC; D'Angelo SP, 2013, BRIT J CANCER, V109, P2340, DOI 10.1038/bjc.2013.590; Yang WT, 2007, RADIOLOGY, V242, P725, DOI 10.1148/radiol.2423060163; Kadouri L, 2013, BREAST CANCER RES TR, V140, P207, DOI 10.1007/s10549-013-2621-z; Cil T, 2008, BREAST CARE, V3, P197, DOI 10.1159/000121469; Gonin-Laurent N, 2007, ONCOGENE, V26, P6106, DOI 10.1038/sj.onc.1210404; Kim S. W., 2008, Sarcoma, P940656, DOI 10.1155/2008/940656; Lakhani SR, 2012, WHO CLASSIFICATION T, P135; Smith TL, 2014, ACTA ONCOL, V53, P235, DOI 10.3109/0284186X.2013.819117; Tanaka A, 2013, J DERMATOL, V40, P215, DOI 10.1111/1346-8138.12051; West JG, 2005, BREAST J, V11, P115, DOI 10.1111/j.1075-122X.2005.21548.x	11	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					427	432		10.1007/s10396-014-0607-z		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700019		
J	Takekawa, H; Suzuki, K; Nishihira, T; Iwasaki, A; Hoshiyama, E; Okamura, M; Numao, A; Suzuki, S; Hirata, K				Takekawa, Hidehiro; Suzuki, Keisuke; Nishihira, Takahito; Iwasaki, Akio; Hoshiyama, Eisei; Okamura, Madoka; Numao, Ayaka; Suzuki, Shiho; Hirata, Koichi			Recurrent juvenile ischemic stroke caused by bow hunter's stroke revealed by carotid duplex ultrasonography	JOURNAL OF MEDICAL ULTRASONICS			English	Article						Juvenile ischemic stroke; Bow hunter's stroke; Carotid duplex ultrasonography	VERTEBRAL ARTERY-OCCLUSION; VERTEBROBASILAR INSUFFICIENCY; MANAGEMENT	Bow hunter's stroke (BHS) is a rare cause of vertebrobasilar insufficiency due to rotational vertebral artery (VA) occlusion associated with head turning. We report a juvenile patient presenting with recurrent ischemic stroke caused by BHS, which was revealed by carotid duplex ultrasonography. Carotid duplex ultrasonography performed in the neutral position showed normal findings. However, disappearance of end-diastolic blood flow of contralateral VAs was observed with head rotation. Digital subtraction angiography confirmed occlusion at C1/2 levels in the VA contralateral to the head rotation, bilaterally. Importantly, our patient did not recognize the association of head rotation and previous episodes of stroke. We suggest that BHS should be considered in patients with cryptogenic stroke occurring in the vertebrobasilar artery territory.	[Takekawa, Hidehiro; Nishihira, Takahito; Iwasaki, Akio; Okamura, Madoka] Dokkyo Med Univ, Dept Neurol, Stroke Div, Shimotsuga, Tochigi 3210293, Japan; [Takekawa, Hidehiro] Dokkyo Med Univ, Ctr Med Ultrason, Shimotsuga, Tochigi 3210293, Japan; [Suzuki, Keisuke; Hoshiyama, Eisei; Numao, Ayaka; Suzuki, Shiho; Hirata, Koichi] Dokkyo Med Univ, Dept Neurol, Shimotsuga, Tochigi 3210293, Japan	Suzuki, K (reprint author), Dokkyo Med Univ, Dept Neurol, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan.	keisuke@dokkyomed.ac.jp					Ikeda DS, 2014, J CLIN NEUROSCI, V21, P1044, DOI 10.1016/j.jocn.2013.10.005; Cornelius JF, 2012, NEUROSURG REV, V35, P127, DOI 10.1007/s10143-011-0343-4; Greiner HM, 2010, CHILD NERV SYST, V26, P1669, DOI 10.1007/s00381-010-1299-3; Hayashi K, 2000, No To Shinkei, V52, P431; HOPE EE, 1983, PEDIATRICS, V72, P335; Iguchi Y, 2006, J NEUROIMAGING, V16, P278, DOI 10.1111/j.1552-6569.2006.00040.x; Kuether TA, 1997, NEUROSURGERY, V41, P427, DOI 10.1097/00006123-199708000-00019; Kuether TA, 1997, NEUROSURGERY, V41, P32; Nakamura K, 1998, NEURORADIOLOGY, V40, P164; Sakai K, 1999, NEUROL MED-CHIR, V39, P696, DOI 10.2176/nmc.39.696; Sakamoto Y, 2011, NEUROLOGY, V77, P1403, DOI 10.1212/WNL.0b013e31823152f9; Tanaka Shohei, 2012, Rinsho Shinkeigaku, V52, P34; Zaidi HA, 2014, WORLD NEUROSURG, V82, P733, DOI 10.1016/j.wneu.2014.02.027	13	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					437	440		10.1007/s10396-015-0611-y		4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700021		
J	Shah, SBH; Matsuoka, R; Ichizuka, K				Shah, Syed Bilal Hussain; Matsuoka, Ryu; Ichizuka, Kiyotake			Two- and three-dimensional sonographic diagnosis of multiple pregnancies (sextuplets)	JOURNAL OF MEDICAL ULTRASONICS			English	Editorial Material						3D/4D ultrasound; Fetus; AIH (artificial insemination by husband); Multiple pregnancies			[Shah, Syed Bilal Hussain; Matsuoka, Ryu; Ichizuka, Kiyotake] Showa Univ Hosp, Shinagawa Ku, Tokyo, Japan	Shah, SBH (reprint author), Showa Univ Hosp, Shinagawa Ku, Tokyo, Japan.	drbilal18@gmail.com					Pretorius DH, 2001, RADIOL CLIN N AM, V39, P499, DOI 10.1016/S0033-8389(05)70294-3	1	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					441	443		10.1007/s10396-014-0602-4		3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700022		
J	Matsumoto, T; Miyakoshi, K; Fukutake, M; Ochiai, D; Minegishi, K; Tanaka, M				Matsumoto, Tadashi; Miyakoshi, Kei; Fukutake, Marie; Ochiai, Daigo; Minegishi, Kazuhiro; Tanaka, Mamoru			Intracranial sonographic features demonstrating in utero development of hemorrhagic brain damage leading to schizencephaly-associated COL4A1 mutation	JOURNAL OF MEDICAL ULTRASONICS			English	Editorial Material						Ventriculomegaly; Schizencephaly; Intracerebral hemorrhage			[Matsumoto, Tadashi; Miyakoshi, Kei; Fukutake, Marie; Ochiai, Daigo; Minegishi, Kazuhiro; Tanaka, Mamoru] Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan	Matsumoto, T (reprint author), Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	tmatsumoto@a2.keio.jp					Gedikbasi A, 2009, J CLIN ULTRASOUND, V37, P467, DOI 10.1002/jcu.20589; Lichtenbelt K D, 2012, Ultrasound Obstet Gynecol, V39, P726, DOI 10.1002/uog.11070	2	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1346-4523	1613-2254		J MED ULTRASON	J. Med. Ultrason.	JUL	2015	42	3					445	446		10.1007/s10396-015-0610-z		2	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CM4RP	WOS:000357672700023		
J	Nishino, S; Fujiwara, T; Watanabe, N; Yamamoto, S				Nishino, Shinya; Fujiwara, Takeo; Watanabe, Naoki; Yamamoto, Susumu			Parameter determination procedure for extended Huckel approximation and its application for solid-state electrolytes	JOURNAL OF MOLECULAR MODELING			English	Article						Extended Huckel approximation; Charge self-consistent scheme; Evaluation function; Downhill simplex method; Solid-state electrolytes	TEMPERATURE IONIC LIQUIDS; PHYSICOCHEMICAL PROPERTIES; MOLECULAR-DYNAMICS; CRYSTAL; VISUALIZATION; CONDUCTIVITY; SIMULATIONS; LI3PS4; CATION	A determination procedure of transferable tight-binding parameters of extended Huckel approximation with charge self-consistency is explained, which is applicable to both molecules and crystalline solids. The parameters are adjusted by optimizing evaluation functions, compared with reference results of energy levels or band structure calculated by, for example, the density functional theory. By introducing the evaluation function, the automatic optimization of the parameters for small molecules and clusters is achieved, which makes it easy to determine an accurate parameter set and a wide application of the TB scheme. A practical procedure of parameter optimization is demon-strated for solid-state electrolytes of Li4GeS4 and Li3PS4.	[Nishino, Shinya; Fujiwara, Takeo] Univ Tokyo, Ctr Res & Dev Higher Educ, Bunkyo Ku, Tokyo 1130033, Japan; [Nishino, Shinya] HULINKS Inc, Informat & Sci Solut Div, Dev Dept 2, Chuo Ku, Tokyo 1030015, Japan; [Watanabe, Naoki] Res Inst Inc, Mizuho Informat, Chiyoda Ku, Tokyo 1018443, Japan; [Yamamoto, Susumu] Tokyo Univ Technol, Sch Comp Sci, Tokyo 1920982, Japan	Nishino, S (reprint author), Univ Tokyo, Ctr Res & Dev Higher Educ, Bunkyo Ku, Tokyo 1130033, Japan.	s_nishino@hulinks.co.jp; fujiwara@coral.t.u-tokyo.ac.jp			Toyota Motor Corporation; JST	The present work is partly supported by the Toyota Motor Corporation, and A-step project supported by JST. The numerical calculation was carried out partly at the Research Center for Computational Science, Okazaki, Japan, and the supercomputer centers at the ISSP, The University of Tokyo. 3D images of structure and MO were produced using VESTA [30] and VMD [31].	Abbott AP, 2004, J PHYS CHEM-US, V5, P1242; ANDERSON AB, 1975, J CHEM PHYS, V62, P1187, DOI 10.1063/1.430562; Anderson OK, 1985, HIGHLIGHTS CONDENSED; Tokuda H, 2004, J PHYS CHEM B, V108, P16593, DOI 10.1021/jp047480r; Kanno R, 2000, SOLID STATE IONICS, V130, P97, DOI 10.1016/S0167-2738(00)00277-0; Momma K, 2011, J APPL CRYSTALLOGR, V44, P1272, DOI 10.1107/S0021889811038970; Liu ZC, 2013, J AM CHEM SOC, V135, P975, DOI 10.1021/ja3110895; NELDER JA, 1965, COMPUT J, V7, P308; Seki S, 2010, J MOL LIQ, V152, P9, DOI 10.1016/j.molliq.2009.10.008; HOFFMANN R, 1964, J CHEM PHYS, V40, P2745, DOI 10.1063/1.1725601; Elstner M, 1998, PHYS REV B, V58, P7260, DOI 10.1103/PhysRevB.58.7260; HOFFMANN R, 1963, J CHEM PHYS, V39, P1397, DOI 10.1063/1.1734456; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Homma K, 2011, SOLID STATE IONICS, V182, P53, DOI 10.1016/j.ssi.2010.10.001; WOLFSBERG M, 1952, J CHEM PHYS, V20, P837, DOI 10.1063/1.1700580; Tokuda H, 2005, J PHYS CHEM B, V109, P6103, DOI 10.1021/jp044626d; Calzaferri G, 1996, J PHYS CHEM-US, V100, P11122, DOI 10.1021/jp960840t; Cerda J, 2000, PHYS REV B, V61, P7965, DOI 10.1103/PhysRevB.61.7965; DRONSKOWSKI R, 1993, J PHYS CHEM-US, V97, P8617, DOI 10.1021/j100135a014; Frisch M. J., 2009, GAUSSIAN 09 REVISION; HOFFMAN R, 1964, J CHEM PHYS, V40, P2474, DOI 10.1063/1.1725550; HOFFMAN R, 1964, J CHEM PHYS, V40, P2480, DOI 10.1063/1.1725551; NATH K, 1990, PHYS REV B, V41, P5652, DOI 10.1103/PhysRevB.41.5652; Nihino S, 2014, PHYS REV B, V90; Nishino S, 2013, J MOL MODEL, V19, P2363, DOI 10.1007/s00894-013-1767-2; Nishino S, 2011, 62 ANN M INT SOC EL; Nishino S, 2012, SOLID STATE IONICS, V225, P22, DOI 10.1016/j.ssi.2012.01.045; TACHEZ M, 1984, SOLID STATE IONICS, V14, P181, DOI 10.1016/0167-2738(84)90097-3; Thiel W, 2014, COMPUT MOL SCI, V4, P145	29	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1610-2940	0948-5023		J MOL MODEL	J. Mol. Model.	JUL	2015	21	7								10.1007/s00894-015-2694-1		13	Biochemistry & Molecular Biology; Biophysics; Chemistry, Multidisciplinary; Computer Science, Interdisciplinary Applications	Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer Science	CM1RQ	WOS:000357458400001		
J	Sano, H; Murata, M; Nambu, A				Sano, Hiromi; Murata, Miho; Nambu, Atsushi			Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease	JOURNAL OF NEUROCHEMISTRY			English	Article						dopaminergic neurons; neuroprotection; neurotrophic factor; Parkinson's disease	NEUROTROPHIC FACTOR; SUBSTANTIA-NIGRA; IN-VIVO; ANTIEPILEPTIC DRUG; GROWTH-FACTOR; MUTANT MICE; CELL-DEATH; NEURONS; BRAIN; MPTP	Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of nigrostriatal dopaminergic neurons and consequent motor dysfunction. Zonisamide (1,2-benzisoxazole-3-methanesulfonamide), which was originally developed as an antiepileptic drug, has been found to have therapeutic benefits for PD. However, the pharmacological mechanisms behind the beneficial actions of zonisamide in PD are not fully understood. Here, we investigated the neuroprotective effects of zonisamide on nigrostriatal dopaminergic neurons of the Engrailed mutant mouse, a genetic model of PD. Chronic administration of zonisamide in Engrailed mutant mice was shown to improve the survival of nigrostriatal dopaminergic neurons compared with that under saline treatment. In addition, dopaminergic terminals in the striatum and the motor function were improved in zonisamide-treated Engrailed mutant mice to the levels of those in control mice. To clarify the mechanism behind the neuroprotective effects of zonisamide, the contents of neurotrophic factors were determined after chronic administration of zonisamide. Brain-derived neurotrophic factor content was increased in the striatum and ventral midbrain of the zonisamide-treated mice compared to saline-treated mice. These findings imply that zonisamide reduces nigrostriatal dopaminergic cell death through brain-derived neurotrophic factor signaling and may have similar beneficial effects in human parkinsonian patients as well.	[Sano, Hiromi; Nambu, Atsushi] Natl Inst Physiol Sci, Div Syst Neurophysiol, Okazaki, Aichi 4448585, Japan; [Sano, Hiromi; Nambu, Atsushi] SOKENDAI, Dept Physiol Sci, Okazaki, Aichi, Japan; [Murata, Miho] Natl Ctr Hosp, Dept Neurol, Natl Ctr Neurol & Psychiat, Kodaira, Tokyo, Japan	Nambu, A (reprint author), Natl Inst Physiol Sci, Div Syst Neurophysiol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.	nambu@nips.ac.jp			Ministry of Education, Culture, Sports, Sciences and Technology (MEXT) of Japan [20700353, 23700479, 25351002]; Health Labour Sciences Research Grant from the Ministry of Health Labour and Welfare of Japan; CREST; Sumitomo Dainippon Pharma Co., Ltd.	This work was supported in part by Grant-in-Aid for Young Scientists (B) (20700353, 23700479) and Grant-in-Aid for Scientific Research (C) (25351002) from the Ministry of Education, Culture, Sports, Sciences and Technology (MEXT) of Japan (to H.S.), Health Labour Sciences Research Grant from the Ministry of Health Labour and Welfare of Japan (to M.M. and A.N.), CREST (to A.N.) and Research Grant from Sumitomo Dainippon Pharma Co., Ltd. (to A.N.). M.M. received honoraria for consulting and/or lecturing from Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Nihon Medi-physics Co., Ltd. However, Sumitomo Dainippon Pharma Co., Ltd. had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank H.H. Simon of Ruprecht-Karls Universitat Heidelberg for providing the Engrailed mutant mice. We also thank S. Chiken, S. Sato, K. Miyamoto and K. Awamura for technical assistance; and the Functional Genomics Facility at the National Institute for Basic Biology for allowing us to use thermal cycler and micro plate reader. The authors have no conflict of interest to declare.	Saueressig H, 1999, DEVELOPMENT, V126, P4201; WURST W, 1994, DEVELOPMENT, V120, P2065; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; Minato H, 1997, EPILEPSIA, V38, P975, DOI 10.1111/j.1528-1157.1997.tb01479.x; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; Levivier M, 1995, J NEUROSCI, V15, P7810; Rissling I, 2009, NEURODEGENER DIS, V6, P102, DOI 10.1159/000207796; Sedelis M, 2001, BEHAV BRAIN RES, V125, P109, DOI 10.1016/S0166-4328(01)00309-6; SCHAUF CL, 1987, BRAIN RES, V413, P185, DOI 10.1016/0006-8993(87)90168-5; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Oo TF, 2003, J NEUROSCI, V23, P5141; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Murata M, 2001, NEUROSCI RES, V41, P397, DOI 10.1016/S0168-0102(01)00298-X; SUZUKI S, 1992, EPILEPSY RES, V12, P21, DOI 10.1016/0920-1211(92)90087-A; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; Murata M, 2004, CURR PHARM DESIGN, V10, P687, DOI 10.2174/1381612043453180; Mori A, 1998, EPILEPSY RES, V30, P153, DOI 10.1016/S0920-1211(97)00097-1; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Jenner P, 2008, NAT REV NEUROSCI, V9, P665, DOI 10.1038/nrn2471; Asanuma M, 2010, ANN NEUROL, V67, P239, DOI 10.1002/ana.21885; Haubenberger D, 2011, NEUROBIOL AGING, V32, P302, DOI 10.1016/j.neurobiolaging.2009.02.015; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Burke RE, 2003, ANN NY ACAD SCI, V991, P69; Golden JP, 2013, J NEUROSCI, V 33, P17095, DOI 10.1523/JNEUROSCI.0890-13.2013; Sgado P, 2006, P NATL ACAD SCI USA, V103, P15242, DOI 10.1073/pnas.0602116103; Fahn S, 2003, ANN NY ACAD SCI, V991, P1; Porritt MJ, 2005, EXP NEUROL, V192, P226, DOI 10.1016/j.expneurol.2004.11.030; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; Obeso JA, 2010, NAT MED, V16, P653, DOI 10.1038/nm.2165; Das A, 2010, NEUROCHEM RES, V35, P2175, DOI 10.1007/s11064-010-0321-1; Klein AB, 2011, INT J NEUROPSYCHOPH, V14, P347, DOI 10.1017/S1461145710000738; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Murata M, 2007, NEUROLOGY, V68, P45, DOI 10.1212/01.wnl.0000250236.75053.16; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bermejo PE, 2007, MOVEMENT DISORD, V22, P2137, DOI 10.1002/mds.21717; Choudhury ME, 2010, J PHARMACOL SCI, V114, P298, DOI 10.1254/jphs.10120FP; Dupont S, 2012, ACTA NEUROL SCAND, V126, P29, DOI 10.1111/ane.12017; ESPINO A, 1995, BRAIN RES, V695, P151, DOI 10.1016/0006-8993(95)00705-U; HAYAKAWA T, 1994, EUR J PHARMACOL, V257, P131; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; Keith B. J., 2008, MOUSE BRAIN STEREOTA; KUNER JM, 1985, CELL, V42, P309, DOI 10.1016/S0092-8674(85)80126-4; ROCK DM, 1989, EPILEPSY RES, V3, P138, DOI 10.1016/0920-1211(89)90041-7; Sgadò Paola, 2008, Parkinsonism Relat Disord, V14 Suppl 2, pS103, DOI 10.1016/j.parkreldis.2008.04.011; SHAW KM, 1980, Q J MED, V49, P283; SHULTS CW, 1995, NEUROREPORT, V6, P1109, DOI 10.1097/00001756-199505300-00009; Sonsalla PK, 2010, EXP NEUROL, V221, P329, DOI 10.1016/j.expneurol.2009.11.018; Ueda Y, 2005, NEUROCHEM RES, V30, P1117, DOI 10.1007/s11064-005-7586-9; Yabe H, 2009, J PHARMACOL SCI, V110, P64, DOI 10.1254/jphs.09019FP; Yano R, 2009, J MOL NEUROSCI, V39, P211, DOI 10.1007/s12031-009-9181-z; Yokoyama H, 2010, METAB BRAIN DIS, V25, P305, DOI 10.1007/s11011-010-9212-z	59	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2015	134	2					371	381		10.1111/jnc.13116		11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CM3QK	WOS:000357598000016		
J	Oshima, T; Miwa, H				Oshima, Tadayuki; Miwa, Hiroto			Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World	JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY			English	Review						Epidemiology; Gastrointestinal diseases; Sex	IRRITABLE-BOWEL-SYNDROME; ROME III CRITERIA; GASTROESOPHAGEAL-REFLUX DISEASE; SEROTONIN TRANSPORTER GENE; GENERALIZED ANXIETY DISORDER; QUALITY-OF-LIFE; RISK-FACTORS; NONULCER DYSPEPSIA; UNINVESTIGATED DYSPEPSIA; SYNDROME SUBTYPES	Functional gastrointestinal disorders (FGIDs), represented by functional dyspepsia (FD) and irritable bowel syndrome (IBS), are a group of disorders that include variable combinations of chronic or recurrent gastrointestinal symptoms not explained by structural or biochemical abnormalities. FGIDs account for a significant percentage of patients seen in primary care settings with abdominal symptoms. Although the definition of FGIDs can easily affect the prevalence, the prevalences of dyspepsia/FD and IBS diagnosed by the Rome III criteria in the general population are 5.3-20.4% and 1.1-29.2%, respectively. Recent reports of FD and IBS defined by the Rome III criteria indicated a female predominance. Regarding the subtype prevalence of FD, postprandial distress syndrome was more prevalent than epigastric pain syndrome (5.6-13.9% vs 0.9-9.5%). The subtype prevalence of IBS is characterized by male predominance for IBS with diarrhea and female predominance for IBS with constipation. Factors affecting the development of FGIDs such as epidemiological factors including genetic and environmental factors, are important. Gene polymorphisms are involved in the development of FGIDs. The prevalence differs among races and geographic areas. Foods may affect the development of FGIDs, but the causal relationships between food and FGIDs are not conclusive. The symptoms often regress and appear in the course of these entities. Building a favorable patient-doctor relationship is effective for controlling symptoms of FGIDs. Physicians should explain that FGIDs are highly prevalent conditions, impair the patients' quality of life even without evident underlying organic causes and are not life-threatening conditions to ensure patients' understanding.	[Oshima, Tadayuki; Miwa, Hiroto] Hyogo Coll Med, Dept Internal Med, Div Gastroenterol, Nishinomiya, Hyogo 6638501, Japan	Oshima, T (reprint author), Hyogo Coll Med, Dept Internal Med, Div Gastroenterol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	t-oshima@hyo-med.ac.jp					Ahlawat Sushil K, 2006, Gend Med, V3, P31, DOI 10.1016/S1550-8579(06)80192-0; Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061; Yang JF, 2013, CLIN GASTROENTEROL H, V11, P262, DOI 10.1016/j.cgh.2012.11.034; Mahadeva S, 2006, WORLD J GASTROENTERO, V12, P2661; van der Veek PPJ, 2005, AM J GASTROENTEROL, V100, P2510, DOI 10.1111/j.1572-0241.2005.00257.x; Krogsgaard LR, 2013, SCAND J GASTROENTERO, V48, P523, DOI 10.3109/00365521.2013.775328; Park JM, 2011, J NEUROGASTROENTEROL, V17, P279, DOI 10.5056/jnm.2011.17.3.279; Saito YA, 2002, AM J GASTROENTEROL, V97, P1910; Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008; Chitkara DK, 2008, AM J GASTROENTEROL, V103, P765, DOI 10.1111/j.1572-0241.2007.01722.x; Andresen V, 2006, GASTROENTEROLOGY, V130, P1985, DOI 10.1053/j.gastro.2006.03.0017; Halder SLS, 2007, GASTROENTEROLOGY, V133, P799, DOI 10.1053/j.gastro.2007.06.010; Kilpatrick LA, 2011, GASTROENTEROLOGY, V140, P1943, DOI 10.1053/j.gastro.2011.03.011; Miwa H, 2012, NEUROGASTROENT MOTIL, V24, P464, DOI 10.1111/j.1365-2982.2011.01872.x; Halmos EP, 2014, GASTROENTEROLOGY, V146, P67, DOI 10.1053/j.gastro.2013.09.046; Kanazawa M, 2004, DIGEST DIS SCI, V49, P1046, DOI 10.1023/B:DDAS.0000034570.52305.10; Van Lelyveld N, 2008, NEUROGASTROENT MOTIL, V20, P767, DOI 10.1111/j.1365-2982.2008.01102.x; Lee S, 2009, ALIMENT PHARM THER, V30, P643, DOI 10.1111/j.1365-2036.2009.04074.x; TALLEY NJ, 1992, AM J EPIDEMIOL, V136, P165; Ong DK, 2010, J GASTROEN HEPATOL, V25, P1366, DOI 10.1111/j.1440-1746.2010.06370.x; Staudacher HM, 2012, J NUTR, V142, P1510, DOI 10.3945/jn.112.159285; Kumano H, 2004, AM J GASTROENTEROL, V99, P370, DOI 10.1111/j.1572-0241.2004.04048.x; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; Holtmann G, 2004, GASTROENTEROLOGY, V126, P971, DOI 10.1053/j.gastro.2004.01.006; Zagari RM, 2010, GASTROENTEROLOGY, V138, P1302, DOI 10.1053/j.gastro.2009.12.057; Dinan TG, 2010, NAT REV GASTRO HEPAT, V7, P465, DOI 10.1038/nrgastro.2010.99; Kawamura A, 2001, J GASTROEN HEPATOL, V16, P384, DOI 10.1046/j.1440-1746.2001.02454.x; Okami Y, 2011, J GASTROENTEROL, V46, P1403, DOI 10.1007/s00535-011-0454-2; Gonsalkorale WM, 2003, GUT, V52, P91, DOI 10.1136/gut.52.1.91; Thompson WG, 1999, GUT, V45, P43; Nakajima S, 2010, J GASTROEN HEPATOL, V25, pS138, DOI 10.1111/j.1440-1746.2010.06244.x; Shepherd SJ, 2008, CLIN GASTROENTEROL H, V6, P765, DOI 10.1016/j.cgh.2008.02.058; Aro P, 2011, ALIMENT PHARM THER, V33, P1215, DOI 10.1111/j.1365-2036.2011.04640.x; Levy RL, 2001, GASTROENTEROLOGY, V121, P799, DOI 10.1053/gast.2001.27995; Li YY, 2002, CHINESE MED J-PEKING, V115, P1082; El-Serag HB, 2004, ALIMENT PHARM THERAP, V19, P643, DOI 10.1111/j.1365-2036.2004.01897.x; Hongo M, 2012, J GASTROEN HEPATOL, V27, P62, DOI 10.1111/j.1440-1746.2011.06949.x; Levy RL, 2004, AM J GASTROENTEROL, V99, P2442, DOI 10.1111/j.1572-0241.2004.40478.x; Yeo A, 2004, GUT, V53, P1452, DOI 10.1136/gut.2003.035451; Mak ADP, 2012, ALIMENT PHARM THER, V36, P800, DOI 10.1111/apt.12036; Adeyemo MA, 2010, ALIMENT PHARM THER, V32, P738, DOI 10.1111/j.1365-2036.2010.04409.x; Arisawa T, 2013, J GASTROENTEROL, V48, P73, DOI 10.1007/s00535-012-0602-3; Makharia GK, 2011, J NEUROGASTROENTEROL, V17, P82, DOI 10.5056/jnm.2011.17.1.82; Niec AM, 1998, AM J GASTROENTEROL, V93, P2184; Chang FY, 2012, ASIA PAC J CLIN NUTR, V21, P594; Bengtson MB, 2006, GUT, V55, P1754, DOI 10.1136/gut.2006.097287; TALLEY NJ, 1994, GASTROENTEROLOGY, V107, P1040; Choung RS, 2012, NEUROGASTROENT MOTIL, V24, P229, DOI 10.1111/j.1365-2982.2011.01845.x; Camilleri M, 2008, AM J PHYSIOL-GASTR L, V295, pG219, DOI 10.1152/ajpgi.90202.2008; Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029; Olafsdottir LB, 2010, DIGESTION, V81, P53, DOI 10.1159/000243783; Villani AC, 2010, GASTROENTEROLOGY, V138, P1502, DOI 10.1053/j.gastro.2009.12.049; Aro P, 2009, GASTROENTEROLOGY, V137, P94, DOI 10.1053/j.gastro.2009.03.039; Bernersen B, 1996, GUT, V38, P822, DOI 10.1136/gut.38.6.822; Drossman DA, 1997, GASTROENTEROLOGY, V112, P2120, DOI 10.1053/gast.1997.v112.agast972120; Okumura T, 2010, J GASTROENTEROL, V45, P187, DOI 10.1007/s00535-009-0168-x; Locke GR, 2000, MAYO CLIN PROC, V75, P907; Barzkar M, 2009, SAUDI MED J, V30, P397; Camilleri CE, 2006, AM J GASTROENTEROL, V101, P581, DOI 10.1111/j.1572-0241.2006.00481.x; Suchy Frederick J, 2010, NIH Consens State Sci Statements, V27, P1; Corsetti M, 2004, AM J GASTROENTEROL, V99, P1152, DOI 10.1111/j.1572-0241.2004.30040.x; Cuperus P, 1996, EUR J CLIN NUTR, V50, P520; Drossman DA, 2005, GASTROENTEROLOGY, V128, P580, DOI 10.1053/j.gastro.2004.12.006; DROSSMAN DA, 1995, ANN INTERN MED, V123, P782; Ebling B, 2011, COLLEGIUM ANTROPOL, V35, P513; Alvarez DFG, 2009, GASTROENTEROL HEPATO, V32, P395, DOI 10.1016/j.gastrohep.2009.01.177; Heitkemper Margaret M, 2009, Gend Med, V6 Suppl 2, P152, DOI 10.1016/j.genm.2009.03.004; Hirakawa K, 1999, J GASTROEN HEPATOL, V14, P1083, DOI 10.1046/j.1440-1746.1999.02012.x; Hongo M, 2006, GASTROENTEROLOGY, V130, pA506; JONES R, 1989, BRIT MED J, V298, P30; Jung HK, 2007, ALIMENT PHARM THERAP, V26, P453, DOI 10.1111/j.1365-2036.2007.03366.x; Kaji M, 2010, J GASTROEN HEPATOL, V25, P1151, DOI 10.1111/j.1440-1746.2010.06249.x; Khan MA, 2014, DIGEST DIS SCI, V60, P1169; Khoshkrood-Mansoori B, 2009, J GASTROINTEST LIVER, V18, P413; Kim SE, 2014, J CLIN GASTROENTEROL, V48, pE12, DOI 10.1097/MCG.0b013e31828f4bc9; Kinoshita Y, 2011, INTERNAL MED, V50, P2269, DOI 10.2169/internalmedicine.50.5678; Kubo M, 2011, NEUROGASTROENT MOTIL, V23, P249, DOI 10.1111/j.1365-2982.2010.01640.x; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lin S, 2014, EUR J GASTROEN HEPAT, V26, P1176, DOI 10.1097/MEG.0000000000000171; Manabe N, 2011, J GASTROEN HEPATOL, V26, P27, DOI 10.1111/j.1440-1746.2011.06628.x; Manabe N, 2010, SCAND J GASTROENTERO, V45, P567, DOI 10.3109/00365521003592663; Matsuzaki J, 2012, NEUROGASTROENT MOTIL, V24, DOI 10.1111/j.1365-2982.2011.01859.x; Min BH, 2014, DIGEST DIS SCI, V59, P2721, DOI 10.1007/s10620-014-3243-y; Miwa Hiroto, 2008, Patient Prefer Adherence, V2, P143; Miwa H, 2015, J GASTROENTEROL, V50, P125, DOI 10.1007/s00535-014-1022-3; MULLAN A, 1994, EUR J CLIN NUTR, V48, P97; Noh Young Wook, 2010, J Neurogastroenterol Motil, V16, P148, DOI 10.5056/jnm.2010.16.2.148; Oshima T, 2015, J GASTROENTEROL, V50, P744, DOI 10.1007/s00535-014-1014-3; Oshima Tadayuki, 2013, Nihon Naika Gakkai Zasshi, V102, P4; Oshima T, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-13; Perveen Irin, 2014, Indian J Gastroenterol, V33, P265, DOI 10.1007/s12664-014-0447-1; Rasmussen S, 2015, SCAND J GASTROENTERO, V50, P162, DOI 10.3109/00365521.2014.983157; SCHLEMPER RJ, 1993, SCAND J GASTROENTERO, V28, P33, DOI 10.3109/00365529309101573; Shaib Y, 2004, AM J GASTROENTEROL, V99, P2210, DOI 10.1111/j.1572-0241.2004.40052.x; Shinozaki M, 2008, J CLIN GASTROENTEROL, V42, P1010, DOI 10.1097/MCG.0b013e318150d006; Sorouri Majid, 2010, Saudi J Gastroenterol, V16, P154, DOI 10.4103/1319-3767.65183; Stanghellini V, 1999, Scand J Gastroenterol Suppl, V231, P29; Tahara T, 2008, DIGEST DIS SCI, V53, P642, DOI 10.1007/s10620-007-9923-0; Tahara Tomomitsu, 2010, J Clin Gastroenterol, V44, pe1, DOI 10.1097/MCG.0b013e3181b5745e; Toyoshima F, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-88; Westbrook JI, 2002, SCAND J GASTROENTERO, V37, P917, DOI 10.1080/003655202760230874; Wigington WC, 2005, CLIN GASTROENTEROL H, V3, P647, DOI 10.1053/S1542-3565(05)00367-8	102	1	1	KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY	GANGNAM-GU	RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU, SEOUL 135-839, SOUTH KOREA	2093-0879	2093-0887		J NEUROGASTROENTEROL	J. Neurogastroenterol. Motil.	JUL	2015	21	3					320	329		10.5056/jnm14165		10	Gastroenterology & Hepatology; Clinical Neurology	Gastroenterology & Hepatology; Neurosciences & Neurology	CM5EB	WOS:000357708500004		
J	Fukumoto, M; Nakano, T; Ueda, Y; Itami, K; Kubo, H				Fukumoto, M.; Nakano, T.; Ueda, Y.; Itami, K.; Kubo, H.			Deuterium retention in tungsten coating layers irradiated with deuterium and carbon ions	JOURNAL OF NUCLEAR MATERIALS			English	Article							THERMAL-DESORPTION; HYDROGEN; DISCHARGES	The effects of carbon ion fraction on deuterium retention in tungsten coating layers were investigated by irradiating the layers with mixed deuterium and carbon ion beams. The mixed ion beams had atomic carbon fractions of up to 3.2% and the sample temperature was either 500 or 700 K. Graphite was formed in the tungsten coating layer at the both temperatures; however, tungsten carbide and ditungsten carbide were not formed at the both temperatures. At 500 K, deuterium was trapped at intrinsic defects and carbon was accumulated in the tungsten coating layer. At 700 K, although trapping deuterium at intrinsic defects was difficult, deuterium was trapped predominantly at carbon accumulated in the tungsten coating layer. Analysis of deuterium desorption spectrum by multipeak fitting suggests that deuterium was retained by C-D bonds in the tungsten coating layer at 700 K. (C) 2015 Elsevier B.V. All rights reserved.	[Fukumoto, M.; Nakano, T.; Itami, K.; Kubo, H.] Japan Atom Energy Agcy, Naka, Ibaraki 3110193, Japan; [Ueda, Y.] Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Fukumoto, M (reprint author), Japan Atom Energy Agcy, 801-1 Mukoyama, Naka, Ibaraki 3110193, Japan.	fukumoto.masakatsu@jaea.go.jp			Japan Society for the Promotion of Science (JSPS) [24760710]	The authors are very grateful to Mr. Wada in Osaka University for XRD measurements of the irradiated tungsten coating layer. This work was supported in part by a Grant-in-Aid for Young Scientists (B) 24760710 from Japan Society for the Promotion of Science (JSPS).	Alimov VK, 2011, J NUCL MATER, V415, pS628, DOI 10.1016/j.jnucmat.2010.08.054; Alimov VK, 2011, J NUCL MATER, V414, P479, DOI 10.1016/j.jnucmat.2011.05.041; Brezinsek S, 2013, J NUCL MATER, V438, pS303, DOI 10.1016/j.jnucmat.2013.01.122; Ogorodnikova OV, 2008, J APPL PHYS, V103, DOI 10.1063/1.2828139; Yahiro Y, 2009, J NUCL MATER, V386-88, P784, DOI 10.1016/j.jnucmat.2008.12.219; ELEVELD H, 1994, J NUCL MATER, V212, P1421, DOI 10.1016/0022-3115(94)91062-6; Ogorodnikova OV, 2011, J NUCL MATER, V419, P194, DOI 10.1016/j.jnucmat.2011.07.023; Sharma SK, 2012, FUSION ENG DES, V87, P77, DOI 10.1016/j.fusengdes.2011.10.001; Poon M, 2008, J NUCL MATER, V374, P390, DOI 10.1016/j.jnucmat.2007.09.028; Ogorodnikova OV, 2003, J NUCL MATER, V313, P469, DOI 10.1016/S0022-3115(02)01375-2; Sugiyama K, 2010, NUCL FUSION, V50, DOI 10.1088/0029-5515/50/3/035001; Atsumi H, 2003, J ALLOY COMPD, V356, P705, DOI 10.1016/S0925-8388(03)00290-1; Fukumoto M, 2011, J NUCL MATER, V415, pS705, DOI 10.1016/j.jnucmat.2010.12.310; Fukumoto M., 2013, PLASMA FUSION RES, V8; Fukumoto M., 2010, J PLASMA FUSION RES, V9, P369; GOLDSCHMIDT HJ, 1963, J LESS-COMMON MET, V5, P181, DOI 10.1016/0022-5088(63)90012-2; Mehrer H., 2007, DIFFUSION SOLIDS, P553; National Institute for Materials Science, IN MAT DAT AT WORK; Niu YR, 2010, FUSION ENG DES, V85, P1521, DOI 10.1016/j.fusengdes.2010.04.032; Otsuka T, 2011, PHYS SCRIPTA, VT145, DOI 10.1088/0031-8949/2011/T145/014035; Pitts RA, 2013, J NUCL MATER, V438, pS48, DOI 10.1016/j.jnucmat.2013.01.008; Shibahara T, 2006, J NUCL MATER, V357, P115, DOI 10.1016/j.jnucmat.2006.06.001; Shibahara T, 2006, NUCL FUSION, V46, P841, DOI 10.1088/0029-5515/46/10/001; Shimada T., 2004, J NUCL MATER, V329-333, P747; Shimada T, 2003, J NUCL MATER, V313, P204, DOI 10.1016/S0022-3115(02)01447-2; Tobita K, 2009, J NUCL MATER, V386-88, P888, DOI 10.1016/j.jnucmat.2008.12.197; Ueda Y, 2004, NUCL FUSION, V44, P62, DOI 10.1088/0029-5515/44/1/007; Yhe J.J., 1996, DIAM RELAT MATER, V5, P1195; Ziegler J. F., 1985, STOPPING RANGE IONS	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	JUL	2015	462						354	359		10.1016/j.jnucmat.2015.02.041		6	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CM2XP	WOS:000357545900041		
J	Perez-Bergquist, AG; Nozawa, T; Shih, CH; Leonard, KJ; Snead, LL; Katoh, Y				Perez-Bergquist, Alejandro G.; Nozawa, Takashi; Shih, Chunghao; Leonard, Keith J.; Snead, Lance L.; Katoh, Yutai			High dose neutron irradiation of Hi-Nicalon Type S silicon carbide composites, Part 1: Microstructural evaluations	JOURNAL OF NUCLEAR MATERIALS			English	Article							RESEARCH-AND-DEVELOPMENT; SIC/SIC COMPOSITES; INDUCED AMORPHIZATION; FUSION APPLICATIONS; SIC FIBERS; GRAPHITE; TEMPERATURE; CARBON	Over the past decade, significant progress has been made in the development of silicon carbide (SiC) composites, composed of near-stoichiometric SiC fibers embedded in a crystalline SiC matrix, to the point that such materials can now be considered nuclear grade. Recent neutron irradiation studies of Hi-Nicalon Type S SiC composites showed excellent radiation response at damage levels of 30-40 dpa at temperatures of 300-800 degrees C. However, more recent studies of these same fiber composites irradiated to damage levels of >70 dpa at similar temperatures showed a marked decrease in ultimate flexural strength, particularly at 300 degrees C. Here, electron microscopy is used to analyze the microstructural evolution of these irradiated composites in order to investigate the cause of the degradation. While minimal changes were observed in Hi-Nicalon Type S SiC composites irradiated at 800 degrees C, substantial microstructural evolution is observed in those irradiated at 300 degrees C. Specifically, carbonaceous particles in the fibers grew by 25% compared to the virgin case, and severe cracking occurred at interphase layers. (C) 2014 Elsevier B.V. All rights reserved.	[Perez-Bergquist, Alejandro G.; Shih, Chunghao; Leonard, Keith J.; Snead, Lance L.; Katoh, Yutai] Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; [Perez-Bergquist, Alejandro G.] Univ Tennessee, Knoxville, TN USA; [Nozawa, Takashi] Japan Atom Energy Agcy, Rokkasho, Aomori, Japan	Perez-Bergquist, AG (reprint author), Oak Ridge Natl Lab, POB 2008 MS6138, Oak Ridge, TN 37831 USA.	perezbergqag@ornl.gov			Office of Fusion Energy Sciences, U.S. Department of Energy [AC05-00OR22725]; UT-Battelle, LLC; Scientific User Facilities Division, Office of Basic Energy Sciences, U.S. Department of Energy	This research was sponsored by the Office of Fusion Energy Sciences, U.S. Department of Energy under Contract DE-AC05-00OR22725 with UT-Battelle, LLC. Samples were irradiated in the High Flux Isotope Reactor, an Office of Science User Facility. The TEM characterization utilized ORNL's Shared Research Equipment (ShaRE) User Facility, which is sponsored by the Scientific User Facilities Division, Office of Basic Energy Sciences, U.S. Department of Energy.	Abe H, 1997, NUCL INSTRUM METH B, V127, P681, DOI 10.1016/S0168-583X(96)01155-X; Snead LL, 1999, J NUCL MATER, V273, P213, DOI 10.1016/S0022-3115(99)00023-9; Sawan ME, 2013, J NUCL MATER, V442, pS370, DOI 10.1016/j.jnucmat.2012.11.018; Snead LL, 2008, J NUCL MATER, V381, P55, DOI 10.1016/j.jnucmat.2008.07.033; Newsome G, 2007, J NUCL MATER, V371, P76, DOI 10.1016/j.jnucmat.2007.05.007; Snead LL, 2011, J NUCL MATER, V417, P330, DOI 10.1016/j.jnucmat.2011.03.005; Kishimoto H, 2005, MATER TRANS, V46, P1923, DOI 10.2320/matertrans.46.1923; Katoh Y, 2011, J NUCL MATER, V417, P416, DOI 10.1016/j.jnucmat.2011.02.006; Fenici P, 1998, J NUCL MATER, V258, P215, DOI 10.1016/S0022-3115(98)00303-1; EVANS AG, 1994, J MATER SCI, V29, P3857, DOI 10.1007/BF00355946; Katoh Y, 2006, FUSION ENG DES, V81, P937, DOI 10.1016/j.fusengdes.2005.08.045; Snead LL, 1996, J NUCL MATER, V233, P26, DOI 10.1016/S0022-3115(96)00318-2; WU CH, 1994, J NUCL MATER, V208, P1, DOI 10.1016/0022-3115(94)90191-0; Katoh Y, 2011, J NUCL MATER, V417, P400, DOI 10.1016/j.jnucmat.2010.12.088; PRICE RJ, 1977, NUCL TECHNOL, V35, P320; Snead LL, 2007, J NUCL MATER, V367, P677, DOI 10.1016/j.jnucmat.2007.03.097; CAUSEY RA, 1995, J NUCL MATER, V220, P823, DOI 10.1016/0022-3115(94)00623-7; Gosset D, 2013, J AM CERAM SOC, V96, P1622, DOI 10.1111/jace.12174; Katoh Y, 2007, J NUCL MATER, V367, P659, DOI 10.1016/j.jnucmat.2007.03.032; Katoh Y, 2004, J NUCL MATER, V329, P587, DOI 10.1016/j.jnucmat.2004.04.157; Katoh Y., 2012, ORNLTM2012459; Katoh Y, 2007, J NUCL MATER, V367, P774, DOI 10.1016/j.jnucmat.2007.03.083; Kohyama A, 2000, J NUCL MATER, V283, P20, DOI 10.1016/S0022-3115(00)00156-2; MOTTA AT, 1992, J NUCL MATER, V195, P277, DOI 10.1016/0022-3115(92)90519-Q; Noda T, 2002, FUSION ENG DES, V61-62, P711, DOI 10.1016/S0920-3796(02)00152-7; Nozawa T, 2011, IOP CONF SER-MAT SCI, V18, DOI 10.1088/1757-899X/18/16/162011; Nozawa T, 2004, J NUCL MATER, V329, P544, DOI 10.1016/j.jnucmat.2004.04.114; PRICE RJ, 1969, J NUCL MATER, V33, P17, DOI 10.1016/0022-3115(69)90003-8; Robertson J, 2003, SEMICOND SCI TECH, V18, pS12, DOI 10.1088/0268-1242/18/3/302; Sauder C, 2007, J AM CERAM SOC, V90, P1146, DOI 10.1111/j.1551-2916.2007.01535.x; Snead LL, 2000, J NUCL MATER, V283, P551, DOI 10.1016/S0022-3115(00)00235-X; Snead LL, 2007, J NUCL MATER, V371, P329, DOI 10.1016/j.jnucmat.2007.05.016; Yan J. Y., 2004, J NUCL MATER, V329-333, P513	33	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	JUL	2015	462						443	449		10.1016/j.jnucmat.2014.06.038		7	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CM2XP	WOS:000357545900053		
J	Katoh, Y; Nozawa, T; Shih, CH; Ozawa, K; Koyanagi, T; Porter, W; Snead, LL				Katoh, Yutai; Nozawa, Takashi; Shih, Chunghao; Ozawa, Kazumi; Koyanagi, Takaaki; Porter, Wally; Snead, Lance L.			High-dose neutron irradiation of Hi-Nicalon Type S silicon carbide composites. Part 2: Mechanical and physical properties	JOURNAL OF NUCLEAR MATERIALS			English	Article							CERAMIC-MATRIX COMPOSITES; SIC/SIC COMPOSITES; STRUCTURAL APPLICATIONS; TEMPERATURE MONITORS; FIBER; BEHAVIOR; DESIGN	Nuclear-grade silicon carbide (SiC) composite material was examined for mechanical and thermophysical properties following high-dose neutron irradiation in the High Flux Isotope Reactor at a temperature range of 573-1073 K. The material was chemical vapor-infiltrated SiC-matrix composite with a two-dimensional satin weave Hi-Nicalon Type S SiC fiber reinforcement and a multilayered pyrocarbon/SiC interphase. Moderate (1073 K) to very severe (573 K) degradation in mechanical properties was found after irradiation to >70 dpa, whereas no evidence was found for progressive evolution in swelling and thermal conductivity. The swelling was found to recover upon annealing beyond the irradiation temperature, indicating the irradiation temperature, but only to a limited extent. The observed strength degradation is attributed primarily to fiber damage for all irradiation temperatures, particularly a combination of severe fiber degradation and likely interphase damage at relatively low irradiation temperatures. (C) 2015 Elsevier B.V. All rights reserved.	[Katoh, Yutai; Shih, Chunghao; Koyanagi, Takaaki; Porter, Wally; Snead, Lance L.] Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; [Nozawa, Takashi; Ozawa, Kazumi] Japan Atom Energy Agcy, Rokkasho, Aomori, Japan	Katoh, Y (reprint author), Oak Ridge Natl Lab, POB 2008 MS6138, Oak Ridge, TN 37831 USA.	katohy@ornl.gov			Office of Fusion Energy Sciences, U.S. Department of Energy [DE-AC05-00OR22725]; Japan Atomic Energy Agency [NFE-10-02779]; UT-Battelle, LLC	The authors acknowledge A.M. Williams, P.S. Tedder, R.A. Meisner, and H. Wang for assistance in conducting experimental research, K.A. Terrani for technical review, and D.M Counce for editorial review. This research was sponsored by the Office of Fusion Energy Sciences, U.S. Department of Energy, and Japan Atomic Energy Agency under contracts DE-AC05-00OR22725 and NFE-10-02779, respectively, with UT-Battelle, LLC. Samples were irradiated in the High Flux Isotope Reactor, an Office of Science User Facility.	Katoh Y, 2014, J NUCL MATER, V448, P448, DOI 10.1016/j.jnucmat.2013.06.040; Snead LL, 2005, J NUCL MATER, V340, P187, DOI 10.1016/j.jnucmat.2004.11.009; Katoh Y, 2010, J NUCL MATER, V403, P48, DOI 10.1016/j.jnucmat.2010.06.002; Newsome G, 2007, J NUCL MATER, V371, P76, DOI 10.1016/j.jnucmat.2007.05.007; Snead LL, 2011, J NUCL MATER, V417, P330, DOI 10.1016/j.jnucmat.2011.03.005; Yueh K, 2014, J NUCL MATER, V448, P380, DOI 10.1016/j.jnucmat.2013.12.004; Katoh Y, 2011, J NUCL MATER, V417, P416, DOI 10.1016/j.jnucmat.2011.02.006; Ivekovic A, 2013, J EUR CERAM SOC, V33, P1577, DOI 10.1016/j.jeurceramsoc.2013.02.013; Ozawa K, 2007, J NUCL MATER, V367, P713, DOI 10.1016/j.jnucmat.2007.03.033; Perez-Bergquist AG, 2015, J NUCL MATER, V462, P443, DOI 10.1016/j.jnucmat.2014.06.038; Bunsell AR, 2006, J MATER SCI, V41, P823, DOI 10.1007/s10853-006-6566-z; Hegeman JBJ, 2005, FUSION ENG DES, V75-79, P789, DOI 10.1016/j.fusengdes.2005.06.307; Katoh Y, 2012, CURR OPIN SOLID ST M, V16, P143, DOI 10.1016/j.cossms.2012.03.005; Naslain R, 2004, COMPOS SCI TECHNOL, V64, P155, DOI 10.1016/S0266-3538(03)00230-6; Katoh Y, 2011, J NUCL MATER, V417, P400, DOI 10.1016/j.jnucmat.2010.12.088; PRICE RJ, 1977, NUCL TECHNOL, V35, P320; CURTIN WA, 1991, J AM CERAM SOC, V74, P2837, DOI 10.1111/j.1151-2916.1991.tb06852.x; Raffray AR, 2001, FUSION ENG DES, V55, P55, DOI 10.1016/S0920-3796(01)00181-8; EVANS AG, 1994, J AM CERAM SOC, V77, P1425, DOI 10.1111/j.1151-2916.1994.tb09739.x; Hinoki T, 2002, J NUCL MATER, V307, P1157, DOI 10.1016/S0022-3115(02)01054-1; Katoh Y., 2002, 19 IAEA FUS EN C, pFT/P1; Katoh Y, 2004, J NUCL MATER, V329, P587, DOI 10.1016/j.jnucmat.2004.04.157; Katoh Y, 2007, J NUCL MATER, V367, P774, DOI 10.1016/j.jnucmat.2007.03.083; Kondo S, 2015, ACTA MATER, V83, P1, DOI 10.1016/j.actamat.2014.07.057; Koyanagi T, 2014, J NUCL MATER, V448, P478, DOI 10.1016/j.jnucmat.2013.10.005; Nozawa T., 2011, 15 INT C FUS REACT M; PALENTINE JE, 1980, J NUCL MATER, V92, P43, DOI 10.1016/0022-3115(80)90140-3; PRICE RJ, 1972, NUCL TECHNOL, V16, P536; Sauder C., 2014, CERAMIC MATRIX COMPO, P609; Shinavsld R.J., 2008, MECH PERFORMANCE DES; Snead LL, 2000, J NUCL MATER, V283, P551, DOI 10.1016/S0022-3115(00)00235-X; SNEAD LL, 1992, J NUCL MATER, V191, P566, DOI 10.1016/0022-3115(92)90829-A; Snead LL, 2007, J NUCL MATER, V371, P329, DOI 10.1016/j.jnucmat.2007.05.016; Snead L.L., 2003, EFFECTS RAD MAT, V1447; Yano T, 1998, J NUCL MATER, V253, P78, DOI 10.1016/S0022-3115(97)00331-0	35	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	JUL	2015	462						450	457		10.1016/j.jnucmat.2014.12.121		8	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CM2XP	WOS:000357545900054		
J	Oka, H; Sato, Y; Hashimoto, N; Ohnuki, S				Oka, Hiroshi; Sato, Yutaka; Hashimoto, Naoyuki; Ohnuki, Somei			Evaluation of multi-layered hardness in ion-irradiated stainless steel by nano-indentation technique	JOURNAL OF NUCLEAR MATERIALS			English	Article							SIZE; ZONE	Depth dependence of hardness in ion-irradiated 316 stainless steel was evaluated by the sectioning of damaged region and subsequent nano-indentation. The range of plastically deformed region by the nano-indentation was supplementarily investigated by transmission electron microscopy. When the indentation depth was the critical indentation depth, h(c) which was derived from the Nix-Gao plot, the dislocation structure was observed from the specimen surface to right below the bottom of the ion-irradiated region. To verify the depth dependence of hardness, the "multi-layer model" was introduced in this study. The multi-layer model is based on the following assumptions; (1) the ion-irradiated region can be divided into sub-layers having their own local hardness, H-L; (2) the hardness can be the product off and H-L in each sub-layer where f is the volume fraction of a deformation zone; and (3) the deformation zone can be a hemisphere. Eventually, through the sectioning and following nano-indentation, H-L, in each sub-layer was experimentally evaluated. Further the correlation between the displacement damage and the irradiation hardening Delta H in this study agreed with that of neutron irradiation experiments. (C) 2015 Elsevier B.V. All rights reserved.	[Oka, Hiroshi; Sato, Yutaka; Hashimoto, Naoyuki; Ohnuki, Somei] Hokkaido Univ, Fac Engn, Kita Ku, Sapporo, Hokkaido 0608628, Japan	Oka, H (reprint author), Hokkaido Univ, Fac Engn, Kita Ku, N-13,W-8, Sapporo, Hokkaido 0608628, Japan.	hiroshi_oka@eng.hokudai.ac.jp			 [24.395]	Authors are grateful to Prof. Ryuta Kasada for many useful discussions and to Prof. Shigeharu Ukai for his permission to use nano-indenter. This work was supported by Grant-in-Aid for JSPS Fellows (Grant Number 24.395).	SAMUELS LE, 1957, J MECH PHYS SOLIDS, V5, P125, DOI 10.1016/0022-5096(57)90056-X; Kasada R, 2011, FUSION ENG DES, V86, P2658, DOI 10.1016/j.fusengdes.2011.03.073; Durst K, 2005, SCRIPTA MATER, V52, P1093, DOI 10.1016/j.scriptamat.2005.02.009; Nix WD, 1998, J MECH PHYS SOLIDS, V46, P411, DOI 10.1016/S0022-5096(97)00086-0; Huang Y, 2006, J MECH PHYS SOLIDS, V54, P1668, DOI 10.1016/j.jmps.2006.02.002; Yabuuchi K, 2014, J NUCL MATER, V446, P142, DOI 10.1016/j.jnucmat.2013.12.009; Inamura M., 1990, SEISAN KENKYU, V42, P257; Kodama M., 1997, P 8 INT S ENV DEGR M, P833; Okada A, 1996, J NUCL MATER, V233, P1016, DOI 10.1016/S0022-3115(96)00115-8; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	JUL	2015	462						470	474		10.1016/j.jnucmat.2015.01.062		5	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CM2XP	WOS:000357545900056		
J	Oyama, Y; Fukahori, H				Oyama, Yumiko; Fukahori, Hiroki			A literature review of factors related to hospital nurses' health-related quality of life	JOURNAL OF NURSING MANAGEMENT			English	Article						health personnel; health-related quality of life; literature review; narrative review; nurses	PSYCHOSOCIAL WORK-ENVIRONMENT; MENTAL-HEALTH; DEMOGRAPHIC CHARACTERISTICS; WORKPLACE STRESSORS; OCCUPATIONAL STRESS; PREDICTORS; CHINA; JAPAN; ABSENTEEISM; VALIDATION	AimTo conduct a literature review in order to determine the predictors of nurses' health-related quality of life and to clarify the implications for nursing management and future study in this area. BackgroundGood health is essential to the performance of health care workers. EvaluationRelevant studies were retrieved from PubMed, Medline, CINAHL, the Japan Medical Abstract Society, and the Technology Information Aggregator, Electronic. The studies selected for this review were published in English or Japanese between 1995 and 2012, investigated nurses' health-related quality of life. The identified predictive factors of each study were categorised according to type. Key issuesBased on the criteria, 22 studies were reviewed. The predictive factors of nurses' health-related quality of life were classified into eight categories. ConclusionsAge and occupational stress should be considered when examining unknown predictive factors of nurses' health-related quality of life. In addition, it may be useful to adopt a conceptual framework and consider patient and organisational factors in future research. Implications for nursing managementIt is necessary to identify nurses' occupational stressors and consider age during job placement in order to support their health.	[Oyama, Yumiko] Tokyo Med & Dent Univ, Doctoral Program Comprehens Hlth Nursing Sci, Tokyo 1138510, Japan; [Fukahori, Hiroki] Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Dept Syst Management Nursing, Tokyo 1138510, Japan	Oyama, Y (reprint author), Tokyo Med & Dent Univ, Doctoral Program Comprehens Hlth Nursing Sci, Dept Syst Management Nursing, Grad Sch Hlth Care Sci,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	yum_kanr@tmd.ac.jp			Policy Based Medical Service Foundation in Japan	This study was supported by a grant from the Policy Based Medical Service Foundation in Japan.	Escriba-Aguir V, 2007, STRESS HEALTH, V23, P153, DOI 10.1002/smi.1131; Lambert VA, 2007, INT NURS REV, V54, P85, DOI 10.1111/j.1466-7657.2007.00512.x; Letvak S, 2005, NURS OUTLOOK, V53, P66, DOI 10.1016/j.outlook.2004.09.005; Lambert VA, 2004, INT J NURS STUD, V41, P671, DOI 10.1016/j.ijnurstu.2004.02.003; Lambert VA, 2007, NURS HEALTH SCI, V9, P120, DOI 10.1111/j.1442-2018.2007.00316.x; Cimete G, 2003, J NURS CARE QUAL, V18, P151; Davey MM, 2009, J NURS MANAGE, V17, P312, DOI 10.1111/j.1365-2834.2008.00958.x; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X; Shiao JSC, 2010, INT ARCH OCC ENV HEA, V83, P823, DOI 10.1007/s00420-009-0501-y; Trinkoff AM, 2001, J OCCUP ENVIRON MED, V43, P355, DOI 10.1097/00043764-200104000-00012; Fronteira I, 2011, J CLIN NURS, V20, P2404, DOI 10.1111/j.1365-2702.2011.03721.x; Arimura M, 2010, IND HEALTH, V48, P811, DOI 10.2486/indhealth.MS1093; Chang EML, 2007, INT J NURS STUD, V44, P1354, DOI 10.1016/j.ijnurstu.2006.06.003; Wang R, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-292; Chang EM, 2006, J PROF NURS, V22, P30, DOI 10.1016/j.profnurs.2005.12.002; Happell B, 2013, J NURS MANAGE, V21, P638, DOI 10.1111/jonm.12037; Cheng YW, 2000, BRIT MED J, V320, P1432, DOI 10.1136/bmj.320.7247.1432; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Lambert VA, 2004, INT J NURS STUD, V41, P85, DOI 10.1016/S0020-7489(03)00080-4; Asaoka S., 2011, RES REPORT MEIJI YAS, V26, P15; Aust B, 2007, INT J NURS STUD, V44, P814, DOI 10.1016/j.ijnurstu.2006.01.008; Centers for Disease Control and Prevention, 2000, MEAS HLTH DAYS POP A; Estryn-Behar M., 2005, HLTH SATISFACTION HE; Fukuhara S, 2004, MANUAL SF 8 JAPANESE; Japanese Federation of Medical Workers' Union, 2010, REP ACT WORK COND SU; Japanese Nursing Association, 2010, REP ACT SURV NIGHT S; Japanese Nursing Association, 2008, REP ACT SURV OV NIGH; Jordan K, 2003, J EPIDEMIOL COMMUN H, V57, P109, DOI 10.1136/jech.57.2.109; Kerr M., 2002, MONITORING HLTH NURS; LaMontagne AD, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-181; Landa JMA, 2008, INT J NURS STUD, V45, P888, DOI 10.1016/j.ijnurstu.2007.03.005; Lang T. A., 2011, REPORT STAT MED ANNO, V2nd, P215; Leary Simon, 2007, Health Serv J, V117, P26; McDowell I., 2006, MEASURING HLTH GUIDE; Mizunuma K., 2006, J HAMAMATSU ROSAI HO, V2005, P108; Musshauser D, 2006, J OCCUP HEALTH, V48, P383, DOI 10.1539/joh.48.383; O'Brien-Pallas L, 2004, EVIDENCE BASED STAND; O'Brien-Pallas L., 2011, SHAPING HLTH POLICY, P231; O'Brien-Pallas L, 2011, J CLIN NURS, V20, P1640, DOI 10.1111/j.1365-2702.2010.03391.x; Shen HC, 2005, J OCCUP HEALTH, V47, P218, DOI 10.1539/joh.47.218; Shields M., 2006, FINDING 2005 NATL SU; Silva AA, 2010, REV SAUDE PUBL, V44, P718, DOI 10.1590/s0034-89102010000400016; Ueda E., 2006, J JAPAN SOC NURSING, V29, P39; Uehara K., 2008, J JAPANESE NURSING S, V39, P33; Wilkins Kathryn, 2008, Health Rep, V19, P7; World Health Organization (WHO) Division of Mental Health and Prevention of Substance Abuse, 1997, WHOQOL MEAS QUAL LIF; Wu SY, 2011, ARCH ENVIRON OCCUP H, V66, P193, DOI 10.1080/19338244.2010.539639; Wu SY, 2010, INT ARCH OCC ENV HEA, V83, P753, DOI 10.1007/s00420-009-0496-4; Wu SY, 2011, IND HEALTH, V49, P158, DOI 10.2486/indhealth.MS1160; Wu SY, 2010, AM J IND MED, V53, P1170, DOI 10.1002/ajim.20864	51	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0966-0429	1365-2834		J NURS MANAGE	J. Nurs. Manag.	JUL	2015	23	5					661	673		10.1111/jonm.12194		13	Management; Nursing	Business & Economics; Nursing	CM2QL	WOS:000357526500014		
J	Irie, K; Tomofuji, T; Ekuni, D; Morita, M; Shimazaki, Y; Darveau, RP				Irie, Koichiro; Tomofuji, Takaaki; Ekuni, Daisuke; Morita, Manabu; Shimazaki, Yoshihiro; Darveau, Richard P.			Impact of Oral Commensal Bacteria on Degradation of Periodontal Connective Tissue in Mice	JOURNAL OF PERIODONTOLOGY			English	Article						Connective tissue; immunity; innate; inflammation; periodontitis	JUNCTIONAL EPITHELIUM; MATRIX METALLOPROTEINASES; INNATE DEFENSE; HOMEOSTASIS; INFLAMMATION; EXPRESSION; MICROBIOTA; RESPONSES; DISEASE; SYSTEM	Background: Innate and adaptive immunosurveillance mechanisms in response to the normal commensal bacteria can affect periodontal innate defense status. However, it is still unclear how commensal bacteria contribute to the inflammatory responses of junctional epithelium (JE) and periodontal connective tissue (PCT). The aim of the present study is to investigate the contribution of commensal bacteria on inflammatory responses in JE and PCT in mice. Methods: The periodontal tissue of germ-free (GF) and specific-pathogen-free (SPF) mice were compared at age 11 to 12 weeks (n = 6 per group). In this study, the number of neutrophils and expression of intercellular adhesion molecule (ICAM)-1, fibroblast growth factor receptor (FGFR)-1, matrix metalloproteinase (MMP)-1, and MMP-8 within the JE and the PCT are evaluated. The collagen density was also determined in PCT stained with picrosirius red (PSR). PSR staining combined with or without polarized light microscopy has been used to assess the organization and maturation of collagen matrix. Results: In the present findings, the area of JE in SPF mice was significantly greater than that in GF mice (P <0.05). In addition, the JE and PCT in SPF mice showed greater migration of neutrophils and higher expression of ICAM-1, FGFR-1, MMP-1, and MMP-8 than those in GF mice (P <0.05). Furthermore, the density of collagen in PCT in SPF mice was lower compared to GF mice (P <0.05). Conclusion: These results indicate that commensal bacteria induced a low-grade inflammatory state in JE and that such conditions may contribute to degradation of collagen in PCT in mice.	[Irie, Koichiro; Shimazaki, Yoshihiro] Aichi Gakuin Univ, Sch Dent, Dept Prevent Dent & Dent Publ Hlth, Nagoya, Aichi 4648650, Japan; [Irie, Koichiro; Darveau, Richard P.] Univ Washington, Sch Dent, Dept Periodont, Seattle, WA 98195 USA; [Irie, Koichiro; Tomofuji, Takaaki; Ekuni, Daisuke; Morita, Manabu] Okayama Univ, Grad Sch Med, Dept Prevent Dent & Dent & Pharmaceut Sci, Okayama, Japan	Irie, K (reprint author), Aichi Gakuin Univ, Sch Dent, Dept Prevent Dent & Dent Publ Hlth, Chikusa Ku, 1-100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.	coichiro@dpc.agu.ac.jp			National Institutes of Health/National Institute for Dental and Craniofacial Research [DE018274]	This work was supported by National Institutes of Health/National Institute for Dental and Craniofacial Research Grant DE018274 (RPD). The authors report no conflicts of interest related to this study.	Curtis MA, 2011, CELL HOST MICROBE, V10, P302, DOI 10.1016/j.chom.2011.09.008; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Sorsa T, 2006, ANN MED, V38, P306, DOI 10.1080/07853890600800103; Zenobia C, 2013, CELL MICROBIOL, V15, P1419, DOI 10.1111/cmi.12127; Irie K, 2014, J DENT RES, V93, P801, DOI 10.1177/0022034514540173; Dixon DR, 2004, PERIODONTOL 2000, V35, P53, DOI 10.1111/j.0906-6713.2004.003556.x; Yamauchi N, 2011, J ENDODONT, V37, P1636, DOI 10.1016/j.joen.2011.08.025; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Hirshberg A, 2007, ORAL ONCOL, V43, P278, DOI 10.1016/j.oraloncology.2006.03.019; Darveau RP, 2009, DNA CELL BIOL, V28, P389, DOI 10.1089/dna.2009.0864; Hayashi Y, 2010, J PERIODONTAL RES, V45, P618, DOI 10.1111/j.1600-0765.2010.01276.x; Smith K, 2007, SEMIN IMMUNOL, V19, P59, DOI 10.1016/j.smim.2006.10.002; Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197; Cosseau C, 2008, INFECT IMMUN, V76, P4163, DOI 10.1128/IAI.00188-08; Fujioka M, 2009, DENT MED RES, V29, P253; Gron B, 2002, APMIS, V110, P892, DOI 10.1034/j.1600-0463.2002.1101208.x; Hakki SS, 2009, J PERIODONTAL RES, V44, P794, DOI 10.1111/j.1600-0765.2008.01192.x; Heymann R, 2001, J PERIODONTOL, V72, P454, DOI 10.1902/jop.2001.72.4.454; Irie K, 2008, J DENT RES, V87, P456; Kasuyama K, 2012, J PERIODONTAL RES, V47, P159, DOI 10.1111/j.1600-0765.2011.01414.x; McClure R, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00386; Schroeder HE, 1997, PERIODONTOL 2000, V13, P91, DOI 10.1111/j.1600-0757.1997.tb00097.x; Tsukamoto Y, 2012, J PERIODONTAL RES, V47, P750, DOI 10.1111/j.1600-0765.2012.01490.x; Victor Dayanand John, 2014, J Int Oral Health, V6, P67	25	0	0	AMER ACAD PERIODONTOLOGY	CHICAGO	737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA	0022-3492	1943-3670		J PERIODONTOL	J. Periodont.	JUL	2015	86	7					899	905		10.1902/jop.2015.150006		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CL8EN	WOS:000357205800009		
J	Konakahara, M				Konakahara, Mayu			An analysis overlapping questions in casual ELF conversation: Cooperative or competitive contribution	JOURNAL OF PRAGMATICS			English	Article						Conversation analysis; English as a lingua franca; Casual conversation; Overlapping questions	LINGUA-FRANCA ENGLISH; TURN-TAKING; ORGANIZATION; TALK	This paper examines how international students from diverse lingua-cultural backgrounds utilize overlapping questions to actively contribute to the development of ongoing interactions on social occasions in British university settings, where English is widely used as a lingua franca (ELF). The data consist of five recordings of elicited casual conversations among friends, and they were analyzed by using a conversation analytic approach. Overlapping talk is frequently reported as a demonstration of active involvement in ELF interactions (e.g., Cogo and Dewey, 2012). Yet little has been explored about overlaps that claim for the turn space. This paper investigates this type of overlap, focusing on overlapping questions. The analysis has shown that an overlapping question results from the simultaneous application of rules 1b (a next speaker self-selects) and 1c (the current speaker continues) of turn-taking by two speakers, although the actual production is sometimes delayed (Murata, 1994). With the overlap, the interactants neither treat the overlap as interruptive nor competitive (Bilmes, 1997; Schegloff, 2000,2002). Rather, they cooperatively move the talk forward without clinging to the overlap. Their use, resolution, and response to overlapping questions are appropriate in interactions, and consequently, they are successful in achieving mutual understanding and developing interpersonal relationships. (C) 2015 Elsevier B.V. All rights reserved.	Waseda Univ, Fac Educ & Integrated Arts & Sci, Shinjuku Ku, Tokyo 1698050, Japan	Konakahara, M (reprint author), Waseda Univ, Fac Educ & Integrated Arts & Sci, Shinjuku Ku, 1-6-1 Nish Waseda, Tokyo 1698050, Japan.	mkonak@y.aoni.waseda.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI [24720273]	This study was partially supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 24720273. I would like to express my sincere gratitude to Prof. Kumiko Murata for her invaluable guidance in this field that helped shape this research. I am also very grateful to the journal editor and anonymous reviewers for their extremely valuable suggestions for improvement.	JEFFERSON G, 1986, HUM STUD, V9, P153, DOI 10.1007/BF00148125; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Bjorkman B, 2011, J PRAGMATICS, V43, P950, DOI 10.1016/j.pragma.2010.07.033; Schegloff EA, 2000, LANG SOC, V29, P1; Canagarajah S, 2007, MOD LANG J, V91, P923, DOI 10.1111/j.1540-4781.2007.00678.x; House J, 2003, J SOCIOLING, V7, P556, DOI 10.1111/j.1467-9841.2003.00242.x; GOODWIN C, 1980, SOCIOL INQ, V50, P272, DOI 10.1111/j.1475-682X.1980.tb00023.x; Bilmes J, 1997, LANG SOC, V26, P507; Bjorge AK, 2012, APPL LINGUIST, V33, P406, DOI 10.1093/applin/ams015; Brown Gillian, 1983, DISCOURSE ANAL; Cogo A., 2012, ANAL ENGLISH LINGUA; Cogo Alessia, 2009, ENGLISH LINGUA FRANC, P254; Davies M. B., 2007, DOING SUCCESSFUL RES; Dewey M., 2007, INT J APPL LINGUISTI, V17, P332, DOI DOI 10.1111/J.1473-4192.2007.00177.X; Eggins S., 1997, ANAL CASUAL CONVERSA; Faerch Claus, 1983, STRATEGIES INTERLANG; Firth A, 1996, J PRAGMATICS, V26, P237, DOI 10.1016/0378-2166(96)00014-8; Firth A, 2009, INTERCULT PRAGMAT, V6, P147, DOI 10.1515/IPRG.2009.009; Firth Alan, 1990, WORLD ENGLISH, V9, P269, DOI 10.1111/j.1467-971X.1990.tb00265.x; Firth Alan, 2013, ENCY APPL LINGUISTIC, P1043; GOLDBERG JA, 1990, J PRAGMATICS, V14, P883, DOI 10.1016/0378-2166(90)90045-F; Goodwin Charles, 1979, EVERYDAY LANGUAGE ST, P97; Grice Herbert P., 1975, PHILOS LANGUAGE, P165; Heath Christian, 2013, HDB CONVERSATION ANA, P283; Hepburn Alexa, 2013, CONVERSATION ANAL, P57; Heritage J, 1984, STRUCTURES SOCIAL AC, P299, DOI DOI 10.1017/CB09780511665868; Higher Education Statistics Agency, 2014, HIGH ED STUD ENR QUA; House Juliane, 2002, EUROSLA YB, V2, P243; Jefferson G, 1984, DISCOURSE ANAL NATUR, P11; Jenkins J., 2014, ENGLISH LINGUA FRANC; Jenks CJ, 2012, APPL LINGUIST, V33, P386, DOI 10.1093/applin/ams014; Kalocsai Karolina, 2011, LATEST TRENDS ENGLIS, P113; Kaur J., 2009, ENGLISH LINGUA FRANC; Kaur J, 2011, J PRAGMATICS, V43, P2704, DOI 10.1016/j.pragma.2011.04.012; Knapp Karlfried, 2002, LINGUA FRANCA COMMUN, P217; Kordon Kathrin, 2006, VIENNA ENGLISH WORKI, V15, P58; Lerner G. H., 2002, LANGUAGE TURN SEQUEN, P225; Levinson S, 1983, PRAGMATICS; Lichtkoppler Julia, 2007, VIENNA ENGLISH WORKI, V16, P39; Mauranen Anna, 2007, LANGUAGE DISCIPLINE, P243; Mauranen Anna, 2006, INT J SOCIOL LANG, V177, P123; McNeill D., 1992, HAND MIND WHAT GESTU; Meierkord Christiane, 2000, INTERPRETING SUCCESS; Murata Kumiko, 1994, CROSS CULTURAL APPRO; Perakyla A., 2004, QUALITATIVE RES THEO, P283; Perakyla A., 2011, QUALITATIVE RES, P365; Rossano F., 2013, HDB CONVERSATION ANA, P308; Schegloff E. A., 2002, HDB SOCIOLOGICAL THE, P287; Schegloff E. A., 1973, SEMIOTICA, V8, P289, DOI 10.1515/semi.1973.8.4.289; Schegloff Emanuel A, 1984, STRUCTURES SOCIAL AC, P266; Schiffrin Deborah, 1987, DISCOURSE MARKERS; Seedhouse Paul, 2005, APPL CONVERSATION AN, P251; Seidlhofer B., 2011, UNDERSTANDING ENGLIS; Seidlhofer B, 2009, WORLD ENGLISH, V28, P236, DOI 10.1111/j.1467-971X.2009.01592.x; Seidlhofer B., 2001, INT J APPL LINGUISTI, V11, P133, DOI DOI 10.1111/1473-4192.00011; Seidlhofer Barbara, 2014, 4 WAS ELF INT WORKSH; Tannen Deborah, 2007, YOU JUST DONT UNDERS; ten Have P., 2007, DOING CONVERSATION A; THOMAS J, 1983, APPL LINGUIST, V4, P91, DOI 10.1093/applin/4.2.91; WEST C, 1977, SOC PROBL, V24, P521, DOI 10.1525/sp.1977.24.5.03a00040; West Candace, 1983, LANGUAGE GENDER SOC, P102; Widdowson H., 2003, DEFINING ISSUES ENGL; Widdowson Henry G., 2014, 7 INT C ENGL LING FR; Wolfartsberger Anita, 2011, LATEST TRENDS ELF RE, P163	64	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-2166	1879-1387		J PRAGMATICS	J. Pragmat.	JUL	2015	84						37	53		10.1016/j.pragma.2015.04.014		17	Linguistics; Language & Linguistics	Linguistics	CM5YC	WOS:000357763900004		
J	Samata, H; Imanaka, S; Hanioka, M; Ozawa, TC				Samata, Hiroaki; Imanaka, Shungo; Hanioka, Masashi; Ozawa, Tadashi C.			Yellow luminescence of co-doped gadolinium oxyhydroxide	JOURNAL OF RARE EARTHS			English	Article						gadolinium oxyhydroxide; phosphor; co-doping; yellow luminescence; rare earths	RARE-EARTH OXYHYDROXIDES; ENERGY-TRANSFER; CRYSTALS; BI3+; SENSITIZATION; PHOSPHORS; NANORODS; EUROPIUM	Crystals of co-doped gadolinium oxyhydroxide (GdOOH), Gd0.98Eu0.02-xTbxOOH and Gd1-y-zDyyBizOOH, were synthesized by a flux method. The color coordinates in the Commission Internationale de I'Eclairage (CIE) chromaticity diagram of Gd0.98Eu0.02-xTbxOOH, obtained under 254 nm irradiation, shifted along a straight line with the changing values of x to include the yellow region. The CIE coordinates of Dy3+ doped in GdOOH were located in the yellow region, while the emission intensity of Dy3+ under 286 nm irradiation increased by more than 40 times when co-doped with Bi3+.	[Samata, Hiroaki; Imanaka, Shungo; Hanioka, Masashi] Kobe Univ, Grad Sch Maritime Sci, Higashinada Ku, Kobe, Hyogo 6580022, Japan; [Ozawa, Tadashi C.] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton, Tsukuba, Ibaraki 3050044, Japan	Samata, H (reprint author), Kobe Univ, Grad Sch Maritime Sci, Higashinada Ku, Kobe, Hyogo 6580022, Japan.	samata@maritime.kobe-u.ac.jp			JSPS KAKENHI [21560696, 24560827]	Project supported by JSPS KAKENHI (21560696, 24560827)	Adachi G, 1999, SCI RARE EARTHS; ANH TK, 1988, J LUMIN, V39, P215, DOI 10.1016/0022-2313(88)90032-4; Ju GF, 2012, J LUMIN, V132, P1853, DOI 10.1016/j.jlumin.2012.03.020; Yang J, 2007, J PHYS CHEM C, V111, P18148, DOI 10.1021/jp0767112; Chang C, 2006, NANOTECHNOLOGY, V17, P1981, DOI 10.1088/0957-4484/17/8/031; Xiao XZ, 2006, J ALLOY COMPD, V421, P252, DOI 10.1016/j.jallcom.2005.11.035; Zhang L, 2012, J ALLOY COMPD, V541, P54, DOI 10.1016/j.jallcom.2012.06.125; Pang R, 2014, J RARE EARTH, V32, P792, DOI 10.1016/S1002-0721(14)60142-3; Taguchi T, 2008, IEEJ T ELECTR ELECTR, V3, P21, DOI 10.1002/tee.20228; Samata H, 2007, J CRYST GROWTH, V304, P448, DOI 10.1016/j.jcrysgro.2007.03.025; HOLSA J, 1985, INORG CHEM, V24, P1539, DOI 10.1021/ic00204a026; Samata H, 2009, J ALLOY COMPD, V468, P566, DOI 10.1016/j.jallcom.2008.01.056; Devi CV, 2014, J ALLOY COMPD, V583, P259, DOI 10.1016/j.jallcom.2013.08.139; Xue YN, 2011, SPECTROCHIM ACTA A, V78, P607, DOI 10.1016/j.saa.2010.11.030; GONDRAND M, 1971, MATER RES BULL, V6, P239, DOI 10.1016/0025-5408(71)90036-5; HOLSA J, 1990, J PHYS CHEM-US, V94, P4835, DOI 10.1021/j100375a016; Izumi F, 2000, MATER SCI FORUM, V321-3, P198; KLEVTSOV PV, 1965, IAN SSSR NEORG MATER, V1, P912; LAMMERS MJJ, 1984, MATER RES BULL, V19, P759, DOI 10.1016/0025-5408(84)90033-3; Liu FX, 2014, J RARE EARTH, V32, P812, DOI 10.1016/S1002-0721(14)60146-0; RAGHUVANSHI GS, 1982, J PHYS CHEM SOLIDS, V43, P781, DOI 10.1016/0022-3697(82)90246-3; Samata H, 2014, J MAT SCI CHEM ENG, V2, P23; Samata H, 2015, J RARE EARTH, V33, P177, DOI 10.1016/S1002-0721(14)60399-9; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Sheina LP, 1965, IAN SSSR NEORG MATER, V1, P2219; Yamamoto A, 2012, PHOSPHOR MAT WAVELEN; YAMAMOTO O, 1985, SOLID STATE IONICS, V17, P107, DOI 10.1016/0167-2738(85)90057-8; Young R.A., 1995, RIETVELD METHOD	28	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1002-0721			J RARE EARTH	J. Rare Earths	JUL	2015	33	7					712	716		10.1016/S1002-0721(14)60475-0		5	Chemistry, Applied	Chemistry	CM1YU	WOS:000357477400006		
J	Chang, LF; Asaka, K; Zhu, ZC; Wang, YJ; Chen, HL				Chang, Longfei; Asaka, Kinji; Zhu, Zicai; Wang, Yanjie; Chen, Hualing			Electromechanical performance of ionic polymer-metal composite under electrode constraint	JOURNAL OF REINFORCED PLASTICS AND COMPOSITES			English	Article						Ionic polymer-metal composites; Young's modulus; anisotropy; electrode morphology	ACTUATORS; GELS	The electro-active performance of ionic polymer-metal composite has been widely reported to be related to the strain caused by the unbalance of local water content. In this paper, the anisotropic strain under electrode constraint in ionic polymer-metal composite during water uptake was investigated. A model was proposed to claim that existence of electrode would lead to anisotropic swelling in ionic polymer-metal composite, and the strain state was significantly affected by the electrode volume proportion as well as the elasticity ratio of the electrode and polymer. Based on Nafion-Pd ionic polymer-metal composite, experiments were carried out to measure the swelling strain during saturation process. Evaluation by the proposed model showed great agreement with the experimental observation, both of which gave the conclusion that, under the surface electrode constraint, strain in the thickness direction was much larger than that in plane directions. At last, based on a formerly-established multi-physical model, it was predicted that for ionic polymer-metal composite, the anisotropy of local swelling can lead to a 10%-15% decrease of the tip displacement.	[Chang, Longfei; Wang, Yanjie; Chen, Hualing] Xi An Jiao Tong Univ, Sch Mech Engn, Xian 710049, Shaanxi, Peoples R China; [Chang, Longfei; Wang, Yanjie; Chen, Hualing] Xi An Jiao Tong Univ, State Key Lab Mech Struct Strength & Vibrat, Xian 710049, Shaanxi, Peoples R China; [Chang, Longfei; Asaka, Kinji; Zhu, Zicai] Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Tokyo, Japan	Chen, HL (reprint author), Xi An Jiao Tong Univ, Sch Mech Engn, 28 Xianning West Rd, Xian 710049, Shaanxi, Peoples R China.	hlchen@mail.xjtu.edu.cn			Foundation for Innovative Research Groups from the National Natural Science Foundation of China [1132 1062]; China Scholarship Council	This study was financially supported by the Foundation for Innovative Research Groups from the National Natural Science Foundation of China (Grant No. 1132 1062); and China Scholarship Council.	WENG GJ, 1984, INT J ENG SCI, V22, P845, DOI 10.1016/0020-7225(84)90033-8; de Gennes PG, 2000, EUROPHYS LETT, V50, P513, DOI 10.1209/epl/i2000-00299-3; Zhao QA, 2011, J PHYS CHEM B, V115, P2717, DOI 10.1021/jp1112125; Nemat-Nasser S, 2002, J APPL PHYS, V92, P2899, DOI 10.1063/1.1495888; Lee S, 2006, SMART MATER STRUCT, V15, P1103, DOI 10.1088/0964-1726/15/4/024; Asaka K, 2000, J ELECTROANAL CHEM, V480, P186, DOI 10.1016/S0022-0728(99)00458-1; Banik MS., 2009, Patent, Patent No. [US007566297, 007566297]; Chang L, 2012, P SPIE; Chang LF, 2012, SMART MATER STRUCT, V21, DOI 10.1088/0964-1726/21/6/065018; Chang LF, 2014, J APPL PHYS, V115, DOI 10.1063/1.4884675; Colozza A, 2004, P NASA DOD C JUL, P318, DOI 10.1109/EH.2004.1310846; Enikov ET, 2005, SENSOR ACTUAT A-PHYS, V122, P264, DOI 10.1016/j.sna.2005.02.042; Hyung-Kun L, 2008, P SPIE; Jiang YL, 2000, MECH MATER, V32, P303; Krishen K, 2009, ACTA ASTRONAUT, V64, P1160, DOI 10.1016/j.actaastro.2009.01.008; Majsztrik PW, 2008, THESIS PRINCETON U U; Murthy M, 2005, P INT S, P132; Nikhil DB, 2010, Patent, Patent No. [WO2010033926, 2010033926]; Sung-Weon Y, 2009, SMART MATER STRUCT, V18; Winter M, 2005, PERIODIC TABLE WEB; Yamaue T, 2005, MACROMOLECULES, V38, P1349, DOI 10.1021/ma047944j; Zhu ZC, 2013, J APPL PHYS, V114, DOI 10.1063/1.4818412; Zhu ZC, 2011, AIP ADV, V1, DOI 10.1063/1.3668286	23	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0731-6844	1530-7964		J REINF PLAST COMP	J. Reinf. Plast. Compos.	JUL	2015	34	14					1136	1143		10.1177/0731684415588770		8	Materials Science, Composites; Polymer Science	Materials Science; Polymer Science	CM2QD	WOS:000357525600003		
J	Inoue, Y; Nakajima, A; Tanaka, E; Inoue, E; Kobayashi, A; Hoshi, D; Sugimoto, N; Seto, Y; Taniguchi, A; Momohara, S; Yamanaka, H				Inoue, Yasushi; Nakajima, Ayako; Tanaka, Eiichi; Inoue, Eisuke; Kobayashi, Akiko; Hoshi, Daisuke; Sugimoto, Naoki; Seto, Yohei; Taniguchi, Atsuo; Momohara, Shigeki; Yamanaka, Hisashi			Effect of Smoking on Remission Proportions Differs Between Male and Female Patients with Rheumatoid Arthritis: A Study Based on the IORRA Survey	JOURNAL OF RHEUMATOLOGY			English	Article						RHEUMATOID ARTHRITIS; SMOKING; SEX DIFFERENCES; DISEASE ACTIVITY; REMISSION	LARGE OBSERVATIONAL COHORT; DISEASE-ACTIVITY; RHEUMATOLOGY/EUROPEAN LEAGUE; PROVISIONAL DEFINITION; CIGARETTE-SMOKING; AMERICAN-COLLEGE; CLINICAL-TRIALS; JOINT DAMAGE; SEX; JAPAN	Objective. To analyze sex difference in the effect of smoking on remission proportions in patients with rheumatoid arthritis (RA). Methods. Subjects were Japanese patients with RA who participated in the IORRA survey conducted in April 2011 and reported smoking status. Clinical characteristics, treatment status, and the percentages achieving remission were compared between subjects stratified by sex and smoking status. To confirm the differential effects of sex and smoking status on remission, we used multivariate logistic regression models with the dependent variable as 28-joint Disease Activity Score (DAS28) remission. Results. Among 810 men and 4206 women, 162 (20.0%) and 3173 (75.4%), respectively, were never smokers; 208 (25.7%) and 314 (7.5%), respectively, were current smokers. In men, never smokers tended to have higher remission proportions than past and current smokers. In contrast, smoking status seemed not to affect remission in women. Except for lower corticosteroid dose in male never smokers, no significant differences were observed in comparing treatment status. By multivariate analyses, male past and current smokers were negatively associated with DAS28-erythrocyte sedimentation rate remission compared to male never smokers [OR 0.66 and 0.61, 95% CI (0.44-0.98) and (0.39-0.96), respectively]. However, female past and current smokers were not associated with remission compared to female never smokers [OR 1.04 and 1.19, 95% CI (0.86-1.25) and (0.91-1.54), respectively]. Conclusion. We demonstrated that the effect of smoking on remission proportions differed between men and women. Our findings suggest that both sex and smoking status are important considerations when planning a treatment strategy for patients with RA.	[Inoue, Yasushi; Nakajima, Ayako; Tanaka, Eiichi; Inoue, Eisuke; Kobayashi, Akiko; Hoshi, Daisuke; Sugimoto, Naoki; Seto, Yohei; Taniguchi, Atsuo; Momohara, Shigeki; Yamanaka, Hisashi] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo 1620054, Japan; Fukuoka Red Cross Hosp, Fukuoka, Japan	Nakajima, A (reprint author), Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10-22 Kawada Cho, Tokyo 1620054, Japan.	ayakonkj@ior.twmu.ac.jp					Abhishek A, 2010, JCR-J CLIN RHEUMATOL, V16, P15, DOI 10.1097/RHU.0b013e3181ca4a2a; Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740; Sugiyama D, 2010, ANN RHEUM DIS, V69, P70, DOI 10.1136/ard.2008.096487; Jonsson T, 1998, APMIS, V106, P970; Nakajima A, 2010, SCAND J RHEUMATOL, V39, P360, DOI 10.3109/03009741003604542; Manfredsdottir VF, 2006, RHEUMATOLOGY, V45, P734, DOI 10.1093/rheumatology/kei240; AHO K, 1991, J RHEUMATOL, V18, P1282; Saevarsdottir S, 2011, ARTHRITIS RHEUM-US, V63, P26, DOI 10.1002/art.27758; Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI 10.1136/ard.2011.149765; Matsuda Y, 2003, ARTHRIT RHEUM-ARTHR, V49, P784, DOI 10.1002/art.11465; Saag KG, 1997, ANN RHEUM DIS, V56, P463, DOI 10.1136/ard.56.8.463; Yamanaka H, 2014, MOD RHEUMATOL, V24, P33, DOI 10.3109/14397595.2013.854059; Katchamart W, 2010, ARTHRIT CARE RES, V62, P1128, DOI 10.1002/acr.20188; Westhoff G, 2008, RHEUMATOLOGY, V47, P849, DOI 10.1093/rheumatology/ken057; Hyrich KL, 2006, RHEUMATOLOGY, V45, P1558, DOI 10.1093/rheumatology/kel149; Wolfe F, 2000, J RHEUMATOL, V27, P630; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Jawaheer D, 2012, J RHEUMATOL, V39, P46, DOI 10.3899/jrheum.110548; Saevarsdottir S, 2011, ANN RHEUM DIS, V70, P469, DOI 10.1136/ard.2010.139212; Soderlin MK, 2012, SCAND J RHEUMATOL, V41, P1, DOI 10.3109/03009742.2011.599073; Willemze A, 2012, NAT REV RHEUMATOL, V8, P144, DOI 10.1038/nrrheum.2011.204; Arend WP, 2012, NAT REV RHEUMATOL, V8, P573, DOI 10.1038/nrrheum.2012.134; van der Woude D, 2009, ARTHRITIS RHEUM, V60, P2262, DOI 10.1002/art.24661; Mattey DL, 2009, J RHEUMATOL, V36, P1180, DOI 10.3899/jrheum.081096; Papadopoulos NG, 2005, CLIN EXP RHEUMATOL, V23, P861; Baka Z, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2751; Borchers AT, 2012, AUTOIMMUN REV, V11, pA413, DOI 10.1016/j.autrev.2011.11.016; Burmester GR, 2007, ARTHRITIS RHEUM, V59, P32; Felson DT, 2011, ARTHRITIS RHEUM-US, V63, P573, DOI 10.1002/art.30129; Forslind K, 2007, ANN RHEUM DIS, V66, P46, DOI 10.1136/ard.2006.056937; Fukuda Y, 2005, ANN EPIDEMIOL, V15, P365, DOI 10.1016/j.annepidem.2004.09.003; Funatogawa I, 2013, B WORLD HEALTH ORGAN, V91, P332, DOI 10.2471/BLT.12.108092; Iikuni N, 2009, J RHEUMATOL, V36, P508, DOI 10.3899/jrheum.080724; Jawaheer D, 2010, J RHEUMATOL, V37, P2475, DOI 10.3899/jrheum.091432; Khan A, 2012, ANN RHEUM DIS, V71, P1588, DOI 10.1136/annrheumdis-2012-201758; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; Molenaar ETH, 2002, ANN RHEUM DIS, V61, P351, DOI 10.1136/ard.61.4.351; Soderlin MK, 2011, SCAND J RHEUMATOL, V40, P249, DOI 10.3109/03009742.2010.541495; Sokka T, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2591; Tanaka E, 2008, ANN RHEUM DIS, V67, P1153, DOI 10.1136/ard.2007.072751; Weyand CM, 1998, ARTHRITIS RHEUM, V41, P817, DOI 10.1002/1529-0131(199805)41:5<817::AID-ART7>3.0.CO;2-S; Yamanaka Hisashi, 2007, Mod Rheumatol, V17, P283, DOI 10.1007/s10165-007-0587-6; Yamanaka Hisashi, 2007, Mod Rheumatol, V17, P98, DOI 10.1007/s10165-006-0546-7	43	1	1	J RHEUMATOL PUBL CO	TORONTO	365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA	0315-162X	1499-2752		J RHEUMATOL	J. Rheumatol.	JUL	2015	42	7					1083	1089		10.3899/jrheum.140376		7	Rheumatology	Rheumatology	CL9FF	WOS:000357280700006		
J	Scott, IC; Rijsdijk, F; Walker, J; Quist, J; Spain, SL; Tan, R; Steer, S; Okada, Y; Raychaudhuri, S; Cope, AP; Lewis, CM				Scott, Ian C.; Rijsdijk, Fruehling; Walker, Jemma; Quist, Jelmar; Spain, Sarah L.; Tan, Rachael; Steer, Sophia; Okada, Yukinori; Raychaudhuri, Soumya; Cope, Andrew P.; Lewis, Cathryn M.			Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis?	JOURNAL OF RHEUMATOLOGY			English	Article						RHEUMATOID ARTHRITIS; RADIOGRAPHY; OUTCOME MEASURES; GENETICS; HLA ANTIGENS	RANDOMIZED CONTROLLED-TRIAL; ENVIRONMENTAL RISK-FACTORS; JOINT DAMAGE; RADIOGRAPHIC PROGRESSION; DESTRUCTION; GLUCOCORTICOIDS; PREDISPOSITION; METAANALYSIS; DISABILITY; STRATEGY	Objective. Genetic variants affect both the development and severity of rheumatoid arthritis (RA). Recent studies have expanded the number of RA susceptibility variants. We tested the hypothesis that these associated with disease severity in a clinical trial cohort of patients with early, active RA. Methods. We evaluated 524 patients with RA enrolled in the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trials. We tested validated susceptibility variants - 69 single-nucleotide polymorphisms (SNP), 15 HLA-DRB1 alleles, and amino acid polymorphisms in 6 HLA molecule positions - for their associations with progression in Larsen scoring, 28-joint Disease Activity Scores, and Health Assessment Questionnaire (HAQ) scores over 2 years using linear mixed-effects and latent growth curve models. Results. HLA variants were associated with joint destruction. The *04: 01 SNP (rs660895, p = 0.0003), *04: 01 allele (p = 0.0002), and HLA-DR beta 1 amino acids histidine at position 13 (p = 0.0005) and valine at position 11 (p = 0.0012) significantly associated with radiological progression. This association was only significant in anticitrullinated protein antibody (ACPA)-positive patients, suggesting that while their effects were not mediated by ACPA, they only predicted joint damage in ACPA-positive RA. Non-HLA variants did not associate with radiograph damage (assessed individually and cumulatively as a weighted genetic risk score). Two SNP - rs11889341 (STAT4, p = 0.0001) and rs653178 (SH2B3-PTPN11, p = 0.0004) - associated with HAQ scores over 6-24 months. Conclusion. HLA susceptibility variants play an important role in determining radiological progression in early, active ACPA-positive RA. Genome-wide and HLA-wide analyses across large populations are required to better characterize the genetic architecture of radiological progression in RA.	[Scott, Ian C.; Walker, Jemma; Quist, Jelmar; Spain, Sarah L.; Lewis, Cathryn M.] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England; [Scott, Ian C.; Tan, Rachael; Cope, Andrew P.] Kings Coll London, Acad Dept Rheumatol, Ctr Mol & Cellular Biol Inflammat, London WC2R 2LS, England; [Rijsdijk, Fruehling; Lewis, Cathryn M.] Kings Coll London, Social Genet & Dev Psychiat SGDP Ctr, Inst Psychiat, London WC2R 2LS, England; Kings Coll London, Dept Rheumatol, Inst Psychiat, London WC2R 2LS, England; [Scott, Ian C.; Walker, Jemma; Quist, Jelmar; Spain, Sarah L.; Lewis, Cathryn M.] Guys Hosp, London SE1 9RT, England; [Okada, Yukinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Div, Tokyo, Japan; [Okada, Yukinori] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan; [Raychaudhuri, Soumya] Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med, Boston, MA 02115 USA; [Steer, Sophia] Kings Coll Hosp London, Dept Rheumatol, London SE5 8RX, England	Scott, IC (reprint author), Guys Hosp, Kings Coll London, Dept Med & Mol Genet, 8th Floor Tower Wing,Great Maze Pond, London SE1 9RT, England.	ian.scott@kcl.ac.uk	Spain, Sarah/G-1968-2010; 	Spain, Sarah/0000-0002-7591-8364; Scott, Ian/0000-0002-1268-9808			Choy EHS, 2008, ANN RHEUM DIS, V67, P656, DOI 10.1136/ard.2007.076299; Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076; Mewar D, 2008, ANN RHEUM DIS, V67, P980, DOI 10.1136/ard.2007.075382; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Liu CY, 2008, MOL MED, V14, P575, DOI 10.2119/2008-00056.Liu; Gremese E, 2013, ANN RHEUM DIS, V72, P858, DOI 10.1136/annrheumdis-2012-201456; Han B, 2014, AM J HUM GENET, V94, P522, DOI 10.1016/j.ajhg.2014.02.013; Sanmarti R, 2007, CLIN RHEUMATOL, V26, P1111, DOI 10.1007/s10067-006-0462-4; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Grigor C, 2004, LANCET, V364, P263, DOI 10.1016/S0140-6736(04)16676-2; Knevel R, 2012, ANN RHEUM DIS, V71, P1753, DOI 10.1136/annrheumdis-2012-201289; Plant D, 2011, ARTHRITIS RHEUM-US, V63, P645, DOI 10.1002/art.30130; Beasley TM, 2009, BEHAV GENET, V39, P580, DOI 10.1007/s10519-009-9281-0; Eyre S, 2012, NAT GENET, V44, P1336, DOI 10.1038/ng.2462; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Karlson EW, 2010, ANN RHEUM DIS, V69, P1077, DOI 10.1136/ard.2009.120170; Krabben A, 2013, ARTHRITIS RHEUM-US, V65, P3051, DOI 10.1002/art.38141; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Viatte S, 2013, J RHEUMATOL, V40, P144, DOI 10.3899/jrheum.121034; Knevel R, 2012, ANN RHEUM DIS, V71, P707, DOI 10.1136/annrheumdis-2011-200627; Teare MD, 2013, ARTHRITIS RHEUM-US, V65, P2555, DOI 10.1002/art.38064; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Brown WM, 2009, DIABETES OBES METAB, V11, P2, DOI 10.1111/j.1463-1326.2008.00997.x; Marinou I, 2010, ANN RHEUM DIS, V69, P476, DOI 10.1136/ard.2009.117721; Scott IC, 2013, RHEUMATOLOGY, V52, P856, DOI 10.1093/rheumatology/kes376; Parkes M, 2013, NAT REV GENET, V14, P661, DOI 10.1038/nrg3502; de Rooy DPC, 2014, ANN RHEUM DIS, V73, P1163, DOI 10.1136/annrheumdis-2013-203375; Knevel R, 2013, ARTHRITIS RHEUM-US, V65, P1684, DOI 10.1002/art.37938; Combe B, 2003, J RHEUMATOL, V30, P2344; Crouch DJM, 2013, EUR J HUM GENET, V21, P109, DOI 10.1038/ejhg.2012.107; Cui J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003394; Deighton C, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b702; Goekoop-Ruiterman Y P M, 2008, Arthritis Rheum, V58, pS126, DOI 10.1002/art.23364; Gorman JD, 2004, ARTHRITIS RHEUM, V50, P400, DOI 10.1002/art.20006; Guo Y, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-100; Higgins J.P.T., COCHRANE HDB SYSTEMA; Jansen LMA, 2000, ANN RHEUM DIS, V59, P223, DOI 10.1136/ard.59.3.223; Jia XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064683; Knevel R, 2014, ANN RHEUM DIS, V73, P2038, DOI 10.1136/annrheumdis-2013-204050; Pedersen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2022; Scott DL, EFFECT ANAKINRA SOLU; Scott IC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003808; Scott IC, 2011, BEST PRACT RES CL RH, V25, P447, DOI 10.1016/j.berh.2011.10.010; Seegobin SD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4439; van der Woude D, 2010, ANN RHEUM DIS, V69, P1110, DOI 10.1136/ard.2009.116384; van Steenbergen HW, 2015, ANN RHEUM DIS, V74, P876, DOI 10.1136/annrheumdis-2013-204277; Viatte S, EULAR 2014 C; Viatte S, 2014, ANN RHEUM DIS, V73, P134, DOI 10.1136/annrheumdis-2014-eular.3155; Wiles NJ, 2000, J RHEUMATOL, V27, P2360; Yarwood A, 2015, ANN RHEUM DIS, V74, P170, DOI 10.1136/annrheumdis-2013-204133	50	0	0	J RHEUMATOL PUBL CO	TORONTO	365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA	0315-162X	1499-2752		J RHEUMATOL	J. Rheumatol.	JUL	2015	42	7					1131	1140		10.3899/jrheum.141211		10	Rheumatology	Rheumatology	CL9FF	WOS:000357280700013		
J	Mori, T; Ito, Y; Kawabe, M; Iwasaki, R; Sakai, H; Murakami, M; Maruo, K				Mori, T.; Ito, Y.; Kawabe, M.; Iwasaki, R.; Sakai, H.; Murakami, M.; Maruo, K.			Three-dimensional conformal radiation therapy for inoperable massive hepatocellular carcinoma in six dogs	JOURNAL OF SMALL ANIMAL PRACTICE			English	Article							INDUCED LIVER-DISEASE; RADIOTHERAPY; HEPATITIS; CRITERIA; INJURY; TUMORS	OBJECTIVESTo evaluate the activity and tolerability of three-dimensional conformal radiation therapy (3D-CRT) in dogs with massive hepatocellular carcinoma. MATERIALS AND METHODSSix dogs with massive hepatocellular carcinoma that were ineligible for surgical resection or with owners who declined surgical resection, and underwent 3D-CRT were retrospectively reviewed. 6 to 10 Gy per fraction was prescribed at isocentre of planning target volume to a total dose of 18 to 42 Gy with 1 to 2 fractions per week for a total of 3 to 7 fractions. Follow-up examinations included physical examination, contrast-enhanced CT scan and blood analysis (complete blood count, electrolytes and serum biochemical panel). RESULTSThe median follow-up time after 3D-CRT was 534 (range, 281 to 1057) days. An objective response was observed in five of six cases. Radiation-induced liver disease developed in one dog but was asymptomatic and reversible. Toxicity was not noted in any other dog. CLINICAL SIGNIFICANCE3D-CRT appears to be a viable treatment option for dogs with inoperable massive hepatocellular carcinoma.	[Mori, T.; Ito, Y.; Kawabe, M.; Iwasaki, R.; Murakami, M.; Maruo, K.] Gifu Univ, Fac Appl Biol Sci, Dept Vet Clin Oncol, Gifu 5011193, Japan; [Sakai, H.] Gifu Univ, Fac Appl Biol Sci, Dept Vet Pathol, Gifu 5011193, Japan	Mori, T (reprint author), Gifu Univ, Fac Appl Biol Sci, Dept Vet Clin Oncol, 1-1 Yanagido, Gifu 5011193, Japan.						Park HC, 2002, INT J RADIAT ONCOL, V54, P150, DOI 10.1016/S0360-3016(02)02864-X; LAWRENCE TS, 1992, INT J RADIAT ONCOL, V23, P781; Cheng SH, 1999, J GASTROEN HEPATOL, V14, P1025, DOI 10.1046/j.1440-1746.1999.01994.x; REED GB, 1966, AM J PATHOL, V48, P597; Liu MT, 2004, JPN J CLIN ONCOL, V34, P532, DOI 10.1093/jjco/hyh089; Pan CC, 2010, INT J RADIAT ONCOL, V76, pS94, DOI 10.1016/j.ijrobp.2009.06.092; Hawkins MA, 2006, CANCER, V106, P1653, DOI 10.1002/cncr.21811; PATNAIK AK, 1980, VET PATHOL, V17, P553; INGOLD JA, 1965, AMER J ROENTGENOL RA, V93, P200; Liang SX, 2006, INT J RADIAT ONCOL, V65, P426, DOI 10.1016/j.ijrobp.2005.12.031; Takeda A, 2012, RADIOTHER ONCOL, V104, P374, DOI 10.1016/j.radonc.2011.12.008; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; LAWRENCE TS, 1995, INT J RADIAT ONCOL, V31, P1237, DOI 10.1016/0360-3016(94)00418-K; Seong J, 2009, LIVER INT, V29, P147, DOI 10.1111/j.1478-3231.2008.01873.x; Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8; LaDue T, 2001, VET RADIOL ULTRASOUN, V42, P475, DOI 10.1111/j.1740-8261.2001.tb00973.x; Liang SX, 2005, CANCER, V103, P2181, DOI 10.1002/cncr.21012; Bae SH, 2012, INT J RADIAT ONCOL, V82, pE603, DOI 10.1016/j.ijrobp.2011.09.053; Cheng JCH, 2002, INT J RADIAT ONCOL, V54, P156, DOI 10.1016/S0360-3016(02)02915-2; Huang BS, 2013, ONCOL LETT, V6, P1514, DOI 10.3892/ol.2013.1582; Kim JY, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-15; KOSOVSKY JE, 1989, J AM ANIM HOSP ASSOC, V25, P203; Kouloulias V, 2013, SCI WORLD J, DOI 10.1155/2013/780141; Liptak JM, 2004, JAVMA-J AM VET MED A, V225, P1225, DOI 10.2460/javma.2004.225.1225; OGATA KIKUAKI, 1963, TOKUSHIMA JOUR EXPTL MED, V9, P240; PATNAIK AK, 1981, VET PATHOL, V18, P427; Tse RV, 2008, CRIT REV ONCOL HEMAT, V67, P113, DOI 10.1016/j.critrevonc.2008.01.005; WHARTON JT, 1973, AM J ROENTGENOL, V117, P73; Wigg A, 2013, LIVER TRANSPLANT, V19, P1119, DOI 10.1002/lt.23714; YAMASAKI SA, 1995, AM J ROENTGENOL, V165, P79	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4510	1748-5827		J SMALL ANIM PRACT	J. Small Anim. Pract.	JUL	2015	56	7					441	445		10.1111/jsap.12352		5	Veterinary Sciences	Veterinary Sciences	CM2ME	WOS:000357513600004		
J	Ji, FH; Chang, R; Zhou, QG; Zhang, W; Ye, M; Sasaki, S; Qiao, S				Ji, Fuhao; Chang, Rui; Zhou, Qiaogen; Zhang, Wei; Ye, Mao; Sasaki, Shigemi; Qiao, Shan			Design and performance of the APPLE-Knot undulator	JOURNAL OF SYNCHROTRON RADIATION			English	Article						undulator; Knot undulator; figure-8 undulator; APPLE undulator; APPLE-8 undulator; Apple-Knot undulator	POLARIZATION; RADIATION	Along with the development of accelerator technology, synchrotron emittance has continuously decreased. This results in increased brightness, but also causes a heavy heat load on beamline optics. Recently, optical surfaces with 0.1 nm micro-roughness and 0.05 mu rad slope error (r.m.s.) have become commercially available and surface distortions due to heat load have become a key factor in determining beamline performance, and heat load has become a serious problem at modern synchrotron radiation facilities. Here, APPLE-Knot undulators which can generate photons with arbitrary polarization, with low on-axis heat load, are reported.	[Chang, Rui; Ye, Mao; Qiao, Shan] Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Funct Mat Informat, Shanghai 200050, Peoples R China; [Ji, Fuhao] Fudan Univ, Dept Phys, State Key Lab Surface Phys, Shanghai 200438, Peoples R China; [Ji, Fuhao] Fudan Univ, Adv Mat Lab, Shanghai 200438, Peoples R China; [Zhou, Qiaogen; Zhang, Wei] Chinese Acad Sci, Shanghai Inst Appl Phys, Shanghai Synchrotron Radiat Facil, Shanghai 201204, Peoples R China; [Sasaki, Shigemi] Hiroshima Univ, Hiroshima Synchrotron Radiat Ctr, Hiroshima 7390046, Japan; [Qiao, Shan] ShanghaiTech Univ, Sch Phys Sci & Technol, Shanghai 200031, Peoples R China	Qiao, S (reprint author), Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Funct Mat Informat, 865 Changning Rd, Shanghai 200050, Peoples R China.	qiaoshan@mail.sim.ac.cn			Natural Science Foundation of China [10979021, 11027401, 11174054, 11304338, 11175238, 11227902]; Ministry of Science and Technology of China (National Basic Research Program) [2011CB921800]; Chinese Academy of Sciences [XDB04010100]	This work is supported by the Natural Science Foundation of China (No. 10979021, 11027401, 11174054, 11304338, 11175238 and 11227902), the Ministry of Science and Technology of China (National Basic Research Program No. 2011CB921800) and the 'Strategic Priority Research Program (B)' of the Chinese Academy of Sciences (Grant No. XDB04010100).	SASAKI S, 1993, NUCL INSTRUM METH A, V331, P763, DOI 10.1016/0168-9002(93)90153-9; Tanaka T, 2001, J SYNCHROTRON RADIAT, V8, P1221, DOI 10.1107/S090904950101425X; TANAKA T, 1995, NUCL INSTRUM METH A, V364, P368, DOI 10.1016/0168-9002(95)00462-9; Chubar O, 1998, J SYNCHROTRON RADIAT, V5, P481, DOI 10.1107/S0909049597013502; Hofmann A., 2004, PHYS SYNCHROTRON RAD; Nahon L, 2012, J SYNCHROTRON RADIAT, V19, P508, DOI 10.1107/S0909049512010588; Onuki H., 2003, UNDULATORS WIGGLERS; Qiao S, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3204452; Sasaki S., 1998, P 6 EPAC STOCKH SWED, P2237; SASAKI S, 1994, NUCL INSTRUM METH A, V347, P83, DOI 10.1016/0168-9002(94)91859-7; Sasaki S., 2013, P 2013 N AM PART ACC, P1043; Xi FC, 2013, J SYNCHROTRON RADIAT, V20, P145, DOI 10.1107/S0909049512039301	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-0495	1600-5775		J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	JUL	2015	22		4				901	907		10.1107/S1600577515006062		7	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CM0YZ	WOS:000357407900005		
J	Hirano, K; Yamashita, Y; Takahashi, Y; Sugiyama, H				Hirano, Keiichi; Yamashita, Yoshiki; Takahashi, Yumiko; Sugiyama, Hiroshi			Development of variable-magnification X-ray Bragg optics	JOURNAL OF SYNCHROTRON RADIATION			English	Article						X-ray magnifier; variable-magnification; dynamical diffraction; imaging; image processing	DOUBLE-CRYSTAL MONOCHROMATOR; ASYMMETRICALLY CUT CRYSTALS; SYNCHROTRON-RADIATION; PERFECT CRYSTALS; POWER-DENSITY; MAGNIFIER; DIFFRACTION; NANOTOMOGRAPHY; PERFORMANCE; RESOLUTION	A novel X-ray Bragg optics is proposed for variable-magnification of an X-ray beam. This X-ray Bragg optics is composed of two magnifiers in a crossed arrangement, and the magnification factor, M, is controlled through the azimuth angle of each magnifier. The basic properties of the X-ray optics such as the magnification factor, image transformation matrix and intrinsic acceptance angle are described based on the dynamical theory of X-ray diffraction. The feasibility of the variable-magnification X-ray Bragg optics was verified at the vertical-wiggler beamline BL-14B of the Photon Factory. For X-ray Bragg magnifiers, Si(220) crystals with an asymmetric angle of 14 degrees were used. The magnification factor was calculated to be tunable between 0.1 and 10.0 at a wavelength of 0.112 nm. At various magnification factors (M >= 1.0), X-ray images of a nylon mesh were observed with an air-cooled X-ray CCD camera. Image deformation caused by the optics could be corrected by using a 2 x 2 transformation matrix and bilinear interpolation method. Not only absorption-contrast but also edge-contrast due to Fresnel diffraction was observed in the magnified images.	[Hirano, Keiichi; Yamashita, Yoshiki; Takahashi, Yumiko; Sugiyama, Hiroshi] High Energy Accelerator Res Org, Inst Mat Struct Sci, Tsukuba, Ibaraki 3050801, Japan	Hirano, K (reprint author), High Energy Accelerator Res Org, Inst Mat Struct Sci, Tsukuba, Ibaraki 3050801, Japan.	keiichi.hirano@kek.jp			Program Advisory Committee of the Photon Factory [2013G054, 2014G021]	This work was performed with the approval of the Program Advisory Committee of the Photon Factory (2013G054 and 2014G021).	McNeil BWJ, 2010, NAT PHOTONICS, V4, P814, DOI 10.1038/nphoton.2010.239; COLE H, 1962, ACTA CRYSTALLOGR, V15, P138, DOI 10.1107/S0365110X62000353; DuMond JWM, 1937, PHYS REV, V52, P0872, DOI 10.1103/PhysRev.52.872; KIRKPATRICK P, 1948, J OPT SOC AM, V38, P766, DOI 10.1364/JOSA.38.000766; BRAUER S, 1995, J SYNCHROTRON RADIAT, V2, P163, DOI 10.1107/S0909049595003190; BATTERMAN BW, 1964, REV MOD PHYS, V36, P681, DOI 10.1103/RevModPhys.36.681; Modregger P, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.054107; Authier A., 2001, DYNAMICAL THEORY XRA; BAEZ AV, 1960, NATURE, V186, P958, DOI 10.1038/186958a0; BLASDELL RC, 1994, NUCL INSTRUM METH A, V347, P327, DOI 10.1016/0168-9002(94)91903-8; BLASDELL RC, 1994, NUCL INSTRUM METH A, V347, P320, DOI 10.1016/0168-9002(94)91901-1; BRAUER S, 1995, REV SCI INSTRUM, V66, P1506, DOI 10.1063/1.1145892; Hirano K, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.040302; Hirano K, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.026402; Hirano K, 2014, NUCL INSTRUM METH A, V741, P78, DOI 10.1016/j.nima.2013.12.038; Honnicke MG, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2814022; HRDY J, 1992, REV SCI INSTRUM, V63, P459; HRDY J, 1993, NUCL INSTRUM METH A, V327, P605, DOI 10.1016/0168-9002(93)90731-V; ISHIKAWA T, 1991, HDB SYNCHROTRON RAD, V3, P63; KHOUNSARY AM, 1992, REV SCI INSTRUM, V63, P461, DOI 10.1063/1.1142732; Kobayashi K, 2001, APPL PHYS LETT, V78, P132, DOI 10.1063/1.1337621; Kohra K., 1972, P 6 INT C XRAY OPT M, P35; LEE WK, 1992, NUCL INSTRUM METH A, V320, P381, DOI 10.1016/0168-9002(92)90798-9; Levi BG, 2002, PHYS TODAY, V55, P23, DOI 10.1063/1.1472383; MACRANDER AT, 1992, NUCL INSTRUM METH A, V319, P188, DOI 10.1016/0168-9002(92)90553-G; NAKAKITA H, 1983, JARQ-JPN AGR RES Q, V16, P239, DOI 10.1107/S0021889883010304; Schafer P, 2003, J PHYS D APPL PHYS, V36, pA113, DOI 10.1088/0022-3727/36/10A/323; Schroer CG, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2053350; SMITHER RK, 1994, NUCL INSTRUM METH A, V347, P313, DOI 10.1016/0168-9002(94)91900-3; Stampanoni M, 2003, APPL PHYS LETT, V82, P2922, DOI 10.1063/1.1569428; Stampanoni M, 2002, J APPL PHYS, V92, P7630, DOI 10.1063/1.1520722; Stampanoni M, 2005, NUCL INSTRUM METH A, V551, P119, DOI 10.1016/j.nima.2005.07.046; Tsusaka Y, 2000, JPN J APPL PHYS 2, V39, pL635, DOI 10.1143/JJAP.39.L635; URUGA T, 1995, REV SCI INSTRUM, V66, P2254, DOI 10.1063/1.1145722; Vagovic P, 2013, J SYNCHROTRON RADIAT, V20, P153, DOI 10.1107/S0909049512044366; Vagovic P, 2014, OPT EXPRESS, V22, P21508, DOI 10.1364/OE.22.021508; Yabashi M, 1999, P SOC PHOTO-OPT INS, V3773, P2, DOI 10.1117/12.370098; Zachariasen W., 1945, THEORY XRAY DIFFRACT	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-0495	1600-5775		J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	JUL	2015	22		4				956	960		10.1107/S1600577515008802		5	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CM0YZ	WOS:000357407900011		
J	Jeon, I; Cui, K; Chiba, T; Anisimov, A; Nasibulin, AG; Kauppinen, EI; Maruyama, S; Matsuo, Y				Jeon, Ii; Cui, Kehang; Chiba, Takaaki; Anisimov, Anton; Nasibulin, Albert G.; Kauppinen, Esko I.; Maruyama, Shigeo; Matsuo, Yutaka			Direct and Dry Deposited Single-Walled Carbon Nanotube Films Doped with MoOx as Electron-Blocking Transparent Electrodes for Flexible Organic Solar Cells	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY			English	Article							THIN-FILMS; HIGH-EFFICIENCY; GRAPHENE; PHOTOVOLTAICS; PERFORMANCE; NETWORKS; DEVICES	Organic solar cells have been regarded as a promising electrical energy source. Transparent and conductive carbon nanotube film offers an alternative to commonly used ITO in photovoltaics with superior flexibility. This communication reports carbon nanotube-based indium-free organic solar cells and their flexible application. Direct and dry deposited carbon nanotube film doped with MoOx functions as an electron-blocking transparent electrode, and its performance is enhanced further by overcoating with PEDOT:PSS. The single-walled carbon nanotube organic solar cell in this work shows a power conversion efficiency of 6.04%. This value is 83% of the leading ITO-based device performance (7.48%). Flexible application shows 3.91% efficiency and is capable of withstanding a severe cyclic flex test.	[Jeon, Ii; Matsuo, Yutaka] Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; [Cui, Kehang; Chiba, Takaaki; Maruyama, Shigeo] Univ Tokyo, Sch Engn, Dept Mech Engn, Bunkyo Ku, Tokyo 1138656, Japan; [Anisimov, Anton] Canatu Ltd, FI-00390 Helsinki, Finland; [Nasibulin, Albert G.; Kauppinen, Esko I.] Aalto Univ, Dept Appl Phys, Sch Sci, FI-00076 Aalto, Finland; [Nasibulin, Albert G.] Skolkovo Inst Sci & Technol, Skolkovo 143025, Moscow Region, Russia; [Maruyama, Shigeo] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058564, Japan; [Nasibulin, Albert G.] St Petersburg State Polytech Univ, Dept Mat Sci, St Petersburg 195251, Russia	Maruyama, S (reprint author), Univ Tokyo, Sch Engn, Dept Mech Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	mamyama@photon.t.u-tokyo.ac.jp; matsuo@chem.s.u-tokyo.ac.jp	Matsuo, Yutaka/C-9897-2011	Matsuo, Yutaka/0000-0001-9084-9670	European Union Seventh Framework Programme (FP7) [604472]; IRENA project by JST-EC DG RTD; Strategic International Collaborative Research Program, SICORP; MOPPI; Ministry of Education and Science of Russian Federation [DOI: RFMEFI58114X0006]; JSPS [15K17983];  [22226006];  [25107002];  [15H02219];  [15H05760]	This work was partly supported by Grants-in-Aid for Scientific Research (22226006, 25107002, 15H02219, 15H05760), the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 604472 (IRENA project, to E.K.), IRENA project by JST-EC DG RTD, Strategic International Collaborative Research Program, SICORP (to S.M. and Y.M.), MOPPI and Ministry of Education and Science of Russian Federation (Project DOI: RFMEFI58114X0006) (to A.N.). The authors also thank the Funding Program for Next-Generation World-Leading Researchers (to Y.M.), the JSPS Grand-in-Aid for Young Scientists (15K17983) (to K.C.), and Japan Student Services Organization (to I.J.).	De Volder MFL, 2013, SCIENCE, V339, P535, DOI 10.1126/science.1222453; Park JS, 2012, J MATER CHEM, V22, P12695, DOI 10.1039/c2jm30710c; Park H, 2014, NANO LETT, V14, P5148, DOI 10.1021/nl501981f; Kim S, 2010, ADV FUNCT MATER, V20, P2310, DOI 10.1002/adfm.200902369; Xu Z, 2009, ADV FUNCT MATER, V19, P1227, DOI 10.1002/adfm.200801286; MESTL G, 1994, J PHYS CHEM-US, V98, P11269, DOI 10.1021/j100095a007; Kaskela A, 2010, NANO LETT, V10, P4349, DOI 10.1021/nl101680s; Cui KH, 2014, J MATER CHEM A, V2, P11311, DOI 10.1039/c4ta01353k; Li DJ, 2014, NANO LETT, V14, P1228, DOI 10.1021/nl404108a; He ZC, 2012, NAT PHOTONICS, V6, P591, DOI 10.1038/NPHOTON.2012.190; Tyler TP, 2011, ADV ENERGY MATER, V1, P785, DOI 10.1002/aenm.201100274; Blouin N, 2007, ADV MATER, V19, P2295, DOI 10.1002/adma.200602496; Zhou YX, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2187945; Dabera GDMR, 2013, ACS NANO, V7, P556, DOI 10.1021/nn304705t; Won S, 2014, NANOSCALE, V6, P6057, DOI 10.1039/c4nr00265b; Maiti UN, 2014, ADV MATER, V26, P40, DOI 10.1002/adma.201303265; Hellstrom SL, 2012, NANO LETT, V12, P3574, DOI 10.1021/nl301207e; Nasibulin AG, 2011, ACS NANO, V5, P3214, DOI 10.1021/nn200338r; Lim CH, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2824575; Unalan HE, 2008, J MATER CHEM, V18, P5909, DOI 10.1039/b810748c; Salvatierra RV, 2013, ADV FUNCT MATER, V23, P1490, DOI 10.1002/adfm.201201878; Du JH, 2014, ADV MATER, V26, P1958, DOI 10.1002/adma.201304135; Liang YY, 2010, ADV MATER, V22, pE135, DOI 10.1002/adma.200903528; Lee JM, 2013, ADV MATER, V25, P2011, DOI 10.1002/adma.201204454; Eo YS, 2009, SYNTHETIC MET, V159, P1910, DOI 10.1016/j.synthmet.2009.05.036; Irfan, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3454779; Kaltenbrunner M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1772; Kim YH, 2012, SOL ENERG MAT SOL C, V96, P244, DOI 10.1016/j.solmat.2011.10.001; Kumar A, 2011, ENERG ENVIRON SCI, V4, P4917, DOI 10.1039/c1ee01368h; KYMAKIS E, 2006, J APPL PHYS, V36, P257, DOI DOI 10.1051/EPJAP:2006148; Lee J. M., 2014, ADV MATER, V27, P2015; Nasibulin AG, 2008, CHEM ENG J, V136, P409, DOI 10.1016/j.cej.2007.04.033; Tanaka S, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3095594; Zhen L., 2014, ACS NANO, V8, P6797	34	2	2	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0002-7863			J AM CHEM SOC	J. Am. Chem. Soc.	JUL 1	2015	137	25					7982	7985		10.1021/jacs.5b03739		4	Chemistry, Multidisciplinary	Chemistry	CM1JD	WOS:000357436300006		
J	Kikkawa, N; Wang, LJ; Morita, A				Kikkawa, Nobuaki; Wang, Lingjian; Morita, Akihiro			Microscopic Barrier Mechanism of Ion Transport through Liquid-Liquid Interface	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY			English	Article							WATER-NITROBENZENE INTERFACE; IMMISCIBLE ORGANIC-SOLVENT; MOLECULAR-DYNAMICS; FREE-ENERGY; LIQUID/LIQUID INTERFACES; TRANSFER KINETICS; PHASE; ELECTROCHEMISTRY; EQUATION	Microscopic mechanism of ion transport through water-oil interface was investigated with molecular dynamics simulation. The formation/breaking of a water finger during the ion passage was explicitly formulated in the free energy surface. The calculated 2D free energy surface clearly revealed a hidden barrier of ion passage accompanied by the water finger. This barrier elucidates the retarded rate of interfacial ion transfer.	[Kikkawa, Nobuaki; Wang, Lingjian; Morita, Akihiro] Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan; [Morita, Akihiro] Kyoto Univ, ESICB, Kyoto 6158520, Japan	Morita, A (reprint author), Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan.	morita@m.tohoku.ac.jp			MEXT, Japan; JSPS;  [25104003];  [26288003]	We thank Prof. S. Amemiya for helpful discussion. This work was supported by the Grants-in-Aid for Scientific Research (nos. 25104003 and 26288003), JSPS and MEXT, Japan.	Girault HH, 2010, ELECTROANAL CHEM, V23, P1; SHAO Y, 1990, J ELECTROANAL CHEM, V282, P59; Darvas M, 2013, J PHYS CHEM B, V117, P16148, DOI 10.1021/jp404699t; GAVACH C, 1975, J ELECTROANAL CHEM, V64, P107, DOI 10.1016/S0022-0728(75)80281-6; Marcus RA, 2000, J CHEM PHYS, V113, P1618, DOI 10.1063/1.481950; Benjamin I, 2008, J PHYS CHEM B, V112, P15801, DOI 10.1021/jp807431f; KAKIUCHI T, 1992, J ELECTROANAL CHEM, V322, P55, DOI 10.1016/0022-0728(92)80066-D; Schmickler W, 1997, J ELECTROANAL CHEM, V426, P5, DOI 10.1016/S0022-0728(97)00063-6; Sugita Y, 2000, J CHEM PHYS, V113, P6042, DOI 10.1063/1.1308516; Kornyshev AA, 2002, J CHEM PHYS, V117, P6766, DOI 10.1063/1.1505862; Kikkawa N, 2012, CHEM PHYS LETT, V534, P19, DOI 10.1016/j.cplett.2012.03.027; Samec Z, 2012, ELECTROCHIM ACTA, V84, P21, DOI 10.1016/j.electacta.2012.03.118; [Anonymous], 2005, FARADAY DISCUSS, V129, P1; Wick CD, 2008, J PHYS CHEM C, V112, P647, DOI 10.1021/jp076608c; Li Q, 2009, ANGEW CHEM INT EDIT, V48, P8010, DOI 10.1002/anie.200903143; Aoki K, 1996, ELECTROCHIM ACTA, V41, P2321, DOI 10.1016/0013-4686(96)00062-X; Benjamin I, 2013, J PHYS CHEM B, V117, P4325, DOI 10.1021/jp306669t; Benjamin L, 1993, Science, V261, P1558, DOI 10.1126/science.261.5128.1558; CALDWELL JW, 1995, J PHYS CHEM-US, V99, P6208, DOI 10.1021/j100016a067; Daikhin LI, 2005, CHEM PHYS, V319, P253, DOI 10.1016/j.chemphys.2005.03.029; Dang LX, 1999, J PHYS CHEM B, V103, P8195, DOI 10.1021/jp991824+; Dang LX, 2001, J PHYS CHEM B, V105, P804, DOI 10.1021/jp003991b; Darvas M, 2011, J PHYS CHEM C, V115, P11140, DOI 10.1021/jp2018605; DEPENOUX B, 1979, J ELECTROANAL CHEM, V99, P77, DOI 10.1016/S0022-0728(79)80412-X; dos Santos DJVA, 2002, CHEMPHYSCHEM, V3, P946, DOI 10.1002/1439-7641(20021115)3:11<946::AID-CPHC946>3.0.CO;2-M; Dryfe R. A. W., 2009, ADV CHEM PHYS, V43, P153; Kusakabe S, 1996, B CHEM SOC JPN, V69, P581, DOI 10.1246/bcsj.69.581; Rose D, 2009, J PHYS CHEM B, V113, P9296, DOI 10.1021/jp904470d; Schweighofer K, 1999, J PHYS CHEM A, V103, P10274, DOI 10.1021/jp991967w; SCHWEIGHOFER KJ, 1995, J PHYS CHEM-US, V99, P9974, DOI 10.1021/j100024a046; Silver BR, 2014, J ELECTROANAL CHEM, V731, P107, DOI 10.1016/j.jelechem.2014.08.017	31	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0002-7863			J AM CHEM SOC	J. Am. Chem. Soc.	JUL 1	2015	137	25					8022	8025		10.1021/jacs.5b04375		4	Chemistry, Multidisciplinary	Chemistry	CM1JD	WOS:000357436300016		
J	Nakatsuka, H; Yamamura, T; Shuto, Y; Tanaka, S; Yoshimura, M; Kitamura, M				Nakatsuka, Hiroshi; Yamamura, Tomoya; Shuto, Yoshihiro; Tanaka, Shinji; Yoshimura, Masahiro; Kitamura, Masato			Mechanism of Asymmetric Hydrogenation of Aromatic Ketones Catalyzed by a Combined System of Ru(pi-CH2C(CH3)CH2)(2)(cod) and the Chiral sp(2)N/sp(3)NH Hybrid Linear N4 Ligand Ph-BINAN-H-Py	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY			English	Article							RUTHENIUM HYDRIDE COMPLEXES; ENANTIOSELECTIVE HYDROGENATION; CARBONYL-COMPOUNDS; BINAP/1,2-DIAMINE-RUTHENIUM(II) COMPLEXES; BIFUNCTIONAL ADDITION; PHOSPHINE-LIGANDS; ARYL KETONES; METAL; ESTERS; ACETOPHENONE	The combination of a GoodwinLions-type chiral N4 ligand, (R)-Ph-BINAN-H-Py ((R)-3,3'-diphenyl-N-2,N-2'-bis((pyridin-2-yl)methyl)-1,1'-binaphthyl-2,2'-diamine; <bold>L</bold>), with Ru(pi-CH2C(CH3)CH2)(2)(cod) (<bold>A</bold>) (cod = 1,5-cyclooctadiene) catalyzes the hydrogenation of acetophenone (<bold>AP</bold>) to (R)-1-phenylethanol (<bold>PE</bold>) with a high enantiomer ratio (er). Almost no Ru complex forms, with <bold>A</bold> and <bold>L</bold> remaining intact throughout the reaction while generating <bold>PE</bold> quantitatively according to [<bold>PE</bold>] = k(obst)(2). An infinitesimal amount of reactive and unstable RuH2<bold>L</bold> (<bold>B</bold>) with C-2-gamma-cis-a stereochemistry is very slowly and irreversibly generated from <bold>A</bold> by the action of H-2 and <bold>L</bold>, which rapidly catalyzes the hydrogenation of <bold>AP</bold> via Noyoris donoracceptor bifunctional mechanism. A CH-pi-stabilized Si-face selective transition state, <bold>C-Si</bold>, gives (R)-<bold>PE</bold> together with an intermediary Ru amide, <bold>D</bold>, which is inhibited predominantly by formation of the Ru enolate of <bold>AP</bold>. The rate-determining hydrogenolysis of <bold>D</bold> completes the cycle. The time-squared term relates both to the preliminary step before the cycle and to the cycle itself, with a highly unusual eight-order difference in the generation and turnover frequency of <bold>B</bold>. This mechanism is fully supported by a series of experiments including a detailed kinetic study, rate law analysis, simulation of t/[<bold>PE</bold>] curves with fitting to the experimental observations at the initial reaction stage, X-ray crystallographic analyses of <bold>B</bold>-related octahedral metal complexes, and Hammett plot analyses of electronically different substrates and ligands in their enantioselectivities.	[Nakatsuka, Hiroshi; Yamamura, Tomoya; Shuto, Yoshihiro; Tanaka, Shinji; Kitamura, Masato] Nagoya Univ, Grad Sch Sci, Grad Sch Pharmaceut Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Nakatsuka, Hiroshi; Yamamura, Tomoya; Shuto, Yoshihiro; Tanaka, Shinji; Kitamura, Masato] Nagoya Univ, Res Ctr Mat Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Yoshimura, Masahiro] Aichi Gakuin Univ, Div Liberal Arts & Sci, Iwasaki, Nisshin 4700195, Japan	Kitamura, M (reprint author), Nagoya Univ, Grad Sch Sci, Grad Sch Pharmaceut Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	kitamura@os.rcms.nagoya-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (Japan) [25E07B212, 23005914]; Advanced Catalytic Transformation Program for Carbon Utilization (ACT-C) from Japan Science and Technology Agency (JST)	This work was aided by a Grant-in-Aid for Scientific Research (No. 25E07B212 and No. 23005914) from the Ministry of Education, Culture, Sports, Science and Technology (Japan) and an Advanced Catalytic Transformation Program for Carbon Utilization (ACT-C) from Japan Science and Technology Agency (JST). We thank Masahiro Tsuzuki for preliminary kinetic study and Prof. Donna G. Blackmond and Prof. John F. Hartwig for valuable discussions for the kinetics.	Abbel R, 2005, J AM CHEM SOC, V127, P1870, DOI 10.1021/ja039396t; Noyori R, 2004, P NATL ACAD SCI USA, V101, P5356, DOI 10.1073/pnas.0307928100; Ohkuma T, 2006, J AM CHEM SOC, V128, P8724, DOI 10.1021/ja0620989; vom Stein T, 2013, CHEMCATCHEM, V5, P439, DOI 10.1002/cctc.201200215; vom Stein T, 2014, J AM CHEM SOC, V136, P13217, DOI 10.1021/ja506023f; Kitamura M, 2013, PURE APPL CHEM, V85, P1121, DOI 10.1351/PAC-CON-12-10-02; SLOUGH GA, 1989, J AM CHEM SOC, V111, P938, DOI 10.1021/ja00185a025; NOYORI R, 1991, ANGEW CHEM INT EDIT, V30, P49, DOI 10.1002/anie.199100491; KITAMURA M, 1988, J AM CHEM SOC, V110, P629, DOI 10.1021/ja00210a070; Makio H, 2002, ADV SYNTH CATAL, V344, P477, DOI 10.1002/1615-4169(200207)344:5<477::AID-ADSC477>3.0.CO;2-6; He YM, 2010, ORG BIOMOL CHEM, V8, P2497, DOI 10.1039/b925199p; Noyori R, 2001, ANGEW CHEM INT EDIT, V40, P40, DOI 10.1002/1521-3773(20010105)40:1<40::AID-ANIE40>3.0.CO;2-5; NOYORI R, 1987, J AM CHEM SOC, V109, P5856, DOI 10.1021/ja00253a051; Sandoval CA, 2006, CHEM-ASIAN J, V1, P102, DOI 10.1002/asia.200600098; Takebayashi S, 2009, ORGANOMETALLICS, V28, P2349, DOI 10.1021/om9002076; OHKUMA T, 1995, J AM CHEM SOC, V117, P2675, DOI 10.1021/ja00114a043; Zhang J, 2005, J AM CHEM SOC, V127, P10840, DOI 10.1021/ja052862b; Ito M, 2001, ORGANOMETALLICS, V20, P379, DOI 10.1021/om000912+; SOAI K, 1995, NATURE, V378, P767, DOI 10.1038/378767a0; Yoon TP, 2003, SCIENCE, V299, P1691, DOI 10.1126/science.1083622; Yamakawa M, 2001, ANGEW CHEM INT EDIT, V40, P2818, DOI 10.1002/1521-3773(20010803)40:15<2818::AID-ANIE2818>3.0.CO;2-Y; Zhang J, 2006, ANGEW CHEM INT EDIT, V45, P1113, DOI 10.1002/anie.200503771; NOYORI R, 1989, MOD SYN MET, V5, P115; Sandoval CA, 2003, J AM CHEM SOC, V125, P13490, DOI 10.1021/ja030272c; Hedberg C, 2005, J AM CHEM SOC, V127, P15083, DOI 10.1021/ja051920q; Hamilton RJ, 2005, J AM CHEM SOC, V127, P4152, DOI 10.1021/ja043339k; Abdur-Rashid K, 2002, J AM CHEM SOC, V124, P15104, DOI 10.1021/ja016817p; Yoshimura M, 2014, TETRAHEDRON LETT, V55, P3635, DOI 10.1016/j.tetlet.2014.04.129; Abdur-Rashid K, 2001, J AM CHEM SOC, V123, P7473, DOI 10.1021/ja015902u; BAU R, 1979, ACCOUNTS CHEM RES, V12, P176, DOI 10.1021/ar50137a003; Birch A. J., 1976, ORG REACTIONS, V24, P1; BONVICIN.P, 1972, J CHEM SOC CHEM COMM, P1188, DOI 10.1039/c39720001188; Brunel JM, 2000, ANGEW CHEM INT EDIT, V39, P1946, DOI 10.1002/1521-3773(20000602)39:11<1946::AID-ANIE1946>3.0.CO;2-I; BRUNNER E, 1979, BER BUNSEN PHYS CHEM, V83, P715; Calvin M., 1939, J AM CHEM SOC, V61, P2230, DOI 10.1021/ja01877a072; Calvin M., 1938, T FARADAY SOC, V34, P1181, DOI 10.1039/tf9383401181; CHIANG Y, 1988, J AM CHEM SOC, V110, P5506, DOI 10.1021/ja00224a039; Clapham SE, 2004, COORDIN CHEM REV, V248, P2201, DOI 10.1016/j.ccr.2004.04.007; Daley CJA, 2002, J AM CHEM SOC, V124, P3680, DOI 10.1021/ja0102991; Fiorini M., 1977, J MOL CATAL, V3, P385; GOLIASZEWSKI A, 1985, TETRAHEDRON, V41, P5779, DOI 10.1016/S0040-4020(01)91417-6; GOODWIN HA, 1960, J AM CHEM SOC, V82, P5013, DOI 10.1021/ja01504a001; Hadzovic A, 2007, ORGANOMETALLICS, V26, P5987, DOI 10.1021/om700849w; Hamilton RJ, 2006, J AM CHEM SOC, V128, P13700, DOI 10.1021/ja065460s; Hamilton RJ, 2008, J AM CHEM SOC, V130, P11979, DOI 10.1021/ja8034812; HARTWIG JF, 1990, J AM CHEM SOC, V112, P3234, DOI 10.1021/ja00164a067; HAYASHI T, 1976, TETRAHEDRON LETT, P4351; HEIL B, 1975, J ORGANOMET CHEM, V94, pC47, DOI 10.1016/S0022-328X(00)86961-2; Huang HM, 2006, J AM CHEM SOC, V128, P8716, DOI 10.1021/ja062451a; Ishibashi Y, 2005, ANGEW CHEM INT EDIT, V44, P7287, DOI 10.1002/anie.200502463; James B. R., 1974, HOMOGENEOUS HYDROGEN, P1; James B. R., 1982, COMPREHENSIVE ORGANO, V8, P285; Karame I, 2004, TETRAHEDRON-ASYMMETR, V15, P1569, DOI 10.1016/j.tetasy.2004.03.023; KITAMURA M, 1986, J AM CHEM SOC, V108, P6071, DOI 10.1021/ja00279a083; KITAMURA M, 1992, J ORG CHEM, V57, P4053, DOI 10.1021/jo00040a068; Kitamura M, 2011, CHEM COMMUN, V47, P842, DOI 10.1039/c0cc01390k; Kitamura M., 2004, RUTHENIUM ORGANIC SY, P3, DOI 10.1002/3527603832.ch2; LEVI A, 1975, J CHEM SOC CHEM COMM, P6, DOI 10.1039/c39750000006; LINDSAY AJ, 1985, J CHEM SOC DALTON, P2321, DOI 10.1039/dt9850002321; Lough A. J., 2011, ORGANOMETALLICS, V30, P1236; LUGINBUHL W, 1991, INORG CHEM, V30, P2350, DOI 10.1021/ic00010a024; MEHTA SPS, 1991, TRANSIT METAL CHEM, V16, P402, DOI 10.1007/BF01129450; Noyori R, 2002, ANGEW CHEM INT EDIT, V41, P2008, DOI 10.1002/1521-3773(20020617)41:12<2008::AID-ANIE2008>3.0.CO;2-4; OHGO Y, 1971, B CHEM SOC JPN, V44, P583, DOI 10.1246/bcsj.44.583; Ohkuma T., 2007, NEW FRONTIERS ASYMME, P1, DOI 10.1002/9780470098004.ch1; Ohkuma T, 2005, J AM CHEM SOC, V127, P8288, DOI 10.1021/ja052071+; OJIMA I, 1977, J CHEM SOC CHEM COMM, P428, DOI 10.1039/c39770000428; Pinel C, 1996, J MOL CATAL A-CHEM, V112, pL157, DOI 10.1016/1381-1169(96)00148-3; POWELL J, 1968, J CHEM SOC A, P159, DOI 10.1039/j19680000159; Prechtl MHG, 2007, CHEM-EUR J, V13, P1539, DOI 10.1002/chem.200600897; Sandoval CA, 2009, CHEM-ASIAN J, V4, P1221, DOI 10.1002/asia.200900171; Schrock R. R., 1970, CHEM COMMUN, P567; Schweda L, 2010, J ORGANOMET CHEM, V695, P2076, DOI 10.1016/j.jorganchem.2010.05.020; Shang G., 2010, CATALYTIC ASYMMETRIC, P343, DOI 10.1002/9780470584248.ch7; SIH CJ, 1973, J AM CHEM SOC, V95, P1676, DOI 10.1021/ja00786a062; Singleton A. D., 1995, J AM CHEM SOC, V117, P9357; Six C, 1999, ORGANOMETALLICS, V18, P3316, DOI 10.1021/om990229r; SOLODAR J, 1975, CHEMTECH, P421; STEBLERROTHLISBERGER M, 1986, POLYHEDRON, V5, P1217, DOI 10.1016/S0277-5387(00)81395-9; TANAKA M, 1973, CHEM LETT, P239, DOI 10.1246/cl.1973.239; Tang WJ, 2003, CHEM REV, V103, P3029, DOI 10.1021/cr020049i; Tommasino ML, 2000, TETRAHEDRON-ASYMMETR, V11, P4835, DOI 10.1016/S0957-4166(00)00489-4; TOROS S, 1980, J ORGANOMET CHEM, V197, P85, DOI 10.1016/S0022-328X(00)84458-7; Tsukamoto M., 2009, SCI SYNTHESIS HOUBEN, V48, P341; Utsumi N, 2010, HETEROCYCLES, V80, P141, DOI 10.3987/COM-09-S(S)34; VENANZI LM, 1982, COORDIN CHEM REV, V43, P251, DOI 10.1016/S0010-8545(00)82099-8; Wade L. G., 1999, ORGANIC CHEM	87	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0002-7863			J AM CHEM SOC	J. Am. Chem. Soc.	JUL 1	2015	137	25					8138	8149		10.1021/jacs.5b02350		12	Chemistry, Multidisciplinary	Chemistry	CM1JD	WOS:000357436300034		
J	Pressman, GS; Movva, R; Topilsky, Y; Clavel, MA; Saldanha, JA; Watanabe, N; Enriquez-Sarano, M				Pressman, Gregg S.; Movva, Rajesh; Topilsky, Yan; Clavel, Marie-Annick; Saldanha, Jason A.; Watanabe, Nozomi; Enriquez-Sarano, Maurice			Mitral Annular Dynamics in Mitral Annular Calcification: A Three-Dimensional Imaging Study	JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY			English	Article						Mitral annular dynamics; Mitral annular calcification; Three-dimensional echocardiography	VALVE-PROLAPSE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; FUNCTIONAL-ANATOMY; AORTIC-VALVE; HEART; PATHOBIOLOGY; PREVALENCE; MECHANICS; INSIGHTS; DISEASE	Background: The mitral annulus displays complex conformational changes during the cardiac cycle that can now be quantified by three-dimensional echocardiography. Mitral annular calcification (MAC) is increasingly encountered, but its structural and dynamic consequences are largely unexplored. The objective of this study was to describe alterations in mitral annular dimensions and dynamics in patients with MAC. Methods: Transthoracic three-dimensional echocardiography was performed in 43 subjects with MAC and 36 age-and sex-matched normal control subjects. Mitral annular dimensions were quantified, using dedicated software, at six time points (three diastolic, three systolic) during the cardiac cycle. Results: In diastole, the calcified annulus was larger and flatter than normal, with increased anteroposterior diameter (29.4 +/- 0.6 vs 27.8 +/- 0.6 mm, P = .046), reduced height (2.8 +/- 0.2 vs 3.6 +/- 0.2 mm, P = .006), and decreased saddle shape (8.960.6% vs 11.460.6%, P = .005). In systole, patients with MAC had greater annular area at all time points (P < .05 for each) compared with control subjects, because of reduced contraction along the anteroposterior diameter (P < .001). Saddle shape increased in early systole (from 10.5% to 13.5%, P = .04) in control subjects but not in those with MAC (P = NS). Valvular alterations were also noted; although mitral valve tent length decreased during systole in both groups, decreases were less in patients with MAC (P < .05 for mid-and late systole). For certain parameters (e.g., annular area), changes were confined largely to those patients with moderate to severe MAC (P = .006 vs control subjects, but nonsignificant for patients with mild MAC). Conclusions: Quantitative three-dimensional echocardiography provides new insights into the dynamic consequences of MAC. This imaging technique demonstrates that the mitral annulus is not made smaller by calcification. However, there is loss of annular contraction, particularly along the anteroposterior diameter, and loss of early systolic folding along the intercommissural diameter. Associated valvular alterations include smaller than usual declines in tenting during systole. These quantitative three-dimensional echocardiographic data provide new insights into the dynamic physiology of the calcified mitral annulus.	[Pressman, Gregg S.; Movva, Rajesh] Albert Einstein Med Ctr, Div Cardiovasc Dis, Philadelphia, PA 19141 USA; [Topilsky, Yan; Clavel, Marie-Annick; Enriquez-Sarano, Maurice] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA; [Saldanha, Jason A.] Dalhousie Univ, Halifax, NS, Canada; [Watanabe, Nozomi] Kawasaki Med Univ, Kurashiki, Okayama, Japan	Pressman, GS (reprint author), Albert Einstein Med Ctr, 5501 Old York Rd,3232 Levy Bldg, Philadelphia, PA 19141 USA.	pressmang@einstein.edu		Pressman, Gregg/0000-0002-0992-1805	Albert Einstein Society (Philadelphia, PA)	This work was supported by a grant from the Albert Einstein Society (Philadelphia, PA). The authors report that they have no relationships relevant to the contents of this report to disclose.	Silbiger JJ, 2009, AM HEART J, V158, P887, DOI 10.1016/j.ahj.2009.10.014; Sengupta PP, 2009, JACC-CARDIOVASC IMAG, V2, P212, DOI 10.1016/j.jcmg.2008.12.005; Grewal J, 2010, CIRCULATION, V121, P1423, DOI 10.1161/CIRCULATIONAHA.109.901181; NESTICO PF, 1984, AM HEART J, V107, P989, DOI 10.1016/0002-8703(84)90840-8; Fox CS, 2006, J AM SOC NEPHROL, V17, P521, DOI 10.1681/ASN.2005060627; Schoen FJ, 2008, CIRCULATION, V118, P1864, DOI 10.1161/CIRCULATIONAHA.108.805911; Silbiger JJ, 2012, AM HEART J, V164, P163, DOI 10.1016/j.ahj.2012.05.014; Boon A, 1997, HEART, V78, P472; Muddassir SM, 2007, INT J CARDIOL, V123, P58, DOI 10.1016/j.ijcard.2006.11.142; Nkomo VT, 2006, LANCET, V368, P1005, DOI 10.1016/S0140-6736(06)69208-8; Fusini L, 2014, AM J CARDIOL, V113, P1867, DOI 10.1016/j.amjcard.2014.03.013; Veronesi F, 2012, J AM SOC ECHOCARDIOG, V25, P524, DOI 10.1016/j.echo.2012.02.002; Veronesi F, 2009, CIRC-CARDIOVASC IMAG, V2, P24, DOI 10.1161/CIRCIMAGING.108.785907; Lansac E, 2002, J THORAC CARDIOV SUR, V123, P911, DOI 10.1067/mtc.2002.12186; Kanjanauthai S, 2010, ATHEROSCLEROSIS, V213, P558, DOI 10.1016/j.atherosclerosis.2010.08.072; Movva R, 2013, J AM SOC ECHOCARDIOG, V26, P1135, DOI 10.1016/j.echo.2013.06.014; Salgo IS, 2002, CIRCULATION, V106, P711, DOI 10.1161/01.CIR.0000025426.39426.83; Topilsky Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000039; Pressman GS, 2010, AM J CARDIOL, V105, P389, DOI 10.1016/j.amjcard.2009.09.042; Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161; Lee APW, 2013, CIRCULATION, V127, P832, DOI 10.1161/CIRCULATIONAHA.112.118083; Barasch E, 2006, AM HEART J, V151, P39, DOI 10.1016/j.ahj.2005.03.052; Charokopos NA, 2006, ANN THORAC SURG, V81, P1877, DOI 10.1016/j.athoracsur.2005.07.039; SANFILIPPO AJ, 1988, HERZ, V13, P284	24	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0894-7317			J AM SOC ECHOCARDIOG	J. Am. Soc. Echocardiogr.	JUL	2015	28	7					786	794		10.1016/j.echo.2015.03.002		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM0TG	WOS:000357390800005		
J	Bettenhausen, A; Hamaji, M; Burt, BM; Osman, S				Bettenhausen, Aaron; Hamaji, Masatsugu; Burt, Bryan M.; Osman, Syed			Pleurectomy and decortication for metastatic renal cell carcinoma	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Editorial Material									[Bettenhausen, Aaron; Osman, Syed] Univ N Dakota, Sch Med & Hlth Sci, Dept Surg, Grand Forks, ND 58201 USA; [Hamaji, Masatsugu] Kyoto Univ Hosp, Dept Thorac Surg, Kyoto 606, Japan; [Burt, Bryan M.] Baylor Coll Med, Dept Gen Thorac Surg, Houston, TX 77030 USA; [Osman, Syed] Altru Hosp, Dept Cardiovasc & Thorac Surg, Grand Forks, ND USA	Bettenhausen, A (reprint author), 2961 24th Ave S 204, Grand Forks, ND 58201 USA.	aaron.b.bettenhausen@my.und.edu					Ohnishi H, 2005, RESPIROLOGY, V10, P128, DOI 10.1111/j.1440-1843.2005.00652.x; SAITOH H, 1981, CANCER, V48, P1487, DOI 10.1002/1097-0142(19810915)48:6<1487::AID-CNCR2820480635>3.0.CO;2-9; Flanigan Robert C, 2003, Curr Treat Options Oncol, V4, P385, DOI 10.1007/s11864-003-0039-2; Kim DY, 2014, WORLD J UROL, V32, P631, DOI 10.1007/s00345-014-1293-6; Sugarbaker David J, 2010, Expert Rev Respir Med, V4, P363, DOI 10.1586/ers.10.35	5	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	JUL	2015	150	1								10.1016/j.jtcvs.2015.05.007		3	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	CL7DC	WOS:000357129900002		
J	Kawajiri, H; Oka, K; Yamasaki, T; Koh, E				Kawajiri, Hidetake; Oka, Katsuhiko; Yamasaki, Takuma; Koh, Eisei			Revisiting the brachiofemoral through-and-through wire technique for hybrid arch repair with a problematic elephant trunk	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Editorial Material							AORTIC-ARCH; PASSAGE		[Kawajiri, Hidetake] Kyoto Prefectural Univ Med, Dept Cardiovasc Surg, Kyoto 6028159, Japan; [Kawajiri, Hidetake; Oka, Katsuhiko; Yamasaki, Takuma; Koh, Eisei] Japanese Red Cross Soc, Kyoto Daini Hosp, Dept Cardiovasc Surg, Kyoto, Japan	Kawajiri, H (reprint author), Kyoto Prefectural Univ Med, Dept Cardiovasc Surg, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028159, Japan.	kawajiricvs@yahoo.co.jp					Joseph G, 2013, J ENDOVASC THER, V20, P223, DOI 10.1583/1545-1550-20.2.223; Bavaria J, 2013, J THORAC CARDIOV SUR, V145, pS85, DOI 10.1016/j.jtcvs.2012.11.044; Lioupis C, 2007, CATHETER CARDIO INTE, V70, P1041, DOI 10.1002/ccd.21298; Matsuda H, 2014, J THORAC CARDIOV SUR, V148, P3246, DOI 10.1016/j.jtcvs.2014.06.078; Obitsu Yukio, 2010, Gen Thorac Cardiovasc Surg, V58, P501, DOI 10.1007/s11748-010-0627-6	5	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	JUL	2015	150	1					250	252		10.1016/j.jtcvs.2015.04.006		3	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	CL7DC	WOS:000357129900067		
J	Morita, S; Tajima, T; Yamazaki, H; Sonoyama, Y; Nishina, Y; Kenji, O; Takagi, T; Kondo, T; Tanabe, K; Sakai, S				Morita, Satoru; Tajima, Tsuyoshi; Yamazaki, Hiroshi; Sonoyama, Yasuyuki; Nishina, Yu; Kenji, Omae; Takagi, Toshio; Kondo, Tsunenori; Tanabe, Kazunari; Sakai, Shuji			Early Postoperative Screening by Contrast-Enhanced CT and Prophylactic Embolization of Detected Pseudoaneurysms Prevents Delayed Hemorrhage after Partial Nephrectomy	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							LAPAROSCOPIC PARTIAL NEPHRECTOMY; RENAL-ARTERY PSEUDOANEURYSM	Purpose: To evaluate retrospectively whether prophylactic embolization of pseudoaneurysms detected on early postoperative screening with computed tomography (CT) after partial nephrectomy can prevent delayed hemorrhage. Materials and Methods: Between January 2012 and May 2014, early postoperative contrast-enhanced CT was performed 3-5 days after partial nephrectomy in 312 patients (group A); CT was not performed in 65 patients (group B) because of renal insufficiency or contrast medium allergy. If pseudoaneurysms were detected on CT in group A, prophylactic embolization was performed. The frequency of delayed hemorrhage occurring more than 3 days after surgery in group A was compared with group B and with 212 patients (group C) who underwent partial nephrectomy between January 2010 and December 2011 without early postoperative CT. Changes in estimated glomerular filtration rate at discharge were compared among the groups. Results: Prophylactic embolization of pseudoaneurysms was performed in 26 patients (8%) in group A. Frequency of delayed hemorrhage in group A (0.6%) was significantly lower than in groups B (4.6%; P = .038) and C (4.7%; P = .005). No major complications attributable to prophylactic embolization were observed. The decrease in estimated glomerular filtration rate in group A (-2% +/- 13%) was smaller than that in group B (-8% +/- 13%; P < .001) and not worse than that in group C (-4% +/- 14%; P = .108). Conclusions: Prophylactic embolization of pseudoaneurysms detected on early postoperative CT can prevent delayed hemorrhage after partial nephrectomy, without major complications.	[Morita, Satoru; Tajima, Tsuyoshi; Yamazaki, Hiroshi; Sonoyama, Yasuyuki; Nishina, Yu; Sakai, Shuji] Tokyo Womens Med Univ Hosp, Dept Diagnost Imaging & Nucl Med Radiol, Tokyo 1628666, Japan; [Kenji, Omae; Takagi, Toshio; Kondo, Tsunenori; Tanabe, Kazunari] Tokyo Womens Med Univ Hosp, Dept Urol, Tokyo 1628666, Japan	Morita, S (reprint author), Tokyo Womens Med Univ Hosp, Dept Diagnost Imaging & Nucl Med Radiol, 8-1 Kawada Cho, Tokyo 1628666, Japan.	i@imodey.com					Albani JM, 2003, UROLOGY, V62, P227, DOI 10.1016/S0090-4295(03)00364-9; Takagi T, 2014, INT J UROL, V21, P880, DOI 10.1111/iju.12462; Cohenpour M, 2007, CLIN RADIOL, V62, P1104, DOI 10.1016/j.crad.2007.06.004; Gill IS, 2002, J UROLOGY, V167, P469, DOI 10.1016/S0022-5347(01)69066-9; Aboumarzouk OM, 2012, EUR UROL, V62, P1023, DOI 10.1016/j.eururo.2012.06.038; Patel HD, 2013, J UROLOGY, V189, P1229, DOI 10.1016/j.juro.2012.10.024; Rogers CG, 2008, EUR UROL, V53, P514, DOI 10.1016/j.eururo.2007.09.047; Montag S, 2011, BJU INT, V107, P1460, DOI 10.1111/j.1464-410X.2010.09645.x; Campbell SC, 2009, J UROLOGY, V182, P1271, DOI 10.1016/j.juro.2009.07.004; Netsch C, 2010, WORLD J UROL, V28, P519, DOI 10.1007/s00345-010-0572-0; Ljungberg B, 2010, EUR UROL, V58, P398, DOI 10.1016/j.eururo.2010.06.032; Ghoneim TP, 2011, J UROLOGY, V185, P2061, DOI 10.1016/j.juro.2011.02.049; Omae K, INT J UROL IN PRESS; Sacks D, 2003, J VASC INTERV RADIOL, V14, pS199	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	JUL	2015	26	7					950	957		10.1016/j.jvir.2015.02.023		8	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	CM3BL	WOS:000357556600003		
J	Yasumoto, T; Yakushiji, H; Ohira, R; Ochi, S; Nakata, S; Hirabuki, N				Yasumoto, Taku; Yakushiji, Hideaki; Ohira, Ryosuke; Ochi, Sayaka; Nakata, Saki; Hirabuki, Norio			Superselective Coaxial Microballoon-Occluded Coil Embolization for Vascular Disorders: A Preliminary Report	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							PULMONARY ARTERIOVENOUS-MALFORMATIONS; FOLLOW-UP; ARTERY ANEURYSMS; VENOUS SAC; EMBOLOTHERAPY; EFFICACY; RECANALIZATION	Purpose: To evaluate the safety and effectiveness of superselective coil embolization with coaxial microballoon occlusion (B-coiling) for vascular disorders. Materials and Methods: Clinical data were retrospectively evaluated for 16 consecutive patients (6 men, 10 women; mean age, 70 y; age range, 57-80 y) with vascular disorders who underwent B-coiling with 0.010-0.014-inch detachable microcoils delivered through a guide-wire lumen of a microballoon catheter. Routine angiographic catheters (4-5 F) were introduced in all cases, including splenic (n = 4) and renal (n = 3) artery aneurysms, pulmonary and renal arteriovenous malformations (AVMs; n = 3 and n = 1, respectively), gastroesophageal varices (GEVs; n = 3), gastroduodenal artery stump pseudoaneurysm (n = 1), and superficial temporal artery aneurysm (n = 1). Results: Complete primary occlusion was achieved in 87.5% of cases (n = 14) without complications. Additional percutaneous transhepatic sclerotherapy by N-butyl cyanoacrylate (NBCA)/iodized oil mixtures without balloon occlusion resulted in successful occlusion of one GEV. Additional balloon-occluded NBCA injection was successfully performed in one renal AVM. Conclusions: Superselective coaxial microballoon embolization with detachable microcoils is a safe and useful treatment. Selective B-coiling induces tight packing under flow control in the treatment of vascular disorders.	[Yasumoto, Taku; Yakushiji, Hideaki; Ohira, Ryosuke; Ochi, Sayaka; Nakata, Saki; Hirabuki, Norio] Toyonaka City Hosp, Dept Radiol, Toyonaka, Osaka 5608565, Japan	Yasumoto, T (reprint author), Toyonaka City Hosp, Dept Radiol, Shibahara 4-14-1, Toyonaka, Osaka 5608565, Japan.	yasumoto@solid.ocn.ne.jp					Hur S, 2011, J VASC INTERV RADIOL, V22, P294, DOI 10.1016/j.jvir.2010.11.020; Ikeda O, 2008, J VASC SURG, V47, P1212, DOI 10.1016/j.jvs.2008.01.032; Lee DW, 1997, ANN THORAC SURG, V64, P930, DOI 10.1016/S0003-4975(97)00815-1; Patel A, 2012, J VASC INTERV RADIOL, V23, P893, DOI 10.1016/j.jvir.2012.03.009; Yasumoto T, 2013, J VASC INTERV RADIOL, V24, P1798, DOI 10.1016/j.jvir.2013.04.030; Irie T, 2013, CARDIOVASC INTER RAD, V36, P706, DOI 10.1007/s00270-012-0476-z; Etezadi V, 2011, J VASC INTERV RADIOL, V22, P1246, DOI 10.1016/j.jvir.2011.05.012; Brinjikji W, 2009, AM J NEURORADIOL, V30, P1513, DOI 10.3174/ajnr.A1633; Hayashi S, 2012, J VASC INTERV RADIOL, V23, P1566, DOI 10.1016/j.jvir.2012.09.008; Takebayashi S, 1998, J UROLOGY, V159, P696, DOI 10.1016/S0022-5347(01)63703-0; WHITE RI, 1988, RADIOLOGY, V169, P663; Baldi S, 2009, CARDIOVASC INTER RAD, V32, P352, DOI 10.1007/s00270-008-9415-4; Dinkel HP, 2002, RADIOLOGY, V223, P709, DOI 10.1148/radiol.2233010953; Gwon DI, 2011, AM J ROENTGENOL, V196, P627; HAITJEMA TJ, 1995, THORAX, V50, P719, DOI 10.1136/thx.50.7.719; Irie T, 2009, JPN J INTERVENT RADI, V26, P49; Moret J, 1997, Interv Neuroradiol, V3, P21; REMYJARDIN M, 1991, RADIOLOGY, V180, P699; Remy-Jardin M, 2006, RADIOLOGY, V239, P576, DOI 10.1148/radiol.2391050333; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; Sagara K, 1998, AM J ROENTGENOL, V170, P727; Tanigawa N, 2009, MINIM INVASIV THER, V18, P311, DOI 10.1080/13645700903201365; Uchiyama D, 2007, J VASC INTERV RADIOL, V18, P447, DOI 10.1016/j.jvir.2006.12.727; Yavuz K, 2013, AM J NEURORADIOL, V34, P1778, DOI 10.3174/ajnr.A3464	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	JUL	2015	26	7					1018	1024		10.1016/j.jvir.2014.11.042		7	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	CM3BL	WOS:000357556600014		
J	Tsukada, J; Hasegawa, I; Torikai, H; Sayama, K; Jinzaki, M; Narimatsu, Y				Tsukada, Jitsuro; Hasegawa, Ichiro; Torikai, Hideyuki; Sayama, Koichi; Jinzaki, Masahiro; Narimatsu, Yoshiaki			Interventional Therapeutic Strategy for Hemoptysis Originating from Infectious Pulmonary Artery Pseudoaneurysms	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							CT ANGIOGRAPHY; LUNG	This study reports 6 cases of hemoptysis originating from infectious pulmonary artery pseudoaneurysms (PAPs). Selective pulmonary angiography revealed PAPs in 5 cases, and segmental pulmonary artery embolization was performed using coils and gelatin sponge particles. Systemic arterial embolization also was performed in 5 cases because of inadequate initial control or for shunts from systemic to pulmonary arteries. At a median follow-up time of 9 months (range, 25 d to 25 mo), no recurrence occurred, although 2 patients died of respiratory failure. Segmental artery embolization combined with systemic artery embolization may be useful in patients with hemoptysis secondary to PAPs.	[Tsukada, Jitsuro; Jinzaki, Masahiro] Keio Univ, Sch Med, Dept Radiol, Shinjuku Ku, Tokyo, Japan; [Hasegawa, Ichiro; Torikai, Hideyuki; Narimatsu, Yoshiaki] Kawasaki Municipal Hosp, Dept Diagnost Radiol, Kawasaki, Kanagawa, Japan; [Sayama, Koichi] Kawasaki Municipal Hosp, Dept Resp Med, Kawasaki, Kanagawa, Japan	Tsukada, J (reprint author), Keio Univ, Sch Med, Dept Radiol, Shinjuku Ku, 35 Shinanomachi, Tokyo, Japan.	jitsuro-t@rad.med.keio.ac.jp					Shin TB, 2007, J VASC INTERV RADIOL, V18, P882, DOI 10.1016/j.jvir.2007.04.023; DEFFEBACH ME, 1987, AM REV RESPIR DIS, V135, P463; Keeling AN, 2008, CARDIOVASC INTER RAD, V31, P196, DOI 10.1007/s00270-007-9122-6; Khalil A, 2008, CHEST, V133, P212, DOI 10.1378/chest.07-1159; PLESSINGER VA, 1949, AM REV TUBERC PULM, V60, P589; Sanyika C, 1999, CARDIOVASC INTER RAD, V22, P457, DOI 10.1007/s002709900432; Sbano H, 2005, AM J ROENTGENOL, V184, P1253; Shin S, 2010, RADIOLOGY, V256, P656, DOI 10.1148/radiol.10091416	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	JUL	2015	26	7					1046	1051		10.1016/j.jvir.2015.04.002		6	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	CM3BL	WOS:000357556600019		
J	Namur, J; Pascale, F; Maeda, N; Sterba, M; Ghegediban, SH; Verret, V; Paci, A; Seck, A; Osuga, K; Wassef, M; Reb, P; Laurent, A				Namur, Julien; Pascale, Florentina; Maeda, Noboru; Sterba, Manon; Ghegediban, Saida Homayra; Verret, Valentin; Paci, Angelo; Seck, Atmane; Osuga, Keigo; Wassef, Michel; Reb, Philippe; Laurent, Alexandre			Safety and Efficacy Compared between Irinotecan-Loaded Microspheres HepaSphere and DC Bead in a Model of VX2 Liver Metastases in the Rabbit	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							DRUG-ELUTING BEADS; ARTERIAL CHEMOEMBOLIZATION TACE; COLORECTAL-CANCER; TRANSARTERIAL CHEMOEMBOLIZATION; TUMOR MODEL; IN-VITRO; DOXORUBICIN; PHARMACOKINETICS; INJECTION; THERAPY	Purpose: To compare irinotecan-eluting HepaSphere (BioSphere Medical, Roissy-en-France, France) and DC Bead (Biocompatibles UK Ltd, London, United Kingdom) embolization microspheres for distribution in tumors, release properties, tolerance, and antitumor effects in a model of liver metastases in the rabbit. Materials and Methods: Multiple liver tumors were created by injection of a VX2 cell suspension in the portal vein of rabbits. After 2 weeks, embolization of the proper hepatic artery was performed with a fixed volume of bland HepaSphere (n = 5), irinotecan-loaded HepaSphere (n = 6), or irinotecan-loaded DC Bead (n = 5) microspheres. Untreated animals injected with VX2 cells served as control animals (n = 5). Plasma pharmacokinetics of irinotecan and its metabolite SN38 were assessed. Histopathology and gene expression analysis were performed 3 days after treatment. Results: Among all treated groups, there was no significant difference in liver enzymes or liver damage on histology. Irinotecan-loaded HepaSphere microspheres showed a faster release of drug than DC Bead microspheres leading to a twofold higher concentration of drug in plasma for HepaSphere microspheres. HepaSphere microspheres were less frequently found inside tumor nodules on histology than DC Bead microspheres (11% vs 48%, P < .001) because of their larger size. Tumor necrosis was significantly greater for rabbits given irinotecan-loaded HepaSphere microspheres (69% of total tumor surface) and rabbits given DC Bead microspheres (50% of total tumor surface) compared with control animals (24% of total tumor surface, P = .006 and P = .047). Conclusions: HepaSphere and DC Bead microspheres loaded with irinotecan caused significant necrosis of tumor nodules in a model of VX2 liver metastases. This outcome was mostly due to irinotecan delivery rather than vascular occlusion by the microspheres and was greater for HepaSphere microspheres compared with DC Bead microspheres.	[Namur, Julien; Pascale, Florentina; Sterba, Manon; Ghegediban, Saida Homayra; Verret, Valentin] Archimmed, F-78350 Jouy En Josas, France; [Maeda, Noboru; Osuga, Keigo] Osaka Univ, Grad Sch Med, Dept Diagnost & Intervent Radiol, Osaka, Japan; [Paci, Angelo; Seck, Atmane] Gustave Roussy, Pharmacol & Drug Anal Dept, Villejuif, France; [Paci, Angelo] Univ Paris 11, Vectorol & Anticancerous Therapeut, Villejuif, France; [Wassef, Michel] Hop Lariboisiere, AP HP, Dept Pathol, F-75475 Paris, France; [Laurent, Alexandre] Hop Lariboisiere, AP HP, Dept Neuroradiol, F-75475 Paris, France; [Wassef, Michel; Laurent, Alexandre] Univ Diderot Paris 7, Paris, France; [Reb, Philippe] Biosphere Med, Roissy En France, France	Namur, J (reprint author), Archimmed, 12 Rue Charles Gaulle, F-78350 Jouy En Josas, France.	julien.namur@archimmed.com					Fiorentini G, 2012, ANTICANCER RES, V32, P1387; Martin RCG, 2012, J GASTROINTEST SURG, V16, P1531, DOI 10.1007/s11605-012-1892-8; Vogl TJ, 2009, RADIOLOGY, V250, P281, DOI 10.1148/radiol.2501080295; Albert M, 2011, CANCER-AM CANCER SOC, V117, P343, DOI 10.1002/cncr.25387; Jordan O, 2010, J VASC INTERV RADIOL, V21, P1084, DOI 10.1016/j.jvir.2010.02.042; Martin RCG, 2011, ANN SURG ONCOL, V18, P192, DOI 10.1245/s10434-010-1288-5; Huppert P, 2014, CARDIOVASC INTER RAD, V37, P154, DOI 10.1007/s00270-013-0632-0; Aliberti C, 2006, ANTICANCER RES, V26, P3793; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Lencioni R, 2014, J VASC INTERV RADIOL, V25, P365, DOI 10.1016/j.jvir.2013.11.027; Baylatry MT, 2011, J BIOMED MATER RES B, V98B, P351, DOI 10.1002/jbm.b.31858; Bower M, 2013, HPB OXFORD, V12, P31; BURGENER FA, 1979, INVEST RADIOL, V14, P410, DOI 10.1097/00004424-197909000-00005; Gruber-Rouh T, 2014, INT J CANCER, V134, P1225, DOI 10.1002/ijc.28443; Ishida H, 2000, SURG ENDOSC-ULTRAS, V14, P239, DOI 10.1007/s004640030047; Jones RP, 2013, EJSO-EUR J SURG ONC, V39, P1122, DOI 10.1016/j.ejso.2013.07.087; lzumi B, 1986, CANCER RES, V46, P4167; Rao PP, 2012, CARDIOVASC INTER RAD, V35, P1448, DOI 10.1007/s00270-012-0343-y; Taketani M, 2007, LIFE SCI, V81, P924, DOI 10.1016/j.lfs.2007.07.026; TANAKA H, 1995, BRIT J CANCER, V72, P650, DOI 10.1038/bjc.1995.389; Tanaka K, 2014, J VASC INTERV RADIOL, V25, p[1727, e1]; Tanaka T, 2014, J VASC INTERV RADIOL, V25, P1037, DOI 10.1016/j.jvir.2014.04.005; Taylor RR, 2007, EUR J PHARM SCI, V30, P7, DOI 10.1016/j.ejps.2006.09.002; Verret V, 2013, CARDIOVASC INTER RAD, V36, P204, DOI 10.1007/s00270-012-0369-1; Wicherts DA, 2007, EJSO-EUR J SURG ONC, V33, pS42, DOI 10.1016/j.ejso.2007.09.017; Yu JS, 2005, CLIN CANCER RES, V11, P2053, DOI 10.1158/1078-0432.CCR-04-1254	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	JUL	2015	26	7					1067	1075		10.1016/j.jvir.2015.03.014		9	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	CM3BL	WOS:000357556600022		
J	Samura, M; Morikage, N; Yamashita, O; Murakami, M; Suehiro, K; Hamano, K				Samura, Makoto; Morikage, Noriyasu; Yamashita, Osamu; Murakami, Masanori; Suehiro, Kotaro; Hamano, Kimikazu			Combination of Aortic Stent Grafting and Arterial Embolization for Bronchial Artery Aneurysm Associated with Bronchial-Pulmonary Arterial Fistula	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Letter									[Samura, Makoto; Morikage, Noriyasu; Yamashita, Osamu; Murakami, Masanori; Suehiro, Kotaro; Hamano, Kimikazu] Yamaguchi Univ, Grad Sch Med, Dept Surg & Clin Sci, Div Vasc Surg, Ube, Yamaguchi, Japan	Samura, M (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Surg & Clin Sci, Div Vasc Surg, I-1-1 Minami Kogushi, Ube, Yamaguchi, Japan.						Tanaka K, 2003, J VASC SURG, V38, P1125, DOI 10.1016/S0741-5214(03)00707-9; Lu PH, 2011, CARDIOVASC INTER RAD, V34, P508, DOI 10.1007/s00270-010-9895-x; Fujita J, 1991, Nihon Kyobu Shikkan Gakkai Zasshi, V29, P1591; Mizuguchi S, 2009, ANN THORAC CARDIOVAS, V15, P115	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	JUL	2015	26	7					1077	1079		10.1016/j.jvir.2015.01.035		3	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	CM3BL	WOS:000357556600023		
J	Kondo, Y; Kimura, O; Tanaka, Y; Ninomiya, M; Iwata, T; Kogure, T; Inoue, J; Sugiyama, M; Morosawa, T; Fujisaka, Y; Shimosegawa, T				Kondo, Yasuteru; Kimura, Osamu; Tanaka, Yasuhito; Ninomiya, Masashi; Iwata, Tomoaki; Kogure, Takayuki; Inoue, Jun; Sugiyama, Masaya; Morosawa, Tatsuki; Fujisaka, Yasuyuki; Shimosegawa, Tooru			Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1(+) Immune Cells	JOURNAL OF VIROLOGY			English	Article							REGULATORY T-CELLS; NATURAL-KILLER-CELLS; HEPATOCELLULAR-CARCINOMA; GENOTYPE-C; LAMIVUDINE THERAPY; RECEPTOR CX3CR1; LIVER-INJURY; INFECTION; FRACTALKINE; HEPATOCYTES	In addition to stellate cells and immune cells, inflamed hepatocytes and hepatoma cells express various kinds of chemokines that attract various kinds of immune cells. Previously, we reported that hepatitis B virus (HBV) replication can induce physiological stress. The aim of this study was to analyze the effect of chemokines produced by HBV-infected hepatocytes and hepatoma cells. A real-time PCR array targeting genes related to chemokines and enzyme-linked immunosorbent assay (ELISA) were carried out to detect the specific chemokines produced by Huh7 cells and HepG2 cells infected with various HBV genotypes. A migration assay, flow cytometry analysis, and immunohistochemistry were carried out to analyze the candidate immune cells that can affect the immunopathogenesis of HBV infection. The expressions of CX3CL1 mRNA and protein were significantly different among HBV genotypes A, B, and C and control cells (mock) (P < 0.05). CD56(+) NK cells and CD8(+) T cells migrated to the hepatoma cells with HBV replication. Moreover, the migration activity of both immune cells was partially cancelled after the treatment of CX3CL1 neutralizing antibody. The expression level of NKG2D on CX3CR1(+) NK cells in HCC with HBV infection was significantly lower than that in hepatocellular carcinoma (HCC) with HCV infection and chronic hepatitis B and C patients (P < 0.05). On the other hand, the frequency of PD-1(high) CX3CR1(+) CD8(+) T cells in HCC with HBV infection was significantly higher than that in HCC with HCV infection and chronic hepatitis B and C (P < 0.05). The expression of CX3CL1 in HBV-replicating hepatocytes and hepatoma cells could contribute to the immunopathogenesis of HBV infection. IMPORTANCE The progressions of the disease are significantly different among HBV genotypes. However, it has not been clear that how different HBV genotypes could induce different inflammatory responses. Here, we first report that the levels of expression of CX3CL1 mRNA and protein were significantly different among HBV genotypes A, B, and C and mock. Not only the differential expression of CX3CL1 among the genotypes but also the phenotype of CX3CR1(+) NK cells and T cells were gradually changed during the progression of the disease status. In addition to in vitro study, the analysis of immunohistochemistry with human samples and NOG mice with human lymphocytes and hepatoma cells supports this phenomenon. The quantification of CX3CL1 could contribute to better understanding of the disease status of HBV infection. Moreover, modifying CX3CL1 might induce an immune response appropriate to the disease status of HBV infection.	[Kondo, Yasuteru; Kimura, Osamu; Ninomiya, Masashi; Iwata, Tomoaki; Kogure, Takayuki; Inoue, Jun; Morosawa, Tatsuki; Fujisaka, Yasuyuki; Shimosegawa, Tooru] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan; [Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med, Dept Virol, Nagoya, Aichi, Japan; [Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med, Liver Unit, Nagoya, Aichi, Japan; [Sugiyama, Masaya] Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Chiba, Japan	Kondo, Y (reprint author), Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan.	yasuteru@ebony.plala.or.jp			Ministry of Education, Culture, Sport, Science, and Technology of Japan [25460970, 23790761]; Ministry of Health, Labor and Welfare	This work was supported in part by a grant-in-aid from the Ministry of Education, Culture, Sport, Science, and Technology of Japan (Y.K. 25460970 and 23790761) and a grant-in-aid from the Ministry of Health, Labor and Welfare.	Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2; Miyakawa Y, 2003, INTERVIROLOGY, V46, P329, DOI 10.1159/000074988; Ebihara T, 2007, INT IMMUNOL, V19, P1145, DOI 10.1093/intimm/dxm073; Tang L, 2007, GENE THER, V14, P1226, DOI 10.1038/sj.gt.3302959; Kondo Y, 2010, J INFECT DIS, V202, P202, DOI 10.1086/653496; Zhou SL, 2012, HEPATOLOGY, V56, P2242, DOI 10.1002/hep.25907; Cooper A, 2005, J IMMUNOL, V175, P3165; Nan XP, 2010, VIRAL IMMUNOL, V23, P63, DOI 10.1089/vim.2009.0061; Deignan T, 2002, J HEPATOL, V37, P101, DOI 10.1016/S0168-8278(02)00072-7; Li N, 2009, BIOCHEM BIOPH RES CO, V390, P630, DOI 10.1016/j.bbrc.2009.10.018; Vilarinho S, 2007, P NATL ACAD SCI USA, V104, P18187, DOI 10.1073/pnas.0708968104; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.012; Capone F, 2010, EUR CYTOKINE NETW, V21, P99, DOI 10.1684/ecn.2010.0192; Tjwa ETTL, 2011, J HEPATOL, V54, P209, DOI 10.1016/j.jhep.2010.07.009; Wiegand J, 2010, SEMIN LIVER DIS, V30, P361, DOI 10.1055/s-0030-1267537; Stoop JN, 2005, HEPATOLOGY, V41, P771, DOI 10.1002/hep.20649; Boni C, 2003, J HEPATOL, V39, P595, DOI 10.1016/S0168-8278(03)00292-7; Shimoda S, 2010, HEPATOLOGY, V51, P567, DOI 10.1002/hep.23318; Huang F, 2010, WORLD J GASTROENTERO, V16, P1832, DOI 10.3748/wjg.v16.i15.1832; Wang Z, 2007, J VIRAL HEPATITIS, V14, P426, DOI 10.1111/j.1365-2893.2006.00813.x; Sugiyama M, 2006, HEPATOLOGY, V44, P915, DOI 10.1002/hep.21345; Chen XJ, 2013, EUR J PHARMACOL, V721, P86, DOI 10.1016/j.ejphar.2013.09.050; Monnier J, 2012, EUR J CANCER, V48, P138, DOI 10.1016/j.ejca.2011.06.044; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; Aoyama T, 2010, HEPATOLOGY, V52, P1390, DOI 10.1002/hep.23795; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Liaw YF, 2010, ANTIVIR THER, V15, P25, DOI 10.3851/IMP1621; Maier H, 2007, J IMMUNOL, V178, P2714; Li FL, 2013, GASTROENTEROLOGY, V144, P392, DOI 10.1053/j.gastro.2012.10.039; Chen YY, 2007, HEPATOLOGY, V46, P706, DOI 10.1002/hep.21872; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Efsen E, 2002, J HEPATOL, V37, P39, DOI 10.1016/S0168-8278(02)00065-X; Frelin L, 2009, J VIROL, V83, P1379, DOI 10.1128/JVI.01902-08; Garcia-Alvarez M, 2011, CYTOKINE, V54, P244, DOI 10.1016/j.cyto.2011.03.001; Hassanshahi G, 2008, IRAN J ALLERGY ASTHM, V7, P61, DOI 07.02/ijaai.6168; Jegaskanda S, 2014, J VIROL, V88, P10412, DOI 10.1128/JVI.00111-14; Joshi-Barve S, 2003, HEPATOLOGY, V38, P1178, DOI 10.1053/jhep.2003.50470; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Kondo Y, 2006, WORLD J GASTROENTERO, V12, P4310; Kondo Y, 2004, J MED VIROL, V74, P425, DOI 10.1002/jmv.20194; Kondo Y, 2004, LIVER INT, V24, P561, DOI 10.1111/j.1478-3231.2004.0982.x; Maeshiro T, 2007, WORLD J GASTROENTERO, V13, P4560; Matsubara T, 2007, J SURG ONCOL, V95, P241, DOI 10.1002/jso.20642; Muhlbauer M, 2005, ONCOL REP, V13, P957; Nakayoshi T, 2003, J MED VIROL, V70, P350, DOI 10.1002/jmv.10270; Ohashi T, 2009, HEPATOL RES, V39, P510, DOI 10.1111/j.1872-034X.2008.00482.x; Sun C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002594; Tang KF, 2009, MED MICROBIOL IMMUN, V198, P27, DOI 10.1007/s00430-008-0101-6; Wasmuth HE, 2008, J HEPATOL, V48, P208, DOI 10.1016/j.jhep.2007.09.008	49	1	1	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	JUL	2015	89	14					7016	7027		10.1128/JVI.00716-15		12	Virology	Virology	CM3XU	WOS:000357619500006		
J	Kuse, N; Rahman, MA; Murakoshi, H; Tran, GV; Chikata, T; Koyanagi, M; Nguyen, KV; Gatanaga, H; Oka, S; Takiguchi, M				Kuse, Nozomi; Rahman, Mohammad Arif; Murakoshi, Hayato; Giang Van Tran; Chikata, Takayuki; Koyanagi, Madoka; Kinh Van Nguyen; Gatanaga, Hiroyuki; Oka, Shinichi; Takiguchi, Masafumi			Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections	JOURNAL OF VIROLOGY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSMITTED DRUG-RESISTANCE; I DOWN-REGULATION; VIROLOGICAL FAILURE; ANTIRETROVIRAL THERAPY; HLA-B-ASTERISK-3501 MOLECULES; NAIVE INDIVIDUALS; CTL RECOGNITION; REPLICATION; PROGRESSION	The effect of antiretroviral drug resistance mutations on cytotoxic T lymphocyte (CTL) recognition has been analyzed in HIV-1 subtype B infections, but it remains unclear in infections by other HIV-1 subtypes that are epidemic in countries where antiretroviral drugs are not effectively used. We investigated the effect of nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI)-resistance mutations (Y181C, Y181I, and Y181V) on epitope recognition by CTLs specific for 3 different HIV-1 epitopes (HLA-A*02:01-restricted IV10, HLA-B*35:01-restricted NY9, and HLA-C*12:02-restricted KY9) in subtype B and subtype A/E infections and the accumulation of these mutations in treatment-naive Japanese and Vietnamese. These NNRTI-resistance mutations critically affected NY9-specific and KY9-specific T cell responses in the subtype B infections, whereas they showed a different effect on IV10-specific T cell responses among the subtype B-infected individuals. These mutations affected IV10-specific T cell responses but weakly affected NY9-specific T cell responses in the subtype A/E infections. The substitution at position 3 of NY9 epitope which was found in the subtype A/E virus differently influenced the peptide binding to HLA-B*35: 01, suggesting that the differences in peptide binding may result in the differences in T cell recognition between the subtype B virus and A/E virus infections. The Y181C mutation was found to be accumulating in treatment-naive Vietnamese infected with the subtype A/E virus. The present study demonstrated different effects of NNRTI-resistance RT181 mutations on CTL responses between the 2 subtype infections. The Y181C mutation may influence HIV-1 control by the CTLs in Vietnam, since this mutation has been accumulating in treatment-naive Vietnamese. IMPORTANCE Antiretroviral therapy leads to the emergence of drug-resistant HIV-1, resulting in virological and clinical failures. Though HIV-1-specific CTLs play a critical role in HIV-1 infection, some of drug resistance mutations located in CTL epitopes are known to affect HIV-1-specific CTL responses. Nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistance RT181 mutations are frequently observed in patients treated with NNRTIs. Such drug resistance mutations may have an influence on immune control by HIV-1-specific CTLs, especially in countries where antiretroviral drugs are not effectively used. We here investigated the effect of three NNRTI-resistance RT181 mutations on immune responses by HIV-1-specific CTLs and the recent accumulation of these mutations in treatment-naive Vietnamese infected with HIV-1 subtype A/E virus. RT181 mutations affected CTL recognition in both subtype A/E and B infections, while the RT Y181C mutation has been accumulating in treatment-naive Vietnamese. The results suggest that the Y181C mutation may influence HIV-1 control by CTLs in Vietnam.	[Kuse, Nozomi; Rahman, Mohammad Arif; Murakoshi, Hayato; Giang Van Tran; Chikata, Takayuki; Koyanagi, Madoka; Gatanaga, Hiroyuki; Oka, Shinichi; Takiguchi, Masafumi] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan; [Takiguchi, Masafumi] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan; [Kinh Van Nguyen] Natl Hosp Trop Dis, Hanoi, Vietnam; [Gatanaga, Hiroyuki; Oka, Shinichi] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan	Takiguchi, M (reprint author), Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan.	masafumi@kumamoto-u.ac.jp			Global COE program "Global Education and Research Center Aiming at the Control of AIDS"; Ministry of Health, Labour, and Welfare; Ministry of Education, Culture, Sports, Science and Technology, Japan; Institute of Tropical Medicine, Nagasaki University; Joint Research Grant	This research was supported by the Global COE program "Global Education and Research Center Aiming at the Control of AIDS," launched as a project commissioned by the Ministry of Education, Culture, Sports, Science and Technology, Japan; by Grants-in-Aid for AIDS Research from the Ministry of Health, Labour, and Welfare and from the Ministry of Education, Culture, Sports, Science and Technology, Japan; and by a Joint Research Grant with the Institute of Tropical Medicine, Nagasaki University.	Tomiyama H, 2005, J IMMUNOL, V174, P36; Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979; Kandathil AJ, 2009, INT J STD AIDS, V20, P522, DOI 10.1258/ijsa.2008.008403; Masimba P, 2013, AIDS RES HUM RETROV, V29, P1229, DOI [10.1089/AID.2011.0367, 10.1089/aid.2011.0367]; Vingerhoets J, 2010, AIDS, V24, P503, DOI 10.1097/QAD.0b013e32833677ac; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; KOUP RA, 1994, J VIROL, V68, P4650; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Rimsky L, 2012, JAIDS-J ACQ IMM DEF, V59, P39, DOI 10.1097/QAI.0b013e31823df4da; BORROW P, 1994, J VIROL, V68, P6103; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Chikata T, 2014, J VIROL, V88, P4764, DOI 10.1128/JVI.00147-14; Lloyd B, 2008, AIDS RES HUM RETROV, V24, P529, DOI 10.1089/aid.2007.0172; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Hu ZX, 2014, J VIROL, V88, P9268, DOI 10.1128/JVI.00695-14; Martinez-Picado J, 2008, VIRUS RES, V134, P104, DOI 10.1016/j.virusres.2007.12.021; Takata H, 2006, J IMMUNOL, V177, P4330; Akari H, 2000, J VIROL, V74, P2907, DOI 10.1128/JVI.74.6.2907-2912.2000; Mason RA, 2004, J IMMUNOL, V172, P7212; Parreira R, 2006, MICROBES INFECT, V8, P2442, DOI 10.1016/j.micinf.2006.05.005; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Anta L, 2013, AIDS, V27, P81, DOI 10.1097/QAD.0b013e3283584500; Avila-Rios S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027812; Brumme CJ, 2013, J VIROL, V87, P8805, DOI 10.1128/JVI.00335-13; Eshleman SH, 2004, JAIDS-J ACQ IMM DEF, V35, P126, DOI 10.1097/00126334-200402010-00004; Gupta S, 2011, ANTIMICROB AGENTS CH, V55, P2872, DOI 10.1128/AAC.01695-10; Hassan AS, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-9; Honda K, 2011, EUR J IMMUNOL, V41, P97, DOI 10.1002/eji.201040841; Hunt GM, 2012, CLIN INFECT DIS, V54, pS334, DOI 10.1093/cid/cir1017; Kawashima Y, 2010, J VIROL, V84, P7151, DOI 10.1128/JVI.00171-10; Kebe K, 2013, AIDS RES HUM RETROV, V29, P242, DOI 10.1089/aid.2011.0300; Li HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072630; Li J, 2009, CHINESE MED J-PEKING, V122, P1081, DOI 10.3760/cma.j.issn.0366-6999.2009.09.013; Chen M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-382; Mueller SM, 2011, JAIDS-J ACQ IMM DEF, V56, P109, DOI 10.1097/QAI.0b013e3181fe946e; Parczewski M, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18929; Rahman MA, 2014, MICROBES INFECT, V16, P434, DOI 10.1016/j.micinf.2014.03.003; Reuman EC, 2010, J ANTIMICROB CHEMOTH, V65, P1477, DOI 10.1093/jac/dkq140; Rhee SY, 2004, ANTIMICROB AGENTS CH, V48, P3122, DOI 10.1128/AAC.48.8.3122-3126.2004; Samri A, 2000, J VIROL, V74, P9306, DOI 10.1128/JVI.74.19.9306-9312.2000; Stanford University, 2014, HIV 1 DRUG RES MUT D; Stanford University. Last update, 2014, MUT PREV ACC SUBT TR; TAKAMIYA Y, 1994, INT IMMUNOL, V6, P255; Tambuyzer L, 2010, AIDS RES HUM RETROV, V26, P1197, DOI 10.1089/aid.2009.0302; Tambuyzer Lotke, 2009, Antivir Ther, V14, P103; Tanuma J, 2014, JAIDS-J ACQ IMM DEF, V66, P358, DOI 10.1097/QAI.0000000000000196; Tomiyama H, 2000, EUR J IMMUNOL, V30, P2521, DOI 10.1002/1521-4141(200009)30:9<2521::AID-IMMU2521>3.0.CO;2-Q; Tomiyama H, 1997, J IMMUNOL, V158, P5026; vanderBurg SH, 1997, J IMMUNOL, V159, P3648; Vollbrecht T, 2012, MED MICROBIOL IMMUN, V201, P201, DOI 10.1007/s00430-011-0222-1; Yusim K, 2013, HIV MOL IMMUNOLOGY D	52	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	JUL	2015	89	14					7363	7372		10.1128/JVI.00974-15		10	Virology	Virology	CM3XU	WOS:000357619500034		
J	Pandey, S; Khanna, P; Yokota, H				Pandey, Shreelekha; Khanna, Pritee; Yokota, Haruo			An effective use of adaptive combination of visual features to retrieve image semantics from a hierarchical image database	JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION			English	Article						Image semantics; Semantic similarity; Visual similarity; Hierarchical image database; Semantic based categorization; Visual features; Visual search space; Search space pruning	ANNOTATION; SEGMENTATION; PICTURES; SEARCH	Correlating semantic and visual similarity of an image is a challenging task. Unlimited possibilities of objects classification in real world are challenges for learning based techniques. Semantics based categorization of images gives a semantically categorized hierarchical image database. This work utilizes the strength of such database and proposes a system for automatic semantics assignment to images using an adaptive combination of multiple visual features. 'Branch Selection Algorithm' selects only a few subtrees to search from this image database. Pruning Algorithms further reduce this search space. Correlation of semantic and visual similarities is also explored to understand overlapping of semantics in visual space. The efficacy of the proposed algorithms analyzed on hierarchical and non-hierarchical databases shows that the system is capable of assigning accurate general and specific semantics to images automatically. (C) 2015 Elsevier Inc. All rights reserved.	[Pandey, Shreelekha; Khanna, Pritee] PDPM Indian Inst Informat Technol Design & Mfg Ja, Jabalpur 482005, MP, India; [Yokota, Haruo] Tokyo Inst Technol, Grad Sch Informat Sci & Engn, Meguro Ku, Tokyo 1528552, Japan	Khanna, P (reprint author), PDPM Indian Inst Informat Technol Design & Mfg Ja, Dumna Aizport Rd, Jabalpur 482005, MP, India.	shreelekha@iiitdmj.ac.in; pkhanna@iiitdmj.ac.in; yokota@cs.titech.ac.jp	Yokota, Haruo/N-6975-2014	Yokota, Haruo/0000-0001-9788-0443	JSPS	This work is done during the JSPS Invitation Fellowship for Research in Japan (Long-Term) from May 2011 to January 2012. The authors acknowledge the support provided by JSPS Fellowship.	Wang XY, 2013, J VIS COMMUN IMAGE R, V24, P63, DOI 10.1016/j.jvcir.2012.10.003; Deng J, 2009, PROC CVPR IEEE, P248; Liu C, 2011, IEEE T PATTERN ANAL, V33, P2368, DOI 10.1109/TPAMI.2011.131; [Anonymous], 2014, GOOGLE IMAGE SEARCH; Monay F, 2007, IEEE T PATTERN ANAL, V29, P1802, DOI 10.1109/TPAMI.2007.1097; Wang XY, 2011, 2011 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV), P209; Wang M, 2014, INFORM SCIENCES, V262, P159, DOI 10.1016/j.ins.2013.11.005; Liu Y, 2007, PATTERN RECOGN, V40, P262, DOI 10.1016/j.patcog.2006.04.045; Deselaers T, 2008, INFORM RETRIEVAL, V11, P77, DOI 10.1007/s10791-007-9039-3; Chen N, 2012, IEEE T PATTERN ANAL, V34, P2365, DOI 10.1109/TPAMI.2012.64; Li J, 2008, IEEE T PATTERN ANAL, V30, P985, DOI 10.1109/TPAMI.2007.70847; Li J, 2003, IEEE T PATTERN ANAL, V25, P1075; Manjunath BS, 1996, IEEE T PATTERN ANAL, V18, P837, DOI 10.1109/34.531803; Feng YS, 2013, IEEE T PATTERN ANAL, V35, P797, DOI 10.1109/TPAMI.2012.118; Wang XJ, 2008, IEEE T PATTERN ANAL, V30, P1919, DOI 10.1109/TPAMI.2008.127; Wang L, 2014, IEEE T PATTERN ANAL, V36, P417, DOI 10.1109/TPAMI.2013.160; Choi MJ, 2012, IEEE T PATTERN ANAL, V34, P240, DOI 10.1109/TPAMI.2011.119; Yu J, 2012, IEEE T IMAGE PROCESS, V21, P3262, DOI 10.1109/TIP.2012.2190083; Deng YN, 2001, IEEE T PATTERN ANAL, V23, P800, DOI 10.1109/34.946985; Shotton J, 2006, LECT NOTES COMPUT SC, V3951, P1; Wang XY, 2011, COMPUT STAND INTER, V33, P59, DOI 10.1016/j.csi.2010.03.004; Liu GH, 2013, PATTERN RECOGN, V46, P188, DOI 10.1016/j.patcog.2012.06.001; Gao Y, 2013, IEEE T IMAGE PROCESS, V22, P363, DOI 10.1109/TIP.2012.2202676; Carneiro G, 2007, IEEE T PATTERN ANAL, V29, P394, DOI 10.1109/TPAMI.2007.61; Wu L, 2013, IEEE T PATTERN ANAL, V35, P716, DOI 10.1109/TPAMI.2012.124; Vassilieva NS, 2009, PROGRAM COMPUT SOFT+, V35, P158, DOI 10.1134/S0361768809030049; Qi GJ, 2009, IEEE T PATTERN ANAL, V31, P1880, DOI 10.1109/TPAMI.2008.218; Yu J, 2014, IEEE T CYBERNETICS, V44, P2431, DOI 10.1109/TCYB.2014.2307862; [Anonymous], 2014, NIST SEMATECH E HDB; Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94; Fei-Fei L., 2007, COMPUTER VISION IMAG, V106, P59, DOI DOI 10.1016/J.CVIU.2005.09.012; Fellbaum C, 1998, WORDNET ELECT LEXICA; Gali R., 2012, 4 INT C COMP INT COM, P243; Hui H.W., 2010, INT J IMAGE PROCESS, V4, P192; Khanna Pritee, 2013, Database and Expert Systems Applications. 24th International Conference, DEXA 2013. Proceedings: LNCS 8055, DOI 10.1007/978-3-642-40285-2_11; Kim JR, 2007, IEEE T CIRC SYST VID, V17, P635, DOI 10.1109/TCSVT.2007.894040; Kinnaree P, 2011, PROCEDIA ENGINEER, V8, P36, DOI 10.1016/j.proeng.2011.03.007; Malik F., 2012, INT C INN MAN TECHN, P624; Marszalek M., 2007, IEEE C COMP VIS PATT, P1; Rubner Y, 1998, SIXTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, P59, DOI 10.1109/ICCV.1998.710701; Sternberg R. J., 2008, COGNITIVE PSYCHOL, V5th; Stricker M., 1995, Proceedings of the SPIE - The International Society for Optical Engineering, V2420, DOI 10.1117/12.205308; Sural S., 2002, JCIS, P664; Wong RCF, 2008, IEEE T PATTERN ANAL, V30, P1933, DOI 10.1109/TPAMI.2008.125; Yu J, 2014, IEEE T IMAGE PROCESS, V23, P2019, DOI 10.1109/TIP.2014.2311377; Yu J, 2014, IEEE T MULTIMEDIA, V16, P159, DOI 10.1109/TMM.2013.2284755	46	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1047-3203	1095-9076		J VIS COMMUN IMAGE R	J. Vis. Commun. Image Represent.	JUL	2015	30						136	152		10.1016/j.jvcir.2015.03.010		17	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CM5XI	WOS:000357761900013		
J	Murakami, T; Kageyama, Y; Nishida, M				Murakami, Tatsuki; Kageyama, Yoichi; Nishida, Makoto			Background replacement using chromatic adaptation transform for visual communication	JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION			English	Article						Visual communication; Background replacement; Chromatic adaptation transform; Illuminant color estimation; Gray world assumption; Dichromatic reflection model; Video chat; Subjective evaluation	COLOR	Replacing a video chat background with a landscape image can generate the realism of a user actually being in the landscape. To enhance this realism, we proposed in our previous study a background replacement method that uses a chromatic adaptation transform. This method can enhance the realism of video chat by fitting the color of the foreground image to an illuminant color of a landscape, which is used as the new background image. However, if an incorrect color of the landscape illuminant is obtained through this method, which estimates the illuminant color on the basis of a gray world assumption, the method might not enhance the realism. This is because it converts the foreground color to an incorrect color. In this paper, we therefore propose a method to estimate illuminant color on the basis of the dichromatic reflection model, which improves background replacement using the chromatic adaptation transform. We perform a subjective evaluation using 13 subjects to examine the effects of the proposed method. The results indicate that the proposed method can effectively enhance the realism of the background replacement video. (C) 2015 Elsevier Inc. All rights reserved.	[Murakami, Tatsuki; Kageyama, Yoichi; Nishida, Makoto] Akita Univ, Akita 0108502, Japan	Murakami, T (reprint author), Akita Univ, 1-1 Tegata Gakuen Machi, Akita 0108502, Japan.	kageyama@ie.akita-u.ac.jp					Comaniciu D, 2002, IEEE T PATTERN ANAL, V24, P603, DOI 10.1109/34.1000236; [Anonymous], 1999, Z8725 JIS; Thurstone LL, 1927, PSYCHOL REV, V34, P273, DOI 10.1037/h0070288; BUCHSBAUM G, 1980, J FRANKLIN I, V310, P1, DOI 10.1016/0016-0032(80)90058-7; Borg I, 2005, MODERN MULTIDIMENSIO; Fairchild M. D., 2013, COLOR APPEARANCE MOD; Morita S., 2005, Transactions of the Institute of Electronics, Information and Communication Engineers D-II, VJ88-D-II; Murakami T., 2013, 7 INT C MAT ENG RES, P262; Murakami T., 2013, J JPN SOC FUZZY THEO, V25, P806; Murakami T, 2013, IEEE SYS MAN CYBERN, P273, DOI 10.1109/SMC.2013.53; SHAFER SA, 1985, COLOR RES APPL, V10, P210, DOI 10.1002/col.5080100409; The Color Science Association of Japan, 2011, HDB COL SCI; Yun T., YUN FREE STACK PHOTO	13	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1047-3203	1095-9076		J VIS COMMUN IMAGE R	J. Vis. Commun. Image Represent.	JUL	2015	30						242	251		10.1016/j.jvcir.2015.04.007		10	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CM5XI	WOS:000357761900022		
J	Hurvitz, SA; Andre, F; Jiang, ZF; Shao, ZM; Mano, MS; Neciosup, SP; Tseng, LM; Zhang, QY; Shen, KW; Liu, DG; Dreosti, LM; Burris, HA; Toi, M; Buyse, ME; Cabaribere, D; Lindsay, MA; Rao, S; Pacaud, LB; Taran, T; Slamon, D				Hurvitz, Sara A.; Andre, Fabrice; Jiang, Zefei; Shao, Zhimin; Mano, Max S.; Neciosup, Silvia P.; Tseng, Ling-Min; Zhang, Qingyuan; Shen, Kunwei; Liu, Donggeng; Dreosti, Lydia M.; Burris, Howard A.; Toi, Masakazu; Buyse, Marc E.; Cabaribere, David; Lindsay, Mary-Ann; Rao, Shantha; Pacaud, Lida Bubuteishvili; Taran, Tetiana; Slamon, Dennis			Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial	LANCET ONCOLOGY			English	Article							MTOR INHIBITORS; OPEN-LABEL; THERAPY; LAPATINIB; CHEMOTHERAPY; PERTUZUMAB; DOCETAXEL; SURVIVAL; WOMEN; RESISTANCE	Background mTOR inhibition reverses trastuzumab resistance via the hyperactivated PIK/AKT/mTOR pathway due to PTEN loss, by sensitising PTEN-deficient tumours to trastuzumab. The BOLERO-1 study assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer. Methods In this phase 3, randomised, double-blind trial, patients were enrolled across 141 sites in 28 countries. Eligible patients were aged 18 years or older, with locally assessed HER2-positive advanced breast cancer, with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, who had not received previous trastuzumab or chemotherapy for advanced breast cancer within 12 months of randomisation, had measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) or bone lesions in the absence of measurable disease, without previous systemic treatment for advanced disease except endocrine therapy. Patients were randomly assigned (2: 1) with an interactive voice and web response system to receive either 10 mg everolimus once a day orally or placebo plus weekly trastuzumab intravenously at 4 mg/kg loading dose on day 1 with subsequent weekly doses of 2 mg/kg of each 4 week cycle plus paclitaxel intravenously at a dose of 80 mg/m(2) on days 1, 8, and 15 of each 4 week cycle. Randomisation was stratified according to previous use of trastuzumab and visceral metastasis. Patients and investigators were masked to the assigned treatments. Identity of experimental treatments was concealed by use of everolimus and placebo that were identical in packaging, labelling, appearance, and administration schedule. The two primary objectives were investigator-assessed progression-free survival in the full study population and in the subset of patients with hormone receptor-negative breast cancer at baseline; the latter was added during the course of the study, before unmasking based on new clinical and biological findings from other studies. All efficacy analyses were based on the intention-to-treat population. Enrolment for this trial is closed and results of the final progression-free survival analyses are presented here. This trial is registered with ClinicalTrials.gov, number NCT00876395. Findings Between Sept 10, 2009, and Dec 16, 2012, 719 patients were randomly assigned to receive everolimus (n=480) or placebo (n=239). Median follow-up was 41.3 months (IQR 35.4-46.6). In the full population, median progression-free survival was 14.95 months (95% CI 14.55-17.91) with everolimus versus 14.49 months (12.29-17.08) with placebo (hazard ratio 0.89, 95% CI 0.73-1.08; p=0.1166). In the HR-negative subpopulation (n=311), median progression-free survival with everolimus was 20.27 months (95% CI 14.95-24.08) versus 13.08 months (10.05-16.56) with placebo (hazard ratio 0.66, 95% CI 0.48-0.91; p=0.0049); however, the protocol-specified significance threshold (p=0.0044) was not crossed. The most common adverse events with everolimus were stomatitis (314 [67%] of 472 patients in the everolimus group vs 77 [32%] of 238 patients in the placebo group), diarrhoea (267 [57%] vs 111 [47%] patients), and alopecia (221 [47%] vs 125 [53%]). The most frequently reported grade 3 or 4 adverse events in the everolimus group versus the placebo group were neutropenia (117 [25%] vs 35 [15%]), stomatitis (59 [13%] vs three [1%]), anaemia (46 [10%] vs six [3%]) and diarrhoea (43 [9%] vs 10 [4%]) On-treatment adverse event-related deaths were reported in 17 (4%) patients in the everolimus group and none in the placebo group. Interpretation Although progression-free survival was not significantly different between groups in the full analysis population, the 7.2 months prolongation we noted with the addition of everolimus in the HR-negative, HER2-positive population warrants further investigation, even if it did not meet prespecified criteria for significance. The safety profile was generally consistent with what was previously reported in BOLERO-3. Proactive monitoring and early management of adverse events in patients given everolimus and chemotherapy is crucial.	[Hurvitz, Sara A.; Slamon, Dennis] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Andre, Fabrice] Univ Paris 11, Inst Gustave Roussy, Dept Med Oncol, Villejuif, France; [Jiang, Zefei] Beijing 307 Hosp PLA, Beijing, Peoples R China; [Shao, Zhimin] Fudan Univ, Canc Hosp, Dept Breast Surg, Shanghai 200433, Peoples R China; [Mano, Max S.] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil; [Neciosup, Silvia P.] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Tseng, Ling-Min] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei 112, Taiwan; [Zhang, Qingyuan] Harbin Med Univ, Tumor Hosp, Dept Med Oncol, Harbin, Peoples R China; [Shen, Kunwei] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China; [Liu, Donggeng] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Dreosti, Lydia M.] Univ Pretoria, Dept Med Oncol, Gauteng, South Africa; [Burris, Howard A.] Sarah Cannon Res Inst, Nashville, TN USA; [Toi, Masakazu] Kyoto Univ, Grad Sch Med, Dept Breast Surg, Kyoto, Japan; [Buyse, Marc E.] Int Drug Dev Inst, Louvain La Neuve, Belgium; [Cabaribere, David] TRIO, Paris, France; [Lindsay, Mary-Ann] TRIO, Edmonton, AB, Canada; [Rao, Shantha; Taran, Tetiana] Novartis Pharmaceut, E Hanover, NJ USA; [Pacaud, Lida Bubuteishvili] Novartis Pharma AG, Basel, Switzerland	Hurvitz, SA (reprint author), Univ Calif Los Angeles, Dept Med, Div Haematol Oncol, Los Angeles, CA 90095 USA.	shurvitz@mednet.ucla.edu			Novartis Pharmaceuticals	Novartis Pharmaceuticals.	Rugo HS, 2014, ANN ONCOL, V25, P808, DOI 10.1093/annonc/mdu009; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Nahta R, 2012, BREAST CANCER RES TR, V135, P39, DOI 10.1007/s10549-012-2067-8; Hurvitz SA, 2013, BREAST CANCER RES TR, V141, P437, DOI 10.1007/s10549-013-2689-5; Rimawi MF, 2013, J CLIN ONCOL, V31, P1726, DOI 10.1200/JCO.2012.44.8027; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Robidoux A, 2013, LANCET ONCOL, V14, P1183, DOI 10.1016/S1470-2045(13)70411-X; Gianni L, 2013, J CLIN ONCOL, V31, P1719, DOI 10.1200/JCO.2012.44.7912; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764; Aapro M, 2014, ANN ONCOL, V25, P763, DOI 10.1093/annonc/mdu021; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Andre F, 2014, LANCET ONCOL, V15, P580, DOI 10.1016/S1470-2045(14)70138-X; Andre F, 2010, J CLIN ONCOL, V28, P5110, DOI 10.1200/JCO.2009.27.8549; Hudis CA, 2007, NEW ENGL J MED, V357, p39e51; Jerusalem GH, 2010, J CLIN ONCOL, V28; NCCN, 2015, NAT COMPR CANC NETW; Peddi PF, 2014, CANCER TREAT REV, V40, P320, DOI 10.1016/j.ctrv.2013.08.004; Piccart M, 2014, ANN ONCOL, V25, P2357, DOI 10.1093/annonc/mdu456; Qiao LW, 2014, INT J CLIN EXP MED, V7, P3333; Robertson J, 2014, SAN ANT BREAST CANC; Schneeweiss A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3690; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Subbiah IM, 2014, CURR TREAT OPTION ON, V15, P41, DOI 10.1007/s11864-013-0262-4; United States Food And Drug Administration (FDA), 2012, EV 2012	37	4	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUL	2015	16	7					816	829		10.1016/S1470-2045(15)00051-0		14	Oncology	Oncology	CL9CU	WOS:000357273600055		
J	Yang, JCH; Sequist, LV; Geater, SL; Tsai, CM; Mok, TSK; Schuler, M; Yamamoto, N; Yu, CJ; Ou, SHI; Zhou, CC; Massey, D; Zazulina, V; Wu, YL				Yang, James C-H; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long			Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6	LANCET ONCOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-3 TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL; CARBOPLATIN-PACLITAXEL; PROLONGED SURVIVAL; GEFITINIB; CHEMOTHERAPY; ERLOTINIB	Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie, common mutations). However, a subset of patients (10%) with mutations in EGFR have tumours that harbour uncommon mutations. There is a paucity of data regarding the sensitivity of these tumours to EGFR inhibitors. Here we present data for the activity of afatinib in patients with advanced non-small-cell lung cancer that have tumours harbouring uncommon EGFR mutations. Methods In this post-hoc analysis, we used prospectively collected data from tyrosine kinase inhibitor-naive patients with EGFR mutation-positive advanced (stage IIIb-IV) lung adenocarcinomas who were given afatinib in a single group phase 2 trial (LUX-Lung 2), and randomised phase 3 trials (LUX-Lung 3 and LUX-Lung 6). Analyses were done in the intention-to-treat population, including all randomly assigned patients with uncommon EGFR mutations. The type of EGFR mutation (exon 19 deletion [del19], Leu858Arg point mutation in exon 21, or other) and ethnic origin (LUX-Lung 3 only; Asian vs non-Asian) were pre-specified stratification factors in the randomised trials. We categorised all uncommon mutations as: point mutations or duplications in exons 18-21 (group 1); de-novo Thr790Met mutations in exon 20 alone or in combination with other mutations (group 2); or exon 20 insertions (group 3). We also assessed outcomes in patients with the most frequent uncommon mutations, Gly719Xaa, Leu861Gln, and Ser768Ile, alone or in combination with other mutations. Response was established by independent radiological review. These trials are registered with ClinicalTrials.gov, numbers NCT00525148, NCT00949650, and NCT01121393. Findings Of 600 patients given afatinib across the three trials, 75 (12%) patients had uncommon EGFR mutations (38 in group 1, 14 in group 2, 23 in group 3). 27 (71.1%, 95% CI 54.1-84.6) patients in group 1 had objective responses, as did two (14.3%, 1.8-42.8) in group 2 and two (8.7%, 1.1-28.0) in group 3. Median progression-free survival was 10.7 months (95% CI 5.6-14. 7) in group 1, 2.9 months (1.2-8.3) in group 2; and 2.7 months (1.8-4.2) in group 3. Median overall survival was 19.4 months (95% CI 16.4-26.9) in group 1, 14.9 months (8.1-24.9) in group 2, and 9.2 months (4.1-14.2) in group 3. For the most frequent uncommon mutations, 14 (77.8%, 95% CI 52.4-93.6) patients with Gly719Xaa had an objective response, as did nine (56.3%, 29.9-80.2) with Leu861Gln, and eight (100.0%, 63.1-100.0) with Ser768Ile. Interpretation Afatinib was active in non-small-cell lung cancer tumours that harboured certain types of uncommon EGFR mutations, especially Gly719Xaa, Leu861Gln, and Ser768Ile, but less active in other mutations types. Clinical benefit was lower in patients with de-novo Thr790Met and exon 20 insertion mutations. These data could help inform clinical decisions for patients with non-small-cell lung cancer harbouring uncommon EGFR mutations.	[Yang, James C-H] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan; [Yang, James C-H] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Geater, Sarayut Lucien] Prince Songkla Univ, Fac Med, Internal Med, Hat Yai, Songkhla, Thailand; [Tsai, Chun-Ming] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Chest Med, Taipei 112, Taiwan; [Tsai, Chun-Ming] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Mok, Tony Shu Kam] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Schuler, Martin] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany; [Schuler, Martin] German Canc Consortium DKTK, Heidelberg, Germany; [Yamamoto, Nobuyuki] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Wakayama Prefec, Japan; [Yu, Chong-Jen] Natl Taiwan Univ, Dept Internal Med, Taipei, Taiwan; [Yu, Chong-Jen] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Ou, Sai-Hong I.] Univ Calif Irvine, Sch Med, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA; [Zhou, Caicun] Shanghai Pulm Hosp, Shanghai, Peoples R China; [Zazulina, Victoria] Clin Dev & Med Affairs, Bracknell, Berks, England; [Massey, Daniel] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England; [Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China; [Wu, Yi-Long] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China	Wu, YL (reprint author), Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China.	syylwu@live.cn		Yu, Chong-Jen/0000-0001-5664-9392; Yang, James Chih-Hsin/0000-0002-5586-5138	Boehringer Ingelheim	Boehringer Ingelheim.	Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Yang JCH, 2012, LANCET ONCOL, V13, P539, DOI 10.1016/S1470-2045(12)70086-4; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; De Pas T, 2011, J THORAC ONCOL, V6, P1895, DOI 10.1097/JTO.0b013e318227e8c6; Beau-Faller M, 2014, ANN ONCOL, V25, P126, DOI 10.1093/annonc/mdt418; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Costa C, 2014, CLIN CANCER RES, V20, P2001, DOI 10.1158/1078-0432.CCR-13-2233; Yasuda H, 2012, LANCET ONCOL, V13, pE23, DOI 10.1016/S1470-2045(11)70129-2; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Wu JY, 2011, CLIN CANCER RES, V17, P3812, DOI 10.1158/1078-0432.CCR-10-3408; Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Asahina H, 2006, LUNG CANCER, V54, P419, DOI 10.1016/j.lungcan.2006.09.005; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Kim DW, 2011, LUNG CANCER, V71, P65, DOI 10.1016/j.lungcan.2010.04.005; Kobayashi S, 2013, J THORAC ONCOL, V8, P118, DOI 10.1097/JTO.0b013e3182781e35; Masago K, 2010, JPN J CLIN ONCOL, V40, P1105, DOI 10.1093/jjco/hyq087; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Watanabe S, 2014, J THORAC ONCOL, V9, P189, DOI 10.1097/JTO.0000000000000048; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Yasuda H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007205	30	8	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUL	2015	16	7					830	838		10.1016/S1470-2045(15)00026-1		9	Oncology	Oncology	CL9CU	WOS:000357273600056		
J	Zhu, AX; Park, JO; Ryoo, BY; Yen, CJ; Poon, R; Pastorelli, D; Blanc, JF; Chung, HC; Baron, AD; Pfiffer, TEF; Okusaka, T; Kubackova, K; Trojan, J; Sastre, J; Chau, I; Chang, SC; Abada, PB; Yang, L; Schwartz, JD; Kudo, M				Zhu, Andrew X.; Park, Joon Oh; Ryoo, Baek-Yeol; Yen, Chia-Jui; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean-Frederic; Chung, Hyun Cheol; Baron, Ari D.; Pfiffer, Tulio Eduardo Flesch; Okusaka, Takuji; Kubackova, Katerina; Trojan, Jorg; Sastre, Javier; Chau, Ian; Chang, Shao-Chun; Abada, Paolo B.; Yang, Ling; Schwartz, Jonathan D.; Kudo, Masatoshi		REACH Trial Investigators	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial	LANCET ONCOLOGY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ALPHA-FETOPROTEIN LEVELS; CANCER; ANGIOGENESIS; MONOTHERAPY; RECEPTOR-2; CIRRHOSIS; SURVIVAL; DESIGN	Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. Findings Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9.2 months (95% CI 8.0-10.6) versus 7.6 months (6.0-9.3) for the placebo group (HR 0.87 [95% CI 0.72-1.05]; p=0.14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]). The most frequently reported (>= 1%) treatment-emergent serious adverse event of any grade or grade 3 or more was malignant neoplasm progression. Interpretation Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma. No new safety signals were noted in eligible patients and the safety profile is manageable.	[Zhu, Andrew X.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Park, Joon Oh] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Ryoo, Baek-Yeol] Univ Ulsan, Sch Med, Asan Med Ctr, Seoul, South Korea; [Yen, Chia-Jui] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan; [Poon, Ronnie] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; [Pastorelli, Davide] Ist Oncol Veneto IRCCS, Padua, Italy; [Blanc, Jean-Frederic] Hop St Andre, Bordeaux, France; [Chung, Hyun Cheol] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; [Baron, Ari D.] Calif Pacific Med Ctr, San Francisco, CA USA; [Pfiffer, Tulio Eduardo Flesch] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil; [Okusaka, Takuji] Natl Canc Ctr, Tokyo, Japan; [Kubackova, Katerina] Univ Hosp Motol, Prague, Czech Republic; [Trojan, Jorg] Univ Hosp, Ctr Canc, Frankfurt, Germany; [Sastre, Javier] Hosp Clin San Carlos, Madrid, Spain; [Chau, Ian] Royal Marsden Hosp, Surrey, England; [Chang, Shao-Chun] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Yang, Ling] Eli Lilly & Co, Bridgewater, NJ USA; [Schwartz, Jonathan D.] Stemline Therapeut Inc, New York, NY USA	Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.	azhu@partners.org			Eli Lilly and Co.	Eli Lilly and Co.	Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Amini A, 2012, CURR CANCER DRUG TAR, V12, P23; Tangkijvanich P, 2000, J CLIN GASTROENTEROL, V31, P302, DOI 10.1097/00004836-200012000-00007; Kim JE, 2011, CANCER CHEMOTH PHARM, V68, P1285, DOI 10.1007/s00280-011-1616-x; Zhu AX, 2013, CLIN CANCER RES, V19, P6614, DOI 10.1158/1078-0432.CCR-13-1442; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Huang JF, 2011, J CLIN PATHOL, V64, P343, DOI 10.1136/jcp.2010.085142; Chiu J, 2012, CANCER-AM CANCER SOC, V118, P5293, DOI 10.1002/cncr.27543; Gomaa AI, 2009, WORLD J GASTROENTERO, V15, P1301, DOI 10.3748/wjg.15.1301; Tugues S, 2011, MOL ASPECTS MED, V32, P88, DOI 10.1016/j.mam.2011.04.004; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Reig M, 2013, HEPATOLOGY, V58, P2023, DOI 10.1002/hep.26586; Sullivan LA, 2010, MABS-AUSTIN, V2, P165; Lencioni R, 2014, INT J CLIN PRACT, V68, P609, DOI 10.1111/ijcp.12352; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30; Shan YF, 2011, MED ONCOL, V28, P1012, DOI 10.1007/s12032-010-9600-6; Spratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537; Garcia JA, 2014, CANCER-AM CANCER SOC, V120, P1647, DOI 10.1002/cncr.28634; Manghisi G, 1998, HEPATOLOGY, V28, P751; CASTELLS L, 1995, LIVER, V15, P159; Ferlay J, 2015, INT J CANCER, V136, pE356; Iavarone M, 2015, HEPATOLOGY, V62, P784, DOI 10.1002/hep.27729; Kelley RK, 2013, J CLIN ONCOL, V31, P3483, DOI 10.1200/JCO.2013.49.7941; Mailey B, 2011, ARCH SURG-CHICAGO, V146, P26, DOI 10.1001/archsurg.2010.295; Pons Fernando, 2005, HPB (Oxford), V7, P35, DOI 10.1080/13651820410024058; Zhang XF, 2009, EJSO-EUR J SURG ONC, V35, P622, DOI 10.1016/j.ejso.2008.08.003; Zhu AX, 2014, ANN ONCOL, V25, P1; Zhu AX, 2015, P AM SOC CLIN ONCOL, V33	31	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUL	2015	16	7					859	870		10.1016/S1470-2045(15)00050-9		12	Oncology	Oncology	CL9CU	WOS:000357273600059		
J	Refaat, J; Samy, MN; Desoukey, SY; Ramadan, MA; Sugimoto, S; Matsunami, K; Kamel, MS				Refaat, John; Samy, Mamdouh N.; Desoukey, Samar Y.; Ramadan, Mahmoud A.; Sugimoto, Sachiko; Matsunami, Katsuyoshi; Kamel, Mohamed S.			Chemical constituents from Chorisia chodatii flowers and their biological activities	MEDICINAL CHEMISTRY RESEARCH			English	Article						Bombacaceae; Chorisia; Cytotoxicity; DPPH; Flavonoids; Phenolics	GLYCOSIDES; CEIBA	From the flowers of Chorisia chodatii Hassl. (family: Bombacaceae), seventeen compounds were isolated and identified, including: two sterols, beta-sitosterol (1) and beta-sitosterol 3-O-beta-D-glucopyranoside (10); two furanoids, 5-hydroxymethyl furfural (3) and (3R,4R,5S)-3,4-dihydroxy-5-methyl-dihydrofuran-2-one (12); two coumarins, scopoletin (8) and aesculetin (9); four phenolic acids and esters, ethyl vanillate (4), vanillic acid (5), protocatechuic acid ethyl ester (6) and p-hydroxy benzoic acid (7); five flavonoids, kaempferol 3-O-beta-D-(6aEuro(3)-acetyl)-glucopyranoside (13), kaempferol 3-O-beta-D-(6aEuro(3)-E-p-coumaroyl)-glucopyranoside (14), kaempferol 3-O-beta-D-glucopyranoside (15), luteolin 7-O-beta-D-glucopyranoside (16) and apigenin 7-O-neohesperidoside (17), in addition to mono-octyl phthalate (2) and succinic acid (11). All the isolated metabolites were reported for the first time from this plant, and among them, compounds (3), (4), (6), (7), (12) and (13) were isolated for the first time from family Bombacaceae. Besides, this is the first report for isolation of (2) in a pure form from a natural source. These phytochemical data revealed important chemotaxonomic value and may broaden the use of this plant in future phytotherapy. Moreover, all of the obtained phytocompounds were evaluated for their DPPH free radical scavenging properties and cytotoxic activities against the human lung cancer cell line A549.	[Refaat, John; Samy, Mamdouh N.; Desoukey, Samar Y.; Kamel, Mohamed S.] Menia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61519, Egypt; [Ramadan, Mahmoud A.] Assiut Univ, Fac Pharm, Dept Pharmacognosy, Assiut 71515, Egypt; [Sugimoto, Sachiko; Matsunami, Katsuyoshi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pharmacognosy, Minami Ku, Hiroshima 7348553, Japan	Refaat, J (reprint author), Menia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61519, Egypt.	Johnrefaat82@yahoo.com					Adjanohoun E.J., 1988, CONTRIBUTION ETUDES, P605; Ancuceanu Robert V, 2004, Altern Med Rev, V9, P402; Dixit P, 2011, BIOORG MED CHEM LETT, V21, P4617, DOI 10.1016/j.bmcl.2011.05.087; SLIMESTAD R, 1995, PHYTOCHEMISTRY, V40, P1537, DOI 10.1016/0031-9422(95)00383-I; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; YAMAGUCHI I, 1993, BIOSCI BIOTECH BIOCH, V57, P1350; Xu Y, 2007, J AGR FOOD CHEM, V55, P3051, DOI 10.1021/jf0631732; Huang SC, 2003, J AGR FOOD CHEM, V51, P2380, DOI 10.1021/jf0210019; Li CZ, 2009, TETRAHEDRON LETT, V50, P5403, DOI 10.1016/j.tetlet.2009.07.053; Liu RM, 2005, J CHROMATOGR A, V1072, P195, DOI 10.1016/j.chroma.2005.03.023; Refaat J, 2013, PHARM BIOL, V51, P100, DOI 10.3109/13880209.2012.698286; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Ley SV, 2004, ORG BIOMOL CHEM, V2, P3618, DOI 10.1029/b412790k; COUSSIO JD, 1964, EXPERIENTIA, V20, P562, DOI 10.1007/BF02150291; Strassheim D, 2000, CANCER RES, V60, P2730; Ashmawy A. M., 2012, The Journal of American Science, V8, P965; Bailey L.H., 1976, HORTUS 3 CONCISE DIC; Chatwal GR, 2001, SPECTROSCOPY, V5th, P213; Chen GY, 2010, ARKIVOC, P179; Costa D. A. D., 2007, Química Nova, V30, P901, DOI 10.1590/S0100-40422007000400026; De Caluwe E, 2010, AFRIKA FOCUS, V23, P11; De-Wu Z, 2010, CHIN J NAT MED, V8, P196; El-Alfy T. S., 2010, Australian Journal of Basic and Applied Sciences, V4, P1334; Eldahshan O. A., 2013, British Journal of Pharmaceutical Research, V3, P46; El-Demerdash A, 2009, REV LATINOAMER QUIMI, V37, P65; Fernandez AM, 1997, J ORG CHEM, V62, P4007, DOI 10.1021/jo970117e; Gibbs P., 2003, Anales del Jardín Botánico de Madrid, V60, P259; Gohari AR, 2011, IRAN J PHARM RES, V10, P247; Hafez S.S., 2003, MANS J PHARM SCI, V19, P40; Hassan A.A., 2009, THESIS MANSOURA U EG; Huxley A., 1992, DICT GARDENING NEW R; Ibrahim S., 2012, Research Journal of Applied Sciences, Engineering and Technology, V4, P2382; Joshi KR, 2013, NAT PROD COMMUN, V8, P583; Lee Dae-Young, 2007, Journal of Applied Biological Chemistry, V50, P144; Mabry TJ, 1970, SYSTEMATIC IDENTIFIC, P4; Markham KR, 1982, TECHNIQUES FLAVONOID; Matsunami K, 2011, CHEM PHARM BULL, V59, P1274, DOI 10.1248/cpb.59.1274; Parker SP, 1997, DICT CHEM, V1st, P372; Paula VF, 1996, QUIM NOVA, V19, P225; Phan Minh Giang, 2006, Chem Pharm Bull (Tokyo), V54, P546, DOI 10.1248/cpb.54.546; Polterai O, 1997, CURR ORG CHEM, V1, P415; Ravenna P, 1998, ONIRA, V3, P42; Smith I, 1960, CHROMATOGR ELECTROPH, P1; Stahl E, 1970, THIN LAYER CHROMATOG, V2nd, P810; Yu-Bo L, 2011, CHIN J NAT MED, V9, P115	45	0	0	SPRINGER BIRKHAUSER	NEW YORK	233 SPRING STREET, 6TH FLOOR, NEW YORK, NY 10013 USA	1054-2523	1554-8120		MED CHEM RES	Med. Chem. Res.	JUL	2015	24	7					2939	2949		10.1007/s00044-015-1342-8		11	Chemistry, Medicinal	Pharmacology & Pharmacy	CM1VI	WOS:000357468200014		
J	Tsuda, T				Tsuda, Takanori			Possible abilities of dietary factors to prevent and treat diabetes via the stimulation of glucagon-like peptide-1 secretion	MOLECULAR NUTRITION & FOOD RESEARCH			English	Review						Diabetes; Dietary factors; Glucagon-like peptide-1; Incretin; Nutrients	ENTEROENDOCRINE CELL-LINE; BATATAS-L. LEAVES; CHAIN FATTY-ACIDS; GLP-1 SECRETION; GLUCOSE-TOLERANCE; INCRETIN SECRETION; ZEIN HYDROLYSATE; CHLOROGENIC ACID; GLUTAG CELLS; ATTENUATES HYPERGLYCEMIA	There is a pressing need for countermeasures against diabetes, which has increased in incidence, becoming a global issue. Glucagon-like peptide-1 (GLP-1), a molecule secreted in enteroendocrine L cells in the lower small and large intestines, is thought to be one of the most important molecular targets for the prevention and treatment of diabetes. There has been increasing interest in the possible ability of dietary factors to treat diabetes via modulating GLP-1 secretion. There is thought to be a close relationship between incretin and diet, and the purported best approach for using dietary factors to increase GLP-1 activity is promotion of secretion of endogenous GLP-1. It have been reported that nutrients as well as various non-nutrient dietary factors can function as GLP-1 secretogogues. Here, we present our findings on the GLP-1 secretion-stimulating functions of two dietary factors, curcumin and extract of edible sweet potato leaves, which contain caffeoylquinic acid derivatives. However, it is necessary to reveal in greater detail the stimulation of GLP-1 secretion by dietary factors for preventing and treating diabetes. It is desirable to clarify the exact GLP-1 secretory pathway, the effect of metabolites derived from dietary factors in gut lumen, and the relationship between incretin and meal.	Chubu Univ, Coll Biosci & Biotechnol, Kasugai, Aichi 4878501, Japan	Tsuda, T (reprint author), Chubu Univ, Coll Biosci & Biotechnol, 1200 Matsumoto Cho, Kasugai, Aichi 4878501, Japan.	tsudat@isc.chubu.ac.jp			Japan Society for Promotion of Science [26450168]	This review was supported in part by Grants-in-Aid for Scientific Research (No. 26450168) from the Japan Society for Promotion of Science.	Gonzalez-Abuin N, 2014, FOOD FUNCT, V5, P2357, DOI [10.1039/c4fo00447g, 10.1039/C4FO00447G]; Kurata R, 2007, J AGR FOOD CHEM, V55, P185, DOI 10.1021/jf0620259; Higuchi N, 2013, ENDOCRINOLOGY, V154, P3089, DOI 10.1210/en.2012-2275; Tunnicliffe JM, 2008, APPL PHYSIOL NUTR ME, V33, P1290, DOI 10.1139/H08-123; Oya M, 2013, J BIOL CHEM, V288, P4513, DOI 10.1074/jbc.M112.402677; Ma J, 2009, DIABETES CARE, V32, P1600, DOI 10.2337/dc09-0723; Reimann F, 2004, DIABETOLOGIA, V47, P1592, DOI 10.1007/s00125-004-1498-0; Gonzalez-Abuin N, 2014, J AGR FOOD CHEM, V62, P1066, DOI 10.1021/jf405239p; Lovshin JA, 2009, NAT REV ENDOCRINOL, V5, P262, DOI 10.1038/nrendo.2009.48; Lauffer LM, 2009, DIABETES, V58, P1058, DOI 10.2337/db08-1237; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Reimann F, 2008, CELL METAB, V8, P532, DOI 10.1016/j.cmet.2008.11.002; Wu TZ, 2012, AM J CLIN NUTR, V95, P78, DOI 10.3945/ajcn.111.021543; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Takikawa M, 2013, BIOCHEM BIOPH RES CO, V435, P165, DOI 10.1016/j.bbrc.2013.04.092; Diakogiannaki E, 2013, DIABETOLOGIA, V56, P2688, DOI 10.1007/s00125-013-3037-3; Pilichiewicz A, 2003, J CLIN ENDOCR METAB, V88, P3829, DOI 10.1210/jc.2003-030199; Hira T, 2009, AM J PHYSIOL-GASTR L, V297, pG663, DOI 10.1152/ajpgi.90635.2008; Edfalk S, 2008, DIABETES, V57, P2280, DOI 10.2337/db08-0307; Rafferty Eamon P, 2011, Sci Pharm, V79, P615, DOI 10.3797/scipharm.1104-16; Geraedts MCP, 2011, MOL NUTR FOOD RES, V55, P476, DOI 10.1002/mnfr.201000142; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Clemmensen C, 2013, ENDOCRINOLOGY, V154, P3978, DOI 10.1210/en.2013-1529; Carrel G, 2011, AM J CLIN NUTR, V94, P997, DOI 10.3945/ajcn.111.017574; Tolhurst G, 2011, ENDOCRINOLOGY, V152, P405, DOI 10.1210/en.2010-0956; Nagai M, 2011, J CLIN BIOCHEM NUTR, V48, P203, DOI 10.3164/jcbn.10-84; Yu YL, 2010, BIOCHEM PHARMACOL, V79, P1000, DOI 10.1016/j.bcp.2009.11.017; Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439; Parnell JA, 2009, AM J CLIN NUTR, V89, P1751, DOI 10.3945/ajcn.2009.27465; Chen Q, 2009, NUTRITION, V25, P340, DOI 10.1016/j.nut.2008.08.012; Herman GA, 2006, J CLIN ENDOCR METAB, V91, P4612, DOI 10.1210/jc.2006-1009; Reimer RA, 2006, J ENDOCRINOL, V191, P159, DOI 10.1677/joe.1.06557; Hara T, 2011, J PHARM SCI-US, V100, P3594, DOI 10.1002/jps.22639; Tolhurst G, 2012, DIABETES, V61, P364, DOI 10.2337/db11-1019; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Shirazi-Beechey SP, 2014, BRIT J NUTR, V111, pS8, DOI 10.1017/S0007114513002286; Sangle GV, 2012, ENDOCRINOLOGY, V153, P564, DOI 10.1210/en.2011-1732; Johnston KL, 2003, AM J CLIN NUTR, V78, P728; Chuengsamarn S, 2012, DIABETES CARE, V35, P2121, DOI 10.2337/dc12-0116; Zhou J, 2008, AM J PHYSIOL-ENDOC M, V295, pE1160, DOI 10.1152/ajpendo.90637.2008; Parker HE, 2009, DIABETOLOGIA, V52, P289, DOI 10.1007/s00125-008-1202-x; Samocha-Bonet D, 2011, J NUTR, V141, P1233, DOI 10.3945/jn.111.139824; Moriya R, 2009, AM J PHYSIOL-ENDOC M, V297, pE1358, DOI 10.1152/ajpendo.00412.2009; Greenfield JR, 2009, AM J CLIN NUTR, V89, P106, DOI 10.3945/ajcn.2008.26362; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Lee SJ, 2009, MOL CELLS, V28, P167, DOI 10.1007/s10059-009-0119-7; Mochida T, 2010, ENDOCRINOLOGY, V151, P3095, DOI 10.1210/en.2009-1510; Katsuma S, 2005, BIOCHEM BIOPH RES CO, V329, P386, DOI 10.1016/j.bbrc.2005.01.0139; Tanaka T, 2008, N-S ARCH PHARMACOL, V377, P515, DOI 10.1007/s00210-007-0250-y; Bodinham CL, 2013, BRIT J NUTR, V110, P1429, DOI 10.1017/S0007114513000731; Choi SE, 2007, J ETHNOPHARMACOL, V110, P49, DOI 10.1016/j.jep.2006.09.001; Civelli O, 2005, TRENDS PHARMACOL SCI, V26, P15, DOI 10.1016/j.tips.2004.11.05; Dalgaard M, 2004, METABOLISM, V53, P77, DOI 10.1016/j.metabol.2003.08.011; Dao TMA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020700; Delzenne NM, 2007, J NUTR, V137, P2547; Dixit SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058655; Gonzalez-Abuin N, 2014, AM J PHYSIOL-CELL PH, V306, pC485, DOI 10.1152/ajpcell.00355.2013; Hira T, 2011, J NUTR SCI VITAMINOL, V57, P30, DOI 10.3177/jnsv.57.30; Hoggard Nigel, 2013, J Nutr Sci, V2, pe22, DOI 10.1017/jns.2013.16; Huang TN, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/625892; Iakoubov R, 2007, ENDOCRINOLOGY, V148, P1089, DOI 10.1210/en.2006-1403; Iwasaki M, 2012, J DIABETES INVEST, V3, P464, DOI 10.1111/j.2040-1124.2012.00214.x; Janssen S, 2013, TRENDS ENDOCRIN MET, V24, P92, DOI 10.1016/j.tem.2012.11.006; Kaji Izumi, 2014, Digestion, V89, P31, DOI 10.1159/000356211; Kuhre RE, 2014, AM J PHYSIOL-GASTR L, V306, pG622, DOI 10.1152/ajpgi.00372.2013; Li SK, 2014, DIABETOLOGIA, V57, P809, DOI 10.1007/s00125-013-3143-2; Liu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091163; Maeda A, 2013, J DIABETES INVEST, V4, P281, DOI 10.1111/jdi.12045; McCarty MF, 2005, MED HYPOTHESES, V64, P848, DOI 10.1016/j.mehy.2004.03.037; Mostofsky E, 2012, CIRC-HEART FAIL, V5, P401, DOI 10.1161/CIRCHEARTFAILURE.112.967299; Nagamine R, 2014, FOOD FUNCT, V5, P2309, DOI [10.1039/c4fo00032c, 10.1039/C4FO00032C]; Navarro M, 2001, NATURE, V414, P209; Olthof MR, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-10; Paulsen SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088227; Phuwamongkolwiwat P, 2014, MOL NUTR FOOD RES, V58, P1581, DOI 10.1002/mnfr.201300871; Scully Tony, 2012, Nature, V485, pS2; Torronen R, 2012, BRIT J NUTR, V107, P1445, DOI 10.1017/S0007114511004557; vansDam RM, 2005, JAMA-J AM MED ASSOC, V294, P97; Zhang J. Q., 2013, ADV MATER SCI ENG, V2013, P2, DOI DOI 10.1371/J0URNAL.P0NE.0056658	79	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1613-4125	1613-4133		MOL NUTR FOOD RES	Mol. Nutr. Food Res.	JUL	2015	59	7					1264	1273		10.1002/mnfr.201400871		10	Food Science & Technology	Food Science & Technology	CM1FX	WOS:000357427700003		
J	Murakami, S				Murakami, Shigeru			Role of taurine in the pathogenesis of obesity	MOLECULAR NUTRITION & FOOD RESEARCH			English	Review						Adipocyte; Bile acids; Obesity; Taurine	HIGH-CHOLESTEROL DIET; HIGH-FAT DIET; HUMAN MITOCHONDRIAL DISEASES; ADIPOSE-TISSUE; BILE-ACIDS; OXIDATIVE STRESS; METABOLIC DISEASE; INFLAMMATORY MEDIATORS; INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES	Taurine is a sulfur-containing amino acid that is present in mammalian tissues in millimolar concentrations. Taurine is involved in a diverse array of biological and physiological functions, including bile salt conjugation, osmoregulation, membrane stabilization, calcium modulation, anti-oxidation, and immunomodulation. The prevalence of obesity and being overweight continues to rise worldwide at an alarming rate. Obesity is associated with a higher risk of metabolic and cardiovascular diseases, cancer, and other clinical conditions. Ingestion of taurine has been shown to alleviate metabolic diseases such as hyperlipidemia, diabetes, hypertension, and obesity in animal models. A global epidemiological survey showed that 24-h urinary taurine excretion, as a marker of dietary taurine intake, was inversely associated with BMI, blood pressure, and plasma cholesterol in humans. In addition, taurine chloramine, an endogenous product derived from activated neutrophils, has been reported to suppress obesity-induced oxidative stress and inflammation in adipocytes. Synthetic activity and concentration of taurine in adipose tissues and plasma have been shown to decrease in humans and animals during the development of obesity, suggesting a relationship between taurine deficiency and obesity. In this review, I summarize the effects of taurine on the progression of obesity in animal models and humans. Furthermore, I discuss possible mechanisms underlying the antiobesity effects of taurine.	Fukui Prefectural Univ, Dept Biosci, Fukui 9101195, Japan	Murakami, S (reprint author), Fukui Prefectural Univ, Dept Biosci, Fukui 9101195, Japan.	murakami@fpu.ac.jp					Abizaid A, 2008, REGUL PEPTIDES, V149, P3, DOI 10.1016/j.regpep.2007.10.006; Mikami N, 2012, J FOOD SCI, V77, pH114, DOI 10.1111/j.1750-3841.2012.02687.x; Chen K, 2009, BRAIN RES, V1279, P131, DOI 10.1016/j.brainres.2009.04.054; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101; UHE AM, 1992, J NUTR, V122, P467; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; Marcinkiewicz J, 1998, IMMUNOPHARMACOLOGY, V40, P27, DOI 10.1016/S0162-3109(98)00023-X; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Batista TM, 2013, MOL NUTR FOOD RES, V57, P423, DOI 10.1002/mnfr.201200345; Merheb M, 2007, DIABETES CARE, V30, P2652, DOI 10.2337/dc07-0872; Murakami S, 2010, AMINO ACIDS, V38, P271, DOI 10.1007/s00726-009-0247-6; Pina-Zentella G, 2012, AMINO ACIDS, V42, P1927, DOI 10.1007/s00726-011-0919-x; Pols TWH, 2011, J HEPATOL, V54, P1263, DOI 10.1016/j.jhep.2010.12.004; Tastesen HS, 2014, AMINO ACIDS, V46, P1659, DOI 10.1007/s00726-014-1715-1; Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200; Okamoto Y, 2006, CLIN SCI, V110, P267, DOI 10.1042/CS20050182; PARK E, 1993, J LEUKOCYTE BIOL, V54, P119; Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P212, DOI 10.1016/j.bbadis.2009.10.007; Rosca MG, 2010, CARDIOVASC RES, V88, P40, DOI 10.1093/cvr/cvq240; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Nakaya Y, 2000, AM J CLIN NUTR, V71, P54; Murakami T, 2010, AMINO ACIDS, V39, P427, DOI 10.1007/s00726-009-0458-x; You JS, 2013, ADV EXP MED BIOL, V776, P105, DOI 10.1007/978-1-4614-6093-0_11; Murakami S, 1996, PHARMACOLOGY, V52, P303, DOI 10.1159/000139395; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Fukuda N, 2011, J NUTR SCI VITAMINOL, V57, P144, DOI 10.3177/jnsv.57.144; Sethi JK, 2007, J LIPID RES, V48, P1253, DOI 10.1194/jlr.R700005-JLR200; Albrecht J, 2005, NEUROCHEM RES, V30, P1615, DOI 10.1007/s11064-005-8986-6; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Zhang M, 2004, AMINO ACIDS, V26, P267, DOI 10.1007/s00726-003-0059-z; Ueki I, 2009, J NUTR, V139, P207, DOI 10.3945/jn.108.099085; Solon CS, 2012, AMINO ACIDS, V42, P2403, DOI 10.1007/s00726-011-1045-5; Kumari N, 2013, ADV EXP MED BIOL, V775, P19, DOI 10.1007/978-1-4614-6130-2_2; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Derosa G, 2013, INFLAMMATION, V36, P914, DOI 10.1007/s10753-013-9620-4; Jong CJ, 2012, AMINO ACIDS, V42, P2223, DOI 10.1007/s00726-011-0962-7; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]; Sun M, 2011, AMINO ACIDS, V40, P1419, DOI 10.1007/s00726-010-0751-8; El Idrissi A, 2008, AMINO ACIDS, V34, P321, DOI 10.1007/s00726-006-0396-9; Murakami S, 2002, LIFE SCI, V70, P2355, DOI 10.1016/S0024-3205(02)01507-2; Marcinkiewicz J, 1995, J LEUKOCYTE BIOL, V58, P667; Chen XC, 2009, HEPATOLOGY, V49, P1554, DOI 10.1002/hep.22811; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; STURMAN JA, 1993, PHYSIOL REV, V73, P119; Gentile CL, 2011, AM J PHYSIOL-REG I, V301, pR1710, DOI 10.1152/ajpregu.00677.2010; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; FUJIHIRA E, 1970, CHEM PHARM BULL, V18, P1636; Air EL, 2002, ENDOCRINOLOGY, V143, P2449, DOI 10.1210/en.143.6.2449; Rosa FT, 2014, EUR J NUTR, V53, P823, DOI 10.1007/s00394-013-0586-7; Camargo RL, 2013, ADV EXP MED BIOL, V776, P93, DOI 10.1007/978-1-4614-6093-0_10; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Sharma R, 2011, CURR MED CHEM, V18, P4029; FRANCONI F, 1995, AM J CLIN NUTR, V61, P1115; Gimeno RE, 2005, CURR OPIN PHARMACOL, V5, P122, DOI 10.1016/j.coph.2005.01.006; Rikimaru M, 2012, INTERNAL MED, V51, P3351, DOI 10.2169/internalmedicine.51.7529; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; MENENDEZ JA, 1991, BRAIN RES, V555, P193, DOI 10.1016/0006-8993(91)90342-S; Yokogoshi H, 1999, J NUTR, V129, P1705; Chang L, 2004, AMINO ACIDS, V27, P37, DOI 10.1007/s00726-004-0096-2; Nardelli TR, 2011, AMINO ACIDS, V41, P901, DOI 10.1007/s00726-010-0789-7; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Chang YY, 2011, J AGR FOOD CHEM, V59, P450, DOI 10.1021/jf103167u; Ide T, 2002, METABOLISM, V51, P1191, DOI 10.1053/meta.2002.34036; Chen SW, 2006, DIGEST DIS SCI, V51, P2225, DOI 10.1007/s10620-006-9359-y; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200; Liaset B, 2009, BBA-MOL CELL BIOL L, V1791, P254, DOI 10.1016/j.bbalip.2009.01.016; Yamori Y, 2001, HYPERTENS RES, V24, P453, DOI 10.1291/hypres.24.453; JACOBSEN JG, 1968, PHYSIOL REV, V48, P424; Ahima RS, 2005, TRENDS ENDOCRIN MET, V16, P307, DOI 10.1016/j.tem.2005.07.010; Bouloumie A, 2005, CURR OPIN CLIN NUTR, V8, P347, DOI 10.1097/01.mco.0000172571.41149.52; Bournat Juan C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P446, DOI 10.1097/MED.0b013e32833c3026; Cao P. J., 2014, NUTR NEUROSCI; Chang L, 2004, ACTA PHARMACOL SIN, V25, P341; Chesney R W, 1985, Adv Pediatr, V32, P1; Chinetti-Gbaguidi G, 2011, CURR OPIN LIPIDOL, V22, P365, DOI 10.1097/MOL.0b013e32834a77b4; Degasperi GR, 2009, METABOLISM, V58, P1087, DOI 10.1016/j.metabol.2009.04.002; Duboc H, 2014, DIGEST LIVER DIS, V46, P302, DOI 10.1016/j.dld.2013.10.021; Feng Lili, 2014, Biochem Pharmacol, V89, P109, DOI 10.1016/j.bcp.2014.02.016; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Das J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012602; Gladine C, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0424-4; Hansen SH, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S23; KENDLER BS, 1989, PREV MED, V18, P79, DOI 10.1016/0091-7435(89)90056-X; KIBE A, 1980, LIPIDS, V15, P224, DOI 10.1007/BF02535831; Kim HM, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S33; Kim KS, 2013, AMINO ACIDS, V45, P1415, DOI 10.1007/s00726-013-1612-z; Lee MY, 2003, ADV EXP MED BIOL, V526, P285; Lee YY, 2011, BRIT J NUTR, V106, P1198, DOI 10.1017/S0007114511001632; Lin S, 2013, MOL NUTR FOOD RES, V57, P2155, DOI 10.1002/mnfr.201300150; Marcinkiewicz J, 2014, AMINO ACIDS, V46, P7, DOI 10.1007/s00726-012-1361-4; McInnes J, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-63; Murakami Shigeru, 1999, Life Sciences, V64, P83; Muz B, 2008, AMINO ACIDS, V35, P397, DOI 10.1007/s00726-007-0605-1; Pliquett RU, 2006, HORM METAB RES, V38, P442, DOI 10.1055/s-2006-947840; Roy A, 2009, FREE RADICAL RES, V43, P995, DOI 10.1080/10715760903164998; Sagara M., 2015, ADV EXP MED IN PRESS; Schaffer SW, 2014, AMINO ACIDS, V46, P47, DOI 10.1007/s00726-012-1414-8; Stefan N, 2002, HORM METAB RES, V34, P469, DOI 10.1055/s-2002-34785; Szendroedi J, 2012, NAT REV ENDOCRINOL, V8, P92, DOI 10.1038/nrendo.2011.138; Takasaki M, 2004, BIOFACTORS, V21, P419; Talior I, 2003, AM J PHYSIOL-ENDOC M, V285, pE295, DOI 10.1152/ajpendo.00044.2003; Tsuboyama-Kasaoka N, 2006, ENDOCRINOLOGY, V147, P3276, DOI 10.1210/en.2005-1007; Vincent HK, 2006, INT J OBESITY, V30, P400, DOI 10.1038/sj.ijo.0803177; WRIGHT CE, 1986, ANNU REV BIOCHEM, V55, P427, DOI 10.1146/annurev.bi.55.070186.002235; Yamamoto K, 2000, PHARMACOLOGY, V60, P27, DOI 10.1159/000028343; Yamori Y, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S21; Yanagita T, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-38; Zhong M, 2010, CURR TOP MED CHEM, V10, P386	112	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1613-4125	1613-4133		MOL NUTR FOOD RES	Mol. Nutr. Food Res.	JUL	2015	59	7					1353	1363		10.1002/mnfr.201500067		11	Food Science & Technology	Food Science & Technology	CM1FX	WOS:000357427700009		
J	Nakamura, K; Matsuoka, H; Nakashima, S; Kanda, T; Nishimaki-Mogami, T; Akiyama, H				Nakamura, Kosuke; Matsuoka, Hideki; Nakashima, Syohei; Kanda, Tomomasa; Nishimaki-Mogami, Tomoko; Akiyama, Hiroshi			Oral administration of apple condensed tannins delays rheumatoid arthritis development in mice via downregulation of T helper 17 (Th17) cell responses	MOLECULAR NUTRITION & FOOD RESEARCH			English	Article						Apple condensed tannins; Oral administration; Phytochemical; Rheumatoid arthritis; T helper	COLLAGEN-INDUCED ARTHRITIS; PERFORMANCE LIQUID-CHROMATOGRAPHY; PHENOLIC-COMPOUNDS; INTERFERON-GAMMA; ANIMAL-MODELS; TGF-BETA; PROCYANIDINS; JUICE; INTERLEUKIN-17; POLYPHENOLS	Apples are known to contain high concentrations of phenolic compounds such as condensed tannins. Consumption of condensed tannins has been reported to reduce the risk of many types of chronic diseases including allergies. However, their therapeutic effectiveness and potential in treating autoimmune disease remain controversial. Here, the effect of oral administration of apple condensed tannins (ACT) prepared from apples (Malus pumila cv. Fuji) on bovine type II collagen (CII)-induced arthritis in DBA1/J mice, a well-established murine model of human rheumatoid arthritis (RA), was evaluated. As compared to the control (without ACT administration) group, RA development was delayed and a significant reduction in the RA clinical score was observed in the ACT-administered group. Using cultured splenocytes isolated from CII-immunized mice, ACT-administration was shown to decrease the CII-induced increases in IL-17 expression and production in vitro. We propose that downregulation of T helper (Th) 17 cells is responsible for the ACT-induced RA suppression.	[Nakamura, Kosuke; Matsuoka, Hideki; Nishimaki-Mogami, Tomoko; Akiyama, Hiroshi] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan; [Nakashima, Syohei; Kanda, Tomomasa] Asahi Grp Holdings Ltd, Moriya, Ibaraki, Japan	Nakamura, K (reprint author), Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan.	kosnakamura@nihs.go.jp			Japanese Ministry of Health, Labor and Welfare; Japan Health Sciences Foundation; Food Safety Commission	This study was supported by a grant from the Japanese Ministry of Health, Labor and Welfare, a grant from the Japan Health Sciences Foundation, and a grant from the Food Safety Commission.	Akiyama H, 2000, BIOL PHARM BULL, V23, P1370; Lubberts E, 2005, ARTHRITIS RES THER, V7, P29, DOI 10.1186/ar1478; Miossec P, 1997, ARTHRITIS RHEUM, V40, P2105, DOI 10.1002/art.1780401203; Benedetti G, 2014, EUR J IMMUNOL, V44, P339, DOI 10.1002/eji.201344184; Shoji T, 2006, J CHROMATOGR A, V1102, P206, DOI 10.1016/j.chroma.2005.10.065; Kanda T, 1998, BIOSCI BIOTECH BIOCH, V62, P1284, DOI 10.1271/bbb.62.1284; DELAGE E, 1991, J CHROMATOGR, V555, P125, DOI 10.1016/S0021-9673(01)87172-7; Bevaart L, 2010, ARTHRITIS RHEUM-US, V62, P2192, DOI 10.1002/art.27503; Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x; Nakae S, 2003, J IMMUNOL, V171, P6173; Afzali B, 2007, CLIN EXP IMMUNOL, V148, P32, DOI 10.1111/j.1365-2249.2007.03356.x; Toy D, 2006, J IMMUNOL, V177, P36; Akiyama H, 2005, FEBS LETT, V579, P4485, DOI 10.1016/j.febslet.2005.07.019; BOISSIER MC, 1995, EUR J IMMUNOL, V25, P1184, DOI 10.1002/eji.1830250508; Boyer J, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-5; Canete JD, 2000, ANN RHEUM DIS, V59, P263, DOI 10.1136/ard.59.4.263; Irmler IM, 2007, J IMMUNOL, V179, P6228; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jun SM, 2012, J NEUROIMMUNOL, V245, P39, DOI 10.1016/j.jneuroim.2012.02.003; Katayama S, 2013, FOOD CHEM, V138, P757, DOI 10.1016/j.foodchem.2012.10.076; Ke Y, 2011, CLIN IMMUNOL, V138, P311, DOI 10.1016/j.clim.2010.12.016; Kojima Takatsugu, 2000, Allergology International, V49, P69, DOI 10.1046/j.1440-1592.2000.00161.x; Miyake M, 2008, BIOSCI BIOTECH BIOCH, V72, P1781, DOI 10.1271/bbb.800741; PEREZILZARBE FJ, 1992, J LIQ CHROMATOGR, V15, P637, DOI 10.1080/10826079208018822; SCHMIDT HWH, 1969, J AGR FOOD CHEM, V17, P344, DOI 10.1021/jf60162a023; VALLES BS, 1994, J AGR FOOD CHEM, V42, P2732; WILSON EL, 1981, J SCI FOOD AGR, V32, P257, DOI 10.1002/jsfa.2740320309	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1613-4125	1613-4133		MOL NUTR FOOD RES	Mol. Nutr. Food Res.	JUL	2015	59	7					1406	1410		10.1002/mnfr.201400909		5	Food Science & Technology	Food Science & Technology	CM1FX	WOS:000357427700015		
J	Wang, XL; Tsuchiya, T; Hase, A				Wang, Xianlong; Tsuchiya, Taku; Hase, Atsushi			Computational support for a pyrolitic lower mantle containing ferric iron	NATURE GEOSCIENCE			English	Article							EARTHS LOWER MANTLE; RAY-EMISSION SPECTROSCOPY; EQUATION-OF-STATE; SILICATE PEROVSKITE; MGSIO3 PEROVSKITE; TEMPERATURE; PRESSURE; STRATIFICATION; FE	The dominant minerals in Earth's lower mantle are thought to be Fe- and Al-bearing MgSiO3 bridgmanite and (Mg, Fe)O ferropericlase(1). However, experimental measurements of the elasticity of these minerals at realistic lower-mantle pressures and temperatures remain impractical. As a result, different compositional models for the Earth's lower mantle have been proposed(2-4). Theoretical simulations, which depend on empirical evaluations of the effects of Fe incorporation into these minerals, support a pyrolitic lower mantle that contains a significant amount of ferropericlase(5,6), much like the Earth's upper mantle. Here we present first-principles computations combined with a lattice dynamics approach that include the effects of Fe2+ and Fe3+ incorporation. We calculate the densities and elastic-wave velocities of several possible lower-mantle compositions with varying amounts of ferropericlase along a mantle geotherm. On the basis of our calculations of aggregate elasticities, we conclude that neither a perovskitic composition (about 9:1 bridgmanite to ferropericlase by volume) nor an olivine-like composition (about 7:3) reproduces the seismological reference model of average Earth properties. However, an intermediate volume fraction (about 8:2) consistent with a pyrolitic composition can reproduce the reference velocities and densities. Bridgmanite that is rich in ferric iron produces the best fit. Our findings support a uniform chemical composition throughout the present-day mantle, which we suggest is the result of whole-mantle convection.	[Wang, Xianlong; Tsuchiya, Taku; Hase, Atsushi] Ehime Univ, Geodynam Res Ctr, Matsuyama, Ehime 7908577, Japan; [Wang, Xianlong; Tsuchiya, Taku] Tokyo Inst Technol, Earth Life Sci Inst, Tokyo 1528550, Japan	Wang, XL (reprint author), Ehime Univ, Geodynam Res Ctr, Matsuyama, Ehime 7908577, Japan.	xianlong@sci.ehime-u.ac.jp; tsuchiya.taku.mg@ehime-u.ac.jp	Tsuchiya, Taku/A-6406-2014	Tsuchiya, Taku/0000-0002-6042-3692	JSPS [25 03023, KAKENHI 20001005, 21740379]; X-ray Free Electron Laser Priority Strategy Program (MEXT); Global CoE program of Earth and Planetary Science, Ehime University, Japan	We thank Z. Zeng and S. Whitaker for helpful comments. This research was supported by JSPS Grants-in-Aid for Scientific Research under Grant No. 25 03023, KAKENHI 20001005 and 21740379, and by the X-ray Free Electron Laser Priority Strategy Program (MEXT). X.W. was supported by research fellowships of the Global CoE program of Earth and Planetary Science, Ehime University, Japan, and of JSPS for Overseas Researchers.	KOHN W, 1965, PHYS REV, V137, P1697; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Wentzcovitch RM, 2006, P NATL ACAD SCI USA, V103, P543, DOI 10.1073/pnas.0506879103; Nishio-Hamane D, 2008, PHYS EARTH PLANET IN, V166, P219, DOI 10.1016/j.pepi.2008.01.002; MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188; Wentzcovitch RM, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.018501; ANISIMOV VI, 1991, PHYS REV B, V44, P943, DOI 10.1103/PhysRevB.44.943; Alfe D, 2009, COMPUT PHYS COMMUN, V180, P2622, DOI 10.1016/j.cpc.2009.03.010; Fiquet G, 2000, GEOPHYS RES LETT, V27, P21, DOI 10.1029/1999GL008397; Badro J, 2003, SCIENCE, V300, P789, DOI 10.1126/science.1081311; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; Cococcioni M, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.035105; Murakami M, 2012, NATURE, V485, P90, DOI 10.1038/nature11004; Li J, 2004, P NATL ACAD SCI USA, V101, P14027, DOI 10.1073/pnas.0405804101; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Karki BB, 1999, SCIENCE, V286, P1705, DOI 10.1126/science.286.5445.1705; McCammon C, 1997, NATURE, V387, P694, DOI 10.1038/42685; Lundin S, 2008, PHYS EARTH PLANET IN, V168, P97, DOI 10.1016/j.pepi.2008.05.002; Giannozzi P, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/39/395502; Metsue A, 2012, GEOPHYS J INT, V190, P310, DOI 10.1111/j.1365-246X.2012.05511.x; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864; Tsuchiya T, 2011, P NATL ACAD SCI USA, V108, P1252, DOI 10.1073/pnas.1013594108; Irifune T, 2010, SCIENCE, V327, P193, DOI 10.1126/science.1181443; Li J, 2006, PHYS CHEM MINER, V33, P575, DOI 10.1007/s00269-006-0105-y; Chantel J, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053075; Cottaar S, 2014, GEOCHEM GEOPHY GEOSY, V15, P1164, DOI 10.1002/2013GC005122; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Frost DJ, 2004, NATURE, V428, P409, DOI 10.1038/nature02413; Fukui H, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2012JB009591; Helffrich G., 1994, NATURE, V412, P501; Jackson I, 1998, GEOPHYS J INT, V134, P291, DOI 10.1046/j.1365-246x.1998.00560.x; Poirier J.P., 2000, INTRO PHYS EARTHS IN; Ricolleau A, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036759; Sinmyo R, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB008179; STIXRUDE L, 1992, SCIENCE, V257, P1099, DOI 10.1126/science.257.5073.1099; Tange Y, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2011JB008988; Tsuchiya T., 2013, PHYS CHEM DEEP EARTH; Tsuchiya T, 2013, J GEOPHYS RES-SOL EA, V118, P83, DOI 10.1029/2012JB009696; Wang XL, 2014, AM MINERAL, V99, P387, DOI 10.2138/am.2014.4518; Zhang JZ, 1999, SCIENCE, V284, P782, DOI 10.1126/science.284.5415.782; Zhang ZG, 2013, EARTH PLANET SC LETT, V379, P1, DOI 10.1016/j.epsl.2013.07.034	41	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1752-0894	1752-0908		NAT GEOSCI	Nat. Geosci.	JUL	2015	8	7					556	U97		10.1038/NGEO2458		5	Geosciences, Multidisciplinary	Geology	CM0XV	WOS:000357404200020		
J	Wang, J; Sun, CX; Gerdes, N; Liu, CL; Liao, MY; Liu, J; Shi, MA; He, AN; Zhou, Y; Sukhova, GK; Chen, HM; Cheng, XW; Kuzuya, M; Murohara, T; Zhang, J; Cheng, X; Jiang, MM; Shull, GE; Rogers, S; Yang, CL; Ke, Q; Jelen, S; Bindels, R; Ellison, DH; Jarolim, P; Libby, P; Shi, GP				Wang, Jing; Sun, Chongxiu; Gerdes, Norbert; Liu, Conglin; Liao, Mengyang; Liu, Jian; Shi, Michael A.; He, Aina; Zhou, Yi; Sukhova, Galina K.; Chen, Huimei; Cheng, Xian Wu; Kuzuya, Masafumi; Murohara, Toyoaki; Zhang, Jie; Cheng, Xiang; Jiang, Mengmeng; Shull, Gary E.; Rogers, Shaunessy; Yang, Chao-Ling; Ke, Qiang; Jelen, Sabina; Bindels, Rene; Ellison, David H.; Jarolim, Petr; Libby, Peter; Shi, Guo-Ping			Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter	NATURE MEDICINE			English	Article							SODIUM-CHLORIDE COTRANSPORTER; IL-18 RECEPTOR; GITELMANS-SYNDROME; INTERFERON-GAMMA; DEFICIENT MICE; IFN-GAMMA; T-CELLS; EXPRESSION; PROTEIN; ACTIVATION	Interleukin-18 (IL18) participates in atherogenesis through several putative mechanisms(1,2). Interruption of IL18 action reduces atherosclerosis in mice(3,4). Here, we show that absence of the IL18 receptor (IL18r) does not affect atherosclerosis in apolipoprotein E-deficient (Apoe(-/-)) mice, nor does it affect IL18 cell surface binding to or signaling in endothelial cells. As identified initially by co-immunoprecipitation with IL18, we found that IL18 interacts with the Na-Cl co-transporter (NCC; also known as SLC12A3), a 12-transmembrane-domain ion transporter protein preferentially expressed in the kidney(5). NCC is expressed in atherosclerotic lesions, where it colocalizes with IL18r. In Apoe(-/-) ice, combined deficiency of IL18r and NCC, but not single deficiency of either protein, protects mice from atherosclerosis. Peritoneal macrophages from Apoe(-/-) ice or from Apoe(-/-) ice lacking IL18r or NCC show IL18 binding and induction of cell signaling and cytokine and chemokine expression, but macrophages from Apoe(-/-) ice with combined deficiency of IL18r and NCC have a blunted response. An interaction between NCC and IL18r on macrophages was detected by co-immunoprecipitation. IL18 binds to the cell surface of NCC-transfected COS-7 cells, which do not express IL18r, and induces cell signaling and cytokine expression. This study identifies NCC as an IL18-binding protein that collaborates with IL18r in cell signaling, inflammatory molecule expression, and experimental atherogenesis.	[Wang, Jing; Sun, Chongxiu; Gerdes, Norbert; Liu, Conglin; Liao, Mengyang; Liu, Jian; Shi, Michael A.; He, Aina; Zhou, Yi; Sukhova, Galina K.; Chen, Huimei; Zhang, Jie; Cheng, Xiang; Ke, Qiang; Libby, Peter; Shi, Guo-Ping] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Wang, Jing; Sun, Chongxiu; Gerdes, Norbert; Liu, Conglin; Liao, Mengyang; Liu, Jian; Shi, Michael A.; He, Aina; Zhou, Yi; Sukhova, Galina K.; Chen, Huimei; Zhang, Jie; Cheng, Xiang; Ke, Qiang; Jarolim, Petr; Libby, Peter; Shi, Guo-Ping] Harvard Univ, Sch Med, Boston, MA USA; [Wang, Jing] Tsinghua Univ, Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Med Mol Biol,Inst Basic Med Sci,Dep, Beijing 100084, Peoples R China; [Sun, Chongxiu] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China; [Gerdes, Norbert] Univ Munich, Inst Cardiovasc Prevent IPEK, Munich, Germany; [Liu, Conglin] Zhengzhou Univ, Affiliated Hosp 1, Inst Clin Med, Zhengzhou 450052, Peoples R China; [Liao, Mengyang; Cheng, Xiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiol, Wuhan 430074, Peoples R China; [Cheng, Xian Wu; Kuzuya, Masafumi; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4648601, Japan; [Cheng, Xian Wu; Kuzuya, Masafumi; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Geriatr, Nagoya, Aichi 4648601, Japan; [Jiang, Mengmeng; Shull, Gary E.] Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; [Rogers, Shaunessy; Yang, Chao-Ling; Ellison, David H.] Oregon Hlth & Sci Univ, Div Nephrol, Portland, OR 97201 USA; [Jelen, Sabina; Bindels, Rene] Radboud Univ Nijmegen, Med Ctr, Dept Physiol, NL-6525 ED Nijmegen, Netherlands; [Jarolim, Petr] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Shi, GP (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	gshi@rics.bwh.harvard.edu	Bindels, Rene/B-9824-2013; Gerdes, Norbert/E-2787-2010; Murohara, Toyoaki/M-4958-2014; Kuzuya, Masafumi/I-1583-2012	Bindels, Rene/0000-0003-1167-1339; Gerdes, Norbert/0000-0002-4546-7208; 	US National Heart, Lung, and Blood Institute [HL60942, HL81090, HL88547, HL34636, HL80472]; American Heart Association Established Investigator Award [0840118N]	This study is supported by grants from the US National Heart, Lung, and Blood Institute (HL60942, HL81090, HL88547 to G.-P.S.; HL34636, HL80472 to P.L.) and by an American Heart Association Established Investigator Award (0840118N to G.-P.S.).	Hoorn EJ, 2011, NAT MED, V17, P1304, DOI 10.1038/nm.2497; Pacheco-Alvarez D, 2006, J BIOL CHEM, V281, P28755, DOI 10.1074/jbc.M603773200; Griffon N, 2003, MOL BRAIN RES, V117, P47, DOI 10.1016/S0169-328X(03)00283-3; Yoshimoto T, 1998, J IMMUNOL, V161, P3400; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Lauwerys BR, 1999, CYTOKINE, V11, P822, DOI 10.1006/cyto.1999.0501; Markadieu N, 2012, AM J PHYSIOL-RENAL, V303, pF886, DOI 10.1152/ajprenal.00114.2012; Reilly RF, 2000, PHYSIOL REV, V80, P277; Gutcher I, 2006, NAT IMMUNOL, V7, P946, DOI 10.1038/ni1377; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Tenger C, 2005, ARTERIOSCL THROM VAS, V25, P791, DOI 10.1161/01.ATV.0000153516.02782.65; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Zhang MZ, 2012, AM J PHYSIOL-RENAL, V302, pF433, DOI 10.1152/ajprenal.00292.2011; French AR, 2006, CYTOKINE, V35, P229, DOI 10.1016/j.cyto.2006.08.006; Riveira-Munoz E, 2007, J AM SOC NEPHROL, V18, P1271, DOI 10.1681/ASN.2006101095; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Hoshino K, 1999, J IMMUNOL, V162, P5041; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Tzanakis I, 2004, MAGNESIUM RES, V17, P102; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Kinoshita K, 2004, J IMMUNOL, V173, P5312; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Rozansky DJ, 2009, J CLIN INVEST, V119, P2601, DOI 10.1172/JCI38323; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Hulthe J, 2006, ATHEROSCLEROSIS, V188, P450, DOI 10.1016/j.atherosclerosis.2005.11.013; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Bostonjoglo M, 1998, J AM SOC NEPHROL, V9, P1347; Gjata M, 2007, Hippokratia, V11, P150; Glaudemans B, 2012, EUR J HUM GENET, V20, P263, DOI 10.1038/ejhg.2011.189; Khan MZH, 2012, BIOCHEM BIOPH RES CO, V425, P456, DOI 10.1016/j.bbrc.2012.07.124; Kunchaparty S, 1999, AM J PHYSIOL-RENAL, V277, pF643; Mallat Z, 2001, CIRC RES, V89, pE41, DOI 10.1161/hh1901.098735; Miyauchi K, 2009, DIABETES RES CLIN PR, V83, P190, DOI 10.1016/j.diabres.2008.11.018; Morris RG, 2006, AM J PHYSIOL-RENAL, V290, pF1416, DOI 10.1152/ajprenal.00421.2005; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; Sugiyama M, 2008, CLIN IMMUNOL, V128, P103, DOI 10.1016/j.clim.2008.03.501; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Yang SS, 2010, HUM MUTAT, V31, P1304, DOI 10.1002/humu.21364; Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014525	48	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2015	21	7					820	+		10.1038/nm.3890		10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CM3SO	WOS:000357604600026		
J	Creixell, P; Reimand, J; Haider, S; Wu, GM; Shibata, T; Vazquez, M; Mustonen, V; Gonzalez-Perez, A; Pearson, J; Sander, C; Raphael, BJ; Marks, DS; Ouellette, BFF; Valencia, A; Bader, GD; Boutros, PC; Stuart, JM; Linding, R; Lopez-Bigas, N; Stein, LD				Creixell, Pau; Reimand, Jueri; Haider, Syed; Wu, Guanming; Shibata, Tatsuhiro; Vazquez, Miguel; Mustonen, Ville; Gonzalez-Perez, Abel; Pearson, John; Sander, Chris; Raphael, Benjamin J.; Marks, Debora S.; Ouellette, B. F. Francis; Valencia, Alfonso; Bader, Gary D.; Boutros, Paul C.; Stuart, Joshua M.; Linding, Rune; Lopez-Bigas, Nuria; Stein, Lincoln D.		Int Canc Genome Consortium	Pathway and network analysis of cancer genomes	NATURE METHODS			English	Article							PROTEIN INTERACTION NETWORKS; SET ENRICHMENT ANALYSIS; INTERACTION DATABASE; MESENCHYMAL TRANSFORMATION; REGULATORY NETWORKS; SIGNALING NETWORKS; GENE-EXPRESSION; IMPACT ANALYSIS; INTEGRATION; MUTATIONS	Genomic information on tumors from 50 cancer types cataloged by the International Cancer Genome Consortium (ICGC) shows that only a few well-studied driver genes are frequently mutated, in contrast to many infrequently mutated genes that may also contribute to tumor biology. Hence there has been large interest in developing pathway and network analysis methods that group genes and illuminate the processes involved. We provide an overview of these analysis techniques and show where they guide mechanistic and translational investigations.	[Creixell, Pau] Tech Univ Denmark, C SIG, DK-2800 Lyngby, Denmark; [Reimand, Jueri; Bader, Gary D.] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Haider, Syed; Wu, Guanming; Ouellette, B. F. Francis; Boutros, Paul C.; Stein, Lincoln D.] Ontario Inst Canc Res, Informat & Biocomp Program, Toronto, ON, Canada; [Wu, Guanming] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Shibata, Tatsuhiro] Natl Canc Ctr, Div Canc Genom, Tokyo 104, Japan; [Vazquez, Miguel; Valencia, Alfonso] Spanish Natl Canc Res Ctr, Struct Biol & Biocomp Programme, Madrid, Spain; [Mustonen, Ville] Wellcome Trust Sanger Inst, Cambridge, England; [Gonzalez-Perez, Abel; Lopez-Bigas, Nuria] Univ Pompeu Fabra, Res Unit Biomed Informat, Barcelona, Spain; [Pearson, John] Univ Queensland, Inst Mol Biosci, Queensland Ctr Med Genom, Brisbane, Qld, Australia; [Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA; [Raphael, Benjamin J.] Brown Univ, Dept Comp Sci, Providence, RI 02912 USA; [Raphael, Benjamin J.] Brown Univ, Ctr Computat Mol Biol, Providence, RI 02912 USA; [Marks, Debora S.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA; [Raphael, Benjamin J.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada; [Boutros, Paul C.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Boutros, Paul C.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada; [Stuart, Joshua M.] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; [Stuart, Joshua M.] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; [Linding, Rune] Univ Copenhagen UCPH, BRIC, Copenhagen, Denmark; [Lopez-Bigas, Nuria] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain; [Stein, Lincoln D.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	Stein, LD (reprint author), Ontario Inst Canc Res, Informat & Biocomp Program, Toronto, ON, Canada.	lincoln.stein@gmail.com	Valencia, Alfonso/I-3127-2015; 	Valencia, Alfonso/0000-0002-8937-6789; Gonzalez-Perez, Abel/0000-0002-8582-4660	US National Cancer Institute [R01-CA180778, U24-CA143858]; Stand Up To Cancer; Prostate Cancer Foundation; Movember Foundation; Ludwig Fund Postdoctoral Fellowship; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute New Investigator Award; Canadian Institutes of Health Research New Investigator Award; US National Institutes of Health (NIH); National Human Genome Research Institute [P41 HG003751]; NRNB (NIH, National Institute of General Medical Sciences) [P41 GM103504]	We gratefully acknowledge the assistance of J. Jennings during preparation of this manuscript. J.M.S. acknowledges support from the US National Cancer Institute (R01-CA180778 and U24-CA143858), Stand Up To Cancer, the Prostate Cancer Foundation and the Movember Foundation. P.C. is currently funded by a Ludwig Fund Postdoctoral Fellowship. P.C.B. and L.D.S. were supported by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. P.C.B. was also supported by a Terry Fox Research Institute New Investigator Award and a Canadian Institutes of Health Research New Investigator Award. L.D.S. and G.W. acknowledge support from the US National Institutes of Health (NIH) and National Human Genome Research Institute (P41 HG003751). G.D.B. is supported by NRNB (NIH, National Institute of General Medical Sciences grant number P41 GM103504).	Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Sonabend AM, 2014, CANCER RES, V74, P1440, DOI 10.1158/0008-5472.CAN-13-2150; Sanghvi JC, 2013, NAT METHODS, V10, P1192, DOI [10.1038/nmeth.2724, 10.1038/NMETH.2724]; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Saez-Rodriguez J, 2008, BIOINFORMATICS, V24, P840, DOI 10.1093/bioinformatics/btn018; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Drier Y, 2013, P NATL ACAD SCI USA, V110, P6388, DOI 10.1073/pnas.1219651110; Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013; Lan A, 2011, NUCLEIC ACIDS RES, V39, pW424, DOI 10.1093/nar/gkr359; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Berry DA, 2011, J CLIN ONCOL, V29, P606, DOI 10.1200/JCO.2010.32.2685; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Kerrien S, 2012, NUCLEIC ACIDS RES, V40, pD841, DOI 10.1093/nar/gkr1088; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Leung A, 2014, BIOINFORMATICS, V30, P2230, DOI 10.1093/bioinformatics/btu172; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Morris MK, 2010, BIOCHEMISTRY-US, V49, P3216, DOI 10.1021/bi902202q; Ng S, 2012, BIOINFORMATICS, V28, pI640, DOI 10.1093/bioinformatics/bts402; Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598; Glaab E, 2012, BIOINFORMATICS, V28, pI451, DOI 10.1093/bioinformatics/bts389; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Vandin F, 2011, J COMPUT BIOL, V18, P507, DOI 10.1089/cmb.2010.0265; Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Dittrich MT, 2008, BIOINFORMATICS, V24, pI223, DOI 10.1093/bioinformatics/btn161; Pe'er D, 2011, CELL, V144, P864, DOI 10.1016/j.cell.2011.03.001; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Califano A, 2012, NAT GENET, V44, P841, DOI 10.1038/ng.2355; Bader GD, 2006, NUCLEIC ACIDS RES, V34, pD504, DOI 10.1093/nar/gkj126; Chatr-aryamontri A, 2013, NUCLEIC ACIDS RES, V41, pD816, DOI 10.1093/nar/gks1158; Bandyopadhyay S, 2010, NAT METHODS, V7, P801, DOI 10.1038/NMETH.1506; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Gonzalez-Perez A, 2013, NAT METHODS, V10, P723, DOI 10.1038/nmeth.2562; Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Hill SM, 2012, BIOINFORMATICS, V28, P2804, DOI 10.1093/bioinformatics/bts514; Brubaker D., 2014, PAC S BIOCOMPUT, DOI [10.1142/9789814583220_0013, DOI 10.1142/9789814583220_0013]; Cancer Genome Atlas Research Network, 2011, NATURE, V474, P609, DOI DOI 10.1038/NATURE10166; Cancer Genome Atlas Research Network, 2008, NATURE, V455, P1061, DOI DOI 10.1038/NATURE07385; Caspi R, 2014, NUCLEIC ACIDS RES, V42, pD459, DOI 10.1093/nar/gkt1103; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chi YY, 2014, STAT MED, V33, P812, DOI 10.1002/sim.5986; Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180; Danussi C, 2013, CANCER RES, V73, P5140, DOI 10.1158/0008-5472.CAN-13-1168-T; Gene Ontology Consortium, 2010, NUCLEIC ACIDS RES, V38, pD331, DOI [10.1093/nar/gkp1018, DOI 10.1093/NAR/GKP1018]; Greenblum SI, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-133; Gundem G, 2012, GENOME MED, V4, DOI 10.1186/gm327; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Krallinger M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S8-S3; Leiserson MDM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003054; Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Morris MK, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001099; Newman WG, 2014, GENES-BASEL, V5, P1001, DOI 10.3390/genes5041001; Paull EO, 2013, BIOINFORMATICS, V29, P2757, DOI 10.1093/bioinformatics/btt471; Razick S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-405; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Wu GM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r112; Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1	74	3	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1548-7091	1548-7105		NAT METHODS	Nat. Methods	JUL	2015	12	7					615	621		10.1038/NMETH.3440		7	Biochemical Research Methods	Biochemistry & Molecular Biology	CM0YH	WOS:000357405700014		
J	Endo, M; Sugiyama, H				Endo, Masayuki; Sugiyama, Hiroshi			DNA NANOTECHNOLOGY Measuring chloride in live cells	NATURE NANOTECHNOLOGY			English	Editorial Material									[Endo, Masayuki; Sugiyama, Hiroshi] Kyoto Univ, Inst Integrated Cell Mat Sci, Sakyo Ku, Kyoto 6068501, Japan	Endo, M (reprint author), Kyoto Univ, Inst Integrated Cell Mat Sci, Sakyo Ku, Kyoto 6068501, Japan.	endo@kuchem.kyoto-u.ac.jp; hs@kuchem.kyoto-u.ac.jp	Sugiyama, Hiroshi/C-7687-2011; Endo, Masayuki/J-5874-2014				Arosio D, 2010, NAT METHODS, V7, P516, DOI [10.1038/nmeth.1471, 10.1038/NMETH.1471]; Krishnan Y, 2011, ANGEW CHEM INT EDIT, V50, P3124, DOI 10.1002/anie.200907223; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; Krishnan Y, 2012, TRENDS CELL BIOL, V22, P624, DOI 10.1016/j.tcb.2012.10.001; Pei H, 2014, ACCOUNTS CHEM RES, V47, P550, DOI 10.1021/ar400195t; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Bregestovski Piotr, 2009, Front Mol Neurosci, V2, P15, DOI 10.3389/neuro.02.015.2009; Saha S, 2015, NAT NANOTECHNOL, V10, P645, DOI [10.1038/nnano.2015.130, 10.1038/NNANO.2015.130]	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-3387	1748-3395		NAT NANOTECHNOL	Nat. Nanotechnol.	JUL	2015	10	7					569	570		10.1038/nnano.2015.142		2	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science & Technology - Other Topics; Materials Science	CM2BW	WOS:000357485600003		
J	Shibata, K; Iwasaki, J; Kanazawa, N; Aizawa, S; Tanigaki, T; Shirai, M; Nakajima, T; Kubota, M; Kawasaki, M; Park, HS; Shindo, D; Nagaosa, N; Tokura, Y				Shibata, K.; Iwasaki, J.; Kanazawa, N.; Aizawa, S.; Tanigaki, T.; Shirai, M.; Nakajima, T.; Kubota, M.; Kawasaki, M.; Park, H. S.; Shindo, D.; Nagaosa, N.; Tokura, Y.			Large anisotropic deformation of skyrmions in strained crystal	NATURE NANOTECHNOLOGY			English	Article							REAL-SPACE OBSERVATION; WEAK FERROMAGNETISM; CHIRAL MAGNET; MNSI; TRANSPORT; LATTICE; MOTION	Mechanical control of magnetism is an important and promising approach in spintronics. To date, strain control has mostly been demonstrated in ferromagnetic structures by exploiting a change in magnetocrystalline anisotropy. It would be desirable to achieve large strain effects on magnetic nanostructures. Here, using in situ Lorentz transmission electron microscopy, we demonstrate that anisotropic strain as small as 0.3% in a chiral magnet of FeGe induces very large deformations in magnetic skyrmions(1,2), as well as distortions of the skyrmion crystal lattice on the order of 20%. Skyrmions are stabilized by the Dzyaloshinskii-Moriya interaction(3,4), originating from a chiral crystal structure. Our results show that the change in the modulation of the strength of this interaction is amplified by two orders of magnitude with respect to changes in the crystal lattice due to an applied strain. Our findings may provide a mechanism to achieve strain control of topological magnetic structures based on the Dzyaloshinskii-Moriya interaction.	[Shibata, K.; Iwasaki, J.; Kanazawa, N.; Kawasaki, M.; Nagaosa, N.; Tokura, Y.] Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan; [Shibata, K.; Iwasaki, J.; Kanazawa, N.; Kawasaki, M.; Nagaosa, N.; Tokura, Y.] Univ Tokyo, QPEC, Tokyo 1138656, Japan; [Aizawa, S.; Tanigaki, T.; Nakajima, T.; Kubota, M.; Kawasaki, M.; Park, H. S.; Shindo, D.; Nagaosa, N.; Tokura, Y.] RIKEN, CEMS, Wako, Saitama 3510198, Japan; [Tanigaki, T.; Shirai, M.] Hitachi Ltd, Cent Res Lab, Hatoyama, Saitama 3500395, Japan; [Kubota, M.] ROHM Co Ltd, Res & Dev Headquarters, Kyoto 6158585, Japan; [Shindo, D.] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan	Shibata, K (reprint author), Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan.	shibata@cmr.t.u-tokyo.ac.jp; tokura@riken.jp	Tokura, Yoshinori/C-7352-2009; Kawasaki, Masashi/B-5826-2008; Iwasaki, Junichi/N-2970-2015; Shindo, Daisuke/I-3865-2012; Nakajima, Taro/G-5191-2010; Nagaosa, Naoto/G-7057-2012	Iwasaki, Junichi/0000-0002-9937-6686; Nakajima, Taro/0000-0001-6557-5508; 	MEXT [24224009]; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program); Japan Society for the Promotion of Science (JSPS) [2609358]; Program for Leading Graduate Schools (MERIT);  [2610547]	The authors thank Y. Okamura, N. Shibata, Y. Ikuhara, T. Matsuda, A. Kikkawa, Y. Nii, D. Morikawa and X.Z. Yu for discussions. This study was supported by a Grant-in-Aid for Scientific Research (grant no. 24224009) from MEXT and by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program). K.S. was supported by the Japan Society for the Promotion of Science (JSPS) through a Grant-in-Aid for JSPS Fellows (no. 2609358) and the Program for Leading Graduate Schools (MERIT). J.I. was supported by a Grant-in-Aid for JSPS Fellows (no. 2610547).	DZYALOSHINSKY I, 1958, J PHYS CHEM SOLIDS, V4, P241, DOI 10.1016/0022-3697(58)90076-3; Mochizuki M, 2014, NAT MATER, V13, P241, DOI [10.1038/nmat3862, 10.1038/NMAT3862]; Yu XZ, 2011, NAT MATER, V10, P106, DOI 10.1038/nmat2916; Rossler UK, 2006, NATURE, V442, P797, DOI 10.1038/nature05056; Adams T, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.237204; Onose Y, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.037603; Nagaosa N, 2013, NAT NANOTECHNOL, V8, P899, DOI [10.1038/nnano.2013.243, 10.1038/NNANO.2013.243]; Muhlbauer S, 2009, SCIENCE, V323, P915, DOI 10.1126/science.1166767; White JS, 2012, J PHYS-CONDENS MAT, V24, DOI 10.1088/0953-8984/24/43/432201; Seki S, 2012, SCIENCE, V336, P198, DOI 10.1126/science.1214143; Fak B, 2005, J PHYS-CONDENS MAT, V17, P1635, DOI 10.1088/0953-8984/17/10/018; Munzer W, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.041203; Schulz T, 2012, NAT PHYS, V8, P301, DOI [10.1038/nphys2231, 10.1038/NPHYS2231]; Ishizuka K, 2005, J ELECTRON MICROSC, V54, P191, DOI 10.1093/jmicro/dfi024; Yu XZ, 2010, NATURE, V465, P901, DOI 10.1038/nature09124; Shibata K, 2013, NAT NANOTECHNOL, V8, P723, DOI 10.1038/nnano.2013.174; Pedrazzini P, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.047204; Jonietz F, 2010, SCIENCE, V330, P1648, DOI 10.1126/science.1195709; Ritz R, 2013, NATURE, V497, P231, DOI 10.1038/nature12023; Ritz R, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.134424; Tonomura A, 2012, NANO LETT, V12, P1673, DOI 10.1021/nl300073m; Moskvin E, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.077207; MORIYA T, 1960, PHYS REV, V120, P91, DOI 10.1103/PhysRev.120.91; BOGDANOV AN, 1989, ZH EKSP TEOR FIZ+, V95, P178; Gayles J., 2015, PREPRINT; Iwasaki J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2442; Koretsune T., 2015, PREPRINT; Morikawa D, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.024408; RICHARDS.M, 1967, ACTA CHEM SCAND, V21, P2305, DOI 10.3891/acta.chem.scand.21-2305; Yu XZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1990	30	4	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-3387	1748-3395		NAT NANOTECHNOL	Nat. Nanotechnol.	JUL	2015	10	7					589	+		10.1038/NNANO.2015.113		5	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science & Technology - Other Topics; Materials Science	CM2BW	WOS:000357485600011		
J	Li, LK; Ye, GJ; Tran, V; Fei, RX; Chen, GR; Wang, HC; Wang, J; Watanabe, K; Taniguchi, T; Yang, L; Chen, XH; Zhang, YB				Li, Likai; Ye, Guo Jun; Tran, Vy; Fei, Ruixiang; Chen, Guorui; Wang, Huichao; Wang, Jian; Watanabe, Kenji; Taniguchi, Takashi; Yang, Li; Chen, Xian Hui; Zhang, Yuanbo			Quantum oscillations in a two-dimensional electron gas in black phosphorus thin films	NATURE NANOTECHNOLOGY			English	Article							TRANSITION-METAL DICHALCOGENIDES; FIELD-EFFECT TRANSISTORS; SINGLE-CRYSTALS; GRAPHENE; MOBILITY	For decades, two-dimensional electron gases (2DEG) have allowed important experimental discoveries(1,2) and conceptual developments in condensed-matter physics(3). When combined with the unique electronic properties of two-dimensional crystals, they allow rich physical phenomena to be probed at the quantum level(4,5). Here, we create a 2DEG in black phosphorus-a recently added member of the two-dimensional atomic crystal family(6-8)-using a gate electric field. The black phosphorus film hosting the 2DEG is placed on a hexagonal boron nitride substrate. The resulting high carrier mobility in the 2DEG allows the observation of quantum oscillations. The temperature and magnetic field dependence of these oscillations yields crucial information about the system, such as cyclotron mass and lifetime of its charge carriers. Our results, coupled with the fact that black phosphorus possesses anisotropic energy bands with a tunable, direct bandgap(6-15), distinguish black phosphorus 2DEG as a system with unique electronic and optoelectronic properties.	[Li, Likai; Chen, Guorui; Zhang, Yuanbo] Fudan Univ, State Key Lab Surface Phys, Shanghai 200433, Peoples R China; [Li, Likai; Chen, Guorui; Zhang, Yuanbo] Fudan Univ, Dept Phys, Shanghai 200433, Peoples R China; [Li, Likai; Ye, Guo Jun; Chen, Guorui; Chen, Xian Hui; Zhang, Yuanbo] Collaborat Innovat Ctr Adv Microstruct, Nanjing 210093, Jiangsu, Peoples R China; [Ye, Guo Jun; Chen, Xian Hui] Univ Sci & Technol China, Key Lab Strongly Coupled Quantum Matter Phys, Hefei 230026, Anhui, Peoples R China; [Ye, Guo Jun; Chen, Xian Hui] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Ye, Guo Jun; Chen, Xian Hui] Univ Sci & Technol China, Dept Phys, Hefei 230026, Anhui, Peoples R China; [Tran, Vy; Fei, Ruixiang; Yang, Li] Washington Univ, Dept Phys, St Louis, MO 63136 USA; [Tran, Vy; Fei, Ruixiang; Yang, Li] Washington Univ, Inst Mat Sci & Engn, St Louis, MO 63136 USA; [Wang, Huichao; Wang, Jian] Peking Univ, Int Ctr Quantum Mat, Sch Phys, Beijing 100871, Peoples R China; [Watanabe, Kenji; Taniguchi, Takashi] Natl Inst Mat Sci, Adv Mat Lab, Tsukuba, Ibaraki 3050044, Japan	Li, LK (reprint author), Fudan Univ, State Key Lab Surface Phys, Shanghai 200433, Peoples R China.	chenxh@ustc.edu.cn; zhyb@fudan.edu.cn			National Science Foundation [DMR-1157490]; State of Florida; US Department of Energy; National Basic Research Program of China (973 Program) [2011CB921802, 2013CB921902, 2012CB922002]; NSF of China [11034001, 11222434]; Samsung Global Research Outreach (GRO) Program; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB04040100]; NSF [DMR-1207141]; National Basic Research Program of China [2013CB934600]; Elemental Strategy Initiative; JSPS [262480621, 25106006]	The authors thank F. Wang, X. Lin, Y-W. Tan, L. He and Y. Liu for discussions, J. Zhao, Q. Wang and Y. Shen for help with sample preparation and S. Hannahs, T. Murphy, D. Graf, J. Billings, B. Pullum, L. Balicas and B. Zeng for help with measurements in high magnetic fields. A portion of this work was performed at the National High Magnetic Field Laboratory, which is supported by National Science Foundation Cooperative Agreement No. DMR-1157490, the State of Florida, and the US Department of Energy. Part of the sample fabrication was conducted at Fudan Nano-fabrication Lab. L.L., G.C. and Y.Z. acknowledge financial support from the National Basic Research Program of China (973 Program; grants nos. 2011CB921802 and 2013CB921902) and the NSF of China (grant no. 11034001). L.L. and Y.Z. also acknowledge support from Samsung Global Research Outreach (GRO) Program. G.J.Y. and X.H.C. acknowledge support from the Strategic Priority Research Program of the Chinese Academy of Sciences (grant no. XDB04040100) and the National Basic Research Program of China (973 Program; grant no. 2012CB922002). V.T., R.F. and L.Y. are supported by the NSF (DMR-1207141). H.W. and J.W. are supported by the National Basic Research Program of China (grant no. 2013CB934600) and the NSF of China (grant no. 11222434). K.W. and T.T. acknowledge support from the Elemental Strategy Initiative conducted by the MEXT, Japan. T.T. also acknowledges support by a Grant-in-Aid for Scientific Research on Innovative Areas, 'Nano Informatics' (grants nos. 262480621 and 25106006) from JSPS.	Xu XD, 2014, NAT PHYS, V10, P343, DOI 10.1038/NPHYS2942; WARSCHAUER DM, 1963, J APPL PHYS, V34, P1853, DOI 10.1063/1.1729699; Nayak C, 2008, REV MOD PHYS, V80, P1083, DOI 10.1103/RevModPhys.80.1083; Liu H, 2014, ACS NANO, V8, P4033, DOI 10.1021/nn501226z; Wang H, 2014, NANO LETT, V14, P6424, DOI 10.1021/nl5029717; AKAHAMA Y, 1983, J PHYS SOC JPN, V52, P2148, DOI 10.1143/JPSJ.52.2148; Das S, 2014, NANO LETT, V14, P5733, DOI 10.1021/nl5025535; Koenig SP, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4868132; ANDO T, 1982, REV MOD PHYS, V54, P437, DOI 10.1103/RevModPhys.54.437; NARITA S, 1983, J PHYS SOC JPN, V52, P3544, DOI 10.1143/JPSJ.52.3544; Zhang S, 2014, ACS NANO, V8, P9590, DOI 10.1021/nn503893j; Dean CR, 2010, NAT NANOTECHNOL, V5, P722, DOI 10.1038/nnano.2010.172; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235; KEYES RW, 1953, PHYS REV, V92, P580, DOI 10.1103/PhysRev.92.580; Li LK, 2014, NAT NANOTECHNOL, V9, P372, DOI [10.1038/nnano.2014.35, 10.1038/NNANO.2014.35]; Podzorov V, 2004, APPL PHYS LETT, V84, P3301, DOI [10.1063/1.1723695, 10.1063/1.17236395]; MARUYAMA Y, 1981, PHYSICA B & C, V105, P99, DOI 10.1016/0378-4363(81)90223-0; Tran V, 2014, PHYS REV B, V89, DOI 10.1103/PhysRevB.89.235319; Gillgren N, 2015, 2D MATER, V2, DOI 10.1088/2053-1583/2/1/011001; Ye JT, 2012, SCIENCE, V338, P1193, DOI 10.1126/science.1228006; Castellanos-Gomez A, 2014, 2D MATER, V1, DOI 10.1088/2053-1583/1/1/011002; Castellanos-Gomez A, 2014, 2D MATER, V1, DOI 10.1088/2053-1583/1/2/025001; Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109; Chen X.-W., 2014, PREPRINT; Datta S., 1995, ELECT TRANSPORT MESO; FANG FF, 1968, PHYS REV, V174, P823, DOI 10.1103/PhysRev.174.823; Sarma S. D., 2004, PERSPECTIVES QUANTUM; Schwierz F., 2003, MODERN MICROWAVE TRA; Shoenberg D., 1984, MAGNETIC OSCILLATION; Sze S. M., 2006, PHYS SEMICONDUCTOR D; TAKAO Y, 1981, PHYSICA B & C, V105, P93, DOI 10.1016/0378-4363(81)90222-9; Tayari V., 2014, PREPRINT; Wang X., 2014, PREPRINT; Xia FN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5458; Yuan H., 2014, PREPRINT; Zhou X. Y., 2014, PREPRINT	36	15	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-3387	1748-3395		NAT NANOTECHNOL	Nat. Nanotechnol.	JUL	2015	10	7					608	+		10.1038/NNANO.2015.91		7	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science & Technology - Other Topics; Materials Science	CM2BW	WOS:000357485600015		
J	Bechara, R; Ikeda, H; Inoue, H				Bechara, Robert; Ikeda, Haruo; Inoue, Haruhiro			Peroral endoscopic myotomy: an evolving treatment for achalasia	NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY			English	Review							LAPAROSCOPIC HELLER MYOTOMY; CARBON-DIOXIDE INSUFFLATION; LOWER ESOPHAGEAL SPHINCTER; PROSPECTIVE SINGLE-CENTER; 100 CONSECUTIVE PATIENTS; SQUAMOUS-CELL CARCINOMA; LONG-TERM OUTCOMES; PNEUMATIC DILATION; SUBMUCOSAL DISSECTION; LEARNING-CURVE	Peroral endoscopic myotomy ( POEM) was first performed in Japan in 2008 for uncomplicated achalasia. With excellent results, it was adopted by highly skilled endoscopists around the world and the indications for POEM were expanded to include advanced sigmoid achalasia, failed surgical myotomy, patients with previous endoscopic treatments and even other spastic oesophageal motility disorders. With increased uptake and performance of POEM, variations in technique and improved management of adverse events have been developed. Now, 6 years since the first case and with >3,000 procedures performed worldwide, long-term data has shown the efficacy of POEM to be long-lasting. A growing body of literature also exists pertaining to the learning curve, application of novel technologies, extended indications and physiologic changes with POEM. Ultimately, this once experimental procedure is evolving towards becoming the preferred treatment for achalasia and other spastic oesophageal motility disorders.	[Bechara, Robert; Ikeda, Haruo; Inoue, Haruhiro] Showa Univ Koto, Ctr Digest Dis, Toyosu Hosp, Koto Ku, Tokyo 1358577, Japan	Bechara, R (reprint author), Showa Univ Koto, Ctr Digest Dis, Toyosu Hosp, Koto Ku, Toyosu 5-1-38, Tokyo 1358577, Japan.	bechara.robert@gmail.com					AGGESTRUP S, 1992, CHEST, V102, P1013, DOI 10.1378/chest.102.4.1013; Andersson M, 2009, DIS ESOPHAGUS, V22, P264, DOI 10.1111/j.1442-2050.2008.00914.x; Kurian AA, 2013, GASTROINTEST ENDOSC, V77, P719, DOI 10.1016/j.gie.2012.12.006; ECKARDT VF, 1992, GASTROENTEROLOGY, V103, P1732; Cai MY, 2014, SURG ENDOSC, V28, P1158, DOI 10.1007/s00464-013-3300-1; Lee CW, 2010, J PEDIATR SURG, V45, P1173, DOI 10.1016/j.jpedsurg.2010.02.086; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Saxena P, 2013, ENDOSCOPY, V45, P579, DOI 10.1055/s-0032-1326398; Onimaru M, 2013, J AM COLL SURGEONS, V217, P598, DOI 10.1016/j.jamcollsurg.2013.05.025; Felix VN, 2013, ANN NY ACAD SCI, V1300, P236, DOI 10.1111/nyas.12254; von Renteln D, 2012, AM J GASTROENTEROL, V107, P411, DOI 10.1038/ajg.2011.388; Inoue H, 2010, ENDOSCOPY, V42, P265, DOI 10.1055/s-0029-1244080; Ujiki MB, 2013, SURGERY, V154, P893, DOI 10.1016/j.surg.2013.04.042; Iqbal A, 2006, DIS ESOPHAGUS, V19, P193, DOI 10.1111/j.1442-2050.2006.00564.x; Francis DL, 2010, GASTROENTEROLOGY, V139, P369, DOI 10.1053/j.gastro.2010.06.024; Kurian AA, 2013, SURG ENDOSC, V27, P3910, DOI 10.1007/s00464-013-3002-8; Vaezi MF, 2002, GUT, V50, P765, DOI 10.1136/gut.50.6.765; von Renteln D, 2013, GASTROENTEROLOGY, V145, P309, DOI 10.1053/j.gastro.2013.04.057; Gockel I, 2008, AM J GASTROENTEROL, V103, P856, DOI 10.1111/j.1572-0241.2007.01667.x; Verlaan T, 2013, GASTROINTEST ENDOSC, V78, P39, DOI 10.1016/j.gie.2013.01.006; Novais PA, 2010, ALIMENT PHARM THER, V32, P1257, DOI 10.1111/j.1365-2036.2010.04461.x; Rohof WO, 2012, GASTROENTEROLOGY, V143, P328, DOI 10.1053/j.gastro.2012.04.048; Brucher BLDM, 2001, WORLD J SURG, V25, P745; Stavropoulos SN, 2013, SURG ENDOSC, V27, P3322, DOI 10.1007/s00464-013-2913-8; Teitelbaum EN, 2014, SURG ENDOSC, V28, P3359, DOI 10.1007/s00464-014-3628-1; Nicodeme F, 2013, CLIN GASTROENTEROL H, V11, P131, DOI 10.1016/j.cgh.2012.10.015; Teitelbaum EN, 2013, SURG ENDOSC, V27, P4547, DOI 10.1007/s00464-013-3121-2; Oelschlager BK, 2003, ARCH SURG-CHICAGO, V138, P490, DOI 10.1001/archsurg.138.5.490; Sharata A, 2013, J GASTROINTEST SURG, V17, P1188, DOI 10.1007/s11605-013-2193-6; PELLEGRINI C, 1992, ANN SURG, V216, P291, DOI 10.1097/00000658-199209000-00008; Familiari P, 2013, J PEDIATR GASTR NUTR, V57, P794, DOI 10.1097/MPG.0b013e3182a803f7; STREITZ JM, 1995, ANN THORAC SURG, V59, P1604, DOI 10.1016/0003-4975(94)00997-L; Maeda Y, 2012, ENDOSCOPY, V44, P565, DOI 10.1055/s-0031-1291664; Wang L, 2009, DIGEST DIS SCI, V54, P2303, DOI 10.1007/s10620-008-0637-8; Kwiatek MA, 2010, GASTROINTEST ENDOSC, V72, P272, DOI 10.1016/j.gie.2010.01.069; Stavropoulos SN, 2014, GASTROINTEST ENDOSC, V80, P1, DOI 10.1016/j.gie.2014.04.014; Katori Y, 2010, ANN ANAT, V192, P33, DOI 10.1016/j.aanat.2009.09.007; Pasricha PJ, 2007, ENDOSCOPY, V39, P761, DOI 10.1055/s-2007-966764; Patti MG, 2001, ARCH SURG-CHICAGO, V136, P870, DOI 10.1001/archsurg.136.8.870; Yaghoobi M, 2013, GASTROINTEST ENDOSC, V78, P468, DOI 10.1016/j.gie.2013.03.1335; Chiu PWY, 2013, GASTROINTEST ENDOSC, V77, P29, DOI 10.1016/j.gie.2012.08.018; Sedlack RE, 2010, GASTROINTEST ENDOSC, V72, P1125, DOI 10.1016/j.gie.2010.09.001; Minami H, 2014, DIGEST ENDOSC, V26, P43, DOI 10.1111/den.12086; Pandolfino JE, 2013, CLIN GASTROENTEROL H, V11, P887, DOI 10.1016/j.cgh.2013.01.032; Vigneswaran Y, 2014, J GASTROINTEST SURG, V18, P1071, DOI 10.1007/s11605-014-2496-2; Gockel I, 2010, J GASTROINTEST SURG, V14, P46, DOI 10.1007/s11605-009-1018-0; Li QL, 2013, J AM COLL SURGEONS, V217, P442, DOI 10.1016/j.jamcollsurg.2013.04.033; Khashab MA, 2014, GASTROINTEST ENDOSC, V79, P136, DOI 10.1016/j.gie.2013.08.021; Louis H, 2012, AM J GASTROENTEROL, V107, P1926, DOI 10.1038/ajg.2012.317; Spiess AE, 1998, JAMA-J AM MED ASSOC, V280, P638, DOI 10.1001/jama.280.7.638; Bhayani NH, 2014, ANN SURG, V259, P1098, DOI 10.1097/SLA.0000000000000268; Wright AS, 2007, SURG ENDOSC, V21, P713, DOI 10.1007/s00464-006-9165-9; Stefanidis D, 2012, SURG ENDOSC, V26, P296, DOI 10.1007/s00464-011-2017-2; Hirota WK, 2006, GASTROINTEST ENDOSC, V63, P570, DOI 10.1016/j.gie.2006.02.004; Shiwaku H, 2013, GASTROINTEST ENDOSC, V77, P149, DOI 10.1016/j.gie.2012.02.008; Eubanks TR, 1999, J AM COLL SURGEONS, V189, P566, DOI 10.1016/S1072-7515(99)00218-5; Campos GM, 2009, ANN SURG, V249, P45, DOI 10.1097/SLA.0b013e31818e43ab; MEYER GW, 1986, J CLIN GASTROENTEROL, V8, P131, DOI 10.1097/00004836-198604000-00005; Hungness ES, 2013, J GASTROINTEST SURG, V17, P228, DOI 10.1007/s11605-012-2030-3; Loviscek MF, 2013, J AM COLL SURGEONS, V216, P736, DOI 10.1016/j.jamcollsurg.2012.12.008; Balaban DH, 1999, GASTROENTEROLOGY, V116, P29, DOI 10.1016/S0016-5085(99)70225-8; Zaninotto G, 2008, ANN SURG, V248, P986, DOI 10.1097/SLA.0b013e3181907bdd; Mayberry J F, 2001, Gastrointest Endosc Clin N Am, V11, P235; Boeckxstaens GE, 2011, NEW ENGL J MED, V364, P1807, DOI 10.1056/NEJMoa1010502; Marlais M, 2011, ARCH DIS CHILD, V96, P192, DOI 10.1136/adc.2009.171975; Leeuwenburgh I, 2010, AM J GASTROENTEROL, V105, P2144, DOI 10.1038/ajg.2010.263; ORTEGA JA, 1980, GASTROINTEST ENDOSC, V26, P8, DOI 10.1016/S0016-5107(80)73249-2; Maeda Y, 2013, ENDOSCOPY, V45, P335, DOI 10.1055/s-0032-1326199; Zhou PH, 2013, ENDOSCOPY, V45, P161, DOI 10.1055/s-0032-1326203; Li QL, 2013, GASTROINTEST ENDOSC, V78, P370, DOI 10.1016/j.gie.2013.04.172; Vaezi MF, 2013, AM J GASTROENTEROL, V108, P1238, DOI 10.1038/ajg.2013.196; Teitelbaum EN, 2014, J GASTROINTEST SURG, V18, P92, DOI 10.1007/s11605-013-2332-0; Askegard-Giesmann JR, 2009, J PEDIATR SURG, V44, P909, DOI 10.1016/j.jpedsurg.2009.01.022; Baldaque-Silva F, 2014, GASTROINTEST ENDOSC, V79, P544, DOI 10.1016/j.gie.2013.10.023; Boeckxstaens GE, 2008, AM J GASTROENTEROL, V103, P1610, DOI 10.1111/j.1572-0241.2008.01967.x; Cai MY, 2014, GASTROINTEST ENDOSC, V80, P1046, DOI 10.1016/j.gie.2014.05.004; CARSEN GM, 1978, RADIOLOGY, V128, P309; Chao S., 2014, J PEDIAT SURG CASE R, V2, P313; Chen WF, 2015, GASTROINTEST ENDOSC, V81, P91, DOI 10.1016/j.gie.2014.06.035; Chen X., 2014, EUR J CARDIO-THORAC, V47, P890; Chiu P, 2011, GASTROINTEST ENDOSC, pAB107, DOI 10.1016/j.gie.2011.03.1187; Chung JI, 2010, GUT LIVER, V4, P31, DOI 10.5009/gnl.2010.4.1.31; Dubale N, 2013, INDIAN J SURG, V75, P504, DOI 10.1007/s12262-013-0909-1; Familiari P., ANN SURG; Familiari P, 2014, UNITED EUR GASTROENT, V2, P77, DOI 10.1177/2050640614521193; Franklin Ashanti L, 2014, World J Gastrointest Endosc, V6, P105, DOI 10.4253/wjge.v6.i4.105; Friedel David, 2013, World J Gastrointest Endosc, V5, P420, DOI 10.4253/wjge.v5.i9.420; Fujimoto Hiroyuki, 2011, Journal of Smooth Muscle Research, V47, P167; Galasso D., 2014, ENDOSCOPY S1, V46, P648; Ghosh SK, 2007, AM J PHYSIOL-GASTR L, V293, P878; Ghoshal UC, 2004, AM J GASTROENTEROL, V99, P2304, DOI 10.1111/j.1572-0241.2004.40099.x; Goda K, 2014, DIS ESOPHAGUS, V27, P267, DOI 10.1111/dote.12090; Gorecki PJ, 2002, SURG ENDOSC, V16, P772, DOI 10.1007/s00464-001-8178-7; Hallal C, 2012, PEDIATR SURG INT, V28, P1211, DOI 10.1007/s00383-012-3214-3; HENDERSON RD, 1987, ANN THORAC SURG, V43, P25; Hu J. W., SURG ENDOSC; Hulselmans M, 2010, CLIN GASTROENTEROL H, V8, P30, DOI 10.1016/j.cgh.2009.09.020; Hunter JG, 1997, ANN SURG, V225, P655, DOI 10.1097/00000658-199706000-00003; Inoue H, 2013, GASTROINTEST ENDOSC, V77, pAB121; JUSTVIER.JO, 1969, SURG GYNECOL OBSTETR, V128, P1081; Kandulski A., DIS ESOPHAGUS; Kerkhof M, 2008, CANCER BIOMARK, V4, P1; Khashab MA, 2015, GASTROINTEST ENDOSC, V81, P1170, DOI 10.1016/j.gie.2014.10.011; KIM CH, 1993, MAYO CLIN PROC, V68, P1067; Ko Weon Jin, 2014, Korean J Gastroenterol, V64, P370; Kos X, 1998, CARDIOVASC INTER RAD, V21, P428, DOI 10.1007/s002709900293; Kristensen HO, 2014, SCAND J GASTROENTERO, V49, P1285, DOI 10.3109/00365521.2014.958096; Kumta Nikhil A, 2014, Clin Endosc, V47, P389, DOI 10.5946/ce.2014.47.5.389; Leconte M, 2007, BRIT J SURG, V94, P1113, DOI 10.1002/bjs.5761; Leeuwenburgh I, 2010, DIS ESOPHAGUS, V23, P506, DOI 10.1111/j.1442-2050.2009.01040.x; Ling T., 2013, ENDOSCOPY         S2, V45, P63; Loviscek L F, 1998, Dis Esophagus, V11, P239; Maradey-Romero Carla, 2014, Curr Gastroenterol Rep, V16, P390, DOI 10.1007/s11894-014-0390-4; Maselli R., 2012, ENDOSCOPY         S2, V44, P285; MAYBERRY JF, 1988, GUT, V29, P90, DOI 10.1136/gut.29.1.90; MEIJSSEN MAC, 1992, GUT, V33, P155, DOI 10.1136/gut.33.2.155; Merrill WH, 2004, ANN THORAC SURG, V78, P608, DOI 10.1016/j.athoracsur.2004.02.089; MICHAL JA, 1980, RADIOLOGY, V134, P246; Minami H, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-22; Minami H., 2014, ENDOSCOPY S1, V46, P79; Modayil R, 2014, GASTROINTEST ENDOSC, V80, P1169, DOI [10.1016/j.gie.2014.03.035, 10.1016/j.gie.2014.03.005]; MEYERS WC, 1995, AM J SURG, V170, P55; Morera C, 2012, J PEDIATR GASTR NUTR, V54, P34, DOI 10.1097/MPG.0b013e3182293d8c; Oda I, 2012, DIGEST ENDOSC, V24, P129, DOI 10.1111/j.1443-1661.2012.01265.x; Omura N, 2006, SURG ENDOSC, V20, P210, DOI 10.1007/s00464-005-0365-5; Onimaru M., GASTROINTEST ENDOSC; Orenstein S. B, 2014, SURG ENDOSC, V29, P1064; OTTINO G, 1987, ANN THORAC SURG, V44, P173; Pandolfino JE, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12097; Park JH, 2009, KOREAN J RADIOL, V10, P361, DOI 10.3348/kjr.2009.10.4.361; Parra V., 2014, GASTROINTEST ENDOSC, V81, P1251; Patel KS, 2015, GASTROINTEST ENDOSC, V81, P1181, DOI 10.1016/j.gie.2014.10.002; PATTI MG, 1995, ARCH SURG-CHICAGO, V130, P609; Patti MG, 1999, ANN SURG, V230, P587, DOI 10.1097/00000658-199910000-00014; PERACCHIA A, 1991, HEPATO-GASTROENTEROL, V38, P514; Petersen RP, 2010, SURG LAPARO ENDO PER, V20, P321, DOI 10.1097/SLE.0b013e3181f39fdb; Ravi K., 2014, GASTROENTEROLOGY, V146, pS; Robinson TN, 2003, J LAPAROENDOSC ADV A, V13, P401, DOI 10.1089/109264203322656487; Rossetti G, 2009, INT SURG, V94, P330; SANDLER RS, 1995, JAMA-J AM MED ASSOC, V274, P1359, DOI 10.1001/jama.274.17.1359; Sedlack RE, 2011, GASTROINTEST ENDOSC, V74, P355, DOI 10.1016/j.gie.2011.02.019; Sharata AM, 2015, J GASTROINTEST SURG, V19, P161, DOI 10.1007/s11605-014-2610-5; Sharp KW, 2002, ANN SURG, V235, P631, DOI 10.1097/00000658-200205000-00004; Shi WB, 2012, WORLD J GASTROENTERO, V18, P7296, DOI 10.3748/wjg.v18.i48.7296; SHIMI S, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P152; Stavropoulos SN, 2014, GASTROINTEST ENDOSC, V79, pAB472; Stefan S., 2013, DIG DIS WEEK ORL FLO; Talukdar R., SURG ENDOSC; Tamhankar AP, 2003, J GASTROINTEST SURG, V7, P990, DOI 10.1016/j.gassur.2003.09.003; Tamiya Y, 2010, ENDOSCOPY, V42, P8, DOI 10.1055/s-0029-1215215; Tannuri ACA, 2010, J PEDIATR SURG, V45, P1463, DOI 10.1016/j.jpedsurg.2009.08.023; Tassios PS, 1999, ENDOSCOPY, V31, P702; Teitelbaum EN, 2014, SURG ENDOSC, V28, P2840, DOI 10.1007/s00464-014-3563-1; Torquati A, 2006, ANN SURG, V243, P587, DOI 10.1097/01.sla.0000216782.10502.47; Tsuji Y, 2011, ENDOSCOPY, V43, P1033, DOI 10.1055/s-0031-1291383; Uemura M, 2012, HEPATO-GASTROENTEROL, V59, P734, DOI 10.5754/hge11547; Duffy PE, 2003, SURG ENDOSC, V17, P1046, DOI 10.1007/s00464-002-8570-y; Valdovinos Miguel A, 2014, Curr Gastroenterol Rep, V16, P421, DOI 10.1007/s11894-014-0421-1; Vilaga AF, 2013, INSIGHTS IMAGING, V4, P759; Vogten JM, 2007, J VASC INTERV RADIOL, V18, P771, DOI 10.1016/j.jvir.2007.02.022; Wang J, DIS ESOPHAGUS; Wang L, 2008, WORLD J GASTROENTERO, V14, P5900, DOI 10.3748/wjg.14.5900; WYCHULIS AR, 1971, J AMER MED ASSOC, V215, P1638, DOI 10.1001/jama.215.10.1638; Yang D., 2014, ENDOSCOPY S1, V46, P11; Yang D, 2013, ENDOSCOPY, V45, P677, DOI 10.1055/s-0033-1344147; Yang D., 2014, ENDOSCOPY S1, V46, P467; Yang S., ACTA RADIOL; Zaninotto G, 2000, J GASTROINTEST SURG, V4, P282, DOI 10.1016/S1091-255X(00)80077-3; Zaninotto G, 2008, BRIT J SURG, V95, P1488, DOI 10.1002/bjs.6413; Zhai Y., 2013, AM J GASTROENTEROL; Zhang Y, 2014, DIGEST ENDOSC, V26, P295, DOI 10.1111/den.12223	171	3	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-5045	1759-5053		NAT REV GASTRO HEPAT	Nat. Rev. Gastroenterol. Hepatol.	JUL	2015	12	7					410	426		10.1038/nrgastro.2015.87		17	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM1IM	WOS:000357434500007		
J	Suzuki, HI; Katsura, A; Yasuda, T; Ueno, T; Mano, H; Sugimoto, K; Miyazono, K				Suzuki, Hiroshi I.; Katsura, Akihiro; Yasuda, Takahiko; Ueno, Toshihide; Mano, Hiroyuki; Sugimoto, Koichi; Miyazono, Kohei			Small-RNA asymmetry is directly driven by mammalian Argonautes	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							MICRORNA STRAND SELECTION; POSTTRANSCRIPTIONAL REGULATION; CRYSTAL-STRUCTURE; MIRNA BIOGENESIS; STRUCTURAL BASIS; SIRNA ASYMMETRY; CELL LYMPHOMA; DICER; EXPRESSION; INTERFERENCE	Asymmetric selection of single-stranded guide RNAs from double-stranded RNA precursors is crucial in RNA silencing-mediated gene regulation. However, the precise mechanisms of small-RNA asymmetry are unclear, especially because asymmetric selection can still occur when the putative asymmetry sensors Drosophila R2D2 and mammalian Dicer are depleted. Here we report a direct contribution of mammalian Argonaute 2 (Ago2) to microRNA (miRNA) asymmetry. Ago2 selects strands with 5'-uridine or 5'-adenosine and thermodynamically unstable 5' ends in parallel through its two sensor regions, which contact the 5' nucleobases and 5'-phosphates of prospective guide strands. Hence, miRNA asymmetry shows superposed patterns reflecting 5'-end nucleotide identity ('digital' pattern) and thermodynamic stability ('analog' pattern). Furthermore, we demonstrate that cancer-associated miRNA variations reprogram asymmetric selection. Finally, our study presents a model of this universal principle, to aid in comprehensive understanding of miRNA function and development of new RNA-silencing therapies in precision medicine.	[Suzuki, Hiroshi I.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Suzuki, Hiroshi I.; Katsura, Akihiro; Miyazono, Kohei] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; [Yasuda, Takahiko; Ueno, Toshihide; Mano, Hiroyuki] Univ Tokyo, Grad Sch Med, Dept Cellular Signaling, Tokyo, Japan; [Sugimoto, Koichi] JR Tokyo Gen Hosp, Dept Hematol & Oncol, Tokyo, Japan	Suzuki, HI (reprint author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	hisuzuki@mit.edu; miyazono@m.u-tokyo.ac.jp			Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad; Ministry of Education, Culture, Sports, Science, and Technology of Japan [24689018, 23112702, 22112002]; Strategic Basic Research Program from the Japan Science and Technology Agency; Cell Science Research Foundation; Skoltech Institute	We thank T. Yamazaki, H. Mihira, A. Mizutani, T. Kosaka, A. Chiu and members of the K.M. and P.A. Sharp laboratories for discussions and assistance; X. Wang (Northwestern University) and T.J. Kelly and J.R. Zamudio (Massachusetts Institute of Technology) for Ago-knockout ES cells; and H. Siomi and P.A. Sharp for critical reading. H.I.S. is supported by a Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad. This work was supported by Grants-in-Aid for Young Scientists (A) (24689018, H.I.S.) and Grants-in-Aid for Scientific Research on Innovative Areas (23112702, H.I.S.; 22112002, K.M.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; the Strategic Basic Research Program from the Japan Science and Technology Agency (H.M. and K.M.); the Cell Science Research Foundation (H.I.S.); the Skoltech Institute (courtesy of P.A. Sharp). The results shown here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov/.	Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Suzuki HI, 2010, J MOL MED, V88, P1085, DOI 10.1007/s00109-010-0650-1; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017; Betancur JG, 2012, RNA, V18, P24, DOI 10.1261/rna.029785.111; Noland CL, 2011, MOL CELL, V43, P110, DOI 10.1016/j.molcel.2011.05.028; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809; [Anonymous], 2013, N ENGL J MED, V368, P2059; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Ro S, 2007, NUCLEIC ACIDS RES, V35, P5944, DOI 10.1093/nar/gkm641; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Frank F, 2012, EMBO J, V31, P3588, DOI 10.1038/emboj.2012.204; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Yang JS, 2011, RNA, V17, P312, DOI 10.1261/rna.2537911; Chiang HR, 2010, GENE DEV, V24, P992, DOI 10.1101/gad.1884710; Noland CL, 2013, RNA, V19, P639, DOI 10.1261/rna.037424.112; Wang LJ, 2006, NUCLEIC ACIDS RES, V34, pW243, DOI 10.1093/nar/gkl298; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Okamura K, 2009, MOL CELL, V36, P431, DOI 10.1016/j.molcel.2009.09.027; Khanin R, 2008, J COMPUT BIOL, V15, P305, DOI 10.1089/cmb.2007.0184; Krol J, 2004, J BIOL CHEM, V279, P42230, DOI 10.1074/jbc.M404931200; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Yoda M, 2010, NAT STRUCT MOL BIOL, V17, P17, DOI 10.1038/nsmb.1733; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Wang YL, 2008, NATURE, V456, P921, DOI 10.1038/nature07666; De N, 2013, MOL CELL, V50, P344, DOI 10.1016/j.molcel.2013.04.001; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Kawamata T, 2009, NAT STRUCT MOL BIOL, V16, P953, DOI 10.1038/nsmb.1630; Park JE, 2011, NATURE, V475, P201, DOI 10.1038/nature10198; Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Hu HY, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-413; Nishida KM, 2013, MOL CELL, V49, P680, DOI 10.1016/j.molcel.2012.12.024; Frank F, 2010, NATURE, V465, P818, DOI 10.1038/nature09039; Suzuki HI, 2013, LEUKEMIA, V27, P2107, DOI 10.1038/leu.2013.121; Boland A, 2011, P NATL ACAD SCI USA, V108, P10466, DOI 10.1073/pnas.1103946108; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Cuccato G, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-19; Gredell JA, 2010, BIOCHEMISTRY-US, V49, P3148, DOI 10.1021/bi902189s; Hartig JV, 2011, NUCLEIC ACIDS RES, V39, P3836, DOI 10.1093/nar/gkq1324; Hu Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep03648; Labbaye C, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-13; Naito Yuki, 2012, Frontiers in Genetics, V3, P102, DOI 10.3389/fgene.2012.00102; Schirle NT, 2012, SCIENCE, V336, P1037, DOI 10.1126/science.1221551; Seitz Hervé, 2011, Silence, V2, P4, DOI 10.1186/1758-907X-2-4; Zamudio JR, 2014, CELL, V156, P920, DOI 10.1016/j.cell.2014.01.041	56	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	JUL	2015	22	7					512	+		10.1038/nsmb.3050		13	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CM3WC	WOS:000357614900002		
J	Suzuki, H; Kaizuka, T; Mizushima, N; Noda, NN				Suzuki, Hironori; Kaizuka, Takeshi; Mizushima, Noboru; Noda, Nobuo N.			Structure of the Atg101-Atg13 complex reveals essential roles of Atg101 in autophagy initiation	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; HORMA DOMAIN; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MOLECULAR-GRAPHICS; FORMATION SITE; PROTEIN; BINDING; MAD2; MACROAUTOPHAGY; ORGANIZATION	Atg101 is an essential component of the autophagy-initiating ULK complex in higher eukaryotes, but it is absent from the functionally equivalent Atg1 complex in budding yeast. Here, we report the crystal structure of the fission yeast Atg101-Atg13 complex. Atg101 has a Hop1, Rev7 and Mad2 (HORMA) architecture similar to that of Atg13. Mad2 HORMA has two distinct conformations (O-Mad2 and C-Mad2), and, intriguingly, Atg101 resembles O-Mad2 rather than the C-Mad2-like Atg13. Atg13 HORMA from higher eukaryotes possesses an inherently unstable fold, which is stabilized by Atg101 via interactions analogous to those between O-Mad2 and C-Mad2. Mutational studies revealed that Atg101 is responsible for recruiting downstream factors to the autophagosome-formation site in mammals via a newly identified WF finger. These data define the molecular functions of Atg101, providing a basis for elucidating the molecular mechanisms of mammalian autophagy initiation by the ULK complex.	[Suzuki, Hironori; Noda, Nobuo N.] Inst Microbial Chem BIKAKEN, Tokyo, Japan; [Kaizuka, Takeshi; Mizushima, Noboru] Univ Tokyo, Grad Sch Med, Tokyo, Japan; [Noda, Nobuo N.] Japan Sci & Technol Agcy, Core Res Evolutionary Sci & Technol, Tokyo, Japan	Noda, NN (reprint author), Inst Microbial Chem BIKAKEN, Tokyo, Japan.	nmizu@m.u-tokyo.ac.jp; nn@bikaken.or.jp	Mizushima, Noboru/C-3635-2009; Noda, Nobuo/P-1397-2015	Noda, Nobuo/0000-0002-6940-8069	Ministry of Education, Culture, Sports, Science and Technology of Japan;  [25111005];  [25111004]	We thank T. Kitamura (University of Tokyo) and S. Yamaoka (Tokyo Medical and Dental University) for retroviral vectors and Plat-E cells and S. Sugano (University of Tokyo) for the pEF321-T plasmid. Synchrotron radiation experiments were performed at beamline BL41XU at SPring-8, Japan. This work was supported by Grants-in-Aid for Scientific Research on Priority Areas 25111005 (to N.M.) and 25111004 (to N.N.N.) and by funding from the Platform for Drug Discovery, Informatics and Structural Life Science (to N.N.N.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Jao CC, 2013, P NATL ACAD SCI USA, V110, P5486, DOI 10.1073/pnas.1220306110; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathol.2.010506.091842; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Itakura E, 2010, AUTOPHAGY, V6, P764; Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mercer CA, 2009, AUTOPHAGY, V5, P649; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01257-2; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Suzuki SW, 2015, P NATL ACAD SCI USA, V112, P3350, DOI 10.1073/pnas.1421092112; Mapelli M, 2007, CELL, V131, P730, DOI 10.1016/j.cell.2007.08.049; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067; Kawamata T, 2008, MOL BIOL CELL, V19, P2039, DOI 10.1091/mbc.E07-10-1048; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Quy PN, 2013, J BIOL CHEM, V288, P1125, DOI 10.1074/jbc.M112.399949; Luo XL, 2008, STRUCTURE, V16, P1616, DOI 10.1016/j.str.2008.10.002; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Suzuki K, 2007, GENES CELLS, V12, P209, DOI 10.1111/j.1365-2443.2007.01050.x; Cheong H, 2008, MOL BIOL CELL, V19, P668, DOI 10.1091/mbc.E07-08-0826; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Hosokawa N, 2009, AUTOPHAGY, V5, P973; Obara K, 2008, J BIOL CHEM, V283, P23972, DOI 10.1074/jbc.M803180200; Fujioka Y, 2014, NAT STRUCT MOL BIOL, V21, P513, DOI 10.1038/nsmb.2822; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Itakura E, 2012, J CELL SCI, V125, P1488, DOI 10.1242/jcs.094110; McNicholas S, 2011, ACTA CRYSTALLOGR D, V67, P386, DOI 10.1107/S0907444911007281; Ragusa MJ, 2012, CELL, V151, P1501, DOI 10.1016/j.cell.2012.11.028; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Demishtein A, 2015, METHODS, V75, P87, DOI 10.1016/j.ymeth.2014.12.020; Hegedus K., 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/470482; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258; Saitoh T, 2002, FEBS LETT, V532, P45, DOI 10.1016/S0014-5793(02)03622-0; Sun LL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003715	49	4	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	JUL	2015	22	7					572	+		10.1038/nsmb.3036		11	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CM3WC	WOS:000357614900009		
J	Matsui, T; Soya, S; Kawanaka, K; Soya, H				Matsui, Takashi; Soya, Shingo; Kawanaka, Kentaro; Soya, Hideaki			Brain Glycogen Decreases During Intense Exercise Without Hypoglycemia: The Possible Involvement of Serotonin	NEUROCHEMICAL RESEARCH			English	Article						Intense exercise; Brain glycogen; Lactate; Serotonin; Blood glucose	TERM-MEMORY FORMATION; EXHAUSTIVE EXERCISE; ENERGY-METABOLISM; RATS; ASTROCYTES; LACTATE; GLUCOSE; RELEASE; MICE; NEUROGENESIS	Brain glycogen stored in astrocytes, a source of lactate as a neuronal energy source, decreases during prolonged exercise with hypoglycemia. However, brain glycogen dynamics during exercise without hypoglycemia remain unknown. Since intense exercise increases brain noradrenaline and serotonin as known inducers for brain glycogenolysis, we hypothesized that brain glycogen decreases with intense exercise not accompanied by hypoglycemia. To test this hypothesis, we employed a well-established acute intense exercise model of swimming in rats. Rats swam for fourteen 20 s bouts with a weight equal to 8 % of their body mass and were sacrificed using high-power (10 kW) microwave irradiation to inactivate brain enzymes for accurate detection of brain glycogen and monoamines. Intense exercise did not alter blood glucose, but did increase blood lactate levels. Immediately after exercise, brain glycogen decreased and brain lactate increased in the hippocampus, cerebellum, cortex, and brainstem. Simultaneously, serotonin turnover in the hippocampus and brainstem mutually increased and were associated with decreased brain glycogen. Intense swimming exercise that does not induce hypoglycemia decreases brain glycogen associated with increased brain lactate, implying an importance of glycogen in brain energetics during intense exercise even without hypoglycemia. Activated serotonergic regulation is a possible underlying mechanism for intense exercise-induced glycogenolysis at least in the hippocampus and brainstem.	[Matsui, Takashi; Soya, Shingo; Soya, Hideaki] Univ Tsukuba, Lab Exercise Biochem & Neuroendocrinol, Inst Hlth & Sport Sci, Tsukuba, Ibaraki 3058574, Japan; [Matsui, Takashi; Kawanaka, Kentaro] Niigata Univ Hlth & Welf, Dept Hlth & Nutr, Niigata, Niigata 9503198, Japan	Soya, H (reprint author), Univ Tsukuba, Lab Exercise Biochem & Neuroendocrinol, Inst Hlth & Sport Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058574, Japan.	hsoya@taiiku.tsukuba.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT); Human High Performance (HHP) project; JSPS	The authors gratefully acknowledge Yukio Ichitani (University of Tsukuba) for his technical assistance for the microwave irradiation. This study was supported, in part, by a Grant-in-Aid for Challenging Exploratory Research of the Japan Society for the Promotion of Science (JSPS); a Grant-in-Aid for JSPS Fellows and the Ministry of Education, Culture, Sports, Science and Technology (MEXT) for the Body and Mind Integrated Sports Sciences (BAMIS) Project (2010-2013); and the Human High Performance (HHP) project (2014). T.M. was supported as a JSPS Research Fellow-SPD (2012-2014).	Kong JM, 2002, J NEUROSCI, V22, P5581; Lee MC, 2012, J APPL PHYSIOL, V113, P1260, DOI 10.1152/japplphysiol.00869.2012; Cruz NF, 2002, J CEREBR BLOOD F MET, V22, P1476, DOI 10.1097/01.WCB.0000034362.37277.C0; Herzog RI, 2008, ENDOCRINOLOGY, V149, P1499, DOI 10.1210/en.2007-1252; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Terada S, 2001, J APPL PHYSIOL, V90, P2019; Shulman RG, 2001, P NATL ACAD SCI USA, V98, P6417, DOI 10.1073/pnas.101129298; Renard CE, 2003, FUND CLIN PHARMACOL, V17, P449, DOI 10.1046/j.1472-8206.2003.00160.x; Brown AM, 2004, J NEUROCHEM, V89, P537, DOI 10.1111/j.1471-4159.2004.02421.x; Duran J, 2013, J CEREBR BLOOD F MET, V33, P550, DOI 10.1038/jcbfm.2012.200; MAGISTRETTI PJ, 1988, DIABETES METAB, V14, P237; Matsui T, 2011, J PHYSIOL-LONDON, V589, P3383, DOI [10.1113/jphysiol.2010.203570, 10.1113/jphysiol.2011.203570]; Secher NH, 2008, J APPL PHYSIOL, V104, P306, DOI 10.1152/japplphysiol.00853.2007; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; Canada SE, 2011, J NEUROSCI RES, V89, P585, DOI 10.1002/jnr.22579; HUTCHINS DA, 1970, BRIT J PHARMACOL, V39, P9; SCHEURINK AJW, 1989, AM J PHYSIOL, V256, pR169; Lovatt D, 2007, J NEUROSCI, V27, P12255, DOI 10.1523/JNEUROSCI.3404-07.2007; Walls AB, 2009, NEUROSCIENCE, V158, P284, DOI 10.1016/j.neuroscience.2008.09.058; Contarteze RVL, 2008, COMP BIOCHEM PHYS A, V151, P415, DOI 10.1016/j.cbpa.2007.03.005; Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; Matsui T, 2012, J PHYSIOL-LONDON, V590, P607, DOI 10.1113/jphysiol.2011.217919; Colgan LA, 2012, J NEUROSCI, V32, P15737, DOI 10.1523/JNEUROSCI.0020-12.2012; Gibbs ME, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00054; Hertz L, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00261; Hirano M, 2006, MOL CELLS, V22, P119; Huang HP, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00029; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; Koshinaka K, 2009, METABOLISM, V58, P246, DOI 10.1016/j.metabol.2008.09.021; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Lee MC, 2013, NEUROSCI LETT, V537, P6, DOI 10.1016/j.neulet.2013.01.005; Mangia S, 2013, NEUROCHEM RES, V38, P470, DOI 10.1007/s11064-012-0962-3; Marcussen AB, 2008, ACTA NEUROL SCAND, V117, P94, DOI 10.1111/j.1600-0404.2007.00910.x; Miura H, 1996, PHARMACOL BIOCHEM BE, V53, P469, DOI 10.1016/0091-3057(95)02019-5; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Muller MS, 2014, BIOCHEM SOC T, V42, P1311, DOI 10.1042/BST20140157; Newman LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028427; Obel Linea F, 2012, Front Neuroenergetics, V4, P3, DOI 10.3389/fnene.2012.00003; Ohiwa N, 2006, NEUROSCI LETT, V395, P46, DOI 10.1016/j.neulet.2005.10.053; PASSONNE.JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; Rasmussen P, 2011, ACTA PHYSIOL, V201, P475, DOI 10.1111/j.1748-1716.2010.02223.x; Sickmann HM, 2005, NEUROCHEM RES, V30, P1295, DOI 10.1007/s11064-005-8801-4; WADA M, 1990, J PHYSIOL-LONDON, V430, P595; Wang L, 2002, BIOMED CHROMATOGR, V16, P427, DOI 10.1002/bmc.177; WATANABE T, 1991, J PHYSIOL-LONDON, V433, P719	47	1	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUL	2015	40	7					1333	1340		10.1007/s11064-015-1594-1		8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CM2KV	WOS:000357509700002		
J	Hashizume, A; Katsuno, M; Suzuki, K; Banno, H; Suga, N; Mano, T; Araki, A; Hijikata, Y; Grunseich, C; Kokkinis, A; Hirakawa, A; Watanabe, H; Yamamoto, M; Fischbeck, KH; Sobue, G				Hashizume, Atsushi; Katsuno, Masahisa; Suzuki, Keisuke; Banno, Haruhiko; Suga, Noriaki; Mano, Tomoo; Araki, Amane; Hijikata, Yasuhiro; Grunseich, Christopher; Kokkinis, Angela; Hirakawa, Akihiro; Watanabe, Hirohisa; Yamamoto, Masahiko; Fischbeck, Kenneth H.; Sobue, Gen			A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study	NEUROMUSCULAR DISORDERS			English	Article						Spinal and bulbar muscular atrophy; Validation; Functional rating scale; Motor neuron disease	QUALITY-OF-LIFE; AMYOTROPHIC-LATERAL-SCLEROSIS; OUTCOME MEASURES; RATING-SCALE; BULBOSPINAL NEURONOPATHY; HUNTINGTONS-DISEASE; RESPONSIVENESS; VALIDATION; DISABILITY; QUESTIONNAIRE	We aimed to develop, validate, and evaluate a disease-specific outcome measure for SBMA: the Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS). We examined the Japanese version (SBMAFRS-J) in 80 Japanese SBMA subjects to evaluate its validity and reliability. We then assessed this scale longitudinally in 41 additional SBMA subjects. The English version (SBMAFRS-E) was also tested in 15 US subjects. The total score of the SBMAFRS-J was distributed normally without an extreme ceiling or floor effect. For SBMAFRS-J, the high intra- and inter-rater agreement was confirmed (intra-class correlation coefficients [TCCs] 0.910 and 0.797, respectively), and internal consistency was satisfactory (Cronbach's alpha 0.700-0.822). In addition, SBMAFRS-J demonstrated concurrent, convergent, and discriminant validity, except for the respiratory subscale. The inter-rater reliability and internal consistency of SBMAFRS-E were also satisfactory. Longitudinally, SBMAFRS-J showed a higher sensitivity to disease progression than the existing clinical measures. In conclusion, we developed and validated a disease-specific functional rating scale for SBMA in both Japanese and English versions, although it needs to be re-assessed in interventional studies with a larger sample size including English speaking subjects. (C) 2015 Elsevier B.V. All rights reserved.	[Hashizume, Atsushi; Katsuno, Masahisa; Suzuki, Keisuke; Banno, Haruhiko; Suga, Noriaki; Mano, Tomoo; Araki, Amane; Hijikata, Yasuhiro; Watanabe, Hirohisa; Sobue, Gen] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Aichi 4668550, Japan; [Banno, Haruhiko] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan; [Grunseich, Christopher; Kokkinis, Angela; Fischbeck, Kenneth H.] NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA; [Hirakawa, Akihiro] Nagoya Univ, Grad Sch Med, Biostat Sect, Ctr Adv Med & Clin Res, Nagoya, Aichi 4668550, Japan; [Yamamoto, Masahiko] Aichi Gakuin Univ, Sch Hlth Sci, Dept Speech Pathol & Audiol, Nisshin 4700195, Japan	Sobue, G (reprint author), Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	Banno, Haruhiko/Q-1029-2015	Banno, Haruhiko/0000-0002-0404-3839	MEXT, Japan [22110005]; KAKENHI grants from MEXT/JSPS, Japan [22110005, 26293206, 26670440, 26670439, 21229011]; Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST); Daiichi Sankyo Foundation of Life Science; Ministry of Health, Labour and Welfare, Japan	Dr. Katsuno is supported by a Grant-in-Aid for Scientific Research on Innovated Areas "Foundation of Synapse and Neurocircuit Pathology" from MEXT, Japan, (22110005); KAKENHI grants from MEXT/JSPS, Japan, (No. 22110005, 26293206, 26670440, and 26670439); and Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST); and a grant from the Daiichi Sankyo Foundation of Life Science.; Dr. Sobue is supported by KAKENHI grants from MEXT/JSPS, Japan (No. 21229011); grants from the Ministry of Health, Labour and Welfare, Japan; and Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST).	Katsuno M, 2012, PROG NEUROBIOL, V99, P246, DOI 10.1016/j.pneurobio.2012.05.007; Marder K, 2000, NEUROLOGY, V54, P452; Fernandez-Rhodes LE, 2011, LANCET NEUROL, V10, P140, DOI 10.1016/S1474-4422(10)70321-5; Wenning GK, 2004, MOVEMENT DISORD, V19, P1391, DOI 10.1002/mds.20255; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Vanhoutte EK, 2012, BRAIN, V135, P1639, DOI 10.1093/brain/awr318; Giordano A, 2009, J NEUROL NEUROSUR PS, V80, P1023, DOI 10.1136/jnnp.2008.171181; Katsuno M, 2010, LANCET NEUROL, V9, P875, DOI 10.1016/S1474-4422(10)70182-4; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Cicchetti F, 2014, ANN NEUROL, V76, P31, DOI 10.1002/ana.24174; Banno H, 2009, ANN NEUROL, V65, P140, DOI 10.1002/ana.21540; Atsuta N, 2006, BRAIN, V129, P1446, DOI 10.1093/brain/awl096; Schmitz-Hubsch T, 2010, NEUROLOGY, V74, P678, DOI 10.1212/WNL.0b013e3181d1a6c9; Shy ME, 2005, NEUROLOGY, V64, P1209; KENNEDY WR, 1968, NEUROLOGY, V18, P671; Muller J, 2004, J NEUROL NEUROSUR PS, V75, P749, DOI 10.1136/jnnp.2003.013441; Hashizume A, 2012, BRAIN, V135, P2838, DOI 10.1093/brain/aws170; Burns J, 2012, ANN NEUROL, V71, P642, DOI 10.1002/ana.23572; Querin G, 2013, NEUROLOGY, V80, P2095, DOI 10.1212/WNL.0b013e318295d766; Draak THP, 2014, NEUROLOGY, V83, P2124, DOI 10.1212/WNL.0000000000001044; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Hashizume A, 2012, J NEUROL, V259, P712, DOI 10.1007/s00415-011-6251-2; Hobart JC, 2007, LANCET NEUROL, V6, P1094, DOI 10.1016/S1474-4422(07)70290-9; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136; Martinez-Martin P, 2008, MOVEMENT DISORD, V23, P1516, DOI 10.1002/mds.22202; Martinez-Martin P, 2006, VALUE HEALTH, V9, P386, DOI 10.1111/j.1524-4733.2006.00131.x; Merkies ISJ, 2009, NEUROMUSCULAR DISORD, V19, P447, DOI 10.1016/j.nmd.2009.04.005; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Oda E, 1996, No To Shinkei, V48, P999; Ohashi Y, 2001, No To Shinkei, V53, P346; Payan CAM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022293; Ravits TM, 2009, NEUROLOGY, V73, P805; Simmons Z, 2006, NEUROLOGY, V67, P1659, DOI 10.1212/01.wnl.0000242887.79115.19; Simon NG, 2014, MUSCLE NERVE, V50, P894, DOI 10.1002/mus.24244; Smith AG, 2014, NEUROLOGY, V83, P2104, DOI 10.1212/WNL.0000000000001058; Sperfeld AD, 2002, ARCH NEUROL-CHICAGO, V59, P1921, DOI 10.1001/archneur.59.12.1921; Brooks BR, 1996, ARCH NEUROL-CHICAGO, V53, P141	37	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-8966	1873-2364		NEUROMUSCULAR DISORD	Neuromusc. Disord.	JUL	2015	25	7					554	562		10.1016/j.nmd.2015.03.008		9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CM5TZ	WOS:000357753100004		
J	Aihara, M; Naito, I; Shimizu, T; Fujimaki, H; Asakura, K; Miyamoto, N; Yoshimoto, Y				Aihara, Masanori; Naito, Isao; Shimizu, Tatsuya; Fujimaki, Hiroya; Asakura, Ken; Miyamoto, Naoko; Yoshimoto, Yuhei			Preoperative embolization of intracranial meningiomas using n-butyl cyanoacrylate	NEURORADIOLOGY			English	Article						Meningioma; n-Butyl cyanoacrylate; Preoperative embolization; Complication	POLYVINYL-ALCOHOL PARTICLES; ARTERIOVENOUS-MALFORMATIONS; TECHNICAL CONSIDERATIONS; COMPLICATIONS; EFFICACY; MICROSPHERES; BENEFIT	Preoperative embolization for intracranial meningioma has been controversial for several decades. This study retrospectively reviewed our experience using n-butyl cyanoacrylate (n-BCA) to identify the factors for effective devascularization and procedure-related complications. Fifty-seven patients who underwent preoperative embolization with n-BCA were analyzed to collect the following data: age, sex, tumor size, location, pathology, and presence or absence of pial arterial supply. The predictive factors for total devascularization and complications were examined using univariate and multivariate analyses. Injected n-BCA penetrated into the tumor vessels in 51 cases (89 %) but resulted in feeder occlusion in 6 (11 %). Angiographic total devascularization was achieved in 29 cases (51 %) and partial devascularization in 28 (49 %). Small size, superficial location, and absence of pial supply were independent factors for total devascularization. No major complication was encountered, but asymptomatic or transient adverse events occurred in nine patients and were significantly associated with elderly patients and large tumors. Preoperative embolization for intracranial meningiomas using n-BCA can attain effective devascularization without major complications. The effect of preoperative embolization on surgical resection or patient outcome is still unknown.	[Aihara, Masanori; Shimizu, Tatsuya; Yoshimoto, Yuhei] Gunma Univ, Grad Sch Med, Dept Neurosurg, Maebashi, Gunma 3718511, Japan; [Naito, Isao; Miyamoto, Naoko] Geriatr Res Inst & Hosp, Dept Neurosurg, Maebashi, Gunma, Japan; [Fujimaki, Hiroya; Asakura, Ken] Maebashi Red Cross Hosp, Dept Neurosurg, Maebashi, Gunma, Japan	Aihara, M (reprint author), Gunma Univ, Grad Sch Med, Dept Neurosurg, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	masa.a6221@gmail.com					MACPHERSON P, 1991, NEURORADIOLOGY, V33, P334; Sluzewski M, 2013, AM J NEURORADIOL, V34, P727, DOI 10.3174/ajnr.A3311; Law-ye B, 2013, ACTA NEUROCHIR, V155, P707, DOI 10.1007/s00701-013-1632-1; Yu SCH, 2004, AM J NEURORADIOL, V25, P506; Carli DFM, 2010, AM J NEURORADIOL, V31, P152, DOI 10.3174/ajnr.A1754; Kallmes DF, 1997, NEURORADIOLOGY, V39, P877; Bendszus M, 2005, AM J NEURORADIOL, V26, P1413; Bendszus M, 2000, NEUROSURGERY, V47, P1306, DOI 10.1097/00006123-200012000-00008; MANELFE C, 1986, AM J NEURORADIOL, V7, P963; LATCHAW RE, 1993, AM J NEURORADIOL, V14, P583; Shah AH, 2013, J NEUROSURG, V119, P364, DOI 10.3171/2013.3.JNS121328; Rosen CL, 2002, ACTA NEUROCHIR, V144, P1157, DOI 10.1007/s00701-002-0965-y; Bendszus M, 2000, AM J NEURORADIOL, V21, P255; Kaji T, 1999, SURG NEUROL, V52, P270, DOI 10.1016/S0090-3019(99)00074-9; WAKHLOO AK, 1993, AM J NEURORADIOL, V14, P571; Ellis JA, 2011, EXPERT REV NEUROTHER, V11, P545, DOI [10.1586/ern.11.29, 10.1586/ERN.11.29]; RICHTER HP, 1983, NEUROSURGERY, V13, P261; DEAN BL, 1994, AM J NEURORADIOL, V15, P1675; Kominami S, 2012, INTERV NEURORADIOL, V18, P133; Gruber A, 2000, MINIM INVAS NEUROSUR, V43, P18, DOI 10.1055/s-2000-8812; Loh Y, 2010, J NEUROSURG, V113, P733, DOI 10.3171/2010.3.JNS09370; Li TL, 2005, INTERV NEURORADIOL, V11, P141; Bendszus M, 2000, NEUROSURGERY, V47, P1311; Miyamoto N, 2015, NEUROL MED-CHIR, V55, P163, DOI 10.2176/nmc.oa.2014-0223; Probst EN, 1999, AM J NEURORADIOL, V20, P1695; Raper DMS, 2014, AM J NEURORADIOL, V35, P1798, DOI 10.3174/ajnr.A3919; Singla A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.9.FOCUS13351	27	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JUL	2015	57	7					713	719		10.1007/s00234-015-1521-9		7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CM4VM	WOS:000357683100007		
J	Mugikura, S; Takahashi, S				Mugikura, Shunji; Takahashi, Shoki			Infarction in the pars libera of the column of fornix including pre (cholinergic)- and post (circuit of Papez fiber tracts)-commissural fibers causes "basal forebrain" amnesia	NEURORADIOLOGY			English	Letter							ANTERIOR COMMUNICATING ARTERY		[Mugikura, Shunji; Takahashi, Shoki] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Aoba Ku, Sendai, Miyagi 9808574, Japan	Mugikura, S (reprint author), Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	mugi@rad.med.tohoku.ac.jp					Markowitsch HJ, 2012, LANCET, V380, P1429, DOI 10.1016/S0140-6736(11)61304-4; MARINKOVIC S, 1990, ACTA NEUROCHIR, V106, P78, DOI 10.1007/BF01809337; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P263; Duvernoy HM, 2013, STRUCTURE FUNCTIONS, V4th, P5; Fujii T, 2008, HBK BEHAV NEUROSCI, V18, P343, DOI 10.1016/S1569-7339(08)00219-1; Meila D, 2015, NEURORADIOLOGY, V57, P41, DOI 10.1007/s00234-014-1438-8; Mugikura S, 2014, AM J NEURORADIOL, V35, P2293, DOI 10.3174/ajnr.A4057	7	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JUL	2015	57	7					757	759		10.1007/s00234-015-1504-x		3	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CM4VM	WOS:000357683100013		
J	Goyama, S; Huang, G; Kurokawa, M; Mulloy, JC				Goyama, S.; Huang, G.; Kurokawa, M.; Mulloy, J. C.			Posttranslational modifications of RUNX1 as potential anticancer targets	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; FAMILIAL PLATELET DISORDER; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; E3 UBIQUITIN LIGASE; POINT MUTATIONS; MYELODYSPLASTIC SYNDROMES; CBF-BETA; TRANSCRIPTIONAL ACTIVITY	The transcription factor RUNX1 is a master regulator of hematopoiesis. Disruption of RUNX1 activity has been implicated in the development of hematopoietic neoplasms. Recent studies also highlight the importance of RUNX1 in solid tumors both as a tumor promoter and a suppressor. Given its central role in cancer development, RUNX1 is an excellent candidate for targeted therapy. A potential strategy to target RUNX1 is through modulation of its posttranslational modifications (PTMs). Numerous studies have shown that RUNX1 activity is regulated by PTMs, including phosphorylation, acetylation, methylation and ubiquitination. These PTMs regulate RUNX1 activity either positively or negatively by altering RUNX1-mediated transcription, promoting protein degradation and affecting protein interactions. In this review, we first summarize the available data on the context-and dosagedependent roles of RUNX1 in various types of neoplasms. We then provide a comprehensive overview of RUNX1 PTMs from biochemical and biologic perspectives. Finally, we discuss how aberrant PTMs of RUNX1 might contribute to tumorigenesis and also strategies to develop anticancer therapies targeting RUNX1 PTMs.	[Goyama, S.; Huang, G.; Mulloy, J. C.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan	Mulloy, JC (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.	susumu.goyama@cchmc.org; james.mulloy@cchmc.org					Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Gorczynski MJ, 2007, CHEM BIOL, V14, P1186, DOI 10.1016/j.chembiol.2007.09.006; Goyama S, 2011, INT J HEMATOL, V94, P126, DOI 10.1007/s12185-011-0858-z; Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Ben-Ami O, 2013, CELL REP, V4, P1131, DOI 10.1016/j.celrep.2013.08.020; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Gu JA, 2010, CANCER PREV RES, V3, P1176, DOI 10.1158/1940-6207.CAPR-09-0265; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043; Huang G, 2011, BLOOD, V118, P6544, DOI 10.1182/blood-2010-11-317909; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Della Gatta G, 2012, NAT MED, V18, P436, DOI 10.1038/nm.2610; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Greif PA, 2012, HAEMATOL-HEMATOL J, V97, P1909, DOI 10.3324/haematol.2012.064667; Goyama S, 2013, J CLIN INVEST, V123, P3876, DOI 10.1172/JCI68557; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Guo H, 2011, J BIOL CHEM, V286, P208, DOI 10.1074/jbc.M110.149013; Owen CJ, 2008, BLOOD, V112, P4639, DOI 10.1182/blood-2008-05-156745; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Herglotz J, 2013, ONCOGENE, V32, P2565, DOI 10.1038/onc.2012.274; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Osato M, 1999, BLOOD, V93, P1817; Mendler JH, 2012, J CLIN ONCOL, V30, P3109, DOI 10.1200/JCO.2011.40.6652; Link KA, 2010, J CELL PHYSIOL, V222, P50, DOI 10.1002/jcp.21950; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Huang H, 2012, GENE DEV, V26, P1587, DOI 10.1101/gad.192054.112; Vu LP, 2013, CELL REP, V5, P1625, DOI 10.1016/j.celrep.2013.11.025; Imai Y, 2000, BLOOD, V96, P3154; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Song WJ, 1999, NAT GENET, V23, P166; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007; Biggs JR, 2006, MOL CELL BIOL, V26, P7420, DOI 10.1128/MCB.00597-06; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Wang CQ, 2014, CELL REP, V8, P767, DOI 10.1016/j.celrep.2014.06.046; Grossmann V, 2013, GENE CHROMOSOME CANC, V52, P410, DOI 10.1002/gcc.22039; Kamikubo Y, 2010, CANCER CELL, V17, P455, DOI 10.1016/j.ccr.2010.03.022; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Bresciani E, 2014, BLOOD, V124, P70, DOI 10.1182/blood-2013-10-531988; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grossmann V, 2011, HAEMATOL-HEMATOL J, V96, P1874, DOI 10.3324/haematol.2011.043919; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang SP, 2011, BJU INT, V107, P486, DOI 10.1111/j.1464-410X.2010.09512.x; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kawazu M, 2005, J IMMUNOL, V174, P3526; Komeno Y, 2014, BLOOD, V123, P3760, DOI 10.1182/blood-2013-08-521252; Kurokawa M, 2006, INT J HEMATOL, V84, P136, DOI 10.1532/IJH97.06070; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Ma SK, 2001, LEUKEMIA, V15, P1442, DOI 10.1038/sj.leu.2402202; Migas A, 2011, PEDIATR BLOOD CANCER, V57, P583, DOI 10.1002/pbc.22980; MITANI K, 1994, EMBO J, V13, P504; Neel BG, 2012, GENE DEV, V26, P1520, DOI 10.1101/gad.198051.112; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nishimoto N, 2011, BLOOD, V118, P2541, DOI 10.1182/blood-2010-10-315440; Peter A, 2009, EUR J HAEMATOL, V83, P420, DOI 10.1111/j.1600-0609.2009.01315.x; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rocquain J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-401; ROMANA SP, 1995, BLOOD, V85, P3662; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Tachibana M, 2008, BIOCHEM BIOPH RES CO, V368, P536, DOI 10.1016/j.bbrc.2008.01.124; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Wang L, 2009, BLOOD CELL MOL DIS, V43, P30, DOI 10.1016/j.bcmd.2009.03.005; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wotton S, 2002, CANCER RES, V62, P7181; Yoshimi M, 2012, EUR J IMMUNOL, V42, P1044, DOI 10.1002/eji.201040746; Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702; Zhang YH, 2004, J BIOL CHEM, V279, P53116, DOI 10.1074/jbc.M405502200; Zhao XH, 2014, BLOOD, V123, P1729, DOI 10.1182/blood-2013-03-489575	102	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3483	3492		10.1038/onc.2014.305		10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	WOS:000357434900001		
J	Iwasawa, J; Miyazaki, S; Hachiya, H; Iesaka, Y				Iwasawa, Jin; Miyazaki, Shinsuke; Hachiya, Hitoshi; Iesaka, Yoshito			Repetitive Implantable Cardioverter Defibrillator Shocks: What is the Mechanism?	PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY			English	Article						implantable cardioverter-defibrillator; lead failure; inappropriate therapy; oversensing; Proarrhythmia			[Iwasawa, Jin; Miyazaki, Shinsuke; Hachiya, Hitoshi; Iesaka, Yoshito] Tsuchiura Kyodo Gen Hosp, Div Cardiol, Cardiovascular Ctr, Ibaraki, Japan	Iwasawa, J (reprint author), Tsuchiura Kyodo Gen Hosp, Cardiovasc Ctr, Div Cardiol, 11-Manabeshin Machi, Tsuchiura, Ibaraki 3000053, Japan.	jin_iwasawa@nifty.com					PINSKI SL, 1995, CIRCULATION, V92, P1651; Veltmann C, 2007, J CARDIOVASC ELECTR, V18, P326, DOI 10.1111/j.1540-8167.2006.00692.x	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0147-8389	1540-8159		PACE	PACE-Pacing Clin. Electrophysiol.	JUL	2015	38	7					899	901		10.1111/pace.12528		3	Cardiac & Cardiovascular Systems; Engineering, Biomedical	Cardiovascular System & Cardiology; Engineering	CL9TX	WOS:000357322100018		
J	Funaki, T; Miyata, I; Shoji, K; Enomoto, Y; Sakamoto, S; Kasahara, M; Miyairi, I				Funaki, Takanori; Miyata, Ippei; Shoji, Kensuke; Enomoto, Yuki; Sakamoto, Seisuke; Kasahara, Mureo; Miyairi, Isao			Therapeutic Drug Monitoring in Neonatal HSV Infection on Continuous Renal Replacement Therapy	PEDIATRICS			English	Article							CONTINUOUS VENOVENOUS HEMODIALYSIS; HERPES-SIMPLEX VIRUS; ACYCLOVIR; HEMODIAFILTRATION	Optimal acyclovir dosing under continuous renal replacement therapy (CRRT) in neonates is unknown. We monitored serum acyclovir levels and herpes simplex virus 1 (HSV-1) DNA levels in a neonate with disseminated HSV-1 infection and renal failure undergoing CRRT. A full-term, 5-day-old female presented with a 2-day history of lethargy and fever. She developed fulminant hepatitis and was diagnosed with HSV-1 infection by real-time polymerase chain reaction. Acyclovir was initiated at 60 mg/kg/day, which was lowered to 20 mg/kg/day because of development of renal failure. She was placed on continuous hemodialysis. Acyclovir dosing was adjusted according to serum acyclovir levels, and HSV-1 viral load was sequentially monitored. Semiquantification of serum HSV-1 levels was performed by real-time polymerase chain reaction. Acyclovir levels were measured by using liquid chromatography-tandem mass spectrometry. Acyclovir was administered at 20 mg/kg intravenously over 1 hour; peak concentration was 18.9 mg/mL. The half-life of acyclovir was estimated to be 2 to 3 h. Viral load remained high during dosing every 24 hours, with a decline of 0.17 log copies/24 hours. Acyclovir dosing was changed to 20 mg/kg/dose every 8 hours, with an average viral load decline of 0.44 log copies/24 hours. Despite the guideline recommendation of 24-hour redosing, acyclovir was dialyzed at a rate that resulted in suboptimal treatment. Individual therapeutic drug monitoring for acyclovir and dosing adjustment may be required to optimize therapy for patients undergoing CRRT.	[Funaki, Takanori; Miyata, Ippei; Shoji, Kensuke; Miyairi, Isao] Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Infect Dis, Tokyo, Japan; [Enomoto, Yuki] Natl Ctr Child Hlth & Dev, Dept Anesthesia & Intens Care, Div Acute & Crit Care, Tokyo, Japan; [Sakamoto, Seisuke; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Div Transplant Surg, Transplant Ctr, Tokyo, Japan	Miyairi, I (reprint author), Dept Med Subspecialties, Div Infect Dis, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	miyairi-i@ncchd.go.jp			National Center for Child Health and Development [24-11-3, 24-8, 24-31]	Supported by funding from the National Center for Child Health and Development to I. Miyairi (24-11-3), M. Kasahara (24-8), and T. Funaki (24-31).	ANDO Y, 1993, J MED VIROL, V41, P170, DOI 10.1002/jmv.1890410214; Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10; Trotman RL, 2005, CLIN INFECT DIS, V41, P1159, DOI 10.1086/444500; Aronoff GR, 2007, DRUG PRESCRIBING REN, V5th, P160; Bleyzac N, 1999, THER DRUG MONIT, V21, P520, DOI 10.1097/00007691-199910000-00005; Boulieu R, 1997, THER DRUG MONIT, V19, P701, DOI 10.1097/00007691-199712000-00016; Crowe LK, 2010, KUCERS USE ANTIBIOTI, V2, P2333; Khajehdehi P, 2000, CLIN NEPHROL, V54, P351; Kimberlin DW, 2012, PRINCIPLES PRACTICE, P1502; Kimberlin DW, 2001, PEDIATRICS, V108; Melvin AJ, 2014, J PEDIAT, V166, P827; Pickering LK, 2012, RED BOOK 2012 REPORT, V29th, P398; Stranska R, 2002, ANTIMICROB AGENTS CH, V46, P2943, DOI 10.1128/AAC.46.9.2943-2947.2002	13	0	0	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2015	136	1					E270	E274		10.1542/peds.2014-3380		5	Pediatrics	Pediatrics	CL9KB	WOS:000357296000035		
J	Bauchau, V; Van Holle, L; Mahaux, O; Holl, K; Sugiyama, K; Buyse, H				Bauchau, Vincent; Van Holle, Lionel; Mahaux, Olivia; Holl, Katsiaryna; Sugiyama, Keiji; Buyse, Hubert			Post-marketing monitoring of intussusception after rotavirus vaccination in Japan	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						human rotavirus vaccine; Rotarix(TM); post-marketing surveillance; intussusception; Japan; pharmacoepidemiology	INFANTS; RISK; VACCINES; CHILDREN; IMMUNIZATION; EFFICACY; SAFETY; MEXICO	PurposeRotarix(TM) was launched in November 2011 in Japan to prevent rotavirus gastroenteritis. Some studies suggest that Rotarix(TM) may have a temporal association with a risk of intussusception (IS). We assessed a possible association between IS and Rotarix(TM) vaccination in Japan. MethodsAll IS cases spontaneously reported post-vaccination (Brighton collaboration levels 1, 2, and 3) were extracted from the GlaxoSmithKline spontaneous report database on the 11th of January 2013. Expected numbers of IS cases were estimated using the number of vaccine doses distributed and the Japanese incidence rate of IS stratified by month of age. The observed versus expected analysis considered the IS cases for each risk period (7 and 30days post-vaccination) and for each vaccine dose (two doses). ResultsBefore January 2013, approximately 601000 Rotarix(TM) doses were distributed in Japan. For a risk period of 7days post-dose 1 and post-dose 2, 10 and five IS cases were observed, whereas 3.4 and 7.6 were expected, providing an observed-to-expected ratio of 2.96 (95% confidence interval [CI]: 1.42; 5.45) and 0.66 (95% CI: 0.21; 1.53), respectively. For a risk period of 30days post-dose 1 and post-dose 2, 14 and eight cases were observed, whereas 14.5 and 32.7 were expected, providing an observed-to-expected ratio of 0.97 (95% CI: 0.53; 1.62) and 0.24 (95% CI: 0.11; 0.48), respectively. ConclusionA statistically significant excess of IS cases was observed within 7days post-dose 1, but not post-dose 2. These results are consistent with previous observations in large post-marketing safety studies in other world regions. (c) 2015 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.	[Bauchau, Vincent; Van Holle, Lionel; Mahaux, Olivia; Buyse, Hubert] GSK Vaccines, Safety Dept, B-1300 Wavre, Belgium; [Holl, Katsiaryna] GSK Vaccines, Hlth Econ Dept, B-1300 Wavre, Belgium; [Sugiyama, Keiji] Japan Vaccine Co Ltd, Tokyo, Japan	Buyse, H (reprint author), GSK Vaccines, Rue Fleming 20, B-1300 Wavre, Belgium.	hubert.x.buyse@gsk.com		Mahaux, Olivia/0000-0002-9361-3118	GlaxoSmithKline Biologicals SA	GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of the present manuscript.	Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016; Haber P, 2013, PEDIATRICS, V131, P1042, DOI 10.1542/peds.2012-2554; Garwood F, 1936, BIOMETRIKA, V28, P437; Buttery JP, 2011, VACCINE, V29, P3061, DOI 10.1016/j.vaccine.2011.01.088; Velazquez FR, 2012, PEDIATR INFECT DIS J, V31, P736, DOI 10.1097/INF.0b013e318253add3; [Anonymous], 2012, PHARM MED DEVICES SA; Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520; Bines JE, 2009, J INFECT DIS, V200, pS282, DOI 10.1086/605051; Bines J, 2002, WHOVB0219; Biswas Pipasha, 2013, J Pharmacol Pharmacother, V4, pS7, DOI 10.4103/0976-500X.120941; Jiang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068482; Kapikian AZ, 1996, J INFECT DIS, V174, pS65; Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008; Meeting of the Immunization Strategic Advisory Group of Experts, 2009, WKLY EPIDEMIOL REC, V84, P220; Miura M, 2013, OPEN J PEDIAT, V03, P311, DOI 10.4236/ojped.2013.34056.; Nakagomi T, 2006, EPIDEMIOL INFECT, V134, P57, DOI 10.1017/S0950268805004644; Noguchi A, 2012, JPN J INFECT DIS, V65, P301; Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952; Takeuchi M, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-36; Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738; Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	JUL	2015	24	7					765	770		10.1002/pds.3800		6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL9VC	WOS:000357325200013		
J	Kansaku, R; Sakakibara, N; Amano, A; Endo, H; Shimabukuro, T; Sueishi, M				Kansaku, Rei; Sakakibara, Naoki; Amano, Atsushi; Endo, Hisako; Shimabukuro, Takashi; Sueishi, Michiaki			Histological difference between pulsed wave laser and continuous wave laser in endovenous laser ablation	PHLEBOLOGY			English	Article						Chronic venous disease; chronic venous insufficiency; endovenous laser treatment; endovenous thermal ablation; pathology/histology	GREAT SAPHENOUS-VEIN; NM DIODE-LASER; THERMAL-DAMAGE; FOLLOW-UP; ABSORPTION; MECHANISM; BLOOD	Background Endovenous laser ablation to saphenous veins has been popular as a minimally invasive treatment for chronic venous insufficiency. However, adverse effects after endovenous laser ablation using continuous wave laser still remain. Pulsed wave with enough short pulse duration and sufficiently long thermal relaxation time may avoid the excess energy delivery, which leads to the perforation of the vein wall. Method (1) Free radiation: Laser is radiated in blood for 10s. (2) Endovenous laser ablation: Veins were filled with blood and placed in saline. Endovenous laser ablations were performed. Results (1) There were clots on the fiber tips with continuous wave laser while no clots with pulsed wave laser. (2) In 980-nm continuous wave, four of 15 specimens had ulcers and 11 of 15 had perforation. In 1470-nm continuous wave with 120J/cm of linear endovenous energy density, two of three presented ulcers and one of three showed perforation. In 1470-nm continuous wave with 60J/cm of linear endovenous energy density, two of four had ulcers and two of four had perforation. In 1320-nm pulsed wave, there were neither ulcers nor perforation in the specimens. Conclusions While endovenous laser ablation using continuous wave results in perforation in many cases, pulsed wave does not lead to perforation.	[Kansaku, Rei; Sakakibara, Naoki; Shimabukuro, Takashi] Edogawa Hosp, Dept Cardiovasc Surg, Tokyo, Japan; [Kansaku, Rei; Sakakibara, Naoki; Amano, Atsushi] Juntendo Univ, Dept Cardiovasc Surg, Tokyo 1138421, Japan; [Endo, Hisako] Edogawa Hosp, Dept Pathol, Tokyo, Japan; [Sueishi, Michiaki] Shinagawa Heart Med Clin, Tokyo, Japan	Kansaku, R (reprint author), Juntendo Univ, Dept Cardiovasc Surg, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	kansaku-ths@umin.ac.jp					ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; Disselhoff BCVM, 2008, PHLEBOLOGY, V23, P69, DOI 10.1258/phleb.2007.007038; Ross EV, 1999, ARCH DERMATOL, V135, P444, DOI 10.1001/archderm.135.4.444; Roggan A, 1999, J BIOMED OPT, V4, P36, DOI 10.1117/1.429919; der Kinderen DJ, 2009, DERMATOL SURG, V35, P1985, DOI 10.1111/j.1524-4725.2009.01317.x; Bush RG, 2008, LASER SURG MED, V40, P676, DOI 10.1002/lsm.20722; Proebstle TM, 2002, J VASC SURG, V35, P729, DOI 10.1067/mva.2002.121132; Fan CM, 2008, PHLEBOLOGY, V23, P206, DOI 10.1258/phleb.2008.008049; Corcos L, 2005, J VASC SURG, V41, P1018, DOI 10.1016/j.jvs.2005.03.002; Amzayyb M, 2010, LASER MED SCI, V25, P439, DOI 10.1007/s10103-009-0749-1; Proebstle TM, 2005, DERMATOL SURG, V31, P1678; Goldman MP, 2004, DERMATOL SURG, V30, P1380, DOI 10.1111/j.1524-4725.2004.30431.x; Goldman MP, 2003, COSMET DERMATOL, V16, P25; Mordon S, 2009, LASER SURG MED, V41, P543, DOI 10.1002/lsm.20809; Pannier F, 2011, PHLEBOLOGY, V26, P35, DOI 10.1258/phleb.2010.009096; Proebstle TM, 2002, DERMATOL SURG, V28, P596, DOI 10.1046/j.1524-4725.2002.01309.x; Proebstle TM, 2006, J VASC SURG, V44, P834, DOI 10.1016/j.jvs.2006.05.052; Schmedt CG, 2006, EUR J VASC ENDOVASC, V32, P318, DOI 10.1016/j.ejvs.2006.04.013; Vuylsteke M, 2010, EUR J VASC ENDOVASC, V40, P110, DOI 10.1016/j.ejvs.2009.09.013; Yang CH, 2006, DERMATOL SURG, V32, P1453, DOI 10.1111/j.1524-4725.2006.32355.x	20	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0268-3555	1758-1125		PHLEBOLOGY	Phlebology	JUL	2015	30	6					429	434		10.1177/0268355514538248		6	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CM2RP	WOS:000357530000007		
J	Uchiyama, C				Uchiyama, Chikako			Dynamics of quantum tomography in an open system	PHYSICA SCRIPTA			English	Article						tomography; muons; quantum dissipative systems	PROJECTION OPERATOR-FORMALISM; LINEAR-DIFFERENTIAL EQUATIONS; STAR-PRODUCT KERNEL; DENSITY-MATRIX; PROBABILITY REPRESENTATION; STATISTICAL-MECHANICS; SYMPLECTIC TOMOGRAPHY; CUMULANT EXPANSION; RIGOROUS SOLUTION; SPIN RELAXATION	In this study, we provide a way to describe the dynamics of quantum tomography in an open system with a generalized master equation, considering a case where the relevant system under tomographic measurement is influenced by the environment. We apply this to spin tomography because such situations typically occur in mu SR (muon spin rotation/relaxation/resonance) experiments where microscopic features of the material are investigated by injecting muons as probes. As a typical example to describe the interaction between muons and a sample material, we use a spin-boson model where the relevant spin interacts with a bosonic environment. We describe the dynamics of a spin tomogram using a time-convolutionless type of generalized master equation that enables us to describe short time scales and/or low-temperature regions. Through numerical evaluation for the case of Ohmic spectral density with an exponential cutoff, a clear interdependency is found between the time evolution of elements of the density operator and a spin tomogram. The formulation in this paper may provide important fundamental information for the analysis of results from, for example, mu SR experiments on short time scales and/or in low-temperature regions using spin tomography.	Univ Yamanashi, Grad Sch, Dept Interdisciplinary Res, Kofu, Yamanashi 4008511, Japan	Uchiyama, C (reprint author), Univ Yamanashi, Grad Sch, Dept Interdisciplinary Res, 4-3-11 Takeda, Kofu, Yamanashi 4008511, Japan.	hchikako@yamanashi.ac.jp			KAKENHI [25287098]	The author appreciates fruitful discussions on the dynamics of open systems for spin tomograms with Professor V I Man'ko, Professor M A Man'ko, Professor S Pascazio and Professor G Marmo. The author also thanks Dipartimento di Fisica, Universita di Bari for its kind hospitality. This work is partially supported by a Grant-in-Aid for Scientific Research (B) (KAKENHI 25287098).	HANGGI P, 1977, Z PHYS B CON MAT, V26, P85, DOI 10.1007/BF01313376; Mancini S, 2001, J PHYS A-MATH GEN, V34, P3461, DOI 10.1088/0305-4470/34/16/314; LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/RevModPhys.59.1; Belousov YM, 2012, OPT SPECTROSC+, V112, P359, DOI 10.1134/S0030400X1203006X; Wigner E, 1932, PHYS REV, V40, P0749, DOI 10.1103/PhysRev.40.749; Man'ko OV, 2002, J PHYS A-MATH GEN, V35, P699, DOI 10.1088/0305-4470/35/3/315; Belousov YM, 2010, J RUSS LASER RES, V31, P421; Man'ko OV, 2000, PHYS SCRIPTA, V62, P446, DOI 10.1238/Physica.Regular.062a00446; SHIBATA F, 1980, J PHYS SOC JPN, V49, P891, DOI 10.1143/JPSJ.49.891; ARECCHI FT, 1972, PHYS REV A, V6, P2211, DOI 10.1103/PhysRevA.6.2211; VOGEL K, 1989, PHYS REV A, V40, P2847, DOI 10.1103/PhysRevA.40.2847; CHATURVEDI S, 1979, Z PHYS B CON MAT, V35, P297, DOI 10.1007/BF01319852; Agarwal GS, 1998, PHYS REV A, V57, P671, DOI 10.1103/PhysRevA.57.671; MANCINI S, 1995, QUANTUM SEMICL OPT, V7, P615, DOI 10.1088/1355-5111/7/4/016; Schiller S, 1996, PHYS REV LETT, V77, P2933, DOI 10.1103/PhysRevLett.77.2933; Mancini S, 1997, FOUND PHYS, V27, P801, DOI 10.1007/BF02550342; TAKAHASHI Y, 1976, J STAT PHYS, V14, P49, DOI 10.1007/BF01020134; GORINI V, 1976, J MATH PHYS, V17, P821, DOI 10.1063/1.522979; Klimov AB, 2002, J PHYS A-MATH GEN, V35, P6101, DOI 10.1088/0305-4470/35/29/312; Man'ko VI, 2004, PHYS LETT A, V327, P353, DOI 10.1016/j.physleta.2004.05.007; SMITHEY DT, 1993, PHYS REV LETT, V70, P1244, DOI 10.1103/PhysRevLett.70.1244; Uchiyama C, 1999, PHYS REV E, V60, P2636, DOI 10.1103/PhysRevE.60.2636; Filippov SN, 2010, J RUSS LASER RES, V31, P32, DOI 10.1007/s10946-010-9122-x; GLAUBER RJ, 1963, PHYS REV LETT, V10, P84, DOI 10.1103/PhysRevLett.10.84; Uchiyama C, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.052108; BERTRAND J, 1987, FOUND PHYS, V17, P397, DOI 10.1007/BF00733376; HEFFNER RH, 1984, PHYS TODAY, V37, P38, DOI 10.1063/1.2915987; Ibort A, 2009, PHYS SCRIPTA, V79, DOI 10.1088/0031-8949/79/06/065013; SHIBATA F, 1995, PHYSICA A, V214, P242, DOI 10.1016/0378-4371(94)00218-I; Asorey M, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.012117; LINDBLAD G, 1976, COMMUN MATH PHYS, V48, P119, DOI 10.1007/BF01608499; SUDARSHAN E, 1961, PHYS REV, V121, P920, DOI 10.1103/PhysRev.121.920; Belousov YM, 2011, J RUSS LASER RES, V32, P584; Mancini S, 1996, PHYS LETT A, V213, P1, DOI 10.1016/0375-9601(96)00107-7; SHIBATA F, 1977, J STAT PHYS, V17, P171, DOI 10.1007/BF01040100; KUBO R, 1963, J MATH PHYS, V4, P174, DOI 10.1063/1.1703941; SHIBATA F, 1993, J PHYS SOC JPN, V62, P381, DOI 10.1143/JPSJ.62.381; Dodonov VV, 1997, PHYS LETT A, V229, P335, DOI 10.1016/S0375-9601(97)00199-0; HASHITSUME N, 1977, J STAT PHYS, V17, P155, DOI 10.1007/BF01040099; Asorey M, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.042115; Belousov Yu. M., 1990, Soviet Physics - Uspekhi, V33, DOI 10.1070/PU1990v033n11ABEH002655; Breuer H-P, 2002, THEORY OPEN QUANTUM; Filippov SN, 2009, J RUSS LASER RES, V30, P129, DOI 10.1007/s10946-009-9065-2; Filippov SN, 2009, J RUSS LASER RES, V30, P224, DOI 10.1007/s10946-009-9077-y; Fukaya A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207603; Husimi K., 1940, Proceedings of the Physico-Mathematical Society of Japan, V22; Landau L.D., 2003, QUANTUM MECH; Man'ko VI, 2004, SYMMETRIES IN SCIENCE XI, P395; Manfko M A, 2006, J RUSS LASER RES, V27, P507; Manfko V I, 1997, SOV PHYS JETP, V85, P430; Miloserdin V Yu, 1979, SOV PHYS USP, V22, P679; Nielsen M, 2000, QUANTUM COMPUTATION; Pauli W, 1933, HDB PHYS; Pauli W, 1980, PRINCIPLES QUANTUM M; Sudarshan E C G, 1963, PHYS REV LETT, V10, P177; VANKAMPE.NG, 1974, PHYSICA, V74, P215, DOI 10.1016/0031-8914(74)90121-9; VANKAMPE.NG, 1974, PHYSICA, V74, P239, DOI 10.1016/0031-8914(74)90122-0; Weiss U, 1999, QUANTUM DISSIPATIVE	58	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-8949	1402-4896		PHYS SCRIPTA	Phys. Scr.	JUL	2015	90	7			SI				074064	10.1088/0031-8949/90/7/074064		8	Physics, Multidisciplinary	Physics	CM2WA	WOS:000357541800065		
J	Shinozaki, Y; Hao, SH; Kojima, M; Sakakibara, H; Ozeki-Iida, Y; Zheng, Y; Fei, ZJ; Zhong, SL; Giovannoni, JJ; Rose, JK; Okabe, Y; Heta, Y; Ezura, H; Ariizumi, T				Shinozaki, Yoshihito; Hao, Shuhei; Kojima, Mikiko; Sakakibara, Hitoshi; Ozeki-Iida, Yuko; Zheng, Yi; Fei, Zhangjun; Zhong, Silin; Giovannoni, James J.; Rose, Jocelyn K. C.; Okabe, Yoshihiro; Heta, Yumi; Ezura, Hiroshi; Ariizumi, Tohru			Ethylene suppresses tomato (Solanum lycopersicum) fruit set through modification of gibberellin metabolism	PLANT JOURNAL			English	Article						ethylene; gibberellin; auxin; fruit set; Solanum lycopersicum; parthenocarpy	CV MICRO-TOM; TIME RT-PCR; PLANT DEVELOPMENT; APICAL SHOOT; BIOSYNTHESIS; GROWTH; POLLINATION; AUXIN; OVARY; ACID	Fruit set in angiosperms marks the transition from flowering to fruit production and a commitment to seed dispersal. Studies with Solanum lycopersicum (tomato) fruit have shown that pollination and subsequent fertilization induce the biosynthesis of several hormones, including auxin and gibberellins (GAs), which stimulate fruit set. Circumstantial evidence suggests that the gaseous hormone ethylene may also influence fruit set, but this has yet to be substantiated with molecular or mechanistic data. Here, we examined fruit set at the biochemical and genetic levels, using hormone and inhibitor treatments, and mutants that affect auxin or ethylene signaling. The expression of system-1 ethylene biosynthetic genes and the production of ethylene decreased during pollination-dependent fruit set in wild-type tomato and during pollination-independent fruit set in the auxin hypersensitive mutant iaa9-3. Blocking ethylene perception in emasculated flowers, using either the ethylene-insensitive Sletr1-1 mutation or 1-methylcyclopropene (1-MCP), resulted in elongated parthenocarpic fruit and increased cell expansion, whereas simultaneous treatment with the GA biosynthesis inhibitor paclobutrazol (PAC) inhibited parthenocarpy. Additionally, the application of the ethylene precursor 1-aminocyclopropane-1-carboxylic acid (ACC) to pollinated ovaries reduced fruit set. Furthermore, Sletr1-1 parthenocarpic fruits did not exhibit increased auxin accumulation, but rather had elevated levels of bioactive GAs, most likely reflecting an increase in transcripts encoding the GA-biosynthetic enzyme SlGA20ox3, as well as a reduction in the levels of transcripts encoding the GA-inactivating enzymes SlGA2ox4 and SlGA2ox5. Taken together, our results suggest that ethylene plays a role in tomato fruit set by suppressing GA metabolism.	[Shinozaki, Yoshihito; Hao, Shuhei; Ozeki-Iida, Yuko; Okabe, Yoshihiro; Heta, Yumi; Ezura, Hiroshi; Ariizumi, Tohru] Univ Tsukuba, Ctr Gene Res, Grad Sch Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Kojima, Mikiko; Sakakibara, Hitoshi] RIKEN, Ctr Sustainable Resource Sci, Yokohama, Kanagawa 2300045, Japan; [Zheng, Yi; Fei, Zhangjun; Giovannoni, James J.] Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; [Zhong, Silin] Chinese Univ Hong Kong, Sch Life Sci, Partner State Key Lab Agrobiotechnol, Hong Kong, Hong Kong, Peoples R China; [Giovannoni, James J.] USDA ARS, Robert W Holley Ctr Agr & Hlth, Ithaca, NY 14853 USA; [Rose, Jocelyn K. C.] Cornell Univ, Sch Integrat Plant Sci, Plant Biol Sect, Ithaca, NY 14853 USA	Ariizumi, T (reprint author), Univ Tsukuba, Ctr Gene Res, Grad Sch Environm Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.	ariizumi.toru.ge@u.tsukuba.ac.jp	Sakakibara, Hitoshi/A-6040-2010; zhong, silin/O-7029-2015	Sakakibara, Hitoshi/0000-0001-5449-6492; zhong, silin/0000-0002-0198-7383	JSPS KAKENHI [23780001]; Program to Disseminate Tenure Tracking System; JSPS; Japan Advanced Plant Science Network; Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan [26013A]; US National Science Foundation [IOS-1339287]; ITC ITF Support to the Partner State Key Laboratories in Hong Kong	This work was supported by JSPS KAKENHI, grant no. 23780001, Program to Disseminate Tenure Tracking System, and JSPS bilateral program to TA, and was supported by the Japan Advanced Plant Science Network, and by Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan (grant no. 26013A) to HE and TA, and support was provided to JKCR, ZF and JGG by a grant from the US National Science Foundation (Plant Genome Research Program; IOS-1339287), and by ITC ITF Support to the Partner State Key Laboratories in Hong Kong to SZ. Seeds of Micro-Tom WT (TOMJPF00001), iaa9-3 (TOMJPE2811), Sletr1-1 (TOMJPE5803) and Sletr1-2 (TOMJPE5704) were obtained from the National BioResource Project, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.	Tieman DM, 2001, PLANT J, V26, P47, DOI 10.1046/j.1365-313x.2001.01006.x; BURG SP, 1965, SCIENCE, V148, P1190, DOI 10.1126/science.148.3674.1190; Alexander L, 2002, J EXP BOT, V53, P2039, DOI 10.1093/jxb/erf072; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.arplant.44.1.283; MAPELLI S, 1978, PLANT CELL PHYSIOL, V19, P1281; Marti E, 2006, J EXP BOT, V57, P2037, DOI 10.1093/jxb/erj154; Serrani JC, 2007, PLANT PHYSIOL, V145, P246, DOI 10.1104/pp.107.098335; Kojima M, 2009, PLANT CELL PHYSIOL, V50, P1201, DOI 10.1093/pcp/pcp057; Bleecker AB, 2000, ANNU REV CELL DEV BI, V16, P1, DOI 10.1146/annurev.cellbio.16.1.1; Matsuo S, 2012, J EXP BOT, V63, P5569, DOI 10.1093/jxb/ers207; Garcia-Hurtado N, 2012, J EXP BOT, V63, P5803, DOI 10.1093/jxb/ers229; Volz R, 2013, DEV CELL, V25, P310, DOI 10.1016/j.devcel.2013.04.001; Llop-Tous I, 2000, PLANT PHYSIOL, V123, P971, DOI 10.1104/pp.123.3.971; Serrani JC, 2008, PLANT J, V56, P922, DOI 10.1111/j.1365-313X.2008.03654.x; van Schie CCN, 2007, PLANT J, V52, P752, DOI 10.1111/j.1365-313X.2007.03273.x; Okabe Y, 2011, PLANT CELL PHYSIOL, V52, P1994, DOI 10.1093/pcp/pcr134; Vandenbussche F, 2007, J EXP BOT, V58, P4269, DOI 10.1093/jxb/erm288; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Marti C, 2007, PLANT J, V52, P865, DOI 10.1111/j.1365-313X.2007.03282.x; Kang CY, 2013, PLANT CELL, V25, P1960, DOI 10.1105/tpc.113.111732; Yamaguchi S, 2008, ANNU REV PLANT BIOL, V59, P225, DOI 10.1146/annurev.arplant.59.032607.092804; Serrani JC, 2007, J PLANT GROWTH REGUL, V26, P211, DOI 10.1007/s00344-007-9014-7; Wang H, 2009, PLANT CELL, V21, P1428, DOI 10.1105/tpc.108.060830; Dorcey E, 2009, PLANT J, V58, P318, DOI 10.1111/j.1365-313X.2008.03781.x; Achard P, 2007, P NATL ACAD SCI USA, V104, P6484, DOI 10.1073/pnas.0610717104; Wang H, 2005, PLANT CELL, V17, P2676, DOI 10.1105/tpc.105.033415; Vriezen WH, 2008, NEW PHYTOL, V177, P60, DOI 10.1111/j.1469-8137.2007.02254.x; Ariizumi T, 2013, BREEDING SCI, V63, P3, DOI 10.1270/jsbbs.63.3; Finch-Savage WE, 2006, NEW PHYTOL, V171, P501, DOI 10.1111/j.1469-8137.2006.01787.x; Olimpieri I, 2007, PLANTA, V226, P877, DOI 10.1007/s00425-007-0533-z; Cara B, 2008, PLANT SCI, V175, P106, DOI 10.1016/j.plantsci.2008.03.021; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Mariotti L, 2011, J PLANT GROWTH REGUL, V30, P405, DOI 10.1007/s00344-011-9204-1; BOHNER J, 1988, PHYSIOL PLANTARUM, V73, P348, DOI 10.1111/j.1399-3054.1988.tb00609.x; BUNGERKIBLER S, 1983, PLANT GROWTH REGUL, V1, P143; Carbonell-Bejerano P, 2011, BMC PLANT BIOL, V11, DOI 10.1186/1471-2229-11-84; Carvalho RF, 2011, PLANT METHODS, V7, DOI 10.1186/1746-4811-7-18; Christmann A, 2006, PLANT BIOLOGY, V8, P314, DOI 10.1055/s-2006-924120; Chusreeaeom K, 2014, MOL GENET GENOMICS, V289, P399, DOI 10.1007/s00438-014-0822-8; De Martinis D, 2002, PLANTA, V214, P806, DOI 10.1007/s00425-001-0684-2; desJong M., 2009, J EXP BOT, V60, P1523; Ding JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070080; Exposito-Rodriguez M, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-131; Fos M, 2001, PHYSIOL PLANTARUM, V111, P545, DOI 10.1034/j.1399-3054.2001.1110416.x; Fos M, 2000, PLANT PHYSIOL, V122, P471, DOI 10.1104/pp.122.2.471; GILLASPY G, 1993, PLANT CELL, V5, P1439, DOI 10.1105/tpc.5.10.1439; Giovannoni JJ, 2004, PLANT CELL, V16, pS170, DOI 10.1105/tpc.019158; Ho LC, 1986, TOMATO CROP, P201; KOSHIOKA M, 1994, J HORTIC SCI, V69, P171; Martinez C, 2013, BMC PLANT BIOL, V13, DOI 10.1186/1471-2229-13-139; McAtee P, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00079; MCMURCHI.EJ, 1972, NATURE, V237, P235, DOI 10.1038/237235a0; Nitsch LMC, 2009, PLANTA, V229, P1335, DOI 10.1007/s00425-009-0913-7; Orzaez D, 1999, PLANTA, V208, P220, DOI 10.1007/s004250050553; Pascual L, 2009, BMC PLANT BIOL, V9, DOI 10.1186/1471-2229-9-67; Rodrigo MJ, 1998, PLANT PHYSIOL, V116, P511, DOI 10.1104/pp.116.2.511; Saito T, 2011, PLANT CELL PHYSIOL, V52, P283, DOI 10.1093/pcp/pcr004; Serrani JC, 2010, PLANT PHYSIOL, V153, P851, DOI 10.1104/pp.110.155424; Sjut V., 1982, Plant Growth Regulation, V1, P243; Van de Poel B, 2012, PLANT PHYSIOL, V160, P1498, DOI 10.1104/pp.112.206086	60	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0960-7412	1365-313X		PLANT J	Plant J.	JUL	2015	83	2					237	251		10.1111/tpj.12882		15	Plant Sciences	Plant Sciences	CM3WX	WOS:000357617200004		
J	Nomura, T; Murase, T; Ogita, S; Kato, Y				Nomura, Taiji; Murase, Tatsunori; Ogita, Shinjiro; Kato, Yasuo			Molecular identification of tuliposide B-converting enzyme: a lactone-forming carboxylesterase from the pollen of tulip	PLANT JOURNAL			English	Article						lactone-forming carboxylesterase; tuliposide-converting enzyme; tuliposide; tulipalin; pollen; tulip; Tulipa gesneriana	ALPHA-METHYLENE-BUTYROLACTONE; 6-TULIPOSIDE B; ENDOPLASMIC-RETICULUM; ARABIDOPSIS; GESNERIANA; STRIGOLACTONE; BIOSYNTHESIS; SUBSTANCES; PERCEPTION; FLAVONOIDS	6-Tuliposides A (PosA) and B (PosB), which are the major secondary metabolites in tulip (Tulipagesneriana), are enzymatically converted to the antimicrobial lactonized aglycons, tulipalins A (PaA) and B (PaB), respectively. We recently identified a PosA-converting enzyme (TCEA) as the first reported member of the lactone-forming carboxylesterases. Herein, we describe the identification of another lactone-forming carboxylesterase, PosB-converting enzyme (TCEB), which preferentially reacts with PosB to give PaB. This enzyme was isolated from tulip pollen, which showed high PosB-converting activity. Purified TCEB exhibited greater activity towards PosB than PosA, which was contrary to that of the TCEA. Novel cDNA (TgTCEB1) encoding the TCEB was isolated from tulip pollen. TgTCEB1 belonged to the carboxylesterase family and was approximately 50% identical to the TgTCEA polypeptides. Functional characterization of the recombinant enzyme verified that TgTCEB1 catalyzed the conversion of PosB to PaB with an activity comparable with the native TCEB. RT-qPCR analysis of each part of plant revealed that TgTCEB1 transcripts were limited almost exclusively to the pollen. Furthermore, the immunostaining of the anther cross-section using anti-TgTCEB1 polyclonal antibody verified that TgTCEB1 was specifically expressed in the pollen grains, but not in the anther cells. N-terminal transit peptide of TgTCEB1 was shown to function as plastid-targeted signal. Taken together, these results indicate that mature TgTCEB1 is specifically localized in plastids of pollen grains. Interestingly, PosB, the substrate of TgTCEB1, accumulated on the pollen surface, but not in the intracellular spaces of pollen grains.	[Nomura, Taiji; Murase, Tatsunori; Ogita, Shinjiro; Kato, Yasuo] Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama 9390398, Japan; [Nomura, Taiji; Murase, Tatsunori; Ogita, Shinjiro; Kato, Yasuo] Toyama Prefectural Univ, Dept Biotechnol, Imizu, Toyama 9390398, Japan	Nomura, T (reprint author), Toyama Prefectural Univ, Biotechnol Res Ctr, 5180 Kurokawa, Imizu, Toyama 9390398, Japan.	tnomura@pu-toyama.ac.jp			Japan Society for the Promotion of Science [23780120, 26850072]	This work was supported by Grants-in-Aid for Young Scientists (B) (No. 23780120 and No. 26850072) from the Japan Society for the Promotion of Science (to T.N.).	Hsieh K, 2007, PLANT CELL, V19, P582, DOI 10.1105/tpc.106.049049; Nagata N, 2010, J PLANT RES, V123, P193, DOI 10.1007/s10265-009-0293-x; Stuhlfelder C, 2004, EUR J BIOCHEM, V271, P2976, DOI 10.1111/j.1432-1033.2004.04227.x; Hamiaux C, 2012, CURR BIOL, V22, P2032, DOI 10.1016/j.cub.2012.08.007; Mendgen T, 2010, BIOORG MED CHEM LETT, V20, P5757, DOI 10.1016/j.bmcl.2010.07.139; Shoji K, 2005, J JPN SOC HORTIC SCI, V74, P469, DOI 10.2503/jjshs.74.469; Guo YX, 2013, P NATL ACAD SCI USA, V110, P8284, DOI 10.1073/pnas.1306265110; Nelson BK, 2007, PLANT J, V51, P1126, DOI 10.1111/j.1365-313X.2007.03212.x; Kitajima A, 2009, PLANT CELL, V21, P2844, DOI 10.1105/tpc.109.068288; Akashi T, 2005, PLANT PHYSIOL, V137, P882, DOI 10.1104/pp.104.056747; Liu L, 2013, PLANT MOL BIOL, V83, P165, DOI 10.1007/s11103-013-0085-5; Natesan SKA, 2005, J EXP BOT, V56, P787, DOI 10.1093/jxb/eri088; Arite T, 2009, PLANT CELL PHYSIOL, V50, P1416, DOI 10.1093/pcp/pcp091; Lallemand B, 2013, PLANT PHYSIOL, V162, P616, DOI 10.1104/pp.112.213124; Forouhar F, 2005, P NATL ACAD SCI USA, V102, P1773, DOI 10.1073/pnas.0409227102; Pacini E, 2011, PLANTA, V234, P217, DOI 10.1007/s00425-011-1462-4; Ueguchi-Tanaka M, 2005, NATURE, V437, P693, DOI 10.1038/nature04028; Gershater MC, 2007, PLANT SCI, V173, P579, DOI 10.1016/j.plantsci.2007.08.008; BEIJERSB.JC, 1972, PHYSIOL PLANT PATHOL, V2, P265, DOI 10.1016/0048-4059(72)90009-4; BERGMAN B H H, 1968, Netherlands Journal of Plant Pathology, V74, P157, DOI 10.1007/BF01977525; BERGMAN BHH, 1967, RECL TRAV CHIM PAY-B, V86, P709; Cheung AY, 1996, TRENDS PLANT SCI, V1, P45, DOI 10.1016/S1360-1385(96)80028-8; Christensen LP, 1999, CONTACT DERMATITIS, V40, P300, DOI 10.1111/j.1600-0536.1999.tb06080.x; Ileperuma NR, 2007, BIOCHEMISTRY-US, V46, P1851, DOI 10.1021/bi062046w; Jenecka A., 2012, DRUG DISCOV TODAY, V17, P561, DOI DOI 10.1016/J.DRUDIS.2012.01.013; Jun-Tao Feng, 2013, Bioorg Med Chem Lett, V23, P4393, DOI 10.1016/j.bmcl.2013.05.073; Kato Y, 2009, TETRAHEDRON LETT, V50, P4751, DOI 10.1016/j.tetlet.2009.06.018; Kato Y, 2009, BIOSCI BIOTECH BIOCH, V73, P1895, DOI 10.1271/bbb.90226; Niwa Y, 2003, PLANT BIOTECHNOL, V20, P1, DOI 10.5511/plantbiotechnology.20.1; Nomura T, 2013, BIOSCI BIOTECH BIOCH, V77, P1042, DOI 10.1271/bbb.130021; Nomura T, 2015, BIOSCI BIOTECH BIOCH, V79, P25, DOI 10.1080/09168451.2014.946395; Nomura T, 2012, PLANT PHYSIOL, V159, P565, DOI 10.1104/pp.112.195388; SCHONBEC.F, 1972, PHYSIOL PLANT PATHOL, V2, P91, DOI 10.1016/0048-4059(72)90015-X; Shigetomi K, 2011, BIOSCI BIOTECH BIOCH, V75, P718, DOI 10.1271/bbb.100845; Shigetomi K, 2010, PHYTOCHEMISTRY, V71, P312, DOI 10.1016/j.phytochem.2009.10.008; Shigetomi K, 2013, BIOSCI BIOTECH BIOCH, V77, P2517, DOI 10.1271/bbb.130663; TSCHESCH.R, 1969, CHEM BER-RECL, V102, P2057, DOI 10.1002/cber.19691020631; TSCHESCH.R, 1968, TETRAHEDRON LETT, P701; vansRossum M. W. P. C., 1998, PHYTOCHEMISTRY, V49, P723; WIERMANN R, 1983, PROTOPLASMA, V118, P230, DOI 10.1007/BF01281807; Yonekura-Sakakibara K, 2014, PLANT J, V79, P769, DOI 10.1111/tpj.12580	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0960-7412	1365-313X		PLANT J	Plant J.	JUL	2015	83	2					252	262		10.1111/tpj.12883		11	Plant Sciences	Plant Sciences	CM3WX	WOS:000357617200005		
J	Kitazaki, K; Arakawa, T; Matsunaga, M; Yui-Kurino, R; Matsuhira, H; Mikami, T; Kubo, T				Kitazaki, Kazuyoshi; Arakawa, Takumi; Matsunaga, Muneyuki; Yui-Kurino, Rika; Matsuhira, Hiroaki; Mikami, Tetsuo; Kubo, Tomohiko			Post-translational mechanisms are associated with fertility restoration of cytoplasmic male sterility in sugar beet (Beta vulgaris)	PLANT JOURNAL			English	Article						cytoplasmic male sterility; fertility restoration; plant mitochondria; protein-protein interaction; Beta vulgarisssp; vulgaris; Blue Native polyacrylamide gel electrophoresis	PENTATRICOPEPTIDE REPEAT PROTEINS; TRANSGENIC PLANTS; T-CYTOPLASM; MITOCHONDRIAL; COMPLEX; SYNTHASE; GENES; RICE; L.; MICROSPOROGENESIS	Genetic conflict between cytoplasmically inherited elements and nuclear genes arising from their different transmission patterns can be seen in cytoplasmic male sterility (CMS), the mitochondrion-encoded inability to shed functional pollen. CMS is associated with a mitochondrial open reading frame (ORF) that is absent from non-sterility inducing mitochondria (S-orf). Nuclear genes that suppress CMS are called restorer-of-fertility (Rf) genes. Post-transcriptional and translational repression of S-orf mediates the molecular action of Rf that encodes a class of RNA-binding proteins with pentatricopeptide repeat (PPR) motifs. Besides the PPR-type of Rfs, there are also non-PPR Rfs, but the molecular interactions between non-PPR Rf and S-orf have not been described. In this study, we investigated the interaction of bvORF20, a non-PPR Rf from sugar beet (Beta vulgaris), with preSatp6, the S-orf from sugar beet. Anthers expressing bvORF20 contained a protein that interacted with preSATP6 protein. Analysis of anthers and transgenic calli expressing a FLAG-tagged bvORF20 suggested the binding of preSATP6 to bvORF20. To see the effect of bvORF20 on preSATP6, which exists as a 250-kDa protein complex in CMS plants, signal bands of preSATP6 in bvORF20-expressing and non-expressing anthers were compared by immunoblotting combined with Blue Native polyacrylamide gel electrophoresis. The signal intensity of the 250-kDa band decreased significantly, and 200- and 150-kDa bands appeared in bvORF20-expressing anthers. Transgenic callus expressing bvORF20 also generated the 200- and 150-kDa bands. The 200-kDa complex is likely to include both preSATP6 and bvORF20. Post-translational interaction between preSATP6 and bvORF20 appears to alter the higher order structure of preSATP6 that may lead to fertility restoration in sugar beet.	[Kitazaki, Kazuyoshi; Arakawa, Takumi; Matsunaga, Muneyuki; Yui-Kurino, Rika; Matsuhira, Hiroaki; Mikami, Tetsuo; Kubo, Tomohiko] Hokkaido Univ, Res Fac Agr, Kita Ku, Sapporo, Hokkaido 0608589, Japan	Kubo, T (reprint author), Hokkaido Univ, Res Fac Agr, Kita Ku, N-9,W-9, Sapporo, Hokkaido 0608589, Japan.	tomohiko@abs.agr.hokudai.ac.jp	Kubo, Tomohiko/B-7738-2012		MEXT/JSPS KAKENHI [18075001, 22580001, 25292001]; Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN)	We thank Dr Kazunori Taguchi and Dr Yosuke Kuroda for providing seeds, and Dr Francoise Budar for her invaluable comments. This work was supported by: MEXT/JSPS KAKENHI, grant numbers 18075001, 22580001 and 25292001; Grants-in-Aid for Scientific Research from the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN); and Grants-in-Aid for Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan.	Luo DP, 2013, NAT GENET, V45, P573, DOI 10.1038/ng.2570; Matsuhira H, 2012, GENETICS, V192, P1347, DOI 10.1534/genetics.112.145409; Kaser M, 2003, J BIOL CHEM, V278, P46414, DOI 10.1074/jbc.M305584200; BOWLER C, 1991, EMBO J, V10, P1723; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Chase CD, 2007, TRENDS GENET, V23, P81, DOI 10.1016/j.tig.2006.12.004; LASER KD, 1972, BOT REV, V38, P425, DOI 10.1007/BF02860010; Satoh M, 2004, MOL GENET GENOMICS, V272, P247, DOI 10.1007/s00438-004-1058-9; Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979; Moritani M, 2013, MOL BREEDING, V32, P91, DOI 10.1007/s11032-013-9854-8; Uyttewaal M, 2008, PLANT CELL, V20, P3331, DOI 10.1105/tpc.107.057208; Barkan A, 2014, ANNU REV PLANT BIOL, V65, P415, DOI 10.1146/annurev-arplant-050213-040159; Chen LT, 2014, ANNU REV PLANT BIOL, V65, P579, DOI 10.1146/annurev-arplant-050213-040119; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Hanson MR, 2004, PLANT CELL, V16, pS154, DOI 10.1105/tpc.015966; Cui XQ, 1996, SCIENCE, V272, P1334, DOI 10.1126/science.272.5266.1334; Kazama T, 2008, PLANT J, V55, P619, DOI 10.1111/j.1365-313X.2008.03529.x; Kerschen A, 2004, FEBS LETT, V566, P223, DOI 10.1016/j.febslet.2004.04.043; Onodera Y, 1999, J PLANT PHYSIOL, V155, P656; Hu J, 2012, PLANT CELL, V24, P109, DOI 10.1105/tpc.111.093211; Sabar M, 2003, EMBO REP, V4, P381, DOI 10.1038/sj.embor.embor800; McBride H, 2010, CURR BIOL, V20, pR274, DOI 10.1016/j.cub.2010.02.011; Werren JH, 2011, P NATL ACAD SCI USA, V108, P10863, DOI 10.1073/pnas.1102343108; Yamamoto MP, 2005, MOL GENET GENOMICS, V273, P342, DOI 10.1007/s00438-005-1140-y; Budar F., 2007, PLANT MITOCHONDRIA, P278, DOI 10.1002/9780470986592.ch9; DEWEY RE, 1987, P NATL ACAD SCI USA, V84, P5374, DOI 10.1073/pnas.84.15.5374; Duroc Y, 2009, PLANT MOL BIOL, V70, P123, DOI 10.1007/s11103-009-9461-6; HALLDEN C, 1991, SEX PLANT REPROD, V4, P215; Kagami H, 2015, METHODS MOL BIOL, V1223, P335, DOI 10.1007/978-1-4939-1695-5_27; KRISHNASAMY S, 1994, PLANT MOL BIOL, V24, P129, DOI 10.1007/BF00040580; Leidhold C, 2007, ANN NY ACAD SCI, V1113, P72, DOI 10.1196/annals.1391.011; LIND C, 1991, PHYSIOL PLANTARUM, V83, P7; MAJEWSKASAWKA A, 1993, SEX PLANT REPROD, V6, P22; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; Rhoads DM, 1998, ARCH BIOCHEM BIOPHYS, V354, P158, DOI 10.1006/abbi.1998.0671; Sambrook J., 1989, MOL CLONING LAB MANU; Touzet P, 2012, ADV BOT RES, V63, P71, DOI 10.1016/B978-0-12-394279-1.00004-1; Zeng XM, 2007, J BIOL CHEM, V282, P36167, DOI 10.1074/jbc.M705436200	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0960-7412	1365-313X		PLANT J	Plant J.	JUL	2015	83	2					290	299		10.1111/tpj.12888		10	Plant Sciences	Plant Sciences	CM3WX	WOS:000357617200008		
J	Sugiura, N; Takahashi, H				Sugiura, Naoto; Takahashi, Hideki			Comparative pollination biology in two sympatric varieties of Cypripedium macranthos (Orchidaceae) on Rebun Island, Hokkaido, Japan	PLANT SPECIES BIOLOGY			English	Article						Bombus; Cypripedium; differential reproductive success; flower color; pollination	LADYS-SLIPPER; DECEPTIVE POLLINATION; VAR. REBUNENSE; FRUIT-SET	Cypripedium macranthos sensu lato typically has purple-pink flowers with no nectar and harvestable pollen. On Rebun Island, Hokkaido, Japan, purple-pink-flowered C.macranthos var. macranthos individuals rarely grow among numerous pale-cream-flowered C.macranthos var. rebunense plants. In both varieties, flower size is similar, their flowering periods completely overlap, and they share the same pollinator (Bombus pseudobaicalensis). However, in only one of 12 years from 2001 to 2012 did var. macranthos attain an annual fruit-set ratio (an estimate of pollination success) higher than that of sympatric var. rebunense plants. These findings strongly suggest that in C.macranthos on Rebun Island, flower color results in the differential pollination success, because the pollinator prefers pale-cream Cypripedium flowers and/or avoids purple-pink ones, thereby producing pollinator-mediated selection favoring pale-cream flowers.	[Sugiura, Naoto] Kumamoto Univ, Grad Sch Sci & Technol, Kumamoto, Japan; [Takahashi, Hideki] Hokkaido Univ, Hokkaido Univ Museum, Sapporo, Hokkaido, Japan	Sugiura, N (reprint author), Kumamoto Univ, Grad Sch Sci & Technol, Kumamoto, Japan.	sugiura@aster.sci.kumamoto-u.ac.jp			Japan Society for the Promotion of Science (JSPS KAKENHI) [16310157]; Ministry of the Environment, Government of Japan (Global Environment Research Fund)	We express our sincere gratitude to Y. Sato, T. Izawa, M. Mochida, and H. Sato for their help during the fieldwork. S. Miyamoto provided information on the distribution of var. macranthos on Rebun Island. J. Sasaki informed us of his observations on bumblebee visits to var. macranthos flowers. K. Furuya, K. Kozawa, and the late K. Inoue kindly helped in a variety of ways. This study was supported by grants from the Japan Society for the Promotion of Science (JSPS KAKENHI grant no. 16310157) and the Ministry of the Environment, Government of Japan (Global Environment Research Fund).	Sugiura N, 2001, J PLANT RES, V114, P171, DOI 10.1007/PL00013980; Bernhardt P, 2010, BOT REV, V76, P204, DOI 10.1007/s12229-010-9042-z; Ren ZX, 2011, P NATL ACAD SCI USA, V108, P7478, DOI 10.1073/pnas.1103384108; Tremblay RL, 2005, BIOL J LINN SOC, V84, P1, DOI 10.1111/j.1095-8312.2004.00400.x; Neiland MRM, 1998, AM J BOT, V85, P1657, DOI 10.2307/2446499; Jersakova J, 2006, BIOL REV, V81, P219, DOI 10.1017/S1464793105006986; Banziger H, 2008, BOT J LINN SOC, V156, P51; Case MA, 2009, BOT J LINN SOC, V160, P1, DOI 10.1111/j.1095-8339.2009.00962.x; Cribb P, 1997, GENUS CYPRIPEDIUM; Edens-Meier R, 2011, TELOPEA, V13, P327; Ferguson C. S., 1999, N AM NATIVE ORCHID J, V5, P180; Heinrich B., 2004, BUMBLEBEE EC NEW PRE; Inoue K., 2003, RED DATA PLANTS, P412; Kanda K., 1984, WILD ORCHIDS JAPAN; Kinota K., 2013, BUMBLEBEES JAPAN; Kinota Kimihiro, 2012, Tsunekibachi, V20, P37; Li P, 2012, BOT J LINN SOC, V170, P50, DOI 10.1111/j.1095-8339.2012.01259.x; Li P, 2006, PLANT SYST EVOL, V262, P53, DOI 10.1007/s00606-006-0456-3; [刘仲健 LIU ZhongJian], 2008, [生态学报, Acta Ecologica Sinica], V28, P111; Maekawa F., 1971, WILD ORCHIDS JAPAN C; Nakajima M., 2012, ILLUSTRATIONS JAPANE; NILSSON LA, 1992, TRENDS ECOL EVOL, V7, P255; NILSSON LA, 1979, BOT NOTISER, V132, P329; Pemberton Robert W., 2013, Lankesteriana, V13, P65; Pridgeon AM, 1999, GENERA ORCHIDACEARUM, V1; Ren Z. -X., 2012, P NATL ACAD SCI USA, V109, P20776; Sasaki J., 2011, HOPPO SANSO, V28, P79; Stoutamire W. P., 1967, MICH BOT, V6, P159; Suetsugu K, 2014, PLANT SPEC BIOL, V29, P294, DOI 10.1111/1442-1984.12016; Sugiura Naoto, 2002, Acta Phytotaxonomica et Geobotanica, V53, P85; Sugiura N, 2002, PLANT SYST EVOL, V235, P189, DOI 10.1007/s00606-002-0229-6; Takahashi H., 2009, J PHYTOGEOGR TAXON, V57, P61; Taniguchi H., 1983, SHIZEN, V38, P62; Umezawa S, 1997, FLORA ISLANDS RISHIR; Washitani I., 1997, FIELD GUIDE BUMBLEBE; Wilson EO, 1971, INSECT SOC, P548; Zheng GL, 2011, ECOL RES, V26, P453, DOI 10.1007/s11284-010-0798-8	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0913-557X	1442-1984		PLANT SPEC BIOL	Plant Spec. Biol.	JUL	2015	30	3					225	230		10.1111/1442-1984.12055		6	Plant Sciences; Ecology	Plant Sciences; Environmental Sciences & Ecology	CM1GR	WOS:000357429800007		
J	Nagano, Y; Hirao, AS; Itino, T				Nagano, Yusuke; Hirao, Akira S.; Itino, Takao			Genetic structure of a hybrid zone between two violets, Viola rossiiHemsl. and V.bissetiiMaxim.: dominance of F-1 individuals in a narrow contact range	PLANT SPECIES BIOLOGY			English	Article						amplified fragment length polymorphism; F-1-dominated hybrid zone; interspecific hybridization; leaf index; Violaceae	PHYLLODOCE-ALEUTICA; FERTILE F(1)S; HYBRIDIZATION; DISPERSAL; RHODODENDRON; FLOW; ERICACEAE; DYNAMICS; PATTERNS; CAERULEA	The genetic composition of a hybrid zone can provide insight into the evolution of diversification in plants. We carried out morphological and amplified fragment length polymorphism analyses to investigate the genetic composition of a hybrid zone between two violets, Viola bissetiiHemsl. and Viola rossiiMaxim. Our aim was to clarify the formation and maintenance of hybrids between these Viola species. We found that most hybrid individuals (V.bissetii x V.rossii) were of the F-1 generation, with a few of the F-2 generation. We found no backcrosses. The scarcity of post-F-1 hybrids indicates that a species barrier is established between the parental species. The F-1-dominated hybrid zone occupied only a narrow, intermediate ecotone between the parental habitats, suggesting that selection by environmental factors against hybrids may help to maintain the current conditions in this hybrid zone.	[Nagano, Yusuke; Itino, Takao] Shinshu Univ, Fac Sci, Dept Biol, Matsumoto, Nagano 390, Japan; [Itino, Takao] Shinshu Univ, Inst Mt Sci, Matsumoto, Nagano 390, Japan; [Hirao, Akira S.] Univ Tsukuba, Sugadaira Montane Res Ctr, Ueda, Nagano, Japan	Nagano, Y (reprint author), Shinshu Univ, Fac Sci, Dept Biol, Matsumoto, Nagano 390, Japan.	ny_thitb2_nmk2@yahoo.co.jp			Global Environmental Research Fund of the Ministry of the Environment, Japan [D-0904]; Research and Education Funding for Japanese Alps Inter-Universities Cooperative Project, MEXT, Japan	The authors thank S. Ueda for technical support, M. Hattori for statistical advice, Y. Kataoka for field survey assistance, S. Duhon for English editing, and two anonymous reviewers for constructive comments. This study was supported by Global Environmental Research Fund of the Ministry of the Environment, Japan (D-0904), and by Research and Education Funding for Japanese Alps Inter-Universities Cooperative Project, MEXT, Japan.	Akiyama S, 2011, NATL MUSEUM NATURE S, V11, P93; Mallet J, 2005, TRENDS ECOL EVOL, V20, P229, DOI 10.1016/j.tree.2005.02.010; Rieseberg LH, 1998, NEW PHYTOL, V140, P599, DOI 10.1046/j.1469-8137.1998.00315.x; NASON JD, 1992, AM J BOT, V79, P101, DOI 10.2307/2445203; Milne RI, 2003, MOL ECOL, V12, P2719, DOI 10.1046/j.1365-294X.2003.01942.x; Anderson EC, 2002, GENETICS, V160, P1217; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Buerkle CA, 2005, MOL ECOL NOTES, V5, P684, DOI 10.1111/j.1471-8286.2005.01011.x; Jiggins CD, 2000, TRENDS ECOL EVOL, V15, P250, DOI 10.1016/S0169-5347(00)01873-5; CULVER DC, 1978, J ECOL, V66, P53, DOI 10.2307/2259181; OHKAWARA K, 1994, OECOLOGIA, V100, P135, DOI 10.1007/BF00317140; Ehrich D, 2006, MOL ECOL NOTES, V6, P603, DOI 10.1111/j.1471-8286.2006.01380.x; Ellstrand NC, 1996, P NATL ACAD SCI USA, V93, P5090, DOI 10.1073/pnas.93.10.5090; ARNOLD ML, 1992, HEREDITY, V68, P399; BEATTIE AJ, 1976, OECOLOGIA, V25, P291, DOI 10.1007/BF00345601; BEATTIE AJ, 1975, AM J BOT, V62, P714, DOI 10.2307/2442060; Broyles SB, 2002, EVOLUTION, V56, P1943; Campbell DR, 2007, AM NAT, V169, P298, DOI 10.1086/510758; Hama E, 2002, WILD VIOLETS JAPAN C; HASHIMOTO T, 1971, Journal of Japanese Botany, V46, P36; Hodges SA, 1996, EVOLUTION, V50, P2504, DOI 10.2307/2410717; Igari M, 2004, VIOLETS OF JAPAN; Kameyama Y, 2008, J EVOLUTION BIOL, V21, P588, DOI 10.1111/j.1420-9101.2007.01476.x; Kameyama Y, 2011, PLANT SPEC BIOL, V26, P93, DOI 10.1111/j.1442-1984.2010.00301.x; KYHOS DW, 1981, SYST BOT, V6, P399, DOI 10.2307/2418451; Ma YP, 2010, AM J BOT, V97, P1749, DOI 10.3732/ajb.1000018; Miyake T, 1998, CAN J BOT, V76, P1806; R Development Core Team, 2012, R LANG ENV STAT COMP; Zha HG, 2010, ANN BOT-LONDON, V105, P89, DOI 10.1093/aob/mcp267	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0913-557X	1442-1984		PLANT SPEC BIOL	Plant Spec. Biol.	JUL	2015	30	3					237	243		10.1111/1442-1984.12054		7	Plant Sciences; Ecology	Plant Sciences; Environmental Sciences & Ecology	CM1GR	WOS:000357429800009		
J	Itoh, K; Itoh, SI; Kamiya, K; Kasuya, N				Itoh, K.; Itoh, S-I; Kamiya, K.; Kasuya, N.			On the spatial structure of solitary radial electric field at the plasma edge in toroidal confinement devices	PLASMA PHYSICS AND CONTROLLED FUSION			English	Article						edge electric field; electric field bifurcation; reduction of transport; electric field biasing	L-H TRANSITION; TOKAMAK PLASMAS; POLOIDAL ROTATION; MODE TRANSITION; LIMIT-CYCLE; TRANSPORT; TURBULENCE; PROFILES; TEXTOR; FLOWS	The solitary radial electric field in the edge of toroidal plasma is studied based on the electric field bifurcation model. Results are applied to tokamak and helical plasmas, and the dependence of the electric field structure on the plasma parameters and geometrical factors is analyzed. The order of magnitude estimate for tokamak plasma is not far from experimental observations. It is shown that, in helical plasmas, the height of electric field structure is reduced substantially owing to the ripple particle transport, while the width is influenced less. The implications of the results for the limit of achievable gradient in the H-mode pedestal are also discussed.	[Itoh, K.] Natl Inst Nat Sci, Natl Inst Fus Sci, Toki, Gifu 5095292, Japan; [Itoh, K.; Itoh, S-I; Kasuya, N.] Kyushu Univ, Res Ctr Plasma Turbulence, Kasuga, Fukuoka 8168580, Japan; [Itoh, S-I; Kasuya, N.] Kyushu Univ, Appl Mech Res Inst, Kasuga, Fukuoka 8168580, Japan; [Kamiya, K.] Japan Atom Energy Agcy, Naka, Ibaraki 3110193, Japan	Itoh, K (reprint author), Natl Inst Nat Sci, Natl Inst Fus Sci, 322-6 Oroshi Cho, Toki, Gifu 5095292, Japan.	itoh@nifs.ac.jp	Kyushu, RIAM/F-4018-2015		JSPS, Japan [15H02155, 23360414, 23244113]; RIAM Kyushu University [NIFS13KOCT001]; National Institute for Fusion Science [NIFS13KOCT001]; LIA-336 programme; Asada Eiichi Research Foundation	Authors acknowledge discussions with Prof K Ida, Prof A Fujisawa, Prof S Inagaki and Dr T Tokuzawa. This work is partly supported by the Grant-in-Aid for Scientific Research of JSPS, Japan (15H02155, 23360414, 23244113), the collaboration programmes of RIAM Kyushu University and of the National Institute for Fusion Science (NIFS13KOCT001), LIA-336 programme, and Asada Eiichi Research Foundation.	Evans TE, 2006, NAT PHYS, V2, P419, DOI 10.1038/nphys312; Tynan GR, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/7/073053; Schmitz L, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.155002; Shaing KC, 2002, PHYS PLASMAS, V9, P3470, DOI 10.1063/1.1491533; Kobayashi T, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.035002; Diamond PH, 2005, PLASMA PHYS CONTR F, V47, pR35, DOI 10.1088/0741-3335/47/5/R01; ITOH SI, 1991, PHYS REV LETT, V67, P2485, DOI 10.1103/PhysRevLett.67.2485; Fujisawa A, 2009, NUCL FUSION, V49, DOI 10.1088/0029-5515/49/1/013001; Ida K, 2005, NUCL FUSION, V45, P391, DOI 10.1088/0029-5515/45/5/010; Colchin RJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.255002; Kim EJ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.185006; Conway GD, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.065001; ITOH SI, 1988, PHYS REV LETT, V60, P2276, DOI 10.1103/PhysRevLett.60.2276; Fujisawa A, 1998, PHYS REV LETT, V81, P2256, DOI 10.1103/PhysRevLett.81.2256; Burrell KH, 2001, REV SCI INSTRUM, V72, P906, DOI 10.1063/1.1321006; Cheng J, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.265002; Chone L, 2014, PHYS PLASMAS, V21, DOI 10.1063/1.4890971; Estrada T, 2010, EPL-EUROPHYS LETT, V92, DOI 10.1209/0295-5075/92/35001; Fukuyama A, 1996, PLASMA PHYS CONTR F, V38, P1319, DOI 10.1088/0741-3335/38/8/029; GROEBNER RJ, 1990, PHYS REV LETT, V64, P3015, DOI 10.1103/PhysRevLett.64.3015; HINTON FL, 1994, PLASMA PHYS CONTR F, V36, pA273, DOI 10.1088/0741-3335/36/7A/040; Itoh K, 1998, PHYS PLASMAS, V5, P4121, DOI 10.1063/1.873145; ITOH K, 1986, J PHYS SOC JPN, V55, P3101, DOI 10.1143/JPSJ.55.3101; Itoh K, 1996, PLASMA PHYS CONTR F, V38, P1, DOI 10.1088/0741-3335/38/1/001; Itoh K, 2013, PLASMA FUSION RES, V8; ITOH SI, 1993, NUCL FUSION, V33, P1445, DOI 10.1088/0029-5515/33/10/I04; Itoh SI, 2014, NUCL FUSION, V54, DOI 10.1088/0029-5515/54/11/114017; Kamiya K, 2014, CONTRIB PLASM PHYS, V54, P591, DOI 10.1002/ctpp.201410013; Kamiya K, 2014, PHYS PLASMAS, V21, DOI 10.1063/1.4904815; Kamiya K, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.045004; Kasuya N, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.195002; Kobayashi T, 2014, P IAEA FUS EN C EX P; Miki K, 2012, PHYS PLASMAS, V19, DOI 10.1063/1.4753931; MOYER RA, 1995, PHYS PLASMAS, V2, P2397, DOI 10.1063/1.871263; Schirmer J, 2006, NUCL FUSION, V46, pS780, DOI 10.1088/0029-5515/46/9/S13; STRINGER TE, 1993, NUCL FUSION, V33, P1249, DOI 10.1088/0029-5515/33/9/I01; Tokuzawa T, 2014, PHYS PLASMAS, V21, DOI 10.1063/1.4876619; WAGNER F, 1982, PHYS REV LETT, V49, P1408, DOI 10.1103/PhysRevLett.49.1408; WEYNANTS RR, 1992, NUCL FUSION, V32, P837, DOI 10.1088/0029-5515/32/5/I10; Weynants RR, 2005, FUSION SCI TECHNOL, V47, P202; WEYNANTS RR, 1990, NUCL FUSION, V30, P945, DOI 10.1088/0029-5515/30/5/015; Xu GS, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.125001; IDA K, 1990, PHYS REV LETT, V65, P1364, DOI 10.1103/PhysRevLett.65.1364; YOSHIZAWA A, 2002, PLASMA FLUID TURBULE; Zhao K J, 2012, IAEA FUS EN C SAN DI	45	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0741-3335	1361-6587		PLASMA PHYS CONTR F	Plasma Phys. Control. Fusion	JUL	2015	57	7							075008	10.1088/0741-3335/57/7/075008		7	Physics, Fluids & Plasmas; Physics, Nuclear	Physics	CM2GC	WOS:000357496900010		
J	Kuroda, K; Wada, M; Uchida, M; Tanaka, H; Maekawa, T				Kuroda, Kengoh; Wada, Manato; Uchida, Masaki; Tanaka, Hitoshi; Maekawa, Takashi			Cross-field potential hill arisen eccentrically in toroidal electron cyclotron resonance plasmas in the Low Aspect ratio Torus Experiment device to regulate electron and ion flows from source to boundary	PLASMA PHYSICS AND CONTROLLED FUSION			English	Article						toroidal ECR plasma; cross-field potential; toroidal drift	TOKAMAK; IONIZATION; STARTUP	We have investigated the electron and ion flows in toroidal electron cyclotron resonance (ECR) plasmas maintained by a 2.45 GHz microwave power around 1 kW under a simple toroidal field in the low aspect ratio torus experiment (LATE) device. We have found that a vertically uniform ridge of electron pressure that also constitutes the source belt of electron impact ionization is formed along just lower field side of the ECR layer and a cross-field potential hill (V-S congruent to 30 V while T-e congruent to 10 eV), eccentrically shifted toward the corner formed by the top panel and the ECR layer, arises. Combination of the hill-driven E x B drift and the vertical drift due to the field gradient and curvature, being referred to as vacuum toroidal field (VTF) drift, realizes steady flows of electrons and ions from the source to the boundary. In particular, the ions, of which VTF drift velocity is much slower than the electron VTF drift velocity near the source belt, are carried by the E x B drift around the hill to the vicinity of the top panel, where the ion VTF drift is enhanced on the steep down slope of potential toward the top panel. On the other hand the electron temperature strongly decreases in this area. Thus the carrier of VTF drift current is replaced from the electrons to the ions before the top panel, enabling the current circulation through the top and bottom panels and the vessel (electrons mainly to the bottom and ions mainly to the top) that keeps the charge neutrality very high. A few percent of electrons from the source turn around the hill by 360 degree and reentry the source belt from the high field side as seed electrons for the impact ionization, keeping the discharge stable.	[Kuroda, Kengoh; Wada, Manato; Uchida, Masaki; Tanaka, Hitoshi; Maekawa, Takashi] Kyoto Univ, Grad Sch Energy Sci, Kyoto 6068502, Japan	Kuroda, K (reprint author), Kyoto Univ, Grad Sch Energy Sci, Kyoto 6068502, Japan.	kuroda.kengoh.65r@st.kyoto-u.ac.jp			JSPS KAKENHI [23360411, 26289357]; NIFS collaboration program in Japan	The present work was supported by JSPS KAKENHI (Grant Number 23360411 and 26289357) and NIFS collaboration program in Japan. Information on various aspects of electron impact ionization and dissociation of hydrogen molecule from Professors Sawada and Fujimoto was quite useful.	SAWADA K, 1995, J APPL PHYS, V78, P2913, DOI 10.1063/1.360037; FOREST CB, 1992, PHYS REV LETT, V68, P3559, DOI 10.1103/PhysRevLett.68.3559; Furno I, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.055004; RYPDAL K, 1994, PLASMA PHYS CONTR F, V36, P1099, DOI 10.1088/0741-3335/36/7/002; FOREST CB, 1994, PHYS PLASMAS, V1, P1568, DOI 10.1063/1.870708; GILGENBACH RM, 1981, NUCL FUSION, V21, P319, DOI 10.1088/0029-5515/21/3/002; Goldston R J, 1995, INTRO PLASMA PHYS; KUBO S, 1983, PHYS REV LETT, V50, P1994, DOI 10.1103/PhysRevLett.50.1994; Maekawa T, 2005, NUCL FUSION, V45, P1439, DOI 10.1088/0029-5515/45/11/026; Muller SH, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.165003; NAKAO S, 1983, PHYS LETT A, V96, P405, DOI 10.1016/0375-9601(83)90325-0; Nishi S, 2010, PLASMA PHYS CONTR F, V52, DOI 10.1088/0741-3335/52/6/065011; Nishi S, 2010, PLASMA PHYS CONTR F, V52, DOI 10.1088/0741-3335/52/12/125004; Parail V V, 1985, P 10 INT C PLASM PHY, V1, P605; PEART B, 1971, J PHYS PT B ATOM M P, V4, P1496, DOI 10.1088/0022-3700/4/11/013; PENG YKM, 1978, NUCL FUSION, V18, P1489, DOI 10.1088/0029-5515/18/11/002; Perez JC, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2168401; Podesta M, 2006, PLASMA PHYS CONTR F, V48, P1053, DOI 10.1088/0741-3335/48/8/001; Stangeby P., 2000, PLASMA BOUNDARY MAGN; TOI K, 1984, PHYS REV LETT, V52, P2144, DOI 10.1103/PhysRevLett.52.2144; YOSHIKAWA S, 1963, PHYS FLUIDS, V6, P1506, DOI 10.1063/1.1710974; Yoshinaga T, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.125005; Zakharov L. E., 1988, Soviet Journal of Plasma Physics, V14	23	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0741-3335	1361-6587		PLASMA PHYS CONTR F	Plasma Phys. Control. Fusion	JUL	2015	57	7							075010	10.1088/0741-3335/57/7/075010		20	Physics, Fluids & Plasmas; Physics, Nuclear	Physics	CM2GC	WOS:000357496900012		
J	McClements, KG; Akers, RJ; Boeglin, WU; Cecconello, M; Keeling, D; Jones, OM; Kirk, A; Klimek, I; Perez, RV; Shinohara, K; Tani, K				McClements, K. G.; Akers, R. J.; Boeglin, W. U.; Cecconello, M.; Keeling, D.; Jones, O. M.; Kirk, A.; Klimek, I.; Perez, R. V.; Shinohara, K.; Tani, K.			The effects of resonant magnetic perturbations on fast ion confinement in the Mega Amp Spherical Tokamak	PLASMA PHYSICS AND CONTROLLED FUSION			English	Article						fast ion transport; RMPs; FIDA; TRANSP; MAST	TRANSPORT; MAST	The effects of resonant magnetic perturbations (RMPs) on the confinement of energetic (neutral beam) ions in the Mega Amp Spherical Tokamak (MAST) are assessed experimentally using measurements of neutrons, fusion protons and fast ion D alpha (FIDA) light emission. In single null-diverted (SND) MAST pulses with relatively low plasma current (400 kA), the total neutron emission dropped by approximately a factor of two when RMPs with toroidal mode number n = 3 were applied. The measured neutron rate during RMPs was much lower than that calculated using the TRANSP plasma simulation code, even when non-classical (but axisymmetric) ad hoc fast ion transport was taken into account in the latter. Sharp drops in spatially-resolved neutron rates, fusion proton rates and FIDA emission were also observed. First principles-based simulations of RMP-induced fast ion transport in MAST, using the F3D-OFMC code, show similar losses for two alternative representations of the MAST first wall, with and without full orbit effects taken into account; for n = 6 RMPs in a 600 kA plasma, the additional loss of beam power due to the RMPs was found in the simulations to be approximately 11%.	[McClements, K. G.; Akers, R. J.; Keeling, D.; Jones, O. M.; Kirk, A.] Culham Sci Ctr, CCFE, Abingdon OX14 3DB, Oxon, England; [Boeglin, W. U.; Perez, R. V.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA; [Cecconello, M.; Klimek, I.] Uppsala Univ, Dept Phys & Astron, SE-75105 Uppsala, Sweden; [Jones, O. M.] Univ Durham, Dept Phys, Durham DH1 3LE, England; [Shinohara, K.] Japan Atom Energy Agcy, Naka, Ibaraki 3110193, Japan; [Tani, K.] Tokyo Inst Technol, Meguro Ku, Tokyo 1528550, Japan	McClements, KG (reprint author), Culham Sci Ctr, CCFE, Abingdon OX14 3DB, Oxon, England.	k.g.mcclements@ccfe.ac.uk			Euratom research and training programme [633053]; RCUK Energy Programme [EP/I501045]	This work has been carried out within the framework of the EUROfusion Consortium and has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 633053 and from the RCUK Energy Programme [grant number EP/I501045]. Helpful discussions with Yueqiang Liu (CCFE), David Pfefferle (CRPP) and Andrew Thornton (CCFE) are gratefully acknowledged. To obtain further information on the data and models underlying this paper please contact PublicationsManager@ccfe.ac.uk. The views and opinions expressed herein do not necessarily reflect those of the European Commission.	Garcia-Munoz M, 2013, PLASMA PHYS CONTR F, V55, DOI 10.1088/0741-3335/55/12/124014; Kirk A, 2010, NUCL FUSION, V50, DOI 10.1088/0029-5515/50/3/034008; TANI K, 1981, J PHYS SOC JPN, V50, P1726, DOI 10.1143/JPSJ.50.1726; RECHESTER AB, 1978, PHYS REV LETT, V40, P38, DOI 10.1103/PhysRevLett.40.38; Pankin A, 2004, COMPUT PHYS COMMUN, V159, P157, DOI 10.1016/j.cpc.2003.11.002; Michael CA, 2013, PLASMA PHYS CONTR F, V55, DOI 10.1088/0741-3335/55/9/095007; Liu YQ, 2011, NUCL FUSION, V51, DOI 10.1088/0029-5515/51/8/083002; Pfefferle D, 2015, NUCL FUSION, V55, DOI 10.1088/0029-5515/55/1/012001; Garcia-Munoz M, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/12/123008; Turnyanskiy M, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/5/053016; Liu YQ, 2012, PLASMA PHYS CONTR F, V54, DOI 10.1088/0741-3335/54/12/124013; [Anonymous], PLASMA PHYS CONTROL; Shinohara K, 2011, NUCL FUSION, V51, DOI 10.1088/0029-5515/51/6/063028; Cecconello M, 2014, PLASMA PHYS CONTROL, V57; Cecconello M, 2014, NUCL INSTRUM METH A, V753, P72, DOI 10.1016/j.nima.2014.03.060; Chapman I T, 2014, NUCL FUSION, V54; Howell DF, 2007, NUCL FUSION, V47, P1336, DOI 10.1088/0029-5515/47/9/034; McClements KG, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2188401; McClements KG, 2007, PLASMA PHYS CONTR F, V49, P1415, DOI 10.1088/0741-3335/49/9/005; McClements KG, 2012, PHYS PLASMAS, V19, DOI 10.1063/1.4737605; Morris A.W., 2014, IEEE T PLASMA SCI, V42, P402; Perez RV, 2014, REV SCI INSTRUM, V85, DOI 10.1063/1.4889736; Tani K, 2012, NUCL FUSION, V52, DOI 10.1088/0029-5515/52/1/013012; Van Zeeland MA, 2014, PLASMA PHYS CONTR F, V56, DOI 10.1088/0741-3335/56/1/015009; Wesson J A, 2004, TOKAMAKS, V3rd, P5	25	2	2	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0741-3335	1361-6587		PLASMA PHYS CONTR F	Plasma Phys. Control. Fusion	JUL	2015	57	7							075003	10.1088/0741-3335/57/7/075003		11	Physics, Fluids & Plasmas; Physics, Nuclear	Physics	CM2GC	WOS:000357496900005		
J	Chiba, S				Chiba, Satoshi			Special Issue: Selected Papers from the Fourth International Symposium on Innovative Nuclear Energy Systems, INES-4-Innovative Nuclear Science and Technology Post Fukushima - held at Ookayama campus of Tokyo Institute of Technology Preface	PROGRESS IN NUCLEAR ENERGY			English	Editorial Material									Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Chiba, S (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528550, Japan.							0	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						1	1		10.1016/j.pnucene.2014.11.001		1	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100001		
J	Yoshioka, K; Kitada, T; Nagaya, Y				Yoshioka, Kenichi; Kitada, Takanori; Nagaya, Yasunobu			Azimuthal flux distribution measurements around fuel rods in reduced-moderation LWR lattices	PROGRESS IN NUCLEAR ENERGY			English	Article						Azimuthal flux measurement; Foil activation; Micro reactor physics; Critical experiment; Monte Carlo; MVP	MULTIBAND METHOD; REACTOR	An advanced analysis method named "micro reactor physics approach" was proposed, and the approach is needed for future reactor design considering the neutron behavior in fuel pellets. In order to validate the approach, neutron flux distribution measurements in a fuel pellet should be required. We have measured azimuthal flux distribution of fuel rods in Toshiba Nuclear Critical Assembly (NCA). A foil activation method with metallic foils was used for the measurement. Measured values were analyzed by a continuous energy Monte Carlo code MVP with the JENDL-3.3 library. The measurements are useful for the validation of an advanced fuel design method considering the neutron behavior in fuel pellets. (C) 2014 Elsevier Ltd. All rights reserved.	[Yoshioka, Kenichi] Toshiba Co Ltd, Power Syst Co, Kawasaki Ku, Kawasaki, Kanagawa 2100862, Japan; [Kitada, Takanori] Osaka Univ, Div Sustainable Energy & Environm Engn, Suita, Osaka 5650871, Japan; [Nagaya, Yasunobu] Japan Atom Energy Agcy, Naka, Ibaraki 3191195, Japan	Yoshioka, K (reprint author), Toshiba Co Ltd, Power Syst Co, Kawasaki Ku, 4-1 Ukishima Cho, Kawasaki, Kanagawa 2100862, Japan.	kenichi.yoshioka@toshiba.co.jp					Shibata K, 2002, J NUCL SCI TECHNOL, V39, P1125, DOI 10.3327/jnst.39.1125; Fauchere CP, 2005, NUCL SCI ENG, V150, P27; Hiraiwa K., 2000, P WORKSH ADV WAT REA; Macku K., 2007, Nuclear Science and Engineering, V155; Nagaya Y, 2005, 1348 JAERI; Sakashita Y., 1999, 7 INT C NUCL ENG ICO; Takeda T, 1996, J NUCL SCI TECHNOL, V33, P604, DOI 10.3327/jnst.33.604; TAKEDA T, 1991, J NUCL SCI TECHNOL, V28, P863; Takeda T., 2003, GLOBAL2003 NEW ORL L; Takeda T, 1999, J ATOM ENERG SOC JPN, V41, P1157; Takeda T., 2002, Journal of Nuclear Science and Technology; Yamaoka M., 2001, 9 INT C NUCL ENG ICO; Yokoyama T., 1998, INT C PHYS NUCL SCI, P1679; Yoshioka K, 2013, J NUCL SCI TECHNOL, V50, P606, DOI 10.1080/00223131.2013.785270	14	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						7	15		10.1016/j.pnucene.2014.07.037		9	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100003		
J	Matsumiya, H; Yoshioka, K; Kikuchi, T; Sugita, T; Higuchi, S; Yoshida, N				Matsumiya, Hiroshi; Yoshioka, Kenichi; Kikuchi, Tsukasa; Sugita, Tsukasa; Higuchi, Shinichi; Yoshida, Noriyuki			Reactivity measurements of SiC for accident-tolerant fuel	PROGRESS IN NUCLEAR ENERGY			English	Article						Reactivity measurement; Accident-tolerant fuel; SiC; NCA; Critical experiment; MCNP	JENDL-4.0; LIBRARY	Silicon carbide (Sic) is a candidate structural material for application with accident-tolerant fuel for light water reactors, which is expected to decrease heat and hydrogen generation resulting from oxidation reaction with high-temperature steam. Although there are studies on irradiation properties of SiC for fusion reactors and gas-cooled reactors, there are no published reports on critical experiments to validate the nuclear reactivity of SIC. We performed SiC nuclear reactivity measurements. Measured reactivity worths of SiC were analyzed by a continuous-energy Monte Carlo code MCNP4c3. We obtained the neutron spectrum-dependent reactivity worths of SiC samples, which imply that the neutron scattering with SiC plays an important role concerning the reactivity worths as well as neutron absorption with SiC. Comparison of analyses with measurements reveals the possibility of room for improvement in SiC cross-sections mainly related to neutron scattering, whereas thermal neutron absorption cross-sections of SiC can well describe the experimental results. (C) 2014 Elsevier Ltd. All rights reserved.	[Matsumiya, Hiroshi; Yoshioka, Kenichi; Kikuchi, Tsukasa; Sugita, Tsukasa; Higuchi, Shinichi] Toshiba Co Ltd, Power Syst Co, Power & Ind Syst R&D Ctr, Kawasaki Ku, Kawasaki, Kanagawa 2100862, Japan; [Yoshida, Noriyuki] Toshiba Co Ltd, Power Syst Co, Isogo Nucl Engn Ctr, Isogo Ku, Yokohama, Kanagawa 2358523, Japan	Matsumiya, H (reprint author), Toshiba Co Ltd, Power Syst Co, Power & Ind Syst R&D Ctr, Kawasaki Ku, 4-1 Ukishima Cho, Kawasaki, Kanagawa 2100862, Japan.	hiroshi.matsumiya@toshiba.co.jp					Shibata K, 2002, J NUCL SCI TECHNOL, V39, P1125, DOI 10.3327/jnst.39.1125; Shibata K, 2011, J NUCL SCI TECHNOL, V48, P1, DOI 10.3327/jnst.48.1; Briesmeister J. F., 2000, LA13709M LOS AL NAT; Chiba G, 2011, J NUCL SCI TECHNOL, V48, P172, DOI 10.3327/jnst.48.172; Hendricks J.S., 2001, X5RNUJSH0117 LOS AL; Higuchi S., 2009, TOPFUEL 2009 PAR FRA; Kitano K., 2013, TOPFUEL 2013 CHARL U	7	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						16	21		10.1016/j.pnucene.2014.07.030		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100004		
J	Pyeon, CH; Yagi, T; Takahashi, Y; Sano, T; Ito, D; Saito, Y; Nakajima, K				Pyeon, Cheol Ho; Yagi, Takahiro; Takahashi, Yoshiyuki; Sano, Tadafumi; Ito, Daisuke; Saito, Yasushi; Nakajima, Ken			Perspectives of research and development of accelerator-driven system in Kyoto University Research Reactor Institute	PROGRESS IN NUCLEAR ENERGY			English	Article						ADS; KUCA; FFAG accelerator; 100 MeV protons	100 MEV PROTONS; SPALLATION	The experimental studies on the accelerator-driven system (ADS) are being conducted for the basic research of nuclear transmutation analyses with the combined use of the core at the Kyoto University Critical Assembly (KUCA) and the fixed-field alternating gradient (FFAG; 100 MeV protons) accelerator, in the Kyoto University Research Reactor Institute. The ADS experiments with 100 MeV protons were carried out to investigate the neutronic characteristics of ADS, and the static and kinetic parameters were accurately analyzed through both the measurements and the Monte Carlo simulations of reactor physics parameters. An upcoming ADS at KUCA could be composed of highly-enriched uranium fueled and Pb-Bi zoned core, and the conversion analyses (Np-237 and Am-241) of nuclear transmutation could be conducted in ADS (hard spectrum core) at KUCA. Also, thermal hydraulics of liquid Pb-Bi are expected to be examined with the use of Pb-Bi test loop and test facilities for the investigation of Pb-Bi liquid characteristics from the viewpoints of single-phase heat transfer and two-phase flow. (C) 2014 Elsevier Ltd. All rights reserved.	[Pyeon, Cheol Ho; Yagi, Takahiro; Takahashi, Yoshiyuki; Sano, Tadafumi; Ito, Daisuke; Saito, Yasushi; Nakajima, Ken] Kyoto Univ, Inst Res Reactor, Nucl Engn Sci Div, Kumatori, Osaka 5900494, Japan	Pyeon, CH (reprint author), Kyoto Univ, Inst Res Reactor, Nucl Engn Sci Div, Kumatori, Osaka 5900494, Japan.	pyeon@rri.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	This work was supported by "KUR Research Program for Scientific Basis of Nuclear Safety" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. The authors are grateful to all the technical staff of KUCA and the FFAG accelerator for their assistance during the experiments.	Yamakawa E, 2013, NUCL INSTRUM METH A, V716, P46, DOI 10.1016/j.nima.2013.03.061; Pyeon CH, 2009, J NUCL SCI TECHNOL, V46, P1091; Pyeon CH, 2013, NUCL ENG TECHNOL, V45, P81, DOI 10.5516/NET.08.2012.003; Pyeon CH, 2011, ANN NUCL ENERGY, V38, P2298, DOI 10.1016/j.anucene.2011.06.024; Pyeon CH, 2014, NUCL SCI ENG, V177, P156; Takahashi Y, 2013, ANN NUCL ENERGY, V54, P162, DOI 10.1016/j.anucene.2012.10.018; Pyeon CH, 2010, J NUCL SCI TECHNOL, V47, P1090; Lim JY, 2012, SCI TECHNOL NUCL INS, DOI 10.1155/2012/395878; Suzuki T, 2003, NUCL ENG DES, V220, P207, DOI 10.1016/S0029-5493(02)00349-7; Shahbunder H, 2010, ANN NUCL ENERGY, V37, P592, DOI 10.1016/j.anucene.2009.12.022; Yagi T, 2013, APPL RADIAT ISOTOPES, V72, P11, DOI 10.1016/j.apradiso.2012.10.009; Chadwick MB, 2006, NUCL DATA SHEETS, V107, P2931, DOI 10.1016/j.nds.2006.11.001; Takada H, 2009, J NUCL SCI TECHNOL, V46, P589, DOI 10.3327/jnst.46.589; Fukahori T., 2002, J NUCL SCI TECHNOL S, P25; HENDRICKS J. S., 2005, LAUR052675 LOS AL NA; KOBAYASHI K., 2002, 1344 JAERI; Lagrange J. B., 2013, NUCL INSTRUM METH A, V691, P55; Mclane V., 2001, BNLNCS44950104REV; Pyeon C. H., 2013, NUCL SCI EN IN PRESS; Saito Y, 2005, NUCL INSTRUM METH A, V542, P168, DOI 10.1016/j.nima.2005.01.095	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						22	27		10.1016/j.pnucene.2014.07.028		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100005		
J	Sambuu, O; Obara, T				Sambuu, Odmaa; Obara, Toru			Comparative study on HTGR designs for passive decay heat removal	PROGRESS IN NUCLEAR ENERGY			English	Article						Passive safety feature; Condition for decay heat removal; Above-ground reactor; Underground reactor; Sensitivity analysis; Small prismatic HTGR		The design parameters of a small high-temperature gas-cooled reactor (HTGR) for passive decay heat removal and located either above-ground or underground have been studied in previous works. In the present work, sensitivity analyses on peak temperatures of both the core and reactor building (RB) after reactor shutdown was conducted for both situations. It was found that the sensitivity of peak temperatures was quite similar for the two situations of the reactor, i.e., above- and below-ground. Therefore, a parametric survey on design parameters for long-life small prismatic HTGRs having features for successful decay heat removal using fundamental heat transfer mechanisms was performed for both reactor concepts. Comparison of the two conditions showed that a passively safe, low-power, underground reactor operating at high initial core temperature could have a practical size of RB. Conversely, for the RB size of an above-ground reactor with passive safety features to be reasonable, it could operate at relatively high power but would need a low initial core temperature. The appropriate sizes of reactor core and RB were evaluated for reactors with powers of 50 MWth, 100 MWth and 300 MWth having different maximum power densities and operating at temperatures of 1123 K, 973 K, and 573 K. (C) 2014 Elsevier Ltd. All rights reserved.	[Sambuu, Odmaa] Tokyo Inst Technol, Dept Nucl Engn, Meguro Ku, Tokyo 1528550, Japan; [Obara, Toru] Tokyo Inst Technol, Res Lab Nucl Reactors, Meguro Ku, Tokyo 1528550, Japan	Sambuu, O (reprint author), Tokyo Inst Technol, Dept Nucl Engn, Meguro Ku, 2-12-1-N1-19 Ookayama, Tokyo 1528550, Japan.	sodmaa1@yahoo.com					MARUYAMA T, 1995, J NUCL MATER, V225, P267, DOI 10.1016/0022-3115(95)00051-8; [Anonymous], 2013, DEC HEAT TABL; Kunitomi K, 1996, NUCL ENG DES, V166, P179, DOI 10.1016/0029-5493(96)01268-X; Hayashi K., 1989, ASSESSMENT FUEL INTE, P89; IAEA, 2003, 1382 IAEATECDOC; Kassir M.K., 1996, BNL52384; Lienhard IV John H, 2011, HEAT TRANSFER TXB; Odmaa S, 2014, J NUCL SCI ENG, V177, P97; Odmaa S., 2012, ANN NUCL ENERGY, V47, P210; Odmaa S., J NUCL SCI ENG UNPUB	10	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						37	45		10.1016/j.pnucene.2014.07.013		9	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100008		
J	Sato, H; Ohashi, H; Nakagawa, S; Tachibana, Y; Kunitomi, K				Sato, Hiroyuki; Ohashi, Hirofumi; Nakagawa, Shigeaki; Tachibana, Yukio; Kunitomi, Kazuhiko			Safety design consideration for HTGR coupling with hydrogen production plant	PROGRESS IN NUCLEAR ENERGY			English	Article						Safety requirement; Nuclear hydrogen production; HTGR; IS process	IODINE-SULFUR PROCESS	Safety requirements and design considerations are examined for a nuclear hydrogen production system that consists of High Temperature Gas-cooled Reactor (HTGR) and a hydrogen production plant by thermochemical water splitting iodine-sulfur process (IS process). Requirements in order to construct hydrogen production plants under conventional chemical plant regulation are identified in order to take into account a fundamental difference in safety philosophy between the nuclear facility and chemical plant and meet requests from the potential users of nuclear heat. In addition, safety requirements for the collocation of the nuclear facility and hydrogen production plant utilizing IS process (IS plant) are investigated. Furthermore, design considerations to comply with the requirements are suggested and the technical feasibility of the design considerations is evaluated. The evaluation results for a reference plant showed that safe distance determined by the chemical plant regulation against combustible gas and hazardous chemical leakages comply with the plant layout design. Furthermore, the results demonstrated the feasibility of IS plant construction under non-nuclear regulation by showing that the tritium concentration in IS plant can be maintained below the regulation limit and reactor normal operation can be achieved during abnormal conditions in the IS plant. These results clarified that design considerations suggested for coupling the IS plant to HTGR are reasonably practicable. The proposed criteria can be used not only for coupling hydrogen production plants but also for other chemical plants such as steam reforming plants, etc. (C) 2014 Elsevier Ltd. All rights reserved.	[Sato, Hiroyuki; Ohashi, Hirofumi; Nakagawa, Shigeaki; Tachibana, Yukio; Kunitomi, Kazuhiko] Japan Atom Energy Agcy, Oarai, Ibaraki, Japan	Sato, H (reprint author), 4002 Narita Cho, Oarai, Ibaraki 3111393, Japan.	sato.hiroyuki09@jaea.go.jp					[Anonymous], 2012, J OCCUP HEALTH, V54, P387; Ermak D.L., 1990, UCRLMA105607; IAEA, 2012, SAF STAND SER; Kunitomi K, 2004, NUCL ENG DES, V233, P45, DOI 10.1016/j.nucengdes.2004.07.010; Kunitomi K, 2007, NUCL ENG TECHNOL, V39, P9; Murakami Tomoyuki, 2008, Transactions of the Atomic Energy Society of Japan, V7; Murakami T., 2006, Transactions of the Atomic Energy Society of Japan, V5; NIOSH, 1997, NIOSH POCK GUID CHEM; Ohashi H, 2008, J NUCL SCI TECHNOL, V45, P1215, DOI 10.3327/jnst.45.1215; Ohashi K., 2007, Transactions of the Atomic Energy Society of Japan, V6; Sakaba N, 2007, INT J HYDROGEN ENERG, V32, P4160, DOI 10.1016/j.ijhydene.2007.06.005; Sakaba Nariaki, 2008, Transactions of the Atomic Energy Society of Japan, V7; Sato H., 2012, THESIS TOKYO I TECHN; The Economic Modeling Working Group of the Generation IV International Forum, 2006, GIFEMWG2006003; US EPA, 2012, AC EXP GUID LEV AEGL, V2012; US NRC, 2001, EV HAB NUCL POW PLAN; US NRC, 1995, NUREGCR5535; US NRC, 1978, EV EXPL POST OCC TRA; US NRC, 2008, NUREGCR6944 US NCR, V6	19	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						46	52		10.1016/j.pnucene.2014.07.032		7	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100009		
J	Kato, Y				Kato, Yukitaka			Contribution of nuclear energy on new energy systems post Fukushima	PROGRESS IN NUCLEAR ENERGY			English	Article						Carbon recycling; Carbon monoxide; High-temperature gas reactor; Ironmaking process; Post Fukushima	REDUCTION; HYDROGEN	Nuclear energy contribution on new energy systems post Fukushima was discussed in this study. A new energy transformation concept based on carbon recycling, called the Active Carbon Recycling Energy System, ACRES, was proposed for a zero carbon dioxide emission process. ACRES is driven with consumption of primary energy that does not emit carbon dioxide such as nuclear and renewable energies. A smart ironmaking system based on ACRES, iACRES, was also proposed. Carbon monoxide was thermodynamically the first candidate for recycling carbon media in iACRES because it had higher energy densities than hydrogen and was highly compatible with conventional iron-making process. From a feasibly study of iACRES driven by high-temperature gas reactor had the most availability for conventional ironmaking processes in the stand point of energy output rate in comparison with solar energy system. It was expected that nuclear energy could contribution on conventional industrial processes by using ACRES as a new energy system post Fukushima. (C) 2014 Elsevier Ltd. All rights reserved.	Tokyo Inst Technol, Nucl Reactors Res Lab, Ctr Res Innovat Nucl Energy Syst, Meguro Ku, Tokyo 1528550, Japan	Kato, Y (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Ctr Res Innovat Nucl Energy Syst, Meguro Ku, 2-12-1-N1-22 Ookayama, Tokyo 1528550, Japan.	yukitaka@nr.titech.ac.jp					Kusama H, 1996, CATAL TODAY, V28, P261, DOI 10.1016/0920-5861(95)00246-4; Jensen SH, 2007, INT J HYDROGEN ENERG, V32, P3253, DOI 10.1016/j.ijhydene.2007.04.042; [Anonymous], 2012, TRADE STAT MINISTRY; Bonalde A, 2005, ISIJ INT, V45, P1255, DOI 10.2355/isijinternational.45.1255; Fujikawa S, 2004, J NUCL SCI TECHNOL, V41, P1245, DOI 10.3327/jnst.41.1245; Japan Agency Natural Res. & Energy, 2005, REV STAND HEAT VAL 2; Kameyama H., 2005, HONEBUTO ENERGY ROAD; Kato Y, 2010, ISIJ INT, V50, P181, DOI 10.2355/isijinternational.50.181; Kawamura A., 2006, KOBE STEEL ENG, V56; Kunitomi K., 2002, Transactions of the Atomic Energy Society of Japan, V1; Minister of Economy, 2006, TRAD IND METI; Murayama T., 1977, TETSU TO HAGANE, V63, P1090; Yamamoto T, 1999, ISIJ INT, V39, P705, DOI 10.2355/isijinternational.39.705	13	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						53	57		10.1016/j.pnucene.2014.07.018		5	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100010		
J	Sasa, T				Sasa, Toshinobu			Design of J-PARC Transmutation Experimental Facility	PROGRESS IN NUCLEAR ENERGY			English	Article						Transmutation; Accelerator-driven system; J-PARC; Transmutation Experimental Facility; Spallation target	ACCELERATOR-DRIVEN SYSTEMS	After the Fukushima accident, nuclear transmutation got much interested as an effective option of nuclear waste management. Japan Atomic Energy Agency (JAEA) proposes the transmutation of minor actinides by accelerator-driven system (ADS) using lead bismuth eutectic alloy (Pb-Bi) as a spallation target and a coolant of subcritical core. Current design of ADS has 800 MWth of rated power, which is driven by 20 MW proton LINAC, to transmute minor actinides generated from 10 units of standard Light Water Reactors. To obtain the data required for ADS design, JAEA plans to build a Transmutation Experimental Facility (TEF) in J-PARC. TEF consists of two buildings, one is an ADS target test facility (TEF-T), which will be installed Pb-Bi spallation target, and the other is Transmutation Physics Experimental Facility (TEF-P), which set up a fast critical/subcritical assembly. TEF will be located at the end of 400 MeV LINAC of J-PARC and accepts 250 kW proton beam. The paper describes an outline of TEF and design of spallation target. (C) 2014 Elsevier Ltd. All rights reserved.	Japan Atom Energy Agcy, Transmutat Sect, J PARC Ctr, Tokai, Ibaraki 3191195, Japan	Sasa, T (reprint author), Japan Atom Energy Agcy, Transmutat Sect, J PARC Ctr, 2-4 Shirakata Shirane, Tokai, Ibaraki 3191195, Japan.	sasa.toshinobu@jaea.go.jp					Niita K., 2010, PHITS PARTICLE HEAVY; Oigawa H., 2001, P GLOB 2001 PAR FRAN; Sasa T., 2005, 2005021 JAERI; Sasa T, 2004, NUCL ENG DES, V230, P209, DOI 10.1016/j.nucengdes.2003.11.033; Soule R, 2004, NUCL SCI ENG, V148, P124; Sugawara T, 2008, 2008026 JAEA; The Joint Project Team of JAERI and KEK, 2000, 2000003 JAERI; Uyttenhove W, 2011, ANN NUCL ENERGY, V38, P1519, DOI 10.1016/j.anucene.2011.03.012	8	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						64	68		10.1016/j.pnucene.2014.07.031		5	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100012		
J	Onishi, T; Koyama, S; Mimura, H				Onishi, Takashi; Koyama, Shin-ichi; Mimura, Hitoshi			Removal of zirconium from spent fuel solution by alginate gel polymer	PROGRESS IN NUCLEAR ENERGY			English	Article						Zirconiuin; Alginate gel polymer; Spent fuel solution	SELECTIVE SEPARATION; MICROCAPSULES; EXTRACTANT; RECOVERY; ACID	The uptake behaviour of zirconium (Zr) in alginate gel polymer and removal of Zr from spent fuel solution have been studied by the batch and column methods. As a first step, alginate gel polymer was synthesized and conditioned. The uptakes of Zr were examined in several concentrations of HNO3 solution (from 0.01 M to 9 M HNO3) by a batch method. Stronger affinity of Zr was shown than strontium (Sr), cobalt (Co), uranium (U) and iron (Fe) in 1 M HNO3. It has been reported that cation binding was stronger with ions of higher charge in the alginate gel polymer. In contrast, the free aqueous ion, Zr4+, is the dominant form of the Zr species in very acidic solution. Therefore, the strong affinity of Zr is explained. The uptake rate of Zr was also evaluated in 2.6 M HNO3 solution, which was close to the HNO3 concentration in actual HLLW from fuel reprocessing. The uptake of Zr reached equilibrium within 2 h. For the column experiment, fission products (FPs) solution containing rare earth elements (REEs), platinum group metals, alkaline metals, alkaline earth metals and the other elements was prepared from actual spent fuel and the concentration of HNO3 was adjusted to 2.6 M. In the column experiment, the alginate gel polymer was packed into a column, and then a chromatographic experiment was performed using the FPs solution prepared from actual spent fuel. As a result, over 95% of the Zr was removed from the FPs solution. Molybdenum (Mo), technetium (Tc), yttrium (Y), palladium (Pd), tellurium (Te), cesium (Cs) and REEs were eluted by the successive use of H2O, and 1 M and 3 M HNO3. (C) 2014 Elsevier Ltd. All rights reserved.	[Onishi, Takashi; Koyama, Shin-ichi] Japan Atom Energy Agcy, Oarai, Ibaraki 3111393, Japan; [Mimura, Hitoshi] Tohoku Univ, Grad Sch Engn, Dept Quantum Sci & Energy Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan	Onishi, T (reprint author), Japan Atom Energy Agcy, Narita Cho 4002, Oarai, Ibaraki 3111393, Japan.	ohnishi.takashi@jaea.go.jp					BENEDICT JT, 1954, J AM CHEM SOC, V76, P2036, DOI 10.1021/ja01637a002; Brown P. L., 2005, SERIES CHEM THERMODY, V8, P97; Koyama S, 2003, J NUCL SCI TECHNOL, V40, P998, DOI 10.3327/jnst.40.998; Masud R. S., 2012, FUELLING FUTURE ADV, P440; Masud RS, 2012, PROCEDIA CHEM, V7, P258, DOI 10.1016/j.proche.2012.10.042; Mimura H, 2001, J RADIOANAL NUCL CH, V247, P33, DOI 10.1023/A:1006742426311; Mimura H., 2010, J ION EXCH, V21, P2; Mimura H, 2011, NUCL ENG DES, V241, P4750, DOI 10.1016/j.nucengdes.2011.03.031; Mimura H, 2002, J NUCL SCI TECHNOL, V39, P655, DOI 10.3327/jnst.39.655; Murao A., 2010, 11 INF EXCH M SAN FR; Outokesh M., 2006, J ION EXCHANGE, V17, P67; Outokesh M, 2006, IND ENG CHEM RES, V45, P3633, DOI 10.1021/ie051109o; Takahashi T., 1960, ALGINIC ACID CATION, V12, P47; Wu Y, 2008, PROG NUCL ENERG, V50, P487, DOI 10.1016/j.pnucene.2007.11.062	14	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						69	73		10.1016/j.pnucene.2014.07.025		5	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100013		
J	Yamazaki, Y; Tachibana, Y; Kaneshiki, T; Nomura, M; Suzuki, T				Yamazaki, Yuki; Tachibana, Yu; Kaneshiki, Toshitaka; Nomura, Masao; Suzuki, Tatsuya			Adsorption behavior of uranium ion using novel phenol-type resins in contaminated water containing seawater	PROGRESS IN NUCLEAR ENERGY			English	Article						Contaminated water; Radioactive nuclides; Phenol-type resins	TANNIN; ADSORBENTS; RECOVERY; REMOVAL; GEL	Bisphenol A-type and tannic acid-type resins embedded in high-porous silica beads were synthesized successfully and the adsorption behavior of U species using their synthesized resins have been studied in simulated seawater in a pH range of 2.0-9.1 and in seawater of pH 7.9 at 298 K. As a result, it was found that U species in sample solutions are strongly adsorbed on the bisphenol A-type and tannic acid-type resins, compared with typical cation-exchange resins and that the obtained distribution coefficients of U species increase with increasing the pH in sample solutions. It can also be noted that this phenomenon is attributable to concentrations of dissociated functional groups contained in the tannic acid-type resin in aqueous solutions. From these results, it was proposed that the adsorption mechanisms of U species with the synthesized resin proceed through the complexation reactions. (C) 2014 Elsevier Ltd. All rights reserved.	[Yamazaki, Yuki; Tachibana, Yu; Suzuki, Tatsuya] Nagaoka Univ Technol, Grad Sch Engn, Dept Nucl Syst Safety Engn, Nagaoka, Niigata 9402188, Japan; [Kaneshiki, Toshitaka; Nomura, Masao] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Tachibana, Y (reprint author), Nagaoka Univ Technol, Grad Sch Engn, Dept Nucl Syst Safety Engn, 1603-1 Kamitomioka, Nagaoka, Niigata 9402188, Japan.	yu_tachibana@vos.nagaokaut.ac.jp			KAKENHI [24226021]	This work was partially supported by the Grant-in-Aid for Scientific Research (S) (KAKENHI No. 24226021).	Kim YH, 2005, WATER RES, V39, P1324; An JH, 2007, APPL CLAY SCI, V36, P256, DOI 10.1016/j.clay.2006.11.001; Zhang HJ, 2013, J RADIOANAL NUCL CH, V298, P1705, DOI 10.1007/s10967-013-2612-x; Kim TJ, 2010, FOOD CHEM, V118, P740, DOI 10.1016/j.foodchem.2009.05.060; Choi SH, 2000, RADIAT PHYS CHEM, V57, P187, DOI 10.1016/S0969-806X(99)00348-5; Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3; Fujinaga T., 2005, OCEAN LAKE CHEM, P14; Grenthe I., 2004, CHEM THERMODYN, p[99, 193, 309]; Gurung M, 2013, CHEM ENG J, V231, P113, DOI 10.1016/j.cej.2013.06.028; Inoue K, 2006, J RADIOANAL NUCL CH, V267, P435, DOI 10.1007/s10967-006-0067-z; Liao XP, 2004, J CHEM TECHNOL BIOT, V79, P335, DOI 10.1002/jctb.974; NAKAJIMA A, 1990, J CHEM TECHNOL BIOT, V47, P31; Ohta A., 2006, GEOCHEMISTRY, V40, P13; SAKAGUCHI T, 1987, SEPAR SCI TECHNOL, V22, P1609, DOI 10.1080/01496398708058421	14	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						74	79		10.1016/j.pnucene.2014.07.020		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100014		
J	Okawa, T; Tatewaki, I; Ishizu, T; Endo, H; Tsuboi, Y; Saitou, H				Okawa, T.; Tatewaki, I.; Ishizu, T.; Endo, H.; Tsuboi, Y.; Saitou, H.			Fuel behavior analysis code FEMAXI-FBR development and validation for core disruptive accident	PROGRESS IN NUCLEAR ENERGY			English	Article						Fuel behavior; Fast reactor fuel; Core disruptive accident; Code development		Japan Nuclear Energy Safety Organization (JNES) is a Technical Safety Organization (TSO) for Japanese Nuclear Regulation Authority to provide technical information on safety reviews including incident and accident analyses of nuclear power plants including Fast Breeder Reactor (FBR). JNES has developed an ASTERIA-FBR code system as an integrated Core Disruptive Accident (CDA) analysis code of the regulatory side for the purpose of evaluating the Unprotected Loss-of-Flow (ULOF) accident of FBR cores. The ASTERIA-FBR consists of three main modules, a thermal-hydraulics calculation module; CONCORD, a fuel behavior calculation module; FEMAXI-FBR, and a neutronic calculation module; dynamic GMVP. The FEMAXI-FBR is based on a LWR fuel behavior simulation code FEMAXI-6 and modified the material properties, the calculation models for steady state and transient operational conditions. The FEMAXI-FBR has been validated by French CABRI slow-TOP (E12) and fast-TOP (BI2) transient test data. Furthermore, the fuel temperature calculation model was validated by B5D Power-To-Melt (PTM) test at the experimental fast reactor JOYO in Japan. Through these validation, the code is found to be capable of evaluating FBR fuel pin behavior from normal to accidental conditions precisely. (C) 2014 Published by Elsevier Ltd.	[Okawa, T.; Tatewaki, I.; Ishizu, T.; Endo, H.] Japan Nucl Energy Safety Org, Minato Ku, Tokyo 1050001, Japan; [Tsuboi, Y.] Toshiba Co Ltd, Isogo Ku, Yokohama, Kanagawa 2358523, Japan; [Saitou, H.] Itochu Technosolut Corp, Chiyoda Ku, Tokyo 1006080, Japan	Okawa, T (reprint author), Japan Nucl Energy Safety Org, Minato Ku, 4-1-28 Toranomon, Tokyo 1050001, Japan.	okawa-tsuyoshi@jnes.go.jp					Inoue M, 2003, J NUCL MATER, V323, P108, DOI [10.1016/j.jnucmat.2003.08.030, 10.1016/j.nucmat.2003.08.030]; Ishizu T., 2012, P 2012 INT C ADV NUC; Ishizu T., 2011, P 19 INT C NUCL ENG; Nagai H., 1983, 1983 ANN M AT EN SOC; Okawa T., 2013, INT C FAST REACT REA; Sato I, 2004, NUCL TECHNOL, V145, P115; Suzuki M., LIGHT WATER REACTOR; Tentner A. M., 2010, ANLGENIV128 NUCL ENG; Tentner A.M., 1987, C E SIM C ORL FL US; Tsuboi Y., 2012, J NUCL SCI TECHNOL, V49; Walter A. E., 2005, STRUCTURE USER MANUA	11	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						80	85		10.1016/j.pnucene.2014.11.002		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100015		
J	Sato, I; Tanaka, K; Koyama, S; Matsushima, K; Matsunaga, J; Hirai, M; Endo, H; Haga, K				Sato, Isamu; Tanaka, Kosuke; Koyama, Shin-ichi; Matsushima, Ken-ichi; Matsunaga, Junji; Hirai, Mutsumi; Endo, Hiroshi; Haga, Kazuo			Chemical form consideration of released fission products from irradiated fast reactor fuels during overheating	PROGRESS IN NUCLEAR ENERGY			English	Article						Severe accident; Fission product; Thermochemisty; Chemical form; Sodium-cooled fast reactor	MIXED-OXIDE FUEL; VAPORIZATION; BEHAVIOR; SODIUM	Experiments simulating overheating conditions of fast reactor severe accidents have been previously carried out with irradiated fuels. For the present study, the chemical forms of the fission products (FPs) included in the irradiated fuels were evaluated by thermochemical equilibrium calculations. At temperatures of 2773 K and 2973 K, the most stable forms of Cs, I, Te, Sb, Pd and Ag are gaseous compounds, and their fractions are about 100% in an oxygen partial pressure range between 10(-5) and 10(3) Pa. Cs and Sb detected in the thermal gradient tube (TGT) in the experiments can take gaseous chemical forms of elemental Cs, CsI, Cs2MoO4, CsO and elemental Sb, SbO, SbTe, respectively. The chemical forms of Cs and Mo are sensitive to the oxygen partial pressure. By comparing experimental results and the estimations, it is seen CsI thermochemically behaves in a manner that traps it in the TGT, while elemental Cs trends to move as fine particles. The moving behavior of the gaseous FPs will obey not only thermochemical principles, but also those of particle dynamics. (C) 2014 Elsevier Ltd. All rights reserved.	[Sato, Isamu; Tanaka, Kosuke; Koyama, Shin-ichi] Japan Atom Energy Agcy, Fukushima Fuels & Mat Dept, Fukushima, Japan; [Matsushima, Ken-ichi; Matsunaga, Junji; Hirai, Mutsumi] Nippon Nucl Fuel Dev Co Ltd, Res Dept 2, Yokohama, Kanagawa, Japan; [Endo, Hiroshi; Haga, Kazuo] Japan Nucl Energy Safety Org, Nucl Energy Syst Safety Div, Tokyo, Japan	Sato, I (reprint author), Japan Atom Energy Agcy, Fukushima Fuels & Mat Dept, Fukushima, Japan.	sato.isamu@jaea.go.jp					MIGNANELLI MA, 1984, J NUCL MATER, V125, P182, DOI 10.1016/0022-3115(84)90545-2; CORDFUNKE EHP, 1993, J NUCL MATER, V201, P57, DOI 10.1016/0022-3115(93)90159-V; YAMAWAKI M, 1993, J NUCL MATER, V201, P257, DOI 10.1016/0022-3115(93)90181-W; Boer R., 1997, J NUCL MATER, V240, P124; BUCKLE ER, 1991, J AEROSOL SCI, V22, P135, DOI 10.1016/0021-8502(91)90023-B; COLLINS JL, 1988, NUCL TECHNOL, V81, P78; CORDFUNKE EHP, 1986, THERMOCHIM ACTA, V108, P45, DOI 10.1016/0040-6031(86)85076-6; Croff A G, 1980, ORNLTM7175; Giordano P, 2010, PROG NUCL ENERG, V52, P109, DOI 10.1016/j.pnucene.2009.09.011; GOTZMANN O, 1993, J NUCL MATER, V201, P267, DOI 10.1016/0022-3115(93)90183-Y; Lorenz R.A., 1981, NUREGCR1773; Lorenz R.A., 1980, NUREGCR1386; Osbone M.F., 1984, NUREGCR3715; PORTMAN R, 1989, THERMOCHIM ACTA, V144, P21, DOI 10.1016/0040-6031(89)85081-6; ROSENBLATT G, 1961, J CHEM PHYS, V35, P788, DOI 10.1063/1.1701217; Sato I, 2003, J NUCL SCI TECHNOL, V40, P104, DOI 10.3327/jnst.40.104; Sato I, 2011, J NUCL MATER, V416, P151, DOI 10.1016/j.jnucmat.2010.11.028; Sato I, 2013, J NUCL MATER, V437, P275, DOI [10.1016/j.jnucmat.2013.02.026, 10.1016/jnucmat.2013.02.026]; STRAIN RV, 1993, J NUCL MATER, V204, P252, DOI 10.1016/0022-3115(93)90224-M; United States Nuclear Regulatory, 1981, NUREG0772	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						86	91		10.1016/j.pnucene.2014.07.033		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100016		
J	Sagara, H; Matsumoto, K; Yamauchi, I; Nakao, K; Han, CY; Onishi, T; Koyama, S; Saito, M				Sagara, Hiroshi; Matsumoto, Koji; Yamauchi, Ippei; Nakao, Kenji; Han, Chi Young; Onishi, Takashi; Koyama, Shin-ichi; Saito, Masaki			Feasibility study of the fast breeder reactor blanket as a target of plutonium denaturing and TRU transmutation for enhancement of the proliferation resistance and the actinide management in the future fuel cycle	PROGRESS IN NUCLEAR ENERGY			English	Article						Material attractiveness; Plutonium denaturing; TRU transmutation; FBR blanket		A comparative study was performed with different designs of the fast breeder reactor (FBR) blanket to evaluate the performance of plutonium breeding accompanied with denaturing, and trans-uranium (TRU) transmutation for enhancement of the proliferation resistance and actinide management in the future fuel cycle. Four designs of the FBR blanket fuel were intercompared, conventional depleted uranium (DU) oxide fuels, DU with TRU oxide fuels, DU with TRU oxide fuels with homogeneous/heterogeneous moderators. As results, with heterogeneous moderator in the axial and the radial blanket fuels, the greatest TRU transmutation and plutonium denaturing performance were attained without deteriorating fuel breeding. Design optimization was performed as for ZrH1.65 moderator rod/pellet arrangement in the axial and the radial blanket fuel assemblies. The optimum number of moderator rods per assembly was 25 (11% of the number of total rods) with proper mutual interval (2-3 cm) and symmetrical arrangement in the radial blanket, and insertion of 1 cm thick ZrH1.65 moderator pellets to 4 and 10 cm from the top and the bottom planes of the active core was the optimum design in the axial blanket, in order to achieve the highest MU transmutation ratio and plutonium denaturing performance without deteriorating fuel breeding. From the non-proliferation aspect, material attractiveness of plutonium were evaluated comparing with the criterion based on decay heat, and required TRU doping ratio in DU with TRU oxide fuel were proved to be as 1.6-2.5 wt.% with heterogeneous moderator, 2.1-3.0 wt.% with homogeneous moderator, and 4.1-5.0 wt.% without moderator. The heterogeneous loading of moderation showed the great advantages in fuel treatment in clear the heat generation limit criterion, as well as mass requirement to the initial and multicycle phase. (C) 2014 Published by Elsevier Ltd.	[Sagara, Hiroshi; Matsumoto, Koji; Yamauchi, Ippei; Nakao, Kenji; Han, Chi Young; Saito, Masaki] Tokyo Inst Technol, Meguro Ku, Tokyo 1528550, Japan; [Onishi, Takashi; Koyama, Shin-ichi] Japan Atom Energy Agcy, O Ari, Ibaraki 3111393, Japan	Sagara, H (reprint author), Tokyo Inst Technol, Meguro Ku, 2-12-1-N1-17 Ookayama, Tokyo 1528550, Japan.	sagara@nr.titech.ac.jp					Okumura K, 2000, J NUCL SCI TECHNOL, V37, P128; Kawaguchi K., 2007, GLOBAL 2007 ID US; Kimura Y, 2011, J NUCL SCI TECHNOL, V48, P715, DOI 10.3327/jnst.48.715; Meiliza Y, 2008, J NUCL SCI TECHNOL, V45, P230, DOI 10.3327/jnst.45.230; Meiliza Y, 2013, J NUCL SCI TECHNOL, V50, P615, DOI 10.1080/00223131.2013.785281; Naganuma M., 2005, TN94002005051 JNC; Nagaya Y., 2004, 1348 JAERI, P1348; Sagara H, 2011, PROG NUCL ENERG, V53, P952, DOI 10.1016/j.pnucene.2011.04.025; Saito M., 2008, T AM NUCL SOC, V98, P669; Saito M., 2005, International Journal of Nuclear Energy Science and Technology, V1; Saito M., 2003, INT C INN TECHN NUCL	11	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						92	97		10.1016/j.pnucene.2014.07.022		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100017		
J	Kikuchi, H; Obara, T				Kikuchi, Haruka; Obara, Toru			Kinetic behavior in criticality accident of two fuel solution tanks	PROGRESS IN NUCLEAR ENERGY			English	Article						Nuclear criticality safety; Criticality accident; Fuel solution; Transient analysis; Neutronic coupling; Radiolytic dissociation gas void	NITRATE SOLUTION	This work aimed at criticality safety in fuel-fabrication or reprocessing facilities. To estimate the expected released energy in criticality accidents of several fuel-solution tanks based on the energy released in a single-fuel-solution-tank accident, the total energy released in a two-tank system was evaluated with different compositions of fuel solutions. The code used for the analysis took into account the neutronic coupling between the tanks. The results made clear that as the fuel enrichment increases, neutronic coupling becomes stronger. The calculated increase of the total energy released in a criticality accident of a system with two fuel-solution tanks compared to that of a system with just one was roughly the same regardless of different feedback model used for the analysis. The results show that the difference in energy release between multiple-tank and single-tank systems of similar composition may be evaluated using the developed transient analysis code. (C) 2014 Elsevier Ltd. All rights reserved.	[Kikuchi, Haruka] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Nucl Engn, Meguro Ku, Tokyo 1528550, Japan; [Obara, Toru] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Kikuchi, H (reprint author), Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Nucl Engn, Meguro Ku, 2-12-1-N1-19 Ookayama, Tokyo 1528550, Japan.	kikuchi.h.ab@m.titech.ac.jp					Kukharchuk O.F., 2000, P INT C MATH COMP NE; Nakajima K, 2002, KINETICS CODE CRITIC; Nakajima Ken, 2002, TRACY TRANSIENT EXPT; Ogawa K, 2008, J NUCL SCI TECHNOL, V45, P1028, DOI 10.3327/jnst.45.1028; Takezawa H, 2012, NUCL SCI ENG, V171, P1; Takezawa Hiroki, 2010, NUCL SCI ENG, V164, P1; Tonoike K, 2003, J NUCL SCI TECHNOL, V40, P238, DOI 10.3327/jnst.40.238; Yamane Yuichi, 2012, ADV NUCL FUEL, P159; Yamane Yuichi, 2003, P 7 INT C NUCL CRIT	9	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						98	101		10.1016/j.pnucene.2014.07.016		4	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100018		
J	Utsuno, Y; Shimizu, N; Otsuka, T; Ebata, S; Honma, M				Utsuno, Yutaka; Shimizu, Noritaka; Otsuka, Takaharu; Ebata, Shuichiro; Honma, Michio			Photonuclear reactions of calcium isotopes calculated with the nuclear shell model	PROGRESS IN NUCLEAR ENERGY			English	Article						Photoabsorption cross section; Shell model; Giant dipole resonance; Pygmy dipole resonance; E1 transition; Lanczos method		Photoabsorption cross sections in calcium isotopes are investigated theoretically with the most advanced nuclear-structure calculations using the nuclear shell model. We show that the photoabsorption cross sections in Ca-48 dominated by a giant dipole resonance (GDR) are well reproduced with the shell model and predict that a pygmy dipole resonance (FOR) appears in Ca-52 in the low-energy tail of GDR. Excellent agreement with the experiment is achieved due to highly correlated many-body wave functions obtained by treating a huge matrix with the dimension of similar to 10(10). (C) 2014 Elsevier Ltd. All rights reserved.	[Utsuno, Yutaka] Japan Atom Energy Agcy, Adv Sci Res Ctr, Tokai, Ibaraki 3191195, Japan; [Utsuno, Yutaka; Shimizu, Noritaka; Otsuka, Takaharu] Univ Tokyo, Ctr Nucl Study, Tokyo 1130033, Japan; [Otsuka, Takaharu] Univ Tokyo, Dept Phys, Tokyo 1130033, Japan; [Otsuka, Takaharu] Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; [Otsuka, Takaharu] Michigan State Univ, Natl Superconducting Cyclotron Lab, E Lansing, MI 48824 USA; [Ebata, Shuichiro] Hokkaido Univ, Meme Media Lab, Sapporo, Hokkaido 0600810, Japan; [Honma, Michio] Univ Aizu, Ctr Math Sci, Aizu Wakamatsu, Fukushima 9658580, Japan	Utsuno, Y (reprint author), Japan Atom Energy Agcy, Adv Sci Res Ctr, Tokai, Ibaraki 3191195, Japan.	utsuno.yutaka@jaea.go.jp			JSPS [21740204, 25870168]; SPIRE Field 5; MEXT of Japan	This work was in part supported by JSPS KAKENHI Grant Numbers 21740204 and 25870168, and by SPIRE Field 5, the MEXT of Japan. This work is a part of the RIKEN-CNS joint research project on large-scale nuclear-structure calculations. Part of the numerical calculations were performed with the BX900 supercomputer at the Japan Atomic Energy Agency and the FX10 supercomputer at the University of Tokyo.	Ebata S, 2010, PHYS REV C, V82, DOI 10.1103/PhysRevC.82.034306; Utsuno Y, 2012, PHYS REV C, V86, DOI 10.1103/PhysRevC.86.051301; BARTEL J, 1982, NUCL PHYS A, V386, P79, DOI 10.1016/0375-9474(82)90403-1; Caurier E, 2001, PHYS LETT B, V522, P240, DOI 10.1016/S0370-2693(01)01246-1; BROWN BA, 1988, ANNU REV NUCL PART S, V38, P29; Inakura T, 2009, PHYS REV C, V80, DOI 10.1103/PhysRevC.80.044301; Valiente-Dobon JJ, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.242502; Schwengner R, 2010, PHYS REV C, V81, DOI 10.1103/PhysRevC.81.054315; OKEEFE GJ, 1987, NUCL PHYS A, V469, P239, DOI 10.1016/0375-9474(87)90108-4; Steppenbeck D, 2013, NATURE, V502, P207, DOI 10.1038/nature12522; Caurier E, 2007, PROG PART NUCL PHYS, V59, P226, DOI 10.1016/j.ppnp.2006.12.012; Barbieri C, 2008, PHYS REV C, V77, DOI 10.1103/PhysRevC.77.024304; Center for Photonuclear Experiments Data (CDFE), 2011, CHART GIANT DIP RES; Honma M., 2008, RIKEN ACCEL PROG REP, V41, P32; Honma M., 2004, PHYS REV C, V69; Inakura T, 2011, PHYS REV C, V84, DOI 10.1103/PhysRevC.84.021302; Oblozinsky P., 2002, Journal of Nuclear Science and Technology; Ring P, 1980, NUCL MANY BODY PROBL; Sagawa H, 1999, PHYS REV C, V59, P3116, DOI 10.1103/PhysRevC.59.3116; Shimizu N., 2013, ARXIV13105431; Utsuno Y, 2012, PROG THEOR PHYS SUPP, P304; Whitehead R. R., 1980, MOMENT METHODS MANY	22	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						102	106		10.1016/j.pnucene.2014.07.036		5	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100019		
J	Katabuchi, T; Tsuda, H; Terada, K; Igashira, M				Katabuchi, Tatsuya; Tsuda, Hiroyuki; Terada, Kazushi; Igashira, Masayuki			Measurement of neutron capture cross sections and neutron capture gamma-ray spectra of Nb-93, Rh-103 and In-115 in keV-energy region	PROGRESS IN NUCLEAR ENERGY			English	Article						Neutron capture cross section; Neutron capture gamma-ray spectrum; Nb-93; Rh-103; In-115; Time-of-flight method	NUCLEAR-SCIENCE; LIBRARY; TA-181	The neutron capture cross sections of Nb-93, Rh-103 and In-115 were measured by the time-of-flight method in the energy region from 15 keV to 100 key. A pulse-height weighting technique was employed to derive the neutron capture cross sections. The neutron capture gamma-ray spectra were derived by unfolding the pulse-height spectra with the detector response functions. (C) 2014 Elsevier Ltd. All rights reserved.	[Katabuchi, Tatsuya; Tsuda, Hiroyuki; Terada, Kazushi; Igashira, Masayuki] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Katabuchi, T (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1-N1-26 Ookayama, Tokyo 1528550, Japan.	buchi@nr.titech.ac.jp					[Anonymous], 2011, ENDF B 7 1 DATA FILE; [Anonymous], 2010, JENDL 4 0 DATA FILE; Shibata K, 2011, J NUCL SCI TECHNOL, V48, P1, DOI 10.3327/jnst.48.1; Chadwick MB, 2006, NUCL DATA SHEETS, V107, P2931, DOI 10.1016/j.nds.2006.11.001; MACKLIN RL, 1967, PHYS REV, V159, P1007, DOI 10.1103/PhysRev.159.1007; Bokhovko M. V., 1991, OBNINSK REPORTS, V2168; Campbell W. W., 1970, THESIS; Han Y., 2011, ENDF B 7 1 DATA FILE; Ichihara A., 2010, JENDL 4 0 DATA FILE; Iwamoto N., 2010, JENDL 4 0 DATA FILE; Kononov V. N., 1977, YAD KONSTANTY; Kunieda S., 2010, JENDL 4 0 DATA FILE; Lee S, 2003, NUCL SCI ENG, V144, P94; MACKLIN RL, 1976, NUCL SCI ENG, V59, P12; MACKLIN RL, 1980, NUCL SCI ENG, V73, P174; Mizuno S, 1999, J NUCL SCI TECHNOL, V36, P493, DOI 10.3327/jnst.36.493; Mughabghab Kim, 2011, ENDF B 7 1 DATA FILE; Ohsaki T, 1999, NUCL INSTRUM METH A, V425, P302, DOI 10.1016/S0168-9002(98)01364-3; REFFO G, 1982, NUCL SCI ENG, V80, P630; SENOO K, 1994, NUCL INSTRUM METH A, V339, P556, DOI 10.1016/0168-9002(94)90193-7; WISSHAK K, 1990, J NUCL PHYS, V42, P1731; XIA Y, 1992, PHYS REV C, V45, P2487, DOI 10.1103/PhysRevC.45.2487; YAMAMURO N, 1980, J NUCL SCI TECHNOL, V17, P582, DOI 10.3327/jnst.17.582; YAMAMURO N, 1978, J NUCL SCI TECHNOL, V15, P637, DOI 10.3327/jnst.15.637	24	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						107	111		10.1016/j.pnucene.2014.07.024		5	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100020		
J	Minato, F; Iwamoto, O				Minato, F.; Iwamoto, O.			An analysis of beta-delayed neutron emission of even-even neutron-rich nuclei with proton-neutron QRPA	PROGRESS IN NUCLEAR ENERGY			English	Article						Random phase approximation; Delayed neutron; Beta decay; Skyrme Hartree Fock; Nuclear data; Nuclear structure	R-PROCESS; HALF-LIVES; FISSION; DECAY; YIELDS; STARS; U-235	beta-delayed neutron emission probabilities of even even nuclei are examined with a proton-neutron quasi-particle random-phase-approximation (pnQRPA). To calculate a light particle evaporation from excited states of daughter nucleus populated by beta-decay, the Hauser-Feshbach statistical model is used. We discuss effects of isospin T = 0 pairing, tensor force and nuclear deformation on the beta-delayed neutron emission probability. We find that the effect of nuclear deformation is essential rather than the that of isospin T = 0 pairing and tensor force to give an appropriate beta-feedings to energy window of neutron emission. The obtained beta-delayed neutron emission probabilities are in reasonable agreement with the experimental data of several typical delayed neutron emitters. The results are also compared with the FRDM + QRPA calculation. We conclude that the present approach is promising to calculate beta-delayed neutron. (C) 2014 Elsevier Ltd. All rights reserved.	[Minato, F.; Iwamoto, O.] Japan Atom Energy Agcy, Nucl Data Ctr, Tokai, Ibaraki 3191195, Japan	Minato, F (reprint author), Japan Atom Energy Agcy, Nucl Data Ctr, Tokai, Ibaraki 3191195, Japan.	minato.futoshi@jaea.go.jp					Fang DL, 2013, PHYS REV C, V88, DOI 10.1103/PhysRevC.88.034304; Minato F, 2009, PHYS REV C, V80, DOI 10.1103/PhysRevC.80.065808; KEEPIN GR, 1957, PHYS REV, V107, P1044, DOI 10.1103/PhysRev.107.1044; Koning AJ, 2003, NUCL PHYS A, V713, P231, DOI 10.1016/S0375-9474(02)01321-0; Lesinski T, 2007, PHYS REV C, V76, DOI 10.1103/PhysRevC.76.014312; Brink DM, 2007, PHYS REV C, V75, DOI 10.1103/PhysRevC.75.064311; Zhi Q, 2013, PHYS REV C, V87, DOI 10.1103/PhysRevC.87.025803; Borzov IN, 2005, PHYS REV C, V71, DOI 10.1103/PhysRevC.71.065801; Langanke K, 2003, REV MOD PHYS, V75, P819, DOI 10.1103/RevModPhys.75.819; BRADY MC, 1989, NUCL SCI ENG, V103, P129; Minato F, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.122501; MENGONI A, 1994, J NUCL SCI TECHNOL, V31, P151, DOI 10.3327/jnst.31.151; Sarriguren P, 1998, NUCL PHYS A, V635, P55, DOI 10.1016/S0375-9474(98)00158-4; Martinez-Pinedo G, 1999, PHYS REV LETT, V83, P4502, DOI 10.1103/PhysRevLett.83.4502; TACHIBANA T, 1990, PROG THEOR PHYS, V84, P641; Engel J, 1999, PHYS REV C, V60, DOI 10.1103/PhysRevC.60.014302; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; Zalewski M, 2009, PHYS REV C, V80, DOI 10.1103/PhysRevC.80.064307; Sarriguren P, 2010, PHYS REV C, V81, DOI 10.1103/PhysRevC.81.064314; Reinhard PG, 1999, PHYS REV C, V60, DOI 10.1103/PhysRevC.60.014316; JENSEN AS, 1984, NUCL PHYS A, V431, P393, DOI 10.1016/0375-9474(84)90116-7; Satula W, 1998, PHYS REV LETT, V81, P3599, DOI 10.1103/PhysRevLett.81.3599; Nishimura S, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.052502; Beigya T., 2006, HDB CALCULATIONS NUC, VRIPL-2; BESANT CB, 1977, J BRIT NUCL ENER SOC, V16, P161; Borzov IN, 2003, PHYS REV C, V67, DOI 10.1103/PhysRevC.67.025802; Cameron A.G.W., 1957, CRL41 AT EN CAN; Campbell J.M., 1999, 994000 LANL; Iwamoto O., 2007, J NUCL SCI TECHNOL, V44, P687; KLAPDOR HV, 1984, ATOM DATA NUCL DATA, V31, P81, DOI 10.1016/0092-640X(84)90017-2; Korgul A, 2012, PHYS REV C, V86, DOI 10.1103/PhysRevC.86.024307; Kratz K.-L., 1973, PHYS REV C, V86, P263; Moller P, 2003, PHYS REV C, V67, DOI 10.1103/PhysRevC.67.055802; Montes F, 2006, PHYS REV C, V73, DOI 10.1103/PhysRevC.73.035801; National Nuclear Data Center, NUDAT 2 5 DAT; Piksaikin VM, 1997, SOC ITAL FI, V59, P485; Ring P, 1980, NUCL MANY BODY PROBL; Rudstam G., 2002, DELAYED NEUTRON DATA, V6; Tain J. L., 2013, 1 RES COORD M IAEA C; THIELEMANN FK, 1983, Z PHYS A-HADRON NUCL, V309, P301, DOI 10.1007/BF01413833; Tuttle R. J., 1979, INDCNDS107G; VAUTHERI.D, 1973, PHYS REV C, V7, P296, DOI 10.1103/PhysRevC.7.296; Wanajo S, 2004, ASTROPHYS J, V606, P1057, DOI 10.1086/383140; Yoshida K., 2013, PROG THEOR EXP PHYS, V2013	44	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						112	117		10.1016/j.pnucene.2014.07.021		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100021		
J	Terada, K; Katabuchi, T; Mizumoto, M; Arai, T; Saito, T; Igashira, M; Hirose, K; Nakamura, S; Kimura, A; Harada, H; Hori, J; Kino, K; Kiyanagi, Y				Terada, Kazushi; Katabuchi, Tatsuya; Mizumoto, Motoharu; Arai, Takuro; Saito, Tatsuhiro; Igashira, Masayuki; Hirose, Kentaro; Nakamura, Shoji; Kimura, Atsushi; Harada, Hideo; Hori, Jun-ichi; Kino, Koichi; Kiyanagi, Yoshiaki			Measurement of neutron capture cross sections of Pd-107 at J-PARC/MLF/ANNRI	PROGRESS IN NUCLEAR ENERGY			English	Article						Neutron capture; Cross section; Palladium-107; Time-of-Flight method; Pulse-height weighting technique; J-PARC		Measurements of the neutron capture cross sections of Pd-107 were carried out at the Materials and Life Science Experimental Facility (MLF) of the Japan Proton Accelerator Research Complex (J-PARC). Gammarays were detected with an NaI(TI) spectrometer of the Accurate Neutron Nucleus Reaction Measurement Instrument (ANNRI). The neutron capture cross sections were determined by the time-of-flight method in the neutron energy region from the thermal to keV energies. (C) 2014 Elsevier Ltd. All rights reserved.	[Terada, Kazushi; Katabuchi, Tatsuya; Mizumoto, Motoharu; Arai, Takuro; Saito, Tatsuhiro; Igashira, Masayuki] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Hirose, Kentaro; Nakamura, Shoji; Kimura, Atsushi; Harada, Hideo] Japan Atom Energy Agcy, Nucl Sci & Engn Directorate, Tokai, Ibaraki 3191195, Japan; [Hori, Jun-ichi] Kyoto Univ, Inst Res Reactor, Kumatori, Osaka 5900494, Japan; [Kino, Koichi; Kiyanagi, Yoshiaki] Hokkaido Univ, Grad Sch Engn, Kita Ku, Sapporo, Hokkaido 0608628, Japan	Terada, K (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1-N1-26 Ookayama, Tokyo 1528550, Japan.	terada.kazushi@jaea.go.jp			JSPS [22226016]	This work was supported by JSPS KAKENHI Grant Number 22226016.	Shibata K, 2011, J NUCL SCI TECHNOL, V48, P1, DOI 10.3327/jnst.48.1; Sato T, 2013, J NUCL SCI TECHNOL, V50, P913, DOI 10.1080/00223131.2013.814553; MACKLIN RL, 1967, PHYS REV, V159, P1007, DOI 10.1103/PhysRev.159.1007; Chiba S., 2010, JENDL 4 0 DATA FILE; Hirose K, 2013, J NUCL SCI TECHNOL, V50, P188, DOI 10.1080/00223131.2013.757470; Igashira M, 2009, NUCL INSTRUM METH A, V600, P332, DOI 10.1016/j.nima.2008.11.085; Iwamoto N., 2010, JENDL 4 0 DATA FILE; JNDC FP Nuclear Data W.G, 2011, ENDFB 7 1 DATA FILE; Katabuchi T., IN PRESS; Kino K, 2011, NUCL INSTRUM METH A, V626, P58, DOI 10.1016/j.nima.2010.10.076; Macklin R.L., 1984, NUCL SCI ENG, V89, P79; Maekawa F, 2010, NUCL INSTRUM METH A, V620, P159, DOI 10.1016/j.nima.2010.04.020; Nakamura S, IN PRESS; Nakamura S, 2007, J NUCL SCI TECHNOL, V44, P103, DOI 10.3327/jnst.44.103; SINGH UN, 1978, NUCL SCI ENG, V67, P54; Takano H., 2002, P 7 INF EXCH M ACT F, P23	16	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						118	121		10.1016/j.pnucene.2014.07.017		4	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100022		
J	Kitagaki, T; Suzuki, T; Kaneshiki, T; Nomura, M				Kitagaki, Toru; Suzuki, Tatsuya; Kaneshiki, Toshitaka; Nomura, Masao			Application of atmospheric-pressure non-thermal plasma to chlorination of hardly soluble materials	PROGRESS IN NUCLEAR ENERGY			English	Article						Atmospheric-pressure non-thermal plasma; Chlorination; Dissolution; Debris; ThO2; CeO2		The chlorination reaction in which hardly soluble materials are chemically converted into soluble chlorides by atmospheric-pressure non-thermal plasma (APNTP) and the effect of the plasma-irradiation conditions on the chlorination reaction were investigated. The CeO2 specimens, which have the same crystallographic structure (CaF2 type, cubic) and valence fluctuation behavior as ThO2, were used to simulate hardly soluble nuclear materials. CCl4 and He mixed gas were used as the plasma discharge. The emission and electrical properties of APNTP and dissolution behaviors of chloride generated by plasma irradiation were evaluated. The results of the emission spectroscopic analysis and electrical property measurements showed that chlorine and carbon were generated from the decomposition of CCl4 caused by the excited atmospheric components and He. Moreover, the production of CeCl3 from CeO2 and a logarithmic progression of the chlorination reaction were indicated with increasing plasma-irradiation time. (C) 2014 Published by Elsevier Ltd.	[Kitagaki, Toru; Suzuki, Tatsuya; Kaneshiki, Toshitaka; Nomura, Masao] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Suzuki, Tatsuya] Nagaoka Univ Technol, Dept Nucl Syst Safety Engn, Nagaoka, Niigata 9402188, Japan	Kitagaki, T (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528550, Japan.	kitagaki.t.ab@m.titech.ac.jp			KAKENHI [23360423]	This work was partially supported by the Grant-in-Aid for Scientific Research (B) (KAKENHI No. 23360423).	Akers D. W., 1986, GENDINF075; [Anonymous], 2004, MALT FOR WINDOWS; Massines F, 1998, J PHYS D APPL PHYS, V31, P3411, DOI 10.1088/0022-3727/31/24/003; FROMHOLD AT, 1982, THIN SOLID FILMS, V95, P297, DOI 10.1016/0040-6090(82)90035-9; Kanazawa S., 1987, P 8 INT S PLASM CHEM, P1839; Katz J.J., 1951, CHEM ASPECT URANIUM; Kogoma M., 2003, J PLASMA FUSION RES, V7910, P1009; Kogoma M., 2003, J PLASMA FUSION RES, V7910, P1000; Suzuki S., 1987, CHEM ASPECTS STREAM; Suzuki T, 2005, SURF COAT TECH, V200, P284, DOI 10.1016/j.surfcoat.2005.02.013; Takeuchi A, 2002, THIN SOLID FILMS, V407, P179, DOI 10.1016/S0040-6090(02)00033-0	11	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						122	125		10.1016/j.pnucene.2014.07.039		4	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100023		
J	Kikuchi, T; Horioka, K; Takahashi, K; Sasaki, T; Aso, T; Harada, N				Kikuchi, Takashi; Horioka, Kazuhiko; Takahashi, Kazumasa; Sasaki, Toru; Aso, Tsukasa; Harada, Nob			Numerical simulation for longitudinal and transverse coupling motion in compact electron beam simulator for heavy ion inertial fusion	PROGRESS IN NUCLEAR ENERGY			English	Article						Inertial confinement fusion; Electron beam; Space charge dominated beam; Beam physics; Compact simulator; High current beam	COMPRESSION; DYNAMICS	For heavy-ion beam driven inertial confinement fusion, space-charge-dominated beams are studied by a compact experimental device, scaled by electrons instead of heavy ions. In this study, space charge effect is investigated numerically in the compact electron beam simulator. Modeling of the compact beam simulator is studied, and a molecular dynamics simulation, which represent a so-called particle particle model, is applied to the calculation of particle dynamics in three-dimensional space. A longitudinal-transverse coupling motion is observed in the multi-particle simulation result. (C) 2014 Elsevier Ltd. All rights reserved.	[Kikuchi, Takashi; Takahashi, Kazumasa; Sasaki, Toru; Aso, Tsukasa; Harada, Nob] Nagaoka Univ Technol, Nagaoka, Niigata 9402188, Japan; [Horioka, Kazuhiko] Tokyo Inst Technol, Yokohama, Kanagawa 2268502, Japan	Kikuchi, T (reprint author), Nagaoka Univ Technol, Kamitomioka 1603-1, Nagaoka, Niigata 9402188, Japan.	tkikuchi@vos.nagaokaut.ac.jp			JSPS [24360105]	This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (B) Grant Number 24360105.	Barnard JJ, 1998, NUCL INSTRUM METH A, V415, P218, DOI 10.1016/S0168-9002(98)00387-8; Nagy S, 2008, LECT NOTES PHYS, V749, P119, DOI 10.1007/978-3-540-77817-2_5; de Hoon MJL, 2003, PHYS PLASMAS, V10, P855, DOI 10.1063/1.1541015; Friedman A, 2009, NUCL INSTRUM METH A, V606, P6, DOI 10.1016/j.nima.2009.03.189; Ho D. D.-M., 1991, Particle Accelerators, V35; Hockney R. W., 1988, COMPUTER SIMULATION; Horioka K, 1998, NUCL INSTRUM METH A, V415, P291, DOI 10.1016/S0168-9002(98)00397-0; Horioka K, 2009, NUCL INSTRUM METH A, V606, P1, DOI 10.1016/j.nima.2009.03.227; Kikuchi T, 2013, EPJ WEB CONF, V59, DOI 10.1051/epjconf/20135909004; Kikuchi T, 2009, NUCL INSTRUM METH A, V606, P31, DOI 10.1016/j.nima.2009.03.181; KIM CH, 1986, AIP C P, V152, P264; Lee EP, 2002, LASER PART BEAMS, V20, P581, DOI 10.1017/S0263034602204152; Lund S. M., 1999, P 1999 PART ACC C NE, V3, P1785, DOI 10.1109/PAC.1999.794259; Lund SM, 2009, PHYS REV SPEC TOP-AC, V12, DOI 10.1103/PhysRevSTAB.12.114801; Nakayama A, 2013, EPJ WEB CONF, V59, DOI 10.1051/epjconf/20135909005; Park Y., 2013, NIFS P, V93, P84; Qin H., 2004, PHYS REV SPEC TOP-AC, VST-AB 5; Sakai Y, 2014, NUCL INSTRUM METH A, V733, P70, DOI 10.1016/j.nima.2013.05.092; Sharp WM, 2005, NUCL INSTRUM METH A, V544, P398, DOI 10.1016/j.nima.2005.01.268; Takayama K, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.054801	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						126	129		10.1016/j.pnucene.2014.07.023		4	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100024		
J	Ohno, Y; Nezu, A; Matsuura, H; Akatsuka, H				Ohno, Yuki; Nezu, Atsushi; Matsuura, Haruaki; Akatsuka, Hiroshi			Spectroscopic study of recombination continuum in arc-heated cold expanding plasma jet	PROGRESS IN NUCLEAR ENERGY			English	Article						Recombination continuum; Cold recombining H-2-He or He plasma; Optical emission spectroscopic measurement; Electron temperature and density	STATIONARY-POPULATION INVERSION; HELIUM PLASMA	Cold recombining H-2 He mixture plasma and pure He plasma with low electron density are generated by arc discharge followed by expansion into a lower-pressure vessel, and their recombination radiation is analyzed by optical emission spectroscopic measurement. Their electron temperature is determined from the continuum spectra, which is found to agree with those determined from the line intensities of LTE levels within 10% accuracy. Meanwhile, the agreement of electron density is found to be about 20-25%. It is experimentally found that the conventional theory of spectral intensity of the recombination continuum explains the observed continuum spectra very well even for very low electron temperature within the range from 0.07 to 0.2 eV. (C) 2014 Elsevier Ltd. All rights reserved.	[Ohno, Yuki; Akatsuka, Hiroshi] Tokyo Inst Technol, Dept Nucl Engn, Meguro Ku, Tokyo 1528550, Japan; [Nezu, Atsushi] Tokyo Inst Technol, Tech Dept, Meguro Ku, Tokyo 1528550, Japan; [Nezu, Atsushi; Matsuura, Haruaki; Akatsuka, Hiroshi] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Akatsuka, H (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1-N1-10 O Okayama, Tokyo 1528550, Japan.	hakatsuk@nr.titech.ac.jp	Akatsuka, Hiroshi/G-3776-2014	Akatsuka, Hiroshi/0000-0002-3567-3833			AKATSUKA H, 1994, CONTRIB PLASM PHYS, V34, P539, DOI 10.1002/ctpp.2150340403; AKATSUKA H, 1995, PLASMA SOURCES SCI T, V4, P125, DOI 10.1088/0963-0252/4/1/013; AKATSUKA H, 1993, REV SCI INSTRUM, V64, P1734, DOI 10.1063/1.1144001; AKATSUKA H, 1994, PHYS REV E, V49, P1534, DOI 10.1103/PhysRevE.49.1534; Nishihara K, 2008, PHYS PLASMAS, V15, DOI 10.1063/1.2907154; COX DP, 1969, ASTROPHYS J, V157, P1157, DOI 10.1086/150144; STANGEBY PC, 1990, NUCL FUSION, V30, P1225, DOI 10.1088/0029-5515/30/7/005; OSULLIVAN G, 1981, J OPT SOC AM, V71, P227, DOI 10.1364/JOSA.71.000227; Bakshi V., 2005, EUV SOURCES LITHOGRA; BRAITHWAITE NS, 1990, PURE APPL CHEM, V62, P1721, DOI 10.1351/pac199062091721; COOPER J, 1966, REP PROG PHYS, V29, P35, DOI 10.1088/0034-4885/29/1/302; Fujimoto T. J., 2004, PLASMA SPECTROSCOPY; Hatayama A., 2004, J PLASMA FUSION RES, V80, P205, DOI 10.1585/jspf.80.205; ITER Physics Basis, 1999, ITER PHYS BASIS, V39, P2391; Kato T., 1990, PURAZUMA SHINDAN KIS; Krasheninnikov SI, 1996, PHYS LETT A, V214, P285, DOI 10.1016/0375-9601(96)00185-5; Kunze HJ, 2009, SPRINGER SER ATOM OP, V56, P1, DOI 10.1007/978-3-642-02233-3; Kuwahara Y., 2007, PLASMA FUSION RES, V2, pS1081, DOI 10.1585/pfr.2.S1081; Mizuochi J, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.036001; Murakami K., 2003, J PLASMA FUSION RES, V79, P1035, DOI 10.1585/jspf.79.1035; Ohno N., 2004, J PLASMA FUSION RES, V80, P212, DOI 10.1585/jspf.80.212; SARMIENTO A, 1985, REV MEX ASTRON ASTR, V11, P61; Sasaki A., 2011, PURAZUMA GENSHI BUNS, P319; Scotti F., 2007, PLASMA FUSION RES, V2, pS1110, DOI 10.1585/pfr.2.S1110; Shikama T., 2003, J PLASMA FUSION RES, V79, P841, DOI 10.1585/jspf.79.841; Stangeby P., 2000, PLASMA BOUNDARY MAGN; Sugioka K., 2003, J PLASMA FUSION RES, V79, P1278, DOI 10.1585/jspf.79.1278; Uesugi Y., 1993, J PLASMA FUSION RES, V69, P1163; Wiese W.L., 1996, ATOMIC MOL OPTICAL P; Pigarov AY, 1996, PHYS LETT A, V222, P251, DOI 10.1016/0375-9601(96)00629-9	30	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						130	135		10.1016/j.pnucene.2014.07.019		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100025		
J	Furukawa, T; Rouillard, F				Furukawa, Tomohiro; Rouillard, Fabien			Oxidation and carburizing of FBR structural materials in carbon dioxide	PROGRESS IN NUCLEAR ENERGY			English	Article						Fast reactor; Supercritical carbon dioxide; Corrosion; Structural materials; CO2 turbine cycle	CORROSION; ALLOYS	A key problem in the application of a supercritical CO2 turbine cycle to a fast breeder reactor is the corrosion of structural materials brought about by supercritical CO2 at high temperatures. In this study, metallurgical analysis of the ferritic-martensitic steels (12Cr-steel and T91) exposed at 400-600 degrees C for up to 8000 h in supercritical CO2 pressurized at 20 MPa and at 550 degrees C for up to 5000 h in CO2 gas at atmospheric pressure has been carried out. Two successive oxide layers formed on the steels were kept under the maximum testing conditions (at 600 degrees C for 8000 h at 20 MPa), and no breakaway corrosion was observed. Each oxide layer thickness increased with exposure time, due to parabolic oxide growth. By using the electron backscattering diffraction technique, the outer oxide layer could be separable into thin Fe2O3 and thick Fe3O4, and the formation behavior was clarified. Carburizing was observed in the base metal just under the oxide layer, and the crystal structure was mainly M23C6. (C) 2014 Elsevier Ltd. All rights reserved.	[Furukawa, Tomohiro] Japan Atom Energy Agcy, Oarai, Ibaraki 3111393, Japan; [Rouillard, Fabien] CEA, Commissariat Energie Atom & Energies Alternat, Paris, France	Furukawa, T (reprint author), Japan Atom Energy Agcy, O Arai Res & Dev Ctr, 4002 Narita, Oarai, Ibaraki 3111393, Japan.	furukawa.tomohiro@jaea.go.jp					Firouzdor V, 2013, CORROS SCI, V69, P281, DOI 10.1016/j.corsci.2012.11.041; Tan L, 2011, CORROS SCI, V53, P3273, DOI 10.1016/j.corsci.2011.06.002; Rouillard F, 2012, OXID MET, V77, P27, DOI 10.1007/s11085-011-9271-5; Rouillard F, 2012, OXID MET, V77, P71, DOI 10.1007/s11085-011-9273-3; Cao G, 2012, CORROS SCI, V60, P246, DOI 10.1016/j.corsci.2012.03.029; Aoto K., 2003, P GLOBAL 2003 NEW OR, P2113; Furukawa T., 2011, PROG NUCL ENERG, V53, P1053; Furukawa T., 2007, 2 TOK TECH MIT S INN, p[17, 43]; Furukawa Tomohiro, 2010, Journal of Power and Energy Systems, V4, DOI 10.1299/jpes.4.252; Jones R.B., 1985, P NUCL FUEL PERFORMA, P41; Nakanishi T., 1975, Journal of the Japan Institute of Metals, V39; Nakanishi T., 1974, J FAPIG, V74, P14; Newcob S.B., 1986, J OXIDATION METALS, V26, P431; Pritchard A.M., 1974, P BNES INT C CORR ST, P234; Taylor J.W., 1974, P BNES INT C CORR ST, P180	15	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						136	141		10.1016/j.pnucene.2014.07.038		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100026		
J	Rueanngoen, A; Imai, M; Yoshida, K; Yano, T				Rueanngoen, Areerak; Imai, Masamitsu; Yoshida, Katsumi; Yano, Toyohiko			Microstructure of low-dose neutron-irradiated Si3N4 and SiAlON ceramics after thermal annealing	PROGRESS IN NUCLEAR ENERGY			English	Article						Neutron irradiation; Thermal annealing; Silicon nitride; SiAlON; Microstructure	BETA-SI3N4; RADIATION; DEFECTS	Four kinds of silicon nitride-related ceramics were neutron irradiated up to 8.5 x 10(24) n/m(2) (E> 0.1 MeV) at 563 K. Induced swelling were almost recovered by thermal annealing up to 1473 K. Microstructure of the as-irradiated silicon nitride-based ceramics and those of after thermal annealing up to 1123, 1223 and 1473 K were observed with a high-resolution transmission electron microscope (HREM) in order to clarify their feature and thermal stability. HREM microstructures of the as-irradiated specimens revealed that the atomic configuration projected onto the basal plane was similar as a perfect crystalline arrangement without lattice distortion. It was confirmed that only point defects or point-like defects were generated during the neutron irradiation of the present condition. In addition, microstructure analysis of thermally annealed specimens did not reveal any voids along grain boundaries and triple junctions. Furthermore, formations of dislocation loops were not confirmed after thermal annealing up to 1473 K, in all Si3N4 and SiAION polymorphs. (C) 2014 Elsevier Ltd. All rights reserved.	[Rueanngoen, Areerak] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Nucl Engn, Meguro Ku, Tokyo 1528550, Japan; [Imai, Masamitsu; Yoshida, Katsumi; Yano, Toyohiko] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Rueanngoen, A (reprint author), Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Nucl Engn, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528550, Japan.	areerak_k@yahoo.com			Japan Society for the Promotion of Science	The study was partly supported by the Grant-in-Aids for Scientific Research from the Japan Society for the Promotion of Science. The irradiation experiment was kindly supported by the staff of the International Research Center for Nuclear Materials Science, Institute for Materials Research, Tohoku University.	Akiyoshi M, 2001, PHILOS MAG A, V81, P683; Akiyoshi M, 2004, J NUCL MATER, V329, P1466, DOI 10.1016/j.jnucmat.2004.04.251; Akiyoshi M, 2001, PHIL MAG LETT, V81, P251, DOI 10.1080/09500830010024657; Snead LL, 2005, J NUCL MATER, V340, P187, DOI 10.1016/j.jnucmat.2004.11.009; Yano T, 2001, J NUCL MATER, V289, P102, DOI 10.1016/S0022-3115(00)00688-7; Sawabe T, 2009, J NUCL MATER, V386-88, P333, DOI 10.1016/j.jnucmat.2008.12.322; Chinard Jr F.W., 1979, J NUCL MATER, V85-86, P393; Chinard Jr F.W., 1987, CERAM INT, V13, P69; Chinard Jr F.W., 1983, RES MECH, V8, P207; Chinard Jr F.W., 1984, J MAT ENERGY SYS, V6, P100; Hazelton C, 1998, J NUCL MATER, V253, P190, DOI 10.1016/S0022-3115(97)00333-4; JENKINS ML, 1994, J NUCL MATER, V216, P124, DOI 10.1016/0022-3115(94)90010-8; Rueanngoen A, 2013, J NUCL MATER, V442, pS394, DOI 10.1016/j.jnucmat.2013.01.336; Rueanngoen A, 2013, J NUCL MATER, V437, P235, DOI 10.1016/j.jnucmat.2013.02.023; Rueanngoen A, 2014, J NUCL MATER, V455, P464, DOI 10.1016/j.jnucmat.2014.07.066; YANO T, 1993, J NUCL MATER, V203, P249, DOI 10.1016/0022-3115(93)90381-8; Yano T, 2011, J NUCL MATER, V417, P972, DOI 10.1016/j.jnucmat.2010.12.190; YOUNGMAN RA, 1983, RADIAT EFF DEFECT S, V74, P267, DOI 10.1080/00337578308218420	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						142	147		10.1016/j.pnucene.2014.07.035		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100027		
J	Yoshida, K; Akimoto, H; Yano, T; Kotani, M; Ogasawara, T				Yoshida, Katsumi; Akimoto, Hiroyuki; Yano, Toyohiko; Kotani, Masaki; Ogasawara, Toshio			Mechanical properties of unidirectional and crossply SiCf/SiC composites using SiC fibers with carbon interphase formed by electrophoretic deposition process	PROGRESS IN NUCLEAR ENERGY			English	Article						SiCf/SiC composite; Components for fusion and fission reactors; Electrophoretic deposition process; Carbon interphase; Mechanical properties; Fiber orientation	SILICON-CARBIDE COMPOSITE; POWER-REACTOR BLANKETS; SIC/SIC COMPOSITES; MATRIX COMPOSITES; STRUCTURAL MATERIAL; GAS-TURBINE; CERAMICS; MICROSTRUCTURE; FABRICATION; DESIGN	Unidirectional (UD) and crossply (CP) SiCf/SiC composites with different fiber volume fraction were fabricated based on EPD and sheet stacking process, and their mechanical properties were evaluated at room temperature. The UD-SiCf/SiC composites showed a pseudo-ductile fracture behavior in bending test. Bending strength and fracture energy of the UD-SiCf/SiC composites with high V-f (66%) was higher than those of the UD-SiCf/SiC composites with low V-f (47%). Although the CP-SiCf/SiC composites also fractured in a non-brittle manner, their bending strength and fracture energy were much lower than the UD-SiCf/SiC composites because the SIC fibers aligned in 90 direction did not work for toughening and strengthening the SiCf/SiC composites. In the UD-SiCf/SiC composites, fiber pullout was clearly observed, and the number of fiber pullout in the UD-SiCf/SiC composites with high V-f was large rather than the UD-SiCf/SiC composites with low V-f. On the other hand, fiber pullout did not appear in the CP-SiCf/SiC composites with low V-f whereas large number of fiber pullout was observed in the CP-SiCf/SiC composites with high V-f. This can be explained by the thickness of the SiC matrix-layers between SiC fiberlayers. (C) 2014 Elsevier Ltd. All rights reserved.	[Yoshida, Katsumi; Yano, Toyohiko] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Akimoto, Hiroyuki] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Nucl Engn, Meguro Ku, Tokyo 1528550, Japan; [Kotani, Masaki; Ogasawara, Toshio] Japan Aerosp Explorat Agcy JAXA, Aerosp Res & Dev Directorate, Adv Composite Res Ctr, Mitaka, Tokyo 1810015, Japan	Yoshida, K (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528550, Japan.	k-yoshida@nr.titech.ac.jp	Ogasawara, Toshio/O-1238-2014	Ogasawara, Toshio/0000-0003-1074-0427			Naslain RR, 2005, INT J APPL CERAM TEC, V2, P75, DOI 10.1111/j.1744-7402.2005.02009.x; Yoshida K, 2009, J NUCL MATER, V386-88, P643, DOI 10.1016/j.jnucmat.2008.12.314; Sarkar P, 1996, J AM CERAM SOC, V79, P1987, DOI 10.1111/j.1151-2916.1996.tb08929.x; Yoshida K, 2009, MATER SCI ENG B-ADV, V161, P188, DOI 10.1016/j.mseb.2008.11.032; Deck CP, 2012, PROG NUCL ENERG, V57, P38, DOI 10.1016/j.pnucene.2011.10.002; Hallstadius L, 2012, PROG NUCL ENERG, V57, P71, DOI 10.1016/j.pnucene.2011.10.008; Boccaccini AR, 2002, CURR OPIN SOLID ST M, V6, P251, DOI 10.1016/S1359-0286(02)00080-3; Beesley CP, 1997, KEY ENG MATER, V127-3, P165; Christin F, 2002, ADV ENG MATER, V4, P903, DOI 10.1002/adem.200290001; Giancarli L, 2000, FUSION ENG DES, V48, P509, DOI 10.1016/S0920-3796(00)00150-2; Giancarli L, 1998, FUSION ENG DES, V41, P165, DOI 10.1016/S0920-3796(97)00200-7; Jones RH, 2003, CERAM ENG SCI PROC, V24, P261; Kagawa Y., 1998, CERAM T, V99, P179; Kaya H, 1999, COMPOS SCI TECHNOL, V59, P861, DOI 10.1016/S0266-3538(99)00016-0; KERANS RJ, 1989, AM CERAM SOC BULL, V68, P429; Naslain R., 1993, COMPOSITES INTERFACE, V1, P253; Ogasawara T., 2004, J PLASMA FUSION RES, V80, P36, DOI 10.1585/jspf.80.36; Sharafat S., 1991, FUSION TECHNOL, V19, P901; Tabellion J, 2004, J MATER SCI, V39, P803, DOI 10.1023/B:JMSC.0000012907.52051.fb; Ueda S, 1998, J NUCL MATER, V258, P1589, DOI 10.1016/S0022-3115(98)00294-3; Yano T., 2003, FRACT COMPLEXITY, V1, P157; Yoshida K, 2010, J CERAM SOC JPN, V118, P82, DOI 10.2109/jcersj2.118.82; Yoshida K, 1998, J NUCL MATER, V258, P1960, DOI 10.1016/S0022-3115(98)00128-7; Yoshida K, 2007, KEY ENG MAT, V352, P77; Yoshida K, 2012, COMPOS SCI TECHNOL, V72, P1665, DOI 10.1016/j.compscitech.2012.07.004	25	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						148	152		10.1016/j.pnucene.2014.07.027		5	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100028		
J	Myagmarjav, O; Ryu, J; Kato, Y				Myagmarjav, Odtsetseg; Ryu, Junichi; Kato, Yukitaka			Dehydration kinetic study of a chemical heat storage material with lithium bromide for a magnesium oxide/water chemical heat pump	PROGRESS IN NUCLEAR ENERGY			English	Article						Thermal energy storage; Chemical heat pump; Lithium bromide	DECOMPOSITION; HYDRATION; BRUCITE	The reaction performance of a novel chemical heat storage composite as thermal energy storage medium were evaluated for use in a magnesium oxide/water chemical heat pump. The composite, called EML, is composed of pure Mg(OH)(2) powder and support materials, including LiBr and expanded graphite to improve reactivity and heat transfer, respectively. The heat storage and heat output capacities of the EML composites were evaluated based on laboratory experiments of dehydration and hydration processes for various molar mixing ratios a of LiBr to Mg(OH)(2) using the thermogravimetric method. The heat storage and heat output capacity of the EML composites increased with increasing a. The EML composite with alpha = 0.100 was estimated to be able to store 1.3 times the heat stored in pure Mg(OH)(2) powder after 30 min. Based on these evaluations, the EML composites exhibited sufficient heat storage, heat output capacity, and good mold-ability for practical use in a heat exchange reactor. The EML composite was accordingly confirmed as a candidate material for use in chemical heat pumps. Thus, potential use of the EML composite in a magnesium oxide/water chemical heat pump coupled with a small nuclear reactor for district heating systems was evaluated based on the experimental results. (C) 2014 Elsevier Ltd. All rights reserved.	[Myagmarjav, Odtsetseg; Kato, Yukitaka] Tokyo Inst Technol, Dept Nucl Engn, Meguro Ku, Tokyo 1528550, Japan; [Ryu, Junichi] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Kato, Y (reprint author), Tokyo Inst Technol, Dept Nucl Engn, Meguro Ku, 2-12-1-N1-22 Ookayama, Tokyo 1528550, Japan.	yukitaka@nr.titech.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [24360404]; COURSE 50 project of the New Energy and Industrial Technology Development Organization (NEDO), Japan	This study received financial support from a Grant-in-Aid for Scientific Research (B) #24360404 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan and from the COURSE 50 project of the New Energy and Industrial Technology Development Organization (NEDO), Japan. The authors greatly appreciate this support.	GORDON RS, 1967, J AM CERAM SOC, V50, P8, DOI 10.1111/j.1151-2916.1967.tb14962.x; Gil A, 2010, RENEW SUST ENERG REV, V14, P31, DOI 10.1016/j.rser.2009.07.035; Olives R, 2001, TRANSPORT POROUS MED, V43, P377, DOI 10.1023/A:1010780623891; Kato Y, 1996, APPL THERM ENG, V16, P853, DOI 10.1016/1359-4311(96)00009-9; Myagmarjav O, 2014, APPL THERM ENG, V63, P170, DOI 10.1016/j.applthermaleng.2013.10.045; Denholm P, 2012, ENERG POLICY, V44, P301, DOI 10.1016/j.enpol.2012.01.055; Fujioka K, 2008, APPL THERM ENG, V28, P304, DOI 10.1016/j.applthermaleng.2006.02.032; Dotzauer E, 2002, APPL ENERG, V73, P277, DOI 10.1016/S0306-2619(02)00078-8; HANCOCK JD, 1972, J AM CERAM SOC, V55, P74, DOI 10.1111/j.1151-2916.1972.tb11213.x; Dincer I., 2002, THERMAL ENERGY STORA; Forsberg C. W., 2008, PROGR NUCL ENERGY, V51, P1; Ishitobi H., 2011, APPL THERM ENG, V50, P1639; Ishitobi H., 2013, THESIS TOKYO I TECHN; Kim S. T., 2012, THESIS TOKYO I TECHN; Myagmarjav O, 2014, J CHEM ENG JPN, V47, P595, DOI 10.1252/jcej.13we301; Zamengo M, 2013, APPL THERM ENG, V61, P853, DOI 10.1016/j.applthermaleng.2013.04.045	16	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						153	158		10.1016/j.pnucene.2014.07.026		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100029		
J	Sawabe, T; Sonoda, T; Kitajima, S				Sawabe, T.; Sonoda, T.; Kitajima, S.			Analysis method of matrix and second phase particles in Zircaloy-2 by atom probe tomography	PROGRESS IN NUCLEAR ENERGY			English	Article						Zirconium alloy; Zircaloy-2; Second phase particle; Corrosion resistance; Atom probe tomography		Properties of second-phase particles (SPPs) influence the corrosion resistance and the anti-hydrogen pickup in Zircaloy-2 claddings. The chemical compositions of Zr(Fe,Cr)(2) and Zr-2(Fe,Ni) SPPs were investigated by means of pulsed laser atom probe tomography. In order to identify the atomic concentration with accuracy, two approaches were applied to the Zr-matrix and the SPPs: the first by using all the visible peaks of the mass spectrum and the second using the representative peaks with the natural abundance of the corresponding isotopes. It was found that the background and tail effects are minimized by the first approach in case of estimating a single phase. The change in the concentration between the Zr-matrix and the SPPs can be estimated more accurately by the second approach, although Sn concentration in the Zr-2(Fe,Ni) SPPs is slightly overestimated. (C) 2014 Elsevier Ltd. All rights reserved.	[Sawabe, T.; Sonoda, T.; Kitajima, S.] CRIEPI, Komae, Tokyo 2018511, Japan	Sawabe, T (reprint author), CRIEPI, Iwado Kita 2-11-1, Komae, Tokyo 2018511, Japan.	sawabe@criepi.denken.or.jp					Miller MK, 2009, MATER CHARACT, V60, P461, DOI 10.1016/j.matchar.2009.02.007; Sawabe T, 2013, J NUCL MATER, V442, P168, DOI 10.1016/j.jnucmat.2013.08.048; GARZAROLLI F, 1994, AM SOC TEST MATER, V1245, P709, DOI 10.1520/STP15216S; Kakiuchi K., 2004, STP ASTM, P349; Lemaignan C, 2012, COMPREHENSIVE NUCLEAR MATERIALS, VOL 2: MATERIAL PROPERTIES/OXIDE FUELS FOR LIGHT WATER REACTORS AND FAST NEUTRON REACTORS, P217; McNaught A. D., 2006, IUPAC COMPENDIUM CHE, DOI DOI 10.1351/GOLDBOOK; MENG XY, 1989, J NUCL MATER, V168, P125, DOI 10.1016/0022-3115(89)90573-4; OSTBERG G, 1962, J NUCL MATER, V7, P103, DOI 10.1016/0022-3115(62)90200-3; Sabol G. P., 2006, STP ASTM, P2; Sell H. J., 2006, STP ASTM, P404; Sonoda T., 2011, MICROSTRUCTURE OBSER; Une K., 2011, STP ASTM, P401	12	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						159	164		10.1016/j.pnucene.2014.07.012		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100030		
J	Duong, TT; Tanaka, H; Tsuzuki, N; Kawai, H; Kikura, H				Thanh Tung Duong; Tanaka, Hiromasa; Tsuzuki, Nobuyoshi; Kawai, Hideki; Kikura, Hiroshige			Effect of cooling temperature of electrodes on Joule-heating flow in cubic cavity	PROGRESS IN NUCLEAR ENERGY			English	Article						Joule heating; Chaotic flow; UVP; PIV; Boundary condition	CONVECTION	The effect of cooling condition of electrode plates on chaotic Joule-heating flow behavior in a cubic cavity has been experimentally investigated. Two electrode plates are immersed in the fluid body and placed on the opposing side wall. They are connected to an AC power source for internal volumetric 'Joule-heating' in the cavity. This chaotic flow which induced by Joule heating is observed within whole the cavity. The chaotic flow is investigated quantitatively by Ultrasonic Velocity Profiling (UVP) method. The chaotic flow behavior is also observed by using Particle Image Velocimetry (PIV) method to understand the effect of temperature distribution in this condition. The chaotic flow behavior generates fluctuations of temperature and velocity. As a result, cooling condition of electrode plates has a strong effect on the Jouleheating flow behavior that the vortex area occurred in the upper part of cavity. On the other hand, in the adiabatic condition, unstable flow appeared in whole cavity. In additional, velocity profiles are analyzed by Fast Fourier Transform (FFT) method about the frequencies of fluctuations. Furthermore, a numerical analysis using Finite Element Method, GSMAC-FEM, is also examined the Joule-heating flow behavior for cubic cavity. (C) 2014 Elsevier Ltd. All rights reserved.	[Thanh Tung Duong; Tanaka, Hiromasa; Tsuzuki, Nobuyoshi; Kikura, Hiroshige] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Kawai, Hideki] Muroran Inst Technol, Dept Mech Engn, Muroran, Hokkaido 0508585, Japan	Duong, TT (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1,N1-7 O Okayama, Tokyo 1528550, Japan.	duongttung@us.nr.titech.ac.jp			Hitachi Nuclear Scholarship Program	One of the authors, T.T. Duong, is supported by Hitachi Nuclear Scholarship Program during this study. The authors would like to thank to Mr. F. Murata and Ms. M. Shimizu belonging to the Vietnam Nuclear Project Division for their assistance in this study.	TAKEDA Y, 1987, NUCL TECHNOL, V79, P120; [Anonymous], 1998, TN841098008 JNC JAEA; Cheng NS, 2008, IND ENG CHEM RES, V47, P3285, DOI 10.1021/ie071349z; Bathchelor G.K., 1959, J FLUID MECH, V5, P113; Benard H., 1901, Journal de Physique, V10, DOI 10.1051/jphystap:0190100100025400; Cristancho Diana M, 2011, Rev. colomb. cienc. quim. farm., V40, P92; Duong T.T., 2013, 8 INT C MULT FLOW 20; Jahn M., 1974, 5 INT HEAT TRANSF C, V3; Kawaguchi T., 2012, 6 INT S APPL LAS TEC; Kohno H, 2005, INT J COMPUT FLUID D, V19, P329, DOI 10.1080/10618560500032764; KULACKI FA, 1972, J FLUID MECH, V55, P271, DOI 10.1017/S0022112072001855; Steinberner U., 1978, 6 INT HEAT TRANSF C, V2, P305; TANAHASHI T, 1990, INT J NUMER METH FL, V11, P479, DOI 10.1002/fld.1650110503; Tsuzuki N., 2011, 48 NAT HEAT TRANSF S; Yanagisawa T., 2010, PHYS REV E, V82	15	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						165	175		10.1016/j.pnucene.2014.07.042		11	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100031		
J	Ihara, T; Tsuzuki, N; Kikura, H				Ihara, Tomonori; Tsuzuki, Nobuyoshi; Kikura, Hiroshige			Development of the ultrasonic buffer rod for the molten glass measurement	PROGRESS IN NUCLEAR ENERGY			English	Article						Buffer rod; Molten glass; Sound velocity; Attenuation coefficient	VELOCITY; WAVES	Design and demonstration of an ultrasonic buffer rod for high temperature fluid especially for the molten glass were studied. Material selection guide for glass melts was established focusing on high temperature strength, attenuation and acoustic impedance. Durability and wettability of ultrasonic buffer rod have been tested for several materials. Frequency of the ultrasound was chosen considering the transmission characteristic of the buffer rod which was investigated employing three dimensional FEM code. The buffer rod tested has tapered shape and cladding on the side wall as a further suppression of trailing echo. Sound velocity and attenuation coefficient measurements in a temperature range of 1000-1200 degrees C were then demonstrated utilizing the designed buffer rod. Signal processing technique to eliminate remained trailing echoes was also performed. Applicability of the ultrasonic measurement using the buffer rod is discussed. (C) 2014 Elsevier Ltd. All rights reserved.	[Ihara, Tomonori; Tsuzuki, Nobuyoshi; Kikura, Hiroshige] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan	Ihara, T (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1-N1-7 Ookayama, Tokyo 1528550, Japan.	ihara@us.nr.titech.ac.jp			Japan Nuclear Fuel Limited; Ministry of Economy, Trade and Industry	The authors greatly appreciate financial assistance from Grant-in-Aid for JSPS Fellows., and part of the research is supported by Japan Nuclear Fuel Limited with Grant-in-Aid by the Ministry of Economy, Trade and Industry.	SATHER A, 1968, J ACOUST SOC AM, V43, P1291, DOI 10.1121/1.1910982; TAKEDA Y, 1987, NUCL TECHNOL, V79, P120; Prasad VSK, 2008, J MATER PROCESS TECH, V207, P315, DOI 10.1016/j.jmatprotec.2008.06.049; Jen CK, 1997, ULTRASONICS, V35, P335, DOI 10.1016/S0041-624X(97)00015-2; Ihara T, 2013, FLOW MEAS INSTRUM, V34, P127, DOI 10.1016/j.flowmeasinst.2013.10.003; Puckett AD, 2005, ULTRASONICS, V43, P197, DOI 10.1016/j.ultras.2004.04.008; Breeuwer R., 2008, Patent No. [WO 20081018997, 20081018997]; Burthan D., 2005, MAT T, V46, P2107; Busby T. S., 1966, TANK BLOCKS GLASS FU; Davis J. R., 1998, METALS HDB DESK EDIT; Greenberg Y, 2008, J NON-CRYST SOLIDS, V354, P4094, DOI [10.1016/j.jnoncrysol.2008.05.038, 10.1016/j.jnoncryso1.2008.05.038]; Ihara T., 2011, P 19 INT C NUCL ENG; Ikegami Y., 2009, P 7 INT C NDE REL ST; Krautkramer J., 1990, ULTRASONIC TESTING M; Matsuno S., 2008, J POWER ENERGY SYST, V2, P447, DOI 10.1299/jpes.2.447; NAGATA K, 1987, METALL TRANS B, V18, P549, DOI 10.1007/BF02654267; Pezant J, 2009, AIP CONF PROC, V1096, P1627, DOI 10.1063/1.3114153; Scholze H., 1991, GLASS NATURE STRUCTU; Tsukada T., 2010, P 2010 FALL M AT EN, pB51; Yang K., 2012, PROC 20TH INT CONF N	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						176	183		10.1016/j.pnucene.2014.07.041		8	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100032		
J	Takahashi, M; Secareanu, R; Mihalache, M; Chapelat, A				Takahashi, Minoru; Secareanu, Radu; Mihalache, Mihail; Chapelat, Alexandre			Fundamental study on heavy metal freezing behavior for stop of water leakage from LWR containment vessel	PROGRESS IN NUCLEAR ENERGY			English	Article						Freezing; Light water reactor; Heavy metal; Lead alloy; Sealing; Leakage		For the application of heavy metal technology to the stop of water leakage from LWR containment vessel, the freezing behavior of molten heavy metal on a metal plate in water and air environments was investigated. Wood's metal (Pb-Bi-Sn-Cd alloy) and gallium were used as a candidate sealing metal and simulant one, respectively, while brass and stainless steel plates were used as a water-leaking structure. The freezing feature is better in cases of the heavy metal discharged to a water-cooled metal plate with higher thermal conductivity at lower heavy metal temperature in a water atmosphere rather than an air atmosphere. An one-dimensional unsteady heat conduction and freezing model could predict the freezing temperature well, which suggested the capability of simulation of practical freezing phenomena of liquid metal for stop of water leakage with the extention of this model. The present result is useful to develop an equipment for stopping the water leakage in a water environment using heavy metal freezing. (C) 2014 Elsevier Ltd. All rights reserved.	[Takahashi, Minoru; Chapelat, Alexandre] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Secareanu, Radu; Mihalache, Mihail] Univ Politehn Bucuresti, Power Energy Fac, RO-060042 Bucharest, Romania	Takahashi, M (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1-N1-18 Ookayama, Tokyo 1528550, Japan.	mtakahas@nr.titech.ac.jp					Rahman MM, 2007, EXP THERM FLUID SCI, V32, P198, DOI 10.1016/j.expthermflusci.2006.11.009; Rahman MM, 2008, NUCL ENG DES, V238, P2706, DOI 10.1016/j.nucengdes.2008.04.008	2	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						184	190		10.1016/j.pnucene.2014.07.029		7	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100033		
J	Liem, PH; Tran, HN; Sembiring, TM				Liem, Peng Hong; Hoai Nam Tran; Sembiring, Tagor Malem			Design optimization of a new homogeneous reactor for medical radioisotope Mo-99/Tc-99m production	PROGRESS IN NUCLEAR ENERGY			English	Article						Homogeneous reactor; Mo-99/Tc-99 medical radioisotope; Design optimization; Mo-99 extraction; Cintichem process		To partly solve the global and regional shortages of Mo-99/Tc-99m supply, a conceptual design of a homogeneous solution reactor for Mo-99/Tc-99m medical radioisotope production is proposed. Some basic characteristics and features of the design are discussed. The new homogeneous solution reactor is designed by taking into account the matured technology for chemically extracting the Mo-99 from the low enriched uranium (LEU) targets (the modified LEU Cintichem process) that has been acquired, demonstrated and licensed commercially for decades by the Center for Radioisotope Production of the National Nuclear Energy Agency of Indonesia (BATAN). Design optimization for obtaining the minimum critical U-235 mass and the maximum reactor power (proportional to Mo-99 production capacity) is presented. (C) 2014 Elsevier Ltd. All rights reserved.	[Liem, Peng Hong] Nippon Adv Informat Serv NAIS Co Inc, Sci Computat Div, Tokai, Ibaraki 3191112, Japan; [Hoai Nam Tran] Duy Tan Univ, Inst Res & Dev, Da Nang, Vietnam; [Sembiring, Tagor Malem] Natl Nucl Energy Agcy BATAN, Ctr Reactor Technol & Nucl Safety, Tangerang Selatan 15310, Banten, Indonesia	Liem, PH (reprint author), Nippon Adv Informat Serv NAIS Co Inc, Sci Computat Div, 416 Muramatsu, Tokai, Ibaraki 3191112, Japan.	liemph@nais.ne.jp					Aliludin Z., 1994, PROCESSING LEU TARGE; Shibata K, 2002, J NUCL SCI TECHNOL, V39, P1125, DOI 10.3327/jnst.39.1125; Batan, 1987, MPR 30 SAF AN REP RE; Glenn D, 1997, NUCL TECHNOL, V118, P142; IAEA, 2008, IAEATECDOC1601; IAEA, 1999, IAEATECDOC1065, P25; Liem P. H., 1998, NUCL ENG DES, V180, P207; Liem P.H., 2013, P 4 INT C ADV NUCL S; Liem P.H., 1996, AT INDONES, V22; Liem P.H., 2013, NUCL ENG DES, V262, P52; Ludwig S., 2002, CCC037117 OAK RIDG N; Nagaya Y., 2005, MVP GMVP 2 GEN PURP, P1348; OECD/NEA, 2011, SUPPL MED RAD PATH R; OECD/NEA, 2010, SUPPL MED RAD REV PO; Okumura K., 2007, SRAC2006 COMP NEUTRO; Parma E., 2009, SUPPL MED RAD TC 99M	16	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	JUL	2015	82						191	196		10.1016/j.pnucene.2014.07.040		6	Nuclear Science & Technology	Nuclear Science & Technology	CM6YH	WOS:000357837100034		
J	Munemasa, Y; Kitaoka, Y				Munemasa, Yasunari; Kitaoka, Yasushi			Autophagy in axonal degeneration in glaucomatous optic neuropathy	PROGRESS IN RETINAL AND EYE RESEARCH			English	Article						Autophagy; Optic nerve; Glaucoma; Senescence	RETINAL GANGLION-CELLS; OPEN-ANGLE GLAUCOMA; NICOTINAMIDE ADENINE-DINUCLEOTIDE; NECROSIS-FACTOR-ALPHA; TRABECULAR MESHWORK CELLS; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; NERVE HEAD; TNF-ALPHA; IN-VIVO	The role of autophagy in retinal ganglion cell (RGC) death is still controversial. Several studies focused on RGC body death, although the axonal degeneration pathway in the optic nerve has not been well documented in spite of evidence that the mechanisms of degeneration of neuronal cell bodies and their axons differ. Axonal degeneration of RGCs is a hallmark of glaucoma, and a pattern of localized retinal nerve fiber layer defects in glaucoma patients indicates that axonal degeneration may precede RGC body death in this condition. As models of preceding axonal degeneration, both the tumor necrosis factor (TNF) injection model and hypertensive glaucoma model may be useful in understanding the mechanism of axonal degeneration of RGCs, and the concept of axonal protection can be an attractive approach to the prevention of neurodegenerative optic nerve disease. Since mitochondria play crucial roles in glaucomatous optic neuropathy and can themselves serve as a part of the autophagosome, it seems that mitochondrial function may alter autophagy machinery. Like other neurodegenerative diseases, optic nerve degeneration may exhibit autophagic flux impairment resulting from elevated intraocular pressure, TNF, traumatic injury, ischemia, oxidative stress, and aging. As a model of aging, we used senescence-accelerated mice to provide new insights. In this review, we attempt to describe the relationship between autophagy and recently reported noteworthy factors including Nmnat, ROCK, and SIRT1 in the degeneration of RGCs and their axons and propose possible mechanisms of axonal protection via modulation of autophagy machinery. (C) 2015 The Authors. Published by Elsevier Ltd.	[Munemasa, Yasunari; Kitaoka, Yasushi] St Marianna Univ, Sch Med, Dept Ophthalmol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan; [Kitaoka, Yasushi] St Marianna Univ, Grad Sch Med, Dept Mol Neurosci, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan	Munemasa, Y (reprint author), St Marianna Univ, Sch Med, Dept Ophthalmol, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	munemasa@marianna-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [24592683, 23792016]; Suzuken Memorial Foundation; Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder	This work was supported by Grants-in-Aid No. 24592683 (YK) and No. 23792016 (YM) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Suzuken Memorial Foundation (YK) and by the Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder (YK).	Akieda-Asai S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011755; Alvarez A, 2007, NEUROBIOL AGING, V28, P533, DOI 10.1016/j.neurobiolaging.2006.02.012; Anekonda T. S., 2008, BMC RES NOTES, V1, P122; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131; Krishnamoorthy RR, 2013, INVEST OPHTH VIS SCI, V54, P5712, DOI 10.1167/iovs.13-12085; Kitaoka Y, 2009, J NEUROPATH EXP NEUR, V68, P915, DOI 10.1097/NEN.0b013e3181afecfa; Kim SH, 2013, MOL VIS, V19, P1667; Mortiboys H, 2008, ANN NEUROL, V64, P555, DOI 10.1002/ana.21492; Osborne NN, 2014, DRUG DISCOV TODAY, V19, P1613, DOI 10.1016/j.drudis.2014.05.010; Toth ML, 2008, AUTOPHAGY, V4, P330; Cepurna WO, 2005, EXP EYE RES, V80, P877, DOI 10.1016/j.exer.2004.12.021; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33; Lingor P, 2008, BRAIN, V131, P250, DOI 10.1093/brain/awm284; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499; Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013; Samuel MA, 2011, J NEUROSCI, V31, P16033, DOI 10.1523/JNEUROSCI.3580-11.2011; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101; Morrison JC, 2005, PROG RETIN EYE RES, V24, P217, DOI 10.1016/j.preteyeres.2004.08.003; Ju WK, 2009, INVEST OPHTH VIS SCI, V50, P707, DOI 10.1167/iovs.08-2499; Castillo K, 2013, AUTOPHAGY, V9, P1308, DOI 10.4161/auto.25188; Kawase K, 2008, BRIT J OPHTHALMOL, V92, P1175, DOI 10.1136/bjo.2007.128819; Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003; Kernt M, 2013, J GLAUCOMA, V22, P404, DOI 10.1097/IJG.0b013e31824caf90; Ahmed Z, 2009, MOL CELL NEUROSCI, V42, P128, DOI 10.1016/j.mcn.2009.06.005; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Koltai E, 2010, MECH AGEING DEV, V131, P21, DOI 10.1016/j.mad.2009.11.002; Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Ohta K, 2010, AUTOPHAGY, V6, P345; Neufeld AH, 2003, NEUROBIOL AGING, V24, P167, DOI 10.1016/S0197-4580(02)00059-3; Cohen DE, 2009, GENE DEV, V23, P2812, DOI 10.1101/gad.1839209; Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X; Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002; Yan XM, 2000, ARCH OPHTHALMOL-CHIC, V118, P666; Porter K, 2013, AUTOPHAGY, V9, P581, DOI 10.4161/auto.23568; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Morgan-Warren PJ, 2013, INVEST OPHTH VIS SCI, V54, P6903, DOI 10.1167/iovs.13-12803; Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009; Rasband MN, 2000, J PHYSIOL-LONDON, V525, P63, DOI 10.1111/j.1469-7793.2000.00063.x; Park HYL, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.26; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Chen D, 2008, EXP GERONTOL, V43, P1086, DOI 10.1016/j.exger.2008.08.050; Ma QY, 2011, EXP GERONTOL, V46, P533, DOI 10.1016/j.exger.2011.02.006; Campisi J, 2005, MECH AGEING DEV, V126, P51, DOI 10.1016/j.mad.2004.09.024; REPKA MX, 1989, OPHTHALMOLOGY, V96, P26; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002; Manning-Bog AB, 2007, NEUROBIOL DIS, V27, P141, DOI 10.1016/j.nbd.2007.03.014; Kitaoka Y, 2006, INVEST OPHTH VIS SCI, V47, P1448, DOI 10.1167/iovs.05-0299; Kojima K, 2012, INVEST OPHTH VIS SCI, V53, P7675, DOI 10.1167/iovs.12-10271; Jeong JK, 2013, NEUROBIOL AGING, V34, P146, DOI 10.1016/j.neurobiolaging.2012.04.002; Bonda DJ, 2011, LANCET NEUROL, V10, P275, DOI 10.1016/S1474-4422(11)70013-8; Yang Y, 2014, J ALZHEIMERS DIS, V40, P929, DOI 10.3233/JAD-132270; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009; Simonsen A, 2008, AUTOPHAGY, V4, P176; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Ban BK, 2013, MOL CELL BIOL, V33, P3907, DOI 10.1128/MCB.00627-13; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Gorenne I, 2013, CIRCULATION, V127, P386, DOI 10.1161/CIRCULATIONAHA.112.124404; Billington RA, 2008, AUTOPHAGY, V4, P385; TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102; Yang FY, 2014, BEHAV BRAIN RES, V264, P82, DOI 10.1016/j.bbr.2014.02.005; Press C, 2008, J NEUROSCI, V28, P4861, DOI 10.1523/JNEUROSCI.0525-08.2008; Mizushima Noboru, 2007, Autophagy, V3, P542; Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88; Marino G, 2010, J CLIN INVEST, V120, P2331, DOI 10.1172/JCI42601; Odagiri S, 2012, ACTA NEUROPATHOL, V124, P173, DOI 10.1007/s00401-012-0975-7; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167; Wolfs RCW, 2000, INVEST OPHTH VIS SCI, V41, P3309; Kitaoka Y, 2011, ENDOCRINOLOGY, V152, P2775, DOI 10.1210/en.2011-0046; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lipinski MM, 2010, P NATL ACAD SCI USA, V107, P14164, DOI 10.1073/pnas.1009485107; Rallis A, 2013, J CELL SCI, V126, P838, DOI 10.1242/jcs.117259; Li GR, 2010, INVEST OPHTH VIS SCI, V51, P2976, DOI 10.1167/iovs.09-4874; Zeng R, 2012, ANN HEMATOL, V91, P407, DOI 10.1007/s00277-011-1315-z; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Carloni S, 2010, AUTOPHAGY, V6, P366; Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Takeda T, 1997, EXP GERONTOL, V32, P117, DOI 10.1016/S0531-5565(96)00068-X; Islam MA, 2014, BIOMATERIALS, V35, P1584, DOI 10.1016/j.biomaterials.2013.11.010; Hwang JW, 2010, ARCH BIOCHEM BIOPHYS, V500, P203, DOI 10.1016/j.abb.2010.05.013; Kim SH, 2008, J NEUROSCI RES, V86, P2943, DOI 10.1002/jnr.21738; Wensor MD, 1998, OPHTHALMOLOGY, V105, P733, DOI 10.1016/S0161-6420(98)94031-3; Wirawan E, 2012, AUTOPHAGY, V8, P6, DOI 10.4161/auto.8.1.16645; Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152; Van Bergen NJ, 2009, INVEST OPHTH VIS SCI, V50, P4267, DOI 10.1167/iovs.09-3484; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Zeng R, 2012, ACTA PHARMACOL SIN, V33, P91, DOI 10.1038/aps.2011.143; Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641; Kimura S, 2009, METHOD ENZYMOL, V452, P1, DOI 10.1016/S0076-6879(08)03601-X; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Takeda T, 2009, NEUROCHEM RES, V34, P639, DOI 10.1007/s11064-009-9922-y; Kim CBY, 1996, NEUROBIOL AGING, V17, P431, DOI 10.1016/0197-4580(96)00038-3; Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787; Brace EJ, 2014, J NEUROSCI, V34, P8398, DOI 10.1523/JNEUROSCI.4715-13.2014; Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3; Wu Z, 2012, BLOOD, V119, P2422, DOI 10.1182/blood-2011-04-350413; Suzuki M, 2014, BBA-MOL BASIS DIS, V1842, P245, DOI 10.1016/j.bbadis.2013.11.023; Balaiya S, 2012, INVEST OPHTH VIS SCI, V53, P4315, DOI 10.1167/iovs.11-9259; Bros H, 2014, EXP NEUROL, V261, P127, DOI 10.1016/j.expneurol.2014.06.018; Calkins D.J., 2013, GAMESTIG OPHTHALMOL, V54, P37; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Cui Q, 2006, J PHARMACOL SCI, V101, P230, DOI 10.1254/jphs.FPJ06003X; Decuypere JP, 2011, J AGING RES, V2011, DOI DOI 10.4061/2011/920178; Deng SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077100; de Oliveira RM, 2010, CURR DRUG TARGETS, V11, P1270; Di Stefano M., 2014, CELL DEATH DIFFER; Ding DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079817; Feilchenfeld Z, 2008, EXP EYE RES, V87, P409, DOI 10.1016/j.exer.2008.07.011; Fields J, 2013, J NEUROVIROL, V19, P89, DOI 10.1007/s13365-012-0145-7; Fossel M, 2002, ANN NY ACAD SCI, V959, P14; Fujino H, 2009, ACTA NEUROPATHOL, V117, P75, DOI 10.1007/s00401-008-0440-9; Gilley J., 2010, PLOS ONE, V8; He LQ, 2013, ACTA PHARMACOL SIN, V34, P605, DOI 10.1038/aps.2012.188; Jain A., 2010, J BIOL CHEM, V285, P22576; Jiang XJ, 2012, OPHTHALMOLOGY, V119, P2245, DOI 10.1016/j.ophtha.2012.05.030; Joshi G., 2014, NEUROBIOL AGING, V36, P664; Kaneko S, 2006, J NEUROSCI, V26, P9794, DOI 10.1523/JNEUROSCI.2116-06.2006; Khan R. S., 2014, ACTA NEUROPATHOL COM, V2, P3; Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391; Koch JC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.191; Kojima K, 2014, NEUROSCI LETT, V581, P37, DOI 10.1016/j.neulet.2014.08.021; Labat-Robert J, 2000, Prog Mol Subcell Biol, V25, P57; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Lee M, 2011, BIOCHEM BIOPH RES CO, V413, P122, DOI 10.1016/j.bbrc.2011.08.067; Li T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028179; Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076; Milde S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001539; Munemasa Y, 2008, INVEST OPHTH VIS SCI, V49, P3535, DOI 10.1167/iovs.08-1716; Munemasa Y, 2010, J NEUROCHEM, V115, P1508, DOI 10.1111/j.1471-4159.2010.07057.x; Nilsson P., 2014, AM J PATHOL, V185, P305; Ozcelik S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062459; Paganelli R, 2002, EXP GERONTOL, V37, P257, DOI 10.1016/S0531-5565(01)00191-7; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514; Planchamp V, 2008, BRAIN, V131, P2606, DOI 10.1093/brain/awn196; Produit-Zengaffinen N, 2014, ADV EXP MED BIOL, V801, P677, DOI 10.1007/978-1-4614-3209-8_85; Pulliero A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098106; Ramirez AE, 2014, BBA-MOL BASIS DIS, V1842, P1495, DOI 10.1016/j.bbadis.2014.04.019; Robert L, 2000, BIOGERONTOLOGY, V1, P123, DOI 10.1023/A:1010048014925; Rodriguez-Navarro JA, 2010, NEUROBIOL DIS, V39, P423, DOI 10.1016/j.nbd.2010.05.014; Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29; Sagawa H, 2007, EXP NEUROL, V205, P230, DOI 10.1016/j.expneurol.2007.02.002; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Soontornniyomkij V, 2012, AGE, V34, P305, DOI 10.1007/s11357-011-9234-4; Su WR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099719; Tanabe F., 2011, AUTOPHAGY, V7, P1462; Tanito M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049680; Torres G, 2011, NEUROSCIENCE, V179, P32, DOI 10.1016/j.neuroscience.2011.01.036; Tucker B.A., 2014, J STEM CELL RES THER, V3, P161; Wang FM, 2013, BONE, V53, P269, DOI 10.1016/j.bone.2012.12.007; Wen YH, 2013, MOL CELL NEUROSCI, V52, P140, DOI 10.1016/j.mcn.2012.11.008; Wostyn P., 2010, MED HYPOTHESES, V74, P973; Xiong X, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001440; Yang HL, 2014, INVEST OPHTH VIS SCI, V55, P6409, DOI 10.1167/iovs.14-14156; Yassa HD, 2014, ACTA HISTOCHEM, V116, P1085, DOI 10.1016/j.acthis.2014.05.001; Zhang YB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.77; Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157	172	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1350-9462			PROG RETIN EYE RES	Prog. Retin. Eye Res.	JUL	2015	47						1	18		10.1016/j.preteyeres.2015.03.002		18	Ophthalmology	Ophthalmology	CL8QH	WOS:000357238700001		
J	Nishida, T; Inui, M; Nomizu, M				Nishida, Teruo; Inui, Makoto; Nomizu, Motoyoshi			Peptide therapies for ocular surface disturbances based on fibronectin-integrin interactions	PROGRESS IN RETINAL AND EYE RESEARCH			English	Article						Epithelial wound healing; Ocular surface disturbances; Fibronectin; Substance P; IGF-1; Peptide therapy	CORNEAL EPITHELIAL-CELLS; GROWTH-FACTOR-I; SERUM EYE DROPS; AMINO-ACID-SEQUENCE; P-DERIVED PEPTIDE; AMNIOTIC MEMBRANE TRANSPLANTATION; DIQUAFOSOL OPHTHALMIC SOLUTION; SUPERFICIAL PUNCTATE KERATOPATHY; 2-PERCENT REBAMIPIDE OPC-12759; NONSUPPRESSIBLE INSULIN-LIKE	The condition of the corneal epithelium is a critical determinant of corneal transparency and clear vision. The corneal epithelium serves as a barrier to protect the eye from external insults, with its smooth surface being essential for its optical properties. Disorders of the corneal epithelium include superficial punctate keratopathy, corneal erosion, and persistent epithelial defects (PEDs). The prompt resolution of these disorders is important for minimization of further damage to the cornea. Currently available treatment modalities for corneal epithelial disorders are based on protection of the ocular surface in order to allow natural healing to proceed. PEDs remain among the most difficult corneal conditions to treat, however. On the basis of characterization of the pathobiology of PEDs at the cell and molecular biological levels, we have strived to develop new modes of treatment for these defects. These treatments rely on two key concepts: provision of a substrate, such as the adhesive glycoprotein fibronectin, for the attachment and migration of corneal epithelial cells, and activation of these cells by biological agents such as the combination of substance P and insulin-like growth factor-1 (IGF-1). Central to both approaches is the role of the fibronectin integrin system in corneal epithelial wound healing. Determination of the minimum amino acid sequences required for the promotion of corneal epithelial wound closure by fibronectin (PHSRN) and by substance P (FGLM-amide) plus IGF-1 (SSSR) has led to the development of peptide eyedrops for the treatment of PEDs that are free of adverse effects of the parent molecules. (C) 2015 The Authors. Published by Elsevier Ltd.	[Nishida, Teruo] Ohshima Hosp Ophthalmol, Hakata Ku, Fukuoka 8120036, Japan; [Nishida, Teruo] Yamaguchi Univ, Ube, Yamaguchi 7558505, Japan; [Inui, Makoto] Yamaguchi Univ, Grad Sch Med, Dept Pharmacol, Ube, Yamaguchi 7558505, Japan; [Nomizu, Motoyoshi] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Biochem, Hachioji, Tokyo 1920392, Japan	Nishida, T (reprint author), 6-8-4 Asutopia, Ube, Yamaguchi 7550152, Japan.	tnishida@cg8.so-net.ne.jp					Al-Kharobi H, 2014, CELL MOL LIFE SCI, V71, P1469, DOI 10.1007/s00018-013-1508-9; ALLANSMITH MR, 1978, AM J OPHTHALMOL, V86, P250; Amano S, 2006, AM J OPHTHALMOL, V141, P472, DOI 10.1016/j.ajo.2005.10.016; Urzua CA, 2012, CURR EYE RES, V37, P684, DOI 10.3109/02713683.2012.674609; Tsubota K, 1999, BRIT J OPHTHALMOL, V83, P390, DOI 10.1136/bjo.83.4.390; Lee SH, 1997, AM J OPHTHALMOL, V123, P303; Lee SJ, 2006, AM J OPHTHALMOL, V141, P1009, DOI 10.1016/j.ajo.2006.01.048; Kimura K, 2007, INVEST OPHTH VIS SCI, V48, P1110, DOI 10.1167/iovs.06-0704; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Vajpayee RB, 2003, BRIT J OPHTHALMOL, V87, P1312, DOI 10.1136/bjo.87.11.1312; Lockwood A, 2006, EYE, V20, P837, DOI 10.1038/sj.eye.6702053; Lambiase A, 2012, CURR OPIN OPHTHALMOL, V23, P296, DOI 10.1097/ICU.0b013e3283543b61; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; Barabino S, 2012, PROG RETIN EYE RES, V31, P271, DOI 10.1016/j.preteyeres.2012.02.003; KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506; Kumagai N, 2002, J ALLERGY CLIN IMMUN, V110, P489, DOI 10.1067/mai.2002.126379; Kohlhaas M, 1998, J CATARACT REFR SURG, V24, P1399; Shaheen BS, 2014, SURV OPHTHALMOL, V59, P263, DOI 10.1016/j.survophthal.2013.09.002; Kao WYJ, 2001, BIOMATERIALS, V22, P2901, DOI 10.1016/S0142-9612(01)00037-0; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; CAMERON JA, 1995, OPHTHALMOLOGY, V102, P985; Belmonte C, 2004, EXP EYE RES, V78, P513, DOI 10.1016/j.exer.2003.09.023; Cosar CB, 2001, CORNEA, V20, P787, DOI 10.1097/00003226-200111000-00002; Lopez-Plandolit S, 2010, CORNEA, V29, P843, DOI 10.1097/ICO.0b013e3181a81820; FUJIKAWA LS, 1981, LAB INVEST, V45, P120; Klenkler B, 2004, EXP EYE RES, V79, P677, DOI 10.1016/j.exer.2004.07.008; Kooijman R, 2006, CYTOKINE GROWTH F R, V17, P305, DOI 10.1016/j.cytogfr.2006.02.002; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Stachs O, 2010, J REFRACT SURG, V26, P159, DOI 10.3928/1081597X-20100224-01; MISHIMA S, 1967, EXP EYE RES, V6, P10, DOI 10.1016/S0014-4835(67)80049-6; Yanai R, 2009, INVEST OPHTH VIS SCI, V50, P2757, DOI 10.1167/iovs.08-2341; Nakamura M, 1997, CURR EYE RES, V16, P275, DOI 10.1076/ceyr.16.3.275.15409; Yu FSX, 2010, BRAIN RES BULL, V81, P229, DOI 10.1016/j.brainresbull.2009.08.024; KORNBLIHTT AR, 1985, EMBO J, V4, P1755; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; McNamara NA, 1998, INVEST OPHTH VIS SCI, V39, P3; Stepp MA, 2006, EXP EYE RES, V83, P3, DOI 10.1016/j.exer.2006.01.010; Singer AJ, 1999, NEW ENGL J MED, V341, P738; Gipson IK, 2004, EXP EYE RES, V78, P379, DOI 10.1016/S0014-4835(03)00204-5; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612; SALMON WD, 1957, J LAB CLIN MED, V49, P825; Urashima H, 2004, CORNEA, V23, P613, DOI 10.1097/01.ico.0000126436.25751.fb; Davidson EP, 2012, INVEST OPHTH VIS SCI, V53, P8067, DOI 10.1167/iovs.12-10826; Muller LJ, 2003, EXP EYE RES, V76, P521, DOI 10.1016/S0014-4835(03)00050-2; Klenkler B, 2007, OCUL SURF, V5, P228; Bonini S, 2003, EYE, V17, P989, DOI 10.1038/sj.eye.6700616; Sosne G, 2007, EXP EYE RES, V84, P663, DOI 10.1016/j.exer.2006.12.004; Sosne G, 2004, INVEST OPHTH VIS SCI, V45, P1095, DOI 10.1167/iovs.03-1002; Nassaralla BA, 2003, OPHTHALMOLOGY, V110, P497, DOI 10.1016/S0161-6420(02)01897-3; Poon AC, 2001, BRIT J OPHTHALMOL, V85, P1188, DOI 10.1136/bjo.85.10.1188; Imanishi J, 2000, PROG RETIN EYE RES, V19, P113, DOI 10.1016/S1350-9462(99)00007-5; SCHULTZ GS, 1988, CORNEA, V7, P96; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; Noble BA, 2004, BRIT J OPHTHALMOL, V88, P647, DOI 10.1136/bjo.2003.026211; SOTOZONO C, 1994, EXP EYE RES, V59, P385, DOI 10.1006/exer.1994.1122; Das M, 2014, BBA-BIOMEMBRANES, V1838, P579, DOI 10.1016/j.bbamem.2013.07.017; Dua HS, 2000, SURV OPHTHALMOL, V44, P415, DOI 10.1016/S0039-6257(00)00109-0; Argueso P, 2001, EXP EYE RES, V73, P281, DOI 10.1006/exer.2001.1045; Nishida T, 2010, EYE CONTACT LENS, V36, P300, DOI 10.1097/ICL.0b013e3181f016d0; Kalyvianaki MI, 2006, AM J OPHTHALMOL, V142, P669, DOI 10.1016/j.ajo.2006.04.054; Nakamura M, 2003, DIABETOLOGIA, V46, P839, DOI 10.1007/s00125-003-1105-9; Margadant C, 2010, FASEB J, V24, P4133, DOI 10.1096/fj.09-151449; Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Nichols KK, 2004, EXPERT OPIN INV DRUG, V13, P47, DOI 10.1517/eoid.13.1.47.25281; Watanabe M, 2003, INVEST OPHTH VIS SCI, V44, P3332, DOI 10.1167/iovs.02-1280; Noda-Tsuruya T, 2006, J REFRACT SURG, V22, P61; AOTA S, 1994, J BIOL CHEM, V269, P24756; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Tsubota K, 2000, INT OPHTHALMOL CLIN, V40, P113, DOI 10.1097/00004397-200010000-00009; Kinoshita S, 2013, OPHTHALMOLOGY, V120, P1158, DOI 10.1016/j.ophtha.2012.12.022; Lambiase A, 2000, INVEST OPHTH VIS SCI, V41, P1063; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; [Anonymous], 1992, ACTA OPHTHALMOL    S; Urashima H, 2012, J OCUL PHARMACOL TH, V28, P264, DOI 10.1089/jop.2011.0147; Sosne G, 2006, EXP EYE RES, V83, P502, DOI 10.1016/j.exer.2006.02.001; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.00031.2002; NISHIDA T, 1990, J CELL PHYSIOL, V145, P549, DOI 10.1002/jcp.1041450323; Cousen P, 2007, J DIABETES COMPLICAT, V21, P371, DOI 10.1016/j.jdiacomp.2006.05.008; Bradley JC, 2008, CLIN EXP OPHTHALMOL, V36, P717, DOI 10.1111/j.1442-9071.2008.01895.x; Blackmore SJ, 2010, CONTACT LENS ANTERIO, V33, P239, DOI 10.1016/j.clae.2010.06.004; Takeji Y, 2012, J OCUL PHARMACOL TH, V28, P259, DOI 10.1089/jop.2011.0142; Yamada N, 2008, BRIT J OPHTHALMOL, V92, P896, DOI 10.1136/bjo.2007.130013; Kim KM, 2012, JPN J OPHTHALMOL, V56, P544, DOI 10.1007/s10384-012-0175-y; CAMPOS M, 1992, AM J OPHTHALMOL, V114, P51; WATANABE K, 1988, INVEST OPHTH VIS SCI, V29, P572; BERTA A, 1990, ACTA OPHTHALMOL, V68, P508; Holland EJ, 1999, CORNEA, V18, P144, DOI 10.1097/00003226-199903000-00002; TERVO K, 1982, INVEST OPHTH VIS SCI, V23, P671; MOSHER DF, 1978, J LAB CLIN MED, V91, P729; WILLIS WE, 1970, CAN J OPHTHALMOLOGY, V5, P239; Yamada N, 2012, CORNEA, V31, P1408, DOI 10.1097/ICO.0b013e31824afd6c; Hattori A, 2009, BIOCHEM BIOPH RES CO, V379, P346, DOI 10.1016/j.bbrc.2008.12.057; Choi JA, 2011, EYE CONTACT LENS, V37, P370, DOI 10.1097/ICL.0b013e318233c9bb; Livant DL, 2000, J CLIN INVEST, V105, P1537, DOI 10.1172/JCI8527; Kinoshita S, 2014, AM J OPHTHALMOL, V157, P576, DOI 10.1016/j.ajo.2013.11.010; Pflugfelder SC, 2011, AM J OPHTHALMOL, V152, P900, DOI 10.1016/j.ajo.2011.08.023; Kinoshita S, 2001, PROG RETIN EYE RES, V20, P639, DOI 10.1016/S1350-9462(01)00007-6; Smith JA, 2007, OCUL SURF, V5, P93; MOSESSON MW, 1980, BLOOD, V56, P145; Koh S, 2013, JPN J OPHTHALMOL, V57, P440, DOI 10.1007/s10384-013-0251-y; Nagano T, 2003, INVEST OPHTH VIS SCI, V44, P3810, DOI 10.1167/iovs.03-0189; Vestergaard AH, 2013, GRAEF ARCH CLIN EXP, V251, P2591, DOI 10.1007/s00417-013-2400-x; Reddy JC, 2013, AM J OPHTHALMOL, V155, P550, DOI 10.1016/j.ajo.2012.09.014; Cho YK, 2013, CURR EYE RES, V38, P9, DOI 10.3109/02713683.2012.720340; Shimazaki-Den S, 2013, CORNEA, V32, P1120, DOI 10.1097/ICO.0b013e3182930b1d; Schrader S, 2006, GRAEF ARCH CLIN EXP, V244, P1345, DOI 10.1007/s00417-006-0257-y; Linna TU, 2000, INVEST OPHTH VIS SCI, V41, P393; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Clemmons DR, 2012, ENDOCRIN METAB CLIN, V41, P425, DOI 10.1016/j.ecl.2012.04.017; Nishida T, 2012, JPN J OPHTHALMOL, V56, P20, DOI 10.1007/s10384-011-0105-4; LIESEGANG TJ, 1985, OPHTHALMOLOGY, V92, P316; Yamada N, 2004, INVEST OPHTH VIS SCI, V45, P1125, DOI 10.1167/iovs.03-0626; GOBBELS M, 1989, GRAEF ARCH CLIN EXP, V227, P142, DOI 10.1007/BF02169787; Fukuda K, 2010, J ALLERGY CLIN IMMUN, V125, P493, DOI 10.1016/j.jaci.2009.10.041; Mokhtarzadeh M, 2011, INVEST OPHTH VIS SCI, V52, P2127, DOI 10.1167/iovs.10-6489; VANBUSKIRK EM, 1979, AM J OPHTHALMOL, V88, P739; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; de Castro F, 1998, EUR J NEUROSCI, V10, P146, DOI 10.1046/j.1460-9568.1998.00037.x; ROSENWASSER GOD, 1989, INT OPHTHALMOL CLIN, V29, P153, DOI 10.1097/00004397-198902930-00005; Matsumoto Y, 2004, OPHTHALMOLOGY, V111, P1115, DOI 10.1016/j.ophtha.2003.10.019; MORRISON PR, 1948, J AM CHEM SOC, V70, P3103, DOI 10.1021/ja01189a080; BEUERMAN RW, 1980, EXP NEUROL, V69, P196, DOI 10.1016/0014-4886(80)90154-5; YOKOI N, 1995, CORNEA, V14, P485; Muller LJ, 1997, INVEST OPHTH VIS SCI, V38, P985; Okada Y, 2010, HISTOL HISTOPATHOL, V25, P771; Nakamura M, 1997, EXP EYE RES, V64, P355, DOI 10.1006/exer.1996.0216; Wakuta M, 2007, INVEST OPHTH VIS SCI, V48, P590, DOI 10.1167/iovs.05-1168; HANNA C, 1961, ARCH OPHTHALMOL-CHIC, V65, P695; Nishida T, 2005, OCUL SURF, V3, P194; NISHIDA T, 1992, INVEST OPHTH VIS SCI, V33, P2464; Kumano Y, 2003, J CATARACT REFR SURG, V29, P757, DOI 10.1016/S0886-3350(02)01840-0; Matsui H, 2001, J CATARACT REFR SURG, V27, P370, DOI 10.1016/S0886-3350(00)00756-2; Tananuvat N, 2001, CORNEA, V20, P802, DOI 10.1097/00003226-200111000-00005; Murakami T, 2004, OPHTHAL RES, V36, P89, DOI 10.1159/000076887; WILSON SE, 1993, INVEST OPHTH VIS SCI, V34, P2544; MURAKAMI J, 1992, J LAB CLIN MED, V120, P86; Davidson EP, 2012, INVEST OPHTH VIS SCI, V53, P1182, DOI 10.1167/iovs.11-8806; Notara M, 2010, EXP EYE RES, V90, P188, DOI 10.1016/j.exer.2009.09.023; Goins KM, 2005, OCUL SURF, V3, P96; Nejima R, 2005, AM J OPHTHALMOL, V139, P64, DOI 10.1016/j.ajo.2004.08.039; Turkoglu E, 2014, SEMIN OPHTHALMOL, V29, P119, DOI 10.3109/08820538.2013.768678; BOISJOLY HM, 1991, CORNEA, V10, P483, DOI 10.1097/00003226-199111000-00004; FOX RI, 1984, ARTHRITIS RHEUM, V27, P459, DOI 10.1002/art.1780270415; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; PAALLYSAHO T, 1991, EXP EYE RES, V52, P261, DOI 10.1016/0014-4835(91)90089-W; Kumar S, 2009, ACTA OPHTHALMOL, V87, P133, DOI 10.1111/j.1755-3768.2008.01347.x; Sosne G, 2012, ANN NY ACAD SCI, V1270, P45, DOI 10.1111/j.1749-6632.2012.06682.x; Saito J, 2003, CORNEA, V22, P15, DOI 10.1097/00003226-200301000-00004; Ramaesh K, 2007, SURV OPHTHALMOL, V52, P50, DOI 10.1016/j.survophthal.2006.10.004; Nishida T, 2009, CURR OPIN OPHTHALMOL, V20, P276, DOI 10.1097/ICU.0b013e32832b758f; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; Arakawa T, 2005, DIGEST DIS SCI, V50, pS3, DOI 10.1007/s10620-005-2800-9; Suzuki K, 2003, PROG RETIN EYE RES, V22, P113, DOI 10.1016/S1350-9462(02)00042-3; Wilson SE, 2001, OPHTHALMOLOGY, V108, P1082, DOI 10.1016/S0161-6420(01)00587-5; ISHIKAWA T, 1994, J REFRACT CORNEAL S, V10, P417; Takamura E, 2012, BRIT J OPHTHALMOL, V96, P1310, DOI 10.1136/bjophthalmol-2011-301448; Roszkowska AM, 2004, OPHTHALMOLOGICA, V218, P350, DOI 10.1159/000079478; Ren HW, 1997, ACTA OPHTHALMOL SCAN, V75, P383; Tsubota K, 1999, OPHTHALMOLOGY, V106, P1984, DOI 10.1016/S0161-6420(99)90412-8; Nishida T, 1996, J CELL PHYSIOL, V169, P159, DOI 10.1002/(SICI)1097-4652(199610)169:1<159::AID-JCP16>3.0.CO;2-8; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Tanaka H, 2013, BRIT J OPHTHALMOL, V97, P912, DOI 10.1136/bjophthalmol-2012-302868; Dunn SP, 2010, ARCH OPHTHALMOL-CHIC, V128, P636, DOI 10.1001/archophthalmol.2010.53; Osei-Bempong C, 2013, BIOESSAYS, V35, P211, DOI 10.1002/bies.201200086; Lemp MA, 2007, OCUL SURF, V5, P75; Marfurt CF, 2010, EXP EYE RES, V90, P478, DOI 10.1016/j.exer.2009.12.010; Melki SA, 2001, SURV OPHTHALMOL, V46, P95, DOI 10.1016/S0039-6257(01)00254-5; Nakamura M, 2012, ADV THER, V29, P579, DOI 10.1007/s12325-012-0033-9; Chuck RS, 2000, J CATARACT REFR SURG, V26, P337, DOI 10.1016/S0886-3350(99)00416-2; Kao WJ, 2001, J BIOMED MATER RES, V55, P79, DOI 10.1002/1097-4636(200104)55:1<79::AID-JBM110>3.0.CO;2-Z; Matsumoto Y, 2012, OPHTHALMOLOGY, V119, P1954, DOI 10.1016/j.ophtha.2012.04.010; Epifano C, 2012, CELL ADHES MIGR, V6, P261, DOI 10.4161/cam.20253; Miyata K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1537, DOI 10.1001/archopht.121.11.1537; NISHIDA T, 1992, J CELL PHYSIOL, V153, P1, DOI 10.1002/jcp.1041530102; ARAKAWA T, 1995, DIGEST DIS SCI, V40, P2469, DOI 10.1007/BF02063257; BAUM J, 1987, AM J OPHTHALMOL, V103, P339; BECKERS HJM, 1993, OPHTHALMIC RES, V25, P192; Belmonte Carlos, 2004, Ocul Surf, V2, P248; Benitez-del-Castillo JM, 2001, CORNEA, V20, P30, DOI 10.1097/00003226-200101000-00005; BERMAN M, 1983, INVEST OPHTH VIS SCI, V24, P1358; BLAU JN, 1969, NEW ENGL J MED, V281, P873, DOI 10.1056/NEJM196910162811604; Brijacak N, 2008, COLLEGIUM ANTROPOL, V32, P21; Brown SM, 1997, ARCH OPHTHALMOL-CHIC, V115, P926; BURY RW, 1976, J MED CHEM, V19, P854, DOI 10.1021/jm00228a028; CAVANAGH HD, 1976, T AM ACAD OPHTHALMOL, V81, P754; Chang B.H., 2011, CORNEA, Vthird, P1101; CHANG MM, 1971, NATURE-NEW BIOL, V232, P86; CHANG SW, 1993, CORNEA, V12, P493, DOI 10.1097/00003226-199311000-00006; Chao C, 2014, OCUL SURF, V12, P32, DOI 10.1016/j.jtos.2013.09.001; Chen HT, 2004, CORNEA, V23, P527, DOI 10.1097/01.ico.0000114127.63670.06; Chikama T, 1998, LANCET, V351, P1783, DOI 10.1016/S0140-6736(98)24024-4; Chikama T, 1999, BIOCHEM BIOPH RES CO, V255, P692, DOI 10.1006/bbrc.1999.0267; Chikamoto N, 2009, JPN J OPHTHALMOL, V53, P464, DOI 10.1007/s10384-009-0693-4; Clark R. A. F, 1996, MOL CELLULAR BIOL WO, V2, P3; COBO LM, 1988, CORNEA, V7, P50; DANIELE S, 1979, A GRAEF ARCH KLIN EX, V210, P159, DOI 10.1007/BF00414564; DANIELE S, 1992, GRAEF ARCH CLIN EXP, V230, P314, DOI 10.1007/BF00165937; DAUGHADA.WH, 1972, NATURE, V235, P107, DOI 10.1038/235107a0; DeRosa AJ, 1998, INT OPHTHALMOL CLIN, V38, P15, DOI 10.1097/00004397-199803840-00004; Bragheeth MA, 2005, BRIT J OPHTHALMOL, V89, P580, DOI 10.1136/bjo.2004.046888; EHINGER B, 1983, ACTA PHYSIOL SCAND, V118, P215, DOI 10.1111/j.1748-1716.1983.tb07265.x; Euler V., 1931, J PHYSL, V72, P74; Foulks Gary N, 2003, Ophthalmol Clin North Am, V16, P29, DOI 10.1016/S0896-1549(02)00105-0; FROESCH ER, 1963, J CLIN INVEST, V42, P1816, DOI 10.1172/JCI104866; Fukuda Ken, 2010, Cornea, V29 Suppl 1, pS62; Fukuda K, 2014, BRIT J OPHTHALMOL, V98, P1751, DOI 10.1136/bjophthalmol-2014-305425; Fukuda Ken, 2010, Allergol Int, V59, P309, DOI 10.2332/allergolint.10-CR-0185; FUKUDA M, 1990, CORNEA, V9, P28; GARCEAU D, 1987, EUR J PHARMACOL, V134, P285, DOI 10.1016/0014-2999(87)90359-1; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Geerling G, 2004, BRIT J OPHTHALMOL, V88, P1467, DOI 10.1136/bjo.2004.044347; Genta RM, 2003, ALIMENT PHARM THERAP, V18, P8, DOI 10.1046/j.1365-2036.18.s1.5.x; Gipson Ilene K, 2007, Invest Ophthalmol Vis Sci, V48, P4391; GLASO M, 1993, APMIS, V101, P914; GOBBELS M, 1992, OPHTHALMOLOGY, V99, P873; GORDON JF, 1995, AM J OPHTHALMOL, V119, P281; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P631, DOI 10.1016/0014-4835(77)90142-7; GRANT MB, 1992, INVEST OPHTH VIS SCI, V33, P3292; Gris O, 2002, CORNEA, V21, P22, DOI 10.1097/00003226-200201000-00006; GRUSHKINLERNER LS, 1991, CURR EYE RES, V10, P75, DOI 10.3109/02713689109007612; Guo P, 2013, CORNEA, V32, P816, DOI 10.1097/ICO.0b013e31826a1e53; GUYON A, 1979, LIFE SCI, V25, P1605, DOI 10.1016/0024-3205(79)90444-2; Hanna C., 1960, ARCH OPHTHALMOL, V64, P536; Haruma K, 2003, ALIMENT PHARM THERAP, V18, P153, DOI 10.1046/j.1365-2036.18.s1.17.x; HO PC, 1975, INVEST OPHTH VISUAL, V14, P630; Hojo K, 2001, BIOORG MED CHEM LETT, V11, P1429, DOI 10.1016/S0960-894X(01)00225-6; Hynes R.O., 1990, FIBRONECTINS; Itakura Hirotaka, 2013, Clin Ophthalmol, V7, P2137, DOI 10.2147/OPTH.S5451; Jaffe M., 1938, ARCH OPHTHALMOL-CHIC, V20, P688; Jones John I., 1995, Progress in Growth Factor Research, V6, P319, DOI 10.1016/0955-2235(95)00015-1; KAHL BF, 1995, PROG RETIN EYE RES, V14, P473, DOI 10.1016/1350-9462(94)00016-9; Kaido M, 2011, INVEST OPHTH VIS SCI, V52, P9516, DOI 10.1167/iovs.11-8412; Kao WJ, 2001, FRONT BIOSCI, V6, pD992, DOI 10.2741/Kao; Kashima Tomoyuki, 2014, Clin Ophthalmol, V8, P1003, DOI 10.2147/OPTH.S40798; Kashima Tomoyuki, 2012, Clin Ophthalmol, V6, P1403, DOI 10.2147/OPTH.S35122; KEEN P, 1982, NEUROSCI LETT, V29, P231, DOI 10.1016/0304-3940(82)90322-6; Kim K S, 1990, Korean J Ophthalmol, V4, P5; Kimura K, 2010, INVEST OPHTH VIS SCI, V51, P4492, DOI 10.1167/iovs.09-4380; Kimura K, 2011, INVEST OPHTH VIS SCI, V52, P3181, DOI 10.1167/iovs.10-5684; Kimura K, 2013, INVEST OPHTH VIS SCI, V54, P2752, DOI 10.1167/iovs.12-11294; Kimura K, 2006, INVEST OPHTH VIS SCI, V47, P4323, DOI 10.1167/iovs.05-1508; KLYCE SD, 1985, INVEST OPHTH VIS SCI, V26, P434; KLYCE SD, 1985, CURR EYE RES, V4, P323, DOI 10.3109/02713688509025145; Ko JA, 2009, J CELL PHYSIOL, V221, P254, DOI 10.1002/jcp.21850; Ko JA, 2009, INVEST OPHTH VIS SCI, V50, P2054, DOI 10.1167/iovs.08-2418; Ko JA, 2010, INVEST OPHTH VIS SCI, V51, P6286, DOI 10.1167/iovs.09-4753; Ko JA, 2012, BIOCHEM BIOPH RES CO, V419, P537, DOI 10.1016/j.bbrc.2012.02.055; Ko JA, 2008, BIOCHEM BIOPH RES CO, V377, P104, DOI 10.1016/j.bbrc.2008.09.085; Ko JA, 2010, BIOCHEM BIOPH RES CO, V403, P305, DOI 10.1016/j.bbrc.2010.11.022; Ko JA, 2014, INVEST OPHTH VIS SCI, V55, P125, DOI 10.1167/iovs.13-12642; Ko JA, 2008, INVEST OPHTH VIS SCI, V49, P113, DOI 10.1167/iovs.07-0353; Ko JA, 2008, BIOCHEM BIOPH RES CO, V370, P424, DOI 10.1016/j.bbrc.2008.03.093; Kojima T, 2008, CORNEA, V27, pS25, DOI 10.1097/ICO.0b013e31817f3a0e; KOTULAK JC, 1980, J AM OPTOM ASSOC, V51, P761; Kumagai N, 2006, PROG RETIN EYE RES, V25, P165, DOI 10.1016/j.preteyeres.2005.09.002; Kumagai N., 2005, ALLERGOL INT, V54, P51, DOI 10.2332/allergolint.54.51; KUWAYAMA Y, 1987, INVEST OPHTH VIS SCI, V28, P1947; LABATROBERT J, 1981, CELL BIOL INT REP, V5, P969; Labat-Robert J, 2012, PATHOL BIOL, V60, P15, DOI 10.1016/j.patbio.2011.10.003; Lambiase A, 1999, Curr Opin Ophthalmol, V10, P270, DOI 10.1097/00055735-199908000-00009; Lau Oliver C F, 2014, Clin Ophthalmol, V8, P327, DOI 10.2147/OPTH.S39699; LAUWERYNS B, 1991, INVEST OPHTH VIS SCI, V32, P2079; LEHTOSALO JI, 1984, HISTOCHEMISTRY, V80, P273, DOI 10.1007/BF00495777; Leiss M, 2008, CURR OPIN CELL BIOL, V20, P502, DOI 10.1016/j.ceb.2008.06.001; LEMP MA, 1989, EYE, V3, P438; Lim Mira, 2003, Ocul Surf, V1, P53; Longmate WM, 2014, ADV WOUND CARE, V3, P229; Magendie P.A., 1824, J PHYSIOL-PARIS, V4, P176; MATHERS WD, 1992, CURR EYE RES, V11, P517, DOI 10.3109/02713689209001807; MATHERS WD, 1988, ARCH OPHTHALMOL-CHIC, V106, P210; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MATSAS R, 1984, BIOCHEM J, V223, P433; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; MCCLUSKEY P, 1987, AUST NZ J OPHTHALMOL, V15, P257, DOI 10.1111/j.1442-9071.1987.tb00081.x; McCulley J P, 1993, Trans Am Ophthalmol Soc, V91, P367; Mensher J H, 1974, Surv Ophthalmol, V19, P1; MILLER A, 1981, NEUROSCI LETT, V23, P243, DOI 10.1016/0304-3940(81)90005-7; Mishima S., 1957, JPN J OPHTHALMOL, V1, P65; MORGAN SJ, 1991, J ALLERGY CLIN IMMUN, V87, P111, DOI 10.1016/0091-6749(91)90221-9; MORIMOTO K, 1993, THROMB HAEMOSTASIS, V69, P387; Morita Y, 2012, JPN J OPHTHALMOL, V56, P26, DOI 10.1007/s10384-011-0104-5; Mort Richard L, 2012, Results Probl Cell Differ, V55, P357, DOI 10.1007/978-3-642-30406-4_19; Mukerji N, 2002, BRIT J OPHTHALMOL, V86, P832, DOI 10.1136/bjo.86.7.832; NAKAGAWA S, 1990, CORNEA, V9, P125; Nakamura M, 1998, BIOCHEM BIOPH RES CO, V242, P16, DOI 10.1006/bbrc.1997.7899; Nakamura M, 2005, CURR EYE RES, V30, P825, DOI 10.1080/02713680591006129; Nakamura M, 1999, BRIT J PHARMACOL, V127, P489, DOI 10.1038/sj.bjp.0702550; NAKAMURA M, 1994, JPN J OPHTHALMOL, V38, P246; Nakamura M, 1997, EXP EYE RES, V65, P321, DOI 10.1006/exer.1997.0345; NAKAMURA M, 1994, J CELL PHYSIOL, V159, P415, DOI 10.1002/jcp.1041590305; Nakamura M, 1998, BIOCHEM BIOPH RES CO, V246, P777, DOI 10.1006/bbrc.1998.8704; Nakamura M, 1997, BRIT J PHARMACOL, V120, P547, DOI 10.1038/sj.bjp.0700923; Nakamura M, 2003, INVEST OPHTH VIS SCI, V44, P2937, DOI 10.1167/iovs.02-0868; Nakamura M, 1994, CONNECT TISSUE, V26, P227; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.neuro.14.1.123; NIELSEN NV, 1978, ACTA OPHTHALMOL, V56, P406; NISHIDA T, 1982, JPN J OPHTHALMOL, V26, P410; NISHIDA T, 1985, OPHTHALMOLOGY, V92, P213; NISHIDA T, 1983, ARCH OPHTHALMOL-CHIC, V101, P1046; Nishida T., 2010, ENCY EYE, P324; Nishida T., 1982, CORNEA, V1, P311; NISHIDA T, 1983, J CELL BIOL, V97, P1653, DOI 10.1083/jcb.97.5.1653; NISHIDA T, 1983, LANCET, V2, P521; NISHIDA T, 1984, JPN J OPHTHALMOL, V28, P196; NISHIDA T, 1982, JPN J OPHTHALMOL, V26, P416; Nishida T, 2012, JPN J OPHTHALMOL, V56, P417, DOI 10.1007/s10384-012-0165-0; NISHIDA T, 1984, ARCH OPHTHALMOL-CHIC, V102, P455; Nishida T., 2011, CORNEA, P3; Nishida T, 1996, Curr Opin Ophthalmol, V7, P2, DOI 10.1097/00055735-199608000-00002; Nishida T., 2006, DRY EYE DIS CLIN GUI, P192; Nishida T, 2007, JPN J OPHTHALMOL, V51, P442, DOI 10.1007/s10384-007-0480-z; NISHIDA T, 1988, INVEST OPHTH VIS SCI, V29, P1820; O'Sullivan F, 2007, CYTOTECHNOLOGY, V53, P101, DOI 10.1007/s10616-007-9063-6; Dillow AK, 2001, BIOMATERIALS, V22, P1493, DOI 10.1016/S0142-9612(00)00304-5; Ofuji K, 2000, JPN J OPHTHALMOL, V44, P1, DOI 10.1016/S0021-5155(99)00168-9; OHASHI H, 1995, EXP CELL RES, V218, P418, DOI 10.1006/excr.1995.1174; OHASHI Y, 1983, JPN J OPHTHALMOL, V27, P547; OHJI M, 1993, INVEST OPHTH VIS SCI, V34, P2487; Pan Q, 2013, COCHRANE DB SYST REV, V8; Panda A, 1999, CORNEA, V18, P299, DOI 10.1097/00003226-199905000-00010; Pannabecker CL, 1944, ARCH OPHTHALMOL-CHIC, V32, P456; Parapuram SK, 2011, INVEST OPHTH VIS SCI, V52, P7799, DOI 10.1167/iovs.10-6945; Paton L, 1926, Br J Ophthalmol, V10, P305, DOI 10.1136/bjo.10.6.305; PAYAN DG, 1989, ANNU REV MED, V40, P341; PERNOW B, 1983, PHARMACOL REV, V35, P85; PFISTER RR, 1973, INVEST OPHTH VISUAL, V12, P654; PHAN TMM, 1987, AM J OPHTHALMOL, V104, P494; Philp D, 2007, ANN NY ACAD SCI, V1112, P95, DOI 10.1196/annals.1415.009; PIERSON RW, 1972, J CELL PHYSIOL, V79, P319, DOI 10.1002/jcp.1040790302; Pushker Neelam, 2001, CLAO Journal, V27, P100; RAO GN, 1985, OPHTHALMOLOGY, V92, P1408; Ren HW, 1996, INVEST OPHTH VIS SCI, V37, P1017; Reynolds Sherrol A, 2006, Optometry, V77, P503, DOI 10.1016/j.optm.2006.05.001; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P4379, DOI 10.1073/pnas.73.12.4379; ROSENBERG M, 1981, AM J OPHTHALMOL, V91, P526; Sacchetti Marta, 2014, Clin Ophthalmol, V8, P571, DOI 10.2147/OPTH.S45921; SAKIYAMA T, 1984, DEV BRAIN RES, V13, P275, DOI 10.1016/0165-3806(84)90162-7; SASAOKA A, 1984, INVEST OPHTH VIS SCI, V25, P351; Schultz R O, 1981, Trans Am Ophthalmol Soc, V79, P180; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Secker GA, 2008, STEM CELL REV, V4, P159, DOI 10.1007/s12015-008-9029-x; Shaver S R, 2001, Curr Opin Drug Discov Devel, V4, P665; Shibasaki Y, 2011, BIOPOLYMERS, V96, P302, DOI 10.1002/bip.21551; SHIMIZU Y, 1982, CELL MOL BIOL, V28, P103; SHIMIZU Y, 1982, INVEST OPHTH VIS SCI, V22, P259; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SOLOWAY MR, 1981, INVEST OPHTH VIS SCI, V20, P47; SOONG HK, 1989, INVEST OPHTH VIS SCI, V30, P1808; SORIA J, 1980, ARTHRITIS RHEUM, V23, P1334, DOI 10.1002/art.1780231125; Sosne Gabriel, 2007, Clin Ophthalmol, V1, P201; Spigelman A V, 1985, Cornea, V4, P169; SPINELLI D, 1984, DOC OPHTHALMOL, V56, P385, DOI 10.1007/BF00155683; SRAMEK SJ, 1987, INVEST OPHTH VIS SCI, V28, P500; STEPP MA, 1993, INVEST OPHTH VIS SCI, V34, P1829; STONE RA, 1982, NEUROSCIENCE, V7, P2459, DOI 10.1016/0306-4522(82)90207-X; STONE RA, 1988, INVEST OPHTH VIS SCI, V29, P305; STONE RA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1207; SUDA T, 1981, Current Eye Research, V1, P553, DOI 10.3109/02713688109069181; Sumich PM, 2003, CLIN EXP OPHTHALMOL, V31, P267, DOI 10.1046/j.1442-9071.2003.00650.x; Tai MC, 2002, CORNEA, V21, P135, DOI 10.1097/00003226-200203000-00001; TERVO K, 1981, NEUROSCI LETT, V25, P95, DOI 10.1016/0304-3940(81)90107-5; TERVO K, 1991, CORNEA, V10, P461, DOI 10.1097/00003226-199111000-00001; TERVO T, 1983, OPHTHALMIC RES, V15, P280; TERVO T, 1982, MED BIOL, V60, P53; TERVO T, 1986, EXP EYE RES, V42, P399, DOI 10.1016/0014-4835(86)90033-3; THOFT RA, 1983, INVEST OPHTH VIS SCI, V24, P1442; TORNQVIST K, 1982, CELL TISSUE RES, V222, P467; TROCME SD, 1989, AM J OPHTHALMOL, V108, P57; Tugal Tutkun I., 1993, EUR J OPHTHALMOL, V3, P66; Turner W A, 1895, Br Med J, V2, P1279; Ueda S, 1989, Acta Ophthalmol Suppl, V192, P80; Ueta M, 2013, J OCUL PHARMACOL TH, V29, P688, DOI 10.1089/jop.2012.0054; WATANABE K, 1991, INVEST OPHTH VIS SCI, V32, P2159; WATANABE K, 1987, INVEST OPHTH VIS SCI, V28, P205; Watanabe M, 2006, INVEST OPHTH VIS SCI, V47, P1862, DOI 10.1167/iovs.05-0591; Watson S.L., 2007, COCHRANE DB SYST REV, V4; Watson SL, 2012, COCHRANE DB SYST REV, V9; White ES, 2001, J IMMUNOL, V167, P5362; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Wilson SE, 1996, INVEST OPHTH VIS SCI, V37, P1582; Yamada M, 2000, AM J OPHTHALMOL, V129, P671, DOI 10.1016/S0002-9394(00)00415-3; Yamada M, 2002, INVEST OPHTH VIS SCI, V43, P2622; Yamada M, 2003, CORNEA, V22, pS48, DOI 10.1097/00003226-200310001-00007; Yamada N, 2006, INVEST OPHTH VIS SCI, V47, P3286, DOI 10.1167/iovs.05-1205; Yamada N, 2005, INVEST OPHTH VIS SCI, V46, P833, DOI 10.1167/iovs.04-0775; Yoon Jinny J, 2014, World J Stem Cells, V6, P391, DOI 10.4252/wjsc.v6.i4.391; Yoon Kyung-Chul, 2005, Korean J Ophthalmol, V19, P174; Yoon KC, 2007, OPHTHALMOLOGY, V114, P1637, DOI 10.1016/j.ophtha.2006.12.014; Zhivov A, 2006, OCUL SURF, V4, P81	394	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1350-9462			PROG RETIN EYE RES	Prog. Retin. Eye Res.	JUL	2015	47						38	63		10.1016/j.preteyeres.2015.01.004		26	Ophthalmology	Ophthalmology	CL8QH	WOS:000357238700003		
J	Masuda, S; Miyagawa, S; Fukushima, S; Sougawa, N; Okimoto, K; Tada, C; Saito, A; Sawa, Y				Masuda, Shigeo; Miyagawa, Shigeru; Fukushima, Satsuki; Sougawa, Nagako; Okimoto, Kaori; Tada, Chika; Saito, Atsuhiro; Sawa, Yoshiki			Eliminating residual iPS cells for safety in clinical application	PROTEIN & CELL			English	News Item							STEM-CELLS		[Masuda, Shigeo; Miyagawa, Shigeru; Fukushima, Satsuki; Sougawa, Nagako; Okimoto, Kaori; Tada, Chika; Saito, Atsuhiro; Sawa, Yoshiki] Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, Suita, Osaka 5650871, Japan	Sawa, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sawa-p@surg1.med.osaka-u.ac.jp					Tateno H, 2011, J BIOL CHEM, V286, P20345, DOI 10.1074/jbc.M111.231274; Huskey NE, 2015, STEM CELL REP, V4, P374, DOI 10.1016/j.stemcr.2015.01.019; Masuda S, 2014, NAT REV CARDIOL, V11, DOI 10.1038/nrcardio.2014.9-c1; Tateno H, 2015, STEM CELL REP, V4, P811, DOI 10.1016/j.stemcr.2015.02.016; Wu T, 2015, STEM CELL REP, V4, P390, DOI 10.1016/j.stemcr.2015.01.012	5	0	0	HIGHER EDUCATION PRESS	BEIJING	SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA	1674-800X	1674-8018		PROTEIN CELL	Protein Cell	JUL	2015	6	7					469	471		10.1007/s13238-015-0170-4		3	Cell Biology	Cell Biology	CM2CI	WOS:000357486900001		
J	Sunohara, Y; Baba, Y; Matsuyama, S; Fujimura, K; Matsumoto, H				Sunohara, Yukari; Baba, Yohei; Matsuyama, Shigeru; Fujimura, Kaori; Matsumoto, Hiroshi			Screening and identification of phytotoxic volatile compounds in medicinal plants and characterizations of a selected compound, eucarvone	PROTOPLASMA			English	Article						Allelochemical; Asarum sieboldii Miq; Eucarvone; Lipid peroxidation; Phytotoxicity; Reactive oxygen species (ROS)	ESSENTIAL OILS; LIPID-PEROXIDATION; HYDROXYL RADICALS; HYDROGEN-PEROXIDE; SEED-GERMINATION; OXIDATIVE STRESS; NATURAL-PRODUCTS; GROWTH; MONOTERPENES; ALUMINUM	Screening and identification of phytotoxic volatile compounds were performed using 71 medicinal plant species to find new natural compounds, and the characterization of the promising compound was investigated to understand the mode of action. The volatile compounds from Asarum sieboldii Miq. showed the strongest inhibitory effect on the hypocotyl growth of lettuce seedlings (Lactuca sativa L.cv. Great Lakes 366), followed by those from Schizonepeta tenuifolia Briquet and Zanthoxylum piperitum (L.) DC.. Gas chromatography-mass spectrometry (GC/MS) identified four volatile compounds, alpha-pinene (2,6,6-trimethylbicyclo[3.1.1]hept-2-ene), beta-pinene (6,6-dimethyl-2-methylenebicyclo[3.1.1]heptane), 3-carene (3,7,7-trimethylbicyclo[4.1.0]hept-3-ene), and eucarvone (2,6,6-trimethy-2,4-cycloheptadien-1-one), from A. sieboldii, and three volatile compounds, limonene (1-methyl-4-(1-methylethenyl)-cyclohexene), menthone (5-methyl-2-(propan-2-yl)cyclohexan-1-one), and pulegone (5-methyl-2-propan-2-ylidenecyclohexan-1-one), from S. tenuifolia. Among these volatile compounds, eucarvone, menthone, and pulegone exhibited strong inhibitory effects on both the root and shoot growth of lettuce seedlings. Eucarvone-induced growth inhibition was species-selective. Cell death, the generation of reactive oxygen species (ROS), and lipid peroxidation were induced in susceptible finger millet seedlings by eucarvone treatment, whereas this compound (a parts per thousand currency sign158 mu M) did not cause the increase of lipid peroxidation and ROS production in tolerant maize. The results of the present study show that eucarvone can have strong phytotoxic activity, which may be due to ROS overproduction and subsequent oxidative damage in finger millet seedlings.	[Sunohara, Yukari; Baba, Yohei; Matsuyama, Shigeru; Fujimura, Kaori; Matsumoto, Hiroshi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan	Sunohara, Y (reprint author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan.	sunohara.yukari.gp@u.tsukuba.ac.jp			Japan Society for the Promotion of Science [25450068]	We would like to thank Dr. Y. Fujii (Tokyo University of Agriculture and Technology, Japan) for his helpful suggestions. This work was partially supported by a Grant-in-Aid for Scientific Research (C) (No. 25450068) from the Japan Society for the Promotion of Science.	ALSAADAWI IS, 1985, J CHEM ECOL, V11, P1527, DOI 10.1007/BF01012198; Fry SC, 1998, BIOCHEM J, V332, P507; Vokou D, 2003, J CHEM ECOL, V29, P2281, DOI 10.1023/A:1026274430898; LANGENHEIM JH, 1994, J CHEM ECOL, V20, P1223, DOI 10.1007/BF02059809; Sodaeizadeh H, 2009, PLANT GROWTH REGUL, V59, P227, DOI 10.1007/s10725-009-9408-6; Chowhan N, 2013, PROTOPLASMA, V250, P691, DOI 10.1007/s00709-012-0446-y; GAFF DF, 1971, J EXP BOT, V22, P756, DOI 10.1093/jxb/22.3.756; Tamas L, 2004, ENVIRON EXP BOT, V51, P281, DOI 10.1016/j.envexpbot.2003.11.007; Duke SO, 2000, WEED RES, V40, P99, DOI 10.1046/j.1365-3180.2000.00161.x; HALLIGAN JP, 1975, ECOLOGY, V56, P999, DOI 10.2307/1936312; Singh HP, 2002, ANN APPL BIOL, V141, P111, DOI 10.1111/j.1744-7348.2002.tb00202.x; Duke SO, 2000, CROP PROT, V19, P583, DOI 10.1016/S0261-2194(00)00076-4; Romagni JG, 2000, J CHEM ECOL, V26, P303, DOI 10.1023/A:1005414216848; VAUGHN SF, 1993, WEED SCI, V41, P114; Umebayashi Y, 2003, J BIOCHEM, V134, P219, DOI 10.1093/jb/mvg132; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; Sekine T, 2007, J CHEM ECOL, V33, P2123, DOI 10.1007/s10886-007-9374-2; Oumzil H, 2002, PHYTOTHER RES, V16, P727, DOI 10.1002/ptr.1045; Yamamoto Y, 2001, PLANT PHYSIOL, V125, P199, DOI 10.1104/pp.125.1.199; Pan JW, 2001, ENVIRON EXP BOT, V46, P71, DOI 10.1016/S0098-8472(01)00083-1; ASPLUND RO, 1968, PHYTOCHEMISTRY, V7, P1995, DOI 10.1016/S0031-9422(00)90758-1; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Yamamoto Y, 2002, PLANT PHYSIOL, V128, P63, DOI 10.1104/pp.128.1.63; Singh HP, 2006, ANN BOT-LONDON, V98, P1261, DOI 10.1093/aob/mcl213; Han CM, 2008, SCI HORTIC-AMSTERDAM, V116, P330, DOI 10.1016/j.scienta.2008.01.005; Nishida N, 2005, J CHEM ECOL, V31, P1187, DOI 10.1007/s10886-005-4256-y; Zunino MP, 2004, PLANTA, V219, P303, DOI 10.1007/s00425-004-1216-7; Coleman WK, 2001, AM J POTATO RES, V78, P345, DOI 10.1007/BF02884343; Dayan F., 1999, Pesticide Outlook, V10, P185; Dayan FE, 2000, J CHEM ECOL, V26, P2079, DOI 10.1023/A:1005512331061; Duke SO, 1996, CROP PROTECTION AGEN, P82; Fitzhenry A, 2005, Granted Innovation Patent (Aust.), Patent No. [AU 2005100476 A4 20050818, 2005100476]; FORNEY LJ, 1982, J BIOL CHEM, V257, P1455; Fujii Yoshiharu, 2003, Weed Biology and Management, V3, P233, DOI 10.1046/j.1444-6162.2003.00111.x; Fujii Y., 2005, Proceedings of the 4th World Congress on Allelopathy, "Establishing the Scientific Base", Wagga Wagga, New South Wales, Australia, 21-26 August 2005, P493; Fujii Y, 1990, WEED RES JAPAN, V35, P362; Haig T, 2008, ALLELOPATHY IN SUSTAINABLE AGRICULTURE AND FORESTRY, P63, DOI 10.1007/978-0-387-77337-7_4; Islam AKMM, 2013, EMIR J FOOD AGR, V25, P692, DOI 10.9755/ejfa.v25i9.16073; Kim J, 2008, FLAVOUR FRAG J, V23, P79, DOI 10.1002/ffj.1858; MAFFEI M, 1987, Planta Medica, V53, P214, DOI 10.1055/s-2006-962675; MULLER CH, 1964, SCIENCE, V143, P471, DOI 10.1126/science.143.3605.471; MULLER WALTER H., 1964, BULL TORREY BOT CLUB, V91, P327, DOI 10.2307/2483297; Pan H, 2011, SHIPIN KEXUE, V32, P190; Park IK, 2006, J ECON ENTOMOL, V99, P1717; POMPELLA A, 1987, AM J PATHOL, V129, P295; Schweikert C, 2000, PHYTOCHEMISTRY, V53, P565, DOI 10.1016/S0031-9422(99)00586-5; Singh HP, 2009, J CHEM ECOL, V35, P154, DOI 10.1007/s10886-009-9595-7; Sunohara Y, 2011, ENVIRON EXP BOT, V74, P74, DOI 10.1016/j.envexpbot.2011.05.001; Vaughn SF, 1996, WEED SCI, V44, P7; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003	50	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0033-183X	1615-6102		PROTOPLASMA	Protoplasma	JUL	2015	252	4					1047	1059		10.1007/s00709-014-0739-4		13	Plant Sciences; Cell Biology	Plant Sciences; Cell Biology	CM1VX	WOS:000357469700011		
J	Ono, Y				Ono, Yutaka			Integrative approach for severe anxiety	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Editorial Material									Ctr Cognit Behav Therapy & Res, Tokyo, Japan	Ono, Y (reprint author), Ctr Cognit Behav Therapy & Res, Tokyo, Japan.							0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		387	387		10.1111/pcn.12310		1	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000001		
J	Shimada-Sugimoto, M; Otowa, T; Hettema, JM				Shimada-Sugimoto, Mihoko; Otowa, Takeshi; Hettema, John M.			Genetics of anxiety disorders: Genetic epidemiological and molecular studies in humans	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Review						anxiety disorders; epidemiology; epigenetic; genetic; gene environmental interaction	POSTTRAUMATIC-STRESS-DISORDER; GENOME-WIDE ASSOCIATION; EARLY-LIFE STRESS; SEROTONIN TRANSPORTER GENE; ENVIRONMENTAL RISK-FACTORS; GLUTAMATE-DECARBOXYLASE 1; PANIC DISORDER; DNA METHYLATION; JAPANESE POPULATION; GLUCOCORTICOID-RECEPTOR	This review provides a broad overview of the state of research in the genetics of anxiety disorders (AD). Genetic epidemiological studies report a moderate level of familial aggregation (odds ratio: 4-6) and heritability estimates are about 30-50%. Twin studies suggest that the genetic architecture of AD is not isomorphic with their classifications, sharing risk factors with each other. So far, linkage and association studies of AD have produced inconclusive results. Genome-wide association studies of AD can provide an unbiased survey of common genetic variations across the entire genome. Given the shared causes of AD that transcend our current diagnostic classifications, clustering anxiety phenotypes into broader groups may be a powerful approach to identifying susceptibility locus for AD. Using such a shared genetic risk factor, meta-analyses of genome-wide association studies of AD conducted by large consortia are needed. Environmental factors also make a substantial contribution to the cause of AD. Although candidate gene studies of gene by environmental (GxE) interaction have appeared recently, no genome-wide search for GxE interactions have been performed. Epigenetic modification of DNA appears to have important effects on gene expression mediating environmental influences on disease risk. Given that GxE can be linked to an epigenetic modification, a combination analysis of genome-wide GxE interaction and methylation could be an alternative method to find risk variants for AD. This genetic research will enable us to utilize more effective strategies for the prevention and treatment of AD in the near future.	[Shimada-Sugimoto, Mihoko] Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo 1130033, Japan; [Otowa, Takeshi] Univ Tokyo, Grad Sch Med, Dept Neuropsychiat, Tokyo 1130033, Japan; [Hettema, John M.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Psychiat, Richmond, VA 23284 USA	Otowa, T (reprint author), Univ Tokyo, Grad Sch Med, Dept Neuropsychiat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	totowa-psy@umin.org			Takeda Pharmaceutical Company	T.O. received a research grant from Takeda Pharmaceutical Company. The other authors have no conflict of interest.	Alisch RS, 2014, J NEUROSCI, V34, P15548, DOI 10.1523/JNEUROSCI.3338-14.2014; Alvarenga ME, 2006, PSYCHOSOM MED, V68, P8, DOI 10.1097/01.psy.0000195872.00987.db; McGrath LM, 2012, DEV PSYCHOPATHOL, V24, P1179, DOI 10.1017/S0954579412000636; Kawamura Y, 2011, J HUM GENET, V56, P852, DOI 10.1038/jhg.2011.117; Demirkan A, 2011, MOL PSYCHIATR, V16, P773, DOI 10.1038/mp.2010.65; Hettema JM, 2001, AM J PSYCHIAT, V158, P1568, DOI 10.1176/appi.ajp.158.10.1568; Hettema JM, 2006, MOL PSYCHIATR, V11, P752, DOI 10.1038/sj.mp.4001845; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P929, DOI 10.1001/archpsyc.60.9.929; Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003; Middeldorp CM, 2005, PSYCHOL MED, V35, P611, DOI 10.1017/S003329170400412X; Zavos HMS, 2012, DEPRESS ANXIETY, V29, P400, DOI 10.1002/da.21921; Almli LM, 2014, INT J NEUROPSYCHOPH, V17, P355, DOI 10.1017/S1461145713001090; Tambs K, 2009, BRIT J PSYCHIAT, V195, P301, DOI 10.1192/bjp.bp.108.059485; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Baker-Andresen D, 2013, LEARN MEMORY, V20, P237, DOI 10.1101/lm.029520.112; Oh JE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.130; Roth TL, 2011, J PSYCHIATR RES, V45, P919, DOI 10.1016/j.jpsychires.2011.01.013; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Yang XJ, 2012, BIOCHEM BIOPH RES CO, V420, P570, DOI 10.1016/j.bbrc.2012.03.035; Maron E, 2010, MOL PSYCHIATR, V15, P681, DOI 10.1038/mp.2009.145; Roth TL, 2009, BIOL PSYCHIAT, V65, P760, DOI 10.1016/j.biopsych.2008.11.028; Ziegler C, 2015, NEUROPSYCHOPHARMACOL, V40, P1528, DOI 10.1038/npp.2015.2; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Hettema JM, 2006, AM J PSYCHIAT, V163, P857, DOI 10.1176/appi.ajp.163.5.857; Karg K, 2011, ARCH GEN PSYCHIAT, V68, P444, DOI 10.1001/archgenpsychiatry.2010.189; Taliaz D, 2010, MOL PSYCHIATR, V15, P80, DOI 10.1038/mp.2009.67; Moffitt TE, 2007, PSYCHOL MED, V37, P441, DOI 10.1017/S0033291706009640; Erhardt A, 2011, MOL PSYCHIATR, V16, P647, DOI 10.1038/mp.2010.41; Scaini S, 2014, J ANXIETY DISORD, V28, P650, DOI 10.1016/j.janxdis.2014.07.002; Murgatroyd C, 2009, NAT NEUROSCI, V12, P1559, DOI 10.1038/nn.2436; Kendler KS, 2007, PSYCHOL MED, V37, P453, DOI 10.1017/S0033291706009135; Oberlander TF, 2008, EPIGENETICS, V3, P97; Donner J, 2012, AM J MED GENET B, V159B, P316, DOI 10.1002/ajmg.b.32029; Klauke B, 2011, DEPRESS ANXIETY, V28, P1048, DOI 10.1002/da.20840; Otowa T, 2010, J HUM GENET, V55, P91, DOI 10.1038/jhg.2009.127; Gunthert KC, 2007, PSYCHOSOM MED, V69, P762, DOI 10.1097/PSY.0b013e318157ad42; Zannas AS, 2014, GENES BRAIN BEHAV, V13, P25, DOI 10.1111/gbb.12104; Chen J, 2012, J NEUROENDOCRINOL, V24, P1055, DOI 10.1111/j.1365-2826.2012.02306.x; Kendler KS, 2001, ARCH GEN PSYCHIAT, V58, P257, DOI 10.1001/archpsyc.58.3.257; Laucht M, 2009, INT J NEUROPSYCHOPH, V12, P737, DOI 10.1017/S1461145708009875; Hettema JM, 2011, BIOL PSYCHIAT, V70, P888, DOI 10.1016/j.biopsych.2011.07.012; Elliott E, 2010, NAT NEUROSCI, V13, P1351, DOI 10.1038/nn.2642; Szyf M, 2015, TRENDS MOL MED, V21, P134, DOI 10.1016/j.molmed.2014.12.004; Van Houtem CMHH, 2013, J ANXIETY DISORD, V27, P379, DOI 10.1016/j.janxdis.2013.04.007; Beach SRH, 2010, AM J MED GENET B, V153B, P710, DOI 10.1002/ajmg.b.31028; Kinnally EL, 2011, BRAIN BEHAV IMMUN, V25, P1548, DOI 10.1016/j.bbi.2011.05.001; Trzaskowski M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058676; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Otowa T, 2009, J HUM GENET, V54, P122, DOI 10.1038/jhg.2008.17; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P273; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Domschke K, 2013, PROG NEURO-PSYCHOPH, V46, P189, DOI 10.1016/j.pnpbp.2013.07.014; Heim C, 2009, CNS SPECTRUMS, V14, P13; Kang HJ, 2013, J AFFECT DISORDERS, V151, P679, DOI 10.1016/j.jad.2013.08.001; Plomin R, 2009, NAT REV GENET, V10, P872, DOI 10.1038/nrg2670; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Kawakami N, 2005, PSYCHIAT CLIN NEUROS, V59, P441, DOI 10.1111/j.1440-1819.2005.01397.x; Webb BT, 2012, EUR J HUM GENET, V20, P1078, DOI 10.1038/ejhg.2012.47; Kang HJ, 2013, PROG NEURO-PSYCHOPH, V44, P23, DOI 10.1016/j.pnpbp.2013.01.006; Lee RS, 2011, PSYCHOPHARMACOLOGY, V218, P303, DOI 10.1007/s00213-011-2307-3; Hettema JM, 2005, ARCH GEN PSYCHIAT, V62, P182, DOI 10.1001/archpsyc.62.2.182; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Sen S, 2004, AM J MED GENET B, V127B, P85, DOI 10.1002/ajmg.b.20158; Ouellet-Morin I, 2013, PSYCHOL MED, V43, P1813, DOI 10.1017/S0033291712002784; Domschke K, 2012, INT J NEUROPSYCHOPH, V15, P1217, DOI 10.1017/S146114571200020X; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Gillespie CF, 2009, DEPRESS ANXIETY, V26, P984, DOI 10.1002/da.20605; Pauls DL, 2014, NAT REV NEUROSCI, V15, P410, DOI 10.1038/nrn3746; Melas PA, 2013, INT J NEUROPSYCHOPH, V16, P1513, DOI 10.1017/S1461145713000102; Lee RS, 2010, ENDOCRINOLOGY, V151, P4332, DOI 10.1210/en.2010-0225; Gatt JM, 2009, MOL PSYCHIATR, V14, P681, DOI 10.1038/mp.2008.143; FYER AJ, 1990, ARCH GEN PSYCHIAT, V47, P252; McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270; Stein MB, 2008, NEUROPSYCHOPHARMACOL, V33, P312, DOI 10.1038/sj.npp.1301422; Bayles R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083223; Binder Elisabeth B, 2012, Biol Mood Anxiety Disord, V2, P17, DOI 10.1186/2045-5380-2-17; Binder EB, 2008, JAMA-J AM MED ASSOC, V299, P1291, DOI 10.1001/jama.299.11.1291; Chantarujikapong SI, 2001, PSYCHIAT RES, V103, P133, DOI 10.1016/S0165-1781(01)00285-2; Cunha Carla, 2010, Front Mol Neurosci, V3, P1, DOI 10.3389/neuro.02.001.2010; Czajkowski N, 2011, PSYCHOL MED, V41, P1987, DOI 10.1017/S0033291710002436; Daskalakis NP, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00369; Erhardt A, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.85; Esler M, 2008, ANN NY ACAD SCI, V1148, P338, DOI 10.1196/annals.1410.064; Esler Murray, 2006, J Psychopharmacol, V20, P60, DOI 10.1177/1359786806066055; Gelernter J, 2003, MOL PSYCHIATR, V8, P71, DOI 10.1038/sj.mp.4001224; Gelernter J, 2004, AM J PSYCHIAT, V161, P59, DOI 10.1176/appi.ajp.161.1.59; Gelernter J, 2001, AM J MED GENET, V105, P548, DOI 10.1002/ajmg.1496; Gregersen N, 2012, EUR J HUM GENET, V20, P84, DOI 10.1038/ejhg.2011.148; Hodes GE, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-1; Hovatta I, 2008, ANN MED, V40, P92, DOI 10.1080/07853890701747096; Jacobson LH, 2010, CURR TOP BEHAV NEURO, V2, P161, DOI 10.1007/7854_2009_31; Kember RL, 2012, BRAIN BEHAV, V2, P455, DOI 10.1002/brb3.69; Klauke B, 2010, DEPRESS ANXIETY, V27, P716, DOI 10.1002/da.20667; Laas K, 2014, INT J NEUROPSYCHOPH, V17, P541, DOI 10.1017/S1461145713001478; Logue MW, 2012, AM J MED GENET B, V159B, P274, DOI 10.1002/ajmg.b.32024; Murphy TM, 2015, PSYCHIAT GENET, V25, P71, DOI 10.1097/YPG.0000000000000055; NOYES R, 1986, ARCH GEN PSYCHIAT, V43, P227; Otowa T, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.89; Otowa T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112559; Park HJ, 2014, CNS NEUROSCI THER, V20, P172, DOI 10.1111/cns.12202; Perroud N, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.60; Reif A, 2012, AM J MED GENET B, V159B, P786, DOI 10.1002/ajmg.b.32085; Ripke S, 2013, MOL PSYCHIATR, V18, P497, DOI DOI 10.1038/MP.2012.21; Roberts S, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.83; Schosser A, 2013, WORLD J BIOL PSYCHIA, V14, P611, DOI 10.3109/15622975.2013.782107; Schraut KG, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.107; Schumacher J, 2011, J MED GENET, V48, P361, DOI 10.1136/jmg.2010.086876; Shimada-Sugimoto M, 2015, BRAIN BEHAV IMMUN, V46, P96, DOI 10.1016/j.bbi.2015.01.002; Smoller JW, 2008, AM J MED GENET C, V148C, P85, DOI 10.1002/ajmg.c.30167; Sotnikov SV, 2014, TRANSL PSYCHIAT, V4, P1; Toda H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097421; Tyagi E, 2015, NEUROBIOL DIS, V73, P307, DOI 10.1016/j.nbd.2014.09.014; Tyrka AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030148; Uher Rudolf, 2014, Front Psychiatry, V5, P48, DOI 10.3389/fpsyt.2014.00048; Vijayendran Meeshanthini, 2012, Front Psychiatry, V3, P55, DOI 10.3389/fpsyt.2012.00055; Walter S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080326; Wray NR, 2009, BIOL PSYCHIAT, V66, P468, DOI 10.1016/j.biopsych.2009.04.030; Wu YH, 2014, ENDOCRINOLOGY, V155, P1751, DOI 10.1210/en.2013-1868	120	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		388	401		10.1111/pcn.12291		14	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000002		
J	Okada, K; Nakao, T; Sanematsu, H; Murayama, K; Honda, S; Tomita, M; Togao, O; Yoshiura, T; Kanba, S				Okada, Kayo; Nakao, Tomohiro; Sanematsu, Hirokuni; Murayama, Keitaro; Honda, Shinichi; Tomita, Mayumi; Togao, Osamu; Yoshiura, Takashi; Kanba, Shigenobu			Biological heterogeneity of obsessive-compulsive disorder: A voxel-based morphometric study based on dimensional assessment	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						insula; magnetic resonance imaging; neuroimaging; obsessive-compulsive disorder; voxel-based morphometry	CEREBRAL BLOOD-FLOW; SYMPTOM DIMENSIONS; MATTER ABNORMALITIES; CHECKING SYMPTOMS; BRAIN ACTIVATION; NEURAL RESPONSES; DISGUST; METAANALYSIS; CORTEX; FEAR	AimAlthough many neuroimaging studies of obsessive-compulsive disorder (OCD) have reported broad abnormalities in gray matter (GM), their results remain inconsistent. One reason for this inconsistency could be the heterogeneity of OCD. In the present study, we aimed to classify alterations in brain anatomy by OCD subtype. MethodsMagnetic resonance imaging examinations of 37 OCD patients and 37 matched healthy controls were conducted using a 3.0-Tesla scanner. In the voxel-based morphometric procedure, preprocessed GM structural images were used to compare the two groups, and multiple regression analysis was used to investigate the correlation between regional GM volume in OCD patients and the OCD symptom dimension type assessed by using the Dimensional Yale-Brown Obsessive-Compulsive Scale. ResultsWe found significant reductions in GM volume in broad areas of the left prefrontal, right orbitofrontal, right parietal, right temporal, and right posterior cingulate cortex in the OCD patients compared to healthy controls. In addition, we found specific negative correlations between symptomatic dimension scores and regional GM volumes, mainly as decreased right cerebellum in aggression/checking' and decreased right insula in contamination/washing'. ConclusionThe pathophysiology of OCD may involve widely distributed neural systems. Moreover, there are distinct correlations among symptomatic dimensions and structural abnormalities.	[Okada, Kayo; Nakao, Tomohiro; Sanematsu, Hirokuni; Murayama, Keitaro; Honda, Shinichi; Kanba, Shigenobu] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 8128582, Japan; [Togao, Osamu; Yoshiura, Takashi] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka 8128582, Japan; [Tomita, Mayumi] Kyushu Univ, Fac Human Environm Studies, Fukuoka 8128582, Japan	Nakao, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tomona@npsych.med.kyushu-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan	We were supported by a Grant-in-Aid for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) from the Ministry of Education, Science, Sports and Culture of Japan in terms of the analysis technique. Katherine Ono provided assistance with language. With regard to financial disclosure, there is no conflict of interest.	Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Pujol J, 2004, ARCH GEN PSYCHIAT, V61, P720, DOI 10.1001/archpsyc.61.7.720; Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2; Mataix-Cols D, 1999, AM J PSYCHIAT, V156, P1409; Nagai M, 2007, EUR PSYCHIAT, V22, P387, DOI 10.1016/j.eurpsy.2007.02.006; Kravitz DJ, 2011, NAT REV NEUROSCI, V12, P217, DOI 10.1038/nrn3008; Radua J, 2009, BRIT J PSYCHIAT, V195, P393, DOI 10.1192/bjp.bp.108.055046; Togao O, 2010, PSYCHIAT RES-NEUROIM, V184, P29, DOI 10.1016/j.pscychresns.2010.06.011; Menzies L, 2008, NEUROSCI BIOBEHAV R, V32, P525, DOI 10.1016/j.neubiorev.2007.09.005; Adler CM, 2000, J PSYCHIAT RES, V34, P317, DOI 10.1016/S0022-3956(00)00022-4; Mataix-Cols D, 2004, ARCH GEN PSYCHIAT, V61, P564, DOI 10.1001/archpsyc.61.6.564; Omori IM, 2007, J PSYCHIATR RES, V41, P776, DOI 10.1016/j.jpsychires.2006.05.005; Davis M, 1997, J NEUROPSYCH CLIN N, V9, P382; Hoenig K, 2002, PSYCHOL MED, V32, P459, DOI 10.1017/S0033291702005421; Phillips ML, 2000, PSYCHOL MED, V30, P1037, DOI 10.1017/S0033291799002652; Whiteside SP, 2004, PSYCHIAT RES-NEUROIM, V132, P69, DOI 10.1016/j.pscychresns.2004.07.001; LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0; Smith R, 2013, J AFFECT DISORDERS, V146, P414, DOI 10.1016/j.jad.2012.07.029; Remijnse PL, 2006, ARCH GEN PSYCHIAT, V63, P1225, DOI 10.1001/archpsyc.63.11.1225; Busatto GF, 2001, J AM ACAD CHILD PSY, V40, P347, DOI 10.1097/00004583-200103000-00015; Valente AA, 2005, BIOL PSYCHIAT, V58, P479, DOI 10.1016/j.biopsych.2005.04.021; Menzies L, 2007, BRAIN, V130, P3223, DOI 10.1093/brain/awm205; Leckman JF, 1997, AM J PSYCHIAT, V154, P911; Alvarenga PG, 2012, J PSYCHIATR RES, V46, P1635, DOI 10.1016/j.jpsychires.2012.09.002; Saxena S, 1998, BRIT J PSYCHIAT, V173, P26; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Nakao T, 2005, BIOL PSYCHIAT, V57, P901, DOI 10.1016/j.biopsycg.2004.12.039; Mataix-Cols D, 2008, EUR J NEUROSCI, V27, P3050, DOI 10.1111/j.1460-9568.2008.06311.x; Bloch MH, 2008, AM J PSYCHIAT, V165, P1532, DOI 10.1176/appi.ajp.2008.08020320; van den Heuvel OA, 2009, BRAIN, V132, P853, DOI 10.1093/brain/awn267; Rosario-Campos MC, 2006, MOL PSYCHIATR, V11, P495, DOI 10.1038/sj.mp.4001798; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Shapira NA, 2003, BIOL PSYCHIAT, V54, P751, DOI 10.1016/S0006-3223(03)00003-9; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Schienle A, 2005, INT J PSYCHOPHYSIOL, V57, P69, DOI 10.1016/j.ijpsycho.2004.12.013; Saxena S, 2001, BIOL PSYCHIAT, V50, P159, DOI 10.1016/S0006-3223(01)01123-4; Nakao T, 2009, J PSYCHIATR RES, V43, P784, DOI 10.1016/j.jpsychires.2008.10.013; Harrison BJ, 2013, BIOL PSYCHIAT, V73, P321, DOI 10.1016/j.biopsych.2012.10.006; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; DESWIT SJ, 2014, AM J PSYCHIAT, V171, P340; Kim JJ, 2001, BRIT J PSYCHIAT, V179, P330, DOI 10.1192/bjp.179.4.330; Matsunaga H, 2008, AM J PSYCHIAT, V165, P251, DOI 10.1176/appi.ajp.2007.07020340; Murayama K., 2012, PROGR NEUROPSYCHOPHA, V40, P160; Nakamae T, 2012, PROG NEURO-PSYCHOPH, V37, P22, DOI 10.1016/j.pnpbp.2011.11.017; Tanaka H, 2003, NEUROPSYCHOBIOLOGY, V47, P206, DOI 10.1159/000071216; ZOHAR J, 1989, ARCH GEN PSYCHIAT, V46, P505	46	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		411	421		10.1111/pcn.12269		11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000004		
J	Takahashi, T; Itoh, H; Nishikawa, Y; Higuchi, Y; Nakamura, M; Sasabayashi, D; Nishiyama, S; Mizukami, Y; Masaoka, Y; Suzuki, M				Takahashi, Tsutomu; Itoh, Hiroko; Nishikawa, Yumiko; Higuchi, Yuko; Nakamura, Mihoko; Sasabayashi, Daiki; Nishiyama, Shimako; Mizukami, Yuko; Masaoka, Yuri; Suzuki, Michio			Possible relation between olfaction and anxiety in healthy subjects	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						anxiety; emotion; healthy subjects; odor; olfaction	OBSESSIVE-COMPULSIVE DISORDER; OF-PENNSYLVANIA SMELL; POSTTRAUMATIC-STRESS-DISORDER; ODOR IDENTIFICATION; TASTE CENTER; PERCEPTION; SENSITIVITY; CONNECTIVITY; EMOTION; ABILITY	AimsWhile olfaction is a sense closely associated with the limbic system and emotions, the relation between emotional status and olfactory functioning has not been well documented. This study aimed to examine the possible effect of anxiety on olfaction in healthy subjects. MethodsWe investigated the effect of state and trait anxiety on the detection and recognition thresholds for five different odors in 124 healthy subjects (62 men and 62 women, mean age=27.2 years) using a T&T olfactometer. ResultsWhile the influences of age, socioeconomic status, IQ, and smoking history on olfaction were not significant, women had a lower recognition threshold for the odor of sweet fruit and a higher detection threshold for that of rotten food as compared with men. Both state and trait anxiety ratings were significantly associated with reduced olfactory ability, especially for identification of rose odor. ConclusionsThese findings suggest that emotional status affects olfactory functioning in healthy subjects. Our findings may also partly explain the mild olfactory impairment reported in clinical conditions, such as anxiety disorders.	[Takahashi, Tsutomu; Itoh, Hiroko; Nishikawa, Yumiko; Higuchi, Yuko; Nakamura, Mihoko; Sasabayashi, Daiki; Nishiyama, Shimako; Mizukami, Yuko; Suzuki, Michio] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Neuropsychiat, Toyama 9300194, Japan; [Masaoka, Yuri] Showa Univ, Sch Med, Dept Physiol, Tokyo 142, Japan	Takahashi, T (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Neuropsychiat, 2630 Sugitani, Toyama 9300194, Japan.	tsutomu@med.u-toyama.ac.jp			Japanese Society for the Promotion of Science [26461739]; JSPS Asian Core Program	This research was supported in part by a Grant-in-Aid for Scientific Research (C) (No. 26461739) from the Japanese Society for the Promotion of Science and a Research Grant from the JSPS Asian Core Program. These funding agencies had no role in the design, methods, informant recruitment, analysis, or preparation of the paper. We would like to thank Assistant Professor Keiko Yamada (Department of Psychiatric Nursing, University of Toyama), as well as Mr Hajime Itoh and Ms Nanaho Yamamoto (Toyama University Hospital), for their assistance in recruiting study participants. There is no conflict of interest to report concerning this research.	Pollatos O, 2007, CHEM SENSES, V32, P583, DOI 10.1093/chemse/bjm027; Matsuoka K, 2006, PSYCHIAT CLIN NEUROS, V60, P332, DOI 10.1111/j.1440-1819.2006.01510.x; Kim MJ, 2011, BEHAV BRAIN RES, V223, P403, DOI 10.1016/j.bbr.2011.04.025; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P241, DOI 10.1023/A:1007754611030; Doty RL, 2009, PHYSIOL BEHAV, V97, P213, DOI 10.1016/j.physbeh.2009.02.032; Croy I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018701; Rolls ET, 2003, EUR J NEUROSCI, V18, P695, DOI 10.1046/j.1460-9568.2003.02779.x; Croy I, 2014, J AFFECT DISORDERS, V160, P80, DOI 10.1016/j.jad.2013.12.026; Ishimaru T, 2007, RHINOLOGY, V45, P224; Dileo JF, 2008, PSYCHOL MED, V38, P523, DOI 10.1017/S0033291707001456; Krusemark EA, 2012, CHEMOSENS PERCEPT, V5, P37, DOI 10.1007/s12078-011-9111-7; Buron E, 2013, PSYCHOPATHOLOGY, V46, P63, DOI 10.1159/000338717; Iwata N, 1998, PSYCHOL REP, V82, P651, DOI 10.2466/PR0.82.2.651-656; Chen D, 2005, CHEM SENSES, V30, P345, DOI 10.1093/chemse/bji029; Atanasova B, 2008, NEUROSCI BIOBEHAV R, V32, P1315, DOI 10.1016/j.neubiorev.2008.05.003; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Segalas C, 2011, DEPRESS ANXIETY, V28, P932, DOI 10.1002/da.20836; Barnett R, 1999, PSYCHOL MED, V29, P1227, DOI 10.1017/S0033291799008818; Pause BM, 2001, J PSYCHIAT RES, V35, P271, DOI 10.1016/S0022-3956(01)00029-2; Brewer WJ, 2007, PSYCHIAT RES, V149, P97, DOI 10.1016/j.psychres.2006.03.005; Doty RL, 1997, CHEM SENSES, V22, P565, DOI 10.1093/chemse/22.5.565; First MB, 1997, STRUCTURED CLIN INTE; GROSSISSEROFF R, 1994, BIOL PSYCHIAT, V35, P798, DOI 10.1016/0006-3223(94)91142-8; Havlicek J, 2012, PERCEPTION, V41, P1246, DOI 10.1068/p7244; Karnekull SC, 2011, CHEM SENSES, V36, P641, DOI 10.1093/chemse/bjr028; Kondo H, 1998, AM J RHINOL, V12, P353, DOI 10.2500/105065898780182390; Krusemark Elizabeth A, 2013, J Neurosci, V33, P15324, DOI 10.1523/JNEUROSCI.1835-13.2013; La Buissonniere-Ariza V, 2013, CHEM SENSES, V38, P577, DOI 10.1093/chemse/bjt028; Larsson M, 2000, J GERONTOL B-PSYCHOL, V55, P304; Masaoka Y, 2013, NEUROSCI LETT, V549, P182, DOI 10.1016/j.neulet.2013.05.077; Masaoka Y, 2005, J PHYSIOL-LONDON, V566, P979, DOI 10.1113/jphysiol.2005.086124; Moberg PJ, 2014, SCHIZOPHRENIA BULL, V40, P50, DOI 10.1093/schbul/sbt049; Naudin M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046938; Novakova L, 2014, CHEMOSENS PERCEPT, V7, P56, DOI 10.1007/s12078-014-9167-2; Okada N, 2014, J BIOL PSYCHIAT, V25, P118; Okada N, 2014, JAPANESE JOURNAL OF, V25, P115; Schablitzky S, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00045; Purdon SE, 2001, J INT NEUROPSYCH SOC, V7, P703, DOI 10.1017/S1355617701766064; ROVEE CK, 1973, B PSYCHONOMIC SOC, V2, P76; Scheinost D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.24; Sladky R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050050; Soudry Y, 2011, EUR ANN OTORHINOLARY, V128, P18, DOI 10.1016/j.anorl.2010.09.007; Turetsky BI, 2012, SCHIZOPHR RES, V139, P260, DOI 10.1016/j.schres.2012.04.016	43	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		431	438		10.1111/pcn.12277		8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000006		
J	Mino, Y; Oshima, I; Shimodera, S				Mino, Y.; Oshima, I; Shimodera, S.			Association between feasibility of discharge, clinical state, and patient attitude among inpatients with schizophrenia in Japan (vol 63, pg 344, 2009)	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Correction									[Oshima, I] Japan Coll Social Work, Fac Social Welf, Tokyo, Japan							Mino Y, 2009, PSYCHIAT CLIN NEUROS, V63, P344, DOI 10.1111/j.1440-1819.2009.01950.x	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		439	439		10.1111/pcn.12305		1	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000008		
J	Nishio, M; Ito, J; Oshima, I; Suzuki, Y; Horiuchi, K; Sono, T; Fukaya, H; Hisanaga, F; Tsukada, K				Nishio, M.; Ito, J.; Oshima, I; Suzuki, Y.; Horiuchi, K.; Sono, T.; Fukaya, H.; Hisanaga, F.; Tsukada, K.			Preliminary outcome study on assertive community treatment in Japan (vol 66, pg 383, 2012)	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Correction									[Oshima, I] Japan Coll Social Work, Fac Social Welf, Tokyo, Japan							Nishio M, 2012, PSYCHIAT CLIN NEUROS, V66, P383, DOI 10.1111/j.1440-1819.2012.02348.x	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		439	439		10.1111/pcn.12306		1	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000009		
J	Sono, T; Oshima, I; Ito, J				Sono, T.; Oshima, I; Ito, J.			Family needs and related factors in caring for a family member with mental illness: adopting assertive community treatment in Japan where family caregivers play a large role in community care (vol 62, pg 584, 2008)	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Correction									[Oshima, I] Japan Coll Social Work, Fac Social Welf, Tokyo, Japan							Sono T, 2008, PSYCHIAT CLIN NEUROS, V62, P584, DOI 10.1111/j.1440-1819.2008.01852.x	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	JUL	2015	69	7			SI		439	439		10.1111/pcn.12304		1	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2NX	WOS:000357519000007		
J	Hidano, N; Hoshino, T; Sugiura, A				Hidano, Noboru; Hoshino, Tadao; Sugiura, Ayako			The effect of seismic hazard risk information on property prices: Evidence from a spatial regression discontinuity design	REGIONAL SCIENCE AND URBAN ECONOMICS			English	Article						Regression discontinuity design; Seismic hazard risk; Property market; Hedonic price; Quasi-experiment	HOUSING-MARKET; SOCIAL INTERACTIONS; TREATMENT RESPONSE; BUYER INFORMATION; HEDONIC PRICES; FLOOD HAZARDS; IDENTIFICATION; EARTHQUAKE; VALUES; MODEL	In this paper, we utilize a spatial two-dimensional regression discontinuity (RD) design to study how Tokyo's property market evaluates information on seismic hazard risk. This approach is superior to the conventional one-dimensional RD design as it is able to account for spatially heterogeneous treatment effects and reduce small-sample biases. Our data consists of residential property transactions from the 23-ward area of Tokyo. Our results show that the unit prices of residential properties in low-risk zones were between 13,970-17,380 JPY higher than those in high-risk zones depending on the type of seismic hazard risk. In addition, we find that information on seismic hazard risk does not significantly affect the prices of newly constructed apartments, which are more resistant to earthquake damage than older residences. (C) 2015 Elsevier B.V. All tights reserved.	[Hidano, Noboru] Tokyo Inst Technol, Ctr Study World Civilizat, Meguro Ku, Tokyo 1528552, Japan; [Hoshino, Tadao] Waseda Univ, Global Educ Ctr, Shinjuku Ku, Tokyo 1698050, Japan; [Sugiura, Ayako] Ogata Appraisal Cooperat, Minato Ku, Tokyo 1050001, Japan	Hidano, N (reprint author), Tokyo Inst Technol, Ctr Study World Civilizat, Meguro Ku, 2-12-1 O-Okayama, Tokyo 1528552, Japan.	hidano.n.aa@m.titech.ac.jp; thoshino@aoni.waseda.jp; sugiura@ogata-office.co.jp		Hoshino, Tadao/0000-0001-9484-2943	JSPS [B-25285071, PD-247943]	Hidano's work is supported by the JSPS Grant-in-Aid for Scientific Research B-25285071. Hoshino acknowledges financial support from the JSPS Grant-in-Aid for Scientific Research PD-247943. The authors would like to sincerely thank Daniel McMillen, Nicolai V. Kuminoff, and three anonymous referees for their constructive comments on the previous draft of the paper.	Papay JP, 2011, J ECONOMETRICS, V161, P203, DOI 10.1016/j.jeconom.2010.12.008; Bin O, 2004, LAND ECON, V80, P490, DOI 10.2307/3655805; Greenstone M, 2009, J ENVIRON ECON MANAG, V57, P21, DOI 10.1016/j.jeem.2008.02.004; Kelejian HH, 1998, J REAL ESTATE FINANC, V17, P99, DOI 10.1023/A:1007707430416; Kuminoff NV, 2010, J ENVIRON ECON MANAG, V60, P145, DOI 10.1016/j.jeem.2010.06.001; Lazzati N, 2015, QUANT ECON, V6, P49, DOI 10.3982/QE308; McCrary J, 2008, J ECONOMETRICS, V142, P698, DOI 10.1016/j.jeconom.2007.05.005; FRIEND I, 1975, AM ECON REV, V65, P900; Lee DS, 2010, J ECON LIT, V48, P281, DOI 10.1257/jel.48.2.281; Chay KY, 2005, J POLIT ECON, V113, P376, DOI 10.1086/427462; Hahn JY, 2001, ECONOMETRICA, V69, P201, DOI 10.1111/1468-0262.00183; Nakagawa M, 2007, REG SCI URBAN ECON, V37, P87, DOI 10.1016/j.regsciurbeco.2006.06.009; BROOKSHIRE DS, 1985, J POLIT ECON, V93, P369, DOI 10.1086/261304; Kelejian HH, 2007, J ECONOMETRICS, V140, P131, DOI 10.1016/j.jeconom.2006.09.005; Ferracci M, 2014, REV ECON STAT, V96, P812, DOI 10.1162/REST_a_00428; Manski CF, 2013, ECONOMET J, V16, pS1, DOI 10.1111/j.1368-423X.2012.00368.x; Naoi M, 2009, REG SCI URBAN ECON, V39, P658, DOI 10.1016/j.regsciurbeco.2009.08.002; Imbens GW, 2008, J ECONOMETRICS, V142, P615, DOI 10.1016/j.jeconom.2007.05.001; Pope JC, 2008, LAND ECON, V84, P551; Conley TG, 1999, J ECONOMETRICS, V92, P1, DOI 10.1016/S0304-4076(98)00084-0; Beron KJ, 1997, LAND ECON, V73, P101, DOI 10.2307/3147080; Pope JC, 2008, J URBAN ECON, V63, P498, DOI 10.1016/j.jue.2007.03.003; Bin O, 2013, J ENVIRON ECON MANAG, V65, P361, DOI 10.1016/j.jeem.2012.12.002; Bin O, 2009, AM J AGR ECON, V91, P1067, DOI 10.1111/j.1467-8276.2009.01316.x; Bin O, 2008, J RISK INSUR, V75, P63, DOI 10.1111/j.1539-6975.2007.00248.x; Cheng MY, 1997, ANN STAT, V25, P1001, DOI 10.1214/aos/1069362735; Fan J., 1996, LOCAL POLYNOMIAL MOD, V66; Frolich M., 2007, 32 U ST GALL DEP EC; Greenstone M, 2008, Q J ECON, V123, P951, DOI 10.1162/qjec.2008.123.3.951; Grout CA, 2011, REG SCI URBAN ECON, V41, P98, DOI 10.1016/j.regsciurbeco.2010.09.002; Hallstrom DG, 2005, J ENVIRON ECON MANAG, V50, P541, DOI 10.1016/j.jeem.2005.05.002; Hidano N., 2002, EC VALUATION ENV PUB; Imbens GW, 2011, WORKING PAPER; KANEMOTO Y, 1988, ECONOMETRICA, V56, P981, DOI 10.2307/1912708; Lee M., 2005, MICROECONOMETRICS PO; Parmetar C. F., 2009, SSRN WORKING PAPER S; Sato K., 2009, WORKING PAPER; Wong V. C., 2012, J EDUC BEHAV STAT, V38, P107	38	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-0462	1879-2308		REG SCI URBAN ECON	Reg. Sci. Urban Econ.	JUL	2015	53						113	122		10.1016/j.regsciurbeco.2015.05.005		10	Economics; Environmental Studies; Urban Studies	Business & Economics; Environmental Sciences & Ecology; Urban Studies	CM5VA	WOS:000357755900009		
J	Kurata, I; Tsuboi, H; Takahashi, H; Yagishita, M; Abe, S; Ebe, H; Takahashi, H; Asashima, H; Hirota, T; Hagiwara, S; Umeda, N; Kondo, Y; Ogishima, H; Suzuki, T; Matsumoto, I; Sumida, T				Kurata, Izumi; Tsuboi, Hiroto; Takahashi, Hidenori; Yagishita, Mizuki; Abe, Saori; Ebe, Hiroshi; Takahashi, Hiroyuki; Asashima, Hiromitsu; Hirota, Tomoya; Hagiwara, Shinya; Umeda, Naoto; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Matsumoto, Isao; Sumida, Takayuki			Clinical vignette	RHEUMATOLOGY			English	Editorial Material								A case of relapsing neurosarcoidosis with brain nodules and hydrocephalus successfully treated by corticosteroid and methotrexate	[Kurata, Izumi; Tsuboi, Hiroto; Takahashi, Hidenori; Yagishita, Mizuki; Abe, Saori; Ebe, Hiroshi; Takahashi, Hiroyuki; Asashima, Hiromitsu; Hirota, Tomoya; Hagiwara, Shinya; Umeda, Naoto; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Matsumoto, Isao; Sumida, Takayuki] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan	Sumida, T (reprint author), Univ Tsukuba, Fac Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	tsumida@md.tsukuba.ac.jp					Brouwer MC, 2009, J NEUROL NEUROSUR PS, V80, P550, DOI 10.1136/jnnp.2008.163725; Nozaki K, 2013, CURR TREAT OPTION NE, V15, P492, DOI 10.1007/s11940-013-0242-9	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324	1462-0332		RHEUMATOLOGY	RHEUMATOLOGY	JUL	2015	54	7					1160	1160		10.1093/rheumatology/kev109		1	Rheumatology	Rheumatology	CM1GY	WOS:000357430500007		
J	Akamata, K; Asano, Y; Taniguchi, T; Yamashita, T; Saigusa, R; Nakamura, K; Noda, S; Aozasa, N; Toyama, T; Takahashi, T; Ichimura, Y; Sumida, H; Tada, Y; Sugaya, M; Kadono, T; Sato, S				Akamata, Kaname; Asano, Yoshihide; Taniguchi, Takashi; Yamashita, Takashi; Saigusa, Ryosuke; Nakamura, Kouki; Noda, Shinji; Aozasa, Naohiko; Toyama, Tetsuo; Takahashi, Takehiro; Ichimura, Yohei; Sumida, Hayakazu; Tada, Yayoi; Sugaya, Makoto; Kadono, Takafumi; Sato, Shinichi			Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis	RHEUMATOLOGY			English	Article						systemic sclerosis; chemerin; transforming growth factor beta; Fli1; digital ulcers	BLEOMYCIN-INDUCED SCLERODERMA; SERUM ADIPONECTIN LEVELS; INTEGRIN ALPHA-V-BETA-5; CLINICAL-SIGNIFICANCE; RHEUMATOID-ARTHRITIS; DERMAL FIBROBLASTS; IN-SCLERODERMA; SKIN SCLEROSIS; FIBROSIS; RECEPTOR	Objectives. Chemerin is a member of adipocytokines with a chemoattractant effect on plasmacytoid dendritic cells and macrophages and pro-angiogenic properties. We investigated the potential role of chemerin in the development of SSc. Methods. Chemerin expression was evaluated by immunostaining and/or real-time quantitative RT-PCR in human and murine skin. The mechanisms regulating chemerin expression in dermal fibroblasts and endothelial cells were examined using the gene silencing technique and chromatin immunoprecipitation. Serum chemerin levels were determined by ELISA in 64 SSc patients and 19 healthy subjects. Results. In SSc lesional skin, chemerin was up-regulated in small blood vessels, while it was down-regulated in fibroblasts surrounded with thickened collagen bundles. The decreased expression of chemerin was significantly reversed by TGF-beta 1 antisense oligonucleotide in cultured SSc dermal fibroblasts and chemerin expression was markedly decreased in dermal fibroblasts of bleomycin-treated mice. Gene silencing of transcription factor Fli1, which binds to the chemerin promoter, induced chemerin expression in human dermal microvascular endothelial cells and Fli1(+/-) mice exhibited elevated chemerin expression in dermal blood vessels. Serum chemerin levels inversely correlated with estimated glomerular filtration rate in SSc patients with renal dysfunction. In SSc patients with normal renal function, patients with digital ulcers had higher serum chemerin levels than those without. Conclusion. Chemerin is down-regulated in SSc dermal fibroblasts by autocrine TGF-beta, while it is up-regulated in SSc dermal blood vessels through endothelial Fli1 deficiency. Increased chemerin expression in dermal blood vessels may be associated with the development of digital ulcers in SSc.	[Akamata, Kaname; Asano, Yoshihide; Taniguchi, Takashi; Yamashita, Takashi; Saigusa, Ryosuke; Nakamura, Kouki; Noda, Shinji; Aozasa, Naohiko; Toyama, Tetsuo; Takahashi, Takehiro; Ichimura, Yohei; Sumida, Hayakazu; Tada, Yayoi; Sugaya, Makoto; Kadono, Takafumi; Sato, Shinichi] Univ Tokyo, Grad Sch Med, Dept Dermatol, Tokyo 1138655, Japan	Asano, Y (reprint author), Univ Tokyo, Grad Sch Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yasano-tky@umin.ac.jp			Ministry of Health, Labour, and Welfare of Japan	This work was supported by a grant for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan.	Noda S, 2013, RHEUMATOLOGY, V52, P790, DOI 10.1093/rheumatology/kes379; Ichimura Y, 2014, ARCH DERMATOL RES, V306, P331, DOI 10.1007/s00403-013-1431-9; Toyama T, 2013, J EUR ACAD DERMATOL, V27, P337, DOI 10.1111/j.1468-3083.2011.04413.x; Hu WC, 2011, DIABETES RES CLIN PR, V91, P159, DOI 10.1016/j.diabres.2010.11.016; Masui Y, 2013, MOD RHEUMATOL, V23, P323, DOI 10.1007/s10165-012-0660-7; Abraham DJ, 2009, RHEUMATOLOGY, V48, P3, DOI 10.1093/rheumatology/ken481; Aozasa N, 2013, J EUR ACAD DERMATOL, V27, P37, DOI 10.1111/j.1468-3083.2011.04354.x; Albanesi C, 2009, J EXP MED, V206, P249, DOI 10.1084/jem.20080129; Masui Y, 2012, J EUR ACAD DERMATOL, V26, P354, DOI 10.1111/j.1468-3083.2011.04077.x; Asano Y, 2010, J DERMATOL, V37, P54, DOI 10.1111/j.1346-8138.2009.00758.x; Bondue B, 2011, CYTOKINE GROWTH F R, V22, P331, DOI 10.1016/j.cytogfr.2011.11.004; Eisinger K, 2012, EXP MOL PATHOL, V92, P90, DOI 10.1016/j.yexmp.2011.10.006; Kaur J, 2010, BIOCHEM BIOPH RES CO, V391, P1762, DOI 10.1016/j.bbrc.2009.12.150; Asano Y, 2005, J IMMUNOL, V175, P7708; Yoshizaki A, 2008, AM J PATHOL, V172, P1650, DOI 10.2353/ajpath.2008.071049; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Asano Y, 2007, J BIOL CHEM, V282, P34672, DOI 10.1074/jbc.M703907200; Asano Y, 2004, AM J PATHOL, V164, P1275, DOI 10.1016/S0002-9440(10)63215-4; Bozaoglu K, 2010, J CLIN ENDOCR METAB, V95, P2476, DOI 10.1210/jc.2010-0042; Masui Y, 2014, RHEUMATOL INT, V34, P1165, DOI 10.1007/s00296-013-2880-3; Levey AS, 1999, ANN INTERN MED, V130, P461; Bhattacharyya S, 2013, AM J PATHOL, V182, P192, DOI 10.1016/j.ajpath.2012.09.007; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Asano Y, 2006, AM J PATHOL, V168, P499, DOI 10.2353/ajpath.2006.041306; Asano Y, 2005, ARTHRITIS RHEUM, V52, P2897, DOI 10.1002/art.21246; Wang N, 2014, CLIN ORAL INVEST, V18, P997, DOI 10.1007/s00784-013-1046-8; Pfau D, 2010, DIABETES CARE, V33, P171, DOI 10.2337/dc09-1351; Wang YQ, 2006, ARTHRITIS RHEUM, V54, P2271, DOI 10.1002/art.21948; Asano Y, 2010, AM J PATHOL, V176, P1983, DOI 10.2353/ajpath.2010.090593; Ernst MC, 2010, TRENDS ENDOCRIN MET, V21, P660, DOI 10.1016/j.tem.2010.08.001; Masui Y, 2013, RHEUMATOLOGY, V52, P1239, DOI 10.1093/rheumatology/ket010; Banas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058709; Kaneko K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3475; Noda S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032272; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; Yamamoto T, 2003, J INVEST DERMATOL, V121, P510, DOI 10.1046/j.1523-1747.2003.12408.x	36	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324	1462-0332		RHEUMATOLOGY	RHEUMATOLOGY	JUL	2015	54	7					1308	1316		10.1093/rheumatology/keu479		9	Rheumatology	Rheumatology	CM1GY	WOS:000357430500027		
J	Honma, KI				Honma, Ken-Ichi			Beautiful hypothesis and an ugly little fact PREFACE	SLEEP AND BIOLOGICAL RHYTHMS			English	Editorial Material									Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan	Honma, KI (reprint author), Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.							0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1446-9235	1479-8425		SLEEP BIOL RHYTHMS	Sleep Biol. Rhythms	JUL	2015	13	3					195	195		10.1111/sbr.12131		1	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CL9VA	WOS:000357325000001		
J	Takahashi, Y; Kanbayashi, T; Hoshikawa, M; Imanishi, A; Sagawa, Y; Tsutsui, K; Takeda, Y; Kusanagi, H; Nishino, S; Shimizu, T				Takahashi, Yuya; Kanbayashi, Takashi; Hoshikawa, Masamitsu; Imanishi, Aya; Sagawa, Yohei; Tsutsui, Kou; Takeda, Yasuhiro; Kusanagi, Hiroaki; Nishino, Seiji; Shimizu, Tetsuo			Relationship of orexin (hypocretin) system and astrocyte activation in Parkinson's disease with hypersomnolence	SLEEP AND BIOLOGICAL RHYTHMS			English	Article						glial fibrillary acidic protein; hypersomnolence; orexin; Parkinson's disease; S100B	EXCESSIVE DAYTIME SLEEPINESS; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; BRAIN-INJURY; NARCOLEPSY; DAMAGE; PATHOLOGY; SERUM; NEUROFILAMENT; MECHANISMS	We studied the relationship of orexin (hypocretin) system and astrocyte activation in hypersomnolence symptom (HS) in Parkinson's disease (PD). In a total of 30 subjects, including five PD patients with HS, eight PD patients without HS, eight patients with narcolepsy, and nine control subjects, orexin and glial fibrillary acidic protein (GFAP) as well as S100B levels in cerebrospinal fluid (CSF), which are markers of astrocyte activation, were measured and compared. In the comparison of orexin levels among the four groups of subjects, only the narcolepsy group showed significantly lower levels. The levels of CSF orexin in the PD patients with HS tended to be lower compared with those in the control group, although the difference was not statistically significant. The majority of reports have indicated that CSF orexin levels are in the normal range in most PD patients, some PD patients with severe HS showed low orexin levels. Compared with those of the control group, GFAP levels were significantly higher in the group of PD with HS and narcolepsy, but not PD without HS. No groups showed a significant difference in S100B levels. In the whole subjects with PD, narcolepsy, and controls, orexin levels were inversely correlated with GFAP. Therefore, increased GFAP may indicate orexin deficiency both in narcolepsy and PD with HS.	[Takahashi, Yuya; Kanbayashi, Takashi; Imanishi, Aya; Sagawa, Yohei; Tsutsui, Kou; Kusanagi, Hiroaki; Shimizu, Tetsuo] Akita Univ, Grad Sch Med, Dept Neuropsychiat, Akita 0108543, Japan; [Kanbayashi, Takashi; Shimizu, Tetsuo] Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, Tsukuba, Ibaraki, Japan; [Hoshikawa, Masamitsu; Takeda, Yasuhiro] Ono Pharmaceut Co Ltd, Dept Biol & Pharmacol, Discovery Res Labs, Osaka, Japan; [Nishino, Seiji] Stanford Univ, Sleep & Circadian Neurobiol Lab, Palo Alto, CA 94304 USA	Takahashi, Y (reprint author), Akita Univ, Grad Sch Med, Dept Neuropsychiat, 1-1-1 Hondo, Akita 0108543, Japan.	yuya@med.akita-u.ac.jp					Thannickal TC, 2007, BRAIN, V130, P1586, DOI 10.1093/brain/awm097; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Peyron C, 2000, NAT MED, V6, P991; Drouot X, 2003, NEUROLOGY, V61, P540; Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9; Asai H, 2009, CLIN NEUROL NEUROSUR, V111, P341, DOI 10.1016/j.clineuro.2008.11.007; Baumann C, 2005, J NEUROL, V252, P139, DOI 10.1007/s00415-005-0614-5; Muramatsu Y, 2003, GLIA, V42, P307, DOI 10.1002/glia.10225; Takano R, 2010, NEUROLOGY, V75, P208, DOI 10.1212/WNL.0b013e3181e2414b; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; Maeda T, 2006, SLEEP MED, V7, P662, DOI 10.1016/j.sleep.2006.05.017; Constantinescu R, 2010, PARKINSONISM RELAT D, V16, P142, DOI 10.1016/j.parkreldis.2009.07.007; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Halliday GM, 2011, MOVEMENT DISORD, V26, P6, DOI [10.1002/mds.23455, 10.1002/23455]; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Su W, 2012, CLIN NEUROL NEUROSUR, V114, P372, DOI 10.1016/j.clineuro.2011.11.002; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Thannickal TC, 2009, SLEEP, V32, P993; Hobson DE, 2002, JAMA-J AM MED ASSOC, V287, P455, DOI 10.1001/jama.287.4.455; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Paus S, 2003, MOVEMENT DISORD, V18, P659, DOI 10.1002/mds.10417; Nishino S, 2005, SLEEP MED REV, V9, P269, DOI 10.1016/j.smrv.2005.03.004; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; Buritica E, 2009, J NEUROTRAUM, V26, P2145, DOI 10.1089/neu.2009.0894; Feneberg E, 2013, SLEEP MED, V14, P692, DOI 10.1016/j.sleep.2013.04.013; Fronczek R, 2008, BRAIN, V131, DOI 10.1093/brain/awm222; Fujii C, 2011, NEUROSCI LETT, V494, P86, DOI 10.1016/j.neulet.2011.02.063; Honda M, 2009, NEUROLOGY, V73, P511, DOI 10.1212/WNL.0b013e3181b2a6af; Ikeda K, 1998, NEUROBIOL AGING S1, V19, P85; Kleindienst A, 2010, ACT NEUR S, V106, P247, DOI 10.1007/978-3-211-98811-4_46; Morozov SG, 1997, VOP MED KHIM, V43, P34; Overeem S, 2002, NEUROLOGY, V58, P498; Pelzold A, 2003, NEUROSCI LETT, V336, P167; Teraoka H, 2013, RINSHO SHINKEIGAKU, V53, P389; Tullberg M, 1998, NEUROLOGY, V50, P1122; Yasui K, 2006, J NEUROL SCI, V250, P120, DOI 10.1016/j.jns.2006.08.004	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1446-9235	1479-8425		SLEEP BIOL RHYTHMS	Sleep Biol. Rhythms	JUL	2015	13	3					252	260		10.1111/sbr.12112		9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CL9VA	WOS:000357325000008		
J	Takahashi, Y; Wakamatsu, S; Tabata, H; Oshitari, T; Natsugari, H; Takahashi, H				Takahashi, Yuka; Wakamatsu, Shintaro; Tabata, Hidetsugu; Oshitari, Tetsuta; Natsugari, Hideaki; Takahashi, Hideyo			Isolation of Atropisomers of N-Benzoylated Pyrroles and Imidazoles	SYNTHESIS-STUTTGART			English	Article						amides; atropisomerism; chirality; heterocycles; pyrroles	7-MEMBERED-RING BENZOLACTAMS; ACTIVE CONFORMATION; AXIAL CHIRALITY; DRUG DISCOVERY; DERIVATIVES; RECEPTOR; NUCLEUS	The stereochemistry of N-benzoylated pyrroles and imidazoles was studied. 2,6-Disubstituted 1-benzoypyrroles and 1-benzoylimidazoles were shown to have an atropisomeric property and their stable atropisomers were isolated.	[Takahashi, Yuka; Wakamatsu, Shintaro; Tabata, Hidetsugu; Oshitari, Tetsuta; Natsugari, Hideaki; Takahashi, Hideyo] Teikyo Univ, Fac Pharma Sci, Itabashi Ku, Tokyo 1738605, Japan	Takahashi, Y (reprint author), Teikyo Univ, Fac Pharma Sci, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	hide-tak@pharm.teikyo-u.ac.jp			Japan Society for the Promotion of Science [24590020]; Astellas Foundation for Research on Metabolic Disorders; MEXT	This work was supported in part by a Grant-in-Aid for Scientific Research (C) (24590020) from the Japan Society for the Promotion of Science. H.T. is grateful for financial support from the Astellas Foundation for Research on Metabolic Disorders (2013) and the MEXT-Supported 53.6 Program for the Strategic Research Foundation at Private Universities (2013-2017).	Clayden J, 2009, ANGEW CHEM INT EDIT, V48, P6398, DOI 10.1002/anie.200901719; Zask A, 2013, CHIRALITY, V25, P265, DOI 10.1002/chir.22145; Wakamatsu S, 2013, CHEM-EUR J, V19, P7056, DOI 10.1002/chem.201300064; Tabata H, 2008, ORG LETT, V10, P4871, DOI 10.1021/ol801968b; Petit M, 2005, J AM CHEM SOC, V127, P14994, DOI 10.1021/ja055666d; Takahashi H, 2011, ORG LETT, V13, P760, DOI 10.1021/ol103008d; Tabata H, 2011, ANGEW CHEM INT EDIT, V50, P3075, DOI 10.1002/anie.201007772; LaPlante SR, 2011, J MED CHEM, V54, P7005, DOI 10.1021/jm200584g; Natsugari H, 1999, J MED CHEM, V42, P3982, DOI 10.1021/jm990220r; STEWART WE, 1970, CHEM REV, V70, P517, DOI 10.1021/cr60267a001; Tabata H, 2014, ORG LETT, V16, P1514, DOI 10.1021/ol500417t; Clayden J., 2004, TETRAHEDRON, V60, P4335; Lee S, 2008, BIOORGAN MED CHEM, V16, P9519, DOI 10.1016/j.bmc.2008.09.037; MATSUO T, 1969, J CHEM SOC CHEM COMM, P501, DOI 10.1039/c29690000501; Staab H, 1962, ANGEW CHEM INT EDIT, V1, P351, DOI [10.1002/anie.196203511, DOI 10.1002/ANIE.196203511]; Tabata H, 2013, J ORG CHEM, V78, P6264, DOI 10.1021/jo401020y; Tabata H, 2011, J ORG CHEM, V76, P5123, DOI 10.1021/jo2008725; Tabata H, 2012, CHEM-EUR J, V18, P1572, DOI 10.1002/chem.201103264	18	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0039-7881	1437-210X		SYNTHESIS-STUTTGART	Synthesis	JUL	2015	47	14					2125	2128		10.1055/s-0034-1380537		4	Chemistry, Organic	Chemistry	CM3UN	WOS:000357610400014		
J	Haro, A; Saitoh, G; Tamiya, S; Nagashima, A				Haro, Akira; Saitoh, Genkichi; Tamiya, Sadafumi; Nagashima, Akira			Four-year natural clinical course of pulmonary epithelioid hemangioendothelioma without therapy	THORACIC CANCER			English	Article						Epithelioid; hemangioendothelioma; observation	OF-THE-LITERATURE; CHEMOTHERAPY	Pulmonary epithelial hemangioendothelioma is a rare low to intermediate malignant vascular tumor originating from vascular endothelial cells. The therapy for this disease, if possible, is surgical resection. However, there is no standard treatment for patients with multiple unresectable lesions. We present the case of a 42-year-old woman treated with a natural clinical course of hemangioendothelioma for four years without therapy. The nodules have increased in number and size extremely slowly, and the patient is alive and asymptomatic four years after diagnosis.	[Haro, Akira; Saitoh, Genkichi; Nagashima, Akira] Kitakyushu Municipal Med Ctr, Dept Thorac Surg, Kokurakita Ku, Fukuoka 8020077, Japan; [Tamiya, Sadafumi] Kitakyushu Municipal Med Ctr, Dept Diagnost Pathol, Kokurakita Ku, Fukuoka 8020077, Japan	Haro, A (reprint author), Kitakyushu Municipal Med Ctr, Dept Thorac Surg, Kokurakita Ku, 2-1-1 Bashaku, Fukuoka 8020077, Japan.	aharo@surg2.med.kyushu-u.ac.jp					Amin RMS, 2006, RESPIROLOGY, V11, P818, DOI 10.1111/j.1400-1843.2006.00923.x; Weissferdt A, 2010, ANN DIAGN PATHOL, V14, P296, DOI 10.1016/j.anndiagpath.2010.03.001; Chevreau C, 2013, CANCER-AM CANCER SOC, V119, P2639, DOI 10.1002/cncr.28109; Bagan P, 2006, ANN THORAC SURG, V82, P2010, DOI 10.1016/j.athoracsur.2006.06.068; Lau K, 2011, CHEST, V140, P1312, DOI 10.1378/chest.11-0039; Fujita K, 2009, Kyobu Geka, V62, P223; Mizota A, 2011, J THORAC ONCOL, V6, P651, DOI 10.1097/JTO.0b013e31820b9e23; Okamura K, 2010, ANN THORAC CARDIOVAS, V16, P432; Ye B, 2013, ONCOL LETT, V5, P1491, DOI 10.3892/ol.2013.1217	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1759-7706	1759-7714		THORAC CANCER	Thorac. Cancer	JUL	2015	6	4					544	547		10.1111/1759-7714.12192		4	Oncology; Respiratory System	Oncology; Respiratory System	CM3ML	WOS:000357586300024		
J	Ebina, Y; Ieko, M; Naito, S; Kobashi, G; Deguchi, M; Minakami, H; Atsumi, T; Yamada, H				Ebina, Yasuhiko; Ieko, Masahiro; Naito, Sumiyoshi; Kobashi, Gen; Deguchi, Masashi; Minakami, Hisanori; Atsumi, Tatsuya; Yamada, Hideto			Low levels of plasma protein S, protein C and coagulation factor XII during early pregnancy and adverse pregnancy outcome	THROMBOSIS AND HAEMOSTASIS			English	Article						Factor XII; pregnancy; pregnancy-induced hypertension; premature delivery; protein C; protein S	GROWTH RESTRICTION; THROMBOPHILIA; DEFICIENCY; THROMBOSIS; PREVALENCE; COMPLICATIONS; FIBRINOLYSIS; INHIBITOR; FREQUENCY; MUTATION	It was the study objective to evaluate whether low levels of plasma protein S (PS) activity, free PS, protein C (PC) activity and coagulation factor XII (FXII) during early pregnancy are related to adverse pregnancy outcomes. Peripheral blood samples were obtained at 8-14 gestational weeks (GW) from a consecutive series of 1,220 women. The levels of plasma PS activity, free PS, PC activity, and FXII were measured. Cut-off values were defined as <1st, <5th, and <10th percentiles of values obtained from 933 women whose pregnancies ended in normal deliveries without complications. PS activity of <10th percentile yielded risks of pregnancy-induced hypertension (PIN) and severe PIH, while free PS level of <5th percentile yielded a risk of pre-eclampsia. FXII level of <1st percentile yielded a risk of premature delivery (PD) at <34 GW. None was associated with PD at <37 GW, fetal growth restriction or fetal loss. A multivariate analysis demonstrated that PS activity of <10th percentile (odds ratio 5.9, 95% confidence interval 1.7-18.1) and body mass index (BMI) >= 25 kg/m(2) (4.3, 1 1.1-13.3) were independent risk factors for severe PIN. Similarly, free PS level of <5th percentile (4.4, 1.0-14.3) and BMI >= 25 kg/m(2) (4.0, 1.3-10.9) were independent risk factors for pre-eclampsia. In conclusion, women with low levels of plasma PS activity and free PS during early pregnancy might have increased risks of PIN, severe PIN or pre-eclampsia. Women with low FXII level might have an increased risk of PD at <34 GW.	[Ebina, Yasuhiko; Deguchi, Masashi; Yamada, Hideto] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo 6500017, Japan; [Ieko, Masahiro] Hlth Sci Univ Hokkaido, Dept Internal Med, Ishikari, Hokkaido 06102, Japan; [Naito, Sumiyoshi] Hlth Sci Univ Hokkaido, Sch Dent, Dept Clin Lab, Ishikari, Hokkaido 06102, Japan; [Kobashi, Gen] Natl Inst Radiol Sci, Dept Planning & Management, Chiba 260, Japan; [Minakami, Hisanori] Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan; [Atsumi, Tatsuya] Hokkaido Univ, Grad Sch Med, Dept Med 2, Sapporo, Hokkaido, Japan	Yamada, H (reprint author), Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	yhideto@med.kobe-u.ac.jp			Japan Society for the Promotion of Science [26462489, 25462593]; Ministry of Health, Labour and Welfare of Japan [H25-Jisedai-Ippan-005]	This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (Grant No. 26462489, 25462593) and the Ministry of Health, Labour and Welfare of Japan (Grant No. H25-Jisedai-Ippan-005).	Abbassi-Ghanavati M, 2009, OBSTET GYNECOL, V114, P1326, DOI 10.1097/AOG.0b013e3181c2bde8; Gader AMA, 2006, INT J GYNECOL OBSTET, V95, P248, DOI 10.1016/j.ijgo.2006.07.014; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1097, DOI 10.1016/0002-9378(95)91333-5; KLUFT C, 1987, SEMIN THROMB HEMOST, V13, P50, DOI 10.1055/s-2007-1003475; Dykes AC, 2001, BRIT J HAEMATOL, V113, P636; Kimura R, 2006, BLOOD, V107, P1737, DOI 10.1182/blood-2005-09-3892; Kujovich JL, 2004, AM J OBSTET GYNECOL, V191, P412, DOI 10.1016/j.ajog.2004.03.001; Rey E, 2003, LANCET, V361, P901, DOI 10.1016/S0140-6736(03)12771-7; Alfirevic Z, 2002, EUR J OBSTET GYN R B, V101, P6, DOI 10.1016/S0301-2115(01)00496-1; Cerneca F, 1997, EUR J OBSTET GYN R B, V73, P31, DOI 10.1016/S0301-2115(97)02734-6; Hojo S, 2008, THROMB RES, V123, P55, DOI 10.1016/j.thromres.2008.01.016; Paidas MJ, 2005, SEMIN PERINATOL, V29, P150, DOI 10.1053/j.semperi.2005.05.008; Yamada H, 2009, J REPROD IMMUNOL, V79, P188, DOI 10.1016/j.jri.2008.11.001; De Bonis M, 2012, EUR J OBSTET GYN R B, V160, P142, DOI 10.1016/j.ejogrb.2011.10.008; Rosendaal FR, 2009, J THROMB HAEMOST, V7, P301, DOI 10.1111/j.1538-7836.2009.03394.x; Gregg JP, 1997, AM J MED GENET, V73, P334, DOI 10.1002/(SICI)1096-8628(19971219)73:3<334::AID-AJMG20>3.0.CO;2-J; Gris JC, 1997, THROMB HAEMOSTASIS, V77, P1096; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; LAMMLE B, 1991, THROMB HAEMOSTASIS, V65, P117; Miyata T, 2009, JAP J CLIN HEMATOL, V50, P381; Nomura T, 2000, THROMB RES, V100, P367, DOI 10.1016/S0049-3848(00)00337-6; Osmanagaoglu Mehmet A., 2005, Archives of Gynecology and Obstetrics, V271, P227, DOI 10.1007/s00404-003-0596-4; Choi JW, 2002, ANN HEMATOL, V81, P611, DOI 10.1007/s00277-002-0549-1; Robertson L, 2006, BRIT J HAEMATOL, V132, P171, DOI 10.1111/j.1365-2141.2005.05847.x; RODEGHIERO F, 1992, THROMB HAEMOSTASIS, V67, P590; Said JM, 2010, THROMB HAEMOSTASIS, V103, P984, DOI 10.1160/TH09-07-0476; Sayin M, 2005, EUR J OBSTET GYN R B, V123, P183, DOI 10.1016/j.ejogrb.2005.03.020; Wu O, 2006, HEALTH TECHNOL ASSES, V10, P1; Yamada H, 2001, SEMIN THROMB HEMOST, V27, P121, DOI 10.1055/s-2001-14070; Yamada H, 2000, GYNECOL OBSTET INVES, V49, P80, DOI 10.1159/000010220	30	1	1	SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN	STUTTGART	HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY	0340-6245			THROMB HAEMOSTASIS	Thromb. Haemost.	JUL	2015	114	1					65	69		10.1160/TH14-11-0928		5	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CM2YH	WOS:000357547800012		
J	Matsuura, Y; Yamashita, A; Iwakiri, T; Sugita, C; Okuyama, N; Kitamura, K; Asada, Y				Matsuura, Yunosuke; Yamashita, Atsushi; Iwakiri, Takashi; Sugita, Chihiro; Okuyama, Nozomi; Kitamura, Kazuo; Asada, Yujiro			Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity	THROMBOSIS AND HAEMOSTASIS			English	Article						Atherothrombosis; hypoxia; hypoxia-inducible factor-1; nuclear factor-kappa B; tissue factor	PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ATHEROSCLEROTIC PLAQUES; UNSTABLE ANGINA-PECTORIS; INDUCIBLE FACTOR-I; GENE-EXPRESSION; TISSUE FACTOR; ATHERECTOMY SPECIMENS; NEOINTIMA FORMATION; FIBRIN DEPOSITION; MACROPHAGES	Atherosclerotic lesions represent a hypoxic milieu. However, the significance of this milieu in atherothrombosis has not been established. We aimed to assess the hypothesis that vascular wall hypoxia promotes arterial thrombus formation. We examined the relation between vascular wall hypoxia and arterial thrombus formation using a rabbit model in which arterial thrombosis was induced by 0.5 %-cholesterol diet and repeated balloon injury of femoral arteries. Vascular wall hypoxia was immunohistochemically detected by pimonidazole hydrochloride, a hypoxia marker. Rabbit neointima and THP-1 macrophages were cultured to analyse prothrombotic factor expression under hypoxic conditions (1 % O-2). Prothrombotic factor expression and nuclear localisation of hypoxia-inducible factor (HIF)-1 alpha and nuclear factor-kappa B (NF-kappa B) p65 were immunohistochemically assessed using human coronary atherectomy plaques. Hypoxic areas were localised in the macrophage-rich deep portion of rabbit neointima and positively correlated with the number of nucleiimmunopositive for HIF-1 alpha and NF-kappa B p65, and tissue factor (IF) expression. Immunopositive areas for glycoprotein IIb/IIIa and fibrin in thrombi were significantly correlated with hypoxic areas in arteries. IF and plasminogen activator inhibitor-1 (PAI-1) expression was increased in neointimal tissues and/or macrophages cultured under hypoxia, and both were suppressed by inhibitors of either HIF-1 or NF-kappa B. In human coronary plaques, the number of HIF-1 alpha-immunopositive nuclei was positively correlated with that of NF-kappa B-immunopositive nuclei and TF-immunopositive and PAI-1-immunopositive area, and it was significantly higher in thrombotic plaques. Vascular wall hypoxia augments the thrombogenic potential of atherosclerotic plaque and thrombus formation on plaques via prothrombotic factor upregulation.	[Matsuura, Yunosuke; Yamashita, Atsushi; Iwakiri, Takashi; Sugita, Chihiro; Okuyama, Nozomi; Asada, Yujiro] Miyazaki Univ, Fac Med, Dept Pathol, Kiyotake, Miyazaki 8891692, Japan; [Matsuura, Yunosuke; Iwakiri, Takashi; Kitamura, Kazuo] Miyazaki Univ, Fac Med, Dept Internal Med, Kiyotake, Miyazaki 8891692, Japan	Asada, Y (reprint author), Miyazaki Univ, Fac Med, Dept Pathol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	yasada@med.miyazaki-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan [23390084, 23790410]	This study was supported in part by Grants-in-Aid for Scientific Research in Japan (Nos. 23390084, 23790410) from the Ministry of Education, Science, Sports and Culture of Japan.	Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Oemar BS, 1998, CIRCULATION, V97, P2494; Kietzmann T, 1999, BLOOD, V94, P4177; RAGHUNATH PN, 1995, ARTERIOSCL THROM VAS, V15, P1432; Sobel BE, 1998, CIRCULATION, V97, P2213; Wilson SH, 2002, ATHEROSCLEROSIS, V160, P147, DOI 10.1016/S0021-9150(01)00546-9; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Parathath S, 2011, CIRC RES, V109, P1141, DOI 10.1161/CIRCRESAHA.111.246363; Monaco C, 2004, P NATL ACAD SCI USA, V101, P5634, DOI 10.1073/pnas.0401060101; Reininger AJ, 2010, J AM COLL CARDIOL, V55, P1147, DOI 10.1016/j.jacc.2009.11.051; Temma T, 2010, J NUCL MED, V51, P1979, DOI 10.2967/jnumed.110.081216; Kruithof EKO, 2008, THROMB HAEMOSTASIS, V100, P969, DOI 10.1160/TH08-04-0269; Majesky MW, 2007, ARTERIOSCL THROM VAS, V27, P1248, DOI 10.1161/ATVBAHA.107.141069; Karshovska E, 2007, ARTERIOSCL THROM VAS, V27, P2540, DOI 10.1161/ATVBAHA.107.151050; Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025; Hatakeyama K, 1997, ATHEROSCLEROSIS, V133, P213, DOI 10.1016/S0021-9150(97)00132-9; Subramanian P, 2010, CIRC RES, V107, P96, DOI 10.1161/CIRCRESAHA.109.212647; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Sluimer JC, 2009, J PATHOL, V218, P7, DOI 10.1002/path.2518; Leppanen O, 2006, ATHEROSCLEROSIS, V188, P323, DOI 10.1016/j.atherosclerosis.2005.11.017; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Semenza GL, 2010, WIRES SYST BIOL MED, V2, P336, DOI 10.1002/wsbm.69; Chen F, 2005, CORONARY ARTERY DIS, V16, P191, DOI 10.1097/00019501-200505000-00009; Deguchi JO, 2009, ARTERIOSCL THROM VAS, V29, P1664, DOI 10.1161/ATVBAHA.109.194043; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Hatakeyama K, 2005, AM J CARDIOL, V95, P632, DOI 10.1016/j.amjcard.2004.11.012; Lee KW, 2003, BLOOD COAGUL FIBRIN, V14, P605, DOI 10.1097/01.mbc.0000061355.73802.ea; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; Marsch E, 2014, ARTERIOSCL THROM VAS, V34, P2545, DOI 10.1161/ATVBAHA.114.304023; Matsuda S, 2011, J THROMB HAEMOST, V9, P201, DOI 10.1111/j.1538-7836.2010.04086.x; Okami N, 2009, CARDIOVASC PATHOL, V18, P294, DOI 10.1016/j.carpath.2008.07.002; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Semenza GL, 2004, J APPL PHYSIOL, V96, P1173, DOI 10.1152/japplphysiol.00770.2003; Semenza GL, 2004, J APPL PHYSIOL, V96, P1170; Shindo J, 2001, CORONARY ARTERY DIS, V12, P573, DOI 10.1097/00019501-200111000-00008; Vink A, 2007, ATHEROSCLEROSIS, V195, pE69, DOI 10.1016/j.atherosclerosis.2007.05.026; Yamashita A, 2008, HISTOL HISTOPATHOL, V23, P127; Yamashita A, 2009, ATHEROSCLEROSIS, V206, P418, DOI 10.1016/j.atherosclerosis.2009.03.014; Yan SF, 1999, ARTERIOSCL THROM VAS, V19, P2029; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Zawadzki C, 2007, ATHEROSCLEROSIS, V195, pE117, DOI 10.1016/j.atherosclerosis.2006.10.012	45	1	1	SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN	STUTTGART	HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY	0340-6245			THROMB HAEMOSTASIS	Thromb. Haemost.	JUL	2015	114	1					158	172		10.1160/TH14-09-0794		15	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CM2YH	WOS:000357547800023		
J	Tashima, Y; Banno, F; Akiyama, M; Miyata, T				Tashima, Yuko; Banno, Fumiaki; Akiyama, Masashi; Miyata, Toshiyuki			Influence of ADAMTS13 deficiency on venous thrombosis in mice	THROMBOSIS AND HAEMOSTASIS			English	Letter							CONTINUOUS BLOOD-FLOW; VON-WILLEBRAND-FACTOR; DEEP-VEIN THROMBOSIS; INFERIOR VENA-CAVA; IN-VIVO; THROMBOCYTOPENIC PURPURA; MOUSE MODEL; THROMBOGENESIS; INFLAMMATION; DOMAINS		[Tashima, Yuko; Banno, Fumiaki; Akiyama, Masashi; Miyata, Toshiyuki] Natl Cerebral & Cardiovasc Ctr, Dept Mol Pathogenesis, Suita, Osaka 5658565, Japan	Miyata, T (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Mol Pathogenesis, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	miyata@ncvc.go.jp					Brill A, 2011, BLOOD, V117, P1400, DOI 10.1182/blood-2010-05-287623; Gandhi C, 2012, BLOOD, V119, P2385, DOI 10.1182/blood-2011-09-376202; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Diaz JA, 2010, THROMB HAEMOSTASIS, V104, P366, DOI 10.1160/TH09-09-0672; Kokame K, 2005, BRIT J HAEMATOL, V129, P93, DOI 10.1111/j.1365-2141.2005.05420.x; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Fujioka M, 2010, BLOOD, V115, P1650, DOI 10.1182/blood-2009-06-230110; Akiyama M, 2009, P NATL ACAD SCI USA, V106, P19274, DOI 10.1073/pnas.0909755106; Banno F, 2006, BLOOD, V107, P3161, DOI 10.1182/blood-2005-07-2765; Lotta LA, 2013, J THROMB HAEMOST, V11, P1228, DOI 10.1111/jth.12291; Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859; De Meyer SF, 2012, BLOOD, V120, P5217, DOI 10.1182/blood-2012-06-439935; Khan MM, 2012, J THROMB HAEMOST, V10, P1665, DOI 10.1111/j.1538-7836.2012.04822.x; Motto DG, 2005, J CLIN INVEST, V115, P2752, DOI 10.1172/JCI26007; Becattini C, 2012, NEW ENGL J MED, V366, P1959, DOI 10.1056/NEJMoa1114238; Diaz JA, 2013, THROMB HAEMOSTASIS, V109, P1158, DOI 10.1160/TH12-09-0711; Banno F, 2010, INT J HEMATOL, V91, P30, DOI 10.1007/s12185-009-0477-0; Banno F, 2009, BLOOD, V113, P5323, DOI 10.1182/blood-2008-07-169359; Doi M, 2012, THROMB HAEMOSTASIS, V108, P1236, DOI 10.1160/TH12-09-0674	20	1	1	SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN	STUTTGART	HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY	0340-6245			THROMB HAEMOSTASIS	Thromb. Haemost.	JUL	2015	114	1					206	207		10.1160/TH14-08-0656		2	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CM2YH	WOS:000357547800027		
J	Shimoyama, N; Nakatsuji, S; Andoh, R; Yamaguchi, Y; Tamura, K; Hoshiya, T				Shimoyama, Natsumi; Nakatsuji, Shunji; Andoh, Rie; Yamaguchi, Yuko; Tamura, Kazutoshi; Hoshiya, Toru			Spontaneously Occurring Formation of Intranuclear and Cytoplasmic Inclusions in Renal Proximal Epithelium Due to Accumulation of d-Amino Acid Oxidase in Wistar Hannover Rats	TOXICOLOGIC PATHOLOGY			English	Article						d-amino acid oxidase; intranuclear and cytoplasmic inclusions; proximal tubular epithelium; Wistar Hannover rat	KIDNEY PEROXISOMES; PROPIVERINE; EXPRESSION; BODIES	Intranuclear and cytoplasmic inclusions in the renal proximal tubular epithelium were observed in nontreated male and female Wistar Hannover rats in a 26-week study (32 weeks of age) and a 104-week study (110 weeks of age). The incidence rates were less than 5% in these two studies. In affected animals, the inclusions were observed in more than 60% of proximal tubular epithelium as various sized (approximately 1-8 m in diameter) round and eosinophilic materials, but not in distal tubules, Henle's loop, or collecting ducts. Ultrastructurally, inclusions appeared finely granular, homogenous with middle-electron density, and without a limiting membrane. These inclusions were determined to be protein histochemically stained by Azan-Mallory and immunoreactive with an antibody against d-amino acid oxidase (DAO). There was no abnormality in in-life observations or in clinical test values suggestive of renal dysfunction. There were no associated degenerative or inflammatory changes in the kidneys, and no similar inclusions were observed in the other organs. These inclusions are very similar to propiverine hydrochloride (propiverine) and norepinephreine/serotonin reuptake inhibitor-induced inclusions. This is the first report of accumulation of DAO and formation of inclusions occurring spontaneously in rat kidneys. The data are important for toxicological studies using Wistar Hannover rats.	[Shimoyama, Natsumi; Andoh, Rie; Yamaguchi, Yuko; Tamura, Kazutoshi; Hoshiya, Toru] BoZo Res Ctr Inc, Gotemba Labs, Div Pathol, Shizuoka 4120039, Japan; [Nakatsuji, Shunji] Astellas Pharma Inc, Drug Safety Res Labs, Toxicol Pathol, Osaka, Japan	Shimoyama, N (reprint author), BoZo Res Ctr Inc, 1284 Kamado, Shizuoka 4120039, Japan.	shimoyama-natsumi@bozo.co.jp					Madersbacher H, 2001, WORLD J UROL, V19, P324, DOI 10.1007/s003450100223; Nickeleit V, 2000, NEPHROL DIAL TRANSPL, V15, P324, DOI 10.1093/ndt/15.3.324; Dietrich DR, 2008, TOXICOL APPL PHARM, V233, P411, DOI 10.1016/j.taap.2008.09.014; Fowler A. B., 1992, ENV HLTH PERSPECT, V100, P57; Fowler A. B., 1994, ENV HLTH PERSPECT, V102, P115; Hard C. G., 2008, TOXICOL PATHOL, V36, P1014; Huang YY, 2008, VET PATHOL, V45, P640, DOI 10.1354/vp.45-5-640; Krug W. A., 2007, AM J PHYSIOL-RENAL, V293, pF382; Missoun F., 2010, African Journal of Biochemistry Research (AJBR), V4, P21; NAKANO S, 1989, Journal of Toxicological Sciences, V14, P13; Okamura T, 2011, J TOXICOL PATHOL, V24, P195, DOI 10.1293/tox.24.195; Peters JM, 1996, MOL PHARMACOL, V50, P67; Radi ZA, 2013, TOXICOL PATHOL, V41, P32, DOI 10.1177/0192623312450629; Schulze C, 1998, VET PATHOL, V35, P209; Stefanini S, 1999, CELL MOL BIOL, V45, P815; Thompson W. S., 1959, AM J PATHOL, V35, P607; USUDA N, 1986, J HISTOCHEM CYTOCHEM, V34, P1709; Uwagawa S., 1992, J TOXICOL PATHOL, V5, P195; YAMASHITA K, 1990, Journal of Toxicological Sciences, V15, P107; Yamate J, 1998, TOXICOL PATHOL, V26, P699; Yamatoya H, 2012, EXP ANIM TOKYO, V61, P467, DOI 10.1538/expanim.61.467; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966	22	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2015	43	5					675	680		10.1177/0192623314560611		6	Pathology; Toxicology	Pathology; Toxicology	CM2UI	WOS:000357537400008		
J	Keenan, CM; Baker, J; Bradley, A; Goodman, DG; Harada, T; Herbert, R; Kaufmann, W; Kellner, R; Mahler, B; Meseck, E; Nolte, T; Rittinghausen, S; Vahle, J; Yoshizawa, K				Keenan, C. M.; Baker, J.; Bradley, A.; Goodman, D. G.; Harada, T.; Herbert, R.; Kaufmann, W.; Kellner, R.; Mahler, B.; Meseck, E.; Nolte, T.; Rittinghausen, S.; Vahle, J.; Yoshizawa, K.			International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Progress to Date and Future Plans	TOXICOLOGIC PATHOLOGY			English	Article						preclinical research and development; rodent pathology; toxicologic pathology		The International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice proposal (INHAND) has been operational since 2005. A Global Editorial Steering Committee manages the overall objectives of the project, and the development of harmonized terminology for each organ system is the responsibility of the Organ Working Groups, drawing upon experts from North America, Europe, and Japan. Great progress has been made with 9 systems published to daterespiratory, hepatobiliary, urinary, central/peripheral nervous systems, male reproductive and mammary, zymbals, clitoral, and preputial glands in Toxicologic Pathology and the integument and soft tissue and female reproductive in the Journal of Toxicologic Pathology as supplements and on a Web sitewww.goReni.org. INHAND nomenclature guides offer diagnostic criteria and guidelines for recording lesions observed in rodent toxicity and carcinogenicity studies. The guides provide representative photomicrographs of morphologic changes, information regarding pathogenesis, and key references. The purpose of this brief communication is to provide an update on the progress of INHAND.	[Keenan, C. M.] CM Keenan ToxPath Consulting, Doylestown, PA 18901 USA; [Baker, J.] Charles River Pathol Associates, Frederick, MD USA; [Bradley, A.] Charles River Labs, Tranent, Scotland; [Harada, T.] Inst Environm Toxicol, Joso, Ibaraki, Japan; [Herbert, R.; Mahler, B.] NIEHS, Res Triangle Pk, NC 27709 USA; [Kaufmann, W.] Merck KGaA, Darmstadt, Germany; [Kellner, R.; Rittinghausen, S.] Fraunhofer ITEM, Hannover, Germany; [Meseck, E.] Novartis Inst Biomed Res, E Hanover, NJ USA; [Nolte, T.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Vahle, J.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Yoshizawa, K.] Kansai Med Univ, Hirakata, Osaka, Japan	Keenan, CM (reprint author), CM Keenan ToxPath Consulting, 874 Limekiln Rd, Doylestown, PA 18901 USA.	charlotte.keenan@msn.com					Keenan CM, 2014, TOXICOL PATHOL, V42, P807, DOI 10.1177/0192623313485451; Vahle J, 2009, TOXICOL PATHOL, V37, P694, DOI 10.1177/0192623309340278	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2015	43	5					730	732		10.1177/0192623314560031		3	Pathology; Toxicology	Pathology; Toxicology	CM2UI	WOS:000357537400013		
J	Anagawa-Nakamura, A; Kakimoto, K; Miyajima, K; Yasui, Y; Kemmochi, Y; Toyoda, K; Taniai, E; Takahashi, A; Shoda, T				Anagawa-Nakamura, Akiko; Kakimoto, Kochi; Miyajima, Katsuhiro; Yasui, Yuzo; Kemmochi, Yusuke; Toyoda, Kaoru; Taniai, Eriko; Takahashi, Akemi; Shoda, Toshiyuki			Immunohistochemical Characterization of Spontaneous Sertoli Cell Clusters in the Seminiferous Tubules of C57BL/6J Mice	TOXICOLOGIC PATHOLOGY			English	Article						Sertoli cell clusters; seminiferous tubules; C57BL; 6J mice; spontaneous; microscopic findings; immunohistochemistry	EXPRESSION; GATA-4; TESTIS	Cell clusters were observed in the seminiferous tubules of C57BL/6J mice as a spontaneous lesion in a 2-week toxicity study, and they were demonstrated to be basically composed of Sertoli cells by immunohistochemistry for claudin-11 and GATA-4 (GATA-binding protein 4), which are both Sertoli cell markers. The clusters were composed of about 5 to 50 cells, which had eosinophilic and occasionally vacuolated cytoplasm with an unclear cell boundary. The cell clusters involved some sperm. No mitotic figures were observed and no immunoreactivity for proliferating cell nuclear antigen (PCNA) was detected in the clusters. In most cases, the cell clusters were observed in seminiferous tubules that also showed degenerative changes. In rare instances, cell aggregates immunohistochemically positive for claudin-11 were observed in the lumen of the epididymis, suggesting that some of the Sertoli cell clusters were sloughed off from the seminiferous epithelium into the epididymal ducts. To our knowledge, this is the first report of Sertoli cell clusters in any animal species except for transgenic or surgically altered animals.	[Anagawa-Nakamura, Akiko; Kakimoto, Kochi; Miyajima, Katsuhiro; Yasui, Yuzo; Kemmochi, Yusuke; Toyoda, Kaoru; Taniai, Eriko; Takahashi, Akemi; Shoda, Toshiyuki] Japan Tobacco Inc, Dept Pathol, Cent Pharmaceut Res Inst, Toxicol Res Labs, Odawara, Kanagawa, Japan	Anagawa-Nakamura, A (reprint author), 23 Naganuki, Hadano, Kanagawa 2570024, Japan.	akiko.nakamura@jt.com					Viger RS, 1998, DEVELOPMENT, V125, P2665; Mazaud-Guittot S, 2010, BIOL REPROD, V82, P202, DOI 10.1095/biolreprod.109.078907; Sridharan S, 2007, BIOL REPROD, V76, P804, DOI 10.1095/biolreprod.106.059212; Weider K, 2011, DIFFERENTIATION, V82, P38, DOI 10.1016/j.diff.2011.03.001; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Kopecky M, 2005, ACTA HISTOCHEM, V107, P279, DOI 10.1016/j.acthis.2005.06.007; Creasy D., 2012, TOXICOL PATHOL, V40, P40; Creasy D., 2001, HDB TOXICOLOGIC PATH, P785; Ketola I, 1999, ENDOCRINOLOGY, V140, P1470, DOI 10.1210/en.140.3.1470; Schrans-Stassen BHGJ, 2001, BIOL REPROD, V65, P771, DOI 10.1095/biolreprod65.3.771	10	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2015	43	5					743	746		10.1177/0192623314565368		4	Pathology; Toxicology	Pathology; Toxicology	CM2UI	WOS:000357537400016		
J	Kawashima, T; Lorkovic, ZJ; Nishihama, R; Ishizaki, K; Axelsson, E; Yelagandula, R; Kohchi, T; Berger, F				Kawashima, Tomokazu; Lorkovic, Zdravko J.; Nishihama, Ryuichi; Ishizaki, Kimitsune; Axelsson, Elin; Yelagandula, Ramesh; Kohchi, Takayuki; Berger, Frederic			Diversification of histone H2A variants during plant evolution	TRENDS IN PLANT SCIENCE			English	Review						chromatin; histone H2A; evolution	NUCLEOSOME CORE PARTICLE; INACTIVE X-CHROMOSOME; CHROMATIN CONDENSATION; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; GAMMA-H2AX FOCI; LAND PLANTS; H1; TRANSCRIPTION; GENOME	Among eukaryotes, the four core histones show an extremely high conservation of their structure and form nucleosomes that compact, protect, and regulate access to genetic information. Nevertheless, in multicellular eukaryotes the two families, histone H2A and histone H3, have diversified significantly in key residues. We present a phylogenetic analysis across the green plant lineage that reveals an early diversification of the H2A family in unicellular green algae and remarkable expansions of H2A variants in flowering plants. We define motifs and domains that differentiate plant H2A proteins into distinct variant classes. In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants.	[Kawashima, Tomokazu; Lorkovic, Zdravko J.; Axelsson, Elin; Yelagandula, Ramesh; Berger, Frederic] Austrian Acad Sci, Gregor Mendel Inst, A-1030 Vienna, Austria; [Nishihama, Ryuichi; Kohchi, Takayuki] Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan; [Ishizaki, Kimitsune] Kobe Univ, Grad Sch Sci, Kobe, Hyogo 6578501, Japan	Berger, F (reprint author), Austrian Acad Sci, Gregor Mendel Inst, Dr Bohrgasse 3, A-1030 Vienna, Austria.	frederic.berger@gmi.oeaw.ac.at		Ishizaki, Kimitsune/0000-0003-0504-8196	Osterreichische Akademie der Wissenschaften (OAW); Osterreichischer Fonds zur Forderung der wissenschaftlichen Forschung (FWF) [P26887]	We are grateful to Paul Talbert for critical comments on the manuscript and members of the Berger lab for discussion of the data. We thank the Joint Genome Institute for providing the genomic assemblies and transcriptomes of the ongoing M. polymorpha genome project. This work was supported by Osterreichische Akademie der Wissenschaften (OAW) and by a grant from the Osterreichischer Fonds zur Forderung der wissenschaftlichen Forschung (FWF) (grant number P26887) to F.B.	Aceituno FF, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-438; Luger K, 2012, NAT REV MOL CELL BIO, V13, P436, DOI 10.1038/nrm3382; Lang J, 2012, NEW PHYTOL, V194, P353, DOI 10.1111/j.1469-8137.2012.04062.x; Soboleva TA, 2012, NAT STRUCT MOL BIOL, V19, P25, DOI 10.1038/nsmb.2161; Zilberman D, 2008, NATURE, V456, P125, DOI 10.1038/nature07324; Cantarino N, 2013, CANCER LETT, V336, P247, DOI 10.1016/j.canlet.2013.03.022; March-Diaz R, 2008, PLANT J, V53, P475, DOI 10.1111/j.1365-313X.2007.03361.x; Maze I, 2014, NAT REV GENET, V15, P259, DOI 10.1038/nrg3673; Soboleva TA, 2014, TRENDS GENET, V30, P199, DOI 10.1016/j.tig.2014.03.002; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Andrews AJ, 2011, ANNU REV BIOPHYS, V40, P99, DOI 10.1146/annurev-biophys-042910-155329; Friesner JD, 2005, MOL BIOL CELL, V16, P2566, DOI 10.1091/mbc.E04-10-0890; Filipescu D, 2013, TRENDS GENET, V29, P630, DOI 10.1016/j.tig.2013.06.002; Coleman-Derr D, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002988; Tolstorukov MY, 2012, MOL CELL, V47, P596, DOI 10.1016/j.molcel.2012.06.011; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Eirin-Lopez JM, 2008, FASEB J, V22, P316, DOI 10.1096/fj.07-9255com; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Sarg B, 2006, J BIOL CHEM, V281, P6573, DOI 10.1074/jbc.M508957200; Mao Z, 2014, CELL RES, V24, P389, DOI 10.1038/cr.2014.30; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Bonisch C, 2012, NUCLEIC ACIDS RES, V40, P10719, DOI 10.1093/nar/gks865; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Kumar SV, 2010, CELL, V140, P136, DOI 10.1016/j.cell.2009.11.006; Biterge B, 2014, CELL TISSUE RES, V356, P457, DOI 10.1007/s00441-014-1862-4; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Pires ND, 2012, PHILOS T R SOC B, V367, P508, DOI 10.1098/rstb.2011.0252; Yelagandula R, 2014, CELL, V158, P98, DOI 10.1016/j.cell.2014.06.006; Stroud H, 2012, P NATL ACAD SCI USA, V109, P5370, DOI 10.1073/pnas.1203145109; Kalashnikova AA, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.1022; Luger K, 1997, NATURE, V389, P251; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Gamble MJ, 2010, CELL CYCLE, V9, P2568, DOI 10.4161/cc.9.13.12144; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Smith AP, 2010, PLANT PHYSIOL, V152, P217, DOI 10.1104/pp.109.145532; Roque A, 2008, NUCLEIC ACIDS RES, V36, P4719, DOI 10.1093/nar/gkn440; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036; Harshman SW, 2013, NUCLEIC ACIDS RES, V41, P9593, DOI 10.1093/nar/gkt700; Muthurajan UM, 2011, J BIOL CHEM, V286, P23852, DOI 10.1074/jbc.M111.244871; Obri A, 2014, NATURE, V505, P648, DOI 10.1038/nature12922; Weber CM, 2014, GENE DEV, V28, P672, DOI 10.1101/gad.238873.114; Qiu YL, 2012, J SYST EVOL, V50, P171, DOI 10.1111/j.1759-6831.2012.00188.x; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Wu WH, 2005, NAT STRUCT MOL BIOL, V12, P1064, DOI 10.1038/nsmb1023; SUZUKI M, 1989, EMBO J, V8, P797; Siegel TN, 2009, GENE DEV, V23, P1063, DOI 10.1101/gad.1790409; Billon Pierre, 2013, Biochim Biophys Acta, V1819, P290; Bowman JL, 2013, CURR OPIN PLANT BIOL, V16, P70, DOI 10.1016/j.pbi.2012.10.001; Buttinelli M, 1999, GENETICA, V106, P117, DOI 10.1023/A:1003745315540; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Jensen K, 2011, MOL GENET GENOMICS, V285, P287, DOI 10.1007/s00438-011-0604-5; Otero S, 2014, CYTOGENET GENOME RES, V143, P114, DOI 10.1159/000365264; PEHRSON JR, 1992, SCIENCE, V257, P1398; Petter M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001292; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; Talbert PB, 2014, TRENDS CELL BIOL, V24, P642, DOI 10.1016/j.tcb.2014.07.006; Talbert PB, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-7; Tomescu AMF, 2014, CURR OPIN PLANT BIOL, V17, P126, DOI 10.1016/j.pbi.2013.11.016; Voile C., 2014, CURR OPIN GENE DEV, V25, P138; Volle C, 2014, CURR OPIN GENET DEV, V25, P8, DOI 10.1016/j.gde.2013.11.006; Whittle CM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000187; Wollmann H, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002658	65	0	0	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1360-1385			TRENDS PLANT SCI	Trends Plant Sci.	JUL	2015	20	7					419	425		10.1016/j.tplants.2015.04.005		7	Plant Sciences	Plant Sciences	CM5UL	WOS:000357754400007		
J	Ma, JF; Yamaji, N				Ma, Jian Feng; Yamaji, Naoki			A cooperative system of silicon transport in plants	TRENDS IN PLANT SCIENCE			English	Review						silicon; stress tolerance; influx; efflux; uptake; distribution	FUNCTIONAL-CHARACTERIZATION; INFLUX TRANSPORTER; EFFLUX TRANSPORTER; RICE; ACCUMULATION; BARLEY; IDENTIFICATION; ARABIDOPSIS; RESISTANCE; FAMILY	The high accumulation of silicon (Si) protects plants from biotic and abiotic stresses. Two different types of Si transporter [Low Silicon 1 (Lsi1) and 2 (Lsi2)] involved in the uptake and distribution of Si have been identified. Lsi1, a Si permeable channel, belongs to the Nod26-like major intrinsic protein (NIP) III subgroup of the aquaporin membrane protein family with a distinct selectivity, whereas Lsi2, an efflux Si transporter, belongs to an uncharacterized anion transporter family. These transporters are localized to the plasma membrane, but, in different plant species, show different expression patterns and tissue or cellular localizations that are associated with different levels of Si accumulation. A recent mathematical modeling study revealed that cooperation of Lsi1 and Lsi2, which show a polarized localization, is required for the efficient transport of Si in rice.	[Ma, Jian Feng; Yamaji, Naoki] Okayama Univ, Inst Plant Sci & Resources, Kurashiki, Okayama 7100046, Japan	Ma, JF (reprint author), Okayama Univ, Inst Plant Sci & Resources, Chuo 2-20-1, Kurashiki, Okayama 7100046, Japan.	maj@rib.okayama-u.ac.jp	YAMAJI, Naoki/B-2524-2011	YAMAJI, Naoki/0000-0002-7499-3004	Ministry of Education, Culture, Sports, Science and Technology of Japan [22119002]	The research was supported by a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 22119002 to J.F.M.).	Belanger RR, 2003, PHYTOPATHOLOGY, V93, P402, DOI 10.1094/PHYTO.2003.93.4.402; Ma JF, 2004, SOIL SCI PLANT NUTR, V50, P11; Wallace IS, 2005, BIOCHEMISTRY-US, V44, P16826, DOI 10.1021/bi0511888; Ma JF, 2006, TRENDS PLANT SCI, V11, P392, DOI 10.1016/j.tplants.2006.06.007; Deshmukh RK, 2013, PLANT MOL BIOL, V83, P303, DOI 10.1007/s11103-013-0087-3; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Hildebrand M, 1997, NATURE, V385, P688, DOI 10.1038/385688b0; Ma JF, 2008, P NATL ACAD SCI USA, V105, P9931, DOI 10.1073/pnas.0802361105; Ma JF, 2003, PLANT SOIL, V249, P383, DOI 10.1023/A:1022842421926; Yamaji N, 2012, PLANT PHYSIOL, V160, P1491, DOI 10.1104/pp.112.204578; Mitani N, 2005, PLANT CELL PHYSIOL, V46, P279, DOI 10.1093/pcp/pci018; Choi WG, 2007, J BIOL CHEM, V282, P24209, DOI 10.1074/jbc.M700982200; Yamaji N, 2008, PLANT CELL, V20, P1381, DOI 10.1105/tpc.108.059311; Fauteux F, 2005, FEMS MICROBIOL LETT, V249, P1, DOI 10.1016/j.femsle.2005.06.034; Chiba Y, 2009, PLANT J, V57, P810, DOI 10.1111/j.1365-313X.2008.03728.x; Ueno D, 2009, J EXP BOT, V60, P3513, DOI 10.1093/jxb/erp191; Zhao XQ, 2010, PLANT PHYSIOL, V153, P1871, DOI 10.1104/pp.110.157867; Mitani N, 2011, PLANT J, V66, P231, DOI 10.1111/j.1365-313X.2011.04483.x; Mitani N, 2009, PLANT CELL PHYSIOL, V50, P5, DOI 10.1093/pcp/pcn110; Mitani N, 2008, PFLUG ARCH EUR J PHY, V456, P679, DOI 10.1007/s00424-007-0408-y; Yamaji N, 2009, PLANT CELL, V21, P2878, DOI 10.1105/tpc.109.069831; Yamaji N, 2011, SOIL SCI PLANT NUTR, V57, P259, DOI 10.1080/00380768.2011.565480; Sasaki A, 2012, PLANT CELL, V24, P2155, DOI 10.1105/tpc.112.096925; Hodson MJ, 2005, ANN BOT-LONDON, V96, P1027, DOI 10.1093/aob/mci255; Ma JF, 2007, NATURE, V448, P209, DOI 10.1038/nature05964; Mitani N, 2005, J EXP BOT, V56, P1255, DOI 10.1093/jxb/eri121; Ma JF, 2006, NATURE, V440, P688, DOI 10.1038/nature04590; Fawe A, 1998, PHYTOPATHOLOGY, V88, P396, DOI 10.1094/PHYTO.1998.88.5.396; Mitani-Ueno N, 2011, J EXP BOT, V62, P4391, DOI 10.1093/jxb/err158; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; Takano J, 2006, PLANT CELL, V18, P1498, DOI 10.1105/tpc.106.041640; Gregoire C, 2012, PLANT J, V72, P320, DOI 10.1111/j.1365-313X.2012.05082.x; Mitani N, 2009, PLANT CELL, V21, P2133, DOI 10.1105/tpc.109.067884; Sakurai G, 2015, PLANT CELL PHYSIOL, V56, P631, DOI 10.1093/pcp/pcv017; Yamaji N, 2007, PLANT PHYSIOL, V143, P1306, DOI 10.1104/pp.106.093005; Takano J, 2002, NATURE, V420, P337, DOI 10.1038/nature01139; Montpetit J, 2012, PLANT MOL BIOL, V79, P35, DOI 10.1007/s11103-012-9892-3; Ye M, 2013, P NATL ACAD SCI USA, V110, pE3631, DOI 10.1073/pnas.1305848110; Bockhaven J.V., 2013, J EXP BOT, V64, P1281; Casey W. H., 2003, PLANT CELL ENVIRON, V27, P51; Datnoff L.E., 2005, APSNET FEATURES; MA J.F., 2002, SOIL FERTILIZER PLAN; Mitani-Ueno Namiki, 2011, Plant Signal Behav, V6, P991; Rodrigues FA, 2004, PHYTOPATHOLOGY, V94, P177, DOI 10.1094/PHYTO.2004.94.2.177; Takahashi E., 1990, Comments on Agricultural and Food Chemistry, V2, P99; Takano Junpei, 2010, Proc Natl Acad Sci U S A, V107, P5220, DOI 10.1073/pnas.0910744107; Tamai K, 2008, PLANT SOIL, V307, P21, DOI 10.1007/s11104-008-9571-y; Wang H., 2014, J PLANT GROWTH REGUL; Yamaji N, 2014, TRENDS PLANT SCI, V19, P556, DOI 10.1016/j.tplants.2014.05.007	49	1	1	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1360-1385			TRENDS PLANT SCI	Trends Plant Sci.	JUL	2015	20	7					435	442		10.1016/j.tplants.2015.04.007		8	Plant Sciences	Plant Sciences	CM5UL	WOS:000357754400009		
J	Nakashima, K; Hiyoshi, S; Ohno, K; Uchida, K; Goto-Koshino, Y; Maeda, S; Mizutani, N; Takeuchi, A; Tsujimoto, H				Nakashima, K.; Hiyoshi, S.; Ohno, K.; Uchida, K.; Goto-Koshino, Y.; Maeda, S.; Mizutani, N.; Takeuchi, A.; Tsujimoto, H.			Prognostic factors in dogs with protein-losing enteropathy	VETERINARY JOURNAL			English	Article						Canine; Chronic enteropathy; Gastrointestinal lymphoma; Intestinal lymphangiectasia; Prognosis	INFLAMMATORY-BOWEL-DISEASE; COMBINATION; DIAGNOSIS; LYMPHOMA	Canine protein-losing enteropathy (PLE) is associated with severe gastrointestinal disorders and has a guarded to poor prognosis although little information is available regarding factors affecting prognosis. The purpose of this study was to identify the prognostic factors for survival of dogs with PLE. Ninety-two dogs diagnosed with PLE from 2006 to 2011 were included in a retrospective cohort study. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Variables recorded at the time of diagnosis were statistically analysed for possible prognostic factors in a univariate and multivariate Cox proportional hazard model. In the multivariate analysis, the predictors for mortality in dogs with PLE were more highly scored in terms of canine inflammatory bowel disease activity index (CIBDAI) (P=0.0003), clonal rearrangement of lymphocyte antigen receptor genes (P=0.003), and elevation of blood urea nitrogen (BUN) (P=0.03). Using histopathological diagnosis, both small- and large-cell lymphomas were associated with significantly shorter survival times than chronic enteritis (CE) and intestinal lymphangiectasia (IL). Normalization of CIBDAI and plasma albumin concentration within 50 days of initial treatment was associated with a longer survival time. In conclusion, CIBDAI, clonal rearrangement of lymphocyte antigen receptor genes, histopathological diagnosis, and response to initial treatments would be valuable in separating the underlying causes and could be important in predicting prognosis in dogs with PLE. (C) 2015 Elsevier Ltd. All rights reserved.	[Nakashima, K.; Hiyoshi, S.; Ohno, K.; Goto-Koshino, Y.; Maeda, S.; Mizutani, N.; Tsujimoto, H.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Internal Med, Bunkyo Ku, Tokyo 1138657, Japan; [Uchida, K.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathol, Bunkyo Ku, Tokyo 1138657, Japan; [Takeuchi, A.] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo 1608582, Japan	Ohno, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Internal Med, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aohno@mail.ecc.u-tokyo.ac.jp					Goodwin LV, 2011, J VET INTERN MED, V25, P273, DOI 10.1111/j.1939-1676.2011.0683.x; Craven M, 2004, J SMALL ANIM PRACT, V45, P336, DOI 10.1111/j.1748-5827.2004.tb00245.x; Allenspach K, 2007, J VET INTERN MED, V21, P700, DOI 10.1892/0891-6640(2007)21[700:CEIDEO]2.0.CO;2; Larson RN, 2012, J VET INTERN MED, V26, P1087, DOI 10.1111/j.1939-1676.2012.00970.x; Fukushima K, 2009, J VET MED SCI, V71, P1673; Rassnick KM, 2009, J VET INTERN MED, V23, P317, DOI 10.1111/j.1939-1676.2008.0270.x; Day MJ, 2008, J COMP PATHOL, V138, pS1, DOI 10.1016/j.jcpa.2008.01.001; Jergens AE, 2003, J VET INTERN MED, V17, P291, DOI 10.1892/0891-6640(2003)017<0291:ASIFDA>2.3.CO;2; Kiupel M, 2011, VET PATHOL, V48, P212, DOI 10.1177/0300985810389479; Dossin O, 2011, VET CLIN N AM-SMALL, V41, P399, DOI 10.1016/j.cvsm.2011.02.002; Bakakos P, 2001, J ALLERGY CLIN IMMUN, V107, P1089, DOI 10.1067/mai.2001.114651; Dandrieux JRS, 2013, JAVMA-J AM VET MED A, V242, P1705, DOI 10.2460/javma.242.12.1705; Valli VE, 2002, WHO INT CLASSIFICATI, V8, P28	13	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	JUL	2015	205	1					28	32		10.1016/j.tvjl.2015.05.001		5	Veterinary Sciences	Veterinary Sciences	CM0GJ	WOS:000357356100006		
J	Nishifuji, K				Nishifuji, K.			Contributions of Histopathology and Molecular Biology for the Discovery of Genodermatoses in Animals: Break the Codes!	VETERINARY PATHOLOGY			English	Editorial Material									Tokyo Univ Agr & Technol, Grad Sch, Div Anim Life Sci, Fuchu, Tokyo 1838509, Japan	Nishifuji, K (reprint author), Tokyo Univ Agr & Technol, Grad Sch, Div Anim Life Sci, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	kojimail@cc.tuat.ac.jp					Charlier C, 2008, NAT GENET, V40, P449, DOI 10.1038/ng.96; Ishida Y, 2006, GENOMICS, V88, P698, DOI 10.1016/j.ygeno.2006.06.006; Grall A, 2012, NAT GENET, V44, P140, DOI 10.1038/ng.1056; Capt A, 2005, J INVEST DERMATOL, V124, P530, DOI 10.1111/j.0022-202X.2004.23584.x; Mauldin EA, 2015, VET PATHOL, V52, P654, DOI 10.1177/0300985814551425	5	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2015	52	4					605	606		10.1177/0300985815570483		2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	CM2MT	WOS:000357515400001		
J	Shibuya, K; Kinoshita, K; Mizutani, M; Oshima, A; Yamashita, R; Matsuda, Y				Shibuya, K.; Kinoshita, K.; Mizutani, M.; Oshima, A.; Yamashita, R.; Matsuda, Y.			Intraocular Ossification in the GSP/pe Chicken With Imperfect Albinism	VETERINARY PATHOLOGY			English	Article						chicken; eyeball; hereditary disease; ossification; retinal pigment epithelium	OSSEOUS METAPLASIA; PROLIFERATIVE VITREORETINOPATHY; EXPRESSION; DISEASE; DOG	The eyes of 2 male and 2 female GSP/pe chickens, the imperfect albino strain, were investigated at 52 weeks of age. Aged chickens of the GSP/pe colony became blind with bilateral ocular enlargement and opaque lenses. Affected eyes (bilateral in 2 males and unilateral in 2 females) were hard and difficult to section; histologic specimens were processed after decalcification. A large portion of the posterior chamber was occupied by cancellous bone containing fibrous and cartilaginous foci. Osseous tissues developed adjacent to the choroid, and no retinal pigment epithelium (RPE) was detected between osseous tissues and the choroid. Small segments of degenerate neuronal retina were scattered in the osseous tissue. The irises and ciliary bodies were deformed by osseous tissue, and the lenses had severe cataracts. These observations suggest that the intraocular osseous tissue may be derived from RPE in the hereditary incomplete-albino strain of chickens.	[Shibuya, K.; Oshima, A.; Yamashita, R.] Nippon Inst Biol Sci, Dept Res & Dev, Tokyo 1980024, Japan; [Kinoshita, K.; Mizutani, M.; Matsuda, Y.] Nagoya Univ, Grad Sch Bioagr Sci, Avian Biosci Res Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Shibuya, K (reprint author), Nippon Inst Biol Sci, Testing Dept, 9-2221-1 Shinmachi, Tokyo 1980024, Japan.	k_shibuya@nibs.or.jp					ALLEN CB, 1987, SCANNING MICROSCOPY, V1, P233; Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062; GRIFFITH JW, 1988, VET PATHOL, V25, P100; Grisanti A, 1995, INVEST OPHTH VIS SCI, V36, P391; Heath S, 2003, VET OPHTHALMOL, V6, P85, DOI 10.1046/j.1463-5224.2003.00256.x; Hodges RD, 1974, HISTOLOGY FOWL, P525; Koinzer S, 2009, ANN ANAT, V191, P563, DOI 10.1016/j.aanat.2009.08.003; Lynch GL, 2007, VET PATHOL, V44, P222, DOI 10.1354/vp.44-2-222; Miller DM, 2004, ARCH OPHTHALMOL-CHIC, V122, P1710, DOI 10.1001/archopht.122.11.1710; MONSELISE M, 1985, OPHTHALMOLOGICA, V190, P225; Munteanu M, 2013, ROM J MORPHOL EMBRYO, V54, P871; Park HS, 2004, KOREAN J PATHOL, V38, P188; Salter DW, 1997, J VET DIAGN INVEST, V9, P407; Toyran S, 2005, BRIT J OPHTHALMOL, V89, P885, DOI 10.1136/bjo.2004.056374; Vemuganti Geeta K., 2002, Indian Journal of Ophthalmology, V50, P183; Yoon YD, 1998, AM J OPHTHALMOL, V125, P558, DOI 10.1016/S0002-9394(99)80201-3	16	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2015	52	4					688	691		10.1177/0300985814559401		4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	CM2MT	WOS:000357515400013		
J	Tsunoda, S; Ishii-Watabe, A				Tsunoda, Shin-ichi; Ishii-Watabe, Akiko			Innovative Approaches for Next-generation Biodrugs Development	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Editorial Material									[Tsunoda, Shin-ichi] Natl Inst Biomed Innovat, Lab Biopharmaceut Res, Osaka 5670085, Japan; [Tsunoda, Shin-ichi] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Biomed Innovat, Suita, Osaka 5650871, Japan; [Ishii-Watabe, Akiko] Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, Tokyo 1588501, Japan	Tsunoda, S (reprint author), Natl Inst Biomed Innovat, Lab Biopharmaceut Res, 7-6-8 Saito Asagi, Osaka 5670085, Japan.	tsunoda@nibiohn.go.jp						0	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					841	842				2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000001		
J	Kamada, H				Kamada, Haruhiko			Development of New Biologics through Creation of a Functional Cytokine Mutant	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						tumor necrosis factor; mutant protein; phage display	TUMOR-NECROSIS-FACTOR; TNF-ALPHA; TRIAL	The clinical use of cytokines is fairly limited because of their characteristics of having significant bioactivity and low stability, although some are useful biopharmaceuticals, such as interferon. Cytokines, which are secreted from various immune cells, show many kinds of bioactivities including unexpected activities; thus it would be desirable to regulate cytokine activity. Recently, we have developed a new drug delivery system (DDS) to create structural mutant cytokines using a phage display system. This system can produce functional mutant proteins that can bind their objective targets specifically. In this study, tumor necrosis factor (TNF) was used as a model cytokine to create agonist and antagonist activities against two TNF receptors TNFR1 and TNFR2, respectively. We created a phage library expressing mutant TNF, where the amino acids in the binding interface between TNF and TNF receptors were alternately exchanged. Affinity panning was performed at the optimum condition and the bioactivities of these mutant TNFs were analyzed to obtain the objective agonists or antagonists. The pharmacological activity and toxicity of these engineered TNF mutants could indicate their potential use as novel biopharmaceutical agents.	Natl Inst Biomed Innovat Hlth & Nutr, Lab Biopharmaceut Res, Osaka 5670085, Japan	Kamada, H (reprint author), Natl Inst Biomed Innovat Hlth & Nutr, Lab Biopharmaceut Res, 7-6-8 Saito Asagi, Osaka 5670085, Japan.	kamada@nibiohn.go.jp					Abe Y, 2008, J IMMUNOL METHODS, V335, P71, DOI 10.1016/j.jim.2008.02.019; Sugita T, 2008, BRIT J PHARMACOL, V153, P1143, DOI 10.1038/sj.bjp.0707678; Shibata H, 2008, J BIOL CHEM, V283, P998, DOI 10.1074/jbc.M707933200; Yamamoto Y, 2003, NAT BIOTECHNOL, V21, P546, DOI 10.1038/nbt812; Bracho F, 2001, CLIN CANCER RES, V7, P58; Engelberg AB, 2009, NEW ENGL J MED, V361, P1917, DOI 10.1056/NEJMp0908496; LENK H, 1989, CANCER CHEMOTH PHARM, V24, P391; Mukai Y, 2009, J BIOCHEM, V146, P167, DOI 10.1093/jb/mvp065; Mukai Y, 2009, J MOL BIOL, V385, P1221, DOI 10.1016/j.jmb.2008.11.053; Nabeshi H, 2009, BIOL PHARM BULL, V32, P1286; Nomura T, 2009, BIOCHEM BIOPH RES CO, V388, P667, DOI 10.1016/j.bbrc.2009.08.052; Nomura T, 2011, J CONTROL RELEASE, V149, P8, DOI 10.1016/j.jconrel.2009.12.015; Shibata H, 2009, BIOMATERIALS, V30, P6638, DOI 10.1016/j.biomaterials.2009.08.041; Shibata H, 2008, CYTOKINE, V44, P229, DOI 10.1016/j.cyto.2008.07.003	14	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					843	849				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000002		
J	Asano, R; Kumagai, I				Asano, Ryutaro; Kumagai, Izumi			Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						antibody engineering; bispecific antibody; anticancer drug; epidermal growth factor receptor (EGFR); CD3	CANCER-IMMUNOTHERAPY; DIABODY; ANTIBODY-528; CELLS	Although antibodies have been used as molecularly targeted agents for difficult-to-treat diseases such as cancers, the high production costs associated with mammalian expression systems continue to be a drawback. In addition, the clinical efficacy of conventional IgG antibodies is limited. Several types of recombinant antibody (e.g. fused with anticancer drugs, multivalent, or multispecific) have been designed in efforts to develop next-generation antibodies with higher functionality. We used protein engineering to construct several anticancer recombinant antibodies by developing bispecific antibodies that induced specific antitumor effects against cancer cells through the recruitment of lymphocytes. We found that a humanized small bispecific antibody (Ex3) that targets epidermal growth factor receptor on tumor cells and CD3 on T lymphocytes had marked anticancer activity. Furthermore, the function of Ex3 was enhanced by fusion with the human Fc region, domain rearrangement, multimerization, and affinity maturation; a combination of these modifications showed at least additive cytotoxic effects. Interestingly, merely rearranging the domain order of Ex3 induced substantial cytotoxic enhancements, even though the structural format remained the same. Here, we describe our efforts to develop highly functional bispecific antibodies as next-generation therapeutic antibodies using protein engineering.	[Asano, Ryutaro; Kumagai, Izumi] Tohoku Univ, Dept Biomol Engn, Grad Sch Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan	Asano, R (reprint author), Tohoku Univ, Dept Biomol Engn, Grad Sch Engn, Aoba Ku, Aoba 6-6-11-608, Sendai, Miyagi 9808579, Japan.	ryutaro@prn.che.tohoku.ac.jp					Nagorsen D, 2011, EXP CELL RES, V317, P1255, DOI 10.1016/j.yexcr.2011.03.010; Cuesta AM, 2010, TRENDS BIOTECHNOL, V28, P355, DOI 10.1016/j.tibtech.2010.03.007; Bargou R, 2008, SCIENCE, V321, P974, DOI 10.1126/science.1158545; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Asano R, 2011, J BIOL CHEM, V286, P1812, DOI 10.1074/jbc.M110.172957; Kontermann RE, 2012, MABS-AUSTIN, V4, P182, DOI 10.4161/mabs.4.2.19000; Kontermann RE, 2012, ARCH BIOCHEM BIOPHYS, V526, P194, DOI 10.1016/j.abb.2012.03.001; Reichert JM, 2012, DRUG DISCOV TODAY, V17, P954, DOI 10.1016/j.drudis.2012.04.006; Asano R, 2008, PROTEIN ENG DES SEL, V21, P597, DOI 10.1093/protein/gzn037; Asano R, 2013, PROTEIN ENG DES SEL, V26, P359, DOI 10.1093/protein/gzt009; Asano R, 2008, J IMMUNOTHER, V31, P752, DOI 10.1097/CJI.0b013e3181849071; Asano R, 2010, J BIOL CHEM, V285, P20844, DOI 10.1074/jbc.M110.120444; Asano R, 2006, CLIN CANCER RES, V12, P4036, DOI 10.1158/1078-0432.CCR-06-0059; Hayashi H, 2004, CANCER IMMUNOL IMMUN, V53, P497, DOI 10.1007/s00262-003-0465-9; Makabe K, 2008, J BIOL CHEM, V283, P1156, DOI 10.1074/jbc.M706190200; Nakanishi T, 2013, PROTEIN ENG DES SEL, V26, P113, DOI 10.1093/protein/gzs088	16	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					851	856				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000003		
J	Ishii-Watabe, A; Tada, M; Suzuki, T; Kawasaki, N				Ishii-Watabe, Akiko; Tada, Minoru; Suzuki, Takuo; Kawasaki, Nana			Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						monoclonal antibody; non-clinical study; fragment crystallizable; receptor	GAMMA RECEPTOR ENGAGEMENT; NEONATAL FC-RECEPTOR; HALF-LIFE; BINDING-AFFINITY; CYTOKINE STORM; MICE; PHARMACOKINETICS; PHAGOCYTOSIS; SPECIFICITY; VARIANTS	Therapeutic monoclonal antibodies (mAbs) exert their effects via binding to specific target molecules, which is expected to show rare off-target adverse reactions. However, nonclinical evaluation of mAbs is difficult because they often lack reactivity toward orthologous targets in animals. During the nonclinical evaluation of mAbs, not only the target molecules but fragment crystallizable (Fc) receptors, which regulate the immune effector functions and pharmacokinetic properties of mAbs, should be considered. In this review, factors for extrapolating nonclinical study results to clinical settings are discussed by focusing on Fc receptors. The human Fe gamma receptor family consists of Fc gamma RI, IIa, IIb, IIIa, and IIIb; Fey receptors in laboratory animals are structurally and functionally different from those in humans. In addition, interactions between human IgG-Fc, a component of therapeutic mAbs, and animal Fc gamma receptors are still not fully understood. With regard to neonatal Pc receptor (FcRn), related molecules comprising the FcRn family are not known; however, critical amino acid residues involved in IgG binding are different between human and mouse. In case of next-generation mAbs with a novel structure or mode of action, knowledge from related drugs is limited. To ensure safety of next-generation mAbs, a thorough understanding of the differences in Fc receptors among species and the interactions between mAbs and Fc receptors is required, and the appropriateness of the nonclinical study design should be carefully examined prior to conducting clinical studies.	[Ishii-Watabe, Akiko; Tada, Minoru; Suzuki, Takuo; Kawasaki, Nana] Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, Tokyo 1588501, Japan	Ishii-Watabe, A (reprint author), Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	watabe@nihs.go.jp					Deng R, 2012, MABS-AUSTIN, V4, P101, DOI 10.4161/mabs.4.1.18543; Li FB, 2012, P NATL ACAD SCI USA, V109, P10966, DOI 10.1073/pnas.1208698109; Li FB, 2011, SCIENCE, V333, P1030, DOI 10.1126/science.1206954; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Dall'Acqua WF, 2006, J BIOL CHEM, V281, P23514, DOI 10.1074/jbc.M604292200; Wilson NS, 2011, CANCER CELL, V19, P101, DOI 10.1016/j.ccr.2010.11.012; Datta-Mannan A, 2007, DRUG METAB DISPOS, V35, P86, DOI 10.1124/dmd.106.011734; Yip V, 2014, MABS-AUSTIN, V6, P689, DOI 10.4161/mabs.28254; Suzuki T, 2010, J IMMUNOL, V184, P1968, DOI 10.4049/jimmunol.0903296; Yeung YA, 2010, CANCER RES, V70, P3269, DOI 10.1158/0008-5472.CAN-09-4580; Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754; Mimoto F, 2013, PROTEIN ENG DES SEL, V26, P589, DOI 10.1093/protein/gzt022; Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601; Richards JO, 2008, MOL CANCER THER, V7, P2517, DOI 10.1158/1535-7163.MCT-08-0201; Igawa T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063236; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Ito A, 2009, J IMMUNOL, V183, P4782, DOI 10.4049/jimmunol.0900699; Tada M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095787; Mimoto F, 2013, MABS-AUSTIN, V5, P229, DOI 10.4161/mabs.23452; Ito A, 2009, CANCER IMMUNOL IMMUN, V58, P1195, DOI 10.1007/s00262-008-0632-0; Stebbings R, 2007, J IMMUNOL, V179, P3325; Baudino L, 2008, J IMMUNOL, V181, P4107; Bugelski PJ, 2009, EXPERT REV CLIN IMMU, V5, P499, DOI [10.1586/eci.09.31, 10.1586/ECI.09.31]; Haraya K, 2014, XENOBIOTICA, V44, P1127, DOI 10.3109/00498254.2014.941963; Ishii A., 2014, PHARM SCI, V74, P1; Ishii A., 2012, FRONTIER ANTIBODY EN, P102; Ishii-Watabe Akiko, 2010, Folia Pharmacologica Japonica, V136, P280, DOI 10.1254/fpj.136.280; Ministry of Health, 2012, PHARMACEUTICALS; Ministry of Health, 2012, DEVELOPMENT; Presta L. G., 2005, U. S. Patent, Patent No. [6911321 B2, 6911321]; Rogers KA, 2006, J IMMUNOL, V177, P3848; Shibata-Koyama M, 2009, EXP HEMATOL, V37, P309, DOI 10.1016/j.exphem.2008.11.006; Shiokawa M, 2010, BIOCHEM BIOPH RES CO, V399, P733, DOI 10.1016/j.bbrc.2010.07.145; Strohl W. R., 2012, THERAPEUTIC ANTIBODY, P405; Strohl W. R., 2012, THERAPEUTIC ANTIBODY, P225; Tada M., 2013, TECHNOLOGY, P72; VANDENHERIKOUDIJK IE, 1995, BLOOD, V86, P3302; Yamaguchi T., 2007, DOKUSEI SHITSUMONBAK, V10, P1	39	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					857	866				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000004		
J	Mizukami, H				Mizukami, Hajime			Sugar Chain Construction of Functional Natural Products Using Plant Glucosyltransferases	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						chemoenzymatic glucosylation; natural product; functional characterization; plant secondary metabolism glycosyltransferase	OLIGOGLUCOSYL QUERCETIN 3-O-GLUCOSIDE; ENZYMATICALLY MODIFIED ISOQUERCITRIN; CATHARANTHUS-ROSEUS; SEQUENTIAL GLUCOSYLATION; GARDENIA-JASMINOIDES; MEDICAGO-TRUNCATULA; SUSPENSION-CULTURES; IN-VIVO; BIOSYNTHESIS; CURCUMIN	Plant secondary product glycosyltransferases belong to family 1 of the glycosyltransferase superfamily and mediate the transfer of a glycosyl residue from activated nucleotide sugars to lipophilic small molecules, thus affecting the solubility, stability and pharmacological activities of the sugar-accepting compounds. The biotechnological application of plant glycosyltransferases in glycoside synthesis has attracted attention because enzymatic glycosylation offers several advantages over chemical methods, including (1) avoiding the use of harsh conditions and toxic catalysts, (2) providing strict control of regio-and stereo-selectivity and (3) high efficiency. This review describes the in vivo and in vitro glycosylation of natural organic compounds using glycosyltransferases, focusing on our investigation of enzymatic synthesis of curcumin glycosides. Our current efforts toward functional characterization of some glycosyltransferases involved in the biosynthesis of iridoids and crocin, as well as in the sugar chain elongation of quercetin glucosides, are described. Finally, I describe the relationship of the structure of sugar chains and the intestinal absorption which was investigated using chemoenzymatically synthesized quercetin glycosides.	Nagoya City Univ, Dept Pharmacognosy, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan	Mizukami, H (reprint author), Nagoya City Univ, Dept Pharmacognosy, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	hajimem@makino.or.jp					Lim EK, 2004, BIOTECHNOL BIOENG, V87, P623, DOI 10.1002/bit.20154; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; Brazier-Hicks M, 2007, P NATL ACAD SCI USA, V104, P20238, DOI 10.1073/pnas.0706421104; Frydman A, 2004, PLANT J, V40, P88, DOI 10.1111/j.1365-313X.2004.02193.x; Noguchi A, 2008, PLANT J, V54, P415, DOI 10.1111/j.1365-313X.2008.03428.x; [Anonymous], 2002, Carbohydrate-active enzymes (CAZY), Patent No. [2337, DE2337]; INOMATA S, 1991, APPL MICROBIOL BIOT, V36, P315; Shao H, 2005, PLANT CELL, V17, P3141, DOI 10.1105/tpc.105.035055; Terasaka K, 2012, FEBS LETT, V586, P4344, DOI 10.1016/j.febslet.2012.10.045; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; MISAWA N, 1995, J BACTERIOL, V177, P6575; Lim EK, 2005, CHEM-EUR J, V11, P5486, DOI 10.1002/chem.200500115; Koch K, 2004, CURR OPIN PLANT BIOL, V7, P235, DOI 10.1016/j.pbi.2004.03.014; Makino T, 2009, BIOL PHARM BULL, V32, P2034, DOI 10.1248/bpb.32.2034; Schwab W, 2003, PHYTOCHEMISTRY, V62, P837, DOI 10.1016/S0031-9422(02)00723-9; PFANDER H, 1982, PHYTOCHEMISTRY, V21, P1039, DOI 10.1016/S0031-9422(00)82412-7; Li LN, 2007, J MOL BIOL, V370, P951, DOI 10.1016/j.jmb.2007.05.036; Obied HK, 2008, NAT PROD REP, V25, P1167, DOI 10.1039/b719736e; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; De Luca V, 2012, METHOD ENZYMOL, V515, P207, DOI 10.1016/B978-0-12-394290-6.00010-0; Sasaki H, 2011, BIOL PHARM BULL, V34, P660, DOI 10.1248/bpb.34.660; Yamazaki Y, 2004, PLANT PHYSIOL, V134, P161, DOI 10.1104/pp.103.029389; Nagatoshi M, 2012, FEBS LETT, V586, P1055, DOI 10.1016/j.febslet.2012.03.003; Bulter T, 1999, GLYCOCONJUGATE J, V16, P147, DOI 10.1023/A:1026444726698; Kaminaga Y, 2004, FEBS LETT, V567, P197, DOI 10.1016/j.febslet.2004.04.056; Contin A, 1998, FEBS LETT, V434, P413, DOI 10.1016/S0014-5793(98)01022-9; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Liscombe DK, 2011, PHYTOCHEMISTRY, V72, P1969, DOI 10.1016/j.phytochem.2011.07.001; Frusciante S, 2014, P NATL ACAD SCI USA, V111, P12246, DOI 10.1073/pnas.1404629111; Nagatoshi M, 2011, J BIOL CHEM, V286, P32866, DOI 10.1074/jbc.M111.242586; Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728; Tundis R, 2008, MINI-REV MED CHEM, V8, P399, DOI 10.2174/138955708783955926; Murata J, 2008, PLANT CELL, V20, P524, DOI 10.1105/tpc.107.056630; ICHIKAWA Y, 1994, METHOD ENZYMOL, V247, P107; Kaminaga Y, 2003, FEBS LETT, V555, P311, DOI 10.1016/S0014-5793(03)01265-1; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012; Asada K, 2013, PLANT CELL, V25, P4123, DOI 10.1105/tpc.113.115154; Bowers MD, 1991, HERBIVORES THEIR INT, VI, P297, DOI DOI 10.1016/B978-0-12-597183-6.50013-9; Chin D, 2013, CURR MED CHEM, V20, P3955; CHOPRA S, 1992, PLANT MOL BIOL, V18, P131, DOI 10.1007/BF00018465; KOMETANI T, 1993, BIOSCI BIOTECH BIOCH, V57, P1290; Kren V., 1997, CHEM, V473; Makino T, 2013, J NAT MED-TOKYO, V67, P881, DOI 10.1007/s11418-013-0760-5; Masada S, 2007, FEBS LETT, V581, P2562, DOI 10.1016/j.febslet.2007.04.074; Masada S, 2009, PLANT CELL PHYSIOL, V50, P1401, DOI 10.1093/pcp/pcp088; Milbury PE, 2001, METHOD ENZYMOL, V335, P15; Mohri K, 2003, CHEM PHARM BULL, V51, P1268, DOI 10.1248/cpb.51.1268; Morita Y, 2005, PLANT J, V42, P353, DOI 10.1111/j.1365-313X.2005.02383.x; Oudin Audrey, 2007, Phytochemistry Reviews, V6, P259, DOI 10.1007/s11101-006-9054-9; PILGRIM H, 1970, PHARMAZIE, V25, P568; Sawada S, 2005, J BIOL CHEM, V280, P899, DOI 10.1074/jbc.M410537200; Shimoda K, 2007, PHYTOCHEMISTRY, V68, P1391, DOI 10.1016/j.phytochem.2007.03.005; Takahashi R, 2015, YAKUGAKU ZASSHI, V135, P33, DOI 10.1248/yakushi.14-00208-1	54	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					867	882				16	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000005		
J	Moriyama, Y				Moriyama, Yoshinori			Vacuolar H+-ATPase and the Secondary Transporters: Their Identification, Mechanism, Function and Physiological Relevance	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						transporter; pump; membrane protein	ASCORBATE TRANSPORTER; ESCHERICHIA-COLI; PROTEINS; RELEASE	Eukaryotic cells possess acidic compartments with pH ranging from 0.1-6.5. Studies in the last couple of decades indicated that the acid pool is established by vacuolar proton ATPase, and is essential for various physiological and pathological processes. I have identified the vacuolar ATPase as well as several secondary transporters which are energetically coupled with vacuolar ATPase. I have also established the protocol for analysis of the structure and function of transporter proteins applicable to essentially all known transporters. In this article, I am going to summarize this study and describe some topics.	Grad Sch Med, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, Okayama 7008530, Japan	Moriyama, Y (reprint author), Grad Sch Med, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, Tsushima Naka 1-1-1, Okayama 7008530, Japan.	moriyama@pharm.okayama-u.ac.jp					Omote H, 2006, TRENDS PHARMACOL SCI, V27, P587, DOI 10.1016/j.tips.2006.09.001; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002; Moriyama Y, 2003, TRENDS PHARMACOL SCI, V24, P511, DOI 10.1016/j.tips.2003.08.002; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; Juge N, 2015, P NATL ACAD SCI USA, V112, P3356, DOI 10.1073/pnas.1417102112; Miyaji T, 2008, P NATL ACAD SCI USA, V105, P11720, DOI 10.1073/pnas.0804015105; Moriyama Y, 2004, J BIOCHEM, V135, P155, DOI 10.1093/jb/mvh018; Fernie AR, 2015, MOL PLANT, V8, P674, DOI 10.1016/j.molp.2015.02.006; Foyer CH, 2015, NAT PLANTS, V1, DOI 10.1038/NPLANTS.2014.12; Hiasa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06836; Juge N., 2006, J BIOL CHEM, V281, P39499; Leviatan S, 2010, J BIOL CHEM, V285, P23548, DOI 10.1074/jbc.M110.125492; Miyaji T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6928; Miyaji T, 2011, J BIOL CHEM, V286, P42881, DOI 10.1074/jbc.M111.277269; Moriyama Y, 1993, Seikagaku, V65, P413; Moriyama Y., 1993, PROTEIN NUCL ACID EN, V38, P2000; Moriyama Y, 1991, Seikagaku, V63, P202; Moriyama Y., 2008, FRONTIERS, P211; Moriyama Y., 2008, PROTEIN NUCL ACID EN, V53, P52; Moriyama Yoshinori, 2011, Seikagaku, V83, P294; Moriyama Y., 2012, TECHNOLOGY, V31, P574; Moriyama Y., 2009, PROTEIN NUCL ACID EN, V54, P148; Omote H, 2013, PHYSIOLOGY, V28, P39, DOI 10.1152/physiol.00033.2012; Sakamoto S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06689; Shouji K., 1969, AKAZUKINCHAN KIOTSUK; Singh S., 2000, FERMATS LAST THEOREM	27	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					883	894				12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000006		
J	Suzuki, R; Ohtsu, F; Goto, N				Suzuki, Ryohei; Ohtsu, Fumiko; Goto, Nobuyuki			Development and Validation of Estimate Equations for Adverse Drug Reactions Using Risk Factors and Subjective Symptoms	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						estimate equation; adverse drug reaction; risk factor; subjective symptom		The purpose of this study was to develop and validate estimate equations for preventing adverse drug reactions (ADRs). We conducted five case-control studies to identify individual risk factors and subjective symptoms associated with the following five ADRs: drug-induced ischemic heart disease; renal damage; muscle disorder; interstitial pneumonia; and leucopenia. We performed logistic regression analysis and obtained eight regression equations for each ADR. We converted these to ADR estimate equations for predicting the likelihood of ADRs. We randomly selected 50 cases with non-individual ADRs from the Case Reports of Adverse Drug Reactions and Poisoning Information System (CARPIS) database of over 65000 case reports of ADRs, and assigned these cases to a validation case group. We then calculated the predictive probability for 50 cases using the eight estimate equations for each ADR. The highest probability for each ADR was set as the probability of each ADR. If the probability was over 50%, the case was interpreted as ADR-positive. We calculated and evaluated the sensitivity, specificity, and positive likelihood ratio of this system. Sensitivity of the estimate equations for muscle disorder and interstitial pneumonia were >= 90%. Specificity and positive likelihood ratios of estimate equations for renal damage, interstitial pneumonia and leucopenia were >= 80% and >= 5, respectively. Our estimate equations thus showed high validity, and are therefore helpful for the prevention or early detection of ADRs.	[Suzuki, Ryohei; Ohtsu, Fumiko; Goto, Nobuyuki] Meijo Univ, Drug Informat, Fac Pharm, Tempaku Ku, Nagoya, Aichi 4680077, Japan; [Suzuki, Ryohei] Natl Hosp Org Higashinagoya Hosp, Meito Ku, Nagoya, Aichi 4658620, Japan	Ohtsu, F (reprint author), Meijo Univ, Drug Informat, Fac Pharm, Tempaku Ku, 150 Yagotoyama, Nagoya, Aichi 4680077, Japan.	fohtsu@meijo-u.ac.jp					Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Agbabiaka TB, 2008, DRUG SAFETY, V31, P21; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239; Hayashi K, 2011, YAKUGAKU ZASSHI, V131, P139, DOI 10.1248/yakushi.131.139; Ohtsu F., 2006, DRUG INF J, V40, P115; Ohtsu F., 2008, 128 ANN M PHARM SOC, P167; Ohtsu F, 2000, YAKUGAKU ZASSHI, V120, P120; Ohtsu F., 2009, 129 ANN M PHARM SOC, P231; Takeda J., 2010, JPN J PHARM HLTH CAR, V36, P735; Yamazaki K., 2011, JAPANESE SOC, P119	10	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					895	916				22	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000007		
J	Murai, Y; Suzuki, H; Mori, M; Tasaka, H; Suzuki, N; Shimada, M; Sato, H; Hirasawa, N; Mano, N; Tomioka, Y				Murai, Yuriko; Suzuki, Hiroyuki; Mori, Masaru; Tasaka, Hidehisa; Suzuki, Naoto; Shimada, Miki; Sato, Hiroshi; Hirasawa, Noriyasu; Mano, Nariyasu; Tomioka, Yoshihisa			Outcomes of a Long-term Case Review Program during the On-site Training of Pharmacy Students	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			English	Article						practical experience; case presentation; case conference; group session; advanced program; problem-based learning		This study sought to determine whether a long-term case review (LTCR) program helped pharmacy students develop their abilities as pharmacists, and how their level of satisfaction changed. LTCRs were comprised of four elements: self-learning, one-on-one bedside training with advising pharmacists, daily group sessions including three members, and weekly plenary sessions (case conferences). This program conducted on-site training in a hospital for 21 fifth-year students. The students were divided into 7 groups. One member of each group was assigned to a ward for bedside training for three weeks, while other member (s) of the central pharmacy provided support through daily group sessions. Each week, students training in the wards delivered case presentations in the case conference. All students, advising pharmacists, and teachers participated in these weekly case conferences. Upon conclusion of the on-site training, a survey was conducted on the program's efficacy. Through information sharing during group discussions, and in case conferences, continuous patient follow up was possible regardless of students' training schedules in wards or in the central pharmacy. After introducing the LTCR, the mean satisfaction level for case conferences (as scored using a 5-point Likert-type scale) increased from 3.4 to 4.3. Students' levels of understanding also improved. Statistically significant increases in students' self-evaluation scores on professional awareness, presentation skills, and logical thinking were also observed. We concluded that the program helped students to gain practical experience, made them more aware of clinical issues, and improved their presentation skills. Through this program, the students gained clinical competency through a deep understanding of the clinical courses of diseases and patient-oriented pharmaceutical care.	[Murai, Yuriko] Tohoku Univ, Grad Sch Pharmaceut Sci, Pharm Educ & Res Ctr, Aoba Ku, Sendai, Miyagi 9808578, Japan; [Murai, Yuriko; Suzuki, Hiroyuki; Mori, Masaru; Tasaka, Hidehisa; Suzuki, Naoto; Shimada, Miki; Sato, Hiroshi; Hirasawa, Noriyasu; Mano, Nariyasu; Tomioka, Yoshihisa] Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Suzuki, Naoto; Shimada, Miki; Sato, Hiroshi; Hirasawa, Noriyasu; Mano, Nariyasu; Tomioka, Yoshihisa] Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan	Murai, Y (reprint author), Tohoku Univ, Grad Sch Pharmaceut Sci, Pharm Educ & Res Ctr, Aoba Ku, 6-3 Aza Aoba, Sendai, Miyagi 9808578, Japan.	y-murai@hosp.tohoku.ac.jp			KAKENHI [23590582]; Japan Society for the Promotion of Science (JSPS)	We wish to thank all of the staff at Tohoku University Hospital for their untiring dedication to the provision of practical experience for pharmacy students. This study was funded by Grant-in-Aid for Scientific Research (KAKENHI Grant Number 23590582) awarded by the Japan Society for the Promotion of Science (JSPS).	Hata T, 2013, YAKUGAKU ZASSHI, V133, P691; Japan Pharmaceutical Association, 2015, ANN REPORT; Kawahara A, 2007, YAKUGAKU ZASSHI, V127, P973, DOI 10.1248/yakushi.127.973; Kurono S., 2012, MED EDUC, V43, P193; Murai Y., 2013, J DRUG INTERACT RES, V36, P39; Myotoku M., 2013, JPN J PHARM HLTH CAR, V39, P675; Nakagawa N., 2013, JPN J PHARM HLTH CAR, V39, P25; Nakamura A, 2007, YAKUGAKU ZASSHI, V127, P947, DOI 10.1248/yakushi.127.947; The Pharmaceutical Society of Japan, 2015, PHARM ED MOD COR CUR; Tomioka Y, 2011, YAKUGAKU ZASSHI, V131, P933	10	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					917	923				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000008		
J	Yamamura, K; Yano, K; Hirooka, Y; Hirashiki, A; Murohara, T; Yamada, K				Yamamura, Keiko; Yano, Koji; Hirooka, Yoshiki; Hirashiki, Akihiro; Murohara, Toyoaki; Yamada, Kiyofumi			A Successful Case of a Patient Undergoing Warfarin and S-1 Therapy Using Internet-based Control of Home-measured PT-INR	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			English	Article						warfarin; S-1; international normalized ratio; home-measured PT-INR prothrombin time; CoaguChek; time in therapeutic range		To avoid major bleeding events in warfarin and S-1 combination therapy, PT-INR levels should be monitored frequently to allow for precise adjustments of the warfarin dose and to verify any side effects reported by the patient. We therefore developed a support system where outpatients obtain a home-measured PT-INR value using the CoaguChek (R) system and submit it along with details of any side effects to us via the Internet using their mobile phone. A 59-year-old man was started on warfarin (1.5 mg/d) and S-1 (100 mg/d), a combination preparation of tegafur, gimeracil, and oteracil potassium, to treat cholangiocarcinoma. The patient sent his data to the hospital pharmacist every two days after starting S-1 therapy. When the PT-INR was outside the target range of 1.5-2.7, the pharmacist, after consulting the physician, instructed the patient to change his warfarin dose by 0.5 mg. On day 24 after starting S-1, PT-INR had increased from 1.6 to 2.8, so the dose was decreased by 0.5 mg. Thereafter, the dose was adjusted by 0.5-1.0 mg during the observation period so that the patient was able to maintain the therapeutic range approximately 90% of the time. We anticipate this system can be applied to S-1 which interact with warfarin, thereby enabling safer anticoagulation therapy.	[Yamamura, Keiko] Aichi Gakuin Univ, Sch Pharm, Chikusa Ku, Nagoya, Aichi 4648650, Japan; [Yano, Koji; Yamada, Kiyofumi] Nagoya Univ, Grad Sch Med, Dept Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; [Hirooka, Yoshiki] Nagoya Univ, Grad Sch Med, Dept Endoscopy, Showa Ku, Nagoya, Aichi 4668560, Japan; [Hirashiki, Akihiro; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Adv Med Cardiopulm Dis, Showa Ku, Nagoya, Aichi 4668560, Japan	Yamamura, K (reprint author), Aichi Gakuin Univ, Sch Pharm, Chikusa Ku, 1-100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.	keiko-y@dpc.agu.ac.jp	清文, 山田/I-7487-2014	清文, 山田/0000-0002-5280-5180	Aichi Gakuin University	We thank all staff who were involved in this study. Funding for the professional translation and editing of this case report was provided by Aichi Gakuin University.	Okuyama Y, 2014, CIRC J, V78, P1342, DOI 10.1253/circj.CJ-13-1256; Morgan CL, 2009, THROMB RES, V124, P37, DOI 10.1016/j.thromres.2008.09.016; STUPANS I, 1995, XENOBIOTICA, V25, P1; Wasif Saif M., 2005, CLIN COLORECTAL CANC, V5, P175	4	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JUL	2015	135	7					925	927				3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL8SS	WOS:000357245000009		
J	Ebisuzaki, T; Quinn, MN; Wada, S; Piotrowski, LW; Takizawa, Y; Casolino, M; Bertaina, ME; Gorodetzky, P; Parizot, E; Tajima, T; Soulard, R; Mourou, G				Ebisuzaki, Toshikazu; Quinn, Mark N.; Wada, Satoshi; Piotrowski, Lech Wiktor; Takizawa, Yoshiyuki; Casolino, Marco; Bertaina, Mario E.; Gorodetzky, Philippe; Parizot, Etienne; Tajima, Toshiki; Soulard, Remi; Mourou, Gerard			Demonstration designs for the remediation of space debris from the International Space Station	ACTA ASTRONAUTICA			English	Article						Space debris; Laser ablation; International Space Station	LASER; REMOVAL; SYSTEM	We present here designs for a staged implementation of an orbiting debris remediation system comprised of a super-wide field-of-view telescope (EUSO) and a novel high efficiency fibre-based laser system (CAN). Initial proof of concept stages will operate from the International Space Station (ISS) where the EUSO telescope has been designed for operation as a detector of ultra-high energy cosmic rays. Equipped with 2.5 m optics and a field of view of +/- 30 degrees, the EUSO telescope can also be utilised for the detection of high velocity fragmentation debris in orbit near the ISS. Further tracking, characterisation and remediation are to be performed by a CAN laser system operating in tandem with the EUSO telescope. For full scale versions of both instruments, the range of the detection/removal operation can be as large as 100 km. Utilising a step-by-step approach of increasing scale we present an analysis of implementation of: 1) Proof of principle demonstration of the detection by a mini-EUSO and operation of 100-fibre CAN laser technology as an ISS based prototype, 2) Technical demonstrator of debris-removal that consists of the EUSO telescope for the detection and a 10,000 fibre CAN laser for tracking and impulse delivery for debris re-entry, and 3) A free-flyer mission dedicated to debris remediation in a polar orbit with the altitude near 800 km. The integration of the two novel technologies aboard the ISS amounts to a novel approach as an immediate response to the serious space debris problem with the existing platform of ISS. (C) 2015 IAA. Published by Elsevier Ltd. All rights reserved.	[Ebisuzaki, Toshikazu; Wada, Satoshi; Piotrowski, Lech Wiktor; Takizawa, Yoshiyuki; Casolino, Marco] RIKEN, Wako, Saitama 3510198, Japan; [Quinn, Mark N.; Tajima, Toshiki; Soulard, Remi; Mourou, Gerard] Ecole Polytech, IZEST, F-91128 Palaiseau, France; [Casolino, Marco; Bertaina, Mario E.] Ist Nazl Fis Nucl, Struct Rome Tor Vergata, Rome, Italy; [Bertaina, Mario E.] Univ Turin, I-10125 Turin, Italy; [Gorodetzky, Philippe; Parizot, Etienne] Univ Paris 07, APC CNRS, F-75013 Paris, France; [Tajima, Toshiki] Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA	Ebisuzaki, T (reprint author), RIKEN, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	ebisu@postman.riken.jp			JSPS KAKENHI [23340081, 24244042]; RIKEN Strategic Research Programs for RD in Japan; CEA; Thales in France; l'Ecole Polytechnique	This work was partially supported by JSPS KAKENHI Nos. 23340081,24244042, and RIKEN Strategic Research Programs for R&D in Japan, the CEA, l'Ecole Polytechnique and Thales in France.	Allen C. W., 1973, ASTROPHYSICAL QUANTI; Kose E, 2014, APPL OPTICS, V53, P528, DOI 10.1364/AO.53.000528; Klenke A, 2013, OPT LETT, V38, P2283, DOI 10.1364/OL.38.002283; Liedahl DA, 2013, ADV SPACE RES, V52, P895, DOI 10.1016/j.asr.2013.05.019; Mourou G, 2013, NAT PHOTONICS, V7, P258; Adams JH, 2013, ASTROPART PHYS, V44, P76, DOI 10.1016/j.astropartphys.2013.01.008; Bourderionnet J., 2011, OPT EXPRESS, V19, P18; Bourderionnet J., 2008, P SPIE EUR SEC DEF I; Casolino M., 2011, ASTROPHYS SPACE SCI, V7, P477; Flegel S., MASTER2009; Liou J.-C., 2013, P 64 INT ASTR C BEIJ; METZGER JD, 1989, J PROPUL POWER, V5, P582, DOI 10.2514/3.23193; Phipps C, 2006, APPL SURF SCI, V252, P4838, DOI 10.1016/j.apsusc.2005.07.079; Phipps CR, 2014, ACTA ASTRONAUT, V104, P243, DOI 10.1016/j.actaastro.2014.08.007; Schall WO, 1998, P SOC PHOTO-OPT INS, V3574, P426, DOI 10.1117/12.334466; Soulard R, 2014, ACTA ASTRONAUT, V105, P192, DOI 10.1016/j.actaastro.2014.09.004; Takahashi Y., 2008, NEW J PHYS, V11	17	3	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0094-5765	1879-2030		ACTA ASTRONAUT	Acta Astronaut.	JUL-AUG	2015	112						102	113		10.1016/j.actaastro.2015.03.004		12	Engineering, Aerospace	Engineering	CL8MC	WOS:000357227800011		
J	Inamori, T; Kawashima, R; Saisutjarit, P; Sako, N; Ohsaki, H				Inamori, Takaya; Kawashima, Rei; Saisutjarit, Phongsatom; Sako, Nobutada; Ohsaki, Hiroyuki			Magnetic plasma deorbit system for nano- and micro-satellites using magnetic torquer interference with space plasma in low Earth orbit	ACTA ASTRONAUTICA			English	Article						Nano- and micro-satellites; Deorbit; Space plasma; Magnetic torquers; Magnetic plasma deorbit	ATTITUDE-CONTROL; SAIL; SIMULATION	We propose a magnetic plasma deorbit (MPD) system using magnetic torquers (MTQs) for inducing the deorbit of nano- and micro-satellites. Currently, orbital space debris from these satellites is a matter of increasing concern to all satellites; however, deorbit systems have not been installed in most of these satellites. In general, nano- and micro-satellites have severe constraints on their power consumption, cost, and mass; therefore, it is difficult to install additional components that are not used in their main missions. The MPD system proposed in this study utilizes a drag force caused by the interaction between in-orbit space plasma and MTQs for attitude control. Because most nano- and micro-satellites already have MTQs installed for use in their attitude control, no additional thrusters and structures need to be installed for this deorbit system. Therefore, many satellites can be made to deorbit after their missions, which will reduce the accumulation of space debris. The present study assesses the duration required for the MPD to achieve deorbit using a plasma drag force model. (C) 2015 IAA. Published by Elsevier Ltd. All rights reserved.	[Inamori, Takaya; Ohsaki, Hiroyuki] Univ Tokyo, Dept Adv Energy, Tokyo, Japan; [Kawashima, Rei] Univ Tokyo, Dept Aeronaut & Astronaut, Tokyo, Japan; [Saisutjarit, Phongsatom] King Mongkuts Univ Technol North Bangkok, Dept Mech & Aerosp Engn, Bangkok, Thailand; [Sako, Nobutada] Canon Elect INC, Tokyo, Japan	Inamori, T (reprint author), Univ Tokyo, Dept Adv Energy, Tokyo, Japan.	takayainamori@gmail.com					Alonso R, 2002, J ASTRONAUT SCI, V50, P453; Crassidis JL, 2005, J GUID CONTROL DYNAM, V28, P115, DOI 10.2514/1.6278; Ashida Y, 2014, J PROPUL POWER, V30, P186, DOI 10.2514/1.B35026; Bilitza D., 1990, INT REFERENCE IONOSP; Fakhari Mehrjardi M., 2009, P SPIE, V7522; Fujita K., 2004, J SPACE TECHNOL SCI, V20; Funaki I., 2007, EARTH PLANET SCI AST, P439; Funaki I, 2007, ASTROPHYS SPACE SCI, V307, P63, DOI 10.1007/s10509-006-9251-4; Heidt H., 2000, 14 ANN AIAA USU C SM; Inamori T, 2011, ACTA ASTRONAUT, V68, P2038, DOI 10.1016/j.actaastro.2010.10.022; Inamori T, 2011, AIRCR ENG AEROSP TEC, V83, P221, DOI 10.1108/00022661111138639; Inamori T, 2011, ADV SPACE RES, V48, P432, DOI 10.1016/j.asr.2011.03.036; Inamori T., 2011, J AEROSP, P594; Komatsu M., 2009, T JPN SOC, V7, P19; Lee S.-H., 2005, ICCAS2005; Markley F., 1988, J ASTRONAUT SCI, V38, P245; Matsumoto M., 2012, J JPN SOC AERONAUT S, V60, P31; Nakasuka S, 2010, ACTA ASTRONAUT, V66, P1099, DOI 10.1016/j.actaastro.2009.09.029; Nishida H, 2006, J SPACECRAFT ROCKETS, V43, P667, DOI 10.2514/1.15717; Nishida H., 2005, 41 AIAA ASME SAE ASE; Nishida H., 2010, 61 INT ASTR C PRAG C; Nishida Hiroyuki, 2009, P SPAC SCI TECHN C K; Ueshima H., 2005, ATTITUDE CONTROL SYS	23	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0094-5765	1879-2030		ACTA ASTRONAUT	Acta Astronaut.	JUL-AUG	2015	112						192	199		10.1016/j.actaastro.2015.02.025		8	Engineering, Aerospace	Engineering	CL8MC	WOS:000357227800019		
J	Kim, HJ; Kim, JS; Woo, JT; Lee, IS; Cha, BY				Kim, Hyo Jung; Kim, Jin Sook; Woo, Je-Tae; Lee, Ik-Soo; Cha, Byung-Yoon			Hyperpigmentation mechanism of methyl 3,5-di-caffeoylquinate through activation of p38 and MITF induction of tyrosinase	ACTA BIOCHIMICA ET BIOPHYSICA SINICA			English	Article						methyl 3; 5-di-caffeoylquinate (3; 5-diCQM); melanogenesis; tyrosinase; microphthalmia-associated transcription factor (MITF); p38 mitogen-activated protein kinase (p38 MAPK)	B16 MELANOMA-CELLS; ACID-DERIVATIVES; PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY; TRANSCRIPTION FACTOR; SKIN PIGMENTATION; VITILIGINOUS SKIN; HUMAN MELANOCYTES; QUINIC ACID; MELANOGENESIS; INHIBITION	Methyl 3,5-di-caffeoylquinate (3,5-diCQM) has been used for the treatment of various diseases in oriental medicine, but its effect on melanogenesis has not been reported yet. In this study, the molecular mechanism of 3,5-diCQM-induced melanogenesis was investigated. It was found that 3,5-diCQM induced synthesis of melanin pigments in murine B16F10 melanoma cells in a concentration-dependent manner. Treatment of cells with 3,5-diCQM for 48 h increased extracellular and intracellular melanin production and tyrosinase activity. The expressions of tyrosinase, tyrosinase-related protein 1 (TRP1), and TRP2 were up-regulated in a dose-dependent manner 48 h after 3,5-diCQM treatment. Western blot analysis showed that 3,5-diCQM increased the phosphorylation of p38 mitogen-activated protein kinase and cAMP responsive element binding as well as the expression of microphthalmia-associated transcription factor. In addition, 3,5-diCQM-stimulated cAMP production, and 3,5-diCQM-induced tyrosinase activity and melanin synthesis were attenuated by H89, a protein kinase A inhibitor. These results suggested that 3,5-diCQM-mediated activation of the p38 pathway may represent a novel approach for an effective therapy for vitiligo and hair graying.	[Kim, Hyo Jung; Woo, Je-Tae; Cha, Byung-Yoon] Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi 4878501, Japan; [Kim, Jin Sook; Lee, Ik-Soo] Korea Inst Oriental Med, KM Convergence Res Div, Taejon 305811, South Korea; [Woo, Je-Tae] Erina Co Inc, Dept Res & Dev, Minato Ku, Tokyo 1050021, Japan	Cha, BY (reprint author), Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi 4878501, Japan.	bycha@isc.chubu.ac.jp			Erina Co., Inc. (Tokyo, Japan) [20140070]	This work was supported by an endowment from Erina Co., Inc. (Tokyo, Japan) (No. 20140070).	Yoshida M, 2005, BIOL PHARM BULL, V28, P173, DOI 10.1248/bpb.28.173; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Connor M, 1999, CLIN EXP PHARMACOL P, V26, P493, DOI 10.1046/j.1440-1681.1999.03049.x; Jang JY, 2009, EXP DERMATOL, V18, P689, DOI 10.1111/j.1600-0625.2009.00857.x; Mishima S, 2005, BIOORGAN MED CHEM, V13, P5814, DOI 10.1016/j.bmc.2005.05.044; Spritz RA, 2007, PIGM CELL RES, V20, P271, DOI 10.1111/j.1600-0749.2007.00384.x; Park SH, 2004, CELL MOL LIFE SCI, V61, P2878, DOI 10.1007/s00018-004-4341-3; Khaled M, 2003, J INVEST DERMATOL, V121, P831, DOI 10.1046/j.1523-1747.2003.12420.x; ENGLARO W, 1995, J BIOL CHEM, V270, P24315; Bellei B, 2010, J BIOL CHEM, V285, P7288, DOI 10.1074/jbc.M109.070573; Park HY, 1999, CELL MOL BIOL, V45, P919; Bertolotto C, 1998, ONCOGENE, V16, P1665, DOI 10.1038/sj.onc.1201685; Bu J, 2008, AM J CHINESE MED, V36, P245, DOI 10.1142/S0192415X08005758; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Yoshimoto M, 2002, BIOSCI BIOTECH BIOCH, V66, P2336, DOI 10.1271/bbb.66.2336; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Robinson WE, 1996, MOL PHARMACOL, V50, P846; Hung TM, 2006, J ETHNOPHARMACOL, V108, P188, DOI 10.1016/j.jep.2006.04.029; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; KAIDBEY KH, 1979, J AM ACAD DERMATOL, V1, P249, DOI 10.1016/S0190-9622(79)70018-1; Westerhof W, 2007, PIGM CELL RES, V20, P345, DOI 10.1111/j.1600-0749.2007.00399.x; Hata K, 2003, J BIOCHEM, V134, P441, DOI 10.1093/jh/mvg162; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Lee J, 2007, LIFE SCI, V81, P249, DOI 10.1016/j.lfs.2007.05.009; Zhu XF, 2004, J AGR FOOD CHEM, V52, P7272, DOI 10.1021/jf0490192; Basnet Purusotam, 1996, Biological and Pharmaceutical Bulletin, V19, P1479; Galvan I, 2012, PHYSIOL BIOCHEM ZOOL, V85, P332, DOI 10.1086/666606; GILCHREST BA, 1979, J INVEST DERMATOL, V73, P141, DOI 10.1111/1523-1747.ep12581580; Gongora L, 2002, LIFE SCI, V71, P2995, DOI 10.1016/S0024-3205(02)02167-7; HATCHOME N, 1987, ARCH DERMATOL, V123, P51, DOI 10.1001/archderm.123.1.51; Hirata N, 2007, BIOORGAN MED CHEM, V15, P4897, DOI 10.1016/j.bmc.2007.04.046; Jang DS, 2010, BIOL PHARM BULL, V33, P329, DOI 10.1248/bpb.33.329; Jun S, 2009, EXP MOL MED, V41, P517; Jung GD, 2001, EXP MOL MED, V33, P131; Kim DS, 2003, ARCH PHARM RES, V26, P739, DOI 10.1007/BF02976685; KOLLIAS N, 1991, J PHOTOCH PHOTOBIO B, V9, P135, DOI 10.1016/1011-1344(91)80147-A; Lin YL, 2011, J AGR FOOD CHEM, V59, P8789, DOI 10.1021/jf201166b; Mallick S, 2002, J BIOSCIENCES, V27, P243, DOI 10.1007/BF02704913; MASON HS, 1960, ARCH BIOCHEM BIOPHYS, V86, P225, DOI 10.1016/0003-9861(60)90409-4; Nagata H, 2004, PIGM CELL RES, V17, P66, DOI 10.1046/j.1600-0749.2003.00113.x; SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R; Sturm RA, 2002, MELANOMA RES, V12, P405, DOI 10.1097/00008390-200209000-00001; Trüeb Ralph M, 2009, Int J Trichology, V1, P6, DOI 10.4103/0974-7753.51923; UEHARA M, 1984, ARCH DERMATOL, V120, P195, DOI 10.1001/archderm.120.2.195; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Yang B, 2005, DRUG METAB DISPOS, V33, P930, DOI 10.1124/dmd.104.002154; Zhu K, 1999, J VIROL, V73, P3309	47	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1672-9145	1745-7270		ACTA BIOCH BIOPH SIN	Acta Biochim. Biophys. Sin.	JUL	2015	47	7					548	556		10.1093/abbs/gmv040		9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CM1DD	WOS:000357419600009		
J	Matsuzaki, R; Tabayashi, K				Matsuzaki, Ryosuke; Tabayashi, Kosuke			Highly Stretchable, Global, and Distributed Local Strain Sensing Line Using GaInSn Electrodes for Wearable Electronics	ADVANCED FUNCTIONAL MATERIALS			English	Article						electrodes; flexible electronics; sensing; strain; wearable electronics	LIQUID-METAL ALLOY; ELASTIC CONDUCTORS; LARGE-AREA; MATRIX; ANTENNAS; DISPLAY; TIRES; LIGHT	For identifying human or finger movement, it is necessary to sense subtle movements at multiple points, including the local strain and global deformation simultaneously; however, this has not yet been realized. Therefore, a highly stretchable, global, and distributed local strain sensing electrode made of GaInSn and polydimethylsiloxane is developed for wearable devices. To investigate the electrical properties of multiple sections of the GaInSn electrode when stretching, tensile, cyclic, and three-point-bending tests are performed. The results demonstrate that the electrode can withstand a strain up to 50% and has little hysteresis without any delay. Moreover, the distributed local strain and global strain can be simultaneously measured using just a single electrode line. Finally, a prototype of a data glove as an application of the strain sensing line is manufactured, and it is demonstrated that the folding state of fingers could be identified. The proposed technology may allow the creation of a lightweight master hand manipulator or 3D data entry device.	[Matsuzaki, Ryosuke; Tabayashi, Kosuke] Tokyo Univ Sci, Dept Mech Engn, Noda, Chiba 2788510, Japan	Matsuzaki, R (reprint author), Tokyo Univ Sci, Dept Mech Engn, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	rmatsuza@rs.tus.ac.jp					[Anonymous], 2009, CRC HDB CHEM PHYS; Morley NB, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.2930813; Kim DH, 2008, P NATL ACAD SCI USA, V105, P18675, DOI 10.1073/pnas.0807476105; Matsuzaki R, 2007, SENSOR ACTUAT A-PHYS, V140, P32, DOI 10.1016/j.sna.2007.06.014; Liu CX, 2010, IEEE T NANOTECHNOL, V9, P590, DOI 10.1109/TNANO.2010.2060350; Zhou LS, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2178213; Matsuzaki R, 2008, SENSOR ACTUAT A-PHYS, V148, P1, DOI 10.1016/j.sna.2008.08.001; Lee P, 2012, ADV MATER, V24, P3326, DOI 10.1002/adma.201200359; Sekitani T, 2008, SCIENCE, V321, P1468, DOI 10.1126/science.1160309; Rogers JA, 2001, P NATL ACAD SCI USA, V98, P4835, DOI 10.1073/pnas.091588098; Surmann P, 2005, ANAL BIOANAL CHEM, V383, P1009, DOI 10.1007/s00216-005-0069-7; Fassler A, 2013, SMART MATER STRUCT, V22, DOI 10.1088/0964-1726/22/5/055023; Kubo M, 2010, ADV MATER, V22, P2749, DOI 10.1002/adma.200904201; So JH, 2009, ADV FUNCT MATER, V19, P3632, DOI 10.1002/adfm.200900604; Park YL, 2012, IEEE SENS J, V12, P2711, DOI 10.1109/JSEN.2012.2200790; Lacour SP, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2201874; Li T, 2006, INT J SOLIDS STRUCT, V43, P2351, DOI 10.1016/j.ijsolstr.2005.04.034; Kim HJ, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2829595; Sekitani T, 2009, NAT MATER, V8, P494, DOI [10.1038/nmat2459, 10.1038/NMAT2459]; Majidi C, 2011, SMART MATER STRUCT, V20, DOI 10.1088/0964-1726/20/10/105017; Rosset S, 2009, ADV FUNCT MATER, V19, P470, DOI 10.1002/adfm.200801218; HEGGERS JP, 1983, ANN PLAS SURG, V11, P38, DOI 10.1097/00000637-198307000-00006; Someya T, 2004, P NATL ACAD SCI USA, V101, P9966, DOI 10.1073/pnas.0401918101; Dickey MD, 2008, ADV FUNCT MATER, V18, P1097, DOI 10.1002/adfm.200701216; Zhu S, 2013, ADV FUNCT MATER, V23, P2308, DOI 10.1002/adfm.201202405; Hanson DE, 2005, POLYMER, V46, P10989, DOI 10.1016/j.polymer.2005.09.039; Hu H., 2007, IEEE SENS C ATL GA O; Kramer R. K., 2011, IEEE INT C ROB AUT S; Liu SLZ, 2015, LAB CHIP, V15, P1376, DOI 10.1039/c4lc01341g; Mohammed MG, 2013, SENSOR ACTUAT A-PHYS, V193, P246, DOI 10.1016/j.sna.2013.01.031; Park Y. -L., 2011, IEEE RSJ INT C INT R	31	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1616-301X	1616-3028		ADV FUNCT MATER	Adv. Funct. Mater.	JUL 1	2015	25	25					3806	3813		10.1002/adfm.201501396		8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	CL9BM	WOS:000357268900001		
J	Asano, K; Izuhara, K				Asano, Koichiro; Izuhara, Kenji			Innate lymphoid cells open a new window on allergic diseases	ALLERGOLOGY INTERNATIONAL			English	Editorial Material							EOSINOPHILIC ESOPHAGITIS		[Asano, Koichiro] Tokai Univ, Sch Med, Dept Med, Div Pulm Med, Hiratsuka, Kanagawa 25912, Japan; [Izuhara, Kenji] Saga Med Sch, Div Med Biochem, Dept Biomol Sci, Saga 8498501, Japan	Izuhara, K (reprint author), Saga Med Sch, Div Med Biochem, Dept Biomol Sci, 5-1-1 Nabeshima, Saga 8498501, Japan.	kizuhara@cc.saga-u.ac.jp					Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Shoda T, 2015, ALLERGOL INT, V64, P260, DOI 10.1016/j.alit.2015.03.002; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Ito J, 2015, ALLERGOL INT, V64, P253, DOI 10.1016/j.alit.2015.02.003; Kabata H, 2015, ALLERGOL INT, V64, P227, DOI 10.1016/j.alit.2015.03.004; Kita H, 2015, ALLERGOL INT, V64, P219, DOI 10.1016/j.alit.2015.04.004; Matsushita K, 2015, ALLERGOL INT, V64, P235, DOI 10.1016/j.alit.2014.12.008; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636	11	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					217	218		10.1016/j.alit.2015.05.001		2	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400001		
J	Kabata, H; Moro, K; Koyasu, S; Asano, K				Kabata, Hiroki; Moro, Kazuyo; Koyasu, Shigeo; Asano, Koichiro			Group 2 innate lymphoid cells and asthma	ALLERGOLOGY INTERNATIONAL			English	Review						Allergy; IL-25; IL-33; Innate immunity; Type 2 cytokines	THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR GATA3; NATURAL HELPER-CELLS; ALLERGIC LUNG INFLAMMATION; GENOME-WIDE ASSOCIATION; TYPE-2 IMMUNE-RESPONSE; AIRWAY HYPERREACTIVITY; INCREASED EXPRESSION; CYTOKINE PRODUCTION; ADAPTIVE IMMUNITY	Group 2 innate lymphoid cells (ILC2s) are recently identified cell populations that produce type 2 cytokines such as IL-5 and IL-13 in response to epithelial cell-derived cytokines. Although ILC2s were initially reported to play a key role in the anti-helminth innate immunity, we now have greater interest in their role in asthma and other allergic diseases. In various asthma mouse models, ILC2s provoke eosinophilic inflammation accompanied by airway hyperresponsiveness independent of acquired immunity. Moreover, recent mouse studies show that ILC2s also promote acquired immunity and Th2 polarization, and various cytokines and lipid mediators influence the functions of ILC2s. Although ILC2s have also been identified in humans, studies on the role of human ILC2s in asthma are very limited. Thus far, human studies have shown that there is a slight difference in responsiveness and production of cytokines between mouse and human ILC2s, and it has been suggested that ILC2s are involved in allergic-type asthma and the exacerbation of asthma. In this review, we focus on mouse and human ILC2s, and discuss their role in asthma. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Kabata, Hiroki] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo 160, Japan; [Kabata, Hiroki] Kawasaki Municipal Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan; [Kabata, Hiroki; Moro, Kazuyo; Koyasu, Shigeo] RIKEN Ctr Integrat Med Sci IMS, Lab Immune Cell Syst, Kawasaki, Kanagawa, Japan; [Moro, Kazuyo] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Tokyo, Japan; [Moro, Kazuyo] Yokohama City Univ, Grad Sch Med Life Sci, Dept Med Life Sci, Div Immunobiol, Yokohama, Kanagawa, Japan; [Koyasu, Shigeo] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan; [Asano, Koichiro] Tokai Univ, Sch Med, Dept Med, Div Pulm Med, Isehara, Kanagawa 2591193, Japan	Asano, K (reprint author), Tokai Univ, Sch Med, Dept Med, Div Pulm Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	ko-asano@tokai-u.jp	Koyasu, Shigeo/J-5583-2015	Koyasu, Shigeo/0000-0001-9585-3038	Japan Society for the Promotion of Science (JSPS) [25461504]; Ministry of Health, Labour, and Welfare, Japan	This work was supported in a Grant-in-Aid for Scientific Research (C)(25461504) to KA from the Japan Society for the Promotion of Science (JSPS) and a Grant-in-Aid for the Research on Allergic disease and Immunology to KA from the Ministry of Health, Labour, and Welfare, Japan.	Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Busse WW, 2001, NEW ENGL J MED, V344, P350; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Meylan F, 2014, MUCOSAL IMMUNOL, V7, P958, DOI 10.1038/mi.2013.114; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Saenz SA, 2013, J EXP MED, V210, P1823, DOI 10.1084/jem.20122332; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Ying S, 2008, J IMMUNOL, V181, P2790; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Petersen BC, 2012, NAT MED, V18, P751, DOI 10.1038/nm.2735; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Yu X, 2014, MUCOSAL IMMUNOL, V7, P730, DOI 10.1038/mi.2013.92; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Ferreira DS, 2012, CLIN EXP ALLERGY, V42, P1459, DOI 10.1111/j.1365-2222.2012.04047.x; Meylan F, 2011, IMMUNOL REV, V244, P188, DOI 10.1111/j.1600-065X.2011.01068.x; Nakae S, 2013, ALLERGOL INT, V62, P13, DOI 10.2332/allergolint.13-RAI-0538; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Furusawa J, 2013, J IMMUNOL, V191, P1818, DOI 10.4049/jimmunol.1300379; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Traister RS, 2015, J ALLERGY CLIN IMMUN, V135, P92, DOI 10.1016/j.jaci.2014.06.023; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Barnig C., 2013, SCI TRANSL MED, V5; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Cheng D, 2014, AM J RESP CRIT CARE, V190, P639, DOI 10.1164/rccm.201403-0505OC; Christianson CA, 2015, J ALLERGY CLIN IMMUN; Doherty TA, 2015, J LEUKOCYTE BIOL, V97, P455, DOI 10.1189/jlb.5BT0814-374R; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Gorski SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003615; Hara K, 2014, J IMMUNOL, V192, P4032, DOI 10.4049/jimmunol.1400110; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim KW, 2009, CHEST, V136, P805, DOI 10.1378/chest.08-2972; Koyasu S, 2015, NAT IMMUNOL, V16, P133, DOI 10.1038/ni.3080; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Okumura S, 2005, J ALLERGY CLIN IMMUN, V115, P272, DOI 10.1016/j.jaci.2004.10.004; Bittar HET, 2015, ANNU REV PATHOL-MECH, V10, P511, DOI 10.1146/annurev-pathol-012414-040343; Yoshimoto T, 2014, ALLERGOL INT, V63, P3, DOI 10.2332/allergolint.13-RA-0657	83	1	1	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					227	234		10.1016/j.alit.2015.03.004		8	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400003		
J	Matsushita, K; Kato, Y; Akasaki, S; Yoshimoto, T				Matsushita, Kazufumi; Kato, Yukinori; Akasaki, Shoko; Yoshimoto, Tomohiro			Proallergic cytokines and group 2 innate lymphoid cells in allergic nasal diseases	ALLERGOLOGY INTERNATIONAL			English	Review						Allergic rhinitis; Chronic rhinosinusitis; Group 2 innate lymphoid cells; Proallergic cytokines; Upper airway	THYMIC STROMAL LYMPHOPOIETIN; TYPE-2 IMMUNE-RESPONSE; NATURAL HELPER-CELLS; CHRONIC RHINOSINUSITIS; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; NONALLERGIC RHINITIS; AIRWAY INFLAMMATION; LUNG INFLAMMATION; GENETIC-VARIANTS	Recent advances in our understanding of proallergic cytokines and group 2 innate lymphoid cells (ILC2s) indicate their critical roles in type 2 immunity-mediated disorders. Proallergic cytokines, interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin, are released from epithelial cells in inflamed tissues and drive type 2 inflammation by acting on innate and acquired immune systems. ILC2s are an innate immune population that responds to proallergic cytokines by producing type 2 cytokines. In line with allergic disorders in the lung, skin, and intestine, emerging evidence suggests the involvement of proallergic cytokines and ILC2s in allergic nasal diseases such as chronic rhinosinusitis with polyps (CRSwNP), allergic fungal rhinosinusitis, and allergic rhinitis (AR). In CRSwNP patients, both proallergic cytokine levels and ILC2s frequency are increased in the nasal mucosa. Increased proallergic cytokine levels correlate with poorer disease outcomes in CRSwNP. Levels of nasal proallergic cytokines are also elevated in AR patients. In addition, animal studies demonstrate that cytokines are essential for the development of AR. It is becoming clear that the proallergic cytokine/ILC2s axis participates in allergic diseases by multiple mechanisms dependent upon the inflammatory context. Thus, a thorough understanding of these cytokines and ILC2s including their tissue-and disease-specific roles is essential for targeting the pathways to achieve therapeutic applications. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Matsushita, Kazufumi; Kato, Yukinori; Akasaki, Shoko; Yoshimoto, Tomohiro] Hyogo Coll Med, Lab Allerg Dis, Inst Adv Med Sci, Nishinomiya, Hyogo 6638501, Japan; [Kato, Yukinori] Univ Fukui, Fac Med Sci, Dept Otorhinolaryngol Head & Neck Surg, Fukui 910, Japan; [Yoshimoto, Tomohiro] Hyogo Coll Med, Dept Immunol & Med Zool, Kobe, Hyogo, Japan	Yoshimoto, T (reprint author), Hyogo Coll Med, Lab Allerg Dis, Inst Adv Med Sci, Dept Immunol & Med Zool, Nishinomiya, Hyogo 6638501, Japan.	tomo@hyo-med.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) [S1001055]; Japan Society for the Promotion of Science [24390253]; Takeda Science Foundation	This work was supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Supported Program for the Strategic Research Foundation at Private Universities (S1001055); the Grant-in-Aid for Scientific Research B (24390253) from the Japan Society for the Promotion of Science, and the Takeda Science Foundation.	Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Kouzaki H, 2013, AM J RESP CELL MOL, V49, P741, DOI 10.1165/rcmb.2012-0304OC; Mou ZL, 2009, ACTA OTO-LARYNGOL, V129, P297, DOI 10.1080/00016480802225884; Li ZP, 2014, IRAN J ALLERGY ASTHM, V13, P412; Melum GR, 2014, J ALLERGY CLIN IMMUN, V134, P613, DOI 10.1016/j.jaci.2014.05.010; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Kamekura R, 2009, CELL TISSUE RES, V338, P283, DOI 10.1007/s00441-009-0855-1; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; De Corso E, 2014, RHINOLOGY, V52, P142, DOI [10.4193/Rhin, 10.4193/Rhino13.102]; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Reh DD, 2010, AM J RHINOL ALLERGY, V24, P105, DOI 10.2500/ajra.2010.24.3446; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; Kamekura R, 2012, CLIN EXP ALLERGY, V42, P218, DOI 10.1111/j.1365-2222.2011.03867.x; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Kim YH, 2012, ALLERGY, V67, P183, DOI 10.1111/j.1398-9995.2011.02735.x; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Gluck J, 2012, INFLAMM RES, V61, P547, DOI 10.1007/s00011-012-0443-9; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Lam M, 2013, INT FORUM ALLERGY RH, V3, P121, DOI 10.1002/alr.21082; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Asaka D, 2012, INT ARCH ALLERGY IMM, V158, P47, DOI 10.1159/000337764; Baba S, 2014, LARYNGOSCOPE, V124, pE115, DOI 10.1002/lary.24462; Barnig C., 2013, SCI TRANSL MED, V5; Birben E, 2014, INT ARCH ALLERGY IMM, V163, P185, DOI 10.1159/000358488; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.90.015; Castano R, 2009, AMJ RHINOL ALLERGY, V23, P377, DOI 10.2500/ajra.2009.23.3303; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Gelardi M, 2008, J BIOL REG HOMEOS AG, V22, P73; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Ho J, 2014, INT FORUM ALLERGY RH, V5, P14; Incorvaia Cristoforo, 2013, World Allergy Organ J, V6, P11, DOI 10.1186/1939-4551-6-11; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kato Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103540; Katotomichelakis M, 2013, AM J RHINOL ALLERGY, V27, P354, DOI 10.2500/ajra.2013.27.3922; Kimura S, 2011, ALLERGY ASTHMA IMMUN, V3, P186, DOI 10.4168/aair.2011.3.3.186; Liu T, 2011, AM J MED SCI, V341, P40, DOI 10.1097/MAJ.0b013e3181f20489; Matsumoto Yuri, 2011, Allergology International, V60, P87, DOI 10.2332/allergolint.10-OA-0230; McKenzie ANJ, 2014, IMMUNITY, V41, P366, DOI 10.1016/j.immuni.2014.09.006; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Nilsson D, 2014, ALLERGY, V69, P1506, DOI [10.1111/all.12495, 10.1111/a11.12495]; Ouyang YH, 2013, ORL J OTO-RHINO-LARY, V75, P37, DOI 10.1159/000346929; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Plonk DP, 2014, CURR OPIN OTOLARYNGO, V22, P221, DOI 10.1097/MOO.0000000000000043; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wang H, 2010, CLIN EXP ALLERGY, V40, P1194, DOI 10.1111/j.1365-2222.2010.03542.x; Xu G, 2010, ALLERGY, V65, P581, DOI 10.1111/j.1398-9995.2009.02252.x; Yoshimoto T, 2014, ALLERGOL INT, V63, P3, DOI 10.2332/allergolint.13-RA-0657; Zhu DD, 2009, CHINESE MED J-PEKING, V122, P2303, DOI 10.3760/cma.j.issn.0366-6999.2009.19.021	65	1	1	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					235	240		10.1016/j.alit.2014.12.008		6	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400004		
J	Ishiyama, K; Yashiro, T; Nakano, N; Kasakura, K; Miura, R; Hara, M; Kawai, F; Maeda, K; Tamura, N; Okumura, K; Ogawa, H; Takasaki, Y; Nishiyama, C				Ishiyama, Kentaro; Yashiro, Takuya; Nakano, Nobuhiro; Kasakura, Kazumi; Miura, Ryosuke; Hara, Mutsuko; Kawai, Fumitaka; Maeda, Keiko; Tamura, Naoto; Okumura, Ko; Ogawa, Hideoki; Takasaki, Yoshinari; Nishiyama, Chiharu			Involvement of PU.1 in NFATc1 promoter function in osteoclast development	ALLERGOLOGY INTERNATIONAL			English	Article						NFATc1; Osteoclasts; Promoter; PU.1; Transcription factor	FC-EPSILON-RI; TRANSCRIPTION FACTOR PU.1; GENE-EXPRESSION; MAST-CELLS; ALPHA; DIFFERENTIATION; INDUCTION; MICE	Background: The transcription factors NFATc1 and PU.1 play important roles in osteoclast development. NFATc1 and PU.1 transactivate osteoclast-specific gene expression and a deficiency in NFATc1 or PU.1 genes causes osteopetrosis due to an insufficient development of osteoclasts. However, the existence of cross-regulation between NFATc1 and PU.1 is largely unknown. In the present study, the role of PU.1 in NFATc1 expression was investigated. Methods: Osteoclasts were generated from mouse bone marrow cells. PU.1 knockdown was performed with siRNA introduction. The mRNA levels in siRNA-introduced cells were determined by quantitative RT-PCR. The involvement of PU.1 in the NFATc1 promoter was analyzed by using a chromatin immunoprecipitation (ChIP) assay and a reporter assay. Retrovirus vector was used for enforced expression of PU.1. Results: Introduction of PU.1 siRNA into bone marrow-derived osteoclasts resulted in a decrease in NFATc1 mRNA level. A ChIP assay showed that PU.1 bound to the NFATc1 promoter in osteoclasts. NFATc1 promoter activity was reduced in PU.1 knockdown cells as assessed by a reporter assay. PU.1 siRNA introduction also downregulated the expression of osteoclast-specific genes and tartrate resistant acid phosphatase (TRAP) activity. Enforced expression of PU.1 using a retrovirus vector increased NFATc1 expression and TRAP activity. When NFATc1 expression was knocked down by using siRNA, the induction of osteoclast-specific genes and TRAP-positive cells was suppressed without affecting the expression level of PU.1. Conclusions: These results indicate that PU.1 is involved in osteoclast development by transactivating NFATc1 expression via direct binding to the NFATc1 promoter. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Ishiyama, Kentaro; Yashiro, Takuya; Nakano, Nobuhiro; Kasakura, Kazumi; Hara, Mutsuko; Kawai, Fumitaka; Maeda, Keiko; Okumura, Ko; Ogawa, Hideoki; Nishiyama, Chiharu] Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Tokyo 113, Japan; [Ishiyama, Kentaro; Tamura, Naoto; Takasaki, Yoshinari] Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Tokyo 113, Japan; [Yashiro, Takuya; Kasakura, Kazumi; Miura, Ryosuke; Nishiyama, Chiharu] Tokyo Univ Sci, Dept Biol Sci & Technol, Fac Ind Sci & Technol, Tokyo 1258585, Japan	Nishiyama, C (reprint author), Tokyo Univ Sci, Dept Biol Sci & Technol, Fac Ind Sci & Technol, Katsushika Ku, 6-3-1 Niijuku, Tokyo 1258585, Japan.	chinishi@rs.tus.ac.jp			Funding Program for Next Generation World-Leading Researchers from the Ministry of Education, Culture, Sports, Science and Technology of Japan [LS111]; Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (JSPS Research Fellowships for Young Scientists) [10792]	This work was supported by the Funding Program for Next Generation World-Leading Researchers from the Ministry of Education, Culture, Sports, Science and Technology of Japan (C. N. #LS111). T. Y. is supported by Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (JSPS Research Fellowships for Young Scientists, #10792).	Kanada S, 2008, J IMMUNOL, V180, P8204; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Kitamura N, 2012, J ALLERGY CLIN IMMUN, V129, P814, DOI 10.1016/j.jaci.2011.10.019; Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200; Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344; Maeda K, 2006, BLOOD, V108, P262, DOI 10.1182/blood-2005-07-2878; Nishiyama C, 2002, J IMMUNOL, V168, P4546; Inage E, 2014, J IMMUNOL, V192, P3936, DOI 10.4049/jimmunol.1302366; Courtial N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076637; Fukai T, 2009, BIOCHEM BIOPH RES CO, V388, P102, DOI 10.1016/j.bbrc.2009.07.126; Kanada S, 2011, BLOOD, V117, P2211, DOI 10.1182/blood-2010-06-291898; McKercher SR, 1996, EMBO J, V15, P5647; Nakano N, 2007, BLOOD, V109, P4846, DOI 10.1182/blood-2006-09-045641; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Yu MJ, 2009, J BIOL CHEM, V284, P32968, DOI 10.1074/jbc.M109.001016	18	1	1	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					241	247		10.1016/j.alit.2015.01.006		7	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400005		
J	Yoshida, N; Hirata, H; Watanabe, M; Sugiyama, K; Arima, M; Fukushima, Y; Ishii, Y				Yoshida, Naruo; Hirata, Hirokuni; Watanabe, Mineaki; Sugiyama, Kumiya; Arima, Masafumi; Fukushima, Yasutsugu; Ishii, Yoshiki			Improved sensitivity to venom specific-immunoglobulin E by spiking with the allergen component in Japanese patients suspected of Hymenoptera venom allergy	ALLERGOLOGY INTERNATIONAL			English	Article						Hymenoptera venom; rPol d 5; rVes v 5; Specific IgE; Spiking	BASOPHIL ACTIVATION TEST; RVES V 5; WASP VENOM; VESPULA VENOM; DIAGNOSIS; IGE; IMMUNOTHERAPY	Background: Ves v 5 and Pol d 5, which constitute antigen 5, are recognized as the major, most potent allergens of family Vespidae. Several studies have reported the diagnostic sensitivity of the novel recombinant (r) Ves v 5 and rPol d 5 allergens in routine clinical laboratory settings by analyzing a group of Vespula and Polistes venom-allergic patients. In this study, we analyzed the sensitivity to venom specific (s)IgE by spiking with rVes v 5 and rPol d 5 in Japanese patients suspected of Hymenoptera venom allergy. Methods: Subjects were 41 patients who had experienced systemic reactions to hornet and/or paper wasp stings. Levels of serum sIgE against hornet and paper wasp venom by spiking with rVes v 5 and rPold d 5, respectively, as improvement testing, compared with hornet and paper wasp venom, as conventional testing, were measured by ImmunoCAP. Results: Of the 41 patients, 33 (80.5%) were positive (>= 0.35 UA/ml) for hornet and/or paper wasp venom in conventional sIgE testing. sIgE levels correlated significantly (P < 0.01) between hornet (R = 0.92) or paper wasp venom (R = 0.78) in improvement testing and conventional testing. To determine specificity, 20 volunteers who had never experienced a Hymenoptera sting were all negative for sIgE against these venoms in both improvement and conventional testing. Improved sensitivity was seen in 8 patients negative for sIgE against both venoms in conventional testing, while improvement testing revealed sIgE against hornet or paper wasp venom in 5 (total 38 (92.7%)) patients. Conclusions: The measurement of sIgE following spiking of rVes v 5 and rPol d 5 by conventional testing in Japanese subjects with sIgE against hornet and paper wasp venom, respectively, improved the sensitivity for detecting Hymenoptera venom allergy. Improvement testing for measuring sIgE levels against hornet and paper wasp venom has potential for serologically elucidating Hymenoptera allergy in Japan. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Yoshida, Naruo; Hirata, Hirokuni; Watanabe, Mineaki; Ishii, Yoshiki] Dokkyo Med Univ, Dept Pulm Med & Clin Immunol, Mibu, Tochigi 3210293, Japan; [Arima, Masafumi] Chiba Univ, Dept Dev Genet, Grad Sch Med, Chiba, Japan; [Sugiyama, Kumiya; Fukushima, Yasutsugu] Dokkyo Med Univ, Koshigaya Hosp, Dept Pulm Med, Saitama, Japan	Hirata, H (reprint author), Dokkyo Med Univ, Dept Pulm Med & Clin Immunol, Mibu, Tochigi 3210293, Japan.	hirokuni@dokkyomed.ac.jp					Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166; Sturm GJ, 2004, ALLERGY, V59, P1110, DOI 10.1111/j.1398-9995.2004.00400.x; de Graaf DC, 2009, J PROTEOMICS, V72, P145, DOI 10.1016/j.jprot.2009.01.017; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; King TP, 2004, ALLERGENS ALLERGEN I, P339; KING TP, 1987, MOL IMMUNOL, V24, P857, DOI 10.1016/0161-5890(87)90188-X; Korosec P, 2012, J ALLERGY CLIN IMMUN, V129, P1406, DOI 10.1016/j.jaci.2011.12.975; Lee EK, 2009, CLIN EXP ALLERGY, V39, P602, DOI 10.1111/j.1365-2222.2008.03181.x; Mueller H L, 1966, J Asthma Res, V3, P331, DOI 10.3109/02770906609106941; Shin YS, 2012, ALLERGY ASTHMA IMMUN, V4, P284, DOI 10.4168/aair.2012.4.5.284; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P248; Sturm GJ, 2012, J ALLERGY CLIN IMMUN, V130, P817, DOI 10.1016/j.jaci.2012.05.047; Vos B, 2013, J ALLERGY CLIN IMMUN, V131, P1225, DOI 10.1016/j.jaci.2012.07.041	16	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					248	252		10.1016/j.alit.2015.01.008		5	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400006		
J	Ito, J; Fujiwara, T; Kojima, R; Nomura, I				Ito, Jun; Fujiwara, Takeo; Kojima, Reiji; Nomura, Ichiro			Racial differences in eosinophilic gastrointestinal disorders among Caucasian and Asian	ALLERGOLOGY INTERNATIONAL			English	Article						Asian; Caucasian; Eosinophilic esophagitis; Eosinophilic gastroenteritis; Eosinophilic gastrointestinal disorders	GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; PROTEIN-LOSING ENTEROPATHY; ORAL VISCOUS BUDESONIDE; JAPANESE CASE SERIES; ENDOSCOPIC FEATURES; CONSENSUS RECOMMENDATIONS; CLINICAL-MANIFESTATIONS; ESOPHAGEAL EOSINOPHILIA; ASYMPTOMATIC SUBJECTS	Background: Although there is an increasing number of eosinophilic gastrointestinal disorders (EGID) cases including eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE), being reported globally, no systematic reviews have been conducted to elucidate the racial differences in these disorders. We aimed to show the racial differences, especially among Caucasians and Asians, in the risk of EoE and EGE. Methods: We conducted a systematic review using PubMed in September 2012. All case reports and case series on EGID that involved human subjects and described race or ethnicity, as well as pathological findings, were included. For the comparison of reported cases between Caucasians and Asians, a chi-squared test was used. Results: Among the 687 studies found in PubMed, 121 studies fulfilled the eligibility criteria. In total, 2621 patients were reviewed. Among Caucasian EGID patients, 94% had EoE; while among Asian EGID patients, 72% had EGE (p < 0.001). Among EoE, Asians were significantly less likely to have dysphagia and heartburn, but more likely to have vomit and abdominal pain, compared to Caucasians (p < 0.001). Further, among EGE, Asians were significantly more likely to have eosinophil-infiltrated colon than Caucasians (OR: 3.22, 95% confidence interval [CI]: 1.60-7.04), but were less likely to have eosinophil-infiltrated stomach (OR: 0.29, 95% CI: 0.17-0.49). Conclusions: We found that EoE occurs more frequently in Caucasian EGID patients than Asian EGID patients, while the reverse is true for EGE. Also, racial disparities in symptoms and eosinophil-infiltrated tissues were observed. Our findings suggest further genetic and environmental studies to elucidate the etiology of EGID. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Ito, Jun; Fujiwara, Takeo] Natl Res Inst Child Hlth & Dev, Dept Social Med, Tokyo 1578535, Japan; [Ito, Jun; Fujiwara, Takeo] Mie Univ, Grad Sch Med, Dept Social Med, Tsu, Mie, Japan; [Kojima, Reiji; Nomura, Ichiro] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan	Fujiwara, T (reprint author), Natl Res Inst Child Hlth & Dev, Dept Social Med, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	fujiwara-tk@ncchd.go.jp			Ministry of Health, Labour and Welfare of Japan, Research for Intractable Diseases [H26-nanchi-ippan-048]	We would like to thank Dr. Julian Tang of the Department of Education for Clinical Research, National Center for Child Health and Development, for proofreading and editing this manuscript. This study was supported by a grant from the Ministry of Health, Labour and Welfare of Japan, Research for Intractable Diseases, (H26-nanchi-ippan-048) to I.N.	Al-Hussaini Abdulrahman A, 2009, Saudi J Gastroenterol, V15, P193, DOI 10.4103/1319-3767.54747; Alnaser Sami, 2007, Saudi J Gastroenterol, V13, P91, DOI 10.4103/1319-3767.32185; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Bohm M, 2012, J CLIN GASTROENTEROL, V46, P567, DOI 10.1097/MCG.0b013e31823d3305; DOBBINS JW, 1977, GASTROENTEROLOGY, V72, P1312; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Sheikh RA, 2009, WORLD J GASTROENTERO, V15, P2156, DOI 10.3748/wjg.15.2156; Lucendo AJ, 2010, SCAND J GASTROENTERO, V45, P1013, DOI 10.3109/00365521003690251; Yamaoka Y, 2008, INTERNAL MED, V47, P1077, DOI 10.2169/internalmedicine.47.0975; Eroglu Y, 2009, PEDIATR INT, V51, P612, DOI 10.1111/j.1442-200X.2008.02796.x; Mishra A, 2002, J IMMUNOL, V168, P2464; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Zhang L, 2011, SCAND J GASTROENTERO, V46, P1074, DOI 10.3109/00365521.2011.579998; Moawad FJ, 2010, ALIMENT PHARM THER, V31, P509, DOI 10.1111/j.1365-2036.2009.04199.x; Furuta GT, 2008, J PEDIATR GASTR NUTR, V47, P234, DOI 10.1097/MPG.0b013e318181b1c3; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1053/S0016-5085(03)01352-0; Kellermayer R, 2008, WORLD J GASTROENTERO, V14, P2270, DOI 10.3748/wjg.14.2270; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lindberg GM, 2008, NAT CLIN PRACT GASTR, V5, P527, DOI 10.1038/ncpgasthep1225; Abu-Sultaneh SMA, 2011, DIGEST DIS SCI, V56, P97, DOI 10.1007/s10620-010-1259-5; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; LEE RG, 1985, AM J SURG PATHOL, V9, P475, DOI 10.1097/00000478-198507000-00002; Yamada Y, 2012, INT ARCH ALLERGY IMM, V158, P83, DOI 10.1159/000337797; Gamble C, 2010, J ALLERGY CLIN IMMUN, V126, P1149, DOI 10.1016/j.jaci.2010.08.049; Jaimes-Hernandez J, 2009, LUPUS, V18, P452, DOI 10.1177/0961203308097573; Flood EM, 2008, CURR MED RES OPIN, V24, P3369, DOI 10.1185/03007990802536900 ; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; Ravi K, 2011, AM J GASTROENTEROL, V106, P851, DOI 10.1038/ajg.2011.7; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Kinoshita Y, 2013, J GASTROENTEROL, V48, P333, DOI 10.1007/s00535-012-0640-x; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Tien FM, 2011, PEDIATR NEONATOL, V52, P272, DOI 10.1016/j.pedneo.2011.06.006; Dellon ES, 2012, GASTROENTEROLOGY, V143, P321, DOI 10.1053/j.gastro.2012.04.049; Dellon ES, 2011, GASTROENTEROLOGY, V141, P1586, DOI 10.1053/j.gastro.2011.06.081; Sperry SLW, 2012, AM J GASTROENTEROL, V107, P215, DOI 10.1038/ajg.2011.342; Aceves SS, 2007, AM J GASTROENTEROL, V102, P2271, DOI 10.1111/j.1572-0241.2007.01379.x; Ravi K, 2011, DIGEST DIS SCI, V56, P1981, DOI 10.1007/s10620-011-1594-1; TALLEY NJ, 1990, GUT, V31, P54, DOI 10.1136/gut.31.1.54; HOEFER RA, 1977, J PEDIATR SURG, V12, P955, DOI 10.1016/0022-3468(77)90606-6; Franciosi JP, 2012, CHILD CARE HLTH DEV, V38, P477, DOI 10.1111/j.1365-2214.2011.01265.x; Joo MK, 2012, J DIGEST DIS, V13, P296, DOI 10.1111/j.1751-2980.2012.00589.x; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Shi YN, 2012, J DIGEST DIS, V13, P304, DOI 10.1111/j.1751-2980.2012.00593.x; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Croese J, 2003, GASTROINTEST ENDOSC, V58, P516, DOI 10.1067/S0016-5107(03)01870-4; Dohil R, 2010, GASTROENTEROLOGY, V139, P418, DOI 10.1053/j.gastro.2010.05.001; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Abe Y, 2011, J GASTROENTEROL, V46, P25, DOI 10.1007/s00535-010-0295-4; Fujishiro H, 2011, J GASTROENTEROL, V46, P1142, DOI 10.1007/s00535-011-0435-5; MARMOT MG, 1976, AM J EPIDEMIOL, V104, P225; Ashraf S, 2009, BMJ CASE REP; Batog C, 2010, INT J STD AIDS, V21, P842, DOI 10.1258/ijsa.2010.010020; Bleibel F, 2012, CASE REP GASTROINTES, V2012; Bo Y, 1996, J Tradit Chin Med, V16, P186; CALDWELL JH, 1979, GASTROENTEROLOGY, V77, P560; Cha JM, 2010, YONSEI MED J, V51, P145, DOI 10.3349/ymj.2010.51.1.145; Chang JY, 2010, CLIN GASTROENTEROL H, V8, P669, DOI 10.1016/j.cgh.2010.04.022; Chen MJ, 2003, WORLD J GASTROENTERO, V9, P2813; Chou CH, 1996, J FORMOS MED ASSOC, V95, P403; Copeland BH, 2004, CLIN MOL ALLERGY, V2, P7, DOI 10.1186/1476-7961-2-7; Engel MA, 2008, DIGEST LIVER DIS, V40, P700, DOI 10.1016/j.dld.2007.04.011; EVERETT GD, 1980, AM J GASTROENTEROL, V74, P519; Fallone CA, 2000, AM J GASTROENTEROL, V95, P659; Fang R C, 1987, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, V20, P154; Fujiwara H, 2002, ANN ALLERG ASTHMA IM, V89, P429; Furuta K, 2006, J GASTROENTEROL, V41, P706, DOI 10.1007/s00535-006-1827-9; Furuta K, 2013, J CLIN BIOCHEM NUTR, V53, P60, DOI 10.3164/jcbn.13-15; Goldstein NA, 2000, ARCH OTOLARYNGOL, V126, P227; Gonsalves N., 2012, GASTROENTEROLOGY, V142, pe1414; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; HABERKERN CM, 1978, GASTROENTEROLOGY, V74, P896; HARMON WA, 1981, J CLIN GASTROENTEROL, V3, P371, DOI 10.1097/00004836-198112000-00013; Hsu Y. Q., 1998, Hong Kong Medical Journal, V4, P226; Hui CK, 2011, SINGAP MED J, V52, pE217; Imai E, 2003, ANN NUCL MED, V17, P601; Ishido K, 2010, DIGEST ENDOSC, V22, P312, DOI 10.1111/j.1443-1661.2010.01012.x; Jawairia M, 2012, CASE REP GASTROINTES; Jingsheng Z, 2012, CASE REP PATHOL, V2012, DOI DOI 10.1155/2012/315428; Kalantar SJ, 1997, DIGEST DIS SCI, V42, P2327, DOI 10.1023/A:1018883121388; KESHAVARZIAN A, 1985, GASTROENTEROLOGY, V88, P1041; Kim HM, 2008, KOREAN J RADIOL, V9, P275, DOI 10.3348/kjr.2008.9.3.275; Kim Nam In, 2010, J Neurogastroenterol Motil, V16, P315, DOI 10.5056/jnm.2010.16.3.315; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; Lee KJ, 1997, CLIN NUCL MED, V22, P536, DOI 10.1097/00003072-199708000-00005; LEVINSON JD, 1977, AM J GASTROENTEROL, V68, P603; Liacouras CA, 2011, J ALLERGY CLIN IMMUN, V128, P21, DOI DOI 10.1016/J.JACI.2011.02.040; Liao Wei-Hsuan, 2012, Chang Gung Med J, V35, P354; Lin HH, 2005, EMERG MED J, V22, P834, DOI 10.1136/emj.2004.016337; Lu HC, 2008, J CHIN MED ASSOC, V71, P362, DOI 10.1016/S1726-4901(08)70140-0; Maeshima A, 1997, J MED, V28, P265; MATSUSHITA M, 1995, AM J GASTROENTEROL, V90, P1868; Mazokopakis E, 2006, MIL MED, V171, P331; MCCRORY WW, 1986, KIDNEY INT, V30, P592, DOI 10.1038/ki.1986.226; MILMAN PJ, 1978, AM J MED SCI, V276, P227, DOI 10.1097/00000441-197809000-00011; Miyamoto T, 1996, INTERNAL MED, V35, P779, DOI 10.2169/internalmedicine.35.779; Miyazono T, 1999, INTERNAL MED, V38, P450, DOI 10.2169/internalmedicine.38.450; MOORE D, 1986, GUT, V27, P1219, DOI 10.1136/gut.27.10.1219; Murata A, 2008, ACTA GASTRO-ENT BELG, V71, P418; Nakahama H, 1998, Respirology, V3, P95, DOI 10.1111/j.1440-1843.1998.tb00103.x; Nicholson AG, 1997, J PATHOL, V183, P233, DOI 10.1002/(SICI)1096-9896(199710)183:2<233::AID-PATH936>3.0.CO;2-Z; Ong Guan-Yeow, 2002, Chang Gung Med J, V25, P56; Otowa Y, 2012, EUR J GASTROEN HEPAT, V24, P727, DOI 10.1097/MEG.0b013e32835272ea; OWENSMITH MS, 1975, AUST NZ J SURG, V45, P257, DOI 10.1111/j.1445-2197.1975.tb05202.x; OYAIZU N, 1985, ACTA PATHOL JAPON, V35, P759; Park Hae-Sim, 1995, Journal of Korean Medical Science, V10, P216; Patel NP, 2011, INT J SURG PATHOL, V19, P290, DOI 10.1177/1066896910363707; Penfield JD, 2010, J CLIN GASTROENTEROL, V44, P22, DOI 10.1097/MCG.0b013e3181a1bee5; PETERSON NE, 1989, PEDIATR RADIOL, V19, P484, DOI 10.1007/BF02387667; Ricker Jonathan, 2011, Therap Adv Gastroenterol, V4, P27, DOI 10.1177/1756283X10384172; ROBERT F, 1977, AM J MED, V62, P139, DOI 10.1016/0002-9343(77)90360-6; Rochester D, 1979, Rev Interam Radiol, V4, P195; RUMANS MC, 1987, AM J GASTROENTEROL, V82, P775; Sandhya P, 2012, JCR-J CLIN RHEUMATOL, V18, P33, DOI 10.1097/RHU.0b013e31823e6b54; Sandrasegaran Kumaresan, 2006, Emerg Radiol, V13, P151, DOI 10.1007/s10140-006-0530-8; SCHULZE K, 1979, DIS COLON RECTUM, V22, P47, DOI 10.1007/BF02586758; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P33; Shin Woon Geon, 2007, Korean Journal of Internal Medicine, V22, P13; Shyu RY, 1998, J CLIN GASTROENTEROL, V27, P54, DOI 10.1097/00004836-199807000-00011; Siewert E, 2006, DIGEST LIVER DIS, V38, P55, DOI 10.1016/j.dld.2005.06.013; Sorser SA, 2012, J GASTROENTEROL, V48, P81; Sun HL, 2001, ASIAN PAC J ALLERGY, V19, P221; Suzuki J, 2003, ASIAN PAC J ALLERGY, V21, P193; Suzuki S, 2012, INT ARCH ALLERGY IMM, V158, P75, DOI 10.1159/000337782; Tai Y G, 1990, J Formos Med Assoc, V89, P901; TAKAHASHI T, 1992, AM J HEMATOL, V40, P295, DOI 10.1002/ajh.2830400410; Takeyama J, 2007, WORLD J GASTROENTERO, V13, P4653; Takeyama Y, 1997, J GASTROEN HEPATOL, V12, P204, DOI 10.1111/j.1440-1746.1997.tb00408.x; Tan ACITL, 2001, EUR J GASTROEN HEPAT, V13, P425, DOI 10.1097/00042737-200104000-00021; Tantibhaedhyangkul U, 2009, ANN CLIN LAB SCI, V39, P99; FORMAN D, 1993, GUT, V34, P1672; THOMAS E, 1975, AM J MED SCI, V269, P259, DOI 10.1097/00000441-197503000-00014; TROUNCE JQ, 1985, ARCH DIS CHILD, V60, P1186; Tsai Ming-Jiunn, 2000, Journal of Microbiology Immunology and Infection, V33, P197; WANG CS, 1990, ACTA CHIR SCAND, V156, P333; Whitaker IS, 2004, EUR J GASTROEN HEPAT, V16, P407, DOI 10.1097/01.meg.0000108170.74393.d5; Yamada Y, 2011, INT ARCH ALLERGY IMM, V155, P40, DOI 10.1159/000327264; Yan BM, 2006, NAT CLIN PRACT GASTR, V3, P285, DOI 10.1038/ncpgasthep0491; Yan BM, 2006, NAT CLIN PRACT GASTR, V3; Yoda A, 2012, INTERNAL MED, V51, P2551, DOI 10.2169/internalmedicine.51.8035; Zhou HB, 2007, WORLD J GASTROENTERO, V13, P1303; Zink DA, 2007, GASTROINTEST ENDOSC, V65, P330, DOI 10.1016/j.gie.2006.07.021; Zuber-Jerger Ina, 2006, J Gastrointestin Liver Dis, V15, P167	147	1	1	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					253	259		10.1016/j.alit.2015.02.003		7	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400007		
J	Shoda, T; Morita, H; Nomura, I; Ishimura, N; Ishihara, S; Matsuda, A; Matsumoto, K; Kinoshita, Y				Shoda, Tetsuo; Morita, Hideaki; Nomura, Ichiro; Ishimura, Norihisa; Ishihara, Shunji; Matsuda, Akio; Matsumoto, Kenji; Kinoshita, Yoshikazu			Comparison of gene expression profiles in eosinophilic esophagitis (EoE) between Japan and Western countries	ALLERGOLOGY INTERNATIONAL			English	Article						Eosinophils; Food hypersensitivity; Gene expression; Japanese; Microarray	ALLERGIC INFLAMMATION; PROVIDES INSIGHT; DIAGNOSIS; PERIOSTIN; DISEASE; INFILTRATION; POPULATION; PREVALENCE; GUIDELINE; CHILDREN	Background: The prevalence rate of eosinophilic esophagitis (EoE) between Japan and Western countries is quite different. Although multiple factors, including the genetic background, lifestyle and dietary habits, may account for the difference, the pathogenic mechanism of EoE has not been fully clarified in Japanese. To elucidate whether EoE's pathogenic mechanisms differ between those populations, we performed transcriptome analysis of esophageal biopsy specimens from Japanese EoE patients and compared the identified gene signatures with published microarray data for EoE patients in the US. Methods: We prospectively enrolled adult Japanese EoE patients (n = 4) according to the 2011 consensus guidelines for diagnosis of EoE. Age-matched healthy volunteer subjects (n = 4) were also enrolled as controls. We assessed the gene expression profiles of esophageal biopsies using microarray technology and then compared the identified gene signatures with earlier data generated in the US. Results: Of 42,545 transcripts represented on the microarray, 385 were differentially expressed between the EoE and control samples (>= 2 fold change and adjusted p-value of <0.05). Our microarray data showed strong overlapping with the data from US patients with EoE. An EoE-specific-transcript signature is typically composed of IL-13-inducible and eosinophil-related genes, including eotaxin-3/C-C chemokine ligand 26 (CCL26). Conclusions: This transcriptome study suggests that the pathogenetic mechanisms of EoE in Japan and Western countries are similar. Our findings may contribute to a better understanding of the pathogenesis of EoE and to more accurate diagnosis of this disease in Japanese individuals. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Shoda, Tetsuo; Morita, Hideaki; Nomura, Ichiro; Matsuda, Akio; Matsumoto, Kenji; Kinoshita, Yoshikazu] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo 1578535, Japan; [Ishimura, Norihisa; Ishihara, Shunji] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, Matsue, Shimane, Japan	Shoda, T (reprint author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	shoda-t@ncchd.go.jp; kinosita@med.shimane-u.ac.jp			Health and Labor Sciences Research Grants, Research on Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan [H24-Nanchi-Ippan-044]	This work was funded by Health and Labor Sciences Research Grants, Research on Intractable Diseases (H24-Nanchi-Ippan-044), from the Ministry of Health, Labour and Welfare, Japan (to IN). We express our sincere gratitude to all the members of the Japanese Research Group for Eosinophilic Gastrointestinal Disorders. We thank Ms. Kazue Takeda and Ms. Michiko Yamada (National Center for Child Health and Development) for their fine technical support, and Lawrence W. Stiver (Tokyo, Japan) for proofreading the manuscript.	Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Orihara K, 2009, J ALLERGY CLIN IMMUN, V124, P612, DOI 10.1016/j.jaci.2009.04.039; Cianferoni Antonella, 2009, Allergology International, V58, P457, DOI 10.2332/allergolint.09-RAI-0138; Ronkainen J, 2007, GUT, V56, P615, DOI 10.1136/gut.2006.107714; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/S0016-5085(03)01515-4; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Izuhara K, 2014, ALLERGOL INT, V63, P143, DOI 10.2332/allergolint.13-RAI-0663; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Furuta GT, 2013, GUT, V62, P1395, DOI 10.1136/gutjnl-2012-303171; Garcia-Marcos L, 2013, PEDIAT ALLERG IMM-UK, V24, P330, DOI 10.1111/pai.12071; Kinoshita Y, 2013, J GASTROENTEROL, V48, P333, DOI 10.1007/s00535-012-0640-x; Fujiwara Y, 2012, INTERNAL MED, V51, P3235, DOI 10.2169/internalmedicine.51.8670; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Kapel RC, 2008, GASTROENTEROLOGY, V134, P1316, DOI 10.1053/j.gastro.2008.02.016; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Fujishiro H, 2011, J GASTROENTEROL, V46, P1142, DOI 10.1007/s00535-011-0435-5; Urisu A, 2014, ALLERGOL INT, V63, P399, DOI 10.2332/allergolint.14-RAI-0770; Spergel JM, 2011, J PEDIATR GASTR NUTR, V52, P300, DOI 10.1097/MPG.0b013e3181eb5a9f; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Matoso A, 2014, HUM PATHOL, V45, P1205, DOI 10.1016/j.humpath.2014.01.021; Nomura I, 2012, CURR ALLERGY ASTHM R, V12, P297, DOI 10.1007/s11882-012-0272-5; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Shimura S, 2014, DIGESTION, V90, P49, DOI 10.1159/000365209; Shoda T, 2013, ALLERGY, V68, P1467, DOI 10.1111/all.12240	29	2	2	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					260	265		10.1016/j.alit.2015.03.002		6	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400008		
J	Kan, T; Hiragun, T; Ishii, K; Hiragun, M; Yanase, Y; Tanaka, A; Hide, M				Kan, Takanobu; Hiragun, Takaaki; Ishii, Kaori; Hiragun, Makiko; Yanase, Yuhki; Tanaka, Akio; Hide, Michihiro			Evaluation of recombinant MGL_1304 produced by Pichia pastoris for clinical application to sweat allergy	ALLERGOLOGY INTERNATIONAL			English	Article						HRT; MGL_1304; Pichia pastoris; Sweat allergy; beta-hexosaminidase release	ATOPIC-DERMATITIS; CHOLINERGIC URTICARIA; HISTAMINE-RELEASE; MAST-CELLS; GUIDELINES; BASOPHILS	Background: We previously identified MGL_1304 secreted by Malassezia globosa as a sweat antigen for patients with atopic dermatitis (AD) and cholinergic urticaria (ChU). However, purifying native MGL_1304 from human sweat or culture supernatant of M. globosa (sup-MGL_1304) is costly and time-consuming. Moreover, recombinant MGL_1304 expressed by using Escherichia coli (TF-rMGL_1304) needs a large chaperon protein and lacks the original glycosylation of yeasts. Thus, we generated a recombinant MGL_1304 by Pichia pastoris (P-rMGL_1304) and investigated its characteristic features. Methods: Recombinant MGL_1304 proteins expressed by E. coli and P. pastoris were generated. Properties of these recombinants and native antigens were compared by western blot analysis, histamine release tests (HRT) of patients with AD and ChU, and beta-hexosaminidase release tests with RBL-48 cells. P-rMGL_1304-specific IgE in sera of patients with AD were measured by sandwich ELISA. Results: Western blot analysis revealed that IgE of patients with AD bound to all MGL_1304 recombinants and native antigens. The histamine releasing ability of P-rMGL_1304 was 100 times higher than that of TF-rMGL_1304, and was comparable to that of sup-MGL_1304. Degranulation rates of RBL-48 cells, sensitized with sera of patients with AD in response to the stimulation of P-rMGL_1304, were comparable to those of sup-MGL_1304, whereas those of TF-rMGL_1304 were relatively weak. The levels of P-rMGL_1304-specific IgE in sera of patients with AD were correlated with their disease severities. Conclusions: P-rMGL_1304 has an antigenicity comparable to the native antigen, and is more useful than TF-rMGL_1304, especially in HRT and degranulation assay of RBL-48 cells. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Kan, Takanobu; Hiragun, Takaaki; Ishii, Kaori; Hiragun, Makiko; Yanase, Yuhki; Tanaka, Akio; Hide, Michihiro] Hiroshima Univ, Dept Dermatol Integrated Hlth Sci, Inst Biomed & Hlth Sci, Hiroshima 7348551, Japan	Hide, M (reprint author), Hiroshima Univ, Dept Dermatol Integrated Hlth Sci, Inst Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	ed1h-w1de-road@hiroshima-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT/JSPS KAKENHI) [19790789, 22591239, 25461669]; Health and Labour Sciences Research Grant; A-STEP program of Japan Science and Technology Agency	We thank Dr. Faiz Kermani for his manuscript review. We also thank Ms. Kazue Uchida and Ms. Tomoko Kawaguchi for technical assistance. This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT/JSPS KAKENHI, Grant numbers 19790789, 22591239, 25461669), Grant-in-Aid for Young Scientists (B), and Scientific Research (C); and Health and Labour Sciences Research Grant; A-STEP program of Japan Science and Technology Agency.	Tanaka A, 2006, EXP DERMATOL, V15, P283, DOI 10.1111/j.0906-6705.2006.00404.x; Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23; Hiragun T, 2013, J ALLERGY CLIN IMMUN, V132, P608, DOI 10.1016/j.jaci.2013.03.047; Takahagi S, 2009, BRIT J DERMATOL, V160, P426, DOI 10.1111/j.1365-2133.2008.08862.x; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Williams JR, 2004, BRIT J DERMATOL, V150, P1154, DOI 10.1111/j.1365-2133.2004.05869.x; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1045, DOI 10.1111/j.1468-3083.2012.04635.x; Dai XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067666; GILFILLAN AM, 1992, J IMMUNOL, V149, P2445; Hiragun M, 2014, ALLERGOL INT, V63, P83, DOI 10.2332/allergolint.13-OA-0611; Lopes M, 2014, BIOTECHNOL PROGR, V30, P1040, DOI 10.1002/btpr.1964; Saeki H, 2009, J DERMATOL, V36, P563, DOI 10.1111/j.1346-8138.2009.00706.x; Shindo H, 2012, ARCH DERMATOL RES, V304, P647, DOI 10.1007/s00403-012-1236-2	13	1	1	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					266	271		10.1016/j.alit.2015.03.003		6	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400009		
J	Okada, Y; Yanagida, N; Sato, S; Ebisawa, M				Okada, Yu; Yanagida, Noriyuki; Sato, Sakura; Ebisawa, Motohiro			Better management of cow's milk allergy using a very low dose food challenge test: A retrospective study	ALLERGOLOGY INTERNATIONAL			English	Article						Milk hypersensitivity; Disease management; Food allergy; Food hypersensitivity; Specific IgE	CLINICAL PREDICTORS; ANAPHYLAXIS GUIDELINES; ORAL IMMUNOTHERAPY; EUROPEAN ACADEMY; NATURAL-HISTORY; RISK-FACTORS; CHILDREN; IMMUNOLOGY; IGE; PREVALENCE	Background: Low dose reactive cow's milk (CM) allergic children are at high risk of persistent CM allergy and a positive oral food challenge (OFC). The present study aimed to evaluate if the results of a very low dose (VL) OFC with these children contributes to better management of CM allergy. Methods: We retrospectively reviewed subjects with CM allergy who underwent a VL OFC with 3 mL heated CM and had a previous allergic reaction to <25 mL heated CM in the 2 years before the OFC. Subjects who passed the OFC were defined as VL tolerant, and subjects who failed were defined as VL reactive. VL tolerant subjects increased the dose to 25 mL heated CM either during an OFC in our hospital or gradually at home. Results: Of the 83 subjects (median age, 4.3 years; range, 1.0-12.9 years) who were included, 41 (49.4%) were VL tolerant, and 42 (51.6%) were VL reactive. Thirty-nine VL reactive subjects had skin and/or respiratory symptoms during the OFC. Most reactions could be treated with an antihistamine and/or a nebulized beta 2 agonist. The VL tolerant subjects consumed 3 mL heated CM or 10 g butter. Within the year following the OFC, 18 VL tolerant subjects (45.0%), but none of the VL reactive subjects, were able to consume 25 mL heated CM (p < 0.001). Conclusions: A VL OFC allows the management of some low dose reactive CM allergic children to change from complete avoidance to partial intake of CM. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.	[Okada, Yu; Yanagida, Noriyuki] Sagamihara Natl Hosp, Dept Pediat, Sagamihara, Kanagawa 2520392, Japan; [Sato, Sakura; Ebisawa, Motohiro] Sagamihara Natl Hosp, Clin Res Ctr Allergol & Rheumatol, Dept Allergy, Sagamihara, Kanagawa 2520392, Japan	Ebisawa, M (reprint author), Sagamihara Natl Hosp, Clin Res Ctr Allergol & Rheumatol, Dept Allergy, Minami Ku, 18-1 Sakuradai, Sagamihara, Kanagawa 2520392, Japan.	m-ebisawa@sagamihara-hosp.gr.jp			Health and Labour Sciences Research Grants of the Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare	We are grateful to Ms. Miho Hasegawa, Ms. Noriko Hayashi, Ms. Chizuko Sugizaki, and all of our co-workers. We would like to thank Editage (www.editage.jp) for English language editing. This study was supported by the Health and Labour Sciences Research Grants of the Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare.	Yanagida N, 2015, ALLERGY ASTHMA IMMUN, V7, P186, DOI 10.4168/aair.2015.7.2.186; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Muraro A, 2014, ALLERGY, V69, P1008, DOI 10.1111/all.12429; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Ebisawa M, 2013, PEDIAT ALLERG IMM-UK, V24, P704, DOI 10.1111/pai.12117; Venter C, 2008, ALLERGY, V63, P354, DOI 10.1111/j.1398-9995.2007.01570.x; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Sato S, 2014, INT ARCH ALLERGY IMM, V164, P1, DOI 10.1159/000361025; Winberg A, 2013, PEDIAT ALLERG IMM-UK, V24, P282, DOI 10.1111/pai.12061; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Bartnikas LM, 2012, ANN ALLERG ASTHMA IM, V109, P309, DOI 10.1016/j.anai.2012.07.026; Elizur A, 2012, J PEDIATR-US, V161, P482, DOI 10.1016/j.jpeds.2012.02.028; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Pajno GB, 2013, PEDIAT ALLERG IMM-UK, V24, P376, DOI 10.1111/pai.12077; Mehr S, 2014, ANN ALLERG ASTHMA IM, V113, P425, DOI 10.1016/j.anai.2014.06.023; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Levy MB, 2014, ANN ALLERG ASTHMA IM, V112, P58, DOI 10.1016/j.anai.2013.10.001; Cianferoni A, 2012, ISR MED ASSOC J, V14, P24; Devenney I, 2006, ACTA PAEDIATR, V95, P1133, DOI 10.1080/08035250500516672; Simons F Estelle R, 2011, World Allergy Organ J, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Spergel JM, 2013, J ALLERGY CLIN IMMUN, V131, P813, DOI 10.1016/j.jaci.2013.01.027	25	2	2	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					272	276		10.1016/j.alit.2015.04.002		5	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400010		
J	Abe, J; Mataki, K; Umetsu, R; Ueda, N; Kato, Y; Nakayama, Y; Kinosada, Y; Hara, H; Inagaki, N; Nakamura, M				Abe, Junko; Mataki, Kanako; Umetsu, Ryogo; Ueda, Natsumi; Kato, Yamato; Nakayama, Yoko; Kinosada, Yasutomi; Hara, Hideaki; Inagaki, Naoki; Nakamura, Mitsuhiro			Stevens-Johnson syndrome and toxic epidermal necrolysis: The Food and Drug Administration adverse event reporting system, 2004-2013	ALLERGOLOGY INTERNATIONAL			English	Letter							EPIDEMIOLOGY		[Abe, Junko; Umetsu, Ryogo; Ueda, Natsumi; Kato, Yamato; Nakayama, Yoko; Nakamura, Mitsuhiro] Gifu Pharmaceut Univ, Drug Informat, Gifu 5011196, Japan; [Abe, Junko] Med Database Co Ltd, Tokyo, Japan; [Mataki, Kanako; Hara, Hideaki; Inagaki, Naoki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan; [Kinosada, Yasutomi] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan	Nakamura, M (reprint author), Gifu Pharmaceut Univ, Drug Informat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	mnakamura@gifu-pu.ac.jp					Kaniwa N, 2008, PHARMACOGENOMICS, V9, P1617, DOI 10.2217/14622416.9.11.1617; van Puijenbroek EP, 2000, EUR J CLIN PHARMACOL, V56, P733, DOI 10.1007/s002280000215; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; Kunimi Yuko, 2011, Allergology International, V60, P525, DOI 10.2332/allergolint.11-OA-0309; Moreau JF, 2014, PEDIATR DERMATOL, V31, P163, DOI 10.1111/pde.12158; Mockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033; van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668; Halevi A, 2000, ANN PHARMACOTHER, V34, P32; Mockenhaupt M, 1996, SEMIN CUTAN MED SURG, V15, P236, DOI 10.1016/S1085-5629(96)80036-8; Yamane Yumiko, 2007, Allergol Int, V56, P419, DOI 10.2332/allergolint.O-07-483	10	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					277	279		10.1016/j.alit.2015.01.002		3	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400011		
J	Kamiya, K; Kamiya, E; Kamiya, Y; Niwa, M; Saito, A; Natsume, T; Niwa, H; Tokura, Y				Kamiya, Koji; Kamiya, Eri; Kamiya, Yasunari; Niwa, Miwako; Saito, Akitoshi; Natsume, Tadashi; Niwa, Haruo; Tokura, Yoshiki			Drug eruption to clavulanic acid with sparing of cellulitis-affecting site	ALLERGOLOGY INTERNATIONAL			English	Letter									[Kamiya, Koji; Tokura, Yoshiki] Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4313192, Japan; [Kamiya, Koji; Kamiya, Eri; Niwa, Miwako; Saito, Akitoshi; Natsume, Tadashi; Niwa, Haruo] Toei Hosp, Dept Gen Med, Kitashitara, Aichi, Japan; [Kamiya, Eri] Japanese Red Cross Nagoya Daini Hosp, Dept Internal Med, Div Endocrinol, Nagoya, Aichi, Japan; [Kamiya, Yasunari] Toei Hosp, Dept Orthopaed Surg, Kitashitara, Aichi, Japan	Kamiya, K (reprint author), Hamamatsu Univ Sch Med, Dept Dermatol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	m01023kk@jichi.ac.jp					Gunderson CG, 2012, J INFECTION, V64, P148, DOI 10.1016/j.jinf.2011.11.004; Baddour LM, 2001, CLIN INFECT DIS, V32, pE17, DOI 10.1086/317530; Fujiyama T, 2014, J DERMATOL SCI, V73, P85, DOI 10.1016/j.jdermsci.2013.08.008; Sanchez-Morillas L, 2010, J ALLERGY CLIN IMMUN, V126, P177, DOI 10.1016/j.jaci.2010.03.012; Torres MJ, 2010, J ALLERGY CLIN IMMUN, V125, P502, DOI 10.1016/j.jaci.2009.11.032	5	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					280	281		10.1016/j.alit.2014.12.007		2	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400012		
J	Yamaguchi, H; Hirasawa, N; Asakawa, S; Okita, K; Tokura, Y				Yamaguchi, Hayato; Hirasawa, Noriyasu; Asakawa, Sanki; Okita, Kiyuki; Tokura, Yoshiki			Intrinsic atopic dermatitis shows high serum nickel concentration	ALLERGOLOGY INTERNATIONAL			English	Letter							BARRIER; ALLERGY		[Yamaguchi, Hayato; Tokura, Yoshiki] Hamamatsu Univ Sch Med, Dept Dermatol, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Hirasawa, Noriyasu; Asakawa, Sanki; Okita, Kiyuki] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pharmacotherapy Life Style Related Dis, Sendai, Miyagi 980, Japan	Yamaguchi, H (reprint author), Hamamatsu Univ Sch Med, Dept Dermatol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	yamaguchihaya@gmail.com					Raghavan B, 2012, EMBO REP, V13, P1109, DOI 10.1038/embor.2012.155; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Yamaguchi H, 2013, J DERMATOL SCI, V72, P240, DOI 10.1016/j.jdermsci.2013.07.009; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Jensen CS, 2003, CONTACT DERMATITIS, V49, P124, DOI 10.1111/j.0105-1873.2003.00157.x; Mori T, 2010, BRIT J DERMATOL, V162, P83, DOI 10.1111/j.1365-2133.2009.09440.x; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Yamaguchi H, 2014, EUR J DERMATOL, V24, P253, DOI 10.1684/ejd.2014.2273	10	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					282	284		10.1016/j.alit.2015.01.003		3	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400013		
J	Manabe, T; Oku, N; Aihara, Y				Manabe, Tetsuharu; Oku, Norihiro; Aihara, Yukoh			Food-dependent exercise-induced anaphylaxis among junior high school students: A 14-year epidemiological comparison	ALLERGOLOGY INTERNATIONAL			English	Letter							WHEAT		[Manabe, Tetsuharu; Oku, Norihiro] Kanagawa Prefectural Ashigarakami Hosp, Dept Pediat, Matsudo, Kanagawa, Japan; [Manabe, Tetsuharu] Sagamihara Natl Hosp, Dept Pediat, Sagamihara, Kanagawa, Japan; [Aihara, Yukoh] Aihara Alslergy & Pediat Clin, Matsudo, Kanagawa, Japan	Manabe, T (reprint author), Kanagawa Prefectural Ashigarakami Hosp, Dept Pediat, Matsudo, Kanagawa, Japan.	t-manabe@sagamihara-hosp.gr.jp					Aihara Y, 2001, J ALLERGY CLIN IMMUN, V107, P1100, DOI 10.1067/mai.2001.115627; Barg W, 2011, CURR ALLERGY ASTHM R, V11, P45, DOI 10.1007/s11882-010-0150-y; Aihara Y, 2001, J ALLERGY CLIN IMMUN, V108, P1035, DOI 10.1067/mai.2001.119914; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Calvani M, 2007, ANN ALLERG ASTHMA IM, V98, P98; Caminiti L, 2007, ALLERGY, V62, P335, DOI 10.1111/j.1398-9995.2006.01289.x; Jo Eun-Jung, 2012, Asia Pac Allergy, V2, P161, DOI 10.5415/apallergy.2012.2.2.161	7	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					285	286		10.1016/j.alit.2015.01.007		2	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400014		
J	Yagami, A; Suzuki, K; Nakamura, M; Sano, A; Kobayashi, T; Iwata, Y; Arima, M; Hara, K; Matsunaga, K				Yagami, Akiko; Suzuki, Kayoko; Nakamura, Masashi; Sano, Akiyo; Kobayashi, Tsukane; Iwata, Yohei; Arima, Masaru; Hara, Kazuhiro; Matsunaga, Kayoko			Occupational food allergy due to parvalbumin and phaseolin induced by epicutaneous sensitization	ALLERGOLOGY INTERNATIONAL			English	Letter									[Yagami, Akiko; Suzuki, Kayoko; Nakamura, Masashi; Sano, Akiyo; Kobayashi, Tsukane; Iwata, Yohei; Arima, Masaru; Matsunaga, Kayoko] Fujita Hlth Univ, Dept Dermatol, Sch Med, Toyoake, Aichi 4701192, Japan; [Nakamura, Masashi; Hara, Kazuhiro] Hoyu Co Ltd, Gen Res & Dev Inst, Nagakute, Aichi 4801136, Japan	Yagami, A (reprint author), Fujita Hlth Univ, Dept Dermatol, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi 4701192, Japan.	ayagami@fujita-hu.ac.jp					Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Heinzerling Lucie, 2013, Clin Transl Allergy, V3, P3, DOI 10.1186/2045-7022-3-3; Hilger C, 2011, ALLERGY, V66, P298; Kasera R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027193; Nakamura M, 2014, ALLERGOL INT, V63, P243, DOI 10.2332/allergolint.13-OA-0618; Nettis E, 2014, Eur Ann Allergy Clin Immunol, V46, P68; Onesimo R, 2012, ISR MED ASSOC J, V14, P11; Rouge P, 2011, ALLERGY, V66, P301, DOI 10.1111/j.1398-9995.2010.02466.x	9	1	1	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					287	288		10.1016/j.alit.2015.03.005		2	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400015		
J	Inoue, Y; Izuhara, K; Ohta, S; Ono, J; Shimojo, N				Inoue, Yuzaburo; Izuhara, Kenji; Ohta, Shoichiro; Ono, Junya; Shimojo, Naoki			No increase in the serum periostin level is detected in elementary school-age children with allergic diseases	ALLERGOLOGY INTERNATIONAL			English	Letter							BRONCHIAL-ASTHMA; CORTICOSTEROIDS; INFLAMMATION; GENES		[Inoue, Yuzaburo; Shimojo, Naoki] Chiba Univ, Dept Pediat, Grad Sch Med, Chiba, Japan; [Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga, Japan; [Ohta, Shoichiro] Saga Med Sch, Dept Lab Med, Saga, Japan; [Ono, Junya] Shino Test Corp, Sagamihara, Kanagawa, Japan	Inoue, Y (reprint author), Chiba Univ, Dept Pediat, Grad Sch Med, Chiba, Japan.	yuzaburo@chiba-u.jp					Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BRM.41.4.1149; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Izuhara K, 2014, ALLERGOL INT, V63, P143, DOI 10.2332/allergolint.13-RAI-0663; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Merle B, 2012, OSTEOPOROSIS INT, V23, P1199, DOI 10.1007/s00198-011-1892-7; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Kou K, 2014, BRIT J DERMATOL, V171, P283, DOI 10.1111/bjd.12943; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972	11	0	0	JAPANESE SOCIETY ALLERGOLOGY	TOKYO	MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN	1323-8930	1440-1592		ALLERGOL INT	Allergol. Int.	JUL	2015	64	3					289	290		10.1016/j.alit.2015.04.001		2	Allergy; Immunology	Allergy; Immunology	CL3WU	WOS:000356883400016		
J	Yamaji, K; Natsuaki, M; Morimoto, T; Ono, K; Furukawa, Y; Nakagawa, Y; Kadota, K; Ando, K; Shirai, S; Watanabe, H; Shiomi, H; Kimura, T				Yamaji, Kyohei; Natsuaki, Masahiro; Morimoto, Takeshi; Ono, Koh; Furukawa, Yutaka; Nakagawa, Yoshihisa; Kadota, Kazushige; Ando, Kenji; Shirai, Shinichi; Watanabe, Hirotoshi; Shiomi, Hiroki; Kimura, Takeshi			Long-Term Outcomes After Coronary Stent Implantation in Patients Presenting With Versus Without Acute Myocardial Infarction (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2)	AMERICAN JOURNAL OF CARDIOLOGY			English	Article							DUAL ANTIPLATELET THERAPY; SIROLIMUS-ELUTING STENT; ST-SEGMENT ELEVATION; RANDOMIZED CONTROLLED-TRIAL; BARE-METAL STENT; CLINICAL-TRIAL; PRIMARY PCI; CLOPIDOGREL; THROMBOSIS; EFFICACY	It has not been adequately addressed yet how long the excess cardiovascular event risk persists after acute myocardial infarction (AMI) compared with stable coronary artery disease. Of 10,470 consecutive patients who underwent percutaneous coronary intervention either with sirolimus-eluting stent (SES) only or with bare-metal stent (BMS) only in the Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2, 3,710 (SES: n = 820 and BMS: n = 2,890) and 6,760 patients (SES: n = 4,258 and BMS: n = 2,502) presented with AMI (AMI group) and without AMI (non-AMI group), respectively. During the median 5-year follow-up, the excess adjusted risk of the AMI group relative to the non-AMI group for the primary outcome measure (cardiac death or myocardial infarction) was significant (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.30 to 1.80, p < 0.001). However, the excess event risk was limited to the early period within 3 months. Late adjusted risk beyond 3 months was similar between the AMI and non-AMI groups (HR 1.16, 95% CI 0.95 to 1.41, p = 0.15). The higher risk of the AMI group relative to the non-AMI group for stent thrombosis (ST) was significant within 3 months (HR 3.38, 95% CI 2.04 to 5.60, p < 0.001), whereas the risk for ST was not different between the 2 groups beyond 3 months (HR 1.11, 95% CI 0.65 to 1.90, p = 0.70). There were no interactions between the types of stents implanted and the risk of the AMI group relative to the non-AMI groups for all the outcome measures including ST. In conclusion, patients with AMI compared with those without AMI were associated with similar late cardiovascular event risk beyond 3 months after percutaneous coronary intervention despite their higher early risk within 3 months. (C) 2015 Elsevier Inc. All rights reserved.	[Yamaji, Kyohei; Ando, Kenji; Shirai, Shinichi] Kokura Mem Hosp, Div Cardiol, Kitakyushu, Fukuoka, Japan; [Natsuaki, Masahiro] Saiseikai Fukuoka Gen Hosp, Div Cardiol, Fukuoka, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Div Gen Med, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan; [Ono, Koh; Watanabe, Hirotoshi; Shiomi, Hiroki; Kimura, Takeshi] Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan; [Furukawa, Yutaka] Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Med, Kobe, Hyogo, Japan; [Nakagawa, Yoshihisa] Tenri Hosp, Div Cardiol, Tenri, Nara 632, Japan; [Kadota, Kazushige] Kurashiki Cent Hosp, Dept Cardiol, Kurashiki, Okayama, Japan	Kimura, T (reprint author), Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan.	taketaka@kuhp.kyoto-ua.ac.jp			Pharmaceuticals and Medical Devices Agency, Tokyo, Japan	This work was supported by Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Dr. Kimura serves as an advisory board member for Cordis Cardiology, Tokyo, Japan; Abbott Vascular, Tokyo, Japan; and Terumo Company, Tokyo, Japan. The remaining authors reported no conflicts of interest.	Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819; Serruys PW, 2005, J AM COLL CARDIOL, V46, P575, DOI 10.1016/j.jacc.2004.12.082; O'Donoghue ML, 2014, JAMA-J AM MED ASSOC, V312, P1006, DOI 10.1001/jama.2014.11061; Hofma SH, 2012, J AM COLL CARDIOL, V60, P381, DOI 10.1016/j.jacc.2012.01.073; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Montalescot G, 2009, LANCET, V373, P723, DOI 10.1016/S0140-6736(09)60441-4; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Sabate M, 2012, LANCET, V380, P1482, DOI 10.1016/S0140-6736(12)61223-9; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Kim BK, 2012, J AM COLL CARDIOL, V60, P1340, DOI 10.1016/j.jacc.2012.06.043; O'Gara PT, 2013, CIRCULATION, V127, pE362, DOI 10.1161/CIR.0b013e3182742cf6; Kimura T, 2012, CIRCULATION, V125, P584, DOI 10.1161/CIRCULATIONAHA.111.046599; Gwon HC, 2012, CIRCULATION, V125, P505, DOI 10.1161/CIRCULATIONAHA.111.059022; Kawaguchi R, 2010, AM J CARDIOL, V106, P1550, DOI 10.1016/j.amjcard.2010.07.035; Feres F, 2013, JAMA-J AM MED ASSOC, V310, P2510, DOI 10.1001/jama.2013.282183; Natsuaki M, 2014, CIRC-CARDIOVASC INTE, V7, P168, DOI 10.1161/CIRCINTERVENTIONS.113.000987; Dargie HJ, 2001, LANCET, V357, P1385; Valgimigli M, 2013, EUR HEART J, V34, P909, DOI 10.1093/eurheartj/ehs460; Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797; Hirsch A, 2009, AM J CARDIOL, V104, P333, DOI 10.1016/j.amjcard.2009.03.052; Colombo A, 2014, J AM COLL CARDIOL, V64, P2086, DOI 10.1016/j.jacc.2014.09.008; de la Torre-Hernandez JM, 2008, J AM COLL CARDIOL, V51, P986, DOI 10.1016/j.jacc.2007.10.057; Gilard M, 2015, J AM COLL CARDIOL, V65, P777, DOI 10.1016/j.jacc.2014.11.008; Kimura Takeshi, 2011, Cardiovasc Interv Ther, V26, P234, DOI 10.1007/s12928-011-0065-0; Mauri L, 2014, NEW ENGL J MED, V371, P2155, DOI 10.1056/NEJMoa1409312; Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Tada T, 2012, CIRC-CARDIOVASC INTE, V5, P381, DOI 10.1161/CIRCINTERVENTIONS.111.967463; Wald DS, 2013, NEW ENGL J MED, V369, P1115, DOI 10.1056/NEJMoa1305520; Yusuf S, 2001, NEW ENGL J MED, V345, P494	30	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9149	1879-1913		AM J CARDIOL	Am. J. Cardiol.	JUL 1	2015	116	1					15	23		10.1016/j.amjcard.2015.03.036		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CL8PI	WOS:000357236200003		
J	Shiomi, H; Morimoto, T; Furukawa, Y; Nakagawa, Y; Tazaki, J; Sakata, R; Okabayashi, H; Hanyu, M; Shimamoto, M; Nishiwaki, N; Komiya, T; Kimura, T				Shiomi, Hiroki; Morimoto, Takeshi; Furukawa, Yutaka; Nakagawa, Yoshihisa; Tazaki, Junichi; Sakata, Ryuzo; Okabayashi, Hitoshi; Hanyu, Michiya; Shimamoto, Mitsuomi; Nishiwaki, Noboru; Komiya, Tatsuhiko; Kimura, Takeshi		CREDO-Kyoto PCI CABG Registry	Comparison of Five-Year Outcome of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting. in Triple-Vessel Coronary Artery Disease (from the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2)	AMERICAN JOURNAL OF CARDIOLOGY			English	Article							EVEROLIMUS-ELUTING STENT; BARE-METAL STENTS; 3-YEAR FOLLOW-UP; SYNTAX TRIAL; MULTIVESSEL REVASCULARIZATION; RANDOMIZED EVALUATION; CLINICAL-OUTCOMES; 3-VESSEL DISEASE; SIROLIMUS; SURGERY	Studies evaluating long-term (>= 5 years) outcomes of percutaneous coronary intervention (PCI) using drug-eluting stents compared with coronary artery bypass grafting (CABG) in patients with triple-vessel coronary artery disease (TVD) are still limited. We identified 2,978 patients with TVD (PCI: n = 1,824, CABG: n = 1,154) of 15,939 patients with first coronary revascularization enrolled in the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCl/CABG Registry Cohort-2. The primary outcome measure in the present analysis was a composite of death, myocardial infarction (MI), and stroke. Median follow-up duration for the surviving patients was 1,973 days (interquartile range 1,700 to 2,244). The cumulative 5-year incidence of death/MI/stroke was significantly higher in the PCI group than in the CABG group (28.2% vs 24.0%, log-rank p = 0.006). After adjusting for con-founders, the excess risk of PCI relative to CABG for death/MI/stroke remained significant (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.13 to 1.68, p = 0.002). The excess risks of PCI relative to CABG for all-cause death, MI, and any coronary revascularization were also significant (HR 1.38, 95% CI 1.10 to 1.74, p = 0.006; HR 2.81, 95% CI 1.69 to 4.66, p < 0.001; and HR 4.10, 95% CI 3.32 to 5.06, p < 0.001, respectively). The risk for stroke was not significantly different between the PCI and CABG groups (FIR 0.88, 95% CI 0.61 to 1.26, p = 0.48). There were no interactions for the primary outcome measure between the mode of revascularization (PCI or CABG) and the subgroup factors such as age, diabetes, and Synergy Between PCI With Taxus and Cardiac Surgery score. In conclusion, CABG compared with PCI was associated with better long-term outcome in patients with TVD. (C) 2015 Elsevier Inc. All rights reserved.	[Shiomi, Hiroki; Tazaki, Junichi; Kimura, Takeshi] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan; [Sakata, Ryuzo] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Surg, Kyoto, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Dept Clin Epidemiol, Kobe, Hyogo, Japan; [Furukawa, Yutaka] Kobe City Med Ctr Gen Hosp, Dept Cardiol, Kobe, Hyogo, Japan; [Nakagawa, Yoshihisa] Tenri Hosp, Dept Cardiol, Nara, Japan; [Okabayashi, Hitoshi] Iwate Med Univ, Dept Cardiovasc Surg, Morioka, Iwate, Japan; [Hanyu, Michiya] Kokura Mem Hosp, Dept Cardiovasc Surg, Kitakyushu, Fukuoka, Japan; [Shimamoto, Mitsuomi] Shizuoka City Shizuoka Hosp, Dept Cardiovasc Surg, Shizuoka, Japan; [Nishiwaki, Noboru] Kinki Univ, Fac Med, Dept Cardiovasc Surg, Nara Hosp, Nara, Japan; [Komiya, Tatsuhiko] Kurashiki Cent Hosp, Dept Cardiovasc Surg, Kurashiki, Okayama, Japan	Kimura, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan.	taketaka@kuhp.kyoto-u.ac.jp			Pharmaceuticals and Medical Devices Agency in Japan (Tokyo, Japan)	This study was supported by the Pharmaceuticals and Medical Devices Agency in Japan (Tokyo, Japan). None of the authors have conflict of interest to disclose.	TOPOL E, 1993, NEW ENGL J MED, V329, P673; Park KW, 2010, AM HEART J, V159, P446, DOI 10.1016/j.ahj.2010.01.001; Tonino PAL, 2009, NEW ENGL J MED, V360, P213, DOI 10.1056/NEJMoa0807611; Tada T, 2013, JACC-CARDIOVASC INTE, V6, P1267, DOI 10.1016/j.jcin.2013.06.015; Kimura T, 2012, CIRCULATION, V126, P1225, DOI 10.1161/CIRCULATIONAHA.112.104059; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Mohr FW, 2013, LANCET, V381, P629, DOI 10.1016/S0140-6736(13)60141-5; Roe MT, 2012, NEW ENGL J MED, V367, P1297, DOI 10.1056/NEJMoa1205512; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Raber L, 2012, CIRCULATION, V125, P1110, DOI 10.1161/CIRCULATIONAHA.111.058560; Natsuaki M, 2013, J AM COLL CARDIOL, V62, P181, DOI 10.1016/j.jacc.2013.04.045; Palmerini T, 2012, LANCET, V379, P1393, DOI 10.1016/S0140-6736(12)60324-9; Farkouh ME, 2012, NEW ENGL J MED, V367, P2375, DOI 10.1056/NEJMoa1211585; Weintraub WS, 2012, NEW ENGL J MED, V366, P1467, DOI 10.1056/NEJMoa1110717; Nakagawa Y, 2010, AM J CARDIOL, V106, P329, DOI 10.1016/j.amjcard.2010.03.031; Epstein AJ, 2011, JAMA-J AM MED ASSOC, V305, P1769, DOI 10.1001/jama.2011.551; Hassan A, 2010, AM HEART J, V160, P958, DOI 10.1016/j.ahj.2010.06.052; Kimura T, 2012, CIRCULATION, V125, P584, DOI 10.1161/CIRCULATIONAHA.111.046599; Iijima R, 2013, INT J CARDIOL, V168, P2588, DOI 10.1016/j.ijcard.2013.03.046; Serruys PW, 2010, J AM COLL CARDIOL, V55, P1093, DOI 10.1016/j.jacc.2009.11.049; Kappetein AP, 2011, EUR HEART J, V32, P2125, DOI 10.1093/eurheartj/ehr213; Shiomi H, 2014, CIRC-CARDIOVASC INTE, V7, P343, DOI 10.1161/CIRCINTERVENTIONS.113.001322; Shiomi H, 2012, AM J CARDIOL, V110, P924, DOI 10.1016/j.amjcard.2012.05.022; Head SJ, 2014, EUR HEART J, V35, P2821, DOI 10.1093/eurheartj/ehu213; Kappetein AP, 2013, EUR J CARDIO-THORAC, V43, P1006, DOI 10.1093/ejcts/ezt017; Kimura Takeshi, 2011, Cardiovasc Interv Ther, V26, P234, DOI 10.1007/s12928-011-0065-0; Park DW, 2011, J AM COLL CARDIOL, V57, P128, DOI 10.1016/j.jacc.2010.09.022; Shiomi H, 2014, AM J CARDIOL, V113, P1652, DOI 10.1016/j.amjcard.2014.02.037; Tazaki J, 2013, EUROINTERVENTION, V9, P437, DOI 10.4244/EIJV9I4A72	29	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9149	1879-1913		AM J CARDIOL	Am. J. Cardiol.	JUL 1	2015	116	1					59	65		10.1016/j.amjcard.2015.03.040		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CL8PI	WOS:000357236200009		
J	Chen, MZ; Tominaga, K; Ahn, JM; Foret, M; Iwamori, N; Matzuk, MM; Mueller, PR; Gaufo, GO				Chen, Meizhen; Tominaga, Kaoru; Ahn, Jungmi; Foret, Michael; Iwamori, Naoki; Matzuk, Martin M.; Mueller, Paul R.; Gaufo, Gary O.			Mrg15 is required in premigratory neural crest cells for postnatal morphogenesis of the skull	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Meeting Abstract	37th Annual Meeting of the Society-for-Craniofacial-Genetics-and-Developmental-Biology (SCGDB)	OCT 18, 2014	Sanford Consortium Regenerat Med, LaJolla, CA	Soc Craniofacial Genet & Dev Biol	Sanford Consortium Regenerat Med				[Chen, Meizhen; Ahn, Jungmi; Foret, Michael; Gaufo, Gary O.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78257 USA; [Tominaga, Kaoru] Jichi Med Univ, Dept Biochem, Shimotsuke, Tochigi 3290498, Japan; [Iwamori, Naoki] Kyushu Univ, Dept Basic Sci, Fukuoka 8128582, Japan; [Matzuk, Martin M.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Mueller, Paul R.] Univ Wisconsin, Dept Human Biol, Green Bay, WI 54311 USA								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUL	2015	167	7					1465	1465				1	Genetics & Heredity	Genetics & Heredity	CL1BB	WOS:000356676200032		
J	Kawano, O; Nakamura, A; Morikawa, S; Uetake, K; Ishizu, K; Tajima, T				Kawano, Osamu; Nakamura, Akie; Morikawa, Shuntaro; Uetake, Kimiaki; Ishizu, Katsura; Tajima, Toshihiro			Spondyloepiphyseal Dysplasia Congenita Caused by Double Heterozygous Mutations in COL2A1	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						type II collagenopathies; spondyloepiphyseal dysplasia; COL2A1; double mutations	FGFR3 MUTATIONS; VARIANTS; GENE; SPECTRUM	Spondyloepiphyseal dysplasia congenita (SEDC) is a group of rare inherited chondrodysplasias characterized by short stature, abnormal epiphyses, and flattened vertebral bodies. SEDC is usually caused by substitution of glycine residue with another amino acid in the triple helical domains of alpha 1 chains, which consist of type II collagen (COL2A1). Herein, we describe a unique case of SEDC with mild coxa vara (SEDC-M) caused by double de novo COL2A1 mutations located on the same allele. One mutation, p.G504S, was previously described in patients with SEDC, whereas the other, p.G612A, was a novel mutation; both were located in the triple helical domain. Neither mutation was identified in the parents and appeared to be de novo. To the best of our knowledge, this is the first study involving a patient with a type II collagenopathy with two COL2A1 mutations on the same allele. The case was characterized by a more severe phenotype compared with previously reported cases involving a single p.G504S mutation, which may have been the result of the double mutation. (C) 2015 Wiley Periodicals, Inc.	[Kawano, Osamu] Obihiro Kyokai Hosp, Dept Pediat, Obihiro, Hokkaido 0800805, Japan; [Uetake, Kimiaki] Obihiro Kousei Hosp, Dept Pediat, Obihiro, Hokkaido, Japan; [Nakamura, Akie; Morikawa, Shuntaro; Ishizu, Katsura; Tajima, Toshihiro] Hokkaido Univ, Sch Med, Dept Pediat, Kita Ku, Sapporo, Hokkaido 060, Japan	Kawano, O (reprint author), Obihiro Kyokai Hosp, Dept Pediat, Higashi 5 Jo Minami 9-2, Obihiro, Hokkaido 0800805, Japan.	kawano_osamu@frontier.hokudai.ac.jp					Kondrashov AS, 2003, HUM MUTAT, V21, P12, DOI 10.1002/humu.10147; Kannu P, 2012, J PAEDIATR CHILD H, V48, pE38, DOI 10.1111/j.1440-1754.2010.01979.x; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; Nishimura G, 2005, HUM MUTAT, V26, P36, DOI 10.1002/humc.20179; Cao LH, 2012, GENET MOL RES, V11, P4130, DOI 10.4238/2012.September.27.1; Goriely A, 2005, P NATL ACAD SCI USA, V102, P6051, DOI 10.1073/pnas.0500267102; Marquis-Nicholson Renate, 2013, Sultan Qaboos Univ Med J, V13, P80; Pannier S, 2009, AM J MED GENET A, V149A, P1296, DOI 10.1002/ajmg.a.32880; Rump P, 2006, AM J MED GENET A, V140A, P284, DOI 10.1002/ajmg.a.31084; Santos HG, 2007, AM J MED GENET A, V143A, P355, DOI 10.1002/ajmg.a.31556; SAVOV A, 1995, HUM MOL GENET, V4, P1169, DOI 10.1093/hmg/4.7.1169; TILLER GE, 1995, NAT GENET, V11, P87, DOI 10.1038/ng0995-87; Williams Charlene J., 1992, Human Mutation, V1, P403, DOI 10.1002/humu.1380010510; WYNNEDAVIES R, 1982, J BONE JOINT SURG BR, V64, P435; Xia XY, 2007, CLIN CHIM ACTA, V382, P148, DOI 10.1016/j.cca.2007.04.005	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUL	2015	167	7					1578	1581		10.1002/ajmg.a.37073		4	Genetics & Heredity	Genetics & Heredity	CL1BB	WOS:000356676200069		
J	Hara, M; Ohba, C; Yamashita, Y; Saitsu, H; Matsumoto, N; Matsuishi, T				Hara, Munetsugu; Ohba, Chihiro; Yamashita, Yushiro; Saitsu, Hirotomo; Matsumoto, Naomichi; Matsuishi, Toyojiro			De Novo SHANK3 Mutation Causes Rett Syndrome-Like Phenotype in a Female Patient	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						Rett syndrome; SHANK3; de novo; frameshift; deletion; whole-exome sequencing	AUTISM SPECTRUM DISORDERS; GENE; DYSFUNCTION	Rett syndrome (RTT) is a neurodevelopmental disorder predominantly affecting females. Females with the MECP2 mutations exhibit a broad spectrum of clinical manifestations ranging from classical Rett syndrome to asymptomatic carriers. Mutations of genes encoding cyclin-dependent kinase-like 5 (CDKL5) and forkhead box G1 (FOXG1) are also found in early onset RTT variants. Here, we present the first report of a female patient with RTT-like phenotype caused by SHANK3 (SH3 and multiple ankylin repeat domain 3) mutation, indicating that the clinical spectrum of SHANK3 mutations may extend to RTT-like phenotype in addition to (severe) developmental delay, absence of expressive speech, autistic behaviors and intellectual disability. (C) 2015 Wiley Periodicals, Inc.	[Hara, Munetsugu] St Marys Hosp, Med Ctr Maternal & Child Hlth, Dept Neonatol, Kurume, Fukuoka, Japan; [Ohba, Chihiro; Saitsu, Hirotomo; Matsumoto, Naomichi] Yokohama City Univ, Dept Human Genet, Grad Sch Med, Kanazawa Ku, Yokohama, Kanagawa 232, Japan; [Yamashita, Yushiro; Matsuishi, Toyojiro] Kurume Univ, Sch Med, Dept Pediat, Kurume, Fukuoka 8300011, Japan; [Yamashita, Yushiro; Matsuishi, Toyojiro] Kurume Univ, Sch Med, Dept Child Hlth, Kurume, Fukuoka 8300011, Japan	Matsuishi, T (reprint author), Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	tmatsu@med.kurume-u.ac.jp			Japan Society for the Promotion of Science [30389283, 13313587, 21591338]; Ministry of Education, Culture, Sports, Science and Technology of Japan [11105137, 12024421]; Applying Health Technology [12944231]; Comprehensive Research on Disability Health and Welfare [13802019]; Research on Intractable Diseases [21-110, 22-133]	Grant sponsor: Japan Society for the Promotion of Science; Grant numbers: 30389283, 13313587, 21591338; Grant sponsor: Ministry of Education, Culture, Sports, Science and Technology of Japan; Grant numbers: 11105137, 12024421; Grant sponsor: Applying Health Technology; Grant number: 12944231; Grant sponsor: Comprehensive Research on Disability Health and Welfare; Grant number: 13802019; Grant sponsor: Research on Intractable Diseases; Grant numbers: 21-110, 22-133.	Peca J, 2011, NATURE, V472, P437, DOI 10.1038/nature09965; Neul JL, 2010, ANN NEUROL, V68, P944, DOI 10.1002/ana.22124; Waga C, 2014, J NEUROCHEM, V128, P280, DOI 10.1111/jnc.12505; Amir RE, 1999, NAT GENET, V23, P185; Chao HT, 2010, NATURE, V468, P263, DOI 10.1038/nature09582; Saitsu H, 2013, NAT GENET, V45, P445, DOI 10.1038/ng.2562; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Boccuto L, 2013, EUR J HUM GENET, V21, P310, DOI 10.1038/ejhg.2012.175; Percy AK, 2010, ANN NEUROL, V68, P951, DOI 10.1002/ana.22154; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Bonaglia MC, 2001, AM J HUM GENET, V69, P261, DOI 10.1086/321293; Neul JL, 2004, NEUROSCIENTIST, V10, P118, DOI 10.1177/1073858403260995; Uchino S, 2013, BRAIN DEV-JPN, V35, P106, DOI 10.1016/j.braindev.2012.05.013; Betancur C, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-17; Herbert MR, 2011, NEW ENGL J MED, V365, P173, DOI 10.1056/NEJMcibr1104261; Pan YZ, 1998, AM J HUM GENET, V62, P1551, DOI 10.1086/301857; Smeets EEJ, 2011, MOL SYNDROMOLOGY, V2, P113	17	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUL	2015	167	7					1593	1596		10.1002/ajmg.a.36775		4	Genetics & Heredity	Genetics & Heredity	CL1BB	WOS:000356676200072		
J	Takagi, M; Shinohara, H; Narumi, S; Nishimura, G; Hasegawa, Y; Hasegawa, T				Takagi, Masaki; Shinohara, Hiroyuki; Narumi, Satoshi; Nishimura, Gen; Hasegawa, Yukihiro; Hasegawa, Tomonobu			Severe Osteogenesis Imperfecta Caused by Double Glycine Substitutions Near the Amino-Terminal Triple Helical Region in COL1A2	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						osteogenesis imperfect; glycine; double mutation	I COLLAGEN; MUTATIONS; MODEL; GENE	Most cases of osteogenesis imperfecta (OI) are caused by heterozygous mutations in COL1A1 or COL1A2, the genes encoding the two type I procollagen alpha chains, proa1 (I) and proa2 (I). We report on a unique case of severe OI, a long term survivor of lethal type II OI, rather than progressively deforming type III, due to double substitutions of glycine residues in COL1A2 (p.Gly208Glu and p.Gly235Asp), located on the same allele. To the best of our knowledge, this is the first example of a patient with double COL1A2 glycine substitution mutations on the same allele. We show for the first time that double COL1A2 glycine substitution mutations located near the amino-terminal triple helical region, which individually are likely to result in mild OI, cause severe OI in combination. (C) 2015 Wiley Periodicals, Inc.	[Takagi, Masaki; Narumi, Satoshi; Hasegawa, Tomonobu] Keio Univ, Sch Med, Dept Pediat, Tokyo 1608582, Japan; [Takagi, Masaki; Shinohara, Hiroyuki; Hasegawa, Yukihiro] Tokyo Metropolitan Childrens Med Ctr, Dept Endocrinol & Metab, Tokyo, Japan; [Nishimura, Gen] Tokyo Metropolitan Childrens Med Ctr, Dept Radiol, Tokyo, Japan	Hasegawa, T (reprint author), Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	thaseg@a6.keio.jp			Ministry of Health, Labour and Welfare of Japan [Jitsuyoka (Nanbyo)-Ippan-014 (23300102)]	This work was supported by a Grant-in-Aid for the Health Science Research Grant for Research on Applying Health Technology [Jitsuyoka (Nanbyo)-Ippan-014 (23300102)] from the Ministry of Health, Labour and Welfare of Japan.	ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; MARINI JC, 1993, J BIOL CHEM, V268, P2667; Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429; WANG Q, 1993, J BIOL CHEM, V268, P25162; PROCKOP DJ, 1989, AM J MED GENET, V34, P60, DOI 10.1002/ajmg.1320340112; Schwarze U, 2004, AM J HUM GENET, V74, P917, DOI 10.1086/420794	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	JUL	2015	167	7					1627	1631		10.1002/ajmg.a.37051		5	Genetics & Heredity	Genetics & Heredity	CL1BB	WOS:000356676200079		
J	Nakatsu, Y; Seno, Y; Kushiyama, A; Sakoda, H; Fujishiro, M; Katasako, A; Mori, K; Matsunaga, Y; Fukushima, T; Kanaoka, R; Yamamotoya, T; Kamata, H; Asano, T				Nakatsu, Yusuke; Seno, Yasuyuki; Kushiyama, Akifumi; Sakoda, Hideyuki; Fujishiro, Midori; Katasako, Aya; Mori, Keiichi; Matsunaga, Yasuka; Fukushima, Toshiaki; Kanaoka, Ryuhei; Yamamotoya, Takeshi; Kamata, Hideaki; Asano, Tomoichiro			The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model	AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY			English	Article						uric acid; nonalcoholic steatohepatitis; xanthine oxidase inhibitor; hyperuricemia; febuxostat	SERUM URIC-ACID; FATTY LIVER-DISEASE; METABOLIC SYNDROME; ATHEROSCLEROSIS; OXIDOREDUCTASE; HYPERTENSION; DYSFUNCTION; FRUCTOSE; OBESITY; INJURY	Xanthine oxidase (XO) is an enzyme involved in the production of uric acid (UA) from purine nucleotides. Numerous recent studies have revealed the likelihood of metabolic syndrome including nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH) to be related to hyperuricemia. However, it remains unclear whether elevated serum UA during the development of NAFLD or NASH is a cause or a consequence of these diseases. In this study, the XO inhibitor febuxostat was administered to two types of NASH model mice. Febuxostat exerted a strong protective effect against NASH development induced by a high-fat diet containing trans fatty acid (HFDT). In contrast, methionine choline-deficient-diet-induced NASH development not accompanied by hyperuricemia showed no UA normalization, suggesting that the ameliorating effect of febuxostat occurs via the normalization of hyperuricemia itself and/or accompanying molecular mechanism(s) such as oxidative stress. In the HFDT-fed mice, hyperuricemia, elevated alanine aminotransferase, and increased Tunnel-positive cells in the liver were normalized by febuxostat administration. In addition, upregulation of fatty acid oxidation-related genes, fibrotic change, and increases in collagen deposition, inflammatory cytokine expressions, and lipid peroxidation in the HFDT-fed mice were also normalized by febuxostat administration. Taken together, these observations indicate that administration of febuxostat has a protective effect against HFDT-induced NASH development, suggesting the importance of XO in its pathogenesis. Thus XO inhibitors are potentially potent therapies for patients with NASH, particularly that associated with hyperuricemia.	[Nakatsu, Yusuke; Seno, Yasuyuki; Katasako, Aya; Mori, Keiichi; Matsunaga, Yasuka; Fukushima, Toshiaki; Kanaoka, Ryuhei; Yamamotoya, Takeshi; Kamata, Hideaki; Asano, Tomoichiro] Hiroshima Univ, Grad Sch Med, Dept Med Sci, Hiroshima, Hiroshima, Japan; [Kushiyama, Akifumi] Asahi Life Fdn, Inst Adult Dis, Div Diabet & Metab, Tokyo, Japan; [Sakoda, Hideyuki] Miyazaki Univ, Fac Med, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Miyazaki, Japan; [Fujishiro, Midori] Univ Tokyo, Dept Internal Med, Grad Sch Med, Tokyo, Japan	Asano, T (reprint author), Hiroshima Univ, Grad Sch Med, Dept Med Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima, Hiroshima, Japan.	tasano@hiroshima-u.ac.jp					Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Masuo K, 2003, HYPERTENSION, V42, P474, DOI 10.1161/01.HYP.0000091371.53502.D3; Klein BEK, 2002, DIABETES CARE, V25, P1790, DOI 10.2337/diacare.25.10.1790; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Kushiyama A, 2012, ARTERIOSCL THROM VAS, V32, P291, DOI 10.1161/ATVBAHA.111.234559; Battelli MG, 2014, BBA-MOL BASIS DIS, V1842, P1502, DOI 10.1016/j.bbadis.2014.05.022; Lim JS, 2010, NAT REV GASTRO HEPAT, V7, P251, DOI 10.1038/nrgastro.2010.41; Zoccali C, 2013, CURR HYPERTENS REP, V15, P531, DOI 10.1007/s11906-013-0391-y; Johnson RJ, 2005, J AM SOC NEPHROL, V16, P1909, DOI 10.1681/ASN.2005010063; Nakagawa T, 2006, AM J PHYSIOL-RENAL, V290, pF625, DOI 10.1152/ajprenal.00140.2005; Khosla UM, 2005, KIDNEY INT, V67, P1739, DOI 10.1111/j.1523-1755.2005.00273.x; Sertoglu E, 2014, CLIN BIOCHEM, V47, P383, DOI 10.1016/j.clinbiochem.2014.01.029; Ishizaka N, 2005, ARTERIOSCL THROM VAS, V25, P1038, DOI 10.1161/01.ATV.0000161274.87407.26; Lin CC, 2008, FOOD CHEM TOXICOL, V46, P3401, DOI 10.1016/j.fct.2008.08.010; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Tsouli SG, 2006, METABOLISM, V55, P1293, DOI 10.1016/j.metabol.2006.05.013; Xu CF, 2015, J HEPATOL, V62, P1412, DOI 10.1016/j.jhep.2015.01.019; Matsuura F, 1998, METABOLISM, V47, P929, DOI 10.1016/S0026-0495(98)90346-8; Bokyo EJ, 2000, DIABETES CARE, V23, P1242; Cicerchi C, 2014, FASEB J, V28, P34339; dela Pena A, 2007, J HEPATOL, V46, P304, DOI 10.1016/j.jhep.2006.08.025; Hsieh PS, 2008, EUR J CLIN INVEST, V38, P640, DOI 10.1111/j.1365-2362.2008.01991.x; Lee HJ, 2014, AM J NEPHROL, V40, P56, DOI 10.1159/000363421; Nomura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075527; Sesti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088569; Tsushima Y, 2013, J BIOL CHEM, V288, P27138, DOI 10.1074/jbc.M113.485094	26	2	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0193-1857	1522-1547		AM J PHYSIOL-GASTR L	Am. J. Physiol.-Gastroint. Liver Physiol.	JUL 1	2015	309	1					G42	G51		10.1152/ajpgi.00443.2014		10	Gastroenterology & Hepatology; Physiology	Gastroenterology & Hepatology; Physiology	CM2GQ	WOS:000357498300005		
J	Delliaux, S; Ichinose, M; Watanabe, K; Fujii, N; Nishiyasu, T				Delliaux, Stephane; Ichinose, Masashi; Watanabe, Kazuhito; Fujii, Naoto; Nishiyasu, Takeshi			Cardiovascular responses to forearm muscle metaboreflex activation during hypercapnia in humans	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						hypercapnia; muscle metaboreflex; hypertension; stroke volume; myocardial oxygen consumption	CHRONIC HEART-FAILURE; SYMPATHETIC-NERVE RESPONSES; EXERCISE PRESSOR REFLEX; HEMODYNAMIC-RESPONSE; VASCULAR-RESISTANCE; OXYGEN-CONSUMPTION; HANDGRIP EXERCISE; INDUCED INCREASES; DYNAMIC EXERCISE; STATIC EXERCISE	We characterized the cardiovascular responses to forearm muscle metaboreflex activation during hypercapnia. Ten healthy males participated under three experimental conditions: 1) hypercapnia (HCA, PETCO2: +10 mmHg, by inhalation of a CO2-enriched gas mixture); 2) muscle metaboreflex activation (MMA, by 5 min of local circulatory occlusion after 1 min of 50% maximum voluntary contraction isometric handgrip under normocapnia); and 3) HCA + MMA. We measured mean arterial pressure (MAP), heart rate (HR), and cardiac output (CO); calculated stroke volume (SV), and total peripheral resistance (TPR); and evaluated myocardial oxygen consumption (M(V) over dot(O2)) and cardiac work (CW) noninvasively. MAP increased in the three experimental conditions but HCA + MMA led to the highest MAP, CO, and HR. Moreover, HCA + MMA increased SV and was associated with the highest M(V) over dot(O2) and CW. HCA and MMA exhibited inhibitory interactions with MAP, HR, TPR, M(V) over dot(O2), and CW, increases of which were smaller during HCA + MMA than the sum of the increases during HCA and MMA alone (MAP: +28 +/- 2 vs. +34 +/- 2 mmHg, P < 0.001; HR: +15 +/- 2 vs. +22 +/- 3 bpm, P < 0.01; TPR: +1.1 +/- 1.4 vs. +3.0 +/- 1.5 mmHg.l.min(-1), P < 0.05; M(V) over dot(O2): +50.25 +/- 4.74 vs. +59.48 +/- 5.37 mmHg.min(-1).10(-2), P < 0.01; CW: +59.10 +/- 7.52 vs. +63.67 +/- 7.71 ml mmHg.min(-1).10(-4), P < 0.05). Oppositely, HCA and MMA interactions were linearly additive for CO (+2.3 +/- 0.4 l/min) and SV (+13 +/- 4 ml). We showed that muscle metaboreflex and hypercapnia interact in healthy humans, reducing vasoconstriction but enhancing SV.	[Delliaux, Stephane] Aix Marseille Univ, MD, DS ACI, UMR 2, Marseille, France; [Delliaux, Stephane] Hop Nord Marseille, APHM, Pole Cardiovasc & Thorac, Lab Physiol Resp Explorat Exercice, Marseille, France; [Delliaux, Stephane] Hop Nord Marseille, AP HP, Pole Cardiovasc & Thorac, Lab Physiol Resp Explorat Exercice, Marseille, France; [Ichinose, Masashi] Meiji Univ, Sch Business & Adm, Tokyo 101, Japan; [Delliaux, Stephane; Ichinose, Masashi; Watanabe, Kazuhito; Fujii, Naoto; Nishiyasu, Takeshi] Univ Tsukuba, Inst Hlth & Sport Sci, Lab Physiol Circulat, Tsukuba, Ibaraki, Japan; [Delliaux, Stephane; Fujii, Naoto] Japan Soc Promot Sci, Tokyo, Japan	Delliaux, S (reprint author), Fac Med Nord, UMR MD2, 51 Blvd Pierre Dramard, F-13015 Marseille, France.	stephane.delliaux@univ-amu.fr			Japanese Society for the Promotion of Science (Ministry of Education, Science and Culture of Japan); Assistance Publique-Hopitaux de Marseille, Marseille, France	This study was supported in part by grants from the Japanese Society for the Promotion of Science (Ministry of Education, Science and Culture of Japan) and from the Assistance Publique-Hopitaux de Marseille, Marseille, France, both to S. Delliaux. F. Naoto is a Japan Society for the Promotion of Science Fellow.	Alam M, 1937, J PHYSIOL-LONDON, V89, P372; Ponikowski P, 2001, CIRCULATION, V103, P967; Crisafulli A, 2006, AM J PHYSIOL-HEART C, V291, pH3035, DOI 10.1152/ajpheart.00221.2006; NELSON RR, 1974, CIRCULATION, V50, P1179; SEALS DR, 1991, J APPL PHYSIOL, V71, P1032; PIEPOLI M, 1995, AM J PHYSIOL-HEART C, V269, pH1428; MARK AL, 1985, CIRC RES, V57, P461; O'Leary DS, 2007, J APPL PHYSIOL, V103, P190, DOI 10.1152/japplphysiol.00139.2007; VICTOR RG, 1989, CIRC RES, V65, P468; Crisafulli A, 2003, MED SCI SPORT EXER, V35, P221, DOI 10.1249/01.MSS.0000048639.02548.24; Boushel R, 2010, ACTA PHYSIOL, V199, P367, DOI 10.1111/j.1748-1716.2010.02133.x; Kaufman MP, 2012, EXP PHYSIOL, V97, P51, DOI 10.1113/expphysiol.2011.057539; Crisafulli A, 2009, EUR J APPL PHYSIOL, V106, P525, DOI 10.1007/s00421-009-1045-2; Chua TP, 1997, EUR HEART J, V18, P480; WALLIN BG, 1989, AM J PHYSIOL, V256, pH105; Notarius CF, 2001, AM J PHYSIOL-HEART C, V280, pH969; Kiely DG, 1996, CHEST, V109, P1215, DOI 10.1378/chest.109.5.1215; Crisafulli A, 2007, AM J PHYSIOL-HEART C, V292, pH2988, DOI 10.1152/ajpheart.00008.2007; PAWELCZYK JA, 1992, J APPL PHYSIOL, V73, P1838; OREGAN RG, 1982, J EXP BIOL, V100, P23; Shoemaker JK, 2007, J APPL PHYSIOL, V103, P228, DOI 10.1152/japplphysiol.01334.2006; Smith SA, 2006, EXP PHYSIOL, V91, P89, DOI 10.1113/expphysiol.2005.032367; Marongiu E, 2013, AM J PHYSIOL-HEART C, V305, pH1387, DOI 10.1152/ajpheart.00397.2013; OLEARY DS, 1995, AM J PHYSIOL-HEART C, V268, pH980; Hammond RL, 2000, AM J PHYSIOL-HEART C, V278, pH818; Giannoni A, 2008, CLIN SCI, V114, P489, DOI 10.1042/CS20070292; Steinback CD, 2009, AM J PHYSIOL-REG I, V296, pR402, DOI 10.1152/ajpregu.90772.2008; BONDEPETERSEN F, 1978, J APPL PHYSIOL, V45, P574; CULLEN DJ, 1974, ANESTHESIOLOGY, V41, P345, DOI 10.1097/00000542-197410000-00006; ROOKE GA, 1982, CIRC RES, V50, P273; AARON EA, 1992, J APPL PHYSIOL, V72, P1818; Chua TP, 1997, CIRCULATION, V96, P2090; Houssiere A, 2005, AM J PHYSIOL-HEART C, V288, pH1724, DOI 10.1152/ajpheart.01043.2004; Ichinose M, 2007, AM J PHYSIOL-HEART C, V293, pH416, DOI 10.1152/ajpheart.01196.2006; Javaheri S, 1999, NEW ENGL J MED, V341, P949, DOI 10.1056/NEJM199909233411304; KONTOS HA, 1967, AM J PHYSIOL, V212, P1070; KONTOS HA, 1968, AM J PHYSIOL, V215, P1403; Longhurst J C, 1979, Int Rev Physiol, V18, P125; Lykidis CK, 2010, EXP PHYSIOL, V95, P194, DOI 10.1113/expphysiol.2009.049999; Lykidis CK, 2009, ADV EXP MED BIOL, V648, P281, DOI 10.1007/978-90-481-2259-2_32; Nishiyasu T, 2007, AM J PHYSIOL-HEART C, V293, pH670, DOI 10.1152/ajpheart.00462.2006; Pitsikoulis C, 2008, RESP PHYSIOL NEUROBI, V164, P373, DOI 10.1016/j.resp.2008.08.010; PRICE HL, 1960, ANESTHESIOLOGY, V21, P652, DOI 10.1097/00000542-196011000-00009; Sagawa K., 1983, HDB PHYSL 2, VIII, P453; SINOWAY LI, 1988, AM J PHYSIOL, V255, pH937; SPYER KM, 1994, J PHYSIOL-LONDON, V474, P1	46	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	JUL 1	2015	309	1					R43	R50		10.1152/ajpregu.00402.2014		8	Physiology	Physiology	CM2JF	WOS:000357505300005		
J	Ramkumar, N; Stuart, D; Calquin, M; Quadri, S; Wang, SP; Van Hoek, AN; Siragy, HM; Ichihara, A; Kohan, DE				Ramkumar, Nirupama; Stuart, Deborah; Calquin, Matias; Quadri, Syed; Wang, Shuping; Van Hoek, Alfred N.; Siragy, Helmy M.; Ichihara, Atsuhiro; Kohan, Donald E.			Nephron-specific deletion of the prorenin receptor causes a urine concentration defect	AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY			English	Article						prorenin receptor; nephron knockout; urine concentration	PRO RENIN RECEPTOR; VACUOLAR H+-ATPASE; ANGIOTENSIN-II INCREASES; RAT RENAL MEDULLA; (PRO)RENIN RECEPTOR; COLLECTING DUCT; SIGNALING PATHWAY; AT(1) RECEPTORS; PROTEIN-KINASE; MICE LACKING	The prorenin receptor (PRR), a recently discovered component of the renin-angiotensin system, is expressed in the nephron in general and the collecting duct in particular. However, the physiological significance of nephron PRR remains unclear, partly due to developmental abnormalities associated with global or renal-specific PRR gene knockout (KO). Therefore, we developed mice with inducible nephron-wide PRR deletion using Pax8-reverse tetracycline transactivator and LC-1 transgenes and loxP flanked PRR alleles such that ablation of PRR occurs in adulthood, after induction with doxycycline. Nephron-specific PRR KO mice have normal survival to similar to 1 yr of age and no renal histological defects. Compared with control mice, PRR KO mice had 65% lower medullary PRR mRNA and protein levels and markedly diminished renal PRR immunofluorescence. During both normal water intake and mild water restriction, PRR KO mice had significantly lower urine osmolality, higher water intake, and higher urine volume compared with control mice. No differences were seen in urine vasopressin excretion, urine Na+ and K+ excretion, plasma Na+, or plasma osmolality between the two groups. However, PRR KO mice had reduced medullary aquaporin-2 levels and arginine vasopressin-stimulated cAMP accumulation in the isolated renal medulla compared with control mice. Taken together, these results suggest nephron PRR can potentially modulate renal water excretion.	[Ramkumar, Nirupama; Stuart, Deborah; Calquin, Matias; Wang, Shuping; Van Hoek, Alfred N.; Kohan, Donald E.] Univ Utah, Hlth Sci Ctr, Div Nephrol & Hypertens, Salt Lake City, UT 84132 USA; [Quadri, Syed; Siragy, Helmy M.] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA; [Ichihara, Atsuhiro] Tokyo Womens Med Univ, Dept Med Endocrinol & Hypertens 2, Tokyo, Japan	Ramkumar, N (reprint author), Univ Utah, Hlth Sci Ctr, Div Nephrol & Hypertens, 30 N 1900 E,4R312 SOM, Salt Lake City, UT 84132 USA.	nirupama.ramkumar@hsc.utah.edu			National Institutes of Health (NIH) [DK-097007]; Veterans Affairs Merit Review; NIH [DK-078757, HL-091535]; Ministry of Education, Science, and Culture of Japan [25293198]	This work was supported in part by National Institutes of Health (NIH) Grant DK-097007 and a Veterans Affairs Merit Review to D. E. Kohan, NIH Grants DK-078757 and HL-091535 to H. M. Siragy, and Ministry of Education, Science, and Culture of Japan Gran 25293198 to A. Ichihara.	Cousin C, 2009, HYPERTENSION, V53, P1077, DOI 10.1161/HYPERTENSIONAHA.108.127258; Gonzalez AA, 2011, HYPERTENSION, V57, P859, DOI 10.1161/HYPERTENSIONAHA.110.167957; Wang F, 2014, HYPERTENSION, V64, P369, DOI 10.1161/HYPERTENSIONAHA.114.03654; Rohrwasser A, 2003, KIDNEY INT, V64, P2155, DOI 10.1046/j.1523-1755.2003.00302.x; Rohrwasser A, 1999, HYPERTENSION, V34, P1265; Casarini DE, 1997, AM J PHYSIOL-RENAL, V272, pF405; Riediger F, 2011, J AM SOC NEPHROL, V22, P2193, DOI 10.1681/ASN.2011020200; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Lu XF, 2013, AM J PHYSIOL-RENAL, V305, pF417, DOI 10.1152/ajprenal.00037.2013; Matavelli LC, 2012, AM J PHYSIOL-RENAL, V303, pF1652, DOI 10.1152/ajprenal.00204.2012; Huang JQ, 2009, ENDOCRINOLOGY, V150, P5557, DOI 10.1210/en.2009-0442; Ramkumar N, 2014, AM J PHYSIOL-RENAL, V307, pF931, DOI 10.1152/ajprenal.00367.2014; Kinouchi K, 2010, CIRC RES, V107, P30, DOI 10.1161/CIRCRESAHA.110.224667; Faresse N, 2012, AM J PHYSIOL-RENAL, V302, pF977, DOI 10.1152/ajprenal.00535.2011; Peti-Peterdi J, 2002, J AM SOC NEPHROL, V13, P1131, DOI 10.1097/01.ASN.0000013292.78621.FD; Liu L, 2011, AM J PHYSIOL-RENAL, V301, pF1195, DOI 10.1152/ajprenal.00339.2011; Oshima Y, 2011, J AM SOC NEPHROL, V22, P2203, DOI 10.1681/ASN.2011020202; Nguyen G, 2010, J AM SOC NEPHROL, V21, P18, DOI 10.1681/ASN.2009030300; Schonig K, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf134; Pisitkun T, 2008, AM J PHYSIOL-RENAL, V295, pF1030, DOI 10.1152/ajprenal.90339.2008; Advani A, 2009, HYPERTENSION, V54, P261, DOI 10.1161/HYPERTENSIONAHA.109.128645; Saris JJ, 2006, HYPERTENSION, V48, P564, DOI 10.1161/01.HYP.0000240064.19301.1b; Ingelfinger Jr, 1999, AM J PHYSIOL-RENAL, V276, pF218; Traykova-Brauch M, 2008, NAT MED, V14, P979, DOI 10.1038/nm.1865; Wang F, 2014, AM J PHYSIOL-RENAL, V307, pF25, DOI 10.1152/ajprenal.00548.2013; Stuart D, 2013, J PHARMACOL EXP THER, V346, P182, DOI 10.1124/jpet.113.205286; Schefe JH, 2008, J HYPERTENS, V26, P1787, DOI 10.1097/HJH.0b013e3283060f2e; Kaneshiro Y, 2006, KIDNEY INT, V70, P641, DOI 10.1038/sj.ki.5001627; Kobori H, 2002, KIDNEY INT, V61, P579, DOI 10.1046/j.1523-1755.2002.00155.x; Oliverio MI, 1998, P NATL ACAD SCI USA, V95, P15496, DOI 10.1073/pnas.95.26.15496; Feldt S, 2008, HYPERTENSION, V51, P682, DOI 10.1161/HYPERTENSIONAHA.107.101444; Gonzalez AA, 2014, AM J MED SCI, V348, P416, DOI 10.1097/MAJ.0000000000000335; Gonzalez AA, 2013, HYPERTENSION, V61, P443, DOI 10.1161/HYPERTENSIONAHA.112.196303; Gonzalez-Villalobos RA, 2011, J AM SOC NEPHROL, V22, P449, DOI 10.1681/ASN.2010060624; Huang JQ, 2012, HYPERTENSION, V59, P317, DOI 10.1161/HYPERTENSIONAHA.111.186056; Huang JQ, 2010, ENDOCRINOLOGY, V151, P3317, DOI 10.1210/en.2009-1368; Mamenko M, 2012, J BIOL CHEM, V287, P660, DOI 10.1074/jbc.M111.298919; McCormick JA, 2014, J CLIN INVEST, V124, P4723, DOI 10.1172/JCI76126; Oliverio MI, 1998, AM J PHYSIOL-RENAL, V274, pF43; Pohl M, 2010, J BIOL CHEM, V285, P41935, DOI 10.1074/jbc.M110.150284; Quadri S, 2014, AM J PHYSIOL-RENAL, V307, pF593, DOI 10.1152/ajprenal.00245.2014; Riquier-brison AV, 2013, MACULA DENSA PRORENI; Song RF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063835; Stegbauer J, 2011, J AM SOC NEPHROL, V22, P2237, DOI 10.1681/ASN.2010101095; YAMADA T, 1995, KIDNEY INT, V48, P745, DOI 10.1038/ki.1995.346	45	1	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1931-857X	1522-1466		AM J PHYSIOL-RENAL	Am. J. Physiol.-Renal Physiol.	JUL 1	2015	309	1					F48	F56		10.1152/ajprenal.00126.2015		9	Physiology; Urology & Nephrology	Physiology; Urology & Nephrology	CM2KB	WOS:000357507500007		
J	Sato, S; Motoi, N; Hiramatsu, M; Miyauchi, E; Ono, H; Saito, Y; Nagano, H; Ninomiya, H; Inamura, K; Uehara, H; Mun, M; Sakao, Y; Okumura, S; Tsuchida, M; Ishikawa, Y				Sato, Seijiro; Motoi, Noriko; Hiramatsu, Miyako; Miyauchi, Eisaku; Ono, Hiroshi; Saito, Yuichi; Nagano, Hiroko; Ninomiya, Hironori; Inamura, Kentaro; Uehara, Hirofumi; Mun, Mingyon; Sakao, Yukinori; Okumura, Sakae; Tsuchida, Masanori; Ishikawa, Yuichi			Pulmonary Adenocarcinoma In Situ Analyses of a Large Series With Reference to Smoking, Driver Mutations, and Receptor Tyrosine Kinase Pathway Activation	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						adenocarcinoma in situ (AIS); lung; smoking; driver mutations; receptor tyrosine kinase pathway	CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; K-RAS GENE; CIGARETTE-SMOKING; BRONCHIOLOALVEOLAR CARCINOMA; HISTOLOGIC SUBTYPES; EGFR MUTATIONS; KRAS MUTATION; NEVER-SMOKERS; GEFITINIB	Lung adenocarcinomas in situ (AISs) often occur in individuals who have never smoked, although smoking is one of the main causes of lung cancer. To characterize AIS and, in particular, determine how AIS might be related to smoking, we collected a large number of AIS cases and examined clinicopathologic features, EGFR and KRAS mutation status, and activation status of receptor tyrosine kinase downstream signal pathways, including pAkt, pERK, and pStat3, using immunohistochemistry. We identified 110 AISs (36 smokers and 74 nonsmokers) among 1549 adenocarcinomas resected surgically during 1995 to 2010. Between the AIS of smokers and nonsmokers, only the sex ratio was significantly different; all the other clinicopathologic factors including TTF-1 and driver mutations were not significantly different: EGFR and KRAS mutation rates (smokers:nonsmokers) were 61:58 (%) (P=0.7) and 6.1:1.4 (%) (P=0.2), respectively, whereas, in invasive adenocarcinomas, the rates were 41:69 (%) (P<0.001) and 9.4:2.3 (%) (P<0.04), respectively. For pAkt and pERK, around 40% to 50% of AISs were positive, and for pStat3, >80% were positive, with no significant differences between smokers and nonsmokers with AIS. Mucinous AIS (n=8) rarely harbored KRAS mutations and expressed significantly less pStat3 (P<0.001) than nonmucinous AIS. Taken together, AIS occurs predominantly in female individuals and nonsmokers. However, characteristics of AIS arising in smokers and nonsmokers were similar in terms of cell lineage, driver mutations, and receptor tyrosine kinase pathway activation. Our results suggest that smoking is not a major cause of AIS. Rather, smoking may play a role in progression of AIS to invasive adenocarcinoma with AIS features.	[Sato, Seijiro; Motoi, Noriko; Hiramatsu, Miyako; Miyauchi, Eisaku; Ono, Hiroshi; Saito, Yuichi; Nagano, Hiroko; Ninomiya, Hironori; Inamura, Kentaro; Ishikawa, Yuichi] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Dept Pathol,Canc Inst Hosp, Tokyo 1358550, Japan; [Uehara, Hirofumi; Mun, Mingyon; Sakao, Yukinori; Okumura, Sakae] Japanese Fdn Canc Res, Dept Thorac Surg Oncol, Canc Inst Hosp, Tokyo 1358550, Japan; [Tsuchida, Masanori] Niigata Univ Hosp, Div Thorac & Cardiovasc Surg, Niigata, Japan	Ishikawa, Y (reprint author), Japanese Fdn Canc Res, Inst Canc, Div Pathol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ishikawa@jfcr.or.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science; Ministry of Health, Labour and Welfare; Smoking Research Foundation	Supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, grants from the Japan Society for the Promotion of Science, the Ministry of Health, Labour and Welfare, and the Smoking Research Foundation. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ali G, 2008, HUM PATHOL, V39, P1465, DOI 10.1016/j.humpath.2008.02.011; Maeda R, 2011, J THORAC ONCOL, V6, P743, DOI 10.1097/JTO.0b013e3182103714; Dutu T, 2005, ANN ONCOL, V16, P1906, DOI 10.1093/annonc/mdi408; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Sakuma Y, 2007, AM J CLIN PATHOL, V128, P100, DOI 10.1309/WVXFGAFLAUX48DU6; Zell JA, 2005, J CLIN ONCOL, V23, P8396, DOI 10.1200/JCO.2005.03.0312; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Shigematsu H, 2005, J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Kreuzer M, 2003, INT J EPIDEMIOL, V32, P263, DOI 10.1093/ije/dyg064; Yatabe Y, 2005, AM J SURG PATHOL, V29, P633, DOI 10.1097/01.pas.0000157935.28066.35; Ninomiya H, 2009, LUNG CANCER, V63, P235, DOI 10.1016/j.lungcan.2008.04.017; Cappuzzo F, 2004, J NATL CANCER I, V96, P1133, DOI 10.1093/jnci/djh217; Hiramatsu M, 2010, LUNG CANCER, V70, P94, DOI 10.1016/j.lungcan.2010.01.001; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Nelson HH, 1999, J NATL CANCER I, V91, P2032, DOI 10.1093/jnci/91.23.2032; Finberg KE, 2007, J MOL DIAGN, V9, P320, DOI 10.2353/jmoldx.2007.060182; Soung YH, 2005, VIRCHOWS ARCH, V446, P483, DOI 10.1007/s00428-005-1254-y; Wislez M, 2010, LUNG CANCER, V68, P185, DOI 10.1016/j.lungcan.2009.05.021; Dacic S, 2010, MODERN PATHOL, V23, P159, DOI 10.1038/modpathol.2009.154; Marchetti A, 2005, J CLIN ONCOL, V23, P857, DOI 10.1200/JCO.2005.08.043; Kitamura H, 1996, AM J SURG PATHOL, V20, P553, DOI 10.1097/00000478-199605000-00002; Fernandez-Cuesta L, 2014, CANCER DISCOV, V4, P415, DOI 10.1158/2159-8290.CD-13-0633; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; Kadota K, 2014, AM J SURG PATHOL, V38, P1118, DOI 10.1097/PAS.0000000000000246; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Dresler CM, 2003, LUNG CANCER-J IASLC, V39, P119, DOI 10.1016/S0169-5002(02)00455-5; Gandara DR, 2004, CLIN CANCER RES, V10, p4205S, DOI 10.1158/1078-0432.CCR-040012; Godtfredsen NS, 2005, JAMA-J AM MED ASSOC, V294, P1505, DOI 10.1001/jama.294.12.1505; Hashimoto T, 2000, AM J PATHOL, V157, P2133, DOI 10.1016/S0002-9440(10)64851-1; Ishikawa Y, 2002, CANCER LETT, V187, P47, DOI 10.1016/S0304-3835(02)00383-X; Kabat GC, 1996, LUNG CANCER-J IASLC, V15, P1, DOI 10.1016/0169-5002(95)00566-8; Kakegawa S, 2011, CANCER-AM CANCER SOC, V117, P4257, DOI 10.1002/cncr.26010; Mountzios G, 2008, CLIN CANCER RES, V14, P4096, DOI 10.1158/1078-0432.CCR-07-4150; Okudela K, 2010, AM J SURG PATHOL, V34, P243, DOI 10.1097/PAS.0b013e3181c79a6f; SUZUKI T, 1990, CANCER RES, V50, P444; Travis WD, 2004, WHO CLASSIFICATION T; Yun YH, 2005, CANCER EPIDEM BIOMAR, V14, P2125, DOI 10.1158/1055-9965.EPI-05-0236	47	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2015	39	7					912	921		10.1097/PAS.0000000000000458		10	Pathology; Surgery	Pathology; Surgery	CL4SQ	WOS:000356944900004		
J	Shirai, T; Mori, K; Tsuchiya, T; Suda, T				Shirai, Toshihiro; Mori, Kazutaka; Tsuchiya, Tomoyoshi; Suda, Takafumi			Resonant frequency as a predictor of phase 3 slope of nitrogen single-breath washout in asthma	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Letter							MECHANICS		[Shirai, Toshihiro] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan; [Mori, Kazutaka; Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Internal Med 2, Hamamatsu, Shizuoka 4313192, Japan; [Tsuchiya, Tomoyoshi] Shizuoka City Shimizu Hosp, Dept Resp Med, Shizuoka, Japan	Shirai, T (reprint author), Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan.	toshihiro-shirai@i.shizuoka-pho.jp					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Shi YX, 2013, J ALLERGY CLIN IMMUN, V131, P718, DOI 10.1016/j.jaci.2012.09.022; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Robinson PD, 2013, EUR RESPIR J, V41, P507, DOI [10.1183/09031936.00069712, 10.1183/0903193600069712]; Bickel S, 2014, CHEST, V146, P841, DOI 10.1378/chest.13-1875; Dellaca RL, 2009, EUR RESPIR J, V33, P1329, DOI 10.1183/09031936.00139608; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Kanazawa H, 2011, J ALLERGY CLIN IMMUN, V127, P899, DOI 10.1016/j.jaci.2010.11.020; Shirai T, 2013, CLIN EXP ALLERGY, V43, P521, DOI 10.1111/cea.12083	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1081-1206	1534-4436		ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	JUL	2015	115	1					73	74				2	Allergy; Immunology	Allergy; Immunology	CL4YL	WOS:000356964000016		
J	Song, IH; Borland, J; Chen, SG; Wajima, T; Peppercorn, AF; Piscitelli, SC				Song, Ivy H.; Borland, Julie; Chen, Shuguang; Wajima, Toshihiro; Peppercorn, Amanda F.; Piscitelli, Stephen C.			Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol	ANNALS OF PHARMACOTHERAPY			English	Article						integrase inhibitor; HIV; drug interaction; healthy subjects; pharmacokinetics	INTEGRASE INHIBITOR DOLUTEGRAVIR; DRUG-INTERACTIONS; HEALTHY WOMEN; OXIDATION; SAFETY	Background: Dolutegravir (DTG; Tivicay; ViiV Healthcare, Research Triangle Park, NC) is an HIV-1-unboosted integrase inhibitor with no cytochrome P450 or uridine 5diphosphate-glucuronosyltransferase inhibition or induction. As DTG is administered to HIV-1-infected women receiving oral contraceptives, assessing the potential for drug interactions was warranted. Objective: To determine the impact of DTG on the pharmacokinetics (PK) and pharmacodynamics (PD) of a common oral contraceptive, norgestimate/ethinyl estradiol (NGM/EE; Ortho-Cyclen; Ortho-McNeil-Janssen Pharmaceuticals, Inc, Raritan, NJ). Methods: This randomized, 2-period, double-blind, placebo-controlled study was conducted within 1 menstrual cycle at 1 clinical center in the United States; 16 women were enrolled. Participants received NGM 0.25 mg/EE 0.035 mg throughout the study. During days 1 to 10, they were randomized to receive twice-daily DTG 50 mg or matching placebo with food and switched to the other treatment during days 12 to 21. Results: Ratios of area under the concentration-time curve from time 0 until end of the dosage interval (AUC(0-)), maximum plasma concentration, and concentration at the end of the dosage interval of norelgestromin with DTG treatment to the same PK parameters with placebo treatment were 0.975, 0.890, and 0.932, respectively; for EE, ratios were 1.03, 0.99, and 1.02, respectively. No significant differences in luteinizing hormone, follicle-stimulating hormone, and progesterone were detected on days 1, 10, 11, 21, and 22. DTG steady-state AUC(0-) was similar to historical data. No severe or grade 3/4 adverse events occurred. Conclusions: DTG had no effect on NGM/EE PK or PD. NGM/EE can be administered with DTG without dose adjustment.	[Song, Ivy H.; Borland, Julie; Chen, Shuguang; Peppercorn, Amanda F.; Piscitelli, Stephen C.] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; [Wajima, Toshihiro] Shionogi & Co Ltd, Osaka, Japan	Song, IH (reprint author), GlaxoSmithKline, Dept Clin Pharmacol, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	ivy.h.song@gsk.com			ViiV Healthcare	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this work was provided by ViiV Healthcare.	Song I, 2012, ANTIMICROB AGENTS CH, V56, P1627, DOI 10.1128/AAC.05739-11; Eron JJ, 2013, J INFECT DIS, V207, P740, DOI 10.1093/infdis/jis750; Tseng A, 2013, EXPERT OPIN DRUG MET, V9, P559, DOI 10.1517/17425255.2013.772579; Bennetto-Hood C, 2014, J CHROMATOGR B, V945, P225, DOI 10.1016/j.jchromb.2013.11.054; [Anonymous], 2013, TIV DOL; [Anonymous], 2010, ORTH CYCL NORG ETH E; Dooley KE, 2013, JAIDS-J ACQ IMM DEF, V62, P21, DOI 10.1097/QAI.0b013e318276cda9; Reese MJ, 2013, DRUG METAB DISPOS, V41, P353, DOI 10.1124/dmd.112.048918; Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09; Song I, 2013, DRUG ALCOHOL DEPEN, V133, P781, DOI 10.1016/j.drugalcdep.2013.08.009; BACK DJ, 1991, J STEROID BIOCHEM, V38, P219, DOI 10.1016/0960-0760(91)90129-S; BACK DJ, 1990, CLIN PHARMACOKINET, V18, P472; GUENGERICH FP, 1988, MOL PHARMACOL, V33, P500; Inglis AML, 2001, J CLIN PHARMACOL, V41, P683, DOI 10.1177/00912700122010456; Roy P, 2005, J CLIN PHARMACOL, V45, P329, DOI 10.1177/0091270004272732; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; Simonson SG, 2004, BRIT J CLIN PHARMACO, V57, P279, DOI 10.1111/j.1365-2125.2003.02015.x; Wilbur K, 2000, CLIN PHARMACOKINET, V38, P355, DOI 10.2165/00003088-200038040-00004	18	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	JUL	2015	49	7					784	789		10.1177/1060028015580637		6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CK8SK	WOS:000356508400005		
J	Hirano, K; Okumura, T; Shimada, Y; Watanabe, T; Yamaguchi, T; Nagata, T; Tsukada, K				Hirano, Katsuhisa; Okumura, Tomoyuki; Shimada, Yutaka; Watanabe, Toru; Yamaguchi, Tetsuji; Nagata, Takuya; Tsukada, Kazuhiro			Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines	ANTICANCER RESEARCH			English	Article						Pancreatic carcinoma; cell line characterization; chemotherapy	CANCER; ADENOCARCINOMA; GEMCITABINE; ERCC1; S-1; P53; CHEMOTHERAPY; POLYMORPHISM; EXPRESSION; SURVIVAL	Background: Pancreatic carcinoma (PC) is among the most lethal types of carcinomas worldwide. We aimed to establish well-defined PC cell lines in order to determine their resistance to chemotherapy. Materials and Methods: Cells cultured from the tumors of two patients were analyzed for xenograft formation, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and TP53 mutations, chemosensitivity, and mRNAs encoding rate-limiting enzymes that metabolize anticancer drugs. Results: The TYPK-1 and TYPK-2 cell lines were established from the lymph node of a locally advanced PC and from the ascites of a multi-metastatic and multi-chemoresistant PC, respectively. Each cell line generated tumors in nude mice. KRAS and TP53 mutations were detected in TYPK-1 but not TYPK-2 cells. TYPK-1 cells were resistant to gemcitabine, and TYPK-2 cells were resistant to oxaliplatin. The gemcitabine sensitivity of each cell line correlated with the expression of mRNAs encoding DCK and SLCAC29A1. Conclusion: TYPK-1 and TYPK-2 cells may contribute to investigations of resistance to anticancer drugs.	[Hirano, Katsuhisa; Okumura, Tomoyuki; Shimada, Yutaka; Watanabe, Toru; Yamaguchi, Tetsuji; Nagata, Takuya; Tsukada, Kazuhiro] Toyama Univ, Dept Surg & Sci, Toyama, Toyama 9390194, Japan	Okumura, T (reprint author), Toyama Univ, Dept Surg & Sci, 2630 Sugitani, Toyama, Toyama 9390194, Japan.	okumura@med.u-toyama.ac.jp					Okusaka T, 2008, CANCER CHEMOTH PHARM, V61, P615, DOI 10.1007/s00280-007-0514-8; Ueno H, 2013, J CLIN ONCOL, V31, P1640, DOI 10.1200/JCO.2012.43.3680; Sarkar FH, 2009, MINERVA CHIR, V64, P489; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Bilici A, 2014, WORLD J GASTROENTERO, V20, P10802, DOI 10.3748/wjg.v20.i31.10802; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Kato M, 1999, CANCER, V85, P832, DOI 10.1002/(SICI)1097-0142(19990215)85:4<832::AID-CNCR10>3.0.CO;2-7; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Fiorini C, 2015, BBA-MOL CELL RES, V1853, P89, DOI 10.1016/j.bbamcr.2014.10.003; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Kamikozuru H, 2008, INT J ONCOL, V32, P1091; Alexakis N, 2004, BRIT J SURG, V91, P1410, DOI 10.1002/bjs.4794; Konstantinidis IT, 2013, ANN SURG, V257, P731, DOI 10.1097/SLA.0b013e318263da2f; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Chang PMH, 2009, CANCER SCI, V100, P278, DOI 10.1111/j.1349-7006.2008.01031.x; Conroy T, N ENG J MED, V364, P1817; Fulushima M, 2001, EUR J CANCER, V37, P1681; Galmarini CM, 2002, INT J CANCER, V97, P439, DOI 10.1002/ijc.1628; IWAMURA T, 1987, JPN J CANCER RES, V78, P54; Kadera BE, 2014, JAMA SURG, V149, P145, DOI 10.1001/jamasurg.2013.2690; Kuramochi H, 2008, CANCER CHEMOTH PHARM, V63, P85, DOI 10.1007/s00280-008-0714-x; Mori R, 2007, ONCOL REP, V17, P1201; Sekine S, 2012, ANTICANCER RES, V32, P3211; Sobin LH, 2009, INT UNION CANC UICC	25	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					3821	3828				8	Oncology	Oncology	CL6YV	WOS:000357116400011		
J	Kuramitsu, Y; Wang, YF; Kitagawa, T; Tokuda, K; Akada, J; Tokunaga, M; Nakamura, K				Kuramitsu, Yasuhiro; Wang, Yufeng; Kitagawa, Takao; Tokuda, Kazuhiro; Akada, Junko; Tokunaga, Masayuki; Nakamura, Kazuyuki			High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells	ANTICANCER RESEARCH			English	Article						HMGB1; MAPKAPK2; gemcitabine-resistant; pancreatic cancer; HSP27	HEAT-SHOCK PROTEINS; HMGB1-MEDIATED AUTOPHAGY; DRUG-RESISTANCE; HSP27; APOPTOSIS; THERAPY; HELPS	Background: Results of our previous studies demonstrated that the expression of heat-shock protein 27 (HSP27) was increased and HSP27 was phosphorylated in the GEM-resistant pancreatic cancer cell line, KLM1-R. The expression of HSP27 is regulated mainly by heat-shock factor 1, but other transcription factors or kinases have been reported to activate HSP27. High-mobility group box 1 (HMGB1) is a nuclear transcription factor. It has been reported that HMGB1 regulates HSP27 gene expression. Mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK2) phosphorylates HSP27. In the present study, we investigated the expression of HMGB1 and MAPKAPK2 in KLM1-R cells. Materials and Methods: The expression levels of HMGB1 and MAPKAPK2 were compared between KLM1 and KLM1-R cells by western blotting. Results: The protein expression of both HMGB1 and MAPKAPK2 were increased in KLM1-R cells compared to KLM1 cells. Conclusion: The increase of both HMGB1 and MAPKAPK2 in KLM1-R cells compared to KLM1 suggest the possibility of the activation of the pathway of HSP27 by HMGB1 and MAPKAPK2 in gemcitabine-resistant KLM1-R cells.	[Kuramitsu, Yasuhiro; Wang, Yufeng; Kitagawa, Takao; Tokuda, Kazuhiro; Akada, Junko; Tokunaga, Masayuki; Nakamura, Kazuyuki] Yamaguchi Univ, Grad Sch Med, Dept Biochem & Funct Prote, Ube, Yamaguchi 7558505, Japan; [Nakamura, Kazuyuki] Tokuyama Med Assoc Hosp, Ctr Clin Labs, Yamaguchi, Japan	Kuramitsu, Y (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Biochem & Funct Prote, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	climates@yamaguchi-u.ac.jp					Mori-Iwamoto S, 2008, MOL MED REP, V1, P429; Gurgis FMS, 2014, MOL PHARMACOL, V85, P345, DOI 10.1124/mol.113.090365; Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008; Kang R, 2011, AUTOPHAGY, V7, P1256, DOI 10.4161/auto.7.10.16753; Suenaga S, 2014, ANTICANCER RES, V34, P141; Mori-Iwamoto S, 2009, PANCREAS, V38, P224, DOI 10.1097/MPA.0b013e3181773970; Kuramitsu Y, 2012, ANTICANCER RES, V32, P2295; Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3; Xiao JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089097; Acunzo J, 2012, INT J BIOCHEM CELL B, V44, P1622, DOI 10.1016/j.biocel.2012.04.002; Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001; Kim J, 2013, J ORAL PATHOL MED, V42, P9, DOI 10.1111/j.1600-0714.2012.01155.x; Taba K, 2011, CHEMOTHERAPY, V57, P12, DOI 10.1159/000321019; Taba K, 2010, ANTICANCER RES, V30, P2539; Maehara S, 2004, INT J CANCER, V112, P184, DOI 10.1002/ijc.20304; Mori-Iwamoto S, 2007, INT J ONCOL, V31, P1345; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; de Thonel A, 2012, INT J BIOCHEM CELL B, V44, P1593, DOI 10.1016/j.biocel.2012.06.012; Burris HA, 1997, J CLIN ONCOL, V15, P2403; Carmichael J, 1996, BRIT J CANCER, V73, P1; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P67, DOI 10.1007/BF00666207; Kim H, 2008, CHEMOTHERAPY, V54, P54, DOI 10.1159/000112417; Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165; Warsame R, 2012, EXPERT REV ANTICANC, V12, P1327, DOI [10.1586/era.12.115, 10.1586/ERA.12.115]	25	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					3861	3865				5	Oncology	Oncology	CL6YV	WOS:000357116400015		
J	Otsuka, T; Mori, M; Yano, Y; Uchida, J; Nishino, K; Kaji, R; Hata, A; Hattori, Y; Urata, Y; Kaneda, T; Tachihara, M; Imamura, F; Katakami, N; Negoro, S; Morita, S; Yokota, S				Otsuka, Tomoyuki; Mori, Masahde; Yano, Yukihiro; Uchida, Junji; Nishino, Kazumi; Kaji, Reiko; Hata, Akito; Hattori, Yoshihiro; Urata, Yoshiko; Kaneda, Toshihiko; Tachihara, Motoko; Imamura, Fumio; Katakami, Nobuyuki; Negoro, Shunichi; Morita, Satoshi; Yokota, Soichiro			Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)	ANTICANCER RESEARCH			English	Article						EGFR-TKI; gefitinib; erlotinib; non-small-cell lung cancer; minor EGFR mutation	EGFR MUTATIONS; OPEN-LABEL; 1ST-LINE TREATMENT; GEFITINIB; CHEMOTHERAPY; EFFICACY; ERLOTINIB; CLASSIFICATION; RESISTANCE; THERAPY	Aim: Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the L858R mutation in exon 21, is rare, and only few data exist on this patient population. The aim of the present study was to describe the clinical characteristics and to clarify the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in patients with NSCLC harboring minor mutations of the EGFR gene. Patients and Methods: This was a multicenter, retrospective study that analyzed specimens from patients with NSCLC who had minor EGFR gene mutations and were treated with EGFR-TKIs between June 2002 and March 2012. Results: Out of 56 patients with minor mutations of the EGFR gene, 44 were treated with either gefitinib or erlotinib. Mutation sites were G719X in exon 18 (n=35), L861Q in exon 21 (n=11), and G874S in exon 21 (n=1). Three patients had both the G719S and the L861Q mutation. The response rate to TKI treatment was 29.5%, and the disease control rate was 63.6%. The median progression-free survival (PFS) was 6.7 months [95% confidence interval (CI)= 2.06-8.66 months]. The median PFS was 7.2 months (95% CI= 4.23-12.3 months) in 32 patients who received first-or second-line treatment with EGFR-TKIs, whereas the median PFS was 1.57 months (95% CI= 0.73-3.8 months) in 12 patients treated with EGFR-TKIs as a third-line or later treatment. In multivariate Cox analysis, erlotinib therapy was associated with a longer PFS than gefitinib (p=0.025). Conclusion: Patients with NSCLC harboring minor mutations of the EGFR gene exhibited a modest response to EGFR-TKI treatment. Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first-or second-line option for patients with NSCLC with minor EGFR mutations.	[Otsuka, Tomoyuki; Mori, Masahde; Yano, Yukihiro; Yokota, Soichiro] Natl Hosp Org Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka 5608552, Japan; [Otsuka, Tomoyuki] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka, Japan; [Uchida, Junji; Nishino, Kazumi; Imamura, Fumio] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Oncol, Osaka, Japan; [Kaji, Reiko; Hata, Akito; Katakami, Nobuyuki] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan; [Hattori, Yoshihiro; Urata, Yoshiko] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan; [Kaneda, Toshihiko] Kobe City Med Ctr West Hosp, Dept Resp Med, Kobe, Hyogo, Japan; [Tachihara, Motoko] Kobe Univ, Grad Sch Med, Dept Resp Med, Kobe, Hyogo 657, Japan; [Negoro, Shunichi] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan; [Morita, Satoshi] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan	Mori, M (reprint author), Natl Hosp Org Toneyama Natl Hosp, Dept Thorac Oncol, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan.	mmori@toneyama.go.jp					Wu JY, 2008, CLIN CANCER RES, V14, P4877, DOI 10.1158/1078-0432.CCR-07-5123; Sun JM, 2009, JPN J CLIN ONCOL, V39, P27, DOI 10.1093/jjco/hyn118; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Kancha RK, 2009, CLIN CANCER RES, V15, P460, DOI 10.1158/1078-0432.CCR-08-1757; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Vallieres E, 2009, J THORAC ONCOL, V4, P1049, DOI 10.1097/JTO.0b013e3181b27799; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Murray S, 2008, J THORAC ONCOL, V3, P832, DOI 10.1097/JTO.0b013e31818071f3; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Wu JY, 2011, CLIN CANCER RES, V17, P3812, DOI 10.1158/1078-0432.CCR-10-3408; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Keam B, 2014, INT J CLIN ONCOL, V19, P594, DOI 10.1007/s10147-013-0602-1; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Igawa S, 2008, ANTICANCER RES, V28, P3855; Kubota K, 2009, J THORAC ONCOL, V4, P1530, DOI 10.1097/JTO.0b013e3181b9e608; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Watanabe S, 2014, J THORAC ONCOL, V9, P189, DOI 10.1097/JTO.0000000000000048; Yang JC, 2013, J THORAC ONCOL, V8	27	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					3885	3891				7	Oncology	Oncology	CL6YV	WOS:000357116400018		
J	Tamiya, M; Tokunaga, S; Okada, H; Suzuki, H; Sasada, S; Okamoto, N; Morishita, N; Shiroyama, T; Otsuka, T; Miyamoto, N; Taira, K; Daga, H; Takeda, K; Hirashima, T				Tamiya, Motohiro; Tokunaga, Shinya; Okada, Hideaki; Suzuki, Hidekazu; Sasada, Shinji; Okamoto, Norio; Morishita, Naoko; Shiroyama, Takayuki; Otsuka, Tomoyuki; Miyamoto, Natsuko; Taira, Koichi; Daga, Haruko; Takeda, Koji; Hirashima, Tomonori			Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study	ANTICANCER RESEARCH			English	Article						Cross-linked N-Telopeptides of type I collagen; NTx; bone metastasis; lung cancer	SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; PROSTATE-CANCER; METABOLIC MARKERS; DOUBLE-BLIND; DIAGNOSIS; DISEASE; SCINTIGRAPHY; GUIDELINES; DENOSUMAB	Background/Aim: The bone resorption biomarker cross-linked N-Telopeptides of type I collagen (NTx) has been shown to aid in the diagnosis of metastatic bone disease from lung cancer (MBDLC). Patients with MBDLC are often treated with zoledronic acid (ZA). ZA reduces the levels of NTx and also lowers the risk of skeletal adverse events in patients with MBDLC. Patients and Methods: Patients with MBDLC at initial diagnosis were included in the study. NTx was measured in serum (sNTx) once a month using the OSTEOMARKTM sNTx assay. MBDLC was assessed by monthly physical examinations and bone scintigraphy every 3 months for 12 months. Results: Twenty patients were enrolled between June and December 2010. The sNTx concentration at baseline was 19.8+/-5.8 nmol bone collagen equivalents (nmol BCE)/l. In the 16 patients receiving ZA, the level of sNTx significantly decreased after the first month of treatment (baseline vs. 1 month of treatment: 21.3+/-5.5 vs. 13.6+/-2.7 nmol BCE/l; p< 0.01). During the follow-up period, 13 of the patients treated with ZA experienced worsening of bone metastasis. There were statistically significant differences in the levels of sNTx at baseline (20.3+/-4.8 nmol BCE/l), at the lowest levels after administration of ZA (11.8+/-2.9 nmol BCE/l vs. baseline; p< 0.001), and at the time of measurable disease progression (14.1+/-4.6 nM BCE/l vs. baseline; p< 0.05). Conclusion: Serial measurements of sNTx in patients with MBDLC treated with ZA may effectively predict disease progression.	[Tamiya, Motohiro; Suzuki, Hidekazu; Okamoto, Norio; Morishita, Naoko; Shiroyama, Takayuki; Otsuka, Tomoyuki; Hirashima, Tomonori] Osaka Prefoctural Hosp Org, Dept Thorac Malignancy, Osaka Prefectural Med Ctr Resp & Allerg Dis, Habikino, Osaka 5838588, Japan; [Tokunaga, Shinya; Okada, Hideaki; Miyamoto, Natsuko; Taira, Koichi; Daga, Haruko; Takeda, Koji] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan; [Sasada, Shinji] Natl Canc Ctr, Resp Endoscopy Div, Dept Thorac Oncol, Tokyo, Japan	Tamiya, M (reprint author), Osaka Prefoctural Hosp Org, Dept Thorac Malignancy, Osaka Prefectural Med Ctr Resp & Allerg Dis, Habikino 3-7-1, Habikino, Osaka 5838588, Japan.	moto19781205@yahoo.co.jp					Delea T, 2004, ONCOLOGY-BASEL, V67, P390, DOI 10.1159/000082923; Chang MC, 2012, ACAD RADIOL, V19, P349, DOI 10.1016/j.acra.2011.10.018; Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z; Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304; Lein M, 2007, EUR UROL, V52, P1381, DOI 10.1016/j.eururo.2007.02.033; Mountzios G, 2011, CLIN LUNG CANCER, V12, P341, DOI 10.1016/j.cllc.2011.03.032; Tamiya M, 2013, CLIN LUNG CANCER, V14, P364, DOI 10.1016/j.cllc.2012.11.006; Spiro SG, 2002, AM J RESP CRIT CARE, V166, P1166, DOI 10.1064/rccm.200202-070S0; Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101; Atley LM, 2000, BONE, V26, P241, DOI 10.1016/S8756-3282(99)00270-7; Lipton A, 2001, CANCER TREAT REV, V27, P181, DOI 10.1053/ctrv.2001.0212; Nishizawa Y, 2013, J BONE MINER METAB, V31, P1, DOI 10.1007/s00774-012-0392-y; Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122; Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105; SOLOWAY MS, 1988, CANCER, V61, P195, DOI 10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y; Bayrak SB, 2012, INT J CLIN ONCOL, V17, P112, DOI 10.1007/s10147-011-0266-7; Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103; Hirsh V, 2008, J THORAC ONCOL, V3, P228, DOI 10.1097/JTO.0b013e3181651c0e; Izumi M, 2001, CANCER, V91, P1487, DOI 10.1002/1097-0142(20010415)91:8<1487::AID-CNCR1156>3.0.CO;2-2; Kaira R, 2010, INT J CLIN ONCOL, V15, P484, DOI 10.1007/s10147-010-0100-7; Kanakis I, 2004, J PHARMACEUT BIOMED, V34, P827, DOI 10.1016/S0731-7085(03)00567-3; Murakami H, 2014, CANCER SCI, V105, P989, DOI 10.1111/cas.12448; Pectasides D, 2005, ANTICANCER RES, V25, P1457; PEREZ DJ, 1983, LANCET, V2, P613; Tamiya M, 2013, CLIN LUNG CANCER, V14, P50, DOI 10.1016/j.cllc.2012.03.012; Yamaguchi T, 2001, Semin Musculoskelet Radiol, V5, P171, DOI 10.1055/s-2001-15676	27	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					3987	3993				7	Oncology	Oncology	CL6YV	WOS:000357116400030		
J	Yoshino, T; Yamazaki, K; Gotoh, M; Nasroulah, F; Gao, L; Yoshizuka, N; Ohtsu, A				Yoshino, Takayuki; Yamazaki, Kentaro; Gotoh, Masahiro; Nasroulah, Federico; Gao, Ling; Yoshizuka, Naoto; Ohtsu, Atsushi			Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma	ANTICANCER RESEARCH			English	Article						Ramucirumab; metastatic colorectal carcinoma; Japanese patients; FOLFIRI; pharmacokinetics	RANDOMIZED PHASE-3 TRIAL; CANCER; FLUOROURACIL; IRINOTECAN; PLACEBO; MONOTHERAPY; MULTICENTER; LEUCOVORIN; RECEPTOR-2	Background: This phase Ib study evaluated the pharmacokinetic profile and safety of ramucirumab, a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor 2, in combination with irinotecan, levofolinate and 5-fluorouracil (FOLFIRI) in Japanese patients with metastatic colorectal carcinoma (mCRC). Patients and Methods: Eligible patients had Eastern Cooperative Oncology Group performance status 0-1, and disease progression during or within 6 months following first-line therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. Six enrolled patients received 8 mg/kg ramucirumab plus FOLFIRI every 2 weeks. Results: One out of six patients experienced a dose-limiting toxicity (grade 2 proteinuria and grade 4 neutropenia, resulting in a dose delay > 2 weeks). All patients experienced at least one grade 3 or higher adverse event: neutropenia (five patients, 83%), proteinuria (two patients; 33%) and anemia, thrombocytopenia and hypertension (one patient each, 17%). There were no serious adverse events or deaths. Conclusion: Ramucirumab plus FOLFIRI was well-tolerated in Japanese patients with mCRC, warranting further investigation of this combination therapy.	[Yoshino, Takayuki; Ohtsu, Atsushi] Natl Canc Ctr Hosp East, Kashiwa, Chiba 2778577, Japan; [Yamazaki, Kentaro] Shizuoka Canc Ctr, Shizuoka, Japan; [Gotoh, Masahiro] Osaka Med Coll Hosp, Takatsuki, Osaka, Japan; [Nasroulah, Federico; Gao, Ling] Eli Lilly & Co, Bridgewater, NJ USA; [Yoshizuka, Naoto] Eli Lilly Japan KK, Kobe, Hyogo, Japan	Yoshino, T (reprint author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	tyoshino@east.ncc.go.jp					Deng R, 2012, EXPERT OPIN DRUG MET, V8, P141, DOI 10.1517/17425255.2012.643868; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0; Zhu AX, 2013, CLIN CANCER RES, V19, P6614, DOI 10.1158/1078-0432.CCR-13-1442; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Spratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Wang D, 2015, J CLIN ONCOL S3, V33; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6	15	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4003	4007				5	Oncology	Oncology	CL6YV	WOS:000357116400032		
J	Akamine, T; Ando, K; Oki, E; Saeki, H; Nakashima, Y; Imamura, Y; Ohgaki, K; Maehara, Y				Akamine, Takaki; Ando, Koji; Oki, Eiji; Saeki, Hiroshi; Nakashima, Yuichiro; Imamura, Yu; Ohgaki, Kippei; Maehara, Yoshihiko			Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report	ANTICANCER RESEARCH			English	Article						GIST; regorafenib monotherapy; liver failure; case report	GASTROINTESTINAL STROMAL TUMORS; INTERSTITIAL-CELLS; PHASE-3 TRIAL; IMATINIB; MULTICENTER; MANAGEMENT; EFFICACY; DISEASE; SAFETY; CAJAL	Background/Aim: Regorafenib has been approved for treatment of patients with unresectable or recurrent gastrointestinal stromal tumors resistant to imatinib or sunitinib. However, regorafenib has severe side-effects, including acute liver failure. We describe the case of a patient with multiple liver metastases of a small intestinal stromal tumor who experienced acute liver failure while being treated with regorafenib. Case Report: A 50-year-old patient with an unresectable small intestinal stromal tumor resistant to prior treatment with imatinib and sunitinib was started on regorafenib, but experienced acute liver failure 10 days later. Plasma exchange and steroid pulse treatment improved her liver function. During liver failure, abdominal ultrasonography showed to-and-fro flow in the portal vein. Lactate dehydrogenase concentration was markedly elevated to 1633 U/l. These findings indicate that liver failure in this patient was due to impaired liver blood flow. Conclusion: Regorafenib may impair liver blood flow, inducing acute liver failure.	[Akamine, Takaki; Ando, Koji; Oki, Eiji; Saeki, Hiroshi; Nakashima, Yuichiro; Imamura, Yu; Ohgaki, Kippei; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8218582, Japan	Oki, E (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8218582, Japan.	okieiji@surg2.med.kyushu-u.ac.jp					Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Robinson TL, 2000, AM J PATHOL, V156, P1157, DOI 10.1016/S0002-9440(10)64984-X; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; De Wit M, 2014, SUPPORT CARE CANCER, V22, P837, DOI 10.1007/s00520-013-2085-z; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Czauderna P, 2000, EUR J PEDIATR SURG, V10, P300, DOI 10.1055/s-2008-1072380; Henry JB, 2001, CLIN DIAGNOSIS MANAG, V20th; Ortega JA, 1997, CANCER-AM CANCER SOC, V79, P2435, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2435::AID-CNCR21>3.0.CO;2-R; Yoshino T, 2014, INVESTIGATIONAL NEW	12	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4037	4041				5	Oncology	Oncology	CL6YV	WOS:000357116400036		
J	Sugita, K; Kawakami, K; Yokokawa, T; Mae, Y; Toya, W; Hagino, A; Suzuki, K; Suenaga, M; Mizunuma, N; Yamaguchi, T; Hama, T				Sugita, Kazuo; Kawakami, Kazuyoshi; Yokokawa, Takashi; Mae, Yutaro; Toya, Wataru; Hagino, Akane; Suzuki, Kenichi; Suenaga, Mitsukuni; Mizunuma, Nobuyuki; Yamaguchi, Toshiharu; Hama, Toshihiro			Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer	ANTICANCER RESEARCH			English	Article						hypothyroidism; regorafenib; thyroid-stimulating hormone; metastatic colorectal cancer	CAPILLARIES; GUIDELINES; DIAGNOSIS	Hypothyroidism is one of the side-effects caused by regorafenib. In the Japanese subset of the CORRECT study, hypothyroidism developed in 1.5% of the patients, but was not grade 3 or higher in any patient. Regorafenib is an oral multi-kinase inhibitor that has the same mechanism of action as sunitinb. However, the reported incidence of sunitinb-related hypothyroidism varies widely, ranging from 16.0% in clinical trials to 35.4% in post-marketing surveillance studies. In general, symptoms of hypothyroidism include fatigue and dysphonia. Hyperthyroidism must, therefore, be appropriately managed in order to maintain patient quality of life and avoid a critical level of hypothyroidism. During the first cycle of treatment with regorafenib, the incidence of abnormal thyroid-stimulating hormone (TSH) elevation was 31.4%. Our results suggest that thyroid function tests should be performed from day 1 of treatment with regorafenib. It would be prudent to consider routine monitoring of thyroid function in all patients who receive regorafenib and to recommend endocrinological consultation as necessary.	[Sugita, Kazuo; Kawakami, Kazuyoshi; Yokokawa, Takashi; Mae, Yutaro; Toya, Wataru; Hagino, Akane; Suzuki, Kenichi; Hama, Toshihiro] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pharm, Koto Ku, Tokyo 1358550, Japan; [Suenaga, Mitsukuni; Mizunuma, Nobuyuki; Yamaguchi, Toshiharu] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Koto Ku, Tokyo 1358550, Japan	Sugita, K (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pharm, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	kazuo.sugita@jfcr.or.jp					Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Wolter P, 2008, BRIT J CANCER, V99, P448, DOI 10.1038/sj.bjc.6604497; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Desai J, 2006, ANN INTERN MED, V145, P660; Jiskra J, 2004, PHYSIOL RES, V53, P693; Wong E, 2007, THYROID, V17, P351, DOI 10.1089/thy.2006.0308; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005; Japan Thyroid Association, 2010, GUID DIAGN THYR DIS; Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005; Laurberg P, 2005, DRUG AGING, V22, P23, DOI 10.2165/00002512-200522010-00002; Pfizer Japan, 2012, POSTM SURV SUT 12 5; Pfizer Japan, 2012, SUT APPR US GUID; Shah Monica, 2006, Dermatol Online J, V12, P1; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; Tamaskar I, 2008, ANN ONCOL, V19, P265, DOI 10.1093/annonc/mdm483	16	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4059	4062				4	Oncology	Oncology	CL6YV	WOS:000357116400039		
J	Hu, Q; Takeishi, K; Yamashita, YI; Ikeda, T; Wang, H; Itoh, S; Harimoto, N; Ikegami, T; Yoshizumi, T; Kawanaka, H; Shikabe, K; Maehaka, Y				Hu, Qingjiang; Takeishi, Kazuki; Yamashita, Yo-Ichi; Ikeda, Tetsuo; Wang, Huanlin; Itoh, Shinji; Harimoto, Norifumi; Ikegami, Toku; Yoshizumi, Tomohaku; Kawanaka, Hirofumi; Shikabe, Ken; Maehaka, Yoshihiko			Splenectomy Followed by Hepatectomy for Hepatocellular Carcinoma with Hypersplenism and Portal Hypertension Caused by Macroglobulinemia	ANTICANCER RESEARCH			English	Article						Splenectomy; hepatocellular carcinoma; hypersplenism; primary macroglobulinemia	LIVER-CIRRHOSIS; LAPAROSCOPIC SPLENECTOMY; VEIN THROMBOSIS; IMPACT; EXPERIENCE	Aim: To describe a patient with hepatocellular carcinoma (HCC), accompanied by hypersplenism and portal hypertension caused by macroglobulinemia, who underwent splenectomy followed by hepatectomy. Case Report: A 74-year-old man was admitted to our Hospital. He had previously developed primary macroglobulinemia, which had been completely cured by chemotherapy. At admission, he had a low platelet count (52x10(3)/mu l), and his liver function was impaired. Imaging showed a 5-cm-sized tumor, an esophageal varix, and splenomegaly, but not liver cirrhosis. The patient underwent splenectomy for hypersplenism and portal hypertension; the weight of his spleen was 2,400 g. After splenectomy, his platelet count increased to 259x10(3)/mu l and his liver function was improved. He safely underwent hepatectomy for HCC. The patient was discharged 14 days later without morbidity. Conclusion: These findings suggest that hepatectomy following splenectomy for hypersplenism and portal hypertension caused by macroglobulinemia, may effectively cure HCC in patients with liver dysfunction and thrombocytopenia.	[Hu, Qingjiang; Takeishi, Kazuki; Yamashita, Yo-Ichi; Ikeda, Tetsuo; Wang, Huanlin; Itoh, Shinji; Harimoto, Norifumi; Ikegami, Toku; Yoshizumi, Tomohaku; Kawanaka, Hirofumi; Shikabe, Ken; Maehaka, Yoshihiko] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan	Takeishi, K (reprint author), Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	qj_hu@surg2.med.kyushu-u.ac.jp					Anegawa G, 2009, J GASTROEN HEPATOL, V24, P1554, DOI 10.1111/j.1440-1746.2009.05906.x; Shimada M, 2000, SURG ENDOSC-ULTRAS, V14, P127; Santos FPS, 2014, LEUKEMIA LYMPHOMA, V55, P121, DOI 10.3109/10428194.2013.794269; Kawanaka H, 2014, J AM COLL SURGEONS, V219, P865, DOI 10.1016/j.jamcollsurg.2014.07.939; Iwakiri Y, 2012, LIVER INT, V32, P199, DOI 10.1111/j.1478-3231.2011.02579.x; Yamashita Y, 2007, J AM COLL SURGEONS, V205, P19, DOI 10.1016/j.jamcollsurg.2007.01.069; Kawanaka H, 2010, ANN SURG, V251, P76, DOI 10.1097/SLA.0b013e3181bdf8ad; Imura S, 2010, HEPATOL RES, V40, P894, DOI 10.1111/j.1872-034X.2010.00688.x; Kinjo N, 2010, BRIT J SURG, V97, P910, DOI 10.1002/bjs.7002; Kawanaka H, 2009, J HEPATO-BILIARY-PAN, V16, P749, DOI 10.1007/s00534-009-0149-8; Toshima T, 2011, J GASTROENTEROL, V46, P705, DOI 10.1007/s00535-010-0365-7; Sugawara Y, 2000, J AM COLL SURGEONS, V190, P446, DOI 10.1016/S1072-7515(99)00294-X; Chen XP, 2005, BRIT J SURG, V92, P334, DOI 10.1002/bjs.4776; Hanazaki K, 2000, J AM COLL SURGEONS, V191, P341, DOI 10.1016/S1072-7515(00)00364-1; Kawanaka H, 2014, BRIT J SURG, V101, P1585, DOI 10.1002/bjs.9622; Manenti A, 2014, CLIN LYMPHO IN PRESS, DOI [10.1016/j.clml.2014.10.005, DOI 10.1016/J.CLML.2014.10.005]; Toros AB, 2013, ISRN HEMATOL, V2013, DOI DOI 10.1155/2013/673781; Wang C, 2012, HEPATO-GASTROENTEROL, V59, P526, DOI 10.5754/hge11260	18	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4077	4081				5	Oncology	Oncology	CL6YV	WOS:000357116400042		
J	Matsumoto, K; Nakamura, K; Shioyama, Y; Sasaki, T; Ohga, S; Yamaguchi, T; Yoshitake, T; Asai, K; Kakiuchi, G; Honda, H				Matsumoto, Keiji; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Sasaki, Tomonari; Ohga, Saiji; Yamaguchi, Toshihiro; Yoshitake, Tadamasa; Asai, Kaori; Kakiuchi, Genyu; Honda, Hiroshi			Treatment Planning Comparison for Carbon Ion Radiotherapy, Proton Therapy and Intensity-modulated Radiotherapy for Spinal Sarcoma	ANTICANCER RESEARCH			English	Article						Carbon ion radiotherapy; proton therapy; patch-field technique; intensity-modulated radiotherapy; spinal sarcoma	RELATIVE BIOLOGICAL EFFECTIVENESS; CHARGED-PARTICLE RADIOTHERAPY; RADIATION-THERAPY; PHASE-II; PHOTON; IRRADIATION; CHORDOMAS; TUMORS; BEAMS	Background/Aim: Carbon ion radiotherapy (CIRT), proton therapy (PT) and intensity-modulated radiotherapy (IMRT) are new radiation modalities suitable for treatment of spinal sarcomas. The objective of the study was to compare the treatment planning of these modalities. Patients and Methods: We conducted a treatment planning comparison of the three modalities using a phantom imitating a spinal sarcoma and then six actual cases with spinal tumors. A uniform biological effective dose (BED) of 90 Gy(10) was prescribed in previously reported fractionation schedules for each modality. The surface/center spinal cord dose constraints were set to BED of 96/77 Gy(E)(3), respectively. Results: CIRT achieved better homogeneity of dose distribution and coverage of target than PT independently of tumor extent around the spinal cord. In IMRT plans, the spinal cord dose was higher than that under CIRT and PT and coverage of the target deteriorated depending on the tumor extension. Conclusion: CIRT was most appropriate for the treatment of advanced spinal sarcomas.	[Matsumoto, Keiji; Nakamura, Katsumasa; Sasaki, Tomonari; Ohga, Saiji; Yamaguchi, Toshihiro; Yoshitake, Tadamasa; Asai, Kaori; Honda, Hiroshi] Kyushu Univ, Dept Clin Radiol, Grad Sch Med Sci, Fukuoka 8128582, Japan; [Shioyama, Yoshiyuki; Kakiuchi, Genyu] SAGA HIMAT Fdn, Ion Beam Therapy Ctr, Tosu, Saga, Japan	Nakamura, K (reprint author), Kyushu Univ, Dept Clin Radiol, Grad Sch Med Sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	nakam@radiol.med.kyushu-u.ac.jp					Tsujii H, 2012, JPN J CLIN ONCOL, V42, P670, DOI 10.1093/jjco/hys104; Matsumoto K, 2013, CANCER-AM CANCER SOC, V119, P3496, DOI 10.1002/cncr.28177; Paganetti H, 2002, INT J RADIAT ONCOL, V53, P407, DOI 10.1016/S0360-3016(02)02754-2; Imai R, 2010, INT J RADIAT ONCOL, V77, P1470, DOI 10.1016/j.ijrobp.2009.06.048; Weber U, 2009, CANCER J, V15, P325, DOI 10.1097/PPO.0b013e3181b01935; Terezakis SA, 2007, INT J RADIAT ONCOL, V69, P1502, DOI 10.1016/j.ijrobp.2007.05.019; Delaney TF, 2014, J SURG ONCOL, V110, P115, DOI 10.1002/jso.23617; Kamada T, 2002, J CLIN ONCOL, V20, P4466, DOI 10.1200/JCO.2002.10.050; Suzuki M, 2000, INT J RADIAT ONCOL, V48, P241, DOI 10.1016/S0360-3016(00)00568-X; Bragg CM, 2006, RADIOTHER ONCOL, V81, P315, DOI 10.1016/j.radonc.2006.10.020; Hill PM, 2013, PHYS MED BIOL, V58, P5527, DOI 10.1088/0031-9155/58/16/5527; HUG EB, 1995, INT J RADIAT ONCOL, V31, P467, DOI 10.1016/0360-3016(94)00390-7; Hug EB, 2001, MED PEDIATR ONCOL, V37, P36, DOI 10.1002/mpo.1160; Hug EB, 2000, INT J RADIAT ONCOL, V47, P979, DOI 10.1016/S0360-3016(00)00545-9; Li YP, 2007, PHYS MED BIOL, V52, pN265, DOI 10.1088/0031-9155/52/12/N01; Marucci L, 2004, INT J RADIAT ONCOL, V59, P551, DOI 10.1016/j.ijrobp.2003.10.058; NOWAKOWSKI VA, 1992, INT J RADIAT ONCOL, V22, P295; Petti PL, 1996, INT J RADIAT ONCOL, V35, P1049, DOI 10.1016/0360-3016(96)00233-7; PETTI PL, 1992, MED PHYS, V19, P137, DOI 10.1118/1.596887; Rutz HP, 2007, INT J RADIAT ONCOL, V67, P512, DOI 10.1016/j.ijrobp.2006.08.052; Talac R, 2002, CLIN ORTHOP RELAT R, P127; Weber DC, 2004, INT J RADIAT ONCOL, V58, P1596, DOI 10.1016/j.ijrobp.2003.11.028	22	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4083	4089				7	Oncology	Oncology	CL6YV	WOS:000357116400043		
J	Toyokawa, T; Ohira, M; Sakurai, K; Kubo, N; Tanaka, H; Muguruma, K; Hirakawa, K				Toyokawa, Takahiro; Ohira, Masaichi; Sakurai, Katsunobu; Kubo, Naoshi; Tanaka, Hiroaki; Muguruma, Kazuya; Hirakawa, Kosei			The Role of Adjuvant Chemotherapy for Patients with Stage IB Gastric Cancer	ANTICANCER RESEARCH			English	Article						Gastric cancer; adjuvant chemotherapy; stage IB	LYMPH-NODE METASTASIS; PROGNOSTIC-SIGNIFICANCE; URACIL-TEGAFUR; SURGERY; ADENOCARCINOMA; SUBCLASSIFICATION; TRIAL; CLASSIFICATION; METAANALYSIS; INVASION	Aim: The present study aimed to examine the survival benefit of adjuvant chemotherapy for the patients with stage IB gastric cancer according to the second English edition of the Japanese Classification of Gastric Carcinoma (2nd JCGC). Patients and Methods: In total, 201 consecutive patients who underwent curative surgery for stage IB gastric cancer according to the 2nd JCGC were retrospectively analyzed. Results: Seventy-four (36.8%) received adjuvant chemotherapy, and 72 (35.8%) had stage II diseases as defined by the 3rd JCGC. The 5-year overall survival (OS) was 86.9%. Multivariate analysis showed that adjuvant chemotherapy was an independent prognostic factor. In the sub-group analysis by stage according to the 3rd JCGC, those with stage II disease had better OS in the adjuvant-chemotherapy group than in the group treated with surgery alone (5-year OS 94.5% vs. 73.9%, p=0.002). Conclusion: Among patients with stage IB gastric cancer by 2nd JCGC, and especially patients with stage II defined by the 3rd JCGC, should be considered for adjuvant-chemotherapy.	[Toyokawa, Takahiro; Ohira, Masaichi; Sakurai, Katsunobu; Kubo, Naoshi; Tanaka, Hiroaki; Muguruma, Kazuya; Hirakawa, Kosei] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Osaka 5458585, Japan	Ohira, M (reprint author), Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	masaichi@med.osaka-cu.ac.jp					Nashimoto A, 2013, GASTRIC CANCER, V16, P1, DOI 10.1007/s10120-012-0163-4; Ahn HS, 2010, CANCER-AM CANCER SOC, V116, P5592, DOI 10.1002/cncr.25550; Roviello F, 2006, J SURG ONCOL, V94, P275, DOI 10.1002/jso.20566; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; [Anonymous], 2011, GASTRIC CANC, V14, P101; Nakajima T, 2007, BRIT J SURG, V94, P1468, DOI 10.1002/bjs.5996; Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534; Yamashita K, 2008, GASTRIC CANCER, V11, P111, DOI 10.1007/s10120-008-0466-7; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Sun P, 2009, BRIT J SURG, V96, P26, DOI 10.1002/bjs.6408; Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792; Araki I, 2015, GASTRIC CANCER, V18, P297, DOI 10.1007/s10120-014-0362-2; Bando E, 2004, BRIT J SURG, V91, P1197, DOI 10.1002/bjs.4541; Bilici A, 2011, DIGEST DIS SCI, V56, P3226, DOI 10.1007/s10620-011-1721-z; Huang BJ, 2009, ANN SURG ONCOL, V16, P61, DOI 10.1245/s10434-008-0193-7; Japanese Gastric Cancer Association, 2011, GASTRIC CANCER, V14, P113, DOI [10.1007/s10120-011-0042-4, DOI 10.1007/S10120-011-0042-4]]; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI DOI 10.1007/S101209800016]; Kunisaki C, 2010, SURGERY, V147, P204, DOI 10.1016/j.surg.2009.08.012; Lu Y, 2008, SURG ONCOL, V17, P317, DOI 10.1016/j.suronc.2008.05.005; Nitti D, 2009, BRIT J SURG, V96, P398, DOI 10.1002/bjs.6487; Noguchi S, 2005, J CLIN ONCOL, V23, P2172, DOI 10.1200/JCO.2005.02.158; Park DJ, 2007, SURGERY, V141, P757, DOI 10.1016/j.surg.2007.01.023; Saka M, 2008, GASTRIC CANCER, V11, P214, DOI 10.1007/s10120-008-0485-4; Sakamoto Junichi, 2004, J Clin Oncol, V22, P484; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Shimada S, 2001, Gastric Cancer, V4, P54, DOI 10.1007/PL00011724; Yokoyama T, 2011, GASTRIC CANCER, V14, P372, DOI 10.1007/s10120-011-0051-3	28	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4091	4097				7	Oncology	Oncology	CL6YV	WOS:000357116400044		
J	Nakanoko, T; Koga, T; Taketani, K; Hirayama, Y; Yoshiya, S; Minagawa, R; Kai, M; Kajiyama, K; Maehara, Y				Nakanoko, Tomonori; Koga, Tadashi; Taketani, Kenji; Hirayama, Yoshie; Yoshiya, Shohei; Minagawa, Ryosuke; Kai, Masanori; Kajiyama, Kiyoshi; Maehara, Yoshihiko			Characteristics and Treatment Strategies for Small Bowel Adenocarcinoma in Advanced-stage Cases	ANTICANCER RESEARCH			English	Article						small bowel adenocarcinoma; curative surgery; definitive chemotherapy; recurrent tumor resection; distant metastasis; unresectable case	SMALL-INTESTINE; REGIONAL ENTERITIS; PROGNOSTIC-FACTORS; TUMORS; CHEMOTHERAPY; NEOPLASMS; DIAGNOSIS	Background: Small bowel adenocarcinoma is an uncommon disease with poor prognosis. Therefore, characteristics and treatment strategies for small bowel adenocarcinoma should be elucidated sufficiently, not only for surgery, but also for chemotherapy. Patients and Methods: Medical records were abstracted to identify patients with small bowel adenocarcinoma who were treated at the Iizuka Hospital, Fukuoka, Japan, between 2004 and 2014. The results of surgical treatment for stage II/III cases and the efficacy of chemotherapy for unresectable stage IV cases were investigated. Results: The median tumor size was 25.6 +/- 19.2 mm, and tumor size was not associated with primary symptoms. Nine of the patients were diagnosed with stage II/III disease and underwent surgical resection. The other three patients were diagnosed with stage IV disease, and two out of those three cases received definitive chemotherapy. In two out of the nine resected cases, recurrence was observed; however, surgical resection of the recurrent tumor was associated with a good prognosis. In stage IV cases that received chemotherapy, survival durations of over 11 months were achieved. In contrast, overall survival in the stage IV case without chemotherapy was 3.3 months. Conclusion: Curative resection and definitive chemotherapy for unresectable cases are effective treatment strategies for small bowel adenocarcinoma.	[Nakanoko, Tomonori; Koga, Tadashi; Taketani, Kenji; Hirayama, Yoshie; Yoshiya, Shohei; Minagawa, Ryosuke; Kai, Masanori; Kajiyama, Kiyoshi] Iizuka Hosp, Fukuoka, Japan; [Maehara, Yoshihiko] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan	Maehara, Y (reprint author), Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	maehara@surg2.med.kyushu.u.ac.jp					Zaanan A, 2010, ANN ONCOL, V21, P1786, DOI 10.1093/annonc/mdq038; Agrawal S, 2007, ANN SURG ONCOL, V14, P2263, DOI 10.1245/s10434-007-9428-2; Dabaja BS, 2004, CANCER, V101, P518, DOI 10.1002/cncr.20404; Horton KM, 2004, J COMPUT ASSIST TOMO, V28, P106, DOI 10.1097/00004728-200401000-00019; Cobrin GM, 2006, CANCER, V107, P22, DOI 10.1002/cncr.21975; Bilimoria KY, 2009, ANN SURG, V249, P63, DOI [10.1097/SLA.0b013e31818e4641, 10.1097/SLA.0b013e31818c4641]; Bakaeen FG, 2000, ARCH SURG-CHICAGO, V135, P635, DOI 10.1001/archsurg.135.6.635; CIRESI DL, 1995, AM SURGEON, V61, P698; COLLIER PE, 1985, CANCER, V55, P516, DOI 10.1002/1097-0142(19850201)55:3<516::AID-CNCR2820550308>3.0.CO;2-K; JIGYASU D, 1984, CANCER, V53, P23, DOI 10.1002/1097-0142(19840101)53:1<23::AID-CNCR2820530106>3.0.CO;2-U; Minardi AJ, 1998, J AM COLL SURGEONS, V186, P664, DOI 10.1016/S1072-7515(98)00092-1; NESBIT RR, 1976, CANCER, V37, P2948, DOI 10.1002/1097-0142(197606)37:6<2948::AID-CNCR2820370652>3.0.CO;2-K; Pan Sai Yi, 2011, World J Gastrointest Oncol, V3, P33, DOI 10.4251/wjgo.v3.i3.33; Reynolds I, 2014, SURG-J R COLL SURG E, V12, P263, DOI 10.1016/j.surge.2014.02.003; RIBEIRO MB, 1991, SURG GYNECOL OBSTET, V173, P343; Shenoy Santosh, 2014, J Gastrointest Cancer, V45, P421, DOI 10.1007/s12029-014-9658-z; Singhal N, 2007, COCHRANE DB SYST REV; Sobin LH, 2010, TNM CLASSIFICATION M; Tsang H, 2008, GUT, V57, P1631, DOI 10.1136/gut.2008.153866; Van Weyenberg SJB, 2010, RADIOLOGY, V254, P765, DOI 10.1148/radiol.09090828; Xiang XJ, 2012, ANTI-CANCER DRUG, V23, P561, DOI 10.1097/CAD.0b013e328350dd0d; Zaanan A, 2011, CANCER-AM CANCER SOC, V117, P1422, DOI 10.1002/cncr.25614; Zouhairi Majed El, 2008, Curr Treat Options Oncol, V9, P388, DOI 10.1007/s11864-009-0098-0	23	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4135	4138				4	Oncology	Oncology	CL6YV	WOS:000357116400051		
J	Harimoto, N; Ikeda, T; Takeishi, K; Itoh, S; Yamashita, YI; Ikegami, T; Yoshizumi, T; Kawanaka, H; Shirabe, K; Maehara, Y				Harimoto, Nokifumi; Ikeda, Tetsuo; Takeishi, Kazuki; Itoh, Shinji; Yamashita, Yo-Ichi; Ikegami, Toru; Yoshizumi, Tomoharu; Kawanaka, Hirofumi; Shirabe, Ken; Maehara, Yoshihiko			Outcomes After Laparoscopic Hepatectomy in the Semi-prone Position for Hepatocellular Carcinoma Located in Segment 6, 7, or 8	ANTICANCER RESEARCH			English	Article						hepatocellular carcinoma; laparoscopic hepatectomy; semi-prone position	LONG-TERM OUTCOMES; SINGLE-CENTER-EXPERIENCE; LIVER RESECTION; HEPATIC RESECTION; TUMORS; METAANALYSIS; POSTEROSUPERIOR; MORBIDITY	Background: This retrospective study investigated outcomes after laparoscopic hepatectomy in the semi-prone position compared to open hepatectomy in the conventional supine position, for HCC (hepatocellular carcinoma) located in segment 6, 7, or 8. Patients and Methods: Patients were divided into two groups according to the surgical approach. The clinicopathological and surgical outcomes were analyzed. Results: There were no significant differences in patient-related or tumor-related factors between the two groups. The laparoscopic-hepatectomy group had significantly less blood loss, fewer postoperative complications, and a shorter hospital stay than the open-hepatectomy group. There were no in-hospital deaths. The postoperative change in the serum C-reactive protein was a significantly larger decrease in the group treated with laparoscopic hepatectomy than that in the open-hepatectomy group. Conclusion: Laparoscopic hepatectomy in the semi-prone position for HCC is safe and minimally invasive, and can reduce intraoperative bleeding, postoperative complications, and hospital stay compared to open hepatectomy.	[Harimoto, Nokifumi; Ikeda, Tetsuo; Takeishi, Kazuki; Itoh, Shinji; Yamashita, Yo-Ichi; Ikegami, Toru; Yoshizumi, Tomoharu; Kawanaka, Hirofumi; Shirabe, Ken; Maehara, Yoshihiko] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan	Harimoto, N (reprint author), Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	harimoto@surg2.med.kyushu-u.ac.jp					Mirnezami R, 2011, HPB, V13, P295, DOI 10.1111/j.1477-2574.2011.00295.x; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Kazaryan AM, 2011, SURG ENDOSC, V25, P3881, DOI 10.1007/s00464-011-1815-x; Taketomi A, 2007, J AM COLL SURGEONS, V204, P580, DOI 10.1016/j.jamcollsurg.2007.01.035; Ikeda T, 2014, SURG ENDOSC, V28, P2484, DOI 10.1007/s00464-014-3469-y; Sarpel U, 2009, ANN SURG ONCOL, V16, P1572, DOI 10.1245/s10434-009-0414-8; Lee W, 2014, J HEPATO-BIL-PAN SCI, V21, pE65, DOI 10.1002/jhbp.123; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Shimada M, 1998, BRIT J SURG, V85, P195; Xiong JJ, 2012, WORLD J GASTROENTERO, V18, P6657, DOI 10.3748/wjg.v18.i45.6657; Parks KR, 2014, HPB, V16, P109, DOI 10.1111/hpb.12117; Cheung TT, 2013, ANN SURG, V257, P506, DOI 10.1097/SLA.0b013e31827b947a; Cho JY, 2008, SURGERY, V144, P32, DOI 10.1016/j.surg.2008.03.020; Takenaka K, 1996, ARCH SURG-CHICAGO, V131, P71; Yin Z, 2013, ANN SURG ONCOL, V20, P1203, DOI 10.1245/s10434-012-2705-8; Cho JY, 2009, ARCH SURG-CHICAGO, V144, P25, DOI 10.1001/archsurg.2008.510; Kiyosawa K, 2002, ONCOLOGY-BASEL, V62, P5, DOI 10.1159/000048269; Hashizume M, 2000, HEPATOB PANCREAT DIS, V7, P270, DOI [10.1007/s005340000070270.534, DOI 10.1007/S005340000070270.534]; Hirokawa F, 2015, SURG ENDOSC, V29, P458, DOI 10.1007/s00464-014-3687-3; Ikeda T, 2011, SURG TODAY, V41, P1592, DOI 10.1007/s00595-010-4479-6; Ikeda T, 2013, J HEPATO-BIL-PAN SCI, V20, P145, DOI 10.1007/s00534-012-0558-y; Liver cancer study group of Japan, 2003, GEN RUL CLIN PATH ST, P34; Shimada M, 2001, SURG ENDOSC-ULTRAS, V15, P541, DOI 10.1007/s004640080099; Uchiyama H, 2013, SURG LAPARO ENDO PER, V23, pE116, DOI 10.1097/SLE.0b013e3182806535	24	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4167	4170				4	Oncology	Oncology	CL6YV	WOS:000357116400057		
J	Tsubamoto, H; Sonoda, T; Ikuta, S; Tani, S; Inoue, K; Yamanaka, N				Tsubamoto, Hiroshi; Sonoda, Takashi; Ikuta, Shinichi; Tani, Satoshi; Inoue, Kayo; Yamanaka, Naoki			Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting	ANTICANCER RESEARCH			English	Article						Pancreatic cancer; second-line chemotherapy; itraconazole; Hedgehog	PHASE-II TRIAL; PLUS GEMCITABINE; NAB-PACLITAXEL; P-GLYCOPROTEIN; CELL CARCINOMA; STEM-CELLS; HEDGEHOG; ANTIFUNGAL; RESISTANCE; SURVIVAL	Background: We evaluated chemotherapy with itraconazole (a common anti-fungal agent that is a potent inhibitor of the Hedgehog pathway, P-glycoprotein, and angiogenesis) for treating progressive pancreatic cancer. Patients and Methods: We retrospectively reviewed the medical charts of patients with histologically-diagnosed pancreatic cancer who had received first-or second-line chemotherapy and subsequent chemotherapy with itraconazole. Results: A total of 38 patients received docetaxel (35 mg/m(2)), gemcitabine (1,000 mg/m(2)), and carboplatin (area under the curve, 4 mg/min/ml) on day 1 and oral itraconazole solution (400 mg) on days -2 to 2, repeated every 2 weeks. One complete response and 13 partial responses were observed, for a response rate of 37%. Eight (21%) patients experienced febrile neutropenia. The median overall survival was 11.4 months (95% confidence interval=8.5-21.2 months). Conclusion: Combination chemotherapy with itraconazole is promising for prolonging overall survival, with acceptable toxicities in the second-line setting of pancreatic cancer.	[Tsubamoto, Hiroshi; Sonoda, Takashi; Inoue, Kayo] Meiwa Hosp, Dept Med Oncol, Nishinomiya, Hyogo 6638186, Japan; [Ikuta, Shinichi; Yamanaka, Naoki] Meiwa Hosp, Dept Surg, Nishinomiya, Hyogo 6638186, Japan; [Tsubamoto, Hiroshi; Inoue, Kayo] Hyogo Coll Med, Dept Obstet & Gynecol, Nishinomiya, Hyogo 6638501, Japan; [Tani, Satoshi] Kohnan Hosp, Dept Med Oncol, Kobe, Hyogo, Japan	Tsubamoto, H (reprint author), Meiwa Hosp, Dept Med Oncol, Agenaruo 4-31, Nishinomiya, Hyogo 6638186, Japan.	tsuba@hyo-med.ac.jp					Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Hong SP, 2009, INT J CANCER, V125, P2323, DOI [10.1002/ijc.24573, 10.1002/ijc.2403]; Huang FT, 2012, INT J ONCOL, V41, P1707, DOI 10.3892/ijo.2012.1597; Tsubamoto H, 2014, ANTICANCER RES, V34, P2007; Tsubamoto H, 2014, ANTICANCER RES, V34, P3839; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Bahra M, 2012, PANCREAS, V41, P222, DOI 10.1097/MPA.0b013e31822896dd; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Jimeno A, 2009, MOL CANCER THER, V8, P310, DOI 10.1158/1535-7163.MCT-08-0924; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Antonarakis ES, 2013, ONCOLOGIST, V18, P163, DOI 10.1634/theoncologist.2012-314; Rahma OE, 2013, ANN ONCOL, V24, P1972, DOI 10.1093/annonc/mdt166; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Astsaturov IA, 2011, AM J CLIN ONCOL-CANC, V34, P70, DOI 10.1097/COC.0b013e3181d2734a; Al-Hajeili M, 2014, ONCOTARGETS THER, V7, P187, DOI 10.2147/OTT.S40705; Rudin CM, 2013, J THORAC ONCOL, V8, P619, DOI 10.1097/JTO.0b013e31828c3950; Chong CR, 2007, ACS CHEM BIOL, V2, P263, DOI 10.1021/cb600362d; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Tsubamoto H, 2014, ANTICANCER RES, V34, P2481; Hosein PJ, 2013, AM J CLIN ONCOL-CANC, V36, P151, DOI 10.1097/COC.0b013e3182436e8c; Chung JW, 2013, HEPATO-GASTROENTEROL, V60, P363, DOI 10.5754/hge11108; Belli C, 2012, WORLD J GASTROENTERO, V18, P4457, DOI 10.3748/wjg.v18.i33.4457; Catenacci DVT, 2013, J CLIN ONCOL S, V31; Chung GG, 2006, CANCER, V106, P1677, DOI 10.1002/cncr.21783; De Jesus-Acosta A, 2014, J CLIN ONCOL, V32; GLOBOCAN, 2013, EST CANC INC MORT PR; Hwang RF, 2012, MOL CANCER RES, V10, P1147, DOI 10.1158/1541-7786.MCR-12-0022; Iida N, 2001, BIOL PHARM BULL, V24, P1032, DOI 10.1248/bpb.24.1032; Japanese Ministry of Health Labor and Welfare, 2012, STAT INV RES; Kethlreddy S, 2007, EXPERT OPIN DRUG MET, V3, P573, DOI 10.1517/17425225.3.4.573; Ko AH, 2010, CANCER CHEMOTH PHARM, V66, P1051, DOI 10.1007/s00280-010-1257-5; Lutz MP, 2005, J CLIN ONCOL, V23, P9250, DOI 10.1200/JCO.2005.02.1980; Shirakawa K, 1999, JPN J CANCER RES, V90, P1380; Takara K, 1999, BIOL PHARM BULL, V22, P1355; Xiros N, 2005, ANN ONCOL, V16, P773, DOI 10.1093/annonc/mdi160; Yao J, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13208	40	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4191	4196				6	Oncology	Oncology	CL6YV	WOS:000357116400061		
J	Furukawa, K; Uwagawa, T; Sakamoto, T; Shiba, H; Tsutsumi, J; Yanaga, K				Furukawa, Kenei; Uwagawa, Tadashi; Sakamoto, Taro; Shiba, Hiroaki; Tsutsumi, Jun; Yanaga, Katsuhiko			Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report	ANTICANCER RESEARCH			English	Article						Biliary duct cancer; neoadjuvant chemotherapy; case report	TRACT CANCER; CHOLANGIOCARCINOMA	A 68-year-old woman was diagnosed with unresectable upper bile duct cancer with suspected invasion of the right hepatic artery and para-aortic lymph node metastasis (T4N3M0, stage IVb). She underwent plastic stent placement for obstructive jaundice and enrolled in our phase I study for unresectable biliary tract cancer consisting of cisplatin (25 mg/m(2) i.v. for 120 min) followed by gemcitabine (1,000 mg/m(2) i.v. for 30 min) on days 1 and 8, and oral S-1 on alternate days. After 8 courses of neoadjuvant chemotherapy without adverse effects, computed tomography showed near-complete disappearance of the tumor of the upper bile duct and of swollen lymph nodes. She then underwent sub-total stomach-preserving pancreatico duodenectomy and lymph node dissection. The pathological stage was pT1N0M0, stage I. The patient made a satisfactory recovery, was discharged 29 days after operation, and remains free of disease at 3 months after the operation under adjuvant chemotherapy using S-1.	[Furukawa, Kenei; Uwagawa, Tadashi; Sakamoto, Taro; Shiba, Hiroaki; Tsutsumi, Jun; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo 1058461, Japan; [Tsutsumi, Jun] Mashiko Hosp, Dept Surg, Saitama, Japan	Furukawa, K (reprint author), Jikei Univ, Sch Med, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	k-furukawa@jikei.ac.jp					Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Morganti AG, 2010, ANN SURG ONCOL, V17, P194, DOI 10.1245/s10434-009-0762-4; DeOliveira ML, 2007, ANN SURG, V245, P755, DOI 10.1097/01.sla.0000251366.62632.d3; Kato A, 2013, ANN SURG ONCOL, V20, P318, DOI 10.1245/s10434-012-2312-8; Adam R, 2009, J CLIN ONCOL, V27, P1829, DOI 10.1200/JCO.2008.19.9273; Japanese Society of Hepato-Biliary-Pancreatic Surgery, 2013, GEN RUL CLIN PATH ST; Oshiro Y, 2013, WORLD J GASTROENTERO, V19, P6934, DOI 10.3748/wjg.v19.i40.6934; Sasaki T, 2012, INVEST NEW DRUG, V30, P708, DOI 10.1007/s10637-010-9553-9; Uwagawa T, 2015, CANCER CHEMOTH PHARM, V75, P191, DOI 10.1007/s00280-014-2636-0	10	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4203	4206				4	Oncology	Oncology	CL6YV	WOS:000357116400063		
J	Enomoto, Y; Kenmotsu, H; Watanabe, N; Baba, T; Murakami, H; Yoh, K; Ogura, T; Takahashi, T; Goto, K; Kato, T				Enomoto, Yasunori; Kenmotsu, Hirotsugu; Watanabe, Naohiro; Baba, Tomohisa; Murakami, Haruyasu; Yoh, Kiyotaka; Ogura, Takashi; Takahashi, Toshiaki; Goto, Koichi; Kato, Terufumi			Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study	ANTICANCER RESEARCH			English	Article						Bevacizumab; interstitial lung disease; non-small cell lung cancer; acute exacerbation	IDIOPATHIC PULMONARY-FIBROSIS; JAPANESE PATIENTS; CHEMOTHERAPY; EXACERBATION; PNEUMONIAS; COHORT	Aim: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). Patients and Methods: Twenty-five patients with non-squamous NSCLC with ILD who underwent CPB therapy between March 2007 and July 2013 were analyzed for treatment profiles. Results: The median age was 67 (range=53-79) years and 96% were men. The triplet chemotherapy was repeated for a median of four cycles. The objective response rate was 72% (18/25), the median progression-free survival time was 7.2 months, and the median overall survival time was 8.5 months. The most frequent adverse event of grade 3 or more was neutropenia (72%, 18/25). Chemotherapy-induced acute exacerbation of ILD occurred in 12% of patients. Conclusion: CPB therapy may be an effective and feasible regimen even for patients with ILD, although clinicians should be concerned regarding neutropenia and acute exacerbation of ILD.	[Enomoto, Yasunori; Baba, Tomohisa; Ogura, Takashi; Kato, Terufumi] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan; [Kenmotsu, Hirotsugu; Murakami, Haruyasu; Takahashi, Toshiaki] Shizuoka Canc Ctr, Div Thorac Oncol, Tokyo, Shizuoka, Japan; [Watanabe, Naohiro; Yoh, Kiyotaka; Goto, Koichi] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan; [Enomoto, Yasunori] Hamamatsu Univ Sch Med, Dept Internal Med 2, Hamamatsu, Shizuoka 4313192, Japan	Enomoto, Y (reprint author), 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan.	yasuyasuyasu29@yahoo.co.jp					Kudoh S, 2008, AM J RESP CRIT CARE, V177, P1348, DOI 10.1164/rccm.200710-1501OC; Kinoshita T, 2012, ONCOL LETT, V4, P477, DOI 10.3892/ol.2012.753; Minegishi Y, 2009, INTERNAL MED, V48, P665, DOI 10.2169/internalmedicine.48.1650; Park J, 2001, EUR RESPIR J, V17, P1216, DOI 10.1183/09031936.01.99055301; Kenmotsu H, 2011, J THORAC ONCOL, V6, P1242, DOI 10.1097/JTO.0b013e318216ee6b; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5; Minegishi Y, 2011, LUNG CANCER, V71, P70, DOI 10.1016/j.lungcan.2010.04.014; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Niho S, 2012, LUNG CANCER, V76, P362, DOI 10.1016/j.lungcan.2011.12.005; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Watanabe N, 2013, RESPIRATION, V85, P326, DOI 10.1159/000342046; Gridelli C, 2007, ONCOLOGIST, V12, P1183, DOI 10.1634/theoncologist.12-10-1183; Kenmotsu H, 2015, CANCER CHEMOTH PHARM, V75, P521, DOI 10.1007/s00280-014-2670-y; National Cancer Institute, COMM TERM CRIT ADV E; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Shimizu R, 2014, CANCER CHEMOTH PHARM, V74, P1159, DOI 10.1007/s00280-014-2590-x; Shukuya T, 2010, ANTICANCER RES, V30, P4357; Suzuki H, 2013, MOL CLIN ONCOL, V1, P480	19	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	JUL	2015	35	7					4259	4263				5	Oncology	Oncology	CL6YV	WOS:000357116400071		
J	Morita, T; Fukuoka, T; Kosaka, A; Imura, T; Sakai, H; Abe, M; Kitamoto, D				Morita, Tomotake; Fukuoka, Tokuma; Kosaka, Ayana; Imura, Tomohiro; Sakai, Hideki; Abe, Masahiko; Kitamoto, Dai			Selective formation of mannosyl-l-arabitol lipid by Pseudozyma tsukubaensis JCM16987	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Mannosylarabitol lipid; L-Arabitol; Glycolipid; Yeast; Pseudozyma	ACYLATED MANNOSYLERYTHRITOL LIPIDS; PARANTARCTICA JCM 11752(T); SURFACE-ACTIVE PROPERTIES; GLYCOLIPID BIOSURFACTANTS; INTERFACIAL PROPERTIES; EFFICIENT PRODUCTION; CANDIDA-ANTARCTICA; IDENTIFICATION; PRODUCER; YEASTS	To develop a structural homolog of mannosylerythritol lipids (MELs), Pseudozyma tsukubaensis JCM16987 (known to be a specific producer of the diastereomer type of mono-acetylated MEL (MEL-B)) was cultivated in medium containing 4 % (w/v) olive oil as the primary carbon source and 4 % l-arabitol as the supplemental sugar alcohol. Based on thin-layer chromatography (TLC), the glycolipid extract showed two major spots corresponding to MEL-B and an unknown glycolipid (GL1). Based on high-performance liquid chromatography after acid hydrolysis, GL1 from the l-arabitol culture showed two primary peaks identical to mannose and arabitol using the sugar analysis column, and one peak identical to l-arabitol was detected using the chiral resolution column. Based on NMR analysis, GL1 was identified as mono-acetylated mannosyl-l-arabitol lipid (MLAL-B) consisting of mannose, with l-arabitol as the sugar moiety. The observed critical micelle concentration (CMC) and surface tension at the CMC (gamma CMC) of MLAL-B were 1.2 x 10(-5) M and 32.8 mN/m, which were significantly higher than MEL-B (CMC = 3.1 x 10(-6) M and gamma cmc = 26.1 mN/m). Furthermore, based on a water-penetration scan, MLAL-B efficiently formed lamellar phase (L-alpha) and myelins at a broad concentration range. Thus, the present glycolipid showed higher hydrophilicity and/or water solubility and increased our understanding of environmentally advanced biosurfactants.	[Morita, Tomotake; Fukuoka, Tokuma; Kosaka, Ayana; Imura, Tomohiro; Kitamoto, Dai] Natl Inst Adv Ind Sci & Technol, Res Inst Innovat Sustainable Chem, Tsukuba, Ibaraki 3058565, Japan; [Sakai, Hideki; Abe, Masahiko] Tokyo Univ Sci, Fac Sci & Technol, Noda, Chiba 2788510, Japan	Kitamoto, D (reprint author), Natl Inst Adv Ind Sci & Technol, Res Inst Innovat Sustainable Chem, Tsukuba Cent 5-2,Higashi 1-1-1, Tsukuba, Ibaraki 3058565, Japan.	dai-kitamoto@aist.go.jp					Fukuoka T, 2008, CARBOHYD RES, V343, P555, DOI 10.1016/j.carres.2007.11.023; [Anonymous], 2002, J BIOSCI BIOENG; Morita T, 2009, APPL MICROBIOL BIOT, V83, P1017, DOI 10.1007/s00253-009-1945-4; Hewald S, 2006, APPL ENVIRON MICROB, V72, P5469, DOI 10.1128/AEM.00506-06; Fukuoka T, 2007, APPL MICROBIOL BIOT, V76, P801, DOI 10.1007/s00253-007-1051-4; Morita T, 2012, APPL MICROBIOL BIOT, V96, P931, DOI 10.1007/s00253-012-4230-x; Imura T, 2006, CHEM-EUR J, V12, P2434, DOI 10.1002/chem.200501199; Morita T, 2006, APPL MICROBIOL BIOT, V73, P305, DOI 10.1007/s00253-006-0466-7; Fukuoka T, 2007, BIOTECHNOL LETT, V29, P1111, DOI 10.1007/s10529-007-9363-0; KITAMOTO D, 1993, J BIOTECHNOL, V29, P91, DOI 10.1016/0168-1656(93)90042-L; Fukuoka T, 2012, CARBOHYD RES, V351, P81, DOI 10.1016/j.carres.2012.01.019; KITAMOTO D, 1990, AGR BIOL CHEM TOKYO, V54, P37; Kitamoto D, 2009, CURR OPIN COLLOID IN, V14, P315, DOI 10.1016/j.cocis.2009.05.009; Konishi M, 2008, APPL MICROBIOL BIOT, V78, P37, DOI 10.1007/s00253-007-1292-2; Lang S, 2002, CURR OPIN COLLOID IN, V7, P12, DOI 10.1016/S1359-0294(02)00007-9; Morita T, 2013, GENOME ANNOUNC, V4, DOI [10.1128/genomeA.00064-13, DOI 10.1128/GENOMEA.00064-13]; Morita T, 2008, J BIOSCI BIOENG, V105, P493, DOI 10.1263/jbb.105.493; Morita T, 2010, APPL MICROBIOL BIOT, V88, P678; Morita T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086490; Morita T, 2008, J OLEO SCI, V57, P123, DOI 10.5650/jos.57.123; Morita T, 2009, BIOTECHNOL APPL BIOC, V53, P39, DOI 10.1042/BA20090033; Morita T, 2007, FEMS YEAST RES, V7, P286, DOI 10.1111/j.1567-1364.2006.00154.x; Morita T, 2008, J OLEO SCI, V57, P557, DOI 10.5650/jos.57.557; Rau U, 2005, APPL MICROBIOL BIOT, V66, P551, DOI 10.1007/s00253-004-1672-9	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	JUL	2015	99	14					5833	5841		10.1007/s00253-015-6575-4		9	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CL2WA	WOS:000356806300007		
J	Mizota, C; Yamanaka, T				Mizota, C.; Yamanaka, T.			A stable isotopic constraint on the origin of sulphur ore excavated from the exotic four-lobe jars that prevailed during late medieval to early modern times in Sakai (Osaka), south-western Japan	ARCHAEOMETRY			English	Article						Early 17th Century; Sakai (Osaka; Japan); East Asia; Volcanic Native Sulphur; Stable Sulphur Isotope Analysis; Gunpowder Ingredient; Maritime Trading Network	FRACTIONATION	Stable sulphur isotope ratios were determined for native sulphur ore that was excavated from exotic four-lobe jars in Sakai, south-western Japan. The jars were buried after a fire event that occurred on 28 April 1615. The sulphur isotopic results (average S-34=+0.5 parts per thousand) were evaluated in terms of comparing ancient documents with a database from new sulphur collections. The origin of the sulphur ore is estimated to be transportation from native sulphur deposits formed around the solfataric fumaroles from Mts Garan and Kuju-Iwozan, in central-eastern Kyushu. These analytical results support the validity of history based on the analysis of ancient documents.	[Mizota, C.] Beppu Univ, Res Inst Cultural Properties, Beppu, Oita 8748501, Japan; [Yamanaka, T.] Okayama Univ, Grad Sch Nat Sci & Technol, Dept Earth Sci, Kita Ku, Okayama 7008530, Japan	Mizota, C (reprint author), Beppu Univ, Res Inst Cultural Properties, Kita Ishigaki 82, Beppu, Oita 8748501, Japan.	mizota@iwate-u.ac.jp					CHAMBERS LA, 1979, GEOMICROBIOL J, V1, P249; UEDA A, 1979, GEOCHEM J, V13, P269; Ziegenbalg SB, 2010, SEDIMENT GEOL, V227, P37, DOI 10.1016/j.sedgeo.2010.03.007; Kusakabe M, 2000, J VOLCANOL GEOTH RES, V97, P287, DOI 10.1016/S0377-0273(99)00161-4; Board of Education Office of Sakai City, 1989, EXC REP CULT PROP, V49, P1; De Jongh C. A., 1925, VERSLAGEN MEDEDEELIN, V17, P1; Delemelle P., 2000, J VOLCANOL GEOTHERM, V97, P31; Dessau G., 1962, ECON GEOL, V57, P410; Itoh K., 2010, INTRIGUING ASIA, V132, P154; Kage T., 2011, STUDIES ASIAN DAIMYO, P1563; Kage T., 2003, SHIGAKU ZASSHI, V112, P153; Kanda T., 2012, SURVEY REPORT WORLD, P571; Kawaguchi Y., 2012, TRADE CERAMICS STUDI, V32, P76; Kinoshita K., 1953, MINING GEOLOGY, V3, P7; Kusakabe M, 1983, B VOLCANOL SOC JAPAN, V28, P245; Mukai K., 2012, TRADE CERAMICS STUDI, V32, P112; Obata J., 1976, STUDIES HIST GOLD SI, VVII, P178; Overseas Mining Association, 1943, SULF RES E IND ARCH, P1; Pagano R., 2012, MINERALOGICAL RECORD, V43, P161; Peterson R. C., 2003, MINERAL REC, V34, P171; SAKAI H, 1957, GEOCHIM COSMOCHIM AC, V12, P150, DOI 10.1016/0016-7037(57)90025-X; Sriwana T, 2000, J VOLCANOL GEOTH RES, V97, P77, DOI 10.1016/S0377-0273(99)00178-X; Taylor R. E., 1994, ACS SYM SER, V550, P481; Thode H. G., 1991, SCOPE, P1; Tsuzuki S., 1989, TRADE CERAMICS STUDI, V9, P123; Yamamoto Shuzo, 2009, Jpn Hosp, P1; Yamauchi S., 2011, KYUSHU SHIGAKU, V160, P35	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-813X	1475-4754		ARCHAEOMETRY	Archaeometry	JUL	2015	57			1	SI		166	174		10.1111/arcm.12106		9	Archaeology; Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Geosciences, Multidisciplinary	Archaeology; Chemistry; Geology	CL5RI	WOS:000357017400010		
J	Mitamura, Y				Mitamura, Yoshinori			Current Status of Left Ventricular Assist Devices and Cell Sheet Engineering for Treatment of Severe Heart Disease in Japan	ARTIFICIAL ORGANS			English	Editorial Material							CULTURED-CELLS		Hokkaido Univ, Grad Sch Informat Sci, Minami Ku, Sapporo, Hokkaido 0050005, Japan	Mitamura, Y (reprint author), Hokkaido Univ, Grad Sch Informat Sci, Minami Ku, 5-5-1-2 Sumikawa, Sapporo, Hokkaido 0050005, Japan.	ymitamura@par.odn.ne.jp					Shimizu T, 2003, BIOMATERIALS, V24, P2309, DOI 10.1016/S0142-9612(03)00110-8; OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005; Sawa Y, 2012, SURG TODAY, V42, P181, DOI 10.1007/s00595-011-0106-4; YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571; Matsuura K, 2012, BIOCHEM BIOPH RES CO, V425, P321, DOI 10.1016/j.bbrc.2012.07.089; Shimizu T, 2006, FASEB J, V20, P708, DOI 10.1096/fj.05-4715fje; Egami M, 2014, ARCH PHARM RES, V37, P96, DOI 10.1007/s12272-013-0299-8; Japan Society for the Promotion of Science, 2010, FUND PROGR WORLD LEA; Kirklin JK, 2014, J HEART LUNG TRANSPL, V33, P12, DOI 10.1016/j.healun.2013.11.001; Masumoto H, 2014, SCI REP-UK, V4, DOI 10.1038/srep06716; Miyagawa S, 2013, JPN J ARTIF ORGANS, V42, P210; Pharmaceutics and Medical Devices Agency Japan, 2014, J MACS STAT REP; Pharmaceutics and Medical Devices Agency Japan, 2015, NUMB PAT ENR JUN 201; Sakaguchi K, 2013, SCI REP-UK, V3, DOI 10.1038/srep01316	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0160-564X	1525-1594		ARTIF ORGANS	Artif. Organs	JUL	2015	39	7					543	549		10.1111/aor.12510		7	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CM0XH	WOS:000357402300005		
J	Hijikata, W; Rao, J; Abe, S; Takatani, S; Shinshi, T				Hijikata, Wataru; Rao, Jun; Abe, Shodai; Takatani, Setsuo; Shinshi, Tadahiko			Sensorless Viscosity Measurement in a Magnetically-Levitated Rotary Blood Pump	ARTIFICIAL ORGANS			English	Article						Sensorless viscosity measurement; Vibrational excitation; Phase difference; Magnetically levitated rotary blood pump; Flow rate estimation	FLOW-RATE MEASUREMENT; PULSATILE FLOW; FAILURE; PRESSURE; MODEL; MOTOR	Controlling the flow rate in an implantable rotary blood pump based on the physiological demand made by the body is important. Even though various methods to estimate the flow rate without using a flow meter have been proposed, no adequate method for measuring the blood viscosity, which is necessary for an accurate estimate of the flow rate, without using additional sensors or mechanisms in a noninvasive way, has yet been realized. We have developed a sensorless method for measuring viscosity in magnetically levitated rotary blood pumps, which requires no additional sensors or mechanisms. By applying vibrational excitation to the impeller using a magnetic bearing, we measured the viscosity of the working fluid by measuring the phase difference between the current in the magnetic bearing and the displacement of the impeller. The measured viscosity showed a high correlation ( R-2 > 0.992) with respect to a reference viscosity. The mean absolute deviation of the measured viscosity was 0.12 mPa.s for several working fluids with viscosities ranging from 1.18 to 5.12 mPa.s. The proposed sensorless measurement method has the possibility of being utilized for estimating flow rate.	[Hijikata, Wataru; Shinshi, Tadahiko] Tokyo Inst Technol, Precis & Intelligence Lab, Yokohama, Kanagawa 2268503, Japan; [Rao, Jun; Abe, Shodai] Tokyo Inst Technol, Interdisciplinary Grad Sch Sci & Engn, Yokohama, Kanagawa 2268503, Japan; [Takatani, Setsuo] MedTech Heart Inc, Div Res & Dev, Tokyo, Japan; [Takatani, Setsuo] Nihon Univ, Sch Med, Dept Cardiovasc Surg, Tokyo, Japan	Hijikata, W (reprint author), Tokyo Inst Technol, Precis & Intelligence Lab, Midori Ku, Mail Box R2-38,4259 Nagatsuta Cho, Yokohama, Kanagawa 2268503, Japan.	hijikata.w.aa@m.titech.ac.jp			JSPS KAKENHI [24360059]	This research is partly supported by JSPS KAKENHI grant number 24360059.	Hoshi H, 2006, ARTIF ORGANS, V30, P324, DOI 10.1111/j.1525-1594.2006.00222.x; AlOmari AH, 2009, PHYSIOL MEAS, V30, P371, DOI 10.1088/0967-3334/30/4/003; Karkouti K, 2005, J THORAC CARDIOV SUR, V129, P391, DOI 10.1016/j.jtcvs.2004.06.028; Baskurt OK, 2003, SEMIN THROMB HEMOST, V29, P435; CHIEN S, 1970, SCIENCE, V168, P977, DOI 10.1126/science.168.3934.977; Malagutti N, 2007, ARTIF ORGANS, V31, P45, DOI 10.1111/j.1525-1594.2007.00339.x; Arakawa M, 2014, J THORAC CARDIOV SUR, V148, P698, DOI 10.1016/j.jtcvs.2013.12.049; Bertram CD, 2005, PHYSIOL MEAS, V26, P99; Granegger M, 2012, ARTIF ORGANS, V36, P691, DOI 10.1111/j.1525-1594.2012.01503.x; Hijikata W, 2008, ARTIF ORGANS, V32, P531, DOI 10.1111/j.1525-1594.2008.00576.x; Holsworth RE, 2012, PERFUSION, V28, P91; Hori Y, 2006, HYDRODYNAMIC LUBRICA, P9; Hoshi H, 2006, ARTIF ORGANS, V30, P949, DOI 10.1111/j.1525-1594.2006.00332.x; Kitamura T, 2000, ARTIF ORGANS, V24, P589, DOI 10.1046/j.1525-1594.2000.06605.x; Pagani Francis D, 2008, Semin Thorac Cardiovasc Surg, V20, P255, DOI 10.1053/j.semtcvs.2008.08.002; Pai CN, 2010, P I MECH ENG H, V224, P1; Pai CN, 2010, FLOW MEAS INSTRUM, V21, P33, DOI 10.1016/j.flowmeasinst.2009.11.003; Someya T, 2009, ARTIF ORGANS, V33, P704, DOI 10.1111/j.1525-1594.2009.00900.x; Tsukiya T, 1997, ARTIF ORGANS, V21, P396; Tsukiya T, 2001, ARTIF ORGANS, V25, P692, DOI 10.1046/j.1525-1594.2001.06858.x; Wakisaka Y, 1997, ARTIF ORGANS, V21, P651, DOI 10.1111/j.1525-1594.1997.tb03716.x; Yu YC, 2010, 5 IEEE C IND EL APPL, P1752	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0160-564X	1525-1594		ARTIF ORGANS	Artif. Organs	JUL	2015	39	7					559	568		10.1111/aor.12440		10	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CM0XH	WOS:000357402300007		
J	Shibata, E; Nagai, K; Takeuchi, R; Noda, Y; Makino, T; Chikata, Y; Hann, M; Yoshimoto, S; Ono, H; Ueda, S; Tamaki, M; Murakami, T; Matsuura, M; Abe, H; Doi, T				Shibata, Eriko; Nagai, Kojiro; Takeuchi, Risa; Noda, Yasuhiro; Makino, Tomomi; Chikata, Yusuke; Hann, Michael; Yoshimoto, Sakiya; Ono, Hiroyuki; Ueda, Sayo; Tamaki, Masanori; Murakami, Taichi; Matsuura, Motokazu; Abe, Hideharu; Doi, Toshio			Re-evaluation of Pre-pump Arterial Pressure to Avoid Inadequate Dialysis and Hemolysis: Importance of Prepump Arterial Pressure Monitoring in Hemodialysis Patients	ARTIFICIAL ORGANS			English	Article						Prepump arterial pressure; Hemolysis; Blood flow; Pressure pillow; Vacuum monitor; Dialysis	BLOOD-FLOW RATES; NEEDLE; ACCESS; COLOR	Prepump arterial pressure (PreAP) is monitored to avoid generating excessive negative pressure. The National Kidney Foundation K/DOQI clinical practice guidelines for vascular access recommend that PreAP should not fall below -250 mm Hg because excessive negative PreAP can lead to a decrease in the delivery of blood flow, inadequate dialysis, and hemolysis. Nonetheless, these recommendations are consistently disregarded in clinical practice and pressure sensors are often removed from the dialysis circuit. Thus far, delivered blood flow has been reported to decrease at values more negative than -150 mm Hg of PreAP. These values have been analyzed by an ultrasonic flowmeter and not directly measured. Furthermore, no known group has evaluated whether PreAP-induced hemolysis occurs at a particular threshold. Therefore, the aim of this study was to clarify the importance of PreAP in the prediction of inadequate dialysis and hemolysis. By using different diameter needles, human blood samples from healthy volunteers were circulated in a closed dialysis circuit. The relationship between PreAP and delivered blood flow or PreAP and hemolysis was investigated. We also investigated the optimal value for PreAP using several empirical monitoring methods, such as a pressure pillow. Our investigation indicated that PreAP is a critical factor in the determination of delivered blood flow and hemolysis, both of which occured at pressure values more negative than -150 mm Hg. With the exception of direct pressure monitoring, commonly used monitoring methods for PreAP were determined to be ineffective. We propose that the use of a vacuum monitor would permit regular measurement of PreAP.	[Shibata, Eriko; Nagai, Kojiro; Yoshimoto, Sakiya; Ono, Hiroyuki; Ueda, Sayo; Tamaki, Masanori; Murakami, Taichi; Matsuura, Motokazu; Abe, Hideharu; Doi, Toshio] Univ Tokushima, Hlth Biosci Inst, Grad Sch Med, Dept Nephrol, Tokushima 7708503, Japan; [Takeuchi, Risa; Noda, Yasuhiro; Makino, Tomomi] Univ Tokushima, Hlth Biosci Inst, Grad Sch Med, Dept Hemodialysis, Tokushima 7708503, Japan; [Chikata, Yusuke] Univ Tokushima, Hlth Biosci Inst, Grad Sch Med, Dept Emergency & Crit Care, Tokushima 7708503, Japan; [Hann, Michael] Naval Med Ctr San Diego, Dept Grad Med Educ, San Diego, CA USA	Nagai, K (reprint author), Univ Tokushima, Hlth Biosci Inst, Grad Sch Med, Dept Nephrol, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	knagai@clin.med.tokushima-u.ac.jp					Mulholland JW, 2000, PERFUSION-UK, V15, P485; Paulson WD, 2012, KIDNEY INT, V81, P132, DOI 10.1038/ki.2011.337; Wiese P, 2004, NEPHROL DIAL TRANSPL, V19, P1956, DOI 10.1093/ndt/gfh244; Basile C, 2008, NEPHROL DIAL TRANSPL, V23, P282, DOI 10.1093/ndt/gfm549; Bauer N, 2008, J VET DIAGN INVEST, V20, P593; Depner T A, 1990, ASAIO Trans, V36, pM456; DeWachter DS, 1996, ASAIO J, V42, pM524; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Mandolfo S, 2006, J Vasc Access, V7, P53; Mehta HK, 2002, AM J KIDNEY DIS, V39, P1231, DOI 10.1053/ajkd.2002.33396; PHILLIPS RA, 1950, J BIOL CHEM, V183, P305; Polaschegg HD, 2006, HEMODIALYSIS HORIZON, P65; Shibata M, 2012, ARTIF ORGANS, V36, P992, DOI 10.1111/j.1525-1594.2012.01490.x; Tan J, 2012, ASAIO J, V58, P522, DOI 10.1097/MAT.0b013e318263210b; Techert F, 2007, J VASC ACCESS, V8, P252; Teodorescu V, 2012, INT J NEPHROL, V2012; Teruel JL, 2000, NEPHRON, V85, P142, DOI 10.1159/000045647; Vascular Access 2006 Work Group, 2006, AM J KIDNEY DIS S, V48, pS176, DOI DOI 10.1053/J.AJKD.2006.04.029; Vascular Access Work Group, 2006, AM J KIDNEY DIS S, V48, pS248, DOI DOI 10.1053/J.AJKD.2006.04.040.MEDLINE; Ward R, 1999, IEEE SPECTRUM, V36, P6; Yamagata K, 2015, CLIN EXP NEPHROL, V19, P54, DOI 10.1007/s10157-014-0978-x	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0160-564X	1525-1594		ARTIF ORGANS	Artif. Organs	JUL	2015	39	7					627	634		10.1111/aor.12448		8	Engineering, Biomedical; Transplantation	Engineering; Transplantation	CM0XH	WOS:000357402300015		
J	Sunagawa, K; Nagamine, I; Kamata, Y; Niino, N; Taniyama, Y; Kinjo, K; Matayoshi, A				Sunagawa, Katsunori; Nagamine, Itsuki; Kamata, Yasuhiro; Niino, Noriko; Taniyama, Yoshihiko; Kinjo, Kazuhide; Matayoshi, Ayano			Nighttime Cooling Is an Effective Method for Improving Milk Production in Lactating Goats Exposed to Hot and Humid Environment	ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES			English	Article						Effective Cooling Periods; Heat Stress; Milk Production; Lactating Goats; Circadian Rhythm; Nighttime Cooling	CORTICOTROPIN-RELEASING-FACTOR; GROWTH-HORMONE-SECRETION; HEAT-PRODUCTION; DIETARY FIBER; DAIRY-COWS; CATTLE; STRESS; CYCLES	Heat production in ruminants follows a diurnal pattern over the course of a day peaking 3 hours following afternoon feeding and then gradually declining to its lowest point prior to morning feeding. In order to clarify the cooling period most effective in reducing decreases in feed intake and milk production, experiments were carried out based on the diurnal rhythm of heat production and heat dissipation. In experiment 1, the effects of hot environment on milk production were investigated. The animals were kept first in a thermoneutral environment (20.0 degrees C, 80.0%) for 12 days, they were then transitioned to a hot environment (32 degrees C, 80.0%) for 13 day before being returned to second thermoneutral environment for a further 12 days. In experiment 2, the effectiveness of daytime cooling or nighttime cooling for improving milk production in hot environment was compared. While ten lactating Japanese Saanen goats (aged 2 years, weighing 41.0 kg) during early lactation were used in experiment 1, ten lactating goats (aged 2 years, weighing 47.5 kg) during mid-lactation were used in experiment 2. The animals were fed 300 g of concentrated feed and excessive amounts of crushed alfalfa hay cubes twice daily. Water was given ad libitum. The animals were milked twice daily. When exposed to a hot environment, milk yield and composition decreased significantly (p<0.05). Milk yield in the hot environment did not change with daytime cooling, but tended to increase with nighttime cooling. Compared to the daytime cooling, milk components percentages in the nighttime cooling were not significantly different but the milk components yields in the nighttime cooling were significantly higher (p<0.05). The results indicate that nighttime cooling is more effective than daytime cooling in the reduction of milk production declines in lactating goats exposed to a hot environment.	[Sunagawa, Katsunori; Nagamine, Itsuki; Kamata, Yasuhiro; Niino, Noriko; Taniyama, Yoshihiko; Kinjo, Kazuhide; Matayoshi, Ayano] Univ Ryukyus, Fac Agr, Nishihara, Okinawa 9030213, Japan	Sunagawa, K (reprint author), Univ Ryukyus, Fac Agr, Nishihara, Okinawa 9030213, Japan.	b986094@agnu-ryukyu.ac.jp			Uruma Foundation	We thank Mr. Glenn McIlvride for his English proofreading on this manuscript. This research was funded in part by a grant from the Uruma Foundation. The computation was mainly carried out using the computer facilities in the Research Institute for Information Technology, Kyushu University.	Ando Satoshi, 1997, Animal Science and Technology, V68, P177; PURWANTO BP, 1990, J AGR SCI, V114, P139; Kadzere CT, 2002, LIVEST PROD SCI, V77, P59, DOI 10.1016/S0301-6226(01)00330-X; West JW, 1999, J ANIM SCI, V77, P21; PEEL CJ, 1987, J DAIRY SCI, V70, P474; ANTONI FA, 1986, ENDOCR REV, V7, P351; AOAC, 1990, OFFICIAL METHODS ANA; BURTON JL, 1994, CAN J ANIM SCI, V74, P167; Chaiyabutr N, 2008, INT J BIOMETEOROL, V52, P575, DOI 10.1007/s00484-008-0151-x; Hales J. R. S., 1974, ENV PHYSL, P107; Jin J, 2013, ANIM SCI J, V84, P130, DOI 10.1111/j.1740-0929.2012.01050.x; Johnson H. D., 1987, BIOCLIMATOLOGY ADAPT, P35; Kasuya E, 2008, J ANIM SCI, V86, P1799, DOI 10.2527/jas.2008-0877; Lu CD, 1989, SMALL RUMINANT RES, V2, P151, DOI 10.1016/0921-4488(89)90040-0; MAGDUB A, 1982, J DAIRY SCI, V65, P2323; MENZAGHI F, 1993, ANN NY ACAD SCI, V697, P142, DOI 10.1111/j.1749-6632.1993.tb49929.x; MITRA R, 1972, J ANIM SCI, V34, P776; Nagamine I., 2014, J WARM REGION SCOC A, V57, P131; PROSSER CG, 1989, BIOTECHNOLOGY IN GROWTH REGULATION, P141; QUABBE HJ, 1981, ENDOCRINOLOGY, V109, P513; SAS, 1990, SAS STAT US GUID, V2; SCOTT IM, 1983, INT J BIOMETEOROL, V27, P47, DOI 10.1007/BF02186300; Sunagawa K, 2002, ASIAN AUSTRAL J ANIM, V15, P859; Thang TV, 2011, ASIAN AUSTRAL J ANIM, V24, P1069, DOI 10.5713/ajas.2011.11063; VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583; West JW, 2003, J DAIRY SCI, V86, P2131, DOI 10.3168/jds.S0022-0302(03)73803-X; YAMAMOTO S, 1979, BRIT J NUTR, V42, P507, DOI 10.1079/BJN19790142	27	0	0	ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC	SEOUL	ROOM 708 SAMMO SPOREX, 1638-32, SEOWON-DONG, GWANAK-GU, SEOUL 151-730, SOUTH KOREA	1011-2367	1976-5517		ASIAN AUSTRAL J ANIM	Asian Australas. J. Anim. Sci.	JUL	2015	28	7					966	975		10.5713/ajas.14.0890		10	Agriculture, Dairy & Animal Science	Agriculture	CL7IK	WOS:000357145500008		
J	Matsumoto, N; Inoue, T; Matsumoto, A; Okazaki, S				Matsumoto, Naoya; Inoue, Takashi; Matsumoto, Akiyuki; Okazaki, Shigetoshi			Correction of depth-induced spherical aberration for deep observation using two-photon excitation fluorescence microscopy with spatial light modulator	BIOMEDICAL OPTICS EXPRESS			English	Article							CONFOCAL MICROSCOPY; IN-VIVO; TISSUE; LASER; RECONSTRUCTION; GENERATION; BRAIN	We demonstrate fluorescence imaging with high fluorescence intensity and depth resolution in which depth-induced spherical aberration (SA) caused by refractive-index mismatch between the medium and biological sample is corrected. To reduce the impact of SA, we incorporate a spatial light modulator into a two-photon excitation fluorescence microscope. Consequently, when fluorescent beads in epoxy resin were observed with this method of SA correction, the fluorescence signal of the observed images was similar to 27 times higher and extension in the direction of the optical axes was similar to 6.5 times shorter at a depth of similar to 890 mu m. Thus, the proposed method increases the depth observable at high resolution. Further, our results show that the method improved the fluorescence intensity of images of the fluorescent beads and the structure of a biological sample. (C) 2015 Optical Society of America	[Matsumoto, Naoya; Inoue, Takashi] Hamamatsu Photon KK, Cent Res Lab, Hamakita Ku, Hamamatsu, Shizuoka 4348601, Japan; [Matsumoto, Akiyuki] Nagoya Univ, Dept Biochem, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; [Okazaki, Shigetoshi] Hamamatsu Univ Sch Med, Med Photon Res Ctr, Appl Med Photon Lab, Dept Med Spect,Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Matsumoto, N (reprint author), Hamamatsu Photon KK, Cent Res Lab, Hamakita Ku, Hamamatsu, Shizuoka 4348601, Japan.	nm@crl.hpk.co.jp			SENTAN, JST	We are grateful to S. Terakawa, K. Kadomatsu, A. Hiruma, H. Toyoda, and T. Hara for their encouragement and T. Miwa, N. Fukuchi, K. Nakamura, and H. Tanaka for their invaluable assitance. This work was partially supported by SENTAN, JST.	Dickie R, 2006, MICROVASC RES, V72, P20, DOI 10.1016/j.mvr.2006.05.003; Botcherby EJ, 2012, P NATL ACAD SCI USA, V109, P2919, DOI 10.1073/pnas.1111662109; Tao XD, 2011, OPT LETT, V36, P1062, DOI 10.1364/OL.36.001062; Susaki EA, 2014, CELL, V157, P726, DOI 10.1016/j.cell.2014.03.042; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Hama H, 2011, NAT NEUROSCI, V14, P1481, DOI 10.1038/nn.2928; Gould TJ, 2012, OPT EXPRESS, V20, P20998, DOI 10.1364/OE.20.020998; Matsumoto N, 2008, J OPT SOC AM A, V25, P1642, DOI 10.1364/JOSAA.25.001642; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Theer P, 2003, OPT LETT, V28, P1022, DOI 10.1364/OL.28.001022; Matsumoto N, 2014, OPT EXPRESS, V22, P24722, DOI 10.1364/OE.22.024722; TOROK P, 1995, J OPT SOC AM A, V12, P2136, DOI 10.1364/JOSAA.12.002136; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; Wang C, 2014, NAT METHODS, V11, P1037, DOI [10.1038/nmeth.3068, 10.1038/NMETH.3068]; Kuwajima T, 2013, DEVELOPMENT, V140, P1364, DOI 10.1242/dev.091844; Itoh H, 2009, OPT EXPRESS, V17, P14367, DOI 10.1364/OE.17.014367; Azucena O, 2010, OPT EXPRESS, V18, P17521, DOI 10.1364/OE.18.017521; Inoue T, 2007, P SOC PHOTO-OPT INS, V6487, pY4870, DOI 10.1117/12.699821; Kawakami R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01014; Kobat D, 2009, OPT EXPRESS, V17, P13354, DOI 10.1364/OE.17.013354; Milkie DE, 2011, OPT LETT, V36, P4206, DOI 10.1364/OL.36.004206; Salter PS, 2014, OPT EXPRESS, V22, P17644, DOI 10.1364/OE.22.017644; Zeng J, 2012, BIOMED OPT EXPRESS, V3, P1898, DOI 10.1364/BOE.3.001898	23	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	JUL 1	2015	6	7					2575	2587		10.1364/BOE.6.002575		13	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	CM1IT	WOS:000357435200023		
J	Nakajima, M; Hiraoka, T; Hirohara, Y; Oshika, T; Mihashi, T				Nakajima, Masashi; Hiraoka, Takahiro; Hirohara, Yoko; Oshika, Tetsuro; Mihashi, Toshifumi			Verification of the lack of correlation between age and longitudinal chromatic aberrations of the human eye from the visible to the infrared	BIOMEDICAL OPTICS EXPRESS			English	Article							OPTICAL COHERENCE TOMOGRAPHY; HIGHER-ORDER ABERRATIONS; WAVE-FRONT ABERRATIONS; MONOCHROMATIC ABERRATIONS; OCULAR ABERRATIONS; ANTERIOR SEGMENT; CRYSTALLINE LENS; REFRACTIVE-INDEX; DOUBLE-PASS; POPULATION	Several researchers studied the longitudinal chromatic aberration (LCA) of the human eye and observed that it does not change due to age. We measured the LCA of 45 subjects' normal right eyes at three distinct wavelengths (561, 690, and 840 nm) using a Hartmann-Shack wavefront aberrometer (HSWA) while consecutively switching between three light sources for wavefront sensing. We confirmed that the LCA of the human eye does not change due to age between 22 and 57 years. (C) 2015 Optical Society of America	[Nakajima, Masashi; Hirohara, Yoko] TOPCON, Eye Care Co, Dev Engn Dept, Tokyo 1748580, Japan; [Hiraoka, Takahiro; Oshika, Tetsuro] Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Ibaraki 3058575, Japan	Nakajima, M (reprint author), Tokyo Inst Technol, Dept Informat Proc, Kanazawa, Ishikawa 2268503, Japan.	mihashi.t.aa@m.titech.ac.jp			Topcon Corp	We are grateful to Tsukuba Hospital personnel and doctors for acquiring data and discussing the results. A part of this research was supported by Topcon Corp.	Thibos LN, 2004, J VISION, V4, P329, DOI 10.1167/4.4.9; Atchison DA, 2005, J OPT SOC AM A, V22, P29, DOI 10.1364/JOSAA.22.000029; Porter J, 2001, J OPT SOC AM A, V18, P1793, DOI 10.1364/JOSAA.18.001793; Kelly JE, 2004, J VISION, V4, P262, DOI 10.1167/4.4.2; Marcos S, 1999, VISION RES, V39, P4309, DOI 10.1016/S0042-6989(99)00145-5; Koretz JF, 2004, J OPT SOC AM A, V21, P346, DOI 10.1364/JOSAA.21.000346; McLellan JS, 2002, NATURE, V417, P174, DOI 10.1038/417174a; Glasser A, 1998, VISION RES, V38, P209, DOI 10.1016/S0042-6989(97)00102-8; Artal P, 2002, J OPT SOC AM A, V19, P137, DOI 10.1364/JOSAA.19.000137; Manzanera S, 2008, OPT EXPRESS, V16, P7748, DOI 10.1364/OE.16.007748; THIBOS LN, 1990, VISION RES, V30, P33, DOI 10.1016/0042-6989(90)90126-6; Guirao A, 2000, J OPT SOC AM A, V17, P1697, DOI 10.1364/JOSAA.17.001697; LopezGil N, 1997, J OPT SOC AM A, V14, P961, DOI 10.1364/JOSAA.14.000961; Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1757, DOI 10.1364/BOE.2.001757; Dubbelman M, 2001, VISION RES, V41, P1867, DOI 10.1016/S0042-6989(01)00057-8; THIBOS LN, 1991, OPTOMETRY VISION SCI, V68, P599, DOI 10.1097/00006324-199108000-00005; Llorente L, 2003, OPTOMETRY VISION SCI, V80, P26, DOI 10.1097/00006324-200301000-00005; Zawadzki RJ, 2008, OPT EXPRESS, V16, P8126, DOI 10.1364/OE.16.008126; Oshika T, 1999, INVEST OPHTH VIS SCI, V40, P1351; Koh S, 2002, AM J OPHTHALMOL, V134, P115, DOI 10.1016/S0002-9394(02)01430-7; Thibos LN, 2002, J REFRACT SURG, V18, pS652; Moffat BA, 2002, VISION RES, V42, P1683, DOI 10.1016/S0042-6989(02)00078-0; BEDFORD RE, 1957, J OPT SOC AM, V47, P564; RYNDERS M, 1995, J OPT SOC AM A, V12, P2348, DOI 10.1364/JOSAA.12.002348; CHARMAN WN, 1976, VISION RES, V16, P999, DOI 10.1016/0042-6989(76)90232-7; Perez-Merino P, 2013, INVEST OPHTH VIS SCI, V54, P2654, DOI 10.1167/iovs.13-11912; Fernandez EJ, 2008, OPT EXPRESS, V16, P21199, DOI 10.1364/OE.16.021199; Mutti DO, 1998, INVEST OPHTH VIS SCI, V39, P120; Artal P, 2006, J VISION, V6, P1, DOI 10.1167/6.1.1; Atchison DA, 2008, J VISION, V8, DOI 10.1167/8.4.29; Benny Y, 2007, J OPT SOC AM A, V24, P1538, DOI 10.1364/JOSAA.24.001538; Brunette I, 2003, INVEST OPHTH VIS SCI, V44, P5438, DOI 10.1167/iovs.02-1042; Castejon-Mochon JF, 2002, VISION RES, V42, P1611; Fernandez E. J., 2004, NEAR INFRARED OCULAR, V2836; Fernandez EJ, 2005, OPT EXPRESS, V13, P8184, DOI 10.1364/OPEX.13.008184; Fujikado T, 2004, AM J OPHTHALMOL, V138, P143, DOI 10.1016/j.ajo.2004.01.051; Hammer DX, 1999, P SOC PHOTO-OPT INS, V3591, P22, DOI 10.1117/12.350572; HOWARTH PA, 1988, J OPT SOC AM A, V5, P2087, DOI 10.1364/JOSAA.5.002087; HOWARTH PA, 1984, OPHTHAL PHYSL OPT, V4, P223, DOI 10.1111/j.1475-1313.1984.tb00359.x; Koh S, 2006, INVEST OPHTH VIS SCI, V47, P3318, DOI 10.1167/iovs.06-0018; KROGER RHH, 1992, J OPT SOC AM A, V9, P1486; Kuroda T, 2002, AM J OPHTHALMOL, V134, P1, DOI 10.1016/S0002-9394(02)01402-2; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P427; Le Grand Y., 1967, FORM SPACE VISION; MALIK NS, 1992, BIOCHIM BIOPHYS ACTA, V1138, P222, DOI 10.1016/0925-4439(92)90041-K; Marcos S, 2001, VISION RES, V41, P3861, DOI 10.1016/S0042-6989(01)00133-X; MILLODOT M, 1976, A GRAEF ARCH KLIN EX, V198, P235, DOI 10.1007/BF00410716; MORDI JA, 1985, AM J OPTOM PHYS OPT, V62, P864; NAVARRO R, 1985, J OPT SOC AM A, V2, P1273, DOI 10.1364/JOSAA.2.001273; POWELL I, 1981, APPL OPTICS, V20, P4152, DOI 10.1364/AO.20.004152; R Core Team, 2013, R LANG ENV STAT COMP; TAKEHANA M, 1987, INVEST OPHTH VIS SCI, V28, P780; THIBOS LN, 1992, APPL OPTICS, V31, P3594, DOI 10.1364/AO.31.003594; Vinas M, 2015, BIOMED OPT EXPRESS, V6, P948, DOI [10.1364/BOE.6.000948, 10.1364/OE.23.00948]; WALD G, 1947, J OPT SOC AM, V37, P321, DOI 10.1364/JOSA.37.000321; WARE C, 1982, GRAEF ARCH CLIN EXP, V218, P39, DOI 10.1007/BF02134100; Wyszecki G, 2000, COLOR SCI; Zar J. H., 2010, BIOSTATISTICAL ANAL	58	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	JUL 1	2015	6	7					2676	2694		10.1364/BOE.6.002676		19	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	CM1IT	WOS:000357435200031		
J	Yamazaki, H; Uchiyama, S; Komatsu, M; Hashimoto, S; Kobayashi, Y; Sakurai, T; Kato, H				Yamazaki, H.; Uchiyama, S.; Komatsu, M.; Hashimoto, S.; Kobayashi, Y.; Sakurai, T.; Kato, H.			Arthroscopic assistance does not improve the functional or radiographic outcome of unstable intra-articular distal radial fractures treated with a volar locking plate A RANDOMISED CONTROLLED TRIAL	BONE & JOINT JOURNAL			English	Article							INTERNAL-FIXATION; OPEN REDUCTION; EXTERNAL FIXATION; DISABILITY; MANAGEMENT	There is no consensus on the benefit of arthroscopically assisted reduction of the articular surface combined with fixation using a volar locking plate for the treatment of intra-articular distal radial fractures. In this study we compared the functional and radiographic outcomes of fluoroscopically and arthroscopically guided reduction of these fractures. Between February 2009 and May 2013, 74 patients with unilateral unstable intra-articular distal radial fractures were randomised equally into the two groups for treatment. The mean age of these 74 patients was 64 years (24 to 92). We compared functional outcomes including active range of movement of the wrist, grip strength and Disabilities of the Arm, Shoulder, and Hand scores at six and 48 weeks; and radiographic outcomes that included gap, step, radial inclination, volar angulation and ulnar variance. There were no significant differences between the techniques with regard to functional outcomes or radiographic parameters. The mean gap and step in the fluoroscopic and arthroscopic groups were comparable at 0.9 mm (standard deviation (SD) 0.7) and 0.7 mm (SD 0.7) and 0.6 mm (SD 0.6) and 0.4 mm (SD 0.5), respectively; p = 0.18 and p = 0.35). Arthroscopic reduction conferred no advantage over conventional fluoroscopic guidance in achieving anatomical reduction of intra-articular distal radial fractures when using a volar locking plate.	[Yamazaki, H.; Komatsu, M.; Hashimoto, S.; Kobayashi, Y.; Sakurai, T.] Aizawa Hosp, Dept Orthoped Surg, Matsumoto, Nagano 3908510, Japan; [Uchiyama, S.; Kato, H.] Aizawa Hosp, Matsumoto, Nagano 3908510, Japan	Yamazaki, H (reprint author), Aizawa Hosp, Dept Orthoped Surg, 1-5-2 Honjo, Matsumoto, Nagano 3908510, Japan.	hiroshiymzk1017@ybb.ne.jp					Abe Yukio, 2008, Tech Hand Up Extrem Surg, V12, P136, DOI 10.1097/BTH.0b013e3181670fe3; Rozental TD, 2009, J BONE JOINT SURG AM, V91A, P1837, DOI 10.2106/JBJS.H.01478; Rhee SH, 2013, BONE JOINT J, V95B, P396, DOI 10.1302/0301-620X.95B3.30514; Wright TW, 2005, J HAND SURG-AM, V30A, P289, DOI 10.1016/j.jhsa.2004.11.014; Richards RS, 1997, J HAND SURG-AM, V22A, P772, DOI 10.1016/S0363-5023(97)80068-8; Mehta JA, 2000, J BONE JOINT SURG BR, V82B, P79, DOI 10.1302/0301-620X.82B1.10101; Souer JS, 2009, J BONE JOINT SURG AM, V91A, P830, DOI 10.2106/JBJS.H.00345; Geissler WB, 1996, J BONE JOINT SURG AM, V78A, P357; Egol K, 2008, J BONE JOINT SURG BR, V90B, P1214, DOI 10.1302/0301-620X.90B9.20521; Swart E, 2012, J HAND SURG-AM, V37A, P957, DOI 10.1016/j.jhsa.2012.01.028; Leung F, 2008, J BONE JOINT SURG AM, V90A, P16, DOI 10.2106/JBJS.F.01581; Imaeda T, 2005, J ORTHOP SCI, V10, P353, DOI 10.1007/s00776-005-0917-5; Auge WK, 2000, ARTHROSCOPY, V16, P830, DOI 10.1053/jars.2000.17717; Boyer MI, 2004, J HAND SURG-AM, V29A, P116, DOI 10.1016/j.jhsa.2003.09.004; Choi WS, 2015, BONE JOINT J, V97B, P229, DOI 10.1302/0301-620X.97B2.34613; Cole RJ, 1997, J HAND SURG-AM, V22A, P792; CULP RW, 1995, ORTHOP CLIN N AM, V26, P739; del Pinal F, 2011, J HAND SURG-AM, V36A, P1694, DOI 10.1016/j.jhsa.2011.07.021; Doi K, 1999, J BONE JOINT SURG AM, V81A, P1093; Edwards CC, 2001, J HAND SURG-AM, V26A, P1036, DOI 10.1053/jhsu.2001.28760; Fernandez DL, 1995, FRACTURE DISTAL RADI, P26; Fess E. E., 1981, CLIN ASSESSMENT RECO; Gehrmann SV, 2008, J HAND SURG-AM, V33A, P421, DOI 10.1016/j.jhsa.2007.12.016; LEVY HJ, 1993, ARTHROSCOPY, V9, P122, DOI 10.1016/S0749-8063(05)80358-5; Lutsky K, 2008, J HAND SURG-AM, V33A, P476, DOI 10.1016/j.jhsa.2007.12.009; Mellstrand-Navarro C, 2014, BONE JOINT J, V96B, P963, DOI 10.1302/0301-620X.96B7.33149; Ruch DS, 2004, ARTHROSCOPY, V20, P225, DOI 10.1016/j.arthro.2004.01.010; Varitimidis SE, 2008, J BONE JOINT SURG BR, V90B, P778, DOI 10.1302/0301-620X.90B6.19809; Wolfe SW, 1995, ARTHROSCOPY, V11, P706, DOI 10.1016/0749-8063(95)90114-0	29	0	0	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	2049-4394			BONE JOINT J	Bone Joint J.	JUL	2015	97B	7					957	962		10.1302/0301-620X.97B7.35354		6	Orthopedics; Surgery	Orthopedics; Surgery	CM2FL	WOS:000357495200016		
J	Vousden, DA; Epp, J; Okuno, H; Nieman, BJ; van Eede, M; Dazai, J; Ragan, T; Bito, H; Frankland, PW; Lerch, JP; Henkelman, RM				Vousden, Dulcie A.; Epp, Jonathan; Okuno, Hiroyuki; Nieman, Brian J.; van Eede, Matthijs; Dazai, Jun; Ragan, Timothy; Bito, Haruhiko; Frankland, Paul W.; Lerch, Jason P.; Henkelman, R. Mark			Whole-brain mapping of behaviourally induced neural activation in mice	BRAIN STRUCTURE & FUNCTION			English	Article						Neuroimaging; Immediate-early genes; Memory; Functional networks; Serial two-photon tomography	CONTEXTUAL FEAR MEMORY; EARLY GENE-EXPRESSION; SYNAPTIC PLASTICITY; FLUORESCENT PROTEIN; MOUSE-BRAIN; IN-VIVO; ARC/ARG3.1; AMYGDALA; MODEL; REGISTRATION	The ability to visualize behaviourally evoked neural activity patterns across the rodent brain is essential for understanding the distributed brain networks mediating particular behaviours. However, current imaging methods are limited in their spatial resolution and/or ability to obtain brain-wide coverage of functional activity. Here, we describe a new automated method for obtaining cellular-level, whole-brain maps of behaviourally induced neural activity in the mouse. This method combines the use of transgenic immediate-early gene reporter mice to visualize neural activity; serial two-photon tomography to image the entire brain at cellular resolution; advanced image processing algorithms to count the activated neurons and align the datasets to the Allen Mouse Brain Atlas; and statistical analysis to identify the network of activated brain regions evoked by behaviour. We demonstrate the use of this approach to determine the whole-brain networks activated during the retrieval of fear memories. Consistent with previous studies, we identified a large network of amygdalar, hippocampal, and neocortical brain regions implicated in fear memory retrieval. Our proposed methods can thus be used to map cellular networks involved in the expression of normal behaviours as well as to investigate in depth circuit dysfunction in mouse models of neurobiological disease.	[Vousden, Dulcie A.; Nieman, Brian J.; van Eede, Matthijs; Dazai, Jun; Lerch, Jason P.; Henkelman, R. Mark] Hosp Sick Children, Mouse Imaging Ctr, Toronto, ON M5T 3H7, Canada; [Vousden, Dulcie A.; Epp, Jonathan; Frankland, Paul W.; Lerch, Jason P.] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Vousden, Dulcie A.; Nieman, Brian J.; Lerch, Jason P.; Henkelman, R. Mark] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Okuno, Hiroyuki; Bito, Haruhiko] Univ Tokyo, Grad Sch Med, Dept Neurochem, CREST JST,Bunkyo Ku, Tokyo 1130033, Japan; [Nieman, Brian J.; Henkelman, R. Mark] Hosp Sick Children, Program Physiol & Expt Med, Toronto, ON M5G 1X8, Canada; [Ragan, Timothy] TissueVision Inc, Cambridge, MA 02139 USA; [Frankland, Paul W.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Frankland, Paul W.] Univ Toronto, Dept Physiol, Toronto, ON, Canada	Vousden, DA (reprint author), Hosp Sick Children, Mouse Imaging Ctr, 25 Orde St, Toronto, ON M5T 3H7, Canada.	d.vousden@utoronto.ca; hbito@m.u-tokyo.ac.jp	Bito, Haruhiko/A-8635-2008; Henkelman, Mark/F-3662-2011		Canadian Foundation for Innovation; Canadian Institute for Health Research (CIHR); Natural Science and Engineering Research Council (NSERC-DV); Ontario Research Foundation; CREST-JST; JSPS (KIBAN); JSPS (WAKATE); MHLW of Japan; Canada Research Chair	Research was supported by the Canadian Foundation for Innovation, Canadian Institute for Health Research (CIHR), Natural Science and Engineering Research Council (NSERC-DV), Ontario Research Foundation, a CREST-JST grant (HB and HO), and by Grants-in-Aid from JSPS (KIBAN to HO, WAKATE to HB) and from MHLW of Japan (to HB and HO). RMH was supported by a Canada Research Chair.	Ferris CF, 2011, REV NEUROSCIENCE, V22, P665, DOI 10.1515/RNS.2011.050; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Lerch JR, 2011, METHODS MOL BIOL, V711, P349, DOI 10.1007/978-1-61737-992-5_17; Alivisatos AP, 2012, NEURON, V74, P970, DOI 10.1016/j.neuron.2012.06.006; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; ZHU XO, 1995, NEUROSCIENCE, V69, P821, DOI 10.1016/0306-4522(95)00320-I; Barth AL, 2007, CURR OPIN NEUROBIOL, V17, P567, DOI 10.1016/j.conb.2007.10.003; Tayler KK, 2013, CURR BIOL, V23, P99, DOI 10.1016/j.cub.2012.11.019; Reijmers LG, 2007, SCIENCE, V317, P1230, DOI 10.1126/science.1143839; Eguchi M, 2009, NEUROIMAGE, V44, P1274, DOI 10.1016/j.neuroimage.2008.10.046; Okuno H, 2012, CELL, V149, P886, DOI 10.1016/j.cell.2012.02.062; Guzowski JF, 2005, CURR OPIN NEUROBIOL, V15, P599, DOI 10.1016/j.conb.2005.08.018; Ragan T, 2012, NAT METHODS, V9, P255, DOI [10.1038/nmeth.1854, 10.1038/NMETH.1854]; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Shepherd JD, 2011, NAT NEUROSCI, V14, P279, DOI 10.1038/nn.2708; CAMPEAU S, 1995, J NEUROSCI, V15, P2312; Mamiya N, 2009, J NEUROSCI, V29, P402, DOI 10.1523/JNEUROSCI.4639-08.2009; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Josselyn SA, 2001, J NEUROSCI, V21, P2404; Corcoran KA, 2011, J NEUROSCI, V31, P11655, DOI 10.1523/JNEUROSCI.2107-11.2011; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Lerch JP, 2008, NEUROIMAGE, V39, P32, DOI 10.1016/j.neuroimage.2007.08.033; Kawashima T, 2009, P NATL ACAD SCI USA, V106, P316, DOI 10.1073/pnas.0806518106; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Tzingounis AV, 2006, NEURON, V52, P403, DOI 10.1016/j.neuron.2006.10.016; Okuno H, 2011, NEUROSCI RES, V69, P175, DOI 10.1016/j.neures.2010.12.007; Peters LL, 2007, NAT REV GENET, V8, P58, DOI 10.1038/nrg2025; Kawashima T, 2013, NAT METHODS, V10, P889, DOI [10.1038/nmeth.2559, 10.1038/NMETH.2559]; Mikuni T, 2013, NEURON, V78, P1024, DOI 10.1016/j.neuron.2013.04.036; Rudinskiy N, 2012, NAT NEUROSCI, V15, P1422, DOI 10.1038/nn.3199; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Huff NC, 2006, J NEUROSCI, V26, P1616, DOI 10.1523/JNEUROSCI.4964-05.2006; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Kerr JND, 2008, NAT REV NEUROSCI, V9, P195, DOI 10.1038/nrn2338; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; CORODIMAS KP, 1995, BEHAV NEUROSCI, V109, P613, DOI 10.1037/0735-7044.109.4.613; Gusev PA, 2005, J NEUROSCI, V25, P9384, DOI 10.1523/JNEUROSCI.0832-05.2005; Henkelman RM, 2010, ANNU REV BIOMED ENG, V12, P143, DOI 10.1146/annurev-bioeng-070909-105343; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Lee I, 2004, HIPPOCAMPUS, V14, P301, DOI 10.1002/hipo.10177; Ploski JE, 2008, J NEUROSCI, V28, P12383, DOI 10.1523/JNEUROSCI.1662-08.2008; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn855; Wheeler AL, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002853; Yamasaki Y, 2012, EUR J NEUROSCI	50	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JUL	2015	220	4					2043	2057		10.1007/s00429-014-0774-0		15	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CL3TY	WOS:000356874700012		
J	Kim, J; Park, TJ; Kwon, N; Lee, D; Kim, S; Kohmura, Y; Ishikawa, T; Kim, KT; Curran, T; Je, JH				Kim, Jinkyung; Park, Tae-Ju; Kwon, Namseop; Lee, Dongmyeong; Kim, Seunghwan; Kohmura, Yoshiki; Ishikawa, Tetsuya; Kim, Kyong-Tai; Curran, Tom; Je, Jung Ho			Dendritic planarity of Purkinje cells is independent of Reelin signaling	BRAIN STRUCTURE & FUNCTION			English	Article						Dendritic planarity; Purkinje cell; Reelin signaling; Migration; Synchrotron X-ray imaging	NEURONAL MIGRATION; MICE LACKING; MUTANT MICE; CRK; PATHWAY; ROLES; MOUSE; DISABLED-1; MORPHOLOGY; RADIOLOGY	The dendritic planarity of Purkinje cells is critical for cerebellar circuit formation. In the absence of Crk and CrkL, the Reelin pathway does not function resulting in partial Purkinje cell migration and defective dendritogenesis. However, the relationships among Purkinje cell migration, dendritic development and Reelin signaling have not been clearly delineated. Here, we use synchrotron X-ray microscopy to obtain 3-D images of Golgi-stained Purkinje cell dendrites. Purkinje cells that failed to migrate completely exhibited conical dendrites with abnormal 3-D arborization and reduced dendritic complexity. Furthermore, their spines were fewer in number with a distorted morphology. In contrast, Purkinje cells that migrated successfully displayed planar dendritic and spine morphologies similar to normal cells, despite reduced dendritic complexity. These results indicate that, during cerebellar formation, Purkinje cells migrate into an environment that supports development of dendritic planarity and spine formation. While Reelin signaling is important for the migration process, it does not make a direct major contribution to dendrite formation.	[Kim, Jinkyung; Kwon, Namseop; Je, Jung Ho] Pohang Univ Sci & Technol POSTECH, Xray Imaging Ctr, Sch Interdisciplinary Biosci & Bioengn, Pohang 790784, South Korea; [Park, Tae-Ju; Curran, Tom] Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Lee, Dongmyeong; Kim, Seunghwan] Pohang Univ Sci & Technol POSTECH, APCTP, Pohang 790784, South Korea; [Lee, Dongmyeong; Kim, Seunghwan] Pohang Univ Sci & Technol POSTECH, Dept Phys, IES NCSL, Pohang 790784, South Korea; [Kohmura, Yoshiki; Ishikawa, Tetsuya] RIKEN SPring 8 Ctr, Sayo, Hyogo 6795198, Japan; [Kim, Kyong-Tai] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, South Korea; [Kim, Kyong-Tai] Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang 790784, South Korea; [Je, Jung Ho] Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, Pohang 790784, South Korea	Curran, T (reprint author), Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	ktk@postech.ac.kr; currant@email.chop.edu; jhje@postech.ac.kr	Curran, Tom/D-7515-2011; Ishikawa, Tetsuya/I-4775-2012	Ishikawa, Tetsuya/0000-0002-6906-9909	National Research Foundation of Korea (NRF) grant - Korea government [2006-0050683]; Pennsylvania Department of Health Cure Formulary grant (SAP) [4100047628]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2006-0050683). This work was also supported by a Pennsylvania Department of Health Cure Formulary grant (SAP#4100047628 to T.C.). We thank Hanna Li for her technical assistance.	SHOLL DA, 1953, J ANAT, V87, P387; Matsuki T, 2008, J CELL SCI, V121, P1869, DOI 10.1242/jcs.027334; Ito M, 2002, NAT REV NEUROSCI, V3, P896, DOI 10.1038/nrn962; Park TJ, 2008, J NEUROSCI, V28, P13551, DOI 10.1523/JNEUROSCI.4323-08.2008; D'Arcangelo G, 2006, EPILEPSY BEHAV, V8, P81, DOI 10.1016/j.yebenh.2005.09.005; Valiente M, 2010, CURR OPIN NEUROBIOL, V20, P68, DOI 10.1016/j.conb.2009.12.003; Wu HR, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022-3727/45/24/242001; Katsuyama Y, 2009, DEV GROWTH DIFFER, V51, P271, DOI 10.1111/j.1440-169X.2009.01102.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Pinzer BR, 2012, NEUROIMAGE, V61, P1336, DOI 10.1016/j.neuroimage.2012.03.029; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009; Chen YT, 2011, OPT LETT, V36, P1269, DOI 10.1364/OL.36.001269; Lo TN, 2007, J PHYS D APPL PHYS, V40, P3172, DOI 10.1088/0022-3727/40/10/021; Margaritondo G, 2004, RIV NUOVO CIMENTO, V27, P1, DOI 10.1393/ncr/i2005-10004-0; Park TJ, 2006, MOL CELL BIOL, V26, P6272, DOI 10.1128/MCB.00472-06; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Friedland DR, 2006, J NEUROSCI METH, V150, P90, DOI 10.1016/j.jneumeth.2005.06.004; Goldowitz D, 1997, J NEUROSCI, V17, P8767; Sugihara I, 1999, J COMP NEUROL, V414, P131; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Hwu Y, 2002, J PHYS D APPL PHYS, V35, pR105, DOI 10.1088/0022-3727/35/13/201; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Rochefort NL, 2012, EMBO REP, V13, P699, DOI 10.1038/embor.2012.102; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; Chen KL, 2004, J CELL SCI, V117, P4527, DOI 10.1242/jcs.01320; Chen YT, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/39/395302; Goffinet A M, 1984, Brain Res, V319, P261; Golgi C, 1995, SULLA FINA ANATOMIA; Greg Stuart NS, 1999, DENDRITES; Huang YC, 2004, BIOCHEM BIOPH RES CO, V318, P204, DOI 10.1016/j.bbrc.2004.04.023; Javier RM, 2012, NAT NEUROSCI, V15, P503, DOI 10.1038/nn.3076; Kim J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00984; Kim J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00468; Kim J., 2011, SCI REP, V1, P1; Krstic D, 2013, NEUROSCIENCE, V246, P108, DOI 10.1016/j.neuroscience.2013.04.042; Kurihara H, 1997, J NEUROSCI, V17, P9613; Lee KJ, 2005, CEREBELLUM, V4, P97, DOI 10.1080/14734220510007842; Shen Q, 2007, NUCL INSTRUM METH A, V582, P77, DOI 10.1016/j.nima.2007.08.169; Smith TG, 1996, J NEUROSCI METH, V69, P123, DOI 10.1016/S0165-0270(96)00080-5	43	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JUL	2015	220	4					2263	2273		10.1007/s00429-014-0780-2		11	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CL3TY	WOS:000356874700028		
J	Tomsett, RJ; Ainsworth, M; Thiele, A; Sanayei, M; Chen, X; Gieselmann, MA; Whittington, MA; Cunningham, MO; Kaiser, M				Tomsett, Richard J.; Ainsworth, Matt; Thiele, Alexander; Sanayei, Mehdi; Chen, Xing; Gieselmann, Marc A.; Whittington, Miles A.; Cunningham, Mark O.; Kaiser, Marcus			Virtual Electrode Recording Tool for EXtracellular potentials (VERTEX): comparing multi-electrode recordings from simulated and biological mammalian cortical tissue	BRAIN STRUCTURE & FUNCTION			English	Article						Local field potential; Computational modelling; Gamma oscillation; Macaque; Neocortex; Microconnectome	HIGH-FREQUENCY OSCILLATIONS; CORTEX IN-VITRO; PERSISTENT GAMMA OSCILLATIONS; LOCAL-FIELD POTENTIALS; MACAQUE STRIATE CORTEX; PRIMARY VISUAL-CORTEX; INTRINSIC CONNECTIONS; INTERNEURON NETWORKS; RECEPTOR ACTIVATION; PYRAMIDAL NEURONS	Local field potentials (LFPs) sampled with extracellular electrodes are frequently used as a measure of population neuronal activity. However, relating such measurements to underlying neuronal behaviour and connectivity is non-trivial. To help study this link, we developed the Virtual Electrode Recording Tool for EXtracellular potentials (VERTEX). We first identified a reduced neuron model that retained the spatial and frequency filtering characteristics of extracellular potentials from neocortical neurons. We then developed VERTEX as an easy-to-use Matlab tool for simulating LFPs from large populations (> 100,000 neurons). A VERTEX-based simulation successfully reproduced features of the LFPs from an in vitro multi-electrode array recording of macaque neocortical tissue. Our model, with virtual electrodes placed anywhere in 3D, allows direct comparisons with the in vitro recording setup. We envisage that VERTEX will stimulate experimentalists, clinicians, and computational neuroscientists to use models to understand the mechanisms underlying measured brain dynamics in health and disease.	[Tomsett, Richard J.; Kaiser, Marcus] Newcastle Univ, Sch Comp Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Tomsett, Richard J.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England; [Tomsett, Richard J.] Okinawa Inst Sci & Technol, Computat Neurosci Unit, Okinawa 9040495, Japan; [Ainsworth, Matt; Whittington, Miles A.] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England; [Thiele, Alexander; Sanayei, Mehdi; Chen, Xing; Gieselmann, Marc A.; Cunningham, Mark O.; Kaiser, Marcus] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Kaiser, M (reprint author), Newcastle Univ, Sch Comp Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	indigentmartian@gmail.com; m.kaiser@ncl.ac.uk	Kaiser, Marcus/A-7166-2008; Tomsett, Richard/B-6892-2015	Kaiser, Marcus/0000-0002-4654-3110; Tomsett, Richard/0000-0002-8999-6515	BBSRC [BB/F016980/1]; CARMEN e-science project; EPSRC [EP/E002331/1, EP/G03950X/1, EP/K026992/1]; MRC; BBSRC; Wellcome Trust; EPSRC; Wolfson Foundation; Wellcome Trust Senior Investigator Award	We thank the anonymous reviewers for their constructive and insightful comments, which helped us to greatly improve the final manuscript. RJT was supported by the BBSRC (BB/F016980/1). MA and MK were funded as part of the CARMEN e-science project (http://www.carmen.org.uk) by the EPSRC (EP/E002331/1). MK also received support from the EPSRC (EP/G03950X/1, EP/K026992/1). AT was supported by the MRC, BBSRC and the Wellcome Trust. MOC was supported by the EPSRC, MRC and the Wolfson Foundation. MW is supported by a Wellcome Trust Senior Investigator Award.	Andersen RA, 2004, TRENDS COGN SCI, V8, P486, DOI 10.1016/j.tics.2004.09.009; Fisahn A, 1998, NATURE, V394, P186, DOI 10.1038/28179; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; Traub RD, 2005, J PHYSIOL-LONDON, V562, P3, DOI 10.1113/johysiol.2004.074641; Izhikevich EM, 2008, P NATL ACAD SCI USA, V105, P3593, DOI 10.1073/pnas.0712231105; Berdondini L, 2009, LAB CHIP, V9, P2644, DOI 10.1039/b907394a; Whittington MA, 2011, DEV NEUROBIOL, V71, P92, DOI 10.1002/dneu.20814; Borgers C, 2005, P NATL ACAD SCI USA, V102, P7002, DOI 10.1073/pnas.0502366102; Holt GR, 1999, J COMPUT NEUROSCI, V6, P169, DOI 10.1023/A:1008832702585; Rubino D, 2006, NAT NEUROSCI, V9, P1549, DOI 10.1038/nn1802; Voges N, 2010, J COMPUT NEUROSCI, V28, P137, DOI 10.1007/s10827-009-0193-z; Schevon CA, 2009, BRAIN, V132, P3047, DOI 10.1093/brain/awp222; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; Ascoli GA, 2007, J NEUROSCI, V27, P9247, DOI 10.1523/JNEUROSCI.2055-07.2007; Traub RD, 2005, J NEUROPHYSIOL, V93, P2194, DOI 10.1152/jn.00983.2004; NICHOLSON C, 1975, J NEUROPHYSIOL, V38, P356; Hutcheon B, 2000, TRENDS NEUROSCI, V23, P216, DOI 10.1016/S0166-2236(00)01547-2; Bartos M, 2007, NAT REV NEUROSCI, V8, P45, DOI 10.1038/nrn2044; Maynard EM, 1997, ELECTROEN CLIN NEURO, V102, P228, DOI 10.1016/S0013-4694(96)95176-0; Logothetis NK, 2007, NEURON, V55, P809, DOI 10.1016/j.neuron.2007.07.027; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; Anastassiou CA, 2011, NAT NEUROSCI, V14, P217, DOI 10.1038/nn.2727; Brette R, 2012, NETWORK-COMP NEURAL, V23, P167, DOI 10.3109/0954898X.2012.730170; Ainsworth M, 2011, J NEUROSCI, V31, P17040, DOI 10.1523/JNEUROSCI.2209-11.2011; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Binzegger T, 2004, J NEUROSCI, V24, P8441, DOI 10.1523/JNEUROSCI.1400-04.2004; Izhikevich EM, 2006, NEURAL COMPUT, V18, P245, DOI 10.1162/089976606775093882; Brette R, 2005, J NEUROPHYSIOL, V94, P3637, DOI 10.1152/jn.00686.2005; Linden H, 2010, J COMPUT NEUROSCI, V29, P423, DOI 10.1007/s10827-010-0245-4; Borgers C, 2005, NEURAL COMPUT, V17, P557, DOI 10.1162/0899766053019908; Frohlich F, 2010, NEURON, V67, P129, DOI 10.1016/j.neuron.2010.06.005; Bedard C, 2009, BIOPHYS J, V96, P2589, DOI 10.1016/j.bpj.2008.12.3951; Einevoll GT, 2013, NAT REV NEUROSCI, V14, P770, DOI 10.1038/nrn3599; Frey U, 2009, BIOSENS BIOELECTRON, V24, P2191, DOI 10.1016/j.bios.2008.11.028; Pafundo DE, 2013, J PHYSIOL-LONDON, V591, P4725, DOI 10.1113/jphysiol.2013.253823; Binzegger T, 2007, J NEUROSCI, V27, P12242, DOI 10.1523/JNEUROSCI.3753-07.2007; Simon A, 2014, EUR J NEUROSCI, V39, P46, DOI 10.1111/ejn.12386; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; Potjans TC, 2014, CEREB CORTEX, V24, P785, DOI 10.1093/cercor/bhs358; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Morrison A, 2005, NEURAL COMPUT, V17, P1776, DOI 10.1162/0899766054026648; Pettersen KH, 2008, BIOPHYS J, V94, P784, DOI 10.1529/biophysj.107.111179; BLASDEL GG, 1985, J NEUROSCI, V5, P3350; Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002; Cunningham MO, 2003, J NEUROSCI, V23, P9761; Voges N, 2010, PROG NEUROBIOL, V92, P277, DOI 10.1016/j.pneurobio.2010.05.001; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Linden H, 2011, NEURON, V72, P859, DOI 10.1016/j.neuron.2011.11.006; Draguhn A, 1998, NATURE, V394, P189, DOI 10.1038/28184; Arsiero M, 2007, J NEUROSCI, V27, P3274, DOI 10.1523/JNEUROSCI.4937-06.2007; Bauer R, 2014, CEREB CORTEX, V24, P487, DOI 10.1093/cercor/bhs327; Brette R, 2012, HANDBOOK OF NEURAL ACTIVITY MEASUREMENT, P1, DOI 10.1017/CBO9780511979958; Brette R, 2011, NEURAL COMPUT, V23, P1503, DOI 10.1162/NECO_a_00123; BUSH PC, 1993, J NEUROSCI METH, V46, P159, DOI 10.1016/0165-0270(93)90151-G; Cunningham MO, 2004, P NATL ACAD SCI USA, V101, P7152, DOI 10.1073/pnas.0402060101; Cunningham MO, 2004, J PHYSIOL-LONDON, V559, P347, DOI 10.1113/jphysiol.2004.068973; Dehghani N, 2010, J COMPUT NEUROSCI, V29, P405, DOI 10.1007/s10827-010-0263-2; Einevoll GT, 2012, NEUROINFORMATICS 201; Leski S, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003137; FITZPATRICK D, 1985, J NEUROSCI, V5, P3329; Gewaltig MO, 2007, SCHOLARPEDIA, V2, P1430, DOI DOI 10.4249/SCHOLARPEDIA.1430; Gleeson P, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000815; Hellwig B, 2000, BIOL CYBERN, V82, P111, DOI 10.1007/PL00007964; Hines Michael L, 2009, Front Neuroinform, V3, P1, DOI 10.3389/neuro.11.001.2009; Holt G, 1998, THESIS CALTECH; Johnston D., 1995, FDN CELLULAR NEUROPH; Le Van Quyen M, 2007, TRENDS NEUROSCI, V30, P365, DOI 10.1016/j.tins.2007.05.006; Linden H, 2014, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00041; Lumer ED, 1997, CEREB CORTEX, V7, P207, DOI 10.1093/cercor/7.3.207; Nunez PL, 2006, ELECT FIELDS BRAIN N; Pettersen KH, 2012, HANDBOOK OF NEURAL ACTIVITY MEASUREMENT, P92; Press W.H., 2007, NUMERICAL RECIPES AR; Roopun AK, 2008, FRONT CELL NEUROSCI, V2, DOI 10.3389/neuro.03.001.2008; Schevon CA, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2056; Zhang MM, 2014, J NEUROSCI, V34, P1409, DOI 10.1523/JNEUROSCI.3877-13.2014	77	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JUL	2015	220	4					2333	2353		10.1007/s00429-014-0793-x		21	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CL3TY	WOS:000356874700033		
J	Perez, NM; Somoza, L; Hernandez, PA; de Vallejo, LG; Leon, R; Sagiya, T; Biain, A; Gonzalez, FJ; Medialdea, T; Barrancos, J; Ibanez, J; Sumino, H; Nogami, K; Romero, C				Perez, N. M.; Somoza, L.; Hernandez, P. A.; Gonzalez de Vallejo, L.; Leon, R.; Sagiya, T.; Biain, A.; Gonzalez, F. J.; Medialdea, T.; Barrancos, J.; Ibanez, J.; Sumino, H.; Nogami, K.; Romero, C.			Reply to comment from Blanco et al. (2015) on "Evidence from acoustic imaging for submarine volcanic activity in 2012 off the west coast of El Hierro (Canary Islands, Spain) by Perez et al. [Bull. Volcanol. (2014), 76:882-896]	BULLETIN OF VOLCANOLOGY			English	Editorial Material							DECEPTION ISLAND; ERUPTION; ANTARCTICA; SEISMICITY; INSIGHTS; TREMOR; ARRAY		[Perez, N. M.; Hernandez, P. A.; Gonzalez de Vallejo, L.; Sagiya, T.; Barrancos, J.; Ibanez, J.; Romero, C.] Inst Volcanol Canarias INVOLCAN, Puerto La Cruz, Canary Isl, Spain; [Somoza, L.; Leon, R.; Biain, A.; Gonzalez, F. J.; Medialdea, T.] IGME, Marine Geol Div, Madrid, Spain; [Perez, N. M.; Hernandez, P. A.; Barrancos, J.] ITER, Div Environm Res, Granadilla De Abona, Canary Isl, Spain; [Gonzalez de Vallejo, L.] Univ Complutense Madrid, Fac Ciencias Geol, Madrid, Spain; [Sagiya, T.] Nagoya Univ, Disaster Mitigat Res Ctr, Nagoya, Aichi 4648601, Japan; [Ibanez, J.] Univ Granada, Inst Andaluz Geofis, Granada, Spain; [Sumino, H.] Univ Tokyo, Geochem Res Ctr, Bunkyo Ku, Tokyo, Japan; [Nogami, K.] Tokyo Inst Technol, Volcan Fluid Res Ctr, Gunma, Japan; [Romero, C.] Univ La Laguna, Fac Geog & Hist, E-38207 San Cristobal la Laguna, Tenerife, Spain	Hernandez, PA (reprint author), Inst Volcanol Canarias INVOLCAN, Puerto La Cruz, Canary Isl, Spain.	phdez@iter.es	Barrancos, Jose/H-7681-2015; 	Barrancos, Jose/0000-0002-6224-5471; Sumino, Hirochika/0000-0002-4689-6231			Alguacil G, 1999, ANN GEOFIS, V42, P417; Almendros J, 2000, J VOLCANOL GEOTH RES, V103, P439, DOI 10.1016/S0377-0273(00)00236-5; Almendros J, 1999, GEOPHYS J INT, V136, P159, DOI 10.1046/j.1365-246X.1999.00699.x; Almendros J, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002930; Chouet BA, 1996, NATURE, V380, P309, DOI 10.1038/380309a0; Rivera J, 2013, GEOLOGY, V41, P355, DOI 10.1130/G33863.1; Pedersen R, 2007, J VOLCANOL GEOTH RES, V162, P73, DOI 10.1016/j.jvolgeores.2006.12.010; Chouet BA, 2013, J VOLCANOL GEOTH RES, V252, P108, DOI 10.1016/j.jvolgeores.2012.11.013; Padron E, 2013, GEOLOGY, V41, P539, DOI 10.1130/G34027.1; Ibanez JM, 2012, GEOPHYS J INT, V191, P659, DOI 10.1111/j.1365-246X.2012.05629.x; Cerdena ID, 2014, B SEISMOL SOC AM, V104, P567, DOI 10.1785/0120130200; Baker ET, 1995, SPECIAL PUBLICATION, V87, P65; Becerril L, 2015, TECTONOPHYSICS, V647, P33, DOI 10.1016/j.tecto.2015.02.006; Blanco MJ, 2015, B VOLCANOL, V76, P882, DOI [10.1007/s00445-014-0882-y, DOI 10.1007/S00445-014-0882-Y]; Caracausi A, 2005, GEOCHEM J, V39, P449; Carmona E, 2010, J GEOPHYS RES, V115, P1, DOI 10.1029/2009JB006865; de Zeeuw-van Dalfsen E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020059; Garcia A, 2006, EOS, V87, P61, DOI [10.1029/2006EO060001, DOI 10.1029/2006EO060001]; Garcia-Yeguas A, 2014, GEOPHYS J INT, V199, P1739, DOI 10.1093/gji/ggu339; Gonzalez PJ, 2013, J GEOPHYS RES-SOL EA, V118, P4361, DOI 10.1002/jgrb.50289; Guillen C, 2012, VOLCANISMO AMBIENTES; Hernandez PA, 2014, REMOTE SENS ENVIRON, V154, P219, DOI 10.1016/j.rse.2014.08.027; Ibanez JM, 2000, J GEOPHYS RES-SOL EA, V105, P13905, DOI 10.1029/2000JB900013; ITALIANO F, 1991, J VOLCANOL GEOTH RES, V46, P125, DOI 10.1016/0377-0273(91)90079-F; Lopez C, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051846; Lu Z, 2000, GEOPHYS RES LETT, V27, P1567, DOI 10.1029/1999GL011283; Lu Z, 2002, J GEOPHYS RES, V107; Melian G, 2014, J GEOPHYS RES-SOL EA, V119, P6976, DOI 10.1002/2014JB011013; Nolasco D, 2012, GEOPH RES ABSTR, V14; Notsu K, 2014, J VOLCANOL GEOTH RES, V270, P90, DOI 10.1016/j.jvolgeores.2013.11.017; Padilla GD, 2013, GEOCHEM GEOPHY GEOSY, V14, P432, DOI 10.1029/2012GC004375; Perez NM, 2014, B VOLCANOL, V76, DOI 10.1007/s00445-014-0882-y; Perez NM, 2007, EOS AM GEOPHYS UNION, V88, P46; Perez NM, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052410; Saccorotti G, 2001, B SEISMOL SOC AM, V91, P561, DOI 10.1785/0120000073; Stich D, 2011, GEOPHYS RES LETT, V38	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0258-8900	1432-0819		B VOLCANOL	Bull. Volcanol.	JUL	2015	77	7								10.1007/s00445-015-0948-5		8	Geosciences, Multidisciplinary	Geology	CM1FS	WOS:000357427200006		
J	Tsunematsu, K; Bonadonna, C				Tsunematsu, Kae; Bonadonna, Costanza			Grain-size features of two large eruptions from Cotopaxi volcano (Ecuador) and implications for the calculation of the total grain-size distribution	BULLETIN OF VOLCANOLOGY			English	Article						Tephra; Total grain-size distribution; Plinian eruptions; Voronoi tessellation; Mdphi	TEPHRA-FALL DEPOSITS; PYROCLASTIC DEPOSITS; COLUMN DYNAMICS; DISPERSAL; RECONSTRUCTION; FRAGMENTATION; SEDIMENTATION; AGGREGATION; PARAMETERS; TRANSPORT	Studies of grain-size distributions of explosive volcanic eruptions provide important insights into fragmentation mechanisms and eruptive conditions and are crucial to the modeling of tephra dispersal. As a result of sedimentation processes and plume dynamics, grain-size features vary significantly both in the downwind and crosswind directions and are difficult to characterize. We have analyzed grain-size features in the downwind and crosswind directions of the two largest eruptions of the last 2000 years of Cotopaxi volcano activity (Ecuador). Crosswind grain-size variations are similar for both eruptions (i.e., layers 3 and 5), while at any given downwind distance from vent, the layer 3 deposit is coarser than the layer 5 one. This suggests that layers 3 and 5 were characterized by similar plume height but that layer 3 was advected by a stronger wind. In addition, both deposits are coarsest along the dispersal axis and become richer in ash in the crosswind direction showing a Gaussian decreasing rate. Deposit thickness also shows a Gaussian crosswind decay, but layer 3 is significantly thicker at all points than is layer 5 due to the former's larger erupted mass. Based on both quantitative analysis of field data and on numerical simulations, we show that tephra deposits associated with large explosive eruptions (i.e., plume height of 30 km) should be sampled out to at least 200 km from the vent (depending on wind speed and tropopause height) in order to derive complete grain-size distributions that are not depleted in fines. Eruptions occurring in a strong wind field at high latitudes (e. g., Iceland) require lesser representative-sampling distances because of the lower tropopause heights.	[Tsunematsu, Kae; Bonadonna, Costanza] Univ Geneva, Sect Earth & Environm Sci, CH-1205 Geneva, Switzerland; [Tsunematsu, Kae] Yamanashi Prefectural Govt, Mt Fuji Res Inst, Fujiyoshida, Yamanashi 4030005, Japan	Tsunematsu, K (reprint author), Univ Geneva, Sect Earth & Environm Sci, 13 Rue Maraichers, CH-1205 Geneva, Switzerland.	kae.tsunematsu@gmail.com			Swiss National Science Foundation [200021-116335]	This project was supported by the Swiss National Science Foundation (No. 200021-116335). We thank Raffaello Cioni, Marco Pistolesi, Sebastien Biass, Licia Costantini, and Mauro Rosi for the support during our field work in Cotopaxi and Sebastien Biass also for his support during the writing phase of this manuscript. We appreciate three reviewers for their helpful comments and advices.	Mastin LG, 2009, J VOLCANOL GEOTH RES, V186, P10, DOI 10.1016/j.jvolgeores.2009.01.008; Folch A, 2012, J VOLCANOL GEOTH RES, V235, P96, DOI 10.1016/j.jvolgeores.2012.05.020; Van Eaton AR, 2012, B VOLCANOL, V74, P1963, DOI 10.1007/s00445-012-0634-9; WILSON L, 1987, GEOPHYS J INT, V89, P657, DOI 10.1111/j.1365-246X.1987.tb05186.x; Eychenne J, 2012, B VOLCANOL, V74, P187, DOI 10.1007/s00445-011-0517-5; Bonadonna C, 2005, B VOLCANOL, V67, P441, DOI 10.1007/s00445-004-0386-2; CAREY SN, 1982, J GEOPHYS RES, V87, P7061, DOI 10.1029/JB087iB08p07061; Volentik ACM, 2010, J VOLCANOL GEOTH RES, V193, P117, DOI 10.1016/j.jvolgeores.2010.03.011; SCHUMACHER R, 1994, J VOLCANOL GEOTH RES, V59, P253, DOI 10.1016/0377-0273(94)90099-X; WOODS AW, 1988, B VOLCANOL, V50, P169, DOI 10.1007/BF01079681; Connor LJ, 2006, STATISTICS IN VOLCANOLOGY, P231; WALKER GPL, 1971, J GEOL, V79, P696; WALKER GPL, 1980, J VOLCANOL GEOTH RES, V8, P69, DOI 10.1016/0377-0273(80)90008-6; FIERSTEIN J, 1992, B VOLCANOL, V54, P156, DOI 10.1007/BF00278005; Parfitt EA, 1998, J VOLCANOL GEOTH RES, V84, P197, DOI 10.1016/S0377-0273(98)00042-0; Brown RJ, 2012, PHYS CHEM EARTH, V45-46, P65, DOI 10.1016/j.pce.2011.11.001; Barberi F, 1995, J VOLCANOL GEOTH RES, V69, P217, DOI 10.1016/0377-0273(95)00017-8; Biass S, 2011, B VOLCANOL, V73, P73, DOI 10.1007/s00445-010-0404-5; Bonadonna C, 2015, J VOLCANOL GEOTH RES, V296, P80, DOI 10.1016/j.jvolgeores.2015.03.009; Bonadonna C, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002034; Bonadonna C, 2013, MODELING VOLCANIC PR, P173; BURSIK MI, 1992, B VOLCANOL, V54, P329, DOI 10.1007/BF00301486; Carey RJ, 2010, B VOLCANOL, V72, P259, DOI 10.1007/s00445-009-0317-3; Carey S.N., 1986, B VOLCANOL, V48, P109, DOI DOI 10.1007/BF01046546; Costantini L, 2010, THESIS U GENEVE SWIT; Inman D.L., 1952, J SEDIMENT PETROL, V22, P125, DOI DOI 10.1306/D42694DB-2B26-11D7-8648000102C1865D; Kaminski E, 1998, J GEOPHYS RES-SOL EA, V103, P29759, DOI 10.1029/98JB02795; Koyaguchi T, 2001, J GEOPHYS RES-SOL EA, V106, P6499, DOI 10.1029/2000JB900426; Koyaguchi T, 2001, J GEOPHYS RES-SOL EA, V106, P6513, DOI 10.1029/2000JB900427; MURROW PJ, 1980, GEOPHYS RES LETT, V7, P893, DOI 10.1029/GL007i011p00893; NEWHALL CG, 1982, J GEOPHYS RES-OC ATM, V87, P1231, DOI 10.1029/JC087iC02p01231; PYLE DM, 1989, B VOLCANOL, V51, P1, DOI 10.1007/BF01086757; Sparks R.S.J., 1986, B VOLCANOL, V48, P3, DOI DOI 10.1007/BF01073509; SPARKS RSJ, 1981, PHILOS T R SOC A, V299, P241, DOI 10.1098/rsta.1981.0023; WALKER GPL, 1981, NEW ZEAL J GEOL GEOP, V24, P305; Walker GPL, 1981, B VOLCANOL, V44, P223, DOI DOI 10.1007/BF02600561; WALKER GPL, 1981, J VOLCANOL GEOTH RES, V9, P395, DOI 10.1016/0377-0273(81)90046-9	37	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0258-8900	1432-0819		B VOLCANOL	Bull. Volcanol.	JUL	2015	77	7							64	10.1007/s00445-015-0949-4		12	Geosciences, Multidisciplinary	Geology	CM1FS	WOS:000357427200007		
J	Xing, AG; Wang, GH; Li, B; Jiang, Y; Feng, Z; Kamai, T				Xing, Aiguo; Wang, Gonghui; Li, Bin; Jiang, Yao; Feng, Zhen; Kamai, Toshitaka			Long-runout mechanism and landsliding behaviour of large catastrophic landslide triggered by heavy rainfall in Guanling, Guizhou, China	CANADIAN GEOTECHNICAL JOURNAL			English	Article						long runout; ring shear tests; shear behaviour; landsliding behaviour; dynamic analysis (DAN) model	RING-SHEAR TESTS; DEBRIS FLOWS; HAZARD ASSESSMENT; RAPID LANDSLIDES; ROCK AVALANCHES; MODEL; MOTION; LIQUEFACTION; DYNAMICS; STRENGTH	A large catastrophic landslide was triggered by a heavy rainfall on 28 June 2010 in Guanling, Guizhou, China. The landslide buried two villages and killed 99 people along the runout path. The landslide involved the failure of about 985 000 m(3) of sandstone from the source area, with a runout of about 1.4 km over a total vertical distance of about 420 m. To understand the possible long-runout mechanism and behaviour of the landslide, a detailed field survey of the landslide was conducted and samples were taken from the runout path. The shear behaviour of the sample based on a series of ring shear tests was examined, and numerical simulation of the landsliding behaviour by using a numerical runout model (DAN-W) was performed in which the shear strength obtained by ring shear tests was used. The experimental results reveal that the residual shear strength measured along the pre-existing shear surface is independent of the shear displacement rate under partially drained conditions, suggesting that the relationship between shear and normal stresses obeys the frictional model. A bulk basal friction angle of 14.4 degrees at the base of the moving mass was then obtained from the test results. The simulated results show that the selected rheological model and parameters based on ring shear tests could provide the best performance in simulating the landslide. Therefore, it is expected that the model and parameters could improve the precision of hazard zonation for areas with geological, topographical, and climatic features similar to the Guanling landslide area.	[Xing, Aiguo] Shanghai Jiao Tong Univ, State Key Lab Ocean Engn, Shanghai 200240, Peoples R China; [Wang, Gonghui; Jiang, Yao; Kamai, Toshitaka] Kyoto Univ, Disaster Prevent Res Inst, Res Ctr Landslides, Kyoto 6110011, Japan; [Li, Bin; Feng, Zhen] Chinese Acad Geol Sci, Inst Geomech, Beijing 100081, Peoples R China	Xing, AG (reprint author), Shanghai Jiao Tong Univ, State Key Lab Ocean Engn, Shanghai 200240, Peoples R China.	xingaiguo@sjtu.edu.cn			National Natural Science Foundation of China [41272382, 41372332]; China geological survey [1212011220140, 12120114079101]; National Science Fund for Distinguished Young Scholars [41225011]	This study was supported by the National Natural Science Foundation of China (Nos. 41272382 and 41372332), Project of China geological survey (Nos. 1212011220140 and 12120114079101), and National Science Fund for Distinguished Young Scholars (No. 41225011). The authors would also like to thank our two anonymous reviewers for their valuable comments that substantially improved this paper.	Wang GH, 2007, J GEOTECH GEOENVIRON, V133, P319, DOI 10.1061/(ASCE)1090-0241(2007)133:3(319); Sassa K, 2004, LANDSLIDES, V1, P7, DOI 10.1007/s10346-003-0004-y; Kuenza K, 2004, LANDSLIDES, V1, P185, DOI 10.1007/s10346-004-0023-3; Crosta GB, 2006, ENG GEOL, V83, P236, DOI 10.1016/j.enggeo.2005.06.039; Pirulli M, 2008, ROCK MECH ROCK ENG, V41, P59, DOI 10.1007/s00603-007-0143-x; Yin YP, 2010, LANDSLIDES, V7, P339, DOI 10.1007/s10346-010-0220-1; Xu Q, 2012, CAN GEOTECH J, V49, P589, DOI [10.1139/T2012-021, 10.1139/t2012-021]; Yin YP, 2011, B ENG GEOL ENVIRON, V70, P15, DOI 10.1007/s10064-010-0334-7; Pudasaini SP, 2013, ENG GEOL, V157, P124, DOI 10.1016/j.enggeo.2013.01.012; Chigira M, 2010, GEOMORPHOLOGY, V118, P225, DOI 10.1016/j.geomorph.2010.01.003; Hungr O, 2005, S-P BKS GEOPHYS SCI, P135; Chen H, 2003, GEOMORPHOLOGY, V51, P269, DOI 10.1016/S0169-555X(02)00224-6; Chen H, 2000, CAN GEOTECH J, V37, P146, DOI 10.1139/cgj-37-1-146; SLADEN JA, 1985, CAN GEOTECH J, V22, P564, DOI 10.1139/t85-076; Huang RQ, 2009, LANDSLIDES, V6, P69, DOI 10.1007/s10346-009-0142-y; Pitman EB, 2005, PHILOS T ROY SOC A, V363, P1573, DOI 10.1098/rsta.2005.1596; Evans SG, 2001, ENG GEOL, V61, P29, DOI 10.1016/S0013-7952(00)00118-6; Dai FC, 2011, GEOMORPHOLOGY, V132, P300, DOI 10.1016/j.geomorph.2011.05.016; VAID YP, 1990, CAN GEOTECH J, V27, P1, DOI 10.1139/t90-001; Crosta GB, 2003, NAT HAZARD EARTH SYS, V3, P523; McDougall S, 2005, CAN GEOTECH J, V42, P1437, DOI 10.1139/T05-064; Sassa K, 2010, LANDSLIDES, V7, P219, DOI 10.1007/s10346-010-0230-z; McDougall S, 2004, CAN GEOTECH J, V41, P1084, DOI 10.1139/T04-052; Bromhead E. N., 1992, STABILITY OF SLOPES; Chen H, 2002, J GEOTECH GEOENVIRON, V128, P1032, DOI 10.1061/(ASCE)1090-0241(2002)128:12(1032); Denlinger R. P., 2004, J GEOPHYS RES, V109, P1; Hungr O, 2009, KSCE J CIV ENG, V13, P281, DOI 10.1007/s12205-009-0281-7; Hungr O., 2004, GEOL SOC AM BULL, V116, P1240, DOI DOI 10.1130/B25362.1; Hungr O, 2005, LANDSLIDE RISK MANAG, P99; HUNGR O, 1995, CAN GEOTECH J, V32, P610, DOI 10.1139/t95-063; ISHIHARA K, 1993, GEOTECHNIQUE, V43, P351; KONRAD JM, 1993, GEOTECHNIQUE, V43, P69; Kramer S. L., 1996, GEOTECHNICAL EARTHQU; OBRIEN JS, 1993, J HYDRAUL ENG-ASCE, V119, P244, DOI 10.1061/(ASCE)0733-9429(1993)119:2(244); Olson SM, 2002, CAN GEOTECH J, V39, P629, DOI 10.1139/T02-001; Poisel R., 2008, GEOMECHANIK TUNNELBA, V1, P358, DOI 10.1002/geot.200800036; SASITHARAN S, 1994, CAN GEOTECH J, V31, P321, DOI 10.1139/t94-040; Sassa K, 1988, P 5 INT S LANDSL LAU, V1, P37; Sassa K., 2010, EARLY WARNING LANDSL; SAVAGE SB, 1989, J FLUID MECH, V199, P177, DOI 10.1017/S0022112089000340; Tika TE, 1996, GEOTECHNIQUE, V46, P197; Tiwari B, 2004, J GEOTECH GEOENVIRON, V130, P217, DOI 10.1061/(ASCE)1090-0241(2004)130:2(217); Vaid YP, 1985, ADV ART TESTING SOIL, P120; Wang GH, 2010, EARTH SURF PROC LAND, V35, P407, DOI 10.1002/esp.1937; Wang GH, 2013, EARTH SURF PROC LAND, V38, P265, DOI 10.1002/esp.3277; Wang GH, 2002, CAN GEOTECH J, V39, P821, DOI 10.1139/T02-032; Xu Q, 2010, LANDSLIDES, V7, P75, DOI 10.1007/s10346-009-0179-y; Yang J, 2002, GEOTECHNIQUE, V52, P757, DOI 10.1680/geot.52.10.757.38845; [殷跃平 Yin Yueping], 2013, [工程地质学报, Journal of Engineering Geology], V21, P6; Yin Y., 2011, J ROCK MECH GEOTECH, V3, P10; Yin YP, 2011, LANDSLIDES, V8, P517, DOI 10.1007/s10346-011-0266-8; Yin YP, 2012, B ENG GEOL ENVIRON, V71, P149, DOI 10.1007/s10064-011-0348-9	52	0	0	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-3674	1208-6010		CAN GEOTECH J	Can. Geotech. J.	JUL	2015	52	7					971	981		10.1139/cgj-2014-0122		11	Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CL7FE	WOS:000357137100011		
J	Oguri, T; Shimokata, T; Ito, I; Yasuda, Y; Sassa, N; Nishiyama, M; Hamada, A; Hasegawa, Y; Ando, Y				Oguri, Tomoyo; Shimokata, Tomoya; Ito, Isao; Yasuda, Yoshinari; Sassa, Naoto; Nishiyama, Masami; Hamada, Akinobu; Hasegawa, Yoshinori; Ando, Yuichi			Extension of the Calvert formula to patients with severe renal insufficiency	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Calvert formula; Carboplatin; Hemodialysis; Pharmacokinetics; Renal insufficiency	ADVANCED OVARIAN-CARCINOMA; CELL LUNG-CANCER; PHARMACOKINETIC ANALYSIS; JAPANESE PATIENTS; PHASE-I; CARBOPLATIN; HEMODIALYSIS; ETOPOSIDE; PACLITAXEL; CHEMOTHERAPY	The Calvert formula was derived from the study among patients with glomerular filtration rates (GFRs) of 33-135 ml/min, and it remains unclear whether the formula can be used to calculate optimal and safe dosages of carboplatin in patients with severe renal insufficiency. We evaluated the utility of this formula in patients with severe renal insufficiency. For pharmacokinetic analysis, we studied nine adult Japanese patients with advanced cancer who had an estimated GFR of lower than 30 ml/min/1.73 m(2), as calculated by the Japanese equation for estimating GFR, or who were receiving hemodialysis. The dose of carboplatin was calculated with the Calvert formula, in which GFR was measured by inulin clearance or was assumed to be 0 in patients requiring hemodialysis. Hemodialysis was started 23 h after the end of carboplatin infusion. Although there was a significant correlation between the estimated and measured carboplatin clearance, the estimated clearance was consistently higher than the measured clearance [mean prediction error +/- A standard deviation = 41.0 +/- A 26.3 %] in all seven patients with renal insufficiency (GFR, median 21.4, range 7.8-31.4 ml/min) and in the two hemodialysis patients. Actual areas under the concentration-time curve (AUC) (mg/ml min) were 5.4, 5.7, 6.2, and 9.0 for the four patients with a target AUC (mg/ml min) of 5; 5.7, 6.2, and 7.1 for the three patients with a target AUC (mg/ml min) of 4; and 5.1 and 8.7 for the two hemodialysis patients with a target AUC (mg/ml min) of 5. The measured clearance of carboplatin ranged from 23.0 to 51.3 ml/min in the seven patients not receiving hemodialysis. The pre-hemodialysis carboplatin clearance in the hemodialysis patients was 20.5 and 11.1 ml/min, respectively. For adult patients with severe renal insufficiency, the Calvert formula causes carboplatin overdosing by overestimating the carboplatin clearance.	[Oguri, Tomoyo; Shimokata, Tomoya; Ando, Yuichi] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Showa Ku, Nagoya, Aichi 4668560, Japan; [Ito, Isao; Yasuda, Yoshinari] Nagoya Univ, Grad Sch Med, Dept Nephrol, Showa Ku, Nagoya, Aichi 4668560, Japan; [Sassa, Naoto] Nagoya Univ, Grad Sch Med, Dept Urol, Showa Ku, Nagoya, Aichi 4668560, Japan; [Nishiyama, Masami] Kumamoto Univ, Res Inst Drug Discovery, Sch Pharm, Chuo Ku, Kumamoto 8620973, Japan; [Hamada, Akinobu] Natl Canc Ctr, Res Inst, Dept Clin Pharmacol Grp Translat Res Support Core, Chuo Ku, Tokyo 1040045, Japan; [Hasegawa, Yoshinori] Nagoya Univ, Grad Sch Med, Dept Resp Med, Showa Ku, Nagoya, Aichi 4668560, Japan	Shimokata, T (reprint author), Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	tshimo@med.nagoya-u.ac.jp			National Cancer Center Research and Development Fund [23-A-16]; Pfizer Co. Ltd.; Nippon Kayaku Co. Ltd.	We are deeply indebted to Ms. Yuka Murasaki and Miki Sagou for their professional assistance in this study. This study was partly supported by the National Cancer Center Research and Development Fund [23-A-16]. Yoshinari Yasuda and Yoshinori Hasegawa have received research Grants from Pfizer Co. Ltd. and a speaker honorarium from Pfizer Co. Ltd. Yuichi Ando has received research Grants from Nippon Kayaku Co. Ltd. and a speaker honorarium from Pfizer Co. Ltd.	Ando Y, 2014, NAGOYA J MED SCI, V76, P1; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1; Oguri T, 2010, CANCER CHEMOTH PHARM, V66, P813, DOI 10.1007/s00280-010-1366-1; Leijen S, 2013, GYNECOL ONCOL, V130, P511, DOI 10.1016/j.ygyno.2013.05.001; EGORIN MJ, 1984, CANCER RES, V44, P5432; Tsuda A, 2014, DIABETES CARE, V37, P596, DOI 10.2337/dc13-1899; MOTZER RJ, 1990, CANCER CHEMOTH PHARM, V27, P234, DOI 10.1007/BF00685719; Shimokata T, 2010, CANCER SCI, V101, P2601, DOI 10.1111/j.1349-7006.2010.01729.x; CHATELUT E, 1994, NEPHRON, V66, P157; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748; Screnci D, 1997, BRIT J CANCER, V76, P502, DOI 10.1038/bjc.1997.416; English MW, 1996, BRIT J CANCER, V73, P776, DOI 10.1038/bjc.1996.135; Carmichael J, 1996, SEMIN ONCOL, V23, P55; Horio M, 2010, CLIN EXP NEPHROL, V14, P427, DOI 10.1007/s10157-010-0325-9; Jeyabalan N, 2000, INT J GYNECOL CANCER, V10, P463, DOI 10.1046/j.1525-1438.2000.00072.x; NEWELL DR, 1989, CANCER CHEMOTH PHARM, V23, P367, DOI 10.1007/BF00435838; Obasaju CK, 1996, CLIN CANCER RES, V2, P549; SHEINER LB, 1981, J PHARMACOKINET BIOP, V9, P503, DOI 10.1007/BF01060893; Takezawa K, 2008, J THORAC ONCOL, V3, P1073, DOI 10.1097/JTO.0b013e318183af89; Thomas HD, 2002, BRIT J CLIN PHARMACO, V53, P83, DOI 10.1046/j.0306-5251.2001.01513.x; Watanabe M, 2002, GYNECOL ONCOL, V84, P335, DOI 10.1006/gyno.2001.6527	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					53	59		10.1007/s00280-015-2769-9		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500007		
J	Watanabe, N; Niho, S; Kirita, K; Umemura, S; Matsumoto, S; Yoh, K; Ohmatsu, H; Goto, K				Watanabe, Naohiro; Niho, Seiji; Kirita, Keisuke; Umemura, Shigeki; Matsumoto, Shingo; Yoh, Kiyotaka; Ohmatsu, Hironobu; Goto, Koichi			Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Acute exacerbation; Docetaxel; Interstitial pneumonia; Non-small cell lung cancer; Platinum	IDIOPATHIC PULMONARY-FIBROSIS; PHASE-III TRIAL; ACUTE EXACERBATIONS; DOUBLE-BLIND; DISEASE; CHEMOTHERAPY; EFFICACY; SAFETY; COMBINATION; THERAPY	The role of second-line chemotherapy in patients with non-small cell lung cancer (NSCLC) and preexisting interstitial pneumonia (IP) previously treated with platinum-based chemotherapy remains uncertain. This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP. A total of 35 patients (median age, 67 years) treated with docetaxel monotherapy in a second-line setting following first-line platinum-based chemotherapy between January 2002 and December 2013 were retrospectively reviewed. The overall response rate and disease control rate were 8.6 % [95 % confidence interval (CI) 0-17.9 %] and 37.1 % (95 % CI 21.1-53.1 %), respectively. The median progression-free survival and median overall survival periods were 1.6 months (95 % CI 1.2-2.0 months) and 5.1 months (95 % CI 3.2-6.7 months), respectively. The incidence of acute exacerbation (AE) of IP following docetaxel monotherapy was 14.3 % (5/35 patients). Of the five patients who developed AE of IP, three patients died. The toxicity of this regimen was substantial, with treatment-related deaths occurring in 5 (14.3 %) patients (AE of IP: 3, sepsis: 2). Docetaxel monotherapy has a poor activity and substantial risks when used for the treatment of platinum-resistant NSCLC with IP. Novel therapeutic approaches should be explored in this setting.	[Watanabe, Naohiro; Niho, Seiji; Kirita, Keisuke; Umemura, Shigeki; Matsumoto, Shingo; Yoh, Kiyotaka; Ohmatsu, Hironobu; Goto, Koichi] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba 2778577, Japan	Niho, S (reprint author), Natl Canc Ctr Hosp East, Dept Thorac Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	siniho@east.ncc.go.jp					Okuda K, 2012, ANTICANCER RES, V32, P5475; Minegishi Y, 2009, INTERNAL MED, V48, P665, DOI 10.2169/internalmedicine.48.1650; Park J, 2001, EUR RESPIR J, V17, P1216, DOI 10.1183/09031936.01.99055301; Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7; Maruyama R, 2008, J CLIN ONCOL, V26, P4244, DOI 10.1200/JCO.2007.15.0185; Kenmotsu H, 2011, J THORAC ONCOL, V6, P1242, DOI 10.1097/JTO.0b013e318216ee6b; TURNERWARWICK M, 1980, THORAX, V35, P496, DOI 10.1136/thx.35.7.496; Kawaguchi T, 2014, J CLIN ONCOL, V32, P1902, DOI 10.1200/JCO.2013.52.4694; KONDOH Y, 1993, CHEST, V103, P1808, DOI 10.1378/chest.103.6.1808; Ozawa Y, 2009, RESPIROLOGY, V14, P723, DOI 10.1111/j.1440-1843.2009.01547.x; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; Antoniou KM, 2013, RESPIRATION, V86, P265, DOI 10.1159/000355485; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5; Minegishi Y, 2011, LUNG CANCER, V71, P70, DOI 10.1016/j.lungcan.2010.04.014; Le Jeune I, 2007, RESP MED, V101, P2534, DOI 10.1016/j.rmed.2007.07.012; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Harris JM, 2010, THORAX, V65, P70, DOI 10.1136/thx.2009.121962; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Isobe K, 2010, RESPIROLOGY, V15, P88, DOI 10.1111/j.1440-1843.2009.01666.x; Watanabe N, 2013, RESPIRATION, V85, P326, DOI 10.1159/000342046; Tamiya A, 2012, ANTICANCER RES, V32, P1103; Bouros D, 2002, CHEST, V121, P1278, DOI 10.1378/chest.121.4.1278; Choi MK, 2014, CANCER CHEMOTH PHARM, V73, P1217, DOI 10.1007/s00280-014-2458-0; Kenmotsu H, 2015, CANCER CHEMOTH PHARM, V75, P521, DOI 10.1007/s00280-014-2670-y; Niho S, 2006, JPN J CLIN ONCOL, V36, P269, DOI 10.1093/jjco/hyl021; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Shimizu R, 2014, CANCER CHEMOTH PHARM, V74, P1159, DOI 10.1007/s00280-014-2590-x; Sobin L, 2009, INT UNION CANC TNM C; Takeda K, 2009, ANN ONCOL, V20, P835, DOI 10.1093/annonc/mdn705; Travis WD, 1999, WHO HISTOLOGICAL CLA	32	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					69	74		10.1007/s00280-015-2775-y		6	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500009		
J	Kotaka, M; Yoshino, T; Oba, K; Shinozaki, K; Touyama, T; Manaka, D; Matsui, T; Ishigure, K; Hasegawa, J; Inoue, K; Goto, K; Sakamoto, J; Saji, S; Ohtsu, A; Watanabe, T				Kotaka, Masahito; Yoshino, Takayuki; Oba, Koji; Shinozaki, Katsunori; Touyama, Tetsuo; Manaka, Dai; Matsui, Takanori; Ishigure, Kiyoshi; Hasegawa, Junichi; Inoue, Keiji; Goto, Koichi; Sakamoto, Junichi; Saji, Shigetoyo; Ohtsu, Atsushi; Watanabe, Toshiaki			Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Colon cancer; mFOLFOX6; Adjuvant; Peripheral sensory neuropathy; Allergic reactions	COLORECTAL-CANCER; DOUBLE-BLIND; FLUOROURACIL; OXALIPLATIN; CHEMOTHERAPY; MULTICENTER; LEUCOVORIN; SURVIVAL; EFFICACY	Adjuvant FOLFOX is a widely accepted standard therapy for resected colon cancer. The incidence of grade 3-4 peripheral sensory neuropathy (PSN) was 12.4 and 5.7 % in the MOSAIC and Eastern MASCOT trials, while that of grade 3-4 allergic reactions (AR) was 2.9 and 3.1 %, respectively. The JFMC41-1001-C2 trial (JOIN trial) investigated the tolerability of modified FOLFOX6 (mFOLFOX6) in Japanese colon cancer patients. Twelve cycles of mFOLFOX6 were given to patients with the same eligibility criteria as in the MOSAIC study: stage II or III curatively resected colon cancer, performance status of 0-1, aged 20 years or older, starting mFOLFOX6 within 7 weeks of surgery, and adequate organ function. The primary endpoints were the incidence of PSN persisting for a parts per thousand yen8 days that interfered with daily activities and the incidence of grade 3-4 AR. The target sample size was 800. From November 2010 to March 2012, 882 patients were enrolled at 198 institutions. Safety was analyzed in 828 patients with finalized data out of 848 patients receiving mFOLFOX6. The incidence of PSN persisting a parts per thousand yen8 days was 3.3 % [95 % confidence interval (CI) 2.2-4.7], while that of grade 3-4 AR was 1.7 % (95 % CI 0.9-2.8). The treatment completion rate was 67.0 %. The median total dosage of oxaliplatin was 811.1 mg/m(2). The overall incidence of grade 3-4 PSN was 5.8 %. Interstitial pneumonitis occurred in one patient. There were no treatment-related deaths. Adjuvant mFOLFOX6 is tolerable for Japanese patients with colon cancer.	[Kotaka, Masahito] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Hyogo, Japan; [Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba 2778577, Japan; [Oba, Koji] Univ Tokyo, Dept Biostat, Sch Publ Hlth, Grad Sch Med & Interfaculty Initiat Informat Stud, Tokyo, Japan; [Shinozaki, Katsunori] Hiroshima Prefectural Hosp, Div Clin Oncol, Hiroshima, Japan; [Touyama, Tetsuo] Nakagami Hosp, Dept Surg, Okinawa, Japan; [Manaka, Dai] Kyoto Katsura Hosp, Dept Surg, Gastrointestinal Ctr, Kyoto, Japan; [Matsui, Takanori] Aichi Hosp, Aichi Canc Ctr, Dept Surg Gastroenterol, Okazaki, Aichi, Japan; [Ishigure, Kiyoshi] Konan Kosei Hosp, Dept Surg, Konan, Japan; [Hasegawa, Junichi] Osaka Rosai Hosp, Dept Surg, Sakai, Osaka, Japan; [Inoue, Keiji] City Hosp, Nagasaki Harbor Med Ctr, Dept Surg, Nagasaki, Japan; [Goto, Koichi] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba 2778577, Japan; [Sakamoto, Junichi; Saji, Shigetoyo] Japanese Fdn Multidisciplinary Treatment Canc, Tokyo, Japan; [Ohtsu, Atsushi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo 104, Japan; [Watanabe, Toshiaki] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan	Yoshino, T (reprint author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba 2778577, Japan.	tyoshino@east.ncc.go.jp			Takeda Pharmaceutical Industry Inc.; Tsumura Co. Ltd.	J.S. received remuneration from Takeda Pharmaceutical Industry Inc. and from Tsumura Co. Ltd. The other authors declare that they have no conflict of interest.	Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T., 2013, CURR COLORECTAL CANC, V9, P261; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936; Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855; Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059; Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362; Loprinzi CL, 2014, J CLIN ONCOL, V32, P997, DOI 10.1200/JCO.2013.52.0536; Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Mamounas E, 1999, J CLIN ONCOL, V17, P1349; Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645; Kono T, 2013, CANCER CHEMOTH PHARM, V72, P1283, DOI 10.1007/s00280-013-2306-7; Allegra CJ, 2009, J CLIN ONCOL, V27, P3385, DOI 10.1200/JCO.2009.21.9220; Erlichman C, 1999, J CLIN ONCOL, V17, P1356; LEE Po-Huang, 2009, ASIA PACIFIC J CLIN, V5, P101; McKenzie S, 2011, CANCER-AM CANCER SOC, V117, P5493, DOI 10.1002/cncr.26245; Nagata N, 2009, HEPATO-GASTROENTEROL, V56, P1346; NCCN, 2014, NCCN CLIN PRACT GUID; Oki E, 2015, INT J CLIN ONCOL; Gray R, 2007, LANCET, V370, P2020; Sobin LH, 2009, TNM CLASSIFICATION M	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					75	84		10.1007/s00280-015-2757-0		10	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500010		
J	Matsuda, C; Munemoto, Y; Mishima, H; Nagata, N; Oshiro, M; Kataoka, M; Sakamoto, J; Aoyama, T; Morita, S; Kono, T				Matsuda, Chu; Munemoto, Yoshinori; Mishima, Hideyuki; Nagata, Naoki; Oshiro, Mitsuru; Kataoka, Masato; Sakamoto, Junichi; Aoyama, Toru; Morita, Satoshi; Kono, Toru			Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Hangeshashinto; TJ-14; Colorectal Cancer; Oral mucositis	CLINICAL-PRACTICE GUIDELINES; HANGE-SHASHIN-TO; GASTROINTESTINAL MUCOSITIS; PROINFLAMMATORY CYTOKINES; COOLING CRYOTHERAPY; HERBAL MEDICINE; NECK-CANCER; STOMATITIS; PREVENTION; TRIAL	Hangeshashinto (TJ-14, a Kampo medicine), which reduces the level of prostaglandin E2 and affects the cyclooxygenase activity, alleviates chemotherapy-induced oral mucositis (COM). We conducted a double-blind, placebo-controlled, randomized comparative trial to investigate whether TJ-14 prevents and controls COM in patients with colorectal cancer. Ninety-three patients with colorectal cancer who developed moderate-to-severe COM (WHO grade a parts per thousand 1) during any cycle of chemotherapy using FOLFOX, FOLFIRI, and/or XELOX treatment were randomly assigned to receive either TJ-14 (n = 46) or placebo (n = 47). Patients received the administration of placebo or TJ-14 for 2 weeks at the start of the next course of chemotherapy. Patients were assessed three times per week for safety and for COM incidence and its severity using the WHO grading. Ninety eligible patients (TJ-14; 43, placebo; 47) per protocol set analysis were included in the analysis after the key-opening. Although the incidence of grade a parts per thousand 2 oral mucositis was lower for patients treated with TJ-14 compared to those treated with placebo, there was no significant difference (48.8 vs. 57.4 %; p = 0.41). The median duration of grade a parts per thousand 2 mucositis was 5.5 versus 10.5 days (p = 0.018). No difference in other treatment toxicity was observed between the two groups, and patients exhibited high compliance in dosing administration. The present study results did not meet the primary endpoint. However, TJ-14 demonstrated a significant effect in the treatment of grade a parts per thousand 2 mucositis in patients with colorectal cancer compared to the placebo.	[Matsuda, Chu] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan; [Munemoto, Yoshinori] Fukui Saiseikai Hosp, Dept Surg, Fukui, Japan; [Mishima, Hideyuki] Aichi Med Univ, Ctr Canc, Nagakute, Aichi 48011, Japan; [Nagata, Naoki] Kitakyushu Gen Hosp, Kitakyushu, Fukuoka, Japan; [Oshiro, Mitsuru] Toho Univ, Sakura Hosp, Sakura, Japan; [Kataoka, Masato] Nagoya Med Ctr, Dept Surg, Nagoya, Aichi, Japan; [Sakamoto, Junichi] Tokai Cent Hosp, Kakamigahara, Japan; [Aoyama, Toru] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Asahi Ku, Yokohama, Kanagawa 2418515, Japan; [Morita, Satoshi] Yokohama City Univ, Dept Biostat & Epidemiol, Yokohama, Kanagawa 232, Japan; [Kono, Toru] Sapporo Higashi Tokushukai Hosp, Adv Surg Ctr, Sapporo, Hokkaido, Japan	Aoyama, T (reprint author), Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2418515, Japan.	aoyamat@kcch.jp			nonprofit organization Epidemiological and Clinical Research Information Network (ECRIN)	This study is supported, in part, by a nonprofit organization Epidemiological and Clinical Research Information Network (ECRIN). We are grateful to Ms. Chigusa Abe for her excellent contribution as the clinical research coordinator for the study. The authors are indebted to Prof. J. Patrick Barron of the Department of International Medical Communications of Tokyo Medical University for his review of the manuscript.	Keefe DM, 2007, CANCER, V109, P820, DOI 10.1002/cncr.22484; Sonis ST, 2004, CANCER, V100, P1995, DOI 10.1002/cncr.20162; Yoshikawa K, 2012, SURG TODAY, V42, P646, DOI 10.1007/s00595-011-0094-4; Keefe DMK, 2004, SUPPORT CARE CANCER, V12, P6, DOI 10.1007/s00520-003-0550-9; Wu HG, 2009, CANCER, V115, P3699, DOI 10.1002/cncr.24414; Kawashima K, 2004, BIOL PHARM BULL, V27, P1599, DOI 10.1248/bpb.27.1599; Elting LS, 2008, CANCER-AM CANCER SOC, V113, P2704, DOI 10.1002/cncr.23898; Epstein JB, 2001, CANCER, V92, P875, DOI 10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1; Morales-Rojas T, 2012, INT J PAEDIATR DENT, V22, P191, DOI 10.1111/j.1365-263X.2011.01175.x; Rubenstein EB, 2004, CANCER-AM CANCER SOC, V100, P2026, DOI 10.1002/cncr.20163; MAHOOD DJ, 1991, J CLIN ONCOL, V9, P449; Sonis ST, 2004, NAT REV CANCER, V4, P277, DOI 10.1038/nrc1318; Mori K, 2003, CANCER CHEMOTH PHARM, V51, P403, DOI 10.1007/s00280-003-0585-0; Anderson PM, 1998, CANCER, V83, P1433, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1433::AID-CNCR22>3.0.CO;2-4; Sorensen JB, 2008, CANCER-AM CANCER SOC, V112, P1600, DOI 10.1002/cncr.23328; Bensky D, 1990, CHINESE HERBAL MED S, P10; CASCINU S, 1994, ORAL ONCOL, V30B, P234; DuenasGonzalez A, 1996, BONE MARROW TRANSPL, V17, P809; Hanson WR, 1997, ADV EXP MED BIOL, V400, P811; Hejna M, 2001, EUR J CANCER, V37, P1994, DOI 10.1016/S0959-8049(01)00132-0; JEBB SA, 1994, BRIT J CANCER, V70, P732, DOI 10.1038/bjc.1994.385; Kase Y, 1997, JPN J PHARMACOL, V75, P407, DOI 10.1254/jjp.75.407; Kawai K, 2010, ANN SURG, V251, P692, DOI 10.1097/SLA.0b013e3181d50299; Kobayashi, 1994, J TRAD MED; Kono T, 2011, J CLIN ONCOL S4, V29; Kono T, 2012, GASTROENTEROLOGY, V142, pS673; Lalla RV, 2010, SUPPORT CARE CANCER, V18, P95, DOI 10.1007/s00520-009-0635-1; Matsui T, 2011, J CLIN ONCOL S, V29; Okuno SH, 1999, AM J CLIN ONCOL-CANC, V22, P258, DOI 10.1097/00000421-199906000-00009; Peterson Douglas E, 2006, J Support Oncol, V4, P9; Sharma R, 2005, LANCET ONCOL, V6, P93, DOI 10.1016/S1470-2045(05)01735-3; Sironi M, 1996, CYTOKINE, V8, P710, DOI 10.1006/cyto.1996.0094; Sironi M, 1997, INT J CLIN LAB RES, V27, P118, DOI 10.1007/BF02912445; Sonis Stephen T, 2007, J Support Oncol, V5, P3; Wymenga ANM, 1999, CLIN CANCER RES, V5, P1363	35	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					97	103		10.1007/s00280-015-2767-y		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500012		
J	Katsuya, Y; Fujiwara, Y; Sunami, K; Utsumi, H; Goto, Y; Kanda, S; Horinouchi, H; Nokihara, H; Yamamoto, N; Takashima, Y; Osawa, S; Ohe, Y; Tamura, T; Hamada, A				Katsuya, Yuki; Fujiwara, Yutaka; Sunami, Kuniko; Utsumi, Hirofumi; Goto, Yasushi; Kanda, Shintaro; Horinouchi, Hidehito; Nokihara, Hiroshi; Yamamoto, Noboru; Takashima, Yuki; Osawa, Satoko; Ohe, Yuichiro; Tamura, Tomohide; Hamada, Akinobu			Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Erlotinib; Pharmacokinetics; Food effect; Absorption; Toxicology	TYROSINE-KINASE INHIBITOR; JAPANESE PATIENTS; CLINICAL PHARMACOKINETICS; CEREBROSPINAL-FLUID; ANTICANCER AGENTS; SOLID TUMORS; PHASE-I; EXPOSURE; FOOD	The recommended dose of erlotinib is 150 mg daily either 1 h before a meal (complete fasting) or 2 h after a meal (2 h post-meal), because of the food effect. We conducted a cross-over pharmacokinetic study to compare the fed bioequivalence in the two conditions. Twenty-three patients with non-small cell lung cancer were included in the analysis. AUC(0-24) and C (max) in the 2-h post-meal status were significantly higher than in the complete fasting status (GMR = 1.33, P < 0.001; GMR = 1.44, P < 0.001, respectively). However, because the concentration of erlotinib did not reach the steady state within 7 days in the complete fasting state, we conducted analyses only on day 14, which showed no significant difference in AUC(0-24) or C (max) between the two conditions. The more rapid increase in AUC(0-24) and C (min) did not produce any earlier and more severe toxic events. The AUC(0-24) increased significantly faster (48-53 % greater) in the 2-h post-meal status than in complete fasting status, which suggested that the two gastric emptying states might differ in their absorption. However, there was no clinically significant difference in bioavailability or toxicity between the two clinically used fed conditions at least in 14 days.	[Katsuya, Yuki; Fujiwara, Yutaka; Sunami, Kuniko; Utsumi, Hirofumi; Goto, Yasushi; Kanda, Shintaro; Horinouchi, Hidehito; Nokihara, Hiroshi; Yamamoto, Noboru; Ohe, Yuichiro; Tamura, Tomohide] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo 1040045, Japan; [Takashima, Yuki; Osawa, Satoko; Hamada, Akinobu] Natl Canc Ctr, Res Inst, Ctr Translat Res Core, Chuo Ku, Tokyo 1040045, Japan; [Fujiwara, Yutaka; Yamamoto, Noboru; Hamada, Akinobu] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Dept Expt Therapeut, Chuo Ku, Tokyo 1040045, Japan	Fujiwara, Y (reprint author), Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	katsuya-tky@umin.ac.jp; yutakafu@ncc.go.jp			National Cancer Center Research and Development Fund from Ministry of Health, Labor, and Welfare of Japan [23-A-16]	We wish to thank all the patients who participated in this study and their families. We also wish to thank the staff of Department of Thoracic Oncology, National Cancer Center Hospital. This study was supported by the National Cancer Center Research and Development Fund (23-A-16) from the Ministry of Health, Labor, and Welfare of Japan.	Fukudo M, 2013, CLIN PHARMACOKINET, V52, P593, DOI 10.1007/s40262-013-0058-5; Mathijssen RHJ, 2014, NAT REV CLIN ONCOL, V11, P272, DOI 10.1038/nrclinonc.2014.40; Hamilton M, 2006, CLIN CANCER RES, V12, P2166, DOI 10.1158/1078-0432.CCR-05-2235; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267; Lu JF, 2006, CLIN PHARMACOL THER, V80, P136, DOI 10.1016/j.clpt.2006.04.007; Ratain MJ, 2011, J CLIN ONCOL, V29, P3958, DOI 10.1200/JCO.2011.37.1617; Nakagawa K, 2012, J THORAC ONCOL, V7, P1296, DOI 10.1097/JTO.0b013e3182598abb; Ling J, 2008, ANTI-CANCER DRUG, V19, P209, DOI 10.1097/CAD.0b013e3282f2d8e4; Rudin CM, 2008, J CLIN ONCOL, V26, P1119, DOI 10.1200/JCO.2007.13.1128; Yamamoto N, 2008, CANCER CHEMOTH PHARM, V61, P489, DOI 10.1007/s00280-007-0494-8; Fujita K, 2014, LUNG CANCER, V86, P113, DOI 10.1016/j.lungcan.2014.07.021; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Singh BN, 2004, CLIN PHARMACOKINET, V43, P1127, DOI 10.2165/00003088-200443150-00005; Soreide E, 1996, ACTA ANAESTH SCAND, V40, P549; Sparreboom A., 2011, PHARMACOKINETIC STUD; Szmulewitz RZ, 2013, CLIN PHARMACOL THER, V93, P242, DOI 10.1038/clpt.2012.245; Tsuchiya K, 2014, JAIDS-J ACQ IMM DEF, V66, P484, DOI 10.1097/QAI.0000000000000222	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					125	132		10.1007/s00280-015-2778-8		8	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500015		
J	Nakayama, I; Suenaga, M; Wakatsuki, T; Ichimura, T; Ozaka, M; Takahari, D; Shinozaki, E; Chin, K; Ueno, M; Mizunuma, N; Yamaguchi, T				Nakayama, Izuma; Suenaga, Mitsukuni; Wakatsuki, Takeru; Ichimura, Takashi; Ozaka, Masato; Takahari, Daisuke; Shinozaki, Eiji; Chin, Keisho; Ueno, Masashi; Mizunuma, Nobuyuki; Yamaguchi, Toshiharu			Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Oxaliplatin; Resectable metastases; R0 resection; Adjuvant chemotherapy; Stage IV colorectal cancer (CRC)	COLON-CANCER; MICROSATELLITE-INSTABILITY; LIVER METASTASES; FLUOROURACIL; SURGERY; LEUCOVORIN; BENEFIT; TRIAL	Surgery is the only potentially curative strategy for patients who have Stage IV colorectal cancer (CRC) with resectable metastases, but relapse is common. Randomized trials of adjuvant 5-FU-based systemic chemotherapy have not demonstrated any benefit after resection of liver metastases. We evaluated the efficacy, safety, and tolerability of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of CRC. We retrospectively studied data for 88 consecutive patients with Stage IV CRC who underwent curative resection of metastases followed by oxaliplatin-based adjuvant chemotherapy between March 2007 and June 2013. The 3-year relapse-free survival (RFS) rate was 54.0 %. There was no significant difference in 3-year RFS between patients with metastases confined to the liver (52.7 %) and patients with extrahepatic metastases (57.2 %). Multivariate analysis revealed that the site of the primary tumor (right-sided colon or left-sided colon/rectum) and the number of metastases (solitary or multiple) were predictors of RFS. Scheduled courses were completed in 80.7 % of the patients. Except for neutropenia (47.7 %), severe adverse events were observed in < 5 % of patients. Oxaliplatin-based adjuvant chemotherapy could be an effective option for selected patients with Stage IV CRC after curative resection of hepatic or extrahepatic metastases, and is both safe and tolerable.	[Nakayama, Izuma; Suenaga, Mitsukuni; Wakatsuki, Takeru; Ichimura, Takashi; Ozaka, Masato; Takahari, Daisuke; Shinozaki, Eiji; Chin, Keisho; Mizunuma, Nobuyuki] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Koto Ku, Tokyo 1358550, Japan; [Ueno, Masashi; Yamaguchi, Toshiharu] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo 1358550, Japan	Suenaga, M (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	m.suenaga@jfcr.or.jp					Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Mitry E, 2008, J CLIN ONCOL, V26, P4906, DOI 10.1200/JCO.2008.17.3781; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; BUFILL JA, 1990, ANN INTERN MED, V113, P779; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Portier G, 2006, J CLIN ONCOL, V24, P4976, DOI 10.1200/JCO.2006.06.8353; Spelt L, 2012, EJSO-EUR J SURG ONC, V38, P16, DOI 10.1016/j.ejso.2011.10.013; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9; Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R; Kim GP, 2007, J CLIN ONCOL, V25, P767, DOI 10.1200/JCO.2006.05.8172; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825; Japanese Society for Cancer of the Colon and Rectum (JSCCR), GUID 2014 TREATM COL; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kato T, 2003, DIS COLON RECTUM, V46, pS22, DOI 10.1097/01.DCR.0000089106.71914.00; Kokudo N, 2007, J CLIN ONCOL, V25, P1299, DOI 10.1200/JCO.2006.09.9069; Lee GH, 2015, EJSO-EUR J SURG ONC, V41, P300, DOI 10.1016/j.ejso.2014.11.001; Suenaga M, 2011, ASIA-PAC J CLIN ONCO, V7, P129, DOI 10.1111/j.1743-7563.2011.01385.x	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					133	139		10.1007/s00280-015-2780-1		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500016		
J	Inoue, Y; Inui, N; Asada, K; Karayama, M; Matsuda, H; Yokomura, K; Koshimizu, N; Imokawa, S; Yamada, T; Shirai, T; Kasamatsu, N; Suda, T				Inoue, Yusuke; Inui, Naoki; Asada, Kazuhiro; Karayama, Masato; Matsuda, Hiroyuki; Yokomura, Koshi; Koshimizu, Naoki; Imokawa, Shiro; Yamada, Takashi; Shirai, Toshihiro; Kasamatsu, Norio; Suda, Takafumi			Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Elderly; Erlotinib; Epidermal growth factor receptor; EGFR mutation; Non-small cell lung cancer	1ST-LINE TREATMENT; JAPANESE PATIENTS; OPEN-LABEL; RANDOMIZED-TRIAL; CHEMOTHERAPY; EGFR; GEFITINIB; MULTICENTER; STATISTICS; THERAPY	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC. Elderly patients aged 75 or older with advanced or recurrent NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) were enrolled in this prospective phase II trial. Patients received 150 mg erlotinib per day orally. The primary end point was the overall response rate. Between March 2013 and November 2014, 32 patients were enrolled with median age 80 years. All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation. The response rate was 56.3 % [95 % confidence interval (CI) 39.4-72.0 %], and the disease control rate was 90.6 % (95 % CI 75.2-97.6 %). Median progression-free survival was 15.5 months (95 % CI 11.2-not reached). Skin disorder was the most common adverse event, and grade 4 drug-related interstitial lung disease occurred in one patient. Erlotinib is effective and tolerated in elderly patients with EGFR mutation-positive NSCLC.	[Inoue, Yusuke; Inui, Naoki; Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Inui, Naoki] Hamamatsu Univ Sch Med, Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka 4313192, Japan; [Asada, Kazuhiro; Shirai, Toshihiro] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka 4208527, Japan; [Karayama, Masato] Hamamatsu Univ Sch Med, Dept Clin Oncol, Hamamatsu, Shizuoka 4313192, Japan; [Matsuda, Hiroyuki] Japanese Red Cross Shizuoka Hosp, Dept Resp Med, Shizuoka 4200853, Japan; [Yokomura, Koshi] Seirei Mikatahara Gen Hosp, Dept Resp Med, Hamamatsu, Shizuoka 4338558, Japan; [Koshimizu, Naoki] Fujieda Municipal Gen Hosp, Dept Resp Med, Fujieda, Shizuoka 4268677, Japan; [Imokawa, Shiro] Iwata City Hosp, Dept Resp Med, Iwata 4388550, Japan; [Yamada, Takashi] Shizuoka City Shizuoka Hosp, Dept Resp Med, Shizuoka 4208630, Japan; [Kasamatsu, Norio] Hamamatsu Med Ctr, Dept Resp Med, Hamamatsu, Shizuoka 4328580, Japan	Inui, N (reprint author), Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	inui@hama-med.ac.jp					Kudoh S, 2008, AM J RESP CRIT CARE, V177, P1348, DOI 10.1164/rccm.200710-1501OC; Fukuhara T, 2015, LUNG CANCER, V88, P181, DOI 10.1016/j.lungcan.2015.02.004; Maemondo M, 2012, J THORAC ONCOL, V7, P1417, DOI 10.1097/JTO.0b013e318260de8b; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Chen YM, 2012, J THORAC ONCOL, V7, P412, DOI 10.1097/JTO.0b013e31823a39e8; De Ruysscher D, 2009, ANN ONCOL, V20, P98, DOI 10.1093/annonc/mdn559; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Serizawa M, 2014, CANCER-AM CANCER SOC, V120, P1471, DOI 10.1002/cncr.28604; Sakakibara T, 2010, ANN ONCOL, V21, P795, DOI 10.1093/annonc/mdp401; Goto K, 2013, LUNG CANCER, V82, P109, DOI 10.1016/j.lungcan.2013.07.003; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Langer CJ, 2002, J NATL CANCER I, V94, P173; Gridelli C, 2005, CHEST, V128, P947, DOI 10.1378/chest.128.2.947; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Jackman DM, 2007, J CLIN ONCOL, V25, P760, DOI 10.1200/JCO.2006.07.5754; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Kusagaya H, 2012, LUNG CANCER, V77, P550, DOI 10.1016/j.lungcan.2012.05.106; Owonikoko TK, 2007, J CLIN ONCOL, V25, P5570, DOI 10.1200/JCO.2007.12.5435; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Jemal A, 2007, CA-CANCER J CLIN, V57, P43; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ershler WB, 1997, J NATL CANCER I, V89, P1489, DOI 10.1093/jnci/89.20.1489; Fujita S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-185; Horiike A, 2012, ANN ONCOL, V23, P413; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Matsuura S, 2011, JPN J CLIN ONCOL, V41, P959, DOI 10.1093/jjco/hyr079; Takahashi K, 2014, CANCER CHEMOTH PHARM, V74, P721, DOI 10.1007/s00280-014-2548-z; Tateishi K, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0450-2; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Yoshioka H, 2014, LUNG CANCER, V86, P201, DOI 10.1016/j.lungcan.2014.09.015	33	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	JUL	2015	76	1					155	161		10.1007/s00280-015-2784-x		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CL5XF	WOS:000357036500018		
J	Takeuchi, S; Baghdadi, M; Tsuchikawa, T; Wada, H; Nakamura, T; Abe, H; Nakanishi, S; Usui, Y; Higuchi, K; Takahashi, M; Inoko, K; Sato, S; Takano, H; Shichinohe, T; Seino, K; Hirano, S				Takeuchi, Shintaro; Baghdadi, Muhammad; Tsuchikawa, Takahiro; Wada, Haruka; Nakamura, Toru; Abe, Hirotake; Nakanishi, Sayaka; Usui, Yuu; Higuchi, Kohtaro; Takahashi, Mizuna; Inoko, Kazuho; Sato, Syoki; Takano, Hironobu; Shichinohe, Toshiaki; Seino, Ken-ichiro; Hirano, Satoshi			Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer	CANCER RESEARCH			English	Article							TUMOR-BEARING MICE; NF-KAPPA-B; SUPPRESSOR-CELLS; NEOADJUVANT CHEMOTHERAPY; GM-CSF; DUCTAL ADENOCARCINOMA; IMMUNOLOGICAL IMPACT; UNITED-STATES; IMMUNE CELLS; PROGRESSION	Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic malignancies. PDAC builds a tumor microenvironment that plays critical roles in tumor progression and metastasis. However, the relationship between chemotherapy and modulation of PDAC-induced tumor microenvironment remains poorly understood. In this study, we report a role of chemotherapy-derived inflammatory response in the enrichment of PDAC microenvironment with immunosuppressive myeloid cells. Granulocyte macrophage colony-stimulating factor (GM-CSF) is a major cytokine associated with oncogenic KRAS in PDAC cells. GM-CSF production was significantly enhanced in various PDAC cell lines or PDAC tumor tissues from patients after treatment with chemotherapy, which induced the differentiation of monocytes into myeloid-derived suppressor cells (MDSC). Furthermore, blockade of GM-CSF with monoclonal antibodies helped to restore T-cell proliferation when cocultured with monocytes stimulated with tumor supernatants. GM-CSF expression was also observed in primary tumors and correlated with poor prognosis in PDAC patients. Together, these results describe a role of GM-CSF in the modification of chemotherapy-treated PDAC microenvironment and suggest that the targeting of GM-CSF may benefit PDAC patients' refractory to current anticancer regimens by defeating MDSC-mediated immune escape. (C)2015 AACR.	[Takeuchi, Shintaro; Tsuchikawa, Takahiro; Nakamura, Toru; Abe, Hirotake; Takahashi, Mizuna; Inoko, Kazuho; Sato, Syoki; Takano, Hironobu; Shichinohe, Toshiaki; Hirano, Satoshi] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol Surg 2, Sapporo, Hokkaido 0600815, Japan; [Takeuchi, Shintaro; Baghdadi, Muhammad; Wada, Haruka; Abe, Hirotake; Nakanishi, Sayaka; Usui, Yuu; Higuchi, Kohtaro; Seino, Ken-ichiro] Hokkaido Univ, Inst Med Genet, Div Immunobiol, Sapporo, Hokkaido 0600815, Japan	Seino, K (reprint author), Hokkaido Univ, Inst Med Genet, Div Immunobiol, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	seino@igm.hokudai.ac.jp; satto@med.hokudai.ac.jp					Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Almand B, 2001, J IMMUNOL, V166, P678; Andre F, 2013, CLIN CANCER RES, V19, P28, DOI 10.1158/1078-0432.CCR-11-2701; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Tanaka K, 2012, INT J ONCOL, V40, P965, DOI 10.3892/ijo.2011.1274; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Song XP, 2005, J IMMUNOL, V175, P8200; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Sawanobori Y, 2008, BLOOD, V111, P5457, DOI 10.1182/blood-2008-01-136895; Halama N, 2011, CANCER RES, V71, P5670, DOI 10.1158/0008-5472.CAN-11-0268; Apte MV, 2013, GASTROENTEROLOGY, V144, P1210, DOI 10.1053/j.gastro.2012.11.037; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Stromnes IM, 2014, GUT, V63, P1769, DOI 10.1136/gutjnl-2013-306271; Dolcetti L, 2010, EUR J IMMUNOL, V40, P22, DOI 10.1002/eji.200939903; Dumitru CA, 2012, CANCER IMMUNOL IMMUN, V61, P1155, DOI 10.1007/s00262-012-1294-5; Mazzoni A, 2002, J IMMUNOL, V168, P689; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Youn JI, 2008, J IMMUNOL, V181, P5791; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Shichinohe T, 1996, J SURG RES, V66, P125, DOI 10.1006/jsre.1996.0383; Hart KM, 2014, IMMUNOL CELL BIOL, V92, P499, DOI 10.1038/icb.2014.13; Tsuchikawa T, 2013, CANCER SCI, V104, P531, DOI 10.1111/cas.12119; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Shaib YH, 2006, ALIMENT PHARM THERAP, V24, P87, DOI 10.1111/j.1365-2036.2006.02961.x; Middleton G, 2014, LANCET ONCOL, V15, P829, DOI 10.1016/S1470-2045(14)70236-0; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; Tsuchikawa T, 2012, ANN SURG ONCOL, V19, P1713, DOI 10.1245/s10434-011-1906-x; Di Mitri D, 2014, NATURE, V515, P134, DOI 10.1038/nature13638; Kato K, 2011, J HEPATO-BIL-PAN SCI, V18, P712, DOI 10.1007/s00534-011-0391-8; Paulson AS, 2013, GASTROENTEROLOGY, V144, P1316, DOI 10.1053/j.gastro.2013.01.078; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Boeck S, 2014, BRIT J CANCER, V111, P1675, DOI 10.1038/bjc.2014.60; Homma Y, 2014, ANN SURG ONCOL, V21, P670, DOI 10.1245/s10434-013-3390-y; Iacobuzio-Donahue CA, 2012, GUT, V61, P1085, DOI 10.1136/gut.2010.236026; Iacobuzio-Donahue CA, 2012, CLIN CANCER RES, V18, P4257, DOI 10.1158/1078-0432.CCR-12-0315; Krysko O, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.156; Satoi S, 2013, J HEPATO-BIL-PAN SCI, V20, P590, DOI 10.1007/s00534-013-0616-0; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Vernon PJ, 2013, J IMMUNOL, V190, P1372, DOI 10.4049/jimmunol.1201151; Virtuoso LP, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-152; White RR, 2014, ANN SURG ONCOL, V21, P1508, DOI 10.1245/s10434-014-3490-3; Zheng L, 2013, GASTROENTEROLOGY, V144, P1230, DOI 10.1053/j.gastro.2012.12.042	50	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	JUL 1	2015	75	13					2629	2640		10.1158/0008-5472.CAN-14-2921		12	Oncology	Oncology	CL9YJ	WOS:000357334700006		
J	Namiki, T; Yaguchi, T; Nakamura, K; Valencia, JC; Coelho, SG; Yin, LL; Kawaguchi, M; Vieira, WD; Kaneko, Y; Tanemura, A; Katayama, I; Yokozeki, H; Kawakami, Y; Hearing, VJ				Namiki, Takeshi; Yaguchi, Tomonori; Nakamura, Kenta; Valencia, Julio C.; Coelho, Sergio G.; Yin, Lanlan; Kawaguchi, Masakazu; Vieira, Wilfred D.; Kaneko, Yasuhiko; Tanemura, Atsushi; Katayama, Ichiro; Yokozeki, Hiroo; Kawakami, Yutaka; Hearing, Vincent J.			NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation	CANCER RESEARCH			English	Article							MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; ACRAL MELANOMA; MUTATIONS; GROWTH; MITF; PROLIFERATION; INHIBITION; ONCOGENE; SURVIVAL	The AMPK-related kinase NUAK2 has been implicated in melanoma growth and survival outcomes, but its therapeutic utility has yet to be confirmed. In this study, we show how its genetic amplification in PTEN-deficient melanomas may rationalize the use of CDK2 inhibitors as a therapeutic strategy. Analysis of array-CGH data revealed that PTEN deficiency is coupled tightly with genomic amplification encompassing the NUAK2 locus, a finding strengthened by immunohistochemical evidence that phospho-Akt overexpression was correlated with NUAK2 expression in clinical specimens of acral melanoma. Functional studies in melanoma cells showed that inactivation of the PI3K pathway upregulated p21 expression and reduced the number of cells in S phase. NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. Immunohistochemical analyses confirmed an association of CDK2 expression with NUAK2 amplification and p-Akt expression in melanomas. Finally, pharmacologic inhibition of CDK2 was sufficient to suppress the growth of NUAK2-amplified and PTEN-deficient melanoma cells in vitro and in vivo. Overall, our results show how CDK2 blockade may offer a promising therapy for genetically defined melanomas, where NUAK2 is amplified and PTEN is deleted. (C) 2015 AACR.	[Namiki, Takeshi; Valencia, Julio C.; Coelho, Sergio G.; Yin, Lanlan; Kawaguchi, Masakazu; Vieira, Wilfred D.; Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Namiki, Takeshi; Yaguchi, Tomonori; Nakamura, Kenta; Kawakami, Yutaka] Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo 1608582, Japan; [Namiki, Takeshi; Yokozeki, Hiroo] Tokyo Med & Dent Univ, Grad Sch, Dept Dermatol, Bunkyo Ku, Tokyo, Japan; [Namiki, Takeshi; Yokozeki, Hiroo] Tokyo Med & Dent Univ, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 113, Japan; [Nakamura, Kenta] Shinshu Univ, Sch Med, Dept Dermatol, Matsumoto, Nagano 390, Japan; [Kaneko, Yasuhiko] Saitama Canc Ctr, Res Inst Clin Oncol, Kita Adachi, Saitama, Japan; [Tanemura, Atsushi; Katayama, Ichiro] Osaka Univ, Grad Sch Med, Dept Dermatol, Suita, Osaka, Japan	Kawakami, Y (reprint author), Keio Univ, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yutakawa@z5.keio.jp			National Cancer Institute at NIH [ZIA BC 010785]; Japan Society for Promotion of Science [26221005]	This work was supported in part by the Intramural Research Program (ZIA BC 010785) of the National Cancer Institute at NIH and Grants-in-Aid for Scientific Research (26221005) from the Japan Society for Promotion of Science.	Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Namiki T, 2011, P NATL ACAD SCI USA, V108, P6597, DOI 10.1073/pnas.1007694108; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Flaherty KT, 2012, NAT REV CANCER, V12, P349, DOI 10.1038/nrc3218; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Tsao H, 2000, CANCER RES, V60, P1800; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Takata M, 2010, PIGM CELL MELANOMA R, V23, P64, DOI 10.1111/j.1755-148X.2009.00645.x; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Ashida A, 2009, INT J CANCER, V124, P862, DOI 10.1002/ijc.24048; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JC130102; Kido K, 2009, CANCER SCI, V100, P1863, DOI 10.1111/j.1349-7006.2009.01266.x; LARUE L, 1992, P NATL ACAD SCI USA, V89, P7816, DOI 10.1073/pnas.89.16.7816; Namiki T, 2011, ONCOTARGET, V2, P695; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200	27	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	JUL 1	2015	75	13					2708	2715		10.1158/0008-5472.CAN-13-3209		8	Oncology	Oncology	CL9YJ	WOS:000357334700013		
J	Ogata, T; Yoshida, T; Tanaka, M; Fukuhara, C; Shimizu, M; Ishii, J; Nishiuchi, A; Inamoto, K; Kimachi, T				Ogata, Tokutaro; Yoshida, Tomoyo; Tanaka, Manami; Fukuhara, Chie; Shimizu, Maki; Ishii, Junko; Nishiuchi, Arisa; Inamoto, Kiyofumi; Kimachi, Tetsutaro			Unusual O-Alkylation of 2-Hydroxy-1,4-naphthoquinone Utilizing Alkoxymethyl Chlorides	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						naphthoquinone; protecting group; hydride; alkylation; heterocycle	ANTICANCER ACTIVITIES; 1,4-NAPHTHOQUINONES; NAPHTHOQUINONES; DERIVATIVES; AGENTS	A new type of O-alkylation of 2-hydroxy-1,4-naphthoquinone with alkoxymethyl chlorides is described. The reaction course can be controlled by the choice of base and yields O-alkylated or O-alkoxymethylated products in high yield with high selectivity.	[Ogata, Tokutaro; Yoshida, Tomoyo; Tanaka, Manami; Fukuhara, Chie; Shimizu, Maki; Ishii, Junko; Nishiuchi, Arisa; Inamoto, Kiyofumi; Kimachi, Tetsutaro] Mukogawa Womens Univ, Sch Pharm & Pharmaceut Sci, Nishinomiya, Hyogo 6638179, Japan	Ogata, T (reprint author), Hokuriku Univ, Fac Pharmaceut Sci, Kanagawa Machi, Kanazawa, Ishikawa 9201181, Japan.	t-ogata@hokuriku-u.ac.jp; tkimachi@mukogawa-u.ac.jp					Babula P, 2009, CURR PHARM ANAL, V5, P47; SNIECKUS V, 1990, CHEM REV, V90, P879, DOI 10.1021/cr00104a001; Kumagai Y, 2012, ANNU REV PHARMACOL, V52, P221, DOI 10.1146/annurev-pharmtox-010611-134517; Belorgey D, 2013, CURR PHARM DESIGN, V19, P2512; Kimachi T, 2009, TETRAHEDRON-ASYMMETR, V20, P1683, DOI 10.1016/j.tetasy.2009.06.025; Kimachi T, 2011, CHEM PHARM BULL, V59, P753; Lien JC, 2002, CHEM PHARM BULL, V50, P672, DOI 10.1248/cpb.50.672; Mizushina Y, 2013, INT J ONCOL, V42, P793, DOI 10.3892/ijo.2013.1771; Ogata T, 2013, TETRAHEDRON, V69, P10470, DOI 10.1016/j.tet.2013.09.081; Pradhan R, 2012, CURR DRUG TARGETS, V13, P1777; SUTTIE JW, 1995, ANNU REV NUTR, V15, P399; Verma Rajeshwar P., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P489, DOI 10.2174/187152006778226512	12	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	JUL	2015	63	7					485	488				4	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CL8SP	WOS:000357244700001		
J	Kondo, S; Asano, Y; Koizumi, N; Tatematsu, K; Sawama, Y; Sasai, Y; Yamauchi, Y; Kuzuya, M; Kurosawa, S				Kondo, Shin-ichi; Asano, Yuna; Koizumi, Natsumi; Tatematsu, Kenjiro; Sawama, Yuka; Sasai, Yasushi; Yamauchi, Yukinori; Kuzuya, Masayuki; Kurosawa, Shigeru			Novel pH-Responsive Polymeric Micelles Prepared through Self-assembly of Amphiphilic Block Copolymer with Poly-4-vinylpyridine Block Synthesized by Mechanochemical Solid-State Polymerization	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						pH responsiveness; polymeric micelle; mechanochemical solid-state polymerization; amphiphilic block copolymer	DRUG-RELEASE; EXTRACELLULAR PH; VINYL MONOMERS; PRODRUGS; DELIVERY; WATER; CARRIERS; DESIGN	We fabricated polymeric micelles containing 5-fluorouracil (5-FU) or fluorescein using the amphiphilic block copolymer, poly-4-vinylpyridine-b-6-O-methacryloyl galactopyranose. Although the polymeric micelles were stable at pH 7.4, they readily decomposed at pH 5, resulting in near complete release of 5-FU. Uptake of polymeric micelles containing fluorescein by HepG2 and HCT116 cells was also investigated. With both cell types, strong fluorescence was observed after a 12-h incubation, but the fluorescence weakened after 24 h of incubation. The fluorescein incorporated into the polymeric micelles was released into acidic organelles (endosome and/or lysosome), from which it diffused throughout the cell. The cytotoxicity of polymeric micelles containing 5-FU was evaluated against HepG2 cells using a CCK-8 assay. The results suggest that polymeric micelles containing 5-FU are more cytotoxic to HepG2 cells than free 5-FU.	[Kondo, Shin-ichi; Asano, Yuna; Koizumi, Natsumi; Sawama, Yuka; Sasai, Yasushi] Gifu Pharmaceut Univ, Lab Pharmaceut Phys Chem, Gifu 5011196, Japan; [Tatematsu, Kenjiro] Gifu Pharmaceut Univ, Lab Radiochem, Gifu 5028585, Japan; [Yamauchi, Yukinori] Matsuyama Univ, Dept Pharmaceut Phys Chem, Coll Pharmaceut Sci, Matsuyama, Ehime 7908578, Japan; [Kuzuya, Masayuki] Chubu Gakuin Univ, Fac Human Welf, Dept Hlth & Welf, Seki, Gifu 5013993, Japan; [Kurosawa, Shigeru] Natl Inst Adv Ind Sci & Technol, Res Inst Environm Management Technol, Tsukuba, Ibaraki 3058565, Japan	Kondo, S (reprint author), Gifu Pharmaceut Univ, Lab Pharmaceut Phys Chem, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	skondo@gifu-pu.ac.jp					Chen W, 2010, J CONTROL RELEASE, V142, P40, DOI 10.1016/j.jconrel.2009.09.023; Kohori F, 1998, J CONTROL RELEASE, V55, P87, DOI 10.1016/S0168-3659(98)00023-6; Francis MF, 2004, PURE APPL CHEM, V76, P1321, DOI 10.1351/pac200476071321; Kondo S, 1998, CHEM PHARM BULL, V46, P1918; Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1; Kondo S, 2007, CHEM PHARM BULL, V55, P389, DOI 10.1248/cpb.55.389; Kondo S, 2000, YAKUGAKU ZASSHI, V120, P1337; Yasugi K, 1999, J CONTROL RELEASE, V62, P89, DOI 10.1016/S0168-3659(99)00028-0; Kondo SI, 1998, CHEM PHARM BULL, V46, P669; Kondo S, 2000, CHEM PHARM BULL, V48, P1882; Kondo S, 2002, CHEM PHARM BULL, V50, P1434, DOI 10.1248/cpb.50.1434; KUZUYA M, 1991, CHEM PHARM BULL, V39, P3018; Akiyoshi K, 2000, MACROMOLECULES, V33, P3244, DOI 10.1021/ma991798d; Djordjevic J, 2005, PHARM RES, V22, P24, DOI 10.1007/s11095-004-9005-3; KUZUYA M, 1991, MACROMOLECULES, V24, P4047, DOI 10.1021/ma00014a013; KONDO S, 1994, CHEM PHARM BULL, V42, P768; Ko J, 2007, J CONTROL RELEASE, V123, P109, DOI 10.1016/j.jconrel.2007.07.012; Kondo SI, 2004, J POLYM SCI POL CHEM, V42, P4161, DOI 10.1002/pola.20245; Kondo S, 2005, CHEM PHARM BULL, V53, P863, DOI 10.1248/cpb.53.863; Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166; KUZUYA M, 1993, J PHYS CHEM-US, V97, P7800, DOI 10.1021/j100132a003; YOKOYAMA M, 1990, J CONTROL RELEASE, V11, P269; Chang GT, 2010, MACROMOL BIOSCI, V10, P1248, DOI 10.1002/mabi.201000117; Katayama Y, 2001, MACROMOLECULES, V34, P8569, DOI 10.1021/ma010966a; Kondo S, 2011, CHEM PHARM BULL, V59, P1200; Kondo S., 1998, CURRENT TRENDS POLYM, V3, P1; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192	27	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	JUL	2015	63	7					489	494				6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CL8SP	WOS:000357244700002		
J	Inoue, Y; Iwazaki, Y; Onuki, Y; Funatani, C; Murata, I; Kanamoto, I				Inoue, Yutaka; Iwazaki, Yuka; Onuki, Yoshinori; Funatani, Chiaki; Murata, Isamu; Kanamoto, Ikuo			Examination of Gelling Agents to Produce Acetaminophen Jelly	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						carrageenan; magnetic resonance imaging (MRI); viscoelasticity; jelly	BETA-CYCLODEXTRIN; SOLID-STATE; INCLUSION; PARACETAMOL; GELS	The current study used 3 types of carrageenan (denoted here as Car) kappa, iota, and lambda to prepare a jelly vehicle for acetaminophen (AAP), and then compared their usefulness as jelly vehicles. The rheological characteristics of each preparation were assessed and then drug elution from the preparation was assessed using dissolution testing. The behavior of each preparation when immersed in water was also examined using magnetic resonance imaging (MRI) in order to better understand the drug elution behaviour of each preparation. Viscoelasticity measurements revealed that 0.75 w/v%-iota-Car and 1.25w/v%-lambda-Car had viscoelasticity values equivalent to that of 0.5w/v%-kappa-Car. Dissolution testing of these 3 preparations indicated that 100% drug elution took 45min with 0.5w/v%-kappa-Car while it took only 5min with 0.75w/v%-iota-Car and 1.25w/v%-lambda-Car. When deuterium oxide was added to kappa-Car 0.5%, the MRI images darkened overall starting immediately after addition. The images revealed that the sample and deuterium oxide quickly mixed. In contrast, images revealed that deuterium oxide gradually penetrated kappa-Car 1.0%. MRI images had uniform contrast, and deuterium oxide took 6h or longer to penetrate the samples overall. These findings suggest that water is less apt to penetrate a jelly with an increased car concentration and a denser 3-dimensional network structure. Differences in the structure of car are said to result in better gelling, with kappa having the best gelling characteristics, followed by iota and then lambda. Thus, this paper discusses the role that vehicle gelling strength plays in the elution of acetaminophen.	[Inoue, Yutaka; Iwazaki, Yuka; Murata, Isamu; Kanamoto, Ikuo] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan; [Onuki, Yoshinori; Funatani, Chiaki] Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, Tokyo 1428501, Japan	Inoue, Y (reprint author), Josai Univ, Fac Pharmaceut Sci, 1-1 Keyakidai, Sakado, Saitama 3500295, Japan.	yinoue@josai.ac.jp					Trabal J, 2008, NUTR HOSP, V23, P500; Kariyo S, 2005, MAGN RESON IMAGING, V23, P249, DOI 10.1016/j.mri.2004.11.019; Sullivan JE, 2011, PEDIATRICS, V127, P580, DOI 10.1542/peds.2010-3852; El-Barghouthi MI, 2006, RUSS J PHYS CHEM+, V80, P1050, DOI 10.1134/S0036024406070090; McDaid C, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14170; Liners F, 2005, GLYCOBIOLOGY, V15, P849, DOI 10.1093/glycob/cwi072; Inoue Y, 2013, INDIAN J PHARM SCI, V75, P435, DOI 10.4103/0250-474X.119825; El-Kemary M, 2011, SPECTROCHIM ACTA A, V79, P1904, DOI 10.1016/j.saa.2011.05.084; Figuelras A, 2007, EUR J PHARM BIOPHARM, V67, P531, DOI 10.1016/j.ejpb.2007.03.005; Kokki Hannu, 2003, Paediatr Drugs, V5, P103, DOI 10.2165/00128072-200305020-00004; Miyazaki S, 2011, BIOL PHARM BULL, V34, P164, DOI 10.1248/bpb.34.164	11	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	JUL	2015	63	7					519	524				6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CL8SP	WOS:000357244700006		
J	Mizoi, K; Mashima, Y; Kawashima, Y; Takahashi, M; Mimori, S; Hosokawa, M; Murakami, Y; Hamana, H				Mizoi, Kenta; Mashima, Yu; Kawashima, Yuya; Takahashi, Masato; Mimori, Seisuke; Hosokawa, Masakiyo; Murakami, Yasuoki; Hamana, Hiroshi			A New Methodology for Functionalization at the 3-Position of Indoles by a Combination of Boron Lewis Acid with Nitriles	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						boron Lewis acid; nitrile; indole; 3-acylindole; 1-(1H-indol-3-yl)alkylamine	FRIEDEL-CRAFTS ALKYLATION; ONE-POT SYNTHESIS; PHOSPHORIC-ACIDS; ACYLATION; 3-ACYLINDOLES; DERIVATIVES; TRICHLORIDE; IMINES; ACCESS; INHIBITORS	We discovered that a reagent comprising a combination of PhBCl2 and nitriles was useful for syntheses of both 3-acylindoles and 1-(1H-indol-3-yl)alkylamine from indoles. The reaction proceeded selectively at the 3-position of indoles providing 3-acylindoles in moderate to high yields on treatment with the above reagent. Furthermore, the reaction provided the corresponding amine products in moderate to high yields after the intermediate imine was reduced by NaBH3CN. These reactions proceeded under mild conditions and are applicable to the formation of indoles functionalized at the 3-position.	[Mizoi, Kenta; Mashima, Yu; Kawashima, Yuya; Takahashi, Masato; Mimori, Seisuke; Hosokawa, Masakiyo; Murakami, Yasuoki; Hamana, Hiroshi] Chiba Inst Sci, Fac Pharm, Choshi, Chiba 2880025, Japan	Mimori, S (reprint author), Chiba Inst Sci, Fac Pharm, 15-8 Shiomi Cho, Choshi, Chiba 2880025, Japan.	smimori@cis.ac.jp; ymurakami@cis.ac.jp					Bagutski V, 2013, J AM CHEM SOC, V135, P474, DOI 10.1021/ja3100963; Weng JQ, 2014, ORG LETT, V16, P776, DOI 10.1021/ol403480v; KETCHA DM, 1985, J ORG CHEM, V50, P5451, DOI 10.1021/jo00350a001; Chen LY, 2011, J ORG CHEM, V76, P7141, DOI 10.1021/jo2011335; Mukai C, 2005, ORG LETT, V7, P5793, DOI 10.1021/ol052179u; Ottoni O, 2001, ORG LETT, V3, P1005, DOI 10.1021/ol007056i; ISHIBASHI H, 1994, CHEM PHARM BULL, V42, P271; Bandini M, 2004, ANGEW CHEM INT EDIT, V43, P550, DOI 10.1002/anie.200301679; Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e; Sirasani G, 2011, ORG LETT, V13, P4736, DOI 10.1021/ol202056w; Ma YH, 2013, CHEM-EUR J, V19, P1189, DOI 10.1002/chem.201203354; Okauchi T, 2000, ORG LETT, V2, P1485, DOI 10.1021/ol005841p; Jiang TS, 2013, ORG LETT, V15, P788, DOI 10.1021/ol303440y; Pais GCG, 2002, J MED CHEM, V45, P3184, DOI 10.1021/jm020037p; Xing CH, 2011, J ORG CHEM, V76, P4125, DOI 10.1021/jo200302x; Lin DZ, 2013, CHEM COMMUN, V49, P2575, DOI 10.1039/c3cc38908a; Goswami K, 2012, J ORG CHEM, V77, P7081, DOI 10.1021/jo300708h; BERGMAN J, 1990, TETRAHEDRON, V46, P6061, DOI 10.1016/S0040-4020(01)87930-8; SUGASAWA T, 1978, J AM CHEM SOC, V100, P4842, DOI 10.1021/ja00483a034; Sirasani G, 2010, J ORG CHEM, V75, P3529, DOI 10.1021/jo100516g; Xu FX, 2010, J ORG CHEM, V75, P8677, DOI 10.1021/jo101640z; Sirasani G, 2009, ORG LETT, V11, P2085, DOI 10.1021/ol9004799; Guchhait SK, 2011, J ORG CHEM, V76, P4753, DOI 10.1021/jo200561f; Kang Q, 2007, J AM CHEM SOC, V129, P1484, DOI 10.1021/ja067417a; Faul MM, 1998, J ORG CHEM, V63, P6053, DOI 10.1021/jo980513c; DeBenedetto MV, 2009, ORG LETT, V11, P835, DOI 10.1021/ol802764j; Gupta R. R., 1999, HETEROCYCLIC CHEM, V2, P233; Gupta R. R., 1999, HETEROCYCLIC CHEM, V2, P212; HAMANA H, 1985, CHEM LETT, P575, DOI 10.1246/cl.1985.575; HAMANA H, 1985, CHEM LETT, P921, DOI 10.1246/cl.1985.921; HAMANA H, 1985, CHEM LETT, P571, DOI 10.1246/cl.1985.571; Kunori M, 1962, NIPPON KAGAKU ZASSHI, V83, P841; Kunori M, 1962, NIPPON KAGAKU ZASSHI, V83, pA5; MURAKAMI Y, 1981, CHEM PHARM BULL, V29, P699; Remers W. A., 1972, INDOLES 1, P66; Remers W. A., 1972, INDOLES 1, P145; Sakai N, 2008, TETRAHEDRON, V64, P9208, DOI 10.1016/j.tet.2008.07.052; TANI M, 1990, CHEM PHARM BULL, V38, P3261; Wanner MJ, 2008, EUR J ORG CHEM, P180, DOI 10.1002/ejoc.200700886; Wu J, 2013, J ORG CHEM, V78, P5611, DOI 10.1021/jo400747d; Wu YS, 2009, J MED CHEM, V52, P4941, DOI 10.1021/jm900060s; Xiao Q, 2008, ORG LETT, V10, P1139, DOI 10.1021/ol8000409; Zhang L, 2009, J COMB CHEM, V11, P640, DOI 10.1021/cc800200h	43	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	JUL	2015	63	7					538	545				8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CL8SP	WOS:000357244700009		
J	Zakaria, MB; Belik, AA; Liu, CH; Hsieh, HY; Liao, YT; Malgras, V; Yamauchi, Y; Wu, KCW				Zakaria, Mohamed B.; Belik, Alexei A.; Liu, Chia-Hung; Hsieh, Han-Yun; Liao, Yu-Te; Malgras, Victor; Yamauchi, Yusuke; Wu, Kevin C-W			Prussian Blue Derived Nanoporous Iron Oxides as Anticancer Drug Carriers for Magnetic-Guided Chemotherapy	CHEMISTRY-AN ASIAN JOURNAL			English	Article						drug delivery; magnetic-guided chemotherapy; nanoparticles; iron oxide; Prussian blue	COORDINATION POLYMERS; PHOTODYNAMIC THERAPY; PHOTOTHERMAL THERAPY; CONTROLLED-RELEASE; DELIVERY SYSTEM; NANOPARTICLES; CANCER; RESISTANCE; CONVERSION; PARTICLES	New nanoporous iron oxide nanoparticles with superparamagnetic behavior were successfully synthesized from Prussian blue (PB) nanocubes through a thermal conversion method and applied to the intracellular drug-delivery systems (DDS) of bladder cancer cells (i.e., T24) with controlled release and magnetic guiding properties. The results of the MTT assay and confocal laser scanning microscopy indicate that the synthesized iron oxide nanoparticles were successfully uptaken by T24 cells with excellent biocompatibility. An anticancer drug, that is, cisplatin, was used as a model drug, and its loading/release behavior was investigated. The intracellular drug delivery efficiency was greatly enhanced for the cisplatin-loaded, PB-derived, magnetic-guided drug-delivery system compared with the non-drug case. The synthesized nanomaterials show great potential as drug vehicles with high biocompatibility, controlled release, and magnetic targeting features for future intracellular DDS.	[Zakaria, Mohamed B.; Yamauchi, Yusuke] Waseda Univ, Fac Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; [Zakaria, Mohamed B.; Belik, Alexei A.; Malgras, Victor; Yamauchi, Yusuke] Natl Inst Mat Sci, World Premier Int WPI Res Ctr Mat Nanoarchitechto, Tsukuba, Ibaraki 3050044, Japan; [Zakaria, Mohamed B.] Tanta Univ, Dept Chem, Fac Sci, Tanta 31527, Gharbeya, Egypt; [Liu, Chia-Hung] Taipei Med Univ, Dept Urol, Shuang Ho Hosp, New Taipei City 23561, Taiwan; [Hsieh, Han-Yun; Liao, Yu-Te; Wu, Kevin C-W] Natl Taiwan Univ, Dept Chem Engn, Taipei 10617, Taiwan; [Wu, Kevin C-W] Natl Hlth Res Inst, Div Med Engn Res, Zhunan 350, Miaoli County, Taiwan	Yamauchi, Y (reprint author), Waseda Univ, Fac Sci & Engn, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698555, Japan.	Yamauchi.Yusuke@nims.go.jp; kevinwu@ntu.edu.tw	Yamauchi, Yusuke/D-2780-2015; Malgras, Victor/A-8221-2015	Malgras, Victor/0000-0002-5667-9118	Culture Affairs & Missions Sector of the Ministry of Higher Education in Egypt; Ministry of Science and Technology (MOST), Taiwan [101-2628-E-002-015-MY3]; National Taiwan University [102R7842, 102R7740, 102R104100]; Center of Strategic Materials Alliance for Research and Technology (SMART Center); National Health Research Institutes of Taiwan [03A1-BNMP14-014]	Mohamed B. Zakaria thanks the Culture Affairs & Missions Sector of the Ministry of Higher Education in Egypt for the financial support. K. C.-W. Wu acknowledge the financial support from the Ministry of Science and Technology (MOST), Taiwan (101-2628-E-002-015-MY3), National Taiwan University (102R7842 and 102R7740), Center of Strategic Materials Alliance for Research and Technology (SMART Center), National Taiwan University (102R104100), and National Health Research Institutes of Taiwan (03A1-BNMP14-014).	Jiang S, 2013, NANOSCALE, V5, P3127, DOI 10.1039/c3nr34005h; Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Zakaria MB, 2014, EUR J INORG CHEM, V2014, P1137, DOI 10.1002/ejic.201301307; Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a; Bureekaew S, 2008, SCI TECHNOL ADV MAT, V9, DOI 10.1088/1468-6996/9/1/014108; Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105; Cheng Y, 2008, J AM CHEM SOC, V130, P10643, DOI 10.1021/ja801631c; Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010; van Lingen AV, 2013, EXPERT OPIN BIOL TH, V13, P1371, DOI 10.1517/14712598.2013.824421; Cheng L, 2012, BIOMATERIALS, V33, P2215, DOI 10.1016/j.biomaterials.2011.11.069; Lin YH, 2005, BIOMATERIALS, V26, P2105, DOI 10.1016/j.biomaterials.2004.06.011; Hu M, 2012, ANGEW CHEM INT EDIT, V51, P984, DOI 10.1002/anie.201105190; [Anonymous], 2012, ANGEW CHEM, V124, P1008; Ming H, 2012, CRYSTENGCOMM, V14, P3387, DOI 10.1039/c2ce25040c; Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012; Lin WB, 2009, ANGEW CHEM INT EDIT, V48, P650, DOI 10.1002/anie.200803387; Li ZW, 2013, BIOMATERIALS, V34, P9160, DOI 10.1016/j.biomaterials.2013.08.041; Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l; Mamot C, 2003, DRUG RESIST UPDATE, V6, P271, DOI 10.1016/S1368-7646(03)00082-7; Namiki Y, 2009, NAT NANOTECHNOL, V4, P598, DOI [10.1038/nnano.2009.202, 10.1038/NNANO.2009.202]; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Kim J, 2008, ADV MATER, V20, P478, DOI 10.1002/adma.200701726; Hirota Y, 2009, PHYSICA C, V469, P1853, DOI 10.1016/j.physc.2009.05.248; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Li ZW, 2014, ADV FUNCT MATER, V24, P2312, DOI 10.1002/adfm.201303345; Mejias R, 2011, BIOMATERIALS, V32, P2938, DOI 10.1016/j.biomaterials.2011.01.008; Torad NL, 2012, J MATER CHEM, V22, P18261, DOI 10.1039/c2jm32805d; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Sudimack J, 2000, ADV DRUG DELIVER REV, V41, P147, DOI 10.1016/S0169-409X(99)00062-9; Roy X, 2011, J AM CHEM SOC, V133, P8420, DOI 10.1021/ja2016075; Fuchigami T, 2012, BIOMATERIALS, V33, P1682, DOI 10.1016/j.biomaterials.2011.11.016; Jabr-Milane LS, 2008, CANCER TREAT REV, V34, P592, DOI 10.1016/j.ctrv.2008.04.003; Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183; Hu M, 2012, CHEM MATER, V24, P2698, DOI 10.1021/cm300615s; Duran JDG, 2008, J PHARM SCI-US, V97, P2948, DOI 10.1002/jps.21249; Yoshizawa Y, 2011, INT J PHARMACEUT, V412, P132, DOI 10.1016/j.ijpharm.2011.04.008; [Anonymous], 2009, ANGEW CHEM, V121, P660; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; KAPUSCINSKI J, 1995, BIOTECH HISTOCHEM, V70, P220, DOI 10.3109/10520299509108199; Taguchi M, 2005, CHEM MATER, V17, P4554, DOI 10.1021/cm051060c	41	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	JUL	2015	10	7					1457	1462		10.1002/asia.201500232		6	Chemistry, Multidisciplinary	Chemistry	CL8EU	WOS:000357206500003		
J	Yoshida, K; Osuka, A				Yoshida, Kota; Osuka, Atsuhiro			Peripherally Hexasulfanylated Subporphyrins	CHEMISTRY-AN ASIAN JOURNAL			English	Article						subporphyrins; sulfanylation; SNAr reaction; fullerenes; porphyrinoids	ARYL-SUBSTITUTED SUBPORPHYRINS; HOST; SUBPHTHALOCYANINES; CORANNULENE; FULLERENES; C-60; CONFORMATION; ABSORPTION; CHEMISTRY; SYSTEMS	Peripherally hexachlorinated meso-triphenyl subporphyrin 4 was prepared by chlorination of meso-triphenyl subporphyrin 1 with N-chlorosuccinimide and was effectively transformed to hexasulfanylated subporphyrins 5-8 via nucleophilic aromatic substitution (SNAr) reactions with the corresponding thiols under basic conditions. The structures of 5-8 have been all well characterized by single-crystal X-ray analysis. (HNMR)-H-1 studies indicated that the meso-phenyl substituents undergo restricted rotation for 5-8, while the -sulfanyl substituents are conformationally flexible in 5, 6, and 8, and are strictly regulated to an anti-conformation in 7. Judging from the absorption spectra, the oxidation and reduction potentials, and the DFT calculations, the substituent effects decrease in the order of 5>6>7>8. Subporphyrin 8 effectively captures C-60 in a 1:1 manner in [D-8]toluene solution.	[Yoshida, Kota; Osuka, Atsuhiro] Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan	Osuka, A (reprint author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.	osuka@kuchem.kyoto-u.ac.jp			JSPS KAKENHI [25220802, 25620031]	The work at Kyoto was supported by JSPS KAKENHI Grant Numbers 25220802 and 25620031.	Gingras M, 2006, ANGEW CHEM INT EDIT, V45, P1686, DOI 10.1002/anie.200500032; Sygula A, 2007, J AM CHEM SOC, V129, P3842, DOI 10.1021/ja070616p; Kitano M, 2012, ANGEW CHEM INT EDIT, V51, P5593, DOI 10.1002/anie.201201853; Sanchez-Molina I, 2013, CHEM SCI, V4, P1338, DOI 10.1039/c3sc21956a; Tsurumaki E, 2015, J AM CHEM SOC, V137, P1056, DOI 10.1021/ja5126269; Fielding L, 2000, TETRAHEDRON, V56, P6151, DOI 10.1016/S0040-4020(00)00492-0; Mizyed S, 2001, J AM CHEM SOC, V123, P12770, DOI 10.1021/ja016761z; Osuka A, 2011, B CHEM SOC JPN, V84, P679, DOI 10.1246/bcsj.20110118; Gingras M, 2008, CHEM-EUR J, V14, P10357, DOI 10.1002/chem.200801198; Inokuma Y, 2006, ANGEW CHEM INT EDIT, V45, P961, DOI 10.1002/anie.200503426; Sanchez-Molina I, 2013, J AM CHEM SOC, V135, P10503, DOI 10.1021/ja404234n; Saga S, 2013, CHEM-EUR J, V19, P11158, DOI 10.1002/chem.201302454; Bredenkotter B, 2007, CHEM-EUR J, V13, P9931, DOI 10.1002/chem.200700915; Takeuchi Y, 2007, J AM CHEM SOC, V129, P8271, DOI 10.1021/ja0712120; Inokuma Y, 2008, J AM CHEM SOC, V130, P12234, DOI 10.1021/ja804846v; Kobayashi N, 2007, ANGEW CHEM INT EDIT, V46, P758, DOI 10.1002/anie.200603520; Claessens CG, 2014, CHEM REV, V114, P2192, DOI 10.1021/cr400088w; Torres T, 2006, ANGEW CHEM INT EDIT, V45, P2834, DOI 10.1002/anie.200504265; [Anonymous], 2009, GAUSSIAN 09 REVISION; Dawe LN, 2012, CHEM COMMUN, V48, P5563, DOI 10.1039/c2cc30652b; Baldridge KK, 2010, ORG BIOMOL CHEM, V8, P53, DOI 10.1039/b919616a; Miyajima D, 2009, J AM CHEM SOC, V131, P44, DOI 10.1021/ja808396b; Tsurumaki E, 2011, J AM CHEM SOC, V133, P11956, DOI 10.1021/ja2056566; Georghiou PE, 2005, J ORG CHEM, V70, P6158, DOI 10.1021/jo0503761; Inokuma Y, 2007, J AM CHEM SOC, V129, P4747, DOI 10.1021/ja069324z; Tsurumaki E, 2009, CHEM-EUR J, V15, P237, DOI 10.1002/chem.200801802; Georghiou PE, 2008, J ORG CHEM, V73, P9040, DOI 10.1021/jo801782z; BAIRD T, 1988, J CHEM SOC CHEM COMM, P1471, DOI 10.1039/c39880001471; Bancu M, 2004, SYNLETT, P173, DOI 10.1055/s-2003-44965; BARBOUR RH, 1983, J CHEM SOC CHEM COMM, P362, DOI 10.1039/c39830000362; Downing G. A., 1996, ANGEW CHEM, V108, P1643, DOI 10.1002/ange.19961081330; Downing G. A., 1994, ANGEW CHEM, V106, P1653, DOI 10.1002/ange.19941061509; DOWNING GA, 1994, ANGEW CHEM INT EDIT, V33, P1587, DOI 10.1002/anie.199415871; Downing GA, 1996, ANGEW CHEM INT EDIT, V35, P1547, DOI 10.1002/anie.199615471; GASPARRO FP, 1977, J CHEM EDUC, V54, P258; Gingras M, 2004, CHEM-EUR J, V10, P2895, DOI 10.1002/chem.200305605; Gingras M., 2006, ANGEW CHEM, V118, P1718, DOI 10.1002/ange.200500032; Hayashi S, 2010, ORG LETT, V12, P4148, DOI 10.1021/ol101746d; Inokuma Y., 2008, ANGEW CHEM, V120, P4918, DOI 10.1002/ange.200801192; Inokuma Y, 2008, ANGEW CHEM INT EDIT, V47, P4840, DOI 10.1002/anie.200801192; Inokuma Y, 2008, DALTON T, P2517, DOI 10.1039/b719808f; Inokuma Y., 2006, ANGEW CHEM, V118, P975, DOI 10.1002/ange.200503426; Kitano M., 2012, ANGEW CHEM, V124, P5691; Kitano M, 2014, J PORPHYR PHTHALOCYA, V18, P659, DOI 10.1142/S1088424614500394; Kitano M, 2012, CHEM-EUR J, V18, P8929, DOI 10.1002/chem.201201256; Kobayashi N., 2007, ANGEW CHEM, V119, P772, DOI 10.1002/ange.200603520; MACNICOL DD, 1982, TETRAHEDRON LETT, V23, P4131, DOI 10.1016/S0040-4039(00)88367-7; Makarova EA, 2008, CHEM COMMUN, P2109, DOI 10.1039/b801712c; Pham D, 2005, ORG LETT, V7, P2805, DOI 10.1021/ol050557p; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shimizu D, 2014, CHEM-EUR J, V20, P16194, DOI 10.1002/chem.201405110; Shimizu S, 2009, INORG CHEM, V48, P7885, DOI 10.1021/ic900880b; Shimizu S, 2011, CHEM COMMUN, V47, P316, DOI 10.1039/c0cc01877e; TESTAFERRI L, 1980, J ORG CHEM, V45, P4376, DOI 10.1021/jo01310a022; Torres T., 2006, ANGEW CHEM, V118, P2900, DOI 10.1002/ange.200504265; Tsurumaki E, 2013, CHEM-ASIAN J, V8, P3042, DOI 10.1002/asia.201300869; Tucker J. H. R., 1997, J CHEM SOC P1, P1303; Zhao S., 2014, SYNTHESIS-STUTTGART, P1674; Ziessel R, 2009, CHEM-EUR J, V15, P4980, DOI 10.1002/chem.200900394	59	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	JUL	2015	10	7					1526	1534		10.1002/asia.201500225		9	Chemistry, Multidisciplinary	Chemistry	CL8EU	WOS:000357206500013		
J	Zakaria, MB; Hu, M; Pramanik, M; Li, CL; Tang, J; Aldalbahi, A; Alshehri, SM; Malgras, V; Yamauchi, Y				Zakaria, Mohamed B.; Hu, Ming; Pramanik, Malay; Li, Cuiling; Tang, Jing; Aldalbahi, Ali; Alshehri, Saad M.; Malgras, Victor; Yamauchi, Yusuke			Synthesis of Nanoporous Ni-Co Mixed Oxides by Thermal Decomposition of Metal-Cyanide Coordination Polymers	CHEMISTRY-AN ASIAN JOURNAL			English	Article						coordination polymers; electrocatalytic activity; metal oxides; nanoporous materials; oxygen evolution reaction	MESOPOROUS SILICA; ELECTRODES; CO3O4; CALCINATION; MORPHOLOGY; HYDROXIDE; TEMPLATE; FILMS	A straightforward strategy to prepare nanoporous metal oxides with well-defined shapes is highly desirable. Through thermal treatment and a proper selection of metal-cyanide coordination polymers, nanoporous nickel-cobalt mixed oxides with different shapes (i.e., flakes and cubes) can be easily prepared. Our nanoporous materials demonstrate high electrocatalytic activity for oxygen evolution reaction.	[Zakaria, Mohamed B.; Hu, Ming; Pramanik, Malay; Li, Cuiling; Tang, Jing; Malgras, Victor; Yamauchi, Yusuke] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton MANA, Tsukuba, Ibaraki 3050044, Japan; [Zakaria, Mohamed B.; Yamauchi, Yusuke] Waseda Univ, Fac Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; [Zakaria, Mohamed B.] Tanta Univ, Dept Chem, Fac Sci, Tanta 31527, Gharbeya, Egypt; [Aldalbahi, Ali; Alshehri, Saad M.; Yamauchi, Yusuke] King Saud Univ, Dept Chem, Coll Sci, Riyadh 11451, Saudi Arabia	Yamauchi, Y (reprint author), Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton MANA, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.	Yamauchi.Yusuke@nims.go.jp	Yamauchi, Yusuke/D-2780-2015; Malgras, Victor/A-8221-2015; Li, Cuiling/E-2014-2015; Hu, Ming/C-3187-2012	Malgras, Victor/0000-0002-5667-9118; 	Culture Affairs & Missions Sector of the Ministry of Higher Education in Egypt; Deanship of Scientific Research, College of Science Research Center, King Saud University	M.B.Z. thanks the Culture Affairs & Missions Sector of the Ministry of Higher Education in Egypt for the financial support. A. A. extends his appreciation to the financial support by the Deanship of Scientific Research, College of Science Research Center, King Saud University.	Cho W, 2011, CHEM COMMUN, V47, P4138, DOI 10.1039/c1cc00079a; Yamauchi Y, 2013, J CERAM SOC JPN, V121, P831, DOI 10.2109/jcersj2.121.831; Hu M, 2013, ANGEW CHEM INT EDIT, V52, P1235, DOI 10.1002/anie.201208501; Wang WX, 2011, CATAL COMMUN, V12, P875, DOI 10.1016/j.catcom.2011.02.001; Mai YJ, 2011, J POWER SOURCES, V196, P6388, DOI 10.1016/j.jpowsour.2011.03.089; Gao MR, 2014, J AM CHEM SOC, V136, P7077, DOI 10.1021/ja502128j; Schuth F, 2001, CHEM MATER, V13, P3184, DOI 10.1021/cm011030j; Zhao DD, 2008, ELECTROCHIM ACTA, V53, P2699, DOI 10.1016/j.electacta.2007.07.053; Xiong SL, 2009, CHEM-EUR J, V15, P5320, DOI 10.1002/chem.200802671; Oveisi H, 2010, CHEM-ASIAN J, V5, P1978, DOI 10.1002/asia.201000351; Hu L, 2012, CHEM-EUR J, V18, P8971, DOI 10.1002/chem.201200770; Zakaria MB, 2014, CHEM-ASIAN J, V9, P1511, DOI 10.1002/asia.201400097; Zhou WJ, 2008, J MATER CHEM, V18, P905, DOI 10.1039/b715070a; Tian BZ, 2003, ADV MATER, V15, P1370, DOI 10.1002/adma.200305211; Gu D, 2014, CHEM SOC REV, V43, P313, DOI 10.1039/c3cs60155b; Jung S, 2009, ANGEW CHEM INT EDIT, V48, P1459, DOI 10.1002/anie.200804816; Yang PD, 1998, NATURE, V396, P152; Hu M, 2013, J AM CHEM SOC, V135, P384, DOI 10.1021/ja3096703; Lian HY, 2011, J PHYS CHEM C, V115, P6581, DOI 10.1021/jp110852p; Ganesan P, 2002, J POWER SOURCES, V111, P109, DOI 10.1016/S0378-7753(02)00301-4; Wu KCW, 2012, J MATER CHEM, V22, P1251, DOI 10.1039/c1jm13811a; Bocca C, 1999, INT J HYDROGEN ENERG, V24, P21, DOI 10.1016/S0360-3199(98)00012-3; Palmas S, 2007, ELECTROCHIM ACTA, V53, P400, DOI 10.1016/j.electacta.2007.01.085; Qin FX, 2013, MATER LETT, V101, P93, DOI 10.1016/j.matlet.2013.03.085; Parast MSY, 2011, INORG CHEM COMMUN, V14, P645, DOI 10.1016/j.inoche.2011.01.040; Cho W, 2009, CHEM COMMUN, P4756, DOI 10.1039/b907281k; Dahal N, 2012, J MATER CHEM, V22, P12675, DOI 10.1039/c2jm30460k; Hu M., 2013, ANGEW CHEM, V125, P1273, DOI 10.1002/ange.201208501; Jung S., 2009, ANGEW CHEM, V121, P1487; Tuysuz H, 2008, CHEM COMMUN, P4022, DOI 10.1039/b808815b; Wang H, 2013, INT J ELECTROCHEM SC, V8, P7734; Wang HJ, 2011, J NANOSCI NANOTECHNO, V11, P3843, DOI 10.1166/jnn.2011.3836	32	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	JUL	2015	10	7					1541	1545		10.1002/asia.201500245		5	Chemistry, Multidisciplinary	Chemistry	CL8EU	WOS:000357206500015		
J	Sahoo, R; Pradhan, M; Roy, A; Dutta, S; Ray, C; Negishi, Y; Pal, A; Pal, T				Sahoo, Ramkrishna; Pradhan, Mukul; Roy, Anindita; Dutta, Soumen; Ray, Chaiti; Negishi, Yuichi; Pal, Anjali; Pal, Tarasankar			Redox-Mediated Synthesis of a Fe3O4-MnO2 Nanocomposite for Dye Adsorption and Pseudocapacitance	CHEMISTRY-AN ASIAN JOURNAL			English	Article						adsorption; capacitors; electrochemistry; nanostructures; redox chemistry	HIGH-PERFORMANCE PSEUDOCAPACITOR; HEAVY-METAL IONS; GRAPHENE OXIDE; AQUEOUS-SOLUTION; WATER-TREATMENT; HIERARCHICAL NANOSTRUCTURES; SUPERIOR PERFORMANCE; ROOM-TEMPERATURE; FACILE SYNTHESIS; MNO2 NANOWIRES	A logically chosen redox reaction of submerged Fe-0 in an aqueous KMnO4 solution has been reported. The template-free reaction conditions produced gram amounts of a hierarchical flowerlike Fe3O4-MnO2 nanocomposite. More precisely, freshly prepared Fe-0 nanoparticles were prepared from air-free hot water under submerged conditions using a door magnet. The black Fe-0 particles were oxidized in water quantitatively by KMnO4 in the solution phase and the nanocomposite was prepared. The material has been used as a dye adsorbent and the representative cationic dye uptake, recovery, and recycling of the dye becomes easy owing to the ferromagnetic properties and surface negative charge of the material. The nanocomposite also showed a higher specific capacitance (327Fg(-1) at 10mVs(-1)) than the reported values of pure MnO2 and Fe3O4. The material exhibited a high energy density as well as a high power density, and remained stable even after a large number of charge-discharge cycles.	[Sahoo, Ramkrishna; Pradhan, Mukul; Roy, Anindita; Dutta, Soumen; Ray, Chaiti; Pal, Tarasankar] Indian Inst Technol, Dept Chem, Kharagpur 721302, W Bengal, India; [Pal, Anjali] Indian Inst Technol, Dept Civil Engn, Kharagpur 721302, W Bengal, India; [Negishi, Yuichi] Tokyo Univ Sci, Dept Appl Chem, Tokyo 1628601, Japan	Pal, T (reprint author), Indian Inst Technol, Dept Chem, Kharagpur 721302, W Bengal, India.	tpal@chem.iitkgp.ernet.in	Dutta, Soumen/N-9610-2014		DST; CSIR, New Delhi, India; Indian Institute of Technology, Kharagpur	The authors are thankful to Professor Kumar Biradha, IIT, Kharagpur for his instrumental support. Authors are also thankful to DST and CSIR, New Delhi, India for financial assistance, and the Indian Institute of Technology, Kharagpur for financial and instrumental support.	Aksu Z, 2005, PROCESS BIOCHEM, V40, P997, DOI 10.1016/j.procbio.2004.04.008; Fei JB, 2011, J MATER CHEM, V21, P11742, DOI 10.1039/c1jm11950h; Mou FZ, 2012, ACS APPL MATER INTER, V4, P3987, DOI 10.1021/am300814q; Jana S, 2007, ORG LETT, V9, P2191, DOI 10.1021/ol070750e; Yantasee W, 2007, ENVIRON SCI TECHNOL, V41, P5114, DOI 10.1021/es0705238; Li BJ, 2011, J MATER CHEM, V21, P10645, DOI 10.1039/c1jm12135a; Ai LH, 2011, J HAZARD MATER, V192, P1515, DOI 10.1016/j.jhazmat.2011.06.068; Zhao ZW, 2012, J MATER CHEM, V22, P9052, DOI 10.1039/c2jm00153e; Giri S, 2014, ADV FUNCT MATER, V24, P1312, DOI 10.1002/adfm.201302158; Dutta S, 2013, RSC ADV, V3, P21475, DOI 10.1039/c3ra44069a; Rodriguez A, 2009, J HAZARD MATER, V172, P1311, DOI 10.1016/j.jhazmat.2009.07.138; Kim EJ, 2013, ACS APPL MATER INTER, V5, P9628, DOI 10.1021/am402615m; Fei JB, 2008, ADV MATER, V20, P452, DOI 10.1002/adma.200701231; Hu JS, 2008, ADV MATER, V20, P2977, DOI 10.1002/adma.200800623; Choi BG, 2012, NANOSCALE, V4, P4983, DOI 10.1039/c2nr30991b; Meher SK, 2010, ELECTROCHIM ACTA, V55, P8388, DOI 10.1016/j.electacta.2010.07.042; Zhu JX, 2012, ACS APPL MATER INTER, V4, P2769, DOI 10.1021/am300388u; Chae JH, 2010, P I MECH ENG A-J POW, V224, P479, DOI 10.1243/09576509JPE861; Meher SK, 2011, J PHYS CHEM C, V115, P25543, DOI 10.1021/jp209165v; Chen HM, 2008, J PHYS CHEM C, V112, P17540, DOI 10.1021/jp806160g; Zhang ZY, 2011, J HAZARD MATER, V193, P325, DOI 10.1016/j.jhazmat.2011.07.033; Fan LL, 2013, COLLOID SURFACE B, V103, P601, DOI 10.1016/j.colsurfb.2012.11.023; Liu MM, 2014, J MATER CHEM A, V2, P12068, DOI 10.1039/c4ta01442a; Wang LX, 2012, DALTON T, V41, P4544, DOI 10.1039/c2dt11827k; Tan YW, 2008, CHEM MATER, V20, P5029, DOI 10.1021/cm801082p; Sahoo R, 2014, J PHYS CHEM C, V118, P11485, DOI 10.1021/jp503393x; Wang X, 2002, J AM CHEM SOC, V124, P2880, DOI 10.1021/ja0177105; Wang L, 2013, NANOSCALE, V5, P3793, DOI 10.1039/c3nr00256j; Meher SK, 2011, NANOSCALE, V3, P683, DOI 10.1039/c0nr00555j; Genuino HC, 2012, J PHYS CHEM C, V116, P12066, DOI 10.1021/jp301342f; Yang PH, 2014, NANO LETT, V14, P731, DOI 10.1021/nl404008e; Feng M, 2013, ACS APPL MATER INTER, V5, P12654, DOI 10.1021/am404011k; Bai S, 2012, CARBON, V50, P2337, DOI 10.1016/j.carbon.2012.01.057; Tian P, 2013, ACS APPL MATER INTER, V5, P12411, DOI 10.1021/am403352y; Winter M, 2004, CHEM REV, V104, P4245, DOI 10.1021/cr020730k; Hu CC, 2006, NANO LETT, V6, P2690, DOI 10.1021/nl061576a; Lin FH, 2011, J PHYS CHEM C, V115, P6591, DOI 10.1021/jp110956k; Li BX, 2006, INORG CHEM, V45, P6404, DOI 10.1021/ic0606274; CONWAY BE, 1991, J ELECTROCHEM SOC, V138, P1539, DOI 10.1149/1.2085829; Xie GQ, 2012, J MATER CHEM, V22, P1033, DOI 10.1039/c1jm13433g; Qu S, 2008, J HAZARD MATER, V160, P643, DOI 10.1016/j.jhazmat.2008.03.037; Fan ZJ, 2011, ADV FUNCT MATER, V21, P2366, DOI 10.1002/adfm.201100058; Yao YJ, 2012, J COLLOID INTERF SCI, V379, P20, DOI 10.1016/j.jcis.2012.04.030; Pang H, 2013, NANOSCALE, V5, P5752, DOI 10.1039/c3nr01460f; Hou Y, 2010, NANO LETT, V10, P2727, DOI 10.1021/nl101723g; Zheng HJ, 2012, J POWER SOURCES, V216, P508, DOI 10.1016/j.jpowsour.2012.06.047; Bai MH, 2014, ACS APPL MATER INTER, V6, P12656, DOI 10.1021/am502630g; Zhu J, 2014, ACS APPL MATER INTER, V6, P17637, DOI 10.1021/am505622c; Sarkar D, 2013, J PHYS CHEM C, V117, P15523, DOI 10.1021/jp4039573; Ai LH, 2012, NANOSCALE, V4, P5401, DOI 10.1039/c2nr31333b; Singh AK, 2014, ACS APPL MATER INTER, V6, P4684, DOI 10.1021/am404995h; Chang PR, 2011, J HAZARD MATER, V186, P2144, DOI 10.1016/j.jhazmat.2010.12.119; Fan LL, 2012, J HAZARD MATER, V215, P272, DOI 10.1016/j.jhazmat.2012.02.068; Mondal C, 2013, LANGMUIR, V29, P9179, DOI 10.1021/la401752n; Xiao HY, 2009, J PHYS CHEM C, V113, P16625, DOI 10.1021/jp9050269; Sinha AK, 2013, J PHYS CHEM C, V117, P23976, DOI 10.1021/jp403527p; Miller JR, 2008, SCIENCE, V321, P651, DOI 10.1126/science.1158736; Tang CH, 2013, ACS APPL MATER INTER, V5, P10574, DOI 10.1021/am402436q; Batchelor-McAuley C, 2008, NEW J CHEM, V32, P1195, DOI 10.1039/b718862e; Chen GZ, 2013, PROG NAT SCI-MATER, V23, P245, DOI 10.1016/j.pnsc.2013.04.001; Conway B. E., 1999, ELECTROCHEMICAL SUPE; Crini G, 2006, BIORESOURCE TECHNOL, V97, P1061, DOI 10.1016/j.biortech.2005.05.001; Huang M., 2014, SCI REP, V4, P3378; Jain R, 2006, INT J ENVIRON POLLUT, V27, P158; Li F., 2015, J MATER CHEM A, DOI [10.1039/C5A00634A, DOI 10.1039/C5A00634A]; Lian LF, 2014, RSC ADV, V4, P40753, DOI 10.1039/c4ra07880b; Liu S, 2015, NANOSCALE, V7, P4890, DOI 10.1039/c5nr00135h; Patil UM, 2014, J MATER CHEM A, V2, P19075, DOI 10.1039/c4ta03953j; Wu R, 2014, J ENV CHEM ENG, V2, P907; Zhang S. W., 2008, Energy Materials, V3, DOI 10.1179/174892409X427940; Zhao CM, 2013, SCI REP-UK, V3, DOI 10.1038/srep02986	71	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	JUL	2015	10	7					1571	1580		10.1002/asia.201500200		10	Chemistry, Multidisciplinary	Chemistry	CL8EU	WOS:000357206500019		
J	Ito, B; Xu, ZY; Yashiro, N				Ito, Banri; Xu, Zhaoyuan; Yashiro, Naomitsu			Does agglomeration promote internationalization of Chinese firms?	CHINA ECONOMIC REVIEW			English	Article						Agglomeration; Export; Spillover; Productivity	HETEROGENEOUS FIRMS; QUANTILE REGRESSION; LEVEL PRODUCTIVITY; EXPORT BEHAVIOR; TRADE; SPILLOVERS; INDUSTRY; MARKETS; LIBERALIZATION; GLOBALIZATION	Knowledge spillover from the agglomeration of exporters can reduce the initial costs of exporting faced by other firms and thereby facilitate exports. We use a large dataset of Chinese manufacturing firms to assess whether industrial agglomeration lowers the minimum productivity level required for exporting and whether it increases a firm's probability of exporting. Semi-parametric quantile regressions reveal that the productivity advantage of exporters against non-exporters is markedly smaller in agglomerated regions. Furthermore, a parametric estimation of an export entry model indicates that the agglomeration of incumbent exporters contributes significantly to export participation, although its magnitude is limited. These spillover effects are generated not only by the agglomeration of exporting foreign invested firms (FIFs), but also, more importantly, by that of indigenous Chinese exporters. Intact, the agglomeration of exporting FIFs only contributes to the export entry of FIFs. (C) 2015 Elsevier Inc. All rights reserved.	[Ito, Banri] Senshu Univ, Sch Econ, Tama Ku, Kawasaki, Kanagawa 2148580, Japan; [Xu, Zhaoyuan] Dev Res Ctr State Council, Res Dept Ind Econ, Beijing 100010, Peoples R China; [Yashiro, Naomitsu] Org Econ Cooperat & Dev, Struct Surveillance Div, Dept Econ, F-75016 Paris, France	Ito, B (reprint author), Senshu Univ, Sch Econ, Tama Ku, 2-1-1 Higashi Mita, Kawasaki, Kanagawa 2148580, Japan.	ito-banri@isc.senshu-u.ac.jp			China Humanities and Social Sciences Youth Foundation of Education Ministry [13YJC79004]; China National Natural Science Foundation [71403302, 71173058]	This paper is a product of joint research between the Development Research Center of the State Council, P. R. China (DRC) and the Research Institute of Economy, Trade and Industry (RIETI). The authors are grateful to Professor Yi Wen, the Editor, and anonymous referees as well as to the participants of the DRC-RIETI joint workshop at RIETI and DRC, the European Trade Study Group Fifteenth Annual Conference in 2013 and seminar participants at Yokohama National University and National Graduate Institute for Policy Studies for their valuable comments. Xu was supported by the China Humanities and Social Sciences Youth Foundation of Education Ministry (Project code: 13YJC79004) and the China National Natural Science Foundation (Project codes: 71403302 & 71173058). Remaining errors are those of the authors. The views expressed in the papers are solely those of the authors, and do not represent those of DRC or RIETI.	Aitken B, 1997, J INT ECON, V43, P103, DOI 10.1016/S0022-1996(96)01464-X; Van Biesebroeck J, 2005, J INT ECON, V67, P373, DOI 10.1016/j.jinteco.2004.12.002; Helpman E, 2004, AM ECON REV, V94, P300, DOI 10.1257/000282804322970814; Bernard AB, 2007, J ECON PERSPECT, V21, P105, DOI 10.1257/jep.21.3.105; Koenker R, 2001, J ECON PERSPECT, V15, P143, DOI 10.1257/jep.15.4.143; Melitz MJ, 2003, ECONOMETRICA, V71, P1695, DOI 10.1111/1468-0262.00467; Fujita M, 2001, ANN REGIONAL SCI, V35, P3, DOI 10.1007/s001680000020; Bernard AB, 2004, REV ECON STAT, V86, P561, DOI 10.1162/003465304323031111; Bai CE, 2004, J INT ECON, V63, P397, DOI 10.1016/S0022-1996(03)00070-9; Cai HB, 2009, ECON J, V119, P764; Cassiman B, 2010, INT J IND ORGAN, V28, P372, DOI 10.1016/j.ijindorg.2010.03.005; Lu JY, 2010, J INT ECON, V81, P197, DOI 10.1016/j.jinteco.2010.03.002; Levinsohn J, 2003, REV ECON STUD, V70, P317, DOI 10.1111/1467-937X.00246; Combes PP, 2012, ECONOMETRICA, V80, P2543, DOI 10.3982/ECTA8442; Lu JY, 2009, J URBAN ECON, V65, P167, DOI 10.1016/j.jue.2008.10.003; Roberts MJ, 1997, AM ECON REV, V87, P545; Melitz MJ, 2008, REV ECON STUD, V75, P295, DOI 10.1111/j.1467-937X.2007.00463.x; Bernard AB, 1999, J INT ECON, V47, P1, DOI 10.1016/S0022-1996(98)00027-0; Brandt L, 2012, J DEV ECON, V97, P339, DOI 10.1016/j.jdeveco.2011.02.002; Olley GS, 1996, ECONOMETRICA, V64, P1263, DOI 10.2307/2171831; Swenson DL, 2008, CAN J ECON, V41, P596; Koenig P, 2009, J URBAN ECON, V66, P186, DOI 10.1016/j.jue.2009.07.002; Bustos P, 2011, AM ECON REV, V101, P304, DOI 10.1257/aer.101.1.304; Ge Y, 2009, WORLD DEV, V37, P550, DOI 10.1016/j.worlddev.2008.07.005; Barrios S, 2003, OXFORD B ECON STAT, V65, P475, DOI 10.1111/1468-0084.t01-1-00058; Arnold JM, 2010, REV INT ECON, V18, P595, DOI 10.1111/j.1467-9396.2010.00888.x; Asheim B. T., 2005, OXFORD HDB INNOVATIO, P291; Breznitz D., 2011, RUN OF THE RED QUEEN; Clerides SK, 1998, Q J ECON, V113, P903, DOI 10.1162/003355398555784; Damijan JP, 2010, WORLD ECON, V33, P374, DOI 10.1111/j.1467-9701.2010.01260.x; Ellison G, 1997, J POLIT ECON, V105, P889, DOI 10.1086/262098; Greenaway D, 2008, EUR ECON REV, V52, P919, DOI 10.1016/j.euroecorev.2007.07.001; JAFFE AB, 1993, Q J ECON, V108, P577, DOI 10.2307/2118401; Henderson V., 2003, J URBAN ECON, V53, P1, DOI DOI 10.1016/S0094-1190(02)00505-3; Pertl L, 2008, REV WORLD ECON, V144, P596, DOI 10.1007/s10290-008-0163-y; Lileeva A, 2010, Q J ECON, V125, P1051; Loecker J., 2007, J INT ECON, V73, P69; Ma Y, 2014, J INT ECON, V92, P349, DOI 10.1016/j.jinteco.2013.11.003; Mayer T., 2007, HAPPY FEW INT EUROPE; Mayneris F, 2015, WORLD BANK ECON REV, V29, P150, DOI 10.1093/wber/lht009; Okubo T, 2014, REG STUD, V48, P1514, DOI 10.1080/00343404.2012.753143; Baldwin RE, 2006, J ECON GEOGR, V6, P323, DOI 10.1093/jeg/lbi020; Pilat D., 2012, CHINA FOCUS LESSONS; Wagner J, 2006, REV WORLD ECON, V142, P195, DOI 10.1007/s10290-006-0063-y; Wakasugi R., 2014, INT JAPANESE FIRMS	45	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1043-951X	1873-7781		CHINA ECON REV	China Econ. Rev.	JUL	2015	34						109	121		10.1016/j.chieco.2015.03.009		13	Economics	Business & Economics	CL5IK	WOS:000356992800008		
J	Cervenka, L; Melenovsky, V; Huskova, Z; Skaroupkova, P; Nishiyama, A; Sadowski, J				Cervenka, Ludek; Melenovsky, Vojtech; Huskova, Zuzana; Skaroupkova, Petra; Nishiyama, Akira; Sadowski, Janusz			Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						aorto-caval fistula; congestive heart failure; epoxyeicosatrienoic acids; hypertension; renal dysfunction; renin-angiotensin system; soluble epoxide hydrolase	ANGIOTENSIN-II; EPOXYEICOSATRIENOIC ACIDS; VOLUME OVERLOAD; CARDIAC-HYPERTROPHY; NITRIC-OXIDE; DISEASE; KIDNEY; ACTIVATION; MECHANISMS; RESPONSES	The detailed mechanisms determining the course of congestive heart failure (CHF) in hypertensive subjects with associated renal dysfunction remain unclear. In Ren-2 transgenic rats (TGR), a model of angiotensin II (ANG II)-dependent hypertension, CHF was induced by volume overload achieved by creation of the aorto-caval fistula (ACF). In these rats we investigated the putative pathophysiological contribution of epoxyeicosatrienoic acids (EETs) and compared it with the role of the renin-angiotensin system (RAS). We found that untreated ACF TGR exhibited marked intrarenal and myocardial deficiency of EETs and impairment of renal function. Chronic treatment of these rats with cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (c-AUCB, 3mg/L in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs, markedly improved survival rate, and increased renal blood flow, glomerular filtration rate and fractional sodium excretion, without altering RAS activity. Chronic angiotensin-converting enzyme inhibition (ACEi) with trandolapril, (6mg/L in drinking water) improved survival rate even more, and also inhibited the development of renal dysfunction; these beneficial actions were associated with significant suppression of the vasoconstrictor/sodium retaining axis and further activation of the vasodilatory/natriuretic axis of the systemic and intrarenal RAS, without modifying tissue availability of biologically active fatty acid epoxides. In conclusion, these findings strongly suggest that chronic sEH inhibition and chronic treatment with ACEi, each of them altering a different vasoactive system, delay or even prevent the onset of decompensation of CHF in ACF TGR, probably by preventing the development of renal dysfunction.	[Cervenka, Ludek; Huskova, Zuzana; Skaroupkova, Petra] Inst Clin & Expt Med, Ctr Med Expt, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Pathophysiol, Prague, Czech Republic; [Melenovsky, Vojtech] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Nishiyama, Akira] Kagawa Univ, Dept Pharmacol, Takamatsu, Kagawa 760, Japan; [Sadowski, Janusz] Polish Acad Sci, Dept Renal & Body Fluid Physiol, M Mossakowski Med Res Ctr, Warsaw, Poland	Cervenka, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathophysiol, Prague, Czech Republic.	luce@medicon.cz			Internal Grant Agency of the Ministry of Health the Czech Republic [NT/14012-3/2013]; Ministry of Health of the Czech Republic [00023001]; European Commission [CZ.2.16/3.1.00/22126]; Internal Grant Agency of Health of the Czech Republic [NT14050-3/2013, NT 14250-3/2013]; Grant Agency of Czech Republic [15-14200S]; Czech Ministry of Education [MSMT-LK12052-KONTAKT II]	This study was primarily supported by grant No. NT/14012-3/2013 awarded by the Internal Grant Agency of the Ministry of Health the Czech Republic to L. C. Z.H. is also supported by the project of the Ministry of Health of the Czech Republic for the development of research organization 00023001 (IKEM) (institutional support). The Centre for Experimental Medicine (IKEM) received financial support from the European Commission within the Operational Program Prague-Competitiveness; project 'CEVKOON' (#CZ.2.16/3.1.00/22126) and this study was also result of non-commercial cooperation between IKEM and OMNIMEDICS Ltd. within the project 'CEVKOON'. V.M. is also supported by grants No. NT14050-3/2013 and NT 14250-3/2013 awarded by the Internal Grant Agency of Health of the Czech Republic and by the grant No. 15-14200S awarded by the Grant Agency of Czech Republic and by grant MSMT-LK12052-KONTAKT II awarded by the Czech Ministry of Education.	Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; Kohagura K, 2000, ACTA PHYSIOL SCAND, V168, P107, DOI 10.1046/j.1365-201X.2000.00638.x; Ai D, 2009, P NATL ACAD SCI USA, V106, P564, DOI 10.1073/pnas.0811022106; GARCIA R, 1990, CARDIOVASC RES, V24, P430, DOI 10.1093/cvr/24.5.430; Hutchinson KR, 2011, J APPL PHYSIOL, V111, P1778, DOI 10.1152/japplphysiol.00691.2011; Cohen-Segev R, 2014, ACTA HISTOCHEM, V116, P1342, DOI 10.1016/j.acthis.2014.08.006; Abassi Z, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/729497; Benes J, 2011, CLIN SCI, V121, P29, DOI 10.1042/CS20100527; Katz AM, 2003, J CELL MOL MED, V7, P1, DOI 10.1111/j.1582-4934.2003.tb00197.x; Campbell WB, 2010, PFLUG ARCH EUR J PHY, V459, P881, DOI 10.1007/s00424-010-0804-6; El-Sherbeni AA, 2013, AAPS J, V15, P112, DOI 10.1208/s12248-012-9425-7; Zhang K, 2013, EUR J PHARMACOL, V701, P33, DOI 10.1016/j.ejphar.2012.12.025; Kurtz TW, 2005, HYPERTENSION, V45, P299, DOI 10.1161/01.HYP.0000150857.39919.cb; Chabova VC, 2010, CLIN SCI, V118, P617, DOI 10.1042/CS20090459; Hwang SH, 2007, J MED CHEM, V50, P3825, DOI 10.1021/jm070270t; Alsaad AMS, 2013, DRUG METAB REV, V45, P173, DOI 10.3109/03602532.2012.754460; Kopkan L, 2012, KIDNEY BLOOD PRESS R, V35, P595, DOI 10.1159/000339883; Roger VL, 2013, CIRC RES, V113, P646, DOI 10.1161/CIRCRESAHA.113.300268; Varcabova S, 2013, CLIN EXP PHARMACOL P, V40, P273, DOI 10.1111/1440-1681.12018; Pacher P, 2008, NAT PROTOC, V3, P1422, DOI 10.1038/nprot.2008.138; Imig JD, 2001, J HYPERTENS, V19, P983, DOI 10.1097/00004872-200105000-00020; Kobori H, 2007, PHARMACOL REV, V59, P251, DOI 10.1124/pr.59.3.3; Chaudhary KR, 2010, J CARDIOVASC PHARM, V55, P67, DOI 10.1097/FJC.0b013e3181c37d69; Neckar J, 2012, CLIN SCI, V122, P513, DOI 10.1042/CS20110622; Williams JM, 2010, J CARDIOVASC PHARM, V56, P336, DOI 10.1097/FJC.0b013e3181f04b1c; Monti J, 2008, NAT GENET, V40, P529, DOI 10.1038/ng.129; Gradman AH, 2006, PROG CARDIOVASC DIS, V48, P326, DOI 10.1016/j.pcad.2006.02.001; [Anonymous], 1996, AM J PHYSIOL-HEART C; Melenovsky V, 2011, MOL CELL BIOCHEM, V354, P83, DOI 10.1007/s11010-011-0808-3; Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051; Kujal P, 2014, CLIN EXP PHARMACOL P, V41, P227, DOI 10.1111/1440-1681.12204; Braunwald E., 2014, LANCET, V385, P812; Dube P, 2011, AM J MED SCI, V342, P348, DOI 10.1097/MAJ.0b013e318232750d; El-Sherbeni AA, 2014, ARCH TOXICOL, V88, P2013, DOI 10.1007/s00204-014-1371-y; ervenka L, 2015, PHYSL RES IN PRESS; ervenka L, 2015, PHYSIOL RES, V64, P11; Fan F, 2015, CURR OPIN NEPHROL HY, V24, P37, DOI 10.1097/MNH.0000000000000088; FOX J, 1992, AM J PHYSIOL, V262, pF902; Giamouzis Gregory, 2013, Curr Heart Fail Rep, V10, P411, DOI 10.1007/s11897-013-0164-6; Honetschlagerova Z, 2013, J HYPERTENS, V31, P321, DOI 10.1097/HJH.0b013e32835b50aa; Honetschlagerova Z, 2011, J PHYSIOL-LONDON, V589, P207, DOI 10.1113/jphysiol.2010.199505; Huskova Z, 2010, J HYPERTENS, V28, P495, DOI 10.1097/HJH.0b013e3283345d69; Imig JD, 1997, AM J PHYSIOL-RENAL, V273, pF274; Imig JD, 2015, HYPERTENSION, V65, P476, DOI 10.1161/HYPERTENSIONAHA.114.03585; Kujal P, 2010, CLIN EXP PHARMACOL P, V37, P1159, DOI 10.1111/j.1440-1681.2010.05453.x; Melenovsky V, 2012, KIDNEY BLOOD PRESS R, V35, P167, DOI 10.1159/000331562; Oliver-Dussault C, 2010, MOL CELL BIOCHEM, V338, P271, DOI 10.1007/s11010-009-0361-5; Schroten NF, 2011, HEART FAIL REV, V17, P191; Sporkova A, 2014, CLIN EXP PHARMACOL P, V41, P1003, DOI 10.1111/1440-1681.12310; Wang X, 2003, J APPL PHYSIOL, V94, P752, DOI 10.1152/japplphysiol.00248.2002	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	JUL	2015	42	7					795	807		10.1111/1440-1681.12419		13	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	CL9UF	WOS:000357322900010		
J	Ohkawa, R; Kurano, M; Mishima, Y; Nojiri, T; Tokuhara, Y; Kishimoto, T; Nakamura, K; Okubo, S; Hosogaya, S; Ozaki, Y; Yokota, H; Igarashi, K; Ikeda, H; Tozuka, M; Yatomi, Y				Ohkawa, Ryunosuke; Kurano, Makoto; Mishima, Yuko; Nojiri, Takahiro; Tokuhara, Yasunori; Kishimoto, Tatsuya; Nakamura, Kazuhiro; Okubo, Shigeo; Hosogaya, Shigemi; Ozaki, Yukio; Yokota, Hiromitsu; Igarashi, Koji; Ikeda, Hitoshi; Tozuka, Minoru; Yatomi, Yutaka			Possible involvement of sphingomyelin in the regulation of the plasma sphingosine 1-phosphate level in human subjects	CLINICAL BIOCHEMISTRY			English	Article						Sphingosine 1-phosphate; Sphingomyelin; Autotaxin	LYSOPHOSPHOLIPASE-D ACTIVITY; CORONARY-ARTERY-DISEASE; LYSOPHOSPHATIDIC ACID; APOLIPOPROTEIN M; LYMPHOCYTE EGRESS; PLATELET ACTIVATION; CLOSE CORRELATION; HEALTHY-SUBJECTS; ENZYMATIC ASSAY; HUMAN SERUM	Objectives: Sphingosine 1-phosphate (SIP) is a bioactive sphingolipid mediator. Although the plasma SIP concentration is reportedly determined by cellular components, including erythrocytes, platelets, and vascular endothelial cells, the possible involvement of other factors, such as serum sphingomyelin (SM) and autotaxin (ATX), remains to be elucidated. Design and methods: We measured SIP using high-performance liquid chromatography (HPLC), SM and lysophosphatidic acid (LPA) using enzymatic assays, ATX antigen using a two-site enzyme immunoassay, and ATX activity using a lysophospholipase D activity assay. To fractionate the lipoproteins, plasma samples were separated using fast protein liquid chromatography (FPLC) utilizing a Superose 6 column. Results: The plasma SIP level was positively correlated with the levels of SM and lysophosphatidylcholine, but not with the level of phosphatidylcholine. Although SM was present in the very low-density lipoprotein (VLDL) fraction, neither the plasma SIP level nor the SM level was affected by feeding. The plasma SIP level was negatively correlated with the ATX activity. Although the incubation of 100 1.unol/L of sphingosylphosphorylcholine (SPC) with the serum resulted in a significant increase in the S1P level because of the presence of ATX, the physiological concentration of SPC did not mimic this effect. Conclusion: The plasma SIP level was affected by the serum SM level, while the possibility of ATX involvement in the increase in the plasma SW level was considered to be remote at least in healthy human subjects. (C) 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[Ohkawa, Ryunosuke; Tozuka, Minoru] Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Analyt Chem Lab, Tokyo, Japan; [Ohkawa, Ryunosuke; Nojiri, Takahiro; Tokuhara, Yasunori; Nakamura, Kazuhiro; Okubo, Shigeo; Yokota, Hiromitsu; Ikeda, Hitoshi; Yatomi, Yutaka] Tokyo Univ Hosp, Dept Clin Lab, Tokyo 113, Japan; [Kurano, Makoto; Ikeda, Hitoshi; Yatomi, Yutaka] Univ Tokyo, Grad Sch Med, Dept Clin Lab Med, Tokyo 1138655, Japan; [Mishima, Yuko] Tokyo Univ Hosp, Dept Transfus Med, Tokyo 113, Japan; [Tokuhara, Yasunori] Kagawa Prefectural Univ Hlth Sci, Dept Med Technol, Pathol Lab, Takamatsu, Kagawa, Japan; [Kishimoto, Tatsuya] Alfresa Pharma Corp, Diagnost R&D Div, Osaka, Japan; [Hosogaya, Shigemi] Tokyo Univ Technol, Sch Hlth Sci, Dept Med Technol, Tokyo, Japan; [Ozaki, Yukio] Univ Yamanashi, Fac Med, Dept Clin & Lab Med, Kofu, Yamanashi, Japan; [Yokota, Hiromitsu] Toho Univ, Fac Sci, Educ Dev Ctr, Clin Lab Program, Chiba 2748510, Japan; [Igarashi, Koji] Tosoh Corp, AIA Res Grp, Reagent Dev Dept, Biosci Div, Yokosuka, Kanagawa, Japan	Yatomi, Y (reprint author), Univ Tokyo, Grad Sch Med, Dept Clin Lab Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yatoyuta-tky@umin.ac.jp			JSPS [22249017, 25253040]; Kurozumi Medical Foundation	This work was supported by JSPS KAKENHI Grant Numbers 22249017 and 25253040 (Y.Y.) and Kurozumi Medical Foundation (R.O.).	Christoffersen C, 2011, P NATL ACAD SCI USA, V108, P9613, DOI 10.1073/pnas.1103187108; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Nakamura K, 2008, CLIN CHIM ACTA, V388, P51, DOI 10.1016/j.cca.2007.10.005; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93; Jiang XC, 2000, ARTERIOSCL THROM VAS, V20, P2614; ZEISEL SH, 1986, J NUTR, V116, P50; Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Chiba K, 2006, CELL MOL IMMUNOL, V3, P11; Gesta S, 2002, J LIPID RES, V43, P904; Kurano M, 2014, BBA-MOL CELL BIOL L, V1841, P1217, DOI 10.1016/j.bbalip.2014.05.002; Brinkmann V, 2004, AM J TRANSPLANT, V4, P1019, DOI 10.1111/j.1600-6143.2004.00476.x; Wiesner P, 2009, J LIPID RES, V50, P574, DOI 10.1194/jlr.D800028-JLR200; Schlitt A, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743-7075-3-5; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; Nelson J, 2006, AM J EPIDEMIOL, V163, P903, DOI 10.1093/aje/kwj140; Ito S, 2013, CORONARY ARTERY DIS, V24, P642, DOI 10.1097/MCA.0000000000000033; Kurano M, 2013, ATHEROSCLEROSIS, V229, P102, DOI 10.1016/j.atherosclerosis.2013.04.024; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Yatomi Y, 1997, J BIOL CHEM, V272, P5291; Yatomi Y, 2006, CURR PHARM DESIGN, V12, P575, DOI 10.2174/138161206775474404; Sic H, 2014, J ALLERGY CLIN IMMUN, V134, P420, DOI 10.1016/j.jaci.2014.01.037; Clair T, 2003, CANCER RES, V63, P5446; Ikeda H, 2010, CLIN CHIM ACTA, V411, P765, DOI 10.1016/j.cca.2010.02.063; Ito S, 2014, CORONARY ARTERY DIS, V25, P311, DOI 10.1097/MCA.0000000000000082; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Knapp M, 2009, MED SCI MONITOR, V15, pCR490; Macey M, 2002, CLIN CHEM, V48, P891; Nojiri T, 2014, J DIABETES INVEST, V5, P639, DOI 10.1111/jdi.12232; Ohkawa R, 2012, CLIN BIOCHEM, V45, P1463, DOI 10.1016/j.clinbiochem.2012.07.093; Ohkawa R, 2008, ANN CLIN BIOCHEM, V45, P356, DOI 10.1258/acb.2007.007189; Ono Y, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-20; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; Sattler K, 2014, CELL PHYSIOL BIOCHEM, V34, P172, DOI 10.1159/000362993; Shiohira S., 2013, PHYSL REP, V1; Takabe K, 2014, J LIPID RES, V55, P1839, DOI 10.1194/jlr.R046656; Thuy AV, 2014, CELL PHYSIOL BIOCHEM, V34, P158, DOI 10.1159/000362992	44	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	JUL	2015	48	10-11					690	697		10.1016/j.clinbiochem.2015.03.019		8	Medical Laboratory Technology	Medical Laboratory Technology	CM0JC	WOS:000357363200012		
J	Karjalainen, K; Jaalouk, DE; Bueso-Ramos, C; Bover, L; Sun, Y; Kuniyasu, A; Driessen, WHP; Cardo-Vila, M; Rietz, C; Zurita, AJ; O'Brien, S; Kantarjian, HM; Cortes, JE; Calin, GA; Koivunen, E; Arap, W; Pasqualini, R				Karjalainen, Katja; Jaalouk, Diana E.; Bueso-Ramos, Carlos; Bover, Laura; Sun, Yan; Kuniyasu, Akihiko; Driessen, Wouter H. P.; Cardo-Vila, Marina; Rietz, Cecilia; Zurita, Amado J.; O'Brien, Susan; Kantarjian, Hagop M.; Cortes, Jorge E.; Calin, George A.; Koivunen, Erkki; Arap, Wadih; Pasqualini, Renata			Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens	CLINICAL CANCER RESEARCH			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; INTERLEUKIN-11 RECEPTOR; CANCER; CELLS; EXPRESSION; GUIDELINES; SELECTION; PEPTIDES; PROSTATE; DISPLAY	Purpose: The IL11 receptor (IL11R) is an established molecular target in primary tumors of bone, such as osteosarcoma, and in secondary bone metastases from solid tumors, such as prostate cancer. However, its potential role in management of hematopoietic malignancies has not yet been determined. Here, we evaluated the IL11R as a candidate therapeutic target in human leukemia and lymphoma. Experimental Design and Results: First, we show that the IL11R protein is expressed in a variety of human leukemia and lymphoma-derived cell lines and in a large panel of bone marrow samples from leukemia and lymphoma patients, whereas expression is absent from nonmalignant control bone marrow. Moreover, a targeted peptidomimetic prototype (termed BMTP-11), specifically bound to leukemia and lymphoma cell membranes, induced ligand-receptor internalization mediated by the IL11R, and resulted in a specific dose-dependent cell death induction in these cells. Finally, a pilot drug lead-optimization program yielded a new myristoylated BMTP-11 analogue with an apparent improved antileukemia cell profile. Conclusions: These results indicate (i) that the IL11R is a suitable cell surface target for ligand-directed applications in human leukemia and lymphoma and (ii) that BMTP-11 and its derivatives have translational potential against this group of malignant diseases. (C) 2015 AACR.	[Karjalainen, Katja; Calin, George A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Karjalainen, Katja; Koivunen, Erkki] Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland; [Jaalouk, Diana E.] Amer Univ Beirut, Dept Biol, Beirut, Lebanon; [Bueso-Ramos, Carlos] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Bover, Laura] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Sun, Yan] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA; [Kuniyasu, Akihiko] Sojo Univ, Dept Mol Cell Pharmacol, Kumamoto, Japan; [Driessen, Wouter H. P.] Roche, Basel, Switzerland; [Cardo-Vila, Marina; Rietz, Cecilia; Arap, Wadih; Pasqualini, Renata] Univ New Mexico, Sch Med, Ctr Canc, Albuquerque, NM 87131 USA; [Cardo-Vila, Marina; Rietz, Cecilia; Pasqualini, Renata] Univ New Mexico, Sch Med, Div Mol Med, Albuquerque, NM 87131 USA; [Zurita, Amado J.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [O'Brien, Susan; Kantarjian, Hagop M.; Cortes, Jorge E.; Calin, George A.; Koivunen, Erkki] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Arap, Wadih] Univ New Mexico, Sch Med, Dept Internal Med, Div Hematol Oncol, Albuquerque, NM 87131 USA	Pasqualini, R (reprint author), Univ New Mexico, 1201 Camino Salud NE, Albuquerque, NM 87131 USA.	warap@salud.unm.edu; rpasqual@salud.unm.edu			Specialized Program in Research Excellence (SPORE) Program in Leukemia at the UTMDACC; Gillson-Longenbaugh Foundation; Kimberly Patterson Fellowship for Leukemia Research	This work was supported by the Specialized Program in Research Excellence (SPORE) Program in Leukemia at the UTMDACC (to R. Pasqualini and W. Arap) and the Gillson-Longenbaugh Foundation (to R. Pasqualini and W. Arap). D.E. Jaalouk received support from the Kimberly Patterson Fellowship for Leukemia Research.	Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Nishimura S, 2008, J BIOL CHEM, V283, P11752, DOI 10.1074/jbc.M708849200; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Lahdenranta J, 2007, FASEB J, V21, P3272, DOI 10.1096/fj.07-8273com; Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998; Lewis VO, 2009, CANCER RES, V69, P1995, DOI 10.1158/0008-5472.CAN-08-4845; Nandurkar HH, 1997, BLOOD, V90, P2148; Takahashi S, 2003, CANCER RES, V63, P5213; Kim N, 2012, INT J CANCER, V131, P2456, DOI 10.1002/ijc.27529; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Ellerby HM, 1999, NAT MED, V5, P1032; Zurita AJ, 2004, CANCER RES, V64, P435, DOI 10.1158/0008-5472.CAN-03-2675; Kolonin MG, 2006, CANCER RES, V66, P34, DOI 10.1158/0008-5471CAN-05-2748; McGuire MJ, 2006, EXP HEMATOL, V34, P443, DOI 10.1016/j.exphem.2005.12.013; Cardo-Vila M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003452; CHEREL M, 1995, BLOOD, V86, P2534; Kimura T, 1999, LEUKEMIA, V13, P1018; Pasqualini R, 2015, CANCER; Pentz RD, 2005, NAT MED, V11, P1145, DOI 10.1038/nm1105-1145; Pentz RD, 2003, HASTINGS CENT REP, V33, P20, DOI 10.2307/3527910; Tsimanis A, 2001, LEUKEMIA LYMPHOMA, V42, P195, DOI 10.3109/10428190109097691	21	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1078-0432	1557-3265		CLIN CANCER RES	Clin. Cancer Res.	JUL 1	2015	21	13					3041	3051		10.1158/1078-0432.CCR-13-3059		11	Oncology	Oncology	CL9ZF	WOS:000357337200021		
J	Kawai, T; Yasuchika, K; Ishii, T; Katayama, H; Yoshitoshi, EY; Ogiso, S; Kita, S; Yasuda, K; Fukumitsu, K; Mizumoto, M; Hatano, E; Uemoto, S				Kawai, Takayuki; Yasuchika, Kentaro; Ishii, Takamichi; Katayama, Hokahiro; Yoshitoshi, Elena Yukie; Ogiso, Satoshi; Kita, Sadahiko; Yasuda, Katsutaro; Fukumitsu, Ken; Mizumoto, Masaki; Hatano, Etsuro; Uemoto, Shinji			Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma	CLINICAL CANCER RESEARCH			English	Article							PROSPECTIVE IDENTIFICATION; CYTOKERATIN-19 EXPRESSION; STEM/PROGENITOR CELLS; INITIATING CELLS; LIVER-CANCER; GROWTH; DIFFERENTIATION; RESISTANCE; INVASION	Purpose: Keratin 19 (K19) is a known marker of poor prognosis and invasion in human hepatocellular carcinoma (HCC). However, the relationship between K19 and cancer stem cells (CSCs) is unclear. Here, we determined whether K19 can be used as a new CSC marker and therapeutic target in HCC. Experimental Design: HCC cell lines were transfected with a K19 promoter-driven enhanced green fluorescence protein gene. CSC characteristics, epithelial-mesenchymal transition (EMT), and TGFb/Smad signaling were examined in FACS-isolated K19(+)/K19(-) cells. K19 and TGFb receptor 1 (TGFbR1) expression in 166 consecutive human HCC surgical specimens was examined immunohistochemically. Results: FACS-isolated single K19(+) cells showed self-renewal and differentiation into K19(-) cells, whereas single K19(-) cells did not produce K19(+) cells. K19(+) cells displayed high proliferation capacity and 5-fluorouracil resistance in vitro. Xenotransplantation into immunodeficient mice revealed that K19(+) cells reproduced, differentiated into K19(-) cells, and generated large tumors at a high frequency in vivo. K19(+) cells were found to be involved in EMT and the activation of TGFb/Smad signaling, and these properties were suppressed by K19 knockdown or treatment with a TGFbR1 inhibitor. The TGFbR1 inhibitor also showed high therapeutic effect against K19(+) tumor in the mouse xenograft model. Immunohistochemistry of HCC specimens showed that compared with K19(-) patients, K19(+) patients had significantly poorer recurrence-free survival and higher tumor TGFbR1 expression. Conclusions: K19 is a new CSC marker associated with EMT and TGFb/Smad signaling, and it would thus be a good therapeutic target for TGFbR1 inhibition. (C) 2015 AACR.	[Kawai, Takayuki; Yasuchika, Kentaro; Katayama, Hokahiro; Yoshitoshi, Elena Yukie; Ogiso, Satoshi; Kita, Sadahiko; Yasuda, Katsutaro; Fukumitsu, Ken; Mizumoto, Masaki; Hatano, Etsuro; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan; [Ishii, Takamichi] Nishikobe Med Ctr, Dept Surg, Kobe, Hyogo, Japan	Yasuchika, K (reprint author), Kyoto Univ, Grad Sch Med, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.	kent@kuhp.kyoto-u.ac.jp			Japan Science and Technology Agency [24791409]	This work was supported by grants from the Scientific Research Fund of the Japan Science and Technology Agency (research project number: 24791409).	Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Durnez A, 2006, HISTOPATHOLOGY, V49, P138, DOI 10.1111/j.1365-2559.2006.02468.x; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; Singh SK, 2003, CANCER RES, V63, P5821; Pratt S, 2005, MOL CANCER THER, V4, P855, DOI 10.1158/1535-7163.MCT-04-0291; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Oertel M, 2008, GASTROENTEROLOGY, V134, P823, DOI 10.1053/j.gastro.2008.01.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Yamanaka K, 2011, LIVER TRANSPLANT, V17, P60, DOI 10.1002/lt.22189; Ishii T, 2008, AM J PHYSIOL-GASTR L, V295, pG313, DOI 10.1152/ajpgi.00072.2008; Chiba T, 2009, CANCER LETT, V286, P145, DOI 10.1016/j.canlet.2009.04.027; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; Mazzocca A, 2009, HEPATOLOGY, V50, P1140, DOI 10.1002/hep.23118; Phillips TM, 2006, J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Dituri F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067109; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Ishii T, 2005, EXP CELL RES, V309, P68, DOI 10.1016/j.yexer.2005.05.028; Ishii T, 2007, STEM CELLS, V25, P3252, DOI 10.1634/stemcells.2007-0199; Ishii T, 2010, CANCER LETT, V294, P25, DOI 10.1016/j.canlet.2010.01.019; Kagaya M, 2001, J HEPATOL, V35, P504, DOI 10.1016/S0168-8278(01)00167-2; Sasaki N, 2011, CANCER LETT, V308, P152, DOI 10.1016/j.canlet.2011.04.023	34	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1078-0432	1557-3265		CLIN CANCER RES	Clin. Cancer Res.	JUL 1	2015	21	13					3081	3091		10.1158/1078-0432.CCR-14-1936		11	Oncology	Oncology	CL9ZF	WOS:000357337200025		
J	Dowling, P; McGrath, K				Dowling, Phelim; McGrath, Kevin			Using Free and Open Source Tools to Manage Software Quality	COMMUNICATIONS OF THE ACM			English	Article									[Dowling, Phelim] TSSG Verificat & Validat Team, Dublin, Ireland; [Dowling, Phelim] Muzu, Dublin, Ireland; [Dowling, Phelim] FeedHenry, Waterford, Ireland; [Dowling, Phelim] Kodacall, Mexico City, DF, Mexico; [Dowling, Phelim] OpenLab Initiat, Santa Cruz, CA USA; [McGrath, Kevin] Waterford Inst Technol, TSSG, Commercializat Team, Waterford, Ireland; [McGrath, Kevin] FeedHenry SWAGGER, London, England; [McGrath, Kevin] COIN, London, England; [McGrath, Kevin] SSGS, Tokyo, Japan; [McGrath, Kevin] EGP, Galway, Ireland; [McGrath, Kevin] Billing4Rent, Galway, Ireland							Clarke P, 2012, J SYST SOFTWARE, V85, P2356, DOI 10.1016/j.jss.2012.05.024; Baldwin H, 2014, REASONS CO SAY YES O; Dowling P, 2014, J SOFTW-EVOL PROC, V26, P468, DOI 10.1002/smr.1611; Kepes B, 2014, FORBES	4	0	0	ASSOC COMPUTING MACHINERY	NEW YORK	2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA	0001-0782	1557-7317		COMMUN ACM	Commun. ACM	JUL	2015	58	7					51	55		10.1145/2755503		5	Computer Science, Hardware & Architecture; Computer Science, Software Engineering; Computer Science, Theory & Methods	Computer Science	CL7BP	WOS:000357125200019		
J	Sarli, BV; da Silva, AL; Paglione, P				Sarli, Bruno Victorino; da Silva, Andre Luis; Paglione, Pedro			Sliding mode attitude control using thrusters and pulse modulation for the ASTER mission	COMPUTATIONAL & APPLIED MATHEMATICS			English	Article						Asteroid mission; Non-linear control; Attitude; ASTER; Sliding mode; PWM; PWPFM		ASTER, the first Brazilian mission to the deep space, targets the exploration of the triple asteroid system known as 2001 SN263. The mission requires an attitude controller robust and capable of coping with the non-linearities and the uncertainties present during the exploration phase. For such requirements, this paper studies the applicability of two controllers, designed based on the sliding mode control (SMC) technique, one of the controllers include an adaptive law used to compensate for the spacecraft's inertia variation. One application is performed where gain scheduling is used for controlling two different phases: exit from tumbling and track a dynamic reference. The actuators of the attitude control loops are impulsive thrusters. They are activated by pulse width modulation (PWM) or pulse width pulse frequency modulation (PWPFM). Simulation studies, performed in realistic scenarios, show that the SMC can maintain stability and performance when these modulation techniques are used to approximate the continuous commands. It is also shown that PWM can provide better performance, but at a higher control cost. In this sense, PWPFM is more appropriate with respect to the fuel consumption and activation times.	[Sarli, Bruno Victorino] Grad Univ Adv Studies, Dept Space & Astronaut Sci, Sagamihara, Kanagawa 2525210, Japan; [da Silva, Andre Luis] Univ Fed ABC, Ctr Engn Modelagem & Ciencias Sociais Aplicadas, BR-09606070 Sao Bernardo Do Campo, SP, Brazil; [Paglione, Pedro] Aeronaut Inst Technol, Aeronaut Engn Div, BR-12228900 Sao Jose Dos Campos, SP, Brazil	da Silva, AL (reprint author), Univ Fed ABC, Ctr Engn Modelagem & Ciencias Sociais Aplicadas, Rua Arcuturus 3, BR-09606070 Sao Bernardo Do Campo, SP, Brazil.	sarli@ac.jaxa.jp; andreluis.silva@ufabc.edu.br; paglione@ita.br	da Silva, Andre/P-8933-2015	da Silva, Andre/0000-0001-7179-3341			Yeh FK, 2010, IET CONTROL THEORY A, V4, P1254, DOI 10.1049/iet-cta.2009.0026; UTKIN VI, 1977, IEEE T AUTOMAT CONTR, V22, P212, DOI 10.1109/TAC.1977.1101446; da Silva AL, 2008, 26 INT C AER SCI ANC; Fang J, 2011, ASTRON J, V141, DOI 10.1088/0004-6256/141/5/154; HUNG JY, 1993, IEEE T IND ELECTRON, V40, P2, DOI 10.1109/41.184817; Macau EE, 2011, 62 INT ASTR C CURR A, P3669; Murray C., 2000, SOLAR SYSTEM DYNAMIC; Qingleia H, 2011, CHINESE J AERONAUT, V24, P32, DOI [10.1016/S1000-9361(11)60005-8, DOI 10.1016/S1000-9361(11)60005-8]; Sarli B, 2012, 39 COSPAR SCI ASS MY, P1680; Sarli BV, 2013, J PHYS CONF SER, V465, DOI 10.1088/1742-6596/465/1/012004; Sidi MJ, 1997, SPACECRAFT DYNAMICS; Slotine J.J.E., 1991, APPL NONLINEAR CONTR; Wytrzyszczak I, 2007, ADV SPACE RES, V40, P134, DOI 10.1016/j.asr.2006.11.020	13	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0101-8205	1807-0302		COMPUT APPL MATH	Comput. Appl. Math.	JUL	2015	34	2					535	556		10.1007/s40314-014-0146-7		22	Mathematics, Applied	Mathematics	CL9AW	WOS:000357267300010		
J	Watanabe, N; Kageyama, R; Ohtsuka, T				Watanabe, Naoki; Kageyama, Ryoichiro; Ohtsuka, Toshiyuki			Hbp1 regulates the timing of neuronal differentiation during cortical development by controlling cell cycle progression	DEVELOPMENT			English	Article						Hbp1; Brain morphology; Cell cycle; Cortical development; Neural stem cells; Neuronal differentiation; Mouse	NEURAL STEM-CELLS; TRANSCRIPTIONAL REPRESSOR HBP1; MURINE CEREBRAL WALL; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; PROGENITOR CELLS; ESSENTIAL ROLES; RADIAL GLIA; MOUSE-BRAIN; G1 PHASE	In the developing mammalian brain, neural stem cells (NSCs) initially expand the progenitor pool by symmetric divisions. NSCs then shift from symmetric to asymmetric division and commence neurogenesis. Although the precise mechanisms regulating the developmental timing of this transition have not been fully elucidated, gradual elongation in the length of the cell cycle and coinciding accumulation of determinants that promote neuronal differentiation might function as a biological clock that regulates the onset of asymmetric division and neurogenesis. We conducted gene expression profiling of embryonic NSCs in the cortical regions and found that expression of high mobility group box transcription factor 1 (Hbp1) was upregulated during neurogenic stages. Induced conditional knockout mice of Hbp1, generated by crossing with Nestin-CreERT2 mice, exhibited a remarkable dilatation of the telencephalic vesicles with a tangentially expanded ventricular zone and a thinner cortical plate containing reduced numbers of neurons. In these Hbp1-deficient mouse embryos, neural stem/progenitor cells continued to divide with a shorter cell cycle length. Moreover, downstream target genes of the Wnt signaling, such as cyclin D1 (Ccnd1) and c-jun (Jun), were upregulated in the germinal zone of the cortical regions. These results indicate that Hbp1 plays a crucial role in regulating the timing of cortical neurogenesis by elongating the cell cycle and that it is essential for normal cortical development.	[Watanabe, Naoki; Kageyama, Ryoichiro; Ohtsuka, Toshiyuki] Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; [Watanabe, Naoki; Kageyama, Ryoichiro; Ohtsuka, Toshiyuki] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; [Watanabe, Naoki; Kageyama, Ryoichiro; Ohtsuka, Toshiyuki] Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan; [Kageyama, Ryoichiro; Ohtsuka, Toshiyuki] Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan; [Kageyama, Ryoichiro] Kyoto Univ, World Premier Int Res Initiat Inst Integrated Cel, Kyoto 6068501, Japan	Ohtsuka, T (reprint author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	tohtsuka@virus.kyoto-u.ac.jp			Core Research for Evolutional Science and Technology [MEXT 22123002, JSPS 24240049, JSPS 23500390]	This work was supported by grants from Core Research for Evolutional Science and Technology (to R.K.), Grant-in-Aid for Scientific Research on Innovative Areas [MEXT 22123002 to R.K.], Scientific Research (A) [JSPS 24240049 to R.K.], and Scientific Research (C) [JSPS 23500390 to T.O.].	Imayoshi I, 2006, GENESIS, V44, P233, DOI 10.1002/dvg.20212; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Artegiani B, 2011, J EXP MED, V208, P937, DOI 10.1084/jem.20102167; Yan ZY, 2014, FEBS LETT, V588, P3038, DOI 10.1016/j.febslet.2014.06.017; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Gao ZL, 2009, NAT NEUROSCI, V12, P1090, DOI 10.1038/nn.2385; Tan SL, 2012, DEVELOPMENT, V139, P3806, DOI 10.1242/dev.082198; Calegari F, 2003, J CELL SCI, V116, P4947, DOI 10.1242/jcs.00825; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Calegari F, 2005, J NEUROSCI, V25, P6533, DOI 10.1523/JNEUROSCI.0778-05.2005; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Dehay C, 2007, NAT REV NEUROSCI, V8, P438, DOI 10.1038/nrn2097; Lange C, 2009, CELL STEM CELL, V5, P320, DOI 10.1016/j.stem.2009.05.026; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Imayoshi I, 2013, SCIENCE, V342, P1203, DOI 10.1126/science.1242366; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014; Kanki H, 2006, EXP ANIM TOKYO, V55, P137, DOI 10.1538/expanim.55.137; Martynoga B, 2005, DEV BIOL, V283, P113, DOI 10.1016/j.ydbio.2005.04.005; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Harima Y, 2013, CELL REP, V3, P1, DOI 10.1016/j.celrep.2012.11.012; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Pilaz LJ, 2009, P NATL ACAD SCI USA, V106, P21924, DOI 10.1073/pnas.0909894106; Sessa A, 2008, NEURON, V60, P56, DOI 10.1016/j.neuron.2008.09.028; Takahashi T, 1999, J NEUROSCI, V19, P10357; Caviness VS, 2003, CEREB CORTEX, V13, P592, DOI 10.1093/cercor/13.6.592; Delalle I, 1999, CEREB CORTEX, V9, P824, DOI 10.1093/cercor/9.8.824; Elfert S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061867; Gartel AL, 1998, ONCOGENE, V17, P3463; Kitagawa M, 1996, EMBO J, V15, P7060; Mairet-Coello G, 2012, DEVELOPMENT, V139, P475, DOI 10.1242/dev.067314; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; Miyama S, 1997, CEREB CORTEX, V7, P678, DOI 10.1093/cercor/7.7.678; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Ohtsuka T, 2006, MOL CELL NEUROSCI, V31, P109, DOI 10.1016/j.mcn.2005.09.006; Ohtsuka T, 2011, STEM CELLS, V29, P1817, DOI 10.1002/stem.731; Sakamoto M, 2003, J BIOL CHEM, V278, P44808, DOI 10.1074/jbc.M300448200; Schwab MH, 2000, J NEUROSCI, V20, P3714; Shih HH, 1998, MOL CELL BIOL, V18, P4732; Shimojo H, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00078	48	0	0	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0950-1991	1477-9129		DEVELOPMENT	Development	JUL 1	2015	142	13					2278	+		10.1242/dev.120477		33	Developmental Biology	Developmental Biology	CL7BM	WOS:000357124900007		
J	Atsuta, Y; Takahashi, Y				Atsuta, Yuji; Takahashi, Yoshiko			FGF8 coordinates tissue elongation and cell epithelialization during early kidney tubulogenesis	DEVELOPMENT			English	Article						Wolffian duct/nephric duct; Chemoattraction; Live imaging; Body axis	CHICK-EMBRYO; INTERMEDIATE MESODERM; AXIAL ELONGATION; LIMB DEVELOPMENT; DUCT FORMATION; MOUSE EMBRYO; GASTRULATION; MIGRATION; SOMITOGENESIS; MORPHOGENESIS	When a tubular structure forms during early embryogenesis, tubular elongation and lumen formation (epithelialization) proceed simultaneously in a spatiotemporally coordinated manner. We here demonstrate, using the Wolffian duct (WD) of early chicken embryos, that this coordination is regulated by the expression of FGF8, which shifts posteriorly during body axis elongation. FGF8 acts as a chemoattractant on the leader cells of the elongating WD and prevents them from epithelialization, whereas static ('rear') cells that receive progressively less FGF8 undergo epithelialization to form a lumen. Thus, FGF8 acts as a binary switch that distinguishes tubular elongation from lumen formation. The posteriorly shifting FGF8 is also known to regulate somite segmentation, suggesting that multiple types of tissue morphogenesis are coordinately regulated by macroscopic changes in body growth.	[Atsuta, Yuji; Takahashi, Yoshiko] Kyoto Univ, Dept Zool, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; [Takahashi, Yoshiko] Japan Sci & Technol Agcy JST, CREST, Tokyo 1020076, Japan	Takahashi, Y (reprint author), Kyoto Univ, Dept Zool, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan.	yotayota@develop.zool.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); Mitsubishi Foundation; Takeda Science Foundation	This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); The Mitsubishi Foundation; and Takeda Science Foundation. Deposited in PMC for immediate release.	Yang XS, 2002, DEV CELL, V3, P425, DOI 10.1016/S1534-5807(02)00256-3; Andrew DJ, 2010, DEV BIOL, V341, P34, DOI 10.1016/j.ydbio.2009.09.024; Cunningham TJ, 2013, CELL REP, V3, P1503, DOI 10.1016/j.celrep.2013.03.036; Orvis GD, 2007, DEV BIOL, V306, P493, DOI 10.1016/j.ydbio.2007.03.027; Watanabe T, 2007, DEV BIOL, V305, P625, DOI 10.1016/j.ydbio.2007.01.042; Tonegawa A, 1997, DEVELOPMENT, V124, P1975; NIWA H, 1991, GENE, V108, P193; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Soofi A, 2012, DEV BIOL, V365, P241, DOI 10.1016/j.ydbio.2012.02.032; Naiche LA, 2011, P NATL ACAD SCI USA, V108, P4018, DOI 10.1073/pnas.1007417108; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200; Karabagli H, 2002, ANAT EMBRYOL, V205, P365, DOI 10.1007/s00429-002-0264-7; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Obara-Ishihara T, 1999, DEVELOPMENT, V126, P1103; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; Lu PF, 2008, SCIENCE, V322, P1506, DOI 10.1126/science.1162783; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Chi X, 2009, DEV CELL, V17, P199, DOI 10.1016/j.devcel.2009.07.013; Shirasaki R, 2006, NEURON, V50, P841, DOI 10.1016/j.neuron.2006.04.030; Boulet AM, 2012, DEV BIOL, V371, P235, DOI 10.1016/j.ydbio.2012.08.017; Perantoni AO, 2005, DEVELOPMENT, V132, P3859, DOI 10.1242/dev.01945; Lunn JS, 2007, DEV BIOL, V302, P536, DOI 10.1016/j.ydbio.2006.10.014; Hiruma T, 2003, J ANAT, V203, P539, DOI 10.1046/j.1469-7580.2003.00245.x; Saito D, 2012, SCIENCE, V336, P1578, DOI 10.1126/science.1222369; Boulet AM, 2004, DEV BIOL, V273, P361, DOI 10.1016/j.ydbio.2004.06.012; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Benazeraf B, 2010, NATURE, V466, P248, DOI 10.1038/nature09151; Tsang TE, 2000, DEV BIOL, V223, P77, DOI 10.1006/dbio.2000.9733; Dubrulle J, 2004, NATURE, V427, P419, DOI 10.1038/nature02216; Antin PB, 2014, NUCLEIC ACIDS RES, V42, pD933, DOI 10.1093/nar/gkt962; Atsuta Y, 2013, DEV GROWTH DIFFER, V55, P579, DOI 10.1111/dgd.12047; Attia L, 2015, DEV DYNAM, V244, P157, DOI 10.1002/dvdy.24241; Chia I, 2011, DEVELOPMENT, V138, P2089, DOI 10.1242/dev.056838; Drawbridge J, 2000, DEV BIOL, V228, P116, DOI 10.1006/dbio.2000.9934; Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556; Kobayashi A, 2004, DEVELOPMENT, V131, P539, DOI 10.1242/dev.00951; Morris AR, 2003, DEVELOPMENT, V130, P5601, DOI 10.1242/dev.00765; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385; Sivak JM, 2005, DEV CELL, V8, P689, DOI 10.1016/j.devcel.2005.02.011; Wynn ML, 2013, PHYS BIOL, V10	41	0	0	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0950-1991	1477-9129		DEVELOPMENT	Development	JUL 1	2015	142	13					2329	+		10.1242/dev.122408		20	Developmental Biology	Developmental Biology	CL7BM	WOS:000357124900011		
J	Otani, T; Oshima, K; Kimpara, A; Takeda, M; Abdu, U; Hayashi, S				Otani, Tetsuhisa; Oshima, Kenzi; Kimpara, Akiyo; Takeda, Michiko; Abdu, Uri; Hayashi, Shigeo			A transport and retention mechanism for the sustained distal localization of Spn-F-IKK epsilon during Drosophila bristle elongation	DEVELOPMENT			English	Article						Cell elongation; Cell polarity; IKK epsilon; Ik2; Dynein; Drosophila	MESSENGER-RNA LOCALIZATION; CYTOPLASMIC DYNEIN; CYTOSKELETON ORGANIZATION; DENDRITIC TRAFFICKING; MITOTIC SPINDLE; JAVELIN-LIKE; CELL-FATE; MOTOR; MELANOGASTER; CHAIN	Stable localization of the signaling complex is essential for the robust morphogenesis of polarized cells. Cell elongation involves molecular signaling centers that coordinately regulate intracellular transport and cytoskeletal structures. In Drosophila bristle elongation, the protein kinase IKK epsilon is activated at the distal tip of the growing bristle and regulates the shuttling movement of recycling endosomes and cytoskeletal organization. However, how the distal tip localization of IKK epsilon is established and maintained during bristle elongation is unknown. Here, we demonstrate that IKK epsilon distal tip localization is regulated by Spindle-F (Spn-F), which is stably retained at the distal tip and functions as an adaptor linking IKK epsilon to cytoplasmic dynein. We found that Javelin-like (Jvl) is a key regulator of Spn-F retention. In jvl mutant bristles, IKK epsilon and Spn-F initially localize to the distal tip but fail to be retained there. In S2 cells, particles that stain positively for Jvl or Spn-F move in a microtubule-dependent manner, whereas Jvl and Spn-F double-positive particles are immobile, indicating that Jvl and Spn-F are transported separately and, upon forming a complex, immobilize each other. These results suggest that polarized transport and selective retention regulate the distal tip localization of the Spn-F-IKK epsilon complex during bristle cell elongation.	[Otani, Tetsuhisa; Oshima, Kenzi; Kimpara, Akiyo; Takeda, Michiko; Hayashi, Shigeo] RIKEN Ctr Dev Biol, Lab Morphogenet Signaling, Kobe, Hyogo 6500047, Japan; [Abdu, Uri] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; [Abdu, Uri] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, IL-84105 Beer Sheva, Israel; [Hayashi, Shigeo] Kobe Univ, Grad Sch Sci, Dept Biol, Kobe, Hyogo 6578501, Japan	Otani, T (reprint author), RIKEN Ctr Dev Biol, Lab Morphogenet Signaling, Kobe, Hyogo 6500047, Japan.	otani@cdb.riken.jp; shayashi@cdb.riken.jp			MEXT/JSPS [24770197]; Israel Science Foundation [968/10];  [22111007]	This work was supported by a MEXT/JSPS Grant-in-Aid for Young Scientists (B) [grant number 24770197] to T.O.; an Israel Science Foundation Grant [968/10] to U.A.; and Grant-in-Aid for Scientific Research on Innovative Areas [grant number 22111007] to S.H. Deposited in PMC for immediate release.	RASMUSSON K, 1994, MOL BIOL CELL, V5, P45; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Hepler PK, 2001, ANNU REV CELL DEV BI, V17, P159, DOI 10.1146/annurev.cellbio.17.1.159; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; BRAND AH, 1993, DEVELOPMENT, V118, P401; Sharp DJ, 2000, MOL BIOL CELL, V11, P241; Benison G, 2007, J MOL BIOL, V371, P457, DOI 10.1016/j.jmb.2007.05.046; Chen YM, 2013, J CELL BIOL, V202, P351, DOI 10.1083/jcb.201302040; Wong MY, 2012, CELL, V148, P1029, DOI 10.1016/j.cell.2011.12.036; XU T, 1993, DEVELOPMENT, V117, P1223; Maeder CI, 2014, CURR OPIN NEUROBIOL, V27, P165, DOI 10.1016/j.conb.2014.03.015; Millecamps S, 2013, NAT REV NEUROSCI, V14, P161, DOI 10.1038/nrn3380; Otani T, 2011, DEV CELL, V20, P219, DOI 10.1016/j.devcel.2011.02.001; Golachowska MR, 2010, TRENDS CELL BIOL, V20, P618, DOI 10.1016/j.tcb.2010.08.004; Kang JS, 2008, CELL, V132, P137, DOI 10.1016/j.cell.2007.11.024; Silvanovich A, 2003, MOL BIOL CELL, V14, P1355, DOI 10.1091/mbc.E02-10-0675; Gepner J, 1996, GENETICS, V142, P865; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; Bitan A, 2012, DEVELOPMENT, V139, P1987, DOI 10.1242/dev.076893; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Williams JC, 2007, P NATL ACAD SCI USA, V104, P10028, DOI 10.1073/pnas.0703614104; Phillis R, 1996, DEVELOPMENT, V122, P2955; Rapali P, 2011, FEBS J, V278, P2980, DOI 10.1111/j.1742-4658.2011.08254.x; Emery G, 2005, CELL, V122, P763, DOI 10.1016/j.cell.2005.08.017; Kuranaga E, 2006, CELL, V126, P583, DOI 10.1016/j.cell.2006.05.048; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Franker MAM, 2013, J CELL SCI, V126, P2319, DOI 10.1242/jcs.115030; Amsalem S, 2013, MOL CELL BIOL, V33, P4371, DOI 10.1128/MCB.00713-13; Dubin-Bar D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-51; Abdu U, 2006, DEVELOPMENT, V133, P1477, DOI 10.1242/dev.02319; Riquelme M, 2013, ANNU REV MICROBIOL, V67, P587, DOI 10.1146/annurev-micro-092412-155652; Apodaca G, 2012, NAT CELL BIOL, V14, P1235, DOI 10.1038/ncb2635; Oshima K, 2006, CURR BIOL, V16, P1531, DOI 10.1016/j.cub.2006.06.032; Bitan A, 2010, MOL CELL BIOL, V30, P496, DOI 10.1128/MCB.00861-09; Dick T, 1996, MOL CELL BIOL, V16, P1966; Koto A, 2009, J CELL BIOL, V187, P219, DOI 10.1083/jcb.200905110; Shapiro RS, 2006, DEVELOPMENT, V133, P1467, DOI 10.1242/dev.02318; Bellaiche Y, 2001, NAT CELL BIOL, V3, P50; de Celis JF, 1999, DEVELOPMENT, V126, P2653; Dubin-Bar D, 2011, DEVELOPMENT, V138, P4661, DOI 10.1242/dev.069161; Encalada SE, 2014, ANNU REV BIOPHYS, V43, P141, DOI 10.1146/annurev-biophys-051013-022746; Fu MM, 2014, TRENDS CELL BIOL, V24, P564, DOI 10.1016/j.tcb.2014.05.002; Gould G. W., 2011, SCI SIGNAL, V4, pe30; LEES AD, 1944, P ROY SOC LOND B BIO, V132, P396; Lees AD, 1942, PROC R SOC SER B-BIO, V131, P87, DOI 10.1098/rspb.1942.0019; Riggs B, 2007, MOL BIOL CELL, V18, P3313, DOI 10.1091/mbc.E07-02-0146; SCHNEIDE.I, 1972, J EMBRYOL EXP MORPH, V27, P353; Schwenk BM, 2014, EMBO J, V33, P450, DOI 10.1002/embj.201385857; Tilney LG, 2005, P NATL ACAD SCI USA, V102, P18785, DOI 10.1073/pnas.0509437102	50	2	2	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0950-1991	1477-9129		DEVELOPMENT	Development	JUL 1	2015	142	13					2338	+		10.1242/dev.121863		36	Developmental Biology	Developmental Biology	CL7BM	WOS:000357124900012		
J	Suzuki, S; Nozawa, Y; Tsukamoto, S; Kaneko, T; Manabe, I; Imai, H; Minami, N				Suzuki, Shinnosuke; Nozawa, Yusuke; Tsukamoto, Satoshi; Kaneko, Takehito; Manabe, Ichiro; Imai, Hiroshi; Minami, Naojiro			CHD1 acts via the Hmgpi pathway to regulate mouse early embryogenesis	DEVELOPMENT			English	Article						Chd1; Embryo development; Epigenetics; Zygotic gene activation; Mouse	EARLY EMBRYONIC-DEVELOPMENT; ZYGOTIC GENOME ACTIVATION; GENE-EXPRESSION; PREIMPLANTATION DEVELOPMENT; IN-VIVO; STEM-CELLS; ALPHA-AMANITIN; SELF-RENEWAL; PLURIPOTENCY; LINEAGE	The protein CHD1 is a member of the family of ATPase-dependent chromatin remodeling factors. CHD1, which recognizes trimethylated histone H3 lysine 4, has been implicated in transcriptional activation in organisms ranging from yeast to humans. It is required for pre-mRNA maturation, maintenance of mouse embryonic stem cell pluripotency and rapid growth of the mouse epiblast. However, the function(s) of CHD1 in mouse preimplantation embryos has not yet been examined. Here, we show that loss of CHD1 function led to embryonic lethality after implantation. In mouse embryos in which Chd1 was targeted by siRNA microinjection, the expression of the key regulators of cell fate specification Pou5f1 (also known as Oct4), Nanog and Cdx2 was dramatically decreased, starting at mid-preimplantation gene activation (MGA). Moreover, expression of Hmgpi and Klf5, which regulate Pou5f1, Nanog and Cdx2, was also significantly suppressed at zygotic gene activation (ZGA). Suppression of Hmgpi expression in Chd1-knockdown embryos continued until the blastocyst stage, whereas suppression of Klf5 expression was relieved by the morula stage. Next, we rescued HMGPI expression via Hmgpi mRNA microinjection in Chd1-knockdown embryos. Consequently, Pou5f1, Nanog and Cdx2 expression was restored at MGA and live offspring were recovered. These findings indicate that CHD1 plays important roles in mouse early embryogenesis via activation of Hmgpi at ZGA.	[Suzuki, Shinnosuke; Nozawa, Yusuke; Imai, Hiroshi; Minami, Naojiro] Kyoto Univ, Grad Sch Agr, Reprod Biol Lab, Kyoto 6068502, Japan; [Tsukamoto, Satoshi] Natl Inst Radiol Sci, Lab Anim & Genome Sci Sect, Chiba 2638555, Japan; [Kaneko, Takehito] Kyoto Univ, Inst Lab Anim, Grad Sch Med, Kyoto 6068501, Japan; [Manabe, Ichiro] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan	Minami, N (reprint author), Kyoto Univ, Grad Sch Agr, Reprod Biol Lab, Kyoto 6068502, Japan.	oog1nao@kais.kyoto-u.ac.jp			Japan Society for the Promotion of Science [23380164]	This work was supported by a Grant-in-Aid for Scientific Research [23380164 to N.M.] from the Japan Society for the Promotion of Science.	Abdalla H, 2009, J REPROD DEVELOP, V55, P356, DOI 10.1262/jrd.20234; Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212; Hamatani T, 2004, DEV CELL, V6, P117, DOI 10.1016/S1534-5807(03)00373-3; Lin SCJ, 2010, DEVELOPMENT, V137, P3953, DOI 10.1242/dev.054775; HO YG, 1995, MOL REPROD DEV, V41, P232, DOI 10.1002/mrd.1080410214; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Chen LY, 2009, CELL RES, V19, P1052, DOI 10.1038/cr.2009.79; Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808; Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; Ralston A, 2010, DEVELOPMENT, V137, P395, DOI 10.1242/dev.038828; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Shi LJ, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-59; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; Konev AY, 2007, SCIENCE, V317, P1087, DOI 10.1126/science.1145339; Burton A, 2010, BRIEF FUNCT GENOMICS, V9, P444, DOI 10.1093/bfgp/elq027; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Home P, 2012, P NATL ACAD SCI USA, V109, P7362, DOI 10.1073/pnas.1201595109; Isaji Y, 2013, J REPROD DEVELOP, V59, P196, DOI 10.1262/jrd.2012-156; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Li L, 2010, DEVELOPMENT, V137, P859, DOI 10.1242/dev.039487; Minami N, 2007, J REPROD DEVELOP, V53, P707, DOI 10.1262/jrd.19029; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040; Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Ema M, 2008, CELL STEM CELL, V3, P555, DOI 10.1016/j.stem.2008.09.003; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Lindeman LC, 2011, DEV CELL, V21, P993, DOI 10.1016/j.devcel.2011.10.008; Yamada M, 2010, HUM MOL GENET, V19, P480, DOI 10.1093/hmg/ddp512; Yagi R, 2007, DEVELOPMENT, V134, P3827, DOI 10.1242/dev.010223; Shao GB, 2008, IN VITRO CELL DEV-AN, V44, P115, DOI 10.1007/s11626-008-9082-4; Corry GN, 2009, BIRTH DEFECTS RES C, V87, P297, DOI 10.1002/bdrc.20165; Do DV, 2013, GENE DEV, V27, P1378, DOI 10.1101/gad.221176.113; Fazzio TG, 2010, CURR OPIN GENET DEV, V20, P500, DOI 10.1016/j.gde.2010.08.001; Guzman-Ayala M, 2015, DEVELOPMENT, V142, P118, DOI 10.1242/dev.114843; Jeong YJ, 2005, MOL REPROD DEV, V71, P284, DOI 10.1002/mrd.20269; LEVEY IL, 1977, J REPROD FERTIL, V50, P147; Mamo S, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-14; Minami N, 2001, BIOL REPROD, V64, P30, DOI 10.1095/biolreprod64.1.30; Rasmussen TP, 2010, J CELL PHYSIOL, V225, P333, DOI 10.1002/jcp.22293; SCHULTZ RM, 1993, BIOESSAYS, V15, P531, DOI 10.1002/bies.950150806; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Stokes DG, 1996, P NATL ACAD SCI USA, V93, P7137, DOI 10.1073/pnas.93.14.7137; Suzuki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074749; Wang K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010622; WARNER CM, 1974, NATURE, V248, P678, DOI 10.1038/248678a0; Zhang K, 2013, DEV BIOL, V373, P359, DOI 10.1016/j.ydbio.2012.10.026	52	0	0	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0950-1991	1477-9129		DEVELOPMENT	Development	JUL 1	2015	142	13					2375	+		10.1242/dev.120493		12	Developmental Biology	Developmental Biology	CL7BM	WOS:000357124900015		
J	Kawai, N; Ogura, Y; Ikuta, T; Saiga, H; Hamada, M; Sakuma, T; Yamamoto, T; Satoh, N; Sasakura, Y				Kawai, Narudo; Ogura, Yosuke; Ikuta, Tetsuro; Saiga, Hidetoshi; Hamada, Mayuko; Sakuma, Tetsushi; Yamamoto, Takashi; Satoh, Nori; Sasakura, Yasunori			Hox10-regulated endodermal cell migration is essential for development of the ascidian intestine	DEVELOPMENTAL BIOLOGY			English	Article						Hox; Collagen type IX; Extracellular matrix; Protrusion; Intestine; Cell migration	CHORDATE CIONA-INTESTINALIS; HOX GENE-FUNCTION; HALOCYNTHIA-RORETZI; NERVOUS-SYSTEM; TRANSCRIPTION FACTORS; IX COLLAGEN; EXPRESSION; CARTILAGE; EMBRYOS; DEGRADATION	Hox cluster genes play crucial roles in development of the metazoan antero-posterior axis. Functions of Hox genes in patterning the central nervous system and limb buds are well known. They are also expressed in chordate endodermal tissues, where their roles in endodermal development are still poorly understood. In the invertebrate chordate, Ciona intestinalis, endodermal tissues are in a premature state during the larval stage, and they differentiate into the digestive tract during metamorphosis. In this study, we showed that disruption of a Hox gene, Ci-Hox10, prevented intestinal formation. Ci-Hox10-knock-down larvae displayed defective migration of endodermal strand cells. Formation of a protrusion, which is important for cell migration, was disrupted in these cells. The collagen type IX gene is a downstream target of Ci-Hox10, and is negatively regulated by Ci-Hox10 and a matrix metalloproteinase ortholog, prior to endodermal cell migration. Inhibition of this regulation prevented cellular migration. These results suggest that Ci-Hox10 regulates endodermal strand cell migration by forming a protrusion and by reconstructing the extracellular matrix. (C) 2015 Elsevier Inc. All rights reserved.	[Kawai, Narudo; Ogura, Yosuke; Sasakura, Yasunori] Univ Tsukuba, Shimoda Marine Res Ctr, Shimoda, Shizuoka 4150025, Japan; [Ikuta, Tetsuro; Saiga, Hidetoshi] Tokyo Metropolitan Univ, Grad Sch Sci & Engn, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; [Hamada, Mayuko; Satoh, Nori] Okinawa Inst Sci & Technol Grad Univ, Marine Genom Unit, Onna, Okinawa 9040495, Japan; [Sakuma, Tetsushi; Yamamoto, Takashi] Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan	Kawai, N (reprint author), Keio Univ, Dept Biol Res & Educ, Ctr Nat Sci, Kohoku Ku, 4-1-1 Hiyoshi, Yokohama, Kanagawa 2238521, Japan.	nkawai@a7.keio.jp			JSPS; MEXT [20681019, 21112004, 23681039]; University of Tsukuba; National Bioresource Project	We would like to thank the members of the Shimoda Marine Research Center at the University of Tsukuba for their assistance with this study. We would also like to thank Drs. Shigeki Fujiwara, Nobuo Yamaguchi, Kunifumi Tagawa and all members of the Department of Zoology, Kyoto University, Misaki Marine Biological Station, University of Tokyo, and the Maizuru Fishery Research Station of Kyoto University for collecting Ciona adults. Drs. Patrick Lemaire and Agnes Roure are acknowledged for their kind provision of Full ORF gateway compatible clones. We thank Dr. Steven Aird for English editing of the manuscript. This study was supported by Grants-in-Aid for Scientific Research from JSPS and MEXT (20681019, 21112004, 23681039) and Innovative Research Support Program (Pilot Models) from University of Tsukuba to YS. Further support was provided by Grants from the National Bioresource Project We also thank OIST Graduate University for its generous support of the Marine Genomics Unit.	Akanuma T, 2002, DEV GENES EVOL, V212, P459, DOI 10.1007/s00427-002-0264-x; Altmann CR, 2001, INT REV CYTOL, V203, P447; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Le SQ, 2008, MOL BIOL EVOL, V25, P1307, DOI 10.1093/molbev/msn067; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Horie T, 2011, NATURE, V469, P525, DOI 10.1038/nature09631; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; Ristoratore F, 1999, DEVELOPMENT, V126, P5149; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Ikuta T, 2004, P NATL ACAD SCI USA, V101, P15118, DOI 10.1073/pnas.0401389101; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Sasakura Y, 2010, MOL GENET GENOMICS, V283, P99, DOI 10.1007/s00438-009-0500-4; Ogura Y, 2011, DEVELOPMENT, V138, P577, DOI 10.1242/dev.053132; Sakuma T, 2013, GENES CELLS, V18, P315, DOI 10.1111/gtc.12037; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Imai KS, 2004, DEVELOPMENT, V131, P4047, DOI 10.1242/dev.01270; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; Lin SD, 2010, J CELL BIOL, V190, P263, DOI 10.1083/jcb.200912128; Zacchetti G, 2007, DEVELOPMENT, V134, P3967, DOI 10.1242/dev.010991; Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Niwano T, 2009, BIOL CELL, V101, P645, DOI 10.1042/BC20090042; Joly JS, 2007, DEV DYNAM, V236, P1832, DOI 10.1002/dvdy.21124; Satou Y, 2005, ZOOL SCI, V22, P837, DOI 10.2108/zsj.22.837; Satou Y, 2001, GENESIS, V30, P103, DOI 10.1002/gene.1040; Gebelein B, 2004, NATURE, V431, P653, DOI 10.1038/nature02946; Sasakura Y, 2012, DEVELOPMENT, V139, P2156, DOI 10.1242/dev.080234; Mallo M, 2010, DEV BIOL, V344, P7, DOI 10.1016/j.ydbio.2010.04.024; Hueber SD, 2008, BIOESSAYS, V30, P965, DOI 10.1002/bies.20823; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Knauper V, 1997, J BIOL CHEM, V272, P7608; Ikuta T, 2010, DEVELOPMENT, V137, P1505, DOI 10.1242/dev.046938; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Corbo JC, 1997, DEVELOPMENT, V124, P589; Arenas-Mena C, 2006, DEV GROWTH DIFFER, V48, P463, DOI 10.1111/j.1440-169x.2006.00883.x; Bae YK, 2012, CELL ADHES MIGR, V6, P397, DOI 10.4161/cam.21103; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; Christiaen L, 2008, SCIENCE, V320, P1349, DOI 10.1126/science.1158170; Cloney R.A., 1978, P255; Creuzet S, 2005, J ANAT, V207, P447; Doodnath R, 2012, PEDIATR SURG INT, V28, P115, DOI 10.1007/s00383-011-2992-3; Eyre DR, 2004, J BIOL CHEM, V279, P2568, DOI 10.1074/jbc.M311653200; Geisen MJ, 2008, PLOS BIOL, V6, P1178, DOI 10.1371/journal.pbio.0060142; Hernandez RM, 2009, J CLIN PERIODONTOL, V36, P1011; Hirano T, 2000, DEV GENES EVOL, V210, P55, DOI 10.1007/s004270050011; Hozumi A, 2013, DEV DYNAM, V242, P30, DOI 10.1002/dvdy.23891; Ikuta T, 2005, DEV DYNAM, V233, P382, DOI 10.1002/dvdy.20374; Kaltenbach SL, 2009, EVOL DEV, V11, P142, DOI 10.1111/j.1525-142X.2009.00315.x; Koussoulakos S, 2004, ANAT EMBRYOL, V209, P93, DOI 10.1007/s00429-004-0436-8; Mizoguchi T, 2008, DEVELOPMENT, V135, P2521, DOI 10.1242/dev.020107; Nakazawa K, 2013, DEV DYNAM, V242, P1172, DOI 10.1002/dvdy.24009; Ohta N, 2010, ZOOL SCI, V27, P842, DOI 10.2108/zsj.27.842; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; Pasini A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046193; Roure A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000916; Sakuma T, 2013, SCI REP-UK, V3, DOI 10.1038/srep03379; Sasakura Y, 2005, P NATL ACAD SCI USA, V102, P15134, DOI 10.1073/pnas.0503640102; Satou Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r152; Satou Y, 2008, DEV GENES EVOL, V218, P715, DOI 10.1007/s00427-008-0219-y; Satou Y, 2002, GENESIS, V33, P153, DOI 10.1002/gene.10119; Satou Y, 2001, DEVELOPMENT, V128, P3559; Shi WY, 2009, DEVELOPMENT, V136, P23, DOI 10.1242/dev.029157; Shoguchi E, 2006, GENOME RES, V16, P297, DOI 10.1101/gr.4156606; Treen N, 2014, DEVELOPMENT, V141, P481, DOI 10.1242/dev.099572; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963; Vizzini A, 2002, BBA-GENE STRUCT EXPR, V1577, P38, DOI 10.1016/S0167-4781(02)00403-7; Wada S, 2003, DEV GENES EVOL, V213, P222, DOI 10.1007/s00427-003-0321-0; WADA S, 1995, MECH DEVELOP, V51, P115, DOI 10.1016/0925-4773(95)00359-9; Watari-Goshima N, 2011, INT J BIOL SCI, V7, P87; Yoshida R, 2012, ZOOL SCI, V29, P11, DOI 10.2108/zsj.29.11	71	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0012-1606	1095-564X		DEV BIOL	Dev. Biol.	JUL 1	2015	403	1					43	56		10.1016/j.ydbio.2015.03.018		14	Developmental Biology	Developmental Biology	CL4FK	WOS:000356907800007		
J	Qi, QB; Downer, MK; Kilpelainen, TO; Taal, HR; Barton, SJ; Ntalla, I; Standl, M; Boraska, V; Huikari, V; Kiefte-de Jong, JC; Korner, A; Lakka, TA; Liu, GF; Magnusson, J; Okuda, M; Raitakari, O; Richmond, R; Scott, RA; Bailey, MES; Scheuermann, K; Holloway, JW; Inskip, H; Isasi, CR; Mossavar-Rahmani, Y; Jaddoe, VWV; Laitinen, J; Lindi, V; Melen, E; Pitsiladis, Y; Pitkanen, N; Snieder, H; Heinrich, J; Timpson, NJ; Wang, T; Yuji, H; Zeggini, E; Dedoussis, GV; Kaplan, RC; Wylie-Rosett, J; Loos, RJF; Hu, FB; Qi, L				Qi, Qibin; Downer, Mary K.; Kilpelaeinen, Tuomas O.; Taal, H. Rob; Barton, Sheila J.; Ntalla, Ioanna; Standl, Marie; Boraska, Vesna; Huikari, Ville; Kiefte-de Jong, Jessica C.; Koerner, Antje; Lakka, Timo A.; Liu, Gaifen; Magnusson, Jessica; Okuda, Masayuki; Raitakari, Olli; Richmond, Rebecca; Scott, Robert A.; Bailey, Mark E. S.; Scheuermann, Kathrin; Holloway, John W.; Inskip, Hazel; Isasi, Carmen R.; Mossavar-Rahmani, Yasmin; Jaddoe, Vincent W. V.; Laitinen, Jaana; Lindi, Virpi; Melen, Erik; Pitsiladis, Yannis; Pitkaenen, Niina; Snieder, Harold; Heinrich, Joachim; Timpson, Nicholas J.; Wang, Tao; Yuji, Hinoda; Zeggini, Eleftheria; Dedoussis, George V.; Kaplan, Robert C.; Wylie-Rosett, Judith; Loos, Ruth J. F.; Hu, Frank B.; Qi, Lu			Dietary Intake, FTO Genetic Variants, and Adiposity: A Combined Analysis of Over 16,000 Children and Adolescents	DIABETES			English	Article							BODY-MASS INDEX; OBESITY-ASSOCIATED GENE; ENERGY-INTAKE; FAT MASS; PHYSICAL-ACTIVITY; FOOD-INTAKE; CHILDHOOD OBESITY; COHORT PROFILE; METABOLIC-RATE; ADULT OBESITY	The FTO gene harbors variation with the strongest effect on adiposity and obesity risk. Previous data support a role for FTO variation in influencing food intake. We conducted a combined analysis of 16,094 boys and girls aged 1-18 years from 14 studies to examine the following: 1) the association between the FTO rs9939609 variant (or a proxy) and total energy and macronutrient intake; and 2) the interaction between the FTO variant and dietary intake, and the effect on BMI. We found that the BMI-increasing allele (minor allele) of the FTO variant was associated with increased total energy intake (effect per allele = 14.3 kcal/day [95% CI 5.9, 22.7 kcal/day], P = 6.5 x 10(-4)), but not with protein, carbohydrate, or fat intake. We also found that protein intake modified the association between the FTO variant and BMI (interactive effect per allele = 0.08 SD [0.03, 0.12 SD], P for interaction = 7.2 x 10(-4)): the association between FTO genotype and BMI was much stronger in individuals with high protein intake (effect per allele = 0.10 SD [0.07, 0.13 SD], P = 8.2 x 10(-10)) than in those with low intake (effect per allele = 0.04 SD [0.01, 0.07 SD], P = 0.02). Our results suggest that the FTO variant that confers a predisposition to higher BMI is associated with higher total energy intake, and that lower dietary protein intake attenuates the association between FTO genotype and adiposity in children and adolescents.	[Qi, Qibin; Isasi, Carmen R.; Mossavar-Rahmani, Yasmin; Wang, Tao; Kaplan, Robert C.; Wylie-Rosett, Judith] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Qi, Qibin; Downer, Mary K.; Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Kilpelaeinen, Tuomas O.; Scott, Robert A.; Loos, Ruth J. F.] Addenbrookes Hosp, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England; [Kilpelaeinen, Tuomas O.; Scott, Robert A.; Loos, Ruth J. F.] Univ Cambridge, Cambridge, England; [Kilpelaeinen, Tuomas O.] Univ Copenhagen, Fac Hlth & Med Sci, Sect Metab Genet, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Taal, H. Rob; Jaddoe, Vincent W. V.] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands; [Taal, H. Rob; Kiefte-de Jong, Jessica C.; Jaddoe, Vincent W. V.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Taal, H. Rob; Jaddoe, Vincent W. V.] Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [Barton, Sheila J.; Inskip, Hazel] Univ Southampton, Fac Med, MRC Lifecourse Epidemiol Unit, Southampton SO9 5NH, Hants, England; [Ntalla, Ioanna; Dedoussis, George V.] Harokopio Univ, Sch Hlth Sci & Educ, Dept Nutr & Dietet, Athens, Greece; [Ntalla, Ioanna] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Standl, Marie; Heinrich, Joachim] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany; [Boraska, Vesna; Zeggini, Eleftheria] Wellcome Trust Sanger Inst, Cambridge, England; [Boraska, Vesna] Univ Split, Sch Med, Dept Med Biol, Split, Croatia; [Huikari, Ville] Univ Oulu, Inst Hlth Sci, Oulu, Finland; [Kiefte-de Jong, Jessica C.] Leiden Univ Coll, Global Publ Hlth, The Hague, Netherlands; [Koerner, Antje; Scheuermann, Kathrin] Univ Leipzig, Dept Womens & Child Hlth, Pediat Res Ctr, D-04109 Leipzig, Germany; [Lakka, Timo A.; Lindi, Virpi] Univ Eastern Finland, Dept Physiol, Inst Biomed, Kuopio, Finland; [Lakka, Timo A.] Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, SF-70210 Kuopio, Finland; [Lakka, Timo A.] Univ Eastern Finland, Kuopio, Finland; [Lakka, Timo A.] Kuopio Res Inst Exercise Med, Kuopio, Finland; [Liu, Gaifen] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurol, Beijing, Peoples R China; [Magnusson, Jessica; Melen, Erik] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Magnusson, Jessica; Melen, Erik] Sachs Children & Youth Hosp, Stockholm, Sweden; [Okuda, Masayuki] Yamaguchi Univ, Grad Sch Sci & Engn, Ube, Yamaguchi 755, Japan; [Raitakari, Olli; Pitkaenen, Niina] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland; [Raitakari, Olli] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-20520 Turku, Finland; [Richmond, Rebecca; Timpson, Nicholas J.] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Bailey, Mark E. S.; Pitsiladis, Yannis] Univ Glasgow, Coll Med Vet & Life Sci, Sch Life Sci, Glasgow, Lanark, Scotland; [Holloway, John W.] Univ Southampton, Fac Med, Human Genet & Med Genom, Southampton SO9 5NH, Hants, England; [Laitinen, Jaana] Finnish Inst Occupat Hlth, Oulu, Finland; [Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Snieder, Harold] Georgia Regents Univ, Dept Pediat, Georgia Prevent Ctr, Augusta, GA USA; [Yuji, Hinoda] Hokkaido Nursing Coll, Chuo Ku, Sapporo, Hokkaido, Japan; [Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Dept Prevent Med, Mindich Child Hlth & Dev Inst, Genet Obes & Related Metab Traits Program,Charles, New York, NY 10029 USA; [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Hu, Frank B.; Qi, Lu] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Med, Boston, MA USA	Qi, QB (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.	qibin.qi@einstein.yu.edu; nhlqi@channing.harvard.edu	Korner, Antje/B-3988-2015; Holloway, John/B-5424-2009; 	Korner, Antje/0000-0001-6001-0356; Holloway, John/0000-0001-9998-0464; Kiefte-de Jong, Jessica/0000-0002-8136-0918; Inskip, Hazel/0000-0001-8897-1749; Zeggini, Eleftheria/0000-0003-4238-659X; Barton, Sheila/0000-0003-4963-4242; Bailey, Mark E. S./0000-0002-9788-2278	Medical Research Council [MC_UU_12013/1-9]; National Institutes of Health (NIH) [HL64972]; Swedish Research Council; Swedish Heart-Lung Foundation; Stockholm County Council (ALF); SFO Epidemiology Program at Karolinska Institutet; Coca-Cola Hellas; German Bundesministerium fuer Forschung und Technology [01 AK 803 A-H, 01 IG 07015 G]; Erasmus University Medical Center, Rotterdam; Netherlands Organisation for Health Research and Development (ZonMw); ZonMw [ZonMw VIDI: 016.136.361]; Dutch Kidney Foundation [C08.2251]; "Kompetenznetz Adipositas" ("Competence Network Obesity") - German Federal Ministry of Education and Research [FKZ: 01GI0826]; Munich Center of Health Sciences (MCHEALTH); NIH [HL64157]; German Research Council (DFG) [CRC 1052]; Integrated Research and Treatment Centre (IFB) Adiposity Diseases; European Commission [279153]; LIFE-Leipzig Research Center for Civilization Diseases, Universitat Leipzig; European Union; European Regional Development Fund (EFRE); Free State of Saxony within the framework of the excellence initiative; Ministry of Social Affairs and Health of Finland; Ministry of Education and Culture of Finland; University of Eastern Finland; Finnish Innovation Fund Sitra; Social Insurance Institution of Finland; Finnish Cultural Foundation; Juho Vainio Foundation; Foundation for Paediatric Research; Paavo Nurmi Foundation; Paulo Foundation; Diabetes Research Foundation; City of Kuopio; Kuopio University Hospital [5031343]; Research Committee of the Kuopio University Hospital Catchment Area; British Heart Foundation; Food Standards Agency; Arthritis Research UK; Academy of Finland [206374, 251360]; Finnish Foundation for Cardiovascular Research; Sigrid Juselius Foundation; Yrjo Jahnsson Foundation; C.G. Sundell Foundation; Special Governmental Grants for Health Sciences Research; Turku University Hospital; Foundation for Pediatric Research; Turku University Foundation; European Union (European Social Fund [ESF]); National Strategic Reference Framework (NSRF)-Research Funding Program: Heracleitus II. Investing in Knowledge Society Through the European Social Fund; Wellcome Trust [098051]; Danish Council for Independent Research [DFF-1333-00124]; Unity Through Knowledge Fund CONNECTIVITY PROGRAM [2A]; National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia	There was no specific funding for this project. Funding sources for the individual authors and for the studies included in the analysis are listed as follows. The ALSPAC study was supported by Medical Research Council grant MC_UU_12013/1-9. The APEX project was supported by National Institutes of Health (NIH) grant HL64972. The authors thank Haidong Zhu, Bernard Gutin, Inger S. Stallmann-Jorgensen, and Yanbin Dong (Georgia Prevention Center, Georgia Regents University, Augusta, GA) for their contributions to conducting the study and data collection. The BAMSE study was funded by The Swedish Research Council, The Swedish Heart-Lung Foundation, Stockholm County Council (ALF), and the SFO Epidemiology Program at Karolinska Institutet. The GENDAI study was partially supported by a research grant from Coca-Cola Hellas. The GENR study is being conducted by the Erasmus Medical Center and Erasmus University Rotterdam in close collaboration with the Municipal Health Service Rotterdam area, Rotterdam, and the Stichting Trombosedienst en Artsenlaboratorium Rijnmond, Rotterdam. The authors thank the children and their parents, general practitioners, hospitals, midwives, and pharmacies in Rotterdam for their contribution. The generation and management of GWAS genotype data for the Generation R Study were performed at the Genetic Laboratory of the Department of Internal Medicine, Erasmus Medical Center, the Netherlands. The authors thank Karol Estrada, Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and Rob de Graaf for their help in creating GRIMP, BigGRID, MediGRID, and Services@MediGRID/D-Grid (funded by the German Bundesministerium fuer Forschung und Technology, grants 01 AK 803 A-H, 01 IG 07015 G) for access to their grid computing resources. The authors also thank Mila Jhamai, Manoushka Ganesh, Pascal Arp, Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters for their help in the creation, management, and quality control of the GWAS database. Also, the authors thank Karol Estrada and Carolina Medina-Gomez for their support in the creation and analysis of imputed data. In addition, the authors thank Henriette Moll for her support in calculating the dietary intakes. The Generation R Study receives financial support from the Erasmus University Medical Center, Rotterdam, and The Netherlands Organisation for Health Research and Development (ZonMw). V.W.V.J. received an additional grant from ZonMw (ZonMw VIDI: 016.136.361). Additional support was provided by a grant from the Dutch Kidney Foundation (C08.2251). The GINI study team thanks the following: Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Institute of Epidemiology I, Munich (J. Heinrich, H.E. Wichmann, S. Sausenthaler, C.-M. Chen, E. Thiering, C.M.T. Tiesler, M. Schnappinger, and P. Rzehak); Department of Pediatrics, Marien-Hospital, Wesel (D. Berdel, A. von Berg, C. Beckmann, and I. Gross); Department of Pediatrics, Ludwig Maximilians University, Munich (S. Koletzko, D. Reinhardt, and S. Krauss-Etschmann); Department of Pediatrics, Technical University, Munich (C. P. Bauer, I. Brockow, A. Grubl, and U. Hoffmann); IUF-Leibniz Research Institute for Environmental Medicine, Dusseldorf (U. Kramer, E. Link, and C. Cramer); and the Centre of Allergy & Environment, Technical University, Munich (H. Behrendt). The LISA study team wishes to acknowledge the following: Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Institute of Epidemiology I, Neuherberg (J. Heinrich, H.E. Wichmann, S. Sausenthaler, C.-M. Chen, and C.M.T.; Tiesler); University of Leipzig, Department of Pediatrics (M. Borte); Department of Environmental Medicine and Hygiene (O. Herbarth); Department of Pediatrics, Marien Hospital, Wesel (A. von Berg); Bad Honnef (B. Schaaf); UFZ-Centre for Environmental Research Leipzig-Halle, Department of Environmental Immunology (I. Lehmann); IUF-Leibniz Research Institute for Environmental Medicine, Dusseldorf (U. Kramer); and Department of Pediatrics, Technical University, Munich (C.P. Bauer and U. Hoffman). This work was supported financially in part by the "Kompetenznetz Adipositas" ("Competence Network Obesity"), which is funded by the German Federal Ministry of Education and Research (FKZ: 01GI0826) and by the Munich Center of Health Sciences (MCHEALTH). The LACHY project was supported by NIH grant HL64157. The LEIPZIG study was supported by German Research Council (DFG) CRC 1052 "Obesity Mechanisms" C05, the Integrated Research and Treatment Centre (IFB) Adiposity Diseases, the European Commission Seventh Framework Programme (FP7/2007-2013) project Beta-JUDO under grant agreement no. 279153, and the LIFE-Leipzig Research Center for Civilization Diseases, Universitat Leipzig, subproject B1 LIFE Child, funded by the European Union, by the European Regional Development Fund (EFRE), and by the Free State of Saxony within the framework of the excellence initiative. The PANIC study was financially supported by grants from the Ministry of Social Affairs and Health of Finland, the Ministry of Education and Culture of Finland, the University of Eastern Finland, the Finnish Innovation Fund Sitra, the Social Insurance Institution of Finland, the Finnish Cultural Foundation, the Juho Vainio Foundation, the Foundation for Paediatric Research, the Paavo Nurmi Foundation, the Paulo Foundation, the Diabetes Research Foundation, the City of Kuopio, the Kuopio University Hospital (EVO-funding no. 5031343), and the Research Committee of the Kuopio University Hospital Catchment Area (the State Research Funding). The authors thank Professor Satoshi Sasaki at the University of Tokyo for dietary assessment and Naoko Okayama of Yamaguchi University for genotyping in the SHUNAN study. The SWS study was supported by the Medical Research Council, the British Heart Foundation, the Food Standards Agency, and Arthritis Research UK. The authors thank the members of the Southampton Women's Survey team, including Cyrus Cooper, Keith Godfrey, and Sian Robinson, and the team of dedicated research nurses and ancillary staff. The authors thank the participants in the Southampton Women's Survey, who gave us so much of their time. The STRIP study was financially supported by the Academy of Finland (grants 206374 and 251360), the Juho Vainio Foundation, the Finnish Foundation for Cardiovascular Research, the Finnish Cultural Foundation, the Ministry of Education and Culture of Finland, the Sigrid Juselius Foundation, the Yrjo Jahnsson Foundation, the C.G. Sundell Foundation, Special Governmental Grants for Health Sciences Research, Turku University Hospital, the Foundation for Pediatric Research, and the Turku University Foundation. The TEENAGE study has been cofinanced by the European Union (European Social Fund [ESF]) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program: Heracleitus II. Investing in Knowledge Society Through the European Social Fund. This work was funded by the Wellcome Trust (grant 098051).; The authors thank all study participants and their families, as well as all volunteers for their contribution to this study. T.O.K. was supported by grant no. DFF-1333-00124 from the Danish Council for Independent Research. V. B. is supported by the Unity Through Knowledge Fund CONNECTIVITY PROGRAM ("Gaining Experience" grant 2A) and the National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia (BRAIN GAIN-Postdoctoral fellowship).	Zhang XM, 2012, DIABETES, V61, P3005, DOI 10.2337/db11-1799; Smemo S, 2014, NATURE, V507, P371, DOI 10.1038/nature13138; Qi L, 2008, DIABETES, V57, P3145, DOI 10.2337/db08-0006; Jaddoe VWV, 2012, EUR J EPIDEMIOL, V27, P739, DOI 10.1007/s10654-012-9735-1; Cheung MK, 2013, INT J OBESITY, V37, P744, DOI 10.1038/ijo.2012.77; Corella D, 2011, J NUTR, V141, P2219, DOI [10.3945/jn.111.143826, 10.3945/jn111.143826]; Manios Y, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-32; Hubacek JA, 2011, PHYSIOL RES, V60, P175; Melen E, 2013, CLIN EXP ALLERGY, V43, P463, DOI 10.1111/cea.12054; McCaffery JM, 2012, AM J CLIN NUTR, V95, P1477, DOI 10.3945/ajcn.111.026955; Hakanen M, 2009, J CLIN ENDOCR METAB, V94, P1281, DOI 10.1210/jc.2008-1199; Wang P, 2011, MOL MED, V17, P523, DOI [10.2119/molmed.2010.00134, 10.2119/molmed.2010.000134]; Timpson NJ, 2008, AM J CLIN NUTR, V88, P971; Monda KL, 2013, NAT GENET, V45, P690, DOI 10.1038/ng.2608; Hebert JR, 1997, AM J EPIDEMIOL, V146, P1046; Cecil JE, 2008, NEW ENGL J MED, V359, P2558, DOI 10.1056/NEJMoa0803839; Johansson L, 1998, AM J CLIN NUTR, V68, P266; Loos RJF, 2014, NAT REV ENDOCRINOL, V10, P51, DOI 10.1038/nrendo.2013.227; Stratigopoulos G, 2008, AM J PHYSIOL-REG I, V294, pR1185, DOI 10.1152/ajpregu.00839.2007; Scott RA, 2010, EUR J HUM GENET, V18, P1339, DOI 10.1038/ejhg.2010.131; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Hasselbalch AL, 2010, J NUTR, V140, P831, DOI 10.3945/jn.109.114439; Stratigopoulos G, 2014, CELL METAB, V19, P767, DOI 10.1016/j.cmet.2014.04.009; Fredriksson R, 2008, ENDOCRINOLOGY, V149, P2062, DOI 10.1210/en.2007-1457; Inskip HM, 2006, INT J EPIDEMIOL, V35, P42, DOI 10.1093/ije/dyi202; Ventura AK, 2006, OBESITY, V14, P1073, DOI 10.1038/oby.2006.123; Gulati P, 2013, P NATL ACAD SCI USA, V110, P2557, DOI 10.1073/pnas.1222796110; Park SL, 2013, AM J EPIDEMIOL, V178, P780, DOI 10.1093/aje/kwt028; Tanofsky-Kraff M, 2009, AM J CLIN NUTR, V90, P1483, DOI 10.3945/ajcn.2009.28439; Sonestedt E, 2009, AM J CLIN NUTR, V90, P1418, DOI 10.3945/ajcn.2009.27958; Moleres A, 2012, BRIT J NUTR, V107, P533, DOI 10.1017/S0007114511003424; Cauchi S, 2009, J MOL MED, V87, P537, DOI 10.1007/s00109-009-0451-6; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Karra E, 2013, J CLIN INVEST, V123, P3539, DOI 10.1172/JCI44403; Church C, 2010, NAT GENET, V42, P1086, DOI 10.1038/ng.713; Haworth CMA, 2008, OBESITY, V16, P2663, DOI 10.1038/oby.2008.434; Simell O, 2009, INT J EPIDEMIOL, V38, P650, DOI 10.1093/ije/dyn072; Gerken T, 2007, SCIENCE, V318, P1469, DOI 10.1126/science.1151710; Huang T, 2014, AM J CLIN NUTR, V99, P1126, DOI 10.3945/ajcn.113.082164; Do R, 2008, DIABETES, V57, P1147, DOI 10.2337/db07-1267; Wardle J, 2009, INT J OBESITY, V33, P42, DOI 10.1038/ijo.2008.174; Jonassaint CR, 2011, AM J MED GENET B, V156B, P454, DOI 10.1002/ajmg.b.31182; Jess T, 2008, INT J OBESITY, V32, P1388, DOI 10.1038/ijo.2008.110; Fischer J, 2009, NATURE, V458, P894, DOI 10.1038/nature07848; Rzehak P, 2010, OBESITY FACTS, V3, P173, DOI 10.1159/000314612; Ntalla I, 2014, PUBLIC HEALTH NUTR, V17, P561, DOI 10.1017/S1368980013000074; Haupt A, 2009, EXP CLIN ENDOCR DIAB, V117, P194, DOI 10.1055/s-0028-1087176; Bauer F, 2009, AM J CLIN NUTR, V90, P951, DOI 10.3945/ajcn.2009.27781; Dina C, 2007, NAT GENET, V39, P724, DOI 10.1038/ng2048; Hardy R, 2010, HUM MOL GENET, V19, P545, DOI 10.1093/hmg/ddp504; Berg A v, 2010, Clin Exp Allergy, V40, P627, DOI 10.1111/j.1365-2222.2009.03444.x; Boender AJ, 2012, OBESITY, V20, P2420, DOI 10.1038/oby.2012.128; Brunkwall L, 2013, FOOD NUTR RES, V57, DOI 10.3402/fnr.v57i0.20028; Cedernaes Jonathan, 2014, Mol Metab, V3, P505, DOI 10.1016/j.molmet.2014.05.003; Church C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000599; Corella D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052344; da Silva CF, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-34; Eloranta AM, 2011, EUR J CLIN NUTR, V65, P1211, DOI 10.1038/ejcn.2011.113; Karasawa S, 2010, ENDOCR J, V57, P293, DOI 10.1507/endocrj.K09E-305; Kilpelainen TO, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001116; Korner A, 2007, J CLIN ENDOCR METAB, V92, P1956, DOI 10.1210/jc.2006-2514; Lappalainen T, 2012, BRIT J NUTR, V108, P1859, DOI 10.1017/S0007114511007410; Lear SA, 2011, GENET RES, V93, P419, DOI 10.1017/S001667231100036X; Lee HJ, 2010, CLIN CHIM ACTA, V411, P1716, DOI 10.1016/j.cca.2010.07.010; Liu GF, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-57; McMurray F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003166; Okuda M, 2011, PEDIATR DIABETES, V12, P494, DOI 10.1111/j.1399-5448.2010.00727.x; Olszewski PK, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-129; Papoutsakis C, 2007, CLIN CHEM LAB MED, V45, P309, DOI 10.1515/CCLM.2007.080; Phillips CM, 2012, J NUTR, V142, P824, DOI 10.3945/jn.111.153460; Qi QB, 2014, HUM MOL GENET, V23, P6961, DOI 10.1093/hmg/ddu411; Scuteri A, 2007, PLOS GENET, V14, pe115, DOI DOI 10.1371/J0URNAL.PGEN.0030115; Sovio U, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001307; Tung YCL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008771	74	1	1	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	JUL	2015	64	7					2467	2476		10.2337/db14-1629		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CL4PA	WOS:000356934000029		
J	Mori, S; Oyama, K; Kikuchi, Y; Mitsudo, T; Hirose, N				Mori, Shuji; Oyama, Kazuki; Kikuchi, Yousuke; Mitsudo, Takako; Hirose, Nobuyuki			Between-Frequency and Between-Ear Gap Detections and Their Relation to Perception of Stop Consonants	EAR AND HEARING			English	Article						Gap detection; Perceptual channel; Stop consonants; Voice-onset time	SILENT TEMPORAL GAPS; CATEGORICAL PERCEPTION; DETECTION THRESHOLDS; SINUSOIDAL MARKERS; WITHIN-CHANNEL; LISTENERS; HEARING; DURATION; LANGUAGE; STIMULI	Objectives: The objective of this study was to examine the hypothesis that between-channel gap detection, which includes between-frequency and between-ear gap detection, and perception of stop consonants, which is mediated by the length of voice-onset time (VOT), share common mechanisms, namely relative-timing operation in monitoring separate perceptual channels. Design: The authors measured gap detection thresholds and identification functions of /ba/ and /pa/ along VOT in 49 native young adult Japanese listeners. There were three gap detection tasks. In the between-frequency task, the leading and trailing markers differed in terms of center frequency (F-c). The leading marker was a broadband noise of 10 to 20,000 Hz. The trailing marker was a 0.5-octave band-passed noise of 1000-, 2000-, 4000-, or 8000-Hz F-c. In the between-ear task, the two markers were spectrally identical but presented to separate ears. In the within-frequency task, the two spectrally identical markers were presented to the same ear. The /ba/-/pa/ identification functions were obtained in a task in which the listeners were presented synthesized speech stimuli of varying VOTs from 10 to 46 msec and asked to identify them as /ba/ or /pa/. Results: The between-ear gap thresholds were significantly positively correlated with the between-frequency gap thresholds (except those obtained with the trailing marker of 4000-Hz F-c). The between-ear gap thresholds were not significantly correlated with the within-frequency gap thresholds, which were significantly correlated with all the between-frequency gap thresholds. The VOT boundaries and slopes of /ba/-/pa/ identification functions were not significantly correlated with any of these gap thresholds. Conclusions: There was a close relation between the between-ear and between-frequency gap detection, supporting the view that these two types of gap detection share common mechanisms of between-channel gap detection. However, there was no evidence for a relation between the perception of stop consonants and the between-frequency/ear gap detection in native Japanese speakers.	[Mori, Shuji; Kikuchi, Yousuke; Mitsudo, Takako; Hirose, Nobuyuki] Kyushu Univ, Fac Informat Sci & Elect Engn, Dept Informat, Fukuoka, Fukuoka 8190395, Japan; [Oyama, Kazuki] Pioneer Corp, Tokyo, Japan	Mori, S (reprint author), Kyushu Univ, Fac Informat Sci & Elect Engn, Dept Informat, Nishi Ku, 744 Motooka, Fukuoka, Fukuoka 8190395, Japan.	mori@inf.kyushu-u.ac.jp			Kawai Foundation for Sound Technology and Music; Japan Society for the Promotion of Science [25240023, 21330169]; Ono Acoustics Research Fund; Education/Research Program/Research Center Formation Project for Female Researchers; Japan Society for the Promotion of Science for Scientific Research [25350017]	The experiments reported in this article were conducted by the second author as part of a Master's thesis submitted to Kyushu University. Special thanks are due to Alex Brandmeyer and Makiko Sadakata for their advice on an early stage of this study. The research was supported by a Research Grant from the Kawai Foundation for Sound Technology and Music, Grants-in-Aid of the Japan Society for the Promotion of Science for Scientific Research (A) 25240023 and (B) 21330169 (to S.M.), Ono Acoustics Research Fund, Education/Research Program/Research Center Formation Project for Female Researchers (to T.M.), and Grant-in-Aid of the Japan Society for the Promotion of Science for Scientific Research (C) 25350017 (to N.H.). The remaining authors declare no other conflict of interest.	Florentine M, 1999, J ACOUST SOC AM, V106, P3512, DOI 10.1121/1.428204; Heinrich A, 2006, J ACOUST SOC AM, V119, P2316, DOI 10.1121/1.2173524; Phillips DP, 2004, PERCEPTION, V33, P371, DOI 10.1068/p5116; Phillips DP, 1997, J ACOUST SOC AM, V101, P3694, DOI 10.1121/1.419376; LISKER L, 1964, WORD, V20, P384; Elangovan S, 2008, EAR HEARING, V29, P761, DOI 10.1097/AUD.0b013e318185ddd2; HACKER MJ, 1979, PERCEPT PSYCHOPHYS, V26, P168, DOI 10.3758/BF03208311; Schneider BA, 1999, J ACOUST SOC AM, V106, P371, DOI 10.1121/1.427062; LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375; Brandmeyer A, 2012, NEUROREPORT, V23, P653, DOI 10.1097/WNR.0b013e32835542cd; Buus S, 1985, TIME RESOLUTION AUDI, P159; DORMAN MF, 1985, J ACOUST SOC AM, V77, P664, DOI 10.1121/1.391885; Formby C, 1996, AUDIT NEUROSCI, V3, P1; FORMBY C, 1991, J ACOUST SOC AM, V89, P830, DOI 10.1121/1.1894643; Grose JH, 2007, J ACOUST SOC AM, V122, P446, DOI 10.1121/1.2735106; Lister JJ, 2005, J SPEECH LANG HEAR R, V48, P482, DOI 10.1044/1092-4388(2005/033); Medina V, 2010, J PHONETICS, V38, P493, DOI 10.1016/j.wocn.2010.06.002; MOORE BCJ, 1989, J ACOUST SOC AM, V85, P1266, DOI 10.1121/1.397457; Ogasawara N, 2011, CONCENTRI STUD LINGU, V37, P155; Phillips D P, 1999, J Am Acad Audiol, V10, P343; Phillips DP, 2002, HEARING RES, V174, P133, DOI 10.1016/S0378-5955(02)00647-0; Phillips DP, 1998, J ACOUST SOC AM, V103, P2064, DOI 10.1121/1.421353; REPP BH, 1982, PSYCHOL BULL, V92, P81, DOI 10.1037//0033-2909.92.1.81; Riney TJ, 2007, J PHONETICS, V35, P439, DOI 10.1016/j.wocn.2006.01.002; Scharf B., 1986, HDB PERVEPTION HUMAN; Serniclaes W, 2005, COGNITION, V98, pB35, DOI 10.1016/j.cognition.2005.03.002; Shimizu K., 1977, STUDIO PHONOLOGICA, V11, P25; Shimizu K., 1999, ONSEI KENKYU, V3, P4; Taylor TL, 1999, J ACOUST SOC AM, V105, P563, DOI 10.1121/1.424593	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-0202	1538-4667		EAR HEARING	Ear Hear.	JUL-AUG	2015	36	4					464	470		10.1097/AUD.0000000000000136		7	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	CL8ZZ	WOS:000357264900008		
J	Aoshima, K; Inoue, E; Sawa, H; Okada, Y				Aoshima, Keisuke; Inoue, Erina; Sawa, Hirofumi; Okada, Yuki			Paternal H3K4 methylation is required for minor zygotic gene activation and early mouse embryonic development	EMBO REPORTS			English	Article						histone methylation; K-M mutant; minor ZGA; Mll3/4	HISTONE VARIANT H3.3; IN-VITRO; PREIMPLANTATION DEVELOPMENT; TRANSCRIPTIONAL ACTIVITY; MATERNAL CHROMATIN; GENOME ACTIVATION; DNA-REPLICATION; ALPHA-AMANITIN; COMPASS FAMILY; OOCYTES	Epigenetic modifications, such as DNA methylation and histone modifications, are dynamically altered predominantly in paternal pronuclei soon after fertilization. To identify which histone modifications are required for early embryonic development, we utilized histone K-M mutants, which prevent endogenous histone methylation at the mutated site. We prepared four single K-M mutants for histone H3.3, K4M, K9M, K27M, and K36M, and demonstrate that overexpression of H3.3 K4M in embryos before fertilization results in developmental arrest, whereas overexpression after fertilization does not affect the development. Furthermore, loss of H3K4 methylation decreases the level of minor zygotic gene activation (ZGA) predominantly in the paternal pronucleus, and we obtained similar results from knockdown of the H3K4 methyltransferase Mll3/4. We therefore conclude that H3K4 methylation, likely established by Mll3/4 at the early pronuclear stage, is essential for the onset of minor ZGA in the paternal pronucleus, which is necessary for subsequent preimplantation development in mice.	[Aoshima, Keisuke; Inoue, Erina; Okada, Yuki] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Pathol & Dev, Bunkyo Ku, Tokyo 113, Japan; [Aoshima, Keisuke; Sawa, Hirofumi] Hokkaido Univ, Div Mol Pathobiol, Ctr Zoonosis Control, Kita Ku, Sapporo, Hokkaido, Japan; [Aoshima, Keisuke] Japan Soc Promot Sci, Chiyoda Ku, Tokyo, Japan; [Okada, Yuki] Japan Sci & Technol Agcy JST, PRESTO, Kawaguchi, Saitama, Japan	Okada, Y (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Pathol & Dev, Bunkyo Ku, Tokyo 113, Japan.	ytokada@iam.u-tokyo.ac.jp	Sawa, Hirofumi/F-6954-2012		JST PRESTO program; Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan [22125007]; Special Coordination Fund for Promoting Science and Technology of MEXT; Naito Foundation; Japan Society for the Promotion of Science	We sincerely appreciate Dr. Hiroshi Kimura (Tokyo Institute of Technology) for kindly providing antibodies, and Dr. Takehiko Itoh (Tokyo Institute of Technology) for his help to analyze the data. We also thank Dr. Sawang Kesdangsakonwut (Hokkaido University) for helping to perform some experiments, and members of the Laboratory of Pathology and Development, Institute of Molecular and Cellular Biosciences for helpful discussion. This research was supported by the JST PRESTO program (Y.O.), a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan (22125007 to Y.O.), the Special Coordination Fund for Promoting Science and Technology of MEXT (Y.O.), The Naito Foundation Subsidy for Female Researchers after Maternity Leave (Y.O.), and Research Fellowships of Japan Society for the Promotion of Science for Young Scientists (K.A.).	Andreu-Vieyra CV, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000453; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Hamatani T, 2004, DEV CELL, V6, P117, DOI 10.1016/S1534-5807(03)00373-3; Miki H, 2006, J REPROD DEVELOP, V52, P239, DOI 10.1262/jrd.17078; Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112; Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; Inoue A, 2014, NAT STRUCT MOL BIOL, V21, P609, DOI 10.1038/nsmb.2839; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Bultman SJ, 2006, GENE DEV, V20, P1744, DOI 10.1101/gad.1435106; Santenard A, 2010, NAT CELL BIOL, V12, P853, DOI 10.1038/ncb2089; Park SJ, 2013, GENE DEV, V27, P2736, DOI 10.1101/gad.227926.113; Paull D, 2013, NATURE, V493, P632, DOI 10.1038/nature11800; Lin CJ, 2014, DEV CELL, V30, P268, DOI 10.1016/j.devcel.2014.06.022; Smith E, 2011, GENE DEV, V25, P661, DOI 10.1101/gad.2015411; Lin CJ, 2013, DEVELOPMENT, V140, P3624, DOI 10.1242/dev.095513; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Shinagawa T, 2014, CELL STEM CELL, V14, P217, DOI 10.1016/j.stem.2013.12.015; Adenot PG, 1997, DEVELOPMENT, V124, P4615; Torres-Padilla ME, 2006, INT J DEV BIOL, V50, P455, DOI 10.1387/ijdb.052073mt; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Yamagata K, 2005, GENESIS, V43, P71, DOI 10.1002/gene.20158; Arney KL, 2002, INT J DEV BIOL, V46, P317; van der Heijden GW, 2005, MECH DEVELOP, V122, P1008, DOI 10.1016/j.mod.2005.04.009; Mohan M, 2011, MOL CELL BIOL, V31, P4310, DOI 10.1128/MCB.06092-11; Eissenberg JC, 2010, DEV BIOL, V339, P240, DOI 10.1016/j.ydbio.2009.08.017; Liu HL, 2004, DEVELOPMENT, V131, P2269, DOI 10.1242/dev.01116; Okada Y, 2010, NATURE, V463, P554, DOI 10.1038/nature08732; Boskovic A, 2012, EPIGENETICS-US, V7, P747, DOI 10.4161/epi.20584; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; Deb M, 2014, CELL MOL LIFE SCI, V71, P3439, DOI 10.1007/s00018-014-1605-4; GOLBUS MS, 1973, J EXP ZOOL, V186, P207, DOI 10.1002/jez.1401860211; LATHAM KE, 1991, DEVELOPMENT, V112, P921; Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503; Lepikhov Konstantin, 2004, BMC Dev Biol, V4, P12, DOI 10.1186/1471-213X-4-12; Liu WQ, 2014, CELL REP, V6, P1008, DOI 10.1016/j.celrep.2014.02.018; Makino Yoshinori, 2014, Front Cell Dev Biol, V2, P30, DOI 10.3389/fcell.2014.00030; Mamo S, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-14; Park SJ, 2015, NUCLEIC ACIDS RES, V43, pD771, DOI 10.1093/nar/gku1001; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WARNER CM, 1974, NATURE, V248, P678, DOI 10.1038/248678a0	44	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-221X	1469-3178		EMBO REP	EMBO Rep.	JUL	2015	16	7					803	812		10.15252/embr.201439700		10	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CL9VI	WOS:000357325800007		
J	Sasaki, M; Orba, Y; Anindita, PD; Ishii, A; Ueno, K; Hang'ombe, BM; Mweeile, AS; Ito, K; Sawa, H				Sasaki, Michihito; Orba, Yasuko; Anindita, Paulina D.; Ishii, Akihiro; Ueno, Keisuke; Hang'ombe, Bernard M.; Mweeile, Aaron S.; Ito, Kimihito; Sawa, Hirofumi			Distinct Lineages of Bufavirus in Wild Shrews and Nonhuman Primates	EMERGING INFECTIOUS DISEASES			English	Article							ENTERIC VIROME; INFECTION; DIARRHEA; VIRUSES; CHILDREN; DOMAIN	Viral metagenomic analysis identified a new parvovirus genome in the intestinal contents of wild shrews in Zambia. Related viruses were detected in spleen tissues from wild shrews and nonhuman primates. Phylogenetic analyses showed that these viruses are related to human bufaviruses, highlighting the presence and genetic diversity of bufaviruses in wildlife.	[Sasaki, Michihito; Orba, Yasuko; Anindita, Paulina D.; Ishii, Akihiro; Ueno, Keisuke; Ito, Kimihito; Sawa, Hirofumi] Hokkaido Univ, Sapporo, Hokkaido 0010020, Japan; [Hang'ombe, Bernard M.; Mweeile, Aaron S.] Univ Zambia, Lusaka, Zambia	Sawa, H (reprint author), Hokkaido Univ, Div Mol Pathobiol, Res Ctr Zoonosis Control, Kita Ku, West 10 North 20, Sapporo, Hokkaido 0010020, Japan.	h-sawa@czc.holcudai.ac.jp	Sawa, Hirofumi/F-6954-2012		Global Institution for Collaborative Research and Education (GI-CoRE); Japan Initiative for Global Research Network of Infectious Diseases (J-GRID) from the Japan Ministry of Education, Culture, Sports, Science, and Technology; Japan Society for the Promotion of Science [24405043]	This work was supported by the Global Institution for Collaborative Research and Education (GI-CoRE) and the Japan Initiative for Global Research Network of Infectious Diseases (J-GRID) from the Japan Ministry of Education, Culture, Sports, Science, and Technology and Grants-in-Aid for Scientific Research (KAKENHI, grant no. 24405043) from the Japan Society for the Promotion of Science.	Smits SL, 2014, EMERG INFECT DIS, V20, P1218, DOI 10.3201/eid2007.140190; Orba Y, 2015, J GEN VIROL, V96, P390, DOI 10.1099/vir.0.070219-0; Walker SL, 1997, J VIROL, V71, P6996; Farr GA, 2005, P NATL ACAD SCI USA, V102, P17148, DOI 10.1073/pnas.0508477102; Vaisanen E, 2014, EMERG INFECT DIS, V20, P1077, DOI 10.3201/eid2006.131674; Phan TG, 2012, J VIROL, V86, P11024, DOI 10.1128/JVI.01427-12; Handley SA, 2012, CELL, V151, P253, DOI 10.1016/j.cell.2012.09.024; Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1; Castellanos M, 2013, BIOCHEM J, V455, P87, DOI 10.1042/BJ20130503; Deng XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061440; Kivovich V, 2012, INT J BIOL SCI, V8, P79, DOI 10.7150/ijbs.8.79; Sasaki M, 2015, J GEN VIROL, V96, P440, DOI 10.1099/vir.0.071209-0; Sasaki M, 2013, EMERG INFECT DIS, P19; Yahiro T, 2014, EMERG INFECT DIS, V20, P1037, DOI 10.3201/eid2006.131430	14	1	1	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	JUL	2015	21	7					1230	1233		10.3201/eid2107.141969		4	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CL5KF	WOS:000356998100024		
J	Okada, K; Natakuathung, W; Na-Ubol, M; Roobthaisong, A; Wongboot, W; Maruyama, F; Nakagawa, I; Chantaroj, S; Hamada, S				Okada, Kazuhisa; Natakuathung, Wirongrong; Na-Ubol, Mathukorn; Roobthaisong, Amonrattana; Wongboot, Warawan; Maruyama, Fumito; Nakagawa, Ichiro; Chantaroj, Siriporn; Hamada, Shigeyuki			Characterization of 3 Megabase-Sized Circular Replicons from Vibrio cholerae	EMERGING INFECTIOUS DISEASES			English	Letter							COMPARATIVE GENOMICS; 2 CHROMOSOMES; TRANSMISSION		[Okada, Kazuhisa; Natakuathung, Wirongrong; Na-Ubol, Mathukorn; Roobthaisong, Amonrattana; Wongboot, Warawan; Hamada, Shigeyuki] Thailand Japan Res Collaborat Ctr Emerging & Reem, Nonthaburi, Thailand; [Okada, Kazuhisa; Hamada, Shigeyuki] Osaka Univ, Osaka, Japan; [Maruyama, Fumito; Nakagawa, Ichiro] Tokyo Med & Dent Univ, Tokyo, Japan; [Chantaroj, Siriporn] Natl Inst Hlth, Nonthaburi, Thailand	Okada, K (reprint author), Minist Publ Hlth, Thailand Japan RCC ERI, DMSc, Tiwanon Rd, Muang 11000, Nonthaburi, Thailand.	kazuhisa@biken.osaka-u.ac.jp					Chun J, 2009, P NATL ACAD SCI USA, V106, P15442, DOI 10.1073/pnas.0907787106; Heidelberg JF, 2000, NATURE, V406, P477; Doyle M, 2007, SCIENCE, V315, P251, DOI 10.1126/science.1137550; Yamaichi Y, 1999, MOL MICROBIOL, V31, P1513, DOI 10.1046/j.1365-2958.1999.01296.x; Reimer AR, 2011, EMERG INFECT DIS, V17, P2113, DOI 10.3201/eid1711.110794; Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392; Kolsto AB, 1999, TRENDS MICROBIOL, V7, P223, DOI 10.1016/S0966-842X(99)01519-X; Okada K, 2005, J BACTERIOL, V187, P752, DOI 10.1128/JB.187.2.752-757.2005; OKADA K, 2012, PLOS ONE, V0007; Yamaichi Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002189	10	0	0	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	JUL	2015	21	7					1262	1263		10.3201/eid2107.141055		2	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CL5KF	WOS:000356998100034		
J	Lv, X; Dong, WJ; Fang, F				Lv, Xin; Dong, Weijia; Fang, Fang			The Asymmetric Effects of Official Interest Rate Changes on China's Stock Market During Different Market Regimes	EMERGING MARKETS FINANCE AND TRADE			English	Article						China's stock market; cumulative abnormal returns (CARs); Markov regime-switching model; official interest rate	MONETARY-POLICY; INVESTOR SENTIMENT; RETURNS; PRICES; NEWS	We investigate the effects of China's official interest rate changes on its stock market. We first prove there is a negative relationship between official rate changes and stock returns, as measured by cumulative abnormal returns (CARs). Then, we divide the Chinese stock market into three regimes (bull, medium, and bear) and indicate that official rate changes have asymmetric effects on CARs during different market regimes, although these effects differ from the effects of interest rate changes on the U.S. market. Specifically, official rate changes have the largest negative effects during bear markets and the smallest effects during medium markets.	[Lv, Xin] Beijing Inst Technol, Ctr Energy & Environm Policy Res, Sch Management Econ, Beijing 100081, Peoples R China; [Dong, Weijia] Nagoya Univ, Grad Sch Econ, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Fang, Fang] Beijing Normal Univ, Sch Econ & Business Adm, Beijing 100875, Peoples R China	Dong, WJ (reprint author), Nagoya Univ, Grad Sch Econ, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	dongweijia0316@163.com					Boyd JH, 2005, J FINANC, V60, P649, DOI 10.1111/j.1540-6261.2005.00742.x; Henry OT, 2009, J BANK FINANC, V33, P405, DOI 10.1016/j.jbankfin.2008.08.001; Cong RG, 2008, ENERG POLICY, V36, P3544, DOI 10.1016/j.enpol.2008.06.006; Chen XJ, 2010, PAC-BASIN FINANC J, V18, P403, DOI 10.1016/j.pacfin.2010.04.003; Gul FA, 2010, J FINANC ECON, V95, P425, DOI 10.1016/j.jfineco.2009.11.005; HAMILTON JD, 1994, J ECONOMETRICS, V64, P307, DOI 10.1016/0304-4076(94)90067-1; Kurov A, 2010, J BANK FINANC, V34, P139, DOI 10.1016/j.jbankfin.2009.07.010; Basistha A, 2008, J BANK FINANC, V32, P2606, DOI 10.1016/j.jbankfin.2008.05.012; Chen SS, 2007, J MONEY CREDIT BANK, V39, P667, DOI 10.1111/j.0022-2879.2007.00040.x; Brown GW, 2005, J BUS, V78, P405, DOI 10.1086/427633; FAMA EF, 1965, J BUS, V38, P34, DOI 10.1086/294743; Ehrmann M, 2004, J MONEY CREDIT BANK, V36, P719, DOI 10.1353/mcb.2004.0063; Morck R, 2000, J FINANC ECON, V58, P215, DOI 10.1016/S0304-405X(00)00071-4; [Anonymous], 2007, J EC PERSPECTIVES, V21, P129; Baker M, 2006, J FINANC, V61, P1645, DOI 10.1111/j.1540-6261.2006.00885.x; Bernanke BS, 2005, J FINANC, V60, P1221, DOI 10.1111/j.1540-6261.2005.00760.x; Chong TTL, 2012, CHINA ECON REV, V23, P122, DOI 10.1016/j.chieco.2011.08.003; Honda Y, 2006, ECON J, V116, P812, DOI 10.1111/j.1468-0297.2006.01113.x; Kaen F. R., 1997, J MULTINATIONAL FINA, V7, P1, DOI 10.1016/S1042-444X(97)00002-9; Lee Cheng F., 2000, REV QUANTITATIVE FIN, V14, P341, DOI 10.1023/A:1008319826042; Lee Cheng. F., 2001, J FINANC RES, V24, P523; Lin T. C., 2008, PACIFIC BASIN FINANC, V19, P571; Lv X., 2012, J CHINESE EC STUDIES, V9, P1; MacKinlay C, 1997, J ECON LIT, V35, P13; Narayan S., 2012, J ASIAN EC, V23, P669; PEARCE DK, 1985, J BUS, V58, P49, DOI 10.1086/296282; Rigobon R, 2003, Q J ECON, V118, P639, DOI 10.1162/003355303321675473; Song H., 1998, INT REV APPL EC, V12, P129, DOI 10.1080/026921719800000029; Thorbecke W, 1997, J FINANC, V52, P635, DOI 10.1111/j.1540-6261.1997.tb04816.x	29	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1540-496X	1558-0938		EMERG MARK FINANC TR	Emerg. Mark. Financ. Trade	JUL-AUG	2015	51	4					826	841		10.1080/1540496X.2015.1047305		16	Business; Economics; International Relations	Business & Economics; International Relations	CL9KG	WOS:000357296500012		
J	Ruiz, WLG; Tomiyasu, T				Ruiz, Wilder Leonardo Gamboa; Tomiyasu, Takashi			Distribution of mercury in sediments from Kagoshima Bay, Japan, and its relationship with physical and chemical factors	ENVIRONMENTAL EARTH SCIENCES			English	Article						Total mercury; Total organic carbon; Marine sediment; Hydrothermal; Kagoshima Bay	TAPAJOS RIVER-BASIN; ATMOSPHERIC MERCURY; SAKURAJIMA-VOLCANO; SURFACE SEDIMENTS; HUMAN HAIR; METHYLMERCURY; CITY; METHYLATION; SPECIATION; BRAZIL	Kagoshima Bay is located on the south coast of Kyushu Island, Japan. Submarine fumaroles present in the northern area have been identified as a natural source of mercury in the bay. The aim of the present work is to study the spatial distribution of mercury in the bottom sediments of the bay and its relationship with major physicochemical properties that might affect the transport of mercury in the ecosystem surrounding this area. Sediment core samples were collected in the north and central areas in surveys performed during 2011 and 2013. The individual core samples were sliced and processed for the analysis of total mercury (T-Hg), chemical composition, total organic carbon (TOC), particle size and magnetic susceptibility. The horizontal distribution of T-Hg indicates that fumaroles are the primary source of Hg in the area; the results indicate a key role of organic matter binding to Hg. In the area to the west of the fumaroles, the relationship between Hg and TOC is characterized by two linear trends that correspond to the upper and lower sections of the cores. From the physicochemical properties, it was suggested that the two distinct linear relations might be caused by a change of the volcanic activity at the Aira Caldera, which is located at the northern part of the bay. The extent of the bay impacted by the Hg generated from the hydrothermal vents has decreased in recent years and is limited to the vicinity of the emission point.	[Ruiz, Wilder Leonardo Gamboa; Tomiyasu, Takashi] Kagoshima Univ, Fac Sci, Grad Sch Sci & Engn, Kagoshima 8900065, Japan	Tomiyasu, T (reprint author), Kagoshima Univ, Fac Sci, Grad Sch Sci & Engn, 1-21-35 Korimoto, Kagoshima 8900065, Japan.	tomy@sci.kagoshima-u.ac.jp					HARADA M, 1995, CRIT REV TOXICOL, V25, P1, DOI 10.3109/10408449509089885; Hahladakis J, 2013, ENVIRON MONIT ASSESS, V185, P2843, DOI 10.1007/s10661-012-2754-2; Liu MX, 2014, ECOTOXICOLOGY, V23, P92, DOI 10.1007/s10646-013-1154-x; SAKAMOTO H, 1995, GEOCHEM J, V29, P97; Celo V, 2006, SCI TOTAL ENVIRON, V368, P126, DOI 10.1016/j.scitotenv.2005.09.043; Malm O, 1995, SCI TOTAL ENVIRON, V175, P141, DOI 10.1016/0048-9697(95)04910-X; SAKAMOTO H, 1985, B CHEM SOC JPN, V58, P580, DOI 10.1246/bcsj.58.580; Pyle DM, 2003, ATMOS ENVIRON, V37, P5115, DOI 10.1016/j.atmosenv.2003.07.011; AKAGI H, 1995, WATER AIR SOIL POLL, V80, P85, DOI 10.1007/BF01189656; Athar R, 2002, WATER AIR SOIL POLL, V138, P165, DOI 10.1023/A:1015594815016; Tomiyasu T, 2000, SCI TOTAL ENVIRON, V259, P231, DOI 10.1016/S0048-9697(00)00585-4; Gallego SM, 1996, PLANT SCI, V121, P151, DOI 10.1016/S0168-9452(96)04528-1; El Bilali L, 2002, APPL GEOCHEM, V17, P1171, DOI 10.1016/S0883-2927(01)00132-9; Ando T, 2010, B ENVIRON CONTAM TOX, V84, P477, DOI 10.1007/s00128-010-9946-7; Whalin L, 2007, MAR CHEM, V107, P278, DOI 10.1016/j.marchem.2007.04.002; Tomiyasu T, 2006, GEOCHEM J, V40, P253, DOI 10.2343/geochemj.40.253; Tomiyasu T, 2007, MAR CHEM, V107, P173, DOI 10.1016/j.marchem.2007.06.014; Merritt KA, 2009, EARTH-SCI REV, V96, P54, DOI 10.1016/j.earscirev.2009.06.002; Sunderland EM, 2006, MAR CHEM, V102, P111, DOI 10.1016/j.marchem.2005.09.019; Pacyna EG, 2010, ATMOS ENVIRON, V44, P2487, DOI 10.1016/j.atmosenv.2009.06.009; Arakami S, 1984, J GEOPHYS RES, V89, P8485, DOI [10.1029/JB089iB10p08485, DOI 10.1029/JB089IB10P08485]; Carranza CU, 1994, REP FAC SCI KAGOSHIM, V27, P23; Graeme Kimberlie A., 1998, Journal of Emergency Medicine, V16, P45, DOI 10.1016/S0736-4679(97)00241-2; Hayasaka S, 1976, REP FAC SCI KAGOSHIM, V9, P53; Kagoshima Meteorological Office, MONTHL COUNT SAK VOL; Kagoshima Prefecture, 1975, ENV REP ENV SURV MER; Kim E, 2014, MAR CHEM, V158, P59, DOI 10.1016/j.marchem.2013.11.004; Kono Y, 2014, BUNSEKI KAGAKU, V63, P17; Miyamoto J, 2008, LICHENOLOGY, V7, P143; Nagase I, 1984, SCI TOTAL ENVIRON, V32, P147, DOI [10.1016/0048-9697(84)90127-X, DOI 10.1016/0048-9697(84)90127-X]; Oki K., 1989, South Pacific Study, V10, P1; Osaka J, 1976, STUDY SUBMARINE VOLC, P48; Sakamoto H, 1993, REP FS KAGOSHIMA U M, V26, P75; Suzuki T, 2004, MERCURY ANAL MANUAL; United Nations Environmental Programme, 2013, GLOB MERC ASS 2013 S; Varekamp J.C., 1986, APPL GEOCHEM, V1, P65, DOI 10.1016/0883-2927(86)90038-7; World Health Organization, 2000, AIR QUAL GUID EUR, V2nd, P157; Xu WH, 2013, MAR POLLUT BULL, V76, P394, DOI 10.1016/j.marpolbul.2013.07.047	38	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1866-6280	1866-6299		ENVIRON EARTH SCI	Environ. Earth Sci.	JUL	2015	74	2					1175	1188		10.1007/s12665-015-4104-5		14	Environmental Sciences; Geosciences, Multidisciplinary; Water Resources	Environmental Sciences & Ecology; Geology; Water Resources	CL3SS	WOS:000356871500027		
J	Gill, SS; Anjum, NA; Gill, R; Yadav, S; Hasanuzzaman, M; Fujita, M; Mishra, P; Sabat, SC; Tuteja, N				Gill, Sarvajeet Singh; Anjum, Naser A.; Gill, Ritu; Yadav, Sandeep; Hasanuzzaman, Mirza; Fujita, Masayuki; Mishra, Panchanand; Sabat, Surendra C.; Tuteja, Narendra			Superoxide dismutase-mentor of abiotic stress tolerance in crop plants	ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH			English	Review						Abiotic stresses; Reactive oxygen species; Oxidative stress; Superoxide dismutase; SOD genetic engineering	INDUCED OXIDATIVE STRESS; ANTIOXIDANT ENZYME-ACTIVITIES; GROWING RICE SEEDLINGS; RELATIVE LYCOPERSICON-PENNELLII; SUSCEPTIBLE WHEAT GENOTYPES; UNGUICULATA L. WALP.; WATER-DEFICIT STRESS; PISUM-SATIVUM-L.; TERM SALT STRESS; CADMIUM STRESS	Abiotic stresses impact growth, development, and productivity, and significantly limit the global agricultural productivity mainly by impairing cellular physiology/biochemistry via elevating reactive oxygen species (ROS) generation. If not metabolized, ROS (such as O-2 (aEuro cent a'), OHaEuro cent, H2O2, or O-1(2)) exceeds the status of antioxidants and cause damage to DNA, proteins, lipids, and other macromolecules, and finally cellular metabolism arrest. Plants are endowed with a family of enzymes called superoxide dismutases (SODs) that protects cells against potential consequences caused by cytotoxic O-2 (aEuro cent a') by catalyzing its conversion to O-2 and H2O2. Hence, SODs constitute the first line of defense against abiotic stress-accrued enhanced ROS and its reaction products. In the light of recent reports, the present effort: (a) overviews abiotic stresses, ROS, and their metabolism; (b) introduces and discusses SODs and their types, significance, and appraises abiotic stress-mediated modulation in plants; (c) analyzes major reports available on genetic engineering of SODs in plants; and finally, (d) highlights major aspects so far least studied in the current context. Literature appraised herein reflects clear information paucity in context with the molecular/genetic insights into the major functions (and underlying mechanisms) performed by SODs, and also with the regulation of SODs by post-translational modifications. If the previous aspects are considered in the future works, the outcome can be significant in sustainably improving plant abiotic stress tolerance and efficiently managing agricultural challenges under changing climatic conditions.	[Gill, Sarvajeet Singh] Maharshi Dayanand Univ, Ctr Biotechnol, Stress Physiol & Mol Biol Lab, Rohtak 124001, Haryana, India; [Anjum, Naser A.] Univ Aveiro, CESAM Ctr Environm & Marine Studies, P-3810193 Aveiro, Portugal; [Anjum, Naser A.] Univ Aveiro, Dept Chem, P-3810193 Aveiro, Portugal; [Yadav, Sandeep; Tuteja, Narendra] ICGEB, Plant Mol Biol Grp, New Delhi 110067, India; [Hasanuzzaman, Mirza] Sher E Bangla Agr Univ, Fac Agr, Dept Agron, Dhaka 1207, Bangladesh; [Fujita, Masayuki] Kagawa Univ, Fac Agr, Dept Appl Biol Sci, Lab Plant Stress Responses, Miki, Kagawa 7610795, Japan; [Mishra, Panchanand; Sabat, Surendra C.] Inst Life Sci, Stress Biol Lab, Gene Funct & Regulat, Bhubaneswar 751023, Odisha, India	Gill, SS (reprint author), Maharshi Dayanand Univ, Ctr Biotechnol, Stress Physiol & Mol Biol Lab, Rohtak 124001, Haryana, India.	ssgill14@yahoo.co.in; anjum@ua.pt; narendra@icgeb.res.in	CESAM, UA/M-3762-2015; 	Anjum, Naser A./0000-0001-9953-0703	DST; CSIR; UGC, Govt. of India, New Delhi; Portuguese Foundation for Science and Technology (FCT) [SFRH/BPD/84671/2012]; Aveiro University Research Institute/Centre for Environmental and Marine Studies (CESAM) [UID/AMB/50017/2013]	SSG, RG, and NT would like to acknowledge the receipt of funds from DST, CSIR, and UGC, Govt. of India, New Delhi. NAA (SFRH/BPD/84671/2012) is grateful to the Portuguese Foundation for Science and Technology (FCT) and the Aveiro University Research Institute/Centre for Environmental and Marine Studies (CESAM) (UID/AMB/50017/2013) for partial financial supports. The authors apologize if some references related to the main theme of the current review could not be cited due to space constraint.	Agarwal S, 2007, BIOL PLANTARUM, V51, P157, DOI 10.1007/s10535-007-0030-z; Ahmed IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077869; Allen RD, 1997, FREE RADIC BIOL MED, V23, P73; Anjum NA, 2008, J PLANT INTERACT, V3, P127, DOI 10.1080/17429140701810732; Anjum NA, 2014, PROTOPLASMA, V251, P1265, DOI 10.1007/s00709-014-0636-x; Anjum NA, 2008, J PLANT INTERACT, V3, P189, DOI 10.1080/17429140701823164; Yu Q, 1999, PLANT SCI, V142, P1, DOI 10.1016/S0168-9452(98)00246-5; Jaleel CA, 2007, CR BIOL, V330, P806, DOI 10.1016/j.crvi.2007.08.009; Wang FZ, 2005, J PLANT PHYSIOL, V162, P465, DOI 10.1016/j.jplph.2004.09.009; Dixit V, 2002, PLANT CELL ENVIRON, V25, P687, DOI 10.1046/j.1365-3040.2002.00843.x; Tanyolac D, 2007, CHEMOSPHERE, V67, P89, DOI 10.1016/j.chemosphere.2006.09.052; Dixon DP, 2010, PHYTOCHEMISTRY, V71, P338, DOI 10.1016/j.phytochem.2009.12.012; Lovdal T, 2010, PHYTOCHEMISTRY, V71, P605, DOI 10.1016/j.phytochem.2009.12.014; Jia XY, 2009, PLANT MOL BIOL, V71, P51, DOI 10.1007/s11103-009-9508-8; Noctor G, 2002, J EXP BOT, V53, P1283, DOI 10.1093/jexbot/53.372.1283; Shalata A, 2001, PHYSIOL PLANTARUM, V112, P487, DOI 10.1034/j.1399-3054.2001.1120405.x; BOWLER C, 1991, EMBO J, V10, P1723; Anjum NA, 2015, ENVIRON SCI POLLUT R, V22, P4099, DOI 10.1007/s11356-014-3917-1; Kwon SY, 2002, PLANT CELL ENVIRON, V25, P873, DOI 10.1046/j.1365-3040.2002.00870.x; Mittova V, 2002, FREE RADICAL RES, V36, P195, DOI 10.1080/10715760290006402; Wang YC, 2010, MOL BIOL REP, V37, P1119, DOI 10.1007/s11033-009-9884-9; Alscher RG, 2002, J EXP BOT, V53, P1331, DOI 10.1093/jexbot/53.372.1331; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; Sairam RK, 2005, BIOL PLANTARUM, V49, P85, DOI 10.1007/s10535-005-5091-2; Gajewska E, 2006, BIOL PLANTARUM, V50, P653, DOI 10.1007/s10535-006-0102-5; Azevedo RA, 1998, PHYSIOL PLANTARUM, V104, P280, DOI 10.1034/j.1399-3054.1998.1040217.x; Lokhande VH, 2011, PLANT GROWTH REGUL, V65, P287, DOI 10.1007/s10725-011-9600-3; Lopez-Huertas E, 1999, BIOCHEM J, V337, P531, DOI 10.1042/0264-6021:3370531; Badawi GH, 2004, PLANT SCI, V166, P919, DOI 10.1016/j.plantsci.2003.12.007; Qadir S, 2004, PLANT SCI, V167, P1171, DOI 10.1016/j.plantsci.2004.06.018; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; Hasanuzzaman M, 2012, CROP STRESS AND ITS MANAGEMENT: PERSPECTIVES AND STRATEGIES, P261, DOI 10.1007/978-94-007-2220-0_8; Sreenivasulu N, 2000, PHYSIOL PLANTARUM, V109, P435, DOI 10.1034/j.1399-3054.2000.100410.x; Sharma I, 2011, ACTA PHYSIOL PLANT, V33, P1723, DOI 10.1007/s11738-010-0709-1; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Youn HD, 1996, BIOCHEM J, V318, P889; Chew YH, 2011, CURR OPIN BIOTECH, V22, P281, DOI 10.1016/j.copbio.2010.11.011; Agrawal SB, 2009, ECOTOX ENVIRON SAFE, V72, P610, DOI 10.1016/j.ecoenv.2007.10.007; Diaz-Vivancos P, 2013, PLANT BIOTECHNOL J, V11, P976, DOI 10.1111/pbi.12090; Manivannan P, 2007, COLLOID SURFACE B, V57, P69, DOI 10.1016/j.colsurfb.2007.01.004; Dat JF, 2003, PLANT J, V33, P621, DOI 10.1046/j.1365-313X.2003.01655.x; CUDD A, 1982, J BIOL CHEM, V257, P1443; Fornazier RF, 2002, BIOL PLANTARUM, V45, P91, DOI 10.1023/A:1015100624229; Kuo WY, 2013, NEW PHYTOL, V197, P99, DOI 10.1111/j.1469-8137.2012.04369.x; Pan Y, 2006, PLANT GROWTH REGUL, V49, P157, DOI 10.1007/s10725-006-9101-y; Dionisio-Sese ML, 1998, PLANT SCI, V135, P1, DOI 10.1016/S0168-9452(98)00025-9; Khan NA, 2007, J AGRON CROP SCI, V193, P435, DOI 10.1111/j.1439-037X.2007.00272.x; Burke EJ, 2006, J HYDROMETEOROL, V7, P1113, DOI 10.1175/JHM544.1; Ekmekci Y, 2008, J PLANT PHYSIOL, V165, P600, DOI 10.1016/j.jplph.2007.01.017; Iqbal N, 2010, AGR SCI CHINA, V9, P519, DOI 10.1016/S1671-2927(09)60125-5; Chaves MM, 2009, ANN BOT-LONDON, V103, P551, DOI 10.1093/aob/mcn125; Wang YH, 2004, PLANT SCI, V167, P671, DOI 10.1016/j.plantsci.2004.03.032; Gill SS, 2010, PLANT PHYSIOL BIOCH, V48, P909, DOI 10.1016/j.plaphy.2010.08.016; TSANG EWT, 1991, PLANT CELL, V3, P783, DOI 10.1105/tpc.3.8.783; Kliebenstein DJ, 1998, PLANT PHYSIOL, V118, P637, DOI 10.1104/pp.118.2.637; MCKERSIE BD, 1993, PLANT PHYSIOL, V103, P1155, DOI 10.1104/pp.103.4.1155; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; Biemelt S, 2000, PLANT CELL ENVIRON, V23, P135, DOI 10.1046/j.1365-3040.2000.00542.x; Tertivanidis K, 2004, TRANSGENIC RES, V13, P225, DOI 10.1023/B:TRAG.0000034610.35724.04; Mobin M, 2007, J PLANT PHYSIOL, V164, P601, DOI 10.1016/j.jplph.2006.03.003; McKersie BD, 1996, PLANT PHYSIOL, V111, P1177; Gill SS, 2013, PLANT PHYSIOL BIOCH, V70, P204, DOI 10.1016/j.plaphy.2013.05.032; Sandalio LM, 2001, J EXP BOT, V52, P2115; Martinez CA, 2001, PLANT SCI, V160, P505, DOI 10.1016/S0168-9452(00)00418-0; Zhao FY, 2006, PLANT SCI, V170, P216, DOI 10.1016/j.plantsci.2005.08.017; Shah K, 2001, PLANT SCI, V161, P1135, DOI 10.1016/S0168-9452(01)00517-9; Hernandez JA, 2000, PLANT CELL ENVIRON, V23, P853, DOI 10.1046/j.1365-3040.2000.00602.x; Simonovicova M, 2004, BIOL PLANTARUM, V48, P261, DOI 10.1023/B:BIOP.0000033454.95515.8a; Srivastava AK, 2005, WORLD J MICROB BIOT, V21, P1291, DOI 10.1007/s11274-005-2442-2; Munne-Bosch S, 2005, J PLANT PHYSIOL, V162, P743, DOI 10.1016/j.jplph.2005.04.022; Sharma P, 2007, PLANT CELL REP, V26, P2027, DOI 10.1007/s00299-007-0416-6; Sharma P, 2005, PLANT GROWTH REGUL, V46, P209, DOI 10.1007/s10725-005-0002-2; Prashanth SR, 2008, TRANSGENIC RES, V17, P281, DOI 10.1007/s11248-007-9099-6; Myouga F, 2008, PLANT CELL, V20, P3148, DOI 10.1105/tpc.108.061341; Sunkar R, 2006, PLANT CELL, V18, P2051, DOI 10.1105/tpc.106.041673; Neto ADD, 2006, ENVIRON EXP BOT, V56, P87, DOI 10.1016/j.envexpbot.2005.01.008; Anjum NA, 2012, ENVIRON EXP BOT, V75, P307, DOI 10.1016/j.envexpbot.2011.07.002; Karlsson M, 2005, J EXP BOT, V56, P2085, DOI 10.1093/jxb/eri207; Zhou ZS, 2008, CHEMOSPHERE, V70, P1500, DOI 10.1016/j.chemosphere.2007.08.028; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Miller AF, 2004, CURR OPIN CHEM BIOL, V8, P162, DOI 10.1016/j.cbpa.2004.02.011; Hartley-Whitaker J, 2001, PLANT CELL ENVIRON, V24, P713, DOI 10.1046/j.0016-8025.2001.00721.x; Gadjev I, 2006, PLANT PHYSIOL, V141, P436, DOI 10.1104/pp.106.078717; McKersie BD, 1999, PLANT PHYSIOL, V119, P839, DOI 10.1104/pp.119.3.839; Wu GH, 1999, PLANT PHYSIOL, V120, P513, DOI 10.1104/pp.120.2.513; Rizhsky L, 2003, J BIOL CHEM, V278, P38921, DOI 10.1074/jbc.M304987200; VanCamp W, 1996, PLANT PHYSIOL, V112, P1703, DOI 10.1104/pp.112.4.1703; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Mishra P, 2013, PROTOPLASMA, V250, P3, DOI 10.1007/s00709-011-0365-3; Leon AM, 2002, PLANT PHYSIOL BIOCH, V40, P813, DOI 10.1016/S0981-9428(02)01444-4; Jaleel CA, 2008, S AFR J BOT, V74, P126, DOI 10.1016/j.sajb.2007.10.003; Jaleel CA, 2008, PESTIC BIOCHEM PHYS, V90, P135, DOI 10.1016/j.pestbp.2007.11.003; Najeeb U, 2011, J HAZARD MATER, V186, P565, DOI 10.1016/j.jhazmat.2010.11.037; Sekmen AH, 2007, PHYSIOL PLANTARUM, V131, P399, DOI 10.1111/j.1399-3054.2007.00970.x; Sairam RK, 2002, PLANT SCI, V162, P897, DOI 10.1016/S0168-9452(02)00037-7; SAKAMOTO A, 1995, FEBS LETT, V358, P62, DOI 10.1016/0014-5793(94)01396-I; WHITE JA, 1988, BIOCHIM BIOPHYS ACTA, V951, P61, DOI 10.1016/0167-4781(88)90025-5; Fink RC, 2002, ARCH BIOCHEM BIOPHYS, V399, P19, DOI 10.1006/abbi.2001.2739; Guo B, 2007, ENVIRON POLLUT, V147, P743, DOI 10.1016/j.envpol.2006.09.007; Munns R, 2002, PLANT CELL ENVIRON, V25, P239, DOI 10.1046/j.0016-8025.2001.00808.x; Israr M, 2006, CHEMOSPHERE, V65, P591, DOI 10.1016/j.chemosphere.2006.02.016; Cao XD, 2004, ENVIRON POLLUT, V128, P317, DOI 10.1016/j.envpol.2003.09.018; Baccouch S, 1998, J PLANT NUTR, V21, P577, DOI 10.1080/01904169809365425; Noctor G, 2002, ANN BOT-LONDON, V89, P841, DOI 10.1093/aob/mcf096; Jaleel CA, 2007, CR BIOL, V330, P674, DOI 10.1016/j.crvi.2007.07.002; Liu YT, 2011, J HAZARD MATER, V189, P724, DOI 10.1016/j.jhazmat.2011.03.032; Diwan H, 2010, PLANT GROWTH REGUL, V61, P97, DOI 10.1007/s10725-010-9454-0; Bagnoli F, 2002, MOL GENET GENOMICS, V267, P321, DOI 10.1007/s00438-002-0664-7; BANNISTER WH, 1991, FREE RADICAL RES COM, V12-3, P349, DOI 10.3109/10715769109145804; BARRA D, 1990, J BIOL CHEM, V265, P17680; Basu U, 2001, PLANT CELL ENVIRON, V24, P1269, DOI 10.1046/j.0016-8025.2001.00783.x; BAUM JA, 1983, PLANT PHYSIOL, V73, P31, DOI 10.1104/pp.73.1.31; Bhattacharjee S., 2012, J BOT, V10, P1, DOI DOI 10.1155/2012/985298; Boominathan R, 2002, NEW PHYTOL, V156, P205, DOI 10.1046/j.1469-8137.2002.00506.x; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; BOSE J, 2013, J EXPT BOT, V65, P1241; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199; BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503; Van Breusegem F, 1999, PLANT CELL PHYSIOL, V40, P515; Chen Z, 2013, RUSS J PLANT PHYSL+, V60, P359, DOI 10.1134/S1021443713030059; Chirkova TV, 1998, RUSS J PLANT PHYSL+, V45, P55; Cho UH, 2005, PLANT SCI, V168, P113, DOI 10.1016/j.plantsci.2004.07.021; Corpas FJ, 2006, PLANT CELL PHYSIOL, V47, P984, DOI 10.1093/pcp/pcj071; Desingh R., 2007, General and Applied Plant Physiology, V33, P221; Dominguez DM, 2010, PHYSIOL PLANTARUM, V139, P289, DOI 10.1111/j.1399-3054.2010.01368.x; Duarte B, 2012, ECOTOX ENVIRON SAFE, V83, P1, DOI 10.1016/j.ecoenv.2012.04.026; Dupont CL, 2008, ENVIRON MICROBIOL, V10, P1831, DOI 10.1111/j.1462-2920.2008.01604.x; Erturk HN, 1999, THESIS VIRGINIA POLY; Eyidogan F, 2003, ACTA PHYSIOL PLANT, V25, P263; Faize M, 2013, J PLANT PHYSIOL, V170, P625, DOI 10.1016/j.jplph.2012.12.016; FAO (Food Agriculture Organization of the United Nations), 2004, FAO PROD YB; Feng Wang, 2006, Plant Cell Rep, V24, P734; Ferreira RR, 2002, J PLANT NUTR, V25, P327, DOI 10.1081/PLN-100108839; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Fu LM, 2013, ENVIRON EXP BOT, V86, P1; Garg N., 2009, PLANT BIOSYST, V143, P8; Gomez J. M., 1999, FREE RADICAL RES, V31, P11, DOI 10.1080/10715769900301261; Gupta Ashima Sen, 1993, Plant Physiology (Rockville), V103, P1067; Gupta M, 2009, CHEMOSPHERE, V74, P1201, DOI 10.1016/j.chemosphere.2008.11.023; Gutteridge J.M.C., 2007, FREE RADICALS BIOL M; Hernandez I, 2009, BIOCHEM BIOPH RES CO, V387, P300, DOI 10.1016/j.bbrc.2009.07.003; Hirayama T, 2010, PLANT J, V61, P1041, DOI 10.1111/j.1365-313X.2010.04124.x; Holzmeister C, 2015, J EXP BOT, V66, P989, DOI 10.1093/jxb/eru458; Israr M, 2006, PLANT PHYSIOL BIOCH, V44, P590, DOI 10.1016/j.plaphy.2006.09.021; Jaleel CA, 2007, COLLOID SURFACE B, V59, P150, DOI 10.1016/j.colsurfb.2007.05.001; Kandhari P, 2004, THESIS U MARYLAND CO; Kanematsu S, 2013, ATYPICAL CYTOSOL LOC, V3A, P31; KANEMATSU S, 1989, PLANT CELL PHYSIOL, V30, P381; Karpinska B, 2004, PLANT MOL BIOL, V56, P255, DOI 10.1007/s11103-004-3354-5; Kasai Tomonari, 2006, Journal of General Plant Pathology, V72, P265, DOI 10.1007/s10327-006-0283-y; Kim HJ, 2008, PLANTA, V228, P281, DOI 10.1007/s00425-008-0734-0; Kumar R.R., 2011, RECENT RES SCI TECHN, V3, P148; KWIATOWSKI J, 1986, BIOCHIM BIOPHYS ACTA, V874, P99, DOI 10.1016/0167-4838(86)90107-X; Lee SH, 2007, J PLANT PHYSIOL, V164, P1626, DOI 10.1016/j.jplph.2007.01.003; Li Y, 2009, ACTA PHYSIOL PLANT, V31, P155, DOI 10.1007/s11738-008-0216-9; Lomonte C, 2010, ENVIRON EXP BOT, V69, P9, DOI 10.1016/j.envexpbot.2010.02.012; Madanala R, 2011, BIOTECHNOL LETT, V33, P2057, DOI 10.1007/s10529-011-0670-0; Manivarman P, 2008, COLLOID SURFACE B, V61, P315, DOI 10.1016/j.colsurfb.2007.09.007; Mann T, 1938, PROC R SOC SER B-BIO, V126, P303, DOI 10.1098/rspb.1938.0058; MARINO M, 1995, PROTEIN ENG, V8, P551, DOI 10.1093/protein/8.6.551; Mishra S, 2006, PLANT PHYSIOL BIOCH, V44, P25, DOI 10.1016/j.plaphy.2006.01.007; Mittler R, 2011, OXIDATIVE STRESS PLA; Mittova V, 2004, J EXP BOT, V55, P1105, DOI 10.1093/jxb/erh113; Molina-Rueda JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056421; Mylona PV, 2010, REACTIVE OXYGEN SPEC, P101, DOI DOI 10.1201/9781439854082-7; Mylona PV, 2007, J EXP BOT, V58, P1301, DOI 10.1093/jxb/erl292; Mylona PV, 1998, FREE RADICAL BIO MED, V25, P576, DOI 10.1016/S0891-5849(98)00090-2; Noriega GO, 2007, BIOMETALS, V20, P841, DOI 10.1007/s10534-006-9077-0; Olsen KM, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-21; Pavelic D, 2000, PLANT PHYSIOL, V124, P1285, DOI 10.1104/pp.124.3.1285; Pitcher LH, 1996, PLANT PHYSIOL, V110, P583; Romero-Puertas MC, 1999, FREE RADICAL RES, V31, P25, DOI 10.1080/10715769900301281; Rossa MM, 2002, J APPL PHYCOL, V14, P151, DOI 10.1023/A:1019985722808; Ruzsa SM, 1999, REDOX REP, V4, P95, DOI 10.1179/135100099101534774; SANDALIO LM, 1987, J PLANT PHYSIOL, V127, P395; SANDALIO LM, 1988, PLANT PHYSIOL, V88, P1215, DOI 10.1104/pp.88.4.1215; Sandalio Luisa M, 2013, Subcell Biochem, V69, P231, DOI 10.1007/978-94-007-6889-5_13; Scandalios JG, 1997, OXIDATIVE STRESS MOL; Schinkel H, 2001, PLANTA, V213, P272, DOI 10.1007/s004250000505; SEHMER L, 1995, J PLANT PHYSIOL, V147, P144; Sharma P, 2012, J BOT, V37, P1; Sarvajeet Singh, 2008, American Journal of Plant Physiology, V3, P25; SMITH MW, 1992, J MOL EVOL, V34, P175; Srivastava S, 2010, B ENVIRON CONTAM TOX, V84, P342, DOI 10.1007/s00128-010-9937-8; Stankovic S, 2013, ENV CHEM SUSTAINABLE, V2, P80; Talukdar D, 2013, ISRN AGRON, DOI [10.1155/2013/284830, DOI 10.1155/2013/284830]; TEPPERMAN JM, 1990, PLANT MOL BIOL, V14, P501, DOI 10.1007/BF00027496; Tuteja N, 2013, CROP IMPROVEMENT ADV, V1st; Tuteja Narendra, 2011, Plant Signal Behav, V6, P173; Tuteja N, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0117-0; Ushimaru T, 1999, PHYSIOL PLANTARUM, V107, P181, DOI 10.1034/j.1399-3054.1999.100205.x; Ushimaru T, 2001, PHYSIOL PLANTARUM, V112, P39, DOI 10.1034/j.1399-3054.2001.1120106.x; Wu F, 2012, ACTA BOT BOREALI-OCC, V10, P005; Wu FeiBo, 2006, Agricultural Sciences in China, V5, P68, DOI 10.1016/S1671-2927(06)60021-7; ZHANG JX, 1995, AM J BOT, V82, P1220, DOI 10.2307/2446244	196	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-1344	1614-7499		ENVIRON SCI POLLUT R	Environ. Sci. Pollut. Res.	JUL	2015	22	14					10375	10394		10.1007/s11356-015-4532-5		20	Environmental Sciences	Environmental Sciences & Ecology	CM0BX	WOS:000357344300001		
J	Ahmed, E; Nagaoka, K; Fayez, M; Abdel-Daim, MM; Samir, H; Watanabe, G				Ahmed, Eman; Nagaoka, Kentaro; Fayez, Mostafa; Abdel-Daim, Mohamed M.; Samir, Haney; Watanabe, Gen			Suppressive effects of long-term exposure to P-nitrophenol on gonadal development, hormonal profile with disruption of tissue integrity, and activation of caspase-3 in male Japanese quail (Coturnix japonica)	ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH			English	Article						Caspase-3; Claudin-1; Diesel exhausts particles; Endocrine disrupting compounds; Hypothalamic-pituitary axis; Japanese quail; P-nitrophenol	DIESEL EXHAUST PARTICLES; ADULT MALE-MICE; IMMATURE MALE RATS; ADRENOCORTICAL FUNCTION; ESTROGENIC ACTIVITIES; BISPHENOL-A; TOXICITY; 3-METHYL-4-NITROPHENOL; METABOLISM; EXPRESSION	P-Nitrophenol (PNP) is considered to be one of nitrophenol derivatives of diesel exhaust particles. PNP is a major metabolite of some organophosphorus compounds. PNP is a persistent organic pollutant as well as one of endocrine-disrupting compounds. Consequently, bioaccumulation of PNP potentiates toxicity. The objectives of the current study were to assess in vivo adverse effects of long-term low doses of PNP exposure on reproductive system during development stage. Twnety-eight-day-old male Japanese quails were orally administered different doses of PNP (0, 0.01, 0.1, 1 mg/kg body weight) daily for 2.5 months. Testicular histopathology, hormones, caspase-3 (CASP3), and claudin-1 (CLDN1) tight junction protein, as well as plasma hormones were analyzed. The results revealed that long-term PNP exposure caused testicular histopathological changes such as vacuolation of spermatogenic cell and spermatocyte with significant testicular and cloacal gland atrophy. PNP activated CASP3 enzyme that is an apoptosis-related cysteine peptidase. Besides, it disrupted the expression of CLDN1. Furthermore, a substantial decrease in plasma concentrations of luteinizing hormone (LH) and testosterone was observed after 2 and 2.5 months in the PNP-treated groups. Meanwhile, the pituitary LH did not significantly change. Site of action of PNP may be peripheral on testicular development and/or centrally on the hypothalamic-pituitary-gonadal axis through reduction of pulsatile secretion of gonadotrophin-releasing hormone. Consequently, it may reduce the sensitivity of the anterior pituitary gland to secrete LH. In conclusion, PNP induced profound endocrine disruption in the form of hormonal imbalance, induction of CASP3, and disruption of CLDN1 expression in the testis. Hence, it may hinder the reproductive processes.	[Ahmed, Eman; Nagaoka, Kentaro; Samir, Haney; Watanabe, Gen] Tokyo Univ Agr & Technol, Dept Vet Med, Vet Physiol Lab, Fuchu, Tokyo 1838509, Japan; [Ahmed, Eman; Fayez, Mostafa; Abdel-Daim, Mohamed M.] Suez Canal Univ, Dept Pharmacol, Fac Vet Med, Ismailia 41522, Egypt; [Samir, Haney] Cairo Univ, Dept Theriogenol, Fac Vet Med, Giza 12211, Egypt	Ahmed, E (reprint author), Tokyo Univ Agr & Technol, Dept Vet Med, Vet Physiol Lab, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	eman_ahmed@vet.suez.edu.eg	Nagaoka, Kentaro/C-2019-2013	Nagaoka, Kentaro/0000-0003-1038-1380	Japan society for the promotion of science [C23510073]	This work was supported by a Grants-in-Aid for scientific research from the Japan society for the promotion of science (C23510073). We thank Dr. GD Niswender, Animal Reproduction and Biotechnology Laboratory, Colorado State University (Fort Collins, CO, USA) for providing antiserum to testosterone; Dr. JA Proudman, USDA-ARS, Biotechnology and Germplasm Laboratory (Beltsville, MD, USA) for LH radioimmunoassay materials; and the Biosignal Research Center, Institute for Molecular and Cellular Regulation, Gunma, Japan for providing antiserum against LH; Dr. Rania Hamad (Department of Pathology, Faculty of Veterinary Medicine, Suez Canal University, Egypt) for her help in histopathological evaluation.	Agency for Toxic Substances and Disease Registry (ATSDR), 1992, TOX PROF NITR; Abu-Qare AW, 2000, ARCH TOXICOL, V74, P388, DOI 10.1007/s002040000133; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; Morrow CMK, 2010, PHILOS T R SOC B, V365, P1679, DOI 10.1098/rstb.2010.0025; OTTINGER MA, 1979, BIOL REPROD, V20, P905, DOI 10.1095/biolreprod20.4.905; Bhushan B, 2000, BIOCHEM BIOPH RES CO, V274, P626, DOI 10.1006/bbrc.2000.3193; STONE R, 1994, SCIENCE, V265, P308, DOI 10.1126/science.8023147; Ball GF, 2010, ILAR J, V51, P310; HESS RA, 1988, J ANDROL, V9, P327; Abu-Qare AW, 2001, TOXICOL LETT, V125, P1, DOI 10.1016/S0378-4274(01)00409-X; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sedqyar M, 2008, J REPROD DEVELOP, V54, P52, DOI 10.1262/jrd.19112; Li CM, 2006, TOXICOL APPL PHARM, V217, P1, DOI 10.1016/j.taap.2006.06.010; Taneda S, 2004, BIOL PHARM BULL, V27, P835, DOI 10.1248/bpb.27.835; Noya Y, 2008, ENVIRON SCI POLLUT R, V15, P318, DOI 10.1007/s11356-008-0006-3; BENKE GM, 1975, TOXICOL APPL PHARM, V31, P254, DOI 10.1016/0041-008X(75)90161-1; Zhang YH, 2013, TOXICOL LETT, V223, P228, DOI 10.1016/j.toxlet.2013.09.011; Gye MC, 2003, ARCH ANDROLOGY, V49, P271, DOI [10.1080/01485010390204913, 10.1080/713828170]; Sharpe RM, 2004, BRIT MED J, V328, P447, DOI 10.1136/bmj.328.7437.447; Timms BG, 2005, P NATL ACAD SCI USA, V102, P7014, DOI 10.1073/pnas.0502544102; MACHIDA M, 1982, BIOCHEM PHARMACOL, V31, P787, DOI 10.1016/0006-2952(82)90464-6; Li XZ, 2009, ENDOCRINE, V36, P98, DOI 10.1007/s12020-009-9192-0; Thompson EL, 2009, BRIT J PHARMACOL, V156, P609, DOI 10.1111/j.1476-5381.2008.00061.x; Park CJ, 2011, THERIOGENOLOGY, V75, P445, DOI 10.1016/j.theriogenology.2010.09.012; Asman WAH, 2005, CHEMOSPHERE, V59, P1023, DOI 10.1016/j.chemosphere.2004.11.048; Furuta C, 2004, BIOL REPROD, V70, P1527, DOI 10.1095/biolreprod.103.024810; Furuta C, 2005, ENDOCRINE, V27, P33, DOI 10.1385/ENDO:27:1:033; Furuya M, 2003, CAN J VET RES, V67, P68; HAMADA T, 1989, J ENDOCRINOL, V122, P697, DOI 10.1677/joe.0.1220697; Hansen WM, 2011, XENOBIOTICS, V1, P1, DOI [10.4081/xeno.2011.e4, DOI 10.4081/XENO.2011.E4]; Ichinose T, 1997, CARCINOGENESIS, V18, P185, DOI 10.1093/carcin/18.1.185; Kaku Atsushi, 1993, Japanese Poultry Science, V30, P413; Kanesaka T, 1992, JPN ANIM REPROD, V31, P186, DOI [10.1262/jrd.38.6_j85, DOI 10.1262/JRD.38.6J85]; Keith HL, 1998, PURE APPL CHEM, V70, P2319, DOI [10.1351/pac199870122319, DOI 10.1351/PAC199870122319]; Kim TS, 2006, CHEMOSPHERE, V62, P926, DOI 10.1016/j.chemosphere.2005.05.038; KRISHNAN KA, 1994, COMP BIOCHEM PHYS B, V108, P253, DOI 10.1016/0305-0491(94)90073-6; Li C, 2007, BIOL PHARM BULL, V30, P2376, DOI 10.1248/bpb.30.2376; Li CM, 2012, TOXICOL LETT, V209, P277, DOI 10.1016/j.toxlet.2012.01.004; Li CM, 2012, INHAL TOXICOL, V24, P599, DOI 10.3109/08958378.2012.702140; Li CM, 2006, J ENDOCRINOL, V189, P555, DOI 10.1677/joe.1.06628; Matsumoto A, 1991, Kaibogaku Zasshi, V66, P81; Mi YL, 2013, ANAT REC, V296, P1650, DOI 10.1002/ar.22765; NISHIOKA MG, 1992, ATMOS ENVIRON A-GEN, V26, P2077, DOI 10.1016/0960-1686(92)90092-Y; OECD, 1993, OECD GUID TEST CHEM; Ohno S, 2002, J STEROID BIOCHEM, V80, P355, DOI 10.1016/S0960-0760(02)00021-3; PERRIN FMR, 1995, J REPROD FERTIL, V103, P223; RISSMAN EF, 1984, J REPROD FERTIL, V71, P411; Sawyer CH, 1971, STEROID HORMONES BRA; Taya K, 1985, Anim Reprod, V31, P186, DOI 10.1262/jrd1977.31.186; US-EPA (US Environmental Protection Agency), 1976, WAT QUAL CRIT; US-EPA (US Environmental Protection Agency), 1996, 712C96141 USEPA; Wingfield JC, 2005, HORM BEHAV, V48, P395, DOI 10.1016/j.yhbeh.2005.06.003; Yue Z, 2011, RES VET SCI, V91, P261, DOI 10.1016/j.rvsc.2010.12.009	53	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-1344	1614-7499		ENVIRON SCI POLLUT R	Environ. Sci. Pollut. Res.	JUL	2015	22	14					10930	10942		10.1007/s11356-015-4245-9		13	Environmental Sciences	Environmental Sciences & Ecology	CM0BX	WOS:000357344300054		
J	Mitsuhashi, J; Nakayama, T; Narai-Kanayama, A				Mitsuhashi, Jun; Nakayama, Tsutomu; Narai-Kanayama, Asako			Mechanism of papain-catalyzed synthesis of oligo-tyrosine peptides	ENZYME AND MICROBIAL TECHNOLOGY			English	Article						Peptide synthesis; Oligo-tyrosine; Papain	ALPHA-CHYMOTRYPSIN; PROTEASE; POLYMERIZATION; SPECIFICITY; PROTECTION; BRAIN; SERUM; ACID	Di-, tri-, and tetra-tyrosine peptides with angiotensin I-converting enzyme inhibitory activity were synthesized by papain-catalyzed polymerization of L-tyrosine ethyl ester in aqueous media at 30 degrees C. Varying the reaction pH from 6.0 to 7.5 and the initial concentration of the ester substrate from 25 to 100 mM, the highest yield of oligo-tyrosine peptides (79% on a substrate basis) was produced at pH 6.5 and 75 mM, respectively. In the reaction initiated with 100 mM of the substrate, approx. 50% yield of insoluble, highly polymerized peptides accumulated. At less than 15 mM, the reaction proceeded poorly; however, from 30 mM to 120 mM a dose-dependent increase in the consumption rate of the substrate was observed with a sigmoidal curve. Meanwhile, each of the tri- and tetra-tyrosine peptides, even at approx. 5 mM, was consumed effectively by papain but was not elongated to insoluble polymers. For deacylation of the acyl-papain intermediate through which a new peptide bond is made, L-tyrosine ethyl ester, even at 5 mM, showed higher nucleophilic activity than di- and tri-tyrosine. These results indicate that the mechanism through which papain polymerizes L-tyrosine ethyl ester is as follows: the first interaction between papain and the ester substrate is a rate-limiting step; oligo-tyrosine peptides produced early in the reaction period are preferentially used as acyl donors, while the initial ester substrate strongly contributes as a nucleophile to the elongation of the peptide product; and the balance between hydrolytic fragmentation and further elongation of oligo-tyrosine peptides is dependent on the surrounding concentration of the ester substrate. (C) 2015 Elsevier Inc. All rights reserved.	[Mitsuhashi, Jun; Nakayama, Tsutomu; Narai-Kanayama, Asako] Nippon Vet & Life Sci Univ, Grad Sch Vet Med & Life Sci, Musashino, Tokyo 1808602, Japan	Narai-Kanayama, A (reprint author), Nippon Vet & Life Sci Univ, Grad Sch Vet Med & Life Sci, 1-7-1 Kyonan Cho, Musashino, Tokyo 1808602, Japan.	a-narai@nvlu.ac.jp					Kitts DD, 2003, CURR PHARM DESIGN, V9, P1309, DOI 10.2174/1381612033454883; Esaki K, 2013, BIOSCI BIOTECH BIOCH, V77, P847, DOI 10.1271/bbb.120747; SEKI E, 1995, NIPPON NOGEIK KAISHI, V69, P1013; GOLOLOBOV MY, 1993, EUR J BIOCHEM, V217, P955, DOI 10.1111/j.1432-1033.1993.tb18326.x; SCHUSTER M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P207, DOI 10.1016/0167-4838(92)90356-I; Guzman F, 2007, ELECTRON J BIOTECHN, V10, P279, DOI 10.2225/vol10-issue2-fulltext-13; Fukuoka T, 2002, BIOMACROMOLECULES, V3, P768, DOI 10.1021/bm020016c; Biegel A, 2006, AMINO ACIDS, V31, P137, DOI 10.1007/s00726-006-0331-0; BODANSZKY M, 1978, INT J PEPT PROT RES, V12, P57; BONGERS J, 1994, PEPTIDES, V15, P183, DOI 10.1016/0196-9781(94)90189-9; Bordusa F, 1997, ANGEW CHEM INT EDIT, V36, P1099, DOI 10.1002/anie.199710991; FitzGerald RJ, 2000, BRIT J NUTR, V84, P533; Hansler M, 1995, J PEPT SCI, V1, P283, DOI 10.1002/psc.310010502; Ito K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3502; Kalser LR, 2001, J PEDIATR-US, V139, P421, DOI 10.1067/mpd.2001.117576; Lombard C, 2005, PROTEIN PEPTIDE LETT, V12, P621, DOI 10.2174/0929866054696118; MAHER TJ, 1990, J PHARM SCI, V79, P685, DOI 10.1002/jps.2600790807; Maruyama H, 2003, J JPN SOC FOOD SCI, V50, P310; Narai-Kanayama A, 2009, ENZYME MICROB TECH, V44, P235, DOI 10.1016/j.enzmictec.2008.11.004; Narai-Kanayama A, 2009, ENZYME MICROB TECH, V45, P457, DOI 10.1016/j.enzmictec.2009.08.002; Narai-Kanayama A, 2008, BBA-GEN SUBJECTS, V1780, P881, DOI 10.1016/j.bbagen.2008.03.009; Narai-Kanayama A, 2010, J BIOTECHNOL, V150, P343, DOI 10.1016/j.jbiotec.2010.09.931; SCHECHTE.I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SCHELLENBERGER V, 1991, Peptide Research, V4, P265; SCHUSTER M, 1991, BIOMED BIOCHIM ACTA, V50, pS122; SCHWARZ A, 1990, BIOTECHNOL APPL BIOC, V12, P188; Stewart JM, 1981, PEPTIDES, V3, P169; Tyrrell Henry A., 1998, Journal of Nutritional and Environmental Medicine (Abingdon), V8, P349, DOI 10.1080/13590849861934; YAMASHIR.D, 1973, J ORG CHEM, V38, P591, DOI 10.1021/jo00943a039	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0141-0229	1879-0909		ENZYME MICROB TECH	Enzyme Microb. Technol.	JUL-AUG	2015	75-76						10	17		10.1016/j.enzmictec.2015.03.007		8	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CL7IM	WOS:000357145700002		
J	Sugawara, M; Katada, C; Komatsu, T; Takahashi, K; Azuma, M; Higuchi, K; Koizumi, W; Atsuda, K				Sugawara, Mitsuhiro; Katada, Chikatoshi; Komatsu, Toshiaki; Takahashi, Kaoru; Azuma, Mizutomo; Higuchi, Katsuhiko; Koizumi, Wasaburo; Atsuda, Koichiro			Association between pharmacokinetic variables and neutropenia after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma	ESOPHAGUS			English	Article						Esophageal cancer; DCF; Neutropenia; Pharmacokinetics; Docetaxel	PREOPERATIVE CHEMOTHERAPY; RANDOMIZED TRIAL; NECK-CANCER; FLUOROURACIL; SURGERY; THERAPY; HEAD	Combined chemotherapy with cisplatin, 5-fluorouracil, and docetaxel (DCF) is a promising regimen for the treatment of esophageal squamous cell carcinoma (ESCC). However, careful attention must be paid to severe neutropenia. A total of 17 patients with ESCC who received DCF therapy (docetaxel 75 mg/m(2) on day 1, cisplatin 75 mg/m(2) on day 1, and 5-fluorouracil 750 mg/m(2) on days 1-5) were studied from December 2010 through May 2012. We assessed the relation between neutropenia and the plasma concentration of each anticancer drug during the first course of DCF therapy. The maximum plasma concentration (C (max)) (mean +/- A SD) of docetaxel was 1,929 +/- A 458 ng/mL, while that of cisplatin was 2,870 +/- A 410 ng/mL, and that of 5-fluorouracil was 448 +/- A 121 ng/mL. The area under the plasma concentration-time curve (AUC) (mean +/- A SD) as calculated by MOMENT analysis was 2,428 +/- A 513 ng/mL h for docetaxel and 135,950 +/- A 22,330 ng/mL h for cisplatin. The AUC of 5-fluorouracil was not calculated. Higher C (max) and AUC values for docetaxel were associated with trends toward lower nadir absolute neutrophil counts (ANCs). The C (max) of docetaxel reflected the AUC of docetaxel. Neither the C (max) nor AUC of docetaxel was related to the occurrence of febrile neutropenia. Higher C (max) or AUC values of docetaxel are associated with a trend toward lower nadir ANCs in patients with ESCC who receive DCF therapy. The C (max) of docetaxel, which is assessable immediately after starting treatment, might be useful for predicting the severity of the nadir ANC or for selecting the management method.	[Sugawara, Mitsuhiro; Komatsu, Toshiaki] Kitasato Univ Hosp, Dept Pharm, Minami Ku, Sagamihara, Kanagawa 2520375, Japan; [Katada, Chikatoshi; Azuma, Mizutomo; Higuchi, Katsuhiko; Koizumi, Wasaburo] Kitasato Univ, Sch Med, Dept Gastroenterol, Minami Ku, Sagamihara, Kanagawa 2520374, Japan; [Takahashi, Kaoru] Kitasato Univ Hosp, Dept Nursing, Minami Ku, Sagamihara, Kanagawa 2520375, Japan; [Atsuda, Koichiro] Kitasato Univ, Sch Pharm, Res & Educ Ctr Clin Pharm, Div Clin Pharm,Minami Ku, Sagamihara, Kanagawa 2520375, Japan	Katada, C (reprint author), Kitasato Univ, Sch Med, Dept Gastroenterol, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	ckatada@med.kitasato-u.ac.jp					Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Hara H, 2013, CANCER SCI, V104, P1455, DOI 10.1111/cas.12274; Watanabe M, 2011, DIGESTION, V83, P146, DOI 10.1159/000321797; Ancona E, 2001, CANCER, V91, P2165, DOI 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095; Kelsen DP, 1998, NEW ENGL J MED, V339, P1979, DOI 10.1056/NEJM199812313392704; Law S, 1997, J THORAC CARDIOV SUR, V114, P210, DOI 10.1016/S0022-5223(97)70147-8; NEUHAUS P, 1992, ARCH SURG-CHICAGO, V127, P1446; Tabata K., 1999, XENOBIO METABOL DISP, V14, P286; Tanaka T, 2012, ESOPHAGUS-TOKYO, V9, P99, DOI 10.1007/s10388-012-0312-1	15	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					209	218		10.1007/s10388-014-0468-y		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800001		
J	Yamamoto, SR; Yano, F; Omura, N; Tsuboi, K; Hoshino, M; Kashiwagi, H; Yanaga, K				Yamamoto, Se Ryung; Yano, Fumiaki; Omura, Nobuo; Tsuboi, Kazuto; Hoshino, Masato; Kashiwagi, Hideyuki; Yanaga, Katsuhiko			Efficacy of laparoscopic Toupet fundoplication for non-erosive reflux disease assessed by combined multichannel intraluminal impedance-pH monitoring	ESOPHAGUS			English	Article						Non-erosive gastroesophageal reflux disease; NERD; Antirelux surgery; Laparoscopic fundoplication; MII-pH	ANTIREFLUX SURGERY; NISSEN FUNDOPLICATION; ACID REFLUX; ESOPHAGITIS; OMEPRAZOLE; CONSENSUS; NERD	Non-erosive gastroesophageal reflux disease (NERD) is the most common form of gastroesophageal reflux disease (GERD). The aim of this study is to evaluate efficacy of laparoscopic Toupet fundoplication for NERD by combined multichannel intraluminal impedance-pH (MII-pH) monitoring. Twenty-eight patients who underwent laparoscopic Toupet fundoplication for NERD had MII-pH monitoring before surgery. Among them, 11 patients accepted to undergo MII-pH monitoring both before and after surgery. Their clinical data were collected in a prospective fashion and retrospectively reviewed. Patients' characteristics, the esophageal function of time pH below 4, DeMeester score, the numbers of acid and nonacid reflux episodes and symptom index (SI) were evaluated. Pre- and postoperative time pH below 4 were 5.8 +/- A 7.1 and 0.7 +/- A 1.3, respectively, and DeMeester score was 19.7 +/- A 23.3 and 2.8 +/- A 3.8, respectively, both of which were significantly different (p = 0.022 and 0.019). Pre- and postoperative numbers of all reflux episodes were 84.3 +/- A 52.5 and 36.2 +/- A 22.8, respectively. Pre- and postoperative acid reflux episodes were 39.5 +/- A 35.2 and 9.9 +/- A 19.2, respectively. There were significant differences in the number of both all and acid reflux episodes (p = 0.001 and 0.012). Those of nonacid reflux episodes were 44.8 +/- A 37.4 and 26.3 +/- A 13.9, respectively, which did not achieve statistical significance (p = 0.068). Six patients (54.5 %) had positive SI preoperatively, but no one had positive SI after surgery. Laparoscopic Toupet fundoplication can control gastroesophageal reflux events in patients with NERD.	[Yamamoto, Se Ryung; Yano, Fumiaki; Omura, Nobuo; Tsuboi, Kazuto; Hoshino, Masato; Kashiwagi, Hideyuki; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Minato Ku, Tokyo 1058461, Japan	Yamamoto, SR (reprint author), Jikei Univ, Sch Med, Dept Surg, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.	kimkim_44@hotmail.com					Martinez SD, 2003, ALIMENT PHARM THERAP, V17, P537, DOI 10.1046/j.0269-2813.2003.01423.x; Fass R, 2007, J CLIN GASTROENTEROL, V41, P131, DOI 10.1097/01.mcg.0000225631.07039.6d; Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x; Carlsson R, 1998, EUR J GASTROEN HEPAT, V10, P119, DOI 10.1097/00042737-199802000-00004; WIENER GJ, 1988, AM J GASTROENTEROL, V83, P358; Tutuian R, 2003, J CLIN GASTROENTEROL, V37, P206, DOI 10.1097/00004836-200309000-00004; Shay S, 2004, AM J GASTROENTEROL, V99, P1037, DOI 10.1111/j.1572-0241.2004.04172.x; Sifrim D, 2004, GUT, V53, P1024, DOI 10.1136/gut.2003.033290; Lind T, 1997, SCAND J GASTROENTERO, V32, P974, DOI 10.3109/00365529709011212; Broeders JAJL, 2010, BRIT J SURG, V97, P1318, DOI 10.1002/bjs.7174; Dean BB, 2004, CLIN GASTROENTEROL H, V2, P656, DOI 10.1053/S1542-3565(04)00288-5; Bammer T, 2002, J GASTROINTEST SURG, V6, P730, DOI 10.1016/S1091-255X(02)00042-2; BANCEWICZ J, 1990, DISEASES OF THE ESOPHAGUS, VOL 2, P177; Broeders JA, 2010, BRIT J SURG, V97, P845, DOI 10.1002/bjs.7023; Desai KM, 2003, J GASTROINTEST SURG, V7, P44, DOI 10.1016/S1091-255X(02)00135-X; Engstrom C, 2012, BRIT J SURG, V99, P1415, DOI 10.1002/bjs.8870; Fass R, 2003, AM J GASTROENTEROL, V98, pS2, DOI 10.1016/S0002-9270(03)00009-1; Kamolz T, 2005, SURG ENDOSC, V19, P494, DOI 10.1007/s00464-003-9267-6; Linke GR, 2008, J GASTROINTEST SURG, V12, P816, DOI 10.1007/s11605-008-0470-6; Omura N, 2006, SURG TODAY, V36, P954, DOI 10.1007/s00595-006-3287-5; Richter JE, 2000, ARCH INTERN MED, V160, P1810, DOI 10.1001/archinte.160.12.1810; Richter JE, 2000, ARCH INTERN MED, V160, P1803, DOI 10.1001/archinte.160.12.1803; Roman S, 2007, BRIT J SURG, V94, P48, DOI 10.1002/bjs.5532; Tokudome K, 2012, WORLD J GASTROENTERO, V18, P5940, DOI 10.3748/wjg.v18.i41.5940	24	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					219	224		10.1007/s10388-014-0469-x		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800002		
J	Akutagawa, K; Iwakiri, R; Hara, M; Fujimoto, K; Fujiwara, Y; Inamori, M; Tanaka, J; Shimatani, T; Akiyama, J; Ando, T; Manabe, N; Kinjo, F; Deguchi, R; Kusano, M				Akutagawa, Kayo; Iwakiri, Ryuichi; Hara, Megumi; Fujimoto, Kazuma; Fujiwara, Yasuhiro; Inamori, Masahiko; Tanaka, Junji; Shimatani, Tomohiko; Akiyama, Junichi; Ando, Takashi; Manabe, Noriaki; Kinjo, Fukunori; Deguchi, Ryuzo; Kusano, Motoyasu			Risk factors for low response to proton-pump inhibitor treatment in reflux esophagitis and non-erosive reflux disease evaluated by the frequency scale for the symptoms of gastroesophageal reflux disease	ESOPHAGUS			English	Article						Multivariate analysis; Proton-pump inhibitor; Questionnaires; Rabeprazole; Risk Factors	MAINTENANCE THERAPY; GASTROINTESTINAL SYMPTOMS; CLINICAL CHARACTERISTICS; CYP2C19 POLYMORPHISM; EROSIVE ESOPHAGITIS; IMPROVES SYMPTOMS; JAPANESE PATIENTS; RABEPRAZOLE; EFFICACY; GERD	This study aimed to evaluate risk factors for resistance to proton-pump inhibitor (PPI) therapy among patients with reflux esophagitis (RE) and nonerosive reflux disease (NERD) in gastroesophageal reflux disease (GERD) using a standardized questionnaire in Japan: the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG). One hundred fifty-eight patients who underwent upper gastrointestinal endoscopy were enrolled: 87 were diagnosed with RE (mean age: 59.5 +/- A 15.1 years; male/female: 47/39) and 71 with NERD (mean age 53.0 +/- A 17.6 years; male/female 22/49). The patients were divided into two groups according to improvement after PPI treatment evaluated by FSSG: rapid responders were patients with a parts per thousand yen50 % improvement according to FSSG, and low responders were those with < 50 % improvement according to FSSG. All patients were treated with the PPI rabeprazole (10 mg/day) for 4 weeks. Response rate to PPI therapy was 65.5 % (57/87) in RE and 54.9 % (39/71) in NERD, indicating that the PPI treatment was more effective for RE. In RE, risk factors for PPI resistance indicated by univariate analysis were low stature and high body mass index. Low stature was a risk factor in multivariate analysis. With regard to NERD, univariate analysis indicated that female gender, high stature, low body weight, and low total FSSG score were risk factors for PPI resistance. Low FSSG score was a risk factor in multivariate analysis. By the present study, we identified the risk factors for PPI resistance in RE and GERD using FSSG.	[Akutagawa, Kayo; Iwakiri, Ryuichi; Fujimoto, Kazuma] Saga Med Sch, Dept Internal Med & Gastrointestinal Endoscopy, Saga 8498501, Japan; [Hara, Megumi] Saga Med Sch, Dept Prevent Med, Saga 8498501, Japan; [Fujiwara, Yasuhiro] Osaka City Univ, Grad Sch Med, Dept Gastroenterol, Osaka 558, Japan; [Inamori, Masahiko] Yokohama City Univ Med, Div Gastroenterol, Yokohama, Kanagawa, Japan; [Tanaka, Junji] Hyogo Coll Med, Div Upper Gastroenterol, Nishinomiya, Hyogo, Japan; [Shimatani, Tomohiko] Hiroshima Univ Hosp, Dept Gen Med, Hiroshima, Japan; [Akiyama, Junichi] Natl Ctr Global Hlth & Med, Dept Gastroenterol, Kawasaki, Kanagawa, Japan; [Ando, Takashi] Kyoto Kuramaguchi Med Ctr, Dept Gastroenterol, Kyoto, Japan; [Manabe, Noriaki] Kawasaki Med Univ, Div Endoscopy & Ultrasonog, Kurashiki, Okayama, Japan; [Kinjo, Fukunori] Univ Ryukyus, Dept Endoscopy, Nishihara, Okinawa 90301, Japan; [Deguchi, Ryuzo] Tokai Univ, Sch Med, Dept Internal Med, Tokyo 151, Japan; [Kusano, Motoyasu] Gunma Univ Hosp, Dept Endoscopy & Endoscop Surg, Gunma, Japan	Akutagawa, K (reprint author), Saga Med Sch, Dept Internal Med & Gastrointestinal Endoscopy, 5-1-1 Nabeshima, Saga 8498501, Japan.	t0424_k0525aku@yahoo.co.jp			Eisai Co., Tokyo, Japan	This study was partly supported by Eisai Co., Tokyo, Japan.	Sugimoto M, 2011, WORLD J GASTROENTERO, V17, P1858, DOI 10.3748/wjg.v17.i14.1858; Furuta T, 2011, J GASTROENTEROL, V46, P1273, DOI 10.1007/s00535-011-0446-2; Lundell LR, 1999, GUT, V45, P172; Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x; Chiba N, 1997, GASTROENTEROLOGY, V112, P1798, DOI 10.1053/gast.1997.v112.pm9178669; Kusano M, 2004, J GASTROENTEROL, V39, P888, DOI 10.1007/s00535-004-1417-7; Mishima I, 2005, SCAND J GASTROENTERO, V40, P1005, DOI 10.1080/00365520510023260; Fujiwara Y, 2009, J GASTROENTEROL, V44, P518, DOI 10.1007/s00535-009-0047-5; Kusano M, 2007, DIGEST DIS SCI, V52, P1673, DOI 10.1007/s10620-006-9674-3; Bai Y, 2013, J GASTROEN HEPATOL, V28, P626, DOI 10.1111/jgh.12125; Miyamoto M, 2010, INTERNAL MED, V49, P1469, DOI 10.2169/internalmedicine.49.3615; Cicala M, 2013, WORLD J GASTROENTERO, V19, P6529, DOI 10.3748/wjg.v19.i39.6529; Fujimoto K, 2004, ALIMENT PHARM THERAP, V20, P5, DOI 10.1111/j.1365-2036.2004.02220.x; Furukawa N, 1999, J GASTROENTEROL, V34, P441, DOI 10.1007/s005350050293; Miner P, 2002, AM J GASTROENTEROL, V97, P1332, DOI 10.1016/S0002-9270(02)04125-4; Kim N, 2011, GUT LIVER, V5, P437, DOI 10.5009/gnl.2011.5.4.437; Tominaga K, 2012, J GASTROENTEROL, V47, P284, DOI 10.1007/s00535-011-0488-5; Carlsson R, 1998, SCAND J GASTROENTERO, V33, P1023; Cloud ML, 1998, DIGEST DIS SCI, V43, P993, DOI 10.1023/A:1018822532736; Danjo A, 2009, J GASTROEN HEPATOL, V24, P633, DOI 10.1111/j.1440-1746.2008.05747.x; El-Serag HB, 2008, DIGESTION, V78, P6, DOI 10.1159/000151249; Fass R, 2003, AM J GASTROENTEROL, V98, pS2, DOI 10.1016/S0002-9270(03)00009-1; Fujimoto K, 2011, INTERNAL MED, V50, P179, DOI 10.2169/internalmedicine.50.4238; Fujimoto K, 2010, J GASTROENTEROL, V45, P1193, DOI 10.1007/s00535-010-0276-7; Fujiwara Y, 2005, AM J GASTROENTEROL, V100, P754, DOI 10.1111/j.1572-0241.2005.40966.x; Hiyama T, 2009, J GASTROEN HEPATOL, V24, P1326, DOI 10.1111/j.1440-1746.2009.05879.x; Hongo M, 2011, J GASTROENTEROL, V46, P297, DOI 10.1007/s00535-010-0342-1; Iwakiri R, 2013, ALIMENT PHARM THER, V38, P729, DOI 10.1111/apt.12444; Jo SY, 2013, J NEUROGASTROENTEROL, V19, P61, DOI 10.5056/jnm.2013.19.1.61; Kawaguchi H, 1996, AM J GASTROENTEROL, V91, P959; Kinoshita Yoshikazu, 2008, Therap Adv Gastroenterol, V1, P191, DOI 10.1177/1756283X08098181; Kinoshita Y, 2012, AM J GASTROENTEROL, V107, P522, DOI 10.1038/ajg.2012.19; Komatsu-Tanaka M, 2012, DIGEST ENDOSC, V24, P407, DOI 10.1111/j.1443-1661.2012.01301.x; Minatsuki C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069891; Nagahara Akihito, 2010, Clin J Gastroenterol, V3, P61, DOI 10.1007/s12328-010-0139-z; Ohkusa T, 2005, ALIMENT PHARM THERAP, V21, P1331, DOI 10.1111/j.1365-2036.2005.02486.x; Robinson M, 2002, ALIMENT PHARM THERAP, V16, P445, DOI 10.1046/j.1365-2036.2002.01181.x; Saitoh T, 2009, HEPATO-GASTROENTEROL, V56, P703; Sakurai K, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-42; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722; Tominaga K, 2014, J GASTROENTEROL, V49, P1392, DOI 10.1007/s00535-013-0896-9; Watanabe A, 2012, DIGESTION, V86, P323, DOI 10.1159/000342393	42	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					225	232		10.1007/s10388-014-0477-x		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800003		
J	Shimoji, H; Karimata, H; Nishimaki, T				Shimoji, Hideaki; Karimata, Hiroyuki; Nishimaki, Tadashi			Early tumor response to induction chemotherapy or chemoradiotherapy is a significant prognostic predictor in patients with initially unresectable T4 esophageal cancer following subsequent surgery	ESOPHAGUS			English	Article						T4 esophageal cancer; Induction therapy; Early tumor response	SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; METASTATIC COLORECTAL-CANCER; NEOADJUVANT THERAPY; CETUXIMAB	Little is known about reliable prognostic predictors after early administration of intensive, multimodal therapies in esophageal cancer patients. We aimed to determine whether early tumor responses (ETR) to preoperative chemotherapy or chemoradiotherapy in T4 esophageal cancer patients could be significant prognostic predictors. Forty-eight patients with suspected T4 esophageal cancers were enrolled in this prospective study to test the efficacy of preoperative induction chemotherapy or chemoradiotherapy followed by esophagectomy, which was feasible in only 37 patients. We performed nested analysis of ETR as a prognostic predictor, using univariate and multivariate analyses. Univariate analyses revealed that the final tumor response (p < 0.001), ETR (p < 0.001), dysphagia improvement (p = 0.002), and post-induction therapy serum albumin levels (p = 0.025) were significant prognostic predictors in the 48 patients. Pretreatment serum squamous cell carcinoma-related antigen levels (p = 0.008), final tumor response (p < 0.001), ETR (p = 0.004), and induction therapy toxicity grading (p = 0.031) were found to be prognostic predictors in 37 patients. ETR absence was associated with an unfavorably short median survival duration in both the 48 (6.4 months) and 37 patients (10.2 months). Final tumor response was the significant sole independent prognostic predictor in both patient groups using multivariate analyses. ETR is a significant prognostic predictor in T4 esophageal cancer patients who underwent induction chemotherapy or chemoradiotherapy and subsequent surgery.	[Shimoji, Hideaki; Karimata, Hiroyuki; Nishimaki, Tadashi] Univ Ryukyus, Grad Sch Med, Dept Digest & Gen Surg, Nishihara, Okinawa 9030215, Japan	Nishimaki, T (reprint author), Univ Ryukyus, Grad Sch Med, Dept Digest & Gen Surg, 207 Uehara, Nishihara, Okinawa 9030215, Japan.	nishimak@med.u-ryukyu.ac.jp					Stahl M, 2009, J CLIN ONCOL, V27, P851, DOI 10.1200/JCO.2008.17.0506; Kosugi S, 2004, WORLD J SURG, V28, P680, DOI 10.1007/s00268-004-6865-y; Francis AM, 2013, ANN SURG, V258, P500, DOI 10.1097/SLA.0b013e3182a196f4; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Kaneko K, 2003, BRIT J CANCER, V88, P18, DOI 10.1038/sj.bjc.6600684; Wieder HA, 2004, J CLIN ONCOL, V22, P900, DOI 10.1200/JCO.2004.07.122; Piessevaux H, 2013, J CLIN ONCOL, V31, P3764, DOI 10.1200/JCO.2012.42.8532; Shimada H, 2008, J AM COLL SURGEONS, V206, P48, DOI 10.1016/j.jamcollsurg.2007.06.013; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Shimoji H, 2013, WORLD J SURG, V37, P2180, DOI 10.1007/s00268-013-2074-x; Motoori M, 2013, MOL CLIN ONCOL, V1, P521; Ngamruengphong S, 2010, DIS ESOPHAGUS, V23, P216, DOI 10.1111/j.1442-2050.2009.00989.x; Piessen G, 2013, ANN SURG, V258, P66, DOI 10.1097/SLA.0b013e31828676c4; Saito H, 1999, BRIT J CANCER, V81, P484, DOI 10.1038/sj.bjc.6690719; Sobin LH, 2002, UICC TNM CLASSIFICAT; The Japan Esophageal Society, 2008, JAP CLASS ES CANC	16	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					233	243		10.1007/s10388-014-0478-9		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800004		
J	Fujiwara, Y; Kohata, Y; Tanigawa, T; Yamagami, H; Shiba, M; Tominaga, K; Watanabe, T; Arakawa, T				Fujiwara, Yasuhiro; Kohata, Yukie; Tanigawa, Tetsuya; Yamagami, Hirokazu; Shiba, Masatsugu; Tominaga, Kazunari; Watanabe, Toshio; Arakawa, Tetsuo			Associations between endoscopic findings and functional assessment via multichannel intraluminal impedance-pH monitoring in patients with non-erosive reflux disease refractory to proton-pump inhibitors	ESOPHAGUS			English	Article						Non-erosive reflux disease; Minimal change; Multichannel intraluminal impedance-pH monitoring; Hyperplasia of vascular network	MINIMAL CHANGE ESOPHAGITIS; INTEROBSERVER AGREEMENT; CHANGE LESIONS; SYMPTOMS; CLASSIFICATION; MULTICENTER; POPULATION; MANAGEMENT; DIAGNOSIS; FAILURE	The clinical significance of minimal changes in non-erosive reflux disease (NERD) is controversial. Multichannel intraluminal impedance-pH (MII-pH) monitoring enables classification of NERD. The aim of this study was to evaluate associations between endoscopic findings and functional assessment via MII-pH monitoring in patients with proton-pump inhibitor (PPI)-refractory NERD. Thirty-four PPI-refractory NERD patients were retrospectively analyzed. On the basis of the MII-pH monitoring results, cases were classified as acid reflux, non-acid reflux, and functional heartburn. Minimal changes such as white turbidity, erythema, loss of fine vascular network pattern at the esophagogastric junction, hyperplasia of vascular network at the middle esophagus, hernia, flap valve grade, and atrophic gastritis were evaluated endoscopically. Among 34 patients, 8 were categorized with acid reflux, 17 with non-acid reflux, and 9 with functional heartburn. There were no differences in the prevalence of minimal changes among the groups, but all cases showing white turbidity of the entire esophageal circumference involved non-acid reflux. The prevalence of hiatal hernia and abnormal flap valve did not differ among the three groups, but the presence of atrophic gastritis was significantly more common in patients with functional heartburn than in those with acid and non-acid reflux. The prevalence of hyperplasia of the vascular network at the middle esophagus was significantly higher in patients with proximal migration than in those without. There are associations between endoscopic findings and functional assessment via MII-pH monitoring. Future studies should pay more attention to the endoscopic findings at the middle esophagus.	[Fujiwara, Yasuhiro; Kohata, Yukie; Tanigawa, Tetsuya; Yamagami, Hirokazu; Shiba, Masatsugu; Tominaga, Kazunari; Watanabe, Toshio; Arakawa, Tetsuo] Osaka City Univ, Grad Sch Med, Dept Gastroenterol, Abeno Ku, Osaka 5458585, Japan	Fujiwara, Y (reprint author), Osaka City Univ, Grad Sch Med, Dept Gastroenterol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	yasu@med.osaka-cu.ac.jp					Amano Y, 2006, ENDOSCOPY, V38, P1032, DOI 10.1055/s-2006-944778; Yoshikawa I, 2005, GASTROINTEST ENDOSC, V62, P698, DOI 10.1016/j.gie.2005.06.027; Hongo M, 2006, J GASTROENTEROL, V41, P95, DOI 10.1007/s00535-006-1775-4; Fass R, 2005, ALIMENT PHARM THERAP, V22, P79, DOI 10.1111/j.1365-2036.2005.02531.x; Kohata Y, 2012, J GASTROEN HEPATOL, V27, P58, DOI 10.1111/j.1440-1746.2012.07074.x; Kim JB, 2012, DIGESTION, V85, P288, DOI 10.1159/000337198; Kusano M, 2008, DIGEST DIS SCI, V53, P3082, DOI 10.1007/s10620-008-0290-2; Jones R, 2009, ALIMENT PHARM THER, V30, P1030, DOI 10.1111/j.1365-2036.2009.04142.x; Nakamura T, 2005, ALIMENT PHARM THERAP, V21, P19, DOI 10.1111/j.1365-2036.2005.02469.x; Hill LD, 1996, GASTROINTEST ENDOSC, V44, P541, DOI 10.1016/S0016-5107(96)70006-8; Kim JH, 2011, ENDOSCOPY, V43, P190, DOI 10.1055/s-0030-1256101; Fujiwara Y, 2009, J GASTROENTEROL, V44, P518, DOI 10.1007/s00535-009-0047-5; Sifrim D, 2004, GUT, V53, P1024, DOI 10.1136/gut.2003.033290; Armstrong D, 1996, GASTROENTEROLOGY, V111, P85, DOI 10.1053/gast.1996.v111.pm8698230; Joh T, 2007, J GASTROENTEROL, V42, P444, DOI 10.1007/s00535-007-2022-3; Zerbib F, 2008, GUT, V57, P156, DOI 10.1136/gut.2007.133470; Fass R, 2009, AM J GASTROENTEROL, V104, pS33, DOI 10.1038/ajg.2009.50; Sifrim D, 2012, GUT, V61, P1340, DOI 10.1136/gutjnl-2011-301897; Lei WY, 2012, DIGESTION, V85, P27, DOI 10.1159/000334715; Sharma P, 2007, GASTROENTEROLOGY, V133, P454, DOI 10.1053/j.gastro.2007.06.006; Kiesslich R, 2004, DIGEST DIS, V22, P221, DOI 10.1159/000080323; Dean BB, 2004, CLIN GASTROENTEROL H, V2, P656, DOI 10.1053/S1542-3565(04)00288-5; Banerjee Rupa, 2008, Clin Gastroenterol Hepatol, V6, pA26, DOI 10.1016/j.cgh.2008.02.022; Hoshihara Y, 2000, Nihon Rinsho, V58, P1808; Kimura K, 1969, ENDOSCOPY, V3, P87, DOI DOI 10.1055/S-0028-1098086; Kogure T, 1972, STOMACH INTESTINE, V7, P1293; Kouzu Teruo, 1992, Stomach and Intestine, V27, P1003; Lee JH, 2008, J GASTROEN HEPATOL, V23, P1153, DOI 10.1111/j.1440-1746.2008.05299.x; Makuuchi H, 1982, Nihon Shokakibyo Gakkai Zasshi, V79, P1557; Manabe N, 2012, ESOPHAGUS-TOKYO, V9, P9, DOI 10.1007/s10388-011-0307-3; Miwa H, 2008, DIS ESOPHAGUS, V21, P355, DOI 10.1111/j.1442-2050.2007.00788.x; Ohara Syuichi, 2005, Nihon Shokakibyo Gakkai Zasshi, V102, P1010; Takubo K, 2005, ARCH PATHOL LAB MED, V129, P159	33	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					244	250		10.1007/s10388-014-0480-2		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800005		
J	Niihara, M; Sato, H; Kusafuka, K; Kamiya, S; Ashida, R; Nakajima, T; Tsubosa, Y				Niihara, Masahiro; Sato, Hiroshi; Kusafuka, Kimihide; Kamiya, Satoshi; Ashida, Ryo; Nakajima, Takashi; Tsubosa, Yasuhiro			Biphasic synovial sarcoma of the cervical esophagus confirmed by the presence of SYT-SSX1 fusion transcripts	ESOPHAGUS			English	Article						Esophagus; Sarcoma; SYT-SSX; RT-PCR; FISH	TRANSLOCATION; CHEMOTHERAPY; SURVIVAL	Synovial sarcoma of the digestive tract, including that of the esophagus, is extremely rare. To our knowledge, only 9 cases of primary synovial sarcoma of the esophagus have been reported worldwide. Here, we describe the case of a 70-year-old man who presented with dysphagia and hoarseness, which he had been experiencing for 4 months. A pigmented polypoid mass was detected at the cervical esophagus and spindle cell sarcoma was suspected on the basis of biopsy findings. Two operations were performed to completely excise both the tumor and regional lymph nodes. The tumor was diagnosed as a biphasic synovial sarcoma on the basis of the detection of SYT-SSX1 fusion transcripts by reverse transcription-polymerase chain reaction and fluorescence in situ hybridization. Twenty-two months following surgery, the patient developed local recurrence and received radiotherapy with 60 Gy in 30 fractions. Post-treatment follow-up uncovered the presence of left cervical lymph node metastases that were then removed. Approximately 1 month after resection, multiple metastases developed in the lungs. At his request, the patient did not receive any chemotherapy and died at 42 months after the first operation.	[Niihara, Masahiro; Kamiya, Satoshi; Ashida, Ryo; Tsubosa, Yasuhiro] Shizuoka Canc Ctr, Div Esophageal Surg, Shizuoka 4118777, Japan; [Sato, Hiroshi] Saitama Med Univ, Saitama Int Med Ctr, Dept Esophagogastr Surg, Saitama, Japan; [Kusafuka, Kimihide; Nakajima, Takashi] Shizuoka Canc Ctr, Div Pathol, Shizuoka 4118777, Japan	Niihara, M (reprint author), Shizuoka Canc Ctr, Div Esophageal Surg, 1007 Shimonagakubo, Shizuoka 4118777, Japan.	m.niihara@scchr.jp					AMR SS, 1984, AM J OTOLARYNG, V5, P266, DOI 10.1016/S0196-0709(84)80037-X; Eilber FC, 2004, ANN SURG, V240, P686, DOI 10.1109/01.sla.0000141710.74073.0d; Butori C, 2006, VIRCHOWS ARCH, V449, P262, DOI 10.1007/s00428-006-0234-1; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; Canter RJ, 2008, CLIN CANCER RES, V14, P8191, DOI 10.1158/1078-0432.CCR-08-0843; Billings SD, 2000, MODERN PATHOL, V13, P68, DOI 10.1038/modpathol.3880011; Knosel T, 2010, EUR J CANCER, V46, P1170, DOI 10.1016/j.ejca.2010.01.032; Kawaguchi S, 2012, CANCER SCI, V103, P1625, DOI 10.1111/j.1349-7006.2012.02370.x; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P93, DOI 10.1016/0165-4608(86)90153-6; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; AntonPacheco J, 1996, J PEDIATR SURG, V31, P1703, DOI 10.1016/S0022-3468(96)90057-3; Bloch MJ, 1987, GASTROENTEROLOGY, V92, P229; de Alencar Mário Henrique Leite, 2012, Rev Col Bras Cir, V39, P441, DOI 10.1590/S0100-69912012000500018; Bonavina L, 1998, Dis Esophagus, V11, P268; Habu S, 1998, SURG TODAY, V28, P401; PALMER BV, 1983, J LARYNGOL OTOL, V97, P1173, DOI 10.1017/S0022215100096171; Saito T, 2006, CANCER RES, V66, P6919, DOI 10.1158/0008-5472.CAN.05.3697; THOMAS RM, 1995, CANCER, V75, P154, DOI 10.1002/1097-0142(19950101)75:1+<154::AID-CNCR2820751305>3.0.CO;2-Z	19	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					251	257		10.1007/s10388-014-0419-7		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800006		
J	Oshikiri, T; Yasuda, T; Harada, H; Ohyama, M; Hasegawa, H; Ohara, T; Sendo, H; Sugimoto, T; Fujino, Y; Tominaga, M; Takahashi, Y				Oshikiri, Taro; Yasuda, Takashi; Harada, Hitoshi; Ohyama, Masato; Hasegawa, Hiroshi; Ohara, Tadayuki; Sendo, Hiroyoshi; Sugimoto, Takemi; Fujino, Yasuhiro; Tominaga, Masahiro; Takahashi, Yuichi			G-CSF-producing esophageal cancer with induction of intense bone marrow FDG uptake	ESOPHAGUS			English	Article						Esophageal cancer; Granulocyte colony-stimulating factor; Esophagectomy; (18)F-fluorodeoxyglucose positron emission tomography/computed tomography; Bone marrow	COLONY-STIMULATING FACTOR; AUTOCRINE GROWTH; CERVICAL-CANCER; CELL CARCINOMA; TUMOR-GROWTH; METASTASES; RECEPTOR; IL-6	We report the first case of esophageal squamous cell carcinoma (SCC) producing granulocyte colony-stimulating factor (G-CSF) with induction of high uptake of (18)F-fluorodeoxyglucose (FDG) throughout the bone marrow. A close relationship between tumor status and serum G-CSF concentration was also seen. A 65-year-old man was admitted to our hospital because of esophageal SCC with leukocytosis and pyrexia. His leukocyte count and serum G-CSF concentration were 15900/mu l and 140 pg/ml, respectively. Positron emission tomography/computed tomography (PET/CT) showed focal intense bone marrow (18)F-FDG uptake. Hypermetabolic activity in the bone marrow was suspected to be an effect of G-CSF. Under the diagnosis of G-CSF-producing esophageal SCC, the patient underwent minimally invasive esophagectomy in the prone position with 2-field lymph node dissection. After removal of the tumor, the leukocyte count and serum G-CSF concentration rapidly normalized. Immunohistochemically, G-CSF expression was found in the cytoplasm of tumor cells. High uptake of (18)F-FDG throughout the bone marrow decreased. The patient left the hospital on postoperative day 10 without any complications. Changes in bone marrow PET/CT findings and serum G-CSF concentration should be helpful in the definitive diagnosis of G-CSF-producing esophageal SCC and serve as an indicator of therapeutic effect.	[Oshikiri, Taro; Yasuda, Takashi; Harada, Hitoshi; Ohyama, Masato; Hasegawa, Hiroshi; Ohara, Tadayuki; Sendo, Hiroyoshi; Sugimoto, Takemi; Fujino, Yasuhiro; Tominaga, Masahiro] Hyogo Canc Ctr, Dept Surg Gastroenterol, Akashi, Hyogo 6738558, Japan; [Takahashi, Yuichi] Hyogo Canc Ctr, Dept Pathol, Akashi, Hyogo 6738558, Japan	Oshikiri, T (reprint author), Hyogo Canc Ctr, Dept Surg Gastroenterol, 13-70 Kitaoji Cho, Akashi, Hyogo 6738558, Japan.	taro_oshikiri@hp.pref.hyogo.jp					Aita K, 2006, PATHOL INT, V56, P413, DOI 10.1111/j.1440-1827.2006.01979.x; Murata Y, 2006, NUCL MED BIOL, V33, P999, DOI 10.1016/j.nucmedbio.2006.09.005; Mabuchi S, 2012, EUR J GYNAECOL ONCOL, V33, P316; Sugawara Y, 1998, J CLIN ONCOL, V16, P173; Kyo S, 2000, GYNECOL ONCOL, V78, P383, DOI 10.1006/gyno.2000.5904; ASANO S, 1977, BLOOD, V49, P845; BABA M, 1995, AM J HEMATOL, V49, P207, DOI 10.1002/ajh.2830490306; Endo Kazuya, 2005, Gastric Cancer, V8, P173, DOI 10.1007/s10120-005-0330-y; Furihata M, 1999, PATHOL INT, V49, P1010, DOI 10.1046/j.1440-1827.1999.00970.x; Hidaka Dai, 2009, Nihon Kokyuki Gakkai Zasshi, V47, P259; HUGHES WF, 1952, ANN INTERN MED, V37, P1085; Japan Esophageal Society, 2007, GUID CLIN PATH STUD; Kawakami H, 2007, J JPN SOC GASTROENTE, V104, P233; KEARNS CM, 1993, J PEDIATR-US, V123, P471, DOI 10.1016/S0022-3476(05)81760-3; Mimatsu K, 2008, ESOPHAGUS, V5, P205; Morooka M, 2008, ANN NUCL MED, V22, P635, DOI 10.1007/s12149-008-0146-z; Nakamoto Y, 2010, CLIN NUCL MED, V35, P74, DOI 10.1097/RLU.0b013e3181c7bf4e; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; ROBINSON WA, 1974, ANN NY ACAD SCI, V230, P212, DOI 10.1111/j.1749-6632.1974.tb14451.x; Sato Y, 2005, J JPN SOC GASTROENTE, V102, P888; Savarese TM, 2001, CANCER LETT, V162, P105, DOI 10.1016/S0304-3835(00)00623-6; TACHIBANA M, 1995, CANCER RES, V55, P3438; Tanabe T, 2009, ESOPHAGUS-TOKYO, V6, P253, DOI 10.1007/s10388-009-0206-z; Tomii K, 1993, JPN J LUNG CANC, V33, P563; Tsutsumi Y, 2005, PATHOL CLIN MED, V23, P543; Tsuzuki H, 1998, CANCER RES, V58, P794	26	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					258	262		10.1007/s10388-014-0421-0		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800007		
J	Tanoue, K; Okumura, H; Uchikado, Y; Owaki, T; Matsumoto, M; Setoyama, T; Kita, Y; Omoto, I; Sasaki, K; Arigami, T; Uenosono, Y; Ishigami, S; Natsugoe, S				Tanoue, Kiyonori; Okumura, Hiroshi; Uchikado, Yasuto; Owaki, Tetsuhiro; Matsumoto, Masataka; Setoyama, Tetsuro; Kita, Yoshiaki; Omoto, Itaru; Sasaki, Ken; Arigami, Takaaki; Uenosono, Yoshikazu; Ishigami, Sumiya; Natsugoe, Shoji			A case of superficial esophageal squamous cell carcinoma invading the lamina propria mucosa with a metastatic lymph node along the celiac artery	ESOPHAGUS			English	Article						Lymph node metastasis; Superficial esophageal cancer; Lamina propria mucosa	POSITRON-EMISSION-TOMOGRAPHY; CANCER	A 62-year-old man was diagnosed with superficial esophageal cancer on upper endoscopy during health screening. Endoscopic examination with iodine staining and narrow-band imaging revealed three superficial erosive lesions in the middle and lower thoracic esophagus. The depth of tumor invasion was diagnosed as shallow invasion into the submucosal layer on endoscopic ultrasonography. Since enhanced computed tomography showed a markedly swollen lymph node at the right cardia, with higher F-deoxyglucose uptake on F-deoxyglucose positron emission tomography, lymph node metastasis was suspected. Then esophagectomy with lymph node dissection was performed, and histopathologic examination of the resected specimen revealed metastasis of squamous cell carcinoma in the huge lymph node along the celiac artery. In superficial esophageal cancer with a distinct depressed lesion, horizontal extension, and especially with erosive esophagitis, the possibility of lymph node metastases should be kept in mind even the depth of tumor invasion was lamina propria mucosa.	[Tanoue, Kiyonori; Okumura, Hiroshi; Uchikado, Yasuto; Matsumoto, Masataka; Setoyama, Tetsuro; Kita, Yoshiaki; Omoto, Itaru; Sasaki, Ken; Arigami, Takaaki; Uenosono, Yoshikazu; Ishigami, Sumiya; Natsugoe, Shoji] Kagoshima Univ, Grad Sch Med, Dept Digest Surg & Breast & Thyroid Surg, Kagoshima 8908520, Japan; [Owaki, Tetsuhiro] Kagoshima Univ, Grad Sch Med, Educ Ctr Doctors Remote Islands & Rural Areas, Kagoshima 8908520, Japan	Okumura, H (reprint author), Kagoshima Univ, Grad Sch Med, Dept Digest Surg & Breast & Thyroid Surg, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.	hokumura@m.kufm.kagoshima-u.ac.jp					Ando N, 2000, ANN SURG, V232, P225, DOI 10.1097/00000658-200008000-00013; Kodama M, 1998, SURGERY, V123, P432, DOI 10.1016/S0039-6060(98)70165-5; Flamen P, 2000, J CLIN ONCOL, V18, P3202; Eguchi T, 2006, MODERN PATHOL, V19, P475, DOI 10.1038/modpathol.3800557; Hatakeyama T, 2012, SURG TODAY, V42, P676, DOI 10.1007/s00595-012-0148-2; Japanese Society for Esophageal Disease, 2008, GUID CLIN PATH STUD, V10th; Kita Y, 2013, ANN SURG ONCOL, V20, P1646, DOI 10.1245/s10434-012-2796-2; Kumagai Y, 2010, DIGEST ENDOSC, V22, P259, DOI 10.1111/j.1443-1661.2010.01010.x; Natsugoe S, 2004, J GASTROINTEST SURG, V8, P631, DOI 10.1016/j.gassur.2004.02.004; Natsugoe S, 1999, HEPATO-GASTROENTEROL, V46, P2398; Natsugoe S, 2005, J SURG ONCOL, V89, P6, DOI 10.1002/jso.20172; NISHIHIRA T, 1995, SURG TODAY, V25, P307; Patti MG, 1997, SURG CLIN N AM, V77, P959, DOI 10.1016/S0039-6109(05)70600-9; Prenzel KL, 2010, ANN THORAC SURG, V90, P1662, DOI 10.1016/j.athoracsur.2010.07.008; Takahashi Y, 2009, DIGEST ENDOSC, V21, P262, DOI 10.1111/j.1443-1661.2009.00904.x	15	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					263	266		10.1007/s10388-014-0425-9		4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800008		
J	Shiozaki, A; Fujiwara, H; Konishi, H; Ishimoto, T; Morimura, R; Murayama, Y; Komatsu, S; Kuriu, Y; Ikoma, H; Kubota, T; Nakanishi, M; Ichikawa, D; Okamoto, K; Sakakura, C; Otsuji, E				Shiozaki, Atsushi; Fujiwara, Hitoshi; Konishi, Hirotaka; Ishimoto, Takeshi; Morimura, Ryo; Murayama, Yasutoshi; Komatsu, Shuhei; Kuriu, Yoshiaki; Ikoma, Hisashi; Kubota, Takeshi; Nakanishi, Masayoshi; Ichikawa, Daisuke; Okamoto, Kazuma; Sakakura, Chouhei; Otsuji, Eigo			Esophagectomy with gastric tube reconstruction for patients who previously underwent free jejunal transfer	ESOPHAGUS			English	Article						Gastric tube reconstruction; Free jejunal transfer; Esophageal cancer	LAPAROSCOPIC TRANSHIATAL APPROACH; RESECTION; CARCINOMA; CANCER; GRAFT	Free jejunal transfer (FJT) has become one of the standard techniques used for reconstruction after total pharyngolaryngocervical esophagectomy (TPLCe); however, there are increasing concerns regarding the incidence of secondary esophageal cancer (EC) in these patients. We performed esophagectomy with gastric tube reconstruction in patients with EC who had previously undergone TPLCe with FJT. Patient 1 was a 53-year-old woman who previously received definitive chemoradiotherapy (dCRT) for middle thoracic EC. She subsequently underwent TPLCe with FJT for hypopharyngeal cancer. However, the recurrence of EC was found in the middle thoracic esophagus. Patient 2 was a 64-year-old man who previously underwent TPLCe with FJT for hypopharyngeal cancer. He subsequently underwent endoscopic submucosal dissection and dCRT for thoracic EC. He was readmitted with severe esophageal stricture following dCRT. Salvage esophagectomy with lymphadenectomy were performed. Right thoracotomy was performed in patient 1, whereas a laparoscopic transhiatal approach was used without thoracotomy in patient 2. After dissection of the thoracic esophagus, a cervical incision was made on the opposite side of the supplying vessels of the free jejunal flap (FJF) in both patients. The FJF was detected and its distal side was carefully exposed without damaging its supplying vessels or those of the permanent tracheal stoma. A gastric tube was pulled up via a posterior mediastinal route, and an anastomosis was made between the FJF and gastric tube. Postoperative recovery was uneventful in patient 1. Although minor anastomotic leakage was found in patient 2, it healed immediately with drainage treatment. The surgical approach for these patients must be chosen carefully in order to preserve the FJF, permanent tracheal stoma, and their blood supplies.	[Shiozaki, Atsushi; Fujiwara, Hitoshi; Konishi, Hirotaka; Ishimoto, Takeshi; Morimura, Ryo; Murayama, Yasutoshi; Komatsu, Shuhei; Kuriu, Yoshiaki; Ikoma, Hisashi; Kubota, Takeshi; Nakanishi, Masayoshi; Ichikawa, Daisuke; Okamoto, Kazuma; Sakakura, Chouhei; Otsuji, Eigo] Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kamigyo Ku, Kyoto 6028566, Japan	Shiozaki, A (reprint author), Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	shiozaki@koto.kpu-m.ac.jp					Ferahkose Z, 2008, DIS ESOPHAGUS, V21, P340, DOI 10.1111/j.1442-2050.2007.00781.x; Nakatsuka T, 2003, J RECONSTR MICROSURG, V19, P363, DOI 10.1055/s-2003-42630; Tachimori Y, 2009, J THORAC CARDIOV SUR, V137, P49, DOI 10.1016/j.jtcvs.2008.05.016; Japan Esophageal Society, 2009, ESOPHAGUS, V6, P71, DOI DOI 10.1007/S10388-009-0193-0]; Japanese Esophageal Society, 2009, ESOPHAGUS, V6, P1, DOI DOI 10.1007/S10388-009-0169-0; Nomura T, 2008, HEPATO-GASTROENTEROL, V55, P1622; Shiozaki A, 2012, ESOPHAGUS-TOKYO, V9, P247, DOI 10.1007/s10388-012-0335-7; Shiozaki A, 2012, DIS ESOPHAGUS; Shiozaki A, 2013, ANTICANCER RES, V33, P2577; Shiozaki A, 2012, ESOPHAGUS-TOKYO, V9, P58, DOI 10.1007/s10388-011-0304-6; Shiozaki A, 2013, MOL CLIN ONCOL; The Japan Society for Esophageal Disease, 2002, COMPR REG ES CANC JA, V3rd; Ueda Y, 2009, GEN THORAC CARDIOVAS, V57, P488; Watanabe M, 2013, DIS ESOPHAGUS	14	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					267	271		10.1007/s10388-014-0426-8		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800009		
J	Mori, N; Fujita, H; Tanaka, T; Matono, S; Nishimura, K; Hino, H; Shirouzu, K; Sueyoshi, S				Mori, Naoki; Fujita, Hiromasa; Tanaka, Toshiaki; Matono, Satoru; Nishimura, Kohei; Hino, Haruhiro; Shirouzu, Kazuo; Sueyoshi, Susumu			Gastropericardial fistula in the gastric tube after esophagectomy for cancer	ESOPHAGUS			English	Article						Gastropericardial fistula; Gastric tube ulcer; Esophagectomy for cancer	HELICOBACTER-PYLORI INFECTION; POSTOPERATIVE RADIOTHERAPY; REPLACEMENT; SUBSTITUTE; MANAGEMENT; ACIDITY; ULCER	A 54-year-old man was admitted at our hospital with a complaint of sudden anterior chest pain. At 1 year previously he had undergone right transthoracic esophagectomy for cancer followed by reconstruction using a gastric tube through a posterior mediastinal route. Upper gastrointestinal endoscopy confirmed a gastropericardial fistula. He was therefore given emergency intensive proton pump inhibitor together with gastric tube decompression using a nasogastric tube. Transabdominal pericardial drainage was surgically performed through a retrosternal space at 4 days after the onset. On the 22nd day after the drainage operation, upper gastrointestinal endoscopy showed healing of the gastropericardial fistula, and he was discharged on the 38th postoperative day. A gastropericardial fistula in the gastric tube following esophagectomy for cancer could be treated with less-invasive procedures including surgical pericardial drainage. Our procedure may be recommended as initial emergency treatment before more invasive procedures such as gastric tube resection and muscle flap plombage.	[Mori, Naoki; Fujita, Hiromasa; Tanaka, Toshiaki; Matono, Satoru; Nishimura, Kohei; Hino, Haruhiro; Shirouzu, Kazuo] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 8300011, Japan; [Sueyoshi, Susumu] Omuta City Hosp, Dept Surg, Omuta, Japan	Mori, N (reprint author), Kurume Univ, Sch Med, Dept Surg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	mori1118@med.kurume-u.ac.jp					FOK M, 1993, SURGERY, V113, P138; Asaka M, 2010, HELICOBACTER, V15, P1, DOI 10.1111/j.1523-5378.2009.00738.x; Gutschow C, 2001, ANN SURG, V233, P509, DOI 10.1097/00000658-200104000-00005; Chey WD, 2007, AM J GASTROENTEROL, V102, P1808, DOI 10.1111/j.1572-0241.2007.01393.x; Kato T, 2010, WORLD J EMERG SURG, V5, DOI 10.1186/1749-7922-5-20; Kim WJ, 2011, ANN THORAC SURG, V91, pE10, DOI 10.1016/j.athoracsur.2010.09.082; Koide N, 2001, J GASTROEN HEPATOL, V16, P137, DOI 10.1046/j.1440-1746.2001.02415.x; Matsubara Toshiki, 2002, Eur J Cardiothorac Surg, V22, P1007, DOI 10.1016/S1010-7940(02)00564-X; Mori N, 2007, DIS ESOPHAGUS, V20, P333, DOI 10.1111/j.1442-2050.2007.00718.x; Motoyama S, 2003, HEPATO-GASTROENTEROL, V50, P666; SHIMA I, 1991, JPN J SURG, V21, P96, DOI 10.1007/BF02470872; Ubukata H, 2011, SURG TODAY, V41, P612, DOI 10.1007/s00595-010-4476-9; UCHIDA Y, 1987, JPN J SURG, V17, P190, DOI 10.1007/BF02470598; van der Velden APS, 2007, J SURG ONCOL, V95, P79, DOI 10.1002/jso.20432; Yamaguchi H, 2011, ESOPHAGUS-TOKYO, V8, P137, DOI 10.1007/s10388-011-0275-7	15	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					272	276		10.1007/s10388-014-0438-4		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800010		
J	Yoshida, T; Tangoku, A; Furukita, Y; Nishino, T; Takechi, H; Kawakami, Y; Morishita, A; Morimoto, M; Fujiwara, S; Inoue, S; Minato, T; Goto, M; Yamamoto, Y; Yuasa, Y; Yamai, H; Seike, J; Miyoshi, T				Yoshida, Takahiro; Tangoku, Akira; Furukita, Yoshihito; Nishino, Takeshi; Takechi, Hirokazu; Kawakami, Yukikiyo; Morishita, Atsushi; Morimoto, Masami; Fujiwara, Satoshi; Inoue, Seiya; Minato, Takuya; Goto, Masakazu; Yamamoto, Yota; Yuasa, Yasuhiro; Yamai, Hiromichi; Seike, Junichi; Miyoshi, Takanori			Long-term survival for advanced esophageal cancer patients with an esophago-bronchial fistula can be achieved by timely multimodality therapy	ESOPHAGUS			English	Article						Advanced esophageal cancer; Esophago-bronchial fistula; Multimodality therapy; Chemotherapy; Chemoradiotherapy; Bypass operation	SQUAMOUS-CELL CARCINOMA; EXPANDABLE METALLIC STENTS; ESOPHAGORESPIRATORY FISTULAS; THORACIC ESOPHAGUS; BYPASS OPERATION; GASTRIC TUBE; CHEMORADIOTHERAPY; PALLIATION; AIRWAY; 5-FLUOROURACIL	We reported four consecutive advanced esophageal cancer patients with esophago-bronchial fistula (EBF) who were managed well and achieved long-term survival with timely multimodality therapy including bypass operation. Eighty-four patients with esophageal cancer located in the upper or middle esophagus who were treated in our institute from 2005 to 2013 were diagnosed with cT4 at the time of admission. Eight (9.5 %) of those 84 cT4 patients developed the esophago-bronchial/tracheal fistula. Out of eight patients, four (50 %) who responded to prior chemotherapy or chemoradiotherapy received esophageal bypass operations to manage their QOL and continue the following therapy. Not only nutrition and quality of life but also fighting spirit were maintained by allowing oral intake and resulted in completion of postoperative chemoradiotherapy in all 4 patients. Multimodality treatment including a bypass operation provided high QOL and long-term survival even in advanced esophageal cancer patients with EBFs.	[Yoshida, Takahiro; Tangoku, Akira; Furukita, Yoshihito; Nishino, Takeshi; Takechi, Hirokazu; Kawakami, Yukikiyo; Morishita, Atsushi; Morimoto, Masami; Fujiwara, Satoshi; Inoue, Seiya; Minato, Takuya; Goto, Masakazu; Yamamoto, Yota; Yuasa, Yasuhiro; Yamai, Hiromichi; Seike, Junichi; Miyoshi, Takanori] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Thorac Endocrine Surg & Oncol, Tokushima, Tokushima 7708503, Japan	Tangoku, A (reprint author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Thorac Endocrine Surg & Oncol, 3-18-15 Kuramoto Cho, Tokushima, Tokushima 7708503, Japan.	tangoku@clin.med.tokushima-u.ac.jp			JSPS KAKENHI [24591945]	The authors are sincerely grateful to the staff of the Department of Radiology in our university hospital for radiotherapy in the multimodality treatments. This work was partially supported by JSPS KAKENHI Grant Number 24591945.	Minato T, 2013, ANN SURG ONCOL, V20, P209, DOI 10.1245/s10434-012-2535-8; Dobrucali A, 2010, WORLD J GASTROENTERO, V16, P5739, DOI 10.3748/wjg.v16.i45.5739; Herth FJF, 2010, EUR RESPIR J, V36, P1370, DOI 10.1183/09031936.00049809; White RE, 2009, LANCET ONCOL, V10, P240, DOI 10.1016/S1470-2045(09)70004-X; FUJITA H, 1995, ANN SURG, V222, P654, DOI 10.1097/00000658-199511000-00008; Aoki T, 2001, DIS ESOPHAGUS, V14, P208, DOI 10.1046/j.1442-2050.2001.00186.x; Kato K, 2011, INT J RADIAT ONCOL, V81, P684, DOI 10.1016/j.ijrobp.2010.06.033; Balazs A, 2008, EUR J CARDIO-THORAC, V34, P1103, DOI 10.1016/j.ejcts.2008.06.025; MANNELL A, 1988, BRIT J SURG, V75, P283, DOI 10.1002/bjs.1800750332; MARTINI N, 1970, J THORAC CARDIOV SUR, V59, P319; Lecleire S, 2006, ALIMENT PHARM THERAP, V23, P1693, DOI 10.1111/j.1365-2036.2006.02946.x; Yamamoto Y, 2012, ANN SURG ONCOL, V19, P757, DOI 10.1245/s10434-011-2071-y; Aoki Y, 2012, SURG TODAY, V42, P1088, DOI 10.1007/s00595-012-0323-5; BOYCE HW, 1984, SEMIN ONCOL, V11, P186; Chen YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042766; Forni E, 1984, Chir Ital, V36, P760; Hamai Y, 2011, SURG TODAY, V41, P560, DOI 10.1007/s00595-009-4298-9; Hamai Y, 2012, ANTICANCER RES, V32, P1785; Hanagiri T, 2011, INT SURG, V96, P189; HIRAI T, 1989, JPN J SURG, V19, P182, DOI 10.1007/BF02471583; Japanese Society for Esophageal Disease, 2008, JAP CLASS ES CANC; Lacerda CF, 2010, BRAS J VIDEO SUR, V34, P191; LORENTZ T, 1989, WORLD J SURG, V13, P472; Meunier B, 1996, ANN THORAC SURG, V62, P373, DOI 10.1016/0003-4975(96)00236-6; Miyata T, 2013, ESOPHAGUS-TOKYO, V10, P27, DOI 10.1007/s10388-012-0338-4; Mroz RM, 2008, J PHYSIOL PHARMACOL, V59, P491; Nishimura Y, 2003, INT J RADIAT ONCOL, V56, P1327, DOI 10.1016/S0360-3016(03)00198-6; ORRINGER MB, 1975, J THORAC CARDIOV SUR, V70, P836; POSTLETHWAIT RW, 1979, ANN SURG, V189, P673, DOI 10.1097/00000658-197906000-00001; Seto Y, 2007, AM J SURG, V193, P192; Sumiyoshi T, 2003, GASTROINTEST ENDOSC, V57, P882, DOI 10.1067/mge.2003.234; Tachibana M, 2002, DYSPHAGIA, V17, P255, DOI 10.1007/s00455-002-0069-9; Whooley BP, 2002, ARCH SURG-CHICAGO, V137, P1228, DOI 10.1001/archsurg.137.11.1228; Yoshida T, 2010, ESOPHAGUS-TOKYO, V7, P95, DOI 10.1007/s10388-010-0234-8	34	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					277	285		10.1007/s10388-014-0435-7		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800011		
J	Asaumi, Y; Miyanaga, T; Matsunaga, M; Sawada, K; Hashizume, Y; Tamamura, Y				Asaumi, Yoshihide; Miyanaga, Tamon; Matsunaga, Masashi; Sawada, Koichiro; Hashizume, Yasuo; Tamamura, Yasuhiro			Hyperbaric oxygen therapy for bleeding due to gastritis induced by chemoradiotherapy for regional recurrence of esophageal cancer post-radical esophagectomy	ESOPHAGUS			English	Article						Hyperbaric oxygen therapy; Radiation gastritis; Esophageal cancer; Recurrence after radical esophagectomy	RADIATION-INDUCED GASTRITIS; ARGON PLASMA COAGULATION; NORMAL TISSUE; RADIOTHERAPY	Chemoradiotherapy is effective for locoregional recurrence of esophageal cancer after esophagectomy, although it is important to watch out for adverse events, especially following the late phase. We encountered a patient with bleeding from the gastric conduit caused by chemoradiation-induced gastritis after chemoradiotherapy for mediastinal lymph node recurrence post-radical esophagectomy for esophageal cancer. A 58-year-old male was undergoing chemoradiotherapy for mediastinal lymph node recurrence. About 3 months after the start of the therapy, the patient presented with anemia and bleeding from the gastric conduit caused by chemoradiation-induced gastritis as assessed by fiber optic upper gastrointestinal endoscopy and blood examination. Multiple sessions of argon plasma coagulation for ablation of the gastric mucosal telangiectasia proved ineffective. However, hyperbaric oxygen therapy was effective and the symptom has not recurred until date after this therapy.	[Asaumi, Yoshihide; Miyanaga, Tamon; Matsunaga, Masashi; Sawada, Koichiro; Hashizume, Yasuo] Fukui Prefectural Hosp, Dept Surg, Fukui, Fukui 9108526, Japan; [Tamamura, Yasuhiro] Fukui Prefectural Hosp, Dept Radiol, Fukui, Fukui 9108526, Japan	Asaumi, Y (reprint author), Fukui Prefectural Hosp, Dept Surg, 2-8-1 Yotsui, Fukui, Fukui 9108526, Japan.	yasaumi@hb.tp1.jp					Maruyama K, 2011, DIS ESOPHAGUS, V24, P166, DOI 10.1111/j.1442-2050.2010.01119.x; MARX RE, 1987, ORAL SURG ORAL MED O, V64, P379, DOI 10.1016/0030-4220(87)90136-8; Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4; AlSarraf M, 1997, J CLIN ONCOL, V15, P277; Zhang L, 2012, WORLD J GASTROENTERO, V18, P7402, DOI 10.3748/wjg.v18.i48.7402; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109; Kantsevoy SV, 2003, GASTROINTEST ENDOSC, V57, P403, DOI 10.1067/mge.2003.115; Kemp H, 2005, ANN THORAC SURG, V80, P1115; Kernstine KH, 1997, DIGEST DIS SCI, V42, P982; Marshall GT, 2007, UNDERSEA HYPERBAR M, V34, P35; Morrow JB, 2000, GASTROINTEST ENDOSC, V51, P498, DOI 10.1016/S0016-5107(00)70460-3; Shukuwa K, 2007, INTERNAL MED, V46, P975, DOI 10.2169/internalmedicine.46.0076; Wada S, 2003, J GASTROEN HEPATOL, V18, P1215, DOI 10.1046/j.1440-1746.2003.03149.x; Yamashita H, 2005, DIS ESOPHAGUS, V18, P215, DOI 10.1111/j.1442-2050.2005.00502.x; Yeung YP, 2000, HEAD NECK-J SCI SPEC, V22, P303, DOI 10.1002/(SICI)1097-0347(200005)22:3<303::AID-HED15>3.0.CO;2-U	15	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					286	289		10.1007/s10388-014-0437-5		4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800012		
J	Shimada, Y; Okumura, T; Hashimoto, I; Nagata, T; Tsukada, K				Shimada, Yutaka; Okumura, Tomoyuki; Hashimoto, Isaya; Nagata, Takuya; Tsukada, Kazuhiro			Left brachiocephalic vein injury during esophagectomy	ESOPHAGUS			English	Article						Retrosternal space; Esophageal resection; Left brachiocephalic vein injury; Damage control surgery; Two-stage surgery	MANAGEMENT	Left brachiocephalic vein injury has not yet been reported during reconstruction after esophagectomy. A 58-year-old male patient was diagnosed with cervical esophageal squamous cell carcinoma and subsequently underwent subtotal esophagectomy followed by neo-adjuvant chemotherapy. The left brachiocephalic vein was accidentally injured when making a retrosternal space. The brachiocephalic vein was ligated followed by rapid sternotomy, and cervical esophagostomy without tumor resection and jejunostomy were performed for damage control. Complete resection of the cervical esophageal tumor and free jejunal transplantation for reconstruction were performed 55 days after the initial surgery. The patient is now well and has survived for more than 34 months after the reconstruction. Surgeons should consider left brachiocephalic vein injury when making a retrosternal space. Damage control surgery and preparation for a second surgery may be important in cases of accidental major vascular injury during esophagectomy.	[Shimada, Yutaka; Okumura, Tomoyuki; Hashimoto, Isaya; Nagata, Takuya; Tsukada, Kazuhiro] Toyama Univ, Grad Sch Med & Pharmaceut Sci Res, Dept Surg & Sci, Toyama 9300194, Japan; [Shimada, Yutaka] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Nanobio Drug Discovery, Sakyo Ku, Kyoto 6068501, Japan	Shimada, Y (reprint author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Nanobio Drug Discovery, Sakyo Ku, Yoshida Shimoadachi Cho 46-29, Kyoto 6068501, Japan.	yshimada@pharm.kyoto-u.ac.jp					Baumgartner FJ, 1999, TEX HEART I J, V26, P177; HINES GL, 1981, J CARDIOVASC SURG, V22, P349; Nair R, 2000, EUR J VASC ENDOVASC, V19, P65, DOI 10.1053/ejvs.1999.0965; ROBBS JV, 1987, SURG GYNECOL OBSTET, V165, P323; Tachimori Y, 2014, ESOPHAGUS-TOKYO, V11, P21, DOI 10.1007/s10388-013-0393-5	5	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					290	294		10.1007/s10388-014-0439-3		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800013		
J	Fukuchi, M; Sakurai, S; Tsukagoshi, R; Naitoh, H; Kuwano, H				Fukuchi, Minoru; Sakurai, Shinji; Tsukagoshi, Ritsuko; Naitoh, Hiroshi; Kuwano, Hiroyuki			A case of large cell neuroendocrine carcinoma of the esophagogastric junction	ESOPHAGUS			English	Article						Large cell neuroendocrine carcinoma; Esophagogastric junction; Chemotherapy	LUNG-CANCER; GASTRIC-CANCER; CLINICOPATHOLOGICAL FEATURES; TUMORS; CHEMOTHERAPY; METAANALYSIS; PROGNOSIS; SURGERY; STOMACH; ENTITY	Neuroendocrine carcinoma of the upper gastrointestinal tract is an uncommon disease that manifests as a highly malignant tumor. We herein report a rare case of large cell neuroendocrine carcinoma of the esophagogastric junction treated with surgery and chemotherapy. A 65-year-old Japanese man was admitted to our hospital for treatment of a tumor of the esophagogastric junction detected by endoscopic examination. Biopsy specimens demonstrated large cell neuroendocrine carcinoma with highly frequent mitoses and positivity for synaptophysin, chromogranin A, and CD56. Computed tomography indicated at least three lymphadenopathies of the left and right cardiac nodes. We performed distal esophagectomy, total gastrectomy and pancreatosplenectomy, and subsequent S-1 adjuvant chemotherapy, but the patient died of liver metastasis 9 months after the surgery. Based on the outcome of the present case, this disease demands establishment of multimodal treatment that includes surgery and chemotherapy.	[Fukuchi, Minoru; Tsukagoshi, Ritsuko; Naitoh, Hiroshi] Gunma Chuo Hosp, Dept Surg, Gunma 3710025, Japan; [Sakurai, Shinji] Gunma Chuo Hosp, Dept Diagnost Pathol, Maebashi, Gumma 3710025, Japan; [Kuwano, Hiroyuki] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gumma 3718511, Japan	Fukuchi, M (reprint author), Gunma Chuo Hosp, Dept Surg, 1-7-13 Kouun Cho, Gunma 3710025, Japan.	mfukuchi@saitama-med.ac.jp					Tsuchiya R, 2005, J THORAC CARDIOV SUR, V129, P977, DOI 10.1016/j.jtcvs.2004.05.030; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; Kalemkerian GP, 2013, J NATL COMPR CANC NE, V11, P78; Rindi G, 1996, WORLD J SURG, V20, P168; Asamura H, 2006, J CLIN ONCOL, V24, P70, DOI 10.1200/JCO.2005.04.1202; Klimstra DS, 2010, PANCREAS, V39, P707, DOI 10.1097/MPA.0b013e3181ec124e; Shia J, 2008, AM J SURG PATHOL, V32, P719, DOI 10.1097/PAS.0b013e318159371c; Ishida M, 2013, AM J SURG PATHOL, V37, P949, DOI 10.1097/PAS.0b013e31828ff59d; Jiang JW, 2010, J THORAC ONCOL, V5, P867; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Jiang SX, 2006, AM J SURG PATHOL, V30, P945, DOI 10.1097/00000478-200608000-00003; Badzio A, 2004, EUR J CARDIO-THORAC, V26, P183, DOI 10.1016/j.ejcts.2004.04.012; Maehara Y, 2000, SURGERY, V128, P408, DOI 10.1067/msy.2000.107265; Matsui K, 1998, ARCH PATHOL LAB MED, V122, P1010; Bosman FT, 2010, WHO CLASSIFICATION T, P13; Eba J, 2014, JPN J CLIN ONCOL, V44, P379, DOI 10.1093/jjco/hyt233; Ishida M, 2012, J GASTROINTEST SURG, V16, P837, DOI 10.1007/s11605-011-1800-7; Japan Esophageal Society, 2009, ESOPHAGUS, V6, P71, DOI DOI 10.1007/S10388-009-0193-0]; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Katai Hitoshi, 1994, Digestive Surgery, V11, P99, DOI 10.1159/000172232; Maehara Y, 1996, BRIT J CANCER, V74, P975, DOI 10.1038/bjc.1996.468; Maru DM, 2008, AM J SURG PATHOL, V32, P1404, DOI 10.1097/PAS.0b013e31816bf41f; Namikawa Tsutomu, 2005, Medical Molecular Morphology, V38, P256, DOI 10.1007/s00795-005-0293-4; Okamoto H, 2012, JPN J GASTROENTEROL, V45, P914; Okita NT, 2011, GASTRIC CANCER, V14, P161, DOI 10.1007/s10120-011-0025-5; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Veits L, 2013, ENDOSCOPY, V45, P16	28	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					295	299		10.1007/s10388-014-0443-7		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800014		
J	Matsuda, Y; Kishida, S; Miyamoto, H; Lee, S; Okawa, M; Fujiwara, Y; Hashiba, R; Edagawa, E; Tanaka, S; Osawa, M; Osugi, H				Matsuda, Yasunori; Kishida, Satoru; Miyamoto, Hikaru; Lee, Shigeru; Okawa, Masato; Fujiwara, Yushi; Hashiba, Ryoya; Edagawa, Eijiro; Tanaka, Sayaka; Osawa, Masahiko; Osugi, Harushi			Cytomegalovirus-associated ulceration of gastric conduit after chemoradiotherapy following esophagectomy for cancer	ESOPHAGUS			English	Article						Cytomegalovirus; Gastric conduit; Radical esophagectomy; Ulceration	IMMUNOCOMPROMISED PATIENTS; DISEASE; TRANSPLANTATION; GANCICLOVIR; PREVENTION; INFECTION; HOST	A 64-year-old man underwent radical esophagectomy for cancer and simultaneous reconstruction using the gastric conduit through the posterior mediastinum. Two courses of adjuvant chemotherapy were performed. Twenty-eight months postoperatively, recurrence of the cancer was detected in the mediastinal lymph nodes, and he underwent concurrent chemoradiotherapy and boost chemotherapy. Endoscopy was then performed to investigate the cause of epigastralgia, and multiple ulcerations were found in the lesser curvature of the gastric conduit. Although a proton-pump inhibitor was orally administered, the ulceration was intractable. Re-examination of the original biopsy specimens and serological testing revealed positivity for cytomegalovirus. The ulcers began to heal after administration of foscarnet sodium. After the treatment, no signs of exacerbation associated with reinstitution of chemotherapy were observed.	[Matsuda, Yasunori; Kishida, Satoru; Miyamoto, Hikaru; Lee, Shigeru; Okawa, Masato; Fujiwara, Yushi; Hashiba, Ryoya; Edagawa, Eijiro; Osugi, Harushi] Osaka City Univ, Grad Sch Med, Dept Surg Gastroenterol, Abeno Ku, Osaka 5458585, Japan; [Tanaka, Sayaka; Osawa, Masahiko] Osaka City Univ, Grad Sch Med, Dept Diagnost Pathol, Osaka 5458585, Japan	Matsuda, Y (reprint author), Osaka City Univ, Grad Sch Med, Dept Surg Gastroenterol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	m1293311@msic.med.osaka-cu.ac.jp					Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; COHEN JI, 1985, MEDICINE, V64, P100; GOODRICH JM, 1993, ANN INTERN MED, V118, P173; [Anonymous], 2007, TREAT GUIDEL MED LET, V5, P59; Gandhi MK, 2004, LANCET INFECT DIS, V4, P725, DOI 10.1016/S1473-3099(04)01202-2; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095; Broers AEC, 2000, BLOOD, V95, P2240; AYULO M, 1980, JAMA-J AM MED ASSOC, V243, P1364, DOI 10.1001/jama.243.13.1364; CHETTY R, 1994, J CLIN PATHOL, V47, P968, DOI 10.1136/jcp.47.11.968; DIETERICH DT, 1987, AM J GASTROENTEROL, V82, P764; Kotton CN, 2013, TRANSPLANTATION, V96, P333, DOI 10.1097/TP.0b013e31829df29d; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; WAGSTAFF AJ, 1994, DRUGS, V48, P199, DOI 10.2165/00003495-199448020-00007; WIRGART BZ, 1990, J VIROL METHODS, V27, P211, DOI 10.1016/0166-0934(90)90137-5	15	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					300	303		10.1007/s10388-014-0441-9		4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800015		
J	Shichinohe, T; Ebihara, Y; Murakami, S; Kurashima, Y; Kuramae, T; Kanai, M; Matsumoto, J; Tsuchikawa, T; Kusano, M; Hirano, S				Shichinohe, Toshiaki; Ebihara, Yuma; Murakami, Soichi; Kurashima, Yo; Kuramae, Taro; Kanai, Motoshi; Matsumoto, Joe; Tsuchikawa, Takahiro; Kusano, Masanobu; Hirano, Satoshi			Septic shock-related acute esophageal necrosis and stenosis: three cases of acquired esophageal stenosis presenting a similar clinical course	ESOPHAGUS			English	Article						Acute esophageal necrosis; Stenosis; Septic shock; Septic shock-related esophageal stenosis; Septic esophageal stenosis	BLACK ESOPHAGUS	We present a case of acute esophageal necrosis (AEN) and two acquired esophageal stenosis cases which showed a similar clinical course after an episode of septic shock. Extensive stenosis of the distal esophagus developed in all cases, which were refractory to dilation therapy and required surgical intervention. The etiology of the latter two cases was deduced from the stenosis after septic shock-induced AEN. Since the diagnosis of AEN is based on its characteristic endoscopic findings which can only be confirmed at the onset of the disease, we therefore called these cases "septic shock-related esophageal stenosis" or abbreviated to "septic esophageal stenosis". Further study of similar cases is required for understanding the etiology and management of AEN and the relevant disorder which may cause esophageal stenosis.	[Shichinohe, Toshiaki; Ebihara, Yuma; Murakami, Soichi; Kurashima, Yo; Kuramae, Taro; Kanai, Motoshi; Matsumoto, Joe; Tsuchikawa, Takahiro; Hirano, Satoshi] Hokkaido Univ, Grad Sch Med, Dept Surg Gastroenterol 2, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Kusano, Masanobu] Otaru Kyokai Hosp, Dept Surg, Otaru, Hokkaido 0470261, Japan	Shichinohe, T (reprint author), Hokkaido Univ, Grad Sch Med, Dept Surg Gastroenterol 2, Kita Ku, West 7,North 15, Sapporo, Hokkaido 0608638, Japan.	shichino@med.hokudai.ac.jp					Spechler SJ, 1999, GASTROENTEROLOGY, V117, P229, DOI 10.1016/S0016-5085(99)70572-X; Gurvits GE, 2007, J GASTROENTEROL, V42, P29, DOI 10.1007/s00535-006-1974-z; GOLDENBERG SP, 1990, GASTROENTEROLOGY, V98, P493; Gurvits GE, 2010, WORLD J GASTROENTERO, V16, P3219, DOI 10.3748/wjg.v16.i26.3219; Kim YH, 2007, WORLD J GASTROENTERO, V13, P5662; Ribeiro U, 1996, BRIT J SURG, V83, P1174, DOI 10.1046/j.1365-2168.1996.02421.x	6	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					304	308		10.1007/s10388-014-0447-3		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800016		
J	Fujiwara, Y; Osugi, H; Lee, S; Kishida, S; Hashiba, R; Matsuda, Y; Edagawa, E				Fujiwara, Yushi; Osugi, Harushi; Lee, Shigeru; Kishida, Satoru; Hashiba, Ryoya; Matsuda, Yasunori; Edagawa, Eijiro			Attention to anomalies of the right pulmonary vein in subcarinal lymph node dissection in radical esophagectomy for cancer	ESOPHAGUS			English	Article						Esophagectomy; Lymph node dissection; Pulmonary vein anomaly	BRONCHUS INTERMEDIUS; POSTERIOR	Here, we report on an anomaly of the right pulmonary vein in the subcarinal area and emphasis the importance of its focus in subcarinal lymph node dissection. A 51-year-old Japanese man underwent thoracoscopic radical esophagectomy with regional lymph node dissection for esophageal carcinoma T1bN1M0, stage IIB. While dissecting the subcarinal lymph node, we encountered a thick vein crossing posterior to the intermediate right bronchus. We recognized the anomalous right pulmonary vein (anomalous V2) that drained into the left atrium from the right posterior segment (S2). We cautiously dissected the subcarinal lymph node and were able to preserve the anomalous vein. This anomalous pulmonary vein can cause serious complications. If the anomalous V2 had been injured or ligated, congestion of the right S2 or cardiac tamponade might have develop. Since anomalous pulmonary veins are easily identified by enhanced computed tomography, careful observation is essential for avoiding their unnecessary injury.	[Fujiwara, Yushi; Osugi, Harushi; Lee, Shigeru; Kishida, Satoru; Hashiba, Ryoya; Matsuda, Yasunori; Edagawa, Eijiro] Osaka City Univ, Grad Sch Med, Dept Surg Gastroenterol, Abeno Ku, Osaka 5458585, Japan	Fujiwara, Y (reprint author), Osaka City Univ, Grad Sch Med, Dept Surg Gastroenterol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	fujiwaray@msic.med.osaka-cu.ac.jp					Akiba T, 2013, ANN THORAC SURG, V95, P1227, DOI 10.1016/j.athoracsur.2013.01.011; Akiba Tadashi, 2010, Gen Thorac Cardiovasc Surg, V58, P331, DOI 10.1007/s11748-010-0592-0; Asai K, 2005, ANN THORAC SURG, V79, P1866, DOI 10.1016/j.athoracsur.2004.12.014; KIM JS, 1995, AM J ROENTGENOL, V165, P1349; Matsubara T, 2003, ANN THORAC SURG, V75, P1026, DOI 10.1016/S0003-4975(02)03980-2; Osugi Harushi, 2005, Ann Thorac Cardiovasc Surg, V11, P221; Yamada S, 2010, INTERACT CARDIOV TH, V10, P851, DOI 10.1510/icvts.2009.221804	7	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					309	311		10.1007/s10388-014-0445-5		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800017		
J	Shibata, T; Noguchi, T; Etoh, T; Inomata, M; Shiraishi, N; Hongo, T; Hirota, J; Miyamoto, S; Kitano, S				Shibata, Tomotaka; Noguchi, Tsuyoshi; Etoh, Tsuyoshi; Inomata, Masafumi; Shiraishi, Norio; Hongo, Tetsuo; Hirota, Jun; Miyamoto, Shinji; Kitano, Seigo			Successful salvage lymphadenectomy after stent grafting for aortic lymph node recurrence of thoracic esophageal carcinoma: a first case report	ESOPHAGUS			English	Article						Esophageal cancer; Salvage surgery; Stent	CANCER; REPAIR	In advanced esophageal carcinoma, aortic complications can be fatal. Here, we report our experience with a patient undergoing salvage lymphadenectomy after preoperative aortic stent grafting for paraaortic lymph node recurrence for esophageal carcinoma. The patient was a 54-year-old man, who underwent subtotal esophagectomy for thoracic esophageal carcinoma. Computed tomography performed 12 months after the initial surgery revealed lymphadenopathy on the left side of the thoracic aorta and radiotherapy was performed for lymph node recurrence. FDG-PET performed after radiotherapy revealed slight growth of the lymph node involvement and an accumulation of FDG. We decided to insert a stent graft into the aorta at the site of tumor invasion before surgery to ensure safety. The tumor was sharply dissected and excised with Cooper's scissors after the aorta had been taped at the levels upstream and downstream from the tumor. After surgery, chylothorax was observed, but resolved with conservative treatment. The patient was discharged 30 days after surgery.	[Shibata, Tomotaka; Etoh, Tsuyoshi; Inomata, Masafumi] Oita Univ, Fac Med, Dept Gastroenterol & Pediat Surg, Oita 8795593, Japan; [Noguchi, Tsuyoshi; Shiraishi, Norio] Oita Univ, Fac Med, Ctr Community Med, Oita 8795593, Japan; [Hongo, Tetsuo] Oita Univ, Fac Med, Dept Radiol, Oita 8795593, Japan; [Hirota, Jun; Miyamoto, Shinji] Oita Univ, Fac Med, Dept Cardiovasc Surg, Oita 8795593, Japan; [Kitano, Seigo] Oita Univ, Oita 8795593, Japan	Shibata, T (reprint author), Oita Univ, Fac Med, Dept Gastroenterol & Pediat Surg, Idaigaoka 1-1,Hasama Machi, Oita 8795593, Japan.	shiba@oita-u.ac.jp					Nienaber CA, 2009, CIRCULATION, V120, P2519, DOI 10.1161/CIRCULATIONAHA.109.886408; Canaud L, 2014, J VASC SURG, V59, P248, DOI 10.1016/j.jvs.2013.07.117; Morita M, 2011, J GASTROENTEROL, V46, P1284, DOI 10.1007/s00535-011-0448-0; Dake MD, 1999, NEW ENGL J MED, V340, P1546, DOI 10.1056/NEJM199905203402004; Ichiyoshi Y, 1999, Jpn J Thorac Cardiovasc Surg, V47, P318; Kabuto T, 1999, Jpn J Thorac Cardiovasc Surg, V47, P611; Kato H, 2005, ANTICANCER RES, V25, P3461; Kubota Suguru, 2013, Gen Thorac Cardiovasc Surg, V61, P560, DOI 10.1007/s11748-013-0280-y; Matono S, 2011, DIS ESOPHAGUS, V24, pE36, DOI 10.1111/j.1442-2050.2011.01234.x; The Japan Esophageal Society, 2008, JAP CLASS ES CANC; Watanabe Y, 1999, Jpn J Thorac Cardiovasc Surg, V47, P495	11	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					312	315		10.1007/s10388-014-0448-2		4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800018		
J	Watanabe, Y; Sato, H; Takase, K; Takeshita, H; Sakuramoto, S; Niihara, M; Tsubosa, Y; Koyama, I				Watanabe, Yukihiro; Sato, Hiroshi; Takase, Kenichiro; Takeshita, Hiroki; Sakuramoto, Shinichi; Niihara, Masahiro; Tsubosa, Yasuhiro; Koyama, Isamu			Esophageal bypass in two patients with a complete response after definitive chemoradiotherapy for thoracic esophageal cancer	ESOPHAGUS			English	Article						Esophageal bypass; Chemoradiotherapy; Esophageal cancer	SQUAMOUS-CELL CARCINOMA; GASTRIC TUBE; THERAPY; STENTS; TRIAL; CHEMOTHERAPY; PALLIATION; CISPLATIN; OPERATION; NUTRITION	Esophageal bypass is a palliative operation for patients with unresectable esophageal cancer and impaired oral intake. This method is recently used to treat complications such as stenosis associated with esophageal cancer or esophagorespiratory fistula after chemoradiotherapy (CRT). However, its outcome has not been evaluated. We describe the effectiveness of esophageal bypass after CRT in two patients with a complete response (CR) but marked deterioration of quality of life due to esophageal stenosis after definitive CRT. The first patient had metastases in the right recurrent nerve lymph nodes and refused to undergo radical resection. The second patient had unresectable esophageal cancer due to invasion into the right subclavian artery. Both patients responded to esophageal bypass with good oral intake and without relapse. These two cases demonstrate that esophageal bypass can be a good, low-invasive surgical option for patients with CR but with esophageal stenosis after definitive CRT.	[Watanabe, Yukihiro; Sato, Hiroshi; Takase, Kenichiro; Takeshita, Hiroki; Sakuramoto, Shinichi; Niihara, Masahiro; Tsubosa, Yasuhiro; Koyama, Isamu] Saitama Med Univ, Int Med Ctr, Gastrointestinal Ctr, Saitama 3501298, Japan	Watanabe, Y (reprint author), Saitama Med Univ, Int Med Ctr, Gastrointestinal Ctr, 1397-1 Yamane, Saitama 3501298, Japan.	watanb@saitama-med.ac.jp					Ohtsu A, 1999, J CLIN ONCOL, V17, P2915; Kinsman KJ, 1996, GASTROINTEST ENDOSC, V43, P196; White RE, 2009, LANCET ONCOL, V10, P240, DOI 10.1016/S1470-2045(09)70004-X; IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172; Seto Y, 2007, AM J SURG, V193, P792, DOI 10.1016/j.amjsurg.2006.07.023; Koretz RL, 2007, AM J GASTROENTEROL, V102, P412, DOI 10.1111/j.1572-0241.2006.01024.x; Yamasaki M, 2011, ONCOLOGY-BASEL, V80, P307, DOI 10.1159/000329806; Bethge N, 1996, GASTROINTEST ENDOSC, V44, P283, DOI 10.1016/S0016-5107(96)70165-7; CHUNG SCS, 1994, LANCET, V343, P521, DOI 10.1016/S0140-6736(94)91467-2; HEIMLICH HJ, 1955, SURGERY, V37, P549; Meunier B, 1996, ANN THORAC SURG, V62, P373, DOI 10.1016/0003-4975(96)00236-6; ORRINGER MB, 1984, SURGERY, V96, P467; Osaka Y, 2004, ONCOL REP, V12, P1121; POSTLETHWAIT RW, 1979, ANN SURG, V189, P673, DOI 10.1097/00000658-197906000-00001; Radrizzani D, 2006, INTENS CARE MED, V32, P1191, DOI 10.1007/s00134-006-0238-y; SEGALIN A, 1989, ANN THORAC SURG, V48, P267; Tamura S, 2012, ANTICANCER RES, V32, P1404; Urschel JD, 2003, MED SCI MONITOR, V9, P173	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					316	321		10.1007/s10388-014-0449-1		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800019		
J	Bekki, Y; Kimura, Y; Morita, M; Zaitsu, Y; Saeki, H; Okamoto, T; Oki, E; Baba, S; Oda, Y; Maehara, Y				Bekki, Yuki; Kimura, Yasue; Morita, Masaru; Zaitsu, Yoko; Saeki, Hiroshi; Okamoto, Tatsuro; Oki, Eiji; Baba, Shingo; Oda, Yoshinao; Maehara, Yoshihiko			Esophageal cancer associated with bilateral hilar lymphadenopathy caused by sarcoid-like reactions: a report of two cases	ESOPHAGUS			English	Article						Esophageal cancer; Hilar lymphadenopathy; FDG-PET/CT	POSITRON-EMISSION-TOMOGRAPHY; RESPONSE EVALUATION CRITERIA; SQUAMOUS-CELL CARCINOMA; SOLID TUMORS; NEOADJUVANT CHEMORADIOTHERAPY; PET; CHEMOTHERAPY; SURGERY	Hilar lymph node metastasis of esophageal cancer is considered to be a distant metastasis and is not indicated for surgical resection. However, its diagnosis is difficult when accompanied by inflammatory diseases such as sarcoidosis. We report two patients with esophageal cancer accompanied by bilateral hilar lymphadenopathy or accumulation on [F-18]-fluorodeoxyglucose positron emission tomography-computed tomography. The first patient underwent surgery because the enlarged bilateral hilar lymph nodes were considered to be nonmalignant lesions owing to superficial carcinoma and symmetric distribution of the hilar lymph nodes. The second patient received chemotherapy, which caused the main tumor to shrink and decreased [F-18]-fluorodeoxyglucose uptake. However, chemotherapy did not affect the hilar lymphadenopathy, which suggests that it was caused by reactive changes rather than metastasis. In both cases, esophagectomy and histological findings revealed that the hilar nodes were caused by sarcoid-like reactions. These findings profoundly influenced our treatment decisions for these patients.	[Bekki, Yuki; Kimura, Yasue; Morita, Masaru; Zaitsu, Yoko; Saeki, Hiroshi; Okamoto, Tatsuro; Oki, Eiji; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, Fukuoka 8128582, Japan; [Baba, Shingo] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Higashi Ku, Fukuoka 8128582, Japan; [Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan	Morita, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	masarum@surg2.med.kyushu-u.ac.jp					Morita M, 2008, SURGERY, V143, P499, DOI 10.1016/j.surg.2007.12.007; Yanagawa M, 2012, J NUCL MED, V53, P872, DOI 10.2967/jnumed.111.098699; Watanabe M, 2011, DIGESTION, V83, P146, DOI 10.1159/000321797; Baba Y, 2013, SURGERY, V153, P234, DOI 10.1016/j.surg.2012.08.001; Kato H, 2008, ONCOL REP, V20, P857, DOI 10.3892/or_00000083; Parra ER, 2004, PATHOL RES PRACT, V200, P701, DOI 10.1016/j.prp.2004.05.006; Rice TW, 2010, ANN SURG ONCOL, V17, P1721, DOI 10.1245/s10434-010-1024-1; Kato H, 2007, ANTICANCER RES, V27, P2627; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Heinle R, 2014, AUTOIMMUN REV, V13, P383, DOI 10.1016/j.autrev.2014.01.035; BRINCKER H, 1986, CANCER TREAT REV, V13, P147, DOI 10.1016/0305-7372(86)90002-2; Watanabe M, 2013, SURG TODAY, V43, P237, DOI 10.1007/s00595-012-0300-z; Sohda M, 2010, ANN SURG ONCOL, V17, P3181, DOI 10.1245/s10434-010-1177-y; BRINCKER H, 1987, MED PEDIATR ONCOL, V15, P82, DOI 10.1002/mpo.2950150207; Kato H, 2007, DIGEST SURG, V24, P88, DOI 10.1159/000101894; Kato H, 2002, AM J SURG, V184, P279, DOI 10.1016/S0002-9610(02)00932-7; Kato H, 2004, ANTICANCER RES, V24, P4091; Kawada Junji, 2012, Gan To Kagaku Ryoho, V39, P2095; LLOMBART A, 1970, EUR J CANCER, V6, P545, DOI 10.1016/0014-2964(70)90076-9; Minami D, 2013, JPN J CLIN ONCOL, V43, P1110, DOI 10.1093/jjco/hyt123; Sawayama H, 2014, ANN SURG ONCOL, V21, P1756, DOI 10.1245/s10434-013-3371-1; Schauer M, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-15; Sloof GW, 2006, BEST PRACT RES CL GA, V20, P941, DOI 10.1016/j.bpg.2006.04.004; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307; Yoshida N, 2014, DIS ESOPHAGUS, V27, P374, DOI 10.1111/dote.12117	25	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					322	326		10.1007/s10388-014-0454-4		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800020		
J	Fujishima, F; Nakamura, Y; Kasajima, A; Ozawa, Y; Ito, K; Taniuchi, S; Watanabe, M; Asonuma, S; Takubo, K; Sasano, H				Fujishima, Fumiyoshi; Nakamura, Yasuhiro; Kasajima, Atsuko; Ozawa, Yohei; Ito, Ken; Taniuchi, Shinji; Watanabe, Mika; Asonuma, Sho; Takubo, Kaiyo; Sasano, Hironobu			Adenocarcinoma in the squamous-lined esophagus without Barrett's mucosa, probably arising from esophageal gland duct	ESOPHAGUS			English	Article						Esophagus; Adenocarcinoma; Immunohistochemistry	ESOPHAGOGASTRIC JUNCTION; ADENOMA; JAPAN	Endoscopic mucosal resection (EMR) was performed for submucosal tumor (SMT)-like lesion of esophagogastric junction in an 81-year-old male. Histopathological findings revealed the presence of adenocarcinoma with high-grade cytological atypia. No foci of Barrett's esophagus and/or heterotopic gastric mucosa were detected in the specimen. Intraepithelial squamous cell carcinoma was also not detected in the adjacent stratified squamous layer. The contour of the tumor was similar to normal esophageal gland ducts but tumor did have immunohistochemical staining patterns similar to esophageal cardiac glands. Esophageal adenocarcinoma arising in the background without the foci of Barrett's esophagus is extremely rare and we reported the case with review of the literature in this study.	[Fujishima, Fumiyoshi; Kasajima, Atsuko; Ito, Ken; Taniuchi, Shinji; Watanabe, Mika; Sasano, Hironobu] Tohoku Univ Hosp, Dept Pathol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Nakamura, Yasuhiro; Ozawa, Yohei; Sasano, Hironobu] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan; [Asonuma, Sho] South Miyagi Med Ctr, Div Gastroenterol, Sendai, Miyagi, Japan; [Takubo, Kaiyo] Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Pathol, Tokyo, Japan	Fujishima, F (reprint author), Tohoku Univ Hosp, Dept Pathol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	ffujishima@patholo2.med.tohoku.ac.jp					Kusano C, 2008, J GASTROEN HEPATOL, V23, P1662, DOI 10.1111/j.1440-1746.2008.05572.x; Harada O, 2007, AM J SURG PATHOL, V31, P469, DOI 10.1097/01.pas.0000213400.64945.9e; Endoh Y, 1999, PATHOL INT, V49, P156, DOI 10.1046/j.1440-1827.1999.00838.x; DeMeester SR, 2006, ANN SURG ONCOL, V13, P12, DOI 10.1245/ASO.2005.12.025; Ko Yutaku, 2009, Nihon Shokakibyo Gakkai Zasshi, V106, P1327; Pollheimer MJ, 2007, ENDOSCOPY, V39, pE46, DOI 10.1055/s-2006-945062; Posner MC, 2005, CANC PRINCIPLES PRAC, P861; Tachimori Y, 2014, ESOPHAGUS-TOKYO, V11, P21, DOI 10.1007/s10388-013-0393-5; Takubo K, 2008, BEST PRACT RES CL GA, V22, P569, DOI 10.1016/j.bpg.2008.02.004; Takubo K, 2007, PATHOLOGY ESOPHAGUS, V2nd; TAKUBO K, 1993, CANCER, V71, P2435, DOI 10.1002/1097-0142(19930415)71:8<2435::AID-CNCR2820710802>3.0.CO;2-A	11	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					327	331		10.1007/s10388-014-0456-2		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800021		
J	Fukuchi, M; Saito, K; Naitoh, H; Kuwano, H				Fukuchi, Minoru; Saito, Kana; Naitoh, Hiroshi; Kuwano, Hiroyuki			Endoscopic gluing for intrathoracic anastomotic fistula following esophagectomy: a case report	ESOPHAGUS			English	Article						Esophagectomy; Anastomotic fistula; Endoscopic gluing	GASTROINTESTINAL-TRACT; PANCREATIC FISTULA; STENT INSERTION; N-BUTYL-2-CYANOACRYLATE; LEAKAGES; CLOSURE; LEAKS	Intrathoracic anastomotic leak/fistula following esophagectomy is a serious complication of this surgery. Patients are often extremely ill; endoscopic procedures have been suggested to avoid further surgical intervention. We herein present a case of a post-esophagectomy intrathoracic anastomotic fistula treated successfully with endoscopic gluing using N-butyl-2-cyanoacrylate. A 74-year-old Japanese woman was admitted to our hospital for treatment of a tumor of the esophagogastric junction. We performed distal esophagectomy, total gastrectomy via a left thoracotomy and laparotomy. Leakage at the esophagojejunostomy site was diagnosed on postoperative day 2. This leak gradually developed into a fistula through the drainage site. Because we judged the anastomotic fistula to be intractable by conservative treatment, we successfully closed the fistula by endoscopic gluing on postoperative day 44. This novel procedure shows that anastomotic fistula following esophagectomy can be sealed safely and effectively by endoscopic injection of N-butyl-2-cyanoacrylate glue.	[Fukuchi, Minoru; Saito, Kana; Naitoh, Hiroshi] Gunma Chuo Hosp, Dept Surg, Gunma 3710025, Japan; [Kuwano, Hiroyuki] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gumma 3718511, Japan	Fukuchi, M (reprint author), Gunma Chuo Hosp, Dept Surg, 1-7-13 Kouun Cho, Gunma 3710025, Japan.	mfukuchi@saitama-med.ac.jp					Voermans RP, 2012, CLIN GASTROENTEROL H, V10, P603, DOI 10.1016/j.cgh.2012.02.005; Rodella L, 1998, ENDOSCOPY, V30, P453, DOI 10.1055/s-2007-1001307; Lippert E, 2011, INT J COLORECTAL DIS, V26, P303, DOI 10.1007/s00384-010-1104-5; Aslan G, 2005, INT J UROL, V12, P838, DOI 10.1111/j.1442-2042.2005.01169.x; Mennigen R, 2013, J GASTROINTEST SURG, V17, P1058, DOI 10.1007/s11605-013-2156-y; Seewald S, 2004, GASTROINTEST ENDOSC, V59, P463, DOI 10.1016/S0016-5107(03)02708-1; Petersen B, 2004, GASTROINTEST ENDOSC, V60, P327, DOI 10.1016/S0016-5107(04)01564-0; Chang CC, 2007, EUR J CARDIO-THORAC, V31, P328, DOI 10.1016/j.ejcts.2006.11.002; Engler S, 1996, DEUT MED WOCHENSCHR, V121, P1396, DOI 10.1055/s-2008-1043159; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Kauer WKH, 2008, SURG ENDOSC, V22, P50, DOI 10.1007/s00464-007-9504-5; Lee YC, 2001, ENDOSCOPY, V33, P184; Raju Gottumukkala S, 2004, Gastroenterology, V127, P1852, DOI 10.1053/j.gastro.2004.10.036; Schweigert M, 2011, ANN THORAC SURG, V92, P513, DOI 10.1016/j.athoracsur.2011.02.083; Schweigert M, 2013, ANN ROY COLL SURG, V95, P43, DOI 10.1308/003588413X13511609956255; Yagci B, 2007, ABDOM IMAGING, V32, P475, DOI 10.1007/s00261-006-9142-8	16	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					332	335		10.1007/s10388-014-0461-5		4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800022		
J	Ono, H; Tanaka, M; Takizawa, K; Kakushima, N; Kawata, N; Imai, K; Hotta, K; Matsubayashi, H				Ono, Hiroyuki; Tanaka, Masaki; Takizawa, Kohei; Kakushima, Naomi; Kawata, Noboru; Imai, Kenichiro; Hotta, Kinichi; Matsubayashi, Hiroyuki			Utility of the over-the-scope-clip system for treating a large esophageal perforation	ESOPHAGUS			English	Article						Clips; Esophagus; Endoscopic surgical procedure; Esophageal perforation	ENDOSCOPIC SUBMUCOSAL DISSECTION	We report here a case of esophageal perforation made by an endoscope while treating cicatrical stenosis that developed after wide circumferential dissection of superficial esophageal carcinoma. Perforation closure with a conventional endoclip was difficult as the perforation was large and the surrounding tissue was fragile as a result of steroids administration for stenosis prevention. To avoid surgical intervention, we employed the over-the-scope-clip system and successfully closed the perforation. The favorable outcome suggests the utility of the over-the-scope-clip system for closing perforations when conventional methods are ineffective.	[Ono, Hiroyuki; Tanaka, Masaki; Takizawa, Kohei; Kakushima, Naomi; Kawata, Noboru; Imai, Kenichiro; Hotta, Kinichi; Matsubayashi, Hiroyuki] Shizuoka Canc Ctr, Div Endoscopy, Nagaizumi, Shizuoka 4118777, Japan	Ono, H (reprint author), Shizuoka Canc Ctr, Div Endoscopy, Shimonagakubo 1007, Nagaizumi, Shizuoka 4118777, Japan.	h.ono@scchr.jp		Hotta, Kinichi/0000-0001-5608-0968	Eisai; AstraZeneca; Taiho; Daiichi-Sankyo; Takeda; Olympus; Zeria; Asuka; Covidien; Gunze	Hiroyuki Ono has received lecture fees from Eisai, AstraZeneca, Taiho, Daiichi-Sankyo, Takeda, Olympus, Zeria, Asuka, Covidien, and Gunze. The remaining authors declare that they have no conflicts of interest.	Fujishiro M, 2006, ENDOSCOPY, V38, P1001, DOI 10.1055/s-2006-944775; Nishiyama N, 2013, WORLD J GASTROENTERO, V19, P2752, DOI 10.3748/wjg.v19.i18.2752; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Takahashi H, 2011, ENDOSCOPY, V43, P184, DOI 10.1055/s-0030-1256109; Haito-Chavez Y, 2014, GASTROINTEST ENDOSC; Oyama Tsuneo, 2005, Clin Gastroenterol Hepatol, V3, pS67, DOI 10.1016/S1542-3565(05)00291-0; The Japan Esophageal Society, 2012, ES CANC DIAGN TREATM	7	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1612-9059	1612-9067		ESOPHAGUS-TOKYO	Esophagus	JUL	2015	12	3					336	339		10.1007/s10388-014-0462-4		4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CM0AO	WOS:000357340800023		
J	Chen, SY; Teerananont, N; Sonthisawate, T; Sreesiri, P; Puemchalad, C; Mochizuki, T; Abe, Y; Toba, M; Yoshimura, Y				Chen, Shih-Yuan; Teerananont, Nattawee; Sonthisawate, Thanita; Sreesiri, Piyanan; Puemchalad, Chanakan; Mochizuki, Takahisa; Abe, Yohko; Toba, Makoto; Yoshimura, Yuji			A cost-effective acid degumming process produces high-quality Jatropha oil in tropical monsoon climates	EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY			English	Article						Alkali and alkaline earth metals; Biodiesel fuel; Degumming; Phosphorus; Vegetable oil refining	SBA-15 MESOPOROUS SILICA; BIODIESEL-BASED NA; VEGETABLE-OILS; FUELS; CATALYSTS	Degumming is an essential step to remove the gum from crude vegetable oil in order to produce high-quality vegetable oil with minimum impurity for various applications, such as food or feedstock for production of biodiesel fuel (BDF). In the tropical monsoon region, degummed Jatropha oil is low-quality and the loss on degumming is serious because the removal of the gum is a difficult task. Herein, a facile and economic process for efficient removal of the gum from crude Jatropha oil was developed with consideration for the tropical monsoon climate in Southeast Asian Nations, in which phosphoric acid (PA) was used as a degumming agent. When crude Jatropha oil was agitated with 0.025wt% of PA and 2 vol% of water at 60 degrees C for 30min, followed by aging at 30 degrees C for 60-120min and filtering through the Teflon-coated filter, the PA-degummed Jatropha oil with ultra-low contents of phosphorus (P), alkali metals and alkaline earth metals was entirely good as oil feedstock for production of high-quality BDF based on the international fuel standards (i.e., EN 14214:2012). Moreover, the degummed Jatropha oil trapped in the unwanted gum was easily recovered by the sieving technique. Practical applications: For the first time, the degumming of crude Jatropha oil in the tropical monsoon climate is thoroughly studied. To form the gum completely, the amounts of PA and water are kept at 0.025wt% and 2vol% of crude Jatropha oil, respectively, and the agitation temperature is kept at 60 degrees C. The gum is removed through the Teflon-coated filter after aging at 30 degrees C for 60-120min, which is similar to the monthly mean temperatures ranging between 26 and 31 degrees C in Thailand. The advantages of this process are that it is simple and cost effective, since expensive instruments for separation and purification are not used, such as high-speed centrifuge or special membrane. Most of the degummed oil trapped in the unwanted gum can be easily recovered through a stainless steel sieve. Accordingly, this process is currently operating on a pilot plant scale in Thailand.	[Chen, Shih-Yuan; Mochizuki, Takahisa; Abe, Yohko; Toba, Makoto; Yoshimura, Yuji] Natl Inst Adv Ind Sci & Technol, Energy Technol Res Inst, Resource Convers Catalyst Grp, Tsukuba, Ibaraki 3058565, Japan; [Teerananont, Nattawee; Sonthisawate, Thanita; Sreesiri, Piyanan; Puemchalad, Chanakan] TISTR, Energy Technol Dept, Khlong Luang, Pathum Thani, Thailand; [Sonthisawate, Thanita] Mie Univ, Grad Sch Engn, Dept Chem Mat, Inorgan Mat Sci Lab, Tsu, Mie 514, Japan	Chen, SY (reprint author), Natl Inst Adv Ind Sci & Technol, Energy Technol Res Inst, Resource Convers Catalyst Grp, 1-1-1 Higashi, Tsukuba, Ibaraki 3058565, Japan.	sy-chen@aist.go.jp			JST-JICA's SATREPS project	This research was supported by JST-JICA's SATREPS project. Acknowledgements are extended to Mr. M. Kaitsuka and Dr. M. Oguma of Collaborative Engine Research Team for Next Generation Vehicle, AIST, for ICP-OES analysis.	Chen SY, 2014, APPL CATAL B-ENVIRON, V148, P344, DOI 10.1016/j.apcatb.2013.11.009; Dijkstra AJ, 2009, EUR J LIPID SCI TECH, V111, P857, DOI 10.1002/ejlt.200900124; Chen SY, 2014, BIORESOURCE TECHNOL, V157, P346, DOI 10.1016/j.biortech.2014.01.097; Chen SY, 2013, CATAL COMMUN, V41, P136, DOI 10.1016/j.catcom.2013.07.021; No SY, 2011, RENEW SUST ENERG REV, V15, P131, DOI 10.1016/j.rser.2010.08.012; Verleyen T, 2002, J AM OIL CHEM SOC, V79, P947, DOI 10.1007/s11746-002-0585-4; Mittelbach M, 2001, J AM OIL CHEM SOC, V78, P573, DOI 10.1007/s11746-001-0306-z; Wilson K, 2012, CATAL SCI TECHNOL, V2, P884, DOI 10.1039/c2cy20038d; Hsu SH, 2013, SEP PURIF TECHNOL, V109, P129, DOI 10.1016/j.seppur.2013.03.005; Brookshear DW, 2013, TOP CATAL, V56, P62, DOI 10.1007/s11244-013-9930-7; Brookshear DW, 2012, CATAL TODAY, V184, P205, DOI 10.1016/j.cattod.2011.12.001; Gilbert N, 2012, NATURE NEWS, DOI [10.1038/nature.2012.11145, DOI 10.1038/NATURE.2012.11145]; Gupta M. K., 2008, PRACTICAL GUIDE VEGE; Jain S, 2011, FUEL, V90, P2045, DOI 10.1016/j.fuel.2011.02.002; List G. R., 1978, J AM OIL CHEM SOC, V55, P208; Liu KT, 2013, FUEL, V111, P180, DOI 10.1016/j.fuel.2013.04.049; Makkar H, 2009, J AM OIL CHEM SOC, V86, P173, DOI 10.1007/s11746-008-1327-6; Melero A., 2009, GREEN CHEM, V11, P1285; Nieuwenhuyzen W. van, 2008, European Journal of Lipid Science and Technology, V110, P472, DOI 10.1002/ejlt.200800041; Rao KS, 2009, J AM OIL CHEM SOC, V86, P197, DOI 10.1007/s11746-008-1325-8; Snowdon R, 2012, NATURE, V490, P37, DOI 10.1038/490037d; Zurfarov O., 2009, EUR J LIPID SCI TECH, V111, P985	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1438-7697	1438-9312		EUR J LIPID SCI TECH	Eur. J. Lipid Sci. Technol.	JUL	2015	117	7					1079	1087		10.1002/ejlt.201400293		9	Food Science & Technology; Nutrition & Dietetics	Food Science & Technology; Nutrition & Dietetics	CM0RZ	WOS:000357387300019		
J	Haraguchi, K; Ning, JY; Li, G				Haraguchi, Kazutoshi; Ning, Jinyan; Li, Guang			Swelling/deswelling behavior of zwitterionic nanocomposite gels consisting of sulfobetaine polymer-clay networks	EUROPEAN POLYMER JOURNAL			English	Article						Nanocomposite gel; Zwitterionic polymer; Polysulfobetaine; Swelling; Thermosensitivity; Polymer-clay network	FREE-RADICAL POLYMERIZATION; HIGH MECHANICAL STRENGTH; CROSS-LINKED HYDROGELS; N-ISOPROPYLACRYLAMIDE; SWELLING PROPERTIES; COPOLYMER NETWORKS; PHASE-TRANSITION; DELIVERY; ADDITIVES; RADIATION	The swelling and thermosensitive behaviors of zwitterionic nanocomposite gels (Zw-NC gels) consisting of sulfobetaine polymer-exfoliated clay networks were investigated in water and aqueous NaCl solutions and compared with those of physically and chemically crosslinked zwitterionic gels and non-zwitterionic NC gels. Zw-NC gels showed different swelling behavior that was strongly dependent on the salt concentration (C-NaCl), clay concentration (C-clay), and temperature. In water, characteristic swelling-to-deswelling behavior and an abnormal increase in the degree of swelling (DS) with increasing C-clay (proportional to crosslink density) were observed. These behaviors were in stark contrast to those obtained with other types of zwitterionic gels. In NaCl solutions, spontaneous deswelling disappeared within small C-NaCl and above the critical point (0.01 M), the DS increased with C-NaCl via an anti-polyelectrolyte effect of the zwitterions and decreased with increasing C-clay. The transparency also changed depending on the C-NaCl C-clay, swelling time, and thermosensitivity of the sulfobetaine polymer. These swelling behaviors and transparency changes of Zw-NC gels were explained by the combined effects of the zwitterionic polymers (anti-polyelectrolyte), ionic clay (polyelectrolyte), and clay as a crosslinker. (C) 2015 Elsevier Ltd. All rights reserved.	[Ning, Jinyan; Li, Guang] Donghua Univ, Coll Mat Sci & Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China; [Haraguchi, Kazutoshi] Nihon Univ, Coll Ind Technol, Dept Appl Mol Chem, Narashino, Chiba 2758575, Japan	Haraguchi, K (reprint author), Nihon Univ, Coll Ind Technol, Dept Appl Mol Chem, Narashino, Chiba 2758575, Japan.	haraguchi.kazutoshi@nihon-u.ac.jp			Ministry of Education, Science, Sport and Culture of Japan [23350117]	This work was supported by the Ministry of Education, Science, Sport and Culture of Japan (Grant-in-Aid 23350117). This work was mostly carried out in Kawamura Institute of Chemical Research, Japan.	Abd Alla SG, 2012, CARBOHYD POLYM, V89, P478, DOI 10.1016/j.carbpol.2012.03.031; Abd El-Rehim HA, 2006, J APPL POLYM SCI, V101, P3572, DOI 10.1002/app.22487; Kabiri K, 2011, POLYM COMPOSITE, V32, P277, DOI 10.1002/pc.21046; Techawanitchai P, 2012, SOFT MATTER, V8, P2844, DOI 10.1039/c2sm07277g; Miyazaki S, 2007, MACROMOLECULES, V40, P4287, DOI 10.1021/ma070104v; Ning JY, 2013, REACT FUNCT POLYM, V73, P969, DOI 10.1016/j.reactfunctpolym.2012.11.005; Haraguchi K, 2005, MACROMOLECULES, V38, P3482, DOI 10.1021/ma047431c; Dave N, 2010, J AM CHEM SOC, V132, P12668, DOI [10.1021/ja106098j, 10.1021/ja106098J]; Kopecek J, 2002, NATURE, V417, P388, DOI 10.1038/417388a; Nisato G, 1999, LANGMUIR, V15, P4236, DOI 10.1021/la981027n; Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521-4095(20020816)14:16<1120::AID-ADMA1120>3.0.CO;2-9; Huang T, 2007, ADV MATER, V19, P1622, DOI 10.1002/adma.200602533; Kamenova I, 2007, MACROMOL SYMP, V254, P122, DOI 10.1002/masy.200750819; CORKHILL PH, 1989, BIOMATERIALS, V10, P3, DOI 10.1016/0142-9612(89)90002-1; Ren HY, 2012, J COLLOID INTERF SCI, V375, P134, DOI 10.1016/j.jcis.2012.02.032; Thiele J, 2014, ADV MATER, V26, P125, DOI 10.1002/adma.201302958; Zhang CJ, 2013, CHEM MATER, V25, P3239, DOI 10.1021/cm401738p; Zohuriaan-Mehr MJ, 2010, J MATER SCI, V45, P5711, DOI 10.1007/s10853-010-4780-1; Son KJ, 2013, ANAL CHEM, V85, P11893, DOI 10.1021/ac402660z; Kostina NY, 2012, BIOMACROMOLECULES, V13, P4164, DOI 10.1021/bm301441x; Liu PS, 2013, BIOMATERIALS, V34, P2442, DOI 10.1016/j.biomaterials.2012.12.029; KHARE AR, 1995, BIOMATERIALS, V16, P559, DOI 10.1016/0142-9612(95)91130-Q; INOMATA H, 1992, LANGMUIR, V8, P687, DOI 10.1021/la00038a064; Chang Y, 2010, BIOMACROMOLECULES, V11, P1101, DOI 10.1021/bm100093g; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; Haraguchi K, 2006, BIOMACROMOLECULES, V7, P3267, DOI 10.1021/bm060549b; Kotobuki N, 2013, J BIOMED MATER RES A, V101, P537, DOI 10.1002/jbm.a.34355; Ning JY, 2013, MACROMOLECULES, V46, P5317, DOI 10.1021/ma4009059; Dhara D, 2000, POLYMER, V41, P6133, DOI 10.1016/S0032-3861(99)00820-4; Qin YM, 2008, POLYM ADVAN TECHNOL, V19, P6, DOI 10.1002/pat.960; Carr LR, 2011, BIOMATERIALS, V32, P6893, DOI 10.1016/j.biomaterials.2011.06.006; Kapoor Y, 2009, BIOMATERIALS, V30, P867, DOI 10.1016/j.biomaterials.2008.10.032; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Babu VR, 2008, EXPERT OPIN DRUG DEL, V5, P403, DOI 10.1517/17425247.5.4.403 ; Flory PJ, 1943, J CHEM PHYS, V11, P521, DOI 10.1063/1.1723792; Tian ZC, 2013, MACROMOLECULES, V46, P2715, DOI 10.1021/ma40043141; Ren HY, 2011, MACROMOLECULES, V44, P8516, DOI 10.1021/ma201272j; Comelles F, 2004, SURFACT DETERG, V7, P97; Georgiev GS, 2001, MACROMOL SYMP, V164, P301, DOI 10.1002/1521-3900(200102)164:1<301::AID-MASY301>3.0.CO;2-P; Haraguchi K, 2007, POLYM J, V43, P223; Jing G, 2012, COLLOID SURF A, V416, P86; Kabiri K, 2005, POLYM ADVAN TECHNOL, V16, P659, DOI 10.1002/pat.637; Lee WF, 1999, J APPL POLYM SCI, V74, P2170, DOI 10.1002/(SICI)1097-4628(19991128)74:9<2170::AID-APP7>3.0.CO;2-Q; Nishikawa M, 2014, J CONTROL RELEASE, V180, P25, DOI 10.1016/j.jconrel.2014.02.001; Oh JK, 2010, CAN J CHEM, V88, P173, DOI 10.1139/V09-158; Sakai T, 2009, MACROMOLECULES, V41, P5379; Shultz DN, 1986, POLYMER, V27, P1734; Smilkov H, 2008, J MATER SCI-MATER M, V19, P2389, DOI 10.1007/s10856-007-3349-2; Xue W, 2001, EUR POLYM J, V37, P869, DOI 10.1016/S0014-3057(00)00220-2; Xue W, 2006, EUR POLYM J, V42, P3015, DOI 10.1016/j.europolymj.2006.07.015; Yasushi Okumura K. I., 2001, ADV MATER, V13, P485; Zhang Z, 2008, J PHYS CHEM B, V112, P5327, DOI 10.1021/jp710683w	52	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0014-3057	1873-1945		EUR POLYM J	Eur. Polym. J.	JUL	2015	68				SI		630	640		10.1016/j.eurpolymj.2015.03.061		11	Polymer Science	Polymer Science	CL8NG	WOS:000357230800055		
J	Kobayashi, T; Iwamoto, Y; Takashima, K; Isomura, A; Kosodo, Y; Kawakami, K; Nishioka, T; Kaibuchi, K; Kageyama, R				Kobayashi, Taeko; Iwamoto, Yumiko; Takashima, Kazuhiro; Isomura, Akihiro; Kosodo, Yoichi; Kawakami, Koichi; Nishioka, Tomoki; Kaibuchi, Kozo; Kageyama, Ryoichiro			Deubiquitinating enzymes regulate Hes1 stability and neuronal differentiation	FEBS JOURNAL			English	Editorial Material						basic helix-loop-helix transcription factor (bHLH); deubiquitination; Hes1; neurodevelopment; oscillation	STEM-CELL DIFFERENTIATION; OSCILLATORY EXPRESSION; SEGMENTATION CLOCK; NEURAL PROGENITORS; USP22; ROLES; RESPONSES; GENES; TRANSCRIPTION; MULTIPOTENCY	Hairy and enhancer of split1 (Hes1), a basic helix-loop-helix transcriptional repressor protein, regulates the maintenance of neural stem/progenitor cells by repressing proneural gene expression via Notch signaling. Previous studies showed that Hes1 expression oscillates in both mouse embryonic stem cells and neural stem cells, and that the oscillation contributes to their potency and differentiation fates. This oscillatory expression depends on the stability of Hes1, which is rapidly degraded by the ubiquitin/proteasome pathway. However, the detailed molecular mechanisms governing Hes1 stability remain unknown. We analyzed Hes1-interacting deubiquitinases purified from mouse embryonic stem cells using an Hes1-specific antibody, and identified the ubiquitin-specific protease 27x (Usp27x) as a new regulator of Hes1. We found that Hes1 was deubiquitinated and stabilized by Usp27x and its homologs ubiquitin-specific protease22 (Usp22) and ubiquitin-specific protease51 (Usp51). Knockdown of Usp22 shortened the half-life of Hes1, delayed its oscillation, and enhanced neuronal differentiation in mouse developing brain, whereas mis-expression of Usp27x reduced neuronal differentiation. These results suggest that these deubiquitinases modulate Hes1 protein dynamics by removing ubiquitin molecules, and thereby regulate neuronal differentiation of stem cells.	[Kobayashi, Taeko; Iwamoto, Yumiko; Takashima, Kazuhiro; Isomura, Akihiro; Kageyama, Ryoichiro] Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; [Kobayashi, Taeko; Isomura, Akihiro; Kageyama, Ryoichiro] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol CREST, Kawaguchi, Saitama, Japan; [Kobayashi, Taeko; Kageyama, Ryoichiro] Kyoto Univ, Grad Sch Med, Kyoto 6068507, Japan; [Kobayashi, Taeko; Kageyama, Ryoichiro] Kyoto Univ, Grad Sch Biostudies, Kyoto 6068507, Japan; [Kosodo, Yoichi] Kawasaki Med Univ, Dept Anat, Kurashiki, Okayama, Japan; [Kawakami, Koichi] Natl Inst Genet, Div Mol & Dev Biol, Shizuoka, Japan; [Nishioka, Tomoki; Kaibuchi, Kozo] Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4648601, Japan; [Kageyama, Ryoichiro] Kyoto Univ, Inst Integrated Cell & Mat Sci, World Premier Int Res Initiat, Kyoto 6068507, Japan	Kobayashi, T (reprint author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	tkobayas@virus.kyoto-u.ac.jp; rkageyam@virus.kyoto-u.ac.jp					Gao YY, 2014, FEBS LETT, V588, P878, DOI 10.1016/j.febslet.2014.02.016; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Ueo T, 2012, DEVELOPMENT, V139, P1071, DOI 10.1242/dev.069070; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Sussman RT, 2013, J BIOL CHEM, V288, P24234, DOI 10.1074/jbc.M113.469783; Lee HJ, 2006, GENE EXPR PATTERNS, V6, P277, DOI 10.1016/j.modgep.2005.07.007; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Yoshiura S, 2007, P NATL ACAD SCI USA, V104, P11292, DOI 10.1073/pnas.0701837104; Masamizu Y, 2006, P NATL ACAD SCI USA, V103, P1313, DOI 10.1073/pnas.0508658103; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Sang LY, 2008, SCIENCE, V321, P1095, DOI 10.1126/science.1155998; Imayoshi I, 2013, SCIENCE, V342, P1203, DOI 10.1126/science.1242366; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Arnold SJ, 2008, GENE DEV, V22, P2479, DOI 10.1101/gad.475408; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014; Urasaki A, 2006, GENETICS, V174, P639, DOI 10.1534/genetics.106.060244; Kobayashi T, 2010, GENES CELLS, V15, P689, DOI 10.1111/j.1365-2443.2010.01413.x; Zhao Y, 2008, MOL CELL, V29, P92, DOI [10.1016/j.molcel.2007.12.011, 10.1016/j.moicel.2007.12.011]; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Sang LY, 2010, TRENDS MOL MED, V16, P17, DOI 10.1016/j.molmed.2009.11.001; Todi SV, 2011, TRENDS NEUROSCI, V34, P370, DOI 10.1016/j.tins.2011.05.004; Imayoshi I, 2014, NEURON, V82, P9, DOI 10.1016/j.neuron.2014.03.018; Nishioka T, 2012, CELL STRUCT FUNCT, V37, P39; Atanassov BS, 2011, EMBO REP, V12, P924, DOI 10.1038/embor.2011.140; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Kobayashi T, 2009, GENE DEV, V23, P1870, DOI 10.1101/gad.1823109; Burrows JF, 2012, FRONT BIOSCI-LANDMRK, V17, P1184, DOI 10.2741/3980; Giudicelli F, 2004, CURR OPIN GENET DEV, V14, P407, DOI 10.1016/j.gde.2004.06.014; Harima Y, 2014, SEMIN CELL DEV BIOL, V34, P85, DOI 10.1016/j.semcdb.2014.04.038; Imayoshi Itaru, 2014, Trends Neurosci, V37, P531, DOI 10.1016/j.tins.2014.07.006; Kobayashi Taeko, 2014, V110, P263, DOI 10.1016/B978-0-12-405943-6.00007-5; Kobayashi T, 2011, GENES-BASEL, V2, P219, DOI 10.3390/genes2010219; Kobayashi T, 2010, CELL CYCLE, V9, P207; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798	39	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-464X	1742-4658		FEBS J	FEBS J.	JUL	2015	282	13					2475	2487		10.1111/febs.13290		13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CL9LH	WOS:000357299500006		
J	Satoh, K; Oti, T; Katoh, A; Ueta, Y; Morris, JF; Sakamoto, T; Sakamoto, H				Satoh, Keita; Oti, Takumi; Katoh, Akiko; Ueta, Yoichi; Morris, John F.; Sakamoto, Tatsuya; Sakamoto, Hirotaka			Invivo processing and release into the circulation of GFP fusion protein in arginine vasopressin enhanced GFP transgenic rats: response to osmotic stimulation	FEBS JOURNAL			English	Article						arginine vasopressin; eGFP; exocytosis; molecular processing; neurosecretion	GREEN FLUORESCENT PROTEIN; HYPOTHALAMIC MAGNOCELLULAR NEURONS; CORE VESICLE EXOCYTOSIS; MUS-MUSCULUS BRAIN; SUPRAOPTIC NUCLEUS; PC12 CELLS; DOCKING STEP; SUPRACHIASMATIC NUCLEUS; EXAGGERATED RESPONSE; KAINIC ACID	Arginine vasopressin (AVP) is a neurohypophysial hormone synthesized as a part of a prepropeptide precursor containing the signal peptide, AVP hormone, AVP-associated neurophysin II and copeptin in the hypothalamic neurosecretory neurons. A transgenic (Tg) rat line expressing the AVP-eGFP fusion gene has been generated. To establish the AVP-eGFP Tg rat as a unique model for an analysis of AVP dynamics invivo, we first examined the invivo molecular dynamics of the AVP-eGFP fusion gene, and then the release of GFP in response to physiological stimuli. Double immunoelectron microscopy demonstrated that GFP was specifically localized in neurosecretory vesicles of AVP neurons in this Tg rat. After stimulation of the posterior pituitary with high potassium we demonstrated the exocytosis of AVP neurosecretory vesicles containing GFP at the ultrastructural level. Biochemical analyses indicated that the AVP-eGFP fusion gene is subjected to invivo post-translational modifications like the native AVP gene, and is packaged into neurosecretory vesicles as a fusion protein: copeptin(1-14)-GFP. Moreover, GFP release into the circulating blood appeared to be augmented after osmotic stimulation, like native AVP. Thus, here we show for the first time the invivo molecular processing of the AVP-eGFP fusion gene and stimulated secretion after osmotic stimulation in rats. Because GFP behaved like native AVP in the hypothalamo-pituitary axis, and in particular was released into the circulation in response to a physiological stimulus, the AVP-eGFP Tg rat model appears to be a powerful tool for analyzing neuroendocrine systems at the organismal level.	[Satoh, Keita; Oti, Takumi; Sakamoto, Tatsuya; Sakamoto, Hirotaka] Okayama Univ, Ushimado Marine Inst, Grad Sch Nat Sci & Technol, Okayama 7014303, Japan; [Katoh, Akiko; Ueta, Yoichi] Univ Occupat & Environm Hlth, Dept Physiol, Sch Med, Kitakyushu, Fukuoka 807, Japan; [Morris, John F.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 2JD, England	Sakamoto, H (reprint author), Okayama Univ, Ushimado Marine Inst, Grad Sch Nat Sci & Technol, 130-17 Kashino, Okayama 7014303, Japan.	hsakamo@okayama-u.ac.jp			MEXT/JSPS [21680031, 23659758, 24680039]; Naito Memorial Grant for Natural Science Researches, Japan [23113518]; Kato Memorial Bioscience Foundation, Japan; Life Science Foundation of Japan; Research Fellowship of JSPS for Young Scientists	This work was supported in part by MEXT/JSPS Grants-in-Aid for Scientific Research (KAKENHI) (21680031, 23659758 and 24680039 to H.S.), by Scientific Research on Innovative Areas (23113518 to Y.U.), by the Naito Memorial Grant for Natural Science Researches, Japan, to H.S., by the Kato Memorial Bioscience Foundation, Japan, to H.S., and by the Life Science Foundation of Japan to H.S. T.O. is supported by a Research Fellowship of JSPS for Young Scientists.	Albers HE, 2014, FRONT NEUROENDOCRIN, V36, P49; AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; Maruyama T, 2010, PEPTIDES, V31, P2089, DOI 10.1016/j.peptides.2010.08.010; CAZALIS M, 1985, J PHYSIOL-LONDON, V369, P45; Szinnai G, 2007, J CLIN ENDOCR METAB, V92, P3973, DOI 10.1210/jc.2007-0232; Balanescu S, 2011, J CLIN ENDOCR METAB, V96, P1046, DOI 10.1210/jc.2010-2499; Rood BD, 2011, J COMP NEUROL, V519, P2434, DOI 10.1002/cne.22635; Sakamoto H, 2007, ENDOCRINOLOGY, V148, P5842, DOI 10.1210/en.2007-0436; Suzuki H, 2009, J NEUROENDOCRINOL, V21, P183, DOI [10.1111/j.1365-2826.2009.01818.x, 10.1111/j.1365-2826.2009.01841.x]; Tobin V, 2012, J NEUROENDOCRINOL, V24, P629, DOI 10.1111/j.1365-2826.2011.02237.x; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Boertien WE, 2012, NEPHROL DIAL TRANSPL, V27, P4131, DOI 10.1093/ndt/gfs070; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; Kawasaki M, 2005, J NEUROENDOCRINOL, V17, P227, DOI 10.1111/j.1365-2826.2005.01297.x; Burckhardt MA, 2014, J CLIN ENDOCR METAB, V99, pE1750, DOI 10.1210/jc.2014-2244; Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822; Rood BD, 2013, J COMP NEUROL, V521, P2321, DOI 10.1002/cne.23288; Ueta Y, 2005, ENDOCRINOLOGY, V146, P406, DOI 10.1210/en.2004-0830; Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044; Suzuki H, 2009, J NEUROSCI, V29, P13182, DOI 10.1523/JNEUROSCI.2624-09.2009; Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Ludwig M, 1998, J NEUROENDOCRINOL, V10, P881; Tsuboi T, 2006, J CELL SCI, V119, P2196, DOI 10.1242/jcs.02962; LAND H, 1982, NATURE, V295, P299, DOI 10.1038/295299a0; Bhandari SS, 2009, CLIN SCI, V116, P257, DOI 10.1042/CS20080140; POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2; Wotjak CT, 1998, NEUROSCIENCE, V85, P1209, DOI 10.1016/S0306-4522(97)00683-0; Blanchard Anne, 2013, J Clin Endocrinol Metab, V98, P2084, DOI 10.1210/jc.2012-3794; Bolignano D, 2014, CLIN CHEM LAB MED, V52, P1147; BUMA P, 1984, HISTOCHEMISTRY, V80, P247, DOI 10.1007/BF00495773; Castel M, 1996, NEUROREPORT, V7, P543, DOI 10.1097/00001756-199601310-00040; CASTEL M, 1986, CELL TISSUE RES, V243, P193; Davies J, 2003, J NEUROENDOCRINOL, V15, P42, DOI 10.1046/j.1365-2826.2003.00865.x; Fujihara H, 2009, ENDOCRINOLOGY, V150, P5633, DOI 10.1210/en.2009-0796; Fujio T, 2006, J NEUROENDOCRINOL, V18, P776, DOI 10.1111/j.1365-2826.2006.01476.x; Iwanaga M, 2011, BRAIN RES, V1424, P1, DOI 10.1016/j.brainres.2011.09.030; Katoh A, 2011, ENDOCRINOLOGY, V152, P2768, DOI 10.1210/en.2011-0006; Kishimoto T, 2006, EMBO J, V25, P673, DOI 10.1038/sj.emboj.7600983; Kolonko A, 2014, CLIN CHEM LAB MED, V52, P1297, DOI 10.1515/cclm-2014-0135; Meijer E, 2010, KIDNEY INT, V77, P832, DOI 10.1038/ki.2010.46; Moritoh S, 2011, MOL VIS, V17, P3254; MORRIS JF, 1988, J EXP BIOL, V139, P81; Ohbuchi T, 2009, BRAIN RES, V1258, P34, DOI 10.1016/j.brainres.2008.12.057; Ohbuchi T, 2010, NEUROSCI LETT, V484, P26, DOI 10.1016/j.neulet.2010.08.010; Ohkubo J, 2014, J NEUROENDOCRINOL, V26, P43, DOI 10.1111/jne.12128; Otero-Garcia M, 2014, BRAIN STRUCT FUNCT, V219, P1055, DOI 10.1007/s00429-013-0553-3; Sato M, 2012, BIOCHEM BIOPH RES CO, V420, P417, DOI 10.1016/j.bbrc.2012.03.010; Schlapbach LJ, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-38; SHERMAN TG, 1986, J NEUROSCI, V6, P1685; Shibata M, 2007, J NEUROENDOCRINOL, V19, P285, DOI 10.1111/j.1365-2826.2007.01532.x; Todoroki M, 2010, STRESS, V13, P281, DOI 10.3109/10253890903383406; Tsuboi T, 2005, J BIOL CHEM, V280, P39253, DOI 10.1074/jbc.M507173200; Tsuboi T, 2006, MOL BIOL CELL, V17, P2101, DOI 10.1091/mbc.E05-11-1047; Tsuboi T, 2007, J NEUROCHEM, V100, P770, DOI 10.1111/j.1471-4159.2006.04266.x; WANG H, 1995, NEUROSCIENCE, V68, P1179, DOI 10.1016/0306-4522(95)00186-M; Wuttke A, 2013, ENDOCRINE, V44, P744, DOI 10.1007/s12020-013-9919-9; Yao ST, 2011, J NEUROSCI METH, V201, P191, DOI 10.1016/j.jneumeth.2011.08.004	58	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-464X	1742-4658		FEBS J	FEBS J.	JUL	2015	282	13					2488	2499		10.1111/febs.13291		12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CL9LH	WOS:000357299500007		
J	Ishikawa, K; Kataoka, M; Yanamoto, T; Nakabayashi, M; Watanabe, M; Ishihara, S; Yamaguchi, S				Ishikawa, Kazuhiko; Kataoka, Misumi; Yanamoto, Toshiaki; Nakabayashi, Makoto; Watanabe, Masahiro; Ishihara, Satoru; Yamaguchi, Shotaro			Crystal structure of -galactosidase from Bacilluscirculans ATCC31382 (BgaD) and the construction of the thermophilic mutants	FEBS JOURNAL			English	Article						crystal structure; galacto-oligosaccharide; prebiotics; protein engineering; thermophilic	CIRCULANS BETA-GALACTOSIDASE; BACILLUS-CIRCULANS; PROTEIN STRUCTURES; LACTOSE; OLIGOSACCHARIDES; PURIFICATION; HYDROLYSIS; MECHANISMS; ALIGNMENT; SEQUENCE	-Galactosidase () from Bacilluscirculans ATCC31382, designated BgaD, exhibits high transglycosylation activity to produce galacto-oligosaccharides. BgaD has been speculated to have a multiple domain architecture including a F5/8-type Cdomain or a discoidin domain in the C-terminal peptide region from amino acid sequence analysis. Here, we solved the first crystal structure of the C-terminal deletion mutant BgaD-D, consisting of sugar binding, Glyco_hydro, catalytic and bacterial Ig-like domains, at 2.5 angstrom. In the asymmetric unit, two molecules of BgaD-D were identified and the value of V-M was estimated to be 5.0 angstrom(3<bold>)Da(</bold>-1). It has been speculated that BgaD-D consists of four domains. From the structural analysis, however, we clarified that BgaD-D consists of five domains. We identified a new domain structure comprised of -sheets in BgaD. The catalytic domain exhibits a TIM barrel structure with a small pocket suited for accommodating the disaccharides. Detailed structural information for the amino acid residues related to activity and substrate specificity was clarified in the catalytic domain. Furthermore, using the structural information, we successfully constructed some thermostable mutants via protein engineering method. DatabaseCoordinates for the BgaD-D structure have been deposited in the Protein Data Bank under accession code	[Ishikawa, Kazuhiko; Kataoka, Misumi; Yanamoto, Toshiaki; Nakabayashi, Makoto; Watanabe, Masahiro] Natl Inst Adv Ind Sci & Technol, Biomass Refinery Res Ctr, Higashihiroshima 7390046, Japan; [Ishihara, Satoru; Yamaguchi, Shotaro] Amano Enzyme Inc, Gifu R&D Ctr, Kakamigahara, Japan	Ishikawa, K (reprint author), Natl Inst Adv Ind Sci & Technol, Biomass Refinery Res Ctr, 3-11-32 Kagamiyama, Higashihiroshima 7390046, Japan.	kazu-ishikawa@aist.go.jp					C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Benson DA, 2014, NUCLEIC ACIDS RES, V42, pD32, DOI 10.1093/nar/gkt1030; Gosling A, 2011, J AGR FOOD CHEM, V59, P3366, DOI 10.1021/jf104397w; Long F, 2008, ACTA CRYSTALLOGR D, V64, P125, DOI 10.1107/S0907444907050172; Hidaka M, 2002, J MOL BIOL, V322, P79, DOI 10.1016/S0022-2836(02)00746-5; YANAHIRA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1021; Maksimainen M, 2012, FEBS J, V279, P1788, DOI 10.1111/j.1742-4658.2012.08555.x; Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314; Ingram CJE, 2009, HUM GENET, V124, P579, DOI 10.1007/s00439-008-0593-6; Song JY, 2011, BIOSCI BIOTECH BIOCH, V75, P268, DOI 10.1271/bbb.100574; Song JY, 2011, BIOSCI BIOTECH BIOCH, V75, P1194, DOI 10.1271/bbb.110014; Henze M, 2014, J BIOTECHNOL, V191, P78, DOI [10.1016/j.jbiotec.2014.07.003, 10.1016/j.jblotec.2014.07.003]; Trevino SR, 2007, J MOL BIOL, V373, P211, DOI 10.1016/j.imb.2007.07.061; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363; Park AR, 2010, APPL MICROBIOL BIOT, V85, P1279, DOI 10.1007/s00253-009-2356-2; Fujimoto H, 1998, GLYCOCONJUGATE J, V15, P155, DOI 10.1023/A:1006916222187; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Macfarlane GT, 2008, J APPL MICROBIOL, V104, P305, DOI 10.1111/j.1365-2672.2007.03520.x; Chen W, 2008, J DAIRY SCI, V91, P1751, DOI 10.3168/jds.2007-617; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Yamashiro K, 2010, PROTEIN ENG DES SEL, V23, P519, DOI 10.1093/protein/gzq021; Cantarel BL, 2009, NUCLEIC ACIDS RES, V37, pD233, DOI 10.1093/nar/gkn663; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; Ito Y, 1997, BIOSCI BIOTECH BIOCH, V61, P1270; Juers DH, 2001, BIOCHEMISTRY-US, V40, P14781, DOI 10.1021/bi011727i; Ladero M, 2003, BIOTECHNOL BIOENG, V81, P241, DOI 10.1002/bit.10466; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Matthews BW, 2005, CR BIOL, V328, P549, DOI 10.1016/j.crvi.2005.03.006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547; Song J, 2013, BIOSCI BIOTECH BIOCH, V77, P73, DOI 10.1271/bbb.120583; vansLeeuwen SS, 2014, CARBOHYD RES, V400, P59	36	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-464X	1742-4658		FEBS J	FEBS J.	JUL	2015	282	13					2540	2552		10.1111/febs.13298		13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CL9LH	WOS:000357299500011		
J	Kyuma, T; Kimura, S; Hanada, Y; Suzuki, T; Sekimizu, K; Kaito, C				Kyuma, Tatsuhiko; Kimura, Satoshi; Hanada, Yuichi; Suzuki, Tsutomu; Sekimizu, Kazuhisa; Kaito, Chikara			Ribosomal RNA methyltransferases contribute to Staphylococcusaureus virulence	FEBS JOURNAL			English	Article						bacterial pathogenesis; immune response; oxidative stress; rRNA modification; translational fidelity	CHROMOSOMAL DNA-REPLICATION; M(2) G-METHYLTRANSFERASES; ESCHERICHIA-COLI; TRANSLATION INITIATION; SUPEROXIDE DISMUTASES; PATHOGENIC BACTERIA; SILKWORM LARVAE; INFECTION MODEL; GENE ENCODES; AUREUS	Post-transcriptional modifications in rRNA, such as methylation, are observed in functionally important regions of the ribosome. The methyltransferases responsible for these modifications work as housekeeping enzymes to fine-tune ribosomal function, and the roles of some methyltransferases become more evident under stress conditions. Recently, the 16S rRNA methyltransferases RsmI and RsmH, which are responsible for cytidine dimethylation at the decoding center of the ribosome, were identified in Escherichiacoli. The physiological relevance of the rRNA modification, however, remains obscure. We identified rsmI and rsmH as novel virulence genes in Staphylococcusaureus using a silkworm infection model. These genes induced 2-O- and N-4-methylations, respectively, of m(4)Cm1412 of S.aureus 16S rRNA. Deletion of either rsmI or rsmH in S.aureus attenuated the virulence of S.aureus in silkworms, and led to its sensitivity to oxidative stress. Dual luciferase assay revealed that the double-knockout strain exhibited decreased translational fidelity under oxidative stress conditions. In addition, administration of N-acetyl-l-cysteine, a free-radical scavenger, restored the killing ability of the double-knockout strain against silkworms. These findings suggest that the methyl-modifications of cytidine at position 1412 in 16S rRNA contribute to S.aureus animal killing by conferring resistance to oxidative stress in host animals.	[Kyuma, Tatsuhiko; Hanada, Yuichi; Sekimizu, Kazuhisa; Kaito, Chikara] Univ Tokyo, Microbiol Lab, Grad Sch Pharmaceut, Tokyo 1130033, Japan; [Kimura, Satoshi; Suzuki, Tsutomu] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo 1130033, Japan	Kaito, C (reprint author), Univ Tokyo, Microbiol Lab, Grad Sch Pharmaceut, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	kaito@mol.f.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731	Japan Society for the Promotion of Science [13J10776]; KANAE Foundation for the promotion of medical sciences; Genome Pharmaceutical Institute;  [23249009];  [24590519];  [25117507]	The present study was supported by Grants-in-Aid for Scientific Research 23249009, 24590519, 25117507 and Japan Society for the Promotion of Science research fellowships for young scientists Grant 13J10776 (TK). The study was supported in part by the KANAE Foundation for the promotion of medical sciences and the Genome Pharmaceutical Institute.	Basturea GN, 2012, J MOL BIOL, V415, P16, DOI 10.1016/j.jmb.2011.10.044; Andersen NM, 2006, J MOL BIOL, V359, P777, DOI 10.1016/j.jmb.2006.04.007; Gustafsson C, 1998, J BACTERIOL, V180, P359; Jozefczuk S, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.18; Toh SM, 2008, RNA, V14, P98, DOI 10.1261/rna.814408; Vesper O, 2011, CELL, V147, P147, DOI 10.1016/j.cell.2011.07.047; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Lynch M, 2000, MICROBES INFECT, V2, P1245, DOI 10.1016/S1286-4579(00)01278-8; Kohchi C, 2009, ANTICANCER RES, V29, P817; Kaito C, 2002, MICROB PATHOGENESIS, V32, P183, DOI 10.1006/mpat.2002.0494; Kurokawa K, 2007, METHOD ENZYMOL, V422, P233, DOI 10.1016/S0076-6879(06)22011-1; Das G, 2008, EMBO J, V27, P840, DOI 10.1038/emboj.2008.20; Nystrom T, 2002, AGEING RES REV, V1, P693, DOI 10.1016/S1568-1637(02)00028-4; Lesnyak DV, 2006, J MOL BIOL, V364, P20, DOI 10.1016/j.jmb.2006.09.009; Osterman IA, 2011, BIOCHIMIE, V93, P725, DOI 10.1016/j.biochi.2010.12.016; Zhou JD, 2013, NUCLEIC ACIDS RES, V41, pD613, DOI 10.1093/nar/gks1235; Nichols RJ, 2011, CELL, V144, P143, DOI 10.1016/j.cell.2010.11.052; PENG HL, 1988, J BACTERIOL, V170, P4365; Karavolos MH, 2003, MICROBIOL-SGM, V149, P2749, DOI 10.1099/mic.0.26353-0; Li Y, 2004, MOL GENET GENOMICS, V271, P447, DOI 10.1007/s00438-004-0996-6; Sergeeva OV, 2015, BIOCHIMIE, V117, P110, DOI 10.1016/j.biochi.2014.11.019; Liu M, 2012, BIOL CHEM, V393, P123, DOI 10.1515/hsz-2011-0247; Xu Z, 2008, NAT STRUCT MOL BIOL, V15, P534, DOI 10.1038/nsmb.1408; Gerashchenko MV, 2012, P NATL ACAD SCI USA, V109, P17394, DOI 10.1073/pnas.1120799109; Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827; Decatur WA, 2002, TRENDS BIOCHEM SCI, V27, P344, DOI 10.1016/S0968-0004(02)02109-6; Miyazaki S, 2012, FEMS MICROBIOL LETT, V326, P116, DOI 10.1111/j.1574-6968.2011.02439.x; Sergiev PV, 2006, J MOL BIOL, V364, P26, DOI 10.1016/j.jmb.2006.09.008; JEMIOLO DK, 1985, NUCLEIC ACIDS RES, V13, P8631, DOI 10.1093/nar/13.23.8631; Kaito C, 2011, MICROB PATHOGENESIS, V51, P142, DOI 10.1016/j.micpath.2011.04.007; Ueda T, 2011, MICROB PATHOGENESIS, V51, P178, DOI 10.1016/j.micpath.2011.04.003; Connolly K, 2008, MOL MICROBIOL, V70, P1062, DOI 10.1111/j.1365-2958.2008.06485.x; Kaito C, 2005, MOL MICROBIOL, V56, P934, DOI 10.1111/j.1365-2958.2005.04596.x; Burakovsky DE, 2012, NUCLEIC ACIDS RES, V40, P7885, DOI 10.1093/nar/gks508; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ichihashi N, 2003, J BIOL CHEM, V278, P28778, DOI 10.1074/jbc.M212202200; Kimura S, 2010, NUCLEIC ACIDS RES, V38, P1341, DOI 10.1093/nar/gkp1073; Baldridge KC, 2013, CRIT REV BIOCHEM MOL, V49, P69; Bujnicki Janusz M., 2001, Acta Microbiologica Polonica, V50, P7; HELSER TL, 1971, NATURE-NEW BIOL, V233, P12; Kaito C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003269; Kaito C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001267; Nagarajan V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-351; [Anonymous], 1991, METHOD ENZYMOL; Palazzolo-Ballance AM, 2008, J IMMUNOL, V180, P500; Sambrook J, 2001, MOL CLONING LAB MANU; Suzuki T, 2007, METHOD ENZYMOL, V425, P211, DOI 10.1016/S0076-6876(07)25009-8	47	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-464X	1742-4658		FEBS J	FEBS J.	JUL	2015	282	13					2570	2584		10.1111/febs.13302		15	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CL9LH	WOS:000357299500013		
J	Tadokoro, T; Kikuma, T; Kitamoto, K				Tadokoro, Takayuki; Kikuma, Takashi; Kitamoto, Katsuhiko			Functional analysis of AoAtg11 in selective autophagy in the filamentous fungus Aspergillus oryzae	FUNGAL BIOLOGY			English	Article						Filamentous fungi; Mitophagy; Pexophagy; The Cvt pathway; Vacuole	SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL PROTEIN; SELF-DIGESTION; MITOPHAGY; PEROXISOMES; PATHWAY; DISEASE; DIFFERENTIATION; MEMBRANE; SURVIVAL	Autophagy is a highly conserved cellular degradation process in eukaryotes and consists of both non-selective and selective types. Selective autophagic processes include pexophagy, mitophagy, and the cytoplasm-to-vacuole targeting (Cvt) pathway of yeast, in which particular vacuolar proteins, such as aminopeptidase I (Ape1), are selectively transported to vacuoles. Although selective autophagy has been mainly studied in the yeasts Saccharomyces cerevisiae and Pichia pastoris, there is evidence for selective autophagy in filamentous fungi; however, the details are poorly understood. In S. cerevisiae, Atg11 is a selective autophagy-specific protein that recognizes and transports substrates to the pre-autophagosomal structure (PAS). Here, we first identified an ATG11 homologue in the filamentous fungus Aspergillus oryzae and analyzed the localization of the corresponding protein, designated AoAtg11, fused to enhanced green fluorescent protein (EGFP). Imaging analysis revealed that AoAtg11 EGFP was localized to PAS-like structures. We next constructed an Aoatg11 disruptant of A. oryzae and showed that AoAtg11 is involved in pexophagy and mitophagy. In addition, AoAtg11 was found to be dispensable for non-selective autophagy and for transporting AoApe1 to vacuoles. Taken together, these results suggest that AoAtg11 is a selective autophagy-specific protein in A. oryzae, and has distinct molecular functions from that of S. cerevisiae Atg11. (C) 2015 The British Mycological Society. Published by Elsevier Ltd. All rights reserved.	[Tadokoro, Takayuki; Kikuma, Takashi; Kitamoto, Katsuhiko] Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Kitamoto, K (reprint author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	akitamo@mail.ecc.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [25292045]	This study was supported by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Grant No. 25292045).	Kikuma T, 2006, EUKARYOT CELL, V5, P1328, DOI 10.1128/EC.00024-06; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Enyenihi AH, 2003, GENETICS, V163, P47; Lynch-Day MA, 2010, FEBS LETT, V584, P1359, DOI 10.1016/j.febslet.2010.02.013; Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Huang J, 2007, CELL CYCLE, V6, P1837; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Shoji JY, 2014, CURR OPIN MICROBIOL, V20, P1, DOI 10.1016/j.mib.2014.03.002; Motley AM, 2012, EMBO J, V31, P2852, DOI 10.1038/emboj.2012.151; Kanki T, 2008, J BIOL CHEM, V283, P32386, DOI 10.1074/jbc.M802403200; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Asakura M, 2009, PLANT CELL, V21, P1291, DOI 10.1105/tpc.108.060996; Machida M, 2005, NATURE, V438, P1157, DOI 10.1038/nature04300; Kanki T, 2009, DEV CELL, V17, P98, DOI 10.1016/j.devcel.2009.06.014; Backues SK, 2012, AUTOPHAGY, V8, P1275, DOI 10.4161/auto.21153; Escano CS, 2009, EUKARYOT CELL, V8, P296, DOI 10.1128/EC.00197-08; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; He YL, 2013, AUTOPHAGY, V9, P1818, DOI 10.4161/auto.26057; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Mabashi Y, 2006, BIOSCI BIOTECH BIOCH, V70, P1882, DOI 10.1271/bbb.60052; Nazarko TY, 2009, MOL BIOL CELL, V20, P3828, DOI 10.1091/mbc.E09-03-0221; Shoji JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015650; Tal R, 2007, J BIOL CHEM, V282, P5617, DOI 10.1074/jbc.M605940200; Tanabe Y, 2011, J BIOL CHEM, V286, P30455, DOI 10.1074/jbc.M111.247338; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; Voigt O, 2013, APPL MICROBIOL BIOT, V97, P9277, DOI 10.1007/s00253-013-5221-2; Yanagisawa S, 2013, FEMS MICROBIOL LETT, V338, P168, DOI 10.1111/1574-6968.12047; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418	32	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1878-6146	1878-6162		FUNGAL BIOL-UK	Fungal Biol.	JUL	2015	119	7					560	567		10.1016/j.funbio.2015.03.001		8	Mycology	Mycology	CL8MI	WOS:000357228400002		
J	Kushibiki, T; Okawa, S; Hirasawa, T; Ishihara, M				Kushibiki, T.; Okawa, S.; Hirasawa, T.; Ishihara, M.			Optogenetic control of insulin secretion by pancreatic beta-cells in vitro and in vivo	GENE THERAPY			English	Article							LIGHT-INDUCED ACTIVATION; OPTICAL CONTROL; NEURAL CIRCUITRY; TRANSGENIC MICE; EXCITABLE CELLS; GLUCOSE; CHANNELRHODOPSIN-2; CHANNELS; NEURONS; TRANSPLANTATION	The present study assessed the ability of optogenetics techniques to provide a better understanding of the control of insulin secretion, particularly regarding pancreatic beta-cell function in homeostasis and pathological conditions such as diabetes mellitus (DM). We used optogenetics to investigate whether insulin secretion and blood glucose homeostasis could be controlled by regulating intracellular calcium ion concentrations ([Ca2+]i) in a mouse pancreatic beta-cell line (MIN6) transfected with the optogenetic protein channelrhodopsin-2 (ChR2). The ChR2-transfected MIN6 (ChR2-MIN6) cells secreted insulin following irradiation with a laser (470 nm). The increase in [Ca2+]i was accompanied by elevated levels of messenger RNAs that encode calcium/calmodulin-dependent protein kinase II delta and adenylate cyclase 1. ChR2-MIN6 cells suspended in matrigel were inoculated into streptozotocin-induced diabetic mice that were then subjected to a glucose tolerance test. Laser irradiation of these mice caused a significant decrease in blood glucose, and the irradiated implanted cells expressed insulin. These findings demonstrate the power of optogenetics to precisely and efficiently controlled insulin secretion by pancreatic beta-cells 'on demand', in contrast to techniques using growth factors or chemical inducers. Optogenetic technology shows great promise for understanding the mechanisms of glucose homeostasis and for developing treatments for metabolic diseases such as DM.	[Kushibiki, T.; Okawa, S.; Hirasawa, T.; Ishihara, M.] Natl Def Med Coll, Dept Med Engn, Tokorozawa, Saitama 3598513, Japan	Kushibiki, T (reprint author), Natl Def Med Coll, Dept Med Engn, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	toshi@ndmc.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) [26116728]; Japan Society for the Promotion of Science (JSPS) [25713009]	This work was supported by The Ministry of Education, Culture, Sports, Science and Technology (MEXT) Grant-in-Aid Project for Scientific Research on Innovative Areas 'Crosstalk between transcriptional control and energy pathways, mediated by hub metabolites' (26116728) and Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists (A) (25713009).	American Diabetes Association, 2014, DIABETES CARE S1, V37, pS81, DOI DOI 10.2337/DC14-S081; Li X, 2005, P NATL ACAD SCI USA, V102, P17816, DOI 10.1073/pnas.0509030102; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; [Anonymous], 2014, NAT DIAB STAT REP ES; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Braun M, 2008, DIABETES, V57, P1618, DOI 10.2337/db07-0991; Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117; Marzorati S, 2014, TRANSPLANTATION, V97, P1019, DOI 10.1097/TP.0000000000000104; Aravanis AM, 2007, J NEURAL ENG, V4, pS143, DOI 10.1088/1741-2560/4/3/S02; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Arenkiel BR, 2007, NEURON, V54, P205, DOI 10.1016/j.neuron.2007.03.005; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Ye HF, 2011, SCIENCE, V332, P1565, DOI 10.1126/science.1203535; Petreanu L, 2007, NAT NEUROSCI, V10, P663, DOI 10.1038/nn1891; Kitaguchi T, 2013, BIOCHEM J, V450, P365, DOI 10.1042/BJ20121022; Nagel G, 2005, CURR BIOL, V15, P2279, DOI 10.1016/j.cub.2005.11.032; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689; Ashcroft FM, 2012, CELL, V148, P1160, DOI 10.1016/j.cell.2012.02.010; Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936; Schroll C, 2006, CURR BIOL, V16, P1741, DOI 10.1016/j.cub.2006.07.023; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126; Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744; Rorsman P, 2012, CELL CALCIUM, V51, P300, DOI 10.1016/j.ceca.2011.11.006; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Bryson JB, 2014, SCIENCE, V344, P94, DOI 10.1126/science.1248523; Ishizuka T, 2006, NEUROSCI RES, V54, P85, DOI 10.1016/j.neures.2005.10.009; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI [10.1038/nmeth.f.324, 10.1038/NMETH.F.324]; Borodinsky Laura N, 2006, Sci STKE, V2006, ppe22, DOI 10.1126/stke.3362006pe22; Cheng MY, 2014, P NATL ACAD SCI USA, V111, P12913, DOI [10.1073/pnas.1404109111, 10.1109/CCIOT.2014.7062494]; Gerace D, 2014, GENE THER, V22, P1; Guo JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5420; Han X, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000299; Kushibiki T, 2014, INT J PHOTOENERGY, V2014, P1; Mohlig M, 1997, ENDOCRINOLOGY, V138, P2577, DOI 10.1210/en.138.6.2577; Newby BN, 2014, TRENDS ENDOCRIN MET, V25, P378, DOI 10.1016/j.tem.2014.05.006; Pastrana E, 2010, NAT METHODS, V8, P24, DOI DOI 10.1038/NMETH.F.323; Reinbothe TM, 2014, ISLETS, V6, DOI 10.4161/isl.28095; Tomita H, 2009, J GENET, V88, P409; Vetere A, 2014, NAT REV DRUG DISCOV, V13, P278, DOI 10.1038/nrd4231; Wang H, 2007, P NATL ACAD SCI USA, V104, P8143, DOI 10.1073/pnas.0700384104	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0969-7128	1476-5462		GENE THER	Gene Ther.	JUL	2015	22	7					553	559		10.1038/gt.2015.23		7	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	CM1FC	WOS:000357425300005		
J	Nakagawa, T; Nakayama, K				Nakagawa, Tadashi; Nakayama, Keiko			Protein monoubiquitylation: targets and diverse functions	GENES TO CELLS			English	Review							E3 UBIQUITIN LIGASE; SKELETAL-MUSCLE PROGENITORS; TRANSLESION DNA-SYNTHESIS; CELL-CYCLE PROGRESSION; CROSS-LINK REPAIR; HISTONE H2B; ALPHA-SYNUCLEIN; PHOSPHOGLYCERATE MUTASE; MONO-UBIQUITINATION; PARKINSONS-DISEASE	Ubiquitin is a 76-amino acid protein whose conjugation to protein targets is a form of post-translational modification. Protein ubiquitylation is characterized by the covalent attachment of the COOH-terminal carboxyl group of ubiquitin to an amino group of the substrate protein. Given that the NH2-terminal amino group is usually masked, internal lysine residues are most often targeted for ubiquitylation. Polyubiquitylation refers to the formation of a polyubiquitin chain on the substrate as a result of the ubiquitylation of conjugated ubiquitin. The structures of such polyubiquitin chains depend on the specific lysine residues of ubiquitin targeted for ubiquitylation. Most of the polyubiquitin chains other than those linked via lysine-63 and methionine-1 of ubiquitin are recognized by the proteasome and serve as a trigger for substrate degradation. In contrast, polyubiquitin chains linked via lysine-63 and methionine-1 serve as a binding platform for proteins that function in immune signal transduction or DNA repair. With the exception of a few targets such as histones, the functions of protein monoubiquitylation have remained less clear. However, recent proteomics analysis has shown that monoubiquitylation occurs more frequently than polyubiquitylation, and studies are beginning to provide insight into its biologically important functions. Here, we summarize recent findings on protein monoubiquitylation to provide an overview of the targets and molecular functions of this modification.	[Nakagawa, Tadashi; Nakayama, Keiko] Tohoku Univ, Div Cell Proliferat, ART, Grad Sch Med, Sendai, Miyagi 9808575, Japan	Nakayama, K (reprint author), Tohoku Univ, Div Cell Proliferat, ART, Grad Sch Med, Sendai, Miyagi 9808575, Japan.	nakayak2@med.tohoku.ac.jp					Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484; Shabek N, 2012, MOL CELL, V48, P87, DOI 10.1016/j.molcel.2012.07.011; Watkins GR, 2012, J BIOL CHEM, V287, P24207, DOI 10.1074/jbc.M112.368613; Bergink S, 2009, NATURE, V458, P461, DOI 10.1038/nature07963; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Havens CG, 2011, GENE DEV, V25, P1568, DOI 10.1101/gad.2068611; Joch M, 2007, MOL BIOL CELL, V18, P3105, DOI 10.1091/mbc.E05-11-1027; Blake JA, 2014, DEVELOPMENT, V141, P737, DOI 10.1242/dev.091785; Terai K, 2010, MOL CELL, V37, P143, DOI 10.1016/j.molcel.2009.12.018; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Hopkins BD, 2014, TRENDS BIOCHEM SCI, V39, P183, DOI 10.1016/j.tibs.2014.02.006; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Lashuel HA, 2013, NAT REV NEUROSCI, V14, P38, DOI 10.1038/nrn3406; Jin LY, 2012, NATURE, V482, P495, DOI 10.1038/nature10822; Xiong Y, 2012, J CELL BIOL, V198, P155, DOI 10.1083/jcb.201202056; Dupont S, 2012, FEBS LETT, V586, P1913, DOI 10.1016/j.febslet.2012.03.037; Corti O, 2011, PHYSIOL REV, V91, P1161, DOI 10.1152/physrev.00022.2010; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Ma CL, 2011, J CELL BIOL, V193, P7, DOI 10.1083/jcb.201010022; Guerrero-Santoro J, 2008, CANCER RES, V68, P5014, DOI 10.1158/0008-5472.CAN-07-6162; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Karlsson AB, 2014, MOL BIOL CELL, V25, P1355, DOI 10.1091/mbc.E13-11-0705; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Wegierski T, 2006, EMBO J, V25, P5659, DOI 10.1038/sj.emboj.7601429; Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Catez F, 2006, NAT STRUCT MOL BIOL, V13, P305, DOI 10.1038/nsmb1077; Xu LZ, 2010, CURR BIOL, V20, P1372, DOI 10.1016/j.cub.2010.06.051; Huang HK, 2000, J BIOL CHEM, V275, P26661; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Kim H, 2012, GENE DEV, V26, P1393, DOI 10.1101/gad.195248.112; Povlsen LK, 2012, NAT CELL BIOL, V14, P1089, DOI 10.1038/ncb2579; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Kaiser SE, 2011, NAT METHODS, V8, P691, DOI [10.1038/nmeth.1649, 10.1038/NMETH.1649]; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825; Boutet SC, 2007, CELL, V130, P349, DOI 10.1016/j.cell.2007.05.044; Bienko M, 2010, MOL CELL, V37, P396, DOI 10.1016/j.molcel.2009.12.039; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Kim JM, 2009, DEV CELL, V16, P314, DOI 10.1016/j.devcel.2009.01.001; Choi YE, 2009, J BIOL CHEM, V284, P12772, DOI 10.1074/jbc.M807550200; Hesse D, 2013, BIOSCIENCE REP, V33, DOI 10.1042/BSR20120082; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Li GH, 2011, CURR OPIN GENET DEV, V21, P175, DOI 10.1016/j.gde.2011.01.022; Eaton Douglas C, 2010, Proc Am Thorac Soc, V7, P54, DOI 10.1513/pats.200909-096JS; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Van Campenhout CA, 2011, DEV CELL, V21, P479, DOI 10.1016/j.devcel.2011.08.003; Lange SS, 2011, NAT REV CANCER, V11, P96, DOI 10.1038/nrc2998; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Jensen D, 2011, J CELL SCI, V124, P1, DOI 10.1242/jcs.069773; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Yin H, 2010, J BIOL CHEM, V285, P13580, DOI 10.1074/jbc.M109.046359; Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019; Jackson Brian C., 2010, Human Genomics, V4, P345; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Eastman SW, 2009, J CELL BIOL, V184, P881, DOI 10.1083/jcb.200808041; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Pavlopoulos E, 2011, CELL, V147, P1369, DOI 10.1016/j.cell.2011.09.056; Agricola E, 2011, MOL CELL, V43, P85, DOI 10.1016/j.molcel.2011.05.020; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhou W, 2008, MOL CELL, V29, P69, DOI 10.1016/j.molcel.2007.11.002; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Rott R, 2008, J BIOL CHEM, V283, P3316, DOI 10.1074/jbc.M704809200; Rott R, 2011, P NATL ACAD SCI USA, V108, P18666, DOI 10.1073/pnas.1105725108; Gardner RG, 2005, MOL CELL BIOL, V25, P6123, DOI 10.1128/MCB.25.14.6123-6139.2005; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Piton A, 2013, AM J HUM GENET, V93, P368, DOI 10.1016/j.ajhg.2013.06.013; Espinosa JM, 2008, GENE DEV, V22, P2743, DOI 10.1101/gad.1732108; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Meray RK, 2007, J BIOL CHEM, V282, P10567, DOI 10.1074/jbc.M611153200; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Moldovan GL, 2009, ANNU REV GENET, V43, P223, DOI 10.1146/annurev-genet-102108-134222; Roberts S, 2012, FEBS J, V279, P3549, DOI 10.1111/j.1742-4658.2012.08729.x; Saigoh K, 1999, NAT GENET, V23, P47; De Domenico I, 2006, EMBO J, V25, P5396, DOI 10.1038/sj.emboj.7601409; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Wisniewski JR, 2007, MOL CELL PROTEOMICS, V6, P72, DOI 10.1074/mcp.M600255-MCP200; Conte D, 2006, MOL CELL BIOL, V26, P699, DOI 10.1128/MCB.26.2.699-708.2006; Tang LY, 2011, EMBO J, V30, P4777, DOI 10.1038/emboj.2011.393; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; McComb S, 2012, CELL DEATH DIFFER, V19, P1791, DOI 10.1038/cdd.2012.59; Jung YS, 2011, MOL CELL BIOL, V31, P3997, DOI 10.1128/MCB.05808-11; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Husnjak K, 2012, ANNU REV BIOCHEM, V81, P291, DOI 10.1146/annurev-biochem-051810-094654; Girao H, 2009, EXP CELL RES, V315, P3587, DOI 10.1016/j.yexcr.2009.10.003; Smit JJ, 2014, EMBO REP, V15, P142, DOI 10.1002/embr.201338166; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Nishiyama A, 2013, NATURE, V502, P249, DOI 10.1038/nature12488; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Fallon L, 2006, NAT CELL BIOL, V8, P834, DOI 10.1038/ncb1441; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; Chen D, 2010, J BIOL CHEM, V285, P38214, DOI 10.1074/jbc.M110.101469; Nie LH, 2007, J BIOL CHEM, V282, P14616, DOI 10.1074/jbc.M610515200; Grou CP, 2012, J BIOL CHEM, V287, P12815, DOI 10.1074/jbc.M112.340158; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Boutet SC, 2010, MOL CELL, V40, P749, DOI 10.1016/j.molcel.2010.09.029; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Moore DJ, 2008, J NEUROCHEM, V105, P1806, DOI 10.1111/j.1471-4159.2008.05261.x; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Nakagawa T, 2008, GENE DEV, V22, P37, DOI 10.1101/gad.1609708; Emre NCT, 2005, MOL CELL, V17, P585, DOI 10.1016/j.molcel.2005.01.007; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Kim JM, 2008, BLOOD, V111, P5215, DOI 10.1182/blood-2007-09-113092; Kruse JP, 2009, J BIOL CHEM, V284, P3250, DOI 10.1074/jbc.M805658200; Ramanathan HN, 2012, CRIT REV BIOCHEM MOL, V47, P17, DOI 10.3109/10409238.2011.620943; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Arnesen T, 2009, P NATL ACAD SCI USA, V106, P8157, DOI 10.1073/pnas.0901931106; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Cao Jian, 2012, Front Oncol, V2, P26, DOI 10.3389/fonc.2012.00026; Da Silva-Ferrada E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025397; Durany N, 1997, BRIT J CANCER, V75, P969, DOI 10.1038/bjc.1997.168; Focant MC, 2013, SYNAPSE, V67, P532, DOI 10.1002/syn.21657; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; Hanson AJ, 2012, MOL CELL, V45, P619, DOI 10.1016/j.molcel.2011.12.032; Jin HS, 2009, CANCER RES, V69, P1782, DOI 10.1158/0008-5472.CAN-08-2256; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; Kravtsova-Ivantsiv Y, 2009, MOL CELL, V33, P496, DOI 10.1016/j.molcel.2009.01.023; Lee JC, 2005, APOPTOSIS, V10, P1483, DOI 10.1007/s10495-005-1833-z; Lin DH, 2005, P NATL ACAD SCI USA, V102, P4306, DOI 10.1073/pnas.0409767102; Marin I, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-267; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; Nakagawa T, 2015, MOL CELL, V57, P247, DOI 10.1016/j.molcel.2014.12.002; Niikura Y, 2015, DEV CELL, V32, P589, DOI 10.1016/j.devcel.2015.01.024; Onishi Y, 2005, BIOCHEM BIOPH RES CO, V336, P799, DOI 10.1016/j.bbrc.2005.08.175; Saha T, 2006, J CELL SCI, V119, P1371, DOI 10.1242/jcs.02851; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Tomida J, 2008, J BIOL CHEM, V283, P9071, DOI 10.1074/jbc.M709835200; Usuba T, 2001, INT J CANCER, V94, P662, DOI 10.1002/ijc.1524; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522	149	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	JUL	2015	20	7					543	562		10.1111/gtc.12250		20	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CM1GX	WOS:000357430400001		
J	Tsujita, T; Baird, L; Furusawa, Y; Katsuoka, F; Hou, Y; Gotoh, S; Kawaguchi, S; Yamamoto, M				Tsujita, Tadayuki; Baird, Liam; Furusawa, Yuki; Katsuoka, Fumiki; Hou, Yoshika; Gotoh, Satomi; Kawaguchi, Shin-ichi; Yamamoto, Masayuki			Discovery of an NRF1-specific inducer from a large-scale chemical library using a direct NRF1-protein monitoring system	GENES TO CELLS			English	Article							PROTEASOME GENE-EXPRESSION; TRANSCRIPTION FACTOR; KEAP1-NRF2 PATHWAY; NRF1; DEGRADATION; MECHANISMS; PROTEIN; STRESS; SELECTION; FACTOR-1	NRF1 (NF-E2-p45-related factor 1) plays an important role in the regulation of genes encoding proteasome subunits, a cystine transporter, and lipid-metabolizing enzymes. Global and tissue-specific disruptions of the Nrf1 gene in mice result in embryonic lethality and spontaneous development of severe tissue defects, respectively, suggesting NRF1 plays a critical role in vivo. Mechanistically, the continuous degradation of the NRF1 protein by the proteasome is regarded as a major regulatory nexus of NRF1 activity. To develop NRF1-specific inducers that act to overcome the phenotypes related to the lack of NRF1 activity, we constructed a novel NRF1 Delta C-Luc fusion protein reporter and developed cell lines that stably express the reporter in Hepa1c1c7 cells for use in high-throughput screening. In screening of a chemical library with this reporter system, we identified two hit compounds that significantly induced luciferase activity. Through an examination of a series of derivatives of one of the hit compounds, we identified T1-20, which induced a 70-fold increase in luciferase activity. T1-20 significantly increased the level of NRF1 protein in the mouse liver, indicating that the compound is also functional in vivo. Thus, these results show the successful identification of the first small chemical compounds which specifically and significantly induce NRF1.	[Tsujita, Tadayuki; Baird, Liam; Furusawa, Yuki; Katsuoka, Fumiki; Hou, Yoshika; Gotoh, Satomi; Yamamoto, Masayuki] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Tsujita, Tadayuki; Kawaguchi, Shin-ichi] Tohoku Univ, Grad Sch Med, Dept Mol Med & Therapy, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Katsuoka, Fumiki; Yamamoto, Masayuki] Tohoku Univ, Grad Sch Med, Dept Biosci Drug Discovery, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Furusawa, Yuki] Mochida Pharmaceut Co Ltd, Pharmaceut Res Ctr, Shizuoka 4128524, Japan; [Katsuoka, Fumiki; Yamamoto, Masayuki] Tohoku Univ, Tohoku Med Megabank Org, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Kawaguchi, Shin-ichi] Osaka Prefecture Univ, Dept Appl Chem, Grad Sch Engn, Naka Ku, Sakai, Osaka 5998531, Japan	Yamamoto, M (reprint author), Tohoku Univ, Grad Sch Med, Dept Med Biochem, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	masiyamamoto@med.tohoku.ac.jp	Kawaguchi, Shin-ichi/D-1182-2012		Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) from MEXT, Japan; JSPS Fellows [24-5784]; JSPS KAKENHI [25750357, 26860168, 24249015, 26111002]; Adaptable and Seamless Technology Transfer Program through Target-driven RD (A-STEP) [J120001909]; Core Research for Evolutional Science and Technology from Japan Science and Technology Agency	We thank Ms Sayoi Inomata and Ms Misaki Takaku for technical assistance and the Biomedical Research Core of Tohoku University Graduate School of Medicine for technical support. We also thank the Open Innovation Center for Drug Discovery, University of Tokyo (OCDD) for supplying the 9600 core chemical library and assisting our high-throughput screening. Y.F. is an employee of Mochida Pharmaceutical Co. Ltd. This work was supported in part by Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) (T.T. and M.Y.)and Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (T.T. and M.Y.) from the MEXT, Japan, Grant-in-Aid for JSPS Fellows 24-5784 (S.K.), JSPS KAKENHI grant 25750357 (T.T.), 26860168 (S. K.), 24249015 (M.Y.), 26111002 (M.Y.), and the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) grant J120001909 (T.T.) and J120001909 (S.K.), the Core Research for Evolutional Science and Technology grant (M.Y.) from Japan Science and Technology Agency.	Ohtsuji M, 2008, J BIOL CHEM, V283, P33554, DOI 10.1074/jbc.M804597200; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Chen LY, 2003, MOL CELL BIOL, V23, P4673, DOI 10.1128/MCB.23.13.4673-4686.2003; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Murphy P, 2000, MECH DEVELOP, V97, P141, DOI 10.1016/S0925-4773(00)00413-5; Kobayashi A, 2011, GENES CELLS, V16, P692, DOI 10.1111/j.1365-2443.2011.01522.x; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Wang HB, 2011, MOL CANCER THER, V10, P69, DOI 10.1158/1535-7163.MCT-10-0581; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; STREKOWSKI L, 1991, J MED CHEM, V34, P1739, DOI 10.1021/jm00109a031; Hosoya T, 2004, ORG BIOMOL CHEM, V2, P637, DOI 10.1039/b316221d; Liby KT, 2012, PHARMACOL REV, V64, P972, DOI 10.1124/pr.111.004846; Tsuchiya Y, 2011, MOL CELL BIOL, V31, P4500, DOI 10.1128/MCB.05663-11; Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029; Lee CS, 2013, FEBS J, V280, P3609, DOI 10.1111/febs.12350; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Tsujita T, 2011, GENES CELLS, V16, P46, DOI 10.1111/j.1365-2443.2010.01466.x; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; Xu ZR, 2005, P NATL ACAD SCI USA, V102, P4120, DOI 10.1073/pnas.0500660102; Tsuchiya Y, 2013, MOL CELL BIOL, V33, P3461, DOI 10.1128/MCB.01271-12; Uruno A, 2015, ARCH BIOCHEM BIOPHYS, V566, P76, DOI 10.1016/j.abb.2014.12.012; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Lee CS, 2011, P NATL ACAD SCI USA, V108, P8408, DOI 10.1073/pnas.1019209108; Steffen J, 2010, MOL CELL, V40, P147, DOI 10.1016/j.molcel.2010.09.012; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Hirotsu Y, 2011, GENES CELLS, V16, P406, DOI 10.1111/j.1365-2443.2011.01496.x; Radhakrishnan SK, 2014, ELIFE, V3, DOI [10.7554/eLife.01856, 10.7554/elife.01856]; SPENCER SR, 1991, BIOCHEM J, V273, P711; Tsujita T, 2015, TOHOKU J EXP MED, V235, P151, DOI 10.1620/tjem.235.151; Tsujita T, 2014, MOL CELL BIOL, V34, P3800, DOI 10.1128/MCB.00110-14; YAMAZAKI H, 2011, MOL CELL BIOL, V32, P808; Zheng HZ, 2015, ANTIOXID REDOX SIGN, V22, P819, DOI 10.1089/ars.2014.6017	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	JUL	2015	20	7					563	577		10.1111/gtc.12248		15	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CM1GX	WOS:000357430400002		
J	Kitamura, Y; Murata, Y; Park, JH; Kotani, T; Imada, S; Saito, Y; Okazawa, H; Azuma, T; Matozaki, T				Kitamura, Yasuaki; Murata, Yoji; Park, Jung-ha; Kotani, Takenori; Imada, Shinya; Saito, Yasuyuki; Okazawa, Hideki; Azuma, Takeshi; Matozaki, Takashi			Regulation by gut commensal bacteria of carcinoembryonic antigen-related cell adhesion molecule expression in the intestinal epithelium	GENES TO CELLS			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ADAPTIVE IMMUNITY; COLON; RECEPTORS; CEACAM1; INNATE; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION; HOMEOSTASIS	Carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 1 and CEACAM20, immunoglobulin superfamily members, are predominantly expressed in intestinal epithelial cells (IECs) and co-localized at the apical surface of these cells. We here showed that the expression of mouse CEACAM1 and CEACAM20 at both mRNA and protein levels was markedly reduced in IECs of the small intestine by the treatment of mice with antibiotics against Gram-positive bacteria. The expression of both proteins was also decreased in IECs of the small intestine from germ-free mice, compared with that from control specific-pathogen-free mice. Exposure of intestinal organoids to IFN-gamma markedly increased the expression of either CEACAM1 or CEACAM20, whereas the exposure to TNF-alpha increased the expression of the former protein, but not that of the latter. In contrast, the expression of CEACAM20, but not of CEACAM1, in intestinal organoids was markedly increased by exposure to butyrate, a short-chain fatty acid produced by bacterial fermentation in the intestine. Collectively, our results suggest that Gram-positive bacteria promote the mRNA expression of CEACAM1 or CEACAM20 in the small intestine. Inflammatory cytokines or butyrate likely participates in such effects of commensal bacteria.	[Kitamura, Yasuaki; Murata, Yoji; Park, Jung-ha; Kotani, Takenori; Imada, Shinya; Saito, Yasuyuki; Okazawa, Hideki; Matozaki, Takashi] Kobe Univ, Grad Sch Med, Div Mol & Cellular Signaling, Dept Biochem & Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Kitamura, Yasuaki; Azuma, Takeshi] Kobe Univ, Grad Sch Med, Div Gastroenterol, Dept Internal Med,Chuo Ku, Kobe, Hyogo 6500017, Japan	Murata, Y (reprint author), Kobe Univ, Grad Sch Med, Div Mol & Cellular Signaling, Dept Biochem & Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	matozaki@med.kobe-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan	The authors would like to thank D. Tanaka and M. Inagaki for technical assistance. This work was supported by a grant-in-aid for Scientific Research (B) and (C), a grant-in-aid for Young Scientists (B) and a grant to the Global Center of Excellence Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Jones RM, 2013, EMBO J, V32, P3017, DOI 10.1038/emboj.2013.224; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; KHOURY KA, 1969, J EXP MED, V130, P659, DOI 10.1084/jem.130.3.659; Guilloteau P, 2010, NUTR RES REV, V23, P366, DOI 10.1017/S0954422410000247; Ou G, 2009, SCAND J IMMUNOL, V69, P150, DOI 10.1111/j.1365-3083.2008.02208.x; Kayama H, 2012, INT IMMUNOL, V24, P673, DOI 10.1093/intimm/dxs094; Beauchemin N, 2013, CANCER METAST REV, V32, P643, DOI 10.1007/s10555-013-9444-6; Zalzali H, 2008, ONCOGENE, V27, P7131, DOI 10.1038/onc.2008.331; Waldecker M, 2008, J NUTR BIOCHEM, V19, P587, DOI 10.1016/j.jnutbio.2007.08.002; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Ivashkiv LB, 2009, NAT IMMUNOL, V10, P340, DOI 10.1038/ni.1706; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Alexander KL, 2014, IMMUNOL REV, V260, P206, DOI 10.1111/imr.12180; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Zebhauser R, 2005, GENOMICS, V86, P566, DOI 10.1016/j.ygeno.2005.07.008; Wichmann A, 2013, CELL HOST MICROBE, V14, P582, DOI 10.1016/j.chom.2013.09.012; Ding QM, 2001, BIOCHEM BIOPH RES CO, V284, P282, DOI 10.1006/bbrc.2001.4969; Chen CJ, 1996, J BIOL CHEM, V271, P28181; Houde C, 2003, J BIOL CHEM, V278, P16929, DOI 10.1074/jbc.M301842200; Kammerer R, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-12; KARIN M, 1995, J BIOL CHEM, V270, P16483; Mori M, 2010, J CELL PHYSIOL, V224, P195, DOI 10.1002/jcp.22122; Muenzner P, 2002, J BIOL CHEM, V277, P7438, DOI 10.1074/jbc.M108135200; Murata Y, 2010, GENES CELLS, V15, P513, DOI 10.1111/j.1365-2443.2010.01398.x; Puhl NJ, 2012, ANAEROBE, V18, P67, DOI 10.1016/j.anaerobe.2011.12.007; Reikvam DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017996; Sadakata H, 2009, GENES CELLS, V14, P295, DOI 10.1111/j.1365-2443.2008.01270.x; Shimada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080604; Yamashita H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092904; Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053359; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	JUL	2015	20	7					578	589		10.1111/gtc.12247		12	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CM1GX	WOS:000357430400003		
J	Fuse, Y; Nakajima, H; Nakajima-Takagi, Y; Nakajima, O; Kobayashi, M				Fuse, Yuji; Nakajima, Hitomi; Nakajima-Takagi, Yaeko; Nakajima, Osamu; Kobayashi, Makoto			Heme-mediated inhibition of Bach1 regulates the liver specificity and transience of the Nrf2-dependent induction of zebrafish heme oxygenase 1	GENES TO CELLS			English	Article							TRANSCRIPTION FACTOR NETWORK; OXIDATIVE STRESS; REPRESSOR BACH1; GENE-EXPRESSION; NRF2; ANTIOXIDANT; ELEMENT; PROTEIN; PATHWAY; SYSTEM	The induction of the gene encoding heme oxygenase 1 (Hmox1, HO-1) by Nrf2 is unique compared with other Nrf2 targets. We previously showed that the Nrf2a-mediated induction of zebrafish hmox1a was liver specific and transient. We screened transcription factors that could repress the induction of hmox1a but not other Nrf2a targets and concluded that Bach1b was a prime candidate. In bach1b-knocked-down larvae, the induction of hmox1a was observed ectopically in nonliver tissues and persisted longer than normal fish, suggesting that Bach1 is the only regulator for both the liver-specific and transient induction of hmox1a. Co-knockdown of bach1b with its co-ortholog bach1a enhanced these effects. To determine why Bach1 could not repress the hmox1a induction in the liver, we analyzed the effects of a heme biosynthesis inhibitor, succinylacetone, and a heme precursor, hemin. Succinylacetone decreased the Nrf2a-mediated hmox1a induction, whereas pre-treatment with hemin caused ectopic induction of hmox1a in nonliver tissues, implying that the high heme levels in the liver may release the repressive activity of Bach1. Our results suggested that Bach1 regulates the liver specificity and transience of the Nrf2a-dependent induction of hmox1a and that heme mediates this regulation through Bach1 inhibition based on its level in each tissue.	[Fuse, Yuji; Nakajima, Hitomi; Nakajima-Takagi, Yaeko; Kobayashi, Makoto] Univ Tsukuba, Fac Med, Dept Mol & Dev Biol, Tsukuba, Ibaraki 3058575, Japan; [Nakajima, Osamu] Yamagata Univ, Mol Genet Res Lab, Yamagata 9909585, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chuo Ku, Chiba 2608670, Japan	Kobayashi, M (reprint author), Univ Tsukuba, Fac Med, Dept Mol & Dev Biol, Tsukuba, Ibaraki 3058575, Japan.	makobayash@md.tsukuba.ac.jp	Kobayashi, Makoto/B-2537-2008		Ministry of Education, Science, Sports and Culture of Japan [24590340, 25118705, 26116705, 26520101]	We thank Katsuki Mukaigasa, Hiroshi Kaneko, Hiroshi Nakano, and Miho Takeuchi for experimental help, Christina-Sylvia Andrea for critical reading of the manuscript, and Miyuki Komeda in fish maintenance. This work was supported by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (to M. K.) (24590340, 25118705, 26116705, and 26520101).	Tan MKM, 2013, MOL CELL, V52, P9, DOI 10.1016/j.molcel.2013.08.018; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; Timme-Laragy AR, 2012, J BIOL CHEM, V287, P4609, DOI 10.1074/jbc.M111.260125; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Li L, 2008, J BIOL CHEM, V283, P3248, DOI 10.1074/jbc.M708702200; Zhang JY, 2006, MOL CELL BIOL, V26, P7942, DOI 10.1128/MCB.00700-06; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Zenke-Kawasaki Y, 2007, MOL CELL BIOL, V27, P6962, DOI 10.1128/MCB.0241-06; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; Igarashi K, 2007, J BIOCHEM, V141, P783, DOI 10.1093/jb/mvm106; Takagi Y, 2004, BIOCHEM BIOPH RES CO, V320, P62, DOI 10.1016/j.bbrc.2004.05.131; Mukaigasa K, 2012, MOL CELL BIOL, V32, P4455, DOI 10.1128/MCB.00481-12; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Suzuki T, 2005, BIOCHEM J, V388, P65, DOI 10.1042/BJ20041860; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; Tsujita T, 2011, GENES CELLS, V16, P46, DOI 10.1111/j.1365-2443.2010.01466.x; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; Wang WP, 2007, J BIOL CHEM, V282, P24670, DOI 10.1074/jbc.M700159200; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Jyrkkanen HK, 2011, BIOCHEM J, V440, P167, DOI 10.1042/BJ20110526; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Itoh K, 2010, ANTIOXID REDOX SIGN, V13, P1665, DOI 10.1089/ars.2010.3222; Kobayashi M, 2009, MOL CELL BIOL, V29, P493, DOI 10.1128/MCB.01080-08; Suzuki H, 2004, EMBO J, V23, P2544, DOI 10.1038/sj.emboj.7600248; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; Igarashi K, 2014, TOHOKU J EXP MED, V232, P229; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Meyer RP, 2002, MOL PHARMACOL, V62, P1061, DOI 10.1124/mol.62.5.1061; Nakajima H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026884; Nakajima H., 2011, PLOS ONE, V7, DOI [10.1371/ annotation/ 50ee3aff- 3010- 4c42- a130- 70509c88a67e.), DOI 10.1371/ANN0TATI0N/50EE3AFF-3010-4C42-A130-70509C88A67E.)]; Wegiel B, 2014, ANTIOXID REDOX SIGN, V20, P1709, DOI 10.1089/ars.2013.5667; Zhang SQ, 2014, DIS MODEL MECH, V7, P837, DOI 10.1242/dmm.014951	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	JUL	2015	20	7					590	600		10.1111/gtc.12249		11	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CM1GX	WOS:000357430400004		
J	Yoshida, M; Ishihama, A; Yamamoto, K				Yoshida, Myu; Ishihama, Akira; Yamamoto, Kaneyoshi			Cross talk in promoter recognition between six NarL-family response regulators of Escherichia coli two-component system	GENES TO CELLS			English	Article							PHOSPHATE-TRANSPORT-SYSTEM; PROKARYOTIC GENOME REGULATION; BARA SENSOR KINASE; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTORS; ACETYL PHOSPHATE; RCS PHOSPHORELAY; GENE-EXPRESSION; ACID RESISTANCE; RNA-POLYMERASE	Bacterial two-component system (TCS) is composed of the sensor kinase (SK) and the response regulator (RR). After monitoring an environmental signal or condition, SK activates RR through phosphorylation, ultimately leading to the signal-dependent regulation of genome transcription. In Escherichia coli, a total of more than 30 SK-RR pairs exist, each forming a cognate signal transduction system. Cross talk of the signal transduction takes place at three stages: signal recognition by SK (stage 1); RR phosphorylation by SK (stage 2); and target recognition by RR (stage 3). Previously, we analyzed the stage 2 cross talk between the whole set of E. coli SK-RR pairs and found that the cross talk takes place for certain combinations. As an initial attempt to identify the stage 3 cross talk at the step of target promoter recognition by RR, we analyzed in this study the cross-recognition of target promoters by six NarL-family RRs, EvgA, NarL, NarP, RcsB, UhpA, and UvrY. Results of both in vivo and in vitro studies indicated that the stage 3 cross talk takes place for limited combinations, in particular, including a multifactor-regulated ydeP promoter.	[Yoshida, Myu; Yamamoto, Kaneyoshi] Hosei Univ, Dept Frontier Biosci, Koganei, Tokyo 1858584, Japan; [Ishihama, Akira; Yamamoto, Kaneyoshi] Hosei Univ, Res Inst Micronano Technol, Koganei, Tokyo 1840003, Japan	Yamamoto, K (reprint author), Hosei Univ, Dept Frontier Biosci, Koganei, Tokyo 1858584, Japan.	kanyamam@hosei.ac.jp			MEXT [S0801037]; JSPS-DST International Collaborations;  [21241047];  [18310133];  [25430173]	We thank Tsubasa Niino, Tomomi Adachi, Takuya Otsuka, and Noriko Iwata for construction of plasmids and E. coli strains. This work was supported by Grants-in-Aid for Scientific Research (A) (21241047), (B) (18310133) and (C) (25430173) to AI, MEXT-Supported Program for the Strategic Research Foundation at Private Universities 2008-2012 (S0801037), and JSPS-DST International Collaborations. We also thank the National BioResource Project (NBRP) of Japan for providing E. coli strains.	Szurmant H, 2007, CURR OPIN STRUC BIOL, V17, P706, DOI 10.1016/j.sbi.2007.08.019; Barbieri CM, 2008, ANAL BIOCHEM, V376, P73, DOI 10.1016/j.ab.2008.02.004; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Ishihama A, 2010, FEMS MICROBIOL REV, V34, P628, DOI 10.1111/j.1574-6976.2010.00227.x; Galperin MY, 2010, CURR OPIN MICROBIOL, V13, P150, DOI 10.1016/j.mib.2010.01.005; Majdalani N, 2005, ANNU REV MICROBIOL, V59, P379, DOI 10.1146/annurev.micro.59.050405.101230; Wang HN, 2000, J BACTERIOL, V182, P5813, DOI 10.1128/JB.182.20.5813-5822.2000; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200; Ogasawara H, 2011, J BACTERIOL, V193, P2587, DOI 10.1128/JB.01468-10; Mondragon V, 2006, J BACTERIOL, V188, P8303, DOI 10.1128/JB.01052-06; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; Pernestig AK, 2001, J BIOL CHEM, V276, P225; Ogasawara H, 2010, MICROBIOL-SGM, V156, P2470, DOI 10.1099/mic.0.039131-0; Ishihama A, 2014, J BACTERIOL, V196, P2718, DOI 10.1128/JB.01579-14; Szurmant H, 2010, CURR OPIN MICROBIOL, V13, P190, DOI 10.1016/j.mib.2010.01.007; Chavez RG, 2010, J BACTERIOL, V192, P2009, DOI 10.1128/JB.01685-09; Laub MT, 2007, ANNU REV GENET, V41, P121, DOI 10.1146/annurev.genet.41.042007.170548; Liu MY, 1997, J BIOL CHEM, V272, P17502, DOI 10.1074/jbc.272.28.17502; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; Oshima T, 2002, MOL MICROBIOL, V46, P281, DOI 10.1046/j.1365-2958.2002.03170.x; Verhamme DT, 2002, MICROBIOL-SGM, V148, P69; Suzuki K, 2002, J BACTERIOL, V184, P5130, DOI 10.1128/JB.184.18.5130-5140.2002; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; GUZMAN LM, 1995, J BACTERIOL, V177, P4121; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; Huang YH, 2006, RES MICROBIOL, V157, P206, DOI 10.1016/j.resmic.2005.11.005; JISHAGE M, 1995, J BACTERIOL, V177, P6832; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Clarke DJ, 2010, FUTURE MICROBIOL, V5, P1173, DOI [10.2217/fmb.10.83, 10.2217/FMB.10.83]; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Blouin K, 1996, APPL ENVIRON MICROB, V62, P2013; Burton NA, 2010, J MOL BIOL, V401, P726, DOI 10.1016/j.jmb.2010.06.054; Castanie-Cornet M. P., 2007, MICROBIOLOGY, V13, P23; Clarke MB, 2005, MOL MICROBIOL, V57, P1734, DOI 10.1111/j.1365-2958.2005.04792.x; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Eguchi Y, 2003, MICROBIOL-SGM, V149, P2819, DOI 10.1099/mic.0.26460-0; Eguchi Y, 2014, J BACTERIOL, V196, P3140, DOI 10.1128/JB.01742-14; Hagiwara D, 2003, J BACTERIOL, V185, P5735, DOI 10.1128/JB.185.19.5735-5746.2003; Hobman JL, 2007, MICROBIOLOGY MONOGRA, V6, P77; Ishihama A, 2012, P JPN ACAD B-PHYS, V88, P485, DOI 10.2183/pjab.88.485; Itou J, 2009, BIOSCI BIOTECH BIOCH, V73, P870, DOI 10.1271/bbb.80795; Johnson MD, 2014, MOL MICROBIOL, V93, P911, DOI 10.1111/mmi.12704; KADNER RJ, 1994, RES MICROBIOL, V145, P381, DOI 10.1016/0923-2508(94)90085-X; KADNER RJ, 1983, J BACTERIOL, V155, P1052; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; Nakano M, 2014, FEMS MICROBIOL LETT, V355, P93, DOI 10.1111/1574-6968.12466; Procaccini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019729; PRUSS BM, 1994, MOL MICROBIOL, V12, P973; Shimada K, 2013, MICROBIOL-SGM, V159, P2501, DOI 10.1099/mic.0.067538-0; Shimada T., 2011, MOL MICROBIOL, V82, P376; STEWART V, 1994, RES MICROBIOL, V145, P450, DOI 10.1016/0923-2508(94)90093-0; STOUT V, 1994, RES MICROBIOL, V145, P389, DOI 10.1016/0923-2508(94)90086-8; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; Verhamme DT, 2002, J BACTERIOL, V184, P4205, DOI 10.1128/JB.184.15.4205-4210.2002; WESTON LA, 1988, J BACTERIOL, V170, P3375; Yamamoto K, 2014, BIOSCI BIOTECH BIOCH, V78, P737, DOI 10.1080/09168451.2014.915731; Yamamoto K, 2011, FEMS MICROBIOL LETT, V323, P88, DOI 10.1111/j.1574-6968.2011.02364.x; Yamamoto K, 2014, MICROBIOL-SGM, V160, P1903, DOI 10.1099/mic.0.079889-0; Yamanaka Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111962; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	64	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	JUL	2015	20	7					601	612		10.1111/gtc.12251		12	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CM1GX	WOS:000357430400005		
J	Imai, H; Miyoshi, T; Murakami, R; Ito, K; Ishino, Y; Uchiumi, T				Imai, Hirotatsu; Miyoshi, Tomohiro; Murakami, Ryo; Ito, Kosuke; Ishino, Yoshizumi; Uchiumi, Toshio			Functional role of the C-terminal tail of the archaeal ribosomal stalk in recruitment of two elongation factors to the sarcin/ricin loop of 23S rRNA	GENES TO CELLS			English	Article							ESCHERICHIA-COLI RIBOSOME; GTPASE-ASSOCIATED CENTER; EF-G; STRUCTURAL BASIS; IN-VITRO; INACTIVATING PROTEIN; TRANSLATION FACTORS; EUKARYOTIC STALK; FACTOR-BINDING; FACTOR TU	Two types of elongation factors alternate in their binding to the factor-binding center of the ribosome. Both binding events are accompanied by GTP hydrolysis and drive the translation elongation cycle. The multicopy ribosomal protein family, termed the stalk, contributes actively to the elongation process. Recent evidence indicates that the mobile C-terminal tail of archaeal stalk aP1 directly interacts with both the elongation factors aEF1A and aEF2. To investigate the functional significance of these interactions in recruitment of elongation factors to the factor-binding center of the ribosome, we substituted the archaeal stalk complex aL10 center dot aP1 for the bL10 center dot bL12 stalk complex in the Escherichia coli 50S subunit. The resultant hybrid ribosome accessed archaeal aEF1A and aEF2 in a manner dependent on the C-terminal tail containing the hydrophobic residues Leu103, Leu106 and Phe107. Bases G2659 and A2660 in the sarcin/ricin loop (SRL) of 23S rRNA were protected against DMS modification by both factors as was A1067 by aEF2. Mutagenesis indicated that this protection was dependent on the intact C-terminal tail of aP1. The results suggest a crucial role for the interactions between the stalk C-terminal tail and elongation factors in their recruitment to the SRL of 23S rRNA within the ribosome.	[Imai, Hirotatsu; Miyoshi, Tomohiro; Murakami, Ryo; Ito, Kosuke; Uchiumi, Toshio] Niigata Univ, Dept Biol, Fac Sci, Nishi Ku, Niigata 9502181, Japan; [Ishino, Yoshizumi] Kyushu Univ, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan	Uchiumi, T (reprint author), Niigata Univ, Dept Biol, Fac Sci, Nishi Ku, 8050 Ikarashi 2-No Cho, Niigata 9502181, Japan.	uchiumi@bio.sc.niigata-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24370073, 26242075]	We thank Yao Min of Hokkaido University for her critical reading of this manuscript and helpful advice about this study. This work was supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan [24370073 to T.U. and 26242075 to Y.I.].	SANTOS C, 1995, J BIOL CHEM, V270, P20608; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Nomura N, 2012, P NATL ACAD SCI USA, V109, P3748, DOI 10.1073/pnas.1112934109; Ban N, 2014, CURR OPIN STRUC BIOL, V24, P165, DOI [10.1016/j.sbi.2014.01.002, 10.1016/j.sbi.2014.91.002]; Gao YG, 2009, SCIENCE, V326, P694, DOI 10.1126/science.1179709; Clementi N, 2010, NAT CHEM BIOL, V6, P344, DOI 10.1038/nchembio.341; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Too PHM, 2009, NUCLEIC ACIDS RES, V37, P602, DOI 10.1093/nar/gkn922; Diaconu M, 2005, CELL, V121, P991, DOI 10.1016/j.cell.2005.04.015; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Harms JM, 2008, MOL CELL, V30, P26, DOI 10.1016/j.molcel.2008.01.009; Schmeing TM, 2009, SCIENCE, V326, P688, DOI 10.1126/science.1179700; Voorhees RM, 2010, SCIENCE, V330, P835, DOI 10.1126/science.1194460; Wilson DN, 2005, CRIT REV BIOCHEM MOL, V40, P243, DOI 10.1080/10409230500256523; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; Benelti D, 2007, METHOD ENZYMOL, V430, P79, DOI 10.1016/S0076-6879(07)30005-0; Chen Y, 2013, NAT STRUCT MOL BIOL, V20, P1077, DOI 10.1038/nsmb.2645; Connell SR, 2007, MOL CELL, V25, P751, DOI 10.1016/j.molcel.2007.01.027; Datta PP, 2005, MOL CELL, V20, P723, DOI 10.1016/j.molcel.2005.10.028; Grela P, 2008, J MOL EVOL, V67, P154, DOI 10.1007/s00239-008-9132-2; Hagiya A, 2005, J BIOL CHEM, V280, P39193, DOI 10.1074/jbc.M506050200; HAMEL E, 1972, J BIOL CHEM, V247, P6810; Hauryliuk V V, 2006, Mol Biol (Mosk), V40, P769; Helgstrand M, 2007, J MOL BIOL, V365, P468, DOI 10.1016/j.jmb.2006.10.025; Ito K, 2014, NUCLEIC ACIDS RES, V42, P14042, DOI 10.1093/nar/gku1248; Kavran JM, 2007, J MOL BIOL, V371, P1047, DOI 10.1016/j.jmb.2007.05.091; Kothe U, 2004, J MOL BIOL, V336, P1011, DOI 10.1016/j.jmb.2003.12.080; Kubarenko AV, 2005, MOL BIOL+, V39, P746; Lambert NJ, 2011, NUCLEIC ACIDS RES, V39, P4827, DOI 10.1093/nar/gkr077; Lee KM, 2012, NUCLEIC ACIDS RES, V40, P3172, DOI 10.1093/nar/gkr1143; Lee KM, 2013, NUCLEIC ACIDS RES, V41, P8776, DOI 10.1093/nar/gkt636; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; Liljas A, 2013, STRUCTURAL ASPECTS OF PROTEIN SYNTHESIS, 2ND EDITION, P149; Miyoshi T, 2008, NUCLEIC ACIDS RES, V36, P1783, DOI 10.1093/nar/gkm1171; Mohr M., 2002, BIOCHEMISTRY-US, V41, P12520; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Moller W., 1974, RIBOSOMES, P711; Naganuma T, 2010, J BIOL CHEM, V285, P4747, DOI 10.1074/jbc.M109.068098; Nomura T, 2006, BIOCHEM J, V396, P565, DOI 10.1042/BJ20060038; Shimizu T, 2002, NUCLEIC ACIDS RES, V30, P2620, DOI 10.1093/nar/gkf379; Stark H, 1997, NATURE, V389, P403; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; Uchiumi T, 2002, J BIOL CHEM, V277, P3857, DOI 10.1074/jbc.M107730200; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; Uchiumi T, 1999, J BIOL CHEM, V274, P27578, DOI 10.1074/jbc.274.39.27578; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wool A. G., 1992, TRENDS BIOCHEM SCI, V17, P266	52	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	JUL	2015	20	7					613	624		10.1111/gtc.12256		12	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CM1GX	WOS:000357430400006		
J	Fujishiro, H; Nakamura, S; Sato, K; Iseki, E				Fujishiro, Hiroshige; Nakamura, Shinichiro; Sato, Kiyoshi; Iseki, Eizo			Prodromal dementia with Lewy bodies	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Review						Alzheimer's disease; Lewy body disease; mild cognitive impairment; neurocognitive disorder; Parkinson's disease	SLEEP BEHAVIOR DISORDER; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS ASSOCIATION WORKGROUPS; I-123-MIBG CARDIAC SCINTIGRAPHY; IDIOPATHIC PARKINSONS-DISEASE; VISUOSPATIAL DEFICITS PREDICT; AUTOPSY-CONFIRMED DEMENTIA; A-BETA DEPOSITION; ALPHA-SYNUCLEIN; BODY DISEASE	Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementing disorder after Alzheimer's disease (AD), but there is limited information regarding the prodromal DLB state compared with that of AD. Parkinson's disease (PD) and DLB share common prodromal symptoms with Lewy body disease (LBD), allowing us to use a common strategy for identifying the individuals with an underlying pathophysiology of LBD. Dysautonomia, olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD) and psychiatric symptoms antedate the onset of dementia by years or even decades in patients with DLB. Although RBD is the most potentially accurate prodromal predictor of DLB, disease progression before the onset of dementia could differ between the prodromal DLB state with and without RBD. Experts who specialize in idiopathic RBD and DLB might need communication in order to clarify the clinical relevance of RBD with the disease progression of DLB. The presence of prodromal LBD symptoms or findings of occipital hypoperfusion/hypometabolism helps us to predict the possible pathophysiological process of LBD in non-demented patients. This approach might provide the opportunity for additional neuroimaging, including cardiac I-123-metaiodobenzylguanidine scintigraphy and dopamine transporter imaging. Although limited radiological findings in patients with prodromal DLB states have been reported, there is now a need for larger clinical multisite studies with pathological verification. The long prodromal phase of DLB provides a critical opportunity for potential intervention with disease-modifying therapy, but only if we are able to clearly identify the diversity in the clinical courses of DLB. In the present article, we reviewed the limited literature regarding the clinical profiles of prodromal DLB. Geriatr Gerontol Int 2015; 15: 817-826.	[Fujishiro, Hiroshige] Nagoya Univ, Grad Sch Med, Dept Sleep Med, Nagoya, Aichi 4668550, Japan; [Nakamura, Shinichiro] Koshigaya Municipal Hosp, Dept Neurol, Koshigaya, Japan; [Sato, Kiyoshi; Iseki, Eizo] Juntendo Univ Sch Med, Juntendo Tokyo Koto Geriatr Med Ctr, PET CT Dementia Res Ctr, Koto, Japan	Fujishiro, H (reprint author), Nagoya Univ, Grad Sch Med, Dept Sleep Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	fujishiro17@hotmail.co.jp			21st Novartis Foundation of Gerontrological Research; Japan Geriatrics Society; Ministry of Education, Culture, Sports, Science and Technology in Japan [20536924]	This study was supported in part by the 21st Novartis Foundation of Gerontrological Research and the Japan Geriatrics Society (2011), and a Grant-in-Aid for Young Scientists (B) 20536924 from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	American Psychiatric Association, 2013, DIAGN STAT MAN DIS; Kantarci K, 2012, NEUROBIOL AGING, V33, P2091, DOI 10.1016/j.neurobiolaging.2011.09.024; Ross GW, 2004, ANN NEUROL, V56, P532, DOI 10.1002/ana.20026; Postuma RB, 2011, ANN NEUROL, V69, P811, DOI 10.1002/ana.22282; Gomperts SN, 2012, MOVEMENT DISORD, V27, P965, DOI 10.1002/mds.25048; Parnetti L, 2008, BIOL PSYCHIAT, V64, P850, DOI 10.1016/j.biopsych.2008.02.016; Iranzo A, 2013, LANCET NEUROL, V12, P443, DOI 10.1016/S1474-4422(13)70056-5; Ballard C, 2006, NEUROLOGY, V67, P1931, DOI 10.1212/01.wnl.0000249130.63615.cc; Orimo S, 2008, BRAIN, V131, P642, DOI 10.1093/brain/awm302; Yoshita M, 2006, NEUROLOGY, V66, P1850, DOI 10.1212/01.wnl.0000219640.59984.a7; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Minoshima S, 2001, ANN NEUROL, V50, P358, DOI 10.1002/ana.1133; Hall S, 2012, ARCH NEUROL-CHICAGO, V69, P1445, DOI 10.1001/archneurol.2012.1654; Schenck CH, 1996, NEUROLOGY, V46, P388; Boot BP, 2012, ANN NEUROL, V71, P49, DOI 10.1002/ana.22655; Postuma RB, 2012, MOVEMENT DISORD, V27, P720, DOI 10.1002/mds.24939; Halliday GM, 2011, ACTA NEUROPATHOL, V122, P187, DOI 10.1007/s00401-011-0852-9; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Boeve BF, 2013, SLEEP MED, V14, P754, DOI 10.1016/j.sleep.2012.10.015; Iranzo A, 2006, LANCET NEUROL, V5, P572, DOI 10.1016/S1474-4422(06)70476-8; Wing YK, 2012, J NEUROL NEUROSUR PS, V83, P470, DOI 10.1136/jnnp-2011-301232; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Frigerio R, 2011, NEUROBIOL AGING, V32, P857, DOI 10.1016/j.neurobiolaging.2009.05.019; Postuma RB, 2009, BRAIN, V132, P3298, DOI 10.1093/brain/awp244; Williams SS, 2009, J NEUROL NEUROSUR PS, V80, P667, DOI 10.1136/jnnp.2008.155895; Bloch A, 2006, NEUROPATH APPL NEURO, V32, P284, DOI 10.1111/j.1365-2990.2006.00727.x; Pletnikova O, 2005, NEUROBIOL AGING, V26, P1183, DOI 10.1016/j.neurobiolaging.2004.10.006; Molano J, 2010, BRAIN, V133, P540, DOI 10.1093/brain/awp280; Fujishiro H, 2008, MOVEMENT DISORD, V23, P1085, DOI 10.1002/mds.21989; Greffard S, 2006, ARCH NEUROL-CHICAGO, V63, P584, DOI 10.1001/archneur.63.4.584; Lashley T, 2008, ACTA NEUROPATHOL, V115, P417, DOI 10.1007/s00401-007-0336-0; Zaccai J, 2008, NEUROLOGY, V70, P1042, DOI 10.1212/01.wnl.0000306697.48738.b6; Chiba Y, 2012, DEMENT GERIATR COGN, V33, P273, DOI 10.1159/000339363; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Onofrj M, 2010, NEUROLOGY, V74, P1598, DOI 10.1212/WNL.0b013e3181df09dd; Miyamoto T, 2008, SLEEP, V31, P717; Tiraboschi P, 2006, BRAIN, V129, P729, DOI 10.1093/brain/awh725; Fujishiro H, 2013, PSYCHOGERIATRICS, V13, P128, DOI 10.1111/psyg.12005; Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398; Fujishiro H, 2008, J NEUROPATH EXP NEUR, V67, P649, DOI 10.1097/NEN.0b013e31817d7a1d; Walker Z, 2007, J NEUROL NEUROSUR PS, V78, P1176, DOI 10.1136/jnnp.2006.110122; Fujimi K, 2008, BRAIN PATHOL, V18, P317, DOI 10.1111/j.1750-3639.2008.00169.x; Ferman TJ, 2011, NEUROLOGY, V77, P875, DOI 10.1212/WNL.0b013e31822c9148; Boeve BF, 2010, ANN NY ACAD SCI, V1184, P15, DOI 10.1111/j.1749-6632.2009.05115.x; Boeve BF, 2007, SLEEP MED, V8, P60, DOI 10.1016/j.sleep.2006.08.017; Ross GW, 2006, MOVEMENT DISORD, V21, P2062, DOI 10.1002/mds.21076; Fujishiro H, 2010, NEUROSCI LETT, V486, P19, DOI 10.1016/j.neulet.2010.09.036; Savica R, 2010, ARCH NEUROL-CHICAGO, V67, P798, DOI 10.1001/archneurol.2010.135; Hamilton JM, 2008, NEUROPSYCHOLOGY, V22, P729, DOI 10.1037/a0012949; Abbott RD, 2007, MOVEMENT DISORD, V22, P1581, DOI 10.1002/mds.21560; Postuma RB, 2012, BRAIN, V135, P1860, DOI 10.1093/brain/aws093; Schenck CH, 2013, SLEEP MED, V14, P744, DOI 10.1016/j.sleep.2012.10.009; Fujishiro H, 2013, J NEUROL SCI, V334, P48, DOI 10.1016/j.jns.2013.07.013; Hurtig HI, 2000, NEUROLOGY, V54, P1916; Kaufmann H, 2004, NEUROLOGY, V63, P1093; Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Iranzo A, 2011, LANCET NEUROL, V10, P797, DOI 10.1016/S1474-4422(11)70152-1; Hamilton JM, 2012, AM J GERIAT PSYCHIAT, V20, P773, DOI 10.1097/JGP.0b013e31823033bc; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Fantini ML, 2011, SLEEP, V34, P619; Tsopelas C, 2011, BRIT J PSYCHIAT, V198, P109, DOI 10.1192/bjp.bp.110.078816; Haaxma CA, 2008, MOVEMENT DISORD, V23, P1707, DOI 10.1002/mds.22197; Ballard C, 1999, AM J PSYCHIAT, V156, P1039; Gaenslen A, 2011, MOVEMENT DISORD, V26, P653, DOI 10.1002/mds.23499; Braak H, 2005, NEUROLOGY, V64, P1404; Postuma RB, 2013, MOVEMENT DISORD, V28, P597, DOI 10.1002/mds.25445; Bliwise DL, 2010, ANN NEUROL, V68, P353, DOI 10.1002/ana.22076; Boeve BF, 2012, PARKINSONISM RELA S1, V18, P41; Colom-Cadena M, 2013, J NEUROPATH EXP NEUR, V72, P1203, DOI 10.1097/NEN.0000000000000018; Dickson DW, 2002, J GERIATR PSYCH NEUR, V15, P210; Dugger BN, 2012, MOVEMENT DISORD, V27, P72, DOI 10.1002/mds.24003; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Ferman TJ, 2013, NEUROLOGY, V81, P2032, DOI 10.1212/01.wnl.0000436942.55281.47; Sinha N, 2012, INT J GERIATR PSYCH, V27, P443, DOI 10.1002/gps.2749; Fujishiro H, 2012, INT J GERIATR PSYCH, V27, P1138, DOI 10.1002/gps.2836; Fujishiro H, 2010, PSYCHOGERIATRICS, V10, P144, DOI 10.1111/j.1479-8301.2010.00325.x; Fujishiro H, 2012, J NEUROL SCI, V315, P115, DOI 10.1016/j.jns.2011.11.012; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Gomperts SN, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0472-6; Halliday GM, 2010, ANN NY ACAD SCI, V16, P653; Iida N, 2013, PSYCHIAT CLIN NEUROS, V67, P281, DOI 10.1111/pcn.12044; Jicha GA, 2010, NEUROBIOL AGING, V31, P1805, DOI 10.1016/j.neurobiolaging.2008.09.017; Kanemaru K, 2000, NEUROLOGY, V54, P1875; KAYE JA, 1994, ARCH NEUROL-CHICAGO, V51, P1205; KOSAKA K, 1990, J NEUROL, V237, P197, DOI 10.1007/BF00314594; Louis ED, 2005, NEUROLOGY, V64, P1157; Louis ED, 2007, MOVEMENT DISORD, V22, P1681, DOI 10.1002/mds.21433; McKeith I, 2007, LANCET NEUROL, V6, P305, DOI 10.1016/S1474-4422(07)70057-1; Miyamoto T, 2011, EUR J NEUROL, V18, P1275, DOI 10.1111/j.1468-1331.2011.03392.x; Miyamoto T, 2010, SLEEP MED, V11, P458, DOI 10.1016/j.sleep.2009.09.013; Nomura T, 2013, SLEEP MED, V14, P131, DOI 10.1016/j.sleep.2012.10.011; Obi K, 2008, EXP NEUROL, V210, P409, DOI 10.1016/j.expneurol.2007.11.019; Poewe W, 2003, NEUROLOGICAL DISORDE, P1081, DOI 10.1016/B978-012125831-3/50270-7; Postuma RB, 2011, ANN NEUROL, V69, P905, DOI 10.1002/ana.22259; Sakakibara Ryuji, 2012, Am J Neurodegener Dis, V1, P146; Siepel FJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002642; Takahashi S, 2009, PSYCHOGERIATRICS, V9, P56, DOI 10.1111/j.1479-8301.2009.00292.x; UCHIYAMA M, 1995, NEUROLOGY, V45, P709; Yamanaka Y, 2007, MOVEMENT DISORD, V22, P595, DOI 10.1002/mds.21332	100	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					817	826		10.1111/ggi.12466		10	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100001		
J	Ishii, T; Gemma, A; Kida, K				Ishii, Takeo; Gemma, Akihiko; Kida, Kozui			Senescence is involved in the pathogenesis of chronic obstructive pulmonary disease through effects on telomeres and the anti-aging molecule fibroblast growth factor 23	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						aging; emphysema; fibroblast growth factor23; genetic variation; telomere	LUNG-FUNCTION; EMPHYSEMA; SUSCEPTIBILITY; SMOKERS; LENGTH; COPD	AimFibroblast growth factor23 knockout mice develop premature aging and emphysema, indicating that dysregulation of the normal aging process is involved in the pathobiology of chronic obstructive pulmonary disease. Thus, we explored the association among a coding single-nucleotide polymorphism of fibroblast growth factor23, its protein concentration in serum and telomere length in patients with chronic obstructive pulmonary disease. MethodsThe study involved 361 smokers; among whom, 244 were patients with chronic obstructive pulmonary disease. We genotyped a coding single-nucleotide polymorphism of fibroblast growth factor23, rs7955866, and measured the telomere length of the peripheral blood cells. We also determined emphysema severity and airflow obstruction using computed tomography and pulmonary function tests, respectively. Furthermore, we analyzed the association between the disease phenotypes and fibroblast growth factor23 genotypes or telomere length of peripheral blood leukocytes, as well as the association between the serum level of the studied protein and its genotypes. ResultsThe mice with Aalleles on rs7955866 showed severe upper lung emphysema (P=0.008). The serum concentration of the tested protein was lower in the mice with Aallele than in the Ghomozygotes (P=0.004). Telomere shortening was associated with airflow obstruction (P=0.009), but not with upper lung emphysema. ConclusionsA variation of fibroblast growth factor23 with a reduced serum concentration appeared to promote emphysema formation. Telomere shortening in peripheral blood leukocytes was not associated with emphysema, but with airflow obstruction in chronic obstructive pulmonary disease through an independent mechanism. Geriatr Gerontol Int 2015; 15: 827-833.	[Ishii, Takeo; Gemma, Akihiko; Kida, Kozui] Nippon Med Sch, Resp Care Clin, Tokyo 1020074, Japan; [Ishii, Takeo; Kida, Kozui] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo 1020074, Japan	Ishii, T (reprint author), Nippon Med Sch, Resp Care Clin, Chiyoda Ku, 4-7-15-8F Kudan Minami, Tokyo 1020074, Japan.	tishii@nms.ac.jp					Agusti AG, 2005, P AM THORAC SOC, V2, P71; Agustí Alvar G N, 2005, Proc Am Thorac Soc, V2, P367, DOI 10.1513/pats.200504-026SR; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ANDERSON AE, 1973, THORAX, V28, P547, DOI 10.1136/thx.28.5.547; Alder JK, 2011, AM J RESP CRIT CARE, V184, P904, DOI 10.1164/rccm.201103-0520OC; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; [Anonymous], 2011, GLOBAL STRATEGY DIAG; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Tsuji T, 2006, AM J RESP CRIT CARE, V174, P886, DOI 10.1164/rccm.200509-1374OC; Faner R, 2012, AM J RESP CRIT CARE, V186, P306, DOI 10.1164/rccm.201202-0282PP; Morla M, 2006, EUR RESPIR J, V27, P525, DOI 10.1183/09031936.06.00087005; Nyunoya T, 2006, AM J RESP CELL MOL, V35, P681, DOI 10.1165/rcmb.2006-0169OC; Ito I, 2005, AM J RESP CRIT CARE, V172, P1378, DOI 10.1164/rccm.200506-953OC; Rode L, 2013, THORAX, V68, P429, DOI 10.1136/thoraxjnl-2012-202544; Brehm JM, 2011, THORAX, V66, P1085, DOI 10.1136/thoraxjnl-2011-200017; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Ishii T, 2013, AM J RESP CRIT CARE, V187, pA2749; Ito K, 2012, INT J CHRONIC OBSTR, V7, P641, DOI 10.2147/COPD.S28250; Japanese Respiratory Society, 2001, J JPN RESP SOC, V3, P1102; Lee BJ, 2011, EXP MOL MED, V43, P169, DOI 10.3858/emm.2011.43.4.018; Lee J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035567; Lee J, 2011, CURR OPIN PULM MED, V17, P90, DOI 10.1097/MCP.0b013e328341cead; Liu JH, 2003, AM J PHYSIOL-LUNG C, V285, pL1106, DOI 10.1152/ajplung.00180.2003; López-Otín Carlos, 2013, Cell, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Mori N, 2008, ASAIO J, V54, P622, DOI 10.1097/MAT.0b013e31818b42be; Wang L, 2010, SEMIN RESP CRIT CARE, V31, P539, DOI 10.1055/s-0030-1265895	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					827	833		10.1111/ggi.12354		7	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100002		
J	Kuroiwa, Y; Miyano, I; Nishinaga, M; Takata, J; Shimizu, Y; Okumiya, K; Matsubayashi, K; Ozawa, T; Kitaoka, H; Doi, Y; Yasuda, N				Kuroiwa, Yumi; Miyano, Ichiro; Nishinaga, Masanori; Takata, Jun; Shimizu, Yuji; Okumiya, Kiyohito; Matsubayashi, Kozo; Ozawa, Toshio; Kitaoka, Hiroaki; Doi, Yoshinori; Yasuda, Nobufumi			Association between level of brachial-ankle pulse wave velocity and onset of activities of daily living impairment in community-dwelling older individuals	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						activities of daily living impairment; arterial stiffness; brachial-ankle pulse wave velocity; fall; mortality	WHITE-MATTER LESIONS; PREDICTS CARDIOVASCULAR EVENTS; TYPE-2 DIABETIC-PATIENTS; ARTERIAL STIFFNESS; HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; MUSCLE MASS; ORTHOSTATIC HYPOTENSION; INDEPENDENT PREDICTOR; GENERAL-POPULATION	AimThe purpose of the present study was to clarify the longitudinal association between brachial-ankle pulse wave velocity (baPWV) and the onset of impairment in activities of daily living (ADL) among community-dwelling individuals. MethodsDeaths and the onsets of ADL impairment during 3 years were followed for 450 individuals without ADL impairment at entry who were aged 65 years or older (men:women 181:269; mean age 77 years). They were dichotomized on the median baPWV value at entry. ResultsWithin 3 years, 28 died and 60 had an onset of ADL impairment. The high baPWV group had a higher incidence of deaths (high baPWV group vs low baPWV group, 9.3% vs 3.1%) and ADL impairment (high baPWV group vs low baPWV group, 20.7% vs 9.3%). After adjustment for age, sex and systolic blood pressure, as compared with the low baPWV group, the high baPWV group had increased risk for mortality (adjusted odds ratio 3.22; 95% confidence interval 1.26-8.22) and the onset of ADL impairment (adjusted odds ratio 1.94; 95% confidence interval 1.03-3.63). When the onset of ADL impairment was grouped according to medical conditions that preceded/accompanied the onset of ADL impairment, elevated baPWV was associated with increased risk for the onset of ADL impairment after/accompanying fall/fracture. ConclusionsThe assessment of arterial stiffness by baPWV contributes to identifying functionally independent community-dwelling older individuals at risk for ADL impairment, in particular ADL impairment associated with fall/fracture, as well as for mortality. Geriatr Gerontol Int 2015; 15: 840-847.	[Kuroiwa, Yumi; Miyano, Ichiro; Yasuda, Nobufumi] Kochi Med Sch, Dept Publ Hlth, Nankoku, Kochi 7838505, Japan; [Takata, Jun] Kochi Med Sch, Ctr Promote Creat Med Educ, Nankoku, Kochi 7838505, Japan; [Shimizu, Yuji; Ozawa, Toshio; Kitaoka, Hiroaki; Doi, Yoshinori] Kochi Med Sch, Dept Med & Geriatr, Nankoku, Kochi 7838505, Japan; [Nishinaga, Masanori] Saitama Mem Hosp, Dept Internal Med, Saitama, Japan; [Okumiya, Kiyohito] Kyoto Univ, Res Inst Human & Nat, Kyoto, Japan; [Matsubayashi, Kozo] Kyoto Univ, Ctr Southeast Asian Studies, Kyoto, Japan	Miyano, I (reprint author), Kochi Med Sch, Dept Publ Hlth, Nankoku, Kochi 7838505, Japan.	miyanoi@kochi-u.ac.jp			Japanese Atherosclerosis Prevention Fund; Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology (NCGG), Japan [23-32]	This study was supported by a Grant-in-Aid from the Japanese Atherosclerosis Prevention Fund and The Research Funding for Longevity Sciences (23-32) from the National Center for Geriatrics and Gerontology (NCGG), Japan.	Abbatecola AM, 2012, AGE, V34, P469, DOI 10.1007/s11357-011-9238-0; Miyano I, 2010, HYPERTENS RES, V33, P678, DOI 10.1038/hr.2010.56; Scuteri A, 2005, J HYPERTENS, V23, P1211, DOI 10.1097/01.hjh.0000170384.38708.b7; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P3384, DOI 10.1161/CIRCULATIONAHA.104.483628; Shokawa T, 2005, CIRC J, V69, P259, DOI 10.1253/circj.69.259; Mattace-Raso FUS, 2006, J HYPERTENS, V24, P339, DOI 10.1097/01.hjh.0000202816.25706.64; Kitahara T, 2005, AM J KIDNEY DIS, V46, P688, DOI 10.1053/j.ajkd.2005.06.016; Janssen I, 2002, J AM GERIATR SOC, V50, P889, DOI 10.1046/j.1532-5415.2002.50216.x; Blacher J, 1999, CIRCULATION, V99, P2434; Blacher J, 1999, HYPERTENSION, V33, P1111; Suzuki E, 2001, DIABETES CARE, V24, P2107, DOI 10.2337/diacare.24.12.2107; BALOH RW, 1995, ARCH NEUROL-CHICAGO, V52, P970; [Anonymous], COMPR SURV LIV COND; Cohn JN, 2004, CIRCULATION, V109, P31, DOI 10.1161/01.CIR.0000133442.99186.39; Turin TC, 2010, HYPERTENS RES, V33, P922, DOI 10.1038/hr.2010.103; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Mattace-Raso FUS, 2006, CIRCULATION, V113, P657, DOI 10.1161/CIRCULATIONAHA.105.555235; Tomiyama H, 2005, CIRC J, V69, P815, DOI 10.1253/circj.69.815; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Yamashina A, 2002, HYPERTENS RES, V25, P359, DOI 10.1291/hypres.25.359; Ochi M, 2010, ATHEROSCLEROSIS, V212, P327, DOI 10.1016/j.atherosclerosis.2010.05.026; Matsubayashi K, 1997, STROKE, V28, P2169; Visser M, 2002, J AM GERIATR SOC, V50, P897, DOI 10.1046/j.1532-5415.2002.50217.x; Laurent S, 2001, HYPERTENSION, V37, P1236; Ryall JG, 2008, BIOGERONTOLOGY, V9, P213, DOI 10.1007/s10522-008-9131-0; BRETELER MMB, 1994, STROKE, V25, P1109; Kim DH, 2008, CLIN NEUROL NEUROSUR, V110, P599, DOI 10.1016/j.clineuro.2008.03.009; Buford TW, 2010, AGEING RES REV, V9, P369, DOI 10.1016/j.arr.2010.04.004; Hansen TW, 2006, CIRCULATION, V113, P664, DOI 10.1161/CIRCULATIONAHA.105.579342; Tomiyama H, 2003, ATHEROSCLEROSIS, V166, P303, DOI 10.1016/S0021-9150(02)00332-5; Kearney-Schwartz A, 2009, STROKE, V40, P1229, DOI 10.1161/STROKEAHA.108.532853; Roman GC, 2002, LANCET NEUROL, V1, P426, DOI 10.1016/S1474-4422(02)00190-4; Boddaert J, 2004, J AM GERIATR SOC, V52, P568, DOI 10.1111/j.1532-5415.2004.52163.x; Cruickshank K, 2002, CIRCULATION, V106, P2085, DOI 10.1161/01.CIR.0000033824.02722.F7; Fujiwara Y, 2005, J GERONTOL A-BIOL, V60, P607; Fukuhara M, 2006, CIRC J, V70, P756, DOI 10.1253/circj.70.756; Matsubayashi K, 1996, LANCET, V347, P60, DOI 10.1016/S0140-6736(96)91592-5; Matsuoka O, 2005, BIOMED PHARMACOTHER, V59, pS40, DOI 10.1016/S0753-3322(05)80008-3; Nakamura M, 2010, HYPERTENS RES, V33, P1018, DOI 10.1038/hr.2010.126; Nishinaga M, 2005, HYPERTENS RES, V28, P657, DOI 10.1291/hypres.28.657; Ohmine T, 2008, HYPERTENS RES, V31, P75, DOI 10.1291/hypres.31.75; Runge M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P167	42	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					840	847		10.1111/ggi.12356		8	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100004		
J	Fukutomi, E; Okumiya, K; Wada, T; Sakamoto, R; Ishimoto, Y; Kimura, Y; Chen, WL; Imai, H; Kasahara, Y; Fujisawa, M; Otsuka, K; Matsubayashi, K				Fukutomi, Eriko; Okumiya, Kiyohito; Wada, Taizo; Sakamoto, Ryota; Ishimoto, Yasuko; Kimura, Yumi; Chen, Wen-Ling; Imai, Hissei; Kasahara, Yoriko; Fujisawa, Michiko; Otsuka, Kuniaki; Matsubayashi, Kozo			Relationships between each category of 25-item frailty risk assessment (Kihon Checklist) and newly certified older adults under Long-Term Care Insurance: A 24-month follow-up study in a rural community in Japan	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						community-dwelling elderly; comprehensive geriatric assessment; Cox regression hazard model; Japan; Kihon Checklist	PEOPLE; PREVENTION; PROGRAM; SYSTEM; HEALTH; INDEX; LIFE	AimThe 25-item Kihon Checklist (KCL) is the official self-administered questionnaire tool to screen frail older adults, consisting of seven categories: physical strength, nutritional status, oral function, houseboundness, cognitive function, depression risk and a score of more than 9 out of 1-20 items. The aim of the present study was to evaluate the relationships between each category of the KCL and newly certified cases under the Long-Term Care Insurance (LTCI) in Japan during 24 months. MethodThe study population consisted of 883 community-dwelling adults aged 65 years or older uncertified by LTCI completing a questionnaire, which included the KCL and scales of basic/advanced activities of daily living (ADL), quality of life (QOL), and depressive symptoms. The participants were categorized into the risk or non-risk group depending on the official criteria of each KCL category. The outcome was the incidence of newly certified cases by LTCI during 24 months. The difference between the risk and non-risk group was analyzed by Cox regression hazard models. ResultsScores in basic/advanced ADL and QOL were higher, and the score in the geriatric depression scale was lower in the non-risk than the risk group in KCL criteria. In men, the incidence of newly certified cases was higher in the risk group of the physical strength category after adjusting for age and the other categories of the KCL. ConclusionThe physical strength category in men was the only significant predictor of the incidence of newly certified cases by LTCI. Further studies are required to improve the assessment item of cognitive function in KCL under LTCI. Geriatr Gerontol Int 2015; 15: 864-871.	[Fukutomi, Eriko; Chen, Wen-Ling; Imai, Hissei; Matsubayashi, Kozo] Kyoto Univ, Sch Publ Hlth, Kyoto, Japan; [Okumiya, Kiyohito; Wada, Taizo; Sakamoto, Ryota; Ishimoto, Yasuko; Kimura, Yumi; Fujisawa, Michiko; Matsubayashi, Kozo] Kyoto Univ, Ctr Southeast Asian Studies, Kyoto, Japan; [Kasahara, Yoriko] Kanto Gakuin Univ, Coll Nursing, Tokyo, Japan; [Otsuka, Kuniaki] Tokyo Womens Med Univ, Tokyo, Japan	Fukutomi, E (reprint author), Kyoto Univ, Ctr Southeast Asian Studies, Sakyo Ku, 46 Shimoadachi Cho, Kyoto 6068501, Japan.	erieri_atara4@hotmail.com					Matsubayashi K, 1997, LANCET, V350, P1521, DOI 10.1016/S0140-6736(05)63944-X; Moriya S, 2013, AUSTRALAS J AGEING, V32, P79, DOI 10.1111/j.1741-6612.2012.00601.x; Yamada M, 2012, J AM MED DIR ASSOC, V13, P507, DOI 10.1016/j.jamda.2012.04.001; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Tsutsui T, 2007, J AM GERIATR SOC, V55, P1458, DOI 10.1111/j.1532-5415.2007.01281.x; Amariglio RE, 2011, J AM GERIATR SOC, V59, P1612, DOI 10.1111/j.1532-5415.2011.03543.x; Fukutomi E, 2013, GERIATR GERONTOL INT, V13, P654, DOI 10.1111/j.1447-0594.2012.00959.x; St John P, 2002, INT J GERIATR PSYCH, V17, P814, DOI 10.1002/gps.559; MORRISON DP, 1983, ACTA PSYCHIAT SCAND, V68, P408, DOI 10.1111/j.1600-0447.1983.tb00948.x; Cabinet Office Government of Japan, 2010, WHIT PAP AG SOC 2010; Fukutomi E, 2013, LANCET, V381, P116, DOI 10.1016/S0140-6736(13)60049-5; Honda A, 2013, GERIATR GER IN PRESS, V14, P328; Japan Public Health Association, 2008, REP HLTH SERV ELD MI; Kikuchi K, 2006, J AM GERIATR SOC, V54, P1014, DOI 10.1111/j.1532-5415.2006.00757.x; Kulminski AM, 2007, J AM GERIATR SOC, V55, P935, DOI 10.1111/j.1532-5415.2007.01155.x; Maki Y, 2012, J AM GERIATR SOC, V60, P505, DOI 10.1111/j.1532-5415.2011.03838.x; Matsubayashi K, 1996, LANCET, V347, P60, DOI 10.1016/S0140-6736(96)91592-5; Ministry of Health Labour and Welfare, 2009, SURV MORB DEM 2009 2; Ministry of Health Labour and Welfare, 2013, 5 YEAR PLAN POL PROM; Niino N., 1991, CLIN GERONTOL, V10, P85; Nishiguchi S, 2013, DEMENT GERIATR COGN, V25, P312; Ogawa Kishiko, 2011, Nihon Ronen Igakkai Zasshi, V48, P545; Sampaio PYS, 2014, GERIATR GERONTOL INT, V14, P561, DOI 10.1111/ggi.12134; Tomata Yasutake, 2011, Nihon Koshu Eisei Zasshi, V58, P3; Umegaki H, 2013, GERIATR GERONTOL INT, V13, P77, DOI 10.1111/j.1447-0594.2012.00864.x; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165	27	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					864	871		10.1111/ggi.12360		8	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100007		
J	Michishita, R; Fukae, C; Mihara, R; Ikenaga, M; Morimura, K; Takeda, N; Yamada, Y; Higaki, Y; Tanaka, H; Kiyonaga, A				Michishita, Ryoma; Fukae, Chika; Mihara, Rikako; Ikenaga, Masahiro; Morimura, Kazuhiro; Takeda, Noriko; Yamada, Yosuke; Higaki, Yasuki; Tanaka, Hiroaki; Kiyonaga, Akira		Nakagawa Study Grp	Association between the physical activity and heart rate corrected-QT interval in older adults	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						older adults; inactivity time; light intensity physical activity; QTc interval	AUTONOMIC NERVOUS-SYSTEM; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR-DISEASE; EXERCISE; RISK; MEN; AGE; DURATION; INSULIN; ZUTPHEN	AimIncreased physical activity can reduce the incidence of cardiovascular disease and the mortality rate. In contrast, a prolonged heart rate corrected-QT (QTc) interval is associated with an increased risk of arrhythmias, sudden cardiac death and coronary artery disease. The present cross-sectional study was designed to clarify the association between the physical activity level and the QTc interval in older adults. MethodsThe participants included 586 older adults (267 men and 319 women, age 71.24.7years) without a history of cardiovascular disease, who were taking cardioactive drugs. Electrocardiography was recorded with a standard resting 12-lead electrocardiograph, while the QTc interval was calculated according to Hodges' formula. The physical activity level was assessed using a triaxial accelerometer. The participants were divided into four categories, which were defined equally quartile distributions of the QTc interval. ResultsAfter adjusting for age, body mass index, waist circumference and the number of steps, the time spent in inactivity was higher and the time spent in light physical activity was significantly lower in the longest QTc interval group than in the shortest QTc interval group in both sexes (P<0.05, respectively). However, there were no significant differences in the time spent in moderate and vigorous physical activities among the four groups in either sex. ConclusionsThese results suggest that a decreased physical activity level, especially inactivity and light intensity physical activity, were associated with QTc interval in older adults. Geriatr Gerontol Int 2015; 15: 895-901.	[Michishita, Ryoma; Fukae, Chika; Mihara, Rikako; Ikenaga, Masahiro; Morimura, Kazuhiro; Higaki, Yasuki; Tanaka, Hiroaki; Kiyonaga, Akira] Fukuoka Univ, Fac Hlth & Sports Sci, Exercise Physiol Lab, Fukuoka 8140180, Japan; [Yamada, Yosuke; Higaki, Yasuki; Tanaka, Hiroaki; Kiyonaga, Akira] Fukuoka Univ, Inst Phys Act, Fukuoka, Japan; [Takeda, Noriko] Natl Inst Hlth & Nutr, Japan Soc Promot Sci, Tokyo 162, Japan; [Yamada, Yosuke] Natl Inst Hlth & Nutr, Dept Nutr Sci, Tokyo 162, Japan; [Takeda, Noriko] Waseda Univ, Fac Sport Sci, Saitama, Japan	Michishita, R (reprint author), Fukuoka Univ, Fac Hlth & Sports Sci, Exercise Physiol Lab, Jonan ku, 8-19-1 Nanakuma, Fukuoka 8140180, Japan.	rmichishita@fukuoka-u.ac.jp			Fukuoka University Institute for Physical Activity via a Technology Scientific Research Budget Basic Research Grant (Strategic Research Infrastructure) from the Japanese Government's Ministry of Education, Culture, Sports, Science and Technology [A19200049]; Central Research Institute of Fukuoka University [136009, 15300339, 25242065]	We thank the members of the Laboratory of Exercise Physiology of Fukuoka University for their help with the data evaluation. We are grateful to the participants of this study. This work was carried out with the support of the Fukuoka University Institute for Physical Activity via a Technology Scientific Research Budget Basic Research Grant (no. A19200049, Strategic Research Infrastructure) from the Japanese Government's Ministry of Education, Culture, Sports, Science and Technology, and the Central Research Institute of Fukuoka University (no. 136009, no. 15300339 and no. 25242065).	Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Dekker JM, 1996, DIABETES, V45, P376, DOI 10.2337/diabetes.45.3.376; Carnethon MR, 2005, JAMA-J AM MED ASSOC, V294, P2981, DOI 10.1001/jama.294.23.2981; Haskell WL, 2007, CIRCULATION, V116, P1081, DOI 10.1161/CIRCULATIONAHA.107.185649; Straus SMJM, 2006, J AM COLL CARDIOL, V47, P362, DOI 10.1016/j.jacc.2005.08.067; Dekker JM, 2004, J AM COLL CARDIOL, V43, P565, DOI 10.1016/j.jacc.2003.09.040; Gando Y, 2010, HYPERTENSION, V56, P540, DOI 10.1161/HYPERTENSIONAHA.110.156331; Ford ES, 2012, INT J EPIDEMIOL, V41, P1338, DOI 10.1093/ije/dys078; RAUTAHARJU PM, 1992, CAN J CARDIOL, V8, P690; Festa A, 2000, AM J CARDIOL, V86, P1117, DOI 10.1016/S0002-9149(00)01170-X; Mozaffarian D, 2008, CIRCULATION, V118, P800, DOI 10.1161/CIRCULATIONAHA.108.785626; Mangoni AA, 2003, AGE AGEING, V32, P326, DOI 10.1093/ageing/32.3.326; Healy GN, 2008, DIABETES CARE, V31, P369, DOI 10.2337/dc07-1795; Yamada Y, 2009, EUR J APPL PHYSIOL, V105, P141, DOI 10.1007/s00421-008-0883-7; DEKKER JM, 1994, CIRCULATION, V90, P779; AMERY A, 1967, CIRCULATION, V36, P231; Hautala AJ, 2009, NEUROSCI BIOBEHAV R, V33, P107, DOI 10.1016/j.neubiorev.2008.04.009; Bertoni AG, 2009, AM J EPIDEMIOL, V169, P444, DOI 10.1093/aje/kwn350; Chiang CE, 2000, J AM COLL CARDIOL, V36, P1, DOI 10.1016/S0735-1097(00)00716-6; HODGES M, 1983, J AM COLL CARDIOL, V1, P694; Ikenaga M, 2014, J PHYS FITNESS SPORT, V3, P147; Matsumura Y, 2008, NATL TECH REP, V56, P60; Michishita R, 2009, J ATHEROSCLER THROMB, V16, P396; Michishita R, 2013, JPN J PHYS FIT SPORT, V62, P283; PFEIFER MA, 1983, AM J MED, V75, P249, DOI 10.1016/0002-9343(83)91201-9; Ueno LM, 2002, J GERONTOL A-BIOL, V57, pM605	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					895	901		10.1111/ggi.12365		7	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100011		
J	Takahashi, K; Kato, A; Igari, T; Sase, E; Shibanuma, A; Kikuchi, K; Nanishi, K; Jimba, M; Yasuoka, J				Takahashi, Kyo; Kato, Atsushi; Igari, Tomoyuki; Sase, Eriko; Shibanuma, Akira; Kikuchi, Kimiyo; Nanishi, Keiko; Jimba, Masamine; Yasuoka, Junko			Sense of coherence as a key to improve homebound status among older adults with urinary incontinence	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						frail elderly; homebound persons; psychological resilience; sense of coherence; urinary incontinence	QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; LOWER-LIMB ISCHEMIA; MENTAL-HEALTH; SOCIAL SUPPORT; PREDICTORS; RESILIENCE; SOCIETY; SCALE; JAPAN	AimBeing homebound is regarded as a negative condition for social participation in Japan. However, little is known about the possibility of psychological resilience to prevent being homebound among older adults with urinary incontinence. The present study aimed to examine the association between sense of coherence as a measure of psychological resilience and being homebound among older adults with urinary incontinence. MethodsA cross-sectional study was carried out in Chiba, Japan. We trained 95 care managers as interviewers, and they collected the data from 411 community-dwelling frail older adults using a pretested structured questionnaire. Logistic regression analysis was run to identify factors associated with being homebound among the participants with urinary incontinence. ResultsOf the participants, 158 (38.4%) had urinary incontinence. Among the participants with urinary incontinence, 52 (32.9%) were homebound. As a result of logistic regression analysis adjusting for age, sex, living status, hobby, types of prevalent diseases, walking ability, perceived social support and subjective social capital, lower meaningfulness in their lives, which is a component of a sense of coherence, remained positively associated with being homebound (adjusted odds ratio 0.79, 95% confidence interval 0.65-0.96). ConclusionsBeing homebound is less prevalent among those who feel challenges, or worthy of investment or engagement in daily life. By improving a sense of meaningfulness, homebound status might be improved among older adults with urinary incontinence. To encourage active social participation of the target population, their psychological resilience (particularly meaningfulness) should be addressed more. Geriatr Gerontol Int 2015; 15: 910-917.	[Takahashi, Kyo; Sase, Eriko; Shibanuma, Akira; Kikuchi, Kimiyo; Nanishi, Keiko; Jimba, Masamine; Yasuoka, Junko] Univ Tokyo, Grad Sch Med, Dept Commun & Global Hlth, Tokyo 1130033, Japan; [Takahashi, Kyo] Natl Rehabil Ctr Persons Disabil, Res Inst, Dept Social Rehabil, Saitama, Japan; [Kato, Atsushi] Japan Toilet Labo, Tokyo, Japan; [Igari, Tomoyuki] Sodegaura Satsukidai Hosp, Chiba, Japan	Yasuoka, J (reprint author), Univ Tokyo, Grad Sch Med, Dept Commun & Global Hlth, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jyasuoka@m.u-tokyo.ac.jp			Kimitsu Health and Welfare Center; LTCI	Our heartfelt appreciation goes to all participants and care managers who kindly cooperated in this study. We also thank the Kimitsu Health and Welfare Center, and LTCI-related institutions in the study site for their generous support.	Abrams P, 2009, INCONTINENCE; Klevsgard R, 2000, EUR J VASC ENDOVASC, V19, P238, DOI 10.1053/ejvs.1999.0995; Eriksson M, 2007, J EPIDEMIOL COMMUN H, V61, P684, DOI 10.1136/jech.2006.047498; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Landefeld CS, 2008, ANN INTERN MED, V148, P449; Klevsgard R, 2001, J VASC SURG, V33, P114, DOI 10.1067/mva.2001.109769; Jamison MG, 2007, INT UROGYNECOL J, V18, P1127, DOI 10.1007/s00192-007-0315-y; Qiu WQ, 2010, J AM GERIATR SOC, V58, P2423, DOI 10.1111/j.1532-5415.2010.03161.x; Eriksson M, 2007, J EPIDEMIOL COMMUN H, V61, P938, DOI 10.1136/jech.2006.056028; Arai H, 2012, GERIATR GERONTOL INT, V12, P16, DOI 10.1111/j.1447-0594.2011.00776.x; Minassian VA, 2003, INT J GYNECOL OBSTET, V82, P327, DOI 10.1016/S0020-7292(03)00220-0; [Anonymous], 2013, HEALTH REP; Motzer SU, 1996, RES NURS HEALTH, V19, P287, DOI 10.1002/(SICI)1098-240X(199608)19:4<287::AID-NUR3>3.0.CO;2-E; Fujita K, 2006, J EPIDEMIOL, V16, P261, DOI 10.2188/jea.16.261; Soet JE, 2003, BIRTH-ISS PERINAT C, V30, P36, DOI 10.1046/j.1523-536X.2003.00215.x; Hoge EA, 2007, DEPRESS ANXIETY, V24, P139, DOI 10.1002/da.20175; Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Langeland E, 2006, PATIENT EDUC COUNS, V62, P212, DOI 10.1016/j.pec.2005.07.004; Turner SW, 2003, BRIT J PSYCHIAT, V182, P444, DOI 10.1192/bjp.182.5.444; Muramatsu N, 2011, GERONTOLOGIST, V51, P425, DOI 10.1093/geront/gnr067; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; [Anonymous], 2011, BMJ-BRIT MED J, DOI DOI 10.1136/BMJ.D4163; PERRY S, 1992, AM J PSYCHIAT, V149, P931; Ganguli M, 1996, J AM GERIATR SOC, V44, P363; Antonovsky A, 1987, UNRAVELING MYSTERY H; Cabinet Office Japan, 2012, ANN REP AG SOC 2012; Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P433; Chiba Prefecture, 2012, CHIB PREF MON; Chiba Prefecture, 2013, CHIB PREF MON; Eriksson M, 2008, HEALTH PROMOT INT, V23, P190, DOI 10.1093/heapro/dan014; Forsberg KA, 2010, J CLIN NURS, V19, P1519, DOI 10.1111/j.1365-2702.2009.03010.x; Haraldsson K, 2005, HEALTH SOC CARE COMM, V13, P224, DOI 10.1111/j.1365-2524.2005.00554.x; Hirai H, 2007, JPN J PUBLIC HLTH, V54, P293; Imuta H, 1998, JPN J PUBLIC HLTH, V45, P883; Iwasa H, 2007, KOUSEI NO SHIHYO, V54, P26; Johansson I, 1998, AGING-CLIN EXP RES, V10, P377; Katz MH, 2006, MULTIVARIABLE ANALYSIS: A PRACTICAL GUIDE FOR CLINICIANS, 2ND EDITION, P1, DOI 10.1017/CBO9780511811692; Kim H K, 2000, J Cross Cult Gerontol, V15, P331, DOI 10.1023/A:1006765300028; Kimitsu City, 2010, KIM CIT MON; Kono A, 2000, JPN J PUBLIC HLTH, V47, P216; MAHONEY F I, 1965, Md State Med J, V14, P61; Miu DKY, 2010, GERIATR GERONTOL INT, V10, P177, DOI 10.1111/j.1447-0594.2009.00574.x; National Institute on Aging, 2013, NAT I AG MON; Shinkai S, 2005, JPN J PUBLIC HLTH, V52, P874; Shinkai S., 2005, JPN J PUBLIC HLTH, V52, P443; The Ministry of Health Labour and Welfare, 2009, MIN HLTH LAB WELF MO; Theeke LA, 2012, J PSYCHOL, V146, P155, DOI 10.1080/00223980.2011.609571; Togari T, 2006, GRANTS IN AID SCI RE, P187; Watanabe M, 2003, J OSAKA MED COLL, V62, P124; Watanabe M, 2007, JPN J GERIATR, V44, P238; Yamazaki Y., 1999, QUALITY NURSING, V5, P825; Yamazaki Y, 2008, STRESS TAISHO NOURYO; Yokoyama H, 2005, JPN J GERONTOL, V26, P424; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	55	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					910	917		10.1111/ggi.12353		8	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100013		
J	Shimada, C; Hirayama, R; Nakazato, K; Arai, K; Ishizaki, T; Aita, K; Shimizu, T; Inamatsu, T; Takahashi, R				Shimada, Chiho; Hirayama, Ryo; Nakazato, Kazuhiro; Arai, Kazuko; Ishizaki, Tatsuro; Aita, Kaoruko; Shimizu, Tetsuro; Inamatsu, Takashi; Takahashi, Ryutaro			What has become more acceptable? Continuity and changes in older adults' attitudes toward end-of-life care in Japan	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Letter									[Shimada, Chiho; Hirayama, Ryo; Nakazato, Kazuhiro; Arai, Kazuko; Ishizaki, Tatsuro; Inamatsu, Takashi; Takahashi, Ryutaro] Tokyo Metropolitan Inst Gerontol, Tokyo, Japan; [Aita, Kaoruko; Shimizu, Tetsuro] Univ Tokyo, Tokyo, Japan	Shimada, C (reprint author), Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.						Matsushita S, 1999, Nihon Ronen Igakkai Zasshi, V36, P45; Ministry of Health Labour and Welfare of Japan, 2014, JINS SAIS DANNK OK I	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					927	928		10.1111/ggi.12475		2	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100015		
J	Kawada, T				Kawada, Tomoyuki			Effect of laughing qigong on an elderly population	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Letter							LAUGHTER; HUMOR; RESIDENTS; EXERCISE; PROGRAM; HEALTH		Nippon Med Sch, Dept Hyg & Publ Hlth, Tokyo 113, Japan	Kawada, T (reprint author), Nippon Med Sch, Dept Hyg & Publ Hlth, 1-1-5 Sendagi, Tokyo 113, Japan.						Martin RA, 2001, PSYCHOL BULL, V127, P504, DOI 10.1037/0033-2909.127.4.504; Bennett PN, 2014, SEMIN DIALYSIS, V27, P488, DOI 10.1111/sdi.12194; Chan CLW, 2012, J ALTERN COMPLEM MED, V18, P641, DOI 10.1089/acm.2011.0347; COUSINS N, 1976, NEW ENGL J MED, V295, P1458, DOI 10.1056/NEJM197612232952605; Hirosaki M, 2013, GERIATR GERONTOL INT, V13, P152, DOI 10.1111/j.1447-0594.2012.00877.x; Hsieh CJ, 2015, GERIATR GERONTOL INT, V15, P165, DOI 10.1111/ggi.12244; Kawada T, 2013, J PSYCHIATR MENT HLT, V20, P662, DOI 10.1111/jpm.12037; Sheldrake R, 2013, EXPLORE-NY, V9, P211, DOI 10.1016/j.explore.2013.04.004; Stuber M, 2009, EVID-BASED COMPL ALT, V6, P271, DOI 10.1093/ecam/nem097	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	JUL	2015	15	7					929	930		10.1111/ggi.12476		2	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CM1FR	WOS:000357427100017		
J	Murayama, H; Nishi, M; Nofuji, Y; Matsuo, E; Taniguchi, Y; Amano, H; Yokoyama, Y; Fujiwara, Y; Shinkai, S				Murayama, Hiroshi; Nishi, Mariko; Nofuji, Yu; Matsuo, Eri; Taniguchi, Yu; Amano, Hidenori; Yokoyama, Yuri; Fujiwara, Yoshinori; Shinkai, Shoji			Longitudinal association between neighborhood cohesion and depressive mood in old age: A Japanese prospective study	HEALTH & PLACE			English	Article						Neighborhood cohesion; Depressive mood; Old age; Longitudinal study; Japan	SOCIAL-ISOLATION; MENTAL-HEALTH; UNITED-STATES; SYMPTOMS; COMMUNITY; PEOPLE; TRUST; ATHEROSCLEROSIS; COMMITMENT; PLACES	Despite increasing evidence of the relationship between neighborhood cohesion and depressive mood, little is known about this longitudinal association in old age. This study examined the association between perceived neighborhood cohesion and depressive mood and the stress-buffering effect of perceived neighborhood cohesion on depressive mood among older Japanese people using the 2010 (baseline) and 2012 (follow-up) Hatoyama Cohort Study datasets. We analyzed 655 participants aged 6584 at baseline. Although perceived neighborhood cohesion at baseline was not associated with depressive mood at follow-up, high neighborhood cohesion partially offset the deleterious effect of anticipated daily stressors on depressive mood. This effect was stronger for long-term residents of the neighborhood. Interventions to strengthen neighborhood cohesion may help reduce the deleterious effect of stressors on older residents' depressive mood. (C) 2015 Elsevier Ltd. All rights reserved.	[Murayama, Hiroshi; Nishi, Mariko; Nofuji, Yu; Matsuo, Eri; Taniguchi, Yu; Amano, Hidenori; Yokoyama, Yuri; Fujiwara, Yoshinori; Shinkai, Shoji] Tokyo Metropolitan Inst Gerontol, Res Team Social Participat & Community Hlth, Itabashi Ku, Tokyo 1730015, Japan	Murayama, H (reprint author), Tokyo Metropolitan Inst Gerontol, Res Team Social Participat & Community Hlth, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	murayama@tmig.or.jp			Research Institute of Science and Technology for Society (RISTEX); Japan Science and Technology Agency; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [24792611]; town of Hatoyama	This study was supported by research grants from the Research Institute of Science and Technology for Society (RISTEX), the Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) KAKENHI Grant no. 24792611, and the town of Hatoyama.	Mair C, 2010, HEALTH PLACE, V16, P811, DOI 10.1016/j.healthplace.2010.04.006; Beard JR, 2009, AM J PUBLIC HEALTH, V99, P1308, DOI 10.2105/AJPH.2007.125104; Mair C, 2008, J EPIDEMIOL COMMUN H, V62, P940, DOI 10.1136/jech.2007.066605; Cattell V, 2001, SOC SCI MED, V52, P1501, DOI 10.1016/S0277-9536(00)00259-8; Hanibuchi T, 2012, HEALTH PLACE, V18, P229, DOI 10.1016/j.healthplace.2011.09.015; HOWES MJ, 1985, J PERS SOC PSYCHOL, V49, P1110, DOI 10.1037//0022-3514.49.4.1110; Murayama H, 2012, J EPIDEMIOL, V22, P179, DOI 10.2188/jea.JE20110128; Schreiner AS, 2003, INT J GERIATR PSYCH, V18, P498, DOI 10.1002/gps.880; Mair C, 2009, ANN EPIDEMIOL, V19, P49, DOI 10.1016/j.annepidem.2008.10.002; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Mujahid MS, 2007, AM J EPIDEMIOL, V165, P858, DOI 10.1093/aje/kwm040; Luppa M, 2012, J AFFECT DISORDERS, V136, P212, DOI 10.1016/j.jad.2010.11.033; Echeverria S, 2008, HEALTH PLACE, V14, P853, DOI 10.1016/j.healthplace.2008.01.004; Wada T, 2004, ARCH GERONTOL GERIAT, V39, P15, DOI 10.1016/j.archger.2003.12.003; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Rowe JW, 1997, GERONTOLOGIST, V37, P433; Stordal E, 2001, ACTA PSYCHIAT SCAND, V104, P210, DOI 10.1034/j.1600-0447.2001.00130.x; Fone D, 2007, INT J EPIDEMIOL, V36, P338, DOI 10.1093/ije/dym04; Aneshensel CS, 2007, J GERONTOL B-PSYCHOL, V62, pS52; Yamagishi T, 1998, AM J SOCIOL, V104, P165, DOI 10.1086/210005; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; Cabinet Office, 2007, WHIT PAP NAT LIF 200; Cacioppo JT, 2003, PERSPECT BIOL MED, V46, pS39, DOI 10.1353/pbm.2003.0049; Davey A, 2004, J GERONTOL B-PSYCHOL, V59, pP270; EMMERSON JP, 1989, BRIT J PSYCHIAT, V155, P787, DOI 10.1192/bjp.155.6.787; Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547; Frey W. H., 2010, J AM SOC AGING, V34, P28; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P419; Kawachi I., 2000, SOCIAL EPIDEMIOLOGY, P174; Kawachi I, 2008, SOCIAL CAPITAL HLTH, P1, DOI 10.1007/978-0-387-71311-3_1; Mair C., 2010, ANN NY ACAD SCI, V1186, P125, DOI DOI 10.1111/J.1749-6632.2009.05333.X; Mikelbank BA, 2004, HOUS POLICY DEBATE, V15, P935; MULLERSPAHN F, 1994, GERONTOLOGY, V40, P10; Murayama H, 2011, J AM GERIATR SOC, V59, P2160, DOI 10.1111/j.1532-5415.2011.03640.x; Murayama H, 2012, J EPIDEMIOL, V22, P551, DOI 10.2188/jea.JE20120015; Murayama H, 2014, URBAN STUD, V51, P2770, DOI 10.1177/0042098013513648; Nakane Chie, 1970, JAPANESE SOC; National Institute of Population and Social Security Research, 2009, NIH SHIK BETS SHOR S; National Institute of Population and Social Security Research, 2007, NIH SHOR SUIK JINK 2; Robinette JW, 2013, SOC SCI MED, V96, P174, DOI 10.1016/j.socscimed.2013.07.027; Subramanian S.V., 2006, METHODS SOCIAL EPIDE, P316; Takagi D, 2013, SOC SCI MED, V83, P81, DOI 10.1016/j.socscimed.2013.01.001; YAMAGISHI T, 1994, MOTIV EMOTION, V18, P129, DOI 10.1007/BF02249397	44	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1353-8292	1873-2054		HEALTH PLACE	Health Place	JUL	2015	34						270	278		10.1016/j.healthplace.2015.05.015		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CM1YD	WOS:000357475600032		
J	Han, ZL; Kohno, K; Fujita, H; Hirakawa, K; Toshiyoshi, H				Han, Zhengli; Kohno, Kenta; Fujita, Hiroyuki; Hirakawa, Kazuhiko; Toshiyoshi, Hiroshi			Tunable Terahertz Filter and Modulator Based on Electrostatic MEMS Reconfigurable SRR Array	IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS			English	Article						MEMS reconfigurable SRR; electrostatic actuation; metamaterial; tunable THz filter; THz modulator	NEGATIVE-INDEX; METAMATERIAL; WAVELENGTH; REFRACTION	This paper demonstrates a tunable terahertz (THz) filter and a modulator based on an electrostatic micro electro mechanical systems (MEMS) reconfigurable split ring resonator (SRR) array. The device uses tunable metamaterial concept, in which an RF-MEMS (radio frequency-MEMS) capacitor is embedded in each SRR unit cell to tune the electromagnetic resonant frequency. By utilizing THz time domain spectroscopy (THz-TDS) measurement and through the voltage actuation, we have controlled the THz transmission of the metamaterial device, and thus demonstrated a tunable filter. Since the low loss material of fused quartz is used as the substrate, the device shows a high contrast ratio THz switch at a given frequency by controlling the capacitance of the RF-MEMS capacitor. The dynamic performance of the switch, i.e., the modulation ability, is also characterized by THz-TDS. The measurement results show up to 2 kHz of the modulation speed with the TDS operated. The device is developed by the surface micromachining process with three photolithography steps.	[Han, Zhengli; Toshiyoshi, Hiroshi] Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; [Kohno, Kenta; Fujita, Hiroyuki; Hirakawa, Kazuhiko] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538904, Japan	Han, ZL (reprint author), Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan.	zhengli@iis.u-tokyo.ac.jp; k-kohno@iis.u-tokyo.ac.jp; hfujita@iis.u-tokyo.ac.jp; hirakawa@iis.u-tokyo.ac.jp; hiro@iis.u-tokyo.ac.jp			Japan Society for the Promotion of Science; Council for Science and Technology Policy; JSPS	Manuscript received October 7, 2014; revised November 27, 2014; accepted December 1, 2014. This work was supported by the Japan Society for the Promotion of Science through the "Funding Program for Next Generation World-Leading Researchers (NEXT Program)" initiated by the Council for Science and Technology Policy and by the JSPS Core-to-Core Program for EUJO-LIMMS.	Padilla WJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.107401; Williams BS, 2007, NAT PHOTONICS, V1, P517, DOI 10.1038/nphoton.2007.166; Soukoulis CM, 2007, SCIENCE, V315, P47, DOI 10.1126/science.1136481; Tao H, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.147401; Yen TJ, 2004, SCIENCE, V303, P1494, DOI 10.1126/science.1094025; Han ZL, 2014, OPT EXPRESS, V22, P21326, DOI 10.1364/OE.22.021326; Driscoll T, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2956675; Singh R, 2011, OPT LETT, V36, P1230, DOI 10.1364/OL.36.001230; Chen HT, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2978071; Tonouchi M, 2007, NAT PHOTONICS, V1, P97, DOI 10.1038/nphoton.2007.3; AUSTON DH, 1984, APPL PHYS LETT, V45, P284, DOI 10.1063/1.95174; Ma FS, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4803048; Plum E, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.035407; Chen HT, 2006, NATURE, V444, P597, DOI 10.1038/nature05343; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; Zhou J, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.223902; Fang N, 2005, SCIENCE, V308, P534, DOI 10.1126/science.1108759; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Dolling G, 2007, OPT LETT, V32, P53, DOI 10.1364/OL.32.000053; Shrekenhamer D, 2011, OPT EXPRESS, V19, P9968, DOI 10.1364/OE.19.009968; Zhu WM, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3664131; Minamide H, 2014, J INFRARED MILLIM TE, V35, P25, DOI 10.1007/s10762-013-0041-0; Miyamaru F, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3327830; Rebeiz G. M., 2002, RF MEMS THEORY DESIG, P66; Toshiyoshi H., 2008, COMPREHENSIVE MICROS, V2, P6; Zhang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.037402	27	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1077-260X	1558-4542		IEEE J SEL TOP QUANT	IEEE J. Sel. Top. Quantum Electron.	JUL-AUG	2015	21	4							2700809	10.1109/JSTQE.2014.2378591		9	Engineering, Electrical & Electronic; Optics; Physics, Applied	Engineering; Optics; Physics	CM0NK	WOS:000357374800001		
J	Kanamori, Y; Hokari, R; Hane, K				Kanamori, Yoshiaki; Hokari, Ryohei; Hane, Kazuhiro			MEMS for Plasmon Control of Optical Metamaterials	IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS			English	Article						Microelectromechanical systems; microfabrication; nanophotonics; optical metamaterials; plasmons	ELECTROMAGNETICALLY INDUCED TRANSPARENCY; NEAR-INFRARED METAMATERIALS; NEGATIVE REFRACTIVE-INDEX; SPLIT-RING RESONATORS; TERAHERTZ METAMATERIALS; PHOTONIC METAMATERIALS; FANO RESONANCE; RECONFIGURABLE METAMATERIAL; MAXWELLS EQUATIONS; SOLAR-CELLS	Metamaterials have attracted a great deal of attention as artificial electromagnetic materials having unique optical characteristics, and various innovative optical applications have been expected. Micro electromechanical systems (MEMS)-based reconfigurable metamaterials are candidate technologies for active optical control. In this paper, we focus on MEMS-based reconfigurable metamaterials operated in the optical region between visible and near-infrared wavelengths. A brief overview of static optical metamaterials and active optical metamaterials driven by MEMS actuators is presented. Moreover, points to be considered for a micromachining process of optical metamaterials are discussed with results of calculations.	[Kanamori, Yoshiaki; Hokari, Ryohei; Hane, Kazuhiro] Tohoku Univ, Dept Nanomech, Sendai, Miyagi 9808579, Japan	Kanamori, Y (reprint author), Tohoku Univ, Dept Nanomech, Sendai, Miyagi 9808579, Japan.	kanamori@hane.mech.tohoku.ac.jp; hokari@hane.mech.tohoku.ac.jp; hane2@hane.mech.tohoku.ac.jp			MEXT KAKENHI [25109702]	This work was supported by MEXT KAKENHI 25109702.	Al-Naib IAI, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2976636; Ju L, 2011, NAT NANOTECHNOL, V6, P630, DOI [10.1038/nnano.2011.146, 10.1038/NNANO.2011.146]; Driscoll T, 2009, SCIENCE, V325, P1518, DOI 10.1126/science.1176580; Billings L, 2013, NATURE, V500, P138, DOI 10.1038/500138a; Zhu WM, 2011, ADV MATER, V23, P1792, DOI 10.1002/adma.201004341; Jiang WX, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.066607; Rahm M, 2008, PHOTONIC NANOSTRUCT, V6, P87, DOI 10.1016/j.photonics.2007.07.013; Wei XZ, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3453477; Pryce IM, 2010, NANO LETT, V10, P4222, DOI 10.1021/nl102684x; Schurig D, 2006, SCIENCE, V314, P977, DOI 10.1126/science.1133628; Liu AQ, 2012, J OPTICS-UK, V14, DOI 10.1088/2040-8978/14/11/114009; Green MA, 2012, NAT PHOTONICS, V6, P130; Xiao SM, 2010, NATURE, V466, P735, DOI 10.1038/nature09278; Kabashin AV, 2009, NAT MATER, V8, P867, DOI [10.1038/nmat2546, 10.1038/NMAT2546]; Fu YH, 2011, ADV FUNCT MATER, V21, P3589, DOI 10.1002/adfm.201101087; Urzhumov Y, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.075112; Pendry JB, 2006, SCIENCE, V312, P1780, DOI 10.1126/science.1125907; Han ZL, 2014, OPT EXPRESS, V22, P21326, DOI 10.1364/OE.22.021326; Liu H, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.235437; POWELL CJ, 1970, J OPT SOC AM, V60, P78, DOI 10.1364/JOSA.60.000078; Moritake Y, 2014, OPT LETT, V39, P4057, DOI 10.1364/OL.39.004057; Zhang X, 2008, NAT MATER, V7, P435, DOI 10.1038/nmat2141; Driscoll T, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2956675; Linden S, 2006, IEEE J SEL TOP QUANT, V12, P1097, DOI 10.1109/JSTQE.2006.880600; Xu XL, 2011, NANO LETT, V11, P3232, DOI 10.1021/nl2014982; Werner DH, 2007, OPT EXPRESS, V15, P3342, DOI 10.1364/OE.15.003342; Dicken MJ, 2009, OPT EXPRESS, V17, P18330, DOI 10.1364/OE.17.018330; O'Hara JF, 2008, OPT EXPRESS, V16, P1786, DOI 10.1364/OE.16.001786; Jiang WX, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2951485; Liu ZW, 2007, SCIENCE, V315, P1686, DOI 10.1126/science.1137368; Lee HJ, 2010, J APPL PHYS, V108, DOI 10.1063/1.3459877; Choi M, 2011, NATURE, V470, P369, DOI 10.1038/nature09776; Zhang W, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4759029; Liu N, 2010, NANO LETT, V10, P1103, DOI 10.1021/nl902621d; Melik R, 2010, OPT EXPRESS, V18, P5000, DOI 10.1364/OE.18.005000; O'Brien K, 2012, OPT LETT, V37, P4089, DOI 10.1364/OL.37.004089; Cai WS, 2007, NAT PHOTONICS, V1, P224, DOI 10.1038/nphoton.2007.28; Tsakmakidis KL, 2007, NATURE, V450, P397, DOI 10.1038/nature06285; Chang YT, 2010, OPT EXPRESS, V18, P9561, DOI 10.1364/OE.18.009561; Zhang S, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.137404; Klein MW, 2006, SCIENCE, V313, P502, DOI 10.1126/science.1129198; Han JG, 2008, OPT EXPRESS, V16, P14390, DOI 10.1364/OE.16.014390; Chen HT, 2009, NAT PHOTONICS, V3, P148, DOI 10.1038/NPHOTON.2009.3; Shao L, 2012, NANO LETT, V12, P1424, DOI 10.1021/nl2041063; Hokari R, 2014, OPT EXPRESS, V22, P3526, DOI 10.1364/OE.22.003526; Chen HT, 2006, NATURE, V444, P597, DOI 10.1038/nature05343; Valentine J, 2008, NATURE, V455, P376, DOI 10.1038/nature07247; Cetin AE, 2011, OPT EXPRESS, V19, P22607, DOI 10.1364/OE.19.022607; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Ou JY, 2011, NANO LETT, V11, P2142, DOI [10.1021/nl200791r, 10.1021/n1200791r]; Zheludev NI, 2012, NAT MATER, V11, P917, DOI [10.1038/nmat3431, 10.1038/NMAT3431]; Luk'yanchuk B, 2010, NAT MATER, V9, P707, DOI [10.1038/nmat2810, 10.1038/NMAT2810]; Hao F, 2008, NANO LETT, V8, P3983, DOI 10.1021/nl802509r; Zhang JJ, 2010, OPT EXPRESS, V18, P17187, DOI 10.1364/OE.18.017187; Chen T, 2012, SENSORS-BASEL, V12, P2742, DOI 10.3390/s120302742; Zhou J, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.223902; Ou JY, 2013, NAT NANOTECHNOL, V8, P252, DOI 10.1038/nnano.2013.25; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Lee SH, 2012, NAT MATER, V11, P936, DOI [10.1038/nmat3433, 10.1038/NMAT3433]; Pendry JB, 2003, J PHYS-CONDENS MAT, V15, P6345, DOI 10.1088/0953-8984/15/37/004; Ishikawa A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.237401; Liu N, 2009, NAT MATER, V8, P758, DOI [10.1038/nmat2495, 10.1038/NMAT2495]; Chen HT, 2008, NAT PHOTONICS, V2, P295, DOI 10.1038/nphoton.2008.52; Menzel C, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.035320; Wang Y, 2012, NANO LETT, V12, P440, DOI 10.1021/nl203763k; Shrekenhamer D, 2011, OPT EXPRESS, V19, P9968, DOI 10.1364/OE.19.009968; Nemec H, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.241108; Tao H, 2011, J INFRARED MILLIM TE, V32, P580, DOI 10.1007/s10762-010-9646-8; BRENDEL R, 1992, J APPL PHYS, V71, P1, DOI 10.1063/1.350737; Cai WS, 2010, OPTICAL METAMATERIALS: FUNDAMENTALS AND APPLICATIONS, P11, DOI 10.1007/978-1-4419-1151-3_2; Christian D., 2008, APPL PHYS LETT, V91; Ekmekci E, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.193103; ERMAN M, 1984, J APPL PHYS, V56, P2664, DOI 10.1063/1.333785; Gu J., 2012, NAT COMMUN, V3; Hokari R, 2014, J OPT SOC AM B, V31, P1000, DOI 10.1364/JOSAB.31.001000; Liu L, 2004, OPT EXPRESS, V12, P4835, DOI 10.1364/OPEX.12.004835; Liu N, 2008, NAT MATER, V7, P31, DOI 10.1038/nmat2072; Lu D., 2012, NAT COMMUN, V3, P1; Melik R, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3250175; Rakic D., 1998, APPL OPTICS, V37, P5271; Chowdhury DR, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3667197; Shen NH, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.037403; Shrekenhamer D, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.177403; Varellen N., 2009, NANO LETT, V9, P1663; Ward AJ, 1996, J MOD OPTIC, V43, P773, DOI 10.1080/09500349608232782; Zhang S, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.047401; Zhu W. M., 2012, NAT COMMUN, V3	88	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1077-260X	1558-4542		IEEE J SEL TOP QUANT	IEEE J. Sel. Top. Quantum Electron.	JUL-AUG	2015	21	4							2701410	10.1109/JSTQE.2014.2385957		10	Engineering, Electrical & Electronic; Optics; Physics, Applied	Engineering; Optics; Physics	CM0NV	WOS:000357376100001		
J	Koyama, F; Nakahama, M				Koyama, Fumio; Nakahama, Masanori			Micromachined Vertical Cavity Surface Emitting Lasers-Athermalization, Tuning, and Multiwavelength Integration	IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS			English	Article						Vertical cavity surface emitting lasers; wavelength division multiplexing; microelectromechanical system (MEMS); tunable lasers	DISTRIBUTED-BRAGG-REFLECTOR; TUNABLE VCSEL; OPTICAL NETWORKS; MEMS-VCSELS; MU-M; WAVELENGTH; GENERATION; FILTER; RANGE; MIRROR	We review the wavelength engineering of micromachined vertical cavity surface emitting lasers (VCSELs), including the wavelength athermalization, wavelength tuning, and multiple wavelength integration. The integration of a thermally actuated cantilever enables us to tailor the temperature dependence of lasing wavelengths. The thermal drift of lasing wavelengths in conventional single-mode semiconductor lasers, which is typically 0.07 nm/K, can be compensated by using the thermal actuation of a cantilever mirror. We are able to realize "athermal operation" of VCSELs under uncooled operations. This novel function could be useful for WDM optical interconnects, local area networks, and access networks with narrow channel spacing under uncooled operations. In addition, continuous wavelength tuning can be realized by using either electrothermal or electrostatic force actuation of the cantilever structure, which provides the athermal and tunable operation at the same time. Also, the lithography defined multi-wavelength integration of an athermal VCSEL array is addressed.	[Koyama, Fumio; Nakahama, Masanori] Tokyo Inst Technol, Photon Integrat Syst Res Ctr, Yokohama, Kanagawa 2268503, Japan; [Koyama, Fumio] King Abdulaziz Univ, Jeddah 21589, Saudi Arabia	Koyama, F (reprint author), Tokyo Inst Technol, Photon Integrat Syst Res Ctr, Yokohama, Kanagawa 2268503, Japan.	koyama@pi.titech.ac.jp; naka-hama.m.aa@m.titech.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [22226008]	This work was supported by Grant-in-Aid for Scientific Research (S) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#22226008).	Adachi S., 1993, EMIS DATA REV SERIES, V7; Ahsen OO, 2013, OPT EXPRESS, V21, P18021, DOI 10.1364/OE.21.018021; Amano T, 2003, J LIGHTWAVE TECHNOL, V21, P596, DOI 10.1109/JLT.2003.809541; Amano T, 2000, IEEE PHOTONIC TECH L, V12, P510, DOI 10.1109/68.841269; Amano T, 2001, IEICE T ELECTRON, VE84C, P678; Chang-Hasnain CJ, 2000, IEEE J SEL TOP QUANT, V6, P978, DOI 10.1109/2944.902146; Coldren LA, 2004, J LIGHTWAVE TECHNOL, V22, P193, DOI 10.1109/JLT.2003.822207; Coldren LA, 2000, IEEE J SEL TOP QUANT, V6, P988, DOI 10.1109/2944.902147; SAKANO S, 1992, IEEE PHOTONIC TECH L, V4, P321, DOI 10.1109/68.127200; Prott C, 2003, IEEE J SEL TOP QUANT, V9, P918, DOI 10.1109/JSTQE.2003.818848; Lackner M, 2003, MEAS SCI TECHNOL, V14, P101, DOI 10.1088/0957-0233/14/1/315; Kim JH, 1998, J VAC SCI TECHNOL B, V16, P558, DOI 10.1116/1.589862; Luo YQ, 2013, J LIGHTWAVE TECHNOL, V31, P587, DOI 10.1109/JLT.2012.2215841; Buus J, 2006, J LIGHTWAVE TECHNOL, V24, P5, DOI 10.1109/JLT.2005.859839; Pezeshki B, 2002, IEEE PHOTONIC TECH L, V14, P1457, DOI 10.1109/LPT.2002.802392; Iga K, 2000, IEEE J SEL TOP QUANT, V6, P1201, DOI 10.1109/2944.902168; Jayaraman V, 2012, ELECTRON LETT, V48, P1331, DOI 10.1049/el.2012.3180; Liu YR, 2005, IEEE PHOTONIC TECH L, V17, P2026, DOI 10.1109/LPT.2005.856367; Jayaraman V, 2012, ELECTRON LETT, V48, P867, DOI 10.1049/el.2012.1552; Gierl C, 2011, OPT EXPRESS, V19, P17336, DOI 10.1364/OE.19.017336; Asaka K., 2014, EUR C OPT COMM CANN; Born M., 1964, PRINCIPLES OPTICS EL; Boucart J, 2003, IEEE PHOTONIC TECH L, V15, P1186, DOI 10.1109/LPT.2003.816673; Chu W.H., 1993, J MICROMECH MICROENG, V3, P4, DOI 10.1088/0960-1317/3/1/002; Fujiwara N, 2003, ELECTRON LETT, V39, P614, DOI 10.1049/el:20030397; Harris JS, 2000, IEEE J SEL TOP QUANT, V6, P1145, DOI 10.1109/2944.902163; Huang MCY, 2007, OPT EXPRESS, V15, P1222, DOI 10.1364/OE.15.001222; Janto W., 2006, 20 INT SEM LAS C KOH; Kogel B, 2012, IEEE J QUANTUM ELECT, V48, P144, DOI 10.1109/JQE.2011.2172191; Koyama F., 1997, P OSA TECH DIG SERIE, V9, P90; Larson MC, 1996, APPL PHYS LETT, V68, P891, DOI 10.1063/1.116221; Li MY, 1998, IEEE PHOTONIC TECH L, V10, P18, DOI 10.1109/68.651087; Liu Y., 2006, OPT FIB COMM C AN CA; Mukaihara T., 2003, P EUR C OPT COMM C R, P718; N Natakeyama, 2003, IEEE PHOTONIC TECH L, V15, P903; Nakahama M., 2014, APPL PHYS LETT, V105; Nakahama M., 2014, OPT EXP, V22, P7; Nakahama M, 2013, IEEE PHOTONIC TECH L, V25, P1747, DOI 10.1109/LPT.2013.2272732; Nakamura H., 2013, OPT FIB COMM C NAT F; Nishiyama N, 2003, ELECTRON LETT, V39, P437, DOI 10.1049/el:20030288; Riemenschneider F, 2004, IEEE PHOTONIC TECH L, V16, P2212, DOI 10.1109/LPT.2004.833885; Sakamoto S, 2007, IEEE PHOTONIC TECH L, V19, P291, DOI 10.1109/LPT.2007.891205; Sano H, 2009, APPL PHYS EXPRESS, V2, DOI 10.1143/APEX.2.072101; Sano H, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4753807; Soderkvist J., 1993, Journal of Micromechanics and Microengineering, V3, DOI 10.1088/0960-1317/3/1/006; Sugihwo F, 1998, J MICROELECTROMECH S, V7, P48, DOI 10.1109/84.661383; Taguchi K., 2013, EUR C OPT COMM LOND; Taubenblatt MA, 2012, J LIGHTWAVE TECHNOL, V30, P448, DOI 10.1109/JLT.2011.2172989; TOHMORI Y, 1983, ELECTRON LETT, V19, P656, DOI 10.1049/el:19830446; Ushigome R, 2002, JPN J APPL PHYS 1, V41, P6364, DOI 10.1143/JJAP.41.6364; WU MS, 1995, ELECTRON LETT, V31, P1671, DOI 10.1049/el:19951159; YOKOUCHI N, 1992, IEEE PHOTONIC TECH L, V4, P701, DOI 10.1109/68.145243; Zhang WJ, 2012, J LIGHTWAVE TECHNOL, V30, P3836, DOI 10.1109/JLT.2012.2212696; Zhou Y, 2008, OPT EXPRESS, V16, P14221, DOI 10.1364/OE.16.014221	54	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1077-260X	1558-4542		IEEE J SEL TOP QUANT	IEEE J. Sel. Top. Quantum Electron.	JUL-AUG	2015	21	4							1700310	10.1109/JSTQE.2015.2389522		10	Engineering, Electrical & Electronic; Optics; Physics, Applied	Engineering; Optics; Physics	CM0NO	WOS:000357375200001		
J	Tanaka, N; Matsumoto, I; Suzuki, M; Kaneko, M; Nitta, K; Seguchi, R; Ooi, A; Takemura, H				Tanaka, Nobuyoshi; Matsumoto, Isao; Suzuki, Mitsutaka; Kaneko, Mami; Nitta, Kanae; Seguchi, Ryuta; Ooi, Akishi; Takemura, Hirofumi			Chitosan tubes can restore the function of resected phrenic nerves	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Chitosan tube; Phrenic nerve; Nerve regeneration	REPAIR; INJURY; REGENERATION	OBJECTIVES: We previously reported that the phrenic nerve could be morphologically repaired by implantation of a chitosan nanofibre tube (C-tube). In the current study, we investigated whether implantation of C-tubes could improve the function of an injured phrenic nerve using a beagle dog model. METHODS: Seven beagle dogs underwent right thoracotomy under general anaesthesia. An approximately 5 mm length of the right phrenic nerve was resected. Five dogs had a C-tube implantation (C-tube group) and other two dogs did not have the C-tube implantation (control group). Diaphragm movements were longitudinally measured by X-ray fluoroscopy before surgery, immediately after the surgery, and 3, 6 and 12 months after the surgery. The diaphragm movement was determined by diaphragm levels at inspiration and expiration phases, and the excursion difference between them was calculated. At 12 months after the surgery, rethoracotomy was performed to examine electrical phrenic nerve conduction. The C-tube and phrenic nerve were then excised for histological assessment of nerve regeneration. RESULTS: Three of the five animals of the C-tube group showed improvement of diaphragm movement with time. In these three animals, slow phrenic nerve conduction was observed. Histological assessment showed that the injured nerve was connected by newly regenerating nerve fibres surrounded by granulation tissue within the C-tube. On the other hand, the animals in the control group and two animals of the C-tube group showed neither improved diaphragm movement, nor electrical conduction to the diaphragm. No nerve fibre regeneration was found by histology. CONCLUSIONS: Our results suggest that, in addition to morphological improvement, C-tube implantation can functionally improve the injured phrenic nerve by promoting phrenic nerve regeneration.	[Tanaka, Nobuyoshi; Matsumoto, Isao; Suzuki, Mitsutaka; Kaneko, Mami; Nitta, Kanae; Seguchi, Ryuta; Takemura, Hirofumi] Kanazawa Univ, Dept Gen & Cardiothorac Surg, Kanazawa, Ishikawa 9208641, Japan; [Ooi, Akishi] Kanazawa Univ, Dept Mol & Cellular Pathol, Kanazawa, Ishikawa 9208641, Japan	Tanaka, N (reprint author), Kanazawa Univ, Dept Gen & Cardiothorac Surg, Takara Machi 13-1, Kanazawa, Ishikawa 9208641, Japan.	tanapiro@ipch.jp			JSPS KAKENHI [21591661]	This work was supported by JSPS KAKENHI (grant number: 21591661).	Wang W, 2008, J BIOMED MATER RES A, V84A, P557, DOI 10.1002/jbm.a.31536; Tripp HF, 1998, J CARDIAC SURG, V13, P218; Dahlin LB, 2001, NEUROSURG CLIN N AM, V12, P341; Archana D, 2013, INT J BIOL MACROMOL, V57, P193, DOI 10.1016/j.ijbiomac.2013.03.002; Beris A, 2007, J NEUROTRAUM, V24, P909, DOI 10.1089/neu.2006.0165; Boriwanwattanarak P., 2008, International Journal of Cosmetic Science, V30, P205, DOI 10.1111/j.1468-2494.2008.00437.x; COLIN W, 1984, J DENT RES, V63, P987, DOI 10.1177/00220345840630071601; Matsumoto I, 2010, INTERACT CARDIOV TH, V10, P498, DOI 10.1510/icvts.2009.227744; MERAV AD, 1983, CHEST, V84, P642, DOI 10.1378/chest.84.5.642; Morelot-Panzini C, 2009, J ELECTROMYOGR KINES, V19, P122, DOI 10.1016/j.jelekin.2007.06.017; Simansky DA, 2002, THORAX, V57, P613, DOI 10.1136/thorax.57.7.613; Uemora T, 2012, BIOCHEM BIOPH RES CO, V419, P130; Yoshitani M, 2007, J THORAC CARDIOV SUR, V133, P726, DOI 10.1016/j.jtcvs.2006.08.089	13	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	JUL	2015	21	1					8	13		10.1093/icvts/ivv091		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM2QW	WOS:000357527800003		
J	Takahashi, Y; Horio, H; Hato, T; Harada, M; Matsutani, N; Kawamura, M				Takahashi, Yusuke; Horio, Hirotoshi; Hato, Tai; Harada, Masahiko; Matsutani, Noriyuki; Kawamura, Masafumi			Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Post-recurrence survival; Prognostic factor; Systemic chemotherapy	PROGNOSTIC-FACTORS; CHEMOTHERAPY; REGISTRY; THERAPY	OBJECTIVES: Despite recent progress in diagnostic technology and therapeutic approaches to non-small-cell lung cancer (NSCLC), 30-75% of patients develop tumour recurrence after resection. However, the details of post-recurrence survival (PRS) are not well understood. We aimed to investigate the predictors of PRS in patients with NSCLC initially completely resected. METHODS: A series of 568 NSCLC patients who had undergone complete resection between 2000 and 2009 were evaluated retrospectively. Patients who had developed recurrent NSCLC after complete resection were subjected to the current analysis. We examined PRS using the Kaplan-Meier method and multivariate Cox regression analyses. RESULTS: Of the 568 patients, 138 (24.3%) were identified as having disease recurrence. The 2-year and 5-year PRS rates were 44.6 and 25.9%, respectively, while the median PRS time was 22.5 months. Non-adenocarcinoma histology [hazard ratio (HR) = 2.825, 95% confidence interval (CI): 1.825-4.367, P < 0.001], serum carcinoembryonic antigen (CEA) at recurrence >= 5.0 mg/dl (HR = 2.205, 95% CI: 1.453-3.344, P < 0.001) and no systemic chemotherapy (HR = 2.137, 95% CI: 1.304-3.247, P = 0.002) were independent prognostic factors for PRS. CONCLUSIONS: The current results showed that non-adenocarcinoma histology, elevated serum CEA at recurrence and no systemic chemotherapy were independent unfavourable post-recurrence prognostic factors. The current data can be informative for patient follow-up after complete resection and further clinical investigation may give us more information about PRS and accurate treatment strategy for recurrent NSCLC after initial complete resection.	[Takahashi, Yusuke; Horio, Hirotoshi; Hato, Tai; Harada, Masahiko] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Surg, Tokyo 1138677, Japan; [Takahashi, Yusuke; Matsutani, Noriyuki; Kawamura, Masafumi] Teikyo Univ, Sch Med, Dept Gen Thorac Surg, Tokyo 173, Japan	Takahashi, Y (reprint author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Surg, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	yusuketakahashigts@gmail.com			Teikyo University Research Grant [TKRG-14-4]	This work is supported by Teikyo University Research Grant (TKRG-14-4).	Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Janku F, 2011, J THORAC ONCOL, V6, P1601, DOI 10.1097/JTO.0b013e31822944b3; Sawabata N, 2011, J THORAC ONCOL, V6, P1229, DOI 10.1097/JTO.0b013e318219aae2; MacDermed DM, 2008, J SURG ONCOL, V98, P202, DOI 10.1002/jso.21102; Katayama T, 2010, SURG ONCOL, V19, pE144, DOI 10.1016/j.suronc.2010.07.002; Sugimura H, 2007, ANN THORAC SURG, V83, P409, DOI 10.1016/j.athoracsur.2006.08.046; Hishida T, 2006, J THORAC CARDIOV SUR, V131, P838, DOI 10.1016/j.jtcvs.2005.11.028; Shimada Y, 2013, CHEST, V143, P1626, DOI 10.1378/chest.12-1717; Asamura H, 2008, J THORAC ONCOL, V3, P46, DOI 10.1097/JTO.0b013e31815e8577; Martin J, 2002, J CLIN ONCOL, V20, P1989, DOI 10.1200/JCO.2002.08.092; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351; Cein K, 2011, CLIN EPIDEMIOL, V3, P139; Jin B, 2010, CHEMOTHERAPY, V56, P417, DOI 10.1159/000317580; Lee GW, 2012, J THORAC ONCOL, V7, P528, DOI 10.1097/JTO.0b013e3182417830; Mitsudomi T, 1996, J SURG ONCOL, V63, P159, DOI 10.1002/(SICI)1096-9098(199611)63:3<159::AID-JSO5>3.0.CO;2-C; Nakagawa T, 2008, EUR J CARDIO-THORAC, V34, P499, DOI 10.1016/j.ejcts.2008.05.016; Schuette W, 2001, LUNG CANCER-J IASLC, V33, pS99, DOI 10.1016/S0169-5002(01)00309-9; Takamochi K, 2000, CHEST, V117, P1577, DOI 10.1378/chest.117.6.1577; Tanner NT, 2012, LUNG CANCER, V76, P131, DOI 10.1016/j.lungcan.2011.11.013; Travis W, 2004, PATHOLOGY GENETICS T; Yamazaki K, 2010, ANTICANCER RES, V30, P1311	24	2	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	JUL	2015	21	1					14	20		10.1093/icvts/ivv085		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM2QW	WOS:000357527800004		
J	Chen, FS; Oga, T; Yamada, T; Sato, M; Aoyama, A; Chin, K; Date, H				Chen, Fengshi; Oga, Toru; Yamada, Tetsu; Sato, Masaaki; Aoyama, Akihiro; Chin, Kazuo; Date, Hiroshi			Lung allocation score and health-related quality of life in Japanese candidates for lung transplantation	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Chronic respiratory failure; Lung allocation score; Lung transplantation; Health-related quality of life; Pulmonary function	OBSTRUCTIVE PULMONARY-DISEASE; EXERCISE CAPACITY; SURVIVAL; FIBROSIS; DYSPNEA; INDEX	OBJECTIVES: The lung allocation score (LAS) system has been implemented to reduce waiting list time and mortality in the USA, but it remains uncertain how the LAS would reflect the impairment in health-related quality of life (HRQOL), which is another lung transplantation treatment goal to be improved in addition to survival. We thus investigated the relationships of the LAS with mortality and HRQOL in Japanese lung transplantation candidates. METHODS: One hundred and two candidates for lung transplantation at Kyoto University Hospital between 2009 and 2013 were consecutively recruited to participate in this study. Their physiological measurements of pulmonary function and 6-min walking distance, as well as patient-reported measurements of HRQOL, dyspnoea and psychological status, were assessed. RESULTS: Among these 102 patients, 22 died during a mean follow-up of 11.6 months. The LAS was significantly correlated to mortality (P = 0.0026), although other physiological measurements were not. However, regarding its relationship with HRQOL, correlation coefficients between the LAS, Medical Outcomes Study 36-item short form and St George's Respiratory Questionnaire (SGRQ) were relatively low, with the highest at 0.31. Multivariate analyses showed that the LAS was less significantly related to the SGRQ total score than dyspnoea, and psychological status. CONCLUSIONS: The LAS was significantly related to mortality in lung transplant candidates in Japan, while, despite its multidimensional scoring, its relationship with health-related quality of life was only weak. Their severity assessment system may be more focused on patients' health and symptoms.	[Chen, Fengshi; Yamada, Tetsu; Sato, Masaaki; Aoyama, Akihiro; Date, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto 6068507, Japan; [Oga, Toru; Chin, Kazuo] Kyoto Univ, Grad Sch Med, Dept Resp Care & Sleep Control Med, Kyoto 6068507, Japan	Date, H (reprint author), Kyoto Univ, Dept Thorac Surg, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hdate@kuhp.kyoto-u.ac.jp					Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Mura M, 2012, EUR RESPIR J, V40, P101, DOI 10.1183/09031936.00106011; Swigris JJ, 2005, THORAX, V60, P588, DOI 10.1136/thx.2004.035220; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; McShane PJ, 2013, SEMIN RESP CRIT CARE, V34, P275, DOI 10.1055/s-0033-1348461; Marin JM, 2011, RESP MED, V105, P916, DOI 10.1016/j.rmed.2011.01.007; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Singer JP, 2013, AM J TRANSPLANT, V13, P839, DOI 10.1111/ajt.12174; Hajiro T, 1998, AM J RESP CRIT CARE, V157, P785; Benza RL, 2012, CHEST, V141, P354, DOI 10.1378/chest.11-0676; Oga T, 2003, AM J RESP CRIT CARE, V167, P544, DOI 10.1164/rccm.200206-583OC; Smits JM, 2011, J HEART LUNG TRANSPL, V30, P22, DOI 10.1016/j.healun.2010.08.006; Chalmers JD, 2014, AM J RESP CRIT CARE, V189, P576, DOI 10.1164/rccm.201309-1575OC; Dijk Wouter D van, 2011, Respir Res, V12, P151, DOI 10.1186/1465-9921-12-151; Fukuhara S, 2011, MANUAL SF 36V2 JAPAN; Oga T, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-85; Singer JP, 2014, THORAX, V69, P445; Singer JP, 2013, SEMIN RESP CRIT CARE, V34, P421, DOI 10.1055/s-0033-1348470; Singer JP, 2013, RESPIRATION, V85, P375, DOI 10.1159/000338110; Tsuang WM, 2013, ANN INTERN MED, V158, P650, DOI 10.7326/0003-4819-158-9-201305070-00004; van der Bij W, 2009, EUR RESPIR MONOGR, P238; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	23	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	JUL	2015	21	1					28	33		10.1093/icvts/ivv101		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM2QW	WOS:000357527800006		
J	Ogawa, H; Uchino, K; Tanaka, Y; Shimizu, N; Okuda, Y; Tane, K; Tauchi, S; Nishio, W; Maniwa, Y; Yoshimura, M				Ogawa, Hiroyuki; Uchino, Kazuya; Tanaka, Yugo; Shimizu, Nahoko; Okuda, Yusuke; Tane, Kenta; Tauchi, Shunsuke; Nishio, Wataru; Maniwa, Yoshimasa; Yoshimura, Masahiro			Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Pleural lavage cytology; Adjuvant chemotherapy; Lung cancer; Surgery	FACTOR RECEPTOR MUTATION; PROGNOSTIC VALUE; CANCER; RESECTION; METAANALYSIS; RECURRENCE; CLASSIFICATION; SURVIVAL; IMPACT	OBJECTIVES: Positive pleural lavage cytology (PLC) findings are considered to be predictive of a poor prognosis in patients with non-small-cell lung cancer (NSCLC). We investigated the clinical benefit of adjuvant chemotherapy for lung adenocarcinoma patients with positive PLC findings. METHODS: We retrospectively reviewed the medical records of lung adenocarcinoma patients who underwent tumour resection and had positive PLC findings between January 2000 and December 2009. RESULTS: Fifty-three patients (4.8%) of 1114 patients with lung adenocarcinoma had positive PLC findings. The median follow-up period was 33.6 months. Adjuvant chemotherapy was administered to 24 patients (adjuvant chemotherapy group); 7, 8 and 9 patients had pathological Stage I, II and III, respectively . The surgery-alone group comprised 29 patients; 12, 8 and 9 patients had pathological Stage I, II and III, respectively. The 5-year recurrence-free survival (RFS) rates were 34.6 and 15.7% (P < 0.01) in adjuvant chemotherapy and surgery-alone groups, respectively. The rate of distant recurrence was significantly reduced in the adjuvant chemotherapy group (25.0 and 58.6%; P = 0.01). Even for Stage I cases, adjuvant chemotherapy tended to improve the 5-year RFS rate compared with surgery alone (60.1 and 29%; P = 0.11). Multivariate analysis for RFS revealed that adjuvant chemotherapy [hazard ratio (HR), 0.45; P = 0.03], tumour size > 30 mm (HR, 2.23; P = 0.02) and lymph node metastasis (HR, 2.67; P < 0.01) were significant independent prognostic factors for recurrence. CONCLUSIONS: Adjuvant chemotherapy for lung adenocarcinoma patients with positive PLC findings significantly improved recurrence-free survival.	[Ogawa, Hiroyuki; Uchino, Kazuya; Shimizu, Nahoko; Okuda, Yusuke; Tane, Kenta; Nishio, Wataru; Yoshimura, Masahiro] Hyogo Canc Ctr, Dept Thorac Surg, Akashi, Hyogo 6738558, Japan; [Ogawa, Hiroyuki; Tanaka, Yugo; Tauchi, Shunsuke; Maniwa, Yoshimasa; Yoshimura, Masahiro] Kobe Univ Hosp, Dept Thorac Surg, Kobe, Hyogo, Japan	Uchino, K (reprint author), Hyogo Canc Ctr, Dept Thorac Surg, 13-70 Kitaoji Cho, Akashi, Hyogo 6738558, Japan.	kazuya-uchino@hp.pref.hyogo.jp			National Cancer Center Research and Development Funds [23-A-18]	This study was supported in part by Grant number 23-A-18 from the National Cancer Center Research and Development Funds.	Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Takenaka T, 2015, EUR J CARDIO-THORAC, V47, P550, DOI 10.1093/ejcts/ezu227; Hamada C, 2005, J CLIN ONCOL, V23, P4999, DOI 10.1200/JCO.2005.09.017; Owonikoko TK, 2007, J CLIN ONCOL, V25, P5570, DOI 10.1200/JCO.2007.12.5435; Jeon JH, 2015, EUR J CARDIO-THORAC, V47, P556, DOI 10.1093/ejcts/ezu177; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Aokage K, 2010, J THORAC CARDIOV SUR, V139, P1246, DOI 10.1016/j.jtcvs.2009.07.049; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351; Dresler CM, 1999, ANN THORAC SURG, V67, P1435, DOI 10.1016/S0003-4975(99)00220-9; Enatsu S, 2006, ANN THORAC SURG, V81, P298, DOI 10.1016/j.athoracsur.2005.06.073; Higashiyama M, 2009, EUR J CARDIO-THORAC, V35, P337, DOI 10.1016/j.ejcts.2008.10.013; Kaneda M, 2012, EUR J CARDIO-THORAC, V41, P1335, DOI 10.1093/ejcts/ezr224; Kawachi Riken, 2009, Interact Cardiovasc Thorac Surg, V9, P265, DOI 10.1510/icvts.2009.202010; Kotoulas C, 2001, EUR J CARDIO-THORAC, V20, P330, DOI 10.1016/S1010-7940(01)00718-7; Lim E, 2010, J THORAC CARDIOV SUR, V139, P1441, DOI 10.1016/j.jtcvs.2009.05.048; Nakagawa T, 2007, ANN THORAC SURG, V83, P204, DOI 10.1016/j.athoracsur.2006.07.035; Ogawa H, 2014, EUR J CARDIO-THORAC, DOI [10.1093/ejcts/ezu429, DOI 10.1093/EJCTS/EZU429]; Okada M, 1999, ANN SURG, V229, P579, DOI 10.1097/00000658-199904000-00019; Okada M, 2003, J THORAC CARDIOV SUR, V126, P1911, DOI 10.1016/S0022-5223(03)00715-3; Saso S, 2012, THORAX, V67, P526, DOI 10.1136/thoraxjnl-2011-200424; Satoh Y, 2007, ANN THORAC SURG, V83, P197, DOI 10.1016/j.athoracsur.2006.08.025; Vicidomini G, 2005, ANN THORAC SURG, V79, P54; Vicidomini G, 2005, ANN THORAC SURG, V79, P254, DOI 10.1016/j.athoracsur.2004.06.115	25	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	JUL	2015	21	1					34	39		10.1093/icvts/ivv098		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM2QW	WOS:000357527800007		
J	Seike, Y; Nishibe, T; Ogino, H; Koizumi, N				Seike, Yoshimasa; Nishibe, Toshiya; Ogino, Hitoshi; Koizumi, Nobusato			Hybrid repair of rare type IIIb endoleaks from an abdominal endograft: repeatedly undetected endoleaks	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Hybrid repair; Type IIIb endoleak; Abdominal endograft	STENT-GRAFT	We report a rare case of massive type IIIb endoleaks from an abdominal endograft, which were difficult to diagnose and required hybrid repair (including open surgery). The patient had previously undergone three catheter interventions for type Ia and II endoleaks after abdominal endografting. However, the abdominal aortic aneurysm gradually enlarged and required hybrid treatment (including an open repair), to successfully perform aneurysmorrhaphy and additional endograft insertions for the massive type IIIb endoleaks.	[Seike, Yoshimasa; Nishibe, Toshiya; Ogino, Hitoshi; Koizumi, Nobusato] Tokyo Med Univ, Dept Cardiovasc Surg, Tokyo 1600023, Japan	Seike, Y (reprint author), Tokyo Med Univ, Dept Cardiovasc Surg, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	ys46421g@ncvc.go.jp					Espinosa G, 2009, J ENDOVASC THER, V16, P125, DOI 10.1583/08-2686.1; Juszkat R, 2009, J VASC INTERV RADIOL, V20, P125, DOI 10.1016/j.jvir.2008.09.029; Lee WA, 2006, J VASC SURG, V44, P183, DOI 10.1016/j.jvs.2006.02.043; Reijnen MMPJ, 2012, J VASC SURG, V56, P538, DOI 10.1016/j.jvs.2012.03.022; Wanhainen A, 2008, J VASC SURG, V48, P723, DOI 10.1016/j.jvs.2008.03.047	5	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	JUL	2015	21	1					129	131		10.1093/icvts/ivv069		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM2QW	WOS:000357527800027		
J	Inoue, T; Hashimoto, K; Bando, K; Yoshitake, M				Inoue, Takahiro; Hashimoto, Kazuhiro; Bando, Ko; Yoshitake, Michio			Left ventricular pseudo-false aneurysm perforating into the right ventricle	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Pseudo-false aneurysm; Left ventricle; Right ventricle; Myocardial infarction		Left ventricular pseudo-false aneurysms are a very rare complication of myocardial infarction. Occasionally, they will perforate into the right ventricle. Their haemodynamic presentation is similar to postinfarction ventricular septal defect. Even with no early clinical symptoms, they can lead to congestive heart failure or sudden fatal rupture. We report on a 67-year old man who developed a large left ventricular pseudo-false aneurysm that perforated into the right ventricle late after acute inferior myocardial infarction. He had undergone percutaneous coronary intervention to the right coronary artery in August 2013. During the surgery performed in July 2014, with only incision at the aneurysm, the small perforation to the right ventricle was closed directly and the large perforation to the left ventricle was closed with a bovine pericardial patch. Considering the late mechanical complications attendant to left ventricular remodelling, physicians should conduct careful long-term follow-up of patients with transmural myocardial infarction, even if previous percutaneous coronary intervention was successfully performed.	[Inoue, Takahiro; Hashimoto, Kazuhiro; Bando, Ko; Yoshitake, Michio] Jikei Univ, Dept Cardiac Surg, Minato Ku, Tokyo 1058461, Japan	Inoue, T (reprint author), Jikei Univ, Dept Cardiac Surg, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.	yokosuka-inoten@jikei.ac.jp					Fukuda I, 1993, Nihon Kyobu Geka Gakkai Zasshi, V41, P332; Ohtani H, 2010, CIRC J, V74, P1986, DOI 10.1253/circj.CJ-10-0285; Stewart S, 1981, ANN THORAC SURG, V31, P59; Tasaki D, 2009, JPN J CARDIOVASC SUR, V38, P208; Yamauchi M, 2002, JPN J CARDIOVASC SUR, V31, P68	5	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	JUL	2015	21	1					137	139		10.1093/icvts/ivv086		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CM2QW	WOS:000357527800030		
J	Hida, T; Murao, K; Oshima, M; Ishigami, T; Kubo, Y				Hida, Tetsuya; Murao, Kazutoshi; Oshima, Mika; Ishigami, Takeshi; Kubo, Yoshiaki			A case of pyoderma gangrenosum associated with anterior necrotizing scleritis in a patient with ulcerative colitis	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter							DISEASE; INVOLVEMENT; THERAPY		[Hida, Tetsuya; Murao, Kazutoshi; Oshima, Mika; Ishigami, Takeshi; Kubo, Yoshiaki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Tokushima 770, Japan	Hida, T (reprint author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Tokushima 770, Japan.	kmurao@tokushima-u.ac.jp					Langan SM, 2012, J INVEST DERMATOL, V132, P2166, DOI 10.1038/jid.2012.130; Smith JR, 2007, NAT CLIN PRACT RHEUM, V3, P219, DOI 10.1038/ncprheum0454; Akpek EK, 2004, OPHTHALMOLOGY, V111, P501, DOI 10.1016/j.ophtha.2003.06.006; Wakefield D, 2013, PROG RETIN EYE RES, V35, P44, DOI 10.1016/j.preteyeres.2013.02.004; Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055; Okhravi N, 2005, SURV OPHTHALMOL, V50, P351, DOI 10.1016/j.survophthal.2005.04.001; Bishop P, 1998, CORNEA, V17, P346; Braun MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1763; HAPPLE R, 1977, ARCH DERMATOL, V113, P1612; Miserocchi E, 2002, OPHTHALMOLOGY, V109, P1941, DOI 10.1016/S0161-6420(02)01165-X	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	JUL	2015	54	7					E269	E270		10.1111/ijd.12791		2	Dermatology	Dermatology	CL3UT	WOS:000356877000006		
J	Mizuno, K; Okamoto, H				Mizuno, Kana; Okamoto, Hiroyuki			Benign lymphangioendothelioma on a vascular birthmark following examination of a cardiac catheter	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter									[Mizuno, Kana; Okamoto, Hiroyuki] Kansai Med Univ, Dept Dermatol, Hirakata, Osaka 5731010, Japan	Mizuno, K (reprint author), Kansai Med Univ, Dept Dermatol, 2-5-1 Shin Machi, Hirakata, Osaka 5731010, Japan.	mizunok@hirakata.kmu.ac.jp					HERRON GS, 1994, J AM ACAD DERMATOL, V31, P362, DOI 10.1016/S0190-9622(94)70173-3; JONES EW, 1990, J AM ACAD DERMATOL, V23, P229, DOI 10.1016/0190-9622(90)70203-T; Kato H, 1996, CLIN EXP DERMATOL, V21, P159, DOI 10.1046/j.1365-2230.1996.d01-186.x; Messeguer F, 2010, Actas Dermosifiliogr, V101, P792, DOI 10.1016/S1578-2190(10)70718-6; Sevila A, 2000, AM J DERMATOPATH, V22, P151, DOI 10.1097/00000372-200004000-00011; Wang L, 2013, J CUTAN PATHOL, V40, P945, DOI 10.1111/cup.12216	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	JUL	2015	54	7					E273	E274		10.1111/ijd.12805		2	Dermatology	Dermatology	CL3UT	WOS:000356877000008		
J	Taylor, P; Lichtschlag, A; Toberman, M; Sayer, MDJ; Reynolds, A; Sato, T; Stahl, H				Taylor, Peter; Lichtschlag, Anna; Toberman, Matthew; Sayer, Martin D. J.; Reynolds, Andy; Sato, Toru; Stahl, Henrik			Impact and recovery of pH in marine sediments subject to a temporary carbon dioxide leak	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						Carbon capture and storage; Sediment pore water; pH; CO2	OCEAN ACIDIFICATION; ARDMUCKNISH BAY; ECOSYSTEM PROCESSES; STORAGE SITE; WATER COLUMN; TRACE-METALS; CO2 RELEASE; MICROELECTRODE; DYNAMICS; OXYGEN	A possible effect of a carbon dioxide leak from an industrial sub-sea floor storage facility, utilised for Carbon Capture and Storage, is that escaping carbon dioxide gas will dissolve in sediment pore waters and reduce their pH. To quantify the scale and duration of such an impact, a novel, field scale experiment was conducted, whereby carbon dioxide gas was injected into unconsolidated sub-sea floor sediments for a sustained period of 37 days. During this time pore water pH in shallow sediment (5 mm depth) above the leak dropped >0.8 unit, relative to a reference zone that was unaffected by the carbon dioxide. After the gas release was stopped, the pore water pH returned to normal background values within a three-week recovery period. Further, the total mass of carbon dioxide dissolved within the sediment pore fluids above the release zone was modelled by the difference in DIC between the reference and release zones. Results showed that between 14 and 63% of the carbon dioxide released during the experiment could remain in the dissolved phase within the sediment pore water. (C) 2014 The Authors. Published by Elsevier Ltd.	[Taylor, Peter; Toberman, Matthew; Sayer, Martin D. J.; Reynolds, Andy; Stahl, Henrik] Scottish Assoc Marine Sci, Scottish Marine Inst, Oban PA37 1QA, Argyll, Scotland; [Lichtschlag, Anna] Univ Southampton, Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England; [Sayer, Martin D. J.] Scottish Assoc Marine Sci, NERC Natl Facil Sci Div, Oban PA37 1QA, Argyll, Scotland; [Sato, Toru] Univ Tokyo, Dept Ocean Technol Policy & Environm, Kashiwa, Chiba 2778561, Japan; [Stahl, Henrik] Zayed Univ, Dubai, U Arab Emirates	Taylor, P (reprint author), Scottish Assoc Marine Sci, Scottish Marine Inst, Oban PA37 1QA, Argyll, Scotland.	pete.taylor@sams.ac.uk			NERC [NE/H013962/1]; Scottish Government; European Social Fund	Funding for this experiment was provided by NERC (NE/H013962/1), the Scottish Government. We thank the Tralee Bay Holiday Park, Lochnell Estates and the inhabitants of Benderloch for hosting the experiment. We acknowledge Marine Scotland and The Crown Estate for permissions to carry out the work. The NERC National Facility for Scientific Diving, the crew of the R. V. Seol Mara based at SAMS provided operational support. Peter Taylor's Ph.D. studentship is funded by the European Social Fund. We thank the two anonymous reviewers for their input, which strengthened this manuscript.	Lee JY, 2013, MAR PETROL GEOL, V47, P43, DOI 10.1016/j.marpetgeo.2013.05.017; Ardelan MV, 2009, SCI TOTAL ENVIRON, V407, P6255, DOI 10.1016/j.scitotenv.2009.09.004; Fabry VJ, 2008, ICES J MAR SCI, V65, P414, DOI 10.1093/icesjms/fsn048; Hall-Spencer JM, 2008, NATURE, V454, P96, DOI 10.1038/nature07051; CANFIELD DE, 1993, MAR GEOL, V113, P27, DOI 10.1016/0025-3227(93)90147-N; Little MG, 2010, ENVIRON SCI TECHNOL, V44, P9225, DOI 10.1021/es102235w; Tankere-Muller S, 2007, MAR CHEM, V106, P192, DOI 10.1016/j.marchem.2006.04.005; [Anonymous], 2001, ELSEV OCEANOGR SERIE; Lichtschlag A, 2015, INT J GREENH GAS CON, V38, P80, DOI 10.1016/j.ijggc.2014.10.008; Widdicombe S, 2008, J EXP MAR BIOL ECOL, V366, P187, DOI 10.1016/j.jembe.2008.07.024; Glud RN, 2008, MAR BIOL RES, V4, P243, DOI 10.1080/17451000801888726; Preisler A, 2007, ISME J, V1, P341, DOI 10.1038/ismej.2007.50; Tait K, 2015, INT J GREENH GAS CON, V38, P171, DOI 10.1016/j.ijggc.2014.11.021; Payan MC, 2012, ENVIRON POLLUT, V162, P29, DOI 10.1016/j.envpol.2011.10.015; CLARK LC, 1953, J APPL PHYSIOL, V6, P189; Doney SC, 2009, ANNU REV MAR SCI, V1, P169, DOI 10.1146/annurev.marine.010908.163834; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Hendriks IE, 2010, ESTUAR COAST SHELF S, V86, P157, DOI 10.1016/j.ecss.2009.11.022; Mori C, 2015, INT J GREENH GAS CON, V38, P153, DOI 10.1016/j.ijggc.2014.11.023; Lichtschlag A, 2010, LIMNOL OCEANOGR, V55, P931, DOI 10.4319/lo.2009.55.2.0931; Atamanchuk D, 2015, INT J GREENH GAS CON, V38, P121, DOI 10.1016/j.ijggc.2014.10.021; Murray F, 2013, MAR POLLUT BULL, V73, P435, DOI 10.1016/j.marpolbul.2012.11.023; Caramanna G, 2011, GREENH GASES, V1, P200, DOI 10.1002/ghg.28; de Beer D, 1997, LIMNOL OCEANOGR, V42, P1590; Kroeker KJ, 2010, ECOL LETT, V13, P1419, DOI 10.1111/j.1461-0248.2010.01518.x; Revsbech NP, 1998, LIMNOL OCEANOGR, V43, P986; Glud RN, 2009, LIMNOL OCEANOGR, V54, P1, DOI 10.4319/lo.2009.54.1.0001; Stahl H, 2006, LIMNOL OCEANOGR-METH, V4, P336; Blackford JC, 2013, ENRGY PROCED, V37, P3387, DOI 10.1016/j.egypro.2013.06.227; Cai WJ, 2000, MAR CHEM, V70, P133, DOI 10.1016/S0304-4203(00)00017-7; Cai W.J., 2000, IN SITU MONITORING A, P75; Cao L, 2008, GEOPHYS RES LETT, V35, P35; Cevatoglu M, 2015, INT J GREENH GAS CON, V38, P26, DOI 10.1016/j.ijggc.2015.03.005; Dalhousie P. O. A., UNESCO EQUATION STAT; Sellami N, 2015, INT J GREENH GAS CON, V38, P44, DOI 10.1016/j.ijggc.2015.02.011; Espa S, 2010, APPL GEOCHEM, V25, P696, DOI 10.1016/j.apgeochem.2010.02.002; Global CCS Institute, 2014, GLOB STAT CCS 2014; Intergovernmental Panel on Climate Change (IPCC), 2005, CARBON DIOXIDE CAPTU; ITALIANO F, 1991, J VOLCANOL GEOTH RES, V46, P125, DOI 10.1016/0377-0273(91)90079-F; Marton J.M., 2014, J GEOPHYS RES-BIOGEO, V119; Overnell J, 2002, ESTUAR COAST SHELF S, V55, P481, DOI 10.1006/ecss.2001.0919; Queiros AM, 2015, INT J GREENH GAS CON, V38, P110, DOI 10.1016/j.ijggc.2014.10.018; Ramsing N., 2014, UNISENSE; REVSBECH NP, 1983, APPL ENVIRON MICROB, V45, P755; Rosas J, 2014, GROUNDWATER, V52, P399, DOI 10.1111/gwat.12078; SCOTTISH ASSOCIATION FOR MARINE SCIENCE, 2013, SAMS WEBC WEATH; Stahl H, 2012, LIMNOL OCEANOGR-METH, V10, P389, DOI 10.4319/lom.2012.10.389; Stumm W., 1996, AQUATIC CHEM; Taylor P, 2015, INT J GREENH GAS CON, V38, P3, DOI 10.1016/j.ijggc.2014.09.007; THORPE SA, 1983, CONT SHELF RES, V1, P353, DOI 10.1016/0278-4343(83)90003-1; THORPE SA, 1983, NATURE, V306, P167, DOI 10.1038/306167a0; Vizzini S, 2010, J ECOL, V98, P1284, DOI 10.1111/j.1365-2745.2010.01730.x; Wang JN, 2013, J GEOPHYS RES-OCEANS, V118, P5994, DOI 10.1002/2013JC008900; Winkler L.W., 1888, DETERMINATION DISSOL	54	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		93	101		10.1016/j.ijggc.2014.09.006		9	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500010		
J	Tsukasaki, A; Suzumura, M; Lichtschlag, A; Stahl, H; James, RH				Tsukasaki, Ayumi; Suzumura, Masahiro; Lichtschlag, Anna; Stahl, Henrik; James, Rachael H.			Phosphorus behavior in sediments during a sub-seabed CO2 controlled release experiment	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						Sub-seabed carbon capture and storage; CCS; CO2 leakage; Marine sediment; Phosphorus; Sequential extraction	MARINE-SEDIMENTS; CARBON-DIOXIDE; SEQUENTIAL EXTRACTION; ENZYME-ACTIVITIES; RISK-ASSESSMENT; SEA; ENVIRONMENT; PHOSPHATE; OXIDATION; STORAGE	The CO2 controlled release experiment "Quantifying and Monitoring Potential Ecosystem Impacts of Geological Carbon Storage" (QICS) assessed the impacts of potential CO2 leakage from sub-seabed carbon capture and storage reservoirs to the marine environment. During QICS, CO2 gas was released into shallow sediment in Ardmucknish Bay, Scotland, in the spring and summer of 2012. As part of this project, we investigated the effects of CO2 leakage on sedimentary phosphorus (P), an essential nutrient for marine productivity. We found no statistically significant effects during QICS, as the solid-phase P content in the sediment was constant before, during, and after exposure to CO2. However, laboratory experiments using marine sediment standard materials as well as QICS sediment revealed substantial differences among these different sediment types in their potential for P release during CO2 exposure. Employing the SEDEX sequential extraction technique to determine the sizes of the major P pools in the sediments, we showed that calcium-bound P can be easily released by CO2 exposure, whereas iron-bound P is a major sink of released P. The overall impacts of CO2 leakage on sediment P behavior appear to be low compared to natural variability. (C) 2015 Elsevier Ltd. All rights reserved.	[Tsukasaki, Ayumi; Suzumura, Masahiro] AIST, Res Inst Environm Management Technol, Natl Inst Adv Ind Sci & Technol AIST, Tsukuba, Ibaraki 3058569, Japan; [Lichtschlag, Anna; James, Rachael H.] Univ Southampton, Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England; [Stahl, Henrik] Scottish Assoc Marine Sci, Scottish Marine Inst, Oban PA37 1QA, Argyll, Scotland; [Stahl, Henrik] Zayed Univ, Dubai, U Arab Emirates	Tsukasaki, A (reprint author), AIST, Res Inst Environm Management Technol, Natl Inst Adv Ind Sci & Technol AIST, 16-1 Onogawa, Tsukuba, Ibaraki 3058569, Japan.	ayumi-tsukasaki@aist.go.jp			Natural Environment Research Council [NE/H013962/1]; Scottish Government; Ministry of Economy, Trade and Industry of Japan	We thank all of the QICS participants for valuable technical support and scientific exchange, in particular Peter Taylor, Belinda Alker, and Carolyn Graves for support during sampling. We also thank the skilled divers of the National Scientific Diving Facility at the Scottish Association for Marine Science for collecting the cores, as well as the landowners (Lochnell Estate) and users (Tralee Bay Holiday Park) for allowing us to conduct this experiment. Funding was kindly provided by the Natural Environment Research Council (NE/H013962/1), the Scottish Government, and the Ministry of Economy, Trade and Industry of Japan.	Anderson LD, 2000, LIMNOL OCEANOGR, V45, P509; ASPILA KI, 1976, ANALYST, V101, P187, DOI 10.1039/an9760100187; Widdicombe S, 2013, MAR POLLUT BULL, V73, P399, DOI 10.1016/j.marpolbul.2013.05.044; Lichtschlag A, 2015, INT J GREENH GAS CON, V38, P80, DOI 10.1016/j.ijggc.2014.10.008; Kuster-Heins K, 2010, MAR GEOL, V274, P95, DOI 10.1016/j.margeo.2010.03.008; Benitez-Nelson CR, 2000, EARTH-SCI REV, V51, P109, DOI 10.1016/S0012-8252(00)00018-0; Ishida H, 2013, MAR POLLUT BULL, V73, P443, DOI 10.1016/j.marpolbul.2013.02.009; JOHNSON KM, 1987, MAR CHEM, V21, P117, DOI 10.1016/0304-4203(87)90033-8; Huesemann MH, 2002, MAR POLLUT BULL, V44, P142, DOI 10.1016/S0025-326X(01)00194-1; Conley DJ, 2009, ENVIRON SCI TECHNOL, V43, P3412, DOI 10.1021/es802762a; Paytan A, 2007, CHEM REV, V107, P563, DOI 10.1021/cr0503613; [Anonymous], A12262009 JIS; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Rozan TF, 2002, LIMNOL OCEANOGR, V47, P1346; SUZUMURA M, 1995, GEOCHEM J, V29, P331; Ishida H, 2005, J OCEANOGR, V61, P835, DOI 10.1007/s10872-006-0003-4; Mayer TD, 2000, WATER RES, V34, P3949, DOI 10.1016/S0043-1354(00)00158-5; Van Noorden R, 2010, NATURE, V463, P871, DOI 10.1038/463871a; Yamada N, 2010, J OCEANOGR, V66, P233; AMANKONAH JO, 1985, COLLOID SURFACE, V15, P295, DOI 10.1016/0166-6622(85)80080-9; Suzumura M, 2008, LIMNOL OCEANOGR-METH, V6, P619; Monastersky R, 2013, NATURE, V504, P339, DOI 10.1038/504339a; Blackford JC, 2013, ENRGY PROCED, V37, P3387, DOI 10.1016/j.egypro.2013.06.227; de Vries P, 2013, MAR POLLUT BULL, V73, P516, DOI 10.1016/j.marpolbul.2013.06.039; Endres S, 2013, BIOGEOSCIENCES, V10, P567, DOI 10.5194/bg-10-567-2013; FISHER TR, 1982, ESTUAR COAST SHELF S, V14, P101, DOI 10.1016/S0302-3524(82)80069-8; Frankowski L, 2002, ESTUAR COAST SHELF S, V54, P1027, DOI 10.1006/ecss.2001.0874; Gattuso J.-P., 2008, BIOGEOSCIENCES; Golterman HL, 1995, HYDROBIOLOGIA, V315, P39, DOI 10.1007/BF00028629; Gomez E, 1999, WATER RES, V33, P2437, DOI 10.1016/S0043-1354(98)00468-0; Kleypas J. A., 2006, WORKSH HELD 18 20 AP; Metz B., 2005, IPCC SPECIAL REPORT; Orr JC, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2005JC003086; ROYAL SOCIETY, 2005, 1205 ROYAL SOC; RUBEN JA, 1987, EVOLUTION, V41, P1187, DOI 10.2307/2409087; RUTTENBERG KC, 1992, LIMNOL OCEANOGR, V37, P1460; Slomp C.P., 2013, PLOS ONE, V8, P1; SUNDBY B, 1992, LIMNOL OCEANOGR, V37, P1129; Taylor P, 2015, INT J GREENH GAS CON, V38, P3, DOI 10.1016/j.ijggc.2014.09.007; Terashima S, 2002, GEOSTANDARD NEWSLETT, V26, P85, DOI 10.1111/j.1751-908X.2002.tb00626.x	40	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		102	109		10.1016/j.ijggc.2014.12.023		8	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500011		
J	Atamanchuk, D; Tengberg, A; Aleynik, D; Fietzek, P; Shitashima, K; Lichtschlag, A; Hall, POJ; Stahl, H				Atamanchuk, Dariia; Tengberg, Anders; Aleynik, Dmitry; Fietzek, Peer; Shitashima, Kiminori; Lichtschlag, Anna; Hall, Per O. J.; Stahl, Henrik			Detection of CO2 leakage from a simulated sub-seabed storage site using three different types of pCO(2) sensors	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						CCS; QICS; CO2 release; Leakage detection; pCO(2) sensors	LIFETIME-BASED OPTODE; CARBON-DIOXIDE; NORTH-SEA; MONITORING TECHNIQUES; OCEAN; IMPACTS; PERFORMANCE; WATERS; FLOOR; VENTS	This work is focused on results from a recent controlled sub-seabed in situ carbon dioxide (CO2) release experiment carried out during May-October 2012 in Ardmucknish Bay on the Scottish west coast. Three types of pCO(2) sensors (fluorescence, NDIR and ISFET-based technologies) were used in combination with multiparameter instruments measuring oxygen, temperature, salinity and currents in the water column at the epicentre of release and further away. It was shown that distribution of seafloor CO2 emissions features high spatial and temporal heterogeneity. The highest pCO(2) values (similar to 1250 mu atm) were detected at low tide around a bubble stream and within centimetres distance from the seafloor. Further up in the water column, 30-100 cm above the seabed, the gradients decreased, but continued to indicate elevated pCO(2) at the epicentre of release throughout the injection campaign with the peak values between 400 and 740 mu atm. High-frequency parallel measurements from two instruments placed within 1 m from each other, relocation of one of the instruments at the release site and 2D horizontal mapping of the release and control sites confirmed a localized impact from CO2 emissions. Observed effects on the water column were temporary and post-injection recovery took <7 days. A multivariate statistical approach was used to recognize the periods when the system was dominated by natural forcing with strong correlation between variation in pCO(2) and O-2, and when it was influenced by purposefully released CO2. Use of a hydrodynamic circulation model, calibrated with in situ data, was crucial to establishing background conditions in this complex and dynamic shallow water system. (C) 2014 Elsevier Ltd. All rights reserved.	[Atamanchuk, Dariia; Tengberg, Anders; Hall, Per O. J.] Univ Gothenburg, Dept Chem & Mol Biol, Marine Chem, SE-41296 Gothenburg, Sweden; [Tengberg, Anders] Aanderaa Data Instruments AS, NO-5828 Bergen, Norway; [Aleynik, Dmitry; Stahl, Henrik] Scottish Assoc Marine Sci, Scottish Marine Inst, Oban PA37 1QA, Argyll, Scotland; [Fietzek, Peer] GEOMAR Helmholtz Ctr Ocean Res, D-24148 Kiel, Germany; [Fietzek, Peer] CONTROS Syst & Solut GmbH, D-24148 Kiel, Germany; [Shitashima, Kiminori] Kyushu Univ, Int Inst Carbon Neutral Energy Res, Nishi Ku, Fukuoka 8190395, Japan; [Lichtschlag, Anna] Univ Southampton, Natl Oceanog Ctr Southampton, Southampton SO14 3ZH, Hants, England; [Stahl, Henrik] Zayed Univ, Dubai, U Arab Emirates	Atamanchuk, D (reprint author), Univ Gothenburg, Dept Chem & Mol Biol, Marine Chem, SE-41296 Gothenburg, Sweden.	Dariia.Atamanchuk@Dal.Ca			SENSEnet (International sensor development network) - a Marie Curie Initial Training Network (ITN) - European Commission [PITN-GA-2009-237868]; UK National Environmental Research Council (NERC); Scottish Government [NE/H013911/1]	This work was financially supported by SENSEnet (International sensor development network) - a Marie Curie Initial Training Network (ITN) funded by the European Commission Seventh Framework Program under contract number PITN-GA-2009-237868. We thank the UK National Environmental Research Council (NERC) and Scottish Government for kindly providing funding to the QICS project (NE/H013911/1). We also acknowledge the Lochnell Estate and Tralee Bay Holiday Park for providing on land site access, the divers at the National Facility of Scientific Diving (NFSD) and the crew on R/V Seol Mara at SAMS for deploying and recovering the instruments. We would like to thank Rachael James and Doug Connelly from the National Oceanography Centre (NOC) in Southampton for seawater sample analysis of DIC and A<INF>T</INF> as well as providing background CTD and currents data for the modelling.	Aleynik D., 2012, HYPOX D2 4 REPORT OX; Haszeldine RS, 2009, SCIENCE, V325, P1647, DOI 10.1126/science.1172246; Shitashima K, 2008, INT J GREENH GAS CON, V2, P95, DOI 10.1016/S1750-5836(07)00092-8; Hall-Spencer JM, 2008, NATURE, V454, P96, DOI 10.1038/nature07051; Miloshevich LM, 2004, J ATMOS OCEAN TECH, V21, P1305, DOI 10.1175/1520-0426(2004)021<1305:DAVOAT>2.0.CO;2; Kano Y, 2010, MAR POLLUT BULL, V60, P215, DOI 10.1016/j.marpolbul.2009.09.024; Shitashima K, 2015, INT J GREENH GAS CON, V38, P135, DOI 10.1016/j.ijggc.2014.12.011; Fiedler B, 2013, J ATMOS OCEAN TECH, V30, P112, DOI 10.1175/JTECH-D-12-00043.1; Lichtschlag A, 2015, INT J GREENH GAS CON, V38, P80, DOI 10.1016/j.ijggc.2014.10.008; Dewar M, 2013, MAR POLLUT BULL, V73, P504, DOI 10.1016/j.marpolbul.2013.03.005; Fietzek P, 2014, J ATMOS OCEAN TECH, V31, P181, DOI 10.1175/JTECH-D-13-00083.1; Martz TR, 2010, LIMNOL OCEANOGR-METH, V8, P172, DOI 10.4319/lom.2010.8.172; Tengberg A, 2006, LIMNOL OCEANOGR-METH, V4, P7; Blackford JC, 2013, ENRGY PROCED, V37, P3379, DOI 10.1016/j.egypro.2013.06.226; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Dickson AG, 2003, MAR CHEM, V80, P185, DOI 10.1016/S0304-4203(02)00133-0; Blackford JC, 2008, MAR POLLUT BULL, V56, P1461, DOI 10.1016/j.marpolbul.2008.04.048; Caramanna G, 2011, GREENH GASES, V1, P200, DOI 10.1002/ghg.28; Brewer PG, 2004, J OCEANOGR, V60, P751, DOI 10.1007/s10872-004-5767-9; Saderne V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062689; Atamanchuk D, 2014, LIMNOL OCEANOGR-METH, V12, P63, DOI 10.4319/lom.2014.12.63; Brewer P.G., 2003, CARBON DIOXIDE DILEM, P43; Cevatoglu M, 2015, INT J GREENH GAS CON, V38, P26, DOI 10.1016/j.ijggc.2015.03.005; Chen CS, 2003, J ATMOS OCEAN TECH, V20, P159, DOI 10.1175/1520-0426(2003)020<0159:AUGFVT>2.0.CO;2; Dissanayake AL, 2012, J HYDRO-ENVIRON RES, V6, P195, DOI 10.1016/j.jher.2012.02.001; Gough C., 2005, 47 TYND CTR; Jeong SM, 2010, INT J GREENH GAS CON, V4, P64, DOI 10.1016/j.ijggc.2009.09.021; Kano Y, 2009, INT J GREENH GAS CON, V3, P617, DOI 10.1016/j.ijggc.2009.03.004; Kirkwood W., 2009, OCEAN 2009 EUR, V1, P11; Kirkwood W., 2005, MTS IEEE OC; Lewis E., 1998, ORNLCDIAC105 US DEP; Pearce J., 2014, GUIDE POTENTIAL IMPA; Shitashima K, 2013, APPL GEOCHEM, V30, P114, DOI 10.1016/j.apgeochem.2012.08.001; Shitashima K., 1998, CHIKYUKAGAKU, V15, P1; Shitashima K., 2010, OCEANS, V1, P20; Shitashima K., 2002, P 2002 INT S UND TEC; Taylor P, 2015, INT J GREENH GAS CON, V38, P3, DOI 10.1016/j.ijggc.2014.09.007; Victoria I, 2011, 2011 IEEE/OES/CWTM TENTH WORKING CONFERENCE ON CURRENT, WAVES AND TURBULENCE MEASUREMENT (CWTM), P237, DOI 10.1109/CWTM.2011.5759558; Vizzini S, 2010, J ECOL, V98, P1284, DOI 10.1111/j.1365-2745.2010.01730.x; Walz P.M., 2008, OC 2008 MTS IEEE KOB, V1-3, P750; Wilkinson M, 2013, INT J GREENH GAS CON, V12, P310, DOI 10.1016/j.ijggc.2012.09.013	41	8	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		121	134		10.1016/j.ijggc.2014.10.021		14	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500013		
J	Shitashima, K; Maeda, Y; Sakamoto, A				Shitashima, Kiminori; Maeda, Yoshiaki; Sakamoto, Atsushi			Detection and monitoring of leaked CO2 through sediment, water column and atmosphere in a sub-seabed CCS experiment	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						QICS; Sub-seabed carbon capture and storage (CCS); In situ pH/pCO(2) sensor; CO2 leakage; Detection and monitoring	SEA-FLOOR; STORAGE; IMPACTS; LEAKAGE; ISLAND; JAPAN	Carbon capture and storage in sub-seabed geological formations (sub-seabed CCS) is currently being studied as a realistic option to mitigate the accumulation of anthropogenic CO2 in the atmosphere. In implementing sub-seabed CCS, detecting and monitoring the impact of the sequestered CO2 on the ocean environment is highly important. The first controlled CO2 release experiment, Quantifying and Monitoring Potential Ecosystem Impacts of Geological Carbon Storage (QICS), took place in Ardmucknish Bay, Oban, in May-September 2012. We applied the in situ pH/pCO(2) sensor to the QICS experiment for detection and monitoring of leaked CO2, and carried out several observations. The cabled real-time sensor was deployed close to the CO2 leakage (bubbling) area, and the fluctuations of in situ pH and pCO(2) above the seafloor were monitored in a land-based container. The long-term sensor was placed on seafloor in three different observation zones. The sediment pH sensor was inserted into the sediment at a depth of 50 cm beneath the seafloor near the CO2 leakage area. Wide-area mapping surveys of pH and pCO(2) in water column around the CO2 leakage area were carried out by using an autonomous underwater vehicle (AUV) installed with sensors. Atmospheric CO2 above the leakage area was observed by using a CO2 analyzer that was attached to the bow of ship of 50 cm above the sea-surface. The behavior of the leaked CO2 is highly dependent on the tidal periodicity (low tide or high tide) during the CO2 gas release period. At low tide, the pH in sediment and overlying seawater decreased due to strong eruption of CO2 gas bubbles, and the CO2 ascended to sea-surface quickly with a little dissolution to seawater and dispersed into the atmosphere. On the other hand, the CO2 bubbles release was lower at high tide due to higher water pressure, and slight low pH seawater and high atmospheric CO2 were detected. After stopping CO2 gas injection, no remarkable variations of pH in sediment and overlying water column were observed for three months. (C) 2014 Elsevier Ltd. All rights reserved.	[Shitashima, Kiminori; Sakamoto, Atsushi] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2 CNER, Fukuoka 8190395, Japan; [Maeda, Yoshiaki] Cent Res Inst Elect Power Ind, Environm Sci Res Lab, Abiko, Chiba 2701194, Japan	Shitashima, K (reprint author), Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2 CNER, 744 Moto Oka, Fukuoka 8190395, Japan.	shita@i2cner.kyushu-u.ac.jp			UK National Environmental Research Council (NERC); Scottish Government [NE/H013911/1]; International Institute for Carbon Neutral Energy Research (WPI-I2CNER); Japanese Ministry of Education, Culture, Sports, Science and Technology	We thank the UK National Environmental Research Council (NERC) and Scottish Government for kindly providing funding to the QICS project (NE/H013911/1). We gratefully acknowledge Dr. H. Stahl of SAMS for kind assistance on the observation, and the divers at the National Facility of Scientific Diving (NFSD) and the crew on R/V Soel Mara at SAMS for deploying and recovering the instruments. We also acknowledge the support of the International Institute for Carbon Neutral Energy Research (WPI-I<SUP>2</SUP>CNER), sponsored by the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Aliani S., 2010, CONTINENT SHELF RES, V30, P1349; Hirayama H, 2007, APPL ENVIRON MICROB, V73, P7642, DOI 10.1128/AEM.01258-07; Shitashima K, 2008, INT J GREENH GAS CON, V2, P95, DOI 10.1016/S1750-5836(07)00092-8; Kano Y, 2010, MAR POLLUT BULL, V60, P215, DOI 10.1016/j.marpolbul.2009.09.024; Dewar M, 2013, MAR POLLUT BULL, V73, P504, DOI 10.1016/j.marpolbul.2013.03.005; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Caramanna G, 2011, GREENH GASES, V1, P200, DOI 10.1002/ghg.28; Dissanayake AL, 2012, J HYDRO-ENVIRON RES, V6, P195, DOI 10.1016/j.jher.2012.02.001; Espa S, 2010, APPL GEOCHEM, V25, P696, DOI 10.1016/j.apgeochem.2010.02.002; Goyet C., 1994, HDB METHODS ANAL VAR; Lewis E., 1998, ORNLCDIAC105 US DEP; Maeda Y, 2015, INT J GREENH GAS CON, V38, P143, DOI 10.1016/j.ijggc.2015.01.017; Shitashima K, 2013, APPL GEOCHEM, V30, P114, DOI 10.1016/j.apgeochem.2012.08.001; Shitashima K., 1998, CHIKYUKAGAKU, V15, P1; Shitashima K, 2002, PROCEEDINGS OF THE 2002 INTERNATIONAL SYMPOSIUM ON UNDERWATER TECHNOLOGY, P106, DOI 10.1109/UT.2002.1002403; Shitashima K., 2005, J OCEANOGR, V14, P297; Shitashima K., 2009, DIFFUSION OBSERVATIO	17	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		135	142		10.1016/j.ijggc.2014.12.011		8	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500014		
J	Maeda, Y; Shitashima, K; Sakamoto, A				Maeda, Yoshiaki; Shitashima, Kiminori; Sakamoto, Atsushi			Mapping observations using AUV and numerical simulations of leaked CO2 diffusion in sub-seabed CO2 release experiment at Ardmucknish Bay	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						QICS; Sub-seabed carbon capture and storage (CCS); Autonomous underwater vehicle (AUV) mapping; CO2 leakage; CO2 gas bubble	SEA-FLOOR; STORAGE; LEAKAGE; MODEL	A controlled sub-seabed CO2 release experiment (QICS: quantifying and monitoring potential impacts of geological carbon storage) was conducted in Ardmucknish Bay, Scotland, in 2012, to quantify the effect of leaked CO2 on marine environments. In this experiment, CO2 was injected beneath the seafloor, and closely monitored as the CO2 was allowed to leak into the overlying water column. We performed mapping observations using an autonomous underwater vehicle (AUV) equipped with sensors to monitor physical and chemical conditions in the vicinity of the CO2 leakage. We also numerically simulated the behavior of the low-pH plume caused by the CO2 leakage, within the calculated tidal current in the bay. The results of AUV mapping observations showed that physical and chemical characteristics of the water mass in Ardmucknish bay are sensitive to tidal variations (low or high tide), and the ascent speed of the leaked CO2 bubble and the pH decrease in the vicinity of the CO2 leakage area are predominantly controlled by the tidal phase in the bay. The observations using an acoustic Doppler current profiler (ADCP) installed in the AUV indicated that the current in the bay flows westwards at high tide and eastwards at low tide. The simulated tidal current agreed well with the tidal current observed by ADCP. Numerical simulation suggested that the pH decrease due to the leaked CO2 is restricted to the vicinity of the CO2 leakage area, and fluctuates greatly with tidal variations. In flood tide periods, diffusion of the low-pH plume caused by the leaked CO2 is barely detectable because low-pH seawater intrudes into the bay from the bay mouth. (C) 2015 Elsevier Ltd. All rights reserved.	[Maeda, Yoshiaki] Cent Res Inst Elect Power Ind, Environm Sci Res Lab, Abiko, Chiba 2701194, Japan; [Shitashima, Kiminori; Sakamoto, Atsushi] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2 CNER, Fukuoka 8190395, Japan	Shitashima, K (reprint author), Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2 CNER, 744 Moto Oka, Fukuoka 8190395, Japan.	shita@i2cner.kyushu-u.ac.jp			UK National Environmental Research Council (NERC); Department of Energy and Climate Change (DECC); Scottish Government [NE/H013911/1]; International Institute for Carbon Neutral Energy Research (WPI-I2CNER); Japanese Ministry of Education, Culture, Sports, Science and Technology	We thank the UK National Environmental Research Council (NERC), Department of Energy and Climate Change (DECC) and Scottish Government for kindly providing funding to the QICS project (NE/H013911/1). We gratefully acknowledge Dr. H. Stahl of the Scottish Association for Marine Science (SAMS) for kind assistance with the observations, and the divers at the National Facility of Scientific Diving (NFSD) and the crew on R.V. Seol Mara at SAMS for deploying and recovering the instruments. We also thank Ms. C. Mori of the University of Tokyo for extracting and digitizing hydrographic data from charts of Ardmucknish Bay. We acknowledge the support of the International Institute for Carbon Neutral Energy Research (WPI-I<SUP>2</SUP>CNER), sponsored by the Japanese Ministry of Education, Culture, Sports, Science and Technology.	GALPERIN B, 1988, J ATMOS SCI, V45, P55, DOI 10.1175/1520-0469(1988)045<0055:AQETEM>2.0.CO;2; Shitashima K, 2008, INT J GREENH GAS CON, V2, P95, DOI 10.1016/S1750-5836(07)00092-8; MELLOR GL, 1982, REV GEOPHYS, V20, P851, DOI 10.1029/RG020i004p00851; Shitashima K, 2015, INT J GREENH GAS CON, V38, P135, DOI 10.1016/j.ijggc.2014.12.011; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Mori C, 2015, INT J GREENH GAS CON, V38, P153, DOI 10.1016/j.ijggc.2014.11.023; BLUMBERG AF, 1983, J GEOPHYS RES-OC ATM, V88, P4579, DOI 10.1029/JC088iC08p04579; Baklid A., 1996, SPE ANN TECHN C EXH, P269; Benjamin S., 2008, COMPACT FAST MATLAB; BLUMBERG A F, 1987, 3 DIMENSIONAL COASTA, V4, P208; Boon J., 2007, WORLD TIDES USER MAN; Kano Y., 2010, MAR POLLUT B, V50, P215; Kano Y, 2009, INT J GREENH GAS CON, V3, P617, DOI 10.1016/j.ijggc.2009.03.004; Kita J., 2015, INT J GREENH GAS CON, V38, P205; Shitashima K, 2013, APPL GEOCHEM, V30, P114, DOI 10.1016/j.apgeochem.2012.08.001; Singh V., 2010, SPE ANN TECHN C EXH; Weiss R., 1974, MAR CHEM, V2, P203, DOI DOI 10.1016/0304-4203(74)90015-2	17	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		143	152		10.1016/j.ijggc.2015.01.017		10	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500015		
J	Mori, C; Sato, T; Kano, Y; Oyama, H; Aleynik, D; Tsumune, D; Maeda, Y				Mori, Chiaki; Sato, Toru; Kano, Yuki; Oyama, Hiroyuki; Aleynik, Dmitry; Tsumune, Daisuke; Maeda, Yoshiaki			Numerical study of the fate of CO2 purposefully injected into the sediment and seeping from seafloor in Ardmucknish Bay	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						Sub-seabed CO2 geological storage; CO2 leakage; CO2 seepage from seafloor; Two-phase flow; Multi-scale ocean model	CARBON-DIOXIDE; OCEAN	To quantify the impact of leaked CO2 purposefully stored in subsea geological formations on the marine ecosystem, CO2 gas was injected into sandy sediments in a small bay in Scotland in 2012. Alongside the experiment, a numerical study was conducted to predict CO2 fate in the bay. CO2 may take the form both of the gas and dissolved phases when it seeps out from the seafloor. The bubble CO2 rises in the water column forming bubble plumes and dissolves into the seawater during its ascent. Measurements indicated that approximately 8-15% of the injected CO2 escaped the sediments in the gas phase and no empirical evidence was seen for fluxes in the dissolved phase. Therefore, it is thought that 85-92% of the CO2 remained within the sediments. However, the results of our numerical study suggest that 10-40% of the injected CO2 stayed in the sediment. Apart from unexpected errors in the present numerical simulation, a possible explanation for this discrepancy may be the heterogeneous nature of the sediment and observations limited in time and space. It is also recognised that the CO2 concentration away from the injection site is undetectably small and that the readily detectable signal is confined to a small area in the vicinity of the injection point. (C) 2014 Elsevier Ltd. All rights reserved.	[Mori, Chiaki; Sato, Toru; Kano, Yuki] Univ Tokyo, Dept Ocean Technol Policy & Environm, Kashiwa, Chiba 2778563, Japan; [Kano, Yuki] Natl Inst Adv Ind Sci & Technol, Inst Georesources & Environm, Tsukuba, Ibaraki 3058567, Japan; [Aleynik, Dmitry] Scottish Assoc Marine Sci, Scottish Marine Inst, Oban PA37 1QA, Argyll, Scotland; [Tsumune, Daisuke; Maeda, Yoshiaki] Cent Res Inst Elect Power Ind, Environm Sci Res Lab, Abiko, Chiba 2701194, Japan	Sato, T (reprint author), Univ Tokyo, Dept Ocean Technol Policy & Environm, 5-1-5 Kashiwa No Ha, Kashiwa, Chiba 2778563, Japan.	sato-t@k.u-tokyo.ac.jp					Sato T, 2004, J OCEANOGR, V60, P807, DOI 10.1007/s10872-004-5773-y; Chen BX, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002567; Sato T, 2006, COAST ENG, V53, P49, DOI 10.1016/j.coastaleng.2005.08.001; PITZER KS, 1994, J CHEM PHYS, V101, P3111, DOI 10.1063/1.467624; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Alendal G, 2001, J GEOPHYS RES-OCEANS, V106, P1085, DOI 10.1029/1999JC000290; Mizumukai K, 2008, ECOL MODEL, V214, P251, DOI 10.1016/j.ecolmodel.2008.02.023; Kita J, 2015, INT J GREENH GAS CON, V38, P202, DOI 10.1016/j.ijggc.2014.11.012; Taylor P, 2015, INT J GREENH GAS CON, V38, P93, DOI 10.1016/j.ijggc.2014.09.006; Harata M., 2010, P OCEANS 2010 SYDN C; Kano K., 2010, MAR POLLUT B, V50, P215; Kano Y, 2009, INT J GREENH GAS CON, V3, P617, DOI 10.1016/j.ijggc.2009.03.004; Kita J., 2006, P 8 INT C GREENH GAS; Marine Environment Committee, 2003, MEC OC MOD OP MAN VE; Matsumoto K., 2000, J OCEANOGR, V56, P567, DOI DOI 10.1023/A:1011157212596; Sato T, 2005, MAR POLLUT BULL, V50, P975, DOI 10.1016/j.marpolbul.2005.04.003; Sellami N., 2015, INT J GREENH GAS CON, V38, P52; Smagorinsky J., 1993, LARGE EDDY SIMULATIO, P3; Taylor P, 2015, INT J GREENH GAS CON, V38, P3, DOI 10.1016/j.ijggc.2014.09.007; UNESCO, 1981, UNESCO TECHN PAP MAR, P36; Weiss R., 1974, MAR CHEM, V2, P203, DOI DOI 10.1016/0304-4203(74)90015-2	21	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		153	161		10.1016/j.ijggc.2014.11.023		9	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500016		
J	Watanabe, Y; Tait, K; Gregory, S; Hayashi, M; Shimamoto, A; Taylor, P; Stahl, H; Green, K; Yoshinaga, I; Suwa, Y; Kita, J				Watanabe, Yuji; Tait, Karen; Gregory, Simon; Hayashi, Masatoshi; Shimamoto, Akifumi; Taylor, Peter; Stahl, Henrik; Green, Kay; Yoshinaga, Ikuo; Suwa, Yuichi; Kita, Jun			Response of the ammonia oxidation activity of microorganisms in surface sediment to a controlled sub-seabed release of CO2	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						CO2 leakage; Marine sediment; Ammonia oxidation; ATP; amoA; hzo	WESTERN ENGLISH-CHANNEL; OXIDIZING ARCHAEA; NITRIFICATION RATES; CARBON-DIOXIDE; SEAWATER ACIDIFICATION; NITROSOMONAS-EUROPAEA; ENVIRONMENTAL-SAMPLES; MARINE-SEDIMENTS; N-2 FIXATION; ACIDIC SOILS	The impact of a sub-seabed CO2 leak from geological sequestration on the microbial process of ammonia oxidation was investigated in the field. Sediment samples were taken before, during and after a controlled sub-seabed CO2 leak at four zones differing in proximity to the CO2 source (epicentre, and 25 m, 75 m, and 450 m distant). The impact of CO2 release on benthic microbial ATP levels was compared to ammonia oxidation rates and the abundance of bacterial and archaeal ammonia amoA genes and transcripts, and also to the abundance of nitrite oxidizer (nirS) and anammox hydrazine oxidoreductase (hzo) genes and transcripts. The major factor influencing measurements was seasonal: only minor differences were detected at the zones impacted by CO2 (epicentre and 25 m distant). This included a small increase to ammonia oxidation after 37 days of CO2 release which was linked to an increase in ammonia availability as a result of mineral dissolution. A CO2 leak on the scale used within this study (<1 tonne day(-1)) would have very little impact to ammonia oxidation within coastal sediments. However, seawater containing 5% CO2 did reduce rates of ammonia oxidation. This was linked to the buffering capacity of the sediment, suggesting that the impact of a sub-seabed leak of stored CO2 on ammonia oxidation would be dependent on both the scale of the CO2 release and sediment type. (C) 2014 Elsevier Ltd. All rights reserved.	[Watanabe, Yuji; Kita, Jun] Res Inst Innovat Technol Earth RITE, Kizugawa, Kyoto 6190292, Japan; [Tait, Karen] Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England; [Gregory, Simon; Green, Kay] British Geol Survey, Ctr Environm Sci, Keyworth NG12 5GG, Notts, England; [Hayashi, Masatoshi; Shimamoto, Akifumi] Gen Environm Technos Co Ltd KANSO Technos, Chuo Ku, Osaka 5410052, Japan; [Taylor, Peter; Stahl, Henrik] Scottish Assoc Marine Sci, Oban PA37, Argyll, Scotland; [Yoshinaga, Ikuo] Tottori Univ Environm Studies, Tottori 6891111, Japan; [Suwa, Yuichi] Chuo Univ, Fac Sci & Engn, Bunkyo Ku, Tokyo 1128551, Japan	Watanabe, Y (reprint author), Res Inst Innovat Technol Earth RITE, 9-2 Kizugawadai, Kizugawa, Kyoto 6190292, Japan.	ywata@rite.or.jp			NERC [NE/H013962/1]; Scottish Government; Ministry of Economy, Trade and Industry of Japan	This study was supported by the NERC-funded program QICS (NE/H013962/1) and the Scottish Government. We are grateful to the staff at the NERC National Facility for Scientific Diving and the crew of the R.V. Seol Mara for operational support and sample collection and also to Ana Queiros and Joana Nunes for assistance with sample collection and preservation. Thanks to the Tralee Bay Holiday Park, Lochnell Estates and the general public of Benderloch for hosting the QICS experiment, and also to Marine Scotland and The Crown Estate for permissions to carry out the research. Simon Gregory and Kay Green publish with permission of the Executive Director, British Geological Survey (NERC). Also, this work was supported by the Ministry of Economy, Trade and Industry of Japan, under the contract 'Research and Development of Underground Storage Technology for Carbon Dioxide'. We were grateful to Dr. Chie Katsuyama and Mina Nakahara for their help to measuring the nitrogen isotope.	Anderson M. J., 2008, PERMANOVA PRIMER GUI; Beman JM, 2006, APPL ENVIRON MICROB, V72, P7767, DOI 10.1128/AEM.00946-06; Abell GCJ, 2010, ISME J, V4, P286, DOI 10.1038/ismej.2009.105; Leininger S, 2006, NATURE, V442, P806, DOI 10.1038/nature04983; Widdicombe S, 2009, MAR ECOL PROG SER, V379, P59, DOI 10.3354/meps07894; Beaubien SE, 2008, INT J GREENH GAS CON, V2, P373, DOI 10.1016/j.ijggc.2008.03.005; Nicol GW, 2008, ENVIRON MICROBIOL, V10, P2966, DOI 10.1111/j.1462-2920.2008.01701.x; Coolen MJL, 2007, ENVIRON MICROBIOL, V9, P1001, DOI 10.1111/j.1462-2920.2006.01227.x; Fulweiler RW, 2011, ESTUAR COAST, V34, P1095, DOI 10.1007/s12237-011-9432-4; Mosier AC, 2008, ENVIRON MICROBIOL, V10, P3002, DOI 10.1111/j.1462-2920.2008.01764.x; Beman JM, 2011, P NATL ACAD SCI USA, V108, P208, DOI 10.1073/pnas.1011053108; Martens-Habbena W, 2009, NATURE, V461, P976, DOI 10.1038/nature08465; Braker G, 1998, APPL ENVIRON MICROB, V64, P3769; Wankel SD, 2011, APPL ENVIRON MICROB, V77, P269, DOI 10.1128/AEM.01318-10; Blackford JC, 2007, J MARINE SYST, V64, P229, DOI 10.1016/j.jmarsys.2006.03.016; Karjalainen H, 2001, AQUAT BOT, V69, P1, DOI 10.1016/S0304-3770(00)00138-8; Zheng YL, 2014, APPL ENVIRON MICROB, V80, P408, DOI 10.1128/AEM.03035-13; Yao H, 2011, APPL ENVIRON MICROB, V77, P4618, DOI 10.1128/AEM.00136-11; McIlvin MR, 2005, ANAL CHEM, V77, P5589, DOI 10.1021/ac050528s; Ishida H, 2013, MAR POLLUT BULL, V73, P443, DOI 10.1016/j.marpolbul.2013.02.009; Huesemann MH, 2002, MAR POLLUT BULL, V44, P142, DOI 10.1016/S0025-326X(01)00194-1; Caffrey JM, 2007, ISME J, V1, P660, DOI 10.1038/ismej.2007.79; Mincer TJ, 2007, ENVIRON MICROBIOL, V9, P1162, DOI 10.1111/j.1462-2920.2007.01239.x; Widdicombe S, 2007, MAR ECOL PROG SER, V341, P111, DOI 10.3354/meps341111; Tait K, 2015, INT J GREENH GAS CON, V38, P171, DOI 10.1016/j.ijggc.2014.11.021; Hutchins DA, 2009, OCEANOGRAPHY, V22, P128; Blackford J, 2009, P I MECH ENG A-J POW, V223, P269, DOI 10.1243/09576509JPE623; Holloway S, 2007, PHILOS T R SOC A, V365, P1095, DOI 10.1098/rsta.2006.1953; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Horak REA, 2013, ISME J, V7, P2023, DOI 10.1038/ismej.2013.75; Schmid MC, 2008, ENVIRON MICROBIOL, V10, P3140, DOI 10.1111/j.1462-2920.2008.01732.x; Atamanchuk D, 2015, INT J GREENH GAS CON, V38, P121, DOI 10.1016/j.ijggc.2014.10.021; Blackford JC, 2008, MAR POLLUT BULL, V56, P1461, DOI 10.1016/j.marpolbul.2008.04.048; Strauss EA, 2000, LIMNOL OCEANOGR, V45, P1854; SUZUKI I, 1974, J BACTERIOL, V120, P556; Zhu QZ, 2006, GEOCHIM COSMOCHIM AC, V70, P4933, DOI 10.1016/j.gca.2006.07.033; Mortimer RJG, 2004, MAR ECOL PROG SER, V276, P37, DOI 10.3354/meps276037; Fu FX, 2008, LIMNOL OCEANOGR, V53, P2472, DOI 10.4319/lo.2008.53.6.2472; Bell TG, 2007, ENVIRON CHEM, V4, P183, DOI 10.1071/EN07032; Tait K, 2014, ESTUAR COAST, V37, P724, DOI 10.1007/s12237-013-9709-x; Bernhard AE, 2010, APPL ENVIRON MICROB, V76, P1285, DOI 10.1128/AEM.02018-09; Hutchins DA, 2007, LIMNOL OCEANOGR, V52, P1293, DOI 10.4319/lo.2007.52.4.1293; Zhang LM, 2012, ISME J, V6, P1032, DOI 10.1038/ismej.2011.168; Gazeau F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094068; Smith CJ, 2006, ENVIRON MICROBIOL, V8, P804, DOI 10.1111/j.1462-2920.2005.00963.x; Rotthauwe JH, 1997, APPL ENVIRON MICROB, V63, P4704; Bell TG, 2008, ENVIRON CHEM, V5, P258, DOI 10.1071/EN07032_CO; Bouskill N.J., 2012, FRONT MICROBIOL, V3, P1; Bowen JL, 2013, MAR ECOL PROG SER, V492, P1, DOI 10.3354/meps10526; Gattuso J. -P., 2011, OCEAN ACIDIFICATION; Gehlen M., 2011, OCEAN ACIDIFICATION, V1, P230; Hornek R, 2006, J MICROBIOL METH, V66, P147, DOI 10.1016/j.mimet.2005.11.001; Isobe K, 2011, MICROBES ENVIRON, V26, P46, DOI 10.1264/jsme2.ME10159; JENKINSON DS, 1979, SOIL BIOL BIOCHEM, V11, P521, DOI 10.1016/0038-0717(79)90012-9; Joye SB, 2008, NITROGEN IN THE MARINE ENVIRONMENT, 2ND EDITION, P867, DOI 10.1016/B978-0-12-372522-6.00019-0; Kitidis K., 2011, GEOPHYS RES LETT, V38; Laverock B, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0441; Li M, 2010, APPL MICROBIOL BIOT, V86, P781, DOI 10.1007/s00253-009-2361-5; Lichtschlag A., 2014, INT J GREEN IN PRESS; Magalhaes CM, 2005, ESTUARIES, V28, P592, DOI 10.1007/BF02696070; Metz B., 2005, IPCC SPECIAL REPORT; Morales SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081742; Stein LY, 1997, APPL ENVIRON MICROB, V63, P4588; Tait K, 2014, MAR ECOL PROG SER, V511, P41, DOI 10.3354/meps10933; Taylor P, 2015, INT J GREENH GAS CON, V38, P3, DOI 10.1016/j.ijggc.2014.09.007; Taylor P., INT J GREEN IN PRESS; Widdicombe S, 2015, INT J GREENH GAS CON, V38, P182, DOI 10.1016/j.ijggc.2015.01.003; Wuchter C, 2006, P NATL ACAD SCI USA, V103, P12317, DOI 10.1073/pnas.0600756103; Wyatt NJ, 2010, J PLANKTON RES, V32, P631, DOI 10.1093/plankt/fbp140	69	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		162	170		10.1016/j.ijggc.2014.11.013		9	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500017		
J	Kita, J; Stahl, H; Hayashi, M; Green, T; Watanabe, Y; Widdicombe, S				Kita, Jun; Stahl, Henrik; Hayashi, Masatoshi; Green, Tammy; Watanabe, Yuji; Widdicombe, Stephen			Benthic megafauna and CO2 bubble dynamics observed by underwater photography during a controlled sub-seabed release of CO2	INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL			English	Article						Offshore CO2 storage; Leakage; Environmental impact; Benthic megafauna	OCEAN ACIDIFICATION; CARBON-DIOXIDE; STORAGE; CCS; RESPONSES; IMPACTS; PROJECT; LEAKAGE; CORAL	In 2012, a controlled sub-seabed release of carbon dioxide (CO2) was conducted in Ardmucknish Bay, a shallow (12 m) coastal bay on the west coast of Scotland. During the experiment, CO2 gas was released 12 m below the seabed for 37 days, causing significant disruption to sediment and water carbonate chemistry as the gas passed up through the sediment and into the overlying water. One of the aims of the study was to investigate how the impacts caused by leakage from geological CO2 Capture and Storage (CCS) could be detected and quantified in the context of natural heterogeneity and dynamics. To do this underwater photography was used to analyze (i) the benthic megafaunal response to the CO2 release and (ii) the dynamics of the CO2 bubble streams, emerging from the seabed into the overlying water column. The frequently observed megafauna species in the study area were Virgularia mirabilis (Cnidaria), Turritella communis (Mollusca), Asterias rubens (Echinodermata), Pagurus bernhardus (Crustacea), Liocarcinus depurator (Crustacea), and Gadus morhua (Osteichthyes). No discernable abnormal behavior was observed for these megafauna, in any of the zones investigated, during or after the CO2 release. Time-lapse photography revealed that the intensity and presence of the CO2 bubble plume was affected by the tides, with the most active bubbling seen at low tides and the larger hydrostatic pressure at high tide suppressing bubbling from the seabed. (C) 2014 Elsevier Ltd. All rights reserved.	[Kita, Jun; Watanabe, Yuji] Res Inst Innovat Technol Earth, Kizugawa, Kyoto 6190292, Japan; [Stahl, Henrik; Green, Tammy] Scottish Assoc Marine Sci, Oban PA37 1QA, Argyll, Scotland; [Hayashi, Masatoshi] Gen Environm Technos Co Ltd, Chuo Ku, Osaka 5410052, Japan; [Widdicombe, Stephen] Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England	Kita, J (reprint author), Res Inst Innovat Technol Earth, 9-2 Kizugawadai, Kizugawa, Kyoto 6190292, Japan.	kita@rite.or.jp			NERC [NE/H013962/1]; Scottish Government; METI of Japan	This work was funded by NERC (NE/H013962/1), the Scottish Government and METI of Japan. We thank the Tralee Bay Holiday Park, Lochnell Estates and the inhabitants of Benderloch for hosting the QICS experiment. We acknowledge Marine Scotland and The Crown Estate for permissions to carry out the research. The NERC National Facility for Scientific Diving, the crew of the R.V. Seol Mara and John Montgomery based at SAMS provided operational support.	Dupont S, 2010, ECOTOXICOLOGY, V19, P449, DOI 10.1007/s10646-010-0463-6; Barry JP, 2013, DEEP-SEA RES PT II, V92, P249, DOI 10.1016/j.dsr2.2013.03.037; Widdicombe S, 2013, MAR POLLUT BULL, V73, P416, DOI 10.1016/j.marpolbul.2012.11.008; Rodolfo-Metalpa R, 2011, NAT CLIM CHANGE, V1, P308, DOI 10.1038/NCLIMATE1200; Inoue S, 2013, NAT CLIM CHANGE, V3, P683, DOI [10.1038/nclimate1855, 10.1038/NCLIMATE1855]; Whiteley NM, 2011, MAR ECOL PROG SER, V430, P257, DOI 10.3354/meps09185; Wittmann AC, 2013, NAT CLIM CHANGE, V3, P995, DOI 10.1038/NCLIMATE1982; Dixson DL, 2010, ECOL LETT, V13, P68, DOI 10.1111/j.1461-0248.2009.01400.x; Ries JB, 2009, GEOLOGY, V37, P1131, DOI 10.1130/G30210A.1; Heap AD, 2014, CONT SHELF RES, V83, P108, DOI 10.1016/j.csr.2014.02.008; Widdicombe S, 2013, MAR POLLUT BULL, V73, P399, DOI 10.1016/j.marpolbul.2013.05.044; Munday PL, 2009, MAR ECOL PROG SER, V388, P235, DOI 10.3354/meps08137; Lichtschlag A, 2015, INT J GREENH GAS CON, V38, P80, DOI 10.1016/j.ijggc.2014.10.008; Hurst TP, 2013, ICES J MAR SCI, V70, P812, DOI 10.1093/icesjms/fst053; Tait K, 2015, INT J GREENH GAS CON, V38, P171, DOI 10.1016/j.ijggc.2014.11.021; Terwel BW, 2012, INT J GREENH GAS CON, V9, P41, DOI 10.1016/j.ijggc.2012.02.017; Kita J, 2013, MAR POLLUT BULL, V73, P402, DOI 10.1016/j.marpolbul.2013.06.026; Blackford J, 2014, NAT CLIM CHANGE, V4, P1011, DOI [10.1038/NCLIMATE2381, 10.1038/nclimate2381]; Atamanchuk D, 2015, INT J GREENH GAS CON, V38, P121, DOI 10.1016/j.ijggc.2014.10.021; Van Noorden R, 2010, NATURE, V463, P871, DOI 10.1038/463871a; Pratt N, 2015, INT J GREENH GAS CON, V38, P193, DOI 10.1016/j.ijggc.2014.10.001; Branch TA, 2013, TRENDS ECOL EVOL, V28, P178, DOI 10.1016/j.tree.2012.10.001; Baumann H., 2011, NAT CLIM CHANGE, V2, P38; Bednarsek N., 2014, P R SOC B, V281, P1; Berges BJP, 2015, INT J GREENH GAS CON, V38, P64, DOI 10.1016/j.ijggc.2015.02.008; Clarke K. R., 2006, PRIMER V6 USER MANUA; Gattuso J. -P., 2011, OCEAN ACIDIFICATION; Heip CHR, 1995, OCEANOGR MAR BIOL, V33, P1; Holloway S., 2006, ENV GEOSCI, V13, P71, DOI DOI 10.1306/EG.11080505015; IEA, 2012, EN TECHN PERSP 2012; Meckel TA, 2013, ENRGY PROCED, V37, P4526, DOI 10.1016/j.egypro.2013.06.359; Nakanishi S, 2009, ENRGY PROCED, V1, P2639, DOI 10.1016/j.egypro.2009.02.031; Schrag DP, 2009, SCIENCE, V325, P1658, DOI 10.1126/science.1175750; Taylor P, 2015, INT J GREENH GAS CON, V38, P3, DOI 10.1016/j.ijggc.2014.09.007; Widdicombe S, 2015, INT J GREENH GAS CON, V38, P182, DOI 10.1016/j.ijggc.2015.01.003; Zeebe R., 2001, CO2 SEAWATER EQUILIB, V65, P2001	36	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-5836	1878-0148		INT J GREENH GAS CON	Int. J. Greenh. Gas Control	JUL	2015	38				SI		202	209		10.1016/j.ijggc.2014.11.012		8	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	CL8LF	WOS:000357225500021		
J	Himoto, Y; Fujimoto, K; Kido, A; Baba, T; Tanaka, S; Morisawa, N; Koyasu, S; Konishi, I; Togashi, K				Himoto, Yuki; Fujimoto, Koji; Kido, Aki; Baba, Tsukasa; Tanaka, Shiro; Morisawa, Nobuko; Koyasu, Sho; Konishi, Ikuo; Togashi, Kaori			Pretreatment Mean Apparent Diffusion Coefficient Is Significantly Correlated With Event-Free Survival in Patients With International Federation of Gynecology and Obstetrics Stage Ib to IIIb Cervical Cancer	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Cervical cancer; Prognostic factor; Magnetic resonance imaging; Apparent diffusion coefficient	SQUAMOUS-CELL CARCINOMA; NEUROENDOCRINE CARCINOMA; PROGNOSTIC-FACTORS; PREDICT; TUMOR; CHEMORADIATION; ADENOCARCINOMA; IMPACT; VALUES	Objectives To assess the prognostic impact of the pretreatment mean apparent diffusion coefficient (ADC(mean)) values of tumors obtained by diffusion-weighted magnetic resonance imaging. We evaluated the prognostic value of the ADC(mean) for event-free survival (EFS) and overall survival (OS) among patients with uterine cervical cancer. Methods/Materials We included 171 patients diagnosed as having International Federation of Gynecology and Obstetrics stage Ib to IIIb cervical cancer by pretreatment magnetic resonance imaging scans, regardless of therapeutic methods. In all patients and in patients with squamous cell carcinoma (SCC; n = 123), the optimal cutoff values of the tumor ADC(mean) for EFS and for OS were determined, respectively. The prognostic significance of the ADC(mean) was evaluated using univariate and multivariate Cox regression analyses. Results In the univariate analyses, the ADC(mean) values were significantly associated with negative effects on EFS both in all patients and in patients with SCC, while not being significantly associated with OS in both groups. In the multivariate analysis, ADC(mean) was an independent biomarker for EFS (P < 0.05) in patients with SCC along with lymph node metastasis and definitive surgery, whereas ADC(mean) was not independently significant in EFS in all patients. Conclusions The pretreatment ADC(mean) value of the tumor was an independent prognostic factor for EFS in International Federation of Gynecology and Obstetrics stage Ib to III SCC of the uterine cervix.	[Himoto, Yuki; Fujimoto, Koji; Kido, Aki; Morisawa, Nobuko; Koyasu, Sho; Togashi, Kaori] Kyoto Univ, Grad Sch Med, Dept Diagnost Imaging & Nucl Med, Kyoto 6068507, Japan; [Baba, Tsukasa; Konishi, Ikuo] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto 6068507, Japan; [Tanaka, Shiro] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto 6068507, Japan	Fujimoto, K (reprint author), Kyoto Univ, Grad Sch Med, Dept Diagnost Imaging & Nucl Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	kfb@kuhp.kyoto-u.ac.jp					Hatakenaka M, 2014, JPN J RADIOL, V32, P80, DOI 10.1007/s11604-013-0272-y; Intaraphet S, 2013, ASIAN PAC J CANCER P, V14, P5355, DOI 10.7314/APJCP.2013.14.9.5355; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Harry VN, 2008, GYNECOL ONCOL, V111, P213, DOI 10.1016/j.ygyno.2008.07.048; Sala E, 2013, RADIOLOGY, V266, P717, DOI 10.1148/radiol.12120315; Somoye G, 2012, EUR RADIOL, V22, P2319, DOI 10.1007/s00330-012-2496-0; Rosenkrantz AB, 2011, J MAGN RESON IMAGING, V33, P128, DOI 10.1002/jmri.22395; Nakamura K, 2012, GYNECOL ONCOL, V127, P478, DOI 10.1016/j.ygyno.2012.07.123; Liu Y, 2009, J COMPUT ASSIST TOMO, V33, P858, DOI 10.1097/RCT.0b013e31819e93af; Kundu S, 2012, J CANCER RES THER, V8, P11, DOI 10.4103/0973-1482.95167; Logsdon MD, 1999, INT J RADIAT ONCOL, V43, P763, DOI 10.1016/S0360-3016(98)00482-9; Aoyagi T, 2011, DIGEST SURG, V28, P252, DOI 10.1159/000328770; Kasamatsu T, 2007, INT J GYNECOL OBSTET, V99, P225, DOI 10.1016/j.ijgo.2007.06.051; Kodama J, 2010, J SURG ONCOL, V101, P413, DOI 10.1002/jso.21499; Nakamura K, 2013, CANCER MED-US, V2, P519, DOI 10.1002/cam4.100; Padhani Anwar R, 2009, Neoplasia, V11, P102; Sauvain JL, 2009, EUR UROL, V56, P987, DOI 10.1016/j.eururo.2008.11.052; Wagner AE, 2013, GYNECOL ONCOL, V129, P517, DOI 10.1016/j.ygyno.2013.03.008; Zulfiqar M, 2013, AM J ROENTGENOL, V200, P624, DOI 10.2214/AJR.12.8679	19	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	JUL	2015	25	6					1079	1085		10.1097/IGC.0000000000000445		7	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CL9HB	WOS:000357286900020		
J	Karatzanis, A; Kalogjera, L; Scadding, G; Velegrakis, S; Kawauchi, H; Cingi, C; Prokopakis, E				Karatzanis, A.; Kalogjera, L.; Scadding, G.; Velegrakis, S.; Kawauchi, H.; Cingi, C.; Prokopakis, E.			Severe Chronic Upper Airway Disease (SCUAD) in children. Definition issues and requirements	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						SCUAD; Paediatric rhinitis; Sinusitis; Diagnosis	CHRONIC RHINOSINUSITIS; PEDIATRIC RHINOSINUSITIS; ALLERGIC RHINITIS; MANAGEMENT	Objectives: Upper airway diseases are extremely common, and a significant proportion of patients are not adequately controlled by contemporary treatment algorithms. The term SCUAD (Severe Chronic Upper Airway Disease) has been previously introduced to describe such cases. However, this term has not been adequately focused on children. Methods: This study aims to address the necessity of the term, as well as further details specifically for children. For this purpose, a review was performed of the current literature, with specific focus on issues regarding SCUAD in children. Results: Paediatric SCUAD represents a heterogeneous group of patients and has significant clinical and socioeconomic implications. Relevant literature is generally lacking and questions regarding definition and pathogenesis remain unanswered. Conclusions: Accurate definition and acknowledgement of paediatric SCUAD cases may lead to better design of future clinical and molecular research protocols. This may provide improved understanding of the underlying disease processes, more accurate data regarding socioeconomic burden, and, above all, more successful treatment and prevention strategies. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Karatzanis, A.; Prokopakis, E.] Univ Crete Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Iraklion, Crete, Greece; [Kalogjera, L.] Univ Hosp Ctr Sestre Milosrdnice, Dept Otorhinolaryngol, Zagreb, Croatia; [Scadding, G.] Royal Natl Throat Nose & Ear Hosp, Dept Allergy & Med Rhinol, London WC1X 8DA, England; [Velegrakis, S.] Univ Erlangen Nurnberg, Dept Otorhinolaryngol Head & Neck Surg, D-91054 Erlangen, Germany; [Kawauchi, H.] Shimane Univ, Sch Med, Dept Otorhinolaryngol, Matsue, Shimane, Japan; [Cingi, C.] Univ Osmangazi, Dept Otolaryngol Head & Neck Surg, Eskisehir, Turkey	Prokopakis, E (reprint author), Univ Hosp Crete, Dept Otorhinolaryngol Head & Neck Surg, A Bldg,3rd Floor,Univ Ave, Iraklion 71110, Crete, Greece.	eprokopakis@med.uoc.gr					Shields BJ, 2003, CHILD CARE HLTH DEV, V29, P281, DOI 10.1046/j.1365-2214.2003.00343.x; Veling MC, 2013, CURR OPIN OTOLARYNGO, V21, P271, DOI 10.1097/MOO.0b013e32835fb399; Shin KS, 2008, INT J PEDIATR OTORHI, V72, P1643, DOI 10.1016/j.ijporl.2008.07.016; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Chang AB, 1998, EUR RESPIR J, V11, P462, DOI 10.1183/09031936.98.11020462; Terrell AM, 2009, LARYNGOSCOPE, V119, P1394, DOI 10.1002/lary.20250; Roberts G, 2013, ALLERGY, V68, P1102, DOI 10.1111/all.12235; Georgalas C, 2014, ALLERGY, V69, P828, DOI 10.1111/all.12413; Prokopakis E, 2013, CURR OPIN ALLERGY CL, V13, P31, DOI 10.1097/ACI.0b013e32835ad0ba; Zhang N, 2010, J ALLERGY CLIN IMMUN, V125, P507, DOI 10.1016/j.jaci.2009.10.015; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Sejima T, 2012, ALLERGOL INT, V61, P115, DOI 10.2332/allergolint.10-OA-0290; Prokopakis EP, 2014, RHINOLOGY, V52, P3, DOI [10.4193/Rhin, 10.4193/Rhino13.049]; Eun YG, 2009, INT J PEDIATR OTORHI, V73, P1412, DOI 10.1016/j.ijporl.2009.07.006; Blaiss MS, 2010, ALLERGY ASTHMA PROC, V31, P375, DOI 10.2500/aap.2010.31.3329; Elwany S, 2011, J LARYNGOL OTOL, V125, P279, DOI 10.1017/S0022215110002586; Jones NS, 1999, J LARYNGOL OTOL, V113, P1; Tosca MA, 2003, ANN ALLERG ASTHMA IM, V91, P71; OTTEN FWA, 1992, CLIN OTOLARYNGOL, V17, P32, DOI 10.1111/j.1365-2273.1992.tb00984.x; Prokopakis EP, 2010, RHINOLOGY, V48, P265, DOI [10.4193/Rhin09.211, 10.4193/Rhino09.211]; Hellings PW, 2010, CURR ALLERGY ASTHM R, V10, P143, DOI 10.1007/s11882-010-0107-1; Civelek E, 2010, AM J RHINOL ALLERGY, V24, P364, DOI 10.2500/ajra.2010.24.3484; Chambers CT, 2002, J PEDIATR PSYCHOL, V27, P27, DOI 10.1093/jpepsy/27.1.27; Clement PAR, 1998, ARCH OTOLARYNGOL, V124, P31; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhino12.000; Georgalas C, 2014, CURR ALLERGY ASTHM R, V14, P14; Gordts F., 1997, Rhinology (Utrecht), V35, P154; Kay DJ, 2003, OTOLARYNG HEAD NECK, V128, P17, DOI 10.1067/mhn.2003.41; Sami AS, 2014, RHINOLOGY, V52, P225, DOI [10.4193/Rhin12-011-2, 10.4193/Rhino12.011-2]; Settipane RA, 2003, ALLERGY ASTHMA PROC, V24, P147	30	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JUL	2015	79	7					965	968		10.1016/j.ijporl.2015.02.024		4	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	CL8RP	WOS:000357242100004		
J	Moriyama, H; Amano, K; Itoh, M; Matsumura, G; Otsuka, N				Moriyama, Hiroshi; Amano, Kaori; Itoh, Masahiro; Matsumura, George; Otsuka, Naruhito			Morphometric aspects of the facial and skeletal muscles in fetuses	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Buccinator mucle; Masseter muscle; Biceps brachii muscle; Muscle fiber; Morphometry; Fetus	ACETYLCHOLINE-RECEPTOR; GROWTH; FIBERS; FETAL	Objectives: There are few research reports providing a comparison of the muscle fiber morphometry between human fetuses and adults. Data on fetal and adult muscle fibers would be valuable in understanding muscle development and a variety of muscle diseases. This study investigated human muscle fiber growth to clarify the difference between the facial muscles and other skeletal muscles. Methods: The materials were obtained from three male fetuses (6-month-old) and 11 Japanese male cadavers aged 43-86 years (average: 71.8). Human buccinator muscles (facial muscles), masseter and biceps brachii muscles (skeletal muscles) were resected. We counted the muscle fibers and measured their transverse area. We also calculated the number of muscle fibers per mm(2) (NMF) and the average transverse area of the muscle fibers (TAMFs). Results: The average of the NMF of the buccinator, masseter and biceps brachii muscles in fetuses had, respectively, 19, 37, and 22 times as many fibers as those in adults. The average fetus/adult ratios of the TAMF of the buccinator, masseter and biceps brachii muscles were 4.0%, 2.4%, 4.1%, respectively. Conclusions: The average NMF for all kinds of muscles decreased after birth; however, the peak in life-span or decreases with the aging process tended to vary with the kind of muscles examined. The average TAMF for all kinds of muscles enlarged after birth. We considered that the enlargement of the TAMF was connected with the emergence of fetal movements and functional demands after birth. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Moriyama, Hiroshi; Otsuka, Naruhito] Showa Univ Sch Med, Dept Anat, Shinagawa Ku, Tokyo 1428555, Japan; [Amano, Kaori; Matsumura, George] Kyorin Univ Sch Med, Dept Anat, Mitaka, Tokyo 1818611, Japan; [Itoh, Masahiro] Tokyo Med Univ, Dept Anat, Shinjuku Ku, Tokyo 1608402, Japan	Moriyama, H (reprint author), Showa Univ Sch Med, Dept Anat, Shinagawa Ku, 5-8 Hatanodai 1, Tokyo 1428555, Japan.	veloce@med.showa-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [B14370007]	We thank Ms. Ikuko Moriyama for assistance in preparing the manuscript. This work was supported by a Grant-in-aid for Scientific Research B14370007 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; DEVRIES JIP, 1985, EARLY HUM DEV, V12, P99, DOI 10.1016/0378-3782(85)90174-4; ROWE RWD, 1969, J ANAT, V104, P519; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; ONTELL M, 1978, AM J ANAT, V152, P539, DOI 10.1002/aja.1001520408; STICKLAND NC, 1981, J ANAT, V132, P557; Borue X, 2004, DEVELOPMENT, V131, P3967, DOI 10.1242/dev.01276; CHIAKULA.JJ, 1965, ANAT REC, V152, P55, DOI 10.1002/ar.1091520107; DICKERSON JWT, 1960, BIOCHEM J, V74, P247; GOLDSPINK G, 1964, J CELL COMPAR PHYSL, V63, P209, DOI 10.1002/jcp.1030630211; Joubert D. M., 1956, Journal of Agricultural Science, V47, P382; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Moriyama Hiroshi, 1995, Okajimas Folia Anatomica Japonica, V72, P185; Moriyama H, 2007, J ORAL MAXIL SURG, V65, P1555, DOI 10.1016/j.joms.2007.05.002; NODEN DM, 1983, AM J ANAT, V168, P257, DOI 10.1002/aja.1001680302; Racca AW, 2013, J PHYSIOL-LONDON, V591, P3049, DOI 10.1113/jphysiol.2013.252650; Shimamura A., 1957, JPN J LEGAL MED, V11, P795; STICKLAN.NC, 1973, ANIM PROD, V16, P135; STICKLAND NC, 1975, BRIT J NUTR, V34, P421; VOGLER C, 1985, ARCH PATHOL LAB MED, V109, P238; Widdowson E M, 1969, Bibl Nutr Dieta, V13, P60; Yamane A, 2002, ZOOL SCI, V19, P207, DOI 10.2108/zsj.19.207; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	23	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JUL	2015	79	7					998	1002		10.1016/j.ijporl.2015.04.009		5	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	CL8RP	WOS:000357242100011		
J	Aithal, V; Kei, J; Driscoll, C; Swanston, A; Murakoshi, M; Wada, H				Aithal, Venkatesh; Kei, Joseph; Driscoll, Carlie; Swanston, Andrew; Murakoshi, Michio; Wada, Hiroshi			Sweep frequency impedance measures in Australian Aboriginal and Caucasian neonates	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Neonates; Middle ear; Sweep frequency impedance measure; Acoustic-mechanical properties; Aboriginal; Caucasian	WIDE-BAND REFLECTANCE; MIDDLE-EAR; OTITIS-MEDIA; OTOACOUSTIC EMISSIONS; CHILDREN; INFANTS; TYMPANOMETRY; OTOSCOPY; BEHAVIOR; REFLEX	Objective: Despite high prevalence of otitis media in Aboriginal children, the acoustic-mechanical properties of their outer and middle ear during the neonatal period remain obscured. The objective of this study was to compare the acoustic-mechanical properties of outer and middle ear using Sweep Frequency Impedance (SFI) measures between Australian Aboriginal and Caucasian neonates. Methods: SFI data from 40 ears of 24 Aboriginal neonates (16 males, 8 females) with mean gestational age of 39.57 weeks (SD = 1.25) and 160 ears of 119 Caucasian neonates (57 males, 62 females) with mean gestational age of 39.28 weeks (SD = 1.25) serving as controls were analysed. SFI data in terms of resonance frequency (RF) and mobility of the outer and middle ear (ASPL) were collected from neonates who passed a test battery that included automated auditory brainstem response, distortion product otoacoustic emissions test and 1000-Hz tympanometry. SFI data were analysed using descriptive statistics and analysis of variance. Results: There was no significant difference in mean gestational age, age of testing and birth weight between the Aboriginal and Caucasian neonates. The mean resonance frequencies for the outer ear (mean RF1 = 264.9 Hz, SD = 58.6 Hz) and middle ear (mean RF2 = 1144 Hz, SD = 228.8 Hz) for Aboriginal neonates were significantly lower than that of Caucasian neonates (mean RF1 = 295.3 Hz, SD = 78.4 Hz and mean RF2 = 1241.8 Hz, SD = 216.6 Hz). However, no significant difference in the mobility of outer ear (Delta SPL1) and middle ear (Delta SPL2) between the two groups was found. Middle ear resonance was absent in 22.5% (9 ears) of Aboriginal ears but present in all Caucasian ears. Conclusions: This study provided evidence that despite passing the test battery, Aboriginal neonates had significantly lower resonance frequencies of the outer and middle ear than Caucasian neonates. Furthermore, 22.5% of Aboriginal neonates showed no middle ear resonance, indicating the possibility of subtle middle ear issues not detected by the test battery. Reasons for the different acoustic-mechanical properties between the two ethnic groups remain unclear and require further investigation. Crown Copyright (C) 2015 Published by Elsevier Ireland Ltd. All rights reserved.	[Aithal, Venkatesh] Townsville Hosp & Hlth Serv, Dept Audiol, Douglas, Qld 4814, Australia; [Aithal, Venkatesh; Kei, Joseph; Driscoll, Carlie] Univ Queensland, Sch Hlth & Rehabil Sci, Hearing Res Unit Children, Brisbane, Qld, Australia; [Swanston, Andrew] Townsville Hosp & Hlth Serv, Dept ENT, Douglas, Qld 4814, Australia; [Murakoshi, Michio] Kagoshima Univ, Dept Mech Engn, Kagoshima 890, Japan; [Wada, Hiroshi] Tohoku Bunka Gakuen Univ, Dept Intelligent Informat Syst, Sendai, Miyagi, Japan	Aithal, V (reprint author), Townsville Hosp & Hlth Serv, Dept Audiol, IMB 79,100 Angus Smith Dr, Douglas, Qld 4814, Australia.	venkatesh.aithal@health.qld.gov.au		Wada, Hiroshi/0000-0001-9538-1624	Healthy Hearing program; Private Practice Research and Education Trust fund; QH Health Practitioners Research & Thesis writing grant	The authors are thankful to: Katrina Roberts, Nursing Director, Health and Wellbeing Service Group, Townville Hospital and Health Service for their support. The authors are also thankful to: Marissa Edmondson, Jewelie-Ann Wright, Rowena Lyons, Nicky Audas and Jackie Bunt from Women's and Children's Institute; Sreedevi Aithal and Karen Nielsen from the Audiology Department for their assistance in the data collection; and Ben Mason, Biomedical Technology Service for calibration and maintenance of equipment. This research was funded by the Healthy Hearing program, Private Practice Research and Education Trust fund, and QH Health Practitioners Research & Thesis writing grant. Part of this paper has been presented at Healthy Hearing Symposium, 9-10 October, 2014, Brisbane, Australia.	ABS (Australian Bureau of Statistics), 2010, HLTH WELF AUSTR AB T; Aithal S., 2012, J AM ACAD AUDIOL, V23, P1; Aithal S, 2014, J AM ACAD AUDIOL, V25, P482, DOI 10.3766/jaaa.25.5.7; Aithal S, 2013, INT J PEDIATR OTORHI, V77, P29, DOI [10.1016/j.ijporl.2012.09.024, 10.1016/j.uporl.2012.09.024]; Aithal V, 2014, J AM ACAD AUDIOL, V25, P343, DOI 10.3766/jaaa.25.4.6; Beers AN, 2010, EAR HEARING, V31, P221, DOI 10.1097/AUD.0b013e3181c00eae; KEEFE DH, 1992, J ACOUST SOC AM, V91, P470, DOI 10.1121/1.402733; HOLTE L, 1991, AUDIOLOGY, V30, P1; BALKANY TJ, 1978, LARYNGOSCOPE, V88, P398, DOI 10.1288/00005537-197803000-00003; Boswell J., 1994, THESIS U SYDNEY SYDN; BOSWELL JB, 1995, ANN OTO RHINOL LARYN, V104, P542; CAVANAUGH RM, 1987, PEDIATRICS, V79, P520; DESA DJ, 1973, ARCH DIS CHILD, V48, P872; Douglas F., 1988, MENZIES SCH HLTH RES, P68; Doyle KJ, 1997, OTOLARYNG HEAD NECK, V116, P597, DOI 10.1016/S0194-5998(97)70234-1; Driscoll C, 2000, SCAND AUDIOL, V29, P103, DOI 10.1080/010503900424516; Foreman A.E.W., 1987, THESIS U SYDNEY SYDN; Hunter LL, 2010, EAR HEARING, V31, P599, DOI 10.1097/AUD.0b013e3181e40ca7; Busa J, 2007, PEDIATRICS, V120, P898, DOI 10.1542/peds.2007-2333; Kei J., 2012, ASSESSING MIDDLE EAR, P39; Lehmann D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-32; Mazlan R., 2009, THESIS U QUEENSLAND; Mazlan R, 2009, EAR HEARING, V30, P295, DOI 10.1097/AUD.0b013e31819c3ea0; Merchant G. R., 2010, EAR HEARING, V31, P1; Murakoshi M., 2012, ASSESSING MIDDLE EAR, P107; Murakoshi M, 2013, INT J PEDIATR OTORHI, V77, P504, DOI 10.1016/j.ijporl.2012.12.020; PAPARELLA MM, 1980, LARYNGOSCOPE, V90, P1089, DOI 10.1288/00005537-198007000-00003; Rebgetz P.T.E., 1988, MENZIES SCH HLTH RES, P67; Sanford CA, 2009, EAR HEARING, V30, P635, DOI 10.1097/AUD.0b013e3181b61cdc; Shahnaz N., 2010, 5 CAN HEAR, V5, P23; SPRAGUE BH, 1985, J SPEECH HEAR RES, V28, P265; WADA H, 1989, AUDIOLOGY, V28, P127; WADA H, 1990, J ACOUST SOC AM, V87, P237, DOI 10.1121/1.399290	33	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JUL	2015	79	7					1024	1029		10.1016/j.ijporl.2015.04.017		6	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	CL8RP	WOS:000357242100016		
J	Yamane, M; Ohnishi, N; Matsumoto, T				Yamane, M.; Ohnishi, N.; Matsumoto, T.			Does Regular Post-exercise Cold Application Attenuate Trained Muscle Adaptation?	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						ice treatment; cryotherapy; exercise; hypertrophy; vascular remodeling	RAT SKELETAL-MUSCLE; HEAT-STRESS; GENE-EXPRESSION; WATER IMMERSION; EXERCISE; RESPONSES; TEMPERATURE; ENDURANCE; EXPOSURE; RECOVERY	This study examined the effects of regular post-exercise cold application on muscular and vascular adaptations induced by moderate-intensity resistance training. 14 male subjects participated in resistance training: 5 sets of 8 wrist-flexion exercises at workload of 70-80% of the single repetition maximum, 3 times a week for 6 weeks. 7 subjects immersed their experimental forearms in cold water (10 +/- 1 degrees C) for 20min after wrist-flexion exercises (cooled group), and the other 7 served as control subjects (noncooled group). Measurements were taken before and after the training period; wrist-flexor thickness, brachial-artery diameter, maximal muscle strength, and local muscle endurance were measured in upper extremities. Wrist-flexor thicknesses of the experimental arms increased after training in both groups, but the extent of each increase was significantly less in the cooled group compared with the noncooled group. Maximal muscle strength and brachial-artery diameter did not increase in the cooled group, while they increased in the noncooled group. Local muscle endurance increased in both groups, but the increase in the cooled group tended to be lower compared to the noncooled group. Regular post-exercise cold application to muscles might attenuate muscular and vascular adaptations to resistance training.	[Yamane, M.] Aichi Mizuho Coll, Human Sci, Nagoya, Aichi 4670867, Japan; [Ohnishi, N.] Mie Prefectural Coll Nursing, Fac Nursing, Tsu, Mie, Japan; [Matsumoto, T.] Chukyo Univ, Grad Sch Hlth & Sport Sci, Lab Exercise Physiol & Biomech, Toyota, Japan	Yamane, M (reprint author), Aichi Mizuho Coll, Human Sci, Mizuho Ku, Shunkocho 2-13, Nagoya, Aichi 4670867, Japan.	mo-yamane@mizuho-c.ac.jp			Descente; Ishimoto Memorial Foundation for the Promotion of Sports Science	We wish to thank all subjects who participated in this study for their cooperation. This study was supported, in part, by a Grant-in Aid from the Descente and Ishimoto Memorial Foundation for the Promotion of Sports Science.	Oishi Y, 2002, J APPL PHYSIOL, V92, P1097, DOI 10.1152/japplphysiol.00739.2001; LOCKE M, 1995, CAN J APPL PHYSIOL, V20, P155; Thompson HS, 2003, ACTA PHYSIOL SCAND, V178, P61, DOI 10.1046/j.1365-201X.2003.01112.x; Harriss DJ, 2013, INT J SPORTS MED, V34, P1025, DOI 10.1055/s-0033-1358756; Butterfield TA, 2006, J ATHL TRAINING, V41, P457; Miyachi M, 2001, J APPL PHYSIOL, V90, P2439; Naito H, 2000, J APPL PHYSIOL, V88, P359; Goto K, 2003, PFLUG ARCH EUR J PHY, V447, P247, DOI 10.1007/s00424-003-1177-x; Yoshihara T, 2013, ACTA PHYSIOL, V207, P416, DOI 10.1111/apha.12040; Selman C, 2002, FREE RADICAL BIO MED, V33, P259; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Deal DN, 2002, J BONE JOINT SURG AM, V84A, P1573; Fischer CP, 2006, EXERC IMMUNOL REV, V12, P6; Franke WD, 1998, CLIN PHYSIOL, V18, P521; Kraus RM, 2004, J APPL PHYSIOL, V96, P1445, DOI 10.1152/japplphysiol.01031.2003; Hudlicka O, 2002, EXP PHYSIOL, V87, P373, DOI 10.1113/eph8702285; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534; Leeder J, 2012, BRIT J SPORT MED, V46, P233, DOI 10.1136/bjsports-2011-090061; Yamane M, 2006, EUR J APPL PHYSIOL, V96, P572, DOI 10.1007/s00421-005-0095-3; Begue G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057141; Bleakley C M, 2012, COCHRANE DB SYST REV, V15; Clanton TL, 2001, J APPL PHYSIOL, V90, P2476; Crewther B, 2006, SPORTS MED, V36, P65, DOI 10.2165/00007256-200636010-00005; Bleakley CM, 2010, BRIT J SPORT MED, V44, P179, DOI 10.1136/bjsm.2009.065565; Gavin TP, 2001, J APPL PHYSIOL, V90, P1219; Halevy O, 2001, AM J PHYSIOL-REG I, V281, pR302; Harris MB, 2001, AM J PHYSIOL-HEART C, V280, pH2271; JOHNSON DJ, 1979, PHYS THER, V59, P1238; Kami K, 2000, J HISTOCHEM CYTOCHEM, V48, P1203, DOI 10.1177/002215540004800904; Knight K L, 1976, ATHL TRAIN, V11, P7; Knight K L, 1995, HUMAN KINETICS, P77; Liu Y, 2003, J APPL PHYSIOL, V94, P2282, DOI 10.1152/japplphysiol.00830.2002; Lloyd PG, 2003, AM J PHYSIOL-HEART C, V284, pH1668, DOI 10.1152/ajpheart.00743.2002; Lynch SA, 1999, SPORTS MED, V27, P61, DOI 10.2165/00007256-199927010-00005; Malm C, 2001, ACTA PHYSIOL SCAND, V171, P233, DOI 10.1046/j.1365-201x.2001.00825.x; McLoughlin TJ, 2003, J APPL PHYSIOL, V94, P876, DOI 10.1152/japplphysiol.00766.2002; Nemet D, 2009, EUR J APPL PHYSIOL, V107, P411, DOI 10.1007/s00421-009-1138-y; RIPPE B, 1978, ACTA PHYSIOL SCAND, V103, P252, DOI 10.1111/j.1748-1716.1978.tb06212.x; Ryan A J, 1973, Exerc Sport Sci Rev, V1, P285; SIEMS WG, 1994, FREE RADICAL BIO MED, V16, P299, DOI 10.1016/0891-5849(94)90030-2; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x	42	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	JUL	2015	36	8					647	653		10.1055/s-0034-1398652		7	Sport Sciences	Sport Sciences	CL8HL	WOS:000357215100006		
J	Hasegawa, Y; Ijichi, T; Kurosawa, Y; Hamaoka, T; Goto, K				Hasegawa, Y.; Ijichi, T.; Kurosawa, Y.; Hamaoka, T.; Goto, K.			Planned Overreaching and Subsequent Short-term Detraining Enhance Cycle Sprint Performance	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						overtraining; rest distribution; phosphocreatine; magnetic resonance spectroscopy; anaerobic power; sprint training	HUMAN SKELETAL-MUSCLE; CREATINE SUPPLEMENTATION; METABOLISM; EXERCISE; PHOSPHOCREATINE; HUMANS; ADAPTATIONS	We investigated the effect of a training program consisting of planned overreaching and subsequent short-term detraining on sprint performance. 24 physically active men participated in an 18-day sprint-training program. They were divided into 2 groups: the overreaching-detraining (OR-DT) and the control (CON) groups. Subjects in the OR-DT group performed 12 consecutive days of maximal cycle sprint training followed by 6 days of detraining, whereas a rest day was provided after every 2 successive training days for the CON group. Peak power output during maximal pedaling increased significantly after 6 days of detraining in the OR-DT group compared with the baseline (P<0.05), whereas no change was observed in CON group. Intramuscular phosphocreatine concentration increased significantly after 12 days of daily training in the OR-DT group (69.3 +/- 45.8% increase vs. baseline, P<0.05), and it was maintained after the detraining period (46.6 +/- 33.6% increase vs. baseline, P<0.05). However, no change was observed in CON group. No significant changes in blood variables were observed after the training period except significant reduction of serum cortisol in the CON group. Daily sprint training and subsequent short-term detraining enhanced peak power output after the detraining period.	[Hasegawa, Y.; Ijichi, T.] Ritsumeikan Univ, Grad Sch Sports & Hlth Sci, Kusatsu, Japan; [Kurosawa, Y.; Hamaoka, T.; Goto, K.] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Japan	Hasegawa, Y (reprint author), Ritsumeikan Univ, Grad Sch Sports & Hlth Sci, Kusatsu, Japan.	uthsgw@gmail.com			Japan Society for the Promotion of Science	The authors thank the subjects for their time and effort and Masako Fujioka for technical assistance. The present study was supported from Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science.	Wyss M, 2000, PHYSIOL REV, V80, P1107; Harriss DJ, 2013, INT J SPORTS MED, V34, P1025, DOI 10.1055/s-0033-1358756; Wiroth JB, 2001, EUR J APPL PHYSIOL, V84, P533, DOI 10.1007/s004210000370; Bishop D, 2011, SPORTS MED, V41, P741, DOI 10.2165/11590560-000000000-00000; Jurimae J, 2011, METABOLISM, V60, P335, DOI 10.1016/j.metabol.2010.02.009; Kemp GJ, 2007, NMR BIOMED, V20, P555, DOI 10.1002/nbm.1192; Hultman E, 1996, J APPL PHYSIOL, V81, P232; Jones AM, 2009, AM J PHYSIOL-REG I, V296, pR1078, DOI 10.1152/ajpregu.90896.2008; HELLSTENWESTING Y, 1993, J APPL PHYSIOL, V74, P2523; Rawson ES, 2002, ACTA PHYSIOL SCAND, V174, P57, DOI 10.1046/j.1365-201x.2002.00924.x; Saraslanidis P, 2011, J SPORT SCI, V29, P1167, DOI 10.1080/02640414.2011.583672; Dawson B, 1998, EUR J APPL PHYSIOL O, V78, P163, DOI 10.1007/s004210050402; Andersen LL, 2005, J APPL PHYSIOL, V99, P87, DOI 10.1152/japplphysiol.00091.2005; Weiss LW, 2004, J STRENGTH COND RES, V18, P765; Burgomaster KA, 2005, J APPL PHYSIOL, V98, P1985, DOI 10.1152/japplphysiol.01095.2004; Parra J, 2000, ACTA PHYSIOL SCAND, V169, P157; Havenetidis K, 2003, J SPORT MED PHYS FIT, V43, P347; Barnett C, 2004, J SCI MED SPORT, V7, P314, DOI 10.1016/S1440-2440(04)80026-4; Casey A, 2000, AM J CLIN NUTR, V72, P607; Ferrari B. D., 2008, INT J SPORTS MED, V29, P668, DOI DOI 10.1055/S-2007-989371; Finn JP, 2001, EUR J APPL PHYSIOL, V84, P238, DOI 10.1007/s004210170011; LINOSSIER MT, 1993, EUR J APPL PHYSIOL O, V67, P408, DOI 10.1007/BF00376456; Ross A, 2001, SPORTS MED, V31, P1063, DOI 10.2165/00007256-200131150-00003; Suzuki Y, 2004, INT J SPORT HLTH SCI, V2, P105, DOI 10.5432/ijshs.2.105; Zoladz JA, 2010, J PHYSIOL SCI, V60, P331, DOI 10.1007/s12576-010-0101-3	25	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	JUL	2015	36	8					666	671		10.1055/s-0034-1390466		6	Sport Sciences	Sport Sciences	CL8HL	WOS:000357215100009		
J	Tanaka, Y; Miyanaga, H; Maeda, Y; Abe, M; Miwa, S				Tanaka, Y.; Miyanaga, H.; Maeda, Y.; Abe, M.; Miwa, S.			A Method for Detecting the Deterioration in the Shock Absorption Capability of Mouthguards	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						ethylene vinyl acetate; intraclass correlations; minimal detectable change; Bland-Altman plot; deterioration; impact injury	SPORT ACTIVITIES; DENTAL INJURIES; MOUTH GUARDS; PREVENTION; ABILITY	Objective methods for mechanical assessment of mouthguards used for a prolonged period of time are currently unavailable. The aim of this experimental study was to establish a quantitative method for assessing the preventive effect of mouthguards. 10 participants volunteered for this study. Impact loads were simulated by dropping a 250-g steel rod from a height of 100mm onto upper front teeth of 10 custom ethylene vinyl acetate mouthguards fixed to a steel receiving rod. The mean output from load cells equilaterally placed between plates at the base of the apparatus was measured as the impact pressure (N). Its attenuation ratio (%) was calculated as the ratio of the difference in impact pressures without and with a mouthguard to impact pressure without a mouthguard. Impact pressure with mouthguard was approximately 60% of that without mouthguard in all cases. Intraclass correlations showed excellent intra-rater and inter-rater reliability for attenuation ratio (0.98 and 0.94, respectively). Bland-Altman plots indicated lack of systematic bias. The results suggest that attenuation ratio of impact pressure calculated by the proposed method is a valid criterion for assessing the preventive effect of mouthguards. The method may enable early detection of mouthguard deterioration and their timely replacement.	[Tanaka, Y.; Miyanaga, H.; Maeda, Y.; Abe, M.; Miwa, S.] Osaka Univ, Grad Sch Dent, Dept Prosthodont Gerodontol & Oral Rehabil, Suita, Osaka 5650871, Japan	Tanaka, Y (reprint author), Osaka Univ, Grad Sch Dent, Dept Prosthodont Typo & Oral Rehabil, Yamadaoka 1-8, Suita, Osaka 5650871, Japan.	yutotanaka.0106@gmail.com			Japan Society for the Promotion of Science [25670816]	The authors would like to thank all the participants and volunteers who participated in this study. The authors appreciate Shinsuke Matsuda for technical suggestions in fabricating mouthguards. This study was supported by a Grant-in-Aid for Scientific Research (No. 25670816) from the Japan Society for the Promotion of Science. The authors declare that they have no conflict of interest, financial or otherwise, relating to the publication of this article.	Harriss DJ, 2013, INT J SPORTS MED, V34, P1025, DOI 10.1055/s-0033-1358756; Haley SM, 2006, PHYS THER, V86, P735; Auroy P, 1996, J PROSTHET DENT, V75, P463, DOI 10.1016/S0022-3913(96)90045-1; Gould TE, 2009, DENT MATER, V25, P771, DOI 10.1016/j.dental.2008.12.005; Cohenca N, 2007, J AM DENT ASSOC, V138, P1121; Duddy FA, 2012, DENT TRAUMATOL, V28, P263, DOI 10.1111/j.1600-9657.2011.01106.x; Maeda Y, 2009, DENT TRAUMATOL, V25, P556, DOI 10.1111/j.1600-9657.2009.00822.x; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; Greasley A, 1997, BRIT J SPORT MED, V31, P31; Biagi R, 2010, EUR J PAEDIATR DENT, V11, P66; Blignaut J B, 1987, Br J Sports Med, V21, P5; Cetinbas T, 2006, DENT TRAUMATOL, V22, P127, DOI 10.1111/j.1600-9657.2006.00397.x; Coto Neide Pena, 2007, Braz Dent J, V18, P324, DOI 10.1590/S0103-64402007000400010; Kumamoto David, 2005, J Calif Dent Assoc, V33, P463; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lieger O, 2006, DENT TRAUMATOL, V22, P1, DOI 10.1111/j.1600-9657.2006.00328.x; Maeda Y, 2013, INT J SPORTS DENT, V6, P7; Maeda Y, 2009, QUINTESSENCE INT, V40, P13; Maeda Y, 2006, BRIT J SPORT MED, V40, P1006, DOI 10.1136/bjsm.2006.030874; Maestrello Christopher L., 1999, Pediatric Dentistry, V21, P340; MCNUTT T, 1989, Pediatric Dentistry, V11, P209; O'Malley Margaret, 2012, J Ir Dent Assoc, V58, P205; Onyeaso CO, 2004, J NATL MED ASSOC, V96, P240; Ozawa T, 2014, DENT TRAUMATOL, V30, P204, DOI 10.1111/edt.12063; Padilla R, 1996, J Calif Dent Assoc, V24, P30; PARK JB, 1994, J PROSTHET DENT, V72, P373, DOI 10.1016/0022-3913(94)90556-8; Rossi Gianluca Del, 2007, J Athl Train, V42, P47; Sasayama C, 2014, J SPORTS DENT, V17, P31; Takahashi M, 2011, ANN JPN PROSTHODONT, V3, P346; Takamata T, 2009, J SPORTS DENT, V2, P62; Takeda T, 2004, DENT TRAUMATOL, V20, P12, DOI 10.1111/j.1600-4469.2004.00210.x; Takeda T, 2006, DENT TRAUMATOL, V22, P77, DOI 10.1111/j.1600-9657.2006.00361.x; Tanaka Y, 2015, INT J SPORTS MED, V36, P254, DOI 10.1055/s-0034-1390498; Yeil Duymu Z, 2009, TURKEY DENT TRAUMATO, V25, P318	34	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	JUL	2015	36	8					684	687		10.1055/s-0034-1398655		4	Sport Sciences	Sport Sciences	CL8HL	WOS:000357215100012		
J	Kashiwadate, T; Tokodai, K; Amada, N; Haga, I; Takayama, T; Nakamura, A; Jimbo, T; Hara, Y; Kawagishi, N; Ohuchi, N				Kashiwadate, Toshiaki; Tokodai, Kazuaki; Amada, Noritoshi; Haga, Izumi; Takayama, Tetsuro; Nakamura, Atsushi; Jimbo, Takuya; Hara, Yasuyuki; Kawagishi, Naoki; Ohuchi, Noriaki			Right versus left retroperitoneoscopic living-donor nephrectomy	INTERNATIONAL UROLOGY AND NEPHROLOGY			English	Article						Donor selection; Graft survival; Kidney transplantation; Laparoscopic surgery; Living donors	KIDNEY; TRANSPLANTATION	To compare the safety and efficacy of right-side and left-side retroperitoneoscopic donor nephrectomy (RDN) using our hybrid technique. We retrospectively reviewed the data obtained from 151 consecutive patients who underwent RDN between May 2005 and July 2013. Right and left nephrectomies were performed in 87 and 64 patients, respectively. We compared these two groups with respect to donors' intraoperative parameters, postoperative outcomes, and recipients' outcomes. There were no significant differences between the two groups regarding donor blood loss, warm ischemia time, donor postoperative creatinine levels, donor postoperative length of hospital stay, recipient creatinine levels at 1 year after transplantation, and 1-year graft survival rate after transplantation. The time required for graft extraction and overall operative time were significantly shorter in the right RDN group than in the left RDN group (152 vs. 168 min, P = 0.016; 175 vs. 195 min, P = 0.0059). Only one case in the right nephrectomy group required open conversion because of uncontrollable bleeding from the inferior vena cava. Although larger sample sizes would be required to evaluate postoperative complication rate, these results indicate that both the right and left RDN could be performed with similar donor and recipient outcomes.	[Kashiwadate, Toshiaki; Tokodai, Kazuaki; Amada, Noritoshi; Haga, Izumi; Takayama, Tetsuro; Nakamura, Atsushi; Jimbo, Takuya] Japan Community Hlth Care Org Sendai Hosp, Dept Surg, Sendai, Miyagi, Japan; [Kashiwadate, Toshiaki; Tokodai, Kazuaki; Hara, Yasuyuki; Kawagishi, Naoki; Ohuchi, Noriaki] Tohoku Univ Hosp, Dept Transplantat Reconstruct & Endoscop Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan	Tokodai, K (reprint author), Japan Community Hlth Care Org Sendai Hosp, Dept Surg, Sendai, Miyagi, Japan.	tsu7ka5so8mi@med.tohoku.ac.jp					RATNER LE, 1995, TRANSPLANTATION, V60, P1047; Tokodai K, 2013, UROLOGY, V82, P1054, DOI 10.1016/j.urology.2013.08.003; Harper JD, 2010, J UROLOGY, V183, P1941, DOI 10.1016/j.juro.2010.01.021; Kohei N, 2010, J ENDOUROL, V24, P1783, DOI 10.1089/end.2009.0493; Kok NFM, 2006, TRANSPLANTATION, V82, P892, DOI 10.1097/01.tp.0000235511.19629.0d; Chin EH, 2007, SURG ENDOSC, V21, P521, DOI 10.1007/s00464-006-9021-y; Derweesh IH, 2005, UROLOGY, V65, P862, DOI 10.1016/j.urology.2004.11.051; Dols LFC, 2009, TRANSPLANTATION, V87, P745, DOI 10.1097/TP.0b013e318198a3a6; Mandal AK, 2001, TRANSPLANTATION, V71, P660, DOI 10.1097/00007890-200103150-00015; Omoto K, 2013, J TRANSPLANT, V2013, DOI 10.1155/2013/546373; Power RE, 2006, BJU INT, V98, P133, DOI 10.1111/j.1464-410X.2006.06265.x; Ruszat R, 2007, TRANSPL P, V39, P1381, DOI 10.1016/j.transproceed.2007.02.069; Tokodai K, 2013, TOHOKU J EXP MED, V229, P227, DOI 10.1620/tjem.229.227; Troppmann C, 2003, AM J TRANSPLANT, V3, P1295, DOI 10.1046/j.1600-6143.2003.00216.x; Yashi M, 2007, J ENDOUROL, V21, P589, DOI 10.1089/end.2006.0326	15	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-1623	1573-2584		INT UROL NEPHROL	Int. Urol. Nephrol.	JUL	2015	47	7					1117	1121		10.1007/s11255-015-1014-0		5	Urology & Nephrology	Urology & Nephrology	CL4DF	WOS:000356902100011		
J	Kim, Y; Miyashita, M; Miyagawa, H				Kim, Yonghyun; Miyashita, Masahiro; Miyagawa, Hisashi			Photocontrol of Elicitor Activity of PIP-1 to Investigate Temporal Factors Involved in Phytoalexin Biosynthesis	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY			English	Article						peptide; photocleavable analog; phytoalexin; MAP kinase; plant immunity	CELL-SUSPENSION CULTURES; COENZYME-A REDUCTASE; PLANT IMMUNE-SYSTEM; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; RESISTANCE GENE; INNATE IMMUNITY; TOBACCO CELLS; IN-VIVO; INDUCTION	The peptide elicitor PIP-1 can induce various immune responses in tobacco cells. Previously, we showed that types of responses induced by PIP-1 are different depending on its stimulation periods; short-term stimulation induces weak responses, whereas long-term stimulation leads to strong responses including production of the phytoalexin capsidiol. However, key components that directly regulate the initiation of capsidiol biosynthesis in response to continuous stimulation with PIP-1 remain unclear. In this study, we designed a photocleavable PIP-1 analog containing 3-amino-3-(2-nitrophenyl)propionic acid as a photocleavable residue. The activity of the analog can be switched off using ultraviolet (UV) irradiation without undesired side effects. This analog induced a significant level of capsidiol production unless UV-irradiated, whereas no capsidiol production was observed when tobacco cells were UV-irradiated 1 h after treatment. Using this analog, we found that the elicitor-inducible 3-hydroxy-3-methylglutaryl-CoA reductase activity is regulated based on the duration of the stimulation with PIP-1, which could be associated with the initiation of capsidiol biosynthesis.	[Kim, Yonghyun; Miyashita, Masahiro; Miyagawa, Hisashi] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan	Miyashita, M (reprint author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan.	miyamasa@kais.kyoto-u.ac.jp			MEXT KAKENHI, Japan [23580148]	This study was partly supported by MEXT KAKENHI (Grant 23580148), Japan.	Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; DALE S, 1995, EUR J BIOCHEM, V233, P506, DOI 10.1111/j.1432-1033.1995.506_2.x; Ishihama N, 2011, PLANT CELL, V23, P1153, DOI 10.1105/tpc.110.081794; Corrie JET, 2003, J AM CHEM SOC, V125, P8546, DOI 10.1021/je034354c; Albert M, 2010, EUR J CELL BIOL, V89, P200, DOI 10.1016/j.ejcb.2009.11.015; CHAPPELL J, 1987, PLANT PHYSIOL, V85, P469, DOI 10.1104/pp.85.2.469; Ausubel FM, 2005, NAT IMMUNOL, V6, P973, DOI 10.1038/ni1253; Glazebrook J, 2005, ANNU REV PHYTOPATHOL, V43, P205, DOI 10.1146/annurev.phyto.43.040204.135923; Bent AF, 2007, ANNU REV PHYTOPATHOL, V45, P399, DOI 10.1146/annurev.phyto.45.062806.094427; Leivar P, 2011, PLANT CELL, V23, P1494, DOI 10.1105/tpc.110.074278; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; LOTAN T, 1990, PLANT PHYSIOL, V93, P811, DOI 10.1104/pp.93.2.811; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; Umezawa N, 2011, CHEMBIOCHEM, V12, P1694, DOI 10.1002/cbic.201100212; Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121; CHAPPELL J, 1991, PLANT PHYSIOL, V97, P693, DOI 10.1104/pp.97.2.693; Yu HT, 2010, CHEM SOC REV, V39, P464, DOI 10.1039/b901255a; Albert M, 2013, J EXP BOT, V64, P5269, DOI 10.1093/jxb/ert275; Vranova E, 2013, ANNU REV PLANT BIOL, V64, P665, DOI 10.1146/annurev-arplant-050312-120116; Wang JW, 2006, BIOCHEM BIOPH RES CO, V340, P1209, DOI 10.1016/j.bbrc.2005.12.126; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; Boller T, 2009, ANNU REV PLANT BIOL, V60, P379, DOI 10.1146/annurev.arplant.57.032905.105346; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Meng XZ, 2013, ANNU REV PHYTOPATHOL, V51, P245, DOI 10.1146/annurev-phyto-082712-102314; CHOI D, 1992, PLANT CELL, V4, P1333, DOI 10.1105/tpc.4.10.1333; Zhao J, 2005, BIOTECHNOL ADV, V23, P283, DOI 10.1016/j.biotechadv.2005.01.003; Romeis T, 1999, PLANT CELL, V11, P273; Gomez-Gomez L, 2002, TRENDS PLANT SCI, V7, P251, DOI 10.1016/S1360-1385(02)02261-6; Yoshioka H, 2001, MOL PLANT MICROBE IN, V14, P725, DOI 10.1094/MPMI.2001.14.6.725; England PM, 1997, P NATL ACAD SCI USA, V94, P11025, DOI 10.1073/pnas.94.20.11025; FLUHR R, 1991, CURR PLANT SCI BIOT, V10, P387; Judkins JC, 2014, ANGEW CHEM INT EDIT, V53, P2110, DOI 10.1002/anie.201307465; Kadota Y, 2005, PLANT CELL PHYSIOL, V46, P156, DOI 10.1093/pcp/pci008; Kim Y, 2014, J AGR FOOD CHEM, V62, P5781, DOI 10.1021/jf501679p; Kiraly L, 2007, J PHYTOPATHOL, V155, P385, DOI 10.1111/j.1439-0434.2007.01264.x; Lawrence DS, 2005, CURR OPIN CHEM BIOL, V9, P570, DOI 10.1016/j.cbpa.2005.09.002; Mansouri H, 2009, PLANT GROWTH REGUL, V58, P269, DOI 10.1007/s10725-009-9375-y; Miyashita M, 2011, CHEMBIOCHEM, V12, P1323, DOI 10.1002/cbic.201000694; Miyata KI, 2006, BIOSCI BIOTECH BIOCH, V70, P2138, DOI 10.1271/bb6.60104; Parker LL, 2006, ANGEW CHEM INT EDIT, V45, P6322, DOI 10.1002/anie.200602439; PEYSER JR, 1987, J ORG CHEM, V52, P4645, DOI 10.1021/jo00229a053; Salerno CP, 2000, J ORG CHEM, V65, P3971, DOI 10.1021/jo9917846; WHITEHEAD IM, 1987, PHYTOCHEMISTRY, V26, P1367, DOI 10.1016/S0031-9422(00)81814-2	43	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0021-8561	1520-5118		J AGR FOOD CHEM	J. Agric. Food Chem.	JUL 1	2015	63	25					5894	5901		10.1021/acs.jafc.5b01910		8	Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology	Agriculture; Chemistry; Food Science & Technology	CM1IU	WOS:000357435400008		
J	Hashimoto, M; Orikasa, Y; Hayashi, H; Watanabe, K; Yoshida, K; Okuyama, H				Hashimoto, Mikako; Orikasa, Yoshitake; Hayashi, Hidenori; Watanabe, Kentaro; Yoshida, Kiyohito; Okuyama, Hidetoshi			Occurrence of trans monounsaturated and polyunsaturated fatty acids in Colwellia psychrerythraea strain 34H	JOURNAL OF BASIC MICROBIOLOGY			English	Article						Colwellia psychrerythraea strain 34H; Docosahexaenoic acid (DHA); Obligate psychrophile; Long-chain polyunsaturated fatty acid; trans Unsaturated fatty acid	PSYCHROPHILIC BACTERIUM; SP-NOV.; EICOSAPENTAENOIC ACID; PSEUDOMONAS-PUTIDA; DOUBLE-BOND; MARINE BACTERIUM; HIGH-PRESSURE; SP. NOV.; VIBRIO; ISOMERIZATION	Colwellia psychrerythraea strain 34H is an obligately psychrophilic bacterium that has been used as a model cold-adapted microorganism because of its psychrophilic growth profile, significant production of cold-active enzymes, and cryoprotectant extracellular polysaccharide substances. However, its fatty acid components, particularly trans unsaturated fatty acids and long-chain polyunsaturated fatty acids (LC-PUFAs), have not been fully investigated. In this study, we biochemically identified 9-trans hexadecenoic acid [16:1(9t)] and LC-PUFAs such as docosahexaenoic acid. These results are comparable with the fact that the strain 34H genome sequence includes pfa and cti genes that are responsible for the biosynthesis of LC-PUFAs and trans unsaturated fatty acids, respectively. Strain 34H cells grown under static conditions at 5 degrees C had higher levels of 16:1(9t) than those grown under shaken conditions, and this change was accompanied by an antiparallel decrease in the levels of 9-cis hexadecenoic acid [16:1(9c)], suggesting that the cis-to-trans isomerization reaction of 16:1(9c) is activated under static (microanaerobic) culture conditions, that is, the enzyme could be activated by the decreased dissolved oxygen concentration of cultures. On the other hand, the levels of LC-PUFAs were too low (less than 3% of the total), even for cells grown at 5 degrees C, to evaluate their cold-adaptive function in this bacterium.	[Hashimoto, Mikako; Okuyama, Hidetoshi] Hokkaido Univ, Grad Sch Environm Sci, Div Biosphere Sci, Course Mol Biol,Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Orikasa, Yoshitake] Obihiro Univ Agr & Vet Med, Dept Food Sci, Obihiro, Hokkaido 080, Japan; [Hayashi, Hidenori] Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime, Japan; [Hayashi, Hidenori] Ehime Univ, Fac Sci, Dept Chem, Matsuyama, Ehime 790, Japan; [Watanabe, Kentaro] Natl Inst Polar Res, Biosci Grp, Tachikawa, Tokyo, Japan; [Yoshida, Kiyohito] Hokkaido Univ, Grad Sch Environm Sci, Div Biosphere Sci, Course Ecol Genet,Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Yoshida, Kiyohito] Hokkaido Univ, Fac Environm Earth Sci, Lab Ecol Genet, Sect Environm Biol,Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Okuyama, Hidetoshi] Hokkaido Univ, Lab Environm Mol Biol, Sect Environm Biol, Fac Environm Earth Sci,Kita Ku, Sapporo, Hokkaido 0600810, Japan	Okuyama, H (reprint author), Hokkaido Univ, Lab Environm Mol Biol, Sect Environm Biol, Fac Environm Earth Sci,Kita Ku, Sapporo, Hokkaido 0600810, Japan.	hoku@ees.hokudai.ac.jp			National Institute of Polar Research, Japan [25-26]; Ministry of Education, Science, Sports, and Culture of Japan [22570130]	C. maris strain ABE-1<SUP>T</SUP> was provided by Professor Y. Takada of Hokkaido University, Sapporo, Japan. This work was partly supported by the National Institute of Polar Research, Japan (no. 25-26) and by a Grant-in-Aid for Scientific Research ((C) no. 22570130) from the Ministry of Education, Science, Sports, and Culture of Japan.	Leiros HKS, 2007, J BIOL CHEM, V282, P21973, DOI 10.1074/jbc.M610174200; Orikasa Y, 2009, FEMS MICROBIOL LETT, V295, P170, DOI 10.1111/j.1574-6968.2009.01582.x; von Wallbrunn A, 2003, J BACTERIOL, V185, P1730, DOI 10.1128/JB.185.5.1730-1733.2003; Junker F, 1999, J BACTERIOL, V181, P5693; Okuyama H, 2007, APPL ENVIRON MICROB, V73, P665, DOI 10.1128/AEM.02270-06; Allen EE, 1999, APPL ENVIRON MICROB, V65, P1710; Bowman JP, 1998, INT J SYST BACTERIOL, V48, P1171; NICHOLS PD, 1986, J MICROBIOL METH, V5, P49, DOI 10.1016/0167-7012(86)90023-0; Hirota K, 2005, INT J SYST EVOL MICR, V55, P2355, DOI 10.1099/ijs.0.63804-0; Keweloh H, 1996, LIPIDS, V31, P129, DOI 10.1007/BF02522611; OKUYAMA H, 1991, BIOCHIM BIOPHYS ACTA, V1084, P13, DOI 10.1016/0005-2760(91)90049-N; Methe BA, 2005, P NATL ACAD SCI USA, V102, P10913, DOI 10.1073/pnas.0504766102; Valentine RC, 2004, PROG LIPID RES, V43, P383, DOI 10.1016/j.plipres.2004.05.004; Marx JG, 2009, CAN J MICROBIOL, V55, P63, DOI 10.1139/W08-130; Kawamoto J, 2009, J BACTERIOL, V191, P632, DOI 10.1128/JB.00881-08; Sukovich DJ, 2010, APPL ENVIRON MICROB, V76, P3850, DOI 10.1128/AEM.00436-10; Heipieper HJ, 2003, FEMS MICROBIOL LETT, V229, P1, DOI 10.1016/S0378-1097(03)000792-4; Hartig C, 2005, APPL ENVIRON MICROB, V71, P1915, DOI 10.1128/AEM.71.4.1915-1922.2005; Huston AL, 2004, APPL ENVIRON MICROB, V70, P3321, DOI 10.1128/AEM.70.6.3321-3328.2004; Nishida T, 2007, FEBS LETT, V581, P4212, DOI 10.1016/j.febslet.2007.07.065; Junge K, 2003, APPL ENVIRON MICROB, V69, P4282, DOI 10.1128/AEM.69.7.4282-4284.2003; Nogi Y, 2004, INT J SYST EVOL MICR, V54, P1627, DOI 10.1099/ijs.0.03049-0; Huston A. L., 2003, THESIS U WASHINGTON; Jung SY, 2006, INT J SYST EVOL MICR, V56, P33, DOI 10.1099/ijs.0.63920-0; Junge K, 2006, CRYOBIOLOGY, V52, P417, DOI 10.1016/j.cryobiol.2006.03.002; Mason OU, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00332; MOSS CW, 1989, J CLIN MICROBIOL, V27, P1467; Motoigi T, 2011, J BASIC MICROB, V51, P484, DOI 10.1002/jobm.201000427; Okuyama H, 1996, ARCH MICROBIOL, V165, P415, DOI 10.1007/s002030050346; OKUYAMA H, 1990, J BACTERIOL, V172, P3515; Shulse CN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020146; Sugihara S, 2010, LIPIDS, V45, P167, DOI 10.1007/s11745-009-3380-9; Sugihara S., 2012, Research Journal of Microbiology, V7, P131; Tsitko IV, 1999, APPL ENVIRON MICROB, V65, P853; Usui K, 2012, BBA-BIOMEMBRANES, V1818, P574, DOI 10.1016/j.bbamem.2011.10.010; Yumoto I, 1998, INT J SYST BACTERIOL, V48, P1357; Zhang DC, 2008, INT J SYST EVOL MICR, V58, P1931, DOI 10.1099/ijs.0.65596-0	37	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0233-111X	1521-4028		J BASIC MICROB	J. Basic Microbiol.	JUL	2015	55	7					838	845		10.1002/jobm.201400815		8	Microbiology	Microbiology	CM2DR	WOS:000357490500004		
J	Pfeiffer, J; Duzevik, D; Rothlauf, F; Bonabeau, E; Yamamoto, K				Pfeiffer, Jella; Duzevik, Dejan; Rothlauf, Franz; Bonabeau, Eric; Yamamoto, Koichi			An Optimized Design of Choice Experiments: A New Approach for Studying Decision Behavior in Choice Task Experiments	JOURNAL OF BEHAVIORAL DECISION MAKING			English	Review						decision strategies; genetic algorithms; choice tasks; experimental design; context-based complexity	MULTIATTRIBUTE BINARY CHOICE; PROCESS TRACING METHODS; PROTOCOL ANALYSIS; CONSUMER CHOICE; INFORMATION ACQUISITION; STRATEGY CLASSIFICATION; MODEL DISCRIMINATION; CONSIDERATION SETS; COGNITIVE EFFORT; TIME PRESSURE	In this paper, we present a new approach for the optimal experimental design problem of generating diagnostic choice tasks, where the respondent's decision strategy can be unambiguously deduced from the observed choice. In this new approach, we applied a genetic algorithm that creates a one-to-one correspondence between a set of predefined decision strategies and the alternatives of the choice task; it also manipulates the characteristics of the choice tasks. In addition, this new approach takes into account the measurement errors that can occur when the preferences of the decision makers are being measured. The proposed genetic algorithm is capable of generating diagnostic choice tasks even when the search space of possible choice tasks is very large. As proof-of-concept, we used this novel approach to generate respondent-specific choice tasks with either low or high context-based complexity that we operationalize by the similarity of alternatives and the conflict between alternatives. We find in an experiment that an increase in the similarity of the alternatives and an increase in the number of conflicts within the choice task lead to an increased use of non-compensatory strategies and a decreased use of compensatory decision strategies. In contrast, the size of the choice tasks, measured by the number of attributes and alternatives, only weakly influences the strategy selection. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Pfeiffer, Jella] Karlsruhe Inst Technol, Inst Informat Syst & Mkt, D-76021 Karlsruhe, Germany; [Duzevik, Dejan] Concentric, Cambridge, MA USA; [Rothlauf, Franz] Johannes Gutenberg Univ Mainz, Dept Informat Syst & Business Adm, D-55122 Mainz, Germany; [Bonabeau, Eric] Icosystem, Cambridge, MA USA; [Bonabeau, Eric] Keck Grad Inst, Minerva Sch, San Francisco, CA USA; [Yamamoto, Koichi] Dentsu, Tokyo, Japan	Pfeiffer, J (reprint author), Karlsruhe Inst Technol, Inst Informat Syst & Mkt, D-76021 Karlsruhe, Germany.	jella.pfeiffer@kit.edu					Anderson N. H, 1974, HDB PERCEPTION; PAYNE JW, 1992, ANNU REV PSYCHOL, V43, P87, DOI 10.1146/annurev.ps.43.020192.000511; TVERSKY A, 1969, PSYCHOL REV, V76, P31, DOI 10.1037/h0026750; Gilbride TJ, 2004, MARKET SCI, V23, P391, DOI 10.1287/mksc.1030.0032; Kohli R, 2007, MARKET SCI, V26, P380, DOI 10.1287/mksc.1060.0241; Lohse GL, 1996, ORGAN BEHAV HUM DEC, V68, P28, DOI 10.1006/obhd.1996.0087; FORD JK, 1989, ORGAN BEHAV HUM DEC, V43, P75, DOI 10.1016/0749-5978(89)90059-9; Luce MF, 1997, J EXP PSYCHOL LEARN, V23, P384, DOI 10.1037/0278-7393.23.2.384; Fasolo B, 2009, PSYCHOL MARKET, V26, P254, DOI 10.1002/mar.20272; TVERSKY A, 1972, PSYCHOL REV, V79, P281, DOI 10.1037/h0032955; Swait J, 2001, J CONSUM RES, V28, P135, DOI 10.1086/321952; PAYNE JW, 1976, ORGAN BEHAV HUM PERF, V16, P366, DOI 10.1016/0030-5073(76)90022-2; JOHNSON EJ, 1985, MANAGE SCI, V31, P395, DOI 10.1287/mnsc.31.4.395; Scheibehenne B, 2010, J CONSUM RES, V37, P409, DOI 10.1086/651235; RUSSO JE, 1983, J EXP PSYCHOL LEARN, V9, P676; Luce MF, 1999, J MARKETING RES, V36, P143, DOI 10.2307/3152089; Goos P, 2010, J STAT PLAN INFER, V140, P851, DOI 10.1016/j.jspi.2009.09.006; Feit EM, 2010, MANAGE SCI, V56, P785, DOI 10.1287/mnsc.1090.1136; Riedl R, 2008, BEHAV RES METHODS, V40, P795, DOI 10.3758/BRM.40.3.795; Martignon L, 2002, THEOR DECIS, V52, P29, DOI 10.1023/A:1015516217425; WRIGHT P, 1975, J MARKETING RES, V12, P60, DOI 10.2307/3150659; Cavagnaro DR, 2010, NEURAL COMPUT, V22, P887, DOI 10.1162/neco.2009.02-09-959; EINHORN HJ, 1981, ANNU REV PSYCHOL, V32, P53, DOI 10.1146/annurev.ps.32.020181.000413; SHUGAN SM, 1980, J CONSUM RES, V7, P99, DOI 10.1086/208799; Garcia-Retamero R, 2007, Q J EXP PSYCHOL, V60, P1197, DOI 10.1080/17470210600937528; Glockner A, 2008, J EXP PSYCHOL LEARN, V34, P1055, DOI 10.1037/0278-7393.34.5.1055; Hoffrage U, 2000, J EXP PSYCHOL LEARN, V26, P566, DOI 10.1037//0278-7393.26.3.566; Myung JI, 2009, PSYCHOL REV, V116, P499, DOI 10.1037/a0016104; Rieskamp J, 2008, ACTA PSYCHOL, V127, P258, DOI 10.1016/j.actpsy.2007.05.004; Fasolo B, 2009, PSYCHOL MARKET, V26, P213, DOI 10.1002/mar.20270; Hauser JR, 2010, J MARKETING RES, V47, P485; Sandor Z, 2005, J MARKETING RES, V42, P210; BETTMAN JR, 1990, ORGAN BEHAV HUM DEC, V45, P111, DOI 10.1016/0749-5978(90)90007-V; DAWES RM, 1979, AM PSYCHOL, V34, P571, DOI 10.1037//0003-066X.34.7.571; Gilbride TJ, 2006, MARKET SCI, V25, P494, DOI 10.1287/mksc.1060.0211; THORNGATE W, 1980, BEHAV SCI, V25, P219, DOI 10.1002/bs.3830250306; Dhami MK, 2001, J BEHAV DECIS MAKING, V14, P141, DOI 10.1002/bdm.371; Broder A, 2000, J EXP PSYCHOL LEARN, V26, P1332, DOI 10.1037/0278-7393.26.5.1332; Rabe-Hesketh S, 2005, J ECONOMETRICS, V128, P301, DOI 10.1016/j.jeconom.2004.08.017; Jasper JD, 2002, BEHAV RES METH INS C, V34, P364, DOI 10.3758/BF03195464; Johnson EJ, 2008, PSYCHOL REV, V115, P263, DOI 10.1037/0033-295X.115.1.263; Arrow K. J., 1951, SOCIAL CHOICE INDIVI; Atkinson A.C., 1992, OPTIMUM EXPT DESIGNS; Back T., 1997, HDB EVOLUTIONARY COM; Ball C, 1997, ORGAN BEHAV HUM DEC, V69, P195, DOI 10.1006/obhd.1997.2681; Ball CT, 1998, ORGAN BEHAV HUM DEC, V76, P70, DOI 10.1006/obhd.1998.2798; BETTMAN JR, 1980, J CONSUM RES, V7, P234, DOI 10.1086/208812; BETTMAN JR, 1993, J EXP PSYCHOL LEARN, V19, P931; BIGGS SF, 1985, MANAGE SCI, V31, P970, DOI 10.1287/mnsc.31.8.970; BOCKENHOLT U, 1991, ORGAN BEHAV HUM DEC, V49, P258, DOI 10.1016/0749-5978(91)90051-T; Broder A, 2003, J BEHAV DECIS MAKING, V16, P193, DOI 10.1002/bdm.442; Cavagnaro D. R., 2013, J RISK INSURANCE UNC, V47, P225; Cavagnaro DR, 2013, MANAGE SCI, V59, P358, DOI 10.1287/mnsc.1120.1558; Chernev A, 2010, J CONSUM RES, V37, P426, DOI 10.1086/655200; COOK GJ, 1993, DECISION SCI, V24, P931, DOI 10.1111/j.1540-5915.1993.tb00497.x; CROW LE, 1980, J MARKETING RES, V17, P34, DOI 10.2307/3151114; Dellaert B. G. C., 1999, MARKET LETT, V10, P139; DeShazo JR, 2002, J ENVIRON ECON MANAG, V44, P123, DOI 10.1006/jeem.2001.1199; Ding M, 2009, MANAGE SCI, V55, P1003, DOI 10.1287/mnsc.1090.1003; Fasolo B, 2005, ADVERT CONS, P325; Fishburn P. C., 1970, UTILITY THEORY DECIS; FISHBURN PC, 1974, MANAGE SCI, V20, P1442, DOI 10.1287/mnsc.20.11.1442; Gigerenzer G., 2001, BOUNDED RATIONALITY; Glockner A, 2009, JUDGM DECIS MAK, V4, P186; Goldberg D. E., 1989, GENETIC ALGORITHMS S; Guo LA, 2010, MANAGE SCI, V56, P1815, DOI 10.1287/mnsc.1100.1200; Harte J. M., 2001, THINK REASONING, V7, P29; HAUSER JR, 1990, J CONSUM RES, V16, P393, DOI 10.1086/209225; Hogarth RM, 2005, MANAGE SCI, V51, P1860, DOI 10.1287/mnsc.1050.0448; Holland J. H., 1975, ADAPTATION NATURAL A; Hunt H. K., 1978, ADV CONSUM RES, P561; Iglesias-Parro S, 2002, THEOR DECIS, V52, P101, DOI 10.1023/A:1015568206548; INADA K, 1964, ECONOMETRICA, V32, P525, DOI 10.2307/1910176; Jekel M, 2011, JUDGM DECIS MAK, V6, P782; Kochenberger GA, 2003, HDB METAHEURISTICS; KUHFELD WF, 1994, J MARKETING RES, V31, P545, DOI 10.2307/3151882; Liu Q, 2011, MARKET SCI, V30, P321, DOI 10.1287/mksc.1100.0629; MONTGOMERY H, 1976, SCAND J PSYCHOL, V17, P283, DOI 10.1111/j.1467-9450.1976.tb00241.x; Payne JW, 1996, ORGAN BEHAV HUM DEC, V66, P131, DOI 10.1006/obhd.1996.0044; Payne J. W., 1993, ADAPTIVE DECISION MA; PAYNE JW, 1988, J EXP PSYCHOL LEARN, V14, P534, DOI 10.1037//0278-7393.14.3.534; PAYNE JW, 1978, ORGAN BEHAV HUM PERF, V22, P17, DOI 10.1016/0030-5073(78)90003-X; Pfeiffer J, 2013, BUS INFORM SYST ENG+, V5, P397, DOI 10.1007/s12599-013-0295-z; Pfeiffer J, 2014, J NEUROSCI PSYCHOL E, V7, P103, DOI 10.1037/npe0000021; Raidl G. R., 2000, P 2000 ACM S APPL CO, P440, DOI 10.1145/335603.335888; Reeves C., 2003, GENETIC ALGORITHMS P; Reisen N, 2008, JUDGM DECIS MAK, V3, P641; Rieskamp J., 1999, SIMPLE HEURISTICS MA; Rothlauf F, 2009, INFORMS J COMPUT, V21, P575, DOI 10.1287/ijoc.1080.0310; RUSSO JE, 1994, J CONSUM RES, V21, P274, DOI 10.1086/209397; SCHMALHOFER F, 1986, Q J EXP PSYCHOL-A, V38, P59; Schulte-Mecklenbeck M, 2011, COMPUT HUM BEHAV, V27, P1771, DOI 10.1016/j.chb.2011.03.004; Schulte-Mecklenbeck M, 2011, HDB PROCESS TRACING; Senter SM, 1999, J EXP PSYCHOL LEARN, V25, P428, DOI 10.1037/0278-7393.25.2.428; Shephard R. N., 1964, HUMAN JUDGMENTS OPTI, P257; Skrondal A, 2003, PSYCHOMETRIKA, V68, P267, DOI 10.1007/BF02294801; stebro T., 2006, MANAGE SCI, V52, P395, DOI [10.1287/mnsc.1050.0468, DOI 10.1287/MNSC.1050.0468]; STONE DN, 1991, ORGAN BEHAV HUM DEC, V49, P42, DOI 10.1016/0749-5978(91)90041-Q; STORER RH, 1992, MANAGE SCI, V38, P1495, DOI 10.1287/mnsc.38.10.1495; Tsetlin I, 2009, MANAGE SCI, V55, P1942, DOI 10.1287/mnsc.1090.1082; Yee M, 2007, MARKET SCI, V26, P532, DOI 10.1287/mksc.1060.0213	101	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-3257	1099-0771		J BEHAV DECIS MAKING	J. Behav. Decis. Mak.	JUL	2015	28	3					262	280		10.1002/bdm.1847		19	Psychology, Applied	Psychology	CL1PW	WOS:000356717200006		
J	Chiu, LD; Palonpon, AF; Smith, NI; Kawata, S; Sodeoka, M; Fujita, K				Chiu, Liang-da; Palonpon, Almar F.; Smith, Nicholas I.; Kawata, Satoshi; Sodeoka, Mikiko; Fujita, Katsumasa			Dual-polarization Raman spectral imaging to extract overlapping molecular fingerprints of living cells	JOURNAL OF BIOPHOTONICS			English	Article						Raman imaging; bio-imaging; polarized Raman; background removal	SPECTROSCOPY; DNA; MICROSCOPY; CYTOCHROME; SCATTERING	Raman spectral imaging is gaining more and more attention in biological studies because of its label-free characteristic. However, the discrimination of overlapping chemical contrasts has been a major challenge. In this study, we introduce an optical method to simultaneously obtain two orthogonally polarized Raman images from a single scan of the sample. We demonstrate how this technique can improve the quality and quantity of the hyperspectral Raman dataset and how the technique is expected to further extend the horizons of Raman spectral imaging in biological studies by providing more detailed chemical information.	[Chiu, Liang-da; Palonpon, Almar F.; Kawata, Satoshi; Fujita, Katsumasa] Osaka Univ, Dept Appl Phys, Suita, Osaka 5650871, Japan; [Palonpon, Almar F.; Sodeoka, Mikiko; Fujita, Katsumasa] Japan Sci & Technol Agcy, ERATO, Sodeoka Live Cell Chem Project, Wako, Saitama 3510198, Japan; [Smith, Nicholas I.] Osaka Univ, Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Sodeoka, Mikiko] RIKEN, Synthet Organ Chem Lab, Wako, Saitama 3510198, Japan	Fujita, K (reprint author), Osaka Univ, Dept Appl Phys, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	fujita@ap.eng.osaka-u.ac.jp	Sodeoka, Mikiko/A-9952-2008	Sodeoka, Mikiko/0000-0002-1344-364X			Shinzawa H, 2009, J RAMAN SPECTROSC, V40, P1720, DOI 10.1002/jrs.2525; Pascut FC, 2013, BBA-GEN SUBJECTS, V1830, P3517, DOI 10.1016/j.bbagen.2013.01.030; Kakita M, 2013, J BIOPHOTONICS, V6, P256, DOI 10.1002/jbio.201200042; Huang CK, 2012, ANAL CHEM, V84, P5661, DOI 10.1021/ac300834f; Palonpon AF, 2013, NAT PROTOC, V8, P677, DOI 10.1038/nprot.2013.030; Uzunbajakava N, 2003, BIOPHYS J, V84, P3968; Hamada K, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2952192; THOMAS GJ, 1995, BIOPHYS J, V68, P1073; Okada M, 2012, P NATL ACAD SCI USA, V109, P28, DOI 10.1073/pnas.1107524108; Carey DM, 1998, J CHEM PHYS, V108, P2669, DOI 10.1063/1.475659; Huang WE, 2004, ANAL CHEM, V76, P4452, DOI 10.1021/ac049753k; Huang YS, 2005, BIOCHEMISTRY-US, V44, P10009, DOI 10.1021/bi050179w; Bernath P., 2005, SPECTRA ATOMS MOL, P293; Brautigam K, 2013, CHEMPHYSCHEM, V14, P550, DOI 10.1002/cphc.201200800; Chiu L. -d., 2013, P SOC PHOTO-OPT INS, V8587; Lim NSJ, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3528006; Ko ACT, 2006, OPT EXPRESS, V14, P203, DOI 10.1364/OPEX.14.000203; Matthaus C, 2012, ANAL CHEM, V84, P8549, DOI 10.1021/ac3012347; Saito Y, 2008, J RAMAN SPECTROSC, V39, P1643, DOI 10.1002/jrs.1953; SPIRO TG, 1972, P NATL ACAD SCI USA, V69, P2622, DOI 10.1073/pnas.69.9.2622; Thomson GA, 2003, J RAMAN SPECTROSC, V34, P345, DOI 10.1002/jrs.991; UEDA T, 1993, BIOPOLYMERS, V33, P1791, DOI 10.1002/bip.360331205	22	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	JUL	2015	8	7					546	554		10.1002/jbio.201300204		9	Biochemical Research Methods; Biophysics; Optics	Biochemistry & Molecular Biology; Biophysics; Optics	CL9WT	WOS:000357330000002		
J	Nagata, T; Hirai, Y; Wang, YC; Nohara, T				Nagata, Tomoki; Hirai, Yasutaka; Wang, Yuncong; Nohara, Toshio			Acute Diastolic Heart Dysfunction Caused by Ruptured Descending Thoracic Aortic Aneurysm with Posterior Mediastinal Hematoma	JOURNAL OF CARDIAC SURGERY			English	Editorial Material									[Nagata, Tomoki; Hirai, Yasutaka; Wang, Yuncong] Nozaki Tokushukai Hosp, Dept Cardiovasc Surg, Daito, Osaka 5740074, Japan; [Nohara, Toshio] Nozaki Tokushukai Hosp, Dept Anesthesiol, Daito, Osaka 5740074, Japan	Nagata, T (reprint author), Nozaki Tokushukai Hosp, Dept Cardiovasc Surg, 2-10-50 Tanigawa, Daito, Osaka 5740074, Japan.	over-drive-tmk@hotmail.co.jp						0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0886-0440	1540-8191		J CARDIAC SURG	J. Card. Surg.	JUL	2015	30	7					589	590		10.1111/jocs.12553		2	Cardiac & Cardiovascular Systems; Surgery	Cardiovascular System & Cardiology; Surgery	CL9UM	WOS:000357323600010		
J	Osawa, K; Miyoshi, T; Morimitsu, Y; Akagi, T; Oe, H; Nakagawa, K; Takaya, Y; Kijima, Y; Sato, S; Kanazawa, S; Ito, H				Osawa, Kazuhiro; Miyoshi, Toru; Morimitsu, Yusuke; Akagi, Teiji; Oe, Hiroki; Nakagawa, Koji; Takaya, Yoichi; Kijima, Yasufumi; Sato, Shuhei; Kanazawa, Susumu; Ito, Hiroshi			Comprehensive assessment of morphology and severity of atrial septal defects in adults by CT	JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY			English	Article						Cardiac computed tomography; Atrial septum defect; Echocardiography; Structural heart disease; Congenital heart disease	CONGENITAL HEART-DISEASE; TRANSTHORACIC ECHOCARDIOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSCATHETER CLOSURE; PERCUTANEOUS CLOSURE; COMPUTED-TOMOGRAPHY; OCCLUDER; CHILDREN; TRIAL	Background: Cardiac CT is an excellent tool for evaluating the anatomy of a secundum atrial septal defect (ASD). However, a comprehensive assessment of its usefulness, including measurement of the pulmonary to systemic blood flow ratio in secundum ASD patients, has not been performed. Objective: Therefore, this study was designed to evaluate the usefulness of CT for assessing the hemodynamics of secundum ASD in adults compared with transesophageal echocardiography (TEE), transthoracic echocardiography, and invasive catheterization. Methods: Fifty adult patients with secundum ASD were enrolled. Cardiac CT scans (128-slice multidetector CT instrument) were acquired. These were followed by 2-dimensional reconstruction of the secundum ASDs to determine the defect size, the rim length between the outer edge of the defect, and the pulmonary to systemic blood flow (Qp/Qs) ratio. Results: The maximum sizes of the secundum ASDs derived from CT and TEE studies were comparable (21.2 +/- 8.0 vs 20.0 +/- 7.3 mm; P = .41; r = 0.960; P < .001). The rim lengths for the aortic, mitral, and tricuspid valves; the inferior vena cava; and posterior atrium were also comparable between CT and TEE measurements. The mean Qp/Qs ratio that was derived from CT measurements was comparable with that found by invasive catheterization (2.3 +/- 0.7 vs 2.3 +/- 0.8; P = .73; r = 0.786; P < .001). Conclusion: Cardiac CT is feasible for assessing pathology and the severity of secundum ASD in adults. (C) 2015 Society of Cardiovascular Computed Tomography. All rights reserved.	[Osawa, Kazuhiro; Miyoshi, Toru; Nakagawa, Koji; Takaya, Yoichi; Kijima, Yasufumi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cardiovasc Med, Okayama 7008558, Japan; [Morimitsu, Yusuke; Sato, Shuhei; Kanazawa, Susumu; Ito, Hiroshi] Okayama Univ Hosp, Dept Radiol, Okayama, Japan; [Akagi, Teiji] Okayama Univ Hosp, Div Cardiac Intens Care Unit, Okayama, Japan; [Oe, Hiroki] Okayama Univ Hosp, Ctr Ultrason Diagnost, Okayama, Japan	Miyoshi, T (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cardiovasc Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	miyoshit@cc.okayama-u.ac.jp					Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3; Jones TK, 2007, J AM COLL CARDIOL, V49, P2215, DOI 10.1016/j.jacc.2006.11.053; Majunke N, 2009, AM J CARDIOL, V103, P550, DOI 10.1016/j.amjcard.2008.10.018; Du ZD, 2002, J AM COLL CARDIOL, V39, P1836, DOI 10.1016/S0735-1097(02)01862-4; Hausleiter J, 2006, CIRCULATION, V113, P1305, DOI 10.1161/CIRCULATIONAHA.105.602490; Ko SF, 2009, AM J ROENTGENOL, V193, P1522, DOI 10.2214/AJR.09.2854; Bartakian S, 2013, JACC-CARDIOVASC INTE, V6, P974, DOI 10.1016/j.jcin.2013.05.007; Goo HW, 2005, INT J CARDIOVAS IMAG, V21, P347, DOI 10.1007/s10554-004-4015-0; Goo HW, 2005, INT J CARDIOVAS IMAG, V21, P367; Johri AM, 2011, HEART, V97, P1441, DOI 10.1136/hrt.2010.205732; Lee T, 2006, PEDIATR RADIOL, V36, P1273, DOI 10.1007/s00247-006-0315-y; Opotowsky AR, 2008, JAMA-J AM MED ASSOC, V299, P521, DOI 10.1001/jama.299.5.521; Osawa K, 2014, HEART, V100, P1008, DOI 10.1136/heartjnl-2013-305468; Osawa K, 2013, CIRC J, V77, P146, DOI 10.1253/circj.CJ-12-0663; Warnes CA, 2008, J AM COLL CARDIOL, V52, pE1, DOI 10.1016/j.jacc.2008.10.001; Watanabe N, 2012, J AM SOC ECHOCARDIOG, V25, P376, DOI 10.1016/j.echo.2012.01.002; WATANABE T, 1982, AM J CARDIOL, V49, P1946, DOI 10.1016/0002-9149(82)90214-4	17	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-5925			J CARDIOVASC COMPUT	J. Cardiovasc. Comput. Tomogr.	JUL-AUG	2015	9	4					354	361		10.1016/j.jcct.2015.04.007		8	Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging	Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging	CL7JL	WOS:000357148200018		
J	Kugimiya, N; Nishimoto, A; Hosoyama, T; Ueno, K; Enoki, T; Li, TS; Hamano, K				Kugimiya, Naruji; Nishimoto, Arata; Hosoyama, Tohru; Ueno, Koji; Enoki, Tadahiko; Li, Tao-Sheng; Hamano, Kimikazu			The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracilresistance in human colon cancer cells	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						c-MYC; ABCB5; 5-fluorouracil resistance; colon cancer	CASSETTE TRANSPORTER GENES; HUMAN COLORECTAL-CANCER; TUMOR-CELLS; ABC TRANSPORTERS; MYC ONCOPROTEIN; EXPRESSION; RESISTANCE; CHEMORESISTANCE; CARCINOMA; CHEMOSENSITIVITY	c-MYC overexpression is frequently observed in various cancers including colon cancer and regulates many biological activities such as aberrant cell proliferation, apoptosis, genomic instability, immortalization and drug resistance. However, the mechanism by which c-MYC confers drug resistance remains to be fully elucidated. In this study, we found that the c-MYC expression level in primary colorectal cancer tissues correlated with the recurrence rate following 5-fluorouracil (5-FU)-based adjuvant chemotherapy. Supporting this finding, overexpression of exogenous c-MYC increased the survival rate following 5-FU treatment in human colon cancer cells, and knockdown of endogenous c-MYC decreased it. Furthermore, c-MYC knockdown decreased the expression level of ABCB5, which is involved in 5-FU resistance. Using a chromatin immunoprecipitation assay, we found that c-MYC bound to the ABCB5 promoter region. c-MYC inhibitor (10058-F4) treatment inhibited c-MYC binding to the ABCB5 promoter, leading to a decrease in ABCB5 expression level. ABCB5 knockdown decreased the survival rate following 5-FU treatment as expected, and the ABCB5 expression level was increased in 5-FU-resistant human colon cancer cells. Finally, using a human colon cancer xenograft murine model, we found that the combined 5-FU and 10058-F4 treatment significantly decreased tumorigenicity in nude mice compared with 5-FU or 10058-F4 treatment alone. 10058-F4 treatment decreased the ABCB5 expression level in the presence or absence of 5-FU. In contrast, 5-FU treatment alone increased the ABCB5 expression level. Taken together, these results suggest that c-MYC confers resistance to 5-FU through regulating ABCB5 expression in human colon cancer cells.	[Kugimiya, Naruji; Nishimoto, Arata; Hosoyama, Tohru; Ueno, Koji; Enoki, Tadahiko; Hamano, Kimikazu] Yamaguchi Univ, Grad Sch Med, Dept Surg & Clin Sci, Ube, Yamaguchi 7558505, Japan; [Li, Tao-Sheng] Nagasaki Univ, Atom Bomb Dis Inst, Dept Stem Cell Biol, Nagasaki 852, Japan	Nishimoto, A (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Surg & Clin Sci, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	anishimo@yamaguchi-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [24791425]; Takeda Science Foundation of Japan	This study was supported by Grant-in-Aid for Young Scientific Research (B) (no. 24791425 to A. Nishimoto) from the Japan Society for the Promotion of Science (JSPS) and by a grant from the Takeda Science Foundation of Japan. The authors thank Dr. Y. Mizukami (Yamaguchi University Center for Gene Research, Ube, Japan) for donating the c-MYC expression vector. We also thank Dr. K. Ueki (Yamaguchi Saiseikai Shimonoseki General Hospital, Shimonoseki, Japan) and Dr. C. Kato (Yamaguchi Rosai Hospital, Sanyo-Onoda, Japan) for their assistance in acquiring samples and collecting information from colorectal cancer patients.	Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Nishimoto A, 2014, INT J ONCOL, V44, P2077, DOI 10.3892/ijo.2014.2367; Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; FINLEY GG, 1989, ONCOGENE, V4, P963; Pratt S, 2005, MOL CANCER THER, V4, P855, DOI 10.1158/1535-7163.MCT-04-0291; Hagmann W, 2009, PANCREATOLOGY, V9, P136, DOI 10.1159/000178884; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Porro A, 2011, MOL CANCER RES, V9, P1054, DOI 10.1158/1541-7786.MCR-10-0510; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Abaza MSI, 2008, TUMOR BIOL, V29, P287, DOI 10.1159/000156706; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Hlavata I, 2012, MUTAGENESIS, V27, P187, DOI 10.1093/mutage/ger075; Nishimoto A, 2013, BIOCHEM BIOPH RES CO, V438, P513, DOI 10.1016/j.bbrc.2013.07.105; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Yuan JH, 2009, CANCER CHEMOTH PHARM, V63, P1103, DOI 10.1007/s00280-008-0838-z; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Walker TL, 1996, BRIT J CANCER, V73, P610, DOI 10.1038/bjc.1996.105; Cao YT, 2013, CANCER RES, V73, P6230, DOI 10.1158/0008-5472.CAN-12-1345; Huang Y, 2006, CANCER LETT, V239, P168, DOI 10.1016/j.canlet.2005.07.032; PARK JG, 1990, J NATL CANCER I, V82, P193, DOI 10.1093/jnci/82.3.193; Pyndiah S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001556; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1582-4934			J CELL MOL MED	J. Cell. Mol. Med.	JUL	2015	19	7					1569	1581		10.1111/jcmm.12531		13	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	CL5VU	WOS:000357031200013		
J	Shimada, K; Furukawa, H; Wada, K; Wei, Y; Tada, Y; Kuwabara, A; Shikata, F; Kanematsu, Y; Lawton, MT; Kitazato, KT; Nagahiro, S; Hashimoto, T				Shimada, Kenji; Furukawa, Hajime; Wada, Kosuke; Wei, Yuan; Tada, Yoshiteru; Kuwabara, Atsushi; Shikata, Fumiaki; Kanematsu, Yasuhisa; Lawton, Michael T.; Kitazato, Keiko T.; Nagahiro, Shinji; Hashimoto, Tomoki			Angiotensin-(1-7) protects against the development of aneurysmal subarachnoid hemorrhage in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						inflammation; Intracranial aneurysm; stroke; subarachnoid hemorrhage	TYPE-1 RECEPTOR BLOCKADE; CONVERTING ENZYME 2; INTRACRANIAL ANEURYSMS; RUPTURE; MAS; HYPERTENSION; ACTIVATION; INVOLVEMENT; PROGRESSION; AGENT	Angiotensin-(1-7) (Ang-(1-7)) can regulate vascular inflammation and remodeling, which are processes that have important roles in the pathophysiology of intracranial aneurysms. In this study, we assessed the effects of Ang-(1-7) in the development of intracranial aneurysm rupture using a mouse model of intracranial aneurysms in which aneurysmal rupture (i.e., aneurysmal subarachnoid hemorrhage) occurs spontaneously and causes neurologic symptoms. Treatment with Ang-(1-7) (0.5 mg/kg/day), Mas receptor antagonist (A779 0.5 mg/kg/day or 2.5 mg/kg/day), or angiotensin II type 2 receptor (AT2R) antagonist (PD 123319, 10 mg/kg/day) was started 6 days after aneurysm induction and continued for 2 weeks. Angiotensin-(1-7) significantly reduced the rupture rate of intracranial aneurysms without affecting the overall incidence of aneurysms. The protective effect of Ang-(1-7) was blocked by the AT2R antagonist, but not by the Mas receptor antagonist. In AT2R knockout mice, the protective effect of Ang-(1-7) was absent. While AT2R mRNA was abundantly expressed in the cerebral arteries and aneurysms, Mas receptor mRNA expression was very scarce in these tissues. Angiotensin-(1-7) reduced the expression of tumor necrosis factor-a and interleukin-1 beta in cerebral arteries. These findings indicate that Ang-(1-7) can protect against the development of aneurysmal rupture in an AT2R-dependent manner.	[Shimada, Kenji; Furukawa, Hajime; Wada, Kosuke; Wei, Yuan; Kuwabara, Atsushi; Shikata, Fumiaki; Hashimoto, Tomoki] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94110 USA; [Shimada, Kenji; Tada, Yoshiteru; Kanematsu, Yasuhisa; Kitazato, Keiko T.; Nagahiro, Shinji] Univ Tokushima, Sch Med, Dept Neurosurg, Tokushima 770, Japan; [Lawton, Michael T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA	Hashimoto, T (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 1001 Potrero Ave,3C-38, San Francisco, CA 94110 USA.	hashimot@anesthesia.ucsf.edu			National Institute of Neurological Disorders and Stroke (NIH/NINDS) [R01NS055876, R01NS082280]; Brain Aneurysm Foundation Shirley Dudek Demmer Chair of Research	The project described was supported by R01NS055876 (TH) and R01NS082280 (TH) from the National Institute of Neurological Disorders and Stroke (NIH/NINDS), and the Brain Aneurysm Foundation Shirley Dudek Demmer Chair of Research (KS).	Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f; Xia HJ, 2009, HYPERTENSION, V53, P210, DOI 10.1161/HYPERTENSIONAHA.108.123844; Moriwaki T, 2006, STROKE, V37, P900, DOI 10.1161/01.STR.0000204028.39783.d9; Hasan DM, 2011, STROKE, V42, P3156, DOI 10.1161/STROKEAHA.111.619411; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Hashimoto T, 2006, NEUROL RES, V28, P372, DOI 10.1179/016164106X14973; Tada Y, 2014, STROKE, V45, P579, DOI 10.1161/STROKEAHA.113.003072; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Iwai M, 2012, HYPERTENSION, V60, P137, DOI 10.1161/HYPERTENSIONAHA.112.191452; Ohshima K, 2014, HYPERTENSION, V63, pE53, DOI 10.1161/HYPERTENSIONAHA.113.02426; Walters PE, 2005, HYPERTENSION, V45, P960, DOI 10.1161/01.HYP.0000160325.59323.b8; Pinto YM, 1998, CARDIOVASC RES, V39, P77, DOI 10.1016/S0008-6363(98)00077-7; Nuki Y, 2009, HYPERTENSION, V54, P1337, DOI 10.1161/HYPERTENSIONAHA.109.138297; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Tesanovic S, 2010, ARTERIOSCL THROM VAS, V30, P1606, DOI 10.1161/ATVBAHA.110.204453; Ferrario CM, 2010, HYPERTENSION, V55, P445, DOI 10.1161/HYPERTENSIONAHA.109.145839; Starke RM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-77; Donoghue M, 2000, CIRC RES, V87, pE1; Elliott KJ, 2013, HYPERTENSION, V61, pE31, DOI 10.1161/HYPERTENSIONAHA.111.00943; Faria-Silva R, 2005, HYPERTENSION, V46, P948, DOI 10.1161/01.HYP.0000174594.17052.33; Yang JM, 2013, ARTERIOSCL THROM VAS, V33, P1978, DOI 10.1161/ATVBAHA.113.301320; Bosnyak S, 2012, J HYPERTENS, V2012; Castro Carlos Henrique de, 2005, Hypertension, V46, P937; Hafko R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069234; Hosaka K, 2014, J NEUROINTERV SURG, V6, P474, DOI 10.1136/neurintsurg-2013-010788; Kanematsu Y, 2011, STROKE, V42, P173, DOI 10.1161/STROKEAHA.110.590976; Lara LD, 2006, BIOCHEM J, V395, P183, DOI 10.1042/BJ20051455; Makino H, 2012, STROKE, V43, P2450, DOI 10.1161/STROKEAHA.112.659821	28	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2015	35	7					1163	1168		10.1038/jcbfm.2015.30		6	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CL7FI	WOS:000357137500014		
J	Park, HS; Lee, S; Son, SW; Feldstein, SB; Kosaka, Y				Park, Hyo-Seok; Lee, Sukyoung; Son, Seok-Woo; Feldstein, Steven B.; Kosaka, Yu			The Impact of Poleward Moisture and Sensible Heat Flux on Arctic Winter Sea Ice Variability*	JOURNAL OF CLIMATE			English	Article							LONGWAVE RADIATION; OBSERVATIONAL DATA; BARENTS SEA; OSCILLATION; REANALYSIS; SYSTEM; TRENDS; EXTENT; MODEL; MJO	The surface warming in recent decades has been most rapid in the Arctic, especially during the winter. Here, by utilizing global reanalysis and satellite datasets, it is shown that the northward flux of moisture into the Arctic during the winter strengthens the downward infrared radiation (IR) by 30-40 W m(-2) over 1-2 weeks. This is followed by a decline of up to 10% in sea ice concentration over the Greenland, Barents, and Kara Seas. A climate model simulation indicates that the wind-induced sea ice drift leads the decline of sea ice thickness during the early stage of the strong downward IR events, but that within one week the cumulative downward IR effect appears to be dominant. Further analysis indicates that strong downward IR events are preceded several days earlier by enhanced convection over the tropical Indian and western Pacific Oceans. This finding suggests that sea ice predictions can benefit from an improved understanding of tropical convection and ensuing planetary wave dynamics.	[Park, Hyo-Seok] Korea Inst Geosci & Mineral Resources, Taejon, South Korea; [Lee, Sukyoung; Son, Seok-Woo] Seoul Natl Univ, Sch Earth & Environm Sci, Seoul, South Korea; [Lee, Sukyoung; Feldstein, Steven B.] Penn State Univ, Dept Meteorol, University Pk, PA 16802 USA; [Kosaka, Yu] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan	Lee, S (reprint author), Penn State Univ, Dept Meteorol, 503 Walker Bldg, University Pk, PA 16802 USA.	sxl31@psu.edu	Kosaka, Yu/C-2792-2009; Son, Seok-Woo /A-8797-2013		Korea Institute of Geoscience and Mineral Resources (KIGAM) - Ministry of Knowledge Economy of Korea; National Research Foundation of Korea (NRF) - Ministry of Education [2013R1A1A1006530]; Seoul National University, South Korea; NSF, USA [AGS-1036858, AGS-1401220]; Japanese Ministry of Environment through the Environment Research and Technology Development Fund [A-1201]; Japan Society for the Promotion of Science [25287120]	We thank the editor and anonymous reviewers for their constructive comments. HSP is supported by the Basic Research Project of the Korea Institute of Geoscience and Mineral Resources (KIGAM) funded by the Ministry of Knowledge Economy of Korea. SWS's work is supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013R1A1A1006530). SL is supported by Seoul National University, South Korea. SBF is supported by NSF Grants AGS-1036858 and AGS-1401220, USA. YK is supported by the Japanese Ministry of Environment through the Environment Research and Technology Development Fund A-1201 and by the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research 25287120.	Johnson NC, 2008, J CLIMATE, V21, P6354, DOI 10.1175/2008JCLI2380.1; Bekryaev RV, 2010, J CLIMATE, V23, P3888, DOI 10.1175/2010JCLI3297.1; Dee DP, 2011, Q J ROY METEOR SOC, V137, P553, DOI 10.1002/qj.828; Liptak J, 2014, J CLIMATE, V27, P914, DOI 10.1175/JCLI-D-13-00186.1; Deser C, 2000, J CLIMATE, V13, P617, DOI 10.1175/1520-0442(2000)013<0617:ASIVIT>2.0.CO;2; Yoo C, 2012, J ATMOS SCI, V69, P2379, DOI 10.1175/JAS-D-11-0261.1; Rigor IG, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019492; Yoo C, 2012, J CLIMATE, V25, P5777, DOI 10.1175/JCLI-D-11-00566.1; Renner AHH, 2014, GEOPHYS RES LETT, V41, P5029, DOI 10.1002/2014GL060369; Donner LJ, 2011, J CLIMATE, V24, P3484, DOI 10.1175/2011JCLI3955.1; Chen YW, 2006, MINER ENG, V19, P19, DOI 10.1016/j.mineng.2005.04.007; Uttal T, 2002, B AM METEOROL SOC, V83, P255, DOI 10.1175/1520-0477(2002)083<0255:SHBOTA>2.3.CO;2; FANG ZF, 1994, J CLIMATE, V7, P1897, DOI 10.1175/1520-0442(1994)007<1897:ASIVOA>2.0.CO;2; Sorteberg A, 2006, J CLIMATE, V19, P4772, DOI 10.1175/JCLI3885.1; Woods C, 2013, GEOPHYS RES LETT, V40, P4717, DOI 10.1002/grl.50912; Holland MM, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL028024; Liebmann B, 1996, B AM METEOROL SOC, V77, P1275; Onogi K, 2007, J METEOROL SOC JPN, V85, P369, DOI 10.2151/jmsj.85.369; Lee S, 2013, SCIENCE, V339, P563, DOI 10.1126/science.1225154; Hansen E, 2013, J GEOPHYS RES-OCEANS, V118, P5202, DOI 10.1002/jgrc.20393; Lee S, 2011, J CLIMATE, V24, P4350, DOI 10.1175/2011JCLI4003.1; Walsh JE, 1998, J CLIMATE, V11, P3030, DOI 10.1175/1520-0442(1998)011<3030:ACRTAI>2.0.CO;2; Ding QH, 2014, NATURE, V509, P209, DOI 10.1038/nature13260; Winton M, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL028017; Eisenman I, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD016164; Francis J. A., 2006, T AM GEOPHYS UNION, V87, P509, DOI [10.1029/2006EO460001, DOI 10.1029/2006EO460001]; Gorodetskaya I. V., 2008, ARCTIC SEA ICE DECLI, V180, P213; Henderson GR, 2014, CLIM DYNAM, V43, P2185, DOI 10.1007/s00382-013-2043-y; Kwok R, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024485; Morcrette JJ, 2002, J CLIMATE, V15, P1875, DOI 10.1175/1520-0442(2002)015<1875:TSDLRI>2.0.CO;2; Rigor IG, 2002, J CLIMATE, V15, P2648, DOI 10.1175/1520-0442(2002)015<2648:ROSITT>2.0.CO;2; Skific N, 2013, J GEOPHYS RES-ATMOS, V118, P2748, DOI 10.1002/jgrd.50292; Smith R, 2010, LAUR1001853 LOS AL N; SWIFT CT, 1985, EOS T AM GEOPHYS UNI, V0066; THORNDIKE AS, 1992, J GEOPHYS RES-OCEANS, V97, P9401, DOI 10.1029/92JC00695; Zhang JL, 2003, MON WEATHER REV, V131, P845, DOI 10.1175/1520-0493(2003)131<0845:MGSIWA>2.0.CO;2	36	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0894-8755	1520-0442		J CLIMATE	J. Clim.	JUL	2015	28	13					5030	5040		10.1175/JCLI-D-15-0074.1		11	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CM2BX	WOS:000357485700002		
J	Yamazaki, N; Kiyohara, Y; Sugaya, N; Uhara, H				Yamazaki, Naoya; Kiyohara, Yoshio; Sugaya, Naofumi; Uhara, Hisashi			Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V600) mutations	JOURNAL OF DERMATOLOGY			English	Article						BRAF; clinical trial; Japanese; melanoma; phase I/II; vemurafenib	BRAF V600E MUTATION; SELECTIVE INHIBITOR; METASTATIC MELANOMA; OPEN-LABEL; RAF; SORAFENIB; KINASE	We investigated the efficacy and safety of vemurafenib in Japanese patients with unresectable or recurrent melanoma with BRAF(V600) mutations. This was a two-step open-label multicenter phase I/II study. Step 1 evaluated the initial safety of vemurafenib 960mg administrated p.o. twice daily in three patients. In step 2, eight patients received vemurafenib 960mg administrated p.o. twice daily for 28-day treatment cycles; the primary outcome measure was response rate, as determined by independent review committee using Response Evaluation Criteria in Solid Tumors version 1.1. Adverse events (AE) experienced by five or more patients were arthralgia (n=10), myalgia (n=8), alopecia (n=7), and rash, maculopapular rash and decreased appetite (n=5 each). Three patients had grade 3 AE. One serious AE occurred in one patient (abnormal hepatic function). Six patients required dose reduction because of AE. One patient died within 28days after the last dose, but death was caused by disease progression and not associated with the study drug. In the eight patients in step 2, overall response rate was 75.0%, none had a complete response and six had a partial response (75.0%). Median response duration was 240.0days, disease control rate 87.5%, median progression-free survival 416.0days and median overall survival 443.0days. In conclusion, vemurafenib treatment resulted in an overall response rate of 75% in Japanese patients with metastatic melanoma with BRAF(V600) mutations. All toxicities were manageable.	[Yamazaki, Naoya] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo 1040045, Japan; [Kiyohara, Yoshio] Shizuoka Canc Ctr, Dept Dermatol, Shizuoka, Japan; [Sugaya, Naofumi] Chugai Pharmaceut, Tokyo, Japan; [Uhara, Hisashi] Shinshu Univ, Sch Med, Dept Dermatol, Nagano, Japan	Yamazaki, N (reprint author), Natl Canc Ctr, Dept Dermatol Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	nyamazak@ncc.go.jp			Chugai Pharmaceutical	We thank the patients, their families and all of the investigators who participated in the study. Medical editorial assistance was provided by Nature Japan KK (Macmillan Medical Communications Tokyo, Japan) and funded by Chugai Pharmaceutical.	Anderson S, 2012, ARCH PATHOL LAB MED, V136, P1385, DOI 10.5858/arpa.2011-0505-OA; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Kwon EJ, 2009, J AM ACAD DERMATOL, V61, P522, DOI 10.1016/j.jaad.2008.10.043; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Ashida A, 2012, J DERMATOL SCI, V66, P240, DOI 10.1016/j.jdermsci.2012.03.005; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Uhara H, 2009, INT J CLIN ONCOL, V14, P490, DOI 10.1007/s10147-009-0941-0; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Anforth RM, 2012, BRIT J DERMATOL, V167, P1153, DOI 10.1111/j.1365-2133.2012.11155.x; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Grippo JF, 2014, CANCER CHEMOTH PHARM, V73, P103, DOI 10.1007/s00280-013-2324-5; Shull AY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043369; Sigrun H, 2014, ASCO2014; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Takata M, 2007, SHINSHU MED J, V55, P3; Williams VL, 2011, INT J DERMATOL, V50, P396, DOI 10.1111/j.1365-4632.2010.04822.x; Yamazaki N, 2015, MELANOMA RES, V25, P9, DOI 10.1097/CMR.0000000000000091	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					661	666		10.1111/1346-8138.12873		6	Dermatology	Dermatology	CL9VZ	WOS:000357327600001		
J	Misago, N; Inoue, T; Nagase, K; Tsuruta, N; Tara-Hashimoto, A; Kimura, H; Takahara, K; Narita, T; Narisawa, Y				Misago, Noriyuki; Inoue, Takuya; Nagase, Kotaro; Tsuruta, Noriko; Tara-Hashimoto, Akiko; Kimura, Hiromi; Takahara, Kanako; Narita, Tomomi; Narisawa, Yutaka			Crater/ulcerated form of infundibular squamous cell carcinoma: A possible distinct entity as a malignant (or high-grade) counterpart to keratoacanthoma	JOURNAL OF DERMATOLOGY			English	Article						follicular squamous cell carcinoma; infundibular squamous cell carcinoma; keratoacanthoma; keratoacanthoma with malignant transformation; keratoacanthoma-like squamous cell carcinoma	SOLITARY KERATOACANTHOMA; RECOGNIZED NEOPLASM; DIFFERENTIATION	Follicular squamous cell carcinoma (SCC) with infundibular differentiation includes the common and crater forms of infundibular SCC. We previously considered the crater/ulcerated infundibular SCC to be a progressive condition of the common form and histopathologically studied an additional five cases of the crater/ulcerated infundibular SCC, the results of which suggested the following characteristic histopathological features and possible developmental process in this type of SCC: (i) a considerable number of continuous hyperplastic follicular infundibula, which may develop at the beginning of the disease; (ii) hyperplastic infundibula exhibiting an abrupt or gradual transition to the SCC component, which frequently change relative to the neoplastic infundibular canal; and (iii) the presence of multiple sites of branching of the neoplastic infundibular canals and/or complete involvement of large cysts in the neoplastic process over the center of the lesion, resulting in ulceration. Based on these histopathological findings, we considered that crater/ulcerated infundibular SCC involve a considerable number of continuous follicular infundibula from the start, although some cases may develop from the common form. We also emphasize the possible aggressive biological behavior of the crater/ulcerated form. Keratoacanthoma (KA) is a unique, benign or borderline malignant neoplasm exhibiting follicular (infundibular/isthmic) differentiation characterized by the involvement of continuous follicular infundibula in multiples. From this standpoint, we consider that crater/ulcerated infundibular SCC is possibly related to KA in terms of histogenesis and is a malignant (or high-grade) counterpart of KA.	[Misago, Noriyuki; Inoue, Takuya; Nagase, Kotaro; Tsuruta, Noriko; Tara-Hashimoto, Akiko; Kimura, Hiromi; Takahara, Kanako; Narita, Tomomi; Narisawa, Yutaka] Saga Univ, Div Dermatol, Dept Internal Med, Fac Med, Saga 8498501, Japan	Misago, N (reprint author), Saga Univ, Div Dermatol, Dept Internal Med, Fac Med, 5-1-1 Nabeshima, Saga 8498501, Japan.	misago@post.saga-med.ac.jp					Weedon DD, 2010, AM J DERMATOPATH, V32, P423, DOI 10.1097/DAD.0b013e3181c4340a; SCHWARTZ RA, 1994, J AM ACAD DERMATOL, V30, P1; ROOK A, 1979, BRIT J DERMATOL, V100, P41, DOI 10.1111/j.1365-2133.1979.tb03568.x; Savage JA, 2014, AM J DERMATOPATH, V36, P422, DOI 10.1097/DAD.0000000000000031; Beham A, 1998, Adv Anat Pathol, V5, P269, DOI 10.1097/00125480-199809000-00001; Carr RA, 2014, DIAGN HISTOPATHOL, V20, P289; Diaz-Cascajo C, 2004, J CUTAN PATHOL, V31, P19, DOI 10.1046/j.0303-6987.2004.0134.x; Forslund O, 2004, J CUTAN PATHOL, V31, P292, DOI 10.1111/j.0303-6987.2003.0150b.x; HODAK E, 1993, AM J DERMATOPATH, V15, P332, DOI 10.1097/00000372-199308000-00007; Kossard S, 2008, AM J DERMATOPATH, V30, P127, DOI 10.1097/DAD.0b013e318161310c; Kossard S, 2012, AM J DERMATOPATH, V34, P675, DOI 10.1097/DAD.0b013e31823fd78b; Mandrell JC, 2009, SEMIN DIAGN PATHOL, V26, P150, DOI 10.1053/j.semdp.2009.09.003; Misago N, 2012, CLIN EXP DERMATOL, V37, P484, DOI 10.1111/j.1365-2230.2012.04366.x; Misago N, 2014, J DERMATOL, V41, P430, DOI 10.1111/1346-8138.12454; Misago N, 2011, AM J DERMATOPATH, V33, P687, DOI 10.1097/DAD.0b013e318205b2c5; Misago N, 2013, J DERMATOL, V40, P443, DOI 10.1111/1346-8138.12104; Misago N, 2014, J CUTAN PATHOL, V41, P437, DOI 10.1111/cup.12317; Shendrik I, 2013, BRIT J DERMATOL, V169, P384, DOI 10.1111/bjd.12374; Takai T, 2015, J DERMATOL, V42, P353, DOI 10.1111/1346-8138.12784; Yus ES, 2000, AM J DERMATOPATH, V22, P305, DOI 10.1097/00000372-200008000-00002	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					667	673		10.1111/1346-8138.12871		7	Dermatology	Dermatology	CL9VZ	WOS:000357327600002		
J	Saleh, MA; Hashimoto, R; Kase, Y; Amagai, M; Yamagami, J				Saleh, Marwah A.; Hashimoto, Rena; Kase, Yuko; Amagai, Masayuki; Yamagami, Jun			Low pathogenicity of anti-desmoglein 3 immunoglobulin G autoantibodies contributes to the atypical clinical phenotypes in pemphigus	JOURNAL OF DERMATOLOGY			English	Article						autoantibodies; desmogleins; pathogenicity; pemphigus	CUTANEOUS TYPE; VULGARIS; FOLIACEUS; LESIONS	The clinical phenotypes of pemphigus can be explained by the desmoglein (Dsg) compensation theory. However, some atypical cases such as cutaneous pemphigus vulgaris (cPV), in which patients have anti-Dsg3 antibodies without oral erosions, do not conform to this theory. To explain the discrepancy between clinical phenotypes and anti-Dsg antibody profiles, the pathogenic strength of immunoglobulin (Ig)G autoantibodies against Dsg3 must be taken into consideration. We analyzed the epitopes and blister-inducing pathogenic strength of the sera from three patients having IgG against Dsg3 without oral erosions with domain-swapped recombinant proteins and dissociation assay using cultured normal human epidermal keratinocytes. The results showed that all sera contained IgG directed against the amino terminal EC1 domain of Dsg3, as is found in most PV sera. However, dissociation assays revealed that the pathogenic strength of the anti-Dsg3 antibodies in all three cases was extremely lower than that of typical PV cases with mucosal involvement. In conclusion, when anti-Dsg3 IgG antibodies are not sufficient to inhibit the expression of Dsg3 in the oral mucosa, but can inhibit the expression in the skin, skin blisters can result. Therefore, the pathogenicity of anti-Dsg3 antibodies should be regarded as a key factor contributing to the clinical phenotype in pemphigus patients with conflicting antibody profiles.	[Saleh, Marwah A.; Hashimoto, Rena; Kase, Yuko; Amagai, Masayuki; Yamagami, Jun] Keio Univ, Sch Med, Dept Dermatol, Tokyo 1608582, Japan; [Kase, Yuko] Japan Blood Prod Org, Cent Res Lab, Kobe, Hyogo, Japan; [Saleh, Marwah A.] Cairo Univ, Sch Med, Dept Dermatol, Cairo, Egypt	Yamagami, J (reprint author), Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yamagamijun@a8.keio.jp	Amagai, Masayuki/K-5325-2013		Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Ministry of Health, Labor and Welfare [H23-028]; Keio University School of Medicine	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Health and Labor Sciences Research Grants for Research on Measures for Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan, Research on Measures for Intractable Diseases Project: matching fund subsidy (H23-028) from the Ministry of Health, Labor and Welfare, and Intramural research fund of Keio University School of Medicine. We thank Ms Minae Suzuki for technical assistance on serological analyses of serum samples and Ms Mariko Okajima for the management of the grant used for this study.	Shirakata Y, 1998, J INVEST DERMATOL, V110, P76, DOI 10.1046/j.1523-1747.1998.00085.x; Sekiguchi M, 2001, J IMMUNOL, V167, P5439; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; Ohyama B, 2012, J INVEST DERMATOL, V132, P1158, DOI 10.1038/jid.2011.448; Ishii K, 2005, J INVEST DERMATOL, V124, P939, DOI 10.1111/j.0022-202X.2005.23714.x; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Nagasaka A, 2005, DERMATOLOGY, V211, P372, DOI 10.1159/000088513; Shinkuma S, 2008, CLIN EXP DERMATOL, V33, P724, DOI 10.1111/j.1365-2230.2008.02871.x; Yoshida K, 2005, J AM ACAD DERMATOL, V52, P839, DOI 10.1016/j.jaad.2005.01.106	9	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					685	689		10.1111/1346-8138.12888		5	Dermatology	Dermatology	CL9VZ	WOS:000357327600005		
J	Hayashi, N; Miyachi, Y; Kawashima, M				Hayashi, Nobukazu; Miyachi, Yoshiki; Kawashima, Makoto			Prevalence of scars and "mini-scars", and their impact on quality of life in Japanese patients with acne	JOURNAL OF DERMATOLOGY			English	Article						acne scar; classification; mini-scar; prevalence; prevention; quality of life	DERMATOLOGY; VERSION; SKINDEX-16; MANAGEMENT; SEVERITY; DISEASES; SCALE; INDEX	There have been very few studies on the prevalence and severity of acne scars in Japanese patients. The aim of the present study was to investigate the prevalence of acne scars and their impact on the quality of life (QOL) in Japanese acne patients. Acne scars were classified as mini-scars (atrophic scars of 0.5 and <2mm in diameter) atrophic scars (2 mm in diameter), and hypertrophic scars. The severity of acne and acne scars were evaluated. The background of patients and their QOL in relation to acne were assessed. Of 240 subjects, 218 (90.8%) had scars. All patients with scars had mini-scars; 61.2% and 14.2% of 240 had atrophic scars and hypertrophic scars, respectively. Severe scarring was found in patients who had experienced severe acne symptoms, although 15.0% of patients with scars had experienced only mild acne symptoms. The total Dermatology Life Quality Index score was significantly higher in patients with scars than in patients without scars (5.9 +/- 4.4 vs 4.2 +/- 4.1). Almost all the patients had small atrophic scars with a diameter of 0.5 or more and less than 2mm, which we have termed mini-scars. Acne scars had a negative impact on patient QOL. Early initiation of treatment is recommended to avoid acne scars.	[Hayashi, Nobukazu] Toranomon Gen Hosp, Dept Dermatol, Tokyo 1058470, Japan; [Kawashima, Makoto] Tokyo Womens Med Univ, Dept Dermatol, Tokyo, Japan; [Miyachi, Yoshiki] Kyoto Univ, Dept Dermatol, Kyoto, Japan	Hayashi, N (reprint author), Toranomon Gen Hosp, Dept Dermatol, Shinjuku Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	hayashi@toranomon.gr.jp			Galderma Japan	This project was financially supported by Galderma Japan.	Dreno B, 2007, DERMATOLOGY, V214, P46, DOI 10.1159/000096912; Hayashi N, 2008, J DERMATOL, V35, P255, DOI 10.1111/j.1346-8138.2008.00462.x; LAYTON AM, 1994, CLIN EXP DERMATOL, V19, P303, DOI 10.1111/j.1365-2230.1994.tb01200.x; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Finlay AY, 1998, SEMIN CUTAN MED SURG, V17, P291, DOI 10.1016/S1085-5629(98)80026-6; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Tan JKL, 2010, J CUTAN MED SURG, V14, P156, DOI 10.2310/7750.2010.09037; Jacob CI, 2001, J AM ACAD DERMATOL, V45, P109, DOI 10.1067/mjd.2001.113451; Hayashi N, 2004, J DERMATOL, V31, P971; Higaki Y, 2002, J DERMATOL, V29, P693; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Miyachi Y, 2011, DERMATOLOGY, V223, P174, DOI 10.1159/000332847; Takahashi N, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-46; Thiboutot D, 2009, J AM ACAD DERMATOL, V60, pS1, DOI 10.1016/j.jaad.2009.01.019	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					690	696		10.1111/1346-8138.12885		7	Dermatology	Dermatology	CL9VZ	WOS:000357327600006		
J	Sakai, N; Maeda, T; Kawakami, H; Uchiyama, M; Harada, K; Tsuboi, R; Mitsuhashi, Y				Sakai, Noriyasu; Maeda, Tatsuro; Kawakami, Hiroshi; Uchiyama, Masaki; Harada, Kazutoshi; Tsuboi, Ryoji; Mitsuhashi, Yoshihiko			Family with Legius syndrome (neurofibromatosis type 1-like syndrome)	JOURNAL OF DERMATOLOGY			English	Article						cafe-au-lait macules; Legius syndrome; neurofibroma; neurofibromatosis type 1; SPRED1	MUTATIONS	Legius syndrome (Online Mendelian Inheritance in Man no.611431) or neurofibromatosis type 1 (NF1)-like syndrome was first reported by Legius etal. in 2007. We herein report the first instance of Legius syndrome occurring in two female siblings in Japan. Both individuals presented cafe-au-lait macules and freckling. Mutation analysis revealed a mutation of c.349C>T resulting in p.Arg117* in the SPRED1 gene as the cause of the Legius syndrome. The National Institutes of Health criteria for NF1 are insufficient to rule out the condition. For this reason, and because the clinical course of each condition is quite different, we stress the need to differentiate Legius syndrome from NF1 clearly.	[Sakai, Noriyasu; Maeda, Tatsuro; Kawakami, Hiroshi; Uchiyama, Masaki; Harada, Kazutoshi; Tsuboi, Ryoji; Mitsuhashi, Yoshihiko] Tokyo Med Univ, Dept Dermatol, Tokyo 1600023, Japan	Mitsuhashi, Y (reprint author), Tokyo Med Univ, Dept Dermatol, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan.	nori@yg8.so-net.ne.jp					Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brems H, 2012, HUM MUTAT, V33, P1538, DOI 10.1002/humu.22152; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Denayer E, 2011, HUM MUTAT, V32, P1985; Muram-Zborovski TM, 2010, AM J MED GENET A, V152A, P1973, DOI 10.1002/ajmg.a.33525; Stevens CA, 2012, AM J MED GENET A, V158A, P1195, DOI 10.1002/ajmg.a.35297; Stevenson D, GENEREVIEWS; Tanito K, 2014, J DERMATOL, V41, P724, DOI 10.1111/1346-8138.12567	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					703	705		10.1111/1346-8138.12862		3	Dermatology	Dermatology	CL9VZ	WOS:000357327600008		
J	Tanese, K; Niizeki, H; Seki, A; Otsuka, A; Kabashima, K; Kosaki, K; Kuwahara, M; Miyakawa, S; Miyasaka, M; Matsuoka, K; Okuyama, T; Shiohama, A; Sasaki, T; Kudoh, J; Amagai, M; Ishiko, A				Tanese, Keiji; Niizeki, Hironori; Seki, Atsuhito; Otsuka, Atsushi; Kabashima, Kenji; Kosaki, Keisuke; Kuwahara, Masamitsu; Miyakawa, Shun-ichi; Miyasaka, Mikiko; Matsuoka, Kentaro; Okuyama, Torayuki; Shiohama, Aiko; Sasaki, Takashi; Kudoh, Jun; Amagai, Masayuki; Ishiko, Akira			Pathological characterization of pachydermia in pachydermoperiostosis	JOURNAL OF DERMATOLOGY			English	Article						dermal edema; elastic fiber degeneration; fibrosis; mucin deposition; pachydermoperiostosis; sebaceous hyperplasia	MUTATIONS; SLCO2A1; GENE	Pachydermoperiostosis is a rare hereditary disease, which presents with the cutaneous manifestations of pachydermia and cutis verticis gyrata. Histological findings in pachydermia frequently include dermal edema, mucin deposition, elastic fiber degeneration, dermal fibrosis and adnexal hyperplasia. However, the severity of these findings varies between clinical reports, and a systematic multiple-case clinicopathological correlative analysis has not been performed to date. In the present study, we reviewed the skin biopsy specimens obtained from the pachydermia of six pachydermoperiostosis patients. The severity of the characteristic histological features was semiquantitatively evaluated and correlated with the grade of pachydermia. Dermal edema, mucin deposition and elastic fiber degeneration were observed in all cases. Patients with severe pachydermia had sebaceous gland hyperplasia and fibrosis. These results suggest that the triad of mucin deposition, dermal edema and elastic fiber degeneration are found from very early stage pachydermia, and could be considered diagnostic findings. To ensure an earlier diagnosis of pachydermoperiostosis, a biopsy should be taken when a patient has grade 1 pachydermia to determine the presence of this histological triad.	[Tanese, Keiji; Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Niizeki, Hironori] Natl Ctr Child Hlth & Dev, Dept Dermatol, Tokyo 1578535, Japan; [Seki, Atsuhito] Natl Ctr Child Hlth & Dev, Dept Orthoped, Tokyo 1578535, Japan; [Otsuka, Atsushi; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Kosaki, Keisuke] Univ Tokyo, Dept Orthopaed Surg, Tokyo, Japan; [Kuwahara, Masamitsu] Nara Med Univ Hosp, Dept Plast Surg, Kashihara, Nara, Japan; [Miyakawa, Shun-ichi] Kawasaki Municipal Hosp, Div Dermatol, Kawasaki, Kanagawa, Japan; [Miyasaka, Mikiko] Natl Ctr Child Hlth & Dev, Dept Radiol, Tokyo 1578535, Japan; [Matsuoka, Kentaro] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo 1578535, Japan; [Okuyama, Torayuki] Natl Ctr Child Hlth & Dev, Dept Clin Lab Med, Tokyo 1578535, Japan; [Shiohama, Aiko; Kudoh, Jun] Keio Univ, Sch Med, Lab Gene Med, Tokyo, Japan; [Sasaki, Takashi] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo, Japan; [Ishiko, Akira] Toho Univ, Sch Med, Dept Dermatol, Tokyo, Japan	Niizeki, H (reprint author), Natl Ctr Child Hlth & Dev, Dept Dermatol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	niizeki-h@ncchd.go.jp	Amagai, Masayuki/K-5325-2013		National Center for Child Health and Development	We thank the patients and their families for their generous cooperation. This work was supported by a grant from the National Center for Child Health and Development (to H. N.).	Zhang ZL, 2012, AM J HUM GENET, V90, P125, DOI 10.1016/j.ajhg.2011.11.019; Castori M, 2005, CLIN GENET, V68, P477, DOI 10.1111/j.1399-0004.00533.x; Nakahigashi K, 2013, ACTA DERM-VENEREOL, V93, P118, DOI 10.2340/00015555-1398; Niitsuma K, 2004, J JPN SOC PLAST RECO, V24, P548; Niizeki H, 2014, J DERMATOL SCI, V75, P193, DOI 10.1016/j.jdermsci.2014.05.008; Sasaki T, 2012, J DERMATOL SCI, V68, P36, DOI 10.1016/j.jdermsci.2012.07.008; Tanese K, 2010, RINSHO HIFUKA, V64, P221	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					710	714		10.1111/1346-8138.12869		5	Dermatology	Dermatology	CL9VZ	WOS:000357327600010		
J	Yoshida, K; Hayashi, R; Fujita, H; Kubota, M; Kondo, M; Shimomura, Y; Niizeki, H				Yoshida, Kazue; Hayashi, Ryota; Fujita, Hideki; Kubota, Masaya; Kondo, Mai; Shimomura, Yutaka; Niizeki, Hironori			Novel homozygous mutation, c.400C > T (p.Arg134*), in the PVRL1 gene underlies cleft lip/palate-ectodermal dysplasia syndrome in an Asian patient	JOURNAL OF DERMATOLOGY			English	Article						adherens junction; cleft lip; palate-ectodermal dysplasia syndrome; ectodermal dysplasia; nectin-1; PVRL1	POLIOVIRUS RECEPTOR; MENTAL-RETARDATION; PALATE; LIP; EXPRESSION; NECTIN-4	Cleft lip/palate-ectodermal dysplasia syndrome is a rare, autosomal recessive disorder caused by homozygous loss-of-function mutations of the poliovirus receptor-like 1 (PVRL1) gene encoding nectin-1. Nectin-1 is a cell-cell adhesion molecule that is important for the initial step in the formation of adherens junctions and tight junctions; it is expressed in keratinocytes, neurons, and the developing face and palate. Clinical manifestations comprise a unique facial appearance with cleft lip/palate, ectodermal dysplasia, cutaneous syndactyly of the fingers and/or toes, and in some cases, mental retardation. We present the first report, to our knowledge, of an Asian individual with cleft lip/palate-ectodermal dysplasia syndrome with a novel PVRL1 mutation. A 7-year-old Japanese boy, the first child of a consanguineous marriage, showed hypohidrotic ectodermal dysplasia with sparse, brittle, fine, dry hair and hypodontia, the unique facial appearance with cleft lip/palate, cutaneous syndactyly of the fingers and mild mental retardation. Scanning electron microscopic examination of the hair demonstrated pili torti and pili trianguli et canaliculi. Mutation analysis of exon 2 of PVRL1 revealed a novel homozygous nonsense mutation, c.400C>T (p.Arg134*). His parents were heterozygous for the mutant alleles. All four PVRL1 mutations identified in cleft lip/palate-ectodermal dysplasia syndrome to date, including this study, resulted in truncated proteins that lack the transmembrane domain and intracellular domain of nectin-1, which is necessary to initiate the cell-cell adhesion process.	[Yoshida, Kazue; Niizeki, Hironori] Natl Ctr Child Hlth & Dev, Dept Dermatol, Tokyo 1578535, Japan; [Hayashi, Ryota; Shimomura, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Lab Genet Skin Dis, Niigata, Japan; [Fujita, Hideki] Natl Ctr Child Hlth & Dev, Dept Med Genet, Tokyo 1578535, Japan; [Kubota, Masaya] Natl Ctr Child Hlth & Dev, Dept Neurol, Tokyo 1578535, Japan; [Kondo, Mai] Natl Ctr Child Hlth & Dev, Dept Allergy, Tokyo 1578535, Japan	Yoshida, K (reprint author), Natl Ctr Child Hlth & Dev, Dept Dermatol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	yoshida-kz@ncchd.go.jp			Takeda Science Foundation, Japan; National Center for Child Health and Development [24-5]	We thank the patient and his family members for their generous cooperation. We also thank Akiko Maruta for secretarial assistance and Maiko Matsuda for technical assistance. This study was supported in parts by a grant from the Takeda Science Foundation, Japan (to Y. S.) and a grant from the National Center for Child Health and Development (24-5) (to H. N.).	Brancati F, 2010, AM J HUM GENET, V87, P265, DOI 10.1016/j.ajhg.2010.07.003; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cocchi F, 1998, J VIROL, V72, P9992; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; BUSTOS T, 1991, AM J MED GENET, V41, P398, DOI 10.1002/ajmg.1320410403; Fantin M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056897; Matsushima H, 2003, BRIT J DERMATOL, V148, P755, DOI 10.1046/j.1365-2133.2003.05225.x; Mollo MR, 2015, EXP DERMATOL, V24, P114, DOI 10.1111/exd.12593; OGUR G, 1988, J MED GENET, V25, P37, DOI 10.1136/jmg.25.1.37; RODINI ESO, 1990, AM J MED GENET, V36, P473, DOI 10.1002/ajmg.1320360420; Suzuki K, 2000, NAT GENET, V25, P427; Wakamatsu K, 2007, J BIOL CHEM, V282, P18173, DOI 10.1074/jbc.M611159200; ZLOTOGORA J, 1987, J MED GENET, V24, P291, DOI 10.1136/jmg.24.5.291; ZLOTOGORA J, 1988, J MED GENET, V25, P503, DOI 10.1136/jmg.25.7.503	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					715	719		10.1111/1346-8138.12882		5	Dermatology	Dermatology	CL9VZ	WOS:000357327600011		
J	Tamagawa-Mineoka, R; Masuda, K; Ueda, S; Nakamura, N; Hotta, E; Hattori, J; Minamiyama, R; Yamazaki, A; Katoh, N				Tamagawa-Mineoka, Risa; Masuda, Koji; Ueda, Sachiko; Nakamura, Naomi; Hotta, Eri; Hattori, Junko; Minamiyama, Rina; Yamazaki, Akiko; Katoh, Norito			Contact sensitivity in patients with recalcitrant atopic dermatitis	JOURNAL OF DERMATOLOGY			English	Article						atopic dermatitis; contact sensitivity; extrinsic; intrinsic; patch testing; sensitization	PATCH TEST REACTIONS; SENSITIZATION; ECZEMA; DISEASE	Patients with atopic dermatitis are usually responsive to conventional treatment such as topical steroids; however, they are sometimes refractory to the treatment. The influence of contact sensitivities on the course of patients with recalcitrant atopic dermatitis is not known. The aim of this study was to investigate whether contact sensitivities affect the course of patients with recalcitrant atopic dermatitis. We evaluated 45 patients with atopic dermatitis who had failed conventional therapy. Patch testing was performed with the Japanese standard series, metal series and/or suspected items. A total of 15 patients had a positive patch test reaction to at least one allergen. The most common allergens were nickel, topical drugs and rubber accelerators. Avoidance of products or food containing allergic substances greatly or partially improved skin symptoms in nine patients. These results suggest that contact allergens and metals may be critical factors causing eczematous lesions in patients with recalcitrant atopic dermatitis.	[Tamagawa-Mineoka, Risa; Masuda, Koji; Ueda, Sachiko; Nakamura, Naomi; Hotta, Eri; Hattori, Junko; Minamiyama, Rina; Yamazaki, Akiko; Katoh, Norito] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kyoto 6028566, Japan	Tamagawa-Mineoka, R (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kamigyo Ku, 465 Kajii Cho,Kawaramachi Hirokoji, Kyoto 6028566, Japan.	risat@koto.kpu-m.ac.jp					Thyssen JP, 2012, ALLERGY, V67, P1157, DOI 10.1111/j.1398-9995.2012.02863.x; Klas PA, 1996, CONTACT DERMATITIS, V34, P121, DOI 10.1111/j.1600-0536.1996.tb02143.x; DOTTERUD LK, 1995, ACTA PAEDIATR, V84, P402, DOI 10.1111/j.1651-2227.1995.tb13659.x; Yamaguchi H, 2013, J DERMATOL SCI, V72, P240, DOI 10.1016/j.jdermsci.2013.07.009; [Anonymous], 1980, ACTA DERM-VENEREOL S; Dotterud LK, 2007, CONTACT DERMATITIS, V56, P10, DOI 10.1111/j.1600-0536.2007.00980.x; JONES HE, 1973, ARCH DERMATOL, V107, P217; CRONIN E, 1993, CONTACT DERMATITIS, V28, P225, DOI 10.1111/j.1600-0536.1993.tb03407.x; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; FORSBECK M, 1976, ACTA DERM-VENEREOL, V56, P135; LAMMINTAUSTA K, 1992, CONTACT DERMATITIS, V26, P234, DOI 10.1111/j.1600-0536.1992.tb00235.x; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; UEHARA M, 1989, ARCH DERMATOL, V125, P366, DOI 10.1001/archderm.125.3.366; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					720	722		10.1111/1346-8138.12866		3	Dermatology	Dermatology	CL9VZ	WOS:000357327600012		
J	Nakajima, R; Miyagaki, T; Oka, T; Nakao, M; Kawaguchi, M; Suga, H; Morimura, S; Kai, H; Asano, Y; Tada, Y; Kadono, T; Sato, S; Sugaya, M				Nakajima, Rina; Miyagaki, Tomomitsu; Oka, Tomonori; Nakao, Momoko; Kawaguchi, Makiko; Suga, Hiraku; Morimura, Sohshi; Kai, Hiromichi; Asano, Yoshihide; Tada, Yayoi; Kadono, Takafumi; Sato, Shinichi; Sugaya, Makoto			Elevated serum galectin-9 levels in patients with atopic dermatitis	JOURNAL OF DERMATOLOGY			English	Article						atopic dermatitis; Eczema Area and Severity Index; epidermal keratinocytes; galectin-9; mast cells	ALLERGIC AIRWAY INFLAMMATION; INVOLVEMENT; CELLS; EOSINOPHILIA; TIM-3	Galectin-9 is a member of the galectin family that has a wide spectrum of biological functions. Among them, galectin-9 has been known mainly as a potent chemoattractant for eosinophils. In addition, galectin-9 alters the T-cell balance by negatively regulating T-helper (Th)1 and Th17 cells, resulting in Th2 polarization. Atopic dermatitis (AD) is a skin allergic disease characterized by peripheral eosinophilia, mast cell activation and predominance of Th2 cells. To investigate possible roles of galectin-9 in AD, we measured serum galectin-9 levels in AD patients and investigated galectin-9 expression in lesional skin by immunohistochemistry. Serum galectin-9 levels in patients with AD were significantly higher than those in healthy controls and correlated with the Eczema Area and Severity Index. Serum galectin-9 levels were decreased after treatment, accompanied by improvement of skin lesions. Immunohistochemical study revealed that galectin-9 was expressed on epidermal keratinocytes and mast cells in lesional skin of AD. Our results suggest that elevated galectin-9 expression is associated with progression of AD and that galectin-9 could be a therapeutic target in AD.	[Nakajima, Rina; Miyagaki, Tomomitsu; Oka, Tomonori; Nakao, Momoko; Kawaguchi, Makiko; Suga, Hiraku; Morimura, Sohshi; Kai, Hiromichi; Asano, Yoshihide; Tada, Yayoi; Kadono, Takafumi; Sato, Shinichi; Sugaya, Makoto] Univ Tokyo, Dept Dermatol, Fac Med, Tokyo 1138655, Japan	Miyagaki, T (reprint author), Univ Tokyo, Dept Dermatol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	miyagakit-der@h.u-tokyo.ac.jp			Ministry of Education, Culture, Sports and Technology	These studies were supported by grants from the Ministry of Education, Culture, Sports and Technology.	Katoh S, 2007, AM J RESP CRIT CARE, V176, P27, DOI 10.1164/rccm.200608-1243OC; Katoh S, 2010, INT ARCH ALLERGY IMM, V153, P294, DOI 10.1159/000314371; Kashio Y, 2003, J IMMUNOL, V170, P3631; Chen X, 2011, ALLERGY, V66, P1038, DOI 10.1111/j.1398-9995.2011.02585.x; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Wiener Z, 2007, J INVEST DERMATOL, V127, P906, DOI 10.1038/sj.jid.5700616; Chabot S, 2002, GLYCOBIOLOGY, V12, P111, DOI 10.1093/glycob/12.2.111; Hirashima Mitsuomi, 2004, Glycoconjugate Journal, V19, P593; Igawa K, 2006, ALLERGY, V61, P1385, DOI 10.1111/j.1398-9995.2006.01130.x; Kearley J, 2007, J EXP MED, V204, P1289, DOI 10.1084/jem.20062093; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Niki T, 2009, J BIOL CHEM, V284, P32344, DOI 10.1074/jbc.M109.035196; Sziksz E, 2010, INT ARCH ALLERGY IMM, V151, P308, DOI 10.1159/000250439; Vega-Carrascal Isabel, 2012, J Inflamm Res, V5, P77, DOI 10.2147/JIR.S34225; Yamamoto H, 2007, INT ARCH ALLERGY IMM, V143, P95, DOI 10.1159/000101414	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					723	726		10.1111/1346-8138.12884		4	Dermatology	Dermatology	CL9VZ	WOS:000357327600013		
J	Kusakari, Y; Yamasaki, K; Takahashi, T; Tsuchiyama, K; Shimada-Omori, R; Nasu-Tamabuchi, M; Aiba, S				Kusakari, Yoshiyuki; Yamasaki, Kenshi; Takahashi, Toshiya; Tsuchiyama, Kenichiro; Shimada-Omori, Ryoko; Nasu-Tamabuchi, Mei; Aiba, Setsuya			Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure	JOURNAL OF DERMATOLOGY			English	Article						adalimumab; biologics; hemodialysis; psoriasis; renal failure	ARTHRITIS	The efficacy and safety of biologic treatments have been established in patients with moderate to severe psoriasis, but there are few reports on biologic therapy for patients with psoriasis complicated by end-stage renal failure on hemodialysis (HD). In this report, we demonstrated the efficacy and safety of adalimumab for patients with severe psoriasis on HD. A 46-year-old Japanese man with a 14-year history of psoriasis was referred to our clinic in September 2009. He had developed hypertension and renal failure during a 7-year history of cyclosporin treatment. With the infliximab treatment, he achieved 75% improvement of the Psoriasis Area and Severity Index (PASI) score within 3months from the PASI of 42.3 before the treatment. However, his renal failure gradually deteriorated, and HD was initiated at 1year after the introduction of infliximab. Because of hydration during the i.v. injection of infliximab, he developed pulmonary edema with every infliximab treatment after starting HD. We switched to ustekinumab treatment, but his psoriasis was not improved. Then, we switched to adalimumab and achieved a PASI-100 response within 2months. The patient received adalimumab treatment for more than a year without any adverse effects. In addition to our case, five articles reported cases of psoriasis patients with renal failure on HD who were treated with biologics. The psoriatic lesions were improved by biologics in these cases, and no severe adverse effects on the renal function were reported. Thus, biologics are a reasonable treatment option for patients with severe psoriasis with renal failure on HD.	[Kusakari, Yoshiyuki; Yamasaki, Kenshi; Takahashi, Toshiya; Tsuchiyama, Kenichiro; Shimada-Omori, Ryoko; Nasu-Tamabuchi, Mei; Aiba, Setsuya] Tohoku Univ, Dept Dermatol, Grad Sch Med, Sendai, Miyagi 9808574, Japan	Kusakari, Y (reprint author), Tohoku Univ, Dept Dermatol, Grad Sch Med, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	ykusakari@derma.med.tohoku.ac.jp					Yang YW, 2011, BRIT J DERMATOL, V165, P1037, DOI 10.1111/j.1365-2133.2011.10494.x; Cassano N, 2008, INT J DERMATOL, V47, P980, DOI 10.1111/j.1365-4632.2008.03619.x; Bustos BD, 2014, INT J DERMATOL, V53, pE299, DOI 10.1111/ijd.12163; Kobak S, 2012, RHEUMATOL INT, V32, P1785, DOI 10.1007/s00296-010-1457-7; Saougou I, 2010, CLIN RHEUMATOL, V29, P1455, DOI 10.1007/s10067-010-1485-4; Shimojima Yasuhiro, 2012, Clin Med Insights Case Rep, V5, P13, DOI 10.4137/CCRep.S8790; Sumida K, 2013, ARTHRIT CARE RES, V65, P471, DOI 10.1002/acr.21800; Wan J, 2013, BMJ-BRIT MED J, V15, P347	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					727	730		10.1111/1346-8138.12901		4	Dermatology	Dermatology	CL9VZ	WOS:000357327600014		
J	Umezawa, Y; Hayashi, M; Kikuchi, S; Fukuchi, O; Yanaba, K; Ito, T; Asahina, A; Saeki, H; Nakagawa, H				Umezawa, Yoshinori; Hayashi, Mitsuha; Kikuchi, Sota; Fukuchi, Osamu; Yanaba, Koichi; Ito, Toshihiro; Asahina, Akihiko; Saeki, Hidehisa; Nakagawa, Hidemi			Ustekinumab treatment in patients with psoriasis undergoing hemodialysis	JOURNAL OF DERMATOLOGY			English	Article						adverse events; biologics; hemodialysis; psoriasis; ustekinumab	MORTALITY; DIALYSIS; DISEASES; THERAPY	Patients with psoriasis undergoing hemodialysis have additional difficulties in treatment compared with general patients. Conventional treatments such as cyclosporin, retinoids and methotrexate are not widely administrated due to the chances of an increase in adverse effects and the possibility of risk to patient survival. Recently, biologic treatments have been recognized as having sufficient efficacy for severe psoriasis with low incidence of organ toxicities. For this reason, biologic treatments may be more preferable for patients on hemodialysis; however, there is not sufficient evidence. We have treated three patients with psoriasis with ustekinumab for 1year, who had been undergoing hemodialysis. They were previously treated with conventional treatments before ustekinumab treatments; however, they did not respond to these treatments sufficiently. Following treatment with ustekinumab, rapid and maintained improvement in psoriasis was observed. Over the course of treatments, two of the three patients encountered no adverse events during their first year of treatment. The other patient discontinued ustekinumab due to elevated levels of C-reactive protein. These findings suggest that ustekinumab may be an appropriate treatment for patients undergoing hemodialysis who are suffering from psoriasis. However, the risk of developing infection remains higher than in general patients.	[Umezawa, Yoshinori; Hayashi, Mitsuha; Kikuchi, Sota; Fukuchi, Osamu; Yanaba, Koichi; Ito, Toshihiro; Asahina, Akihiko; Nakagawa, Hidemi] Jikei Univ, Dept Dermatol, Sch Med, Tokyo 1058461, Japan; [Saeki, Hidehisa] Nippon Med Sch, Dept Dermatol, Tokyo 113, Japan	Umezawa, Y (reprint author), Jikei Univ, Dept Dermatol, Sch Med, Minato Ku, 3-25-8 Nishishimbashi, Tokyo 1058461, Japan.	yoshinori.umezawa@jikei.ac.jp			Tanabe Mitsubishi; AbbVie	Hidemi Nakagawa has received consultancy/speaker honoraria and grants from Tanabe Mitsubishi and AbbVie, and speaker honoraria from Janssen. The other authors have no conflicts of interest to declare.	Gelfand JM, 2007, ARCH DERMATOL, V143, P1493, DOI 10.1001/archderm.143.12.1493; Gudjonsson JE, 2004, CLIN EXP IMMUNOL, V135, P1, DOI 10.1046/j.1365-2249.2004.02310.x; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Prodanovich S, 2009, ARCH DERMATOL, V145, P700, DOI 10.1001/archdermatol.2009.94; BUSELMEIER TJ, 1978, BRIT MED J, V1, P1139; Cassano N, 2008, INT J DERMATOL, V47, P980, DOI 10.1111/j.1365-4632.2008.03619.x; FRIEDMAN EA, 1979, ANN INTERN MED, V90, P132; Gottenberg JE, 2003, ARTHRITIS RHEUM, V48, P2019, DOI 10.1002/art.11163; HALEVY S, 1981, ARCH DERMATOL, V117, P69, DOI 10.1001/archderm.117.2.69; Pertosa G, 2000, KIDNEY INT, V58, pS104; PESERICO A, 1979, ARCH DERMATOL, V115, P1169; Saougou I, 2010, CLIN RHEUMATOL, V29, P1455, DOI 10.1007/s10067-010-1485-4; Shimojima Yasuhiro, 2012, Clin Med Insights Case Rep, V5, P13, DOI 10.4137/CCRep.S8790; Sobh M A, 1987, Nephrol Dial Transplant, V2, P351; Yamamoto T, 2006, J EUR ACAD DERMATOL, V20, P1139, DOI 10.1111/j.1468-3083.2006.01636.x	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					731	734		10.1111/1346-8138.12903		4	Dermatology	Dermatology	CL9VZ	WOS:000357327600015		
J	Yoshitake, T; Takeda, A; Ohki, K; Inoue, Y; Yamawaki, T; Otsuka, S; Akimoto, M; Nemoto, M; Shimakura, Y; Sato, A				Yoshitake, Toshihiro; Takeda, Akira; Ohki, Kensaku; Inoue, Yuko; Yamawaki, Takanori; Otsuka, Saori; Akimoto, Minekatsu; Nemoto, Mitsuru; Shimakura, Yasuhito; Sato, Akio			Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia	JOURNAL OF DERMATOLOGY			English	Article						androgenetic alopecia; finasteride; Japanese; modified global photographic assessment; modified Norwood-Hamilton scale	PATTERN HAIR LOSS; 1 MG; CLASSIFICATION	Finasteride is standard medical treatment for androgenetic alopecia; however, no large studies with 5years or more of follow up have been performed in Japan. The authors followed Japanese men with androgenetic alopecia treated with finasteride for 5years to evaluate long-term treatment efficacy. Of 903 men treated with finasteride (1mg/day), 801 patients were evaluated over 5years by modified global photographic assessment. Although the proportion of improvement was high (99.4%), modified global photographic assessment scores after 5years of treatment were lower in patients with more advanced disease as measured by the modified Norwood-Hamilton scale. After separating patients into sufficient and insufficient efficacy groups according to the modified global photographic assessment score after 5years (scores 6 and <6, respectively), multivariate analysis showed that independent risk factors of insufficient efficacy were age at start of treatment of 40years or more (P=0.021) and classification on the modified Norwood-Hamilton scale (P<0.001), whereas presence of stress at start of treatment was a negative predictor (P=0.025). In conclusion, continuous finasteride treatment for 5years improved androgenetic alopecia with sustained effect among Japanese. Younger age and less advanced disease at start of treatment were the key predictors of higher finasteride efficacy.	[Yoshitake, Toshihiro; Otsuka, Saori; Sato, Akio] Kitasato Univ, Dept Regenerat Plast Surg, Sch Med, Sagamihara, Kanagawa 2520374, Japan; [Yoshitake, Toshihiro; Takeda, Akira; Akimoto, Minekatsu; Nemoto, Mitsuru; Shimakura, Yasuhito] Kitasato Univ, Dept Plast & Aesthet Surg, Sch Med, Sagamihara, Kanagawa 2520374, Japan; [Yoshitake, Toshihiro; Takeda, Akira; Ohki, Kensaku; Inoue, Yuko; Yamawaki, Takanori; Sato, Akio] Tokyo Mem Clin Hirayama, Tokyo, Japan	Sato, A (reprint author), Kitasato Univ, Dept Regenerat Plast Surg, Sch Med, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	drsato@crux.ocn.ne.jp					Sato A, 2012, J DERMATOL, V39, P27, DOI 10.1111/j.1346-8138.2011.01378.x; Lee WS, 2007, J AM ACAD DERMATOL, V57, P37, DOI 10.1016/j.jaad.2006.12.029; Franbourg A, 2003, J AM ACAD DERMATOL, V48, pS115, DOI 10.1067/mjd.2003.277; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; Olsen EA, 2012, J AM ACAD DERMATOL, V67, P379, DOI 10.1016/j.jaad.2011.10.027; HAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708, DOI 10.1111/j.1749-6632.1951.tb31971.x; Hayashi S, 1976, BIOL DIS HAIR, P555; Hori Y, 1987, MED SCI HAIR, P148; Kawashima M, 2006, JPN J CLIN DERMATOL, V60, P521; Kawashima M, 2004, EUR J DERMATOL, V14, P247; NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359; Otsuka H, 1988, KOSHOKAISHI, V12, P192; Pinkus F, 1927, HDB HAUT UND GESCH 1, P239; Takashima I, 1981, HAIR RES STATUS FUTU, P287, DOI 10.1007/978-3-642-81650-5; Kaufman KD, 2002, EUR J DERMATOL, V12, P38	15	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					735	738		10.1111/1346-8138.12890		4	Dermatology	Dermatology	CL9VZ	WOS:000357327600016		
J	Yagami, A; Suzuki, K; Sano, A; Takahashi, M; Kobayashi, T; Morita, Y; Ando, A; Iwata, Y; Matsunaga, K				Yagami, Akiko; Suzuki, Kayoko; Sano, Akiyo; Takahashi, Masayuki; Kobayashi, Tsukane; Morita, Yusuke; Ando, Aki; Iwata, Yohei; Matsunaga, Kayoko			Rhododendrol-induced leukoderma accompanied by allergic contact dermatitis caused by a non-rhododendrol skin-lightening agent, 5,5 '-dipropylbiphenyl-2,2 '-diol	JOURNAL OF DERMATOLOGY			English	Letter							MECHANISM		[Yagami, Akiko; Suzuki, Kayoko; Sano, Akiyo; Takahashi, Masayuki; Kobayashi, Tsukane; Morita, Yusuke; Ando, Aki; Iwata, Yohei; Matsunaga, Kayoko] Fujita Hlth Univ, Sch Med, Dept Dermatol, Toyoake, Aichi 4701192, Japan; [Suzuki, Kayoko] Kariya Toyota Gen Hosp, Dept Dermatol, Kariya, Aichi, Japan	Yagami, A (reprint author), Fujita Hlth Univ, Sch Med, Dept Dermatol, 1-98 Toyoake, Toyoake, Aichi 4701192, Japan.	ayagami@fujita-hu.ac.jp					Nakamura K, 2003, PIGM CELL RES, V16, P494, DOI 10.1034/j.1600-0749.2003.00084.x; Sasaki M, 2014, PIGM CELL MELANOMA R, V27, P754, DOI 10.1111/pcmr.12269; INOUE T, 1978, YAKUGAKU ZASSHI, V98, P41; Shiomi M, 2013, J HIMEJI RED CROSS H, V37, P5; Suzuki K, 2012, CONTACT DERMATITIS, V66, P46	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					739	740		10.1111/1346-8138.12878		2	Dermatology	Dermatology	CL9VZ	WOS:000357327600017		
J	Asai, J; Wada, M; Ueda, Y; Kataoka, Y; Taura, M; Takenaka, H; Katoh, N				Asai, Jun; Wada, Makoto; Ueda, Yukiko; Kataoka, Yukiko; Taura, Maiko; Takenaka, Hideya; Katoh, Norito			Case of atrial fibrillation induced by interferon beta treatment for melanoma	JOURNAL OF DERMATOLOGY			English	Letter							THERAPY		[Asai, Jun; Wada, Makoto; Ueda, Yukiko; Kataoka, Yukiko; Taura, Maiko; Takenaka, Hideya; Katoh, Norito] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kyoto 6028566, Japan	Asai, J (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kamigyo Ku, 465 Kajii Cho,Kawaramachi Hirokoji, Kyoto 6028566, Japan.	jasai@koto.kpu-m.ac.jp					Kirkwood JM, 1996, J CLIN ONCOL, V14, P7; SONNENBLICK M, 1991, CHEST, V99, P557, DOI 10.1378/chest.99.3.557; Fujiwara T, 2001, INTERNAL MED, V40, P105, DOI 10.2169/internalmedicine.40.105; Matsumoto T, 2013, J EUR ACAD DERMATOL, V27, P1514, DOI 10.1111/jdv.12040; SARNA GP, 1987, J BIOL RESP MODIF, V6, P375	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					740	741		10.1111/1346-8138.12874		2	Dermatology	Dermatology	CL9VZ	WOS:000357327600018		
J	Nakajima, H; Matsushima, T; Sano, S				Nakajima, Hideki; Matsushima, Tomoko; Sano, Shigetoshi			Primary cutaneous adenoid cystic carcinoma arising from folliculitis decalvans	JOURNAL OF DERMATOLOGY			English	Letter									[Nakajima, Hideki; Matsushima, Tomoko; Sano, Shigetoshi] Kochi Univ, Kochi Med Sch, Dept Dermatol, Nankoku, Kochi 7838505, Japan	Nakajima, H (reprint author), Kochi Univ, Kochi Med Sch, Dept Dermatol, Okoh Cho, Nankoku, Kochi 7838505, Japan.	nakajima@kochi-u.ac.jp					Naylor E, 2008, J AM ACAD DERMATOL, V58, P636, DOI 10.1016/j.jaad.2007.12.005; Rocas D, 2014, AM J DERMATOPATH, V36, P223, DOI 10.1097/DAD.0b013e31829ae1e7; Gondivkar SM, 2011, ORAL ONCOL, V47, P231, DOI 10.1016/j.oraloncology.2011.01.009; Dores GM, 2010, J AM ACAD DERMATOL, V63, P71, DOI 10.1016/j.jaad.2009.07.027; Yip L, 2008, BRIT J DERMATOL, V159, P481, DOI 10.1111/j.1365-2133.2008.08634.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					741	743		10.1111/1346-8138.12880		3	Dermatology	Dermatology	CL9VZ	WOS:000357327600019		
J	Nanba, M; Kaneko, T; Kato, T; Mitsuishi, T				Nanba, Mio; Kaneko, Takehiko; Kato, Toshihiko; Mitsuishi, Tsuyoshi			Human papillomavirus types 16 and 82 were detected in penile, perianal and periungual Bowen's disease lesions of a homosexual patient	JOURNAL OF DERMATOLOGY			English	Letter							PRIMERS		[Nanba, Mio; Kaneko, Takehiko] Fratern Mem Hosp, Dept Dermatol, Tokyo, Japan; [Kato, Toshihiko] Nippon Med Sch, Res Inst Vaccine Therapy Tumors & Infect Dis, Tokyo 113, Japan; [Mitsuishi, Tsuyoshi] Tokyo Womens Med Univ, Dept Dermatol, Yachiyo Med Ctr, Chiba 2768524, Japan	Mitsuishi, T (reprint author), Tokyo Womens Med Univ, Dept Dermatol, Yachiyo Med Ctr, 477-96 Ohwada Shinden, Chiba 2768524, Japan.	mitsuishi.tsuyoshi@twmu.ac.jp					Alam M, 2003, J AM ACAD DERMATOL, V48, P385, DOI 10.1067/mjd.2003.184; YOSHIKAWA H, 1991, JPN J CANCER RES, V82, P524; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Mitsuishi T, 2003, HUM PATHOL, V34, P886, DOI 10.1016/S0046-8177(03)00352-6; Ohishi K, 2011, J DERMATOL SCI, V63, P69, DOI 10.1016/j.jdermsci.2011.04.006	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					744	746		10.1111/1346-8138.12883		3	Dermatology	Dermatology	CL9VZ	WOS:000357327600021		
J	Kurokawa, I; Hayashi, N				Kurokawa, Ichiro; Hayashi, Nobukazu		Japan Acne Res Soc	Questionnaire surveillance of hidradenitis suppurativa in Japan	JOURNAL OF DERMATOLOGY			English	Letter									[Kurokawa, Ichiro] Meiwa Hosp, Dept Dermatol, Nishinomiya, Hyogo 6638186, Japan; [Hayashi, Nobukazu] Toranomon Gen Hosp, Dept Dermatol, Tokyo, Japan	Kurokawa, I (reprint author), Meiwa Hosp, Dept Dermatol, 4-31 Agenaruo Cho, Nishinomiya, Hyogo 6638186, Japan.	kurokawa.i@meiwa-hospital.com					Von der Werth JM, 2000, BRIT J DERMATOL, V142, P947, DOI 10.1046/j.1365-2133.2000.03476.x; Revuz J, 2009, J EUR ACAD DERMATOL, V23, P985, DOI 10.1111/j.1468-3083.2009.03356.x; Jemec GBE, 2006, HIDRADENITIS SUPPURA; Kurzen H, 2008, EXP DERMATOL, V17, P455, DOI [10.1111/j.1600-0625.2008.00712_1.x, 10.1111/j.1600-0625.2008.00712.x]	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					747	749		10.1111/1346-8138.12881		3	Dermatology	Dermatology	CL9VZ	WOS:000357327600023		
J	Kikuchi, N; Hiraiwa, T; Ohashi, T; Hanami, Y; Yamamoto, T				Kikuchi, Nobuyuki; Hiraiwa, Tomoko; Ohashi, Takenobu; Hanami, Yuka; Yamamoto, Toshiyuki			Lupus erythematosus profundus in a patient with myasthenia gravis	JOURNAL OF DERMATOLOGY			English	Letter									[Kikuchi, Nobuyuki; Hiraiwa, Tomoko; Ohashi, Takenobu; Hanami, Yuka; Yamamoto, Toshiyuki] Fukushima Med Univ, Dept Dermatol, Fukushima, Fukushima 9601295, Japan	Kikuchi, N (reprint author), Fukushima Med Univ, Dept Dermatol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.	nobuyuk@fmu.ac.jp					Yu C, 2013, J AUTOIMMUN, V41, P34, DOI 10.1016/j.jaut.2013.01.007; Shelly S, 2011, CELL MOL IMMUNOL, V8, P199, DOI 10.1038/cmi.2010.74; Barbosa RE, 2000, LUPUS, V9, P158; Castrejon I, 2011, SCAND J RHEUMATOL, V40, P486, DOI 10.3109/03009742.2011.575077; Yamamoto T, 2007, CLIN EXP DERMATOL, V32, P278, DOI 10.1111/j.1365-2230.2007.02358.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					749	750		10.1111/1346-8138.12875		2	Dermatology	Dermatology	CL9VZ	WOS:000357327600024		
J	Miura, T; Yamamoto, T				Miura, Takako; Yamamoto, Toshiyuki			Pediatric linear scleroderma initially developed with angioma serpiginosum-like appearances	JOURNAL OF DERMATOLOGY			English	Letter							SYSTEMIC-LUPUS-ERYTHEMATOSUS		[Miura, Takako; Yamamoto, Toshiyuki] Fukushima Med Univ, Dept Dermatol, Fukushima, Fukushima 9601295, Japan	Miura, T (reprint author), Fukushima Med Univ, Dept Dermatol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.	m-takako@fmu.ac.jp					Yu C, 2013, J AUTOIMMUN, V41, P34, DOI 10.1016/j.jaut.2013.01.007; Shelly S, 2011, CELL MOL IMMUNOL, V8, P199, DOI 10.1038/cmi.2010.74; Barbosa RE, 2000, LUPUS, V9, P158; Castrejon I, 2011, SCAND J RHEUMATOL, V40, P486, DOI 10.3109/03009742.2011.575077; Yamamoto T, 2007, CLIN EXP DERMATOL, V32, P278, DOI 10.1111/j.1365-2230.2007.02358.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					750	751		10.1111/1346-8138.12896		2	Dermatology	Dermatology	CL9VZ	WOS:000357327600025		
J	Ito, T; Shimomura, Y; Hayashi, R; Tokura, Y				Ito, Taisuke; Shimomura, Yutaka; Hayashi, Ryota; Tokura, Yoshiki			Identification of a novel mutation, c.686delAins18 (p.Asp229Glyfs*22), in the LIPH gene as a compound heterozygote with c.736T > A (p.Cys246Ser) in autosomal recessive woolly hair/hypotrichosis	JOURNAL OF DERMATOLOGY			English	Letter							PA-PLA(1)ALPHA; HAIR		[Ito, Taisuke; Tokura, Yoshiki] Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4313192, Japan; [Shimomura, Yutaka; Hayashi, Ryota] Niigata Univ, Grad Sch Med & Dent Sci, Lab Genet Skin Dis, Niigata, Japan; [Shimomura, Yutaka; Hayashi, Ryota] Niigata Univ, Grad Sch Med & Dent Sci, Div Dermatol, Niigata, Japan	Ito, T (reprint author), Hamamatsu Univ Sch Med, Dept Dermatol, 1-20-1 Handayama,Higashi Ward, Hamamatsu, Shizuoka 4313192, Japan.	itoutai@hama-med.ac.jp					Hayashi R, 2014, J DERMATOL, V41, P937, DOI 10.1111/1346-8138.12612; Hayashi R, 2014, J DERMATOL, V41, P890, DOI 10.1111/1346-8138.12623; Shimomura Y, 2009, J INVEST DERMATOL, V129, P622, DOI 10.1038/jid.2008.290; Shinkuma S, 2012, J INVEST DERMATOL, V132, P2093, DOI 10.1038/jid.2012.96; Yoshizawa M, 2013, J DERMATOL SCI, V72, P61, DOI 10.1016/j.jdermsci.2013.05.001	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					752	753		10.1111/1346-8138.12889		2	Dermatology	Dermatology	CL9VZ	WOS:000357327600026		
J	Amakata, M; Teraki, Y				Amakata, Masato; Teraki, Yuichi			Case of circumscribed hypokeratosis on the dorsum of the index finger	JOURNAL OF DERMATOLOGY			English	Letter							HLA-B-ASTERISK-5801; ALLOPURINOL		[Amakata, Masato; Teraki, Yuichi] Saitama Med Univ, Saitama Med Ctr, Dept Dermatol, Kawagoe, Saitama 3508550, Japan	Teraki, Y (reprint author), Saitama Med Univ, Saitama Med Ctr, Dept Dermatol, 1981 Kamoda, Kawagoe, Saitama 3508550, Japan.	teraki@saitama-med.ac.jp					Tassaneeyakul W, 2009, PHARMACOGENET GENOM, V19, P704, DOI 10.1097/FPC.0b013e328330a3b8; Cristallo AF, 2011, INT J IMMUNOGENET, V38, P303, DOI 10.1111/j.1744-313X.2011.01011.x; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Cheng CY, 2014, J IMMUNOL RES, V2014; Eickman EE, 2011, BMC MED GENET, V12, P118	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					754	756		10.1111/1346-8138.12892		3	Dermatology	Dermatology	CL9VZ	WOS:000357327600028		
J	Okahashi, K; Oiso, N; Ishii, N; Uchida, S; Matsuda, H; Hashimoto, T; Kawada, A				Okahashi, Kazunori; Oiso, Naoki; Ishii, Norito; Uchida, Shusuke; Matsuda, Hiromasa; Hashimoto, Takashi; Kawada, Akira			Bullous pemphigoid associated with psoriasis: A possible example of an inverse intramolecular epitope-spreading phenomenon	JOURNAL OF DERMATOLOGY			English	Letter									[Okahashi, Kazunori; Oiso, Naoki; Uchida, Shusuke; Matsuda, Hiromasa; Kawada, Akira] Kinki Univ, Fac Med, Dept Dermatol, Osaka 5898511, Japan; [Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan; [Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Inst Cutaneous Cell Biol, Kurume, Fukuoka 830, Japan	Oiso, N (reprint author), Kinki Univ, Fac Med, Dept Dermatol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	naoiso@med.kindai.ac.jp					Fairley JA, 2013, J AM ACAD DERMATOL, V68, P395, DOI 10.1016/j.jaad.2012.09.012; Tsuruta D, 2011, J DERMATOL SCI, V62, P1, DOI 10.1016/j.jdermsci.2011.01.005; Nishie W, 2014, J DERMATOL SCI, V73, P179, DOI 10.1016/j.jdermsci.2013.12.001; Uchida S, 2014, J DERMATOL, V41, P1003, DOI 10.1111/1346-8138.12650	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	JUL	2015	42	7					758	759		10.1111/1346-8138.12891		2	Dermatology	Dermatology	CL9VZ	WOS:000357327600030		
J	Ikeda, D				Ikeda, Daisuke			Optimal inflation rates with the trending relative price of investment	JOURNAL OF ECONOMIC DYNAMICS & CONTROL			English	Article						Optimal inflation rates; Trend inflation; Sticky prices; Bayesian estimation	OPTIMAL MONETARY-POLICY; NOMINAL RIGIDITIES; BUSINESS CYCLES; UNITED-STATES; EURO AREA; MODELS; FACTS; TARGETS; SHOCKS	I study the effect of the trending relative price of investment on the optimal target rate of inflation in an estimated dynamic general equilibrium model of the U.S. economy. The price of investment has a decreasing trend relative to that of consumption because of investment-specific technological progress. If the prices of investment goods are sticky, a benevolent planner puts weight on stabilizing these prices, which works to raise the optimal target rate of inflation in terms of the price of consumption. The estimated model shows a high degree of price stickiness in an investment sector and the resulting optimal target rate of inflation is significantly positive. This result is robust to an extended model in which the prices of some categories of investment goods are flexible. (C) 2015 Elsevier B.V. All rights reserved.	Bank Japan, Inst Monetary & Econ Studies, Chuo Ku, Tokyo 1038660, Japan	Ikeda, D (reprint author), Bank Japan, Inst Monetary & Econ Studies, Chuo Ku, 2-1-1 Nihonbashi Hongokucho, Tokyo 1038660, Japan.	daisuke.ikeda@boj.or.jp					Amano R, 2009, J MONETARY ECON, V56, P353, DOI 10.1016/j.jmoneco.2009.03.001; Christiano LJ, 2005, J POLIT ECON, V113, P1, DOI 10.1086/426038; Schmitt-Grohe S, 2004, J ECON THEORY, V114, P198, DOI 10.1016/S0022-0531(03)00111-X; Erceg CJ, 2000, J MONETARY ECON, V46, P281, DOI 10.1016/S0304-3932(00)00028-3; Smets F, 2007, AM ECON REV, V97, P586, DOI 10.1257/aer.97.3.586; Cummins JG, 2002, REV ECON DYNAM, V5, P243, DOI 10.1006/redy.2002.0168; Aoki K, 2001, J MONETARY ECON, V48, P55, DOI 10.1016/S0304-3932(01)00069-1; An S, 2007, ECONOMET REV, V26, P113, DOI 10.1080/07474930701220071; Vermeulen P, 2012, J MONEY CREDIT BANK, V44, P1631, DOI 10.1111/j.1538-4616.2012.00547.x; Coibion O, 2012, REV ECON STUD, V79, P1371, DOI 10.1093/restud/rds013; Khan A, 2003, REV ECON STUD, V70, P825, DOI 10.1111/1467-937X.00269; Altig D, 2011, REV ECON DYNAM, V14, P225, DOI 10.1016/j.red.2010.01.001; Fisher JDM, 2006, J POLIT ECON, V114, P413, DOI 10.1086/505048; Justiniano A, 2010, J MONETARY ECON, V57, P132, DOI 10.1016/j.jmoneco.2009.12.008; Ball L, 2001, J MONETARY ECON, V47, P31, DOI 10.1016/S0304-3932(00)00043-X; Bils Mark, 2004, J POLIT ECON, V112, P947; CALVO GA, 1983, J MONETARY ECON, V12, P383, DOI 10.1016/0304-3932(83)90060-0; Carlstrom CT, 2010, MACROECON DYN, V14, P136, DOI 10.1017/S136510050909004X; Clarida R, 2000, Q J ECON, V115, P147, DOI 10.1162/003355300554692; Dhyne E, 2006, J ECON PERSPECT, V20, P171, DOI 10.1257/jep.20.2.171; Eberly J, 2012, J MONETARY ECON, V59, P370, DOI 10.1016/j.jmoneco.2012.05.002; Fuentes-Albero Cristina, 2009, 433 FED RES BANK MIN; Gordon Robert J., 1990, NATL BUREAU EC RES M; Hammond Gill, 2012, CCBS HDB, V29; Huang X. D., 2005, J MONETARY ECON, V52, P1435; Justiniano Alejandro, 2011, REV ECON DYNAM, V14, P101; Kim J, 2009, J MONETARY ECON, V56, P365, DOI 10.1016/j.jmoneco.2009.03.004; Kim J, 2011, J ECON DYN CONTROL, V35, P2064, DOI 10.1016/j.jedc.2011.08.002; Schmitt-Grohe S, 2012, J MONETARY ECON, V59, P393, DOI 10.1016/j.jmoneco.2012.02.002; Schmitt-Grohe S., 2007, MONETARY POLICY INFL, V11, P125; Schmitt-Grohe Stephanie, 2010, HDB MONETARY EC, V3; Shirota Toyoichiro, 2007, J MONETARY ECON, V51, P575; Nakamura E, 2008, Q J ECON, V123, P1415, DOI 10.1162/qjec.2008.123.4.1415; Wolman AL, 2011, J MONEY CREDIT BANK, V43, P355, DOI 10.1111/j.1538-4616.2010.00377.x; Woodford M, 2003, INTEREST AND PRICES: FOUNDATIONS OF A THEORY OF MONETARY POLICY, P1; Yun T, 1996, J MONETARY ECON, V37, P345, DOI 10.1016/S0304-3932(96)90040-9	36	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-1889	1879-1743		J ECON DYN CONTROL	J. Econ. Dyn. Control	JUL	2015	56						20	33		10.1016/j.jedc.2015.04.003		14	Economics	Business & Economics	CL8KK	WOS:000357223400002		
J	Oya, M; Kitaguchi, T; Harada, K; Numano, R; Sato, T; Kojima, M; Tsuboi, T				Oya, Manami; Kitaguchi, Tetsuya; Harada, Kazuki; Numano, Rika; Sato, Takahiro; Kojima, Masayasu; Tsuboi, Takashi			Low glucose-induced ghrelin secretion is mediated by an ATP-sensitive potassium channel	JOURNAL OF ENDOCRINOLOGY			English	Article						ATP-sensitive potassium channel; calcium channel; exocytosis; ghrelin; glucose; total internal reflection fluorescence microscopy	HORMONE-RELEASING PEPTIDE; CIRCULATING GHRELIN; INSULIN-SECRETION; ACTIVE FORM; MIN6 CELLS; HUMANS; RECEPTOR; HOMEOSTASIS; PANCREAS; ALPHA	Ghrelin is synthesized in X/A-like cells of the gastric mucosa, which plays an important role in the regulation of energy homeostasis. Although ghrelin secretion is known to be induced by neurotransmitters or hormones or by nutrient sensing in the ghrelin-secreting cells themselves, the mechanism of ghrelin secretion is not clearly understood. In the present study, we found that changing the extracellular glucose concentration from elevated (25 mM) to optimal (10 mM) caused an increase in the intracellular Ca2+ concentration ([Ca2+](i)) in ghrelin-secreting mouse ghrelinoma 3-1 (MGN3-1) cells (n = 32, P < 0.01), whereas changing the glucose concentration from elevated to lowered (5 or 1 mM) had little effect on [Ca2+](i) increase. Overexpression of a closed form of an ATP-sensitive K+ (K-ATP) channel mutant suppressed the 10 mM glucose-induced [Ca2+](i) increase (n = 8, P < 0.01) and exocytotic events (n = 6, P < 0.01). We also found that a low concentration of a K-ATP channel opener, diazoxide, with 25 mM glucose induced [Ca2+](i) increase (n=23, P < 0.01) and ghrelin secretion (n >= 3, P < 0.05). In contrast, the application of a low concentration of a K-ATP channel blocker, tolbutamide, significantly induced [Ca2+](i) increase (n = 15, P < 0.01) and ghrelin secretion (n >= 3, P < 0.05) under 5 mM glucose. Furthermore, the application of voltage-dependent Ca2+ channel inhibitors suppressed the 10 mM glucose-induced [Ca2+](i) increase (n >= 26, P < 0.01) and ghrelin secretion (n >= 5, P < 0.05). These findings suggest that K-ATP and voltage-dependent Ca2+ channels are involved in glucose-dependent ghrelin secretion in MGN3-1 cells.	[Oya, Manami; Harada, Kazuki; Tsuboi, Takashi] Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro, Tokyo 1538902, Japan; [Kitaguchi, Tetsuya] WASEDA Biosci Res Inst Singapore WABIOS, Cell Signaling Grp, Singapore 138667, Singapore; [Kitaguchi, Tetsuya] Waseda Univ, Org Univ Res Initiat, Shinjuku Ku, Tokyo 1620041, Japan; [Numano, Rika] Toyohashi Univ Technol, EIIRIS, Dept Environm & Life Sci, Toyohashi, Aichi 4418580, Japan; [Sato, Takahiro; Kojima, Masayasu] Kurume Univ, Inst Life Sci, Mol Genet, Kurume, Fukuoka 8390864, Japan	Tsuboi, T (reprint author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, 3-8-1 Komaba, Meguro, Tokyo 1538902, Japan.	takatsuboi@bio.c.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24590350, 25350970, 26460289]; Pharmacological Research Foundation, Tokyo; Takeda Science Foundation	This work w as funded in part by a Grant-in-Aid for Science Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant numbers 24590350, 25350970, and 26460289), by the Pharmacological Research Foundation, Tokyo, and by the Takeda Science Foundation.	Sakata I, 2012, AM J PHYSIOL-ENDOC M, V302, pE1300, DOI 10.1152/ajpendo.00041.2012; Broglio F, 2004, CLIN ENDOCRINOL, V61, P503, DOI 10.1111/j.1365-2265.2004.02121.x; Kamegai J, 2001, ENDOCRINOLOGY, V142, P4154, DOI 10.1210/en.142.9.4154; Oya M, 2013, J BIOL CHEM, V288, P4513, DOI 10.1074/jbc.M112.402677; Shiiya T, 2002, J CLIN ENDOCR METAB, V87, P240, DOI 10.1210/jc.87.1.240; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Masuda Y, 2000, BIOCHEM BIOPH RES CO, V276, P905, DOI 10.1006/bbrc.2000.3568; Quesada I, 2008, J ENDOCRINOL, V199, P5, DOI 10.1677/JOE-08-0290; Foster-Schubert KE, 2008, J CLIN ENDOCR METAB, V93, P1971, DOI 10.1210/jc.2007-2289; Oya M, 2013, BIOCHEM BIOPH RES CO, V438, P145, DOI 10.1016/j.bbrc.2013.07.043; Takaya K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/jc.85.12.4908; Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Nagaya N, 2006, INTERNAL MED, V45, P127, DOI 10.2169/internalmedicine.45.1402; Tolle V, 2002, ENDOCRINOLOGY, V143, P1353, DOI 10.1210/en.143.4.1353; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Mori R, 2011, EUR J IMMUNOL, V41, P3230, DOI 10.1002/eji.201141640; Thompson NM, 2004, ENDOCRINOLOGY, V145, P234, DOI 10.1210/en.2003-0899; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Tsuboi T, 2006, DIABETES, V55, P1057, DOI 10.2337/diabetes.55.04.06.db05-1577; Iwakura H, 2010, ENDOCRINOLOGY, V151, P2940, DOI 10.1210/en.2010-0090; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; McTaggart JS, 2010, J PHYSIOL-LONDON, V588, P3201, DOI 10.1113/jphysiol.2010.191767; Iwakura H, 2011, ENDOCRINOLOGY, V152, P2619, DOI 10.1210/en.2010-1455; Nagaya N, 2003, REGUL PEPTIDES, V114, P71, DOI 10.1016/S0167-0115(03)00117-4; Suzuki M, 1997, DIABETES, V46, P1440, DOI 10.2337/diabetes.46.9.1440; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Kitaguchi T, 2013, BIOCHEM J, V450, P365, DOI 10.1042/BJ20121022; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Ariyasu H, 2001, J CLIN ENDOCR METAB, V86, P4753, DOI 10.1210/jc.86.10.4753; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Romero A, 2010, EUR J ENDOCRINOL, V163, P1, DOI 10.1530/EJE-10-0099; Oya M, 2011, GENES CELLS, V16, P608, DOI 10.1111/j.1365-2443.2011.01509.x; Aoki R, 2010, BIOCHEM J, V429, P497, DOI 10.1042/BJ20091839; Drucker DJ, 2007, J CLIN INVEST, V117, P24, DOI 10.1172/JCI30076; Williams DL, 2003, ENDOCRINOLOGY, V144, P2765, DOI 10.1210/en.2003-0381; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P509, DOI 10.1111/j.1469-7793.2000.00509.x; Cassoni P, 2001, J CLIN ENDOCR METAB, V86, P1738, DOI 10.1210/jc.86.4.1738; Ashcroft FM, 2013, NAT REV ENDOCRINOL, V9, P660, DOI 10.1038/nrendo.2013.166; Gromada J, 2007, ENDOCR REV, V28, P84, DOI 10.1210/er.2006-0007; Ariyasu H, 2002, ENDOCRINOLOGY, V143, P3341, DOI 10.1210/en.2002-220225; Janssen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040168; Koster JC, 2002, P NATL ACAD SCI USA, V99, P16992, DOI 10.1073/pnas.012479199; MacDonald PE, 2007, PLOS BIOL, V5, P1236, DOI 10.1371/journal.pbio.0050143; McCowen KC, 2002, J ENDOCRINOL, V175, pR7, DOI 10.1677/joe.0.175R007; Nakai Y, 2003, EUR J ENDOCRINOL, V149, pR1, DOI 10.1530/eje.0.149R001; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Sato M, 2012, BIOCHEM BIOPH RES CO, V420, P417, DOI 10.1016/j.bbrc.2012.03.010; Suzuki M, 1999, DIABETOLOGIA, V42, P1204, DOI 10.1007/s001250051293; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811	50	0	0	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795	1479-6805		J ENDOCRINOL	J. Endocrinol.	JUL	2015	226	1					25	34		10.1530/JOE-15-0090		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CM3IE	WOS:000357574600005		
J	Hamano, K; Nakagawa, Y; Ohtsu, Y; Li, LF; Medina, J; Tanaka, Y; Masuda, K; Komatsu, M; Kojima, I				Hamano, Kunihisa; Nakagawa, Yuko; Ohtsu, Yoshiaki; Li, Longfei; Medina, Johan; Tanaka, Yuji; Masuda, Katsuyoshi; Komatsu, Mitsuhisa; Kojima, Itaru			Lactisole inhibits the glucose-sensing receptor T1R3 expressed in mouse pancreatic beta-cells	JOURNAL OF ENDOCRINOLOGY			English	Article						beta-cell; insulin secretion; sweet taste receptor; glucose	SWEET TASTE RECEPTOR; STIMULATED INSULIN-SECRETION; SIGNALING SYSTEMS; GUSTDUCIN; ACID; RESPONSES; PATTERNS; SUBUNITS; RELEASE; LINE	Glucose activates the glucose-sensing receptor T1R3 and facilitates its own metabolism in pancreatic beta-cells. An inhibitor of this receptor would be helpful in elucidating the physiological function of the glucose-sensing receptor. The present study was conducted to examine whether or not lactisole can be used as an inhibitor of the glucose-sensing receptor. In MIN6 cells, in a dose-dependent manner, lactisole inhibited insulin secretion induced by sweeteners, acesulfame-K, sucralose and glycyrrhizin. The IC50 was similar to 4 mmol/l. Lactisole attenuated the elevation of cytoplasmic Ca2+ concentration ([Ca2+](c)) evoked by sucralose and acesulfame-K but did not affect the elevation of intracellular cAMP concentration ([cAMP](c)) induced by these sweeteners. Lactisole also inhibited the action of glucose in MIN6 cells. Thus, lactisole significantly reduced elevations of intracellular [NADH] and intracellular [ATP] induced by glucose, and also inhibited glucose-induced insulin secretion. To further examine the effect of lactisole on T1R3, we prepared HEK293 cells stably expressing mouse T1R3. In these cells, sucralose elevated both [Ca2+](c) and [cAMP](c). Lactisole attenuated the sucralose-induced increase in [Ca2+](c) but did not affect the elevation of [cAMP](c). Finally, lactisole inhibited insulin secretion induced by a high concentration of glucose in mouse islets. These results indicate that the mouse glucose-sensing receptor was inhibited by lactisole. Lactisole may be useful in assessing the role of the glucose-sensing receptor in mouse pancreatic beta-cells.	[Hamano, Kunihisa; Nakagawa, Yuko; Ohtsu, Yoshiaki; Li, Longfei; Medina, Johan; Kojima, Itaru] Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan; [Hamano, Kunihisa; Tanaka, Yuji] Natl Def Med Coll, Dept Gen Med, Tokorozawa, Saitama 359, Japan; [Masuda, Katsuyoshi] Suntory Inst Bioorgan Res, Osaka 618, Japan; [Komatsu, Mitsuhisa] Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 390, Japan	Kojima, I (reprint author), Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan.	ikojima@gunma-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan	This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.	AIZAWA T, 1994, AM J PHYSIOL, V266, pC622; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.040384101; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; Roper SD, 2013, SEMIN CELL DEV BIOL, V24, P71, DOI 10.1016/j.semcdb.2012.12.002; Nakagawa Y, 2014, ENDOCR J, V61, P119; Geraedts MCP, 2012, AM J PHYSIOL-ENDOC M, V303, pE464, DOI 10.1152/ajpendo.00163.2012; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Bezencon C, 2007, CHEM SENSES, V32, P41, DOI 10.1093/chemse/bjl034; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Medina A, 2014, ENDOCR J, V61, P797, DOI 10.1507/endocrj.EJ14-0221; Sclafani A, 1997, PHYSIOL BEHAV, V61, P25, DOI 10.1016/S0031-9384(96)00316-2; Newsholme P, 2014, J ENDOCRINOL, V221, pR105, DOI 10.1530/JOE-13-0616; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Kojima I, 2015, J DIABETES INVEST, V6, P256, DOI 10.1111/jdi.12304; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104; Oya M, 2011, GENES CELLS, V16, P608, DOI 10.1111/j.1365-2443.2011.01509.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126; Jiang PH, 2005, J BIOL CHEM, V280, P15238, DOI 10.1074/jbc.M414287200; Henquin JC, 2009, DIABETOLOGIA, V52, P739, DOI 10.1007/s00125-009-1314-y; Kyriazis GA, 2012, P NATL ACAD SCI USA, V109, pE524, DOI 10.1073/pnas.1115183109; Nakagawa Y, 2013, ENDOCR J, V60, P1191, DOI 10.1507/endocrj.EJ13-0282; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; JOHNSON C, 1994, CHEM SENSES, V19, P349, DOI 10.1093/chemse/19.4.349; Kojima I, 2014, ENDOCRINOL METAB, V29, P1, DOI 10.3803/EnM.2014.29.1.12; Kyriazis GA, 2014, ENDOCRINOLOGY, V155, P2112, DOI 10.1210/en.2013-2015; Malaisse WJ, 2014, DIABETOLOGIA, V57, P1287, DOI 10.1007/s00125-014-3221-0; Masubuchi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054500; Masuda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035380; Nakagawa Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005106; Nakakura T, 2012, ENDOCRINOLOGY, V153, P4171, DOI 10.1210/en.2012-1164; Ohtsu Y, 2014, MOL CELL ENDOCRINOL, V394, P70, DOI 10.1016/j.mce.2014.07.004; Roper SD, 2007, PFLUG ARCH EUR J PHY, V454, P759, DOI 10.1007/s00424-007-0247-x; Shigemura N, 2008, BIOCHEM BIOPH RES CO, V367, P356, DOI [10.1016/j.bbrc.2007.12.146, 10.1016/j.bbre.2007.12.146]; Temussi P, 2007, ADV FOOD NUTR RES, V53, P199, DOI 10.1016/S1043-4526(07)53006-8	38	1	1	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795	1479-6805		J ENDOCRINOL	J. Endocrinol.	JUL	2015	226	1					57	66		10.1530/JOE-15-0102		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CM3IE	WOS:000357574600008		
J	Naznin, F; Toshinai, K; Waise, TMZ; NamKoong, C; Moin, ASM; Sakoda, H; Nakazato, M				Naznin, Farhana; Toshinai, Koji; Waise, T. M. Zaved; NamKoong, Cherl; Moin, Abu Saleh Md; Sakoda, Hideyuki; Nakazato, Masamitsu			Diet-induced obesity causes peripheral and central ghrelin resistance by promoting inflammation	JOURNAL OF ENDOCRINOLOGY			English	Article						ghrelin; diet-induced obesity; nodose ganglion; vagus nerve; inflammation	HIGH-FAT DIET; FOOD-INTAKE; INSULIN-RESISTANCE; VAGUS NERVE; HYPOTHALAMIC INFLAMMATION; NPY/AGRP NEURONS; NODOSE GANGLION; MICE; PATHWAY; CELLS	Ghrelin, a stomach-derived orexigenic peptide, transmits starvation signals to the hypothalamus via the vagus afferent nerve. Peripheral administration of ghrelin does not induce food intake in high fat diet (HFD)-induced obese mice. We investigated whether this ghrelin resistance was caused by dysfunction of the vagus afferent pathway. Administration (s.c.) of ghrelin did not induce food intake, suppression of oxygen consumption, electrical activity of the vagal afferent nerve, phosphorylation of ERK2 and AMP-activated protein kinase alpha in the nodose ganglion, or Fos expression in hypothalamic arcuate nucleus of mice fed a HFD for 12 weeks. Administration of anti-ghrelin IgG did not induce suppression of food intake in HFD-fed mice. Expression levels of ghrelin receptor mRNA in the nodose ganglion and hypothalamus of HFD-fed mice were reduced. Inflammatory responses, including upregulation of macrophage/microglia markers and inflammatory cytokines, occurred in the nodose ganglion and hypothalamus of HFD-fed mice. A HFD blunted ghrelin signaling in the nodose ganglion via a mechanism involving in situ activation of inflammation. These results indicate that ghrelin resistance in the obese state may be caused by dysregulation of ghrelin signaling via the vagal afferent.	[Naznin, Farhana; Toshinai, Koji; Waise, T. M. Zaved; NamKoong, Cherl; Moin, Abu Saleh Md; Sakoda, Hideyuki; Nakazato, Masamitsu] Miyazaki Univ, Fac Med, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Kiyotake, Miyazaki 8891692, Japan; [Toshinai, Koji] Shigakkan Univ, Fac Wellness, Dept Sports & Fitness, Obu 4748651, Japan; [Nakazato, Masamitsu] AMED CREST, Agcy Med Res & Dev, Chiyoda Ku, Tokyo 1000004, Japan	Nakazato, M (reprint author), Miyazaki Univ, Fac Med, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	nakazato@med.miyazaki-u.ac.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI [25293216]; Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), AMED	This work was supported in part by Japan Society for the Promotion of Science (JSPS) KAKENHI (no. 25293216) and Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), AMED to M N.	Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI [10.1172/JCI34260, 10.1172/JC134260]; Shiiya T, 2002, J CLIN ENDOCR METAB, V87, P240, DOI 10.1210/jc.87.1.240; Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Martin TL, 2006, J BIOL CHEM, V281, P18933, DOI 10.1074/jbc.M512831200; Thaler JP, 2013, DIABETES, V62, P2629, DOI 10.2337/db12-1605; Henkel JS, 2006, MOL CELL NEUROSCI, V31, P427, DOI 10.1016/j.mcn.2005.10.016; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Rinaman L, 2010, BRAIN RES, V1350, P18, DOI 10.1016/j.brainres.2010.03.059; Toshinai K, 2003, ENDOCRINOLOGY, V144, P1506, DOI 10.1210/en.2002-220788; Gardiner JV, 2010, GASTROENTEROLOGY, V138, P2468, DOI 10.1053/j.gastro.2010.02.012; Konturek SJ, 2004, J PHYSIOL PHARMACOL, V55, P137; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Briggs DI, 2010, ENDOCRINOLOGY, V151, P4745, DOI 10.1210/en.2010-0556; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Zhuo H, 1997, PROG NEUROBIOL, V52, P79, DOI 10.1016/S0301-0082(97)00003-8; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; McFarlane MR, 2014, CELL METAB, V20, P54, DOI 10.1016/j.cmet.2014.04.007; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JC1200421134; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Daly DM, 2011, J PHYSIOL-LONDON, V589, P2857, DOI 10.1113/jphysiol.2010.204594; Andrews ZB, 2010, ENDOCRINOLOGY, V151, P2078, DOI 10.1210/en.2009-0850; Date Y, 2006, CELL METAB, V4, P323, DOI 10.1016/j.cmet.2006.09.004; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Mousseaux D, 2006, BRIT J PHARMACOL, V148, P350, DOI 10.1038/sj.bjp.0706727; Perreault M, 2004, INT J OBESITY, V28, P879, DOI 10.1038/sj.ijo.0802640; De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520; Druce MR, 2005, INT J OBESITY, V29, P1130, DOI 10.1038/sj/ijo.0803001; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Berkseth KE, 2014, ENDOCRINOLOGY, V155, P2858, DOI 10.1210/en.2014-1121; Briggs DI, 2014, ENDOCRINOLOGY, V155, P2411, DOI 10.1210/en.2013-1861; Cai DS, 2011, ANN NY ACAD SCI, V1243, pE1, DOI 10.1111/j.1749-6632.2011.06388.x; Date Y, 2005, ENDOCRINOLOGY, V146, P3518, DOI 10.1210/en.2004-1240; Goehler LE, 1999, J NEUROSCI, V19, P2799; Gutkind JS, 2000, SCI STKE, V2000, pre1, DOI [10.1126/stke.2000.40.re1, DOI 10.1126/STKE.2000.40.RE1]; Hosoi T, 2005, AUTON NEUROSCI-BASIC, V120, P104, DOI 10.1016/j.autneu.2004.11.012; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Posey KA, 2009, AM J PHYSIOL-ENDOC M, V296, pE1003, DOI 10.1152/ajpendo.90377.2008	42	3	3	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795	1479-6805		J ENDOCRINOL	J. Endocrinol.	JUL	2015	226	1					81	92		10.1530/JOE-15-0139		12	Endocrinology & Metabolism	Endocrinology & Metabolism	CM3IE	WOS:000357574600010		
J	Yoshioka, S; Nakao, W				Yoshioka, Shunsuke; Nakao, Wataru			Methodology for evaluating self-healing agent of structural ceramics	JOURNAL OF INTELLIGENT MATERIAL SYSTEMS AND STRUCTURES			English	Article						Self-healing; ceramics; nano-composite; methodology; oxidation; recovery; thermo-gravity and differential temperature analysis; strength	COMPOSITE CERAMICS; OXYGEN; DIFFUSION; OXIDATION; STRENGTH; BEHAVIOR	Simple methodology for evaluating availability of self-healing agent has been established from the investigation on the relationship between oxidation behavior of self-healing agent and self-healing phenomena. The consistency of the established methodology was discussed by comparison in the lower bound of the available temperature range (TH-low) of mullite/TiSi2 composite. From thermo-gravity and differential temperature analysis, the available temperature range for 10-h healing ( ) was estimated to be 563 degrees C. On the other hand, the value of the lower bound of the available temperature range for 10-h healing () was experimentally determined to be 600 degrees C from strength recovery tests. These values showed a good consistency. Also, the data on 1-h healing of mullite/TiSi2 and the reference data on alumina/SiC self-healing ceramics exhibited good consistency. Therefore, the proposed methodology is sufficient for evaluating the advanced healing agent.	[Yoshioka, Shunsuke] Yokohama Natl Univ, Grad Sch Engn, Yokohama, Kanagawa 2408501, Japan; [Nakao, Wataru] Yokohama Natl Univ, Fac Engn, Yokohama, Kanagawa 2408501, Japan	Yoshioka, S (reprint author), Yokohama Natl Univ, Grad Sch Engn, Hodogaya Ku, 79-5 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	yoshioka-shunsuke-tg@ynu.jp			Kumagai Foundation for Science and Technology	This investigation was financially supported by the Kumagai Foundation for Science and Technology.	Abe O, 2004, SOLID STATE IONICS, V172, P553, DOI 10.1016/j.ssi.2004.02.062; Abe O, 2005, J EUR CERAM SOC, V26, P689, DOI DOI 10.1016/J.JEURCERAMSOC.2005.06.020; Akahira T, 1971, REPORT CHIBA I TECHN, V16, P246; Ando K., 2003, Journal of the Society of Materials Science, Japan, V52; Ando K, 1999, FATIGUE FRACT ENG M, V22, P897, DOI 10.1046/j.1460-2695.1999.00210.x; Muehlenbachs K, 1977, CAN MINERAL, V15, P179; Ando K, 2002, J EUR CERAM SOC, V22, P1313, DOI 10.1016/S0955-2219(01)00431-9; [Anonymous], THERMOCHEMICAL DATA; Maruoka D, 2013, CERAM INT, V39, P3221, DOI 10.1016/j.ceramint.2012.10.008; Osada T, 2009, J AM CERAM SOC, V92, P864, DOI 10.1111/j.1551-2916.2009.02992.x; Heuer AH, 2008, J EUR CERAM SOC, V28, P1495, DOI 10.1016/j.jeurceramsoc.2007.12.020; [Anonymous], BINARY ALLOY PHASE D; TAYLOR SR, 1964, GEOCHIM COSMOCHIM AC, V28, P1273, DOI 10.1016/0016-7037(64)90129-2; [Anonymous], 1998, IN CRYST STRUCT ICSD; Fielitz P, 2004, J AM CERAM SOC, V87, P2232, DOI 10.1111/j.1151-2916.2004.tb07497.x; Houjou K, 2004, J EUR CERAM SOC, V24, P2329, DOI 10.1016/S0955-2219(03)00645-9; Iida Y, 2011, P ICM P 2011 CORV OR, P194; Kingery WD, 1960, WILEY SERIES SCI TEC, P256; Kochubry V, 2008, ITSC P MAASTR 2 4 JU; Nakao W, 2012, SMART MATER STRUCT, V21, DOI 10.1088/0964-1726/21/2/025002; Nakao W, 2009, SELF HEALING MAT FUN, P183	21	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1045-389X	1530-8138		J INTEL MAT SYST STR	J. Intell. Mater. Syst. Struct.	JUL	2015	26	11					1395	1403		10.1177/1045389X14544137		9	Materials Science, Multidisciplinary	Materials Science	CL9KY	WOS:000357298400006		
J	Fuchiwaki, Y; Takaoka, H				Fuchiwaki, Y.; Takaoka, H.			UV-laser-assisted modification of poly(methyl methacrylate) and its application to capillary-driven-flow immunoassay	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						laser ablation; poly(methyl methacrylate); concave; procollagen type I C-peptide; antibody immobilization; UV laser	POLYMETHYLMETHACRYLATE; ELISA; SERUM	A concave microchannel surface was formed by nanosecond pulse laser ablation to allow antibody immobilization on a capillary flow immunoassay chip. Microscopic analysis showed that UV laser ablation of poly(methyl methacrylate) at 193 nm and 1.76 J . cm(-2) allowed excellent immobilization of Cy5 conjugated antibody. The concave structure was 10 mu m deep and 260 mu m wide and supported uniform antibody printing on the microchannel surface. The characteristics of immobilized antibodies on this surface and on a commercially available polymer coating were comparable. Quantitative analysis of procollagen type I C-peptide (PICP) at different concentrations provided a linear relationship in the range 0-600 ng ml(-1) PICP, which is sufficient for clinical estimation of PICP in the blood. The results may provide a new benchmark for a mechatronic antibody immobilization-based capillary flow immunoassay chip.	[Fuchiwaki, Y.; Takaoka, H.] Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Takamatsu, Kagawa 7610395, Japan; [Fuchiwaki, Y.] CEA, LETI, MINATEC, F-38054 Grenoble 9, France	Fuchiwaki, Y (reprint author), Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, 2217-14 Hayashi Cho, Takamatsu, Kagawa 7610395, Japan.	yu-fuchiwaki@aist.go.jp			Amada Foundation for Laser Processing; Ministry of Education, Culture, Sports, Science and Technology, Japan [24710146]	This work was supported by the Amada Foundation for Laser Processing and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (24710146).	Abe K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053620; Herrmann M, 2007, LAB CHIP, V7, P1546, DOI 10.1039/b707883h; Fiddes LK, 2010, BIOMATERIALS, V31, P315, DOI 10.1016/j.biomaterials.2009.09.040; Geissler M, 2009, ACS APPL MATER INTER, V1, P1387, DOI 10.1021/am900285g; Didar TF, 2012, ANAL CHEM, V84, P1012, DOI 10.1021/ac2025877; Paun IA, 2009, APPL SURF SCI, V255, P9856, DOI 10.1016/j.apsusc.2009.04.106; Weng KY, 2008, LAB CHIP, V8, P1216, DOI 10.1039/b801878b; Cheng CM, 2010, ANGEW CHEM INT EDIT, V49, P4771, DOI 10.1002/anie.201001005; KOHDA K, 1991, GUT, V32, P624, DOI 10.1136/gut.32.6.624; Wochnowski C, 2005, POLYM DEGRAD STABIL, V89, P252, DOI 10.1016/j.polymdegradstab.2004.11.024; Wochnowski C, 2000, APPL SURF SCI, V154, P706, DOI 10.1016/S0169-4332(99)00435-3; PARFITT AM, 1987, J BONE MINER RES, V2, P427; Yetisen AK, 2013, LAB CHIP, V13, P2210, DOI 10.1039/c3lc50169h; Temiz Y, 2014, J MICROMECH MICROENG, V24, DOI 10.1088/0960-1317/24/9/097001; Mao XL, 2012, LAB CHIP, V12, P1412, DOI 10.1039/c2lc90022j; Juncker D, 2002, ANAL CHEM, V74, P6139, DOI 10.1021/ac0261449; Honrado C, 2014, J MICROMECH MICROENG, V24, DOI 10.1088/0960-1317/24/12/125023; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996; Fu E, 2012, ANAL CHEM, V15, P4574; Fuchiwaki Y, 2014, SENSOR ACTUAT A-PHYS, V219, P1, DOI 10.1016/j.sna.2014.08.010; KUPER S, 1989, APPL PHYS A-MATER, V49, P211, DOI 10.1007/BF00616301; Ristell J, 1991, CALCIF TISSUE INT S, V49, pS24; Spicar-Mihalic P, 2014, J MICROMECH MICROENG, V23; Teixidor D., 2012, J MANUFACT PROCESS, V14, P435; Yatsushiro S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018807	25	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	JUL	2015	25	7							075008	10.1088/0960-1317/25/7/075008		8	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CL4AZ	WOS:000356896100019		
J	Hosono, M; Noda, K; Matsumoto, K; Shimoyama, I				Hosono, Minako; Noda, Kentaro; Matsumoto, Kiyoshi; Shimoyama, Isao			Dynamic performance analysis of a micro cantilever embedded in elastomer	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						dynamic characteristics; piezoresistive; cantilever; PDMS	TACTILE SENSOR; SILICON	This paper reports on the dynamic characteristics of a micro silicon standing cantilever embedded in a silicone elastomer, polydimethylsiloxane (PDMS). This combined structure, which consists of materials with significantly different Young's moduli, is employed as a tactile sensor for shear-strain measurement. The frequency responses of the tactile sensor show no resonance near the intrinsic resonant frequency of the standing cantilever, whereas the resonant point was observed near the intrinsic resonant frequency of the PDMS covering. In addition, when the oscillation frequency is below the resonant frequency of the tactile sensor, the standing cantilever can follow the oscillating deformation of the PDMS covering with no delay, and the sensitivity of the tactile sensor does not change. The analytical and experimental results show that the PDMS covering has a dominant influence on the dynamic behavior of the embedded cantilever, and the tactile sensor can be applied to both static and oscillating input in the same way.	[Hosono, Minako] Ind Res Inst Shizuoka Prefecture, Dept Mech & Elect, Numadu City, Shizuoka, Japan; [Noda, Kentaro; Shimoyama, Isao] Univ Tokyo, Bunkyo Ku, Grad Sch Informat Sci & Technol, Dept Mechanoinformat, Tokyo 113, Japan; [Matsumoto, Kiyoshi; Shimoyama, Isao] Univ Tokyo, Bunkyo Ku, Informat & Robot Technol Res Initiat, Tokyo 113, Japan	Hosono, M (reprint author), Ind Res Inst Shizuoka Prefecture, Dept Mech & Elect, 3981-1 Ooka, Numadu City, Shizuoka, Japan.	isao@i.u-tokyo.ac.jp			JSPS KAKENHI [25820083, 09J07228]; Tateishi Science and Technology Foundation [2031016]	The photolithography masks were made using the University of Tokyo VLSI Design and Education Center (VDEC)' s 8 inch EB writer F5112 + VD01 donated by ADVANTEST Corporation. This work was partially supported by JSPS KAKENHI Grant Number 25820083, 09J07228, and Tateishi Science and Technology Foundation Grant Number 2031016.	Dargahi J, 2000, J MICROELECTROMECH S, V9, P329, DOI 10.1109/84.870059; WORTMAN JJ, 1965, J APPL PHYS, V36, P153, DOI 10.1063/1.1713863; Tibrewala A, 2009, J MICROMECH MICROENG, V19, DOI 10.1088/0960-1317/19/12/125005; Fuard D, 2008, MICROELECTRON ENG, V85, P1289, DOI 10.1016/j.mee.2008.02.004; Hwang ES, 2007, J MICROELECTROMECH S, V16, P556, DOI 10.1109/JMEMS.2007.896716; Noda K, 2006, SENSOR ACTUAT A-PHYS, V127, P295, DOI 10.1016/j.sna.2005.09.023; Beyeler F, 2009, J MICROELECTROMECH S, V18, P433, DOI 10.1109/JMEMS.2009.2013387; Kwak MK, 2011, ADV MATER, V23, P3949, DOI 10.1002/adma.201101694; Takahashi H, 2013, SENSOR ACTUAT A-PHYS, V199, P43, DOI 10.1016/j.sna.2013.05.002; Iwase E, 2005, J MICROELECTROMECH S, V14, P1265, DOI 10.1109/JMEMS.2005.851814; Tiwana MI, 2011, SENSOR ACTUAT A-PHYS, V165, P164, DOI 10.1016/j.sna.2010.09.012; Tiwana MI, 2012, SENSOR ACTUAT A-PHYS, V179, P17, DOI 10.1016/j.sna.2012.02.051; Lee HK, 2008, J MICROELECTROMECH S, V17, P934, DOI 10.1109/JMEMS.2008.921727; Yousef H, 2011, SENSOR ACTUAT A-PHYS, V167, P171, DOI 10.1016/j.sna.2011.02.038; Byungjune C, 2005, IEEE RSJ INT C INT R, P2638; Govindaraju A, 2005, J MICROMECH MICROENG, V15, P1303, DOI 10.1088/0960-1317/15/6/023; GREENWOOD JC, 1988, J PHYS E SCI INSTRUM, V21, P1114, DOI 10.1088/0022-3735/21/12/001; Huang CY, 2007, IEEE SENS J, V7, P1554, DOI 10.1109/JSEN.2007.908236; Madou M J, 2002, FUNDAMENTALS MICROFA, V2nd, P201; Noda K, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960-1317/22/11/115025; Sato K, 2012, IEEE 25 INT C MICR M, P603; Sohgawa M, 2009, SOL STAT SENS ACT MI, P284; Valdastri P, 2005, SENSOR ACTUAT A-PHYS, V123-24, P249, DOI 10.1016/j.sna.2005.01.006; Wen CC, 2008, SENSOR ACTUAT A-PHYS, V145, P14, DOI 10.1016/j.sna.2007.10.011	24	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	JUL	2015	25	7							075006	10.1088/0960-1317/25/7/075006		8	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CL4AZ	WOS:000356896100017		
J	Sun, B; Nogami, H; Pen, Y; Sawada, R				Sun, Bin; Nogami, Hirfoumi; Pen, Yao; Sawada, Renshi			Microelectromagnetic actuator based on a 3D printing process for fiber scanner application	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						3D printing; electromagnetic actuator; fiber scanner; tilted coil	OPTICAL COHERENCE TOMOGRAPHY; MIRROR	A novel electromagnetic-actuated fiber scanner has been proposed for ultra-thin scanning fiber endoscope application. A free-fixed optical fiber cantilever with a cylindrical magnet can be driven and vibrated by a tilted coil on a tube surface under electromagnetic force. The tiny coil with a large tilt angle as the actuator is fabricated by a new three-dimensional (3D) printing technology and handmade hybrid process. It is an efficient and low-cost method for fabricating tiny 3D tilted coils compared with the complicated micromachining process. A 2.0 mm outer diameter tilted coil has been successfully developed. The line pitch, tilt angle, resistance and turns of this fabricated coil are 75 mu m, 60 degrees, 20 Omega and 100 turns, respectively. The scanning motion of the assembled scanner utilizing the fabricated 3D coil, fiber and a small magnet has been measured by a high-speed camera. The scanner consists of a 9 mm-length optical fiber, a 2 mm outer diameter cylindrical magnet, a jig and a fabricated tilted coil. The displacement of the fiber tip in the scanner is observed and measured when the alternative current-driven voltage was applied to the tilted coil, and 126.8 mu m maximum displacement has been obtained. The present fiber scanner with 3D tilted coil has promise for use as an important inspecting device for biomedical endoscope application.	[Sun, Bin; Nogami, Hirfoumi; Pen, Yao; Sawada, Renshi] Kyushu Univ, Fukuoka, Fukuoka 8190395, Japan	Sun, B (reprint author), Kyushu Univ, Fukuoka, Fukuoka 8190395, Japan.	sun.nanomicro416@gmail.com			Selco Co., Ltd., Ohaza Mikageshinden Komoro City, Nagano, Japan	The authors would like to thank Selco Co., Ltd., 2130-1, Ohaza Mikageshinden Komoro City, Nagano, 384-0808, Japan, for its support and help with the 3D print fabrication.	Yeow JTW, 2005, SENSOR ACTUAT A-PHYS, V117, P331, DOI 10.1016/j.sna.2004.06.021; Pan YT, 2001, OPT LETT, V26, P1966, DOI 10.1364/OL.26.001966; Judy JW, 1997, J MICROELECTROMECH S, V6, P249, DOI 10.1109/84.623114; Bakke T, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/6/064010; Catanzaro A, 2003, GASTROINTEST ENDOSC, V57, P300, DOI 10.1067/mge.2003.113; HU FR, 2012, INT J LIGHT ELECT OP, V123, P387; Izhar U, 2011, SENSOR ACTUAT A-PHYS, V167, P152, DOI 10.1016/j.sna.2011.04.003; Jung W, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2195092; Matsunaga T, 2010, PROC IEEE MICR ELECT, P999; Seibel EJ, 2003, P SOC PHOTO-OPT INS, V4957, P46, DOI 10.1117/12.478049; SEIBEL EJ, 2001, P SOC PHOTO-OPT INS, V4158, P29, DOI 10.1117/12.413801; Smits JG, 2005, J MICROMECH MICROENG, V15, P1285, DOI 10.1088/0960-1317/15/6/021; Wang LQ, 2009, J SIGNAL PROCESS SYS, V54, P7, DOI 10.1007/s11265-008-0197-3; Wu L, 2009, J MICRO-NANOLITH MEM, V8, DOI 10.1117/1.3082186; Xu Y, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/12/125005; Zara JM, 2003, OPT LETT, V28, P628, DOI 10.1364/OL.28.000628	16	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	JUL	2015	25	7							075014	10.1088/0960-1317/25/7/075014		8	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CL4AZ	WOS:000356896100025		
J	Saito-Kato, M; Tanimura, Y; Mori, S; Julius, ML				Saito-Kato, Megumi; Tanimura, Yoshihiro; Mori, Shinobu; Julius, Matthew L.			Morphological evolution of Stephanodiscus (Bacillariophyta) in Lake Biwa from a 300 ka fossil record	JOURNAL OF MICROPALAEONTOLOGY			English	Article						diatoms; evolutionary rate; Lake Biwa; morphological evolution; phylogeny	SP-NOV BACILLARIOPHYTA; CICHLID FISHES; LIFE-CYCLE; DIATOM; JAPAN; VICTORIA; CLIMATE; MODELS; BAIKAL; FAUNA	A series of intermittent changes in Stephanodiscus (Bacillariophyta) valve morphology was observed in sediment core materials collected from Lake Biwa, Japan. A constant sedimentation rate reveals a continuous but punctuated pattern of morphological evolution. Morphological parameters, including maximum diameter and fascicle number v. diameter ratio (fascicle density), showed long periods of stasis and less than 10 000-year directional changes. Specifically, directional decreases in fascicle density occurred at 200-190 and 160-150 ka, and increases in maximum diameter occurred at 130-120 ka. According to a morphology-based species definition, a non-branching phylogenetic lineage originating from a cosmopolitan ancestor can be presumed from a morphology-based cladistic analysis and the biostratigraphic record. Evolutionary modes were selected from directional change, random walk, stasis and combined models by a statistical test, paleoTS, to clarify that the sequential changes are composed of relatively long stasis modes and short directional change modes. Global climate change was probably an influence during the early stages of the history of Lake Biwa.	[Saito-Kato, Megumi; Tanimura, Yoshihiro] Natl Museum Nat & Sci, Dept Geol & Paleontol, Tsukuba, Ibaraki 3050005, Japan; [Julius, Matthew L.] St Cloud State Univ, Dept Biol Sci, St Cloud, MN 56379 USA	Saito-Kato, M (reprint author), Natl Museum Nat & Sci, Dept Geol & Paleontol, 4-1-1 Amakubo, Tsukuba, Ibaraki 3050005, Japan.	memekato@kahaku.go.jp			 [200306364]	We are grateful to Dr E. Cox and especially Dr G. Hunt for their reviews. This work was partly supported by Grant-in-Aid for JSPS Fellows (200306364) for M. S.-K.	Roopnarine PD, 1999, PALEOBIOLOGY, V25, P41; Johnson TC, 1996, SCIENCE, V273, P1091, DOI 10.1126/science.273.5278.1091; Verheyen E, 2003, SCIENCE, V300, P325, DOI 10.1126/science.1080699; Nishino M, 2000, ADV ECOL RES, V31, P151, DOI 10.1016/S0065-2504(00)31011-X; de Garidel-Thoron T, 2005, NATURE, V433, P294, DOI 10.1038/nature03189; Hunt G, 2008, PALEOBIOLOGY, V34, P360, DOI 10.1666/07073.1; MALMGREN BA, 1983, PALEOBIOLOGY, V9, P377; Hunt G, 2006, PALEOBIOLOGY, V32, P578, DOI 10.1666/05070.1; Barron J.A., 1987, SILICEOUS SEDIMENTAR, P164; Edlund MB, 1996, J PHYCOL, V32, P165, DOI 10.1111/j.0022-3646.1996.00165.x; EDLUND MB, 2006, NOVA HEDWIGIA S, V130, P339; Eldredge N., 1972, P82; Erwin D.H., 1995, NEW APPROACHES SPECI; Goto T., 1998, DIATOM, V14, P35; HAKANSSON H, 1986, NORD J BOT, V6, P501, DOI 10.1111/j.1756-1051.1986.tb00906.x; Hopkins MJ, 2012, P NATL ACAD SCI USA, V109, P20520, DOI 10.1073/pnas.1209901109; Horie S., 1972, PALEOLIMNOLOGY LAKE, V1; Hunt G, 2010, PALAEONTOLOGY, V53, P1255, DOI 10.1111/j.1475-4983.2010.01007.x; Hunt G, 2012, PALEOBIOLOGY, V38, P351, DOI 10.1666/11047.1; Hunt G., 2008, EVOLUTION GEOBIOLOGY, V14, P117; Kato M, 2003, PHYCOLOGIA, V42, P292, DOI 10.2216/i0031-8884-42-3-292.1; Kawabe T., 1981, J GEOLOGICAL SOC JAP, V87, P457; Khursevich GK, 2005, QUATERN INT, V136, P95, DOI 10.1016/j.quaint.2004.11.011; Kuwae M, 2007, DIATOM, V23, P71; Machida H., 2003, ATLAS TEPHRA JAPAN; Machida H., 1991, QUATERNARY RES, V30, P439; Maddison D.R., 2005, MACCLADE VERSION 4 0; Meier R., 2000, SPECIES CONCEPTS PHY; MEYERS PA, 1993, QUATERNARY RES, V39, P154, DOI 10.1006/qres.1993.1019; Miyoshi N, 1999, REV PALAEOBOT PALYNO, V104, P267, DOI 10.1016/S0034-6667(98)00058-X; Mori S., 1974, PALEOLIMNOLOGY LAKE, V2, P247; Mori S., 1984, LAKE BIWA, P531; Mori S., 1975, PALEOLIMNOL LAKE BIW, V3, P368; Nakagawa T, 2008, GEOLOGY, V36, P491, DOI 10.1130/G24586A.1; Potapova M, 1997, J PHYCOL, V33, P924, DOI 10.1111/j.0022-3646.1997.00924.x; ROUND F. E., 1990, DIATOMS BIOL MORPHOL; Smith A.B., 1994, SYSTEMATICS FOSSIL R; Swofford D.L., 1998, PAUP PHYLOGENETIC AN; Takemura K., 1976, PALEOLIMNOLOGY LAKE, V4, P79; Tanaka H, 2000, DIATOM RES, V15, P149; Tanaka M., 1985, B MIZUNAMI FOSSIL MU, V12, P57; THERIOT E, 1992, SYST BIOL, V41, P141, DOI 10.2307/2992517; Theriot E., 1984, BACILLARIA, V7, P37; Theriot EC, 2006, PALEOBIOLOGY, V32, P38, DOI 10.1666/0094-8373(2006)032[0038:LQRMEO]2.0.CO;2; Tuji Akihiro, 2000, Phycological Research, V48, P231, DOI 10.1046/j.1440-1835.2000.00207.x; Tuji Akihiro, 2002, Phycological Research, V50, P313, DOI 10.1111/j.1440-1835.2002.tb00163.x; Tuji A., 2001, LAKE BIWA MONOGRAPHS, V7; Yokoyama T., 1984, LAKE BIWA MONOGRAPHI, V54, P43; Yoshikawa S., 1991, EARTH SCI, V45, P81; Yoshikawa S., 1993, EARTH SCI, V47, P97	50	0	0	GEOLOGICAL SOC PUBL HOUSE	BATH	UNIT 7, BRASSMILL ENTERPRISE CENTRE, BRASSMILL LANE, BATH BA1 3JN, AVON, ENGLAND	0262-821X			J MICROPALAEONTOL	J. Micropalaentol.	JUL	2015	34		2				165	179		10.1144/jmpaleo2014-015		15	Paleontology	Paleontology	CM1HF	WOS:000357431200004		
J	Del Portillo, A; Lagana, SM; Yao, Y; Uehara, T; Jhala, N; Ganguly, T; Nagy, P; Gutierrez, J; Luna, A; Abrams, J; Liu, Y; Brand, R; Sepulveda, JL; Falk, GW; Sepulveda, AR				Del Portillo, Armando; Lagana, Stephen M.; Yao, Yuan; Uehara, Takeshi; Jhala, Nirag; Ganguly, Tapan; Nagy, Peter; Gutierrez, Jorge; Luna, Aesis; Abrams, Julian; Liu, Yang; Brand, Randall; Sepulveda, Jorge L.; Falk, Gary W.; Sepulveda, Antonia R.			Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							HIGH-GRADE DYSPLASIA; DIAGNOSIS; SURVEILLANCE; MANAGEMENT; METAANALYSIS; MULTICENTER; PROGRESSION; BIOMARKERS; MORTALITY; HISTOLOGY	Barrett's intestinal metaplasia (BIM) may harbor genomic mutations before the histologic appearance of dysplasia and cancer and requires frequent surveillance.,We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus by testing nonneoplastic BIM. Formalin-fixed, paraffin-embedded (FFPE) routine biopsy or endoscopic mucosal resection samples from 32 patients were tested: nonprogressors to HGD or EAC (BIM-NP) with BIM, who never had a diagnosis of dysplasia or EAC (N = 13); progressors to HGD or EAC (BIM-P) with BIM and a worse diagnosis of HGD or EAC (N = 15); and four BIM-negative samples. No mutations were detected in the BIM-NP (0 of 13) or BIM-negative samples, whereas the BIM-P samples had mutations in 6 (75 %) of 8 cases in TP53, APC, and CDKN2A (P = 0.0005), detected in samples with as low as 20% BIM. We found that next-generation sequencing from routine FFPE nonneoplastic Barrett's esophagus samples can detect multiple mutations in minute areas of BIM with high analytical sensitivity. Next-generation sequencing panels for detection of TP53 and possibly combined mutations in other genes, such as APC and CDKN2A, may be useful in the clinical setting to improve dysplasia and cancer surveillance in patients with Barrett's esophagus.	[Del Portillo, Armando; Lagana, Stephen M.; Nagy, Peter; Gutierrez, Jorge; Luna, Aesis; Sepulveda, Jorge L.; Sepulveda, Antonia R.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Abrams, Julian] Columbia Univ, Div Gastroenterol, New York, NY 10032 USA; [Yao, Yuan; Jhala, Nirag] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Ganguly, Tapan] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; [Falk, Gary W.] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; [Uehara, Takeshi] Shinshu Univ, Dept Pathol, Nagano, Japan; [Liu, Yang; Brand, Randall] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	Sepulveda, AR (reprint author), Columbia Univ, Dept Pathol & Cell Biol, 630 W 168th St,VC-14,Room 212, New York, NY 10032 USA.	as4400@columbia.edu		Falk, Gary/0000-0002-7143-1436	Clinical and Translational Research Institute-Pilots Across the Spirit Program (CTSI-PATS) pilot grant from the Institute for Translational Medicine and Therapeutics (University of Pennsylvania, Philadelphia, PA); Department of Pathology and Cell Biology (Columbia University, New York City, NY); BETRNET consortium [5U54CA163004]; NIH [UL1TR000005, R01EB016657, R01CA185363]	Supported in part by a Clinical and Translational Research Institute-Pilots Across the Spirit Program (CTSI-PATS) pilot grant from the Institute for Translational Medicine and Therapeutics (University of Pennsylvania, Philadelphia, PA; A.R.S. and G.W.F.); the Department of Pathology and Cell Biology (Columbia University, New York City, NY); pilot award 5U54CA163004 from the BETRNET consortium (A.R.S.); and NIH grants UL1TR000005 (Y.L. and R.B.), R01EB016657 (Y.L.), and R01CA185363 (Y.L.).	Li XH, 2014, CANCER PREV RES, V7, P114, DOI 10.1158/1940-6207.CAPR-13-0289; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; Corley DA, 2013, GASTROENTEROLOGY, V145, P312, DOI 10.1053/j.gastro.2013.05.004; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Downs-Kelly E, 2008, AM J GASTROENTEROL, V103, P2333, DOI 10.1111/j.1572-0241.2008.02020.x; Jin Z, 2009, CANCER RES, V69, P4112, DOI 10.1158/0008-5472.CAN-09-0028; Pohl H, 2010, CANCER EPIDEM BIOMAR, V19, P1468, DOI 10.1158/1055-9965.EPI-10-0012; BLOUNT PL, 1994, CANCER RES, V54, P2292; Gaddam S, 2013, GASTROENTEROLOGY, V145, P548, DOI 10.1053/j.gastro.2013.05.040; Prasad GA, 2008, CANCER, V113, P470, DOI [10.1002/cncr.23573, 10.1002/cncr23573]; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Sikkema M, 2010, CLIN GASTROENTEROL H, V8, P235, DOI 10.1016/j.cgh.2009.10.010; Spechler SJ, 2011, GASTROENTEROLOGY, V140, P1084, DOI 10.1053/j.gastro.2011.01.030; Weaver JMJ, 2014, NAT GENET, V46, P837, DOI 10.1038/ng.3013; Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Wani S, 2009, AM J GASTROENTEROL, V104, P502, DOI 10.1038/ajg.2008.31; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Barr H, 2011, ANN NY ACAD SCI, V1232, P76, DOI 10.1111/j.1749-6632.2011.06046.x; Biondi Antonio, 2010, Front Biosci (Elite Ed), V2, P489, DOI 10.2741/e107; Caygill CPJ, 2011, ANN NY ACAD SCI, V1232, P196, DOI 10.1111/j.1749-6632.2011.06052.x; Kaz AM, 2014, CANCER LETT, V342, P193, DOI 10.1016/j.canlet.2012.02.036; Spechler SJ, 2011, GASTROENTEROLOGY, V140, pE18, DOI 10.1053/j.gastro.2011.01.031; Vaezi MF, 2013, GASTROENTEROLOGY, V145, P503, DOI 10.1053/j.gastro.2013.07.020; Younes M, 1997, DIGEST DIS SCI, V42, P697, DOI 10.1023/A:1018828207371; ZAR J. H., 1999, BIOSTATISTICAL ANAL	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2015	17	4					412	419		10.1016/j.jmoldx.2015.02.006		8	Pathology	Pathology	CM1LE	WOS:000357441600010		
J	Tanahashi, K; Natsume, A; Ohka, F; Motomura, K; Alim, A; Tanaka, I; Senga, T; Harada, I; Fukuyama, R; Sumiyoshi, N; Sekido, Y; Wakabayashi, T				Tanahashi, Kuniaki; Natsume, Atsushi; Ohka, Fumiharu; Motomura, Kazuya; Alim, Adiljan; Tanaka, Ichidai; Senga, Takeshi; Harada, Ichiro; Fukuyama, Ryuichi; Sumiyoshi, Naoyuki; Sekido, Yoshitaka; Wakabayashi, Toshihiko			Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Meningioma; Merlin; YAP	MEDIATES CONTACT INHIBITION; SUPPRESSOR GENE-PRODUCT; HIPPO SIGNALING-PATHWAY; SIZE-CONTROL; ORGAN SIZE; YAP; NF2; PROLIFERATION; TRANSCRIPTION; GROWTH	The NF2 gene product Merlin is a protein containing ezrin, radixin, and moesin domains; it is a member of the 4.1 protein superfamily associated with the membrane cytoskeleton and also interacts with cell surface molecules. The mammalian Hippo cascade, a downstream signaling cascade of merlin, inactivates the Yes-associated protein (YAP). Yes-associated protein is activated by loss of the NF2 gene and functions as an oncogene in meningioma cells; however, the factors controlling YAP expression, phosphorylation, and subcellular localization in meningiomas have not been fully elucidated. Here, we demonstrate that merlin expression is heterogeneous in 1 NF2 gene-negative and 3 NF2 gene-positive World Health Organization grade I meningiomas. In the NF2 gene-positive meningiomas, regions with low levels of merlin (tumor rims) had greater numbers of cells with nuclear YAP versus regions with high merlin levels (tumor cores). Merlin expression and YAP phosphorylation were also affected by cell density in the IOMM-Lee and HKBMM human meningioma cell lines; nuclear localization of YAP was regulated by cell density and extracellular matrix (ECM) stiffness in IOMM-Lee cells. These results suggest that cell density and ECM stiffness may contribute to the heterogeneous loss of merlin and increased nuclear YAP expression in human meningiomas.	[Tanahashi, Kuniaki; Natsume, Atsushi; Ohka, Fumiharu; Motomura, Kazuya; Alim, Adiljan; Wakabayashi, Toshihiko] Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 4668550, Japan; [Senga, Takeshi] Nagoya Univ, Sch Med, Div Canc Biol, Nagoya, Aichi 4668550, Japan; [Tanaka, Ichidai; Sekido, Yoshitaka] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; [Tanaka, Ichidai] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4668550, Japan; [Harada, Ichiro] Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Tokyo 152, Japan; [Fukuyama, Ryuichi; Sumiyoshi, Naoyuki] Konan Kosei Hosp, Div Clin Pathol, Konan, Aichi, Japan	Natsume, A (reprint author), Nagoya Univ, Sch Med, Dept Neurosurg, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	anatsume@med.nagoya-u.ac.jp					Hartmann C, 2006, BRAIN PATHOL, V16, P15, DOI 10.1111/j.1750-3639.2006.tb00557.x; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Evans DGR, 2009, GENET MED, V11, P599, DOI 10.1097/GIM.0b013e3181ac9a27; Helias-Rodzewicz Z, 2010, GENE CHROMOSOME CANC, V49, P1161, DOI 10.1002/gcc.20825; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1102/gad.226302; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Imoto I, 2001, CANCER RES, V61, P6629; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Hao YW, 2008, J BIOL CHEM, V283, P5496; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Yip AK, 2013, BIOPHYS J, V104, P19, DOI 10.1016/j.bpj.2012.11.3805; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Kalamarides M, 2008, BRAIN PATHOL, V18, P62, DOI 10.1111/j.1750-3639.2007.00105.x; Baia GS, 2012, MOL CANCER RES, V10, P904, DOI 10.1158/1541-7786.MCR-12-0116; Fernandez LA, 2009, GENE DEV, V23, P2729, DOI DOI 10.1101/GAD.1824509; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2015	74	7					704	709		10.1097/NEN.0000000000000211		6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CL4QA	WOS:000356937000005		
J	Sugawara, T; Aoyagi, M; Ogishima, T; Kawano, Y; Tamaki, M; Yano, T; Tsunoda, A; Ohno, K; Maehara, T; Kishimoto, S				Sugawara, Takashi; Aoyagi, Masaru; Ogishima, Takahiro; Kawano, Yoshihisa; Tamaki, Masashi; Yano, Tomoyuki; Tsunoda, Atsunobu; Ohno, Kikuo; Maehara, Taketoshi; Kishimoto, Seiji			Extended orbital exenteration for sinonasal malignancy with orbital apex extension: surgical technique and clinical analysis	JOURNAL OF NEUROSURGERY			English	Article						craniofacial resection; orbital exenteration; sinonasal malignancies; surgical technique	ANTERIOR CRANIOFACIAL RESECTION; SKULL BASE; TUMORS	OBJECT The majority of sinonasal malignancies present with advanced disease, and cure rates are generally poor. Surgical extirpation remains the mainstay of treatment. In cases of sinonasal malignancy with orbital apex extension, gross-total tumor resection requires orbital exenteration and bony skull base resection around the orbital apex to provide sufficient margins. In this retrospective study, the authors describe their surgical strategy in and technique for orbital exenteration with orbital apex resection in patients at Tokyo Medical and Dental University who had sinonasal malignancy with orbital apex extension. They also analyzed the clinical features of and the results in these patients. METHODS Between February 2001 and August 2012 at the authors' institution, sinonasal malignancy with orbital apex extension was treated using craniofacial tumor resection with orbital exenteration including skull base bone around the orbital apex. The authors describe this technique and analyze the surgical indications, extent of resection, primary tumor location, outcome, pathological findings, and neoadjuvant and adjuvant therapies of the patients who underwent the technique. RESULTS The patients consisted of 12 men and 3 women with a mean age of 47.7 years (range 14-79 years). The longest postoperative follow-up was 9.5 years, and the shortest was 0.67 year (mean 3.0 years). Tumor originated at the ethmoid sinus in 6 patients (40%), maxillary sinus in 5 (33%), nasal cavity in 2 (13%), and orbital cavity and maxillary bone in 1 patient each (7%). Histological analysis of tumor specimens revealed squamous cell carcinoma in 9 patients (60%), rhabdomyosarcoma in 2 (13%), and small cell carcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma, and Ewing sarcoma in 1 patient each (7%). Two patients experienced recurrences at 1 and 5 months after treatment; these patients died at 5 and 10 months after surgery, respectively. Estimated 5-year recurrence-free survival (RFS) was 86.7%, and estimated 5-year overall survival (OS) was 86.2%; there was no perioperative mortality. None of the patients had new neurological deficits as a result of the surgery, but 5 patients suffered infectious complications from the graft transplanted into the cavity after resection. There were no other perioperative complications. CONCLUSIONS These authors are the first to describe a technique for extended orbital exenteration with orbital apex skull base resection. The technique provided sufficient margins for gross-total resection of the sinonasal malignancy with orbital apex extension. The estimated 5-year OS and RFS rates were high, and the perioperative complication rate was acceptably low, demonstrating the safety and efficacy of this technique.	[Sugawara, Takashi; Aoyagi, Masaru; Ogishima, Takahiro; Kawano, Yoshihisa; Ohno, Kikuo; Maehara, Taketoshi] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo 1138519, Japan; [Tsunoda, Atsunobu; Kishimoto, Seiji] Tokyo Med & Dent Univ, Dept Head & Neck Surg, Tokyo 1138519, Japan; [Yano, Tomoyuki] Tokyo Med & Dent Univ, Dept Plast & Reconstruct Surg, Tokyo 1138519, Japan; [Kishimoto, Seiji] Kameda Med Ctr, Dept Head & Neck Surg, Chiba, Japan; [Tamaki, Masashi] Musashino Red Cross Hosp, Dept Neurosurg, Tokyo, Japan	Sugawara, T (reprint author), Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	sugawara.nsrg@tmd.ac.jp					Patel SG, 2003, CANCER, V98, P1179, DOI 10.1002/cncr.11630; Ganly I, 2005, HEAD NECK-J SCI SPEC, V27, P575, DOI 10.1002/hed.20165; Fukumitsu N, 2012, INT J RADIAT ONCOL, V83, P704, DOI 10.1016/j.ijrobp.2011.07.032; Cantu G, 2012, HEAD NECK-J SCI SPEC, V34, P78, DOI 10.1002/hed.21685; Cantu G, 1999, HEAD NECK-J SCI SPEC, V21, P185; DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667; MCCAFFREY TV, 1994, LARYNGOSCOPE, V104, P940; Shah JP, 1997, ARCH OTOLARYNGOL, V123, P1312; Solero CL, 2000, NEUROSURGERY, V47, P1296, DOI 10.1097/00006123-200012000-00007; Suarez C, 2004, HEAD NECK-J SCI SPEC, V26, P136, DOI 10.1002/hed.10358	10	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					52	58		10.3171/2014.9.JNS141256		7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200007		
J	Satomi, J; Ghaibeh, AA; Moriguchi, H; Nagahiro, S				Satomi, Junichiro; Ghaibeh, A. Ammar; Moriguchi, Hiroki; Nagahiro, Shinji			Predictability of the future development of aggressive behavior of cranial dural arteriovenous fistulas based on decision tree analysis	JOURNAL OF NEUROSURGERY			English	Article						predictability; decision tree analysis; dural arteriovenous fistulas; vascular disorders	CORTICAL VENOUS REFLUX; NATURAL-HISTORY; CLINICAL-COURSE; CLASSIFICATION; MALFORMATIONS; MANAGEMENT; DRAINAGE	OBJECT The severity of clinical signs and symptoms of cranial dural arteriovenous fistulas (DAVFs) are well correlated with their pattern of venous drainage. Although the presence of cortical venous drainage can be considered a potential predictor of aggressive DAVF behaviors, such as intracranial hemorrhage or progressive neurological deficits due to venous congestion, accurate statistical analyses are currently not available. Using a decision tree data mining method, the authors aimed at clarifying the predictability of the future development of aggressive behaviors of DAVF and at identifying the main causative factors. METHODS Of 266 DAVF patients, 89 were eligible for analysis. Under observational management, 51 patients presented with intracranial hemorrhage/infarction during the follow-up period. RESULTS The authors created a decision tree able to assess the risk for the development of aggressive DAVF behavior. Evaluated by 10-fold cross-validation, the decision tree's accuracy, sensitivity, and specificity were 85.28%, 88.33%, and 80.83%, respectively. The tree shows that the main factor in symptomatic patients was the presence of cortical venous drainage. In its absence, the lesion location determined the risk of a DAVF developing aggressive behavior. CONCLUSIONS Decision tree analysis accurately predicts the future development of aggressive DAVF behavior.	[Satomi, Junichiro; Nagahiro, Shinji] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Neurosurg, Tokushima 7708503, Japan; [Ghaibeh, A. Ammar; Moriguchi, Hiroki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med Informat, Tokushima 7708503, Japan	Satomi, J (reprint author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Neurosurg, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	junichirosatomi@gmail.com					Podgorelec Vili, 2002, J Med Syst, V26, P445, DOI 10.1023/A:1016409317640; Satomi J, 2005, NEUROSURGERY, V56, P494, DOI 10.1227/01.NEU.0000153750.95524.62; van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Braga-Neto UM, 2004, BIOINFORMATICS, V20, P374, DOI 10.1093/bioinformatics/btg419; Bulters DO, 2012, NEUROSURGERY, V70, P312, DOI 10.1227/NEU.0b013e318230966f; Gross BA, 2012, NEUROSURGERY, V71, P594, DOI 10.1227/NEU.0b013e31825eabdb; Satomi J, 2002, J NEUROSURG, V97, P767, DOI 10.3171/jns.2002.97.4.0767; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485; AWAD IA, 1990, J NEUROSURG, V72, P839, DOI 10.3171/jns.1990.72.6.0839; Duffau H, 1999, J NEUROSURG, V90, P78, DOI 10.3171/jns.1999.90.1.0078; LASJAUNIAS P, 1986, J NEUROSURG, V64, P724, DOI 10.3171/jns.1986.64.5.0724; Guyon I., 2003, Journal of Machine Learning Research, V3, DOI 10.1162/153244303322753616; Jamous MA, 2004, NEUROL MED-CHIR, V44, P516, DOI 10.2176/nmc.44.516; Quinlan J. R., 1986, Machine Learning, V1, DOI 10.1023/A:1022643204877; Shah MN, 2012, J NEUROSURG, V117, P539, DOI 10.3171/2012.5.JNS111257; Strom RG, 2009, NEUROSURGERY, V64, P241, DOI 10.1227/01.NEU.0000338066.30665.B2; Zipfel GJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0928	19	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					86	90		10.3171/2014.10.JNS141429		5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200012		
J	Kanemaru, K; Kinouchi, H; Yoshioka, H; Yagi, T; Wakai, T; Hashimoto, K; Fukumoto, Y; Umeda, T; Onishi, H; Nishiyama, Y; Horikoshi, T				Kanemaru, Kazuya; Kinouchi, Hiroyuki; Yoshioka, Hideyuki; Yagi, Takashi; Wakai, Takuma; Hashimoto, Koji; Fukumoto, Yuichiro; Umeda, Takako; Onishi, Hiroshi; Nishiyama, Yoshihisa; Horikoshi, Toru			Cerebral hemodynamic disturbance in dural arteriovenous fistula with retrograde leptomeningeal venous drainage: a prospective study using I-123-iodoamphetamine single photon emission computed tomography	JOURNAL OF NEUROSURGERY			English	Article						dural arteriovenous fistula; endovascular treatment; retrograde leptomeningeal venous drainage; single photon emission computed tomography; venous congestion; vascular disorders	CLINICAL-COURSE; PRETREATMENT; MALFORMATION; REFLUX	OBJECT The severity of cerebral hemodynamic disturbance caused by retrograde leptomeningeal venous drainage (RLVD) of a dural arteriovenous fistula (dAVF) is related to neurological morbidity and unfavorable outcome. However, the cerebral hemodynamics of this disorder have not been elucidated well. The aim of this study was to assess the relationship between the cerebral venous congestive encephalopathy represented as a high-intensity area (HIA) on T2-weighted MR images and the cerebral hemodynamics examined by I-123-iodoamphetamine (IMP) single photon emission computed tomography (SPECT), as well as the predictive value of I-123-IMP SPECT for the development and reversibility of venous congestion encephalopathy. METHODS Based on the pre- and posttreatment T2 HIAs associated with venous congestion encephalopathy, patients were divided into 3 groups: a normal group, an edema group, and an infarction group. The regional cerebral blood flow (rCBF) at the region with RLVD was analyzed by I-123-IMP SPECT, and the results were compared among the groups. RESULTS There were 11, 6, and 3 patients in the normal, edema, and infarction groups, respectively. No patients in the normal group showed any symptoms related to venous congestion. In contrast, all patients in the edema and infarction groups developed neurological symptoms. The rCBF in the edema group was significantly lower than that in the normal group, and significantly higher than that in the infarction group. The cerebral vascular reactivity (CVR) of the infarction, group was significantly lower than that of the normal and edema groups. After treatment, the neurological signs disappeared in the edema group, but only partial improvement was seen in the infarction group. The rCBF also significantly increased in the normal and edema groups, but not in the infarction group. CONCLUSIONS Quantitative rCBF measurement is useful for evaluating hemodynamic disturbance in dAVF with RLVD. The reduction of rCBF was strongly correlated with the severity of venous congestive encephalopathy, and loss of CVR is a reliable indicator of irreversible venous infarction caused by RLVD.	[Kanemaru, Kazuya; Kinouchi, Hiroyuki; Yoshioka, Hideyuki; Yagi, Takashi; Wakai, Takuma; Hashimoto, Koji; Fukumoto, Yuichiro; Nishiyama, Yoshihisa; Horikoshi, Toru] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Neurosurg, Chuo Ku, Kofu, Yamanashi 4093898, Japan; [Umeda, Takako; Onishi, Hiroshi] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Radiol, Chuo Ku, Kofu, Yamanashi 4093898, Japan	Kinouchi, H (reprint author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Neurosurg, Chuo Ku, 1110 Shimokato, Kofu, Yamanashi 4093898, Japan.	hkinouchi@yamanashi.ac.jp					van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44; Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485; Iida H, 2010, J NUCL MED, V51, P1624, DOI 10.2967/jnumed.110.078352; COGNARD C, 1995, RADIOLOGY, V194, P671; Kai Y, 2009, NEURORADIOLOGY, V51, P731, DOI 10.1007/s00234-009-0567-y; BORDEN JA, 1995, J NEUROSURG, V82, P705; Duffau H, 1997, ACTA NEUROCHIR, V139, P914, DOI 10.1007/BF01411299; Kai Y, 2003, AM J NEURORADIOL, V24, P619; Kawaguchi T, INTERV NEURORADIO S1, V10, P127; KURATA A, 1994, J NEUROSURG, V80, P552, DOI 10.3171/jns.1994.80.3.0552; Kuroda S, 2004, NEUROSURGERY, V54, P585, DOI 10.1227/01.NEU.000018863.30871.FD; Kuwayama N, 2005, ACT NEUR S, V94, P123; Mineta T, 1991, Neurol Med Chir (Tokyo), V31, P41, DOI 10.2176/nmc.31.41; NENCINI P, 1993, J NEUROL NEUROSUR PS, V56, P929, DOI 10.1136/jnnp.56.8.929; Strom RG, 2009, NEUROSURGERY, V64, P241, DOI 10.1227/01.NEU.0000338066.30665.B2	15	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					110	117		10.3171/2014.10.JNS141576		8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200016		
J	Nishijima, Y; Niizuma, K; Fujimura, M; Akamatsu, Y; Shimizu, H; Tominaga, T				Nishijima, Yasuo; Niizuma, Kuniyasu; Fujimura, Miki; Akamatsu, Yosuke; Shimizu, Hiroaki; Tominaga, Teiji			Consistent delayed unilateral neuronal death after modified transient focal cerebral ischemia in mice that mimics neuronal injury after transient global cerebral ischemia	JOURNAL OF NEUROSURGERY			English	Article						apoptosis; delayed neuronal death; hippocampus; laser speckle flowmetry; mice; unilateral	CAROTID-ARTERY OCCLUSION; FOREBRAIN ISCHEMIA; LASER SPECKLE; MOUSE MODEL; STRAIN; DAMAGE; BRAIN; SUSCEPTIBILITY; VASCULATURE; HIPPOCAMPUS	OBJECT Numerous studies have attempted to reveal the pathophysiology of ischemic neuronal injury using a representative transient global cerebral ischemia (tGCI) model in rodents; however, most of them have used gerbil or rat models. Recent advances in transgene and gene-knockout technology have enabled the precise molecular mechanisms of ischemic brain injury to be investigated. Because the predominant species for the study of genetic mutations is the mouse, a representative mouse model of tGCI is of particular importance. However, simple mouse models of tGC1 are less reproducible; therefore, a more complex process or longer duration of ischemia, which causes a high mortality rate, has been used in previous tGCI models in mice. In this study, the authors aimed to overcome these problems and attempted to produce consistent unilateral delayed hippocampal CA1 neuronal death in mice. METHODS C57BL/6 mice were subjected to short-term unilateral cerebral ischemia using a 4-mm silicone-coated intraluminal suture to obstruct the origin of the posterior cerebral artery (PCA), and regional cerebral blood flow (rCBF) of the PCA territory was measured using laser speckle flowmetry. The mice were randomly assigned to groups of different ischemic durations and histologically evaluated at different time points after ischemia. The survival rate and neurological score of the group that experienced 15 minutes of ischemia were also evaluated. RESULTS Consistent neuronal death was observed in the medial CA1 subregion 4 days after 15 minutes of ischemia in the group of mice with a reduction in rCBF of < 65% in the PCA territory during ischemia. Morphologically degenerated cells were mostly positive for terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick-end labeling and cleaved caspase 3 staining 4 days after ischemia. The survival rates of the mice 24 hours (n = 24), 4 days (n = 15), and 7 days (n = 7) after being subjected to 15 minutes of ischemia were 95.8%, 100%, and 100%, respectively, and the mice had slight motor deficits. CONCLUSIONS The authors established a model of delayed unilateral hippocampal neuronal death in C57BL16 Mice by inducing ischemia in the PCA territory using an intraluminal suture method and established inclusion criteria for PCA-territory rCBF monitored by laser speckle flowmetry. This model may be useful for investigating the precise molecular mechanisms of ischemic brain injury.	[Nishijima, Yasuo; Niizuma, Kuniyasu; Fujimura, Miki; Akamatsu, Yosuke; Shimizu, Hiroaki; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan	Niizuma, K (reprint author), Tohoku Univ, Grad Sch Med, Dept Neurosurg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	niizuma@nsg.med.tohoku.ac.jp			JSPS [24659642]	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. The following grant funded this study: JSPS KAKENHI grant no. 24659642.	PULSINELLI WA, 1979, STROKE, V10, P267; Fujii M, 1997, STROKE, V28, P1805; Zhen G, 2007, J NEUROSCI METH, V166, P73, DOI 10.1016/j.jneumeth.2007.06.029; Wellons JC, 2000, BRAIN RES, V868, P14, DOI 10.1016/S0006-8993(00)02216-2; Dorr A, 2007, NEUROIMAGE, V35, P1409, DOI 10.1016/j.neuroimage.2006.12.040; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319; Kreisman NR, 2000, J NEUROPHYSIOL, V83, P1031; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; Yonekura I, 2004, J CEREBR BLOOD F MET, V24, P151, DOI 10.1097/01.WCB.0000096063.84070.Cl; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570; Olsson T, 2003, BRAIN RES, V982, P260, DOI 10.1016/S0006-8993(03)03014-2; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5; Sheng HX, 1999, J NEUROSCI METH, V88, P103, DOI 10.1016/S0165-0270(99)00018-7; Onken M, 2012, J NEUROSCI METH, V204, P254, DOI 10.1016/j.jneumeth.2011.11.022; Yoshioka H, 2011, J NEUROTRAUM, V28, P649, DOI 10.1089/neu.2010.1662; Panahian N, 1996, NEUROSCIENCE, V72, P343, DOI 10.1016/0306-4522(95)00563-3; Forrester KR, 2002, MED BIOL ENG COMPUT, V40, P687, DOI 10.1007/BF02345307; Akamatsu Y, 2012, J NEUROSURG, V116, P657, DOI 10.3171/2011.11.JNS111167; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; de Araujo FLB, 2012, J NEUROL SCI, V312, P73, DOI 10.1016/j.jns.2011.08.019; GINSBERG MD, 1989, STROKE, V20, P1627; Kawahara N, 2002, NEUROSCI LETT, V322, P91, DOI 10.1016/S0304-3940(02)00101-5; Keskintepe L, 2007, TRANSGENIC RES, V16, P751, DOI 10.1007/s11248-007-9125-8; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Pegorini S, 2005, BRIT J PHARMACOL, V144, P727, DOI 10.1038/sj.bjp.0706115; Tiireyen K, 2005, NEUROSURGERY, V56, P196; Wei G, 2010, J NEUROSCI METH, V185, P230, DOI 10.1016/j.jneumeth.2009.09.026	29	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					243	253		10.3171/2014.9.JNS14778		11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200031		
J	Fujimaki, T				Fujimaki, Takamitsu			Vertebral artery pexy for microvascular decompression	JOURNAL OF NEUROSURGERY			English	Letter							HEMIFACIAL SPASM		Saitama Med Univ, Moroyama, Saitama, Japan	Fujimaki, T (reprint author), Saitama Med Univ, Moroyama, Saitama, Japan.						Sulica L, 2008, LARYNGOSCOPE, V118, P1303, DOI 10.1097/MLG.0b013e31816f27ee; BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201; Ferreira M, 2011, J NEUROSURG, V114, P1800, DOI 10.3171/2010.12.JNS10891; Fujimaki T, 2005, JPN J NEUROSURG TOKY, V14, P78; Kim JP, 2008, J KOREAN NEUROSURG S, V44, P131, DOI 10.3340/jkns.2008.44.3.131; 2011, J NEUROSURG, V114, P1800	6	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					293	294				2	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200042		
J	Suo, R; Li, HQ; Yoshinaga, K; Nagai, T; Mizobe, H; Kojima, K; Nagao, K; Beppu, F; Gotoh, N				Suo, Rei; Li, Haoqi; Yoshinaga, Kazuaki; Nagai, Toshiharu; Mizobe, Hoyo; Kojima, Koichi; Nagao, Koji; Beppu, Fumiaki; Gotoh, Naohiro			Generation of Tetracosahexaenoic Acid in Benthic Marine Organisms	JOURNAL OF OLEO SCIENCE			English	Article						docosahexaenoic acid; lipid metabolism; N-3 highly unsaturated fatty acid; starfish; tetracosahexaenoic acid	FATTY-ACIDS; POSITIONAL DISTRIBUTION; ALL-CIS-6,9,12,15,18,21-TETRACOSAHEXAENOIC ACID; 4,7,10,13,16,19-DOCOSAHEXAENOIC ACID; EICOSANOID PRODUCTION; LIPIDS; METABOLISM	Tetracosahexaenoic acid (THA, 24:6n-3) has been shown to have the strongest ability to suppress accumulation of lipids in HepG2 cells among well-known n-3 highly unsaturated fatty acids, such as EPA and DHA. In this study, a method for mass production of THA was investigated using distributions of THA and DHA in thirty-two marine organisms, such as starfishes, right-eyed flounders, shellfishes, and sharks. The fatty acid composition of the marine organisms was analyzed using GC-FID and THA was detected in starfish, right-eyed flounder, and shark. Furthermore, the ratio of DHA and THA (DHA/THA) in each sample was calculated using chromatogram peak area of GC-FID, and the value was found to be lower than 1 in some starfishes. As a result, THA was thought to be synthesized in the starfishes. In contrast, the value of DHA/THA for right-eyed flounder and sharks was greater than 1. The THA accumulation in right-eyed flounder was considered to be because of the starfishes that the flounder consumes as part of its diet. DHA is synthesized from THA by beta-oxidation in peroxisomes, in the Sprecher's shunt. The high accumulation of THA observed in the flounder would be caused by the decreasing enzyme activation due to beta-oxidation in the peroxisomes of the starfishes. Understanding the differences in THA between aquatic species could also potentially allow us to understand why THA is generated in marine animals.	[Suo, Rei; Li, Haoqi; Beppu, Fumiaki; Gotoh, Naohiro] Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, Tokyo 1088477, Japan; [Yoshinaga, Kazuaki; Nagai, Toshiharu; Mizobe, Hoyo; Kojima, Koichi] Tsukishima Foods Ind Co Ltd, Edogawa Ku, Tokyo 1348520, Japan; [Nagao, Koji] Saga Univ, Dept Appl Biochem & Food Sci, Saga, Saga 8408502, Japan	Gotoh, N (reprint author), Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, 4-5-7 Konan, Tokyo 1088477, Japan.	ngotoh@kaiyodai.ac.jp	BEPPU, Fumiaki/O-1986-2014; GOTOH, Naohiro/O-1975-2014				VOSS A, 1991, J BIOL CHEM, V266, P19995; Ishihara K, 1998, LIPIDS, V33, P1107, DOI 10.1007/s11745-998-0312-9; Nichols PD, 2003, LIPIDS, V38, P1207, DOI 10.1007/s11745-003-1180-z; Camoes F, 2015, BBA-MOL CELL RES, V1853, P111, DOI 10.1016/j.bbamcr.2014.10.005; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ikeda I, 1998, LIPIDS, V33, P897, DOI 10.1007/s11745-998-0286-7; LINKO RR, 1970, J AM OIL CHEM SOC, V47, P42, DOI 10.1007/BF02541455; Luthria DL, 1996, J BIOL CHEM, V271, P16020; Mansour MP, 2005, BIOCHEM SYST ECOL, V33, P659, DOI 10.1016/j.bse.2004.12.011; Nagao K, 2014, J OLEO SCI, V63, P979, DOI 10.5650/jos.ess14118; OTA T, 1994, FISHERIES SCI, V60, P171; TAKAGI T, 1986, LIPIDS, V21, P430, DOI 10.1007/BF02536398; Tomita Y, 2009, FISHERIES SCI, V75, P445, DOI 10.1007/s12562-008-0048-y; VYSOTSKII MV, 1991, BIOCHIM BIOPHYS ACTA, V1083, P161, DOI 10.1016/0005-2760(91)90037-I; Wanasundara UN, 1997, J FOOD LIPIDS, V4, P51, DOI 10.1111/j.1745-4522.1997.tb00080.x	15	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUL	2015	64	7					721	727		10.5650/jos.ess15079		7	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CM0DK	WOS:000357348400004		
J	Arai, K; Mizobuchi, Y; Tokuji, Y; Aida, K; Yamashita, S; Ohnishi, M; Kinoshita, M				Arai, Katsuhito; Mizobuchi, Yu; Tokuji, Yoshihiko; Aida, Kazuhiko; Yamashita, Shinji; Ohnishi, Masao; Kinoshita, Mikio			Effects of Dietary Plant-Origin Glucosylceramide on Bowel Inflammation in DSS-Treated Mice	JOURNAL OF OLEO SCIENCE			English	Article						glucosylceramide; IBD; plant lipid; sphingolipid; cytokine	COLON-CANCER; SPHINGOLIPID CLASSES; WHEAT-FLOUR; CELLS; APOPTOSIS; COLITIS; SPHINGOMYELIN; INTESTINE; DISEASE; MODEL	The effects of dietary plant-origin glucosylceramide (GlcCer) on symptoms similar to those of inflammatory bowel diseasewere investigated in dextran sulfate sodium salt (DSS)-treated mice. Dietary GlcCer suppressed decreases in body weight due to DSS administration. To determine its effects on the colon, we examined its surface under a microscope following toluidine blue staining. Dietary GlcCer decreased DSS-induced chorionic crypt injury and elevated myeloperoxidase levels. Moreover, dietary GlcCer significantly suppressed the production of cytokines by the intestinal mucosa. These results provide evidence for the suppression of DSS-induced inflammation by dietary GlcCer.	[Arai, Katsuhito; Mizobuchi, Yu; Tokuji, Yoshihiko; Yamashita, Shinji; Ohnishi, Masao; Kinoshita, Mikio] Obihiro Univ Agr & Vet Med, Dept Food Sci, Obihiro, Hokkaido 0808555, Japan; [Aida, Kazuhiko] Nippon Flour Mills Co Ltd, Cent Lab, Atsugi, Kanagawa 2430041, Japan	Kinoshita, M (reprint author), Obihiro Univ Agr & Vet Med, Dept Food Sci, Inada Cho, Obihiro, Hokkaido 0808555, Japan.	kinosita@obihiro.ac.jp	Tokuji, Yoshihiko/F-6744-2015	Tokuji, Yoshihiko/0000-0001-6476-3363			Aida K., 2005, J OLEO SCI, V54, P45; Aida KK, 2004, J OLEO SCI, V53, P503; Yunoki K, 2008, BIOSCI BIOTECH BIOCH, V72, P222, DOI 10.1271/bbb.70463; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; BIERI JG, 1979, J NUTR, V109, P925; Adam D, 2001, NATURE, V412, P467, DOI 10.1038/35087720; Duan RD, 2009, PROG LIPID RES, V48, P62, DOI 10.1016/j.plipres.2008.04.003; Vesper H, 1999, J NUTR, V129, P1239; Sugawara T, 2003, J NUTR, V133, P2777; Rogler G, 1998, WORLD J SURG, V22, P382; Fischbeck A, 2011, GUT, V60, P55, DOI 10.1136/gut.2009.201988; Nilsson A, 2006, J LIPID RES, V47, P154, DOI 10.1194/jlr.M500357-JLR200; Menaldino DS, 2003, PHARMACOL RES, V47, P373, DOI 10.1016/S1043-6618(03)00054-9; Kunisawa J, 2012, NUTRIENTS, V4, P154, DOI 10.3390/nu4030154; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70; Mazzei JC, 2011, J NUTR BIOCHEM, V22, P1160, DOI 10.1016/j.jnutbio.2010.09.017; Maines LW, 2008, DIGEST DIS SCI, V53, P997, DOI 10.1007/s10620-007-0133-6; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; Fujino Y, 1976, Biochim Biophys Acta, V486, P161; Hattori T, 2007, INT J HYPERTHER, V23, P591, DOI 10.1080/02656730701708328; Kinoshita M, 1999, ARTERIOSCL THROM VAS, V19, P2323; Kinoshita M, 2009, J FOOD LIPIDS, V16, P200, DOI 10.1111/j.1745-4522.2009.01141.x; OHNISHI M, 1985, AGR BIOL CHEM TOKYO, V49, P3609; OHNISHI M, 1985, AGR BIOL CHEM TOKYO, V49, P3327; SNOW AD, 1983, CANCER RES, V43, P4838; Sugawara T, 2002, BIOSCI BIOTECH BIOCH, V66, P2228, DOI 10.1271/bbb.66.2228; Yoshioka K, 2012, SCAND J IMMUNOL, V75, P16, DOI 10.1111/j.1365-3083.2011.02607.x; Yoshioka Y, 2008, INT IMMUNOPHARMACOL, V8, P1802, DOI 10.1016/j.intimp.2008.08.021; Zigmond E, 2007, GUT, V56, P82, DOI 10.1136/gut.2006.095497	29	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUL	2015	64	7					737	742		10.5650/jos.ess15005		6	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CM0DK	WOS:000357348400006		
J	Nagai, N; Yoshioka, C; Tanino, T; Ito, Y; Okamoto, N; Shimomura, Y				Nagai, Noriaki; Yoshioka, Chiaki; Tanino, Tadatoshi; Ito, Yoshimasa; Okamoto, Norio; Shimomura, Yoshikazu			Decrease in Corneal Damage due to Benzalkonium Chloride by the Addition of Mannitol into Timolol Maleate Eye Drops	JOURNAL OF OLEO SCIENCE			English	Article						mannitol; benzalkonium chloride; cornea; timolol maleate; preservative	CHANG CONJUNCTIVAL CELLS; OXIDATIVE STRESS; EPITHELIAL-CELLS; IN-VITRO; GLAUCOMA; LATANOPROST; TRAVOPROST; APOPTOSIS; RABBIT; PERMEABILITY	We investigated the protective effects of mannitol on corneal damage caused by benzalkonium chloride (BAC), which is used as a preservative in commercially available timolol maleate eye drops, using rat debrided corneal epithelium and a human cornea epithelial cell line (HCE-T). Corneal wounds were monitored using a fundus camera TRC-50X equipped with a digital camera; eye drops were instilled into rat eyes five times a day after corneal epithelial abrasion. The viability of HCE-T cells was calculated by TetraColor One; and Escherichia coli (ATCC 8739) were used to measure antimicrobial activity. The reducing effects on transcorneal penetration and intraocular pressure (IOP) of the eye drops were determined using rabbits. The corneal wound healing rate and rate constant (k(H)), as well as cell viability, were higher following treatment with 0.005% BAC solution containing 0.5% mannitol than in the case BAC solution alone; the antimicrobial activity was approximately the same for BAC solutions with and without mannitol. In addition, the k(H) for rat eyes instilled with commercially available timolol maleate eye drops containing 0.5% mannitol was significantly higher than that for eyes instilled with timolol maleate eye drops without mannitol, and the addition of mannitol did not affect the corneal penetration or TOP reducing effect of the timolol maleate eye drops. A preservative system comprising BAC and mannitol may provide effective therapy for glaucoma patients requiring long-term treatment with anti-glaucoma agents.	[Nagai, Noriaki; Yoshioka, Chiaki; Tanino, Tadatoshi; Ito, Yoshimasa] Kinki Univ, Fac Pharm, Osaka 5778502, Japan; [Okamoto, Norio; Shimomura, Yoshikazu] Kinki Univ, Fac Med, Dept Ophthalmol, Osaka 5898511, Japan	Ito, Y (reprint author), Kinki Univ, Fac Pharm 1, 3-4-1 Kowakae, Osaka 5778502, Japan.	itoyoshi@phar.kindai.ac.jp					Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; WILSON WS, 1975, BRIT J OPHTHALMOL, V59, P667, DOI 10.1136/bjo.59.11.667; ARMALY MF, 1980, ARCH OPHTHALMOL-CHIC, V98, P2163; Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P642; Nagai N, 2009, BIOL PHARM BULL, V32, P933; Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832; KUPPENS EVMJ, 1995, BRIT J OPHTHALMOL, V79, P339, DOI 10.1136/bjo.79.4.339; Zagon IS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1082, DOI 10.1001/archopht.125.8.1082; Guenoun JM, 2005, INVEST OPHTH VIS SCI, V46, P4594, DOI 10.1167/iovs.05-0776; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; Guenoun JM, 2005, INVEST OPHTH VIS SCI, V46, P2444, DOI 10.1167/iovs.04-1331; BURSTEIN NL, 1980, INVEST OPHTH VIS SCI, V19, P308; Chung SH, 2006, MOL VIS, V12, P415; De Saint, 2000, CURR EYE RES, V20, P85; De Saint, 1999, INVEST OPHTH VIS SCI, V40, P619; Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P2525; Dunbar CA, 1998, KONA, V16, P7; IWATA S, 1980, YAKUGAKU ZASSHI, V100, P402; Liu JH, 2010, J OCUL PHARMACOL TH, V26, P249, DOI 10.1089/jop.2009.0127; Nagai N, 2013, J OLEO SCI, V62, P159, DOI 10.5650/jos.62.159; Nagai N, 2010, J OLEO SCI, V59, P135, DOI 10.5650/jos.59.135; Okamoto N, 2010, J OLEO SCI, V59, P423, DOI 10.5650/jos.59.423; Pisella PJ, 2000, OPHTHALMIC RES, V32, P3, DOI 10.1159/000055579; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635; Rolando M, 1991, THE LACRIMAL SYSTEM, P89; Yakuji Nippo Ltd, 2006, JAP PHARM, P15	26	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUL	2015	64	7					743	750		10.5650/jos.ess14275		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CM0DK	WOS:000357348400007		
J	Matsuoka, K; Kase, A; Matsuo, T; Ashida, Y				Matsuoka, Keisuke; Kase, Asumi; Matsuo, Takashi; Ashida, Yusuke			Competitive Solubilization of Cholesterol/Cholesteryl Oleate and Seven Species of Sterol/Stanol in Model Intestinal Solution System	JOURNAL OF OLEO SCIENCE			English	Article						bile salt; solubilization; cholesterol; sterol; stanol; model intestinal solution	BILE-SALT MICELLES; PLANT STEROLS; CHOLESTEROL ABSORPTION; AROMATIC-COMPOUNDS; LIPID SYSTEMS; SITOSTEROL; STANOL; DETERMINANTS; PHYTOSTEROLS; SOLUBILITIES	The addition of plant sterols/stanols (sterols or stanols) can reduce the solubilization of cholesterol in a model intestinal solution system. We studied the molecular structure of seven different sterols/stanols and the effect they had on the solubilization of cholesterol or cholesterol ester in a model intestinal solution. The differences in the molecular structures of the sterol/stanol species influenced their abilities to reduce the solubility of cholesterol in the competitive solubilization experiments. Cholestanol whose molecular structure resembled cholesterol was the most effective at reducing the solubilization of cholesterol and cholesterol ester, with the solubilities of cholesterol and cholesteryl oleate being 41% and 39% respectively of the values observed for the single solubilizate systems. beta-Sitosterol was also able to reduce the solubilities of cholesterol and cholesteryl oleate to 43% and 45% of those observed in a single solubilizate system. Both, stigmasterol and brassicasterol have an unsaturated double bond in a steroid side chain and did not exhibit major cholesterol-lowering effects. These results were reflected by the Gibbs free energy change values (Delta G(0)) for solubilization, where the sterol/stanol species with cholesterol-lowering effects had similar or larger negative Delta G(0) values than those observed for cholesterol.	[Matsuoka, Keisuke] Saitama Univ, Chem Lab, Fac Educ, Sakura Ku, Saitama, Saitama 3388570, Japan; [Kase, Asumi; Matsuo, Takashi; Ashida, Yusuke] Showa Pharmaceut Univ, Dept Phys Chem, Machida, Tokyo 1948543, Japan	Matsuoka, K (reprint author), Saitama Univ, Chem Lab, Fac Educ, Sakura Ku, 255 Shimo Okubo, Saitama, Saitama 3388570, Japan.	matsuokakei@mail.saitama-u.ac.jp			Japan Society for the Promotion of Science [21790043]	This study was supported by a Grant-in-Aid for Young Scientists (B) (21790043) from the Japan Society for the Promotion of Science.	Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; ARMSTRONG MJ, 1987, J LIPID RES, V28, P1144; Matsuoka K, 2008, CHEM PHYS LIPIDS, V154, P87, DOI 10.1016/j.chemphyslip.2008.05.002; Rasmussen HE, 2006, J NUTR, V136, P2722; RICHMOND W, 1973, CLIN CHEM, V19, P1350; Sugioka H, 1998, BBA-LIPID LIPID MET, V1394, P99, DOI 10.1016/S0005-2760(98)00090-3; Matsuoka K, 2010, CHEM PHYS LIPIDS, V163, P397, DOI 10.1016/j.chemphyslip.2010.03.006; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Trautwein EA, 2003, EUR J LIPID SCI TECH, V105, P171, DOI 10.1002/ejlt.200390033; Katan MB, 2003, MAYO CLIN PROC, V78, P965; de Jong A, 2003, J NUTR BIOCHEM, V14, P362, DOI 10.1016/S0955-2863(03)00002-0; Miettinen TA, 2004, ANN MED, V36, P126, DOI 10.1080/07853890310021625; IKEDA I, 1989, J NUTR SCI VITAMINOL, V35, P361; VAHOUNY GV, 1983, AM J CLIN NUTR, V37, P805; MAZER NA, 1980, BIOCHEMISTRY-US, V19, P601, DOI 10.1021/bi00545a001; Doi Y, 2004, J PHYS CHEM B, V108, P2594, DOI 10.1021/jp0304879; Hamada T, 2006, LIPIDS, V41, P551, DOI 10.1007/s11745-006-5004-y; Hayes KC, 2004, J NUTR, V134, P1395; Ishizaki T, 2005, FOODS FOOD INGRE J J, V210, P512; KOCHHAR SP, 1983, PROG LIPID RES, V22, P161, DOI 10.1016/0163-7827(83)90008-5; Matsuoka K, 2007, CHEM PHYS LIPIDS, V148, P51, DOI 10.1016/j.chemphyslip.2007.04.007; Matsuoka K, 2002, BBA-MOL CELL BIOL L, V1580, P200, DOI 10.1016/S1388-1981(01)00204-9; Matsuoka K, 2012, CHEM PHYS LIPIDS, V165, P7, DOI 10.1016/j.chemphyslip.2011.10.004; Matsuoka K, 2007, B CHEM SOC JPN, V80, P2334, DOI 10.1246/bcsj.80.2334; Mel'nikov SM, 2004, CHEM PHYS LIPIDS, V127, P121, DOI 10.1016/j.chemphyslip.2003.09.015; MONTET JC, 1971, BIOCHIMIE, V53, P751, DOI 10.1016/S0300-9084(71)80115-3; Nagadome S, 2001, LANGMUIR, V17, P4405, DOI 10.1021/la010087h; O'Neill FH, 2005, AM J CARDIOL, V96, p29D, DOI 10.1016/j.amjcard.2005.03.017; STAGGERS JE, 1990, BIOCHEMISTRY-US, V29, P2028, DOI 10.1021/bi00460a011; WAUCHOPE RD, 1972, J CHEM ENG DATA, V17, P38, DOI 10.1021/je60052a020	30	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUL	2015	64	7					783	791		10.5650/jos.ess15044		9	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CM0DK	WOS:000357348400011		
J	Umeno, A; Takashima, M; Murotomi, K; Nakajima, Y; Koike, T; Matsuo, T; Yoshida, Y				Umeno, Aya; Takashima, Mizuki; Murotomi, Kazutoshi; Nakajima, Yoshihiro; Koike, Taisuke; Matsuo, Toshiki; Yoshida, Yasukazu			Radical-scavenging Activity and Antioxidative Effects of Olive Leaf Components Oleuropein and Hydroxytyrosol in Comparison with Homovanillic Alcohol	JOURNAL OF OLEO SCIENCE			English	Article						antioxidant; oleuropein; free radical; lipid peroxidation; olive leaf	LIPID-PEROXIDATION; VITAMIN-E; CAPACITY; OIL; REACTIVITY; BO-653; CHAIN	Olive leaf has great potential as a natural antioxidant, and one of its major phenolic components is oleuropein. In this study, the antioxidant activity of oleuropein against oxygen-centered radicals was measured by examining its sparing effects on the peroxyl radical-induced decay of fluorescein and pyrogallol red, in comparison with related compounds. The antioxidant capacity of oleuropein against lipid peroxidation was also assessed through its effect on the free radical-induced oxidation of methyl linoleate in a micelle system. On a molar basis, oleuropein and hydroxytyrosol inhibited the decay of fluorescein for longer than both homovanillic alcohol and the vitamin-E mimic 2-carboxy-2,5,7,8-tetramethyl-6-chromanol (Trolox), but did not suppress pyrogallol red decay in a concentration-dependent manner. Measurement of the fluorescein decay period revealed that the stoichiometric number of oleuropein and hydroxytyrosol against peroxyl radicals was twice that of Trolox, which is substantially higher than expectations based on chemical structure. Oleuropein and hydroxytyrosol were also more effective than Trolox and homovanillic alcohol at suppressing the oxidation of methyl linoleate in the micelle system. Thus, both oleuropein and hydroxytyrosol exhibit high antioxidative activity against lipid peroxidation induced by oxygen-centered radicals, but the high reactivity of phenolic/catecholic radicals makes their mechanism of action complex.	[Umeno, Aya; Murotomi, Kazutoshi; Nakajima, Yoshihiro; Yoshida, Yasukazu] Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Takamatsu, Kagawa 7610395, Japan; [Takashima, Mizuki] Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Ikeda, Osaka 5638577, Japan; [Koike, Taisuke; Matsuo, Toshiki] Eisai Food & Chem Co Ltd, Chuo Ku, Tokyo 1030027, Japan	Yoshida, Y (reprint author), AIST, Hlth Res Inst, 2217-14 Hayashi Cho, Takamatsu, Kagawa 7610395, Japan.	yoshida-ya@aist.go.jp			Oil & Fat Industry Kaikan; Adaptable and Seamless Technology Transfer Program through target-driven RD, JST	We thank Prof. Etsuo Niki for his excellent advice in preparing this paper. This work was partially supported by a Grant-in-Aid of Foundation, Oil & Fat Industry Kaikan and Adaptable and Seamless Technology Transfer Program through target-driven R&D, JST.	Deiana M, 2010, FOOD CHEM TOXICOL, V48, P3008, DOI 10.1016/j.fct.2010.07.041; Khayyal MT, 2002, ARZNEIMITTEL-FORSCH, V52, P797; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; Niki E, 2010, FREE RADICAL BIO MED, V49, P503, DOI 10.1016/j.freeradbiomed.2010.04.016; Rietjens SJ, 2007, J AGR FOOD CHEM, V55, P7609, DOI 10.1021/jf0706934; Valavanidis A, 2004, J AGR FOOD CHEM, V52, P2358, DOI 10.1021/jf030491h; Incani A, 2010, MOL NUTR FOOD RES, V54, P788, DOI 10.1002/mnfr.200900098; Fujisawa S, 2004, CHEM PHYS LIPIDS, V130, P189, DOI 10.1016/j.chemphyslip.2004.03.005; NIKI E, 1982, CHEM LETT, P789, DOI 10.1246/cl.1982.789; Niki E, 2008, J AGR FOOD CHEM, V56, P8255, DOI 10.1021/jf800605x; Niki E, 2008, BIOORG MED CHEM LETT, V18, P2464, DOI 10.1016/j.bmcl.2008.02.038; Omata Y, 2009, FOOD CHEM, V114, P429, DOI 10.1016/j.foodchem.2008.09.066; Sgarbossa A, 2012, CHEM-BIOL INTERACT, V199, P87, DOI 10.1016/j.cbi.2012.06.006; Stoyanovsky DA, 2011, ANAL CHEM, V83, P6432, DOI 10.1021/ac200418s; Takashima M, 2012, BIOFACTORS, V38, P240, DOI 10.1002/biof.1014; Terao J, 2009, FORUM NUTR, V61, P87, DOI 10.1159/000212741; Watanabe A, 2000, J AM CHEM SOC, V122, P5438, DOI 10.1021/ja9942080	17	1	1	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	JUL	2015	64	7					793	800		10.5650/jos.ess15042		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CM0DK	WOS:000357348400012		
J	Torigoe, T; Sato, S; Nagayama, Y; Sato, T; Yamazaki, H				Torigoe, T.; Sato, S.; Nagayama, Y.; Sato, T.; Yamazaki, H.			Influence of patent ductus arteriosus and ventilators on electrical velocimetry for measuring cardiac output in very-low/low birth weight infants	JOURNAL OF PERINATOLOGY			English	Article							GOAL-DIRECTED THERAPY; THERMODILUTION; SURGERY; ECHOCARDIOGRAPHY; METAANALYSIS; PRECISION; CHILDREN	OBJECTIVE: We evaluated electrical velocimetry, a noninvasive method for continuous cardiac output measurement, in very-low and low birth weight infants and the influence of patent ductus arteriosus (PDA) and ventilators on this method. STUDY DESIGN: This prospective study compared 81 pairs of simultaneous cardiac output measurements by electrical velocimetry and transthoracic echocardiography in 28 patients. Data were compared by correlation, Bland-Altman analysis and two-way analysis of variance. RESULTS: The two methods exhibited a high correlation (r = 0.859, P<0.0001). The bias (mean difference of the methods) and percent error (100 x 1.96 x s. d./mean cardiac output) were -6ml min(-1) and 29.2%, respectively. PDA significantly affected the bias (P = 0.0004), but ventilators did not (P = 0.14). Hemodynamically significant PDA had a larger bias (-36 ml min(-1)) and higher percent error (38.6%). CONCLUSIONS: Although influenced by PDA, electrical velocimetry was generally interchangeable with transthoracic echocardiography even using ventilators.	[Torigoe, T.; Nagayama, Y.; Sato, T.; Yamazaki, H.] Niigata City Gen Hosp, Dept Neonatol, Niigata 9501197, Japan; [Sato, S.] Niigata City Gen Hosp, Dept Pediat, Niigata 9501197, Japan	Torigoe, T (reprint author), Niigata City Gen Hosp, Dept Neonatol, Chuo Ku, 463-7 Shumoku, Niigata 9501197, Japan.	tsukasa-t-vw12@zd5.so-net.ne.jp					Mertens L, 2011, J AM SOC ECHOCARDIOG, V24, P1057, DOI 10.1016/j.echo.2011.07.014; Ehrenkranz RA, 1999, PEDIATRICS, V104, P280, DOI 10.1542/peds.104.2.280; Norozi K, 2008, BRIT J ANAESTH, V100, P88, DOI 10.1093/bja/aem320; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Grollmuss O, 2012, INTENS CARE MED, V38, P1032, DOI 10.1007/s00134-012-2530-3; Critchley LAH, 1999, J CLIN MONITOR COMP, V15, P85, DOI 10.1023/A:1009982611386; Zoremba N, 2007, ACTA ANAESTH SCAND, V51, P1314, DOI 10.1111/j.1399-6576.2007.01445.x; Pearse R, 2005, CRIT CARE, V9, pR687, DOI 10.1186/cc3887; Raaijmakers E, 1999, CRIT CARE MED, V27, P1203, DOI 10.1097/00003246-199906000-00053; Noori S, 2012, ARCH DIS CHILD-FETAL, V97, pF340, DOI 10.1136/fetalneonatal-2011-301090; BLAND JM, 1986, LANCET, V1, P307; Cecconi M, 2009, CRIT CARE, V13, DOI 10.1186/cc7129; Fakler U, 2007, J THORAC CARDIOV SUR, V133, P224, DOI 10.1016/j.jtcvs.2006.07.038; Futier E, 2010, CRIT CARE, V14, DOI 10.1186/cc9310; Lobo SM, 2006, CRIT CARE, V10, DOI 10.1186/4913; Mekis D, 2008, EUR J ANAESTH, V25, P237, DOI 10.1017/S0265021507002669; Osthaus WA, 2007, PEDIATR ANESTH, V17, P749, DOI 10.1111/j.1460-9592.2007.02210.x; Raue W, 2009, EUR J ANAESTH, V26, P1067, DOI 10.1097/EJA.0b013e32832bfd94; Schmidt C, 2005, BRIT J ANAESTH, V95, P603, DOI 10.1093/bja/aei224; SHAFFER SG, 1987, PEDIATRICS, V79, P702; Tomaske M, 2008, BRIT J ANAESTH, V100, P517, DOI 10.1093/bja/aen024; Vijlbrief DC, 2012, NEONATOLOGY, V102, P243, DOI 10.1159/000339117	22	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	JUL	2015	35	7					485	489		10.1038/jp.2014.245		5	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CL6EA	WOS:000357059200006		
J	Dassanayake, ABN; Fujii, Y; Fukuda, D; Kodama, J				Dassanayake, A. B. N.; Fujii, Yoshiaki; Fukuda, Daisuke; Kodama, Jun-ichi			A new approach to evaluate effective stress coefficient for strength in Kimachi sandstone	JOURNAL OF PETROLEUM SCIENCE AND ENGINEERING			English	Article						Effective stress coefficient; Modified Failure Envelope Method; Peak strength; Residual strength; Bulk modulus	ROCK; PERMEABILITY; COMPRESSION	This paper is devoted to the experimental investigation of effective stress coefficient for peak and residual strengths of saturated Kimachi sandstone. Authors have described the Modified Failure Envelope Method (MFEM), which can be used to obtain the effective stress coefficients for peak and residual strengths (alpha(-Peak) and alpha(-Residual)). The effective stress coefficients for intact and fractured Kimachi sandstone (alpha(-Biot's) and alpha(-Fractured)) were also evaluated using conventional methods, and the data were compared with the coefficient values obtained by MFEM for the peak and residual strengths. The effective stress coefficient for intact rock, alpha(-Biot's) decreased with increasing confining pressure, and was in the range 1 > alpha(-Biot's) > 0.8. The effective stress coefficient for fractured rock, alpha(-Fractured), was larger than that for intact rock and was close to unity. The effective stress coefficient calculated for peak strengths, alpha(-Peak), using both the single and multistage MFEMs, decreased with increasing effective confining pressure and was in the range 0.8 > alpha(-Peak) > 0.4. For residual strength states, effective stress coefficient, alpha(-Residual), was between the peak strength value and that for intact rock. Based on the results, multistage MFEM is suitable for obtaining an effective stress coefficient for the peak strength, alpha(-Peak). An equation to obtain the effective stress coefficient from total confining pressure and pore pressure, and a method to choose the coefficients for elastic stress analyses and failure evaluations for intact rock structures or structures in rock mass were proposed. (C) 2015 Elsevier B.V. All rights reserved.	[Dassanayake, A. B. N.; Fujii, Yoshiaki; Fukuda, Daisuke; Kodama, Jun-ichi] Hokkaido Univ, Grad Sch Engn, Rock Mech Lab, Sapporo, Hokkaido 0608628, Japan	Dassanayake, ABN (reprint author), Hokkaido Univ, Grad Sch Engn, Rock Mech Lab, N13W8, Sapporo, Hokkaido 0608628, Japan.	abndassanayake@gmail.com	Fujii, Yoshiaki/A-5701-2012; FUKUDA, Daisuke/C-5422-2013	Fujii, Yoshiaki/0000-0003-0431-4093; 	KAKENHI [26420840]	This work was partially supported by KAKENHI (26420840).	Alam A.A., 2009, EUROPEC EAGE C EXH 8, P1; Alam AKMB, 2014, INT J ROCK MECH MIN, V65, P49, DOI 10.1016/j.ijrmms.2013.11.006; Alam MM, 2010, J PETROL SCI ENG, V70, P282, DOI 10.1016/j.petrol.2009.11.021; Youn H, 2010, INT J ROCK MECH MIN, V47, P678, DOI 10.1016/j.ijrmms.2009.12.017; Dhakal G, 2002, ENG GEOL, V65, P31, DOI 10.1016/S0013-7952(01)00101-6; Biot M., 1941, J APPL PHYS, V12, P155; Biot M. A., 1957, ASME J APPL MECH, V24, P594; Blot M.A., 1955, J APPL PHYS, V26, P182; Detournay E., 1993, COMPREHENSIVE ROCK E, VII, P113; Franquet J.A., 1999, P 37 US S ROCK MECH, P349; Geertsma J., 1957, PETROLEUM T AIME, V210, P331; Hu DW, 2010, INT J ROCK MECH MIN, V47, P962, DOI 10.1016/j.ijrmms.2010.06.007; KOVARI K, 1983, INT J ROCK MECH MIN, V20, P283; Jaeger J.C., 2007, FUNDAMENTALS ROCK ME, V4th, P97; Makhnenko R.M., 2013, P 5 BIOT C POR VIENN; NUR A, 1971, J GEOPHYS RES, V76, P6414, DOI 10.1029/JB076i026p06414; Sheng Q.Y., 2012, ROCK MECH ROCK ENG, V45, P583; Terzaghi K, 1936, 1ST P INT C SOIL MEC, VI, P54; Zhang K, 2009, ACTA MECH SOLIDA SIN, V22, P251; Zimmerman R. W., 1991, COMPRESSIBILITY SAND	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-4105	1873-4715		J PETROL SCI ENG	J. Pet. Sci. Eng.	JUL	2015	131						70	79		10.1016/j.petrol.2015.04.015		10	Energy & Fuels; Engineering, Petroleum	Energy & Fuels; Engineering	CL8LA	WOS:000357225000007		
J	Nariai, T; Fujita, K; Kawane, K; Mori, M; Nakayama, R; Matsuda, K; Katayama, S; Fukuda, N; Hori, S; Iwata, M; Hasegawa, F; Suzuki, K; Kato, H				Nariai, Tetsuro; Fujita, Katsuya; Kawane, Kenji; Mori, Masaya; Nakayama, Ryo; Matsuda, Koichi; Katayama, Seiji; Fukuda, Nobuhisa; Hori, Seiji; Iwata, Masato; Hasegawa, Futoshi; Suzuki, Kuniko; Kato, Hiroshi			DSR-71167, a Novel Mineralocorticoid Receptor Antagonist with Carbonic Anhydrase Inhibitory Activity, Separates Urinary Sodium Excretion and Serum Potassium Elevation in Rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							CHRONIC KIDNEY-DISEASE; HEART-FAILURE; ALDOSTERONE ANTAGONISTS; MYOCARDIAL-INFARCTION; HYPERKALEMIA; ACETAZOLAMIDE; HYPERTENSION; BLOCKADE; INJURY; SPIRONOLACTONE	Mineralocorticoid receptor (MR) antagonists, such as spironolactone (SPI) and eplerenone (EPL), are useful for treating hypertension and heart failure. However, these two agents have the serious side effect of hyperkalemia. We hypothesized that adding the ability to inhibit carbonic anhydrase (CA) would reduce the risk of hyperkalemia associated with MR antagonists. We investigated the profiles of DSR-71167 [2-([(2,2-difluoroethyl)amino]methyl)-2'-fluoro- N-(3-methoxy-4-sulfamoylphenyl)biphenyl-4-carboxamide hydrochloride; an MR antagonist with weak CA inhibitory activity] with regard to antimineralocorticoid actions by examining relationships between the urinary excretion of sodium (index of antimineralocorticoid action) in deoxycorticosterone acetate-treated rats and elevation of serum levels of potassium in potassium-loaded rats compared with a DSR-71167 derivative without CA inhibition (2-(hydroxymethyl)-N-[4-(methylsulfonyl) phenyl]-2'-(trifluoromethyl) biphenyl-4-carboxamide), SPI, and EPL. DSR-71167 dose-dependently increased urinary excretion of sodium in deoxycorticosterone acetate-treated rats without elevating serum levels of potassium in potassium-loaded rats. 2-(Hydroxymethyl)-N-[4-(methylsulfonyl) phenyl]2'-( trifluoromethyl) biphenyl-4-carboxamide, SPI, and EPL elevated serum levels of potassium significantly in potassium-loaded rats at doses that increased MR inhibitory activity. We confirmed that DSR-71167 significantly increases urinary bicarbonate and decreases blood bicarbonate, as pharmacodynamic markers of CA inhibition, in intact rats. Chronic DSR-71167 administration showed antihypertensive effects in high salt-loaded Dahl hypertensive rats. These results demonstrate that DSR-71167 is a novel type of MR antagonist, with CA inhibitory activity, which is expected to become a safer MR antagonist with a low potential risk for hyperkalemia.	[Nariai, Tetsuro; Fujita, Katsuya; Kawane, Kenji; Mori, Masaya; Nakayama, Ryo; Matsuda, Koichi; Katayama, Seiji; Fukuda, Nobuhisa; Hori, Seiji; Iwata, Masato; Hasegawa, Futoshi; Suzuki, Kuniko; Kato, Hiroshi] Sumitomo Dainippon Pharma Co, Drug Res Div, Suita, Osaka 5640053, Japan	Fujita, K (reprint author), Sumitomo Dainippon Pharma Co, Drug Res Div, 33-94 Enoki Cho, Suita, Osaka 5640053, Japan.	tetsuro-nariai@ds-pharma.co.jp; katsuya-fujita@ds-pharma.co.jp					Einhorn LM, 2009, ARCH INTERN MED, V169, P1156, DOI 10.1001/archinternmed.2009.132; Mavrakanas TA, 2014, EUR J INTERN MED, V25, P173, DOI 10.1016/j.ejim.2013.11.007; Shibata S, 2007, HYPERTENSION, V49, P355, DOI 10.1161/01.HYP.0000255636.11931.a2; Albert NM, 2009, JAMA-J AM MED ASSOC, V302, P1658, DOI 10.1001/jama.2009.1493; Nariai T, 2012, PHARMACOLOGY, V89, P44, DOI 10.1159/000335559; Kolkhof P, 2014, J CARDIOVASC PHARM, V64, P69, DOI 10.1097/FJC.0000000000000091; Chapagain A, 2012, QJM-INT J MED, V105, P1049, DOI 10.1093/qjmed/hcs106; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Nagase M, 2008, CLIN EXP NEPHROL, V12, P233, DOI 10.1007/s10157-008-0034-9; Meyers MJ, 2010, J MED CHEM, V53, P5979, DOI 10.1021/jm100505n; Rocha R, 1998, HYPERTENSION, V31, P451; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056/NEJMoa1009492; Khosla N, 2009, AM J NEPHROL, V30, P418, DOI 10.1159/000237742; Nariai T, 2011, J PHARMACOL SCI, V115, P346, DOI 10.1254/jphs.10285FP; Pitt B, 2013, EUR HEART J, V34, P2453, DOI 10.1093/eurheartj/eht187; Williams JS, 2003, J CLIN ENDOCR METAB, V88, P2364, DOI 10.1210/jc.2003-030490; Nariai T, 2012, J CARDIOVASC PHARM, V59, P458, DOI 10.1097/FJC.0b013e3182495543; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Goyal A, 2012, JAMA-J AM MED ASSOC, V307, P157, DOI 10.1001/jama.2011.1967; Schiffrin EL, 2006, HYPERTENSION, V47, P312, DOI 10.1161/01.HYP.0000201443.63240.a7; Brandish Philip E., 2008, Journal of Pharmacological and Toxicological Methods, V57, P155, DOI 10.1016/j.vascn.2008.01.002; BRECHUE WF, 1990, J APPL PHYSIOL, V69, P1397; Grossmann WM, 2000, CEREBROVASC DIS, V10, P65, DOI 10.1159/000016027; HELLER I, 1985, ARCH INTERN MED, V145, P1815, DOI 10.1001/archinte.145.10.1815; JEUNEMAITRE X, 1987, AM J CARDIOL, V60, P820, DOI 10.1016/0002-9149(87)91030-7; KASS MA, 1981, OPHTHALMOLOGY, V88, P261; Nagashima K, 1996, BIOL PHARM BULL, V19, P940; Nishiyama A, 2009, J PHARMACOL SCI, V109, P1, DOI 10.1254/jphs.08R12FM; Poggio R, 2010, POSTGRAD MED J, V86, P136, DOI 10.1136/pgmj.2008.072058; Puscas I, 1999, RES COMMUN MOL PATH, V105, P213; Roscioni SS, 2012, NAT REV NEPHROL, V8, P691, DOI 10.1038/nrneph.2012.217; Samuel JL, 2010, NAT REV CARDIOL, V7, P125, DOI 10.1038/nrcardio.2009.244; Swenson ER, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0467-3; Young MJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE883; Zhou XY, 2011, CLIN EXP HYPERTENS, V33, P538, DOI 10.3109/10641963.2011.566956	36	2	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	2015	354	1					2	9		10.1124/jpet.114.221341		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL6SG	WOS:000357096900001		
J	Akamine, T; Koyanagi, S; Kusunose, N; Hashimoto, H; Taniguchi, M; Matsunaga, N; Ohdo, S				Akamine, Takahiro; Koyanagi, Satoru; Kusunose, Naoki; Hashimoto, Hana; Taniguchi, Marie; Matsunaga, Naoya; Ohdo, Shigehiro			Dosing Time-Dependent Changes in the Analgesic Effect of Pregabalin on Diabetic Neuropathy in Mice	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							INTESTINAL EXPRESSION; ALPHA ACTIVITY; TRANSPORTER; GABAPENTIN; GENE; CHRONOTHERAPY; TRANSCRIPTION; INHIBITION; CANCER; MODEL	Patients with diabetes often develop peripheral nerve complications, including numbness and pain in the extremities. Diabetes-induced peripheral neuropathic pain is characterized by hypersensitivity to innocuous stimuli, known as tactile allodynia. Pregabalin (PGN) is currently used to treat diabetes-induced peripheral neuropathy and alleviates allodynia. In the present study, we demonstrated that the antiallodynic effect of PGN on diabetic mice was modulated by circadian changes in its intestinal absorption. A single intraperitoneal administration of 200 mg/kg streptozotocin (STZ) to mice induced type I diabetic pathologic changes that were accompanied by tactile allodynia. The intensity of tactile allodynia in STZ-induced diabetic mice was alleviated by the oral administration of PGN; however, the antiallodynic effect varied according to its dosing time. The analgesic effect of PGN was enhanced by its administration at the times of day when its intestinal absorption was accelerated. Organic cation transporter novel type 1 (Octn1) mediated the uptake of PGN into intestinal epithelial cells. The expression of Octn1 in the small intestine of STZ-induced diabetic mice oscillated in a circadian time-dependent manner. This oscillation in Octn1 appeared to cause the time of day-dependent changes in the intestinal absorption of PGN. Similar dosing time dependencies of the antiallodynic effect of PGN and oscillation in Octn1 expression were also detected in type II diabetic db/db mice. These results suggested that the dosing time-dependent differences in the analgesic effect of PGN were attributable to circadian oscillations in the intestinal expression of Octn1 and also that optimizing its dosing schedule may assist in achieving rational pharmacotherapy for diabetes-induced peripheral neuropathic pain.	[Akamine, Takahiro; Koyanagi, Satoru; Kusunose, Naoki; Hashimoto, Hana; Taniguchi, Marie; Matsunaga, Naoya; Ohdo, Shigehiro] Kyushu Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Fukuoka 8128582, Japan	Ohdo, S (reprint author), Kyushu Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	ohdo@phar.kyushu-u.ac.jp			Japan Society for the Promotion of Science [25253038, 24390149 15H04765, 25670079, 26670317]	This work was partially supported by a Grant-in-Aid for Scientific Research (A) [25253038 (to S.O.)]; a Grant-in-Aid for Scientific Research (B) [24390149 15H04765 (to S.K.)]; and a Grant-in-Aid for Challenging Exploratory Research [25670079 (to S.O.); 26670317 (to S.K.)] from the Japan Society for the Promotion of Science.	Hamdan AM, 2012, J BIOL CHEM, V287, P17224, DOI 10.1074/jbc.M111.333377; Ohdo S, 2001, NAT MED, V7, P356, DOI 10.1038/85507; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Dooley DJ, 2002, SYNAPSE, V45, P171, DOI 10.1002/syn.10094; Tamai I, 2000, J BIOL CHEM, V275, P40064, DOI 10.1074/jbc.M005340200; Levi F, 1997, LANCET, V350, P681, DOI 10.1016/S0140-6736(97)03358-8; Vermeij TAC, 2004, J CHROMATOGR B, V810, P297, DOI 10.1016/j.jchromb.2004.08.018; Lamhonwah AM, 2003, BIOCHEM BIOPH RES CO, V301, P98, DOI 10.1016/S0920-291X(02)02946-7; Stearns AT, 2008, J PHARMACOL SCI, V108, P144, DOI 10.1254/jphs.08100SC; Laposky AD, 2008, AM J PHYSIOL-REG I, V295, pR2059, DOI 10.1152/ajpregu.00026.2008; Fink K, 2002, NEUROPHARMACOLOGY, V42, P229, DOI 10.1016/S0028-3908(01)00172-1; Rosenstock J, 2004, PAIN, V110, P628, DOI 10.1016/j.pain.2004.05.001; Grundemann D, 2005, P NATL ACAD SCI USA, V102, P5256, DOI 10.1073/pnas.0408624102; Bleasby K, 2006, XENOBIOTICA, V36, P963, DOI 10.1080/00498250600861751; Gachon F, 2004, CHROMOSOMA, V113, P103, DOI 10.1007/s00412-004-0296-2; BLAY RA, 1985, DIABETES, V34, P1288, DOI 10.2337/diabetes.34.12.1288; Bostwick J, 2010, MOL CELL BIOCHEM, V338, P203, DOI 10.1007/s11010-009-0354-4; Iwamoto T, 2011, BIOSCI BIOTECH BIOCH, V75, P925, DOI 10.1271/bbb.100887; Jezyk N, 1999, PHARMACEUT RES, V16, P519, DOI 10.1023/A:1018866928335; Kavoussi R, 2006, EUR NEUROPSYCHOPHARM, V16, pS128, DOI 10.1016/j.euroneuro.2006.04.005; Kusunose N, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-83; Lemmer Björn, 2005, Expert Opin Drug Deliv, V2, P667, DOI 10.1517/17425247.2.4.667; Matsunaga N, 2008, HEPATOLOGY, V48, P240, DOI 10.1002/hep.22304; Murakami Y, 2008, GASTROENTEROLOGY, V135, P1636, DOI 10.1053/j.gastro.2008.07.073; Okamura A, 2014, J BIOL CHEM, V289, P25296, DOI 10.1074/jbc.M114.577023; Parker L, 2015, PAIN PRACT, V15, P82, DOI 10.1111/papr.12193; Piyapolrungroj N, 2001, PHARMACEUT RES, V18, P1126, DOI 10.1023/A:1010970809090; To H, 2011, CHRONOBIOL INT, V28, P267, DOI 10.3109/07420528.2011.553017; Tsuji A, 1996, PHARM RES-DORDR, V13, P963, DOI 10.1023/A:1016086003070; Wada E, 2015, MOL PHARMACOL, V87, P314, DOI 10.1124/mol.114.094979	30	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	2015	354	1					65	72		10.1124/jpet.115.223891		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CL6SG	WOS:000357096900008		
J	Fujimori, A; Sato, T				Fujimori, Azusa; Sato, Takahiro			Productivity and technology diffusion in India: The spillover effects from foreign direct investment	JOURNAL OF POLICY MODELING			English	Article						Quality ladder model; FDI spillovers; Productivity; Indian economy	MANUFACTURING FIRMS; LOCAL-PARTICIPATION; ECONOMIC-GROWTH; DOMESTIC FIRMS; PANEL-DATA; MATTER; LIBERALIZATION; EFFICIENCY; FDI	In this paper, we examine the spillover effects from foreign direct investment (FIJI) in the Indian manufacturing industries under the capital liberalisation period using macro aggregated panel data (1995-2004). In the first step, we estimate the total factor productivity (IVY) of each industry using a Cobb Douglas-type production function. In the second step, we examine the relationship between the level of TFP and the level of FDI in each industry, where we distinguish FDI spillover effects two types: short run and long run. In addition, we test FDI spillover both as an intra-industry effect and an inter-industry effect, also called backward linkage. Our main findings are that the FDI stock increases the TFP, especially through backward linkage, although the TFP level fell in the short run. (C) 2015 Society for Policy Modeling. Published by Elsevier Inc. All rights reserved.	[Fujimori, Azusa] Osaka Seikei Univ, Fac Management, Higashiyodogawa Ku, Osaka 5330007, Japan; [Sato, Takahiro] Kobe Univ, Res Inst Econ & Business Adm, Nada Ku, Kobe, Hyogo 6578501, Japan	Fujimori, A (reprint author), Osaka Seikei Univ, Fac Management, Higashiyodogawa Ku, 3-10-62 Aikawa, Osaka 5330007, Japan.	Fujimori-a@osaka-seikei.ac.jp			collaborative research project "The Internationalization of Japanese Firms and Industrial Dynamics in India" [25301022]; Japan Society for the Promotion of Science (JSPS) KAKENHI	We gratefully acknowledge the financial support from the collaborative research project "The Internationalization of Japanese Firms and Industrial Dynamics in India" (Grant No. 25301022) sponsored by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (B).	Aghion R, 1992, ECONOMETRICA, V60, P323; Kathuria V, 2002, OXFORD ECON PAP, V54, P688, DOI 10.1093/oep/54.4.688; Alfaro L, 2004, J INT ECON, V64, P89, DOI 10.1016/S0022-1996(03)00081-3; Javorcik BS, 2004, AM ECON REV, V94, P605, DOI 10.1257/0002828041464605; Blomstrom M, 1999, EUR ECON REV, V43, P915, DOI 10.1016/S0014-2921(98)00104-4; Adams S, 2009, J POLICY MODEL, V31, P939, DOI 10.1016/j.jpolmod.2009.03.003; ARELLANO M, 1991, REV ECON STUD, V58, P277, DOI 10.2307/2297968; BLOMSTROM M, 1983, WORLD DEV, V11, P493, DOI 10.1016/0305-750X(83)90016-5; Liu ZQ, 2008, J DEV ECON, V85, P176, DOI 10.1016/j.jdeveco.2006.07.001; KOKKO A, 1994, J DEV ECON, V43, P279, DOI 10.1016/0304-3878(94)90008-6; Levinsohn J, 2003, REV ECON STUD, V70, P317, DOI 10.1111/1467-937X.00246; Saggi K, 2002, WORLD BANK RES OBSER, V17, P191, DOI 10.1093/wbro/17.2.191; Kathuria V, 2001, APPL ECON, V33, P625, DOI 10.1080/000368401750106207; Aitken BJ, 1999, AM ECON REV, V89, P605, DOI 10.1257/aer.89.3.605; Borensztein E, 1998, J INT ECON, V45, P115, DOI 10.1016/S0022-1996(97)00033-0; Javorcik BS, 2008, J DEV ECON, V85, P194, DOI 10.1016/j.jdeveco.2006.08.005; Akinlo AE, 2004, J POLICY MODEL, V26, P627, DOI 10.1016/j.jpolmod.2004.04.011; Djankov S, 2000, WORLD BANK ECON REV, V14, P49; Barro R. J., 2004, EC GROWTH; BLOMSTROM M, 1986, J IND ECON, V35, P97, DOI 10.2307/2098609; Bosco M. G., 2001, TRANSNATIONAL CORPOR, V10, P43; Goldar B, 2003, DEV ECON, V41, P436, DOI 10.1111/j.1746-1049.2003.tb01010.x; Goldar B., 2004, ECON POLIT WEEKLY, V20, P5033; Grossman G., 1991, INNOVATION GROWTH GL; HADDAD M, 1993, J DEV ECON, V42, P51, DOI 10.1016/0304-3878(93)90072-U; Javorcik BS, 2011, J DEV ECON, V96, P126, DOI 10.1016/j.jdeveco.2010.05.008; Keller W, 2010, HBK ECON, V2, P793, DOI 10.1016/S0169-7218(10)02003-4; Kokko A., 1996, J INT DEV, V8, P517, DOI [10.1002/(SICI)1099-1328(199607)8:4<lessthan>517::AID-JID298<greaterthan>3.0.CO;2-P, DOI 10.1002/(SICI)1099-1328(199607)8:4<517::AID-JID298>3.0.CO;2-P]; Kolcko A., 1996, J DEV STUD, V32, P602; Li X., 2001, EC SYSTEMS, V25, P305, DOI DOI 10.1016/S0939-3625(01)00029-2; Maldd S. S., 2004, AM J AGR ECON, V86, P795; Pertin A., 2004, STATA J, V4, P113; Takii S, 2005, J DEV ECON, V76, P521, DOI 10.1016/j.jdeveco.2004.01.006	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-8938	1873-8060		J POLICY MODEL	J. Policy Model.	JUL-AUG	2015	37	4					630	651		10.1016/j.jpolmod.2015.04.002		22	Economics	Business & Economics	CM1JP	WOS:000357437500006		
J	Nambu, M; Tatsukami, Y; Morisaka, H; Kuroda, K; Ueda, M				Nambu, Mami; Tatsukami, Yohei; Morisaka, Hironobu; Kuroda, Kouichi; Ueda, Mitsuyoshi			Quantitative time-course proteome analysis of Mesorhizobium loti during nodule maturation	JOURNAL OF PROTEOMICS			English	Article						Mesorhizobium loti; Lotus japonicus; Symbiosis; Quantitative proteome analysis; Plant-microbe interaction	SIGNAL-TRANSDUCTION PROTEIN; QUORUM-SENSING SIGNALS; RHIZOBIUM-LEGUMINOSARUM; SINORHIZOBIUM-MELILOTI; NITROGEN-FIXATION; BRADYRHIZOBIUM-JAPONICUM; ESCHERICHIA-COLI; ROOT-NODULES; GLUTAMINE-SYNTHETASE; TRANSPORT MUTANTS	Rhizobia are nitrogen-fixing bacteria that establish a symbiotic relationship with leguminous plants. To understand the mechanism by which rhizobia alter their metabolism to establish successful nitrogen-fixing symbiotic relationship with hosts, Lotus japonicus were inoculated with Mesorhizobium loti. Bacteroids were isolated from nodules harvested at 2 weeks (the early stage of nodule development), and at 3 and 4 weeks (the intermediate stage of nodule development) post-inoculation. Using a quantitative time-course proteome analysis, we quantified the variations in the production of 537 proteins in M. loti bacteroids during the course of nodule maturation. The results revealed significant changes in the carbon and amino acid metabolisms by M. loll upon differentiating into bacteroids. Furthermore, our findings suggested that M. loll enters a nitrogen-deficient condition during the early stages of nodule development, and then a nitrogen-rich condition during the intermediate stages of nodule development. In addition, our data indicated that M. loll assimilated ammonia during the intermediate stages of nodule development. Our results provide new insights into the course of physiological transitions undergone by M. loti during nodule maturation. (C) 2015 Elsevier B.V. All rights reserved.	[Nambu, Mami; Tatsukami, Yohei; Morisaka, Hironobu; Kuroda, Kouichi; Ueda, Mitsuyoshi] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan; [Tatsukami, Yohei] Japan Soc Promot Sci, Sakyo Ku, Kyoto 6068502, Japan; [Morisaka, Hironobu; Ueda, Mitsuyoshi] Kyoto Ind Sci & Technol Innovat Ctr, Shimogyo Ku, Kyoto 6008813, Japan	Ueda, M (reprint author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	miueda@kais.kyoto-u.ac.jp			Sekisui Chemical Co., Ltd.; JST-CREST; Japan Society for the Promotion of Science [26-1156];  [25289293]	This work was supported by the 12th Innovations Inspired by Nature Research Support of Sekisui Chemical Co., Ltd., by a Grant-in-Aid for Scientific Research (B) (No. 25289293), by JST-CREST, and by the Japan Society for the Promotion of Science (grant 26-1156).	Seefeldt LC, 2009, ANNU REV BIOCHEM, V78, P701, DOI 10.1146/annurev.biochem.78.070907.103812; Lodwig EM, 2003, NATURE, V422, P722, DOI 10.1038/nature01527; BECARD G, 1988, NEW PHYTOL, V108, P211, DOI 10.1111/j.1469-8137.1988.tb03698.x; OSTERAS M, 1991, MOL GEN GENET, V230, P257, DOI 10.1007/BF00290676; Tyers M, 2003, NATURE, V422, P193, DOI 10.1038/nature01510; Ott T, 2005, CURR BIOL, V15, P531, DOI 10.1016/j.cub.2005.01.042; Yates JR, 2009, ANNU REV BIOMED ENG, V11, P49, DOI 10.1146/annurev-bioeng-061008-124934; Patriarca EJ, 2002, MICROBIOL MOL BIOL R, V66, P203, DOI 10.1128/MMBR.66.2.203-222.2002; Iwasaki M, 2010, ANAL CHEM, V82, P2616, DOI 10.1021/ac100343q; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443; Allaway D, 2000, MOL MICROBIOL, V36, P508, DOI 10.1046/j.1365-2958.2000.01884.x; Larrainzar E, 2007, PLANT PHYSIOL, V144, P1495, DOI 10.1104/pp.107.101618; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Kumagai H, 2007, PLANT PHYSIOL, V143, P1293, DOI 10.1104/pp.106.095356; FINAN TM, 1983, J BACTERIOL, V154, P1403; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Hosie AHF, 2002, J BACTERIOL, V184, P4071, DOI 10.1128/JB.184.15.4071-4080.2002; Tate R, 2004, MOL PLANT MICROBE IN, V17, P720, DOI 10.1094/MPMI.2004.17.7.720; Djordjevic MA, 2004, PROTEOMICS, V4, P1859, DOI 10.1002/pmic.20300802; Motokawa M, 2002, J CHROMATOGR A, V961, P53, DOI 10.1016/S0021-9673(02)00133-4; Uchiumi T, 2004, J BACTERIOL, V186, P2439, DOI 10.1128/JB.186.8.2439-2448.2004; Barra-Bily L, 2010, J BACTERIOL, V192, P1719, DOI 10.1128/JB.01429-09; Sato S, 2008, DNA RES, V15, P227, DOI 10.1093/dnares/dsn008; BUENO R, 1985, J BACTERIOL, V164, P816; Prell J, 2006, TRENDS MICROBIOL, V14, P161, DOI 10.1016/j.tim.2006.02.005; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; Sarma AD, 2006, PROTEOMICS, V6, P3008, DOI 10.1002/pmic.200500783; Becana M, 2000, PHYSIOL PLANTARUM, V109, P372, DOI 10.1034/j.1399-3054.2000.100402.x; Aoki W, 2013, J PROTEOMICS, V91, P417, DOI 10.1016/j.jprot.2013.07.031; Atkinson MR, 1998, MOL MICROBIOL, V29, P431, DOI 10.1046/j.1365-2958.1998.00932.x; Beckers G, 2001, MICROBIOL-SGM, V147, P2961; Chen HC, 2003, J BACTERIOL, V185, P5029, DOI 10.1128/JB.185.17.5029-5036.2003; Chungopast S, 2014, J PLANT PHYSIOL, V171, P104, DOI 10.1016/j.jplph.2013.10.015; Delmotte N, 2010, PROTEOMICS, V10, P1391, DOI 10.1002/pmic.200900710; FINAN TM, 1991, MOL PLANT MICROBE IN, V4, P386, DOI 10.1094/MPMI-4-386; Gao MS, 2007, MOL PLANT MICROBE IN, V20, P843, DOI 10.1094/MPMI-20-7-0843; Hanyu M, 2009, J BACTERIOL, V191, P1463, DOI 10.1128/JB.01583-08; Hempel J, 2009, J BIOTECHNOL, V140, P51, DOI 10.1016/j.jbiotec.2008.11.002; Kawaguchi M, 2000, J PLANT RES, V113, P507, DOI 10.1007/PL00013961; LUDWIG RA, 1984, P NATL ACAD SCI-BIOL, V81, P1566, DOI 10.1073/pnas.81.5.1566; Matsui K, 2013, APPL ENVIRON MICROB, V79, P6576, DOI 10.1128/AEM.02137-13; MCKAY IA, 1989, ARCH MICROBIOL, V152, P606, DOI 10.1007/BF00425495; RONSON CW, 1981, P NATL ACAD SCI-BIOL, V78, P4284, DOI 10.1073/pnas.78.7.4284; Sarma AD, 2005, PROTEOMICS, V5, P4170, DOI 10.1002/pmic.200401296; SAROSO S, 1986, J GEN MICROBIOL, V132, P243; Tatsukami Y, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-180; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; VERMA DPS, 1992, PLANT CELL, V4, P373; WATSON RJ, 1993, J BACTERIOL, V175, P1919	50	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1874-3919	1876-7737		J PROTEOMICS	J. Proteomics	JUL 1	2015	125						112	120		10.1016/j.jprot.2015.04.034		9	Biochemical Research Methods	Biochemistry & Molecular Biology	CL8RY	WOS:000357243000011		
J	Nangaku, M; Inagi, R; Mimura, I; Tanaka, T				Nangaku, Masaomi; Inagi, Reiko; Mimura, Imari; Tanaka, Tetsuhiro			Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy?	JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY			English	Editorial Material						hypoxia; chronic kidney disease; acute renal failure; HIF; microRNA; AKI	KIDNEY; INJURY; HIF-1-ALPHA; EXPRESSION		[Nangaku, Masaomi; Tanaka, Tetsuhiro] Univ Tokyo, Div Nephrol & Endocrinol, Grad Sch Med, Tokyo 1138655, Japan; [Inagi, Reiko] Univ Tokyo, Div Chron Kidney Dis Pathophysiol, Grad Sch Med, Tokyo 1138655, Japan; [Mimura, Imari] Univ Tokyo, Res Ctr Adv Sci & Technol, Grad Sch Med, Tokyo 1138655, Japan	Nangaku, M (reprint author), Univ Tokyo, Div Nephrol & Endocrinol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	mnangaku-tky@umin.ac.jp					Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Xu XL, 2012, KIDNEY INT, V82, P1167, DOI 10.1038/ki.2012.241; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Schley G, 2012, AM J PATHOL, V181, P1595, DOI 10.1016/j.ajpath.2012.07.010; Zhang DS, 2014, J AM SOC NEPHROL, V25, P2278, DOI 10.1681/ASN.2013080902; Bhatt K, 2015, J AM SOC NEPHROL, V26, P1588, DOI 10.1681/ASN.2014050463; Matsumoto M, 2003, J AM SOC NEPHROL, V14, P1825, DOI 10.1097/01.ASN.0000074239.22357.06; Nangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681/ASN.2005070757; Mimura I, 2013, SEMIN NEPHROL, V33, P375, DOI 10.1016/j.semnephrol.2013.05.009; Muratsu-Ikeda S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041462; Peng J, KIDNEY INT; Tanaka T, 2013, NAT REV NEPHROL, V9, P211, DOI 10.1038/nrneph.2013.35; Ying Y, 2014, J AM SOC NEPHROL, V25, P2707, DOI 10.1681/ASN.2013121270; Yu XF, 2012, NEPHROL DIAL TRANSPL, V27, P3110, DOI 10.1093/ndt/gfr754	15	0	0	AMER SOC NEPHROLOGY	WASHINGTON	1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA	1046-6673	1533-3450		J AM SOC NEPHROL	J. Am. Soc. Nephrol.	JUL	2015	26	7					1478	1480		10.1681/ASN.2014121161		3	Urology & Nephrology	Urology & Nephrology	CM0UE	WOS:000357393300002		
J	Kikuchi, E; Mori, T; Zeniya, M; Isobe, K; Ishigami-Yuasa, M; Fujii, S; Kagechika, H; Ishihara, T; Mizushima, T; Sasaki, S; Sohara, E; Rai, T; Uchida, S				Kikuchi, Eriko; Mori, Takayasu; Zeniya, Moko; Isobe, Kiyoshi; Ishigami-Yuasa, Mari; Fujii, Shinya; Kagechika, Hiroyuki; Ishihara, Tomoaki; Mizushima, Tohru; Sasaki, Sei; Sohara, Eisei; Rai, Tatemitsu; Uchida, Shinichi			Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters	JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY			English	Article						cell physiology; transport physiology; cell signaling; hypertension	PSEUDOHYPOALDOSTERONISM TYPE-II; VASCULAR SMOOTH-MUSCLE; BLOOD-PRESSURE; NA+-K+-2CL(-) COTRANSPORTER; HUMAN HYPERTENSION; PROTEIN-KINASE; PHOSPHORYLATION CASCADE; NA-K-2CL COTRANSPORTER; ANGIOTENSIN-II; PATHWAY	Upon activation by with-no-lysine kinases, STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) phosphorylates and activates SLC12A transporters such as the Na+-Cl- cotransporter (NCC) and Na+-K+-2Cl(-) cotransporter type 1 (NKCC1) and type 2 (NKCC2); these transporters have important roles in regulating BP through NaCl reabsorption and vasoconstriction. SPAK knockout mice are viable and display hypotension with decreased activity (phosphorylation) of NCC and NKCC1 in the kidneys and aorta, respectively. Therefore, agents that inhibit SPAK activity could be a new class of antihypertensive drugs with dual actions (i.e., NaCl diuresis and vasodilation). In this study, we developed a new ELISA-based screening system to find novel SPAK inhibitors and screened >20,000 small-molecule compounds. Furthermore, we used a drug repositioning strategy to identify existing drugs that inhibit SPAK activity. As a result, we discovered one small-molecule compound (Stock 1S-14279) and an antiparasitic agent (Closantel) that inhibited SPAK-regulated phosphorylation and activation of NCC and NKCC1 in vitro and in mice. Notably, these compounds had structural similarity and inhibited SPAK in an ATP-insensitive manner. We propose that the two compounds found in this study may have great potential as novel antihypertensive drugs.	[Kikuchi, Eriko; Mori, Takayasu; Zeniya, Moko; Isobe, Kiyoshi; Sasaki, Sei; Sohara, Eisei; Rai, Tatemitsu; Uchida, Shinichi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Nephrol, Tokyo 1138519, Japan; [Ishigami-Yuasa, Mari; Kagechika, Hiroyuki] Tokyo Med & Dent Univ, Chem Biol Screening Ctr, Tokyo 1138519, Japan; [Fujii, Shinya; Kagechika, Hiroyuki] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Tokyo 1138519, Japan; [Ishihara, Tomoaki; Mizushima, Tohru] Keio Univ, Fac Pharm, Dept Analyt Chem, Tokyo, Japan	Uchida, S (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Nephrol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	suchida.kid@tmd.ac.jp			Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Salt Science Research Foundation [1422]; Takeda Science Foundation; Banyu Foundation; Vehicle Racing Commemorative Foundation	This study was supported in part by Grants-in-Aid for Scientific Research (S) and (A) from the Japan Society for the Promotion of Science; a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a Health and Labor Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan; and grants from the Salt Science Research Foundation (no. 1422), the Takeda Science Foundation, the Banyu Foundation, and the Vehicle Racing Commemorative Foundation.	Akar F, 2001, AM J PHYSIOL-CELL PH, V281, pC579; Mutig K, 2007, AM J PHYSIOL-RENAL, V293, pF1166, DOI 10.1152/ajprenal.00196.2007; Nishida H, 2012, HYPERTENSION, V60, P981, DOI 10.1161/HYPERTENSIONAHA.112.201509; Bers DM, 2003, CARDIOVASC RES, V57, P897, DOI 10.1016/S0008-6363(02)00656-9; Lin SH, 2011, P NATL ACAD SCI USA, V108, P17538, DOI 10.1073/pnas.1107452108; Achard JM, 2001, CLIN EXP PHARMACOL P, V28, P1048, DOI 10.1046/j.1440-1681.2001.03575.x; Talati G, 2010, BIOCHEM BIOPH RES CO, V393, P844, DOI 10.1016/j.bbrc.2010.02.096; Garg P, 2007, AM J PHYSIOL-HEART C, V292, pH2100, DOI 10.1152/ajpheart.01402.2006; Yang SS, 2007, CELL METAB, V5, P331, DOI 10.1016/j.cmet.2007.03.009; Chiga M, 2008, KIDNEY INT, V74, P1403, DOI 10.1038/ki.2008.451; Castaneda-Bueno M, 2012, P NATL ACAD SCI USA, V109, P7929, DOI 10.1073/pnas.1200947109; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Zeniya M, 2013, HYPERTENSION, V62, P872, DOI 10.1161/HYPERTENSIONAHA.113.01543; Richardson C, 2008, J CELL SCI, V121, P675, DOI 10.1242/jcs.025312; Ohno M, 2011, HISTOCHEM CELL BIOL, V136, P25, DOI 10.1007/s00418-011-0827-x; Uchida S, 2010, PFLUG ARCH EUR J PHY, V460, P695, DOI 10.1007/s00424-010-0848-7; Chiga M, 2011, J CELL SCI, V124, P1391, DOI 10.1242/jcs.084111; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Garuti L, 2010, CURR MED CHEM, V17, P2804; Wakabayashi M, 2013, CELL REP, V3, P858, DOI 10.1016/j.celrep.2013.02.024; Filippi BM, 2011, EMBO J, V30, P1730, DOI 10.1038/emboj.2011.78; Richardson C, 2008, J CELL SCI, V121, P3293, DOI 10.1242/jcs.029223; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Richardson C, 2011, J CELL SCI, V124, P789, DOI 10.1242/jcs.077230; Susa K, 2012, CLIN EXP NEPHROL, V16, P530, DOI 10.1007/s10157-012-0590-x; Yang SS, 2010, J AM SOC NEPHROL, V21, P1868, DOI 10.1681/ASN.2009121295; Mori T, 2013, BIOCHEM J, V455, P339, DOI 10.1042/BJ20130597; Butini S, 2011, J MED CHEM, V54, P1401, DOI 10.1021/jm101438u; Diepens RJW, 2004, AM J PHYSIOL-RENAL, V286, pF483, DOI 10.1152/ajprenal.00231.2003; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Kahle KT, 2008, TRENDS ENDOCRIN MET, V19, P91, DOI 10.1016/j.tem.2008.01.001; Koltsova SV, 2009, BIOCHEM BIOPH RES CO, V379, P1080, DOI 10.1016/j.bbrc.2009.01.018; Meyer JW, 2002, AM J PHYSIOL-HEART C, V283, pH1846, DOI 10.1152/ajpheart.00083.2002; Naito S, 2011, CLIN EXP NEPHROL, V15, P195, DOI 10.1007/s10157-010-0378-9; Pedersen SF, 2006, AM J PHYSIOL-REG I, V291, pR1, DOI 10.1152/ajpregu.00782.2005; Sohara E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024277; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Zagorska A, 2007, J CELL BIOL, V176, P89, DOI 10.1083/jcb.200605093	39	3	3	AMER SOC NEPHROLOGY	WASHINGTON	1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA	1046-6673	1533-3450		J AM SOC NEPHROL	J. Am. Soc. Nephrol.	JUL	2015	26	7					1525	1536		10.1681/ASN.2014060560		12	Urology & Nephrology	Urology & Nephrology	CM0UE	WOS:000357393300009		
J	Schulman, G; Berl, T; Beck, GJ; Remuzzi, G; Ritz, E; Arita, K; Kato, A; Shimizu, M				Schulman, Gerald; Berl, Tomas; Beck, Gerald J.; Remuzzi, Giuseppe; Ritz, Eberhard; Arita, Kiyoshi; Kato, Akira; Shimizu, Miho			Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD	JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY			English	Article						CKD; creatinine; GFR; randomized controlled trials	CHRONIC KIDNEY-DISEASE; INDOXYL SULFATE; RENAL OUTCOMES; ORAL ADSORBENT; UREMIC TOXINS; DOUBLE-BLIND; RISK; NEPHROPATHY; MODERATE; MULTICENTER	Reduced GFR in patients with CKD causes systemic accumulation of uremic toxins, which has been correlated with disease progression and increased morbidity. The orally administered spherical carbon adsorbent AST-120 reduces systemic toxin absorption through gastrointestinal sequestration, which may slow disease progression in these patients. The multinational, randomized, double-blind, placebo-controlled Evaluating Prevention of Progression in CKD (EPPIC)-1 and EPPIC-2 trials evaluated the effects of AST-120 on the progression of CKD when added to standard therapy. We randomly assigned 2035 adults with moderate to severe disease (serum creatinine at screening, 2.0-5.0 mg/dl for men and 1.5-5.0 mg/dl for women) to receive either placebo or AST-120 (9 g/d). The primary end point was a composite of dialysis initiation, kidney transplantation, and serum creatinine doubling. Each trial continued until accrual of 291 primary end points. The time to primary end point was similar between the AST-120 and the placebo groups in both trials (EPPIC-1: hazard ratio, 1.03; 95% confidence interval, 0.84 to 1.27; P=0.78) (EPPIC-2: hazard ratio, 0.91; 95% confidence interval, 0.74 to 1.12; P=0.37); a pooled analysis of both trials showed similar results. The estimated median time to primary end points for the placebo groups was 124 weeks for power calculations, but actual times were 189.0 and 170.3 weeks for EPPIC-1 and EPPIC-2, respectively. Thus, disease progression was more gradual than expected in the trial populations. In conclusion, the benefit of adding AST-120 to standard therapy in patients with moderate to severe CKD is not supported by these data.	[Schulman, Gerald] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Berl, Tomas] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Beck, Gerald J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Remuzzi, Giuseppe] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy; [Ritz, Eberhard] Heidelberg Univ, Heidelberg, Germany; [Arita, Kiyoshi; Shimizu, Miho] Mitsubishi Tanabe Pharma Corp, Tokyo, Japan; [Kato, Akira] Kureha Corp, Tokyo, Japan	Schulman, G (reprint author), Vanderbilt Univ, Sch Med, 1211 21st Ave, Nashville, TN 37212 USA.	gerald.schulman@vanderbilt.edu			Mitsubishi Tanabe Pharma Corporation; Kureha Corporation; Mitsubishi Tanabe Pharma America	The EPPIC trials were sponsored by Mitsubishi Tanabe Pharma Corporation and Kureha Corporation. Medical writing and editorial support provided by ApotheCom (Yardley, PA) was funded by Mitsubishi Tanabe Pharma America.	Akizawa T, 1998, KIDNEY DIAL, V45, P373; Andrassy KM, 2013, KIDNEY INT, V84, P622, DOI 10.1038/ki.2013.243; Marier JF, 2006, AM J NEPHROL, V26, P136, DOI 10.1159/000092242; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5; Meijers BKI, 2010, CLIN J AM SOC NEPHRO, V5, P1182, DOI 10.2215/CJN.07971109; Mann JFE, 2008, LANCET, V372, P547, DOI 10.1016/S0140-6736(08)61236-2; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609; Matsushita K, 2012, JAMA-J AM MED ASSOC, V307, P1941, DOI 10.1001/jama.2012.3954; Lekawanvijit S, 2012, CIRC RES, V111, P1470, DOI 10.1161/CIRCRESAHA.112.278457; Schulman G, 2006, AM J KIDNEY DIS, V47, P565, DOI 10.1053/j.ajkd.2005.12.036; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; Keane WF, 2003, KIDNEY INT, V63, P1499, DOI 10.1046/j.1523-1755.2003.00885.x; Wu IW, 2011, NEPHROL DIAL TRANSPL, V26, P938, DOI 10.1093/ndt/gfq580; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; James MT, 2010, LANCET, V375, P1296, DOI 10.1016/S0140-6736(09)62004-3; Hatakeyama S, 2012, INT J NEPHROL, V2012; Kidney Disease Outcomes Quality Initiative (K/DOQI), 2004, AM J KIDNEY DIS S, V43, pS1; Konishi K, 2008, DIABETES RES CLIN PR, V81, P310, DOI 10.1016/j.diabres.2008.04.024; Nakamura T, 2011, METABOLISM, V60, P260, DOI 10.1016/j.metabol.2010.01.023; National Institutes of Health, 2012, USRDS 2012 ANN DAT R; National Kidney Foundation, 2012, AM J KIDNEY DIS, V60, P850, DOI DOI 10.1053/J.AJKD.2012.07.005; National Kidney Foundation, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577; Navaneethan SD, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007004.pub2; NIWA T, 1991, NEPHRON, V57, P84, DOI 10.1159/000186222; Shoji T, 2007, NEPHRON CLIN PRACT, V105, P99, DOI 10.1159/000097985; Yorioka N, 2008, J NEPHROL, V21, P213	32	3	3	AMER SOC NEPHROLOGY	WASHINGTON	1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA	1046-6673	1533-3450		J AM SOC NEPHROL	J. Am. Soc. Nephrol.	JUL	2015	26	7					1732	1746		10.1681/ASN.2014010042		15	Urology & Nephrology	Urology & Nephrology	CM0UE	WOS:000357393300027		
J	Fukushima, Y; Matsuo, S; Setoguchi, T; Shiomi, N; Hashimoto, T; Kim, HD; Yu, S				Fukushima, Yusuke; Matsuo, Shigeru; Setoguchi, Toshiaki; Shiomi, Norimasa; Hashimoto, Tokitada; Kim, Heuy Dong; Yu, Shen			Effect of Nozzle Inlet Shape on Annular Swirling Flow with Non-Equilibrium Condensation	JOURNAL OF THERMAL SCIENCE			English	Article						compressible flow; non-equilibrium condensation; supersonic annular nozzle; swirl flow; simulation		Recently, by combining a swirl flow with non-equilibrium condensation phenomena of condensate gas generated in a supersonic flow, a separating and extracting techniques of condensate gas have been developed. This technique can reduce the size of the device and don't use chemicals. In the present study, by using a non-equilibrium condensation phenomenon of moist air occurred in the supersonic flow in the annular nozzle composed of an inner body and an outer nozzle with a swirl, the possibility of separation of the condensable gas and the effect of shape of nozzle inlet on the flow field were examined numerically.	[Fukushima, Yusuke] Saga Univ, Grad Sch Sci & Engn, Saga, Saga 8408502, Japan; [Matsuo, Shigeru; Hashimoto, Tokitada] Saga Univ, Dept Adv Technol Fus, Saga, Saga 8408502, Japan; [Setoguchi, Toshiaki] Saga Univ, Inst Ocean Energy, Saga, Saga 8408502, Japan; [Shiomi, Norimasa] Saga Univ, Dept Mech Engn, Saga, Saga 8408502, Japan; [Kim, Heuy Dong] Andong Natl Univ, Sch Mech Engn, Andong 760749, South Korea; [Yu, Shen] Chinese Acad Sci, Inst Engn Thermophys, Beijing 100080, Peoples R China	Fukushima, Y (reprint author), Saga Univ, Grad Sch Sci & Engn, 1 Honjo Machi, Saga, Saga 8408502, Japan.				JSPS KAKENHI [26420116]	This work was supported by JSPS KAKENHI Grand number 26420116.	Wilcox DC, 2008, AIAA J, V46, P2823, DOI 10.2514/1.36541; Wen C, 2012, ADV POWDER TECHNOL, V23, P228, DOI 10.1016/j.apt.2011.02.012; Chakravarthy S. P., 1984, AIAA PAPER, P84; FURUKAWA M, 1992, J TURBOMACH, V114, P599, DOI 10.1115/1.2929184; Kaneko H., 2007, J JAPAN I ENERGY, V86, P232; MATSUO K, 1985, B JSME, V28, P1416; Prast B., 2006, 5 INT C CFD PROC IND, P1; Wegener P. P., 1958, ADVANCES APPLIED MEC, V5, P307, DOI 10.1016/S0065-2156(08)70022-X	8	0	0	SCIENCE PRESS	BEIJING	16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA	1003-2169	1993-033X		J THERM SCI	J. Therm. Sci.	JUL-AUG	2015	24	4					344	349		10.1007/s11630-015-0793-z		6	Thermodynamics; Engineering, Mechanical	Thermodynamics; Engineering	CM1LN	WOS:000357442500005		
J	Kerr, KM; Tsao, MS; Nicholson, AG; Yatabe, Y; Wistuba, II; Hirsch, FR				Kerr, Keith M.; Tsao, Ming-Sound; Nicholson, Andrew G.; Yatabe, Yasushi; Wistuba, Ignacio I.; Hirsch, Fred R.		IASLC Pathology Comm	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?	JOURNAL OF THORACIC ONCOLOGY			English	Article						Immune check-point inhibitors; PD-1; PD-L1; Immunohistochemistry; Biomarker assay	NIVOLUMAB ANTI-PD-1; SAFETY; BMS-936558; EXPRESSION; ONO-4538; ANTIBODY; OUTCOMES; PD-L1	Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising clinical results. Anti-PD-L1 immunohistochemistry (IHC) may be a biomarker to select patients more likely to respond to these treatments. However, the development of at least four different therapeutics, each with a different anti-PD-L1 IHC assay, has raised concerns among pathologists and oncologists alike. This article reviews existing data on the IHC biomarker aspects of studies using these drugs in non-small-cell lung cancer (NSCLC) and considers the challenges ahead, should these drug/IHC assay combinations reach routine practice. For each the known biomarker assays in development, there is a different monoclonal IHC antibody clone, produced by one of two diagnostics companies. Each test requires proprietary staining platforms and uses different definitions of a positive test for PD-L1 expression, on tumor cells and, in one test, also on tumor infiltrating immune cells. There are still considerable gaps in our knowledge of the technical aspects of these tests, and of the biological implications and associations of PD-L1 expression in NSCLC, considering heterogeneity of expression, dynamic changes in expression, and prognostic implications among other factors. The International Association for the Study of Lung Cancer Pathology Committee raises the prospect of trying not only to harmonize and standardize testing for PD-L1 by IHC, at least at a technical level, but also, ideally, as a predictive marker, to facilitate availability of this test and a promising treatment for patients with NSCLC.	[Kerr, Keith M.] Univ Aberdeen, Sch Med, Dept Pathol, Aberdeen Royal Infirm, Aberdeen AB9 2ZD, Scotland; [Tsao, Ming-Sound] Univ Toronto, Dept Pathol, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada; [Nicholson, Andrew G.] Royal Brompton & Harefield Hosp NHS Fdn Trust, Dept Histopathol, London, England; [Yatabe, Yasushi] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Hirsch, Fred R.] Univ Colorado, Dept Pathol, Div Med Oncol, Denver, CO 80202 USA	Kerr, KM (reprint author), Aberdeen Royal Infirm, Dept Pathol, Aberdeen AB25 2ZD, Scotland.	k.kerr@abdn.ac.uk					Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Brahmer JR, 2013, J CLIN ONCOL, V31, P1021, DOI 10.1200/JCO.2012.45.8703; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Ramalingam SS, 2014, INT J RADIAT ONCOL, V90, P1266, DOI 10.1016/j.ijrobp.2014.09.038; Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Yang CY, 2014, EUR J CANCER, V50, P1361, DOI 10.1016/j.ejca.2014.01.018; Bussolati G, 2008, J CLIN PATHOL, V61, P1184, DOI 10.1136/jcp.2007.047720; Antonia SJ, 2014, J CLIN ONCOL, V32; Brahmer JR, 2014, J CLIN ONCOL, V32; Brahmer JR, 2014, ASCO M, V32, P8112; Garon E. B., 2014, ANN ONCOL, V25, P1, DOI [10.1093/annonc/mdu438, DOI 10.1093/ANNONC/MDU438]; Garon EB, 2014, J CLIN ONCOL, V32; Gettinger S, 2014, INT J RAD ONCOL S, V90, P170; Gettinger SN, 2014, J CLIN ONCOL, V32; Powderly JD, 2013, J CLIN ONCOL S, V31, P3001; Rizvi NA, 2014, INT J RADIAT ONCOL, V90, pS31; Segal NH, 2014, ASCO M, V32, P3002; Soria JC, 2013, EUROPEAN J CANC S, V49; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					985	989		10.1097/JTO.0000000000000526		5	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100002		
J	Rami-Porta, R; Bolejack, V; Crowley, J; Ball, D; Kim, J; Lyons, G; Rice, T; Suzuki, K; Thomas, CF; Travis, WD; Wu, YL				Rami-Porta, Ramon; Bolejack, Vanessa; Crowley, John; Ball, David; Kim, Jhingook; Lyons, Gustavo; Rice, Thomas; Suzuki, Kenji; Thomas, Charles F., Jr.; Travis, William D.; Wu, Yi-Long		IASLC Staging Prognostic Factors	The IASLC Lung Cancer Staging Project Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer	JOURNAL OF THORACIC ONCOLOGY			English	Article						Lung cancer; Lung cancer staging; T component; T descriptors; TNM classification; Tumor size	VISCERAL PLEURAL INVASION; TNM CLASSIFICATION; 7TH EDITION; PROGNOSTIC-SIGNIFICANCE; COMPUTED-TOMOGRAPHY; SURGICAL-TREATMENT; TUMOR SIZE; SURVIVAL; ADENOCARCINOMA; IMPACT	Introduction: An international database was collected to inform the 8(th) edition of the anatomic classification of lung cancer. The present analyses concern its primary tumor (T) component. Methods: From 1999 to 2010, 77,156 evaluable patients, 70,967 with non-small-cell lung cancer, were collected; and 33,115 had either a clinical or a pathological classification, known tumor size, sufficient T information, and no metastases. Survival was measured from date of diagnosis or surgery for clinically and pathologically staged tumors. Tumor-size cutpoints were evaluated by the running log-rank statistics. T descriptors were evaluated in a multivariate Cox regression analysis adjusted for age, gender, histological type, and geographic region. Results: The 3-cm cutpoint significantly separates T1 from T2. From 1 to 5cm, each centimeter separates tumors of significantly different prognosis. Prognosis of tumors greater than 5cm but less than or equal to 7cm is equivalent to T3, and that of those greater than 7cm to T4. Bronchial involvement less than 2cm from carina, but without involving it, and total atelectasis/pneumonitis have a T2 prognosis. Involvement of the diaphragm has a T4 prognosis. Invasion of the mediastinal pleura is a descriptor seldom used. Conclusions: Recommended changes are as follows: to subclassify T1 into T1a (1cm), T1b (>1 to 2cm), and T1c (>2 to 3cm); to subclassify T2 into T2a (>3 to 4cm) and T2b (>4 to 5cm); to reclassify tumors greater than 5 to less than or equal to 7cm as T3; to reclassify tumors greater than 7cm as T4; to group involvement of main bronchus as T2 regardless of distance from carina; to group partial and total atelectasis/pneumonitis as T2; to reclassify diaphragm invasion as T4; and to delete mediastinal pleura invasion as a T descriptor.	[Rami-Porta, Ramon] Univ Barcelona, Dept Thorac Surg, Hosp Univ Mutua Terrassa, Barcelona, Spain; [Rami-Porta, Ramon] CIBERES Lung Canc Grp, Barcelona, Spain; [Bolejack, Vanessa; Crowley, John] Canc Res & Biostat, Seattle, WA USA; [Ball, David] Peter MacCallum Canc Ctr, Dept Radiotherapy, Melbourne, Vic, Australia; [Kim, Jhingook] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac Surg, Seoul, South Korea; [Lyons, Gustavo] Hosp Britanico, Dept Thorac Surg, Buenos Aires, DF, Argentina; [Rice, Thomas] Cleveland Clin, Dept Thorac Surg, Cleveland, OH 44106 USA; [Suzuki, Kenji] Juntendo Univ, Dept Thorac Surg, Tokyo, Japan; [Thomas, Charles F., Jr.] Mayo Clin, Dept Internal Med & Pulmonol, Rochester, MN USA; [Travis, William D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Wu, Yi-Long] Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China; [Wu, Yi-Long] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China	Rami-Porta, R (reprint author), Hosp Univ Mutua Terrassa, Dept Thorac Surg, Plaza Dr Robert 5, Barcelona 08221, Spain.	rramip@yahoo.es	Fong, Kwun/G-6369-2010; 	Rami-Porta, Ramon/0000-0003-3366-7664	International Association for the Study of Lung Cancer (IASLC); IASLC; Roche	David Ball has declared ongoing board memberships of Lilly Oncology, Astra Zeneca and Boehring-Ingelheim. John Crowley has declared that his work is fundded by the International Association for the Study of Lung Cancer (IASLC) and has received grants and support to travel from the IASLC. Vanessa Bolejack has declared that her work is currently funded by the International Association for the Study of Lung Cancer (IASLC) and that she has received grants and support to travel and to write and review articles from the IASLC. William D. Travis has declared that he is a current member of the Board of the International Association for the Study of Lung Cancer, but this activity has no financial implications. Yi-Long Wu has declared he currently receives payment for lectures from Roche.	Boffa DJ, 2011, ANN SURG ONCOL, V18, P1, DOI 10.1245/s10434-010-1427-z; Maeda R, 2011, CHEST, V140, P1494, DOI 10.1378/chest.10-3279; Kawase A, 2013, J THORAC ONCOL, V8, P606, DOI 10.1097/JTO.0b013e31828632b8; Fibla JJ, 2012, LUNG CANCER, V78, P259, DOI 10.1016/j.lungcan.2012.09.010; Boffa DJ, 2010, J THORAC ONCOL, V5, P1779, DOI 10.1097/JTO.0b013e3181ee80c7; Nitadori J, 2013, CHEST, V144, P1622, DOI 10.1378/chest.13-0394; Tsutani Y, 2012, J THORAC CARDIOV SUR, V143, P607, DOI 10.1016/j.jtcvs.2011.10.037; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; COX DR, 1972, J R STAT SOC B, V34, P187; Goldstraw P, 2006, J THORAC ONCOL, V1, P281, DOI 10.1097/01243894-200605000-00002; Kudo Y, 2012, LUNG CANCER, V78, P153, DOI 10.1016/j.lungcan.2012.08.004; Horeweg N, 2013, AM J RESP CRIT CARE, V187, P848, DOI 10.1164/rccm.201209-1651OC; Giroux DJ, 2009, J THORAC ONCOL, V4, P679, DOI 10.1097/JTO.0b013e3181a52370; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Maeyashiki T, 2013, EUR J CARDIO-THORAC, V43, P915, DOI 10.1093/ejcts/ezs516; Travis WD, 2008, J THORAC ONCOL, V3, P1384, DOI 10.1097/JTO.0b013e31818e0d9f; Shim HS, 2009, LUNG CANCER, V65, P161, DOI 10.1016/j.lungcan.2008.11.008; Yoshida J, 2009, J THORAC ONCOL, V4, P959, DOI 10.1097/JTO.0b013e3181a85d5e; Ball D, 2013, J THORAC ONCOL, V8, P315, DOI 10.1097/JTO.0b013e31827dc74d; Crowley J, 1997, P 1 SEATTL S BIOST S, P199; Edge SB, 2010, CANC STAGING MANUAL, P253; Goldstraw P, 2009, STAGING MANUAL THORA, P57; Goldstraw P, 2009, STAGING MANUAL THORA, P32; Padilla J, 1999, Arch Bronconeumol, V35, P297; R Core Team, 2013, R LANG ENV STAT COMP; Rami-Porta R, 2010, EUR RESPIR J, V36, P237, DOI 10.1183/09031936.00016210; Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334; Rocco G, 1999, ANN THORAC SURG, V68, P2065, DOI 10.1016/S0003-4975(99)01121-2; Sobin L, 2009, TNM CLASSIFICATION M, V7th, P7; Sobin LH, 2009, TNM CLASSIFICATION M, P138; The National Lung Screening Trial Research Team Reduced, 2011, NEW ENGL J MED, V365, P395; Wittekind C, 2012, TNM SUPPLEMENT COMME, V4th; Yokoi K, 2000, J THORAC CARDIOV SUR, V120, P799, DOI 10.1067/mtc.2000.109706	33	6	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					990	1003		10.1097/JTO.0000000000000559		14	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100003		
J	Robles, AI; Arai, E; Mathe, EA; Okayama, H; Schetter, AJ; Brown, D; Petersen, D; Bowman, ED; Noro, R; Welsh, JA; Edelman, DC; Stevenson, HS; Wang, YH; Tsuchiya, N; Kohno, T; Skaug, V; Mollerup, S; Haugen, A; Meltzer, PS; Yokota, J; Kanai, Y; Harris, CC				Robles, Ana I.; Arai, Eri; Mathe, Ewy A.; Okayama, Hirokazu; Schetter, Aaron J.; Brown, Derek; Petersen, David; Bowman, Elise D.; Noro, Rintaro; Welsh, Judith A.; Edelman, Daniel C.; Stevenson, Holly S.; Wang, Yonghong; Tsuchiya, Naoto; Kohno, Takashi; Skaug, Vidar; Mollerup, Steen; Haugen, Aage; Meltzer, Paul S.; Yokota, Jun; Kanai, Yae; Harris, Curtis C.			An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers	JOURNAL OF THORACIC ONCOLOGY			English	Article						NSCLC; Adenocarcinoma; Precision medicine; Prognosis; Stage I	ADJUVANT-CISPLATIN-EVALUATION; GENE-EXPRESSION SIGNATURE; INTERNATIONAL-ASSOCIATION; CANCER STATISTICS; CELL SIGNATURE; EZH2; SURVIVAL; MARKERS; TISSUE	Introduction: Up to 30% stage I lung cancer patients suffer recurrence within 5 years of curative surgery. We sought to improve existing protein-coding gene and microRNA expression prognostic classifiers by incorporating epigenetic biomarkers. Methods: Genome-wide screening of DNA methylation and pyrosequencing analysis of HOXA9 promoter methylation were performed in two independently collected cohorts of stage I lung adenocarcinoma. The prognostic value of HOXA9 promoter methylation alone and in combination with mRNA and miRNA biomarkers was assessed by Cox regression and Kaplan-Meier survival analysis in both cohorts. Results: Promoters of genes marked by polycomb in embryonic stem cells were methylated de novo in tumors and identified patients with poor prognosis. The HOXA9 locus was methylated de novo in stage I tumors (p < 0.0005). High HOXA9 promoter methylation was associated with worse cancer-specific survival (hazard ratio [HR], 2.6; p = 0.02) and recurrence-free survival (HR, 3.0; p = 0.01), and identified high-risk patients in stratified analysis of stages IA and IB. Four protein-coding gene (XPO1, BRCA1, HIF1, and DLC1), miR-21 expression, and HOXA9 promoter methylation were each independently associated with outcome (HR, 2.8; p = 0.002; HR, 2.3; p = 0.01; and HR, 2.4; p = 0.005, respectively), and when combined, identified high-risk, therapy naive, stage I patients (HR, 10.2; p = 3x10(-5)). All associations were confirmed in two independently collected cohorts. Conclusion: A prognostic classifier comprising three types of genomic and epigenomic data may help guide the postoperative management of stage I lung cancer patients at high risk of recurrence.	[Robles, Ana I.; Mathe, Ewy A.; Okayama, Hirokazu; Schetter, Aaron J.; Brown, Derek; Bowman, Elise D.; Noro, Rintaro; Welsh, Judith A.; Harris, Curtis C.] NCI, Human Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; [Arai, Eri; Kanai, Yae] Natl Canc Ctr, Res Inst, Div Mol Pathol, Tokyo 104, Japan; [Petersen, David; Edelman, Daniel C.; Stevenson, Holly S.; Wang, Yonghong; Meltzer, Paul S.] NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA; [Tsuchiya, Naoto; Kohno, Takashi] Natl Canc Ctr, Res Inst, Div Genome Biol, Tokyo 104, Japan; [Skaug, Vidar; Mollerup, Steen; Haugen, Aage] Natl Inst Occupat Hlth, Dept Chem & Biol Working Environm, Oslo, Norway; [Yokota, Jun] Inst Predict & Personalized Med Canc IMPPC, Genom & Epigen Canc Predict Program, Badalona, Barcelona, Spain	Harris, CC (reprint author), NCI, Human Carcinogenesis Lab, CCR, NIH, 37 Convent Dr,Rm 3068A, Bethesda, MD 20892 USA.	curtis_harris@nih.gov			Intramural Research Program of the National Cancer Institute, NIH; Department of Defense Congressionally Directed Medical Research Program [PR093793]; Norwegian Cancer Society; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), Japan [10-42, 10-43]; Ministry of Health, Labor and Welfare, Japan; National Cancer Center Research and Development Fund [26-A-1]	This research was supported by the Intramural Research Program of the National Cancer Institute, NIH; Department of Defense Congressionally Directed Medical Research Program Grant PR093793; the Norwegian Cancer Society; the Program for Promotion of Fundamental Studies in Health Sciences (10-42 and 10-43) of the National Institute of Biomedical Innovation (NiBio), Japan; and Grants-in-Aid from the Ministry of Health, Labor and Welfare, Japan. National Cancer Center Biobank was supported by the National Cancer Center Research and Development Fund (26-A-1).	Akagi I, 2013, CANCER RES, V73, P3821, DOI 10.1158/0008-5472.CAN-13-0031; Kikuchi J, 2012, LUNG CANCER, V78, P138, DOI 10.1016/j.lungcan.2012.08.003; Shinjo K, 2012, CARCINOGENESIS, V33, P1277, DOI 10.1093/carcin/bgs154; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516; [Anonymous], 2014, NATURE, V511, P543; Lindeman NI, 2013, J THORAC ONCOL, V8, P823, DOI 10.1097/JTO.0b013e318290868f; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128; Seike M, 2007, J NATL CANCER I, V99, P1257, DOI 10.1093/jnci/djm083; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Douillard JY, 2010, J THORAC ONCOL, V5, P220, DOI 10.1097/JTO.0b013e3181c814e7; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Sato T, 2014, INT J CANCER, V135, P319, DOI 10.1002/ijc.28684; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Mathe EA, 2014, CANCER RES, V74, P3259, DOI 10.1158/0008-5472.CAN-14-0109; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; McShane LM, 2012, J CLIN ONCOL, V30, P4223, DOI 10.1200/JCO.2012.42.6858; Saito M, 2011, CLIN CANCER RES, V17, P1875, DOI 10.1158/1078-0432.CCR-10-2961; Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550; Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Sugimura H, 2007, ANN THORAC SURG, V83, P409, DOI 10.1016/j.athoracsur.2006.08.046; HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510; Butts CA, 2010, J CLIN ONCOL, V28, P29, DOI 10.1200/JCO.2009.24.0333; Subramanian J, 2010, J NATL CANCER I, V102, P464, DOI 10.1093/jnci/djq025; Subramanian J, 2010, NAT REV CLIN ONCOL, V7, P327, DOI 10.1038/nrclinonc.2010.60; Hawes SE, 2010, LUNG CANCER, V69, P172, DOI 10.1016/j.lungcan.2009.11.002; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Chansky K, 2009, J THORAC ONCOL, V4, P792, DOI 10.1097/JTO.0b013e3181a7716e; Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946; Carvalho RH, 2013, J THORAC ONCOL, V8, P562, DOI 10.1097/JTO.0b013e3182863ed2; Hassan KA, 2009, CLIN CANCER RES, V15, P6386, DOI 10.1158/1078-0432.CCR-09-1105; National Comprehensive Cancer Network, NONSM CELL LUNG CANC; Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Okayama H, 2014, CANCER EPIDEM BIOMAR, V23, P2884, DOI 10.1158/1055-9965.EPI-14-0182; Ryan BM, 2014, J THORAC ONCOL, V9, P1494, DOI 10.1097/JTO.0000000000000278; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Sato T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059444; Selamat SA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021443; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Walter K, 2012, CLIN CANCER RES, V18, P2360, DOI 10.1158/1078-0432.CCR-11-2635-T	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					1037	1048		10.1097/JTO.0000000000000560		12	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100008		
J	Nishio, M; Murakami, H; Horiike, A; Takahashi, T; Hirai, F; Suenaga, N; Tajima, T; Tokushige, K; Ishii, M; Boral, A; Robson, M; Seto, T				Nishio, Makoto; Murakami, Haruyasu; Horiike, Atsushi; Takahashi, Toshiaki; Hirai, Fumihiko; Suenaga, Naoko; Tajima, Takeshi; Tokushige, Kota; Ishii, Masami; Boral, Anthony; Robson, Matthew; Seto, Takashi			Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors	JOURNAL OF THORACIC ONCOLOGY			English	Article						ALK rearranged; non-small-cell lung cancer; Ceritinib; Alectinib	ALK; CRIZOTINIB; RESISTANCE; INHIBITOR; EML4-ALK; CH5424802; ALECTINIB; FEATURES; SAFETY; FUSION	Introduction: Anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel ALK inhibitor (ALKi), in Japanese patients with ALK-rearranged malignancies. Methods: This phase I, multicenter, open-label study (NCT01634763) enrolled adult patients with ALK-rearranged (by fluorescence in situ hybridization and/or immunohistochemistry) locally advanced/metastatic malignancy that had progressed despite standard therapy. The study comprised two parts: dose escalation and dose expansion. Ceritinib (single-dose) was administered orally in the 3-day PK run-in period, then once daily, in 21-day cycles. Adaptive dose escalations were guided by a Bayesian model. Results: Twenty patients (80% with ALKi treatment history [ALKi-pretreated]; 19 NSCLC; one inflammatory myofibroblastic tumor) received ceritinib 300 to 750mg (19 during dose escalation, one in dose expansion). Two dose-limiting toxicities occurred: grade 3 lipase increase (600mg); grade 3 drug-induced liver injury (750mg). The most common adverse events were gastrointestinal (nausea: 95%; diarrhea, vomiting: 75%). Ceritinib PK profile was dose proportional across 300 to 750mg dosages; steady state was reached by day 15. Overall response rate was 55% (11 of 20 patients). Among patients with NSCLC, partial response was observed in two of four ALKi-naive patients, five of nine crizotinib-pretreated patients, two of four alectinib-pretreated patients, and one of two crizotinib and alectinib/ASP3026 pretreated patients. The ASP3026-pretreated inflammatory myofibroblastic tumor patient achieved partial response. Conclusions: Ceritinib maximum-tolerated dose was 750mg once daily in Japanese patients. Antitumor activity was observed irrespective of prior ALKi treatment history. Dose expansion, examining the activity of ceritinib in alectinib-resistant patients, is ongoing.	[Nishio, Makoto; Horiike, Atsushi] Canc Inst Hosp JFCR, Tokyo 1358550, Japan; [Murakami, Haruyasu; Takahashi, Toshiaki] Shizuoka Canc Ctr, Shizuoka, Japan; [Hirai, Fumihiko; Seto, Takashi] Kyushu Natl Canc Ctr, Fukuoka, Japan; [Suenaga, Naoko; Tajima, Takeshi; Tokushige, Kota; Ishii, Masami] Novartis Pharma KK, Tokyo, Japan; [Robson, Matthew] Novartis Pharmaceut, E Hanover, NJ USA; [Boral, Anthony] Novartis Inst Biomed Res, Cambridge, MA USA	Nishio, M (reprint author), Canc Inst Hosp JFCR, Dept Thorac Med Oncol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	mnishio@jfcr.or.jp			Novartis Pharmaceuticals Corporation; Novartis Pharma K.K.	The authors thank the participating patients, their families, all study co-investigators, and research coordinators. We thank Ioana Dumitrescu, QXV Communications, United Kingdom (funded by Novartis Pharmaceuticals Corporation) and Shiva Krishna Rachamadugu, Novartis Healthcare Pvt. Ltd. for providing medical editorial assistance with this article. This study was sponsored by Novartis Pharma K.K.	MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Rodig SJ, 2009, CLIN CANCER RES, V15, P5216, DOI 10.1158/1078-0432.CCR-09-0802; Marsilje TH, 2013, J MED CHEM, V56, P5675, DOI 10.1021/jm400402q; Gadgeel SM, 2014, LANCET ONCOL, V15, P1119, DOI 10.1016/S1470-2045(14)70362-6; Neuenschwander B, 2008, STAT MED, V27, P2420, DOI 10.1002/sim.3230; Paik JH, 2011, J THORAC ONCOL, V6, P466, DOI 10.1097/JTO.0b013e31820b82e8; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Seto T, 2013, LANCET ONCOL, V14, P590, DOI 10.1016/S1470-2045(13)70142-6; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2013, J CLIN ONCOL, V31, P1105, DOI 10.1200/JCO.2012.44.5353; Barreca A, 2011, J MOL ENDOCRINOL, V47, pR11, DOI 10.1530/JME-11-0004; Choi Chang Min, 2013, Tuberc Respir Dis (Seoul), V75, P236, DOI 10.4046/trd.2013.75.6.236; Felip E, 2014, ESMO; Gainor JF, 2015, J THORAC ONCOL, V10, P232, DOI 10.1097/JTO.0000000000000455; Katayama R, 2014, CLIN CANC RES; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kim DW, 2012, J CLIN ONCOL S, V30, P2012; Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI 10.1056/NEJMoa1311107; Tan DSW, 2014, J CLIN ONCOL S, V32, p5s	26	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					1058	1066		10.1097/JTO.0000000000000566		9	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100010		
J	Iida, T; Shiba, M; Yoshino, I; Miyaoka, E; Asamura, H; Date, H; Okumura, M; Tada, H; Nakanishi, Y; Dosaka-Akita, H; Kobayashi, H; Takahashi, K; Inoue, M; Yokoi, K				Iida, Tomohiko; Shiba, Mitsutoshi; Yoshino, Ichiro; Miyaoka, Etsuo; Asamura, Hisao; Date, Hiroshi; Okumura, Meinoshin; Tada, Hirohito; Nakanishi, Yoichi; Dosaka-Akita, Hirotoshi; Kobayashi, Hideo; Takahashi, Kazuhisa; Inoue, Masayoshi; Yokoi, Kohei		Japanese Joint Comm Lung Canc	Surgical Intervention for Non-Small-Cell Lung Cancer Patients with Pleural Carcinomatosis Results From the Japanese Lung Cancer Registry in 2004	JOURNAL OF THORACIC ONCOLOGY			English	Article						Non-small-cell lung cancer; Pleural carcinomatosis; Malignant pleural effusion; Malignant pleural nodule; Surgical treatment	HYPOTONIC CISPLATIN TREATMENT; FORTHCOMING 7TH EDITION; TNM CLASSIFICATION; STAGING PROJECT; THORACOTOMY; EFFUSION; DISSEMINATION; PLEURITIS; PROGNOSIS; RESECTION	Introduction: A subset of non-small-cell lung cancer (NSCLC) patients with malignant pleural effusion and/or malignant pleural nodules is now classified as stage IV and is generally considered a contraindication to surgery. However, several reports have demonstrated that the prognosis of patients with pleural carcinomatosis first detected at thoracotomy is relatively favorable. The aim of this study was to describe the results of surgical intervention in NSCLC patients with pleural carcinomatosis in Japan. Methods: In 2010, the Japanese Joint Committee of Lung Cancer Registry conducted a nationwide registration of lung cancer patients who underwent surgery in 2004. Using this database, we performed a retrospective study focused on pleural carcinomatosis. We examined the clinicopathological features, the current status of therapy, and surgical outcomes in patients with pleural carcinomatosis. Results: Among the 11,420 registered NSCLC patients, 329 (2.9%) patients had pleural carcinomatosis. The median survival time and 5-year survival rate of 313 patients without other metastatic disease were 34.0 months and 29.3%, respectively. Primary tumor resection was performed in 256 (81.8%) patients, and macroscopic complete resection was achieved in 152 (48.6%) patients, with 5-year survival rates of 33.1% and 37.1%, respectively. Multivariate analysis revealed that Eastern Cooperative Oncology Group performance status (p < 0.001), best stage nodal status (p = 0.002), and the presence or absence of gross residual tumor (p = 0.013) were independent predictors of survival. Conclusion: In our surgical registry for NSCLC, patients with pleural carcinomatosis accounted for 2.9%, and macroscopic complete resection for them was associated with better survival.	[Iida, Tomohiko; Shiba, Mitsutoshi] Kimitsu Cent Hosp, Dept Thorac Surg, Kisarazu, Chiba 2928535, Japan; [Yoshino, Ichiro] Chiba Univ, Dept Gen Thorac Surg, Grad Sch Med, Chiba, Japan; [Miyaoka, Etsuo] Tokyo Univ Sci, Dept Math, Tokyo 162, Japan; [Asamura, Hisao] Keio Univ, Sch Med, Div Thorac Surg, Tokyo, Japan; [Date, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto, Japan; [Okumura, Meinoshin; Inoue, Masayoshi] Osaka Univ, Dept Gen Thorac Surg, Grad Sch Med, Osaka, Japan; [Tada, Hirohito] Suita Tokushukai Hosp, Dept Gen Thorac Surg, Osaka, Japan; [Nakanishi, Yoichi] Kyushu Univ, Dept Clin Med, Chest Dis Res Inst, Fac Med Sci, Fukuoka 812, Japan; [Dosaka-Akita, Hirotoshi] Hokkaido Univ, Dept Med Oncol, Grad Sch Med, Sapporo, Hokkaido, Japan; [Kobayashi, Hideo] Natl Def Med Coll, Div Resp Dis, Tokorozawa, Saitama 359, Japan; [Takahashi, Kazuhisa] Juntendo Univ, Div Resp Med, Fac Med, Tokyo, Japan; [Takahashi, Kazuhisa] Grad Sch Med, Tokyo, Japan; [Yokoi, Kohei] Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Nagoya, Aichi 4648601, Japan	Iida, T (reprint author), Kimitsu Cent Hosp, Dept Thorac Surg, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan.	hptiida@hotmail.co.jp					Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Postmus PE, 2007, J THORAC ONCOL, V2, P686, DOI 10.1097/JTO.0b013e31811f4703; Sawabata N, 2011, J THORAC ONCOL, V6, P1229, DOI 10.1097/JTO.0b013e318219aae2; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Fiorelli A, 2013, INTERACT CARDIOV TH, V17, P407, DOI 10.1093/icvts/ivt153; Fukuse T, 2001, LUNG CANCER-J IASLC, V34, P75, DOI 10.1016/S0169-5002(01)00228-8; Ichinose Y, 1997, J SURG ONCOL, V66, P196, DOI 10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7; ICHINOSE Y, 1993, J THORAC CARDIOV SUR, V105, P1041; Ichinose Y, 2000, SURG TODAY, V30, P1062; Kimura M, 2010, INTERACT CARDIOV TH, V10, P568, DOI 10.1510/icvts.2009.225110; Kimura M, 2013, MOL CLIN ONCOL, V1, P949; KODAMA K, 1993, CANCER, V72, P426, DOI 10.1002/1097-0142(19930715)72:2<426::AID-CNCR2820720218>3.0.CO;2-S; MARTINI N, 1990, SEMIN SURG ONCOL, V6, P248, DOI 10.1002/ssu.2980060505; Mordant P, 2011, EUR J CARDIO-THORAC, V40, P1444, DOI 10.1016/j.ejcts.2011.02.076; Ohta Y, 2000, ANN THORAC SURG, V69, P1025, DOI 10.1016/S0003-4975(99)01579-9; Okamoto T, 2012, EUR J CARDIO-THORAC, V41, P25, DOI 10.1016/j.ejcts.2011.04.010; Sahn SA., 2009, GEN THORACIC SURG, P875; Sawabata N, 2002, ANN THORAC SURG, V73, P412, DOI 10.1016/S0003-4975(01)03426-9; Shiba M, 2001, ANN THORAC SURG, V71, P1765, DOI 10.1016/S0003-4975(01)02589-9; Sobin LH, 2009, TNM CLASSIFICATION M; The Japan Lung, 2010, GEN RUL CLIN PATH RE, V7th	22	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					1076	1082		10.1097/JTO.0000000000000554		7	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100012		
J	Foster, NR; Renfro, LA; Schild, SE; Redman, MW; Wang, XFF; Dahlberg, SE; Ding, KY; Bradbury, PA; Ramalingam, SS; Gandara, DR; Shibata, T; Saijo, N; Vokes, EE; Adjei, AA; Mandrekar, SJ				Foster, Nathan R.; Renfro, Lindsay A.; Schild, Steven E.; Redman, Mary W.; Wang, Xiaofei F.; Dahlberg, Suzanne E.; Ding, Keyue; Bradbury, Penelope A.; Ramalingam, Suresh S.; Gandara, David R.; Shibata, Taro; Saijo, Nagahiro; Vokes, Everett E.; Adjei, Alex A.; Mandrekar, Sumithra J.			Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer	JOURNAL OF THORACIC ONCOLOGY			English	Article						Extensive-stage small-cell lung cancer; Surrogate endpoints; Pooled analysis; Progression-free survival; Overall survival	PHASE-III TRIAL; RANDOMIZED CLINICAL-TRIALS; CISPLATIN PLUS ETOPOSIDE; METASTATIC BREAST-CANCER; INDIVIDUAL PATIENT DATA; LEUKEMIA GROUP-B; COLORECTAL-CANCER; DISEASE PROGRESSION; TUMOR RESPONSE; COLON-CANCER	Introduction: We previously reported that progression-free survival (PFS) may be a candidate surrogate end point for overall survival (OS) in first-line extensive-stage small-cell lung cancer (ES-SCLC) using data from three randomized trials (Foster, Cancer 2011). In this validation study (N0424-Alliance), we assessed the patient-level and trial-level surrogacy of PFS using data from seven new first-line phase II/III ES-SCLC trials and across all 10 trials as well (seven new, three previous). Methods: Individual patient data were utilized across the seven new trials (2259 patients) and all 10 trials (2855 patients). Patient-level surrogacy (Kendall's ) was assessed using the Clayton copula bivariate survival model. Trial-level surrogacy was assessed through association of the log hazard ratios on OS and PFS across trials, including weighted (by trial size) least squares regression (WLS R-2) of Cox model effects and correlation of the copula effects (copula R-2). The minimum effect on the surrogate (MES) needed to detect a nonzero treatment effect on OS was also calculated. Results: The median OS and PFS across all 10 trials were 9.8 and 5.9 months, respectively. PFS showed strong surrogacy within the 7 new trials (copula R-2 = 0.90 [standard error = 0.27], WLS R-2 = 0.83 [95% confidence interval: 0.43, 0.95]; MES = 0.67, and Kendall's = 0.58) and across all 10 trials (copula R-2 = 0.81 [standard errors = 0.25], WLS R-2 = 0.77 [95% confidence interval: 0.47-0.91], MES = 0.70, and Kendall's = 0.57). Conclusions: PFS demonstrated strong surrogacy for OS in first-line ES-SCLC based on this external validation study of individual patient data. PFS is a good alternative end point to OS and should be considered when resource constraints (time or patient) might make it useful or desirable in place of OS. Additional analyses are needed to assess its appropriateness for targeted agents in this disease setting.	[Foster, Nathan R.; Renfro, Lindsay A.; Mandrekar, Sumithra J.] Mayo Clin, Div Biomed Stat & Informat, Alliance Stat & Data Ctr, Rochester, MN 55905 USA; [Schild, Steven E.] Mayo Clin, Dept Radiat Oncol, Scottsdale, AZ USA; [Redman, Mary W.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; [Wang, Xiaofei F.] Duke Univ, Dept Biostat & Bioinformat, Alliance Stat & Data Ctr, Durham, NC USA; [Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Ding, Keyue; Bradbury, Penelope A.] Queen Univ, Dept Oncol, NCIC Clin Trials Grp, Kingston, ON, Canada; [Ramalingam, Suresh S.] Emory Univ, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; [Gandara, David R.] UC Davis Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA; [Shibata, Taro] Natl Canc Ctr, Dept Stat Data Ctr Operat Off, Japan Clin Oncol Grp Data Ctr, Ctr Res Adm & Support, Tokyo 104, Japan; [Saijo, Nagahiro] Japanese Soc Med Oncol, Dept Med Oncol, Tokyo, Japan; [Vokes, Everett E.] Univ Chicago, Dept Med, Med & Biol Sci Ctr, Chicago, IL 60637 USA; [Adjei, Alex A.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	Foster, NR (reprint author), Mayo Clin, Div Biomed Stat & Informat, Alliance Stat & Data Ctr, Rochester, MN 55905 USA.	foster.nathan@mayo.edu			National Cancer Institute [CA25224, CA31946, CA33601]; Canadian Cancer Society Research Institute [021039, 015469]; Ministry of Health, Labour and Welfare in Japan	This study was supported, in part, by grants from the National Cancer Institute to the North Central Cancer Treatment Group (CA25224) and to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair, CA31946) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). NCIC Clinical Trials Group is supported by funding received from the Canadian Cancer Society Research Institute (Grants #021039 and #015469) and the JCOG trial was supported by the Grant of Ministry of Health, Labour and Welfare in Japan. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute, the National Institute of Health, or the other groups (JCOG, Canadian Cancer Society Research Institute).	Niell HB, 2005, J CLIN ONCOL, V23, P3752, DOI 10.1200/JCO.2005.09.071; Burzykowski T, 2008, J CLIN ONCOL, V26, P1987, DOI 10.1200/JCO.2007.10.8407; Collette L, 2005, J CLIN ONCOL, V23, P6139, DOI 10.1200/JCO.2005.08.156; EVANS WK, 1987, ANN INTERN MED, V107, P451; Hanna N, 2006, J CLIN ONCOL, V24, P2038, DOI 10.1200/JCO.2005.04.8595; Buyse M, 2008, STAT METHODS MED RES, V17, P467, DOI 10.1177/0962280207081864; O'Brien MER, 2006, J CLIN ONCOL, V24, P5441, DOI 10.1200/JCO.2006.06.5821; MAKSYMIUK AW, 1994, J CLIN ONCOL, V12, P70; Soria JC, 2010, ANN ONCOL, V21, P2324, DOI 10.1093/annonc/mdq204; Burzykowski T, 2001, J ROY STAT SOC C-APP, V50, P405, DOI 10.1111/1467-9876.00244; Freidlin B, 2007, J CLIN ONCOL, V25, P2122, DOI 10.1200/JCO.2006.09.6198; Broglio KR, 2009, JNCI-J NATL CANCER I, V101, P1642, DOI 10.1093/jnci/djp369; Sridhara R, 2013, CLIN CANCER RES, V19, P2613, DOI 10.1158/1078-0432.CCR-12-2938; Sargent DJ, 2005, J CLIN ONCOL, V23, P8664, DOI 10.1200/JCO.2005.01.6071; Mauguen A, 2013, LANCET ONCOL, V14, P619, DOI 10.1016/S1470-2045(13)70158-X; Rudin CM, 2008, J CLIN ONCOL, V26, P870, DOI 10.1200/JCO.2007.14.3461; Bast RC, 2007, GYNECOL ONCOL, V107, P173, DOI 10.1016/j.ygyno.2007.08.092; Okamoto H, 2007, BRIT J CANCER, V97, P162, DOI 10.1038/sj.bjc.6603810; Dancey JE, 2009, EUR J CANCER, V45, P281, DOI 10.1016/j.ejca.2008.10.042; ROTH BJ, 1992, J CLIN ONCOL, V10, P282; Foster NR, 2011, CANCER-AM CANCER SOC, V117, P1262, DOI 10.1002/cncr.25526; Booth CM, 2012, J CLIN ONCOL, V30, P1030, DOI 10.1200/JCO.2011.38.7571; Panageas KS, 2007, J NATL CANCER I, V99, P428, DOI 10.1093/jnci/djk091; Paoletti X, 2013, JNCI-J NATL CANCER I, V105, P1667, DOI 10.1093/jnci/djt269; Pujol JL, 2000, BRIT J CANCER, V83, P8; Lara PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061; Sargent DJ, 2007, J CLIN ONCOL, V25, P4569, DOI 10.1200/JCO.2006.10.4323; Buyse M, 2007, J CLIN ONCOL, V25, P5218, DOI 10.1200/JCO.2007.11.8836; Murray N, 1999, J CLIN ONCOL, V17, P2300; Bhattacharya S, 2009, J CLIN ONCOL, V27, P5958, DOI 10.1200/JCO.2009.22.4329; Buyse M, 2003, BIOMARKERS CLIN DRUG, P149; Buyse ME, 2008, J CLIN ONCOL, V26; Ferraldeschi R, 2009, ANN ONCOL, V20, P801, DOI 10.1093/annonc/mdp247; Hackshaw A, 2005, BRIT J CANCER, V93, P1215, DOI 10.1038/sj.bjc.6602858; Laporte S., 2013, BMJ OPEN, V3, P1; Miksad RA, 2008, INT J TECHNOL ASSESS, V24, P371, DOI 10.1017/S0266462308080495; MILLER AA, 1995, J CLIN ONCOL, V13, P1871; Noda Kazumasa, 2002, New England Journal of Medicine, V346, P85, DOI 10.1056/NEJMoa003034; Qi YW, 2012, CANCER-AM CANCER SOC, V118, P5358, DOI 10.1002/cncr.27528; Renfro LA, 2014, J BIOPHARM STAT; Rowland KM, 1996, J CLIN ONCOL, V14, P135; Schabath MB, 2014, LUNG CANCER, V86, P14, DOI 10.1016/j.lungcan.2014.07.014; Schaefer PL, 2003, AM J CLIN ONCOL-CANC, V26, P236, DOI 10.1097/00000421-200306000-00005; Sherrill B, 2008, BRIT J CANCER, V99, P1572, DOI 10.1038/sj.bjc.6604759; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tang PA, 2007, J CLIN ONCOL, V25, P4562, DOI 10.1200/JCO.2006.08.1935	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					1099	1106		10.1097/JTO.0000000000000548		8	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100015		
J	Umehara, T; Aoki, M; Harada, A; Watanabe, Y; Sato, M				Umehara, Tadashi; Aoki, Masaya; Harada, Aya; Watanabe, Yui; Sato, Masami			A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch	JOURNAL OF THORACIC ONCOLOGY			English	Article							DISEASE		[Umehara, Tadashi; Aoki, Masaya; Harada, Aya; Watanabe, Yui; Sato, Masami] Kagoshima Univ, Dept Gen Thorac Surg, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan	Sato, M (reprint author), Kagoshima Univ, Dept Gen Thorac Surg, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	m-sato@m2.kufm.kagoshima-u.ac.jp					Maekawa K, 2011, CHEST, V140, P723, DOI 10.1378/chest.10-2315; Field SK, 2004, CHEST, V126, P566, DOI 10.1378/chest.126.2.566; Morimoto Kozo, 2011, Kekkaku, V86, P547; Spaggiari L, 2013, ANN THORAC SURG, V95, P1717, DOI 10.1016/j.athoracsur.2013.01.088	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	JUL	2015	10	7					1118	1119		10.1097/JTO.0000000000000413		2	Oncology; Respiratory System	Oncology; Respiratory System	CL4SK	WOS:000356944100019		
J	Yanagida, S; Nishizawa, N; Mizoguchi, K; Hatakeyama, H; Fukuda, S				Yanagida, Saori; Nishizawa, Noriko; Mizoguchi, Kenji; Hatakeyama, Hiromitsu; Fukuda, Satoshi			Voice Onset Time for the Word-Initial Voiceless Consonant /t/ in Japanese Spasmodic Dysphonia-A Comparison With Normal Controls	JOURNAL OF VOICE			English	Article						Adductor spasmodic dysphonia; Abductor spasmodic dysphonia; Acoustic analysis; Voice onset time	BOTULINUM TOXIN INJECTION; LIFE V-RQOL; SYMPTOMS; THERAPY	Objectives. Voice onset time (VOT) for word-initial voiceless consonants in adductor spasmodic dysphonia (ADSD) and abductor spasmodic dysphonia (ABSD) patients were measured to determine (1) which acoustic measures differed from the controls and (2) whether acoustic measures were related to the pause or silence between the test word and the preceding word. Methods. Forty-eight patients with ADSD and nine patients with ABSD, as well as 20 matched normal controls read a story in which the word "taiyo" (the sun) was repeated three times, each differentiated by the position of the word in the sentence. The target of measurement was the VOT for the word-initial voiceless consonant /t/. Results. When the target syllable appeared in a sentence following a comma, or at the beginning of a sentence following a period, the ABSD patients' VOTs were significantly longer than those of the ADSD patients and controls. Abnormal prolongation of the VOTs was related to the pause or silence between the test word and the preceding word. Conclusions. VOTs in spasmodic dysphonia (SD) may vary according to the SD subtype or speaking conditions. VOT measurement was suggested to be a useful method for quantifying voice symptoms in SD.	[Yanagida, Saori; Nishizawa, Noriko] Hlth Sci Univ Hokkaido, Sch Psychol Sci, Dept Commun Disorders, Sapporo, Hokkaido 0028072, Japan; [Nishizawa, Noriko; Mizoguchi, Kenji; Hatakeyama, Hiromitsu; Fukuda, Satoshi] Hokkaido Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med, Sapporo, Hokkaido, Japan	Yanagida, S (reprint author), Hlth Sci Univ Hokkaido, Sch Psychol Sci, Dept Commun Disorders, 2-5 Ainosato, Sapporo, Hokkaido 0028072, Japan.	s.yanagi@hoku-iryo-u.ac.jp					Morzaria S, 2012, J VOICE, V26, P378, DOI 10.1016/j.jvoice.2010.07.011; Stewart CF, 1997, J VOICE, V11, P95, DOI 10.1016/S0892-1997(97)80029-X; Allen JS, 2003, J ACOUST SOC AM, V113, P544, DOI 10.1121/1.1528172; Katada A, 2004, NEUROSCI RES, V50, P153, DOI 10.1016/j.neures.2004.06.016; Rubin AD, 2004, ARCH OTOLARYNGOL, V130, P415, DOI 10.1001/archotol.130.4.415; Braden MN, 2010, J VOICE, V24, P242, DOI 10.1016/j.jvoice.2008.08.003; Cannito MP, 2004, ARCH OTOLARYNGOL, V130, P1393, DOI 10.1001/archotol.130.12.1393; Cannito MP, 2014, J VOICE, V28; Cantarella G, 2006, OTOLARYNG HEAD NECK, V134, P419, DOI 10.1016/j.otohns.2005.10.028; CrevierBuchman L, 1997, J VOICE, V11, P232, DOI 10.1016/S0892-1997(97)80082-3; Edgar JD, 2001, J VOICE, V15, P362, DOI 10.1016/S0892-1997(01)00038-8; Erickson ML, 2003, AM J SPEECH-LANG PAT, V12, P416, DOI 10.1044/1058-0360(2003/087); Gamboa J, 1998, J VOICE, V12, P444, DOI 10.1016/S0892-1997(98)80053-2; Hamano T, 1999, CLIN NEUROPHYSIOL, V110, P508, DOI 10.1016/S1388-2457(98)00045-5; HIROSE H, 1978, PHONETICA, V35, P1; Hogikyan ND, 2001, J VOICE, V15, P576, DOI 10.1016/S0892-1997(01)00060-1; KLATT DH, 1975, J SPEECH HEAR RES, V18, P686; MERSON RM, 1979, LARYNGOSCOPE, V89, P129; MURRY T, 1995, J VOICE, V9, P460, DOI 10.1016/S0892-1997(05)80211-5; Sanuki T, 2010, OTOLARYNG HEAD NECK, V142, P540, DOI 10.1016/j.otohns.2009.12.018; Sapienza CM, 1998, J VOICE, V12, P214, DOI 10.1016/S0892-1997(98)80041-6; Sapoenza CM, 2000, J VOICE, V14, P502; Sugito M, 1990, STUD PHON SPEECH COM, P199; WOO P, 1992, J VOICE, V6, P344, DOI 10.1016/S0892-1997(05)80031-1; ZWIRNER P, 1991, J VOICE, V5, P78, DOI 10.1016/S0892-1997(05)80167-5	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0892-1997	1873-4588		J VOICE	J. Voice	JUL	2015	29	4					450	454		10.1016/j.jvoice.2014.09.028		5	Otorhinolaryngology	Otorhinolaryngology	CL3UJ	WOS:000356875800009		
J	Nomoto, M; Tokashiki, R; Hiramatsu, H; Konomi, U; Motohashi, R; Sakurai, E; Toyomura, F; Ueda, Y; Inoue, S; Tsukahara, K; Suzuki, M				Nomoto, Masaki; Tokashiki, Ryoji; Hiramatsu, Hiroyuki; Konomi, Ujimoto; Motohashi, Rei; Sakurai, Eriko; Toyomura, Fumimasa; Ueda, Yuri; Inoue, Shun; Tsukahara, Kiyoaki; Suzuki, Mamoru			The Comparison of Thyroarytenoid Muscle Myectomy and Type II Thyroplasty for Spasmodic Dysphonia	JOURNAL OF VOICE			English	Article						Spasmodic dysphonia; Thyroarytenoid muscle myectomy; Type II thyroplasty; Surgery	SURGICAL-TREATMENT; SPASTIC DYSPHONIA; BOTULINUM TOXIN	Objective. Surgical treatments for adductor spasmodic dysphonia include bilateral thyroarytenoid muscle myectomy (TAM) and type II thyroplasty (TPII), both of which are commonly performed. The present study aimed to compare the effects of TAM and TPII. Study Design. Retrospective study. Methods. Subjects were 30 and 35 patients who underwent TAM and TPII, between March 2008 and November 2012. Voice quality was evaluated based on "voice handicap index 10 (VHI10)'' and auditory impressions before and 6 months after surgery using five parameters: "strangulation,'' "interruption,'' "tremor,'' "grade,'' and "breathiness.'' Results. Comparison of the two procedures revealed significant improvements in VHI10, strangulation, interruption, and tremor, and a significant decline in breathiness after surgery. In particular, VHI10 was improved by more than six points in 90% of patients with TAM, and 96% with TPII. No significant difference was observed between the severities of two procedures preoperatively. Comparison of each postoperative score between the two procedures revealed that TAM significantly improved strangulation, interruption, and tremor, and significantly worsened breathiness, with no significant difference in VHI10. Scatter plots (x: preoperative scores; y: postoperative scores) and regression lines of evaluation items demonstrated that TAM is more effective than TPII in severe cases. Conclusions. Compared with TPII, TAM tends to improve strangulation, interruption, and tremor; however, it tends to worsen breathiness postoperatively. Postoperative VHI10 scores did not differ significantly between the two procedures. Given favorable improvement rates, both surgical procedures were considered effective.	[Nomoto, Masaki; Tokashiki, Ryoji; Hiramatsu, Hiroyuki; Konomi, Ujimoto; Motohashi, Rei; Sakurai, Eriko; Toyomura, Fumimasa; Ueda, Yuri; Tsukahara, Kiyoaki; Suzuki, Mamoru] Tokyo Med Univ, Dept Otorhinolaryngol, Tokyo 1600023, Japan; [Nomoto, Masaki] Nishitokyo Cent Gen Hosp, Tokyo, Japan; [Tokashiki, Ryoji; Inoue, Shun] Shinjuku Voice Clin, Tokyo, Japan	Nomoto, M (reprint author), Tokyo Med Univ, Dept Otorhinolaryngol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	laryngonomo@yahoo.co.jp					DeBodt MS, 1997, J VOICE, V11, P74, DOI 10.1016/S0892-1997(97)80026-4; Isshiki N, 1998, LARYNGOSCOPE, V108, P1761, DOI 10.1097/00005537-199812000-00001; Rosen CA, 2004, LARYNGOSCOPE, V114, P1549, DOI 10.1097/00005537-200409000-00009; Berke GS, 1999, ANN OTO RHINOL LARYN, V108, P227; BLITZER A, 1988, LARYNGOSCOPE, V98, P193; Chan SW, 2004, LARYNGOSCOPE, V114, P1604, DOI 10.1097/00005537-200409000-00019; DEDO HH, 1976, ANN OTO RHINOL LARYN, V85, P451; Isshiki N, 2000, ANN OTO RHINOL LARYN, V109, P187; Jacobson BH, 1997, AM J SPEECH-LANG PAT, V6, P66; MILLER RH, 1987, ARCH OTOLARYNGOL, V113, P603; Nakamura K, 2009, J JPN BRONCHOESOPHOG, V60, P231; Nakamura K, 2008, ACTA OTO-LARYNGOL, V128, P1348, DOI 10.1080/00016480801965019; Nash EA, 1996, LARYNGOSCOPE, V106, P484, DOI 10.1097/00005537-199604000-00017; Nomoto M, 2013, J JPN BRONCHOESOPHOG, V64, P8; Sanuki T, 2007, LARYNGOSCOPE, V117, P2255, DOI 10.1097/MLG.0b013e31814684fa; Su CY, 2007, ANN OTO RHINOL LARYN, V116, P11	16	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0892-1997	1873-4588		J VOICE	J. Voice	JUL	2015	29	4					501	506		10.1016/j.jvoice.2014.09.030		6	Otorhinolaryngology	Otorhinolaryngology	CL3UJ	WOS:000356875800018		
J	Wu, D; Yang, QS; Tamura, Y				Wu, Di; Yang, Qingshan; Tamura, Yukio			Estimation of internal forces in cladding support components due to wind-induced overall behaviors of long-span roof structure	JOURNAL OF WIND ENGINEERING AND INDUSTRIAL AERODYNAMICS			English	Article						Internal forces; Cladding support components; Long-span roof structures; Overall behaviors; Local behaviors	PROPER ORTHOGONAL DECOMPOSITION; LOAD; PRESSURE; DISTRIBUTIONS	Wind-induced internal forces in cladding support components of a long-span roof structure depend on local behaviors caused by local wind loads and wind-induced overall behaviors of the main structural frame. Based on the pioneering work of Ding and Tamura (2013); Ding et al. (2012), a new method is proposed to estimate internal forces in cladding support components due to wind-induced overall behaviors directly. A detailed investigation on the contributions of wind-induced overall and local behaviors for internal forces in cladding support components of a space truss structure is performed. The results demonstrate that the bending moments and shear forces in cladding support components are dominated by local wind loads acting on the corresponding tributary areas, and the axial forces are caused by the overall displacements of the main structural frame. Considering only the local behavior will underestimate the axial forces in cladding support components significantly, which may lead to buckling failure. (C) 2015 Elsevier Ltd. All rights reserved.	[Wu, Di; Yang, Qingshan; Tamura, Yukio] Beijing Jiaotong Univ, Sch Civil Engn, Beijings Key Lab Struct Wind Engn & Urban Wind En, Beijing, Peoples R China; [Tamura, Yukio] Tokyo Polytech Univ, Wind Engn Res Ctr, Atsugi, Kanagawa, Japan	Wu, D (reprint author), Beijing Jiaotong Univ, Sch Civil Engn, Beijings Key Lab Struct Wind Engn & Urban Wind En, Beijing, Peoples R China.	forseti2001@163.com			National Natural Science Foundation of China [51308039, 91215302]; 111 Project of China [B13002]; Fundamental Research Funds for the Central Universities [2013JBM057, 2010JBZ011]	This study is supported in part by the National Natural Science Foundation of China (51308039, 91215302), the 111 Project of China (B13002) and the Fundamental Research Funds for the Central Universities (2013JBM057, 2010JBZ011). These supports are gratefully acknowledged.	KAREEM A, 1994, J OFFSHORE MECH ARCT, V116, P137, DOI 10.1115/1.2920142; Sadek F, 2002, J ENG MECH-ASCE, V128, P530, DOI 10.1061/(ASCE)0733-9399(2002)128:5(530); Holmes JD, 2002, J WIND ENG IND AEROD, V90, P91, DOI 10.1016/S0167-6105(01)00164-7; Tieleman HW, 2008, J WIND ENG IND AEROD, V96, P1111, DOI 10.1016/j.jweia.2007.06.035; Chen XZ, 2004, J STRUCT ENG-ASCE, V130, P1425, DOI 10.1061/(ASCE)0733-9445(2004)130:10(1425); Katsumura A, 2007, J WIND ENG IND AEROD, V95, P1145, DOI 10.1016/j.jweia.2007.01.020; Tamura Y, 1999, J FLUID STRUCT, V13, P1069, DOI 10.1006/jfls.1999.0242; Chen XZ, 2005, J ENG MECH-ASCE, V131, P325, DOI 10.1061/(ASCE)0733-9399(2005)131:4(325); Ding ZB, 2012, J WIND ENG IND AEROD, V107, P192, DOI 10.1016/j.jweia.2012.04.015; Ding ZB, 2013, J WIND ENG IND AEROD, V115, P162, DOI 10.1016/j.jweia.2013.01.013; HOLMES JD, 1990, J WIND ENG IND AEROD, V33, P219, DOI 10.1016/0167-6105(90)90037-D; Kown D.K., 2011, J STRUCT ENG, V137, P1611; Shen Shizhao, 1999, STABILITY RETICULATE; Uematsu Y, 1997, J WIND ENG IND AEROD, V66, P227, DOI 10.1016/S0167-6105(97)00133-5; Winterstein SR, 2000, J SOL ENERG-T ASME, V122, P122, DOI 10.1115/1.1288028; Yang QS, 2013, J STRUCT ENG-ASCE, V139, P997, DOI 10.1061/(ASCE)ST.1943-541X.0000715	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-6105	1872-8197		J WIND ENG IND AEROD	J. Wind Eng. Ind. Aerodyn.	JUL	2015	142						15	25		10.1016/j.jweia.2015.03.005		11	Engineering, Civil; Mechanics	Engineering; Mechanics	CL5GP	WOS:000356988100002		
J	Tominaga, Y				Tominaga, Yoshihide			Flow around a high-rise building using steady and unsteady RANS CFD: Effect of large-scale fluctuations on the velocity statistics	JOURNAL OF WIND ENGINEERING AND INDUSTRIAL AERODYNAMICS			English	Article						Computational fluid dynamics (CFD); Unsteady RANS (URANS); Steady RANS (SRANS); Large-scale fluctuation; High-rise building	K-EPSILON MODELS; PEDESTRIAN WIND ENVIRONMENT; SURFACE BOUNDARY-LAYER; TURBULENCE MODELS; BLUFF-BODY; POLLUTANT DISPERSION; COOPERATIVE PROJECT; EDDY SIMULATION; SQUARE CYLINDER; SEPARATED FLOW	In this study, the performance of the unsteady Reynolds-averaged Navier-Stokes (URANS) turbulence modeling of the flow field around a high-rise building with a 1:1:2 shape was examined. The unsteady fluctuation behind the building was successfully reproduced by URANS computation using the k-omega shear stress transport (SST) model. This reproduction could not be achieved by other turbulence models, namely, the standard k-epsilon, renormalization group theory (RNG) k-epsilon, realizable k-epsilon, and standard k-omega models. The URANS computation using the k-omega SST model successfully contributed to the reproduction of a certain part of the large-scale unsteady flow patterns around the building, and enabled more accurate prediction of the velocity distributions behind the building compared to the steady-RANS computation. However, the URANS computation overestimated the flow separation at the building corners. A modified epsilon-equation was introduced into the RNG k-epsilon model to enable its use to reproduce the periodic fluctuation and more accurately predict the flow separation on the roof of the building. The modification took into consideration the effects of the mean-flow periodicity on the energy transfer between large-scale fluctuations and small-scale turbulence. Overall, the results of the URANS computation using the RNG k-epsilon model with the modified epsilon-equation exhibited the best agreement with experimental results. (C) 2015 Elsevier Ltd. All rights reserved.	Niigata Inst Technol, Dept Architecture & Bldg Engn, Kashiwazaki 9451195, Japan	Tominaga, Y (reprint author), Niigata Inst Technol, Dept Architecture & Bldg Engn, 1719 Fujihashi, Kashiwazaki 9451195, Japan.	tominaga@abe.niit.ac.jp	Tominaga, Yoshihide/P-4104-2014	Tominaga, Yoshihide/0000-0002-4329-0787	 [25420616]	The author would like to express his gratitude for the financial support provided through the Grants-in-Aid for Scientific Research in Japan (No. 25420616). The author would also like to thank Mr. Kotaro Maruya, former undergraduate student of the Niigata Institute of Technology, for his assistance with the experiments and computations performed in this study.	Abrishamchi A, 2012, J FLUID STRUCT, V28, P244, DOI 10.1016/j.jfluidstructs.2011.10.002; Murakami S, 1998, J WIND ENG IND AEROD, V74-6, P1, DOI 10.1016/S0167-6105(98)00004-X; Pellegrino A, 2013, J WIND ENG IND AEROD, V121, P131, DOI 10.1016/j.jweia.2013.08.002; Mannini C, 2010, COMPUT FLUIDS, V39, P1609, DOI 10.1016/j.compfluid.2010.05.014; Tominaga Y, 2010, BUILD ENVIRON, V45, P2231, DOI 10.1016/j.buildenv.2010.04.004; Shimada K, 2002, J FLUID STRUCT, V16, P465, DOI 10.1006/jfls.2001.0433; Blocken B, 2014, J WIND ENG IND AEROD, V129, P69, DOI 10.1016/j.jweia.2014.03.008; Gousseau P, 2011, J HAZARD MATER, V194, P422, DOI 10.1016/j.jhazmat.2011.08.008; Tsuchiya M, 1997, J WIND ENG IND AEROD, V67-8, P169, DOI 10.1016/S0167-6105(97)00071-8; Menter FR, 2010, FLOW TURBUL COMBUST, V85, P113, DOI 10.1007/s10494-010-9264-5; Stathopoulos T, 2002, WIND STRUCT, V5, P193; SHIH TH, 1995, COMPUT FLUIDS, V24, P227, DOI 10.1016/0045-7930(94)00032-T; HUSSAIN AKM, 1970, J FLUID MECH, V41, P241, DOI 10.1017/S0022112070000605; Blocken B, 2007, ATMOS ENVIRON, V41, P238, DOI 10.1016/j.atmosenv.2006.08.019; Stathopoulos T, 1997, J WIND ENG IND AEROD, V67-8, P509, DOI 10.1016/S0167-6105(97)00097-4; Bosch G, 1998, INT J NUMER METH FL, V28, P601, DOI 10.1002/(SICI)1097-0363(19980930)28:4<601::AID-FLD732>3.0.CO;2-F; Ramponi R, 2012, BUILD ENVIRON, V53, P34, DOI 10.1016/j.buildenv.2012.01.004; Spalart PR, 2000, INT J HEAT FLUID FL, V21, P252, DOI 10.1016/S0142-727X(00)00007-2; Tominaga Y, 2008, J WIND ENG IND AEROD, V96, P1749, DOI 10.1016/j.jweia.2008.02.058; Spalart PR, 2006, THEOR COMP FLUID DYN, V20, P181, DOI 10.1007/s00162-006-0015-0; MURAKAMI S, 1993, J WIND ENG IND AEROD, V46-7, P21, DOI 10.1016/0167-6105(93)90112-2; Mannini C, 2010, J WIND ENG IND AEROD, V98, P742, DOI 10.1016/j.jweia.2010.06.010; Yoshie R, 2007, J WIND ENG IND AEROD, V95, P1551, DOI 10.1016/j.jweia.2007.02.023; Tominaga Y, 2008, J WIND ENG IND AEROD, V96, P389, DOI 10.1016/j.jweia.2008.01.004; YAKHOT V, 1992, PHYS FLUIDS A-FLUID, V4, P1510, DOI 10.1063/1.858424; Blocken B, 2011, J BUILD PERFORM SIMU, V4, P157, DOI 10.1080/19401493.2010.513740; Yuan C, 2012, BUILD ENVIRON, V50, P176, DOI 10.1016/j.buildenv.2011.10.023; Tominaga Y, 2013, ATMOS ENVIRON, V79, P716, DOI 10.1016/j.atmosenv.2013.07.028; Murakami S, 1997, J WIND ENG IND AEROD, V67-8, P3, DOI 10.1016/S0167-6105(97)00230-4; Mochida A, 2008, J WIND ENG IND AEROD, V96, P1498, DOI 10.1016/j.jweia.2008.02.033; Gousseau P, 2013, COMPUT FLUIDS, V79, P120, DOI 10.1016/j.compfluid.2013.03.006; Shao JT, 2012, BUILD ENVIRON, V57, P145, DOI 10.1016/j.buildenv.2012.04.018; Rodi W, 1997, J WIND ENG IND AEROD, V71, P55; Blocken B, 2012, ENVIRON MODELL SOFTW, V30, P15, DOI 10.1016/j.envsoft.2011.11.009; Casey M., 2000, BEST PRACTICE GUIDEL; DURBIN PA, 1995, AIAA J, V33, P659, DOI 10.2514/3.12628; Franke J., 2007, BEST PRACTICE GUIDEL; Hanjalic K, 2008, J WIND ENG IND AEROD, V96, P1537, DOI 10.1016/j.jweia.2008.02.054; Iaccarino G, 2003, INT J HEAT FLUID FL, V24, P147, DOI 10.1016/S0142-727X(02)00210-2; Kato M., 1993, P 9 S TURB SHEAR FLO, P10; Launder B. E., 1972, MATH MODELS TURBULEN; Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, DOI 10.1016/0045-7825(74)90029-2; Meng T, 1998, J WIND ENG, V76, P55; MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149; Mochida A, 2002, WIND STRUCT, V5, P227; MURAKAMI S, 1995, J WIND ENG IND AEROD, V54, P191, DOI 10.1016/0167-6105(94)00043-D; Ramesh V, 2006, INT J NUMER METHOD H, V16, P660, DOI 10.1108/09615530610679048; RODI W, 1993, J WIND ENG IND AEROD, V46-7, P3, DOI 10.1016/0167-6105(93)90111-Z; Spalart P.R., 1997, ADV LES DNS; Wilcox D. C., 1998, TURBULENCE MODELING; Younis BA, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2166458; Younis B.A., 2005, J COMPUTATIONAL MECH, V37, P408	52	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-6105	1872-8197		J WIND ENG IND AEROD	J. Wind Eng. Ind. Aerodyn.	JUL	2015	142						93	103		10.1016/j.jweia.2015.03.013		11	Engineering, Civil; Mechanics	Engineering; Mechanics	CL5GP	WOS:000356988100008		
J	Horie, S				Horie, Shigeo			Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?	KIDNEY INTERNATIONAL			English	Editorial Material								The vasopressin inhibitor tolvaptan is clinically effective in slowing growth of renal cysts and reduction in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD), but these effects are mitigated by the associated polyuria. Changes of total kidney volume, eGFR, and symptoms will guide physicians and patients in tolvaptan treatment. Guidance about when to initiate treatment in the course of ADPKD may be forthcoming. Ongoing long-term observations will inform future recommendations about tolvaptan use in ADPKD.	[Horie, Shigeo] Juntendo Univ, Dept Urol, Grad Sch Med, Tokyo 1138431, Japan	Horie, S (reprint author), Juntendo Univ, Dept Urol, Grad Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138431, Japan.	shorie@juntendo.ac.jp					Torres VE, 2012, NEW ENGL J MED, V367, P2407, DOI 10.1056/NEJMoa1205511; Erickson KF, 2013, ANN INTERN MED, V159, P382, DOI 10.7326/0003-4819-159-6-201309170-00004; Chapman AB, 2015, KIDNEY INT, V88, P17, DOI 10.1038/ki.2015.59; IVY DD, 1995, J AM SOC NEPHROL, V5, P2032; Lentine KL, 2010, CLIN J AM SOC NEPHRO, V5, P1471, DOI 10.2215/CJN.00780110; Bhutani H, 2015, KIDNEY INT, V88, P146, DOI 10.1038/ki.2015.71; Muto S, 2015, CLIN EXP NEPHROL; US Food and Drug Administration, 2013, CARD REN DRUGS ADV C	8	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	JUL	2015	88	1					14	16		10.1038/ki.2015.143		3	Urology & Nephrology	Urology & Nephrology	CL7FN	WOS:000357138000005		
J	Chapman, AB; Devuyst, O; Eckardt, KU; Gansevoort, RT; Harris, T; Horie, S; Kasiske, BL; Odland, D; Pei, Y; Perrone, RD; Pirson, Y; Schrier, RW; Torra, R; Torres, VE; Watnick, T; Wheeler, DC				Chapman, Arlene B.; Devuyst, Olivier; Eckardt, Kai-Uwe; Gansevoort, Ron T.; Harris, Tess; Horie, Shigeo; Kasiske, Bertram L.; Odland, Dwight; Pei, York; Perrone, Ronald D.; Pirson, Yves; Schrier, Robert W.; Torra, Roser; Torres, Vicente E.; Watnick, Terry; Wheeler, David C.		Conference Participants	Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	KIDNEY INTERNATIONAL			English	Review						ADPKD; diagnosis; end-stage renal disease; management; patient support; polycystic kidney disease	RENAL REPLACEMENT THERAPY; PREIMPLANTATION GENETIC DIAGNOSIS; UNRUPTURED INTRACRANIAL ANEURYSMS; LONG-ACTING SOMATOSTATIN; INDIVIDUAL PATIENT DATA; LEFT-VENTRICULAR MASS; QUALITY-OF-LIFE; LIVER-DISEASE; CYST INFECTION; FOLLOW-UP	Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals and is the fourth most common cause for renal replacement therapy worldwide. There have been many recent advances in the understanding of its molecular genetics and biology, and in the diagnosis and management of its manifestations. Yet, diagnosis, evaluation, prevention, and treatment vary widely and there are no broadly accepted practice guidelines. Barriers to translation of basic science breakthroughs to clinical care exist, with considerable heterogeneity across countries. The Kidney Disease: Improving Global Outcomes Controversies Conference on ADPKD brought together a panel of multidisciplinary clinical expertise and engaged patients to identify areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support. These are summarized in this review.	[Chapman, Arlene B.] Emory Univ, Sch Med, Atlanta, GA USA; [Devuyst, Olivier] Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Eckardt, Kai-Uwe] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany; [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Harris, Tess] PKD Int, Geneva, Switzerland; [Horie, Shigeo] Juntendo Univ, Grad Sch Med, Tokyo, Japan; [Kasiske, Bertram L.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Odland, Dwight] PKD Fdn, Kansas City, MO USA; [Pei, York] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada; [Perrone, Ronald D.] Tufts Med Ctr, Boston, MA USA; [Perrone, Ronald D.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Pirson, Yves] Catholic Univ Louvain, B-1200 Brussels, Belgium; [Schrier, Robert W.] Univ Colorado, Denver, CO 80202 USA; [Torra, Roser] Univ Autonoma Barcelona, Fundacio Puigvert, REDinREN, E-08193 Barcelona, Spain; [Torres, Vicente E.] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA; [Watnick, Terry] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Wheeler, David C.] UCL, London, England	Torres, VE (reprint author), Mayo Clin, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55905 USA.	olivier.devuyst@uzh.ch; torres.vicente@mayo.edu			CRISP; MODIFIER; SPRINT; Abbott/Abbvie; Bayer; Ipsen; Otsuka; Dutch Kidney Foundation; Rockwell; Sanofi-Genzyme; Vertex; NIH; NIH, NIDDK; PKD Foundation	ABC declared having served on the Otsuka Steering Committee and received grant support from CRISP, MODIFIER, and SPRINT. OD declared having served on Steering Committee for the TEMPO studies. RTG declared having received consultancy fees from Abbott/Abbvie, Bayer, Ipsen and Otsuka (all paid to employer UMCG); research support from the Dutch Kidney Foundation and Ipsen. TH declared having received honoraria from Otsuka Europe and Otsuka Japan. SH declared having received consultancy fees and speaker honorarium from Otsuka. BLK declared having received consultancy fees from Rockwell and speaker honoraria from Rockpoint and Sanofi; NIH grant for a study on Living Kidney Donors. Y Pei declared having received consultancy fees from Otsuka. RDP declared having received consultancy fees from Otsuka (all paid to employer Tufts Medical Center), Sanofi-Genzyme, and Vertex; research support from Otsuka. Y Pirson declared having received speaker honorarium from Otsuka. RWS declared having received consultancy fees from Otsuka and research support from NIH on slowing progression of ADPKD. VET declared having received grant support from NIH, NIDDK, and Otsuka. TW declared having received consultancy fees from PKD Foundation; research support from Otsuka; royalties from a joint licensing agreement with Athena Laboratories and Johns Hopkins on sales of PKD gene testing. DCW declared having received consultancy fees from Otsuka. KUE, DO, and RT reported no relevant disclosures.	Abbott Kevin C, 2002, BMC Nephrol, V3, P7, DOI 10.1186/1471-2369-3-7; Abramowicz D, 2013, NEPHROL DIAL TRANSPL, V10, P427; Abu-Wasel B, 2013, WORLD J GASTROENTERO, V19, P5775, DOI 10.3748/wjg.v19.i35.5775; Agarwal Mayank Mohan, 2011, Curr Urol Rep, V12, P3, DOI 10.1007/s11934-010-0152-2; Andreoni KA, 1999, TRANSPLANTATION, V67, P262, DOI 10.1097/00007890-199901270-00013; Temmerman F, 2013, ALIMENT PHARM THER, V38, P397, DOI 10.1111/apt.12384; Jacquet A, 2011, TRANSPL INT, V24, P582, DOI 10.1111/j.1432-2277.2011.01237.x; Paul BM, 2014, KIDNEY INT, V85, P383, DOI 10.1038/ki.2013.227; Sallee M, 2009, CLIN J AM SOC NEPHRO, V4, P1183, DOI 10.2215/CJN.01870309; Bae KT, 2006, CLIN J AM SOC NEPHRO, V1, P64, DOI 10.2215/CJN.00080605; Dambreville S, 2010, MAGN RESON MED, V63, P940, DOI 10.1002/mrm.22278; Yamamoto T, 2012, TRANSPLANTATION, V93, P794, DOI 10.1097/TP.0b013e318246f910; Consugar MB, 2008, KIDNEY INT, V74, P1468, DOI 10.1038/ki.2008.485; Qu ML, 2011, AM J ROENTGENOL, V196, P1279, DOI 10.2214/AJR.10.5041; Caroli A, 2013, LANCET, V382, P1485, DOI 10.1016/S0140-6736(13)61407-5; Pourfarziani V, 2007, TRANSPL P, V39, P1054, DOI 10.1016/j.transproceed.2007.02.007; O'Neill WC, 2005, AM J KIDNEY DIS, V46, P1058, DOI 10.1053/j.ajkd.2005.08.026; Pei Y, 2001, AM J HUM GENET, V68, P355, DOI 10.1086/318188; Bakker J, 1999, RADIOLOGY, V211, P623; TORRES VE, 1993, AM J KIDNEY DIS, V22, P513; Kirkman MA, 2011, BJU INT, V108, P590, DOI 10.1111/j.1464-410X.2010.09938.x; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Hateboer N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3; Jouret F, 2011, CLIN J AM SOC NEPHRO, V6, P1644, DOI 10.2215/CJN.06900810; Perrone RD, 2001, AM J KIDNEY DIS, V38, P777, DOI 10.1053/ajkd.2001.27720; Chang LJ, 2013, HUM REPROD, V28, P1435, DOI 10.1093/humrep/det048; Meier-Kriesche HU, 2000, KIDNEY INT, V58, P1311, DOI 10.1046/j.1523-1755.2000.00287.x; Walsh N, 2012, AM J KIDNEY DIS, V59, P858, DOI 10.1053/j.ajkd.2011.12.018; Kramer A, 2009, J UROLOGY, V181, P724, DOI 10.1016/j.juro.2008.10.008; Meijer E, 2014, AM J KIDNEY DIS, V63, P446, DOI 10.1053/j.ajkd.2013.10.011; Torres VE, 2012, NEW ENGL J MED, V367, P2407, DOI 10.1056/NEJMoa1205511; Abedini S, 2009, TRANSPLANTATION, V87, P112, DOI 10.1097/TP.0b013e31818bfce8; Sherstha R, 1997, HEPATOLOGY, V26, P1282; Hajj P, 2009, UROLOGY, V74, P631, DOI 10.1016/j.urology.2009.02.078; Audrezet MP, 2012, HUM MUTAT, V33, P1239, DOI 10.1002/humu.22103; Rossetti S, 2007, J AM SOC NEPHROL, V18, P2143, DOI 10.1681/ASN.2006121387; CHAPMAN AB, 1994, J AM SOC NEPHROL, V5, P1178; Hogan MC, 2012, NEPHROL DIAL TRANSPL, V27, P3532, DOI 10.1093/ndt/gfs152; Ruggenenti P, 2005, KIDNEY INT, V68, P206, DOI 10.1111/j.1523-1755.2005.00395.x; Orskov B, 2010, CLIN J AM SOC NEPHRO, V5, P2034, DOI 10.2215/CJN.01460210; Irazabal MV, 2011, CLIN J AM SOC NEPHRO, V6, P1274, DOI 10.2215/CJN.09731110; Casteleijn NF, 2014, AM J KIDNEY DIS, V63, P1019, DOI 10.1053/j.ajkd.2013.12.011; Fuller TF, 2005, J UROLOGY, V174, P2284, DOI 10.1097/01.ju.0000181208.06507.aa; Pei Y, 2009, J AM SOC NEPHROL, V20, P205, DOI 10.1681/ASN.2008050507; Torres VE, 2007, LANCET, V369, P1287, DOI 10.1016/S0140-6736(07)60601-1; Fick-Brosnahan GM, 2002, AM J KIDNEY DIS, V39, P1127, DOI 10.1053/ajkd.2002.33379; Harris PC, 2006, J AM SOC NEPHROL, V17, P3013, DOI 10.1681/ASN.2006080835; Chapman AB, 2012, CLIN J AM SOC NEPHRO, V7, P479, DOI 10.2215/CJN.09500911; [Anonymous], 2013, KIDNEY INT S, V3, P1, DOI DOI 10.1038/KISUP.2012.73; Lee DI, 2004, J ENDOUROL, V18, P379, DOI 10.1089/089277904323056942; Bajwa ZH, 2001, KIDNEY INT, V60, P1631, DOI 10.1046/j.1523-1755.2001.00985.x; Hogan MC, 2010, J AM SOC NEPHROL, V21, P1052, DOI 10.1681/ASN.2009121291; Bonsib SM, 2009, CLIN J AM SOC NEPHRO, V4, P1998, DOI 10.2215/CJN.02020309; Wetmore JB, 2014, J AM SOC NEPHROL, V25, P2335, DOI 10.1681/ASN.2013101122; Van Keimpema L, 2009, GASTROENTEROLOGY, V137, P1661, DOI 10.1053/j.gastro.2009.07.052; Xu HW, 2011, STROKE, V42, P204, DOI 10.1161/STROKEAHA.110.578740; Drenth JPH, 2010, HEPATOLOGY, V52, P2223, DOI 10.1002/hep.24036; Pei Y, 2012, KIDNEY INT, V81, P412, DOI 10.1038/ki.2011.370; Grantham JJ, 2006, CLIN J AM SOC NEPHRO, V1, P148, DOI 10.2215/CJN.00330705; Cornelis F, 2010, AM J TRANSPLANT, V10, P2363, DOI 10.1111/j.1600-6143.2010.03251.x; Gevers TJG, 2013, GASTROENTEROLOGY, V145, P357, DOI 10.1053/j.gastro.2013.04.055; van Keimpema L, 2011, TRANSPL INT, V24, P1239, DOI 10.1111/j.1432-2277.2011.01360.x; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Devuyst O, 2014, LANCET, V383, P1844, DOI 10.1016/S0140-6736(14)60659-0; Jilg CA, 2013, NEPHRON CLIN PRACT, V123, P13, DOI 10.1159/000351049; Kistler AD, 2009, KIDNEY INT, V75, P235, DOI 10.1038/ki.2008.558; Li L, 2011, AM J KIDNEY DIS, V57, P903, DOI 10.1053/j.ajkd.2011.01.019; Vujic M, 2010, J AM SOC NEPHROL, V21, P1097, DOI 10.1681/ASN.2009101070; Rizk D, 2009, CLIN J AM SOC NEPHRO, V4, P560, DOI 10.2215/CJN.02410508; Caroli A, 2010, CLIN J AM SOC NEPHRO, V5, P783, DOI 10.2215/CJN.05380709; Schnelldorfer T, 2009, ANN SURG, V250, P112, DOI 10.1097/SLA.0b013e3181ad83dc; Kumar S, 2008, KIDNEY INT, V74, P946, DOI 10.1038/ki.2008.352; Jouret F, 2012, NEPHROL DIAL TRANSPL, V27, P3746, DOI 10.1093/ndt/gfs352; Patel P, 2011, ANN ROY COLL SURG, V93, P391, DOI 10.1308/003588411X582690; Grampsas SA, 2000, AM J KIDNEY DIS, V36, P53, DOI 10.1053/ajkd.2000.8266; Rossetti S, 2009, KIDNEY INT, V75, P848, DOI 10.1038/ki.2008.686; Barua M, 2009, J AM SOC NEPHROL, V20, P1833, DOI 10.1681/ASN.2009020162; Bleeker-Rovers Chantal P, 2003, Am J Kidney Dis, V41, pE18, DOI 10.1016/S0272-6386(03)00368-8; Cadnapaphornchai MA, 2014, CLIN J AM SOC NEPHRO, V9, P889, DOI 10.2215/CJN.08350813; Cadnapaphornchai MA, 2008, KIDNEY INT, V74, P1192, DOI 10.1038/ki.2008.397; Caroli A, 2011, AM J PATHOL, V179, P619, DOI 10.1016/j.ajpath.2011.04.036; CHAPMAN AB, 1991, ANN INTERN MED, V115, P769; CHAPMAN AB, 1994, J AM SOC NEPHROL, V5, P1349; Chapuis O, 2004, AM J KIDNEY DIS, V43, P161, DOI 10.1053/j.ajkd.2003.07.026; Collins SC, 2013, CURR OPIN OBSTET GYN, V25, P201, DOI 10.1097/GCO.0b013e32835faafe; CORNECLE GE, 2013, J AM SOC NEPHROL, V24, P1006; Ecder Tevfik, 2013, Curr Hypertens Rev, V9, P2; Eng MK, 2008, TRANSPL P, V40, P1747, DOI 10.1016/j.transproceed.2008.01.065; Everson Gregory T, 2008, Expert Rev Gastroenterol Hepatol, V2, P563, DOI 10.1586/17474124.2.4.563; Fassett RG, 2010, SCAND J UROL NEPHROL, V44, P56, DOI 10.3109/00365590903359908; FDA, 2013, CARD REN DRUG ADV CO; Grantham JJ, 2006, NEW ENGL J MED, V354, P2122; Haseebuddin M, 2012, J UROLOGY, V188, P1239, DOI 10.1016/j.juro.2012.06.026; Hogan Marie C, 2010, Adv Chronic Kidney Dis, V17, pe1, DOI 10.1053/j.ackd.2010.01.005; Irazabal MV, 2014, J AM SOC NEPHROL, V1, P160; Jiang T, 2013, EUR J RADIOL, V82, P1840, DOI 10.1016/j.ejrad.2013.01.024; Kidney Disease, 2012, KIDNEY INT S, P337; Lantinga MA, 2014, NEPHROL DIAL TRANSPL, DOI 10.1093/ndt/gfu227; Lipke MC, 2007, J UROLOGY, V177, P627, DOI 10.1016/j.juro.2006.09.026; Martinez V, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-186; Miskulin DC, 2014, AM J KIDNEY DIS, V63, P214, DOI 10.1053/j.ajkd.2013.08.017; Mosconi G, 2013, TRANSPL P, V45, P2635, DOI 10.1016/j.transproceed.2013.07.016; Mufti UB, 2010, J ENDOUROL, V24, P1557, DOI 10.1089/end.2010.0093; National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004, PEDIATRICS, V114, P555, DOI DOI 10.1542/PEDS.114.2; Neeff HP, 2013, NEPHROL DIAL TRANSPL, V28, P466, DOI 10.1093/ndt/gfs118; Orskov B, 2012, NEPHROL DIAL TRANSPL, V27, P1607, DOI 10.1093/ndt/gfr467; Orskov B, 2010, AM J NEPHROL, V31, P53, DOI 10.1159/000256657; Pei Y, 2015, J AM SOC NEPHROL, V26, P746, DOI 10.1681/ASN.2014030297; Piccoli GB, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-48; Pirson Y, 2002, J AM SOC NEPHROL, V13, P269; Reed B, 2008, AM J KIDNEY DIS, V52, P1042, DOI 10.1053/j.ajkd.2008.05.015; Rossetti S, 2012, J AM SOC NEPHROL, V23, P915, DOI 10.1681/ASN.2011101032; Rozanski J, 2005, TRANSPLANT P, V37, P666, DOI 10.1016/j.transproceed.2004.12.1115; Ruggenenti P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032533; Schrier RW, 2014, NEW ENGL J MED, V371, P2255, DOI 10.1056/NEJMoa1402685; Schrier RW, 2011, AM J KIDNEY DIS, V57, P811, DOI 10.1053/j.ajkd.2011.02.379; Schrier RW, 2004, J AM SOC NEPHROL, V15, P1023, DOI 10.1097/01.ASN.0000118527.74850.66; Shetty SV, 2013, INT J CARDIOL, V162, pE58, DOI 10.1016/j.ijcard.2012.05.114; Spithoven EM, 2014, NEPHROL DIAL TRANSPL, V29, P15, DOI 10.1093/ndt/gfu017; Spithoven EM, 2013, AM J KIDNEY DIS, V62, P531, DOI 10.1053/j.ajkd.2013.03.030; Stiasny B, 2002, CLIN NEPHROL, V58, P16; Suwabe T, 2012, CLIN EXP NEPHROL, V16, P892, DOI 10.1007/s10157-012-0650-2; TELENTI A, 1990, MAYO CLIN PROC, V65, P933; The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2013, J HYPERTENS, V31, P1281; Torres VE, 2007, CLIN J AM SOC NEPHRO, V2, P112, DOI 10.2215/CJN.00910306; Torres VE, 2015, ANNU REV MED, V66, P195, DOI 10.1146/annurev-med-050913-022838; Torres VE, 2014, NEW ENGL J MED, V371, P2267, DOI 10.1056/NEJMoa1402686; Umbreit EC, 2010, J UROLOGY, V183, P183, DOI 10.1016/j.juro.2009.08.141; Valente JF, 2001, NEPHROL DIAL TRANSPL, V16, P160, DOI 10.1093/ndt/16.1.160; Verhoest G, 2012, JSLS-J SOC LAPAROEND, V16, P437, DOI 10.4293/108680812X13462882736178; Vikse BE, 2013, LANCET, V382, P104, DOI 10.1016/S0140-6736(13)60741-2; Yili Liu, 2012, Urol Res, V40, P87, DOI 10.1007/s00240-011-0390-x	132	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	JUL	2015	88	1					17	27		10.1038/ki.2015.59		11	Urology & Nephrology	Urology & Nephrology	CL7FN	WOS:000357138000006		
J	Peti-Peterdi, J; Kidokoro, K; Riquier-Brison, A				Peti-Peterdi, Janos; Kidokoro, Kengo; Riquier-Brison, Anne			Novel in vivo techniques to visualize kidney anatomy and function	KIDNEY INTERNATIONAL			English	Review						glomerulus; intracellular calcium; intravital imaging; multiphoton microscopy; podocyte	MULTIPHOTON MICROSCOPY; 2-PHOTON MICROSCOPY; GLOMERULAR-FILTRATION; ANGIOTENSIN-II; PROXIMAL TUBULE; LIVING ANIMALS; PODOCYTE; CALCIUM; INJURY; ZEBRAFISH	Intravital imaging using multiphoton microscopy (MPM) has become an increasingly popular and widely used experimental technique in kidney research over the past few years. MPM allows deep optical sectioning of the intact, living kidney tissue with submicron resolution, which is unparalleled among intravital imaging approaches. MPM has solved a long-standing critical technical barrier in renal research to study several complex and inaccessible cell types and anatomical structures in vivo in their native environment. Comprehensive and quantitative kidney structure and function MPM studies helped our better understanding of the cellular and molecular mechanisms of the healthy and diseased kidney. This review summarizes recent in vivo MPM studies with a focus on the glomerulus and the filtration barrier, although select, glomerulus-related renal vascular and tubular functions are also mentioned. The latest applications of serial MPM of the same glomerulus in vivo, in the intact kidney over several days, during the progression of glomerular disease are discussed. This visual approach, in combination with genetically encoded fluorescent markers of cell lineage, has helped track the fate and function (e.g., cell calcium changes) of single podocytes during the development of glomerular pathologies, and provided visual proof for the highly dynamic, rather than static, nature of the glomerular environment. Future intravital imaging applications have the promise to further push the limits of optical microscopy, and to advance our understanding of the mechanisms of kidney injury. Also, MPM will help to study new mechanisms of tissue repair and regeneration, a cutting-edge area of kidney research.	[Peti-Peterdi, Janos; Kidokoro, Kengo; Riquier-Brison, Anne] Univ So Calif, Dept Physiol & Biophys, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; [Peti-Peterdi, Janos; Kidokoro, Kengo; Riquier-Brison, Anne] Univ So Calif, Dept Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; [Kidokoro, Kengo] Kawasaki Med Univ, Dept Nephrol & Hypertens, Kurashiki, Okayama, Japan	Peti-Peterdi, J (reprint author), Univ So Calif, Dept Physiol & Biophys, Zilkha Neurogenet Inst, 1501 San Pablo St, Los Angeles, CA 90033 USA.	petipete@usc.edu			US National Institutes of Health [DK64324, DK100944]; American Heart Association [15GRNT23040039]	This work was supported in part by US National Institutes of Health grants DK64324 and DK100944, and by the American Heart Association grant 15GRNT23040039 to JP-P. We greatly appreciate the technical help of James L Burford with MPM imaging.	Ai HW, 2015, ANAL BIOANAL CHEM, V407, P9, DOI 10.1007/s00216-014-8236-3; Rosivall L, 2006, AM J PHYSIOL-RENAL, V291, pF1241, DOI 10.1152/ajprenal.00203.2006; Nitschke R, 2000, KIDNEY INT, V57, P41, DOI 10.1046/j.1523-1755.2000.00810.x; Dunn KW, 2002, AM J PHYSIOL-CELL PH, V283, pC905, DOI 10.1152/ajpcell.00159.2002; Salmon AHJ, 2012, J AM SOC NEPHROL, V23, P1339, DOI 10.1681/ASN.2012010017; Hall AM, 2013, KIDNEY INT, V83, P72, DOI 10.1038/ki.2012.328; Mundel P, 2010, KIDNEY INT, V77, P571, DOI 10.1038/ki.2009.424; Keir L, 2011, PEDIATR NEPHROL, V26, P523, DOI 10.1007/s00467-010-1637-4; Burford JL, 2014, J CLIN INVEST, V124, P2050, DOI 10.1172/JCI71702; Gee JM, 2014, NEURON, V83, P1058, DOI 10.1016/j.neuron.2014.07.024; Nakano D, 2012, J AM SOC NEPHROL, V23, P1847, DOI 10.1681/ASN.2012010078; Hackl MJ, 2013, NAT MED, V19, P1661, DOI 10.1038/nm.3405; Hohne M, 2013, AM J PATHOL, V182, P332, DOI 10.1016/j.ajpath.2012.11.002; Wang E, 2012, KIDNEY INT, V81, P112, DOI 10.1038/ki.2011.294; HOLSTEINRATHLOU NH, 1986, ACTA PHYSIOL SCAND, V126, P333, DOI 10.1111/j.1748-1716.1986.tb07824.x; Hall AM, 2011, J AM SOC NEPHROL, V22, P1297, DOI 10.1681/ASN.2010101054; Zhou WB, 2012, J AM SOC NEPHROL, V23, P1039, DOI 10.1681/ASN.2011080776; Sipos A, 2007, KIDNEY INT, V72, P1188, DOI 10.1038/sj.ki.5002461; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Bencina M, 2013, SENSORS-BASEL, V13, P16736, DOI 10.3390/s131216736; Salmon AHJ, 2007, AM J PHYSIOL-RENAL, V293, pF1777, DOI 10.1152/ajprenal.00187.2007; Peti-Peterdi J, 2006, AM J PHYSIOL-RENAL, V291, pF473, DOI 10.1152/ajprenal.00425.2005; Molitoris BA, 2005, AM J PHYSIOL-RENAL, V288, pF1084, DOI 10.1152/ajprenal.00473.2004; Grgic I, 2012, J AM SOC NEPHROL, V23, P785, DOI 10.1681/ASN.2011100988; Ilatovskaya DV, 2014, KIDNEY INT, V86, P506, DOI 10.1038/ki.2014.71; Endlich N, 2014, J AM SOC NEPHROL, V25, P681, DOI 10.1681/ASN.2013020178; Devi S, 2013, NAT MED, V19, P107, DOI 10.1038/nm.3024; Toma I, 2008, J CLIN INVEST, V118, P2526, DOI 10.1172/JCI33293; Witte S, 2011, P NATL ACAD SCI USA, V108, P5970, DOI 10.1073/pnas.1018743108; Kang JJ, 2006, AM J PHYSIOL-RENAL, V291, pF495, DOI 10.1152/ajprenal.00521.2005; Dunn KW, 2006, NEPHRON EXP NEPHROL, V103, pE33, DOI 10.1159/000090614; Mundel P, 1997, J AM SOC NEPHROL, V8, P697; Schaldecker T, 2013, J CLIN INVEST, V123, P5298, DOI 10.1172/JCI71165; Xi JF, 2012, OPT LETT, V37, P362, DOI 10.1364/OL.37.000362; Russo LM, 2007, KIDNEY INT, V71, P504, DOI 10.1038/sj.ki.5002041; Arosio D, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00258; Brasen JC, 2014, AM J PHYSIOL-RENAL, V307, pF1249, DOI 10.1152/ajprenal.00174.2014; Corridon PR, 2013, AM J PHYSIOL-RENAL, V304, pF1217, DOI 10.1152/ajprenal.00070.2013; Croix CS, 2007, BIOTECHNIQUES, V43, P14, DOI 10.2144/000112509; Dana H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108697; Hall AM, 2014, PHYSIOLOGY, V29, P334, DOI 10.1152/physiol.00010.2014; Han Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113873; Kang S, 2013, NANOOPTICS ENHANCING, P411; Khoury CC, 2012, BIOCHEM BIOPH RES CO, V427, P525, DOI 10.1016/j.bbrc.2012.09.089; Kistler AD, 2014, SCI REP-UK, V4, DOI 10.1038/srep03872; Kotb AM, 2014, AM J PHYSIOL-RENAL, V307, pF1427, DOI 10.1152/ajprenal.00029.2014; Marsh DJ, 2005, AM J PHYSIOL-REG I, V288, pR1143, DOI 10.1152/ajpregu.00539.2004; Mundel Peter, 1995, Anatomy and Embryology, V192, P385; O'Connor Amber K, 2013, Cilia, V2, P8, DOI 10.1186/2046-2530-2-8; Peppiatt-Wildman CM, 2012, NEPHRON EXP NEPHROL, V121, pE49, DOI 10.1159/000342812; Peti-Peterdi I, 2002, AM J PHYSIOL-RENAL, V283, pF197; Peti-Peterdi I, 2009, PHYSIOLOGY, V24, P88; Peti-Peterdi J, 2005, AM J PHYSIOL-RENAL, V288, pF1079, DOI 10.1152/ajprenal.00385.2004; Peti-Peterdi J, 2010, J AM SOC NEPHROL, V21, P1835; Peti-Peterdi J, 2014, NEPHRON EXP NEPHROL, V126, P86, DOI 10.1159/000360673; Peti-Peterdi J, 2012, AM J PHYSIOL-RENAL, V302, pF227; Praetorius HA, 2005, AM J PHYSIOL-RENAL, V288, pF133; Sandoval PM, 2012, J AM SOC NEPHROL, V23, P447; Sandoval RM, 2004, AM J PHYSIOL-CELL PH, V287, pC517, DOI 10.1152/ajpcell.00006.2004; Schiessl IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052499; Schiessl IM, 2013, AM J PHYSIOL-RENAL, V305, pF1189, DOI 10.1152/ajprenal.00377.2013; Schlondorff D, 2014, KIDNEY INT, V85, P991, DOI 10.1038/ki.2014.51; Suleiman H, 2013, ELIFE, V2; Svenningsen P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00292; Tanner GA, 2009, AM J PHYSIOL-RENAL, V296, pF1258, DOI 10.1152/ajprenal.90638.2008; Toma I, 2006, NEPHRON PHYSIOL, V103, P71, DOI 10.1159/000090622; Vasilyev A, 2009, PLOS BIOL, V7, P101, DOI 10.1371/journal.pbio.1000009; Yu WM, 2007, AM J PHYSIOL-RENAL, V292, pF1873, DOI 10.1152/ajprenal.00218.2006	69	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	JUL	2015	88	1					44	51		10.1038/ki.2015.65		8	Urology & Nephrology	Urology & Nephrology	CL7FN	WOS:000357138000009		
J	Jimi, K; Tomiyama, H; Miyaoka, Y; Watanabe, K; Kotobuki, T; Kanno, Y				Jimi, Kanako; Tomiyama, Hirofumi; Miyaoka, Yoshitaka; Watanabe, Kanna; Kotobuki, Tomoka; Kanno, Yoshihiko			Evaluating central blood pressure in dialysis patients	KIDNEY INTERNATIONAL			English	Letter							HEMODIALYSIS		[Jimi, Kanako; Miyaoka, Yoshitaka; Watanabe, Kanna; Kotobuki, Tomoka; Kanno, Yoshihiko] Tokyo Med Univ, Dept Nephrol, Tokyo 1600023, Japan; [Tomiyama, Hirofumi] Tokyo Med Univ, Dept Cardiol, Tokyo 1600023, Japan	Kanno, Y (reprint author), Tokyo Med Univ, Dept Nephrol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	kannoyh@tokyo-med.ac.jp					Laurent S, 2014, HYPERTENSION, V64, P709, DOI 10.1161/HYPERTENSIONAHA.114.03282; Peters CD, 2014, KIDNEY INT, V86, P625, DOI 10.1038/ki.2014.69; Mitchell GF, 2004, HYPERTENSION, V43, P1239, DOI 10.1161/01.HYP.0000128420.01881.aa; Suzuki H, 2008, AM J KIDNEY DIS, V52, P501, DOI 10.1053/j.ajkd.2008.04.031	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	JUL	2015	88	1					193	193		10.1038/ki.2015.90		1	Urology & Nephrology	Urology & Nephrology	CL7FN	WOS:000357138000025		
J	Kamei, D; Akiba, T				Kamei, Daigo; Akiba, Takashi			Coefficient of variation among ferritin measurement methods in hemodialysis and standard serum ferritin level	KIDNEY INTERNATIONAL			English	Letter									[Kamei, Daigo; Akiba, Takashi] Tokyo Womens Med Univ, Kidney Ctr, Dept Blood Purificat, Tokyo 1628666, Japan	Kamei, D (reprint author), Tokyo Womens Med Univ, Kidney Ctr, Dept Blood Purificat, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	kamei-wak@umin.net					[Anonymous], 2014, PRES SIT ISS JAP MED, V507, P7; Ford BA, 2009, KIDNEY INT, V75, P104, DOI 10.1038/ki.2008.526; Kuragano T, 2014, KIDNEY INT, V86, P845; Subcommittee for Radioisotope in vitro Test Medical Science and Pharmaceutical Committee Japan Radioisotope Association Immunoassay Research Society of Japan (Japan Radioisotope Association), 2009, RADIOISOTOPES, V58, P655	4	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	JUL	2015	88	1					197	197		10.1038/ki.2015.126		1	Urology & Nephrology	Urology & Nephrology	CL7FN	WOS:000357138000031		
J	Kuragano, T; Matsumura, O; Matsuda, A; Hara, T; Kiyomoto, H; Murata, T; Kitamura, K; Fujimoto, S; Hase, H; Joki, N; Fukatsu, A; Inoue, T; Itakura, Y; Nakanishi, T				Kuragano, Takahiro; Matsumura, Osamu; Matsuda, Akihiko; Hara, Taiga; Kiyomoto, Hideyasu; Murata, Toshiaki; Kitamura, Kenichiro; Fujimoto, Shouichi; Hase, Hiroki; Joki, Nobuhiko; Fukatsu, Atushi; Inoue, Toru; Itakura, Yukihiro; Nakanishi, Takeshi			Coefficient of variation among ferritin measurement methods in hemodialysis and standard serum ferritin level Reply	KIDNEY INTERNATIONAL			English	Letter							CHRONIC KIDNEY-DISEASE		[Kuragano, Takahiro; Nakanishi, Takeshi] Hyogo Coll Med, Div Nephrol & Dialysis, Dept Internal Med, Nishinomiya, Hyogo 6638510, Japan; [Matsumura, Osamu] Musashi Ranzan Hosp, Dept Internal Med, Musashi, Japan; [Matsuda, Akihiko] Saitama Med Univ, Nephrol & Blood Purificat, Saitama Med Ctr, Kawagoe, Saitama, Japan; [Hara, Taiga] Kagawa Univ, Div Nephrol & Dialysis, Dept Cardiorenal & Cerebrovasc Med, Fac Med, Takamatsu, Kagawa 760, Japan; [Kiyomoto, Hideyasu] Tohoku Univ, Grad Sch Med, Div Nephrol Endocrinol & Vasc Biol, Dept Med, Sendai, Miyagi 980, Japan; [Murata, Toshiaki] Fukuoka Univ, Dept Internal Med, Fac Med, Div Nephrol & Rheumatol, Fukuoka 81401, Japan; [Kitamura, Kenichiro] Univ Yamanashi, Fac Med, Dept Internal Med 3, Chuo Ku, Kofu, Yamanashi, Japan; [Fujimoto, Shouichi] Univ Miyazaki Hosp, Div Dialysis, Miyazaki, Japan; [Hase, Hiroki; Joki, Nobuhiko] Toho Univ, Ohashi Med Ctr, Dept Nephrol, Tokyo, Japan; [Fukatsu, Atushi] Yachiyo Hosp, Dept Internal Med, Anjo, Japan; [Inoue, Toru] Higashikouri Hosp, Dept Internal Med, Hirakata, Osaka, Japan; [Itakura, Yukihiro] Itakura Clin, Dept Internal Med, Tokorozawa, Saitama, Japan	Kuragano, T (reprint author), Hyogo Coll Med, Div Nephrol & Dialysis, Dept Internal Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638510, Japan.	kuragano@hyo-med.ac.jp					Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; Ford BA, 2009, KIDNEY INT, V75, P104, DOI 10.1038/ki.2008.526; Kamei D, 2015, KIDNEY INT, V88, P197, DOI 10.1038/ki.2015.126; Yahiro M, 2012, CLIN EXP NEPHROL, V16, P448, DOI 10.1007/s10157-011-0584-0	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	JUL	2015	88	1					197	198		10.1038/ki.2015.129		4	Urology & Nephrology	Urology & Nephrology	CL7FN	WOS:000357138000032		
J	Saijo, H; Tatsumi, N; Arihiro, S; Kato, T; Okabe, M; Tajiri, H; Hashimoto, H				Saijo, Hiroki; Tatsumi, Norifumi; Arihiro, Seiji; Kato, Tomohiro; Okabe, Masataka; Tajiri, Hisao; Hashimoto, Hisashi			Microangiopathy triggers, and inducible nitric oxide synthase exacerbates dextran sulfate sodium-induced colitis	LABORATORY INVESTIGATION			English	Article							INFLAMMATORY-BOWEL-DISEASE; CONFOCAL LASER ENDOMICROSCOPY; EXPERIMENTAL MURINE COLITIS; ULCERATIVE-COLITIS; VASCULAR-PERMEABILITY; INCREASED EXPRESSION; ISCHEMIC COLITIS; GROWTH-FACTOR; MICE; NEURONS	Ulcerative colitis (UC) is a representative clinical manifestation of inflammatory bowel disease that causes chronic gastrointestinal tract inflammation. Dextran sulfate sodium (DSS)-induced colitis mice have been used to investigate UC pathogenesis, and in this UC model, disturbance and impairment of the mucosal epithelium have been reported to cause colitis. However, how DSS sporadically breaks down the epithelium remains unclear. In this study, we focused on the colonic microcirculation and myenteric neurons of DSS-induced colitis. Moreover, we examined the potential of myenteric neurons as a target to prevent exacerbation of colitis. Fluorescent angiographic and histopathological studies revealed that DSS administration elicited blood vessel disruption before epithelial disorders appeared. Ischemic conditions in the lamina propria induced inducible nitric oxide synthase (iNOS) expression in myenteric neurons as colitis aggravated. When neuronal activity was inhibited with butylscopolamine, neuronal iNOS expression decreased, and the exacerbation of colitis was prevented. These results suggested that DSS-induced colitis was triggered by microcirculatory disturbance in the mucosa, and that excessive neuronal excitation aggravated colitis. During remission periods of human UC, endoscopic inspection of the colonic microcirculation may enable the early detection of disease recurrence, and inhibition of neuronal iNOS expression may prevent the disease from worsening.	[Saijo, Hiroki; Tatsumi, Norifumi; Okabe, Masataka; Hashimoto, Hisashi] Jikei Univ, Sch Med, Dept Anat, Tokyo 1058461, Japan; [Saijo, Hiroki; Arihiro, Seiji; Tajiri, Hisao] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 1058461, Japan; [Kato, Tomohiro; Tajiri, Hisao] Jikei Univ, Sch Med, Dept Endoscopy, Tokyo 1058461, Japan	Hashimoto, H (reprint author), Jikei Univ, Sch Med, Dept Anat, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.	hashimoto.anat@jikei.ac.jp					Abe H, 2013, BIOSCI BIOTECH BIOCH, V77, P971, DOI 10.1271/bbb.120923; ALLEVA E, 1985, PHYSIOL BEHAV, V34, P519, DOI 10.1016/0031-9384(85)90043-5; Gan SI, 2003, AM J GASTROENTEROL, V98, P2363, DOI 10.1016/S0002-9270(03)00702-0; Jowett SL, 2004, GUT, V53, P1479, DOI 10.1136/gut.2003.024828; Raufman JP, 2011, CARCINOGENESIS, V32, P1396, DOI 10.1093/carcin/bgr118; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Boismenu R, 2000, J LEUKOCYTE BIOL, V67, P267; Yoshida Y, 2000, ALIMENT PHARM THERAP, V14, P26, DOI 10.1046/j.1365-2036.2000.014s1026.x; da Silva APB, 2009, LAB INVEST, V89, P1169, DOI 10.1038/labinvest.2009.80; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Bock F, 2007, INVEST OPHTH VIS SCI, V48, P2545, DOI 10.1167/iovs.06-0570; Estape N, 2002, PHARMACOL BIOCHEM BE, V72, P319, DOI 10.1016/S0091-3057(01)00747-X; Tolstanova G, 2009, J PHARMACOL EXP THER, V328, P749, DOI 10.1124/jpet.108.145128; Matsuura M, 2005, GASTROENTEROLOGY, V128, P975, DOI 10.1053/j.gastro.2005.01.006; MURTHY SNS, 1993, DIGEST DIS SCI, V38, P1722, DOI 10.1007/BF01303184; Furness JB, 2000, J AUTONOM NERV SYST, V81, P87, DOI 10.1016/S0165-1838(00)00127-2; Kitajima S, 1999, J VET MED SCI, V61, P67, DOI 10.1292/jvms.61.67; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643; Kimura H, 1998, GUT, V42, P180; Reinhardt C, 2012, NATURE, V483, P627, DOI 10.1038/nature10893; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.citrevonc.2005.12.003; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; BENNETT HS, 1976, STAIN TECHNOL, V51, P71; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; Caprara C, 2011, INVEST OPHTH VIS SCI, V52, P2109, DOI 10.1167/iovs.10-6222; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Watanabe O, 2008, J GASTROEN HEPATOL, V23, pS286, DOI 10.1111/j.1440-1746.2008.05559.x; Trojanowska M, 2010, NAT REV RHEUMATOL, V6, P453, DOI 10.1038/nrrheum.2010.102; Ko IK, 2010, MOL THER, V18, P1365, DOI 10.1038/mt.2010.54; Beck PL, 2004, AM J PHYSIOL-GASTR L, V286, pG137, DOI 10.1152/ajpgi.00309.2003; Hoffman A, 2006, ENDOSCOPY, V38, P1275, DOI 10.1055/s-2006-944813; COOPER HS, 1993, LAB INVEST, V69, P238; Mizoguchi A, 2008, J GASTROENTEROL, V43, P1, DOI 10.1007/s00535-007-2111-3; Aoi Y, 2008, J PHYSIOL PHARMACOL, V59, P315; Chassaing B, 2014, CURR PROTOC IMMUNOL, V104; Clarke WT, 2010, J CELL SCI, V123, P2543, DOI 10.1242/jcs.059113; Cromer WE, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-207; Dieleman L A, 1995, Inflamm Bowel Dis, V1, P266; Dijkstra G, 2002, SCAND J GASTROENTERO, V37, P546, DOI 10.1080/00365520252903099; Franklin RM, 1982, TECHNIQUES IMMUNOCYT, P251; GAMSE R, 1980, BRIT J PHARMACOL, V68, P207; GRIFFEN TS, 1982, DIS COLON RECTUM, V25, P638, DOI 10.1007/BF02629530; Hashimoto H, 1998, DEV DYNAM, V212, P157, DOI 10.1002/(SICI)1097-0177(199805)212:1<157::AID-AJA14>3.0.CO;2-4; Irkorucu O, 2008, DIGEST DIS SCI, V53, P1618, DOI 10.1007/s10620-007-0033-9; Johansson MEV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012238; Kurashima Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2023; Martin Y, 2013, PROTOCOL EX IN PRESS; McCaffery DM, 1999, GUT, V45, P864; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; Nakamura M, 2006, CLIN HEMORHEOL MICRO, V34, P193; Neumann H, 2010, GASTROENTEROLOGY, V139, P388, DOI 10.1053/j.gastro.2010.06.029; Ni J, 1996, GUT, V39, P234, DOI 10.1136/gut.39.2.234; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Shifrin H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057668	58	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	JUL	2015	95	7					728	748		10.1038/labinvest.2015.60		21	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	CL6EI	WOS:000357060000003		
J	Yamashita, K; Nagai, H; Toyokuni, S				Yamashita, Kyoko; Nagai, Hirotaka; Toyokuni, Shinya			Receptor role of the annexin A2 in the mesothelial endocytosis of crocidolite fibers	LABORATORY INVESTIGATION			English	Article							OXIDATIVE STRESS; ASBESTOS FIBERS; DNA-DAMAGE; CELLS; PHAGOCYTOSIS; CARCINOGENESIS; LUNG; CHRYSOTILE; SURFACE; MACROPHAGES	Asbestos-induced mesothelioma is a worldwide problem. Parietal mesothelial cells internalize asbestos fibers that traverse the entire lung parenchyma, an action that is linked to mesothelial carcinogenesis. Thus far, vitronectin purified from serum reportedly enhances the internalization of crocidolite by mesothelial cells via integrin alpha v beta 5. To reveal another mechanism by which mesothelial cells endocytose (phagocytose) asbestos, we first evaluated the effects of serum on asbestos uptake, which proved to be nonessential. Thereafter, we undertook a study to identify proteins on the surface of mesothelial cells (MeT5A) that act as receptors for asbestos uptake based on the assumption that receptors bind to asbestos with physical affinity. To this end, we incubated the membrane fraction of MeT5A cells with crocidolite or chrysotile and evaluated the adsorbed proteins using sodium dodecyl sulfate polyacrylamide gel analysis. Next, we extensively identified the proteins using an in-solution or in-gel digestion coupled with mass spectrometry. Among the identified proteins, annexin A2 (ANXA2) and transferrin receptor protein 1 (TFRC) were distinguished because of their high score and presence at the cell surface. Crocidolite uptake by MeT5A cells was significantly decreased by shRNA (short hairpin RNA)-induced knockdown of ANXA2 and direct blockade of cell surface ANXA2 using anti-ANXA2 antibody. In addition, abundant ANXA2 protein was present on the cell membrane of mesothelial cells, particularly facing the somatic cavity. These findings demonstrate that ANXA2 has a role in the mesothelial phagocytosis of crocidolite and may serve as its receptor.	[Yamashita, Kyoko; Nagai, Hirotaka; Toyokuni, Shinya] Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Nagoya, Aichi 4668550, Japan	Toyokuni, S (reprint author), Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	toyokuni@med.nagoya-u.ac.jp	Toyokuni, Shinya/C-1358-2010; yamashita, kyoko/H-9913-2013	Toyokuni, Shinya/0000-0002-5757-1109; 	National Cancer Center Research and Development Fund [25-A-5]; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [24390094, 221S0001-04, 24108001]; Japan Society for the Promotion of Science Fellows	We acknowledge the Division for Medical Research Engineering, Nagoya University Graduate School of Medicine, for technical support of mass spectrometry, and we also thank Nobuaki Misawa for excellent technical assistance regarding the pathologic specimens. This work was supported in part by the National Cancer Center Research and Development Fund (25-A-5), a grant-in-aid for research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (24390094; 221S0001-04; 24108001) and a grant-in-aid from the Japan Society for the Promotion of Science Fellows (to HN).	Aierken D, 2014, NAGOYA J MED SCI, V76, P149; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338; Nagai H, 2011, P NATL ACAD SCI USA, V108, pE1330, DOI 10.1073/pnas.1110013108; Flannagan RS, 2012, ANNU REV PATHOL-MECH, V7, P61, DOI 10.1146/annurev-pathol-011811-132445; Bharadwaj A, 2013, INT J MOL SCI, V14, P6259, DOI 10.3390/ijms14036259; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Swisher JFA, 2010, BLOOD, V115, P549, DOI 10.1182/blood-2009-06-226944; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; O'Reilly KMA, 2007, AM FAM PHYSICIAN, V75, P683; Law AL, 2009, MOL BIOL CELL, V20, P3896, DOI 10.1091/mbc.E08-12-1204; Hayes MJ, 2004, TRAFFIC, V5, P571, DOI 10.1111/j.1600-0854.2004.00210.x; Carbone M, 2007, NAT REV CANCER, V7, P147, DOI 10.1038/nrc2068; Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/nnano.2012.207, 10.1038/NNANO.2012.207]; Nagai H, 2011, CANCER SCI, V102, P2118, DOI 10.1111/j.1349-7006.2011.02087.x; VALERIO F, 1987, ENVIRON RES, V44, P312, DOI 10.1016/S0013-9351(87)80240-2; MacCorkle RA, 2006, CELL MOTIL CYTOSKEL, V63, P646, DOI 10.1002/cm.20151; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Morel E, 2009, DEV CELL, V16, P445, DOI 10.1016/j.devcel.2009.01.007; GOODGLICK LA, 1986, CANCER RES, V46, P5558; Hodgson JT, 2000, ANN OCCUP HYG, V44, P565, DOI 10.1016/S0003-4878(00)00045-4; Melendez AJ, 2008, BIOSCIENCE REP, V28, P287, DOI 10.1042/BSR20080082; Aisen P, 2004, INT J BIOCHEM CELL B, V36, P2137, DOI 10.1016/j.biocel.2004.02.007; Cavazza A, 1996, CANCER, V77, P1379, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.3.CO;2-5; RESNICK D, 1993, J BIOL CHEM, V268, P3538; Carbone M, 2012, CLIN CANCER RES, V18, P598, DOI 10.1158/1078-0432.CCR-11-2259; Liu WH, 2000, AM J RESP CELL MOL, V23, P371; BOYLAN AM, 1995, J CLIN INVEST, V96, P1987, DOI 10.1172/JCI118246; Carbone M, 2011, J CELL PHYSL, V227, P44, DOI DOI 10.1002/JCP.22724; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Hou YC, 2008, CANCER INVEST, V26, P809, DOI 10.1080/07357900801898664; IARC Asbestos (Chrysotile Amosite Crocidolite Tremolite Actinolite and Anthophyllite), 2012, IARC MON EV CARC R C, V100C, P219; JAURAND MC, 1979, AM J PATHOL, V94, P529; Jiang L, 2008, CANCER SCI, V99, P2142, DOI 10.1111/j.1349-7006.2008.00934.x; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; KAMP DW, 1990, J LAB CLIN MED, V116, P289; Kubo Y, 2012, J CLIN BIOCHEM NUTR, V51, P221, DOI 10.3164/jcbn.12-39; MCDONALD AD, 1982, ANN OCCUP HYG, V26, P417, DOI 10.1093/annhyg/26.3.417; MCLEMORE T, 1979, CANCER LETT, V6, P183, DOI 10.1016/S0304-3835(79)80032-4; Pande P, 2006, TOXICOL APPL PHARM, V210, P70, DOI 10.1016/j.taap.2005.07.017; Roggli VL, 2004, PATHOLOGY ASBESTOS A; Sarkar S, 2012, AM J PHYSIOL-GASTR L, V302, pG712, DOI 10.1152/ajpgi.00406.2011; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; Toyokuni S, 2009, NAGOYA J MED SCI, V71, P1; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Vitra RL, SOME FACTS ASBESTOS; WANG NS, 1987, AM J PATHOL, V126, P343; Wu J, 2000, AM J PHYSIOL-LUNG C, V279, pL916; Yamashita K, 2013, J CLIN BIOCHEM NUTR, V53, P27, DOI 10.3164/jcbn.12-104	50	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	JUL	2015	95	7					749	764		10.1038/labinvest.2015.28		16	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	CL6EI	WOS:000357060000004		
J	Matsushita, K; Coresh, J; Sang, YY; Chalmers, J; Fox, C; Guallar, E; Jafar, T; Jassal, SK; Landman, GWD; Muntner, P; Roderick, P; Sairenchi, T; Schottker, B; Shankar, A; Shlipak, M; Tonelli, M; Townend, J; van Zuilen, A; Yamagishi, K; Yamashita, K; Gansevoort, R; Sarnak, M; Warnock, DG; Woodward, M; Arnlov, J				Matsushita, Kunihiro; Coresh, Josef; Sang, Yingying; Chalmers, John; Fox, Caroline; Guallar, Eliseo; Jafar, Tazeen; Jassal, Simerjot K.; Landman, Gijs W. D.; Muntner, Paul; Roderick, Paul; Sairenchi, Toshimi; Schoettker, Ben; Shankar, Anoop; Shlipak, Michael; Tonelli, Marcello; Townend, Jonathan; van Zuilen, Arjan; Yamagishi, Kazumasa; Yamashita, Kentaro; Gansevoort, Ron; Sarnak, Mark; Warnock, David G.; Woodward, Mark; Arnlov, Johan		CKD Prognosis Consortium	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data	LANCET DIABETES & ENDOCRINOLOGY			English	Article							CHRONIC KIDNEY-DISEASE; ARTERY-DISEASE; CYSTATIN C; RISK; CREATININE; MORTALITY; HEART; CKD; ASSOCIATION; EQUATION	Background The usefulness of estimated glomerular filtration rate (eGFR) and albuminuria for prediction of cardiovascular outcomes is controversial. We aimed to assess the addition of creatinine-based eGFR and albuminuria to traditional risk factors for prediction of cardiovascular risk with a meta-analytic approach. Methods We meta-analysed individual-level data for 637 315 individuals without a history of cardiovascular disease from 24 cohorts (median follow-up 4.2-19.0 years) included in the Chronic Kidney Disease Prognosis Consortium. We assessed C statistic difference and reclassification improvement for cardiovascular mortality and fatal and non-fatal cases of coronary heart disease, stroke, and heart failure in a 5 year timeframe, contrasting prediction models for traditional risk factors with and without creatinine-based eGFR, albuminuria (either albumin-to-creatinine ratio [ACR] or semi-quantitative dipstick proteinuria), or both. Findings The addition of eGFR and ACR significantly improved the discrimination of cardiovascular outcomes beyond traditional risk factors in general populations, but the improvement was greater with ACR than with eGFR, and more evident for cardiovascular mortality (C statistic difference 0.0139 [95% CI 0.0105- 0.0174] for ACR and 0.0065 [0.0042-0.0088] for eGFR) and heart failure (0.0196 [0.0108-0.0284] and 0.0109 [0.0059-0.0159]) than for coronary disease (0.0048 [0.0029-0.0067] and 0.0036 [0.0019-0.0054]) and stroke (0.0105 [0.0058-0.0151]and 0.0036 [0.0004-0.0069]). Dipstick proteinuria showed smaller improvement than ACR. The discrimination improvement with eGFR or ACR was especially evident in individuals with diabetes or hypertension, but remained significant with ACR for cardiovascular mortality and heart failure in those without either of these disorders. In individuals with chronic kidney disease, the combination of eGFR and ACR for risk discrimination outperformed most single traditional predictors; the C statistic for cardiovascular mortality fell by 0.0227 (0.0158-0.0296) after omission of eGFR and ACR compared with less than 0.007 for any single modifiable traditional predictor. Interpretation Creatinine-based eGFR and albuminuria should be taken into account for cardiovascular prediction, especially when these measures are already assessed for clinical purpose or if cardiovascular mortality and heart failure are outcomes of interest. ACR could have particularly broad implications for cardiovascular prediction. In populations with chronic kidney disease, the simultaneous assessment of eGFR and ACR could facilitate improved classification of cardiovascular risk, supporting current guidelines for chronic kidney disease. Our results lend some support to also incorporating eGFR and ACR into assessments of cardiovascular risk in the general population.	[Matsushita, Kunihiro; Coresh, Josef; Sang, Yingying; Guallar, Eliseo; Woodward, Mark] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Chalmers, John; Woodward, Mark] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Fox, Caroline] NHLBI, Framingham Heart Study & Ctr Populat Studies, Framingham, MA USA; [Jafar, Tazeen] Duke NUS Grad Med Sch, Singapore, Singapore; [Jassal, Simerjot K.] VA San Diego Healthcare, San Diego, CA USA; [Jassal, Simerjot K.] Univ Calif San Diego, San Diego, CA 92103 USA; [Landman, Gijs W. D.] Isala Hosp, Diabet Ctr Zwolle, Zwolle, Netherlands; [Muntner, Paul; Warnock, David G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA; [Roderick, Paul] Univ Southampton, Fac Med, Primary Care & Populat Sci, Southampton SO9 5NH, Hants, England; [Sairenchi, Toshimi] Dokkyo Med Univ, Sch Med, Dept Publ Hlth, Shimotsuga, Tochigi, Japan; [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Shlipak, Michael] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA; [Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Shlipak, Michael] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Tonelli, Marcello] Univ Calgary, Dept Med, Calgary, AB, Canada; [Townend, Jonathan] Queen Elizabeth Hosp, Dept Cardiol, Birmingham B15 2TH, W Midlands, England; [van Zuilen, Arjan] Univ Utrecht, Med Ctr, Dept Hypertens & Nephrol, Utrecht, Netherlands; [Yamagishi, Kazumasa] Univ Tsukuba, Fac Med, Dept Publ Hlth Med, Tsukuba, Ibaraki, Japan; [Yamashita, Kentaro] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4648601, Japan; [Gansevoort, Ron] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands; [Sarnak, Mark] Tufts Med Ctr, Div Nephrol, Boston, MA USA; [Woodward, Mark] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Arnlov, Johan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Arnlov, Johan] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden	Coresh, J (reprint author), Data Coordinating Ctr, Chron Kidney Dis Prognosis Consortium, Baltimore, MD 21205 USA.	ckdpc@jhmi.edu	Wetzels, Jack/A-1720-2014; Woodward, Mark/D-8492-2015; Tonelli, Marcello/B-3028-2009		US National Kidney Foundation; National Institute of Diabetes and Digestive and Kidney Diseases	US National Kidney Foundation, National Institute of Diabetes and Digestive and Kidney Diseases.	American Diabetes Association, 2012, DIABETES CARE S1, V35, pS4, DOI DOI 10.2337/DC12-S004; Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477; de Zeeuw D, 2004, CIRCULATION, V110, P921, DOI 10.1161/01.CIR.0000139860.33974.28; Hallan S, 2007, ARCH INTERN MED, V167, P2490, DOI 10.1001/archinte.167.22.2490; Garimella PS, 2012, AM J KIDNEY DIS, V60, P641, DOI 10.1053/j.ajkd.2012.02.340; Nerpin E, 2011, NEPHROL DIAL TRANSPL, V26, P2820, DOI 10.1093/ndt/gfq848; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Kerr KF, 2014, EPIDEMIOLOGY, V25, P114, DOI 10.1097/EDE.0000000000000018; Moyer VA, 2012, ANN INTERN MED, V157, P567, DOI 10.7326/0003-4819-157-8-201210160-00533; Gutierrez OM, 2013, JAMA-J AM MED ASSOC, V310, P706, DOI 10.1001/jama.2013.8777; Perk J, 2012, EUR HEART J, V33, P1635, DOI 10.1093/eurheartj/ehs092; Levin A, 2014, KIDNEY INT, V85, P49, DOI 10.1038/ki.2013.444; Levey AS, 2009, ANN INTERN MED, V150, P604; Matsushita K, 2012, JAMA-J AM MED ASSOC, V307, P1941, DOI 10.1001/jama.2012.3954; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092; Herzog CA, 2011, KIDNEY INT, V80, P572, DOI 10.1038/ki.2011.223; Inker LA, 2013, NEPHROL DIAL TRANSPL, V28, P1390, DOI 10.1093/ndt/gft003; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560; Clase CM, 2011, ANN INTERN MED, V154, P310, DOI [10.7326/0003-4819-154-5-201103010-00005, 10.1059/0003-4819-154-5-201103010-00005]; Shlipak MG, 2013, NEW ENGL J MED, V369, P932, DOI 10.1056/NEJMoa1214234; Ix JH, 2010, CIRCULATION, V121, P1295, DOI 10.1161/CIRCULATIONAHA.109.924266; Borenstein M, 2009, INTRO METAANALYSIS; Chen SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053662; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Go AS, 2013, CIRCULATION, V129, pe28, DOI DOI 10.1161/01.CIR.0000441139.02102.80; Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98; Ito H, 2011, AM J EPIDEMIOL, V174, P949, DOI 10.1093/aje/kwr185; Morigi M, 2002, J AM SOC NEPHROL, V13, P1179; Stevens PE, 2007, KIDNEY INT, V72, P92, DOI 10.1038/sj.ki.5002273; Weiner DE, 2007, AM J MED, V120, P552	33	4	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	2213-8587			LANCET DIABETES ENDO	Lancet Diabetes Endocrinol.	JUL	2015	3	7					514	525		10.1016/S2213-8587(15)00040-6		12	Endocrinology & Metabolism	Endocrinology & Metabolism	CM1DC	WOS:000357419500027		
J	Chambers, JC; Loh, M; Lehne, B; Drong, A; Kriebel, J; Motta, V; Wahl, S; Elliott, HR; Rota, F; Scott, WR; Zhang, WH; Tan, ST; Campanella, G; Chadeau-Hyam, M; Yengo, L; Richmond, RC; Adamowicz-Brice, M; Afzal, U; Bozaoglu, K; Mok, ZY; Ng, HK; Pattou, F; Prokisch, H; Rozario, MA; Tarantini, L; Abbott, J; Ala-Korpela, M; Albetti, B; Ammerpohl, O; Bertazzi, PA; Blancher, C; Caiazzo, R; Danesh, J; Gaunt, TR; de Lusignan, S; Gieger, C; Illig, T; Jha, S; Jones, S; Jowett, J; Kangas, AJ; Kasturiratne, A; Kato, N; Kotea, N; Kowlessur, S; Pitkaniemi, J; Punjabi, P; Saleheen, D; Schafmayer, C; Soininen, P; Tai, ES; Thorand, B; Tuomilehto, J; Wickremasinghe, AR; Kyrtopoulos, SA; Aitman, TJ; Herder, C; Hampe, J; Cauchi, S; Relton, CL; Froguel, P; Soong, R; Vineis, P; Jarvelin, MR; Scott, J; Grallert, H; Bollati, V; Elliott, P; McCarthy, MI; Kooner, JS				Chambers, John C.; Loh, Marie; Lehne, Benjamin; Drong, Alexander; Kriebel, Jennifer; Motta, Valeria; Wahl, Simone; Elliott, Hannah R.; Rota, Federica; Scott, William R.; Zhang, Weihua; Tan, Sian-Tsung; Campanella, Gianluca; Chadeau-Hyam, Marc; Yengo, Loic; Richmond, Rebecca C.; Adamowicz-Brice, Martyna; Afzal, Uzma; Bozaoglu, Kiymet; Mok, Zuan Yu; Ng, Hong Kiat; Pattou, Francois; Prokisch, Holger; Rozario, Michelle Ann; Tarantini, Letizia; Abbott, James; Ala-Korpela, Mika; Albetti, Benedetta; Ammerpohl, Ole; Bertazzi, Pier Alberto; Blancher, Christine; Caiazzo, Robert; Danesh, John; Gaunt, Tom R.; de Lusignan, Simon; Gieger, Christian; Illig, Thomas; Jha, Sujeet; Jones, Simon; Jowett, Jeremy; Kangas, Antti J.; Kasturiratne, Anuradhani; Kato, Norihiro; Kotea, Navaratnam; Kowlessur, Sudhir; Pitkaeniemi, Janne; Punjabi, Prakash; Saleheen, Danish; Schafmayer, Clemens; Soininen, Pasi; Tai, E-Shyong; Thorand, Barbara; Tuomilehto, Jaakko; Wickremasinghe, Ananda Rajitha; Kyrtopoulos, Soterios A.; Aitman, Timothy J.; Herder, Christian; Hampe, Jochen; Cauchi, Stephane; Relton, Caroline L.; Froguel, Philippe; Soong, Richie; Vineis, Paolo; Jarvelin, Marjo-Riitta; Scott, James; Grallert, Harald; Bollati, Valentina; Elliott, Paul; McCarthy, Mark I.; Kooner, Jaspal S.			Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study	LANCET DIABETES & ENDOCRINOLOGY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; SUSCEPTIBILITY LOCI; INSULIN-RESISTANCE; OBESITY; EXPRESSION; GLUCOSE; PROTEIN; INFLAMMATION; MELLITUS; STRESS	Background Indian Asians, who make up a quarter of the world's population, are at high risk of developing type 2 diabetes. We investigated whether DNA methylation is associated with future type 2 diabetes incidence in Indian Asians and whether differences in methylation patterns between Indian Asians and Europeans are associated with, and could be used to predict, differences in the magnitude of risk of developing type 2 diabetes. Methods We did a nested case-control study of DNA methylation in Indian Asians and Europeans with incident type 2 diabetes who were identified from the 8-year follow-up of 25 372 participants in the London Life Sciences Prospective Population (LOLIPOP) study. Patients were recruited between May 1, 2002, and Sept 12, 2008. We did epigenome-wide association analysis using samples from Indian Asians with incident type 2 diabetes and age-matched and sex-matched Indian Asian controls, followed by replication testing of top-ranking signals in Europeans. For both discovery and replication, DNA methylation was measured in the baseline blood sample, which was collected before the onset of type 2 diabetes. Epigenome-wide significance was set at p<1 x 10(-7). We compared methylation levels between Indian Asian and European controls without type 2 diabetes at baseline to estimate the potential contribution of DNA methylation to increased risk of future type 2 diabetes incidence among Indian Asians. Findings 1608 (11.9%) of 13 535 Indian Asians and 306 (4.3%) of 7066 Europeans developed type 2 diabetes over a mean of 8.5 years (SD 1.8) of follow-up. The age-adjusted and sex-adjusted incidence of type 2 diabetes was 3.1 times (95% CI 2.8-3.6; p < 0.0001) higher among Indian Asians than among Europeans, and remained 2.5 times (2.1-2.9; p<0.0001) higher after adjustment for adiposity, physical activity, family history of type 2 diabetes, and baseline glycaemic measures. The mean absolute difference in methylation level between type 2 diabetes cases and controls ranged from 0.5% (SD 0.1) to 1.1% (0.2). Methylation markers at five loci were associated with future type 2 diabetes incidence; the relative risk per 1% increase in methylation was 1.09 (95% CI 1.07-1.11; p=1.3 x 10(-17)) for ABCG1, 0.94 (0.92-0.95; p=4.2 x 10(-11)) for PHOSPHO1, 0.94 (0.92-0.96; p= 1.4 x 10(-9)) for SOCS3, 1.07 (1.04-1.09; p = 2.1 x 10(- 10)) for SREBF1, and 0.92 (0.90-0.94; p= 1.2 x 10(-17)) for TXNIP. A methylation score combining results for the five loci was associated with future type 2 diabetes incidence (relative risk quartile 4 vs quartile 13.51, 95% CI 2.79-4.42; p= 1.3 x 10(-26)), and was independent of established risk factors. Methylation score was higher among Indian Asians than Europeans (p = 1 x 10(-34)). Interpretation DNA methylation might provide new insights into the pathways underlying type 2 diabetes and off er new opportunities for risk stratification and prevention of type 2 diabetes among Indian Asians.	[Chambers, John C.; Loh, Marie; Lehne, Benjamin; Scott, William R.; Zhang, Weihua; Campanella, Gianluca; Chadeau-Hyam, Marc; Afzal, Uzma; Froguel, Philippe; Vineis, Paolo; Jarvelin, Marjo-Riitta; Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London W2 1PG, England; [Chambers, John C.; Jarvelin, Marjo-Riitta; Elliott, Paul; Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, MRC PHE Ctr Environm & Hlth, London W2 1PG, England; [Scott, William R.; Tan, Sian-Tsung; Scott, James; Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London W2 1PG, England; [Abbott, James] Univ London Imperial Coll Sci Technol & Med, Bioinformat Support Serv, London W2 1PG, England; [Chambers, John C.; Zhang, Weihua; Tan, Sian-Tsung; Afzal, Uzma; Kooner, Jaspal S.] Ealing Hosp NHS Trust, Southall, Middx, England; [Chambers, John C.; Punjabi, Prakash; Kooner, Jaspal S.] Imperial Coll Healthcare NHS Trust, London, England; [Loh, Marie] ASTAR, Translat Lab Genet Med, Singapore, Singapore; [Blancher, Christine] Univ Oxford, Oxford Genom Ctr, High Throughput Genom, Oxford, England; [Drong, Alexander; McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; [Kriebel, Jennifer; Wahl, Simone; Gieger, Christian; Grallert, Harald] German Res Ctr Environm Hlth, Res Unit Mol Epidemiol, Neuherberg, Germany; [Gieger, Christian] German Res Ctr Environm Hlth, Inst Genet Epidemiol, Neuherberg, Germany; [Kriebel, Jennifer; Wahl, Simone; Gieger, Christian; Thorand, Barbara; Grallert, Harald] German Res Ctr Environm Hlth, Inst Epidemiol 2, Neuherberg, Germany; [Prokisch, Holger] German Res Ctr Environm Hlth, Inst Human Genet, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Kriebel, Jennifer; Wahl, Simone; Thorand, Barbara; Grallert, Harald] German Ctr Diabet Res, Munich, Germany; [Motta, Valeria; Rota, Federica; Tarantini, Letizia; Albetti, Benedetta; Bertazzi, Pier Alberto; Bollati, Valentina] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy; [Ala-Korpela, Mika] Univ Bristol, Computat Med, Bristol, Avon, England; [Elliott, Hannah R.; Richmond, Rebecca C.; Caiazzo, Robert; Gaunt, Tom R.; Relton, Caroline L.] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Yengo, Loic; Pattou, Francois; Caiazzo, Robert; Cauchi, Stephane; Froguel, Philippe] European Genom Inst Diabet, Lille, France; [Yengo, Loic; Cauchi, Stephane; Froguel, Philippe] Inst Pasteur, CNRS, UMR8199, F-59019 Lille, France; [Yengo, Loic; Pattou, Francois; Cauchi, Stephane; Froguel, Philippe] Univ Lille 2, Lille, France; [Adamowicz-Brice, Martyna; Aitman, Timothy J.] Hammersmith Hosp, Imperial Coll, Ctr Clin Sci, Med Res Council,Physiol Genom & Med Grp, London, England; [Bozaoglu, Kiymet; Caiazzo, Robert; Jowett, Jeremy] Baker IDI Heart & Diabet Inst, Genom & Syst Biol, Melbourne, Vic, Australia; [Mok, Zuan Yu; Ng, Hong Kiat; Rozario, Michelle Ann; Soong, Richie] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Tai, E-Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117548, Singapore; [Tai, E-Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore; [Pattou, Francois] Claude Huriez Hosp, INSERM, UMR859, Lille, France; [Prokisch, Holger] Tech Univ Munich, Inst Human Genet, D-80290 Munich, Germany; [Ala-Korpela, Mika; Kangas, Antti J.; Soininen, Pasi] Univ Oulu, Computat Med, Oulu, Finland; [Loh, Marie; Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland; [Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland; [Ala-Korpela, Mika; Soininen, Pasi] Univ Eastern Finland, Sch Pharm, NMR Metabol Lab, Kuopio, Finland; [Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Care, Oulu, Finland; [Ammerpohl, Ole] Univ Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany; [Schafmayer, Clemens] Univ Hosp Schleswig Holstein, Dept Visceral & Thorac Surg, Kiel, Germany; [Danesh, John] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [de Lusignan, Simon; Jones, Simon] Univ Surrey, Guildford GU2 5XH, Surrey, England; [Illig, Thomas] Hannover Med Sch, Unifi Biobank, Hannover, Germany; [Jha, Sujeet] Max Healthcare, Dept Endocrinol Diabet & Obes, New Delhi, India; [Kasturiratne, Anuradhani; Wickremasinghe, Ananda Rajitha] Univ Kelaniya, Fac Med, Dept Publ Hlth, Ragama, Sri Lanka; [Kato, Norihiro] Natl Ctr Global Hlth & Med, Res Inst, Dept Gene Diagnost & Therapeut, Tokyo, Japan; [Kotea, Navaratnam] Univ Mauritius, Dept Hlth Sci, Reduit, Mauritius; [Kowlessur, Sudhir] Minist Hlth & Qual Life, Port Louis, Mauritius; [Pitkaeniemi, Janne] Univ Helsinki, Sch Med, Hjelt Inst, FIN-00014 Helsinki, Finland; [Tuomilehto, Jaakko] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland; [Pitkaeniemi, Janne] Inst Stat & Epidemiol Canc Res, Finnish Canc Registry, Helsinki, Finland; [Saleheen, Danish] Ctr Non Communicable Dis, Karachi, Pakistan; [Saleheen, Danish] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge, England; [Saleheen, Danish] Univ Penn, Perelman Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA; [Tai, E-Shyong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore; [Kyrtopoulos, Soterios A.] Natl Hellen Res Fdn, Inst Biol Pharmaceut Chem & Biotechnol, Athens, Greece; [Herder, Christian] Univ Dusseldorf, Leibniz Ctr Diabet Res Heinrich, Inst Clin Diabetol, German Diabet Ctr, Dusseldorf, Germany; [Herder, Christian] German Ctr Diabet Res, Dusseldorf, Germany; [Hampe, Jochen] Tech Univ Dresden, Univ Hosp, Dept Med 1, D-01062 Dresden, Germany; [Soong, Richie] Natl Univ Singapore Hosp, Dept Pathol, Singapore, Singapore; [Vineis, Paolo] HuGeF Fdn, Turin, Italy; [McCarthy, Mark I.] Churchill Hosp, Hlth Res Biomed Res Ctr, Oxford Natl Inst, Oxford OX3 7LJ, England	Chambers, JC (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London W2 1PG, England.	john.chambers@ic.ac.uk; j.kooner@ic.ac.uk	Grallert, Harald/B-3424-2013; Hampe, Jochen/A-2555-2010; Gaunt, Tom/O-3918-2014; Campanella, Gianluca/G-2617-2010	Hampe, Jochen/0000-0002-2421-6127; Gaunt, Tom/0000-0003-0924-3247; caiazzo, robert/0000-0001-5383-0540; Campanella, Gianluca/0000-0002-5411-6338	European Union; UK National Institute for Health Research; Wellcome Trust; UK Medical Research Council; Action on Hearing Loss; UK Biotechnology and Biological Sciences Research Council; Oak Foundation; Economic and Social Research Council; Helmholtz Zentrum Munchen; German Research Center for Environmental Health; German Federal Ministry of Education and Research; German Center for Diabetes Research; Munich Center for Health Sciences; Ministry of Science and Research of the State of North Rhine-Westphalia; German Federal Ministry of Health	The European Union, the UK National Institute for Health Research, the Wellcome Trust, the UK Medical Research Council, Action on Hearing Loss, the UK Biotechnology and Biological Sciences Research Council, the Oak Foundation, the Economic and Social Research Council, Helmholtz Zentrum Munchen, the German Research Center for Environmental Health, the German Federal Ministry of Education and Research, the German Center for Diabetes Research, the Munich Center for Health Sciences, the Ministry of Science and Research of the State of North Rhine-Westphalia, and the German Federal Ministry of Health.	Wallace TM, 2002, DIABETIC MED, V19, P527, DOI 10.1046/j.1464-5491.2002.00745.x; Tarling EJ, 2013, CURR OPIN LIPIDOL, V24, P138, DOI 10.1097/MOL.0b013e32835da122; Nyamdorj R, 2010, INT J OBESITY, V34, P332, DOI 10.1038/ijo.2009.225; [Anonymous], 2012, NAT GENET, DOI DOI 10.1038/NG.1019; Ma RCW, 2013, ANN NY ACAD SCI, V1281, P64, DOI 10.1111/nyas.12098; Volkmar M, 2012, EMBO J, V31, P1405, DOI 10.1038/emboj.2011.503; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Murgatroyd C, 2009, NAT NEUROSCI, V12, P1559, DOI 10.1038/nn.2436; Dowen RH, 2012, P NATL ACAD SCI USA, V109, pE2183, DOI 10.1073/pnas.1209329109; Xu XJ, 2013, EPIGENETICS-US, V8, P522, DOI 10.4161/epi.24506; Morris AP, 2012, NAT GENET, V44, P981, DOI 10.1038/ng.2383; Kruit JK, 2012, DIABETES, V61, P659, DOI 10.2337/db11-1341; Toperoff G, 2012, HUM MOL GENET, V21, P371, DOI 10.1093/hmg/ddr472; Holle R, 2005, GESUNDHEITSWESEN, V67, pS19, DOI 10.1055/s-2005-858235; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Sekiya M, 2007, J LIPID RES, V48, P1581, DOI 10.1194/jlr.M700033-JLR200; Hidalgo B, 2014, DIABETES, V63, P801, DOI 10.2337/db13-1100; Wurtz P, 2013, DIABETES CARE, V36, P648, DOI 10.2337/dc12-0895; Nilsson E, 2014, DIABETES, V63, P2962, DOI 10.2337/db13-1459; Ribel-Madsen R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051302; Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609; Patel CJ, 2013, HUM GENET, V132, P495, DOI 10.1007/s00439-012-1258-z; Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37; Kooner JS, 2011, NAT GENET, V43, P984, DOI 10.1038/ng.921; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120; Cha-Molstad H, 2009, J BIOL CHEM, V284, P16898, DOI 10.1074/jbc.M109.010504; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Drong AW, 2012, CLIN PHARMACOL THER, V92, P707, DOI 10.1038/clpt.2012.149; Chambers JC, 2000, LANCET, V355, P523, DOI 10.1016/S0140-6736(99)93019-2; Gu HF, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-20; Hall MA, 2013, PAC S BIOCOMPUT, V2014, P200; Hand LE, 2013, ENDOCRINOLOGY, V154, P2081, DOI 10.1210/en.2012-2051; Hansen K, 2013, MINIFI ANAL ILLUMINA; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; International Diabetes Federation, 2014, IDF DIABETES ATLAS; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Lehne B, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0600-x; Martin-Nunez GM, 2014, EPIGENETICS-US, V9, P1322, DOI 10.4161/15592294.2014.969617; McCarthy MI, 2010, NEW ENGL J MED, V363, P2339, DOI 10.1056/NEJMra0906948; McRae AF, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r73; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Vitto MF, 2012, HORM METAB RES, V44, P885, DOI 10.1055/s-0032-1321819	42	7	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	2213-8587			LANCET DIABETES ENDO	Lancet Diabetes Endocrinol.	JUL	2015	3	7					526	534		10.1016/S2213-8587(15)00127-8		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CM1DC	WOS:000357419500028		
J	Yamashita, YI; Yoshida, Y; Kurihara, T; Itoh, S; Harimoto, N; Ikegami, T; Yoshizumi, T; Uchiyama, H; Shirabe, K; Maehara, Y				Yamashita, Yo-Ichi; Yoshida, Yoshihiro; Kurihara, Takeshi; Itoh, Shinji; Harimoto, Norifumi; Ikegami, Toru; Yoshizumi, Tomoharu; Uchiyama, Hideaki; Shirabe, Ken; Maehara, Yoshihiko			Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation	LIVER TRANSPLANTATION			English	Article							HEPATIC RESECTION; PROGNOSTIC-FACTORS; INTRAHEPATIC RECURRENCE; RADIOFREQUENCY ABLATION; SURVIVAL ANALYSIS; TUMOR SIZE; CIRRHOSIS; LIPIODOLIZATION; EXPERIENCE; STRATEGY	The aims of this study were to evaluate the efficacy of repeat hepatectomy (Hx) and salvage living donor liver transplantation (LDLT) for recurrent hepatocellular carcinoma (HCC). A retrospective cohort study was performed to analyze the surgical results of repeat Hx and salvage LDLT for patients with recurrent HCC within the Milan criteria from 1989 to 2012. A total of 159 patients were divided into 2 groups: a repeat Hx group (n=146) and a salvage LDLT group (n=13). Operative results and patient prognoses were compared between the 2 groups. The operative invasiveness, including the operation time (229.1 +/- 97.7 versus 862.9 +/- 194.4 minutes; P<0.0001) and blood loss (596.3 +/- 764.9 versus 24,690 +/- 59,014.4 g; P<0.0001), were significantly higher in the salvage LDLT group. The early surgical results, such as morbidity (31% versus 62%; P=0.0111) and the duration of hospital stay (20 +/- 22 versus 35 +/- 21 days; P=0.0180), were significantly worse in the salvage LDLT group. There was no significant difference in the overall survival (OS) rate, but the disease-free survival rate of the salvage LDLT group was significantly better (P=0.0002). The OS rate of patients with grade B liver damage in the repeat Hx group was significantly worse (P<0.0001), and the 5-year OS rate was quite low, that is, 20% (liver damage A, 77% for the repeat Hx group and 75% for the salvage LDLT group). The prognosis of patients with grade B liver damage after repeat Hx for recurrent HCC is poor, and salvage LDLT would be a potent option for such patients. Liver Transpl 21:961-968, 2015. (c) 2015 AASLD.	[Yamashita, Yo-Ichi; Yoshida, Yoshihiro; Kurihara, Takeshi; Itoh, Shinji; Harimoto, Norifumi; Ikegami, Toru; Yoshizumi, Tomoharu; Uchiyama, Hideaki; Shirabe, Ken; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan	Yamashita, YI (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yamashi@surg2.med.kyushu-u.ac.jp			Ministry of Education, Science, and Culture of Japan [25462093]	This study was partly funded by a Grant-in-Aid (no. 25462093) from the Ministry of Education, Science, and Culture of Japan.	Ravaioli M, 2004, TRANSPLANTATION, V78, P1780, DOI 10.1097/01.TP.0000145892.97114.EE; Chan ACY, 2013, LIVER TRANSPLANT, V19, P411, DOI 10.1002/lt.23605; Chan DL, 2014, J GASTROEN HEPATOL, V29, P31, DOI 10.1111/jgh.12399; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Taketomi A, 2009, TRANSPLANTATION, V87, P531, DOI 10.1097/TP.0b013e3181943bee; Adam R, 2003, ANN SURG, V238, P508, DOI 10.1097/01.sla.0000090449.87109.44; Taketomi A, 2007, J AM COLL SURGEONS, V204, P580, DOI 10.1016/j.jamcollsurg.2007.01.035; LEE PH, 1995, ANN SURG, V222, P670, DOI 10.1097/00000658-199511000-00010; Fuks D, 2012, HEPATOLOGY, V55, P132, DOI 10.1002/hep.24680; Yoshizumi T, 2013, HEPATOL RES, V43, P709, DOI 10.1111/hepr.12016; Ohba T, 2012, SURG TODAY, V42, P526, DOI 10.1007/s00595-011-0090-8; Poon RTP, 1999, ANN SURG, V229, P216, DOI 10.1097/00000658-199902000-00009; Harimoto N, 2013, TRANSPLANTATION, V96, P1008, DOI 10.1097/TP.0b013e3182a53f2b; Yamashita Y, 2007, J AM COLL SURGEONS, V205, P19, DOI 10.1016/j.jamcollsurg.2007.01.069; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; Poon RTP, 2002, ANN SURG, V235, P373, DOI 10.1097/00000658-200203000-00009; SHIRABE K, 1991, HEPATOLOGY, V14, P802, DOI 10.1002/hep.1840140510; Maggs JRL, 2012, ALIMENT PHARM THER, V35, P1113, DOI 10.1111/j.1365-2036.2012.05072.x; Makuuchi M, 2008, HEPATOL RES, V38, P37, DOI 10.1111/j.1872-034X.2007.00216.x; Mori Y, 2009, HEPATOL INT, V3, P509, DOI 10.1007/s12072-009-9131-4; Minagawa M, 2003, ANN SURG, V238, P703, DOI 10.1097/01.sla.0000094549.11754.e6; Yamashita Y, 2014, AM J SURG, V207, P890, DOI 10.1016/j.amjsurg.2013.07.028; Chan ACY, 2012, WORLD J SURG, V36, P151, DOI 10.1007/s00268-011-1323-0; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; FAN ST, 1995, ARCH SURG-CHICAGO, V130, P198; FURUTA T, 1990, HEPATO-GASTROENTEROL, V37, P494; Ikegami T, 2014, J AM COLL SURGEONS, V219, pE39, DOI 10.1016/j.jamcollsurg.2014.04.021; Itamoto T, 2007, SURGERY, V141, P589, DOI 10.1016/j.surg.2006.12.014; KANEMATSU T, 1989, HEPATOLOGY, V10, P98, DOI 10.1002/hep.1840100119; Kubo S, 2008, WORLD J SURG, V32, P632, DOI 10.1007/s00268-007-9365-z; Lau H, 1997, BRIT J SURG, V84, P1255; Liu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048932; Liver Cancer Study Group of Japan, 2010, GEN RUL CLIN PATH ST; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Ng KK, 2008, ARCH SURG-CHICAGO, V143, P68, DOI 10.1001/archsurg.2007.15; Parfitt Jeremy R, 2007, Liver Transpl, V13, P543, DOI 10.1002/lt.21078; Rodriguez-Sanjuan JC, 2008, WORLD J SURG, V32, P1489, DOI 10.1007/s00268-008-9559-z; Sapisochin G, 2010, WORLD J SURG, V34, P2146, DOI 10.1007/s00268-010-0583-4; Shimada M, 1998, ANN SURG, V227, P80, DOI 10.1097/00000658-199801000-00012; Shirabe K, 1996, CANCER, V77, P1050, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1050::AID-CNCR7>3.3.CO;2-O; Taketomi A, 2010, J AM COLL SURGEONS, V211, P456, DOI 10.1016/j.jamcollsurg.2010.04.018; Uchiyama H, 2014, AM J TRANSPLANT, V14, P367, DOI 10.1111/ajt.12559; URATA K, 1994, J SURG ONCOL, V56, P54, DOI 10.1002/jso.2930560113; Vennarecci G, 2007, TRANSPL P, V39, P1857, DOI 10.1016/j.transproceed.2007.05.073; Wu LW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041820; Yamashita Y, 2013, SURGERY, V154, P1038, DOI 10.1016/j.surg.2013.04.046; Yoshizumi T, 2011, TRANSPLANTATION, V91, pE61, DOI 10.1097/TP.0b013e318210de92	47	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465	1527-6473		LIVER TRANSPLANT	Liver Transplant.	JUL	2015	21	7					961	968		10.1002/lt.24111		8	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	CL5QF	WOS:000357014100015		
J	Hirao, H; Uchida, Y; Kadono, K; Tanaka, H; Niki, T; Yamauchi, A; Hata, K; Watanabe, T; Terajima, H; Uemoto, S				Hirao, Hirofumi; Uchida, Yoichiro; Kadono, Kentaro; Tanaka, Hirokazu; Niki, Toshiro; Yamauchi, Akira; Hata, Koichiro; Watanabe, Takeshi; Terajima, Hiroaki; Uemoto, Shinji			The protective function of galectin-9 in liver ischemia and reperfusion injury in mice	LIVER TRANSPLANTATION			English	Article							HEPATIC ISCHEMIA/REPERFUSION INJURY; REGULATORY T-CELLS; MOUSE-LIVER; KUPFFER CELLS; TH2 CELLS; ACTIVATION; IMMUNITY; PATHWAY; TIM-3; INFLAMMATION	Galectin-9 (Gal-9) has gained attention as a multifaceted player in adaptive and innate immunity. To elucidate the role of Gal-9, we used a mouse model of partial liver ischemia/reperfusion injury (IRI) with wild type (WT) and Gal-9 knockout (KO) mice as well as a recombinant galectin-9 (reGal-9) protein. We found that the expression of Gal-9 was enhanced endogenously in the liver especially by hepatocytes and Kupffer cells during warm IRI for a mouse liver, which causes massive destruction of liver tissue. Gal-9 was released into the extracellular space in the liver and the highest levels in the plasma at 1 hour after reperfusion. The present study elucidates a novel role of Gal-9 signaling in mouse liver IRI, by using Gal-9-deficient mice and a stable form of reGal-9 protein. In the circumstance of Gal-9 absence, liver damage due to ischemia/reperfusion (IR) exacerbated the severity as compared with WT. On the other hand, exogenously administered reGal-9 significantly ameliorated hepatocellular damage. It decreased the local infiltration of the inflammatory cells such as T cells, neutrophils, and macrophages, and it reduced the expression of proinflammatory cytokines/chemokines; then, it strongly suppressed the apoptosis of the liver cells. Interestingly, severe liver damage due to IR in Gal-9 KO mice was improved by the administration of reGal-9. In conclusion, Gal-9 engagement ameliorated local inflammation and liver damage induced by IR, and the present study suggests a significant role of Gal-9 in the maintenance of hepatic homeostasis. In conclusion, targeting Gal-9 represents a novel approach to protect from inflammation such as liver IRI. Exogenous Gal-9 treatment will be a new therapeutic strategy against innate immunity-dominated liver tissue damage. Liver Transpl 21:969-981, 2015. (c) 2015 AASLD.	[Hirao, Hirofumi; Uchida, Yoichiro; Kadono, Kentaro; Tanaka, Hirokazu; Hata, Koichiro; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Surg, Div Hepatopancreatobiliary Surg & Transplantat, Kyoto, Japan; [Hirao, Hirofumi; Uchida, Yoichiro; Kadono, Kentaro; Terajima, Hiroaki] Kitano Hosp, Dept Gastroenterol Surg & Oncol, Osaka, Osaka 5308480, Japan; [Yamauchi, Akira] Kitano Hosp, Dept Breast Surg, Osaka, Osaka 5308480, Japan; [Watanabe, Takeshi] Kitano Hosp, Tazuke Kofukai Med Res Inst, Osaka, Osaka 5308480, Japan; [Niki, Toshiro] Kagawa Univ, Dept Immunol & Immunopathol, Fac Med, Takamatsu, Kagawa 760, Japan; [Niki, Toshiro] GalPharma Co Ltd, Takamatsu, Kagawa, Japan	Uchida, Y (reprint author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Gastroenterol Surg & Oncol, Kita Ku, 2-4-20 Ohgimachi, Osaka, Osaka 5308480, Japan.	uchiday@kuhp.kyoto-u.ac.jp			Kitano Research Scholarships; Uehara Memorial Foundation	This work was funded by Grants-in-Aid for Scientific Research, Kitano Research Scholarships, and Research Scholarships of Uehara Memorial Foundation.	Uchida Y, 2010, HEPATOLOGY, V51, P1363, DOI 10.1002/hep.23442; Seki M, 2008, CLIN IMMUNOL, V127, P78, DOI 10.1016/j.clim.2008.01.006; Wang F, 2008, TRANSPL IMMUNOL, V19, P12, DOI 10.1016/j.trim.2008.01.008; Teoh NC, 2003, J GASTROEN HEPATOL, V18, P891, DOI 10.1046/j.1440-1746.2003.03056.x; Nace GW, 2013, HEPATOLOGY, V58, P374, DOI 10.1002/hep.26346; Seki M, 2007, ARTHRITIS RHEUM-US, V56, P3968, DOI 10.1002/art.23076; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Wada J, 1997, J BIOL CHEM, V272, P6078; Chou FC, 2009, EUR J IMMUNOL, V39, P2403, DOI 10.1002/eji.200839177; JAESCHKE H, 1991, FREE RADICAL RES COM, V15, P277, DOI 10.3109/10715769109105223; Kanzaki M, 2012, ENDOCRINOLOGY, V153, P612, DOI 10.1210/en.2011-1579; Zwacka RM, 1997, J CLIN INVEST, V100, P279, DOI 10.1172/JCI119533; Tsung A, 2005, J IMMUNOL, V175, P7661; Uchida Y, 2010, GASTROENTEROLOGY, V139, P2195, DOI 10.1053/j.gastro.2010.07.003; Lv K, 2011, CLIN IMMUNOL, V140, P92, DOI 10.1016/j.clim.2011.03.017; Zhai Y, 2004, J IMMUNOL, V173, P7115; SUZUKI S, 1993, TRANSPLANTATION, V55, P1265; Uchida Y, 2010, TRANSPLANTATION, V89, P1050, DOI 10.1097/TP.0b013e3181d45a98; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; Shen XD, 2009, HEPATOLOGY, V50, P1537, DOI 10.1002/hep.23153; Kishore U, 1997, MATRIX BIOL, V15, P583, DOI 10.1016/S0945-053X(97)90035-4; Lentsch AB, 2000, HEPATOLOGY, V32, P169, DOI 10.1053/jhep.2000.9323; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Lentsch AB, 1998, HEPATOLOGY, V27, P1172; Farmer D. G., 2000, TRANSPLANT REV, V14, P106, DOI 10.1053/tr.2000.4651; Gooden MJM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065616; Hanschen M, 2008, TRANSPLANTATION, V86, P710, DOI 10.1097/TP.0b013e3181821aa7; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699; Kadowaki T, 2013, CRIT CARE, V17, DOI 10.1186/cc13147; Khademi M, 2004, J IMMUNOL, V172, P7169; Liu YX, 2015, J HEPATOL, V62, P563, DOI 10.1016/j.jhep.2014.10.034; Lv K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048379; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Mengshol JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009504; Nishi N, 2005, FEBS LETT, V579, P2058, DOI 10.1016/j.febslet.2005.02.054; Rudiger HA, 2003, J INVEST SURG, V16, P149, DOI 10.1080/08941930390205764; Uchida Y, 2009, LIVER TRANSPLANT, V15, P939, DOI 10.1002/lt.21770; vansKooyk Y, 2008, NAT IMMUNOL, V9, P593; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465	1527-6473		LIVER TRANSPLANT	Liver Transplant.	JUL	2015	21	7					969	981		10.1002/lt.24159		13	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	CL5QF	WOS:000357014100016		
J	Kaido, T; Hammad, A; Uemoto, S				Kaido, Toshimi; Hammad, Ahmed; Uemoto, Shinji			Perioperative Changes in Nutritional Parameters and Impact of Graft Size in Patients Undergoing Adult Living Donor Liver Transplantation Reply	LIVER TRANSPLANTATION			English	Letter									[Kaido, Toshimi; Hammad, Ahmed; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Div Hepatobiliarypancreat & Transplant Surg, Dept Surg,Sakyo Ku, Kyoto 6068507, Japan; [Hammad, Ahmed] Mansoura Univ, Dept Surg, Mansoura, Egypt	Kaido, T (reprint author), Kyoto Univ, Grad Sch Med, Div Hepatobiliarypancreat & Transplant Surg, Dept Surg,Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	kaido@kuhp.kyoto-u.ac.jp					Agilli M, 2015, LIVER TRANSPLANT, V21, P1001, DOI 10.1002/lt.24156; Gharekhani A, 2014, J RENAL NUTR, V24, P177, DOI 10.1053/j.jrn.2014.01.014; Hammad A, 2014, LIVER TRANSPLANT, V20, P1486, DOI 10.1002/lt.23992	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465	1527-6473		LIVER TRANSPLANT	Liver Transplant.	JUL	2015	21	7					1003	1004		10.1002/lt.24152		2	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	CL5QF	WOS:000357014100020		
J	Michinobu, T				Michinobu, Tsuyoshi			Click Functionalization of Aromatic Polymers for Organic Electronic Device Applications	MACROMOLECULAR CHEMISTRY AND PHYSICS			English	Article						charge transfer; charge transport; conjugated polymers; functionalization of polymers; redox polymers	CHARGE-TRANSFER INTERACTIONS; STABLE METABOLIC INTERMEDIATE; SOLAR-CELLS; TRANSFER CHROMOPHORES; CONJUGATED POLYMERS; CHEMISTRY; POLYMERIZATION; TCNQ; POSTFUNCTIONALIZATION; ALKYNES	The [2 + 2] cycloaddition-retroelectrocyclization between electron-rich alkynes and tetracyanoethylene (TCNE)/7,7,8,8-tetracyanoquinodimethane (TCNQ), yielding the tetracyanated donor-acceptor (D-A) chromophores, is a new class of click chemistry reactions, due to the high efficiencies, no byproducts, and applicability to polymer syntheses. As compared to the conventional click reactions represented by the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC), these new click reactions provide fascinating optoelectronic properties originating from the D-A chromophore structures formed. A series of -conjugated aromatic polymers containing electron-rich alkynes were successfully functionalized by these click reactions, producing novel organic or organometallic materials featuring conducting and photovoltaic properties in thin film electronic devices. This review article describes the recent results of the author's research group. The power of click chemistry is highlighted by the polymer synthesis using CuAAC. This is followed by the alkyne-TCNE/TCNQ postfunctionalization to produce high-performance aromatic polymers for use as active components in organic electronic devices, such as thin film transistors, organic solar cells and polymer memory devices.	Tokyo Inst Technol, Dept Organ & Polymer Mat, Meguro Ku, Tokyo 1528552, Japan	Michinobu, T (reprint author), Tokyo Inst Technol, Dept Organ & Polymer Mat, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528552, Japan.	michinobu.t.aa@m.titech.ac.jp			Support for Tokyotech Advanced Researchers (STAR); Futaba Electronics Memorial Foundation; Takahashi Industrial and Economic Research Foundation; Shorai Foundation for Science and Technology; Foundation for the Promotion of the Industrial Explosives Technology; Mukai Science and Technology Foundation; Maekawa Houonkai Foundation; General Sekiyu R&D Encouragement Assistance Foundation	Financial support from the Support for Tokyotech Advanced Researchers (STAR), the Futaba Electronics Memorial Foundation, the Takahashi Industrial and Economic Research Foundation, the Shorai Foundation for Science and Technology, the Foundation for the Promotion of the Industrial Explosives Technology, the Mukai Science and Technology Foundation, the Maekawa Houonkai Foundation, and the General Sekiyu R&D Encouragement Assistance Foundation is gratefully acknowledged. The author is also indebted to his students and collaborators whose names appear in the references.	Connelly NG, 1996, CHEM REV, V96, P877, DOI 10.1021/cr940053x; Lowe AB, 2010, J MATER CHEM, V20, P4745, DOI 10.1039/b917102a; Kempe K, 2012, CHEM SOC REV, V41, P176, DOI 10.1039/c1cs15107j; Li HK, 2013, MACROMOLECULES, V46, P3907, DOI 10.1021/ma400609m; Ko YG, 2014, MACROMOLECULES, V47, P8154, DOI 10.1021/ma5021402; Michinobu T, 2011, CHEM SOC REV, V40, P2306, DOI 10.1039/c0cs00205d; Ko YG, 2014, ACS APPL MATER INTER, V6, P8415, DOI 10.1021/am5013134; Qin AJ, 2010, CHEM SOC REV, V39, P2522, DOI 10.1039/b909064a; Koyama Y, 2012, CHEM COMMUN, V48, P10304, DOI 10.1039/c2cc35158g; Cheawchan S, 2013, POLYMER, V54, P4501, DOI 10.1016/j.polymer.2013.06.020; Hizal G, 2011, J POLYM SCI POL CHEM, V49, P4103, DOI 10.1002/pola.24835; Michinobu T, 2014, J MATER CHEM C, V2, P3367, DOI 10.1039/c3tc32165g; Walzer K, 2007, CHEM REV, V107, P1233, DOI 10.1021/cr050156n; Qin AJ, 2009, ADV FUNCT MATER, V19, P1891, DOI 10.1002/adfm.200801933; Durmaz H, 2012, POLYM CHEM-UK, V3, P825, DOI 10.1039/c1py00471a; Koyama Y, 2008, CHEM LETT, V37, P918, DOI 10.1246/cl.2008.918; Kato S, 2010, CHEM COMMUN, V46, P1994, DOI 10.1039/b926601a; Sumerlin BS, 2010, MACROMOLECULES, V43, P1, DOI 10.1021/ma901447e; Koos C, 2009, NAT PHOTONICS, V3, P216, DOI 10.1038/NPHOTON.2009.25; Heremans P, 2011, CHEM MATER, V23, P341, DOI 10.1021/cm102006v; Tsoi WC, 2011, MACROMOLECULES, V44, P2944, DOI 10.1021/ma102841e; Facchetti A, 2013, MATER TODAY, V16, P123, DOI 10.1016/j.mattod.2013.04.005; Morimoto M, 2011, CHEM COMMUN, V47, P9819, DOI 10.1039/c1cc13476k; Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924; Guo X, 2013, PROG POLYM SCI, V38, P1832, DOI 10.1016/j.progpolymsci.2013.09.005; Michinobu T, 2006, CHEM-EUR J, V12, P1889, DOI 10.1002/chem.200501113; Iha RK, 2009, CHEM REV, V109, P5620, DOI 10.1021/cr900138t; Zhang Y, 2013, ADV MATER, V25, P7038, DOI 10.1002/adma.201302159; Kivala M, 2009, ACCOUNTS CHEM RES, V42, P235, DOI 10.1021/ar8001238; Esembeson B, 2008, ADV MATER, V20, P4584, DOI 10.1002/adma.200801552; Qin AJ, 2010, MACROMOLECULES, V43, P8693, DOI 10.1021/ma101064u; Lin WP, 2014, ADV MATER, V26, P570, DOI 10.1002/adma.201302637; Li HK, 2012, POLYM CHEM-UK, V3, P1075, DOI 10.1039/c2py00586g; Baskin JM, 2007, P NATL ACAD SCI USA, V104, P16793, DOI 10.1073/pnas.0707090104; Kurosawa T, 2013, POLYM CHEM-UK, V4, P16, DOI 10.1039/c2py20632c; Cheng YJ, 2009, CHEM REV, V109, P5868, DOI 10.1021/cr900182s; BRUCE MI, 1982, J ORGANOMET CHEM, V226, pC1, DOI 10.1016/S0022-328X(00)83397-5; Bruce MI, 2013, J ORGANOMET CHEM, V730, P3, DOI 10.1016/j.jorganchem.2012.11.004; Chou YH, 2015, POLYM CHEM-UK, V6, P341, DOI 10.1039/c4py01213e; Espeel P, 2015, MACROMOLECULES, V48, P2, DOI 10.1021/ma501386v; Fujita H, 2012, MACROMOLECULES, V45, P9643, DOI 10.1021/ma301692b; Kato S. -i., 2008, CHEM-EUR J, V15, P8687; Kee Y. -G., 2009, MACROMOLECULES, V42, P7709; Kivala M, 2007, CHEM COMMUN, P4731, DOI 10.1039/b713683h; Kivala M, 2009, CHEM-EUR J, V15, P4111, DOI 10.1002/chem.200802563; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5; Koszelewski D, 2012, CHEM-ASIAN J, V7, P1887, DOI 10.1002/asia.201200179; Li YR, 2012, J POLYM SCI POL CHEM, V50, P2111, DOI 10.1002/pola.25990; Liu CL, 2011, POLYM CHEM-UK, V2, P2169, DOI 10.1039/c1py00189b; Lowe AB, 2014, POLYM CHEM-UK, V5, P4820, DOI 10.1039/c4py00339j; Lutz JF, 2008, ANGEW CHEM INT EDIT, V47, P2182, DOI 10.1002/anie.200705365; Michinobu T, 2012, POLYM CHEM-UK, V3, P1427, DOI 10.1039/c2py20079a; Michinobu T, 2008, CHEM LETT, V37, P154, DOI 10.1246/cl.2008.154; Michinobu T, 2009, MACROMOLECULES, V42, P5903, DOI 10.1021/ma9013324; Michinobu T, 2008, J AM CHEM SOC, V130, P14074, DOI 10.1021/ja8061612; Michinobu T, 2010, PURE APPL CHEM, V82, P1001, DOI 10.1351/PAC-CON-09-09-09; Michinobu T., 2010, MATERIALS, V3, P4774; Michinobu T, 2011, POLYM J, V43, P648, DOI 10.1038/pj.2011.40; Mityashin A, 2012, ADV MATER, V24, P1535, DOI 10.1002/adma.201104269; Shoji T, 2008, CHEM-EUR J, V14, P8398, DOI 10.1002/chem.200701981; Tanici F., 2014, CHEM-EUR J, V20, P202; Tasdelen A., 2011, POLYM CHEM, V2, P2133; Theato P., 2013, FUNCTIONA POLUM POST; Tunca U, 2013, MACROMOL RAPID COMM, V34, P38, DOI 10.1002/marc.201200656; Tunca U, 2014, J POLYM SCI POL CHEM, V52, P3147, DOI 10.1002/pola.27379; Washino Y, 2012, POLYM BULL, V69, P137, DOI 10.1007/s00289-011-0693-7; Washino Y, 2011, POLYM J, V43, P364, DOI 10.1038/pj.2011.2; Washino Y, 2011, MACROMOL RAPID COMM, V32, P644, DOI 10.1002/marc.201100025; Washino Y, 2014, MACROMOL CHEM PHYS, V215, P1485, DOI 10.1002/macp.201400275; Yoshida S, 2011, SCI REP-UK, V1, DOI 10.1038/srep00082; Yuan YP, 2011, J POLYM SCI POL CHEM, V49, P225, DOI 10.1002/pola.24443; Yuan YP, 2013, MACROMOL CHEM PHYS, V214, P1465, DOI 10.1002/macp.201300245; Yuan YP, 2013, CHEM SCI, V4, P345, DOI 10.1039/c2sc21334f	73	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1022-1352	1521-3935		MACROMOL CHEM PHYS	Macromol. Chem. Phys.	JUL	2015	216	13					1387	1395		10.1002/macp.201500086		9	Polymer Science	Polymer Science	CL9ZC	WOS:000357336900004		
J	Murase, N; Taniguchi, SI; Takano, E; Kitayama, Y; Takeuchi, T				Murase, Nobuo; Taniguchi, Shin-Ichi; Takano, Eri; Kitayama, Yukiya; Takeuchi, Toshifumi			Fluorescence Reporting of Binding Interactions of Target Molecules with Core-Shell-Type Cortisol-Imprinted Polymer Particles Using Environmentally Responsible Fluorescent-Labeled Cortisol	MACROMOLECULAR CHEMISTRY AND PHYSICS			English	Article						core-shell nanoparticles; emulsifier-free emulsion polymerization; fluorescent-labeled cortisol; molecular imprinting; molecular recognition	PROTEIN RECOGNITION; ARTIFICIAL ANTIBODIES; SIGNAL-TRANSDUCTION; PROSTHETIC GROUPS; NANOPARTICLES; SITES	Core-shell-type molecularly imprinted polymer particles (MIP-NPs) bearing specific binding cavities for cortisol in their shell layers by two-step emulsifier-free emulsion polymerizations are synthesized, where both the strategies of semicovalent molecular imprinting and noncovalent molecular imprinting are concurrently performed using methacryloyl cortisol and itaconic acid as a template molecule and a functional monomer, respectively. Newly designed fluorescent reporter molecules, dansyl-labeled cortisol, to investigate the binding capability of MIP-NPs toward cortisol by fluorescence measurements are developed. The binding rate constant (k(a)) and affinity constant (K-a) of MIP-NPs toward cortisol are successfully estimated by curve fitting for fluorescence spectral shift. The k(a) value of MIP-NPs is 1.8 times larger than that of reference MIP-NPs prepared using only methacryloyl cortisol without itaconic acid (semicovalent imprinting), indicating that the concurrent demonstration of both the semicovalent imprinting and noncovalent imprinting processes is effective for constructing high affinity binding cavities for cortisol.	[Murase, Nobuo; Takano, Eri; Kitayama, Yukiya; Takeuchi, Toshifumi] Kobe Univ, Grad Sch Engn, Nada Ku, Kobe, Hyogo 6578501, Japan; [Taniguchi, Shin-Ichi] Hitachi Ltd, Yokohama Res Lab, Totsuka Ku, Yokohama, Kanagawa 2440817, Japan	Takeuchi, T (reprint author), Kobe Univ, Grad Sch Engn, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.	takeuchi@gold.kobe-u.ac.jp	Takeuchi, Toshifumi/E-6379-2014	Takeuchi, Toshifumi/0000-0002-5641-2333			Sunayama H, 2010, BIOSENS BIOELECTRON, V26, P458, DOI 10.1016/j.bios.2010.07.091; Zhang Z, 2014, RSC ADV, V4, P20677, DOI 10.1039/c4ra00668b; Suga Y, 2013, CHEM COMMUN, V49, P8450, DOI 10.1039/c3cc40484f; Nishino H, 2006, ANGEW CHEM INT EDIT, V45, P2392, DOI 10.1002/anie.200503760; Takeuchi T, 2006, ORG BIOMOL CHEM, V4, P565, DOI 10.1039/b514432a; DRESSENDORFER RA, 1992, J STEROID BIOCHEM, V43, P683, DOI 10.1016/0960-0760(92)90294-S; Takeuchi T, 2008, ORG BIOMOL CHEM, V6, P2459, DOI 10.1039/b715737c; Hoshino Y, 2010, J AM CHEM SOC, V132, P6644, DOI 10.1021/ja102148f; Taguchi H, 2015, ANALYST, V140, P1448, DOI 10.1039/c4an02299h; Wan W, 2013, ANGEW CHEM INT EDIT, V52, P7023, DOI 10.1002/anie.201300322; Haupt K, 2000, CHEM REV, V100, P2495, DOI 10.1021/cr990099w; Rosmond R, 1998, J CLIN ENDOCR METAB, V83, P1853, DOI 10.1210/jc.83.6.1853; Poma A, 2010, TRENDS BIOTECHNOL, V28, P629, DOI 10.1016/j.tibtech.2010.08.006; Wei ST, 2006, BIOSENS BIOELECTRON, V21, P1943, DOI 10.1016/j.bios.2005.09.017; Sunayama H, 2014, CHEM COMMUN, V50, P1347, DOI 10.1039/c3cc47759b; Yamaguchi M, 2013, BIOSENS BIOELECTRON, V41, P186, DOI 10.1016/j.bios.2012.08.016; WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121; Takeda K, 2009, J AM CHEM SOC, V131, P8833, DOI 10.1021/ja9004317; Baggiani C, 2000, TALANTA, V51, P71, DOI 10.1016/S0039-9140(99)00251-9; Tan CJ, 2007, ANAL BIOANAL CHEM, V389, P369, DOI 10.1007/s00216-007-1362-4; Ramstrom O, 1996, CHEM BIOL, V3, P471, DOI 10.1016/S1074-5521(96)90095-2; Chen LX, 2011, CHEM SOC REV, V40, P2922, DOI 10.1039/c0cs00084a; Matsui J, 2000, ANAL CHEM, V72, P1810, DOI 10.1021/ac9911950; Li SJ, 2014, PROG POLYM SCI, V39, P145, DOI 10.1016/j.progpolymsci.2013.10.002; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; Ma Y, 2013, ANGEW CHEM INT EDIT, V52, P1511, DOI 10.1002/anie.201206514; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; Gordic M., 2008, THEORETICAL MODELING; Haupt K., 2012, MOL IMPRINTING; HUANG CM, 1989, CLIN CHEM, V35, P125; Huang H, 2010, J LIPID RES, V51, P1157, DOI 10.1194/jlr.M003244; Kamon Y, 2014, POLYM CHEM-UK, V5, P4764, DOI 10.1039/c4py00350k; Komiyama M, 2003, MOL IMPRINTING FUNDA; Lee SW, 2013, HANDBOOK OF MOLECULAR IMPRINTING: ADVANCED SENSOR APPLICATIONS, P1; Sasaki S, 2015, J BIOSCI BIOENG, V119, P200, DOI 10.1016/j.jbiosc.2014.06.019; Sellergren B., 2000, MOL IMPRINTED POLYM; Takeuchi T, 2014, ANGEW CHEM INT EDIT, V53, P12765, DOI 10.1002/anie.201406852; Tsuruoka M, 1996, J BIOTECHNOL, V48, P201, DOI 10.1016/0168-1656(96)01510-6; Uchida A, 2013, RSC ADV, V3, P25306, DOI 10.1039/c3ra43660h	39	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1022-1352	1521-3935		MACROMOL CHEM PHYS	Macromol. Chem. Phys.	JUL	2015	216	13					1396	1404		10.1002/macp.201500065		9	Polymer Science	Polymer Science	CL9ZC	WOS:000357336900005		
J	Takata, Y; Yamamoto, K; Kadokawa, J				Takata, Yusei; Yamamoto, Kazuya; Kadokawa, Jun-ichi			Preparation of pH-Responsive Amphoteric Glycogen Hydrogels by -Glucan Phosphorylase-Catalyzed Successive Enzymatic Reactions	MACROMOLECULAR CHEMISTRY AND PHYSICS			English	Article						amphoteric; branched; enzymes; phosphorylase; polysaccharides	ANTIPARALLEL DOUBLE HELIX; THERMOSTABLE PHOSPHORYLASE; BRANCHING ENZYME; ALPHA-GLUCURONYLATION; CYCLIZATION REACTION; GLUCURONIC ACID; 1-PHOSPHATE; AMYLOSE	The thermostable -glucan phosphorylase-catalyzed enzymatic -glucuronylation and subsequent -glucosaminylation of glycogen using -d-glucuronic acid 1-phosphate (GlcA-1-P) and -d-glucosamine 1-phosphate (GlcN-1-P), respectively, produce amphoteric glycogens. The products exhibit the inherent isoelectric points, which change depending on the GlcA/GlcN ratios. Chain elongation of amyloses from the nonfunctionalized, nonreducing ends of the products through the thermostable -glucan phosphorylase-catalyzed enzymatic polymerization of -d-glucose 1-phosphate monomers is demonstrated to yield amphoteric glycogen hydrogels. The produced hydrogels exhibit pH-responsive behavior.	[Takata, Yusei; Yamamoto, Kazuya; Kadokawa, Jun-ichi] Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, Kagoshima 8900065, Japan	Kadokawa, J (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, 1-21-40 Korimoto, Kagoshima 8900065, Japan.	kadokawa@eng.kagoshima-u.ac.jp					Takata H, 1996, J BACTERIOL, V178, P1600; Heeres A, 1997, CARBOHYD RES, V299, P221, DOI 10.1016/S0008-6215(97)00030-X; Righetti PG, 2004, J CHROMATOGR A, V1037, P491, DOI 10.1016/j.chroma.2003.11.025; Ohdan K, 2006, BIOCATAL BIOTRANSFOR, V24, P77, DOI 10.1080/10242420600598152; Kadokawa J, 2011, CHEM REV, V111, P4308, DOI 10.1021/cr100285v; Takata H, 1996, CARBOHYD RES, V295, P91, DOI 10.1016/S0008-6215(96)90126-3; Nawaji M, 2008, CARBOHYD RES, V343, P2692, DOI 10.1016/j.carres.2008.08.013; Takemoto Y, 2013, CARBOHYD RES, V366, P38, DOI 10.1016/j.carres.2012.11.007; Yanase M, 2005, APPL ENVIRON MICROB, V71, P5433, DOI 10.1128/AEM.71.9.5433-5439.2005; Takata H, 2009, CARBOHYD RES, V344, P654, DOI 10.1016/j.carres.2009.01.008; Kitaoka M, 2002, TRENDS GLYCOSCI GLYC, V14, P35; ZIEGAST G, 1987, CARBOHYD RES, V160, P185, DOI 10.1016/0008-6215(87)80311-7; Kadokawa J, 2013, TRENDS GLYCOSCI GLYC, V25, P57, DOI 10.4052/tigg.25.57; EISENHABER F, 1992, BIOPOLYMERS, V32, P1643, DOI 10.1002/bip.360321207; Yanase M, 2006, J SCI FOOD AGR, V86, P1631, DOI 10.1002/jsfa.2513; Takata H, 1997, J FERMENT BIOENG, V84, P119, DOI 10.1016/S0922-338X(97)82539-1; Umegatani Y, 2012, CARBOHYD RES, V350, P81, DOI 10.1016/j.carres.2011.12.022; HINRICHS W, 1987, SCIENCE, V238, P205, DOI 10.1126/science.238.4824.205; Bhuiyan SH, 2003, J MOL CATAL B-ENZYM, V22, P173, DOI 10.1016/S1381-1177(03)00029-8; CALDER PC, 1991, INT J BIOCHEM, V23, P1335, DOI 10.1016/0020-711X(91)90274-Q; Izawa H, 2009, MACROMOL BIOSCI, V9, P1098, DOI 10.1002/mabi.200900106; Kadokawa J., 2011, OLIGOSACCHARIDES SOU, P269; Kasapis S, 2009, MODERN BIOPOLYMER SCIENCE: BRIDGING THE DIVIDE BETWEEN FUNDAMENTAL TREATISE AND INDUSTRIAL APPLICATION, pIX, DOI 10.1016/B978-0-12-374195-0.00022-7; MANNERS DJ, 1991, CARBOHYD POLYM, V16, P37, DOI 10.1016/0144-8617(91)90071-J; Schuerch C., 1986, ENCY POLYM SCI ENG, V13, P87; Schulz G.E., 1979, PRINCIPLES PROTEIN S; Takata Y, 2014, MACROMOL BIOSCI, V14, P1437, DOI 10.1002/mabi.201400204	27	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1022-1352	1521-3935		MACROMOL CHEM PHYS	Macromol. Chem. Phys.	JUL	2015	216	13					1415	1420		10.1002/macp.201500151		6	Polymer Science	Polymer Science	CL9ZC	WOS:000357336900007		
J	Maira, B; Chammingkwan, P; Terano, M; Taniike, T				Maira, Bulbul; Chammingkwan, Patchanee; Terano, Minoru; Taniike, Toshiaki			New Reactor Granule Technology for Highly Filled Nanocomposites: Effective Flame Retardation of Polypropylene/Magnesium Hydroxide Nanocomposites	MACROMOLECULAR MATERIALS AND ENGINEERING			English	Article						additive-free dispersion; flame retardance; highly filled polymer nanocomposites; nanocomposites; polyolefins	MAGNESIUM-HYDROXIDE; MECHANICAL-PROPERTIES; G-MA; COMPOSITES; CRYSTALLIZATION; BEHAVIOR	A novel additive-free reactor granule technology is reported for the fabrication of polyolefin-based nanocomposites, which involves in situ generation of nanoparticles with unprecedented dispersion even at high filler loadings. Polypropylene reactor powder obtained by catalyzed propylene polymerization is first impregnated with magnesium ethoxide (Mg(OEt)(2)) solution. After the solvent drying and pre-hydrolysis, the powder is melt mixed to convert partially hydrolyzed Mg(OEt)(2) into magnesium hydroxide (Mg(OH)(2)). Thus, prepared PP/Mg(OH)(2) composites exhibit uniform dispersion of the in situ formed Mg(OH)(2) nanoparticles even at a high filler loading (e.g., 20wt%) without the use of dispersants, which is unexpected for the combination of hydrophilic filler and hydrophobic matrices. The obtained nanocomposites significantly improve the flame retardancy at a filler loading much lower than those for conventional composites.	[Maira, Bulbul; Chammingkwan, Patchanee; Terano, Minoru; Taniike, Toshiaki] Japan Adv Inst Sci & Technol, Sch Mat Sci, Nomi, Ishikawa 9231292, Japan	Taniike, T (reprint author), Japan Adv Inst Sci & Technol, Sch Mat Sci, 1-1 Asahidai, Nomi, Ishikawa 9231292, Japan.	taniike@jaist.ac.jp					Ghanbari D, 2013, COMPOS PART B-ENG, V45, P550, DOI 10.1016/j.compositesb.2012.09.007; Lim JW, 2006, POLYM INT, V55, P204, DOI 10.1002/pi.1942; Rothon RN, 1996, POLYM DEGRAD STABIL, V54, P383, DOI 10.1016/S0141-3910(96)00067-5; Braun U, 2004, MACROMOL CHEM PHYS, V205, P2185, DOI 10.1002/macp.200400255; Lu HD, 2004, MACROMOL MATER ENG, V289, P984, DOI 10.1002/mame.200400165; Jung HS, 2003, J COLLOID INTERF SCI, V259, P127, DOI 10.1016/S0021-9797(03)00034-1; Morlat S, 2004, CHEM MATER, V16, P377, DOI 10.1021/cm031079k; Tai CM, 2001, J APPL POLYM SCI, V80, P2718, DOI 10.1002/app.1386; Mailhot B, 2003, POLYM DEGRAD STABIL, V82, P163, DOI 10.1016/S0141-3910(03)00179-4; Chen XL, 2009, J MATER SCI, V44, P1324, DOI 10.1007/s10853-009-3273-6; Liu SP, 2009, COMPOS SCI TECHNOL, V69, P1873, DOI 10.1016/j.compscitech.2009.04.004; Hasegawa N, 2000, J APPL POLYM SCI, V78, P1918, DOI 10.1002/1097-4628(20001209)78:11<1918::AID-APP100>3.0.CO;2-H; Huang X., 2004, IEEE T DIELECT EL IN, V11, P797; Lin ZD, 2004, J APPL POLYM SCI, V91, P3899, DOI 10.1002/app.13595; Mguni LL, 2013, J SOL-GEL SCI TECHN, V66, P91, DOI 10.1007/s10971-013-2971-3; Oyama HT, 2011, J MACROMOL SCI B, V50, P463, DOI 10.1080/00222341003780996; Pavlidou E, 2005, J PHYS CONF SER, V10, P190, DOI [10.1088/1742-6596/10/1/047, 10.1088/1742/6596/10/1/047]; Peponi L, 2014, MAT SCI ENG R, V85, P1, DOI 10.1016/j.mser.2014.08.002; Shen L, 2012, COMPOS PART A-APPL S, V43, P1177, DOI 10.1016/j.compositesa.2012.02.014; Titelman GI, 2002, POLYM DEGRAD STABIL, V77, P345, DOI 10.1016/S0141-3910(02)00064-2; Wang Y, 2005, J APPL POLYM SCI, V97, P1667, DOI 10.1002/app.21557	21	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1438-7492	1439-2054		MACROMOL MATER ENG	Macromol. Mater. Eng.	JUL	2015	300	7					679	683		10.1002/mame.201500012		5	Materials Science, Multidisciplinary; Polymer Science	Materials Science; Polymer Science	CM0WR	WOS:000357400400002		
J	Takei, S; Yokoyama, Y; Hanabata, M				Takei, Satoshi; Yokoyama, Yoshiyuki; Hanabata, Makoto			Nanomorphology of Polymer Blends for a Light-Scattering Thermosetting Plate Based on Self-Assembly	MACROMOLECULAR MATERIALS AND ENGINEERING			English	Article						light-scattering plate; non-nanoparticles; self-assembly	LIQUID-CRYSTAL DISPLAY; FLUORESCENT LAMPS; BACKLIGHT SYSTEM; NANOCOMPOSITES; NANOPARTICLES; FABRICATION; COMPOSITES	An approach to optical plate production using the nanomorphology of polymer blends in light-scattering thermosetting plates based on self-assembly was investigated without using the conventional approach of blending nanoparticles such as silica sol, zirconia sol, phosphor, or chromophore into the polymer matrix. For this purpose, two specified polymers having carboxylic acid and epoxy groups were blended using a light-emitting diode for use in liquid crystal displays. The developed light-scattering thermosetting plate containing poly(acrylic acid) with the carboxylic acid at four different weight average molecular weights in a cycloaliphatic epoxy polymer was shown to achieve regular nanoparticles of 30-350nm for light-scattering, light-scattering rates of over 10% at a wavelength of 300nm, a thermal stability up to 230 degrees C, O-2 gas barrier properties approximately 50 times smaller than that of polyethylene, and solvent resistance after polymerizing.	[Takei, Satoshi; Hanabata, Makoto] Toyama Prefectural Univ, Ecomat Engn, Toyama 9390398, Japan; [Takei, Satoshi] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan; [Yokoyama, Yoshiyuki] Toyama Ind Technol Ctr, Toyama 9390866, Japan	Takei, S (reprint author), Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan.	takeis@pu-toyama.ac.jp			JSPS [25790036]; JSPS Bilateral Joint Research Projects [14039901-000025]; Regional Innovation Strategy Support Program Toyama Nanotech Cluster of Ministry of Education, Culture, Sports, Science and Technology, Japan; Asahi Glass Foundation; Iketani Science and Technology Foundation; Tokyo Ohka Foundation; Die and Mould Technology Promotion Foundation; Amada Foundation	The author is deeply grateful to Professor C. Grant Willson of the University of Texas at Austin for encouragement. This work was supported by JSPS Grant-in-Aid for scientific research no. 25790036, JSPS Bilateral Joint Research Projects No. 14039901-000025, and Regional Innovation Strategy Support Program Toyama Nanotech Cluster 2014 of Ministry of Education, Culture, Sports, Science and Technology, Japan. This project was also partially supported by The Asahi Glass Foundation, The Iketani Science and Technology Foundation, The Tokyo Ohka Foundation, The Die and Mould Technology Promotion Foundation, and The Amada Foundation.	Agabekov V. E., 2007, INT C LAS APPL TECHN; Xiong Y, 2013, OPT COMMUN, V296, P41, DOI 10.1016/j.optcom.2013.01.045; Song SS, 2013, APPL SURF SCI, V273, P652, DOI 10.1016/j.apsusc.2013.02.103; Demir MM, 2007, MACROMOLECULES, V40, P1089, DOI 10.1021/ma062184t; Takei S, 2007, JPN J APPL PHYS 1, V46, P949, DOI 10.1143/JJAP.46.949; Tagaya A, 2001, APPL OPTICS, V40, P6274, DOI 10.1364/AO.40.006274; Takei S, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4732092; Lin FC, 2012, J DISP TECHNOL, V8, P699, DOI 10.1109/JDT.2012.2215839; Lin CH, 2009, J DISP TECHNOL, V5, P323, DOI 10.1109/JDT.2009.2023606; Kim YJ, 2010, LANGMUIR, V26, P7555, DOI 10.1021/la904362x; Park HG, 2011, SOFT MATTER, V7, P5610, DOI 10.1039/c1sm05083d; Cho D, 2011, J DISP TECHNOL, V7, P29, DOI 10.1109/JDT.2010.2090338; Cho GS, 2005, IEEE T PLASMA SCI, V33, P1410, DOI 10.1109/TPS.2005.852434; Demirel I, 2014, IEEE T POWER ELECTR, V29, P3514, DOI 10.1109/TPEL.2013.2278715; de Oliveira PW, 2010, ADV ENG MATER, V12, P349, DOI 10.1002/adem.201000116; Hinotani K., 1988, DISPL RES C 1988 198, P52; Jamil M, 2011, CURR SCI INDIA, V101, P1544; Kim BS, 2012, POLYM BULL, V68, P2097, DOI 10.1007/s00289-011-0668-8; Kim CG, 2007, IEEE T IND ELECTRON, V54, P365, DOI 10.1109/TIE.2006.885146; Kumakura T., 2012, SID S, P780; Liu Y, 2010, MACROMOL RAPID COMM, V31, P1509, DOI 10.1002/marc.201000337; Mikhailova Nadezhda V, 2010, 2010 11th International Conference and Seminar on Micro/Nanotechnologies and Electron Devices (EDM 2010), DOI 10.1109/EDM.2010.5568810; MONTGOMERY GP, 1987, APPL OPTICS, V26, P738, DOI 10.1364/AO.26.000738; Moon HS, 2010, MOL CRYST LIQ CRYST, V531, P90, DOI 10.1080/15421406.2010.499335; Nakazaki S., 2004, ELECT IMAGING, P50; Park SR, 2007, OPT EXPRESS, V15, P2888, DOI 10.1364/OE.15.002888; SanaLim G., 2014, J MAT CHEM C; Takei S, 2013, J MICRO-NANOLITH MEM, V12, DOI 10.1117/1.JMM.12.3.031113; Urakabe T., 1996, J LIGHT VIS ENV, V20, P20, DOI 10.2150/jlve.20.2_20; Wang C., 2013, J NANOPART RES, V15, P1; Wang JH, 2009, OPT LASER TECHNOL, V41, P804, DOI 10.1016/j.optlastec.2008.12.005; Winsor M., 2007, SID S, P979; Yang B., 2002, ELECT IMAGING, P226; Zhang Y., 2010, VAC EL SOURC C NAN I, P141	34	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1438-7492	1439-2054		MACROMOL MATER ENG	Macromol. Mater. Eng.	JUL	2015	300	7					730	736		10.1002/mame.201500025		7	Materials Science, Multidisciplinary; Polymer Science	Materials Science; Polymer Science	CM0WR	WOS:000357400400007		
J	Bednarowicz, M; Dobosz, B; Krzyminiewski, R; Halupka-Bryl, M; Deptula, T; Nagasaki, Y				Bednarowicz, M.; Dobosz, B.; Krzyminiewski, R.; Halupka-Bryl, M.; Deptula, T.; Nagasaki, Y.			ESR studies of redox-active PMNT-PEG-PMNT polymer	MATERIALS CHEMISTRY AND PHYSICS			English	Article						Electron paramagnetic resonance (EPR); Polymers; Crystal structure; Computer modelling and simulation	ANTIOXIDANT PROPERTIES; NANOPARTICLES; SPECTRA; ENHANCEMENT; RESOLUTION; NITROXIDE; RESONANCE; RADICALS; DYNAMICS; EPR	The paper presents the electron spin resonance (ESR) measurements of nitroxide radical-containing PMNT-PEG-PMNT triblock copolymer in different solvents: water, dimethyl formamide (DMF) and chloroform. Temperature dependence of electron spin resonance spectra were measured for each probe and several spectroscopic parameters describing physical properties, such as g-spectroscopic splitting factor value, resonance field (H-r), peak-to-peak line width (Delta H-pp) and correlation time (tau) were calculated and discussed. For the determination of the parameters characterizing the dynamics of TEMPO radicals in complex spectra the computer resolution enhancement method (CREM) and EasySpin software for ESR spectra simulations were used. (C) 2015 Elsevier B.V. All rights reserved.	[Bednarowicz, M.; Dobosz, B.; Krzyminiewski, R.; Halupka-Bryl, M.; Deptula, T.] Adam Mickiewicz Univ, Dept Phys, NanoBioMed Ctr, Med Phys Div, PL-61614 Poznan, Poland; [Nagasaki, Y.] Univ Tsukuba, Grad Sch Pure & Appl Sci, Dept Mat Sci, Tsukuba, Ibaraki 3058573, Japan; [Nagasaki, Y.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Masters Sch Med Sci, Tsukuba, Ibaraki 3058575, Japan; [Nagasaki, Y.] Univ Tsukuba, Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Satellite Lab, Tsukuba, Ibaraki 3058573, Japan	Bednarowicz, M (reprint author), Adam Mickiewicz Univ, Dept Phys, NanoBioMed Ctr, Med Phys Div, Umultowska 85 St, PL-61614 Poznan, Poland.	magda.bednarowicz@gmail.com			International PhD Projects Program of Foundation for Polish Science [MPD/2009-3/3]; European Regional Development Fund	Three of the authors (M. B., M.H.-B. and T.D.) were financially supported by the International PhD Projects Program of Foundation for Polish Science (grant no. MPD/2009-3/3) operated within the Innovative Economy Operational Programme (IE OP) 2007-2013 within European Regional Development Fund.	Yoshitomi T, 2011, BIOMATERIALS, V32, P8021, DOI 10.1016/j.biomaterials.2011.07.014; Bajaj I, 2011, BIORESOURCE TECHNOL, V102, P5551, DOI 10.1016/j.biortech.2011.02.047; van Lith R, 2014, BIOMATERIALS, V35, P8113, DOI 10.1016/j.biomaterials.2014.06.004; KIVELSON D, 1960, J CHEM PHYS, V33, P1094, DOI 10.1063/1.1731340; Chechik V, 2004, FARADAY DISCUSS, V125, P279, DOI 10.1039/b302730a; Pua ML, 2013, J CONTROL RELEASE, V172, P914, DOI 10.1016/j.jconrel.2013.10.009; Zhao QL, 2006, FREE RADICAL BIO MED, V40, P1131, DOI 10.1016/j.freeradbiomed.2005.10.064; Flory PI, 1942, J CHEM PHYS, V10, P51, DOI 10.1063/1.1723621; Dobosz B, 2014, J PHYS CHEM SOLIDS, V75, P594, DOI 10.1016/j.jpcs.2014.01.013; Li JK, 1998, J CONTROL RELEASE, V56, P117, DOI 10.1016/S0168-3659(98)00089-3; Huggins ML, 1941, J CHEM PHYS, V9, P440, DOI 10.1063/1.1750930; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; Yoshitomi T, 2009, BIOMACROMOLECULES, V10, P596, DOI 10.1021/bm801278n; Stoll S, 2006, J MAGN RESON, V178, P42, DOI 10.1016/j.jmr.2005.08.013; Kempe S, 2010, EUR J PHARM BIOPHARM, V74, P55, DOI 10.1016/j.ejpb.2009.08.007; Athanasiou K. A., 1996, BIOMATERIALS, V17; Caillol S, 2003, MACROMOLECULES, V36, P1118, DOI 10.1021/ma021187c; Chechik V., APPL MAGNETIC RESONA, V40, P311; Earle K. A., 2006, ADV ESR METHODS POLY, ppp53, DOI 10.1002/047005350X.ch3; Fridovich J., 1978, SCIENCE, P875; HEDBERG A, 1968, J CHEM PHYS, V48, P4822, DOI 10.1063/1.1668089; Kashiwabara H., 1987, ADV POLYM SCI, V82, P143; Kayal S, 2010, MAT SCI ENG C-MATER, V30, P484, DOI 10.1016/j.msec.2010.01.006; Koper A., 1985, ACTA MAGNETICA, VII, P3; Krzyminiewski R, 1994, MOL PHYS REP, V6, P174; Krzyminiewski R, 1998, J MOL STRUCT, V471, P243, DOI 10.1016/S0022-2860(98)00442-6; Madisetti V. K., 1998, DIGITAL SIGNAL PROCE; Mitchell J. B., 2005, CANCER, V103, P1302; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; Simonsen U, 2009, PHARMACOL THERAPEUT, V122, P109, DOI 10.1016/j.pharmthera.2009.02.002; Upadhyay J, 2013, MATER LETT, V102, P33, DOI 10.1016/j.matlet.2013.03.099; Weil J. A., 2007, ELECT PARAMAGNETIC R; Yang J, 2014, BIOMACROMOLECULES, V15, P3942, DOI 10.1021/bm5010004; Yoshitomi T, 2009, BIOCONJUGATE CHEM, V20, P1792, DOI 10.1021/bc900214f; Zhou L, 2000, POLYMER, V41, P4679, DOI 10.1016/S0032-3861(99)00605-9	35	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0254-0584	1879-3312		MATER CHEM PHYS	Mater. Chem. Phys.	JUL 1	2015	161						250	255		10.1016/j.matchemphys.2015.05.045		6	Materials Science, Multidisciplinary	Materials Science	CL7GD	WOS:000357139600031		
J	Saito, KS; Tanaka, R				Saito, Kichi-Suke; Tanaka, Ryotaro			New geometric properties of Banach spaces	MATHEMATISCHE NACHRICHTEN			English	Article						Absolute norms; psi-uniform smoothness; psi*-uniform convexity; Generalized Beckner's inequalities	ABSOLUTE NORMS; DIRECT SUMS; SMOOTHNESS; C-2	In this paper, we introduce new geometric properties as generalizations of p-uniform smoothness and q-uniform convexity of Banach spaces. Furthermore, using generalized Beckner's inequality, we characterize the properties in terms of norm inequalities. As an application, we consider the duality relation. (C) 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim	[Saito, Kichi-Suke] Niigata Univ, Dept Math, Fac Sci, Niigata 9502181, Japan; [Tanaka, Ryotaro] Niigata Univ, Grad Sch Sci & Technol, Dept Math Sci, Niigata 9502181, Japan	Saito, KS (reprint author), Niigata Univ, Dept Math, Fac Sci, Niigata 9502181, Japan.	saito@math.sc.niigata-u.ac.jp; ryotarotanaka@m.sc.niigata-u.ac.jp					BECKNER W, 1975, ANN MATH, V102, P159, DOI 10.2307/1970980; Takahashi Y, 2002, J INEQUAL APPL, V7, P179, DOI 10.1080/10255830290019762; Beauzamy B, 1985, INTRO BANACH SPACES; Bhatia R, 1997, MATRIX ANAL; Duncan J, 1973, NUMERICAL RANGES 2; Lindenstrauss J., 1979, CLASSICAL BANACH SPA; Mitani KI, 2005, MATH INEQUAL APPL, V8, P147; Mitani KI, 2003, J CONVEX ANAL, V10, P89; Mitani KI, 2009, NONLINEAR ANAL-THEOR, V71, P5238, DOI 10.1016/j.na.2009.04.007; Saito KS, 2015, ANN FUNCT ANAL, V6, P267, DOI 10.15352/afa/06-1-20; Saito KS, 2000, J MATH ANAL APPL, V244, P515, DOI 10.1006/jmaa.2000.6727; Saito KS, 2000, J MATH ANAL APPL, V252, P879, DOI 10.1006/jmaa.2000.7139; Takahashi Y, 2002, J NONLINEAR CONVEX A, V3, P267; Tanaka R, 2013, J MATH INEQUAL, V7, P543, DOI 10.7153/jmi-07-50	14	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0025-584X	1522-2616		MATH NACHR	Math. Nachr.	JUL	2015	288	10					1163	1178		10.1002/mana.201400180		16	Mathematics	Mathematics	CL9GD	WOS:000357284000006		
J	Tong, T; Wolz, R; Wang, ZH; Gao, QQ; Misawa, K; Fujiwara, M; Mori, K; Hajnal, JV; Rueckert, D				Tong, Tong; Wolz, Robin; Wang, Zehan; Gao, Qinquan; Misawa, Kazunari; Fujiwara, Michitaka; Mori, Kensaku; Hajnal, Joseph V.; Rueckert, Daniel			Discriminative dictionary learning for abdominal multi-organ segmentation	MEDICAL IMAGE ANALYSIS			English	Article						Abdominal multi-organ segmentation; Discriminative dictionary learning; Local atlas selection; Patch based	BRAIN MRI SEGMENTATION; ACTIVE SHAPE MODELS; CT IMAGES; AUTOMATED SEGMENTATION; PROBABILISTIC ATLAS; GRAPH CUTS; LIVER; CONSTRUCTION; HIPPOCAMPUS; REGISTRATION	An automated segmentation method is presented for multi-organ segmentation in abdominal CT images. Dictionary learning and sparse coding techniques are used in the proposed method to generate target specific priors for segmentation. The method simultaneously learns dictionaries which have reconstructive power and classifiers which have discriminative ability from a set of selected atlases. Based on the learnt dictionaries and classifiers, probabilistic atlases are then generated to provide priors for the segmentation of unseen target images. The final segmentation is obtained by applying a post-processing step based on a graph-cuts method. In addition, this paper proposes a voxel-wise local atlas selection strategy to deal with high Inter-subject variation in abdominal CT images. The segmentation performance of the proposed method with different atlas selection strategies are also compared. Our proposed method has been evaluated on a database of 150 abdominal CT images and achieves a promising segmentation performance with Dice overlap values of 94.9%, 93.6%, 71.1%, and 92.5% for liver, kidneys, pancreas, and spleen, respectively. (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Tong, Tong; Wolz, Robin; Wang, Zehan; Gao, Qinquan; Rueckert, Daniel] Univ London Imperial Coll Sci Technol & Med, Biomed Image Anal Grp, Dept Comp, London SW7 2AZ, England; [Misawa, Kazunari] Aichi Canc Ctr, Nagoya, Aichi 4648681, Japan; [Fujiwara, Michitaka] Nagoya Univ Hosp, Nagoya, Aichi 4660065, Japan; [Mori, Kensaku] Nagoya Univ, Informat & Commun, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Hajnal, Joseph V.] Kings Coll London, St Thomas Hosp, Div Imaging Sci & Biomed Engn, Ctr Developing Brain, London SE1 7EH, England	Tong, T (reprint author), Univ London Imperial Coll Sci Technol & Med, Biomed Image Anal Grp, Dept Comp, 180 Queens Gate, London SW7 2AZ, England.	t.tong11@imperial.ac.uk					Aharon M, 2006, IEEE T SIGNAL PROCES, V54, P4311, DOI 10.1109/TSP.2006.881199; Park H, 2003, IEEE T MED IMAGING, V22, P483, DOI 10.1109/TMI.2003.809139; Rousseau F, 2011, IEEE T MED IMAGING, V30, P1852, DOI 10.1109/TMI.2011.2156806; Shi F, 2010, NEUROIMAGE, V51, P684, DOI 10.1016/j.neuroimage.2010.02.025; Linguraru MG, 2012, MED IMAGE ANAL, V16, P904, DOI 10.1016/j.media.2012.02.001; Linguraru MG, 2010, MED PHYS, V37, P771, DOI 10.1118/1.3284530; Wimmer A, 2009, LECT NOTES COMPUT SC, V5762, P26; Aljabar P, 2009, NEUROIMAGE, V46, P726, DOI 10.1016/j.neuroimage.2009.02.018; Shimizu A, 2010, INT J COMPUT ASS RAD, V5, P85, DOI 10.1007/s11548-009-0384-0; van der Lijn F, 2008, NEUROIMAGE, V43, P708, DOI 10.1016/j.neuroimage.2008.07.058; Spiegel M, 2009, COMPUT MED IMAG GRAP, V33, P29, DOI 10.1016/j.compmedimag.2008.10.002; Pluim JPW, 2003, IEEE T MED IMAGING, V22, P986, DOI 10.1109/TMI.2003.815867; Wolz R, 2013, IEEE T MED IMAGING, V32, P1723, DOI 10.1109/TMI.2013.2265805; Cao YH, 2011, LECT NOTES COMPUT SC, V6893, P272; Shimizu A, 2007, INT J COMPUT ASS RAD, V2, P135, DOI 10.1007/s11548-007-0135-z; Wolz R, 2009, 2009 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: FROM NANO TO MACRO, VOLS 1 AND 2, P470, DOI 10.1109/ISBI.2009.5193086; van Rikxoort EM, 2010, MED IMAGE ANAL, V14, P39, DOI 10.1016/j.media.2009.10.001; Chen XJ, 2012, IEEE T IMAGE PROCESS, V21, P2035, DOI 10.1109/TIP.2012.2186306; Heckemann RA, 2006, NEUROIMAGE, V33, P115, DOI 10.1016/j.neuroimage.2006.05.061; Tong T, 2013, NEUROIMAGE, V76, P11, DOI 10.1016/j.neuroimage.2013.02.069; Wolz R, 2010, NEUROIMAGE, V49, P1316, DOI 10.1016/j.neuroimage.2009.09.069; Okada T, 2008, ACAD RADIOL, V15, P1390, DOI 10.1016/j.acra.2008.07.008; Heimann T, 2009, IEEE T MED IMAGING, V28, P1251, DOI 10.1109/TMI.2009.2013851; Coupe P, 2011, NEUROIMAGE, V54, P940, DOI 10.1016/j.neuroimage.2010.09.018; Awate SP, 2014, IEEE T MED IMAGING, V33, P1803, DOI 10.1109/TMI.2014.2321281; Bagci U, 2012, IEEE T MED IMAGING, V31, P777, DOI 10.1109/TMI.2011.2180920; Cerrolaza JJ, 2014, LECT NOTES COMPUT SC, V8675, P1, DOI 10.1007/978-3-319-10443-0_1; Chu C., 2013, MED IMAGE COMPUTING, V8150, P165; COOTES TF, 1995, COMPUT VIS IMAGE UND, V61, P38, DOI 10.1006/cviu.1995.1004; Eskildsen S., 2011, NEUROIMAGE, V59, P2362, DOI [DOI 10.1016/J.NEUROIMAGE.2011.09.012, 10.1016/j.neuroimage.2011.09.012]; Gao LM, 1998, INVEST RADIOL, V33, P348, DOI 10.1097/00004424-199806000-00006; Heimann T, 2006, LECT NOTES COMPUT SC, V4191, P41; Liu F, 2004, P SOC PHOTO-OPT INS, V5370, P1466, DOI 10.1117/12.535276; Mairal J., 2009, P 26 ANN INT C MACH, P689, DOI DOI 10.1145/1553374.1553463; Oda M., 2012, LNCS, V7029, P181; Okada T., 2012, LECT NOTES COMPUTER, V7029, P173; Okada T, 2013, LECT NOTES COMPUT SC, V8151, P275, DOI 10.1007/978-3-642-40760-4_35; Okada T, 2008, LECT NOTES COMPUT SC, V5241, P502, DOI 10.1007/978-3-540-85988-8_60; Shimizu A, 2011, LECT NOTES COMPUT SC, V6533, P214, DOI 10.1007/978-3-642-18421-5_21; Ta VT, 2014, LECT NOTES COMPUT SC, V8675, P105; Wang HK, 2012, IEEE T MED IMAGING, V31, P88, DOI 10.1109/TMI.2011.2165294; Wang LC, 2010, LECT NOTES COMPUT SC, V6326, P21; Wang ZH, 2014, LECT NOTES COMPUT SC, V8673, P666; Wang ZH, 2013, LECT NOTES COMPUT SC, V8184, P98	44	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1361-8415	1361-8423		MED IMAGE ANAL	Med. Image Anal.	JUL	2015	23	1					92	104		10.1016/j.media.2015.04.015		13	Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	CM0EQ	WOS:000357351600008		
J	Zywicki, P; Ping, DH; Abe, T; Garbacz, H; Yamabe-Mitarai, Y; Kurzydlowski, KJ				Zywicki, P.; Ping, D. H.; Abe, T.; Garbacz, H.; Yamabe-Mitarai, Y.; Kurzydlowski, K. J.			Effect of Pd Addition on the Microstructure of Ti-30Nb Alloy	METALS AND MATERIALS INTERNATIONAL			English	Article						shape memory alloys; microstructure; twinning; phase transformation; transmission electron microscopy (TEM)	INDUCED OMEGA PHASE; TI-V ALLOYS; TENSILE PROPERTIES; DEFORMATION-BEHAVIOR; TITANIUM-ALLOYS; BETA; MARTENSITE; TRANSFORMATION; STABILITY; MO	The effect of Pd addition on deformation mechanisms, phase transitions and twinning has been extensively investigated in as-cast beta-type Ti-30Nb (wt%) alloy using electron backscattered diffraction and transmission electron microscopy techniques. The addition of Pd resulted in refinement of the metastable omega phase. The {112}<111>-type twinning was found to strongly depend on the size of the omega particles. No beta phase twins were observed in the binary alloy with larger omega particles. In the ternary alloy with much finer omega particles, {332}<113> and abundant {112}<111>-type twins were detected. On the contrary, the volume fraction of stress-induced alpha" martensite in the binary alloy was higher than that in the ternary one. Based on the analysis of phase diagrams and Gibbs free energy calculations, such complex phase transition and twinning phenomena have been explained in terms of relative phase stability between the omega particles and the beta matrix.	[Zywicki, P.; Garbacz, H.; Kurzydlowski, K. J.] Warsaw Univ Technol, Fac Mat Sci & Engn, PL-02507 Warsaw, Poland; [Zywicki, P.; Ping, D. H.; Abe, T.; Yamabe-Mitarai, Y.] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050047, Japan	Zywicki, P (reprint author), Warsaw Univ Technol, Fac Mat Sci & Engn, Woloska 141, PL-02507 Warsaw, Poland.	p.zywicki@inmat.pw.edu.pl					FROST PD, 1954, T AM SOC METAL, V46, P231; Cheng GM, 2013, SCRIPTA MATER, V68, P130, DOI 10.1016/j.scriptamat.2012.09.033; Hsiung LM, 2000, ACTA MATER, V48, P4851, DOI 10.1016/S1359-6454(00)00287-1; Tobe H, 2014, ACTA MATER, V64, P345, DOI 10.1016/j.actamat.2013.10.048; Greninger AB, 1935, NATURE, V135, P916, DOI 10.1038/135916c0; Ping DH, 2014, ACTA METALL SIN-ENGL, V27, P1, DOI 10.1007/s40195-013-0014-2; GIESSEN BC, 1980, METALL TRANS A, V11, P709, DOI 10.1007/BF02661200; Ping DH, 2013, MATER CHEM PHYS, V139, P830, DOI 10.1016/j.matchemphys.2013.02.040; PRASETYO A, 1976, ACTA METALL MATER, V24, P1009, DOI 10.1016/0001-6160(76)90131-0; CHRISTIAN JW, 1995, PROG MATER SCI, V39, P1, DOI 10.1016/0079-6425(94)00007-7; DINSDALE AT, 1991, CALPHAD, V15, P317, DOI 10.1016/0364-5916(91)90030-N; SIKKA SK, 1982, PROG MATER SCI, V27, P245, DOI 10.1016/0079-6425(82)90002-0; DUERIG TW, 1980, METALL TRANS A, V11, P1987, DOI 10.1007/BF02655118; YEDNERAL AF, 1972, PHYS MET METALLOGR, V33, P89; AYER R, 1992, METALL TRANS A, V23, P2447, DOI 10.1007/BF02658048; Wu SQ, 2014, ACTA MATER, V62, P122, DOI 10.1016/j.actamat.2013.09.040; HICKMAN BS, 1969, J MATER SCI, V4, P554, DOI 10.1007/BF00550217; Abdel-Hady M, 2006, SCRIPTA MATER, V55, P477, DOI 10.1016/j.scriptamat.2006.04.022; HANADA S, 1987, METALL TRANS A, V18, P265, DOI 10.1007/BF02825707; Ping DH, 2006, SCRIPTA MATER, V54, P1305, DOI 10.1016/j.scriptamat.2005.12.022; Min XH, 2012, MAT SCI ENG A-STRUCT, V554, P53, DOI 10.1016/j.msea.2012.06.009; Ahmed M, 2015, ACTA MATER, V84, P124, DOI 10.1016/j.actamat.2014.10.043; Biesiekierski A, 2014, MATER DESIGN, V59, P303, DOI 10.1016/j.matdes.2014.02.058; Shao G, 2000, ACTA MATER, V48, P3671, DOI 10.1016/S1359-6454(00)00168-3; MOFFAT DL, 1988, METALL TRANS A, V19, P2389, DOI 10.1007/BF02645466; Arciniegas M, 2008, PHILOS MAG, V88, P2529, DOI 10.1080/14786430802375667; Balluffi R. W., 1980, GRAIN BOUNDARY STRUC, P448; Chandrasekharaiah M. S., 1988, B ALLOY PHASE DIAGRA, V9, P449, DOI 10.1007/BF02881865; Chen S. L., 2002, CALPHAD, V26, P188; Cui CY, 2009, J ALLOY COMPD, V471, P248, DOI 10.1016/j.jallcom.2008.03.057; DEFONTAI.D, 1970, ACTA METALL MATER, V18, P275, DOI 10.1016/0001-6160(70)90035-0; FEENEY JA, 1970, METALL TRANS, V1, P3309; Furuhara T., 1994, T MAKI MAT T, V12, P843; Guo CP, 2011, CALPHAD, V35, P512, DOI 10.1016/j.calphad.2011.07.004; Hall E. O., 1954, TWINNING DIFFUSIONLE, P1; Hirth J. P., 1992, THOERY DISLOCATIONS, P811; Klassen-Nekhlyudova M. V., 1964, MECH TWINNING CRYSTA, P106; Li L, 2015, J ALLOY COMPD, V625, P188, DOI 10.1016/j.jallcom.2014.11.082; Lin DJ, 2002, MATER CHEM PHYS, V76, P191, DOI 10.1016/S0254-0584(01)00511-9; Liu L., 2011, PHYS REV LETT, V106, P636; Morinaga M., 1988, P 6 WORLD C TIT CANN, P1601; O'Neill H., 1928, J IRON STEEL I, V117, P689; OKA M, 1978, J JPN I MET, V42, P814; PARIS HG, 1976, METALL TRANS A, V7, P273, DOI 10.1007/BF02644467; SASS SL, 1969, ACTA METALL MATER, V17, P813, DOI 10.1016/0001-6160(69)90100-X; SILCOCK JM, 1958, ACTA METALL MATER, V6, P481, DOI 10.1016/0001-6160(58)90111-1; Talling RJ, 2009, ACTA MATER, V57, P1188, DOI 10.1016/j.actamat.2008.11.013; WASILEWS.RJ, 1970, METALL TRANS, V1, P2641; WASILEWSKI RJ, 1977, METALL TRANS A, V8, P391, DOI 10.1007/BF02661747; Yang Y, 2008, SCRIPTA MATER, V58, P9, DOI 10.1016/j.scriptamat.2007.09.010	50	0	0	KOREAN INST METALS MATERIALS	SEOUL	KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881, SOUTH KOREA	1598-9623	2005-4149		MET MATER INT	Met. Mater.-Int.	JUL	2015	21	4					617	622		10.1007/s12540-015-4593-5		6	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CM0EP	WOS:000357351500001		
J	Lee, JS; Maruyama, K				Lee, J. S.; Maruyama, K.			Mechanism of Microstructural Deterioration Preceding Type IV Failure in Weldment of Mod.9Cr-1Mo Steel	METALS AND MATERIALS INTERNATIONAL			English	Article						alloy; creep; embrittlement; fracture; microstructure	HIGH CR STEEL; MARTENSITIC STEEL; CREEP; BEHAVIOR; CRACKING; HAZ	The objective of the present study was to elucidate the cavity formation mechanism of Type IV failure in weldment of advanced high-Cr ferritic steels. A welded joint of Mod.9Cr-1Mo steel was creep tested at 650 degrees C under 83 MPa. The creep fracture mode was Type IV failure in the heat affect zone (HAZ). Microstructural characterization of the HAZ and the fracture location, were performed before and after the creep test. The Type IV cracking started in the inter-critical HAZ at a location having fine grain size and coarse M23C6 precipitates. Moreover, the grain structure of the inter-critical HAZ, which is a mixture of soft alpha and hard alpha' grains, plays an important role in the stage of cavity evolution into a crack along the grain boundary. This is due to the heterogeneity of local strain between the two kinds of grains. By a synergistic effect of the strain concentration, the coarse precipitates and heterogeneous strain distribution among grains in the inter critical HAZ, facilitates the nucleation and growth of creep cavities, resulting in premature failure of welded joints.	[Lee, J. S.] Tohoku Univ, Dept Mat Sci, Sendai, Miyagi 9808579, Japan; [Maruyama, K.] Tohoku Univ, Grad Sch Environm Studies, Sendai, Miyagi 9808579, Japan	Lee, JS (reprint author), Tohoku Univ, Dept Mat Sci, Sendai, Miyagi 9808579, Japan.	jslee3@posco.com					Albert SK, 2002, ISIJ INT, V42, P1497, DOI 10.2355/isijinternational.42.1497; Albert SK, 2003, INT J PRES VES PIP, V80, P405, DOI 10.1016/S0308-0161(03)00072-3; Matsui M, 2001, ISIJ INT, V41, pS126, DOI 10.2355/isijinternational.41.Suppl_S126; Tabuchi M, 2001, INT J PRES VES PIP, V78, P779, DOI 10.1016/S0308-0161(01)00090-4; Laha K, 2001, METALL MATER TRANS A, V32, P115, DOI 10.1007/s11661-001-0107-9; Shen YZ, 2014, MET MATER INT, V20, P503, DOI 10.1007/s12540-014-3014-5; Brear JM, 2000, KEY ENG MAT, V171-1, P35; Cerjak H., 1998, C P ADV HEAT RES STE, P541; Cermak J., 1996, SCRIPTA MATER, V35, P441; Ellis F. V., 1998, REV TYPE 4 CRACKING, P125; Evans R. W., 1985, CREEP METALS ALLOYS, P19; Hasegawa Y., 2001, P 3 C ADV MAT TECHN, P457; ISEDA A, 1991, TETSU TO HAGANE, V77, P582; Lee J. S., 2004, P 2 INT C ADV STRUCT, V2, P838; Lee J. S., 2004, P 4 INT S RISK EC SA, P211; Lee Y. M., 2014, MET MATER INT, V20, P223; Letofsky E., 2001, P 3 C ADV MAT TECHN, P133; Maruyama K, 2001, ISIJ INT, V41, P641, DOI 10.2355/isijinternational.41.641; Masuyama F, 2000, KEY ENG MAT, V171-1, P99; Matsui M., 2003, Journal of the Society of Materials Science, Japan, V52; Middleton C. J., 2001, P 3 C ADV MAT TECHN, P69; Suzuki K., 2000, TETSU TO HAGANE, V86, P52; Tabuchi M, 2003, MATER SCI RES INT, V9, P23; Tabuchi M., 2001, J SOC MAT SCI JPN, V50, P116; Viswanathan R., 1989, DAMAGE MECH LIFE ASS, P206	25	1	1	KOREAN INST METALS MATERIALS	SEOUL	KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881, SOUTH KOREA	1598-9623	2005-4149		MET MATER INT	Met. Mater.-Int.	JUL	2015	21	4					639	645		10.1007/s12540-015-4569-5		7	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CM0EP	WOS:000357351500004		
J	Bataev, IA; Hokamoto, K; Keno, H; Bataev, AA; Balagansky, IA; Vinogradov, AV				Bataev, I. A.; Hokamoto, K.; Keno, H.; Bataev, A. A.; Balagansky, I. A.; Vinogradov, A. V.			Metallic Glass Formation at the Interface of Explosively Welded Nb and Stainless Steel	METALS AND MATERIALS INTERNATIONAL			English	Article						joining; solidification; amorphous materials; transmission electron microscopy (TEM); microstructure	WELDING TECHNIQUE; HIGH-PRESSURE; MECHANISM; MULTILAYER; ALLOYS; PLATE	The interface between explosively welded niobium and stainless steel SUS 304 was studied using scanning electron microscopy, transmission electron microscopy and energy dispersive X-Ray spectroscopy. The wavy interface along which vortex zones were located was observed. The vortex zones formed due to the mixing of materials typically had amorphous structure. Inoue's criteria of glass formation were used to explain this result. The effect of the composition, cooling rate and pressure on the glass formation are discussed. The conditions of deformation, heating, and cooling as well as shockwaves propagation were numerically simulated. We show that the conditions of vortex zone formation resemble the conditions of rapid solidification processes. In contrast to the "classical" methods of rapid solidification of melt, the conditions of metastable phase formation during explosive welding are significantly complicated by the fluctuations of composition and pressure. Possible metastable structures formation at the interface of some common explosively joined materials is predicted.	[Bataev, I. A.; Bataev, A. A.; Balagansky, I. A.; Vinogradov, A. V.] Novosibirsk State Tech Univ, Novosibirsk 630092, Russia; [Hokamoto, K.; Keno, H.] Kumamoto Univ, Inst Pulsed Power Sci, Kumamoto 8608555, Japan	Bataev, IA (reprint author), Novosibirsk State Tech Univ, Pr K Marksa 20, Novosibirsk 630092, Russia.	ivanbataev@ngs.ru					BAHRANI AS, 1967, PROC R SOC LON SER-A, V296, P123, DOI 10.1098/rspa.1967.0010; Li XJ, 2012, SCI TECHNOL WELD JOI, V17, P36, DOI 10.1179/1362171811Y.0000000071; ISHIMASA T, 1985, PHYS REV LETT, V55, P511, DOI 10.1103/PhysRevLett.55.511; Kiselev SP, 2012, COMBUST EXPLO SHOCK+, V48, P214, DOI 10.1134/S0010508212020116; Liu WD, 2009, APPL SURF SCI, V255, P9343, DOI 10.1016/j.apsusc.2009.07.033; Inoue A, 2000, ACTA MATER, V48, P279, DOI 10.1016/S1359-6454(99)00300-6; Hokamoto K, 2009, J ALLOY COMPD, V472, P507, DOI 10.1016/j.jallcom.2008.05.002; Manikandan P, 2011, J NUCL MATER, V418, P281, DOI 10.1016/j.jnucmat.2011.07.013; Takeuchi A, 2010, INTERMETALLICS, V18, P1779, DOI 10.1016/j.intermet.2010.06.003; Bataev IA, 2012, MATER DESIGN, V35, P225, DOI 10.1016/j.matdes.2011.09.030; Mousavi AAA, 2005, J MECH PHYS SOLIDS, V53, P2501, DOI 10.1016/j.jmps.2005.06.001; Chiba A, 2004, MATER SCI FORUM, V465-466, P465; Wang X, 2012, MATER DESIGN, V35, P210, DOI 10.1016/j.matdes.2011.09.047; Nishida M, 1995, MATER T JIM, V36, P1338; Honarpisheh M, 2012, MATER DESIGN, V37, P122, DOI 10.1016/j.matdes.2011.12.045; CHEN H, 1988, PHYS REV LETT, V60, P1645, DOI 10.1103/PhysRevLett.60.1645; Baker H., 1992, ASM HDB, V3; Banker J., 1993, EXPLOSION WELDING AS, V6, P303; Bataev I, 2011, ADV MATER RES-SWITZ, V287-290, P108, DOI 10.4028/www.scientific.net/AMR.287-290.108; Bataev IA, 2012, PHYS MET METALLOGR+, V113, P947, DOI 10.1134/S0031918X12070022; Chen S. Y., 2013, J APPL PHYS, V113; Crossland B., 1976, MET TECHNOL, V3, P8; Crossland B., 1982, EXPLOSIVE WELDING ME, P233; Deribas A. A., 1980, PHYS EXPLOSIVE HARDE, P218; Hu Z. Q., 2001, Science and Technology of Advanced Materials, V2, DOI 10.1016/S1468-6996(01)00024-9; Kato H, 2004, APPL PHYS LETT, V85, P2205, DOI 10.1063/1.1790028; Lee K, 2006, MATER TRANS, V47, P1178, DOI 10.2320/matertrans.47.1178; Liu X. R., 2007, APPL PHYS LETT, V91; MAO ZL, 1993, J MATER SCI LETT, V12, P1729, DOI 10.1007/BF00418846; Paul H., 2014, P 12 INT S EXPL PROD, P45; Senkov O. N., 2001, MAT RES B, V36, P2183; Setyawan A. D., 2007, MAT SCI ENG A-STRUCT, V448-451, P903; Xiaojie L., 1993, CHINESE J HIGH PRESS, V7, P214; XU YF, 1990, APPL PHYS LETT, V56, P1957, DOI 10.1063/1.103227; Yan HH, 2008, COMBUST EXPLO SHOCK+, V44, P491, DOI 10.1007/s10573-008-0076-z; Yavari A. R., 2012, PHYS REV LETT, V109	36	1	1	KOREAN INST METALS MATERIALS	SEOUL	KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881, SOUTH KOREA	1598-9623	2005-4149		MET MATER INT	Met. Mater.-Int.	JUL	2015	21	4					713	718		10.1007/s12540-015-5020-7		6	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CM0EP	WOS:000357351500015		
J	Kulak, O; Chen, H; Holohan, B; Wu, XF; He, HW; Borek, D; Otwinowski, Z; Yamaguchi, K; Garofalo, LA; Ma, ZQ; Wright, W; Chen, C; Shay, JW; Zhang, XW; Lum, L				Kulak, Ozlem; Chen, Hua; Holohan, Brody; Wu, Xiaofeng; He, Huawei; Borek, Dominika; Otwinowski, Zbyszek; Yamaguchi, Kiyoshi; Garofalo, Lauren A.; Ma, Zhiqiang; Wright, Woodring; Chen, Chuo; Shay, Jerry W.; Zhang, Xuewu; Lum, Lawrence			Disruption of Wnt/beta-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells	MOLECULAR AND CELLULAR BIOLOGY			English	Article							TERT PROMOTER MUTATIONS; STEM-CELLS; ADP-RIBOSYLATION; STRUCTURAL BASIS; CANCER; MELANOMA; VARIANTS; TRF1; DIFFERENTIATION; THERAPEUTICS	Maintenance of chromosomal ends (telomeres) directly contributes to cancer cell immortalization. The telomere protection enzymes belonging to the tankyrase (Tnks) subfamily of poly(ADP-ribose) polymerases (PARPs) have recently been shown to also control transcriptional response to secreted Wnt signaling molecules. Whereas Tnks inhibitors are currently being developed as therapeutic agents for targeting Wnt-related cancers and as modulators of Wnt signaling in tissue-engineering agendas, their impact on telomere length maintenance remains unclear. Here, we leveraged a collection of Wnt pathway inhibitors with previously unassigned mechanisms of action to identify novel pharmacophores supporting Tnks inhibition. A multifaceted experimental approach that included structural, biochemical, and cell biological analyses revealed two distinct chemotypes with selectivity for Tnks enzymes. Using these reagents, we revealed that Tnks inhibition rapidly induces DNA damage at telomeres and telomeric shortening upon long-term chemical exposure in cultured cells. On the other hand, inhibitors of the Wnt acyltransferase Porcupine (Porcn) elicited neither effect. Thus, Tnks inhibitors impact telomere length maintenance independently of their affects on Wnt/beta-catenin signaling. We discuss the implications of these findings for anticancer and regenerative medicine agendas dependent upon chemical inhibitors of Wnt/beta-catenin signaling.	[Kulak, Ozlem; Holohan, Brody; Wu, Xiaofeng; Wright, Woodring; Shay, Jerry W.; Lum, Lawrence] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Chen, Hua; He, Huawei; Zhang, Xuewu] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Borek, Dominika; Otwinowski, Zbyszek; Garofalo, Lauren A.; Ma, Zhiqiang; Chen, Chuo] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Chen, Hua; He, Huawei; Borek, Dominika; Otwinowski, Zbyszek; Zhang, Xuewu] Univ Texas SW Med Ctr Dallas, Dept Biophys, Dallas, TX 75390 USA; [Yamaguchi, Kiyoshi] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Genome Res, Tokyo, Japan	Zhang, XW (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.	Xuewu.zhang@utsouthwestern.edu; Lawrence.lum@utsouthwestern.edu	Borek, Dominika/D-2943-2011	Borek, Dominika/0000-0002-4321-6253	National Institutes of Health [R01CA168761, R01GM053163, P50-CA70907, C06 RR30414]; Simmons Cancer Center Support Grant [5P30 CA142543]; Welch Foundation [I-1665, I-1702, I-1596]; Cancer Prevention and Research Institute of Texas [RP130212, RP140661]; Virginia Murchison Linthicum Scholar in Medical Research at UTSW; fund from the Japan Society for the Promotion of Science (JSPS) for the Institutional Program for Young Researcher Overseas Visits; U.S. Department of Energy Office of Biological and Environmental Research [DE-AC02-06CH11357]	This work was supported, in whole or in part, by National Institutes of Health grants R01CA168761 (L.L.), R01GM053163 (Z.O.), and P50-CA70907 (L.L.); Simmons Cancer Center Support Grant 5P30 CA142543 (J.W.S); Welch Foundation grants I-1665 (L.L.), I-1702 (X.Z.), and I-1596 (C.C.); and Cancer Prevention and Research Institute of Texas grant RP130212 (L.L. and C.C.) and grant RP140661 (X.Z.). X.Z. is a Virginia Murchison Linthicum Scholar in Medical Research at UTSW. J.W.S is the Southland Financial Corporation Distinguished Chair in Geriatric Research. This work was supported by the fund from the Japan Society for the Promotion of Science (JSPS) for the Institutional Program for Young Researcher Overseas Visits (K.Y.). The results in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center, at the Advanced Photon Source. Argonne is operated by University of Chicago Argonne, LLC, for the U.S. Department of Energy Office of Biological and Environmental Research under contract DE-AC02-06CH11357. This work was performed in a space constructed with support from National Institutes of Health grant C06 RR30414.	Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Zhang Y, 2012, J BIOL CHEM, V287, P32494, DOI 10.1074/jbc.M112.368282; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009; Gonzalez R, 2011, ANGEW CHEM INT EDIT, V50, P11181, DOI 10.1002/anie.201103909; Lehtio L, 2008, J MOL BIOL, V379, P136, DOI 10.1016/j.jmb.2008.03.058; Ozaki Y, 2012, MOL CELL, V47, P694, DOI 10.1016/j.molcel.2012.06.033; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Ren YM, 2011, J MOL CELL CARDIOL, V51, P280, DOI 10.1016/j.yjmcc.2011.04.012; Huang SXL, 2014, NAT BIOTECHNOL, V32, P84, DOI 10.1038/nbt.2754; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Lum L, 2012, SCIENCE, V337, P922, DOI 10.1126/science.1228179; Williams SCP, 2013, NAT MED, V19, P6, DOI 10.1038/nm0113-6; Cho-Park PF, 2013, CELL, V153, P614, DOI 10.1016/j.cell.2013.03.040; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108; Lehtio L, 2013, FEBS J, V280, P3576, DOI 10.1111/febs.12320; Borah S, 2015, SCIENCE, V347, P1006, DOI 10.1126/science.1260200; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Narytnyk A, 2014, STEM CELL REV REP, V10, P316, DOI 10.1007/s12015-013-9493-9; Narwal M, 2012, J MED CHEM, V55, P1360, DOI 10.1021/jm201510p; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Ghaedi M, 2013, J CLIN INVEST, V123, P4950, DOI 10.1172/JCI68793; Thompson PA, 2013, CLIN CANCER RES, V19, P6578, DOI 10.1158/1078-0432.CCR-13-1117; Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868; Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121; Munoz P, 2009, MOL CELL BIOL, V29, P1608, DOI 10.1128/MCB.01339-08; Dodge ME, 2011, ANNU REV PHARMACOL, V51, P289, DOI 10.1146/annurev-pharmtox-010510-100558; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Walsh KM, 2014, NAT GENET, V46, P731, DOI 10.1038/ng.3004; Chang W, 2005, BIOCHEM J, V391, P177, DOI 10.1042/BJ20050885; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Guettler S, 2011, CELL, V147, P1340, DOI 10.1016/j.cell.2011.10.046; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Shay JW, 2011, SEMIN CANCER BIOL, V21, P349, DOI 10.1016/j.semcancer.2011.10.001; Lian XJ, 2013, NAT PROTOC, V8, P162, DOI 10.1038/nprot.2012.150; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Cerone MA, 2011, CANCER RES, V71, P3328, DOI 10.1158/0008-5472.CAN-10-2734; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Chiang YJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002639; Diala I, 2013, EMBO REP, V14, P356, DOI 10.1038/embor.2013.16; Gunaydin H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033740; Haikarainen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065404; Jacob LS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001225; Kim MK, 2014, MOL BIOL CELL, V25, P30, DOI 10.1091/mbc.E13-08-0479; Ludlow AT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku439; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Sarek G, 2015, MOL CELL, V57, P622, DOI 10.1016/j.molcel.2014.12.024; Tian XH, 2014, ONCOL REP, V32, P1999, DOI 10.3892/or.2014.3460; Wang HM, 2011, ACS CHEM BIOL, V6, P192, DOI 10.1021/cb100323z; Zimmermann M, 2014, GENE DEV, V28, P2477, DOI 10.1101/gad.251611.114	60	2	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0270-7306	1098-5549		MOL CELL BIOL	Mol. Cell. Biol.	JUL	2015	35	14					2425	2435		10.1128/MCB.00392-15		11	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CM1RL	WOS:000357457900005		
J	Sakai, M; Watanabe, Y; Someya, T; Araki, K; Shibuya, M; Niizato, K; Oshima, K; Kunii, Y; Yabe, H; Matsumoto, J; Wada, A; Hino, M; Hashimoto, T; Hishimoto, A; Kitamura, N; Iritani, S; Shirakawa, O; Maeda, K; Miyashita, A; Niwa, S; Takahashi, H; Kakita, A; Kuwano, R; Nawa, H				Sakai, Miwako; Watanabe, Yuichiro; Someya, Toshiyuki; Araki, Kazuaki; Shibuya, Masako; Niizato, Kazuhiro; Oshima, Kenichi; Kunii, Yasuto; Yabe, Hirooki; Matsumoto, Junya; Wada, Akira; Hino, Mizuki; Hashimoto, Takeshi; Hishimoto, Akitoyo; Kitamura, Noboru; Iritani, Shuji; Shirakawa, Osamu; Maeda, Kiyoshi; Miyashita, Akinori; Niwa, Shin-ichi; Takahashi, Hitoshi; Kakita, Akiyoshi; Kuwano, Ryozo; Nawa, Hiroyuki			Assessment of copy number variations in the brain genome of schizophrenia patients	MOLECULAR CYTOGENETICS			English	Article						CNV; Caudate; Genome instability; Schizophrenia; Somatic mutation	ATAXIA-TELANGIECTASIA BRAIN; ALZHEIMERS-DISEASE; SOMATIC MOSAICISM; BIPOLAR DISORDER; NEUROPSYCHIATRIC DISEASES; ACTIVATING MUTATIONS; CELL GENOMICS; HUMAN TISSUES; ANEUPLOIDY; DNA	Background: Cytogenomic mutations and chromosomal abnormality are implicated in the neuropathology of several brain diseases. Cell heterogeneity of brain tissues makes their detection and validation difficult, however. In the present study, we analyzed gene dosage alterations in brain DNA of schizophrenia patients and compared those with the copy number variations (CNVs) identified in schizophrenia patients as well as with those in Asian lymphocyte DNA and attempted to obtain hints at the pathological contribution of cytogenomic instability to schizophrenia. Results: Brain DNA was extracted from postmortem striatum of schizophrenia patients and control subjects (n = 48 each) and subjected to the direct two color microarray analysis that limits technical data variations. Disease-associated biases of relative DNA doses were statistically analyzed with Bonferroni's compensation on the premise of brain cell mosaicism. We found that the relative gene dosage of 85 regions significantly varied among a million of probe sites. In the candidate CNV regions, 26 regions had no overlaps with the common CNVs found in Asian populations and included the genes (i.e., ANTXRL, CHST9, DNM3, NDST3, SDK1, STRC, SKY) that are associated with schizophrenia and/or other psychiatric diseases. The majority of these candidate CNVs exhibited high statistical probabilities but their signal differences in gene dosage were less than 1.5-fold. For test evaluation, we rather selected the 10 candidate CNV regions that exhibited higher aberration scores or larger global effects and were thus confirmable by PCR. Quantitative PCR verified the loss of gene dosage at two loci (1p36.21 and 1p13.3) and confirmed the global variation of the copy number distributions at two loci (11p15.4 and 13q21.1), both indicating the utility of the present strategy. These test loci, however, exhibited the same somatic CNV patterns in the other brain region. Conclusions: The present study lists the candidate regions potentially representing cytogenomic CNVs in the brain of schizophrenia patients, although the significant but modest alterations in their brain genome doses largely remain to be characterized further.	[Sakai, Miwako; Araki, Kazuaki; Nawa, Hiroyuki] Niigata Univ, Brain Res Inst, Dept Mol Neurobiol, Niigata 9518585, Japan; [Sakai, Miwako; Watanabe, Yuichiro; Someya, Toshiyuki; Shibuya, Masako] Niigata Univ, Grad Sch Med & Dent Sci, Dept Psychiat, Niigata 9518510, Japan; [Niizato, Kazuhiro; Oshima, Kenichi; Iritani, Shuji] Matsuzawa Hosp, Setagaya Ku, Tokyo 1560057, Japan; [Kunii, Yasuto; Yabe, Hirooki; Matsumoto, Junya; Wada, Akira; Hino, Mizuki; Niwa, Shin-ichi] Fukushima Med Univ, Sch Med, Dept Neuropsychiat, Fukushima 9601295, Japan; [Hashimoto, Takeshi; Hishimoto, Akitoyo; Kitamura, Noboru; Shirakawa, Osamu; Maeda, Kiyoshi] Kobe Univ, Grad Sch Med, Div Psychiat & Neurol, Kobe, Hyogo 6500017, Japan; [Iritani, Shuji] Nagoya Univ, Grad Sch Med, Dept Mental Hlth, Nagoya, Aichi 4668550, Japan; [Shirakawa, Osamu] Kinki Univ, Fac Med, Dept Neuropsychiat, Osaka 5898511, Japan; [Maeda, Kiyoshi] Kobe Univ, Sch Med, Dept Social Rehabil, Kobe, Hyogo 6540142, Japan; [Miyashita, Akinori; Kuwano, Ryozo] Niigata Univ, Brain Res Inst, Dept Mol Genet, Niigata 9518585, Japan; [Takahashi, Hitoshi; Kakita, Akiyoshi] Niigata Univ, Pathol & Brain Dis Res Ctr, Brain Res Inst, Niigata 9518585, Japan	Nawa, H (reprint author), Niigata Univ, Brain Res Inst, Dept Mol Neurobiol, 1-757 Asahimachi Dori, Niigata 9518585, Japan.	hnawa@bri.niigata-u.ac.jp			grant for Promotion of Niigata University Research Projects;  [24116010];  [21659273]	This work was supported by Grant-in-Aids for Scientific Research on Innovative Areas (No. 24116010) and for Challenging Exploratory Research (No. 21659273) and a grant for Promotion of Niigata University Research Projects.	Yang YH, 2002, NAT REV GENET, V3, P579; Iourov IY, 2012, CURR GENOMICS, V13, P477, DOI 10.2174/138920212802510439; Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217; Yurov YB, 2001, BRAIN DEV-JPN, V23, pS186, DOI 10.1016/S0387-7604(01)00363-1; Malhotra D, 2011, NEURON, V72, P951, DOI 10.1016/j.neuron.2011.11.007; Priebe L, 2012, MOL PSYCHIATR, V17, P421, DOI 10.1038/mp.2011.8; Yurov YB, 2007, J MED GENET, V44, P521, DOI 10.1136/jmg.2007.049312; Kirov G, 2012, MOL PSYCHIATR, V17, P142, DOI 10.1038/mp.2011.154; Park H, 2010, NAT GENET, V42, P400, DOI 10.1038/ng.555; Xu HY, 2011, HUM MUTAT, V32, P1341, DOI 10.1002/humu.21601; Pamphlett R, 2011, MUSCLE NERVE, V44, P492, DOI 10.1002/mus.22095; Lindhurst MJ, 2012, NAT GENET, V44, P928, DOI 10.1038/ng.2332; Iourov IY, 2008, CURR GENOMICS, V9, P452, DOI 10.2174/138920208786241216; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; De S, 2011, TRENDS GENET, V27, P217, DOI 10.1016/j.tig.2011.03.002; Iourov IY, 2013, CYTOGENET GENOME RES, V139, P181, DOI 10.1159/000347053; Watanabe Y, 2010, SCHIZOPHR RES, V124, P236, DOI 10.1016/j.schres.2010.08.001; Abyzov A, 2012, NATURE, V492, P438, DOI 10.1038/nature11629; Singer T, 2010, TRENDS NEUROSCI, V33, P345, DOI 10.1016/j.tins.2010.04.001; Kurek KC, 2012, AM J HUM GENET, V90, P1108, DOI 10.1016/j.ajhg.2012.05.006; Iourov IY, 2009, HUM MOL GENET, V18, P2656, DOI 10.1093/hmg/ddp207; Malhotra D, 2012, CELL, V148, P1223, DOI 10.1016/j.cell.2012.02.039; Girirajan S, 2011, ANNU REV GENET, V45, P203, DOI 10.1146/annurev-genet-102209-163544; Erickson RP, 2010, MUTAT RES-REV MUTAT, V705, P96, DOI 10.1016/j.mrrev.2010.04.002; Francey LJ, 2012, AM J MED GENET A, V158A, P298, DOI 10.1002/ajmg.a.34391; Peterson SE, 2012, J NEUROSCI, V32, P16213, DOI 10.1523/JNEUROSCI.3706-12.2012; Arendt T, 2010, AM J PATHOL, V177, P15, DOI 10.2353/ajpath.2010.090955; Ye TZ, 2012, BIOL PSYCHIAT, V72, P651, DOI 10.1016/j.biopsych.2012.06.014; Piotrowski A, 2008, HUM MUTAT, V29, P1118, DOI 10.1002/humu.20815; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Pidsley R, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0483-2; Etheridge SP, 2011, AM J MED GENET A, V155A, P2578, DOI 10.1002/ajmg.a.34223; Krumm N, 2013, AM J HUM GENET, V93, P595, DOI 10.1016/j.ajhg.2013.07.024; Mosch B, 2007, J NEUROSCI, V27, P6859, DOI 10.1523/JNEUROSCI.0379-07.2007; Iourov IY, 2009, NEUROBIOL DIS, V34, P212, DOI 10.1016/j.nbd.2009.01.003; Rees E, 2011, BIOL PSYCHIAT, V70, P1109, DOI 10.1016/j.biopsych.2011.07.011; Xu B, 2008, NAT GENET, V40, P880, DOI 10.1038/ng.162; Purcell SM, 2014, NATURE, V506, P185, DOI 10.1038/nature12975; Bloom RJ, 2013, SCHIZOPHR RES, V146, P289, DOI 10.1016/j.schres.2013.02.021; Bundo M, 2014, NEURON, V81, P306, DOI 10.1016/j.neuron.2013.10.053; Chen JM, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-60; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Filho Aguinaldo Bonalumi, 2011, Am J Med Genet A, V155A, P1152, DOI 10.1002/ajmg.a.33942; Huang KC, 2013, BMC GENOMICS S5, V14, pS10; Lee JM, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-29; Lencz T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3739; Mkrtchyan H, 2010, CURR GENOMICS, V11, P426, DOI 10.2174/138920210793176047; Terracciano A, 2012, NEUROGENETICS, V13, P341, DOI 10.1007/s10048-012-0342-9; The International Schizophrenia Consortium, 2009, NATURE, V460, P748; Tsubahara M, 2012, CLIN ENDOCRINOL, V76, P420, DOI 10.1111/j.1365-2265.2011.04224.x; Whale AS, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks203; Williams SL, 2013, PLOS GENET, V9, P10; Yang AH, 2003, J NEUROSCI, V23, P10454; Yurov YB, 2008, SCHIZOPHR RES, V98, P139, DOI 10.1016/j.schres.2007.07.035; Yurov YB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000558; Zhang DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014511	56	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1755-8166			MOL CYTOGENET	Mol. Cytogenet.	JUL 1	2015	8								46	10.1186/s13039-015-0144-5		9	Genetics & Heredity	Genetics & Heredity	CL8VQ	WOS:000357252600001		
J	Xu, S; Lun, Y; Brignol, N; Hamler, R; Schilling, A; Frascella, M; Sullivan, S; Boyd, RE; Chang, K; Soska, R; Garcia, A; Feng, J; Yasukawa, H; Shardlow, C; Churchill, A; Ketkar, A; Robertson, N; Miyamoto, M; Mihara, K; Benjamin, ER; Lockhart, DJ; Hirato, T; Fowles, S; Valenzano, KJ; Khanna, R				Xu, Su; Lun, Yi; Brignol, Nastry; Hamler, Rick; Schilling, Adriane; Frascella, Michelle; Sullivan, Sean; Boyd, Robert E.; Chang, Kate; Soska, Rebecca; Garcia, Anadina; Feng, Jessie; Yasukawa, Hidehito; Shardlow, Carole; Churchill, Alison; Ketkar, Amol; Robertson, Nicola; Miyamoto, Masahito; Mihara, Kazutoshi; Benjamin, Elfrida R.; Lockhart, David J.; Hirato, Tohru; Fowles, Susie; Valenzano, Kenneth J.; Khanna, Richie			Coformulation of a Novel Human alpha-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice	MOLECULAR THERAPY			English	Article							ENZYME REPLACEMENT THERAPY; AGALSIDASE-BETA THERAPY; IDENTIFY MUTANT FORMS; PHARMACOGENETIC APPROACH; ISOFAGOMINE INCREASES; LYSOSOMAL STORAGE; CLINICAL-TRIAL; DISEASE; SAFETY; GLOBOTRIAOSYLSPHINGOSINE	Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene that encodes a-galactosidase A and is characterized by pathological accumulation of globotriaosylceramide and globotriaosylsphingosine. Earlier, the authors demonstrated that oral coadministration of the pharmacological chaperone AT1001 (migalastat HCl; 1-deoxygalactonojirimycin HCl) prior to intravenous administration of enzyme replacement therapy improved the pharmacological properties of the enzyme. In this study, the authors investigated the effects of coformulating AT1001 with a proprietary recombinant human alpha-galactosidase A (ATB100) into a single intravenous formulation. AT1001 increased the physical stability and reduced aggregation of ATB100 at neutral pH in vitro, and increased the potency for ATB100-mediated globotriaosylceramide reduction in cultured Fabry fibroblasts. In Fabry mice, AT1001 coformulation increased the total exposure of active enzyme, and increased ATB100 levels in cardiomyocytes, cardiac vascular endothelial cells, renal distal tubular epithelial cells, and glomerular cells, cell types that do not show substantial uptake with enzyme replacement therapy alone. Notably, AT1001 coformulation also leads to greater tissue globotriaosylceramide reduction when compared with ATB100 alone, which was positively correlated with reductions in plasma globotriaosylsphingosine. Collectively, these data indicate that intravenous administration of ATB100 coformulated with AT1001 may provide an improved therapy for Fabry disease and thus warrants further investigation.	[Xu, Su; Lun, Yi; Brignol, Nastry; Hamler, Rick; Schilling, Adriane; Frascella, Michelle; Sullivan, Sean; Boyd, Robert E.; Chang, Kate; Soska, Rebecca; Garcia, Anadina; Feng, Jessie; Valenzano, Kenneth J.; Khanna, Richie] Amicus Therapeut Inc, Cranbury, NJ 08512 USA; [Yasukawa, Hidehito; Miyamoto, Masahito; Mihara, Kazutoshi; Hirato, Tohru] JCR Pharmaceut, Kobe, Hyogo, Japan; [Shardlow, Carole; Churchill, Alison; Robertson, Nicola; Fowles, Susie] GlaxoSmithKline R&D, Ware, Herts, England; [Ketkar, Amol] GlaxoSmithKline R&D, King Of Prussia, PA USA; [Lockhart, David J.] TranscripTx Inc, San Francisco, CA USA	Khanna, R (reprint author), Amicus Therapeut Inc, 1 Cedar Brook Dr, Cranbury, NJ 08512 USA.	rkhanna@amicusrx.com					Alpan Goker-, 2015, PLOS ONE UNPUB; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Yam GHF, 2006, AM J PHYSIOL-CELL PH, V290, pC1076, DOI 10.1152/ajpcell.00426.2005; Coutinho MF, 2012, MOL GENET METAB, V105, P542, DOI 10.1016/j.ymgme.2011.12.012; Porto C, 2012, J INHERIT METAB DIS, V35, P513, DOI 10.1007/s10545-011-9424-3; Rombach SM, 2010, BBA-MOL BASIS DIS, V1802, P741, DOI 10.1016/j.bbadis.2010.05.003; Togawa T, 2010, BIOCHEM BIOPH RES CO, V399, P716, DOI 10.1016/j.bbrc.2010.08.006; Yam GHF, 2005, FASEB J, V19, P12, DOI 10.1096/fj.04-2375com; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Bodensteiner D, 2008, GENET MED, V10, P353, DOI 10.1097/GIM.0b013e318170f868; Eng CM, 2001, AM J HUM GENET, V68, P711, DOI 10.1086/318809; Hughes DA, 2008, HEART, V94, P153, DOI 10.1136/hrt.2006.104026; Lee K, 2003, GLYCOBIOLOGY, V13, P305, DOI 10.1093/glycob.cwg034; Asano N, 2000, TETRAHEDRON-ASYMMETR, V11, P1645, DOI 10.1016/S0957-4166(00)00113-0; Germain DP, 2007, J AM SOC NEPHROL, V18, P1547, DOI 10.1681/ASN.2006080816; Thurberg BL, 2002, KIDNEY INT, V62, P1933, DOI 10.1046/j.1523-1755.2002.00675.x; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Aerts JM, 2008, P NATL ACAD SCI USA, V105, P2812, DOI 10.1073/pnas.0712309105; Togawa T, 2010, MOL GENET METAB, V100, P257, DOI 10.1016/j.ymgme.2010.03.020; West M, 2009, J AM SOC NEPHROL, V20, P1132, DOI 10.1681/ASN.2008080870; Valenzano KJ, 2011, ASSAY DRUG DEV TECHN, V9, P213, DOI 10.1089/adt.2011.0370; Porto C, 2009, MOL THER, V17, P964, DOI 10.1038/mt.2009.53; Benjamin ER, 2012, MOL THER, V20, P717, DOI 10.1038/mt.2011.271; Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321; Khanna R, 2010, MOL THER, V18, P23, DOI 10.1038/mt.2009.220; Shen JS, 2008, BIOCHEM BIOPH RES CO, V369, P1071, DOI 10.1016/j.bbrc.2008.02.125; Schiffmann R, 2006, VIRCHOWS ARCH, V448, P337, DOI 10.1007/s00428-005-0089-x; Flanagan JJ, 2009, HUM MUTAT, V30, P1683, DOI 10.1002/humu.21121; Benichou B, 2009, MOL GENET METAB, V96, P4, DOI 10.1016/j.ymgme.2008.10.004; Benjamin ER, 2009, J INHERIT METAB DIS, V32, P424, DOI 10.1007/s10545-009-1077-0; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; Askari H, 2007, VIRCHOWS ARCH, V451, P823, DOI 10.1007/s00428-007-0468-6; Benjamin E, 2014, J INHERIT METAB DIS, V37, pS161; Desnick RJ, 2001, METABOLIC MOL BASES, V3, P3733; Fan JQ, 2003, METHOD ENZYMOL, V363, P412; Germain DP, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-91; Germain DP, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-30; Giugliani R, 2013, MOL GENET METAB, V109, P86, DOI 10.1016/j.ymgme.2013.01.009; Gold H, 2011, EUR J ORG CHEM, P1652, DOI 10.1002/ejoc.201001690; Hughes D, 2014, J INHERIT METAB DIS, V37, pS158; Ishii S, 2009, J PHARMACOL EXP THER, V328, P723, DOI 10.1124/jpet.108.149054; Johnson FK, 2013, CLIN PHARM DRUG DEV, V2, P120, DOI 10.1002/cpdd.1; Keslova-Veselikova J, 2008, VIRCHOWS ARCH, V452, P651, DOI 10.1007/s00428-008-0586-9; Khanna R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040776; Khanna R, 2010, FEBS J, V277, P1618, DOI 10.1111/j.1742-4658.2010.07588.x; MAYES JS, 1982, AM J HUM GENET, V34, P602; Schiffmann R, 2008, AM SOC HUM GEN C PHI; Shin SH, 2007, BIOCHEM BIOPH RES CO, V359, P168, DOI 10.1016/j.bbrc.2007.05.082; Johnson FK, 2012, J INHERIT METAB DIS, V35, pS96; Tesmoingt C, 2009, BRIT J CLIN PHARMACO, V68, P765, DOI 10.1111/j.1365-2125.2009.03501.x; Thurberg B, 2008, MOL GENET METOBOL, V93, P39, DOI 10.1016/j.ymgme.2007.10.108; Wu X, 2011, J INHERIT METAB DIS, V34, pS190; Wu XY, 2011, HUM MUTAT, V32, P965, DOI 10.1002/humu.21530; Young-Gqamana B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057631	54	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	JUL	2015	23	7					1169	1181		10.1038/mt.2015.87		13	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	CM0FY	WOS:000357355000007		
J	Yano, S; Miwa, S; Kishimoto, H; Toneri, M; Hiroshima, Y; Yamamoto, M; Bouvet, M; Urata, Y; Tazawa, H; Kagawa, S; Fujiwara, T; Hoffman, RM				Yano, Shuya; Miwa, Shinji; Kishimoto, Hiroyuki; Toneri, Makoto; Hiroshima, Yukihiko; Yamamoto, Mako; Bouvet, Michael; Urata, Yasuo; Tazawa, Hiroshi; Kagawa, Shunsuke; Fujiwara, Toshiyoshi; Hoffman, Robert M.			Experimental Curative Fluorescence-guided Surgery of Highly Invasive Glioblastoma Multiforme Selectively Labeled With a Killer-reporter Adenovirus	MOLECULAR THERAPY			English	Article							ORTHOTOPIC MOUSE MODELS; HUMAN COLON-CANCER; ANTI-CEA ANTIBODY; METASTATIC PANCREATIC-CANCER; LYMPH-NODE METASTASIS; HUMAN BRAIN-TUMORS; TELOMERASE ACTIVITY; IN-VIVO; IMAGING-SYSTEM; 5-AMINOLEVULINIC ACID	Fluorescence-guided surgery (FGS) of cancer is an area of intense current interest. However, although benefits have been demonstrated with FGS, curative strategies need to be developed. Glioblastoma multiforme (GBM) is one of the most invasive of cancers and is not totally resectable using standard bright-light surgery (BLS) or current FGS strategies. We report here a curative strategy for FGS of GBM. In this study, telomerase-dependent adenovirus OBP-401 infection brightly and selectively labeled GBM with green fluorescent protein (GFP) for FGS in orthotopic nude mouse models. OBP-401-based FGS enabled curative resection of GBM without recurrence for at least 150 days, compared to less than 30 days with BLS.	[Yano, Shuya; Miwa, Shinji; Toneri, Makoto; Hiroshima, Yukihiko; Yamamoto, Mako; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA 92111 USA; [Yano, Shuya; Miwa, Shinji; Toneri, Makoto; Hiroshima, Yukihiko; Yamamoto, Mako; Bouvet, Michael; Hoffman, Robert M.] Univ Calif San Diego, San Diego, CA 92103 USA; [Kishimoto, Hiroyuki; Kagawa, Shunsuke; Fujiwara, Toshiyoshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg, Okayama 7008530, Japan; [Urata, Yasuo] Oncolys BioPharm Inc, Tokyo, Japan; [Tazawa, Hiroshi] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan	Hoffman, RM (reprint author), AntiCancer Inc, 7917 Ostrow St, San Diego, CA 92111 USA.	all@anticancer.com	TAZAWA, Hiroshi/B-2247-2011	TAZAWA, Hiroshi/0000-0003-4658-1050	Ministry of Education, Science and Culture, Japan; Ministry of Health and Welfare, Japan; National Cancer Institute [CA132971, CA142669]	This paper is dedicated to the memory of A. R. Moossa. This study was supported by grants-in-aid from the Ministry of Education, Science and Culture, Japan, and grants from the Ministry of Health and Welfare, Japan, and supported in part by National Cancer Institute grants CA132971 and CA142669.	Metildi CA, 2013, J SURG RES, V179, P87, DOI 10.1016/j.jss.2012.08.052; Kaushal S, 2008, J GASTROINTEST SURG, V12, P1938, DOI 10.1007/s11605-008-0581-0; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Metildi CA, 2012, J AM COLL SURGEONS, V215, P126, DOI 10.1016/j.jamcollsurg.2012.02.021; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927; Kishimoto H, 2011, CELL CYCLE, V10, P2737, DOI 10.4161/cc.10.16.16756; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Metildi CA, 2014, J SURG ONCOL, V109, P451, DOI 10.1002/jso.23507; McElroy M, 2008, WORLD J SURG, V32, P1057, DOI 10.1007/s00268-007-9452-1; Senft C, 2011, LANCET ONCOL, V12, P997, DOI 10.1016/S1470-2045(11)70196-6; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Metildi CA, 2014, J AM COLL SURGEONS, V219, P132, DOI 10.1016/j.jamcollsurg.2014.02.021; van Dam GM, 2011, NAT MED, V17, P1315, DOI 10.1038/nm.2472; Ishizawa T, 2009, CANCER, V115, P2491, DOI 10.1002/cncr.24291; Hiroshima Y, 2014, J LAPAROENDOSC ADV S, V24, P241, DOI 10.1089/lap.2013.0418; Walsh KM, 2014, NAT GENET, V46, P731, DOI 10.1038/ng.3004; Hiraga S, 1998, CANCER RES, V58, P2117; Kishimoto H, 2009, P NATL ACAD SCI USA, V106, P14514, DOI 10.1073/pnas.0906388106; Yano S, 2013, CLIN CANCER RES, V19, P6495, DOI 10.1158/1078-0432.CCR-13-0742; Tazawa H, 2012, INT J CANCER, V131, P2939, DOI 10.1002/ijc.27589; Momiyama M, 2013, ANTICANCER RES, V33, P1367; DeMasters BKK, 1997, AM J CLIN PATHOL, V107, P548; Uchugonova A, 2013, J CELL BIOCHEM, V114, P99, DOI 10.1002/jcb.24305; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262; Aldave G, 2013, NEUROSURGERY, V72, P915, DOI 10.1227/NEU.0b013e31828c3974; Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9; Bouvet M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003375; Eyupoglu IY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044885; Harada K, 2000, J NEUROSURG, V93, P618, DOI 10.3171/jns.2000.93.4.0618; Hiroshima Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099977; Hiroshima Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114310; Hiroshima Y, 2014, J SURG RES, V187, P510, DOI 10.1016/j.jss.2013.11.1083; Huang F, 1999, J NEURO-ONCOL, V43, P137, DOI 10.1023/A:1006258817785; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Kishimoto H, 2009, MOL CANCER THER, V8, P3001, DOI 10.1158/1535-7163.MCT-09-0556; Kojima T, 2010, ANN SURG, V251, P1079, DOI 10.1097/SLA.0b013e3181deb69d; Kojima T, 2009, J CLIN INVEST, V119, P3172, DOI 10.1172/JCI38609; Kuroda S, 2010, CANCER RES, V70, P9339, DOI 10.1158/0008-5472.CAN-10-2333; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; Metildi CA, 2012, J AM COLL SURGEONS, V214, P997, DOI 10.1016/j.jamcollsurg.2012.02.009; Metildi CA, 2014, ANN SURG ONCOL, V21, P1405, DOI 10.1245/s10434-014-3495-y; Metildi CA, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/290634; Metildi CA, 2013, ANN SURG ONCOL, V3, P693; Momiyama M, 2013, ANTICANCER RES, V33, P107; Sasaki T, 2011, CLIN CANCER RES, V17, P1828, DOI 10.1158/1078-0432.CCR-10-2066; Tran Cao HS, 2012, HEPATO-GASTROENTEROL, V59, P1994; Urano Y., 2011, SCI TRANSL MED, V3; Yamashita S, 2012, ANN SURG ONCOL, V19, P728, DOI 10.1245/s10434-011-2145-x; Yano S, 2015, ONCOTARGET IN PRESS	51	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	JUL	2015	23	7					1182	1188		10.1038/mt.2015.63		7	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	CM0FY	WOS:000357355000008		
J	Moulay, G; Ohtani, T; Ogut, O; Guenzel, A; Behfar, A; Zakeri, R; Haines, P; Storlie, J; Bowen, L; Pham, L; Kaye, D; Sandhu, G; O'Connor, M; Russell, S; Redfield, M				Moulay, Gilles; Ohtani, Tomohito; Ogut, Ozgur; Guenzel, Adam; Behfar, Atta; Zakeri, Rosita; Haines, Philip; Storlie, Jimmy; Bowen, Lorna; Linh Pham; Kaye, David; Sandhu, Gurpreet; O'Connor, Michael; Russell, Stephen; Redfield, Margaret			Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression	MOLECULAR THERAPY			English	Article							ADENOASSOCIATED VIRAL VECTORS; VIRUS SEROTYPE-9 LEADS; ADVANCED HEART-FAILURE; REPORTER GENE; IN-VIVO; TRANSENDOCARDIAL DELIVERY; MUSCULAR-DYSTROPHY; LARGE ANIMALS; TRANSDUCTION; EFFICIENT	Heart failure is a leading cause of morbidity and mortality, and cardiac gene delivery has the potential to provide novel therapeutic approaches. Adeno-associated virus serotype 9 (AAV9) transduces the rodent heart efficiently, but cardiotropism, immune tolerance, and optimal delivery strategies in large animals are unclear. In this study, an AAV9 vector encoding canine sodium iodide symporter (NIS) was administered to adult immunocompetent dogs via epicardial injection, coronary infusion without and with cardiac recirculation, or endocardial injection via a novel catheter with curved needle and both end- and side-holes. As NIS mediates cellular uptake of clinical radioisotopes, expression was tracked by single-photon emission computerized tomography (SPECT) imaging in addition to Western blot and immunohistochemistry. Direct epicardial or endocardial injection resulted in strong cardiac expression, whereas expression after intracoronary infusion or cardiac recirculation was undetectable. A threshold myocardial injection dose that provides robust noninnmunogenic expression was identified. The extent of transmural myocardial expression was greater with the novel catheter versus straight. end-hole needle delivery. Furthermore, the authors demonstrate that cardiac NIS reporter gene expression and duration can be quantified using serial noninvasive SPECT imaging up to 1 year after vector administration. These data are relevant to efforts to develop cardiac gene delivery as heart failure therapy.	[Moulay, Gilles; Ogut, Ozgur; Guenzel, Adam; Behfar, Atta; Zakeri, Rosita; Storlie, Jimmy; Bowen, Lorna; Linh Pham; Sandhu, Gurpreet; O'Connor, Michael; Russell, Stephen; Redfield, Margaret] Mayo Clin, Rochester, MN 55905 USA; [Ohtani, Tomohito] Osaka Univ, Osaka, Japan; [Haines, Philip] Univ Penn, Philadelphia, PA 19104 USA; [Kaye, David] Baker Heart Res Inst, Melbourne, Vic, Australia	Redfield, M (reprint author), Mayo Clin, Cardiorenal Lab, 200 First St SW, Rochester, MN 55905 USA.	redfield.margaret@mayo.edu			NIH [RO1 HL105418]	The authors wish to thank Chad Dewhirst and Broke Gentzler for technical assistance with SPECT imaging. This work was supported by NIH funding RO1 HL105418. The authors have no conflict of interest to disclose.	Byrne MJ, 2008, GENE THER, V15, P1550, DOI 10.1038/gt.2008.120; Vandendriessche T, 2007, J THROMB HAEMOST, V5, P16, DOI 10.1111/j.1538-7836.2006.02220.x; Blankinship MJ, 2004, MOL THER, V10, P671, DOI 10.1016/j.ymthe.2004.07.016; Yue YP, 2008, MOL THER, V16, P1944, DOI 10.1038/mt.2008.207; Penheiter AR, 2012, CURR GENE THER, V12, P33; Bish LT, 2012, MOL THER, V20, P580, DOI 10.1038/mt.2011.264; Kaye DM, 2007, J AM COLL CARDIOL, V50, P253, DOI 10.1016/j.jacc.2007.03.047; Kotchey NM, 2011, MOL THER, V19, P1079, DOI 10.1038/mt.2011.3; Lock M, 2010, HUM GENE THER, V21, P1259, DOI 10.1089/hum.2010.055; Zsebo K, 2014, CIRC RES, V114, P101, DOI 10.1161/CIRCRESAHA.113.302421; Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014; Pacak CA, 2006, CIRC RES, V99, pE3, DOI 10.1161/01.RES.0000237661.18885.f6; Zuckier LS, 2004, J NUCL MED, V45, P500; Behfar A, 2013, CIRC-CARDIOVASC INTE, V6, P710, DOI 10.1161/CIRCINTERVENTIONS.112.000422; Jessup M, 2011, CIRCULATION, V124, P304, DOI 10.1161/CIRCULATIONAHA.111.022889; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76; Kawase Y, 2011, J AM COLL CARDIOL, V57, P1169, DOI 10.1016/j.jacc.2010.11.023; Gao GP, 2011, HUM GENE THER, V22, P979, DOI 10.1089/hum.2011.042; Pan XF, 2013, HUM GENE THER, V24, P584, DOI 10.1089/hum.2013.044; Miyagawa M, 2005, EUR J NUCL MED MOL I, V32, P1108, DOI 10.1007/s00259-005-1854-4; Pepe M, 2010, CIRC RES, V106, P1893, DOI 10.1161/CIRCRESAHA.110.220855; Bish LT, 2008, MOL THER, V16, P1953, DOI 10.1038/mt.2008.202; GIBBONS RJ, 1989, CIRCULATION, V80, P1277; Han YS, 2011, CYTOSKELETON, V68, P18, DOI 10.1002/cm.20491; Hingorani M, 2010, CURR CANCER DRUG TAR, V10, P242; Lee KH, 2005, J NUCL MED, V46, P652; Mariani JA, 2011, EUR J HEART FAIL, V13, P247, DOI 10.1093/eurjhf/hfq234; Miyagawa M, 2005, CARDIOVASC RES, V65, P195, DOI 10.1016/j.cardiores.2004.10.001; Moulay G, 2010, CTS-CLIN TRANSL SCI, V3, P333, DOI 10.1111/j.1752-8062.2010.00245.x; Moulay G, 2010, GENE THER, V17, P1400, DOI 10.1038/gt.2010.94; Pleger ST, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002097; Rao VP, 2008, TRANSPLANTATION, V84, P1662; Ricci D, 2008, EUR J CARDIO-THORAC, V33, P32, DOI 10.1016/j.ejcts.2007.09.033; Richard-Fiardo P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034086; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Wang ZJ, 2007, HUM GENE THER, V18, P18, DOI 10.1089/hum.2006.093	36	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	JUL	2015	23	7					1211	1221		10.1038/mt.2015.78		11	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	CM0FY	WOS:000357355000011		
J	Zhao, XX; Toyooka, T; Kubota, T; Yang, G; Ibuki, Y				Zhao, Xiaoxu; Toyooka, Tatsushi; Kubota, Toru; Yang, Guang; Ibuki, Yuko			gamma-H2AX induced by linear alkylbenzene sulfonates is due to deoxyribonuclease-1 translocation to the nucleus via actin disruption	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS			English	Article						Deoxyribonuclease-1; Actin; DNA double strand breaks; gamma-H2AX; Linear alkylbenzene sulfonates	HISTONE H2AX PHOSPHORYLATION; DOUBLE-STRAND BREAKS; DNA-DAMAGE; OXIDATIVE STRESS; CELLS; GENOTOXICITY; SURFACTANTS; INDUCTION; TOXICITY; SLUDGE	Phosphorylation of histone H2AX (gamma-H2AX) occurs following formation of DNA double strand breaks (DS135). Other types of DNA damage also generate DSBs through DNA replication and repair, leading to the production of gamma-H2AX. In the present study, we demonstrated that linear alkylbenzene sulfonates (LAS), the most widely used and non-genotoxic anionic surfactants, could generate gamma-H2AX via a novel pathway. Breast adenocarcinoma MCF-7 cells were treated with five kinds of LAS with alkyl chains ranging from 10 to 14 carbon units (C-10-C(14)LAS). The generation of DSBs and subsequent production of gamma-H2AX increased in a manner that depended on the number of carbon units in LAS. gamma-H2AX could also be generated with non-cytotoxic doses of LAS and was independent of the cell cycle, indicating the non-apoptotic and DNA replication-independent formation of DSBs. The generation of gamma-H2AX could be attenuated by EGTA and ZnCl2, deoxyribonuclease-1 (DNase 1) inhibitors, as well as by the knockdown of DNase I. LAS weakened the interaction between DNase I and actin, and the enhanced release of DNase I was dependent on the number of carbon units in LAS. DNase I released by the LAS treatment translocated to the nucleus, in which DNase I attacked DNA and generated gamma-H2AX. These results suggested that the LAS-induced generation of gamma-H2AX could be attributed to the translocation of DNase I to the nucleus through the disruption of actin, and not to LAS-induced DNA damage. (C) 2015 Elsevier B.V. All rights reserved.	[Zhao, Xiaoxu; Toyooka, Tatsushi; Kubota, Toru; Yang, Guang; Ibuki, Yuko] Univ Shizuoka, Grad Div Nutr & Environm Sci, Shizuoka 4228526, Japan	Ibuki, Y (reprint author), Univ Shizuoka, Grad Div Nutr & Environm Sci, Shizuoka 4228526, Japan.	ibuki@u-shizuoka-ken.ac.jp			Ministry of Health, Labour and Welfare, Japan; JSPS KAKENHI [24510084]	We would like to thank Dr. Ayako Goto and Dr. Rensuke Goto for their valuable advice regarding the preparation of this manuscript. This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare, Japan, and a Grant-in-Aid from JSPS KAKENHI (24510084).	Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Ibuki Y, 2008, CHEM RES TOXICOL, V21, P1770, DOI 10.1021/tx800129n; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.biochem.55.1.987; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Kubota T, 2014, PHOTOCHEM PHOTOBIOL, V90, P845, DOI 10.1111/php.12268; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Alvarez-Munoz D, 2009, CHEMOSPHERE, V74, P1216, DOI 10.1016/j.chemosphere.2008.11.032; Vock EH, 1998, MUTAT RES-GEN TOX EN, V413, P83, DOI 10.1016/S1383-5718(98)00019-9; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; Martinez-Zamudio R, 2012, MOL CELL BIOL, V32, P2490, DOI 10.1128/MCB.06667-11; Garcia MT, 2006, WATER RES, V40, P2958, DOI 10.1016/j.watres.2006.05.033; Zhao H, 2011, CYTOM PART A, V79A, P897, DOI 10.1002/cyto.a.21137; Eskandani M, 2013, DNA CELL BIOL, V32, P498, DOI 10.1089/dna.2013.2059; Tanaka T, 2007, CYTOM PART A, V71A, P648, DOI 10.1002/cyto.a.20426; Dominguez R, 2011, ANNU REV BIOPHYS, V40, P169, DOI 10.1146/annurev-biophys-042910-155359; HITCHCOCK SE, 1980, J BIOL CHEM, V255, P5668; Eulitz D, 2007, APOPTOSIS, V12, P1511, DOI 10.1007/s10495-007-0078-4; Sage E, 2011, MUTAT RES-FUND MOL M, V711, P123, DOI 10.1016/j.mrfmmm.2010.12.010; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Basnakian AG, 2002, J AM SOC NEPHROL, V13; Cardew AS, 2010, METHODS MOL BIOL, V613, P153, DOI 10.1007/978-1-60327-418-0_10; Carrier F., 2013, MOL CELL PHARM, V5, P51; Ciszak L, 1999, BBA-MOL CELL RES, V1451, P141, DOI 10.1016/S0167-4889(99)00083-X; DEALMEIDA JLG, 1994, J AM OIL CHEM SOC, V71, P675; Garcia MT, 2002, CHEMOSPHERE, V49, P279, DOI 10.1016/S0045-6535(02)00182-0; Gueroult M, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001000; HERA, 2013, 68411303 CAS; Ishihama M, 2008, TOXICOL IN VITRO, V22, P1861, DOI 10.1016/j.tiv.2008.09.005; Ismail IH, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1169; Kekec G., 2015, TOXICOL IND HEALTH, V4, P377; Liwarska-Bizukojc E, 2005, CHEMOSPHERE, V58, P1249, DOI 10.1016/j.chemosphere.2004.10.031; Rosen MJ, 2001, ENVIRON SCI TECHNOL, V35, P954, DOI 10.1021/es0015411; Shin IJ, 2011, ONCOL REP, V25, P1313, DOI 10.3892/or.2011.1214; Toyooka T, 2012, MUTAT RES-GEN TOX EN, V741, P57, DOI 10.1016/j.mrgentox.2011.10.006; Toyooka T, 2009, MUTAT RES-GEN TOX EN, V676, P34, DOI 10.1016/j.mrgentox.2009.03.002; Toyooka T, 2011, J INVEST DERMATOL, V131, P1313, DOI 10.1038/jid.2011.28; Wu ZH, 2010, ECOTOXICOLOGY, V19, P761, DOI 10.1007/s10646-009-0453-8	39	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0027-5107	1873-135X		MUTAT RES-FUND MOL M	Mutat. Res.-Fundam. Mol. Mech. Mutagen.	JUL	2015	777						33	42		10.1016/j.mrfmmm.2015.04.006		10	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	CL1WR	WOS:000356736100005		
J	Ding, J; Chen, JH; Wang, YQ; Kataoka, M; Ma, LX; Zhou, PZ; Hu, XY; Lin, ZQ; Nie, M; Deng, ZL; Pu, WT; Wang, DZ				Ding, Jian; Chen, Jinghai; Wang, Yanqun; Kataoka, Masaharu; Ma, Lixin; Zhou, Pingzhu; Hu, Xiaoyun; Lin, Zhiqiang; Nie, Mao; Deng, Zhong-Liang; Pu, William T.; Wang, Da-Zhi			Trbp regulates heart function through microRNA-mediated Sox6 repression	NATURE GENETICS			English	Article							RNA-BINDING-PROTEIN; GENE-EXPRESSION; DILATED CARDIOMYOPATHY; CARDIAC-HYPERTROPHY; MUSCLE PERFORMANCE; TROPONIN-C; MUTATION; DICER; PROLIFERATION; MYOPATHY	Cardiomyopathy is associated with altered expression of genes encoding contractile proteins. Here we show that Trbp (Tarbp2), an RNA-binding protein, is required for normal heart function. Cardiac-specific inactivation in mice of Trbp (Trbp(cKO)) caused progressive cardiomyopathy and lethal heart failure. Loss of Trbp function resulted in upregulation of Sox6, repression of genes encoding normal cardiac slow-twitch myofiber proteins and pathologically increased expression of genes encoding skeletal fast-twitch myofiber proteins. Remarkably, knockdown of Sox6 fully rescued the Trbp-mutant phenotype, whereas mice overexpressing Sox6 phenocopied Trbp(cKO) mice. Trbp inactivation was mechanistically linked to Sox6 upregulation through altered processing of miR-208a, which is a direct inhibitor of Sox6. Transgenic overexpression of Mir208a sufficiently repressed Sox6, restored the balance in gene expression for fast-and slow-twitch myofiber proteins, and rescued cardiac function in Trbp(cKO) mice. Together, our studies identify a new Trbp-mediated microRNA-processing mechanism in the regulation of a linear genetic cascade essential for normal heart function.	[Ding, Jian; Chen, Jinghai; Kataoka, Masaharu; Ma, Lixin; Zhou, Pingzhu; Hu, Xiaoyun; Lin, Zhiqiang; Nie, Mao; Pu, William T.; Wang, Da-Zhi] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Cardiol, Boston, MA 02139 USA; [Wang, Yanqun] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Kataoka, Masaharu] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan; [Ma, Lixin] Hubei Univ, Coll Life Sci, Wuhan, Peoples R China; [Nie, Mao; Deng, Zhong-Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Chongqing, Peoples R China; [Pu, William T.; Wang, Da-Zhi] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Wang, DZ (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Cardiol, Boston, MA 02139 USA.	dwang@enders.tch.harvard.edu	Ding, Jian/F-6996-2015		March of Dimes Foundation; Muscular Dystrophy Association; US National Institutes of Health [HL085635, HL116919]; Banyu Life Science Foundation International	We thank D. Clapham and members of the Wang laboratory for advice and support. We thank R. Espinoza-Lewis, G. Wang and F. Gu for technical support. We thank F.F. Wang for careful reading of the manuscript. Work in the Wang laboratory is supported by the March of Dimes Foundation, the Muscular Dystrophy Association and the US National Institutes of Health (HL085635 and HL116919). M.K. was supported by Banyu Life Science Foundation International.	An CI, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-59; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Seok HY, 2014, CIRC RES, V114, P1585, DOI 10.1161/CIRCRESAHA.114.303784; LAING NG, 1995, NAT GENET, V9, P75, DOI 10.1038/ng0195-75; Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Tajsharghi H, 2007, ARCH NEUROL-CHICAGO, V64, P1334, DOI 10.1001/archneur.64.9.1334; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; van Rooij E, 2009, DEV CELL, V17, P662, DOI 10.1016/j.devcel.2009.10.013; Chen JF, 2008, P NATL ACAD SCI USA, V105, P2111, DOI 10.1073/pnas.0710228105; Creemers EE, 2011, NAT REV GENET, V12, P357, DOI 10.1038/nrg2983; Jiang JM, 2013, SCIENCE, V342, P111, DOI 10.1126/science.1236921; Kimber E, 2006, NEUROLOGY, V67, P597, DOI 10.1212/01.wnl.0000230168.05328.f4; Fukunaga R, 2012, CELL, V151, P533, DOI 10.1016/j.cell.2012.09.027; Trivedi CM, 2010, DEV CELL, V19, P450, DOI 10.1016/j.devcel.2010.08.012; Mogensen J, 2004, J AM COLL CARDIOL, V44, P2033, DOI 10.1016/j.jacc.2004.08.027; Chen JH, 2013, CIRC RES, V112, P1557, DOI 10.1161/CIRCRESAHA.112.300658; Morton SU, 2008, P NATL ACAD SCI USA, V105, P17830, DOI 10.1073/pnas.0804673105; Landstrom AP, 2008, J MOL CELL CARDIOL, V45, P281, DOI 10.1016/j.yjmcc.2008.05.003; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Lee LW, 2010, RNA, V16, P2170, DOI 10.1261/rna.2225110; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030; Liu N, 2008, GENE DEV, V22, P3242, DOI 10.1101/gad.1738708; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Lin ZQ, 2014, CIRC RES, V115, P354, DOI 10.1161/CIRCRESAHA.115.303632; De Vito C, 2012, CANCER CELL, V21, P807, DOI 10.1016/j.ccr.2012.04.023; Quiat D, 2011, P NATL ACAD SCI USA, V108, P10196, DOI 10.1073/pnas.1107413108; Huang ZP, 2013, CIRC RES, V112, P1234, DOI 10.1161/CIRCRESAHA.112.300682; Matkovich SJ, 2013, CIRC RES, V113, P62, DOI 10.1161/CIRCRESAHA.113.300975; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Lee HY, 2012, RNA, V18, P2012, DOI 10.1261/rna.035501.112; Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Feng HZ, 2010, AM J PHYSIOL-HEART C, V299, pH97, DOI 10.1152/ajpheart.01105.2009; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193; Heidersbach A, 2013, ELIFE, V2, DOI 10.7554/eLife.01323; Huang W, 2009, NUCLEIC ACIDS RES, V37, P1, DOI DOI 10.1093/NAR/GKN923; Huang W., 2009, NAT PROTOC, V4, P44, DOI DOI 10.1038/NPR0T.2008.211; Kim Y, 2014, CELL REP, V9, P1061, DOI 10.1016/j.celrep.2014.09.039; Olson TM, 2002, CIRCULATION, V105, P2337, DOI 10.1161/01.CIR.0000018444.47798.94; Petchey LK, 2014, P NATL ACAD SCI USA, V111, P9515, DOI 10.1073/pnas.1406191111; Shieh JTC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019481; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Trivedi CM, 2011, J MOL CELL CARDIOL, V50, P1056, DOI 10.1016/j.yjmcc.2011.02.015; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; Yu ZB, 2012, AM J PHYSIOL-CELL PH, V303, pC24, DOI 10.1152/ajpcell.00026.2012; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	50	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2015	47	7					776	+		10.1038/ng.3324		10	Genetics & Heredity	Genetics & Heredity	CL6PW	WOS:000357090300015		
J	Xu, C; Liberatore, KL; MacAlister, CA; Huang, ZJ; Chu, YH; Jiang, K; Brooks, C; Ogawa-Ohnishi, M; Xiong, GY; Pauly, M; Van Eck, J; Matsubayashi, Y; van der Knaap, E; Lippman, ZB				Xu, Cao; Liberatore, Katie L.; MacAlister, Cora A.; Huang, Zejun; Chu, Yi-Hsuan; Jiang, Ke; Brooks, Christopher; Ogawa-Ohnishi, Mari; Xiong, Guangyan; Pauly, Markus; Van Eck, Joyce; Matsubayashi, Yoshikatsu; van der Knaap, Esther; Lippman, Zachary B.			A cascade of arabinosyltransferases controls shoot meristem size in tomato	NATURE GENETICS			English	Article							RECEPTOR-LIKE KINASE; EXTREME FRUIT SIZE; ARABIDOPSIS-THALIANA; APICAL MERISTEM; INFLORESCENCE ARCHITECTURE; ORGAN DEVELOPMENT; GENE ENCODES; CELL; EVOLUTION; CLAVATA1	Shoot meristems of plants are composed of stem cells that are continuously replenished through a classical feedback circuit involving the homeobox WUSCHEL (WUS) gene and the CLAVATA (CLV) gene signaling pathway. In CLV signaling, the CLV1 receptor complex is bound by CLV3, a secreted peptide modified with sugars. However, the pathway responsible for modifying CLV3 and its relevance for CLV signaling are unknown. Here we show that tomato inflorescence branching mutants with extra flower and fruit organs due to enlarged meristems are defective in arabinosyltransferase genes. The most extreme mutant is disrupted in a hydroxyproline O-arabinosyltransferase and can be rescued with arabinosylated CLV3. Weaker mutants are defective in arabinosyltransferases that extend arabinose chains, indicating that CLV3 must be fully arabinosylated to maintain meristem size. Finally, we show that a mutation in CLV3 increased fruit size during domestication. Our findings uncover a new layer of complexity in the control of plant stem cell proliferation.	[Xu, Cao; Liberatore, Katie L.; MacAlister, Cora A.; Jiang, Ke; Brooks, Christopher; Lippman, Zachary B.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Liberatore, Katie L.; Lippman, Zachary B.] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; [Huang, Zejun; Chu, Yi-Hsuan; van der Knaap, Esther] Ohio State Univ, Dept Hort & Crop Sci, Wooster, OH USA; [Ogawa-Ohnishi, Mari; Matsubayashi, Yoshikatsu] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Xiong, Guangyan; Pauly, Markus] Univ Calif Berkeley, Energy Biosci Inst, Berkeley, CA 94720 USA; [Pauly, Markus] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Van Eck, Joyce] Boyce Thompson Inst Plant Sci, Ithaca, NY USA	Lippman, ZB (reprint author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	lippman@cshl.edu			Energy Biosciences Institute; Fred Dickinson Chair; National Science Foundation Graduate Research Fellowship [DGE-0914548]; Gordon and Betty Moore Foundation Fellowship from the Life Sciences Research Foundation; National Science Foundation Plant Genome Research Program [0922661, 1237880]; Agriculture and Food Research Initiative competitive grant of the US Department of Agriculture National Institute of Food and Agriculture [2015-67013-22823]	We thank members of the Lippman laboratory, especially S. Thomain for her initial finding of FAB2 and for invaluable conversations that helped shape this work. We thank D. Zamir (Hebrew University of Jerusalem) for providing mutants and also Y. Eshed (Weizmann Institute of Science) for providing mutants and comments on the manuscript. We thank S. Hearn at the Cold Spring Harbor Laboratory St. Giles Advanced Microscopy Center for providing technical service for transmission electron microscopy. We thank W. Wang for assistance with tomato transformation, X. Song for advice on peptide assays, DuPont Pioneer for research support, and T. Mulligan, A. Krainer and staff from Cornell University's Long Island Horticultural Research and Extension Center in Riverhead, New York, for assistance with plant care. This research was supported by the Energy Biosciences Institute and the Fred Dickinson Chair for M.P., a National Science Foundation Graduate Research Fellowship (DGE-0914548) to K.L.L., a Gordon and Betty Moore Foundation Fellowship from the Life Sciences Research Foundation to C.A.M., grants from the National Science Foundation Plant Genome Research Program to E.v.d.K. (0922661) and to J.V.E. and Z.B.L. (1237880), and an Agriculture and Food Research Initiative competitive grant (2015-67013-22823) of the US Department of Agriculture National Institute of Food and Agriculture to Z.B.L.	Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; Nimchuk ZL, 2011, PLANT CELL, V23, P851, DOI 10.1105/tpc.110.075622; Bommert P, 2013, NAT GENET, V45, P334, DOI 10.1038/ng.2534; Muller R, 2006, PLANT CELL, V18, P1188, DOI 10.1105/tpc.105.040444; Munos S, 2011, PLANT PHYSIOL, V156, P2244, DOI 10.1104/pp.111.173997; Schnabel EL, 2011, PLANT PHYSIOL, V157, P328, DOI 10.1104/pp.111.178756; Muller R, 2008, PLANT CELL, V20, P934, DOI 10.1105/tpc.107.057547; Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925; Cannon MC, 2008, P NATL ACAD SCI USA, V105, P2226, DOI 10.1073/pnas.0711980105; Velasquez SM, 2011, SCIENCE, V332, P1401, DOI 10.1126/science.1206657; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199; Ohyama K, 2009, NAT CHEM BIOL, V5, P578, DOI 10.1038/nchembio.182; Ogawa-Ohnishi M, 2013, NAT CHEM BIOL, V9, P726, DOI [10.1038/nchembio.1351, 10.1038/NCHEMBIO.1351]; Gille S, 2009, P NATL ACAD SCI USA, V106, P14699, DOI 10.1073/pnas.0905434106; Tanksley SD, 2004, PLANT CELL, V16, pS181, DOI 10.1105/tpc.018119; Belhaj K, 2015, CURR OPIN BIOTECH, V32, P76, DOI 10.1016/j.copbio.2014.11.007; Shinohara H, 2013, PLANT CELL PHYSIOL, V54, P369, DOI 10.1093/pcp/pcs174; Lombard V, 2014, NUCLEIC ACIDS RES, V42, pD490, DOI 10.1093/nar/gkt1178; Nelson BK, 2007, PLANT J, V51, P1126, DOI 10.1111/j.1365-313X.2007.03212.x; Cong B, 2008, NAT GENET, V40, P800, DOI 10.1038/ng.144; Lamport DTA, 2011, PLANT PHYSIOL, V156, P11, DOI 10.1104/pp.110.169011; Huang ZJ, 2011, THEOR APPL GENET, V123, P465, DOI 10.1007/s00122-011-1599-3; Prusinkiewicz P, 2007, SCIENCE, V316, P1452, DOI 10.1126/science.1140429; Park SJ, 2012, P NATL ACAD SCI USA, V109, P639, DOI 10.1073/pnas.1114963109; Sato S, 2012, NATURE, V485, P635, DOI 10.1038/nature11119; Reinhardt D, 2003, DEVELOPMENT, V130, P4073, DOI 10.1242/dev.00596; Egelund J, 2007, PLANT MOL BIOL, V64, P439, DOI 10.1007/s11103-007-9162-y; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Kinoshita A, 2010, DEVELOPMENT, V137, P3911, DOI 10.1242/dev.048199; Lippman Z, 2001, GENETICS, V158, P413; Doebley J, 2004, ANNU REV GENET, V38, P37, DOI 10.1146/annurev.genet.38.072902.092425; Brooks C, 2014, PLANT PHYSIOL, V166, P1292, DOI 10.1104/pp.114.247577; Nimchuk ZL, 2015, DEVELOPMENT, V142, P1043, DOI 10.1242/dev.119677; Pautler M, 2013, PLANT CELL PHYSIOL, V54, P302, DOI 10.1093/pcp/pct025; Betsuyaku S, 2011, PLANT CELL PHYSIOL, V52, P14, DOI 10.1093/pcp/pcq157; Barton MK, 2010, DEV BIOL, V341, P95, DOI 10.1016/j.ydbio.2009.11.029; Xiong GY, 2013, MOL PLANT, V6, P1373, DOI 10.1093/mp/sst014; DeYoung BJ, 2008, GENETICS, V180, P895, DOI 10.1534/genetics.108.091108; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; Menda N, 2004, PLANT J, V38, P861, DOI 10.1111/j.1365-313X.2004.02088.x; Saint-Jore-Dupas C, 2006, PLANT CELL, V18, P3182, DOI 10.1105/tpc.105.036400; Barrero LS, 2004, THEOR APPL GENET, V109, P669, DOI 10.1007/s00122-004-1676-y; Chevalier L, 2010, PLANT J, V64, P977, DOI 10.1111/j.1365-313X.2010.04388.x; DEYOUNG BJ, 2006, ARABIDOPSIS PLANT J, V45, P1; Dievart A, 2003, PLANT CELL, V15, P1198, DOI 10.1105/tpc.010504; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Fan CC, 2014, MOL PLANT, V7, P1788, DOI 10.1093/mp/ssu090; Fiers M, 2006, PLANT PHYSIOL, V141, P1284, DOI 10.1104/pp.106.080671; Fletcher Jennifer C., 1999, Science (Washington D C), V283, P1911, DOI 10.1126/science.283.5409.1911; Jackson D., 1992, MOL PLANT PATHOL, P163; Lippman ZB, 2008, PLOS BIOL, V6, P2424, DOI 10.1371/journal.pbio.0060288; Matsubayashi Yoshikatsu, 2011, Arabidopsis Book, V9, pe0150, DOI 10.1199/tab.0150; Park SJ, 2014, CURR OPIN PLANT BIOL, V17, P70, DOI 10.1016/j.pbi.2013.11.006; Petersen B.L., 2011, ANN PLANT REV PLANT; Rickett H. W., 1944, BOT REV, V10, P187, DOI 10.1007/BF02861094; Stahl Y, 2010, CURR OPIN PLANT BIOL, V13, P53, DOI 10.1016/j.pbi.2009.09.008; van der Knaap E, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00227; Xu C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1743; Xu TT, 2013, BMC PLANT BIOL, V13, DOI 10.1186/1471-2229-13-225; Yin Y., 2011, ANN PLANT REV PLANT; Zhang Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-827	62	4	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2015	47	7					784	+		10.1038/ng.3309		12	Genetics & Heredity	Genetics & Heredity	CL6PW	WOS:000357090300016		
J	Okada, Y; Momozawa, Y; Ashikawa, K; Kanai, M; Matsuda, K; Kamatani, Y; Takahashi, A; Kubo, M				Okada, Yukinori; Momozawa, Yukihide; Ashikawa, Kyota; Kanai, Masahiro; Matsuda, Koichi; Kamatani, Yoichiro; Takahashi, Atsushi; Kubo, Michiaki			Construction of a population-specific HLA imputation reference panel and its application to Graves' disease risk in Japanese	NATURE GENETICS			English	Article							GENOME-WIDE ASSOCIATION; SEROPOSITIVE RHEUMATOID-ARTHRITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; HAPLOTYPE BLOCKS; LOCI; MHC; ALLELES; SUSCEPTIBILITY; IDENTIFICATION; HLA-DRB1	To fine map association signals of human leukocyte antigen (HLA) variants in the major histocompatibility complex (MHC) region, we constructed a Japanese population-specific reference panel (n = 908). We conducted trans-ancestry comparisons of linkage disequilibrium (LD) and haplotype structure for HLA variants using an entropy-based LD measurement,., and a visualization tool to capture high-dimensional variables. Our Japanese reference panel exhibited stronger LD between HLA genes than European or other East Asian populations, characterized by one population-specific common long-range HLA haplotype. We applied HLA imputation to genome-wide association study (GWAS) data for Graves' disease in Japanese (n = 9,003) and found that amino acid polymorphisms of multiple class I and class II HLA genes independently contribute to disease risk (HLA-DPB1, HLA-A, HLA-B and HLA-DRB1; P < 2.3 x 10(-6)), with the strongest impact at HLA-DPB1 (P = 1.6 x 10(-42)). Our study illustrates the value of population-specific HLA reference panels.	[Okada, Yukinori; Kanai, Masahiro] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Divers, Tokyo, Japan; [Okada, Yukinori; Kamatani, Yoichiro; Takahashi, Atsushi] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan; [Momozawa, Yukihide; Ashikawa, Kyota] RIKEN Ctr Integrat Med Sci, Lab Genotyping Dev, Yokohama, Kanagawa, Japan; [Matsuda, Koichi] Univ Tokyo, Ctr Human Genome, Inst Med Sci, Mol Med Lab, Tokyo, Japan	Okada, Y (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Divers, Tokyo, Japan.	yokada.brc@tmd.ac.jp; michiaki.kubo@riken.jp			Japan Science and Technology Agency (JST); Japan Society of the Promotion of Science (JSPS); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Takeda Science Foundation; Gout Research Foundation; Tokyo Biochemical Research Foundation; Japan Rheumatism Foundation; Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government	We thank N. Kumasaka who originally developed the Disentangler software. We acknowledge T. Aoi and C. Inai for technical assistance and the members of BioBank Japan and the Rotary Club of Osaka-Midosuji District 2660 Rotary International for supporting our study. Y.O. was supported by the Japan Science and Technology Agency (JST), the Japan Society of the Promotion of Science (JSPS), the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Takeda Science Foundation, the Gout Research Foundation, the Tokyo Biochemical Research Foundation and the Japan Rheumatism Foundation. The BioBank Japan Project was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government.	Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076; Nakajima M, 2014, NAT GENET, V46, P1012, DOI 10.1038/ng.3045; Pillai NE, 2014, HUM MOL GENET, V23, P4443, DOI 10.1093/hmg/ddu149; Han B, 2014, AM J HUM GENET, V94, P522, DOI 10.1016/j.ajhg.2014.02.013; Simmonds MJ, 2007, HUM MOL GENET, V16, P2149, DOI 10.1093/hmg/ddm165; Okada Y, 2011, GASTROENTEROLOGY, V141, P864, DOI 10.1053/j.gastro.2011.05.048; Kamatani Y, 2009, NAT GENET, V41, P591, DOI 10.1038/ng.348; Brix TH, 2001, J CLIN ENDOCR METAB, V86, P930, DOI 10.1210/jc.86.2.930; de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885; Ban Y, 2004, GENES IMMUN, V5, P203, DOI 10.1038/sj.gene.6364059; Jin H, 2014, P NATL ACAD SCI USA, V111, P3787, DOI 10.1073/pnas.1401105111; Zhao SX, 2013, HUM MOL GENET, V22, P3347, DOI 10.1093/hmg/ddt183; de Bakker PIW, 2012, HUM MOL GENET, V21, pR29, DOI 10.1093/hmg/dds384; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Ueda S, 2014, J CLIN ENDOCR METAB, V99, pE379, DOI 10.1210/jc.2013-2841; Chu X, 2011, NAT GENET, V43, P897, DOI 10.1038/ng.898; Miyadera H, 2015, J CLIN INVEST, V125, P275, DOI 10.1172/JCI74961; Yamaguchi-Kabata Y, 2008, AM J HUM GENET, V83, P445, DOI 10.1016/j.ajhg.2008.08.019; Okada Y, 2014, AM J HUM GENET, V95, P162, DOI 10.1016/j.ajhg.2014.07.002; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Gourraud PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097282; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Jia XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064683; Kawashima M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046806; Kumasaka N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010207; Nakabayashi K, 2011, J HUM GENET, V56, P772, DOI 10.1038/jhg.2011.99; Nakamura Yusuke, 2007, Clin Adv Hematol Oncol, V5, P696; Nothnagel M, 2002, HUM HERED, V54, P186, DOI 10.1159/000070664; Nothnagel M, 2005, AM J HUM GENET, V77, P988, DOI 10.1086/498175; Okada Y, 2009, ARTHRITIS RHEUM, V60, P3582, DOI 10.1002/art.24939; Okada Y, 2010, ANN RHEUM DIS, V69, P1569, DOI 10.1136/ard.2009.118018; Okada Y, 2014, HUM MOL GENET, V23, P6916, DOI 10.1093/hmg/ddu387; ONUMA H, 1994, HUM IMMUNOL, V39, P195, DOI 10.1016/0198-8859(94)90260-7; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707	34	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2015	47	7					798	+		10.1038/ng.3310		7	Genetics & Heredity	Genetics & Heredity	CL6PW	WOS:000357090300018		
J	Chen, YC; Auer-Grumbach, M; Matsukawa, S; Zitzelsberger, M; Themistocleous, AC; Strom, TM; Samara, C; Moore, AW; Cho, LTY; Young, GT; Weiss, C; Schabhuttl, M; Stucka, R; Schmid, AB; Parman, Y; Graul-Neumann, L; Heinritz, W; Passarge, E; Watson, RM; Hertz, JM; Moog, U; Baumgartner, M; Valente, EM; Pereira, D; Restrepo, CM; Katona, I; Dusl, M; Stendel, C; Wieland, T; Stafford, F; Reimann, F; Von Au, K; Finke, C; Willems, PJ; Nahorski, MS; Shaikh, SS; Carvalho, OP; Nicholas, AK; Karbani, G; McAleer, MA; Cilio, MR; McHugh, JC; Murphy, SM; Irvine, AD; Jensen, UB; Windhager, R; Weis, J; Bergmann, C; Rautenstrauss, B; Baets-, J; De Jonghe, P; Reilly, MM; Kropatsch, R; Kurth, I; Chrast, R; Michiue, T; Bennett, DLH; Woods, CG; Senderek, J				Chen, Ya-Chun; Auer-Grumbach, Michaela; Matsukawa, Shinya; Zitzelsberger, Manuela; Themistocleous, Andreas C.; Strom, Tim M.; Samara, Chrysanthi; Moore, Adrian W.; Cho, Lily Ting-Yin; Young, Gareth T.; Weiss, Caecilia; Schabhuettl, Maria; Stucka, Rolf; Schmid, Annina B.; Parman, Yesim; Graul-Neumann, Luitgard; Heinritz, Wolfram; Passarge, Eberhard; Watson, Rosemarie M.; Hertz, Jens Michael; Moog, Ute; Baumgartner, Manuela; Valente, Enza Maria; Pereira, Diego; Restrepo, Carlos M.; Katona, Istvan; Dusl, Marina; Stendel, Claudia; Wieland, Thomas; Stafford, Fay; Reimann, Frank; Von Au, Katja; Finke, Christian; Willems, Patrick J.; Nahorski, Michael S.; Shaikh, Samiha S.; Carvalho, Ofelia P.; Nicholas, Adeline K.; Karbani, Gulshan; McAleer, Maeve A.; Cilio, Maria Roberta; McHugh, John C.; Murphy, Sinead M.; Irvine, Alan D.; Jensen, Uffe Birk; Windhager, Reinhard; Weis, Joachim; Bergmann, Carsten; Rautenstrauss, Bernd; Baets, Jonathan; De Jonghe, Peter; Reilly, Mary M.; Kropatsch, Regina; Kurth, Ingo; Chrast, Roman; Michiue, Tatsuo; Bennett, David L. H.; Woods, C. Geoffrey; Senderek, Jan			Transcriptional regulator PRDM12 is essential for human pain perception	NATURE GENETICS			English	Article							STEM-CELLS; SET DOMAIN; EPIGENETIC CONTROL; NEURAL CREST; PROTEIN; MUTATIONS; NEUROGENESIS; EXPRESSION; GENE; NEUROPATHY	Pain perception has evolved as a warning mechanism to alert organisms to tissue damage and dangerous environments(1,2). In humans, however, undesirable, excessive or chronic pain is a common and major societal burden for which available medical treatments are currently suboptimal(3,4). New therapeutic options have recently been derived from studies of individuals with congenital insensitivity to pain (CIP)(5,6). Here we identified 10 different homozygous mutations in PRDM12 (encoding PRDI-BF1 and RIZ homology domain-containing protein 12) in subjects with CIP from 11 families. Prdm proteins are a family of epigenetic regulators that control neural specification and neurogenesis(7,8). We determined that Prdm12 is expressed in nociceptors and their progenitors and participates in the development of sensory neurons in Xenopus embryos. Moreover, CIP-associated mutants abrogate the histone-modifying potential associated with wild-type Prdm12. Prdm12 emerges as a key factor in the orchestration of sensory neurogenesis and may hold promise as a target for new pain therapeutics(9,10).	[Chen, Ya-Chun; Stafford, Fay; Nahorski, Michael S.; Shaikh, Samiha S.; Carvalho, Ofelia P.; Woods, C. Geoffrey] Univ Cambridge, Dept Med Genet, Cambridge, England; [Chen, Ya-Chun; Stafford, Fay; Nahorski, Michael S.; Shaikh, Samiha S.; Carvalho, Ofelia P.; Nicholas, Adeline K.; Woods, C. Geoffrey] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England; [Auer-Grumbach, Michaela; Schabhuettl, Maria; Cilio, Maria Roberta; Windhager, Reinhard] Med Univ Vienna, Dept Orthopaed, Vienna, Austria; [Matsukawa, Shinya; Baets, Jonathan; Michiue, Tatsuo] Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo, Japan; [Zitzelsberger, Manuela; Weiss, Caecilia; Stucka, Rolf; Dusl, Marina; Stendel, Claudia; Rautenstrauss, Bernd; Senderek, Jan] Univ Munich, Friedrich Baur Inst, Munich, Germany; [Themistocleous, Andreas C.; Schmid, Annina B.; Bennett, David L. H.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Themistocleous, Andreas C.] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Brain Funct Res Grp, Johannesburg, South Africa; [Strom, Tim M.; Wieland, Thomas] Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany; [Strom, Tim M.; Chrast, Roman] Tech Univ Munich, Inst Human Genet, D-80290 Munich, Germany; [Samara, Chrysanthi] Univ Lausanne, Dept Med Genet, Lausanne, Switzerland; RIKEN Brain Sci Inst, Dis Mech Res Core, Saitama, Japan; [Cho, Lily Ting-Yin; Young, Gareth T.] Pfizer, Neusentis Res Unit, Cambridge, England; [Schmid, Annina B.] Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld, Australia; [Parman, Yesim] Istanbul Univ, Dept Neurol, Istanbul, Turkey; [Graul-Neumann, Luitgard] Univ Med Berlin, Ambulantes Gesundheitszentrum Charite Campus Virc, Berlin, Germany; [Heinritz, Wolfram] Praxis Humangenetik Cottbus, Cottbus, Germany; [Heinritz, Wolfram; Passarge, Eberhard] Univ Leipzig, Inst Humangenet, D-04109 Leipzig, Germany; [Passarge, Eberhard] Univ Klinikum Essen, Inst Humangenet, Essen, Germany; [Watson, Rosemarie M.; McAleer, Maeve A.; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Dermatol, Dublin, Ireland; [Hertz, Jens Michael] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark; [Moog, Ute] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany; [Baumgartner, Manuela] Krankenhaus Barmherzigen Schwestern Linz, Neuropadiatr Ambulanz, Linz, Austria; [Valente, Enza Maria] Casa Sollievo Sofferenza, Neurogenet Unit, San Giovanni Rotondo, Italy; [Pereira, Diego] Univ San Jose Bogota, Hosp Infantil, Dept Cirugia Plast, Bogota, Colombia; [Restrepo, Carlos M.] Univ Rosario, Unidad Genet, Bogota, Colombia; [Katona, Istvan; Weis, Joachim] Uniklin RWTH Aachen, Inst Neuropathol, Aachen, Germany; [Stendel, Claudia] German Ctr Neurodegenerat Dis DZNE, Munich, Germany; [Reimann, Frank] Univ Cambridge, Dept Clin Biochem, Cambridge, England; [Von Au, Katja] Uni Med Berlin, SP7 Neuropadiat Charite, Berlin, Germany; [Finke, Christian] Uni Med Berlin, Arbeitsbereich Kinderzahnmed, ChariteCentrum Zahn Mund & Kieferheilkunde, Berlin, Germany; [Willems, Patrick J.] GENDIA, GENet DIAgnost Network, Antwerp, Belgium; [Karbani, Gulshan] Chapel Allerton Hosp, Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England; [Cilio, Maria Roberta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Cilio, Maria Roberta] Bambino Gesu Pediat Hosp, Dept Neurosci, Rome, Italy; [Cilio, Maria Roberta] Res Inst, Rome, Italy; [McHugh, John C.] Our Ladys Childrens Hosp, Dept Neurol & Neurophysiol, Dublin, Ireland; [Murphy, Sinead M.] Adelaide & Meath Hosp, Dept Neurol, Dublin, Ireland; [Murphy, Sinead M.] Trin Coll, Acad Unit Neurol, Dublin, Ireland; [Irvine, Alan D.] Trin Coll, Clin Med, Dublin, Ireland; [Jensen, Uffe Birk] Aarhus Univ Hosp, Dept Clin Genet, DK-8000 Aarhus, Denmark; [Bergmann, Carsten] Ctr Human Genet, Bioscientia, Ingelheim, Germany; [Bergmann, Carsten] Univ Freiburg, Med Ctr, Div Renal, Dept Med, D-79106 Freiburg, Germany; [Bergmann, Carsten] Univ Freiburg, Med Ctr, Clin Res Ctr, D-79106 Freiburg, Germany; [Rautenstrauss, Bernd] Med Genet Zentrum, Munich, Germany; [De Jonghe, Peter] Univ Antwerp, VIB Dept Mol Genet, Neurogenet Grp, B-2020 Antwerp, Belgium; [Baets, Jonathan; De Jonghe, Peter] Univ Antwerp, Inst Born Bunge, Neurogenet Lab, B-2020 Antwerp, Belgium; [Baets, Jonathan; De Jonghe, Peter] Univ Antwerp Hosp, Dept Neurol, Antwerp, Belgium; [Reilly, Mary M.] Natl Hosp Neurol, UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England; [Kropatsch, Regina] Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany; [Kurth, Ingo] Jena Univ Hosp, Inst Human Genet, Jena, Germany; [Chrast, Roman] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Chrast, Roman] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	Woods, CG (reprint author), Univ Cambridge, Dept Med Genet, Cambridge, England.	cw347@cam.ac.uk; jan.senderek@med.uni-muenchen.de	Schmid, Annina/F-3070-2010; Hertz, Jens Michael/H-6269-2014; Weis, Joachim/G-1984-2014; Senderek, Jan/F-8405-2015; 	Schmid, Annina/0000-0001-7759-0211; Weis, Joachim/0000-0003-3280-6773; Katona, Istvan/0000-0002-0955-8911; Kurth, Ingo/0000-0002-5642-8378; Senderek, Jan/0000-0002-8263-1783; Irvine, Alan/0000-0002-9048-2044	Cambridge NIHR Biomedical Research Centre; Austrian Science Fond [P23223-B19]; UK Medical Research Council; Association Belge contre les Maladies Neuromusculaires; EU [2012-305121]; Deutsche Forschungsgemeinschaft [CRC/SFB 1140, KU1587/4-1]; Gebert-Ruf Stiftung [GRS-046/09]; Friedrich-Baur Stiftung	The authors are grateful for the participation of the patients and their families in this study. The help of all contributing medical, technical and administrative staff is greatly appreciated. We thank S. Malik for her invaluable work with family A, J.R.P. Madrid and F. Axelrod for advice and discussion and M.F. Passarge for helpful suggestions on the text. D.L.H.B. is a senior Wellcome Clinical Scientist (ref. no. 095698z/11/z). This work was supported by Cambridge NIHR Biomedical Research Centre (Y.-C.C., F.S. and C.G.W.), Austrian Science Fond (P23223-B19 to M.A.-G.), the UK Medical Research Council (M.S.N. and S.S.S.), Association Belge contre les Maladies Neuromusculaires and EU FP7/2007-2013 (grant 2012-305121 (NEUROMICS) to J.B. and P.D.J.), Deutsche Forschungsgemeinschaft (CRC/SFB 1140 to C.B. and KU1587/4-1 to I. Kurth), Gebert-Ruf Stiftung (GRS-046/09 to R.C. and J.S.), and Friedrich-Baur Stiftung (J.S.).	Arnaud E, 2009, P NATL ACAD SCI USA, V106, P17528, DOI 10.1073/pnas.0905523106; Stendel C, 2010, BRAIN, V133, P2462, DOI 10.1093/brain/awq168; Hohenauer T, 2012, DEVELOPMENT, V139, P2267, DOI 10.1242/dev.070110; Hu XL, 2012, PROTEIN CELL, V3, P278, DOI 10.1007/s13238-012-2916-6; Doppler K, 2013, J PERIPHER NERV SYST, V18, P168, DOI 10.1111/jns5.12023; Rossi CC, 2009, DEV DYNAM, V238, P931, DOI 10.1002/dvdy.21915; Carvalho OP, 2011, J MED GENET, V48, P131, DOI 10.1136/jmg.2010.081455; Holmes D, 2012, NAT REV DRUG DISCOV, V11, P337, DOI 10.1038/nrd3732; Dubin AE, 2010, J CLIN INVEST, V120, P3760, DOI 10.1172/JCI42843; Amir RE, 1999, NAT GENET, V23, P185; Tan SL, 2012, DEVELOPMENT, V139, P3806, DOI 10.1242/dev.082198; Sato T, 2005, DEVELOPMENT, V132, P2355, DOI 10.1242/dev.01823; Bennett DLH, 2014, LANCET NEUROL, V13, P587, DOI 10.1016/S1474-4422(14)70024-9; Klein CJ, 2011, NAT GENET, V43, P595, DOI 10.1038/ng.830; Endo K, 2012, NAT NEUROSCI, V15, P224, DOI 10.1038/nn.2998; Schlosser G, 2006, DEV BIOL, V294, P303, DOI 10.1016/j.ydbio.2006.03.009; Zannino DA, 2014, DEV BIOL, V390, P247, DOI 10.1016/j.ydbio.2014.02.025; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; MERSKEY H, 1979, PAIN, V7, P271, DOI 10.1016/0304-3959(79)90084-8; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Jakovcevski M, 2012, NAT MED, V18, P1194, DOI 10.1038/nm.2828; Hall BK, 2008, J BIOSCIENCES, V33, P781; Moore AW, 2002, SCIENCE, V297, P1355, DOI 10.1126/science.1072387; Boshnjaku V, 2011, EPIGENETICS-US, V6, P1207, DOI 10.4161/epi.6.10.17592; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr/212802; Nicholas AK, 2009, J MED GENET, V46, P249, DOI 10.1136/jmg.2008.062380; Kleefstra T, 2006, AM J HUM GENET, V79, P370, DOI 10.1086/505693; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Young GT, 2014, MOL THER, V22, P1530, DOI 10.1038/mt.2014.86; Grove EA, 1998, DEVELOPMENT, V125, P2315; Goldberg YP, 2012, CLIN GENET, V82, P367, DOI 10.1111/j.1399-0004.2012.01942.x; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Chambers SM, 2012, NAT BIOTECHNOL, V30, P715, DOI 10.1038/nbt.2249; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Wong KC, 2014, BIOINFORMATICS, V30, P1112, DOI 10.1093/bioinformatics/btt769; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Einarsdottir E, 2004, HUM MOL GENET, V13, P799, DOI 10.1093/hmg/ddh096; Leipold E, 2013, NAT GENET, V45, P1399, DOI 10.1038/ng.2767; Chittka A, 2012, J BIOL CHEM, V287, P42995, DOI 10.1074/jbc.M112.392746; Denk F, 2012, NEURON, V73, P435, DOI 10.1016/j.neuron.2012.01.012; Cox JJ, 2006, NATURE, V444, P894, DOI 10.1038/nature05413; Albrecht A, 2005, CURR OPIN GENET DEV, V15, P285, DOI 10.1016/j.gde.2005.04.003; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Crow M, 2013, GENOME MED, V5, DOI 10.1186/gm416; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hughes J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003290; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Jobe EM, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00059; Kinameri E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003859; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OCHOA J, 1969, ACTA NEUROPATHOL, V13, P197; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Yang Chia-Ming, 2013, Cell Struct Funct, V38, P197	56	5	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2015	47	7					803	+		10.1038/ng.3308		9	Genetics & Heredity	Genetics & Heredity	CL6PW	WOS:000357090300019		
J	Fabrika, S; Ueda, Y; Vinokurov, A; Sholukhova, O; Shidatsu, M				Fabrika, Sergei; Ueda, Yoshihiro; Vinokurov, Alexander; Sholukhova, Olga; Shidatsu, Megumi			Supercritical accretion disks in ultraluminous X-ray sources and SS 433	NATURE PHYSICS			English	Letter							BLACK-HOLE; GRO J1655-40; MASS; STARS; SPECTRA	The black hole mass and accretion rate in ultraluminous X-ray sources (ULXs) in external galaxies, whose X-ray luminosities exceed those of the brightest black holes in our Galaxy by hundreds and thousands of times(1,2), is an unsolved problem. Here we report that all ULXs ever spectroscopically observed have almost the same optical spectra, apparently of WNL type (late nitrogen Wolf-Rayet stars) or LBV (luminous blue variables) in their hot state, which are very scarce stellar objects. We show that the spectra do not originate from WNL/LBV-type donors but from very hot winds from the accretion disks with nearly normal hydrogen content, which have similar physical conditions to the stellar winds from these stars. The optical spectra are similar to that of SS 433, the only known supercritical accretor in our Galaxy(3), although the ULX spectra indicate a higher wind temperature. Our results suggest that ULXs with X-ray luminosities of similar to 10(40) erg s(-1) must constitute a homogeneous class of objects, which most likely have supercritical accretion disks.	[Fabrika, Sergei; Vinokurov, Alexander; Sholukhova, Olga] Special Astrophys Observ, Nizhnii Arkhyz 369167, Russia; [Fabrika, Sergei] Kazan Fed Univ, Kazan 420008, Russia; [Ueda, Yoshihiro; Shidatsu, Megumi] Kyoto Univ, Dept Astron, Kyoto 6068502, Japan	Fabrika, S (reprint author), Special Astrophys Observ, Nizhnii Arkhyz 369167, Russia.	fabrika@sao.ru					Cseh D, 2013, MON NOT R ASTRON SOC, V435, P2896, DOI 10.1093/mnras/stt1484; Walborn NR, 2000, PUBL ASTRON SOC PAC, V112, P50, DOI 10.1086/316490; Hamann WR, 1998, ASTRON ASTROPHYS, V333, P251; Liu JF, 2013, NATURE, V503, P500, DOI 10.1038/nature12762; Madau P, 2001, ASTROPHYS J, V551, pL27, DOI 10.1086/319848; Feng H, 2011, NEW ASTRON REV, V55, P166, DOI 10.1016/j.newar.2011.08.002; SHAKURA NI, 1973, ASTRON ASTROPHYS, V24, P337; Poutanen J, 2007, MON NOT R ASTRON SOC, V377, P1187, DOI 10.1111/j.1365-2966.2007.11668.x; Roberts TP, 2011, ASTRON NACHR, V332, P398, DOI 10.1002/asna.201011508; Bregman J. N., 2012, PREPRINT; CHARLES PA, 1989, ESA SP PUBL, V296, P103; Crowther PA, 2011, MON NOT R ASTRON SOC, V416, P1311, DOI 10.1111/j.1365-2966.2011.19129.x; Crowther PA, 1997, ASTRON ASTROPHYS, V320, P500; Fabrika S., 2004, ASTROPHYS SPACE PHYS, V12, P1; Fuchs Y, 2006, ASTRON ASTROPHYS, V445, P1041, DOI 10.1051/0004-6361:20042160; GRANDI SA, 1982, PUBL ASTRON SOC PAC, V94, P80, DOI 10.1086/130945; Hunstead RW, 1997, ASTR SOC P, V121, P63; Kubota K, 2010, ASTROPHYS J, V709, P1374, DOI 10.1088/0004-637X/709/2/1374; Makishima K, 2000, ASTROPHYS J, V535, P632, DOI 10.1086/308868; Miller-Jones JCA, 2009, ASTROPHYS J LETT, V706, pL230, DOI 10.1088/0004-637X/706/2/L230; Motch C, 2014, NATURE, V514, P198, DOI 10.1038/nature13730; Ohsuga K, 2011, ASTROPHYS J, V736, DOI 10.1088/0004-637X/736/1/2; Sholukhova ON, 2011, ASTROPHYS BULL, V66, P123, DOI 10.1134/S1990341311020015; Soria R, 1998, ASTROPHYS J, V495, pL95, DOI 10.1086/311225; Soria R, 1999, MON NOT R ASTRON SOC, V310, P71, DOI 10.1046/j.1365-8711.1999.02933.x; Tao L, 2011, ASTROPHYS J, V737, DOI 10.1088/0004-637X/737/2/81; Vinokurov A, 2013, ASTROPHYS BULL, V68, P139, DOI 10.1134/S1990341313020028	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-2473	1745-2481		NAT PHYS	Nat. Phys.	JUL	2015	11	7					551	553		10.1038/NPHYS3348		3	Physics, Multidisciplinary	Physics	CL8BP	WOS:000357197300019		
J	Kirino, Y; Remmers, EF				Kirino, Yohei; Remmers, Elaine F.			Genetic architectures of seropositive and seronegative rheumatic diseases	NATURE REVIEWS RHEUMATOLOGY			English	Review							SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; PSORIASIS SUSCEPTIBILITY LOCI; INFLAMMATORY-BOWEL-DISEASE; CHINESE HAN POPULATION; MHC CLASS-I; RISK LOCI; ANKYLOSING-SPONDYLITIS; JAPANESE POPULATION; CROHNS-DISEASE	Rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis and some other rheumatic diseases are genetically complex, with evidence of familial clustering, but not of Mendelian inheritance. These diseases are thought to result from contributions and interactions of multiple genetic and nongenetic risk factors, which have small effects individually. Genome-wide association studies (GWAS) of large collections of data from cases and controls have revealed many genetic factors that contribute to nonMendelian rheumatic diseases, thus providing insights into associated molecular mechanisms. This Review summarizes methods for the identification of gene variants that influence genetically complex diseases and focuses on what we have learned about the rheumatic diseases for which GWAS have been reported. Our review of the disease-associated loci identified to date reveals greater sharing of risk loci among the groups of seropositive (diseases in which specific autoantibodies are often present) or seronegative diseases than between these two groups. The nature of the shared and discordant loci suggests important similarities and differences among these diseases.	[Kirino, Yohei] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; [Remmers, Elaine F.] NHGRI, NIH, Inflammatory Dis Sect, Bethesda, MD 20892 USA	Remmers, EF (reprint author), NHGRI, NIH, Inflammatory Dis Sect, 10 Ctr Dr,MSC 1849, Bethesda, MD 20892 USA.	elaine.remmers@nih.gov			Japan Society for the Promotion of Science [26713036]; Naito Memorial Foundation; Uehara Memorial Foundation; Japan Intractable Diseases Research Foundation; Japan Rheumatic Disease Foundation; Yokohama Foundation for Advancement of Medical Science	The authors thank M. J. Ombrello and D. L. Kastner for their comments on this manuscript. Y.K. is supported by grants from Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (Grant No. 26713036), The Naito Memorial Foundation, The Uehara Memorial Foundation, Japan Intractable Diseases Research Foundation, Japan Rheumatic Disease Foundation, and Yokohama Foundation for Advancement of Medical Science.	1000 Genomes, 2015, DEEP CAT HUM GEN VAR; Allanore Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002091; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Lin ZM, 2012, NAT GENET, V44, P73, DOI 10.1038/ng.1005; Martin JE, 2012, HUM MOL GENET, V21, P2825, DOI 10.1093/hmg/dds099; Kochi Y, 2010, NAT GENET, V42, P515, DOI 10.1038/ng.583; Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076; Fraussen J, 2014, AUTOIMMUN REV, V13, P1126, DOI 10.1016/j.autrev.2014.07.002; Terao C, 2011, HUM MOL GENET, V20, P2680, DOI 10.1093/hmg/ddr161; Edwards SL, 2013, AM J HUM GENET, V93, P779, DOI 10.1016/j.ajhg.2013.10.012; Capon F, 2008, HUM MOL GENET, V17, P1938, DOI 10.1093/hmg/ddn091; Mease P, 2011, ARTHRITIS RHEUM-US, V63, P939, DOI 10.1002/art.30176; JUJI T, 1984, TISSUE ANTIGENS, V24, P316, DOI 10.1111/j.1399-0039.1984.tb02144.x; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Musunuru K, 2010, NATURE, V466, P714, DOI 10.1038/nature09266; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Dilthey AT, 2011, BIOINFORMATICS, V27, P968, DOI 10.1093/bioinformatics/btr061; Reeves E, 2013, J IMMUNOL, V191, P35, DOI 10.4049/jimmunol.1300598; Stahl EA, 2012, NAT GENET, V44, P483, DOI 10.1038/ng.2232; Cortes A, 2013, NAT GENET, V45, P730, DOI 10.1038/ng.2667; Yang J, 2011, HUM MOL GENET, V20, P601, DOI 10.1093/hmg/ddq474; Ellinghaus E, 2010, NAT GENET, V42, P991, DOI 10.1038/ng.689; Li YZ, 2013, NAT GENET, V45, P1361, DOI 10.1038/ng.2779; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625; Han B, 2014, AM J HUM GENET, V94, P522, DOI 10.1016/j.ajhg.2014.02.013; Ramos PS, 2011, ARTHRITIS RHEUM-US, V63, P2049, DOI 10.1002/art.30356; Zuk O, 2014, P NATL ACAD SCI USA, V111, pE455, DOI 10.1073/pnas.1322563111; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Yang WL, 2013, AM J HUM GENET, V92, P41, DOI 10.1016/j.ajhg.2012.11.018; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361; Lessard CJ, 2012, AM J HUM GENET, V90, P648, DOI 10.1016/j.ajhg.2012.02.023; Morris DL, 2012, AM J HUM GENET, V91, P778, DOI 10.1016/j.ajhg.2012.08.026; Irigoyen P, 2005, ARTHRITIS RHEUM, V52, P3813, DOI 10.1002/art.21419; Jostins L, 2011, HUM MOL GENET, V20, pR182, DOI 10.1093/hmg/ddr378; Casanova JL, 2009, J EXP MED, V206, P1839, DOI 10.1084/jem.20091683; Yamazaki K, 2013, GASTROENTEROLOGY, V144, P781, DOI 10.1053/j.gastro.2012.12.021; Baccala R, 2007, NAT MED, V13, P543, DOI 10.1038/nm1590; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Hunt KA, 2013, NATURE, V498, P232, DOI 10.1038/nature12170; Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193; Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796; Panoutsopoulou K, 2013, HUM MOL GENET, V22, pR16, DOI 10.1093/hmg/ddt376; Zhang J, 2014, HUM MOL GENET, V23, P524, DOI 10.1093/hmg/ddt424; Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817; Schmitt MW, 2012, P NATL ACAD SCI USA, V109, P14508, DOI 10.1073/pnas.1208715109; Stuart PE, 2010, NAT GENET, V42, P1000, DOI 10.1038/ng.693; Lou DI, 2013, P NATL ACAD SCI USA, V110, P19872, DOI 10.1073/pnas.1319590110; Cheng H, 2014, J INVEST DERMATOL, V134, P359, DOI 10.1038/jid.2013.317; Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75; Eyre S, 2012, NAT GENET, V44, P1336, DOI 10.1038/ng.2462; Tang HY, 2014, NAT GENET, V46, P45, DOI 10.1038/ng.2827; Radstake TRDJ, 2010, NAT GENET, V42, P426, DOI 10.1038/ng.565; Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981; Trynka G, 2013, NAT GENET, V45, P124, DOI 10.1038/ng.2504; Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513; Raychaudhuri S, 2008, NAT GENET, V40, P1216, DOI 10.1038/ng.233; Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213; HELIOVAARA M, 1993, J RHEUMATOL, V20, P1830; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Onouchi Y, 2012, NAT GENET, V44, P517, DOI 10.1038/ng.2220; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608; Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873; Verpoort KN, 2005, ARTHRITIS RHEUM, V52, P3058, DOI 10.1002/art.21302; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Kozyrev SV, 2008, NAT GENET, V40, P211, DOI 10.1038/ng.79; Kim-Howard X, 2014, HUM MOL GENET, V23, P1656, DOI 10.1093/hmg/ddt532; Padyukov L, 2011, ANN RHEUM DIS, V70, P259, DOI 10.1136/ard.2009.126821; Honda K, 2012, ANNU REV IMMUNOL, V30, P759, DOI 10.1146/annurev-immunol-020711-074937; Hu XL, 2011, AM J HUM GENET, V89, P496, DOI 10.1016/j.ajhg.2011.09.002; Kirino Y, 2013, P NATL ACAD SCI USA, V110, P8134, DOI 10.1073/pnas.1306352110; Quinton JF, 1998, GUT, V42, P788; Belot A, 2013, ARTHRITIS RHEUM-US, V65, P2161, DOI 10.1002/art.38008; McAllister K, 2013, ARTHRITIS RHEUM-US, V65, P3058, DOI 10.1002/art.38183; Ombrello MJ, 2014, BEST PRACT RES CL RH, V28, P175, DOI 10.1016/j.berh.2014.05.001; Reveille JD, 1998, ARTHRITIS RHEUM, V41, P1161, DOI 10.1002/1529-0131(199807)41:7<1161::AID-ART4>3.0.CO;2-K; Xie G, 2013, ARTHRITIS RHEUM-US, V65, P2457, DOI 10.1002/art.38036; Kirino Y, 2013, NAT GENET, V45, P202, DOI 10.1038/ng.2520; Haroon N, 2010, NAT REV RHEUMATOL, V6, P461, DOI 10.1038/nrrheum.2010.85; Bowness P, 2011, J IMMUNOL, V186, P2672, DOI 10.4049/jimmunol.1002653; Cargill M, 1999, NAT GENET, V22, P231; Lessard CJ, 2013, NAT GENET, V45, P1284, DOI 10.1038/ng.2792; Diogo D, 2013, AM J HUM GENET, V92, P15, DOI 10.1016/j.ajhg.2012.11.012; Mayes MD, 2014, AM J HUM GENET, V94, P47, DOI 10.1016/j.ajhg.2013.12.002; Coustet B, 2011, ARTHRITIS RHEUM-US, V63, P2091, DOI 10.1002/art.30379; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Remmers EF, 2007, NEW ENGL J MED, V357, P977, DOI 10.1056/NEJMoa073003; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Ellinghaus E, 2012, J INVEST DERMATOL, V132, P1133, DOI 10.1038/jid.2011.415; Jiang L, 2014, ARTHRITIS RHEUMATOL, V66, P1121, DOI 10.1002/art.38353; Lyons PA, 2012, NEW ENGL J MED, V367, P214, DOI 10.1056/NEJMoa1108735; Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467; Achkar JP, 2012, GENES IMMUN, V13, P245, DOI 10.1038/gene.2011.79; Mahdi H, 2009, NAT GENET, V41, P1319, DOI 10.1038/ng.480; Hinks A, 2013, NAT GENET, V45, P664, DOI 10.1038/ng.2614; Suzuki A, 2003, NAT GENET, V34, P395, DOI 10.1038/ng1206; Li H, 2013, HUM GENET, V132, P293, DOI 10.1007/s00439-012-1250-7; Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Henrichsen CN, 2009, HUM MOL GENET, V18, pR1, DOI 10.1093/hmg/ddp011; Julia A, 2013, GUT, V62, P1440, DOI 10.1136/gutjnl-2012-302865; Suzuki A, 2008, NAT GENET, V40, P1224, DOI 10.1038/ng.205; Katz U, 2010, AUTOIMMUN REV, V10, P46, DOI 10.1016/j.autrev.2010.07.005; Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694; Hall JC, 2010, NAT REV RHEUMATOL, V6, P40, DOI 10.1038/nrrheum.2009.237; Hughes T, 2011, ARTHRITIS RHEUM-US, V63, P1689, DOI 10.1002/art.30320; Bonfiglioli R, 2008, CLIN RHEUMATOL, V27, P709, DOI 10.1007/s10067-007-0770-3; Huffmeier U, 2010, NAT GENET, V42, P996, DOI 10.1038/ng.688; Manjarrez-Orduno N, 2012, NAT GENET, V44, P1227, DOI 10.1038/ng.2439; Sun LD, 2010, NAT GENET, V42, P1005, DOI 10.1038/ng.690; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Costenbader KH, 2012, AUTOIMMUN REV, V11, P604, DOI 10.1016/j.autrev.2011.10.022; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Lee YC, 2012, NAT GENET, V44, P522, DOI 10.1038/ng.2227; Raychaudhuri S, 2009, NAT GENET, V41, P1313, DOI 10.1038/ng.479; Raj T, 2013, AM J HUM GENET, V92, P517, DOI 10.1016/j.ajhg.2013.03.001; Ombrello MJ, 2014, P NATL ACAD SCI USA, V111, P8867, DOI 10.1073/pnas.1406575111; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Armstrong DL, 2014, GENES IMMUN, V15, P347, DOI 10.1038/gene.2014.23; Terao C, 2013, AM J HUM GENET, V93, P289, DOI 10.1016/j.ajhg.2013.05.024; Okada Y, 2014, AM J HUM GENET, V95, P162, DOI 10.1016/j.ajhg.2014.07.002; Okada Y, 2012, NAT GENET, V44, P511, DOI 10.1038/ng.2231; York IA, 2006, P NATL ACAD SCI USA, V103, P9202, DOI 10.1073/pnas.0603095103; Jacob CO, 2009, P NATL ACAD SCI USA, V106, P6256, DOI 10.1073/pnas.0901181106; Palm O, 2002, J RHEUMATOL, V29, P511; Chen M, 2012, NAT REV NEPHROL, V8, P476, DOI 10.1038/nrneph.2012.108; Apel M, 2013, ARTHRITIS RHEUM-US, V65, P1224, DOI 10.1002/art.37885; Bossini-Castillo L., 2014, ANN RHEUM DIS, V74, pe15; Graham DSC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002341; Deng Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003336; de Paoli FV, 2014, SCAND J RHEUMATOL, V43, P342, DOI 10.3109/03009742.2013.812238; ENCODE, 2015, ENCY DNA EL; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Fumagalli M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002355; Gorlova O, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002178; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; International HapMap Consortium, 2015, INT HAPMAP PROJ; Izawa K, 2012, DNA RES, V19, P143, DOI 10.1093/dnares/dsr047; Jia XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064683; Kenny EE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002559; Kim K, 2012, ANN RHEUM DIS, V71, P1809, DOI 10.1136/annrheumdis-2011-201110; Kim K, 2015, ANN RHEUM DIS, V74, DOI 10.1136/annrheumdis-2013-204749; Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624; Molineros JE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003222; Myouzen K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002949; National Human Genome Research Institute, 2015, CATALOG PUBLISHED GE; National Institutes of Health, 2015, ROADM EP PROJ; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Okada Y, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002455; Okada Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087645; Omoyinmi E, 2014, ARTHRITIS RHEUMATOL, V66, P197, DOI 10.1002/art.38217; Pyo CW, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-89; Ramos PS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002406; Raychaudhuri S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000534; Saruhan-Direskeneli G, 2013, AM J HUM GENET, V93, P298, DOI 10.1016/j.ajhg.2013.05.026; Sheng YJ, 2011, RHEUMATOLOGY, V50, P682, DOI 10.1093/rheumatology/keq313; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Terao C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020457; Teruel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068295; Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Xavier J. M., 2013, ANN RHEUM DIS, V74, P618; Yang WL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000841; Yu ZY, 2013, RHEUMATOL INT, V33, P2079, DOI 10.1007/s00296-013-2697-0; Zaitlen N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003520; Zhang Y, 2015, HUM MOL GENET, V24, P274, DOI 10.1093/hmg/ddu429; Zochling J, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0438-8	170	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4790	1759-4804		NAT REV RHEUMATOL	Nat. Rev. Rheumatol.	JUL	2015	11	7					401	414		10.1038/nrrheum.2015.41		14	Rheumatology	Rheumatology	CL7CR	WOS:000357128300005		
J	Kinoshita, M; Obata, K; Tanaka, M				Kinoshita, Masako; Obata, Kaoru; Tanaka, Masami			Latitude has more significant impact on prevalence of multiple sclerosis than ultraviolet level or sunshine duration in Japanese population	NEUROLOGICAL SCIENCES			English	Article						Multiple sclerosis; Prevalence; Latitude; Ultraviolet; Actual sunshine duration	SPINAL-CORD LESIONS; NATIONWIDE SURVEY; SEX; EPIDEMIOLOGY; ASSOCIATION; VETERANS; EXPOSURE; ORIGINS; RACE	Higher latitude is known to be associated with higher prevalence of multiple sclerosis (MS). We investigated the degree of impact of latitude, ultraviolet (UV) radiation, and sunshine on the prevalence of MS in Japan, which has 47 prefectures with a variety of climates. MS prevalence in each prefecture was collected from database of the Ministry of Health, Labour, and Welfare of Japan. Latitude of each prefecture was represented by that of the capital city. Data of UV radiation level and annual actual sunshine duration were obtained from databases of Japan Meteorological Agency. We performed linear correlation analyses of MS prevalence against latitude, UV radiation, and annual actual sunshine duration. MS prevalence significantly correlated to latitude (Pearson's correlation, r = 0.69, p < 0.001) and UV radiation level (r = -0.65, p < 0.001) but not to annual actual sunshine duration (r = -0.37, p = 0.011). Stepwise multiple linear regression analyses revealed significant correlation between MS prevalence and only latitude (p < 0.001). While our result shows that both latitude and the UV intensity have significant relationship to MS prevalence, the stronger relevance of the former suggests an existence of risk factors other than UV radiation.	[Kinoshita, Masako] Natl Utano Hosp, Dept Neurol, Natl Hosp Org, Ukyo Ku, Kyoto 6168255, Japan; [Obata, Kaoru; Tanaka, Masami] Natl Utano Hosp, MS Ctr, Natl Hosp Org, Kyoto 6168255, Japan	Kinoshita, M (reprint author), Natl Utano Hosp, Dept Neurol, Natl Hosp Org, Ukyo Ku, Kyoto 6168255, Japan.	machak@kuhp.kyoto-u.ac.jp			Ministry of Health, Labour, and Welfare of Japan	This study was supported in part by the Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour, and Welfare of Japan.	Karafet TM, 1999, AM J HUM GENET, V64, P817, DOI 10.1086/302282; Tajima A, 2004, J HUM GENET, V49, P187, DOI 10.1007/s10038-004-0131-x; Houzen H, 2012, J NEUROL SCI, V323, P117, DOI 10.1016/j.jns.2012.08.032; Nonaka I, 2007, ANN HUM GENET, V71, P480, DOI 10.1111/j.1469-1809.2006.00343.x; Hammer MF, 2006, J HUM GENET, V51, P47, DOI 10.1007/s10038-005-0322-0; Wallin MT, 2004, ANN NEUROL, V55, P65, DOI 10.1002/ana.10788; van der Mei IAF, 2003, BRIT MED J, V327, P316, DOI 10.1136/bmj.327.7410.316; HAMMOND SR, 1988, BRAIN, V111, P1, DOI 10.1093/brain/111.1.1; Ramagopalan SV, 2011, NEUROLOGY, V76, P1410, DOI 10.1212/WNL.0b013e318216715e; Lechner-Scott J, 2012, MULT SCLER J, V18, P974, DOI 10.1177/1352458511431729; Simpson S, 2011, J NEUROL NEUROSUR PS, V82, P1132, DOI 10.1136/jnnp.2011.240432; Orton SM, 2011, NEUROLOGY, V76, P425, DOI 10.1212/WNL.0b013e31820a0a9f; Kampman MT, 2008, NEUROEPIDEMIOLOGY, V30, P140, DOI 10.1159/000122330; Matsuoka T, 2007, BRAIN, V130, P1206, DOI 10.1093/brain/awm027; KURTZKE JF, 1979, NEUROLOGY, V29, P1228; Osoegawa M, 2009, MULT SCLER, V15, P159, DOI 10.1177/1352458508098372; Yamaguchi-Kabata Y, 2008, AM J HUM GENET, V83, P445, DOI 10.1016/j.ajhg.2008.08.019; Araki Y, 2013, J NEUROL SCI, V330, P67, DOI 10.1016/j.jns.2013.04.006; Dancey C. P., 2004, STAT MATH PSYCHOL US; Dobson R, 2013, J NEUROL NEUROSUR PS, V84, P909, DOI 10.1136/jnnp-2012-304695; Kinoshita M, 2013, NEUROLOGY, V80, P132; KUROIWA Y, 1983, Neuroepidemiology, V2, P62, DOI 10.1159/000110511; KUROIWA Y, 1975, NEUROLOGY, V25, P845; Risco J, 2011, MULT SCLER J, V17, P1055, DOI 10.1177/1352458511405562; SCHUMACH.GA, 1965, ANN NY ACAD SCI, V122, P552; SHIBASAKI H, 1992, J TROP GEOGR NEUROL, V2, P73; Taylor BV, 2010, MULT SCLER, V16, P1422, DOI 10.1177/1352458510379614; Vukusic S, 2007, J NEUROL NEUROSUR PS, V78, P707, DOI 10.1136/jnnp.2006.101196	28	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	JUL	2015	36	7					1147	1151		10.1007/s10072-015-2150-0		5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CL5ZH	WOS:000357043900009		
J	Kobayashi, M				Kobayashi, Makoto			Unidirectional ocular flutter: report of a case with abnormal saccadic characteristics	NEUROLOGICAL SCIENCES			English	Letter							OSCILLATIONS		Asahi Gen Hosp, Dept Neurol, Chiba 2892511, Japan	Kobayashi, M (reprint author), Asahi Gen Hosp, Dept Neurol, 1326 I Asahi, Chiba 2892511, Japan.	ma-ko@pg7.so-net.ne.jp					Abadi R, 2004, VISION RES, V44, P2675, DOI 10.1016/j.visres.2004.05.009; Ramat S, 2005, EXP BRAIN RES, V160, P89, DOI 10.1007/s00221-004-1989-8; LEIGH R. J., 2006, NEUROLOGY EYE MOVEME; Verhaeghe S, 2007, J NEUROL NEUROSUR PS, V78, P764, DOI 10.1136/jnnp.2006.107797; ZEE DS, 1979, ANN NEUROL, V5, P405, DOI 10.1002/ana.410050502	5	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	JUL	2015	36	7					1273	1276		10.1007/s10072-014-2006-z		4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CL5ZH	WOS:000357043900032		
J	Takizawa, T; Suzuki, S; Suzuki, N				Takizawa, Tsubasa; Suzuki, Shigeaki; Suzuki, Norihiro			When do we judge IVIg for myasthenia gravis ineffective?	NEUROLOGICAL SCIENCES			English	Letter							IMMUNOGLOBULIN		[Takizawa, Tsubasa; Suzuki, Shigeaki; Suzuki, Norihiro] Keio Univ, Dept Neurol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan	Takizawa, T (reprint author), Keio Univ, Dept Neurol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	tsubasa.takizawa@z5.keio.jp	Suzuki, Shigeaki/N-9555-2013; Suzuki, Norihiro/J-5125-2013				Ciafaloni E, 2001, NEUROLOGY, V56, P97; Barth D, 2011, NEUROLOGY, V76, P2017, DOI 10.1212/WNL.0b013e31821e5505; Zinman L, 2007, NEUROLOGY, V68, P837, DOI 10.1212/01.wnl.0000256698.69121.45; Suzuki S, 2011, J NEUROIMMUNOL, V230, P148, DOI 10.1016/j.jneuroim.2010.10.023; Sorgun MH, 2014, NEUROL SCI, V35, P891, DOI 10.1007/s10072-013-1621-4	5	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	JUL	2015	36	7					1295	1297		10.1007/s10072-014-2039-3		3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CL5ZH	WOS:000357043900039		
J	Sasamori, T; Hida, K; Osanai, T; Yano, S; Seki, T; Houkin, K				Sasamori, Toru; Hida, Kazutoshi; Osanai, Toshiya; Yano, Shunsuke; Seki, Toshitaka; Houkin, Kiyohiro			A Survey of Chronic Pain Due to Spinal Dural Arteriovenous Fistulae	NEUROSURGERY			English	Article						Chronic pain; Spinal cord atrophy; Spinal dural arteriovenous fistulae	VENOUS CONGESTIVE MYELOPATHY; NEUROPATHIC PAIN; CORD-INJURY; MANAGEMENT; FEATURES; SERIES	BACKGROUND:Chronic pain due to spinal dural arteriovenous fistulae (SDAVF) during follow-up is a serious issue because it can affect patients' quality of life. The severity of posttreatment chronic leg pain in patients with SDAVF is unclear.OBJECTIVE:To investigate the prevalence, severity, and characteristics of chronic leg pain in patients with SDAVF and to examine the clinical factors associated with chronic pain.METHODS:We conducted a survey of their chronic posttreatment leg pain in 49 SDAVF patients. It consisted of a numeric rating scale and a neuropathic pain symptom inventory (NPSI). Of the 49 patients, 32 (65.3%) completed the questionnaire. There were 24 males and 8 females whose mean age was 69.1 years. The mean follow-up period was 86.3 months.RESULTS:Chronic leg pain was reported by 26 (81.3%) of 32 patients; 14 experienced pain before treatment and 12 had new-onset posttreatment pain. The pain was reported as moderate to severe by 21 (80.8%) of 26 patients; the mean numeric rating scale and NPSI scores were 6.0 2.3 and 17.4 10.3, respectively. The NPSI subscores were significantly higher for spontaneous pain and paresthesia/dysesthesia than for paroxysmal pain. We found no significant clinical factors related to chronic posttreatment pain; on magnetic resonance imaging scans we identified spinal cord atrophy in 8 patients with chronic pain.CONCLUSION:Most of our SDAVF patients reported moderate to severe chronic leg pain characterized by spontaneous pain and paresthesia/dysesthesia. Spinal cord atrophy on magnetic resonance imaging scans was a characteristic in patients with chronic pain.ABBREVIATIONS:ALS, Aminoff-Logue scaleNPSI, neuropathic pain symptom inventoryNRS, numeric rating scaleSCI, spinal cord injurySDAVF, spinal dural arteriovenous fistulae	[Sasamori, Toru; Osanai, Toshiya; Seki, Toshitaka; Houkin, Kiyohiro] Hokkaido Univ Grad Sch Med, Dept Neurosurg, Sapporo, Hokkaido 0608638, Japan; [Hida, Kazutoshi; Yano, Shunsuke] Sapporo Azabu Neurosurg Hosp, Sapporo, Hokkaido, Japan	Sasamori, T (reprint author), Hokkaido Univ Grad Sch Med, Dept Neurosurg, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	mo_ri25@yahoo.co.jp					HASSLER W, 1989, J NEUROSURG, V70, P360, DOI 10.3171/jns.1989.70.3.0360; Shinoyama M, 2010, WORLD NEUROSURG, V73, P401, DOI 10.1016/j.wneu.2010.01.003; AMINOFF MJ, 1974, BRAIN, V97, P211, DOI 10.1093/brain/97.1.211; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Jellema K, 2006, BRAIN, V129, P3150, DOI 10.1093/brain/awl220; Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024; Sherif C, 2008, NEURORADIOLOGY, V50, P67, DOI 10.1007/s00234-007-0303-4; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; Attal N., 2009, Annals of Physical and Rehabilitation Medicine, V52, P124, DOI 10.1016/j.rehab.2008.12.011; Cardenas DD, 2006, J SPINAL CORD MED, V29, P109; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F; Behrens S, 1999, J NEUROL, V246, P181, DOI 10.1007/s004150050331; Brown A, 2012, EXP NEUROL, V235, P133, DOI 10.1016/j.expneurol.2011.11.004; Cenzato M, 2004, NEUROSURGERY, V55, P815, DOI 10.1227/01.NEU.0000137630.50959.A7; Foix C, 1926, REV NEUROL-FRANCE, V46, P1; HURST RW, 1995, NEUROLOGY, V45, P1309; Kimura A, 2007, NEUROPATHOLOGY, V27, P284, DOI 10.1111/j.1440-1789.2007.00758.x; Matsuo K, 2008, NEUROPATHOLOGY, V28, P303, DOI 10.1111/j.1440-1789.2007.00880.x; Nakamura M, 2012, J ORTHOP SCI, V17, P352, DOI 10.1007/s00776-012-0236-6; Narvid J, 2008, NEUROSURGERY, V62, P159, DOI [10.1227/01.NEU.0000311073.71733.C4, 10.1227/01.NEU.0000296997.82103.47]; Saladino A, 2010, NEUROSURGERY, V67, P1350, DOI 10.1227/NEU.0b013e3181ef2821	22	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUL	2015	77	1					113	118		10.1227/NEU.0000000000000745		6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL2LS	WOS:000356776100028		
J	Mochizuki, H; Mihara, M				Mochizuki, Hideki; Mihara, Masahito			Less Constraint, Non-invasive Rehabilitation System for Patients with Neurological Disease Using Functional Near Infrared Spectroscopy	NEUROTHERAPEUTICS			English	Meeting Abstract									[Mochizuki, Hideki; Mihara, Masahito] Osaka Univ, Suita, Osaka 565, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JUL	2015	12	3					682	683				2	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CL9WP	WOS:000357329600028		
J	Honda, M; Satake, S; Suzuki, Y; Yoshida, M; Hayashi, N; Kamiya, K; Matsuyama, A; Shinohara, K; Matsunaga, G; Nakata, M; Ide, S; Urano, H				Honda, M.; Satake, S.; Suzuki, Y.; Yoshida, M.; Hayashi, N.; Kamiya, K.; Matsuyama, A.; Shinohara, K.; Matsunaga, G.; Nakata, M.; Ide, S.; Urano, H.			Integrated modelling of toroidal rotation with the 3D non-local drift-kinetic code and boundary models for JT-60U analyses and predictive simulations	NUCLEAR FUSION			English	Article						tokamak; transport; toroidal rotation; integrated modelling; NTV; boundary modelling; radial electric field	SCRAPE-OFF LAYER; MOMENTUM TRANSPORT; FIELD RIPPLE; H-MODE; TOKAMAK; PLASMA; DISSIPATION; EQUILIBRIA; REGIMES	The integrated simulation framework for toroidal momentum transport is developed, which self-consistently calculates the neoclassical toroidal viscosity (NTV), the radial electric field Er and the resultant toroidal rotation V-phi together with the scrape-off-layer (SOL) physics-based boundary model. The coupling of three codes, the 1.5D transport code TOPICS, the three-dimensional (3D) equilibrium code VMEC and the 3D delta f drift-kinetic equation solver FORTEC-3D, makes it possible to calculate the NTV due to the non-axisymmetric perturbed magnetic field caused by toroidal field coils. Analyses reveal that the NTV significantly influences V-phi in JT-60U and Er holds the key to determine the NTV profile. The sensitivity of the V-phi profile to the boundary rotation necessitates a boundary condition modelling for toroidal momentum. Owing to the high-resolution measurement system in JT-60U, the Er gradient is found to be virtually zero at the separatrix regardless of toroidal rotation velocities. Focusing on E-r, the boundary model of toroidal momentum is developed in conjunction with the SOL/divertor plasma code D5PM. This modelling realizes self-consistent predictive simulations for operation scenario development in ITER.	[Honda, M.; Yoshida, M.; Hayashi, N.; Kamiya, K.; Shinohara, K.; Matsunaga, G.; Ide, S.; Urano, H.] Japan Atom Energy Agcy, Naka, Ibaraki 3110193, Japan; [Satake, S.; Suzuki, Y.] Natl Inst Fus Sci, Toki, Gifu 5095292, Japan; [Satake, S.; Suzuki, Y.] Grad Univ Adv Studies SOKENDAI, Toki, Gifu 5095292, Japan; [Matsuyama, A.; Nakata, M.] Japan Atom Energy Agcy, Rokkasho, Aomori 0393212, Japan	Honda, M (reprint author), Japan Atom Energy Agcy, Naka, Ibaraki 3110193, Japan.	honda.mitsuru@jaea.go.jp			Japan Society for the Promotion of Science (JSPS) [25820442]	The authors would like to thank Dr Y. Kamada for beneficial comments and suggestions. One of the authors (MH) is grateful to Dr S.H. Kim for providing the CORSICA data of the ITER Hydrogen L-mode operation scenario and to Messrs. I. Kamata, T. Kuwata and M. Suzuki for numerical assistance. This work was supported by a Grant-in-Aid for Young Scientists (B) (No 25820442) from the Japan Society for the Promotion of Science (JSPS) and was carried out using the HELIOS supercomputer system at International Fusion Energy Research Centre, Aomori, Japan, under the Broader Approach collaboration between Euratom and Japan, implemented by Fusion for Energy and JAEA.	Suzuki Y, 2003, NUCL FUSION, V43, P406, DOI 10.1088/0029-5515/43/6/303; Yoshida M, 2012, NUCL FUSION, V52, DOI 10.1088/0029-5515/52/12/123005; Solomon WM, 2011, NUCL FUSION, V51, DOI 10.1088/0029-5515/51/7/073010; HIRSHMAN SP, 1986, COMPUT PHYS COMMUN, V43, P143, DOI 10.1016/0010-4655(86)90058-5; Rice JE, 2007, NUCL FUSION, V47, P1618, DOI 10.1088/0029-5515/47/11/025; Budny RV, 2008, NUCL FUSION, V48, DOI 10.1088/0029-5515/48/7/075005; Shaing KC, 2012, PLASMA PHYS CONTR F, V54, DOI 10.1088/0741-3335/54/12/124033; Rice JE, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.215001; Asakura N, 2000, PHYS REV LETT, V84, P3093, DOI 10.1103/PhysRevLett.84.3093; Garofalo AM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.195005; Shinohara K, 2007, NUCL FUSION, V47, P997, DOI 10.1088/0029-5515/47/8/034; Hayashi N, 2010, PHYS PLASMAS, V17, DOI 10.1063/1.3327917; Chankin AV, 2007, NUCL FUSION, V47, P479, DOI 10.1088/0029-5515/47/5/013; Cole AJ, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.065001; Diamond PH, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/10/104019; Viezzer E, 2014, NUCL FUSION, V54, DOI 10.1088/0029-5515/54/1/012003; Honda M, 2010, COMPUT PHYS COMMUN, V181, P1490, DOI 10.1016/j.cpc.2010.04.014; Budny RV, 2009, NUCL FUSION, V49, DOI 10.1088/0029-5515/49/8/085008; Budny RV, 2012, NUCL FUSION, V52, DOI 10.1088/0029-5515/52/1/013001; Shaing KC, 2003, PHYS PLASMAS, V10, P1443, DOI 10.1063/1.1567285; Shinohara K, 2012, NUCL FUSION, V52, DOI 10.1088/0029-5515/52/9/094008; Honda M, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/7/073050; Degrassie JS, 2009, NUCL FUSION, V49, DOI 10.1088/0029-5515/49/8/085020; Honda M, 2006, NUCL FUSION, V46, P580, DOI 10.1088/0029-5515/46/5/009; Takizuka T, 2009, NUCL FUSION, V49, DOI 10.1088/0029-5515/49/7/075038; Tala T, 2011, NUCL FUSION, V51, DOI 10.1088/0029-5515/51/12/123002; Zhu W, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.225002; Garofalo AM, 2009, PHYS PLASMAS, V16, DOI 10.1063/1.3129164; Hayashi N, 2007, J NUCL MATER, V363, P1044, DOI 10.1016/j.jnucmat.2007.01.159; Degrassie JS, 2009, PLASMA PHYS CONTR F, V51, DOI 10.1088/0741-3335/51/12/124047; Grierson BA, 2012, PHYS PLASMAS, V19, DOI 10.1063/1.3694656; Yoshida M, 2007, NUCL FUSION, V47, P856, DOI 10.1088/0029-5515/47/8/017; Cole AJ, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.225002; McDermott RM, 2014, NUCL FUSION, V54, DOI 10.1088/0029-5515/54/4/043009; Satake S, 2011, PLASMA PHYS CONTR F, V53, DOI 10.1088/0741-3335/53/5/054018; Kamiya K, 2012, NUCL FUSION, V52, DOI 10.1088/0029-5515/52/11/114010; Putterich T, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.025001; Kikuchi M, 1995, PLASMA PHYS CONTR F, V37, P1215, DOI 10.1088/0741-3335/37/11/003; Artaud JF, 2010, NUCL FUSION, V50, DOI 10.1088/0029-5515/50/4/043001; Crotinger J.A, 1997, UCRLID126284 LLNL; Erba M, 1997, PLASMA PHYS CONTR F, V39, P261, DOI 10.1088/0741-3335/39/2/004; HIRSHMAN SP, 1991, J COMPUT PHYS, V96, P99, DOI 10.1016/0021-9991(91)90267-O; Honda M, 2014, NUCL FUSION, V54, DOI 10.1088/0029-5515/54/11/114005; Honda M, 2014, PHYS PLASMAS, V21, DOI 10.1063/1.4895795; Honda M, 2012, NUCL FUSION, V52, DOI 10.1088/0029-5515/52/2/023021; Kamiya K, 2014, CONTRIB PLASM PHYS, V54, P591, DOI 10.1002/ctpp.201410013; Kamiya K, 2014, PHYS PLASMAS, V21, DOI 10.1063/1.4904815; Nishijima D, 2005, PLASMA PHYS CONTR F, V47, P89, DOI 10.1088/0741-3335/47/1/006; Rice JE, 2004, NUCL FUSION, V44, P379, DOI 10.1088/0029-5515/44/3/001; Satake S., 2008, PLASMA FUSION RES, V3, pS1062; Satake S, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/11/113033; Sun Y, 2013, NUCL FUSION, V53, DOI 10.1088/0029-5515/53/9/093010; Tala T., 2012, P INT C FUS EN SAN D; Yoshida M, 2006, PLASMA PHYS CONTR F, V48, P1673, DOI 10.1088/0741-3335/48/11/008	54	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0029-5515	1741-4326		NUCL FUSION	Nucl. Fusion	JUL	2015	55	7							073033	10.1088/0029-5515/55/7/073033		11	Physics, Fluids & Plasmas; Physics, Nuclear	Physics	CL8YD	WOS:000357259600033		
J	Ichiguchi, K; Suzuki, Y; Sato, M; Todo, Y; Nicolas, T; Sakakibara, S; Ohdachi, S; Narushima, Y; Carreras, BA				Ichiguchi, K.; Suzuki, Y.; Sato, M.; Todo, Y.; Nicolas, T.; Sakakibara, S.; Ohdachi, S.; Narushima, Y.; Carreras, B. A.			Three-dimensional MHD analysis of heliotron plasma with RMP	NUCLEAR FUSION			English	Article						magnetohydrodynamics (MHD); numerical simulation; heliotron; resonant magnetic perturbation (RMP); pressure driven mode	DESIGN	The interaction between pressure driven modes and magnetic islands generated by a resonant magnetic perturbation (RMP) in the large helical device (LHD) is numerically analyzed. In this analysis, three-dimensional treatment is essential in the equilibrium and dynamics calculations, because the equilibrium pressure profile is deformed by the RMP. The deformation changes the linear mode structure from the interchange type to the ballooning-like type that is localized around the X-point of the island in the equilibrium magnetic field including the RMP. This mode causes a pressure collapse in the nonlinear evolution, which spreads from the X-point to the core. Therefore, the spatial phase of the collapse is fixed to the island geometry. The fixed phase agrees with the LHD experimental results with a natural error field.	[Ichiguchi, K.; Suzuki, Y.; Sato, M.; Todo, Y.; Nicolas, T.; Sakakibara, S.; Ohdachi, S.; Narushima, Y.] Natl Inst Fus Sci, Toki, Gifu 5095292, Japan; [Ichiguchi, K.; Suzuki, Y.; Sato, M.; Todo, Y.; Sakakibara, S.; Ohdachi, S.; Narushima, Y.] Grad Univ Adv Studies, SOKENDAI, Toki, Gifu 5095292, Japan; [Carreras, B. A.] Univ Carlos III Madrid, Madrid 28911, Spain	Ichiguchi, K (reprint author), Natl Inst Fus Sci, 322-6 Oroshi Cho, Toki, Gifu 5095292, Japan.	ichiguch@nifs.ac.jp			National Institute for Fusion Science (NIFS) [NIFS14KNST063, NIFS14KLTT003]; JSPS KAKENHI [22560822, 26-04728]; 'Catedras de Excelencia' at Universidad Carlos III de Madrid	This work was supported by budgets NIFS14KNST063 and NIFS14KLTT003 of National Institute for Fusion Science (NIFS) and JSPS KAKENHI of Grant Numbers 22560822 and 26-04728. Super computers, Plasma Simulator in NIFS and Helios in the Computational Simulation Center of the International Fusion Energy Research Center, were utilized for the numerical calculations. One of the authors (BAC) gratefully acknowledge support of this work by the 'Catedras de Excelencia' at Universidad Carlos III de Madrid. Visit visualization software is utilized in plotting some of the figures.	Strauss HR, 2009, NUCL FUSION, V49, DOI 10.1088/0029-5515/49/5/055025; Ichiguchi K, 1996, NUCL FUSION, V36, P1145, DOI 10.1088/0029-5515/36/9/I04; Carreras BA, 1998, PHYS PLASMAS, V5, P3700, DOI 10.1063/1.872980; Evans TE, 2008, NUCL FUSION, V48, DOI 10.1088/0029-5515/48/2/024002; GLASSER AH, 1975, PHYS FLUIDS, V18, P875, DOI 10.1063/1.861224; Chapman IT, 2014, NUCL FUSION, V54, DOI 10.1088/0029-5515/54/8/083006; Becoulet M, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.115001; Sakakibara S, 2013, PLASMA PHYS CONTR F, V55, DOI 10.1088/0741-3335/55/1/014014; Ichiguchi K, 2013, PLASMA PHYS CONTR F, V55, DOI 10.1088/0741-3335/55/1/014009; Motojima O, 2000, NUCL FUSION, V40, P599, DOI 10.1088/0029-5515/40/3Y/322; Saito K, 2010, PHYS PLASMAS, V17, DOI 10.1063/1.3442732; Yamada H, 2011, NUCL FUSION, V51, DOI 10.1088/0029-5515/51/9/094021; Orain F, 2013, PHYS PLASMAS, V20, DOI 10.1063/1.4824820; Bateman G., 1978, MHD INSTABILITIES; Ichiguchi K., 2014, PLASMA FUSION RES, V9; IIYOSHI A, 1990, FUSION TECHNOL, V17, P169; Saito Kinya, 2011, Plasma and Fusion Research, V6, DOI 10.1585/pfr.6.2403072; Todo Yasushi, 2010, Plasma and Fusion Research, V5, DOI 10.1585/pfr.5.S2062	18	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0029-5515	1741-4326		NUCL FUSION	Nucl. Fusion	JUL	2015	55	7							073023	10.1088/0029-5515/55/7/073023		10	Physics, Fluids & Plasmas; Physics, Nuclear	Physics	CL8YD	WOS:000357259600023		
